Word	Tag	Begin-End
Famotidine	O	0-10
-	O	10-11
associated	O	11-21
delirium	B	22-30
.	O	30-31

A	O	32-33
series	O	34-40
of	O	41-43
six	O	44-47
cases	O	48-53
.	O	53-54

Famotidine	O	55-65
is	O	66-68
a	O	69-70
histamine	O	71-80
H2	O	81-83
-	O	83-84
receptor	O	84-92
antagonist	O	93-103
used	O	104-108
in	O	109-111
inpatient	O	112-121
settings	O	122-130
for	O	131-134
prevention	O	135-145
of	O	146-148
stress	O	149-155
ulcers	B	156-162
and	O	163-166
is	O	167-169
showing	O	170-177
increasing	O	178-188
popularity	O	189-199
because	O	200-207
of	O	208-210
its	O	211-214
low	O	215-218
cost	O	219-223
.	O	223-224

Although	O	225-233
all	O	234-237
of	O	238-240
the	O	241-244
currently	O	245-254
available	O	255-264
H2	O	265-267
-	O	267-268
receptor	O	268-276
antagonists	O	277-288
have	O	289-293
shown	O	294-299
the	O	300-303
propensity	O	304-314
to	O	315-317
cause	O	318-323
delirium	B	324-332
,	O	332-333
only	O	334-338
two	O	339-342
previously	O	343-353
reported	O	354-362
cases	O	363-368
have	O	369-373
been	O	374-378
associated	O	379-389
with	O	390-394
famotidine	O	395-405
.	O	405-406

The	O	407-410
authors	O	411-418
report	O	419-425
on	O	426-428
six	O	429-432
cases	O	433-438
of	O	439-441
famotidine	O	442-452
-	O	452-453
associated	O	453-463
delirium	B	464-472
in	O	473-475
hospitalized	O	476-488
patients	O	489-497
who	O	498-501
cleared	O	502-509
completely	O	510-520
upon	O	521-525
removal	O	526-533
of	O	534-536
famotidine	O	537-547
.	O	547-548

The	O	549-552
pharmacokinetics	O	553-569
of	O	570-572
famotidine	O	573-583
are	O	584-587
reviewed	O	588-596
,	O	596-597
with	O	598-602
no	O	603-605
change	O	606-612
in	O	613-615
its	O	616-619
metabolism	O	620-630
in	O	631-633
the	O	634-637
elderly	O	638-645
population	O	646-656
seen	O	657-661
.	O	661-662

The	O	663-666
implications	O	667-679
of	O	680-682
using	O	683-688
famotidine	O	689-699
in	O	700-702
elderly	O	703-710
persons	O	711-718
are	O	719-722
discussed	O	723-732
.	O	732-733

Indomethacin	O	0-12
induced	O	13-20
hypotension	B	21-32
in	O	33-35
sodium	O	36-42
and	O	43-46
volume	O	47-53
depleted	O	54-62
rats	O	63-67
.	O	67-68

After	O	69-74
a	O	75-76
single	O	77-83
oral	O	84-88
dose	O	89-93
of	O	94-96
4	O	97-98
mg	O	99-101
/	O	101-102
kg	O	102-104
indomethacin	O	105-117
(	O	118-119
IDM	O	119-122
)	O	122-123
to	O	124-126
sodium	O	127-133
and	O	134-137
volume	O	138-144
depleted	O	145-153
rats	O	154-158
plasma	O	159-165
renin	O	166-171
activity	O	172-180
(	O	181-182
PRA	O	182-185
)	O	185-186
and	O	187-190
systolic	O	191-199
blood	O	200-205
pressure	O	206-214
fell	O	215-219
significantly	O	220-233
within	O	234-240
four	O	241-245
hours	O	246-251
.	O	251-252

In	O	253-255
sodium	O	256-262
repleted	O	263-271
animals	O	272-279
indomethacin	O	280-292
did	O	293-296
not	O	297-300
change	O	301-307
systolic	O	308-316
blood	O	317-322
pressure	O	323-331
(	O	332-333
BP	O	333-335
)	O	335-336
although	O	337-345
plasma	O	346-352
renin	O	353-358
activity	O	359-367
was	O	368-371
decreased	O	372-381
.	O	381-382

Thus	O	383-387
,	O	387-388
indomethacin	O	389-401
by	O	402-404
inhibition	O	405-415
of	O	416-418
prostaglandin	O	419-432
synthesis	O	433-442
may	O	443-446
diminish	O	447-455
the	O	456-459
blood	O	460-465
pressure	O	466-474
maintaining	O	475-486
effect	O	487-493
of	O	494-496
the	O	497-500
stimulated	O	501-511
renin	O	512-517
-	O	517-518
angiotensin	O	518-529
system	O	530-536
in	O	537-539
sodium	O	540-546
and	O	547-550
volume	O	551-557
depletion	O	558-567
.	O	567-568

Late	O	0-4
-	O	4-5
onset	O	5-10
scleroderma	B	11-22
renal	I	23-28
crisis	I	29-35
induced	O	36-43
by	O	44-46
tacrolimus	O	47-57
and	O	58-61
prednisolone	O	62-74
:	O	74-75
a	O	76-77
case	O	78-82
report	O	83-89
.	O	89-90

Scleroderma	B	91-102
renal	I	103-108
crisis	I	109-115
(	O	116-117
SRC	B	117-120
)	O	120-121
is	O	122-124
a	O	125-126
rare	O	127-131
complication	O	132-144
of	O	145-147
systemic	B	148-156
sclerosis	I	157-166
(	O	167-168
SSc	B	168-171
)	O	171-172
but	O	173-176
can	O	177-180
be	O	181-183
severe	O	184-190
enough	O	191-197
to	O	198-200
require	O	201-208
temporary	O	209-218
or	O	219-221
permanent	O	222-231
renal	O	232-237
replacement	O	238-249
therapy	O	250-257
.	O	257-258

Moderate	O	259-267
to	O	268-270
high	O	271-275
dose	O	276-280
corticosteroid	O	281-295
use	O	296-299
is	O	300-302
recognized	O	303-313
as	O	314-316
a	O	317-318
major	O	319-324
risk	O	325-329
factor	O	330-336
for	O	337-340
SRC	B	341-344
.	O	344-345

Furthermore	O	346-357
,	O	357-358
there	O	359-364
have	O	365-369
been	O	370-374
reports	O	375-382
of	O	383-385
thrombotic	B	386-396
microangiopathy	I	397-412
precipitated	O	413-425
by	O	426-428
cyclosporine	O	429-441
in	O	442-444
patients	O	445-453
with	O	454-458
SSc	B	459-462
.	O	462-463

In	O	464-466
this	O	467-471
article	O	472-479
,	O	479-480
we	O	481-483
report	O	484-490
a	O	491-492
patient	O	493-500
with	O	501-505
SRC	B	506-509
induced	O	510-517
by	O	518-520
tacrolimus	O	521-531
and	O	532-535
corticosteroids	O	536-551
.	O	551-552

The	O	553-556
aim	O	557-560
of	O	561-563
this	O	564-568
work	O	569-573
is	O	574-576
to	O	577-579
call	O	580-584
attention	O	585-594
to	O	595-597
the	O	598-601
risk	O	602-606
of	O	607-609
tacrolimus	O	610-620
use	O	621-624
in	O	625-627
patients	O	628-636
with	O	637-641
SSc	B	642-645
.	O	645-646

The	O	0-3
risk	O	4-8
and	O	9-12
associated	O	13-23
factors	O	24-31
of	O	32-34
methamphetamine	O	35-50
psychosis	B	51-60
in	O	61-63
methamphetamine	O	64-79
-	O	79-80
dependent	O	80-89
patients	O	90-98
in	O	99-101
Malaysia	O	102-110
.	O	110-111

OBJECTIVE	O	112-121
:	O	121-122
The	O	123-126
objective	O	127-136
of	O	137-139
this	O	140-144
study	O	145-150
was	O	151-154
to	O	155-157
determine	O	158-167
the	O	168-171
risk	O	172-176
of	O	177-179
lifetime	O	180-188
and	O	189-192
current	O	193-200
methamphetamine	O	201-216
-	O	216-217
induced	O	217-224
psychosis	B	225-234
in	O	235-237
patients	O	238-246
with	O	247-251
methamphetamine	O	252-267
dependence	O	268-278
.	O	278-279

The	O	280-283
association	O	284-295
between	O	296-303
psychiatric	O	304-315
co	O	316-318
-	O	318-319
morbidity	O	319-328
and	O	329-332
methamphetamine	O	333-348
-	O	348-349
induced	O	349-356
psychosis	B	357-366
was	O	367-370
also	O	371-375
studied	O	376-383
.	O	383-384

METHODS	O	385-392
:	O	392-393
This	O	394-398
was	O	399-402
a	O	403-404
cross	O	405-410
-	O	410-411
sectional	O	411-420
study	O	421-426
conducted	O	427-436
concurrently	O	437-449
at	O	450-452
a	O	453-454
teaching	O	455-463
hospital	O	464-472
and	O	473-476
a	O	477-478
drug	O	479-483
rehabilitation	O	484-498
center	O	499-505
in	O	506-508
Malaysia	O	509-517
.	O	517-518

Patients	O	519-527
with	O	528-532
the	O	533-536
diagnosis	O	537-546
of	O	547-549
methamphetamine	O	550-565
based	O	566-571
on	O	572-574
DSM	O	575-578
-	O	578-579
IV	O	579-581
were	O	582-586
interviewed	O	587-598
using	O	599-604
the	O	605-608
Mini	O	609-613
International	O	614-627
Neuropsychiatric	O	628-644
Interview	O	645-654
(	O	655-656
M	O	656-657
.	O	657-658
I	O	658-659
.	O	657-658
N	O	660-661
.	O	657-658
I	O	658-659
.	O	657-658
)	O	664-665
for	O	666-669
methamphetamine	O	670-685
-	O	685-686
induced	O	686-693
psychosis	B	694-703
and	O	704-707
other	O	708-713
Axis	O	714-718
I	O	719-720
psychiatric	B	721-732
disorders	I	733-742
.	O	742-743

The	O	744-747
information	O	748-759
on	O	760-762
sociodemographic	O	763-779
background	O	780-790
and	O	791-794
drug	O	795-799
use	O	800-803
history	O	804-811
was	O	812-815
obtained	O	816-824
from	O	825-829
interview	O	830-839
or	O	840-842
medical	O	843-850
records	O	851-858
.	O	858-859

RESULTS	O	860-867
:	O	867-868
Of	O	869-871
292	O	872-875
subjects	O	876-884
,	O	884-885
47	O	886-888
.	O	888-889
9	O	889-890
%	O	890-891
of	O	892-894
the	O	895-898
subjects	O	899-907
had	O	908-911
a	O	912-913
past	O	914-918
history	O	919-926
of	O	927-929
psychotic	B	930-939
symptoms	I	940-948
and	O	949-952
13	O	953-955
.	O	955-956
0	O	956-957
%	O	957-958
of	O	959-961
the	O	962-965
patients	O	966-974
were	O	975-979
having	O	980-986
current	O	987-994
psychotic	B	995-1004
symptoms	I	1005-1013
.	O	1013-1014

Co	O	1015-1017
-	O	1017-1018
morbid	O	1018-1024
major	O	1025-1030
depressive	B	1031-1041
disorder	I	1042-1050
(	O	1051-1052
OR	O	1052-1054
=	O	1054-1055
7	O	1055-1056
.	O	1056-1057
18	O	1057-1059
,	O	1059-1060

95	O	1061-1063
CI	O	1064-1066
=	O	1066-1067
2	O	1067-1068
.	O	1068-1069
612	O	1069-1072
-	O	1072-1073
19	O	1073-1075
.	O	1068-1069
708	O	1076-1079
)	O	1079-1080
,	O	1080-1081

bipolar	B	1082-1089
disorder	I	1090-1098
(	O	1099-1100
OR	O	1100-1102
=	O	1102-1103
13	O	1103-1105
.	O	1105-1106
807	O	1106-1109
,	O	1109-1110

95	O	1111-1113
CI	O	1114-1116
=	O	1116-1117
5	O	1117-1118
.	O	1118-1119
194	O	1119-1122
-	O	1122-1123
36	O	1123-1125
.	O	1118-1119
706	O	1126-1129
)	O	1129-1130
,	O	1130-1131

antisocial	B	1132-1142
personality	I	1143-1154
disorder	I	1155-1163
(	O	1164-1165
OR	O	1165-1167
=	O	1167-1168
12	O	1168-1170
.	O	1170-1171
619	O	1171-1174
,	O	1174-1175

95	O	1176-1178
CI	O	1179-1181
=	O	1181-1182
6	O	1182-1183
.	O	1183-1184
702	O	1184-1187
-	O	1187-1188
23	O	1188-1190
.	O	1183-1184
759	O	1191-1194
)	O	1194-1195
and	O	1196-1199
heavy	O	1200-1205
methamphetamine	O	1206-1221
uses	O	1222-1226
were	O	1227-1231
significantly	O	1232-1245
associated	O	1246-1256
with	O	1257-1261
lifetime	O	1262-1270
methamphetamine	O	1271-1286
-	O	1286-1287
induced	O	1287-1294
psychosis	B	1295-1304
after	O	1305-1310
adjusted	O	1311-1319
for	O	1320-1323
other	O	1324-1329
factors	O	1330-1337
.	O	1337-1338

Major	B	1339-1344
depressive	I	1345-1355
disorder	I	1356-1364
(	O	1365-1366
OR	O	1366-1368
=	O	1368-1369
2	O	1369-1370
.	O	1370-1371
870	O	1371-1374
,	O	1374-1375

CI	O	1376-1378
=	O	1378-1379
1	O	1379-1380
.	O	1380-1381
154	O	1381-1384
-	O	1384-1385
7	O	1385-1386
.	O	1380-1381
142	O	1387-1390
)	O	1390-1391

and	O	1392-1395
antisocial	B	1396-1406
personality	I	1407-1418
disorder	I	1419-1427
(	O	1428-1429
OR	O	1429-1431
=	O	1431-1432
3	O	1432-1433
.	O	1433-1434
299	O	1434-1437
,	O	1437-1438

95	O	1439-1441
CI	O	1442-1444
=	O	1444-1445
1	O	1445-1446
.	O	1446-1447
375	O	1447-1450
-	O	1450-1451
7	O	1448-1449
.	O	1446-1447
914	O	1453-1456
)	O	1456-1457

were	O	1458-1462
the	O	1463-1466
only	O	1467-1471
factors	O	1472-1479
associated	O	1480-1490
with	O	1491-1495
current	O	1496-1503
psychosis	B	1504-1513
.	O	1513-1514

CONCLUSION	O	1515-1525
:	O	1525-1526
There	O	1527-1532
was	O	1533-1536
a	O	1537-1538
high	O	1539-1543
risk	O	1544-1548
of	O	1549-1551
psychosis	B	1552-1561
in	O	1562-1564
patients	O	1565-1573
with	O	1574-1578
methamphetamine	O	1579-1594
dependence	O	1595-1605
.	O	1605-1606

It	O	1607-1609
was	O	1610-1613
associated	O	1614-1624
with	O	1625-1629
co	O	1630-1632
-	O	1632-1633
morbid	O	1633-1639
affective	B	1640-1649
disorder	I	1650-1658
,	O	1658-1659
antisocial	B	1660-1670
personality	I	1671-1682
,	O	1682-1683
and	O	1684-1687
heavy	O	1688-1693
methamphetamine	O	1694-1709
use	O	1710-1713
.	O	1713-1714

It	O	1715-1717
is	O	1718-1720
recommended	O	1721-1732
that	O	1733-1737
all	O	1738-1741
cases	O	1742-1747
of	O	1748-1750
methamphetamine	O	1751-1766
dependence	O	1767-1777
should	O	1778-1784
be	O	1785-1787
screened	O	1788-1796
for	O	1797-1800
psychotic	B	1801-1810
symptoms	I	1811-1819
.	O	1819-1820

Cerebellar	O	0-10
sensory	O	11-18
processing	O	19-29
alterations	O	30-41
impact	O	42-48
motor	O	49-54
cortical	O	55-63
plasticity	O	64-74
in	O	75-77
Parkinson	B	78-87
'	I	87-88
s	I	84-85
disease	I	90-97
:	O	97-98
clues	O	99-104
from	O	105-109
dyskinetic	B	110-120
patients	O	121-129
.	O	129-130

The	O	131-134
plasticity	O	135-145
of	O	146-148
primary	O	149-156
motor	O	157-162
cortex	O	163-169
(	O	170-171
M1	O	171-173
)	O	173-174
in	O	175-177
patients	O	178-186
with	O	187-191
Parkinson	B	192-201
'	I	201-202
s	I	198-199
disease	I	204-211
(	O	212-213
PD	B	213-215
)	O	215-216
and	O	217-220
levodopa	O	221-229
-	O	229-230
induced	O	230-237
dyskinesias	B	238-249
(	O	250-251
LIDs	B	251-255
)	O	255-256
is	O	257-259
severely	O	260-268
impaired	O	269-277
.	O	277-278

We	O	279-281
recently	O	282-290
reported	O	291-299
in	O	300-302
young	O	303-308
healthy	O	309-316
subjects	O	317-325
that	O	326-330
inhibitory	O	331-341
cerebellar	O	342-352
stimulation	O	353-364
enhanced	O	365-373
the	O	374-377
sensorimotor	O	378-390
plasticity	O	391-401
of	O	402-404
M1	O	405-407
that	O	408-412
was	O	413-416
induced	O	417-424
by	O	425-427
paired	O	428-434
associative	O	435-446
stimulation	O	447-458
(	O	459-460
PAS	O	460-463
)	O	463-464
.	O	464-465

This	O	466-470
study	O	471-476
demonstrates	O	477-489
that	O	490-494
the	O	495-498
deficient	O	499-508
sensorimotor	O	509-521
M1	O	522-524
plasticity	O	525-535
in	O	536-538
16	O	539-541
patients	O	542-550
with	O	551-555
LIDs	B	556-560
could	O	561-566
be	O	567-569
reinstated	O	570-580
by	O	581-583
a	O	584-585
single	O	586-592
session	O	593-600
of	O	601-603
real	O	604-608
inhibitory	O	609-619
cerebellar	O	620-630
stimulation	O	631-642
but	O	643-646
not	O	647-650
sham	O	651-655
stimulation	O	656-667
.	O	667-668

This	O	669-673
was	O	674-677
evident	O	678-685
only	O	686-690
when	O	691-695
a	O	696-697
sensory	O	698-705
component	O	706-715
was	O	716-719
involved	O	720-728
in	O	729-731
the	O	732-735
induction	O	736-745
of	O	746-748
plasticity	O	749-759
,	O	759-760
indicating	O	761-771
that	O	772-776
cerebellar	O	777-787
sensory	O	788-795
processing	O	796-806
function	O	807-815
is	O	816-818
involved	O	819-827
in	O	828-830
the	O	831-834
resurgence	O	835-845
of	O	846-848
M1	O	849-851
plasticity	O	852-862
.	O	862-863

The	O	864-867
benefit	O	868-875
of	O	876-878
inhibitory	O	879-889
cerebellar	O	890-900
stimulation	O	901-912
on	O	913-915
LIDs	B	916-920
is	O	921-923
known	O	924-929
.	O	929-930

To	O	931-933
explore	O	934-941
whether	O	942-949
this	O	950-954
benefit	O	955-962
is	O	963-965
linked	O	966-972
to	O	973-975
the	O	976-979
restoration	O	980-991
of	O	992-994
sensorimotor	O	995-1007
plasticity	O	1008-1018
of	O	1019-1021
M1	O	1022-1024
,	O	1024-1025
we	O	1026-1028
conducted	O	1029-1038
an	O	1039-1041
additional	O	1042-1052
study	O	1053-1058
looking	O	1059-1066
at	O	1067-1069
changes	O	1070-1077
in	O	1078-1080
LIDs	B	1081-1085
and	O	1086-1089
PAS	O	1090-1093
-	O	1093-1094
induced	O	1094-1101
plasticity	O	1102-1112
after	O	1113-1118
10	O	1119-1121
sessions	O	1122-1130
of	O	1131-1133
either	O	1134-1140
bilateral	O	1141-1150
,	O	1150-1151
real	O	1152-1156
inhibitory	O	1157-1167
cerebellar	O	1168-1178
stimulation	O	1179-1190
or	O	1191-1193
sham	O	1194-1198
stimulation	O	1199-1210
.	O	1210-1211

Only	O	1212-1216
real	O	1217-1221
and	O	1222-1225
not	O	1226-1229
sham	O	1230-1234
stimulation	O	1235-1246
had	O	1247-1250
an	O	1251-1253
antidyskinetic	O	1254-1268
effect	O	1269-1275
and	O	1276-1279
it	O	1280-1282
was	O	1283-1286
paralleled	O	1287-1297
by	O	1298-1300
a	O	1301-1302
resurgence	O	1303-1313
in	O	1314-1316
the	O	1317-1320
sensorimotor	O	1321-1333
plasticity	O	1334-1344
of	O	1345-1347
M1	O	1348-1350
.	O	1350-1351

These	O	1352-1357
results	O	1358-1365
suggest	O	1366-1373
that	O	1374-1378
alterations	O	1379-1390
in	O	1391-1393
cerebellar	O	1394-1404
sensory	O	1405-1412
processing	O	1413-1423
function	O	1424-1432
,	O	1432-1433
occurring	O	1434-1443
secondary	O	1444-1453
to	O	1454-1456
abnormal	O	1457-1465
basal	O	1466-1471
ganglia	O	1472-1479
signals	O	1480-1487
reaching	O	1488-1496
it	O	1497-1499
,	O	1499-1500
may	O	1501-1504
be	O	1505-1507
an	O	1508-1510
important	O	1511-1520
element	O	1521-1528
contributing	O	1529-1541
to	O	1542-1544
the	O	1545-1548
maladaptive	O	1549-1560
sensorimotor	O	1561-1573
plasticity	O	1574-1584
of	O	1585-1587
M1	O	1588-1590
and	O	1591-1594
the	O	1595-1598
emergence	O	1599-1608
of	O	1609-1611
abnormal	B	1612-1620
involuntary	I	1621-1632
movements	I	1633-1642
.	O	1642-1643

The	O	0-3
function	O	4-12
of	O	13-15
P2X3	O	16-20
receptor	O	21-29
and	O	30-33
NK1	O	34-37
receptor	O	38-46
antagonists	O	47-58
on	O	59-61
cyclophosphamide	O	62-78
-	O	78-79
induced	O	79-86
cystitis	B	87-95
in	O	96-98
rats	O	99-103
.	O	103-104

PURPOSE	O	105-112
:	O	112-113
The	O	114-117
purpose	O	118-125
of	O	126-128
the	O	129-132
study	O	133-138
is	O	139-141
to	O	142-144
explore	O	145-152
the	O	153-156
function	O	157-165
of	O	166-168
P2X3	O	169-173
and	O	174-177
NK1	O	178-181
receptors	O	182-191
antagonists	O	192-203
on	O	204-206
cyclophosphamide	O	207-223
(	O	224-225
CYP	O	225-228
)	O	228-229
-	O	229-230
induced	O	230-237
cystitis	B	238-246
in	O	247-249
rats	O	250-254
.	O	254-255

METHODS	O	256-263
:	O	263-264
Sixty	O	265-270
female	O	271-277
Sprague	O	278-285
-	O	285-286
Dawley	O	286-292
(	O	293-294
SD	O	294-296
)	O	296-297
rats	O	298-302
were	O	303-307
randomly	O	308-316
divided	O	317-324
into	O	325-329
three	O	330-335
groups	O	336-342
.	O	342-343

The	O	344-347
rats	O	348-352
in	O	353-355
the	O	356-359
control	O	360-367
group	O	368-373
were	O	374-378
intraperitoneally	O	379-396
(	O	397-398
i	O	398-399
.	O	399-400
p	O	400-401
.	O	399-400
)	O	402-403
injected	O	404-412
with	O	413-417
0	O	418-419
.	O	419-420
9	O	420-421
%	O	421-422
saline	O	423-429
(	O	430-431
4	O	431-432
ml	O	433-435
/	O	435-436
kg	O	436-438
)	O	438-439
;	O	439-440
the	O	441-444
rats	O	445-449
in	O	450-452
the	O	453-456
model	O	457-462
group	O	463-468
were	O	469-473
i	O	474-475
.	O	475-476
p	O	476-477
.	O	475-476
injected	O	479-487
with	O	488-492
CYP	O	493-496
(	O	497-498
150	O	498-501
mg	O	502-504
/	O	504-505
kg	O	505-507
)	O	507-508
;	O	508-509
and	O	510-513
the	O	514-517
rats	O	518-522
in	O	523-525
the	O	526-529
intervention	O	530-542
group	O	543-548
were	O	549-553
i	O	554-555
.	O	555-556
p	O	556-557
.	O	555-556
injected	O	559-567
with	O	568-572
CYP	O	573-576
with	O	577-581
subsequently	O	582-594
perfusion	O	595-604
of	O	605-607
bladder	O	608-615
with	O	616-620
P2X3	O	621-625
and	O	626-629
NK1	O	630-633
receptors	O	634-643
'	O	643-644
antagonists	O	645-656
,	O	656-657
Suramin	O	658-665
and	O	666-669
GR	O	670-672
82334	O	673-678
.	O	678-679

Spontaneous	O	680-691
pain	B	692-696
behaviors	O	697-706
following	O	707-716
the	O	717-720
administration	O	721-735
of	O	736-738
CYP	O	739-742
were	O	743-747
observed	O	748-756
.	O	756-757

Urodynamic	O	758-768
parameters	O	769-779
,	O	779-780
bladder	O	781-788
pressure	O	789-797
-	O	797-798
volume	O	798-804
curve	O	805-810
,	O	810-811
maximum	O	812-819
voiding	O	820-827
pressure	O	828-836
(	O	837-838
MVP	O	838-841
)	O	841-842
,	O	842-843
and	O	844-847
maximum	O	848-855
cystometric	O	856-867
capacity	O	868-876
(	O	877-878
MCC	O	878-881
)	O	881-882
,	O	882-883
were	O	884-888
recorded	O	889-897
.	O	897-898

Pathological	O	899-911
changes	O	912-919
in	O	920-922
bladder	O	923-930
tissue	O	931-937
were	O	938-942
observed	O	943-951
.	O	951-952

Immunofluorescence	O	953-971
was	O	972-975
used	O	976-980
to	O	981-983
detect	O	984-990
the	O	991-994
expression	O	995-1005
of	O	1006-1008
P2X3	O	1009-1013
and	O	1014-1017
NK1	O	1018-1021
receptors	O	1022-1031
in	O	1032-1034
bladder	O	1035-1042
.	O	1042-1043

RESULTS	O	1044-1051
:	O	1051-1052
Cyclophosphamide	O	1053-1069
treatment	O	1070-1079
increased	O	1080-1089
the	O	1090-1093
spontaneous	O	1094-1105
pain	B	1106-1110
behaviors	O	1111-1120
scores	O	1121-1127
.	O	1127-1128

The	O	1129-1132
incidence	O	1133-1142
of	O	1143-1145
bladder	O	1146-1153
instability	O	1154-1165
during	O	1166-1172
urine	O	1173-1178
storage	O	1179-1186
period	O	1187-1193
of	O	1194-1196
model	O	1197-1202
group	O	1203-1208
was	O	1209-1212
significantly	O	1213-1226
higher	O	1227-1233
than	O	1234-1238
intervention	O	1239-1251
group	O	1252-1257
(	O	1258-1259
X	O	1259-1260
(	O	1258-1259
2	O	1261-1262
)	O	1262-1263
=	O	1264-1265
7	O	1266-1267
.	O	1267-1268
619	O	1268-1271
,	O	1271-1272
P	O	1273-1274
=	O	1275-1276
0	O	1277-1278
.	O	1278-1279
007	O	1279-1282
)	O	1282-1283
and	O	1284-1287
control	O	1288-1295
group	O	1296-1301
(	O	1302-1303
X	O	1303-1304
(	O	1302-1303
2	O	1305-1306
)	O	1306-1307
=	O	1308-1309
13	O	1310-1312
.	O	1312-1313
755	O	1313-1316
,	O	1316-1317

P	O	1318-1319
=	O	1320-1321
0	O	1322-1323
.	O	1323-1324
000	O	1324-1327
)	O	1327-1328
.	O	1323-1324

MCC	O	1330-1333
in	O	1334-1336
the	O	1337-1340
model	O	1341-1346
group	O	1347-1352
was	O	1353-1356
lower	O	1357-1362
than	O	1363-1367
the	O	1368-1371
control	O	1372-1379
and	O	1380-1383
intervention	O	1384-1396
groups	O	1397-1403
(	O	1404-1405
P	O	1405-1406
<	O	1407-1408
0	O	1409-1410
.	O	1410-1411
01	O	1411-1413
)	O	1413-1414
.	O	1410-1411

Histological	O	1416-1428
changes	O	1429-1436
evident	O	1437-1444
in	O	1445-1447
model	O	1448-1453
and	O	1454-1457
intervention	O	1458-1470
groups	O	1471-1477
rats	O	1478-1482
'	O	1482-1483
bladder	O	1484-1491
included	O	1492-1500
edema	B	1501-1506
,	O	1506-1507
vasodilation	O	1508-1520
,	O	1520-1521
and	O	1522-1525
infiltration	O	1526-1538
of	O	1539-1541
inflammatory	O	1542-1554
cells	O	1555-1560
.	O	1560-1561

In	O	1562-1564
model	O	1565-1570
group	O	1571-1576
,	O	1576-1577
the	O	1578-1581
expression	O	1582-1592
of	O	1593-1595
P2X3	O	1596-1600
receptor	O	1601-1609
increased	O	1610-1619
in	O	1620-1622
urothelium	O	1623-1633
and	O	1634-1637
suburothelium	O	1638-1651
,	O	1651-1652
and	O	1653-1656
NK1	O	1657-1660
receptor	O	1661-1669
increased	O	1670-1679
in	O	1680-1682
suburothelium	O	1683-1696
,	O	1696-1697
while	O	1698-1703
the	O	1704-1707
expression	O	1708-1718
of	O	1719-1721
them	O	1722-1726
in	O	1727-1729
intervention	O	1730-1742
group	O	1743-1748
was	O	1749-1752
lower	O	1753-1758
.	O	1758-1759

CONCLUSIONS	O	1760-1771
:	O	1771-1772
In	O	1773-1775
CYP	O	1776-1779
-	O	1779-1780
induced	O	1780-1787
cystitis	B	1788-1796
,	O	1796-1797
the	O	1798-1801
expression	O	1802-1812
of	O	1813-1815
P2X3	O	1816-1820
and	O	1821-1824
NK1	O	1825-1828
receptors	O	1829-1838
increased	O	1839-1848
in	O	1849-1851
urothelium	O	1852-1862
and	O	1863-1866
/	O	1866-1867
or	O	1867-1869
suburothelium	O	1870-1883
.	O	1883-1884

Perfusion	O	1885-1894
of	O	1895-1897
bladder	O	1898-1905
with	O	1906-1910
P2X3	O	1911-1915
and	O	1916-1919
NK1	O	1920-1923
receptors	O	1924-1933
antagonists	O	1934-1945
ameliorated	O	1946-1957
the	O	1958-1961
bladder	O	1962-1969
function	O	1970-1978
.	O	1978-1979

Acute	O	0-5
hepatitis	B	6-15
associated	O	16-26
with	O	27-31
clopidogrel	O	32-43
:	O	43-44
a	O	45-46
case	O	47-51
report	O	52-58
and	O	59-62
review	O	63-69
of	O	70-72
the	O	73-76
literature	O	77-87
.	O	87-88

Drug	O	89-93
-	O	93-94
induced	O	94-101
hepatotoxicity	B	102-116
is	O	117-119
a	O	120-121
common	O	122-128
cause	O	129-134
of	O	135-137
acute	O	138-143
hepatitis	B	144-153
,	O	153-154
and	O	155-158
the	O	159-162
recognition	O	163-174
of	O	175-177
the	O	178-181
responsible	O	182-193
drug	O	194-198
may	O	199-202
be	O	203-205
difficult	O	206-215
.	O	215-216

We	O	217-219
describe	O	220-228
a	O	229-230
case	O	231-235
of	O	236-238
clopidogrel	O	239-250
-	O	250-251
related	O	251-258
acute	O	259-264
hepatitis	B	265-274
.	O	274-275

The	O	276-279
diagnosis	O	280-289
is	O	290-292
strongly	O	293-301
suggested	O	302-311
by	O	312-314
an	O	315-317
accurate	O	318-326
medical	O	327-334
history	O	335-342
and	O	343-346
liver	O	347-352
biopsy	O	353-359
.	O	359-360

Reports	O	361-368
about	O	369-374
cases	O	375-380
of	O	381-383
hepatotoxicity	B	384-398
due	O	399-402
to	O	403-405
clopidogrel	O	406-417
are	O	418-421
increasing	O	422-432
in	O	433-435
the	O	436-439
last	O	440-444
few	O	445-448
years	O	449-454
,	O	454-455
after	O	456-461
the	O	462-465
increased	O	466-475
use	O	476-479
of	O	480-482
this	O	483-487
drug	O	488-492
.	O	492-493

In	O	494-496
conclusion	O	497-507
,	O	507-508
we	O	509-511
believe	O	512-519
that	O	520-524
physicians	O	525-535
should	O	536-542
carefully	O	543-552
consider	O	553-561
the	O	562-565
risk	O	566-570
of	O	571-573
drug	O	574-578
-	O	578-579
induced	O	579-586
hepatic	B	587-594
injury	I	595-601
when	O	602-606
clopidogrel	O	607-618
is	O	619-621
prescribed	O	622-632
.	O	632-633

Bortezomib	O	0-10
and	O	11-14
dexamethasone	O	15-28
as	O	29-31
salvage	O	32-39
therapy	O	40-47
in	O	48-50
patients	O	51-59
with	O	60-64
relapsed	O	65-73
/	O	73-74
refractory	O	74-84
multiple	B	85-93
myeloma	I	94-101
:	O	101-102
analysis	O	103-111
of	O	112-114
long	O	115-119
-	O	119-120
term	O	120-124
clinical	O	125-133
outcomes	O	134-142
.	O	142-143

Bortezomib	O	144-154
(	O	155-156
bort	O	156-160
)	O	160-161
-	O	161-162
dexamethasone	O	162-175
(	O	176-177
dex	O	177-180
)	O	180-181
is	O	182-184
an	O	185-187
effective	O	188-197
therapy	O	198-205
for	O	206-209
relapsed	O	210-218
/	O	218-219
refractory	O	219-229
(	O	230-231
R	O	231-232
/	O	232-233
R	O	231-232
)	O	234-235
multiple	B	236-244
myeloma	I	245-252
(	O	253-254
MM	B	254-256
)	O	256-257
.	O	257-258

This	O	259-263
retrospective	O	264-277
study	O	278-283
investigated	O	284-296
the	O	297-300
combination	O	301-312
of	O	313-315
bort	O	316-320
(	O	321-322
1	O	322-323
.	O	323-324
3	O	324-325
mg	O	326-328
/	O	328-329
m	O	326-327
(	O	330-331
2	O	331-332
)	O	332-333
on	O	334-336
days	O	337-341
1	O	342-343
,	O	343-344
4	O	345-346
,	O	346-347
8	O	348-349
,	O	349-350
and	O	351-354
11	O	355-357
every	O	358-363
3	O	364-365
weeks	O	366-371
)	O	371-372
and	O	373-376
dex	O	377-380
(	O	381-382
20	O	382-384
mg	O	385-387
on	O	388-390
the	O	391-394
day	O	395-398
of	O	399-401
and	O	402-405
the	O	406-409
day	O	410-413
after	O	414-419
bort	O	420-424
)	O	424-425
as	O	426-428
salvage	O	429-436
treatment	O	437-446
in	O	447-449
85	O	450-452
patients	O	453-461
with	O	462-466
R	O	467-468
/	O	468-469
R	O	467-468
MM	B	471-473
after	O	474-479
prior	O	480-485
autologous	O	486-496
stem	O	497-501
cell	O	502-506
transplantation	O	507-522
or	O	523-525
conventional	O	526-538
chemotherapy	O	539-551
.	O	551-552

The	O	553-556
median	O	557-563
number	O	564-570
of	O	571-573
prior	O	574-579
lines	O	580-585
of	O	586-588
therapy	O	589-596
was	O	597-600
2	O	601-602
.	O	602-603
Eighty	O	604-610
-	O	610-611
seven	O	611-616
percent	O	617-624
of	O	625-627
the	O	628-631
patients	O	632-640
had	O	641-644
received	O	645-653
immunomodulatory	O	654-670
drugs	O	671-676
included	O	677-685
in	O	686-688
some	O	689-693
line	O	694-698
of	O	699-701
therapy	O	702-709
before	O	710-716
bort	O	717-721
-	O	721-722
dex	O	722-725
.	O	725-726

The	O	727-730
median	O	731-737
number	O	738-744
of	O	745-747
bort	O	748-752
-	O	752-753
dex	O	753-756
cycles	O	757-763
was	O	764-767
6	O	768-769
,	O	769-770
up	O	771-773
to	O	774-776
a	O	777-778
maximum	O	779-786
of	O	787-789
12	O	790-792
cycles	O	793-799
.	O	799-800

On	O	801-803
an	O	804-806
intention	O	807-816
-	O	816-817
to	O	817-819
-	O	816-817
treat	O	820-825
basis	O	826-831
,	O	831-832
55	O	833-835
%	O	836-837
of	O	838-840
the	O	841-844
patients	O	845-853
achieved	O	854-862
at	O	863-865
least	O	866-871
partial	O	872-879
response	O	880-888
,	O	888-889
including	O	890-899
19	O	900-902
%	O	903-904
CR	O	905-907
and	O	908-911
35	O	912-914
%	O	915-916
achieved	O	917-925
at	O	926-928
least	O	929-934
very	O	935-939
good	O	940-944
partial	O	945-952
response	O	953-961
.	O	961-962

Median	O	963-969
durations	O	970-979
of	O	980-982
response	O	983-991
,	O	991-992
time	O	993-997
to	O	998-1000
next	O	1001-1005
therapy	O	1006-1013
and	O	1014-1017
treatment	O	1018-1027
-	O	1027-1028
free	O	1028-1032
interval	O	1033-1041
were	O	1042-1046
8	O	1047-1048
,	O	1048-1049
11	O	1050-1052
.	O	1052-1053
2	O	1053-1054
,	O	1054-1055
and	O	1056-1059
5	O	1060-1061
.	O	1061-1062
1	O	1062-1063
months	O	1064-1070
,	O	1070-1071
respectively	O	1072-1084
.	O	1084-1085

The	O	1086-1089
most	O	1090-1094
relevant	O	1095-1103
adverse	O	1104-1111
event	O	1112-1117
was	O	1118-1121
peripheral	B	1122-1132
neuropathy	I	1133-1143
,	O	1143-1144
which	O	1145-1150
occurred	O	1151-1159
in	O	1160-1162
78	O	1163-1165
%	O	1166-1167
of	O	1168-1170
the	O	1171-1174
patients	O	1175-1183
(	O	1184-1185
grade	O	1185-1190
II	O	1191-1193
,	O	1193-1194
38	O	1195-1197
%	O	1198-1199
;	O	1199-1200
grade	O	1201-1206
III	O	1207-1210
,	O	1210-1211
21	O	1212-1214
%	O	1215-1216
)	O	1216-1217
and	O	1218-1221
led	O	1222-1225
to	O	1226-1228
treatment	O	1229-1238
discontinuation	O	1239-1254
in	O	1255-1257
6	O	1258-1259
%	O	1260-1261
.	O	1261-1262

With	O	1263-1267
a	O	1268-1269
median	O	1270-1276
follow	O	1277-1283
up	O	1284-1286
of	O	1287-1289
22	O	1290-1292
months	O	1293-1299
,	O	1299-1300
median	O	1301-1307
time	O	1308-1312
to	O	1313-1315
progression	O	1316-1327
,	O	1327-1328
progression	O	1329-1340
-	O	1340-1341
free	O	1341-1345
survival	O	1346-1354
(	O	1355-1356
PFS	O	1356-1359
)	O	1359-1360
and	O	1361-1364
overall	O	1365-1372
survival	O	1373-1381
(	O	1382-1383
OS	O	1383-1385
)	O	1385-1386
were	O	1387-1391
8	O	1392-1393
.	O	1393-1394
9	O	1394-1395
,	O	1395-1396
8	O	1397-1398
.	O	1398-1399
7	O	1399-1400
,	O	1400-1401
and	O	1402-1405
22	O	1406-1408
months	O	1409-1415
,	O	1415-1416
respectively	O	1417-1429
.	O	1429-1430

Prolonged	O	1431-1440
PFS	O	1441-1444
and	O	1445-1448
OS	O	1449-1451
were	O	1452-1456
observed	O	1457-1465
in	O	1466-1468
patients	O	1469-1477
achieving	O	1478-1487
CR	O	1488-1490
and	O	1491-1494
receiving	O	1495-1504
bort	O	1505-1509
-	O	1509-1510
dex	O	1510-1513
a	O	1514-1515
single	O	1516-1522
line	O	1523-1527
of	O	1528-1530
prior	O	1531-1536
therapy	O	1537-1544
.	O	1544-1545

Bort	O	1546-1550
-	O	1550-1551
dex	O	1551-1554
was	O	1555-1558
an	O	1559-1561
effective	O	1562-1571
salvage	O	1572-1579
treatment	O	1580-1589
for	O	1590-1593
MM	B	1594-1596
patients	O	1597-1605
,	O	1605-1606
particularly	O	1607-1619
for	O	1620-1623
those	O	1624-1629
in	O	1630-1632
first	O	1633-1638
relapse	O	1639-1646
.	O	1646-1647

Pubertal	O	0-8
exposure	O	9-17
to	O	18-20
Bisphenol	O	21-30
A	O	31-32
increases	O	33-42
anxiety	B	43-50
-	O	50-51
like	O	51-55
behavior	O	56-64
and	O	65-68
decreases	O	69-78
acetylcholinesterase	O	79-99
activity	O	100-108
of	O	109-111
hippocampus	O	112-123
in	O	124-126
adult	O	127-132
male	O	133-137
mice	O	138-142
.	O	142-143

The	O	144-147
negative	O	148-156
effects	O	157-164
of	O	165-167
Bisphenol	O	168-177
A	O	178-179
(	O	180-181
BPA	O	181-184
)	O	184-185
on	O	186-188
neurodevelopment	O	189-205
and	O	206-209
behaviors	O	210-219
have	O	220-224
been	O	225-229
well	O	230-234
established	O	235-246
.	O	246-247

Acetylcholinesterase	O	248-268
(	O	269-270
AChE	O	270-274
)	O	274-275
is	O	276-278
a	O	279-280
regulatory	O	281-291
enzyme	O	292-298
which	O	299-304
is	O	305-307
involved	O	308-316
in	O	317-319
anxiety	B	320-327
-	O	327-328
like	O	328-332
behavior	O	333-341
.	O	341-342

This	O	343-347
study	O	348-353
investigated	O	354-366
behavioral	O	367-377
phenotypes	O	378-388
and	O	389-392
AChE	O	393-397
activity	O	398-406
in	O	407-409
male	O	410-414
mice	O	415-419
following	O	420-429
BPA	O	430-433
exposure	O	434-442
during	O	443-449
puberty	O	450-457
.	O	457-458

On	O	459-461
postnatal	O	462-471
day	O	472-475
(	O	476-477
PND	O	477-480
)	O	480-481
35	O	482-484
,	O	484-485
male	O	486-490
mice	O	491-495
were	O	496-500
exposed	O	501-508
to	O	509-511
50mg	O	512-516
BPA	O	517-520
/	O	520-521
kg	O	521-523
diet	O	524-528
per	O	529-532
day	O	533-536
for	O	537-540
a	O	541-542
period	O	543-549
of	O	550-552
35	O	553-555
days	O	556-560
.	O	560-561

On	O	562-564
PND71	O	565-570
,	O	570-571
a	O	572-573
behavioral	O	574-584
assay	O	585-590
was	O	591-594
performed	O	595-604
using	O	605-610
the	O	611-614
elevated	O	615-623
plus	O	624-628
maze	O	629-633
(	O	634-635
EPM	O	635-638
)	O	638-639
and	O	640-643
the	O	644-647
light	O	648-653
/	O	653-654
dark	O	654-658
test	O	659-663
.	O	663-664

In	O	665-667
addition	O	668-676
,	O	676-677
AChE	O	678-682
activity	O	683-691
was	O	692-695
measured	O	696-704
in	O	705-707
the	O	708-711
prefrontal	O	712-722
cortex	O	723-729
,	O	729-730
hypothalamus	O	731-743
,	O	743-744
cerebellum	O	745-755
and	O	756-759
hippocampus	O	760-771
.	O	771-772

Results	O	773-780
from	O	781-785
our	O	786-789
behavioral	O	790-800
phenotyping	O	801-812
indicated	O	813-822
that	O	823-827
anxiety	B	828-835
-	O	835-836
like	O	836-840
behavior	O	841-849
was	O	850-853
increased	O	854-863
in	O	864-866
mice	O	867-871
exposed	O	872-879
to	O	880-882
BPA	O	883-886
.	O	886-887

AChE	O	888-892
activity	O	893-901
was	O	902-905
significantly	O	906-919
decreased	O	920-929
in	O	930-932
the	O	933-936
hippocampus	O	937-948
of	O	949-951
mice	O	952-956
with	O	957-961
BPA	O	962-965
compared	O	966-974
to	O	975-977
control	O	978-985
mice	O	986-990
,	O	990-991
whereas	O	992-999
no	O	1000-1002
difference	O	1003-1013
was	O	1014-1017
found	O	1018-1023
in	O	1024-1026
the	O	1027-1030
prefrontal	O	1031-1041
cortex	O	1042-1048
,	O	1048-1049
hypothalamus	O	1050-1062
and	O	1063-1066
cerebellum	O	1067-1077
.	O	1077-1078

Our	O	1079-1082
findings	O	1083-1091
showed	O	1092-1098
that	O	1099-1103
pubertal	O	1104-1112
BPA	O	1113-1116
exposure	O	1117-1125
increased	O	1126-1135
anxiety	B	1136-1143
-	O	1143-1144
like	O	1144-1148
behavior	O	1149-1157
,	O	1157-1158
which	O	1159-1164
may	O	1165-1168
be	O	1169-1171
associated	O	1172-1182
with	O	1183-1187
decreased	O	1188-1197
AChE	O	1198-1202
activity	O	1203-1211
of	O	1212-1214
the	O	1215-1218
hippocampus	O	1219-1230
in	O	1231-1233
adult	O	1234-1239
male	O	1240-1244
mice	O	1245-1249
.	O	1249-1250

Further	O	1251-1258
studies	O	1259-1266
are	O	1267-1270
necessary	O	1271-1280
to	O	1281-1283
investigate	O	1284-1295
the	O	1296-1299
cholinergic	O	1300-1311
signaling	O	1312-1321
of	O	1322-1324
the	O	1325-1328
hippocampus	O	1329-1340
in	O	1341-1343
PBE	O	1344-1347
induced	O	1348-1355
anxiety	B	1356-1363
-	O	1363-1364
like	O	1364-1368
behaviors	O	1369-1378
.	O	1378-1379

Biochemical	O	0-11
effects	O	12-19
of	O	20-22
Solidago	O	23-31
virgaurea	O	32-41
extract	O	42-49
on	O	50-52
experimental	O	53-65
cardiotoxicity	B	66-80
.	O	80-81

Cardiovascular	B	82-96
diseases	I	97-105
(	O	106-107
CVDs	B	107-111
)	O	111-112
are	O	113-116
the	O	117-120
major	O	121-126
health	O	127-133
problem	O	134-141
of	O	142-144
advanced	O	145-153
as	O	154-156
well	O	157-161
as	O	162-164
developing	O	165-175
countries	O	176-185
of	O	186-188
the	O	189-192
world	O	193-198
.	O	198-199

The	O	200-203
aim	O	204-207
of	O	208-210
the	O	211-214
present	O	215-222
study	O	223-228
was	O	229-232
to	O	233-235
investigate	O	236-247
the	O	248-251
protective	O	252-262
effect	O	263-269
of	O	270-272
the	O	273-276
Solidago	O	277-285
virgaurea	O	286-295
extract	O	296-303
on	O	304-306
isoproterenol	O	307-320
-	O	320-321
induced	O	321-328
cardiotoxicity	B	329-343
in	O	344-346
rats	O	347-351
.	O	351-352

The	O	353-356
subcutaneous	O	357-369
injection	O	370-379
of	O	380-382
isoproterenol	O	383-396
(	O	397-398
30	O	398-400
mg	O	401-403
/	O	403-404
kg	O	404-406
)	O	406-407
into	O	408-412
rats	O	413-417
twice	O	418-423
at	O	424-426
an	O	427-429
interval	O	430-438
of	O	439-441
24	O	442-444
h	O	445-446
,	O	446-447
for	O	448-451
two	O	452-455
consecutive	O	456-467
days	O	468-472
,	O	472-473
led	O	474-477
to	O	478-480
a	O	481-482
significant	O	483-494
increase	O	495-503
in	O	504-506
serum	O	507-512
lactate	O	513-520
dehydrogenase	O	521-534
,	O	534-535
creatine	O	536-544
phosphokinase	O	545-558
,	O	558-559
alanine	O	560-567
transaminase	O	568-580
,	O	580-581
aspartate	O	582-591
transaminase	O	592-604
,	O	604-605
and	O	606-609
angiotensin	O	610-621
-	O	621-622
converting	O	622-632
enzyme	O	633-639
activities	O	640-650
,	O	650-651
total	O	652-657
cholesterol	O	658-669
,	O	669-670
triglycerides	O	671-684
,	O	684-685
free	O	686-690
serum	O	691-696
fatty	O	697-702
acid	O	703-707
,	O	707-708
cardiac	O	709-716
tissue	O	717-723
malondialdehyde	O	724-739
(	O	740-741
MDA	O	741-744
)	O	744-745
,	O	745-746
and	O	747-750
nitric	O	751-757
oxide	O	758-763
levels	O	764-770
and	O	771-774
a	O	775-776
significant	O	777-788
decrease	O	789-797
in	O	798-800
levels	O	801-807
of	O	808-810
glutathione	O	811-822
and	O	823-826
superoxide	O	827-837
dismutase	O	838-847
in	O	848-850
cardiac	O	851-858
tissue	O	859-865
as	O	866-868
compared	O	869-877
to	O	878-880
the	O	881-884
normal	O	885-891
control	O	892-899
group	O	900-905
(	O	906-907
P	O	907-908
<	O	909-910
0	O	911-912
.	O	912-913
05	O	913-915
)	O	915-916
.	O	912-913

Pretreatment	O	918-930
with	O	931-935
S	O	936-937
.	O	937-938
virgaurea	O	939-948
extract	O	949-956
for	O	957-960
5	O	961-962
weeks	O	963-968
at	O	969-971
a	O	972-973
dose	O	974-978
of	O	979-981
250	O	982-985
mg	O	986-988
/	O	988-989
kg	O	989-991
followed	O	992-1000
by	O	1001-1003
isoproterenol	O	1004-1017
injection	O	1018-1027
significantly	O	1028-1041
prevented	O	1042-1051
the	O	1052-1055
observed	O	1056-1064
alterations	O	1065-1076
.	O	1076-1077

Captopril	O	1078-1087
(	O	1088-1089
50	O	1089-1091
mg	O	1092-1094
/	O	1094-1095
kg	O	1095-1097
/	O	1094-1095
day	O	1098-1101
,	O	1101-1102
given	O	1103-1108
orally	O	1109-1115
)	O	1115-1116
,	O	1116-1117
an	O	1118-1120
inhibitor	O	1121-1130
of	O	1131-1133
angiotensin	O	1134-1145
-	O	1145-1146
converting	O	1146-1156
enzyme	O	1157-1163
used	O	1164-1168
as	O	1169-1171
a	O	1172-1173
standard	O	1174-1182
cardioprotective	O	1183-1199
drug	O	1200-1204
,	O	1204-1205
was	O	1206-1209
used	O	1210-1214
as	O	1215-1217
a	O	1218-1219
positive	O	1220-1228
control	O	1229-1236
in	O	1237-1239
this	O	1240-1244
study	O	1245-1250
.	O	1250-1251

The	O	1252-1255
data	O	1256-1260
of	O	1261-1263
the	O	1264-1267
present	O	1268-1275
study	O	1276-1281
suggest	O	1282-1289
that	O	1290-1294
S	O	1295-1296
.	O	1296-1297
virgaurea	O	1298-1307
extract	O	1308-1315
exerts	O	1316-1322
its	O	1323-1326
protective	O	1327-1337
effect	O	1338-1344
by	O	1345-1347
decreasing	O	1348-1358
MDA	O	1359-1362
level	O	1363-1368
and	O	1369-1372
increasing	O	1373-1383
the	O	1384-1387
antioxidant	O	1388-1399
status	O	1400-1406
in	O	1407-1409
isoproterenol	O	1410-1423
-	O	1423-1424
treated	O	1424-1431
rats	O	1432-1436
.	O	1436-1437

The	O	1438-1441
study	O	1442-1447
emphasizes	O	1448-1458
the	O	1459-1462
beneficial	O	1463-1473
action	O	1474-1480
of	O	1481-1483
S	O	1484-1485
.	O	1485-1486
virgaurea	O	1487-1496
extract	O	1497-1504
as	O	1505-1507
a	O	1508-1509
cardioprotective	O	1510-1526
agent	O	1527-1532
.	O	1532-1533

"	O	0-1
Real	O	1-5
-	O	5-6
world	O	6-11
"	O	0-1
data	O	13-17
on	O	18-20
the	O	21-24
efficacy	O	25-33
and	O	34-37
safety	O	38-44
of	O	45-47
lenalidomide	O	48-60
and	O	61-64
dexamethasone	O	65-78
in	O	79-81
patients	O	82-90
with	O	91-95
relapsed	O	96-104
/	O	104-105
refractory	O	105-115
multiple	B	116-124
myeloma	I	125-132
who	O	133-136
were	O	137-141
treated	O	142-149
according	O	150-159
to	O	160-162
the	O	163-166
standard	O	167-175
clinical	O	176-184
practice	O	185-193
:	O	193-194
a	O	195-196
study	O	197-202
of	O	203-205
the	O	206-209
Greek	O	210-215
Myeloma	B	216-223
Study	O	224-229
Group	O	230-235
.	O	235-236

Lenalidomide	O	237-249
and	O	250-253
dexamethasone	O	254-267
(	O	268-269
RD	O	269-271
)	O	271-272
is	O	273-275
a	O	276-277
standard	O	278-286
of	O	287-289
care	O	290-294
for	O	295-298
relapsed	O	299-307
/	O	307-308
refractory	O	308-318
multiple	B	319-327
myeloma	I	328-335
(	O	336-337
RRMM	B	337-341
)	O	341-342
,	O	342-343
but	O	344-347
there	O	348-353
is	O	354-356
limited	O	357-364
published	O	365-374
data	O	375-379
on	O	380-382
its	O	383-386
efficacy	O	387-395
and	O	396-399
safety	O	400-406
in	O	407-409
the	O	410-413
"	O	414-415
real	O	415-419
world	O	420-425
"	O	425-426
(	O	427-428
RW	O	428-430
)	O	430-431
,	O	431-432
according	O	433-442
to	O	443-445
the	O	446-449
International	O	450-463
Society	O	464-471
of	O	472-474
Pharmacoeconomics	O	475-492
and	O	493-496
Outcomes	O	497-505
Research	O	506-514
definition	O	515-525
.	O	525-526

We	O	527-529
studied	O	530-537
212	O	538-541
RRMM	B	542-546
patients	O	547-555
who	O	556-559
received	O	560-568
RD	O	569-571
in	O	572-574
RW	O	575-577
.	O	577-578

Objective	O	579-588
response	O	589-597
(	O	598-599
>	O	599-600
PR	O	600-602
(	O	603-604
partial	O	604-611
response	O	612-620
)	O	620-621
)	O	620-621
rate	O	623-627
was	O	628-631
77	O	632-634
.	O	634-635
4	O	635-636
%	O	637-638
(	O	639-640
complete	O	640-648
response	O	649-657
(	O	658-659
CR	O	659-661
)	O	661-662
,	O	662-663
20	O	664-666
.	O	666-667
2	O	664-665
%	O	669-670
)	O	670-671
.	O	671-672

Median	O	673-679
time	O	680-684
to	O	685-687
first	O	688-693
and	O	694-697
best	O	698-702
response	O	703-711
was	O	712-715
2	O	716-717
and	O	718-721
5	O	722-723
months	O	724-730
,	O	730-731
respectively	O	732-744
.	O	744-745

Median	O	746-752
time	O	753-757
to	O	758-760
CR	O	761-763
when	O	764-768
RD	O	769-771
was	O	772-775
given	O	776-781
as	O	782-784
2nd	O	785-788
or	O	789-791
>	O	792-793
2	O	793-794
(	O	794-795
nd	O	795-797
)	O	797-798
-	O	798-799
line	O	799-803
treatment	O	804-813
at	O	814-816
4	O	817-818
and	O	819-822
11	O	823-825
months	O	826-832
,	O	832-833
respectively	O	834-846
.	O	846-847

Quality	O	848-855
of	O	856-858
response	O	859-867
was	O	868-871
independent	O	872-883
of	O	884-886
previous	O	887-895
lines	O	896-901
of	O	902-904
therapies	O	905-914
or	O	915-917
previous	O	918-926
exposure	O	927-935
to	O	936-938
thalidomide	O	939-950
or	O	951-953
bortezomib	O	954-964
.	O	964-965

Median	O	966-972
duration	O	973-981
of	O	982-984
response	O	985-993
was	O	994-997
34	O	998-1000
.	O	1000-1001
4	O	999-1000
months	O	1003-1009
,	O	1009-1010
and	O	1011-1014
it	O	1015-1017
was	O	1018-1021
higher	O	1022-1028
in	O	1029-1031
patients	O	1032-1040
who	O	1041-1044
received	O	1045-1053
RD	O	1054-1056
until	O	1057-1062
progression	O	1063-1074
(	O	1075-1076
not	O	1076-1079
reached	O	1080-1087
versus	O	1088-1094
19	O	1095-1097
months	O	1098-1104
,	O	1104-1105
p	O	1106-1107
<	O	1108-1109
0	O	1110-1111
.	O	1111-1112
001	O	1112-1115
)	O	1115-1116
.	O	1111-1112

Improvement	O	1118-1129
of	O	1130-1132
humoral	O	1133-1140
immunity	O	1141-1149
occurred	O	1150-1158
in	O	1159-1161
60	O	1162-1164
%	O	1165-1166
of	O	1167-1169
responders	O	1170-1180
(	O	1181-1182
p	O	1182-1183
<	O	1184-1185
0	O	1186-1187
.	O	1187-1188
001	O	1188-1191
)	O	1191-1192
and	O	1193-1196
in	O	1197-1199
the	O	1200-1203
majority	O	1204-1212
of	O	1213-1215
patients	O	1216-1224
who	O	1225-1228
achieved	O	1229-1237
stable	O	1238-1244
disease	O	1245-1252
.	O	1252-1253

Adverse	O	1254-1261
events	O	1262-1268
were	O	1269-1273
reported	O	1274-1282
in	O	1283-1285
68	O	1286-1288
.	O	1288-1289
9	O	1289-1290
%	O	1291-1292
of	O	1293-1295
patients	O	1296-1304
(	O	1305-1306
myelosuppression	B	1306-1322
in	O	1323-1325
49	O	1326-1328
.	O	1328-1329
4	O	1326-1327
%	O	1331-1332
)	O	1332-1333
and	O	1334-1337
12	O	1338-1340
.	O	1340-1341
7	O	1341-1342
%	O	1343-1344
of	O	1345-1347
patients	O	1348-1356
needed	O	1357-1363
hospitalization	O	1364-1379
.	O	1379-1380

Peripheral	B	1381-1391
neuropathy	I	1392-1402
was	O	1403-1406
observed	O	1407-1415
only	O	1416-1420
in	O	1421-1423
2	O	1424-1425
.	O	1425-1426
5	O	1426-1427
%	O	1428-1429
of	O	1430-1432
patients	O	1433-1441
and	O	1442-1445
deep	B	1446-1450
vein	I	1451-1455
thrombosis	I	1456-1466
in	O	1467-1469
5	O	1470-1471
.	O	1471-1472
7	O	1472-1473
%	O	1474-1475
.	O	1475-1476

Dose	O	1477-1481
reductions	O	1482-1492
were	O	1493-1497
needed	O	1498-1504
in	O	1505-1507
31	O	1508-1510
%	O	1511-1512
of	O	1513-1515
patients	O	1516-1524
and	O	1525-1528
permanent	O	1529-1538
discontinuation	O	1539-1554
in	O	1555-1557
38	O	1558-1560
.	O	1560-1561
9	O	1561-1562
%	O	1563-1564
.	O	1564-1565

Median	O	1566-1572
time	O	1573-1577
to	O	1578-1580
treatment	O	1581-1590
discontinuation	O	1591-1606
was	O	1607-1610
16	O	1611-1613
.	O	1613-1614
8	O	1614-1615
months	O	1616-1622
.	O	1622-1623

Performance	O	1624-1635
status	O	1636-1642
(	O	1643-1644
PS	O	1644-1646
)	O	1646-1647
and	O	1648-1651
initial	O	1652-1659
lenalidomide	O	1660-1672
dose	O	1673-1677
predicted	O	1678-1687
for	O	1688-1691
treatment	O	1692-1701
discontinuation	O	1702-1717
.	O	1717-1718

Extra	O	1719-1724
-	O	1724-1725
medullary	O	1725-1734
relapses	O	1735-1743
occurred	O	1744-1752
in	O	1753-1755
3	O	1756-1757
.	O	1757-1758
8	O	1758-1759
%	O	1760-1761
of	O	1762-1764
patients	O	1765-1773
.	O	1773-1774

Our	O	1775-1778
study	O	1779-1784
confirms	O	1785-1793
that	O	1794-1798
RD	O	1799-1801
is	O	1802-1804
effective	O	1805-1814
and	O	1815-1818
safe	O	1819-1823
in	O	1824-1826
RRMM	B	1827-1831
in	O	1832-1834
the	O	1835-1838
RW	O	1839-1841
;	O	1841-1842
it	O	1843-1845
produces	O	1846-1854
durable	O	1855-1862
responses	O	1863-1872
especially	O	1873-1883
in	O	1884-1886
patients	O	1887-1895
who	O	1896-1899
continue	O	1900-1908
on	O	1909-1911
treatment	O	1912-1921
till	O	1922-1926
progression	O	1927-1938
and	O	1939-1942
improves	O	1943-1951
humoral	O	1952-1959
immunity	O	1960-1968
even	O	1969-1973
in	O	1974-1976
patients	O	1977-1985
with	O	1986-1990
stable	O	1991-1997
disease	O	1998-2005
.	O	2005-2006

The	O	0-3
cytogenetic	O	4-15
action	O	16-22
of	O	23-25
ifosfamide	O	26-36
,	O	36-37
mesna	O	38-43
,	O	43-44
and	O	45-48
their	O	49-54
combination	O	55-66
on	O	67-69
peripheral	O	70-80
rabbit	O	81-87
lymphocytes	O	88-99
:	O	99-100
an	O	101-103
in	O	104-106
vivo	O	107-111
/	O	111-112
in	O	112-114
vitro	O	115-120
cytogenetic	O	121-132
study	O	133-138
.	O	138-139

Ifosfamide	O	140-150
(	O	151-152
IFO	O	152-155
)	O	155-156
is	O	157-159
an	O	160-162
alkylating	O	163-173
nitrogen	O	174-182
mustard	O	183-190
,	O	190-191
administrated	O	192-205
as	O	206-208
an	O	209-211
antineoplasmic	O	212-226
agent	O	227-232
.	O	232-233

It	O	234-236
is	O	237-239
characterized	O	240-253
by	O	254-256
its	O	257-260
intense	O	261-268
urotoxic	O	269-277
action	O	278-284
,	O	284-285
leading	O	286-293
to	O	294-296
hemorrhagic	B	297-308
cystitis	I	309-317
.	O	317-318

This	O	319-323
side	O	324-328
effect	O	329-335
of	O	336-338
IFO	O	339-342
raises	O	343-349
the	O	350-353
requirement	O	354-365
for	O	366-369
the	O	370-373
co	O	374-376
-	O	376-377
administration	O	377-391
with	O	392-396
sodium	O	397-403
2	O	404-405
-	O	405-406
sulfanylethanesulfonate	O	406-429
(	O	430-431
Mesna	O	431-436
)	O	436-437
aiming	O	438-444
to	O	445-447
avoid	O	448-453
or	O	454-456
minimize	O	457-465
this	O	466-470
effect	O	471-477
.	O	477-478

IFO	O	479-482
and	O	483-486
Mesna	O	487-492
were	O	493-497
administrated	O	498-511
separately	O	512-522
on	O	523-525
rabbit	O	526-532
'	O	532-533
s	O	533-534
lymphocytes	O	535-546
in	O	547-549
vivo	O	550-554
,	O	554-555
which	O	556-561
were	O	562-566
later	O	567-572
developed	O	573-582
in	O	583-585
vitro	O	586-591
.	O	591-592

Cytogenetic	O	593-604
markers	O	605-612
for	O	613-616
sister	O	617-623
chromatid	O	624-633
exchanges	O	634-643
(	O	644-645
SCEs	O	645-649
)	O	649-650
,	O	650-651
proliferation	O	652-665
rate	O	666-670
index	O	671-676
(	O	677-678
PRI	O	678-681
)	O	681-682
and	O	683-686
Mitotic	O	687-694
Index	O	695-700
were	O	701-705
recorded	O	706-714
.	O	714-715

Mesna	O	716-721
'	O	721-722
s	O	718-719
action	O	724-730
,	O	730-731
in	O	732-734
conjunction	O	735-746
with	O	747-751
IFO	O	752-755
reduces	O	756-763
the	O	764-767
frequency	O	768-777
of	O	778-780
SCEs	O	781-785
,	O	785-786
in	O	787-789
comparison	O	790-800
with	O	801-805
the	O	806-809
SCEs	O	810-814
recordings	O	815-825
obtained	O	826-834
when	O	835-839
IFO	O	840-843
is	O	844-846
administered	O	847-859
alone	O	860-865
.	O	865-866

In	O	867-869
addition	O	870-878
to	O	879-881
this	O	882-886
,	O	886-887
when	O	888-892
high	O	893-897
concentrations	O	898-912
of	O	913-915
Mesna	O	916-921
were	O	922-926
administered	O	927-939
alone	O	940-945
significant	O	946-957
reductions	O	958-968
of	O	969-971
the	O	972-975
PRI	O	976-979
were	O	980-984
noted	O	985-990
,	O	990-991
than	O	992-996
with	O	997-1001
IFO	O	1002-1005
acting	O	1006-1012
at	O	1013-1015
the	O	1016-1019
same	O	1020-1024
concentration	O	1025-1038
on	O	1039-1041
the	O	1042-1045
lymphocytes	O	1046-1057
.	O	1057-1058

Mesna	O	1059-1064
significantly	O	1065-1078
reduces	O	1079-1086
IFO	O	1087-1090
'	O	1090-1091
s	O	1091-1092
genotoxicity	B	1093-1105
,	O	1105-1106
while	O	1107-1112
when	O	1113-1117
administered	O	1118-1130
in	O	1131-1133
high	O	1134-1138
concentrations	O	1139-1153
it	O	1154-1156
acts	O	1157-1161
in	O	1162-1164
an	O	1165-1167
inhibitory	O	1168-1178
fashion	O	1179-1186
on	O	1187-1189
the	O	1190-1193
cytostatic	O	1194-1204
action	O	1205-1211
of	O	1212-1214
the	O	1215-1218
drug	O	1219-1223
.	O	1223-1224

Risk	O	0-4
factors	O	5-12
and	O	13-16
predictors	O	17-27
of	O	28-30
levodopa	O	31-39
-	O	39-40
induced	O	40-47
dyskinesia	B	48-58
among	O	59-64
multiethnic	O	65-76
Malaysians	O	77-87
with	O	88-92
Parkinson	B	93-102
'	I	102-103
s	I	99-100
disease	I	105-112
.	O	112-113

Chronic	O	114-121
pulsatile	O	122-131
levodopa	O	132-140
therapy	O	141-148
for	O	149-152
Parkinson	B	153-162
'	I	162-163
s	I	159-160
disease	I	165-172
(	O	173-174
PD	B	174-176
)	O	176-177
leads	O	178-183
to	O	184-186
the	O	187-190
development	O	191-202
of	O	203-205
motor	O	206-211
fluctuations	O	212-224
and	O	225-228
dyskinesia	B	229-239
.	O	239-240

We	O	241-243
studied	O	244-251
the	O	252-255
prevalence	O	256-266
and	O	267-270
predictors	O	271-281
of	O	282-284
levodopa	O	285-293
-	O	293-294
induced	O	294-301
dyskinesia	B	302-312
among	O	313-318
multiethnic	O	319-330
Malaysian	O	331-340
patients	O	341-349
with	O	350-354
PD	B	355-357
.	O	357-358

METHODS	O	359-366
:	O	366-367
This	O	368-372
is	O	373-375
a	O	376-377
cross	O	378-383
-	O	383-384
sectional	O	384-393
study	O	394-399
involving	O	400-409
95	O	410-412
patients	O	413-421
with	O	422-426
PD	B	427-429
on	O	430-432
uninterrupted	O	433-446
levodopa	O	447-455
therapy	O	456-463
for	O	464-467
at	O	468-470
least	O	471-476
6	O	477-478
months	O	479-485
.	O	485-486

The	O	487-490
instrument	O	491-501
used	O	502-506
was	O	507-510
the	O	511-514
UPDRS	O	515-520
questionnaires	O	521-535
.	O	535-536

The	O	537-540
predictors	O	541-551
of	O	552-554
dyskinesia	B	555-565
were	O	566-570
determined	O	571-581
using	O	582-587
multivariate	O	588-600
logistic	O	601-609
regression	O	610-620
analysis	O	621-629
.	O	629-630

RESULTS	O	631-638
:	O	638-639
The	O	640-643
mean	O	644-648
age	O	649-652
was	O	653-656
65	O	657-659
.	O	659-660
6	O	657-658
+	O	662-663
8	O	664-665
.	O	665-666
5	O	666-667
years	O	668-673
.	O	673-674

The	O	675-678
mean	O	679-683
onset	O	684-689
age	O	690-693
was	O	694-697
58	O	698-700
.	O	700-701
5	O	698-699
+	O	703-704
9	O	705-706
.	O	706-707
8	O	707-708
years	O	709-714
.	O	714-715

The	O	716-719
median	O	720-726
disease	O	727-734
duration	O	735-743
was	O	744-747
6	O	748-749
(	O	750-751
7	O	751-752
)	O	752-753
years	O	754-759
.	O	759-760

Dyskinesia	B	761-771
was	O	772-775
present	O	776-783
in	O	784-786
44	O	787-789
%	O	789-790
(	O	791-792
n	O	792-793
=	O	794-795
42	O	796-798
)	O	798-799
with	O	800-804
median	O	805-811
levodopa	O	812-820
therapy	O	821-828
of	O	829-831
3	O	832-833
years	O	834-839
.	O	839-840

There	O	841-846
were	O	847-851
64	O	852-854
.	O	854-855
3	O	855-856
%	O	856-857
Chinese	O	858-865
,	O	865-866
31	O	867-869
%	O	869-870
Malays	O	871-877
,	O	877-878
and	O	879-882
3	O	883-884
.	O	884-885
7	O	885-886
%	O	886-887
Indians	O	888-895
and	O	896-899
other	O	900-905
ethnic	O	906-912
groups	O	913-919
.	O	919-920

Eighty	O	921-927
-	O	927-928
one	O	928-931
percent	O	932-939
of	O	940-942
patients	O	943-951
with	O	952-956
dyskinesia	B	957-967
had	O	968-971
clinical	O	972-980
fluctuations	O	981-993
.	O	993-994

Patients	O	995-1003
with	O	1004-1008
dyskinesia	B	1009-1019
had	O	1020-1023
lower	O	1024-1029
onset	O	1030-1035
age	O	1036-1039
(	O	1040-1041
p	O	1042-1043
<	O	1044-1045
0	O	1046-1047
.	O	1047-1048
001	O	1048-1051
)	O	1051-1052
,	O	1052-1053
longer	O	1054-1060
duration	O	1061-1069
of	O	1070-1072
levodopa	O	1073-1081
therapy	O	1082-1089
(	O	1090-1091
p	O	1092-1093
<	O	1094-1095
0	O	1096-1097
.	O	1097-1098
001	O	1098-1101
)	O	1101-1102
,	O	1102-1103
longer	O	1104-1110
disease	O	1111-1118
duration	O	1119-1127
(	O	1128-1129
p	O	1130-1131
<	O	1132-1133
0	O	1134-1135
.	O	1135-1136
001	O	1136-1139
)	O	1139-1140
,	O	1140-1141
higher	O	1142-1148
total	O	1149-1154
daily	O	1155-1160
levodopa	O	1161-1169
dose	O	1170-1174
(	O	1175-1176
p	O	1177-1178
<	O	1179-1180
0	O	1181-1182
.	O	1182-1183
001	O	1183-1186
)	O	1186-1187
,	O	1187-1188
and	O	1189-1192
higher	O	1193-1199
total	O	1200-1205
UPDRS	O	1206-1211
scores	O	1212-1218
(	O	1219-1220
p	O	1221-1222
=	O	1223-1224
0	O	1225-1226
.	O	1226-1227
005	O	1227-1230
)	O	1230-1231
than	O	1232-1236
patients	O	1237-1245
without	O	1246-1253
dyskinesia	B	1254-1264
.	O	1264-1265

The	O	1266-1269
three	O	1270-1275
significant	O	1276-1287
predictors	O	1288-1298
of	O	1299-1301
dyskinesia	B	1302-1312
were	O	1313-1317
duration	O	1318-1326
of	O	1327-1329
levodopa	O	1330-1338
therapy	O	1339-1346
,	O	1346-1347
onset	O	1348-1353
age	O	1354-1357
,	O	1357-1358
and	O	1359-1362
total	O	1363-1368
daily	O	1369-1374
levodopa	O	1375-1383
dose	O	1384-1388
.	O	1388-1389

CONCLUSIONS	O	1390-1401
:	O	1401-1402
The	O	1403-1406
prevalence	O	1407-1417
of	O	1418-1420
levodopa	O	1421-1429
-	O	1429-1430
induced	O	1430-1437
dyskinesia	B	1438-1448
in	O	1449-1451
our	O	1452-1455
patients	O	1456-1464
was	O	1465-1468
44	O	1469-1471
%	O	1471-1472
.	O	1472-1473

The	O	1474-1477
most	O	1478-1482
significant	O	1483-1494
predictors	O	1495-1505
were	O	1506-1510
duration	O	1511-1519
of	O	1520-1522
levodopa	O	1523-1531
therapy	O	1532-1539
,	O	1539-1540
total	O	1541-1546
daily	O	1547-1552
levodopa	O	1553-1561
dose	O	1562-1566
,	O	1566-1567
and	O	1568-1571
onset	O	1572-1577
age	O	1578-1581
.	O	1581-1582

An	O	0-2
unexpected	O	3-13
diagnosis	O	14-23
in	O	24-26
a	O	27-28
renal	O	29-34
-	O	34-35
transplant	O	35-45
patient	O	46-53
with	O	54-58
proteinuria	B	59-70
treated	O	71-78
with	O	79-83
everolimus	O	84-94
:	O	94-95
AL	B	96-98
amyloidosis	B	99-110
.	O	110-111

Proteinuria	B	112-123
is	O	124-126
an	O	127-129
expected	O	130-138
complication	O	139-151
in	O	152-154
transplant	O	155-165
patients	O	166-174
treated	O	175-182
with	O	183-187
mammalian	O	188-197
target	O	198-204
of	O	205-207
rapamycin	O	208-217
inhibitors	O	218-228
(	O	229-230
mTOR	O	230-234
-	O	234-235
i	O	235-236
)	O	236-237
.	O	237-238

However	O	239-246
,	O	246-247
clinical	O	248-256
suspicion	O	257-266
should	O	267-273
always	O	274-280
be	O	281-283
supported	O	284-293
by	O	294-296
histological	O	297-309
evidence	O	310-318
in	O	319-321
order	O	322-327
to	O	328-330
investigate	O	331-342
potential	O	343-352
alternate	O	353-362
diagnoses	O	363-372
such	O	373-377
as	O	378-380
acute	O	381-386
or	O	387-389
chronic	O	390-397
rejection	O	398-407
,	O	407-408
interstitial	O	409-421
fibrosis	B	422-430
and	O	431-434
tubular	O	435-442
atrophy	B	443-450
,	O	450-451
or	O	452-454
recurrent	O	455-464
or	O	465-467
de	O	468-470
novo	O	471-475
glomerulopathy	B	476-490
.	O	490-491

In	O	492-494
this	O	495-499
case	O	500-504
we	O	505-507
report	O	508-514
the	O	515-518
unexpected	O	519-529
diagnosis	O	530-539
of	O	540-542
amyloidosis	B	543-554
in	O	555-557
a	O	558-559
renal	O	560-565
-	O	565-566
transplant	O	566-576
patient	O	577-584
with	O	585-589
pre	O	590-593
-	O	593-594
transplant	O	594-604
monoclonal	O	605-615
gammapathy	O	616-626
of	O	627-629
undetermined	O	630-642
significance	O	643-655
who	O	656-659
developed	O	660-669
proteinuria	B	670-681
after	O	682-687
conversion	O	688-698
from	O	699-703
tacrolimus	O	704-714
to	O	715-717
everolimus	O	718-728
.	O	728-729

An	O	0-2
investigation	O	3-16
of	O	17-19
the	O	20-23
pattern	O	24-31
of	O	32-34
kidney	B	35-41
injury	I	42-48
in	O	49-51
HIV	O	52-55
-	O	55-56
positive	O	56-64
persons	O	65-72
exposed	O	73-80
to	O	81-83
tenofovir	O	84-93
disoproxil	O	94-104
fumarate	O	105-113
:	O	113-114
an	O	115-117
examination	O	118-129
of	O	130-132
a	O	133-134
large	O	135-140
population	O	141-151
database	O	152-160
(	O	161-162
MHRA	O	162-166
database	O	167-175
)	O	175-176
.	O	176-177

The	O	178-181
potential	O	182-191
for	O	192-195
tenofovir	O	196-205
to	O	206-208
cause	O	209-214
a	O	215-216
range	O	217-222
of	O	223-225
kidney	O	226-232
syndromes	O	233-242
has	O	243-246
been	O	247-251
established	O	252-263
from	O	264-268
mechanistic	O	269-280
and	O	281-284
randomised	O	285-295
clinical	O	296-304
trials	O	305-311
.	O	311-312

However	O	313-320
,	O	320-321
the	O	322-325
exact	O	326-331
pattern	O	332-339
of	O	340-342
kidney	O	343-349
involvement	O	350-361
is	O	362-364
still	O	365-370
uncertain	O	371-380
.	O	380-381

We	O	382-384
undertook	O	385-394
a	O	395-396
descriptive	O	397-408
analysis	O	409-417
of	O	418-420
Yellow	O	421-427
Card	O	428-432
records	O	433-440
of	O	441-443
407	O	444-447
HIV	O	448-451
-	O	451-452
positive	O	452-460
persons	O	461-468
taking	O	469-475
tenofovir	O	476-485
disoproxil	O	486-496
fumarate	O	497-505
(	O	506-507
TDF	O	507-510
)	O	510-511
as	O	512-514
part	O	515-519
of	O	520-522
their	O	523-528
antiretroviral	O	529-543
therapy	O	544-551
regimen	O	552-559
and	O	560-563
submitted	O	564-573
to	O	574-576
the	O	577-580
Medicines	O	581-590
and	O	591-594
Healthcare	O	595-605
Products	O	606-614
Regulatory	O	615-625
Agency	O	626-632
(	O	633-634
MHRA	O	634-638
)	O	638-639
with	O	640-644
suspected	O	645-654
kidney	O	655-661
adverse	O	662-669
effects	O	670-677
.	O	677-678

Reports	O	679-686
that	O	687-691
satisfy	O	692-699
defined	O	700-707
criteria	O	708-716
were	O	717-721
classified	O	722-732
as	O	733-735
acute	B	736-741
kidney	I	742-748
injury	I	749-755
,	O	755-756
kidney	B	757-763
tubular	I	764-771
dysfunction	I	772-783
and	O	784-787
Fanconi	B	788-795
syndrome	I	796-804
.	O	804-805

Of	O	806-808
the	O	809-812
407	O	813-816
Yellow	O	817-823
Card	O	824-828
records	O	829-836
analysed	O	837-845
,	O	845-846
106	O	847-850
satisfied	O	851-860
criteria	O	861-869
for	O	870-873
TDF	O	874-877
-	O	877-878
related	O	878-885
kidney	B	886-892
disease	I	893-900
,	O	900-901
of	O	902-904
which	O	905-910
53	O	911-913
(	O	914-915
50	O	915-917
%	O	917-918
)	O	918-919
had	O	920-923
features	O	924-932
of	O	933-935
kidney	B	936-942
tubular	I	943-950
dysfunction	I	951-962
,	O	962-963
35	O	964-966
(	O	967-968
33	O	968-970
%	O	970-971
)	O	971-972
were	O	973-977
found	O	978-983
to	O	984-986
have	O	987-991
features	O	992-1000
of	O	1001-1003
glomerular	B	1004-1014
dysfunction	I	1015-1026
and	O	1027-1030
18	O	1031-1033
(	O	1034-1035
17	O	1035-1037
%	O	1037-1038
)	O	1038-1039
had	O	1040-1043
Fanconi	B	1044-1051
syndrome	I	1052-1060
.	O	1060-1061

The	O	1062-1065
median	O	1066-1072
TDF	O	1073-1076
exposure	O	1077-1085
was	O	1086-1089
316	O	1090-1093
days	O	1094-1098
(	O	1099-1100
interquartile	O	1100-1113
range	O	1114-1119
120	O	1120-1123
-	O	1123-1124
740	O	1124-1127
)	O	1127-1128
.	O	1128-1129

The	O	1130-1133
incidence	O	1134-1143
of	O	1144-1146
hospitalisation	O	1147-1162
for	O	1163-1166
TDF	O	1167-1170
kidney	O	1171-1177
adverse	O	1178-1185
effects	O	1186-1193
was	O	1194-1197
high	O	1198-1202
,	O	1202-1203
particularly	O	1204-1216
amongst	O	1217-1224
patients	O	1225-1233
with	O	1234-1238
features	O	1239-1247
of	O	1248-1250
Fanconi	B	1251-1258
syndrome	I	1259-1267
.	O	1267-1268

The	O	1269-1272
pattern	O	1273-1280
of	O	1281-1283
kidney	O	1284-1290
syndromes	O	1291-1300
in	O	1301-1303
this	O	1304-1308
population	O	1309-1319
series	O	1320-1326
mirrors	O	1327-1334
that	O	1335-1339
reported	O	1340-1348
in	O	1349-1351
randomised	O	1352-1362
clinical	O	1363-1371
trials	O	1372-1378
.	O	1378-1379

Cessation	O	1380-1389
of	O	1390-1392
TDF	O	1393-1396
was	O	1397-1400
associated	O	1401-1411
with	O	1412-1416
complete	O	1417-1425
restoration	O	1426-1437
of	O	1438-1440
kidney	O	1441-1447
function	O	1448-1456
in	O	1457-1459
up	O	1460-1462
half	O	1463-1467
of	O	1468-1470
the	O	1471-1474
patients	O	1475-1483
in	O	1484-1486
this	O	1487-1491
report	O	1492-1498
.	O	1498-1499

Incidence	O	0-9
of	O	10-12
postoperative	B	13-26
delirium	I	27-35
is	O	36-38
high	O	39-43
even	O	44-48
in	O	49-51
a	O	52-53
population	O	54-64
without	O	65-72
known	O	73-78
risk	O	79-83
factors	O	84-91
.	O	91-92

PURPOSE	O	93-100
:	O	100-101
Postoperative	B	102-115
delirium	I	116-124
is	O	125-127
a	O	128-129
recognized	O	130-140
complication	O	141-153
in	O	154-156
populations	O	157-168
at	O	169-171
risk	O	172-176
.	O	176-177

The	O	178-181
aim	O	182-185
of	O	186-188
this	O	189-193
study	O	194-199
is	O	200-202
to	O	203-205
assess	O	206-212
the	O	213-216
prevalence	O	217-227
of	O	228-230
early	O	231-236
postoperative	B	237-250
delirium	I	251-259
in	O	260-262
a	O	263-264
population	O	265-275
without	O	276-283
known	O	284-289
risk	O	290-294
factors	O	295-302
admitted	O	303-311
to	O	312-314
the	O	315-318
ICU	O	319-322
for	O	323-326
postoperative	O	327-340
monitoring	O	341-351
after	O	352-357
elective	O	358-366
major	O	367-372
surgery	O	373-380
.	O	380-381

The	O	382-385
secondary	O	386-395
outcome	O	396-403
investigated	O	404-416
is	O	417-419
to	O	420-422
identify	O	423-431
eventual	O	432-440
independent	O	441-452
risk	O	453-457
factors	O	458-465
among	O	466-471
demographic	O	472-483
data	O	484-488
and	O	489-492
anesthetic	O	493-503
drugs	O	504-509
used	O	510-514
.	O	514-515

METHODS	O	516-523
:	O	523-524
An	O	525-527
observational	O	528-541
,	O	541-542
prospective	O	543-554
study	O	555-560
was	O	561-564
conducted	O	565-574
on	O	575-577
a	O	578-579
consecutive	O	580-591
cohort	O	592-598
of	O	599-601
patients	O	602-610
admitted	O	611-619
to	O	620-622
our	O	623-626
ICU	O	627-630
within	O	631-637
and	O	638-641
for	O	642-645
at	O	646-648
least	O	649-654
24	O	655-657
h	O	658-659
after	O	660-665
major	O	666-671
surgical	O	672-680
procedures	O	681-691
.	O	691-692

Exclusion	O	693-702
criteria	O	703-711
were	O	712-716
any	O	717-720
preexisting	O	721-732
predisposing	O	733-745
factor	O	746-752
for	O	753-756
delirium	B	757-765
or	O	766-768
other	O	769-774
potentially	O	775-786
confounding	O	787-798
neurological	B	799-811
dysfunctions	I	812-824
.	O	824-825

Patients	O	826-834
were	O	835-839
assessed	O	840-848
daily	O	849-854
using	O	855-860
the	O	861-864
confusion	B	865-874
assessment	O	875-885
method	O	886-892
for	O	893-896
the	O	897-900
ICU	O	901-904
scale	O	905-910
for	O	911-914
3	O	915-916
days	O	917-921
after	O	922-927
the	O	928-931
surgical	O	932-940
procedure	O	941-950
.	O	950-951

Early	O	952-957
postoperative	B	958-971
delirium	I	972-980
incidence	O	981-990
risk	O	991-995
factors	O	996-1003
were	O	1004-1008
then	O	1009-1013
assessed	O	1014-1022
through	O	1023-1030
three	O	1031-1036
different	O	1037-1046
multiple	O	1047-1055
regression	O	1056-1066
models	O	1067-1073
.	O	1073-1074

RESULTS	O	1075-1082
:	O	1082-1083
According	O	1084-1093
to	O	1094-1096
the	O	1097-1100
confusion	O	1101-1110
assessment	O	1111-1121
method	O	1122-1128
for	O	1129-1132
the	O	1133-1136
ICU	O	1137-1140
scale	O	1141-1146
,	O	1146-1147
28	O	1148-1150
%	O	1151-1152
of	O	1153-1155
patients	O	1156-1164
were	O	1165-1169
diagnosed	O	1170-1179
with	O	1180-1184
early	O	1185-1190
postoperative	B	1191-1204
delirium	I	1205-1213
.	O	1213-1214

The	O	1215-1218
use	O	1219-1222
of	O	1223-1225
thiopentone	O	1226-1237
was	O	1238-1241
significantly	O	1242-1255
associated	O	1256-1266
with	O	1267-1271
an	O	1272-1274
eight	O	1275-1280
-	O	1280-1281
fold	O	1281-1285
-	O	1280-1281
higher	O	1286-1292
risk	O	1293-1297
for	O	1298-1301
delirium	B	1302-1310
compared	O	1311-1319
to	O	1320-1322
propofol	O	1323-1331
(	O	1332-1333
57	O	1333-1335
.	O	1335-1336
1	O	1336-1337
%	O	1337-1338
vs	O	1339-1341
.	O	1341-1342
7	O	1343-1344
.	O	1344-1345
1	O	1345-1346
%	O	1346-1347
,	O	1347-1348
RR	O	1349-1351
=	O	1352-1353
8	O	1354-1355
.	O	1355-1356
0	O	1356-1357
,	O	1357-1358
X2	O	1359-1361
=	O	1362-1363
4	O	1364-1365
.	O	1365-1366
256	O	1366-1369
;	O	1369-1370
df	O	1371-1373
=	O	1374-1375
1	O	1376-1377
;	O	1377-1378
0	O	1379-1380
.	O	1380-1381
05	O	1381-1383
<	O	1384-1385
p	O	1386-1387
<	O	1388-1389
0	O	1390-1391
.	O	1391-1392
02	O	1392-1394
)	O	1394-1395
.	O	1391-1392

CONCLUSION	O	1397-1407
:	O	1407-1408
In	O	1409-1411
this	O	1412-1416
study	O	1417-1422
early	O	1423-1428
postoperative	B	1429-1442
delirium	I	1443-1451
was	O	1452-1455
found	O	1456-1461
to	O	1462-1464
be	O	1465-1467
a	O	1468-1469
very	O	1470-1474
common	O	1475-1481
complication	O	1482-1494
after	O	1495-1500
major	O	1501-1506
surgery	O	1507-1514
,	O	1514-1515
even	O	1516-1520
in	O	1521-1523
a	O	1524-1525
population	O	1526-1536
without	O	1537-1544
known	O	1545-1550
risk	O	1551-1555
factors	O	1556-1563
.	O	1563-1564

Thiopentone	O	1565-1576
was	O	1577-1580
independently	O	1581-1594
associated	O	1595-1605
with	O	1606-1610
an	O	1611-1613
increase	O	1614-1622
in	O	1623-1625
its	O	1626-1629
relative	O	1630-1638
risk	O	1639-1643
.	O	1643-1644

A	O	0-1
single	O	2-8
neurotoxic	B	9-19
dose	O	20-24
of	O	25-27
methamphetamine	O	28-43
induces	O	44-51
a	O	52-53
long	O	54-58
-	O	58-59
lasting	O	59-66
depressive	B	67-77
-	O	77-78
like	O	78-82
behaviour	O	83-92
in	O	93-95
mice	O	96-100
.	O	100-101

Methamphetamine	O	102-117
(	O	118-119
METH	O	119-123
)	O	123-124
triggers	O	125-133
a	O	134-135
disruption	O	136-146
of	O	147-149
the	O	150-153
monoaminergic	O	154-167
system	O	168-174
and	O	175-178
METH	O	179-183
abuse	O	184-189
leads	O	190-195
to	O	196-198
negative	O	199-207
emotional	O	208-217
states	O	218-224
including	O	225-234
depressive	B	235-245
symptoms	I	246-254
during	O	255-261
drug	O	262-266
withdrawal	O	267-277
.	O	277-278

However	O	279-286
,	O	286-287
it	O	288-290
is	O	291-293
currently	O	294-303
unknown	O	304-311
if	O	312-314
the	O	315-318
acute	O	319-324
toxic	O	325-330
dosage	O	331-337
of	O	338-340
METH	O	341-345
also	O	346-350
causes	O	351-357
a	O	358-359
long	O	360-364
-	O	364-365
lasting	O	365-372
depressive	B	373-383
phenotype	O	384-393
and	O	394-397
persistent	O	398-408
monoaminergic	O	409-422
deficits	O	423-431
.	O	431-432

Thus	O	433-437
,	O	437-438
we	O	439-441
now	O	442-445
assessed	O	446-454
the	O	455-458
depressive	B	459-469
-	O	469-470
like	O	470-474
behaviour	O	475-484
in	O	485-487
mice	O	488-492
at	O	493-495
early	O	496-501
and	O	502-505
long	O	506-510
-	O	510-511
term	O	511-515
periods	O	516-523
following	O	524-533
a	O	534-535
single	O	536-542
high	O	543-547
METH	O	548-552
dose	O	553-557
(	O	558-559
30	O	559-561
mg	O	562-564
/	O	564-565
kg	O	565-567
,	O	567-568
i	O	569-570
.	O	570-571
p	O	571-572
.	O	570-571
)	O	573-574
.	O	570-571

METH	O	576-580
did	O	581-584
not	O	585-588
alter	O	589-594
the	O	595-598
motor	O	599-604
function	O	605-613
and	O	614-617
procedural	O	618-628
memory	O	629-635
of	O	636-638
mice	O	639-643
as	O	644-646
assessed	O	647-655
by	O	656-658
swimming	O	659-667
speed	O	668-673
and	O	674-677
escape	O	678-684
latency	O	685-692
to	O	693-695
find	O	696-700
the	O	701-704
platform	O	705-713
in	O	714-716
a	O	717-718
cued	O	719-723
version	O	724-731
of	O	732-734
the	O	735-738
water	O	739-744
maze	O	745-749
task	O	750-754
.	O	754-755

However	O	756-763
,	O	763-764
METH	O	765-769
significantly	O	770-783
increased	O	784-793
the	O	794-797
immobility	O	798-808
time	O	809-813
in	O	814-816
the	O	817-820
tail	O	821-825
suspension	O	826-836
test	O	837-841
at	O	842-844
3	O	845-846
and	O	847-850
49	O	851-853
days	O	854-858
post	O	859-863
-	O	863-864
administration	O	864-878
.	O	878-879

This	O	880-884
depressive	B	885-895
-	O	895-896
like	O	896-900
profile	O	901-908
induced	O	909-916
by	O	917-919
METH	O	920-924
was	O	925-928
accompanied	O	929-940
by	O	941-943
a	O	944-945
marked	O	946-952
depletion	O	953-962
of	O	963-965
frontostriatal	O	966-980
dopaminergic	O	981-993
and	O	994-997
serotonergic	O	998-1010
neurotransmission	O	1011-1028
,	O	1028-1029
indicated	O	1030-1039
by	O	1040-1042
a	O	1043-1044
reduction	O	1045-1054
in	O	1055-1057
the	O	1058-1061
levels	O	1062-1068
of	O	1069-1071
dopamine	O	1072-1080
,	O	1080-1081
DOPAC	O	1082-1087
and	O	1088-1091
HVA	O	1092-1095
,	O	1095-1096
tyrosine	O	1097-1105
hydroxylase	O	1106-1117
and	O	1118-1121
serotonin	O	1122-1131
,	O	1131-1132
observed	O	1133-1141
at	O	1142-1144
both	O	1145-1149
3	O	1150-1151
and	O	1152-1155
49	O	1156-1158
days	O	1159-1163
post	O	1164-1168
-	O	1168-1169
administration	O	1169-1183
.	O	1183-1184

In	O	1185-1187
parallel	O	1188-1196
,	O	1196-1197
another	O	1198-1205
neurochemical	O	1206-1219
feature	O	1220-1227
of	O	1228-1230
depression	B	1231-1241
-	O	1241-1242
-	O	1241-1242
astroglial	O	1243-1253
dysfunction	O	1254-1265
-	O	1265-1266
-	O	1265-1266
was	O	1267-1270
unaffected	O	1271-1281
in	O	1282-1284
the	O	1285-1288
cortex	O	1289-1295
and	O	1296-1299
the	O	1300-1303
striatal	O	1304-1312
levels	O	1313-1319
of	O	1320-1322
the	O	1323-1326
astrocytic	O	1327-1337
protein	O	1338-1345
marker	O	1346-1352
,	O	1352-1353
glial	O	1354-1359
fibrillary	O	1360-1370
acidic	O	1371-1377
protein	O	1378-1385
,	O	1385-1386
were	O	1387-1391
only	O	1392-1396
transiently	O	1397-1408
increased	O	1409-1418
at	O	1419-1421
3	O	1422-1423
days	O	1424-1428
.	O	1428-1429

These	O	1430-1435
findings	O	1436-1444
demonstrate	O	1445-1456
for	O	1457-1460
the	O	1461-1464
first	O	1465-1470
time	O	1471-1475
that	O	1476-1480
a	O	1481-1482
single	O	1483-1489
high	O	1490-1494
dose	O	1495-1499
of	O	1500-1502
METH	O	1503-1507
induces	O	1508-1515
long	O	1516-1520
-	O	1520-1521
lasting	O	1521-1528
depressive	B	1529-1539
-	O	1539-1540
like	O	1540-1544
behaviour	O	1545-1554
in	O	1555-1557
mice	O	1558-1562
associated	O	1563-1573
with	O	1574-1578
a	O	1579-1580
persistent	O	1581-1591
disruption	O	1592-1602
of	O	1603-1605
frontostriatal	O	1606-1620
dopaminergic	O	1621-1633
and	O	1634-1637
serotonergic	O	1638-1650
homoeostasis	O	1651-1663
.	O	1663-1664

Linezolid	O	0-9
-	O	9-10
induced	O	10-17
optic	B	18-23
neuropathy	I	24-34
.	O	34-35

Many	O	36-40
systemic	O	41-49
antimicrobials	O	50-64
have	O	65-69
been	O	70-74
implicated	O	75-85
to	O	86-88
cause	O	89-94
ocular	O	95-101
adverse	O	102-109
effects	O	110-117
.	O	117-118

This	O	119-123
is	O	124-126
especially	O	127-137
relevant	O	138-146
in	O	147-149
multidrug	O	150-159
therapy	O	160-167
where	O	168-173
more	O	174-178
than	O	179-183
one	O	184-187
drug	O	188-192
can	O	193-196
cause	O	197-202
a	O	203-204
similar	O	205-212
ocular	O	213-219
adverse	O	220-227
effect	O	228-234
.	O	234-235

We	O	236-238
describe	O	239-247
a	O	248-249
case	O	250-254
of	O	255-257
progressive	O	258-269
loss	B	270-274
of	I	275-277
vision	I	278-284
associated	O	285-295
with	O	296-300
linezolid	O	301-310
therapy	O	311-318
.	O	318-319

A	O	320-321
45	O	322-324
-	O	324-325
year	O	325-329
-	O	324-325
old	O	330-333
male	O	334-338
patient	O	339-346
who	O	347-350
was	O	351-354
on	O	355-357
treatment	O	358-367
with	O	368-372
multiple	O	373-381
second	O	382-388
-	O	388-389
line	O	389-393
anti	O	394-398
-	O	398-399
tuberculous	O	399-410
drugs	O	411-416
including	O	417-426
linezolid	O	427-436
and	O	437-440
ethambutol	O	441-451
for	O	452-455
extensively	B	456-467
drug	I	468-472
-	I	472-473
resistant	I	473-482
tuberculosis	I	483-495
(	O	496-497
XDR	B	497-500
-	I	500-501
TB	I	501-503
)	O	503-504
presented	O	505-514
to	O	515-517
us	O	518-520
with	O	521-525
painless	O	526-534
progressive	O	535-546
loss	B	547-551
of	I	552-554
vision	I	555-561
in	O	562-564
both	O	565-569
eyes	O	570-574
.	O	574-575

Color	O	576-581
vision	O	582-588
was	O	589-592
defective	O	593-602
and	O	603-606
fundus	O	607-613
examination	O	614-625
revealed	O	626-634
optic	B	635-640
disc	I	641-645
edema	I	646-651
in	O	652-654
both	O	655-659
eyes	O	660-664
.	O	664-665

Ethambutol	O	666-676
-	O	676-677
induced	O	677-684
toxic	B	685-690
optic	I	691-696
neuropathy	I	697-707
was	O	708-711
suspected	O	712-721
and	O	722-725
tablet	O	726-732
ethambutol	O	733-743
was	O	744-747
withdrawn	O	748-757
.	O	757-758

Deterioration	B	759-772
of	I	773-775
vision	I	776-782
occurred	O	783-791
despite	O	792-799
withdrawal	O	800-810
of	O	811-813
ethambutol	O	814-824
.	O	824-825

Discontinuation	O	826-841
of	O	842-844
linezolid	O	845-854
resulted	O	855-863
in	O	864-866
marked	O	867-873
improvement	O	874-885
of	O	886-888
vision	O	889-895
.	O	895-896

Our	O	897-900
report	O	901-907
emphasizes	O	908-918
the	O	919-922
need	O	923-927
for	O	928-931
monitoring	O	932-942
of	O	943-945
visual	O	946-952
function	O	953-961
in	O	962-964
patients	O	965-973
on	O	974-976
long	O	977-981
-	O	981-982
term	O	982-986
linezolid	O	987-996
treatment	O	997-1006
.	O	1006-1007

Resuscitation	O	0-13
with	O	14-18
lipid	O	19-24
,	O	24-25
epinephrine	O	26-37
,	O	37-38
or	O	39-41
both	O	42-46
in	O	47-49
levobupivacaine	O	50-65
-	O	65-66
induced	O	66-73
cardiac	B	74-81
toxicity	I	82-90
in	O	91-93
newborn	O	94-101
piglets	O	102-109
.	O	109-110

BACKGROUND	O	111-121
:	O	121-122
The	O	123-126
optimal	O	127-134
dosing	O	135-141
regimens	O	142-150
of	O	151-153
lipid	O	154-159
emulsion	O	160-168
,	O	168-169
epinephrine	O	170-181
,	O	181-182
or	O	183-185
both	O	186-190
are	O	191-194
not	O	195-198
yet	O	199-202
determined	O	203-213
in	O	214-216
neonates	O	217-225
in	O	226-228
cases	O	229-234
of	O	235-237
local	O	238-243
anaesthetic	O	244-255
systemic	O	256-264
toxicity	B	265-273
(	O	274-275
LAST	O	275-279
)	O	279-280
.	O	280-281

METHODS	O	282-289
:	O	289-290
Newborn	O	291-298
piglets	O	299-306
received	O	307-315
levobupivacaine	O	316-331
until	O	332-337
cardiovascular	B	338-352
collapse	I	353-361
occurred	O	362-370
.	O	370-371

Standard	O	372-380
cardiopulmonary	O	381-396
resuscitation	O	397-410
was	O	411-414
started	O	415-422
and	O	423-426
electrocardiogram	O	427-444
(	O	445-446
ECG	O	446-449
)	O	449-450
was	O	451-454
monitored	O	455-464
for	O	465-468
ventricular	B	469-480
tachycardia	I	481-492
,	O	492-493
fibrillation	B	494-506
,	O	506-507
or	O	508-510
QRS	O	511-514
prolongation	O	515-527
.	O	527-528

Piglets	O	529-536
were	O	537-541
then	O	542-546
randomly	O	547-555
allocated	O	556-565
to	O	566-568
four	O	569-573
groups	O	574-580
:	O	580-581
control	O	582-589
(	O	590-591
saline	O	591-597
)	O	597-598
,	O	598-599
Intralipid	O	600-610
(	O	610-611
)	O	612-613
alone	O	614-619
,	O	619-620
epinephrine	O	621-632
alone	O	633-638
,	O	638-639
or	O	640-642
a	O	643-644
combination	O	645-656
of	O	657-659
Intralipd	O	660-669
plus	O	670-674
epinephrine	O	675-686
.	O	686-687

Resuscitation	O	688-701
continued	O	702-711
for	O	712-715
30	O	716-718
min	O	719-722
or	O	723-725
until	O	726-731
there	O	732-737
was	O	738-741
a	O	742-743
return	O	744-750
of	O	751-753
spontaneous	O	754-765
circulation	O	766-777
(	O	778-779
ROSC	O	779-783
)	O	783-784
accompanied	O	785-796
by	O	797-799
a	O	800-801
mean	O	802-806
arterial	O	807-815
pressure	O	816-824
at	O	825-827
or	O	828-830
superior	O	831-839
to	O	840-842
the	O	843-846
baseline	O	847-855
pressure	O	856-864
and	O	865-868
normal	O	869-875
sinus	O	876-881
rhythm	O	882-888
for	O	889-892
a	O	893-894
period	O	895-901
of	O	902-904
30	O	905-907
min	O	908-911
.	O	911-912

RESULTS	O	913-920
:	O	920-921
ROSC	O	922-926
was	O	927-930
achieved	O	931-939
in	O	940-942
only	O	943-947
one	O	948-951
of	O	952-954
the	O	955-958
control	O	959-966
piglets	O	967-974
compared	O	975-983
with	O	984-988
most	O	989-993
of	O	994-996
the	O	997-1000
treated	O	1001-1008
piglets	O	1009-1016
.	O	1016-1017

Mortality	O	1018-1027
was	O	1028-1031
not	O	1032-1035
significantly	O	1036-1049
different	O	1050-1059
between	O	1060-1067
the	O	1068-1071
three	O	1072-1077
treatment	O	1078-1087
groups	O	1088-1094
,	O	1094-1095
but	O	1096-1099
was	O	1100-1103
significantly	O	1104-1117
lower	O	1118-1123
in	O	1124-1126
all	O	1127-1130
the	O	1131-1134
treatment	O	1135-1144
groups	O	1145-1151
compared	O	1152-1160
with	O	1161-1165
control	O	1166-1173
.	O	1173-1174

The	O	1175-1178
number	O	1179-1185
of	O	1186-1188
ECG	O	1189-1192
abnormalities	O	1193-1206
was	O	1207-1210
zero	O	1211-1215
in	O	1216-1218
the	O	1219-1222
Intralipid	O	1223-1233
only	O	1234-1238
group	O	1239-1244
,	O	1244-1245
but	O	1246-1249
14	O	1250-1252
and	O	1253-1256
17	O	1257-1259
,	O	1259-1260
respectively	O	1261-1273
,	O	1273-1274
in	O	1275-1277
the	O	1278-1281
epinephrine	O	1282-1293
and	O	1294-1297
epinephrine	O	1298-1309
plus	O	1310-1314
lipid	O	1315-1320
groups	O	1321-1327
(	O	1328-1329
P	O	1329-1330
<	O	1330-1331
0	O	1331-1332
.	O	1332-1333
05	O	1333-1335
)	O	1335-1336
.	O	1332-1333

CONCLUSIONS	O	1338-1349
:	O	1349-1350
Lipid	O	1351-1356
emulsion	O	1357-1365
with	O	1366-1370
or	O	1371-1373
without	O	1374-1381
epinephrine	O	1382-1393
,	O	1393-1394
or	O	1395-1397
epinephrine	O	1398-1409
alone	O	1410-1415
were	O	1416-1420
equally	O	1421-1428
effective	O	1429-1438
in	O	1439-1441
achieving	O	1442-1451
a	O	1452-1453
return	O	1454-1460
to	O	1461-1463
spontaneous	O	1464-1475
circulation	O	1476-1487
in	O	1488-1490
this	O	1491-1495
model	O	1496-1501
of	O	1502-1504
LAST	O	1505-1509
.	O	1509-1510

Epinephrine	O	1511-1522
alone	O	1523-1528
or	O	1529-1531
in	O	1532-1534
combination	O	1535-1546
with	O	1547-1551
lipid	O	1552-1557
was	O	1558-1561
associated	O	1562-1572
with	O	1573-1577
an	O	1578-1580
increased	O	1581-1590
number	O	1591-1597
of	O	1598-1600
ECG	O	1601-1604
abnormalities	O	1605-1618
compared	O	1619-1627
with	O	1628-1632
lipid	O	1633-1638
emulsion	O	1639-1647
alone	O	1648-1653
.	O	1653-1654

Incidence	O	0-9
of	O	10-12
heparin	O	13-20
-	O	20-21
induced	O	21-28
thrombocytopenia	B	29-45
type	I	46-50
II	I	51-53
and	O	54-57
postoperative	O	58-71
recovery	O	72-80
of	O	81-83
platelet	O	84-92
count	O	93-98
in	O	99-101
liver	O	102-107
graft	O	108-113
recipients	O	114-124
:	O	124-125
a	O	126-127
retrospective	O	128-141
cohort	O	142-148
analysis	O	149-157
.	O	157-158

BACKGROUND	O	159-169
:	O	169-170
Thrombocytopenia	B	171-187
in	O	188-190
patients	O	191-199
with	O	200-204
end	B	205-208
-	I	208-209
stage	I	209-214
liver	I	215-220
disease	I	221-228
is	O	229-231
a	O	232-233
common	O	234-240
disorder	O	241-249
caused	O	250-256
mainly	O	257-263
by	O	264-266
portal	B	267-273
hypertension	I	274-286
,	O	286-287
low	O	288-291
levels	O	292-298
of	O	299-301
thrombopoetin	O	302-315
,	O	315-316
and	O	317-320
endotoxemia	B	321-332
.	O	332-333

The	O	334-337
impact	O	338-344
of	O	345-347
immune	O	348-354
-	O	354-355
mediated	O	355-363
heparin	O	364-371
-	O	371-372
induced	O	372-379
thrombocytopenia	B	380-396
type	I	397-401
II	I	402-404
(	O	405-406
HIT	B	406-409
type	I	410-414
II	I	415-417
)	O	417-418
as	O	419-421
a	O	422-423
cause	O	424-429
of	O	430-432
thrombocytopenia	B	433-449
after	O	450-455
liver	O	456-461
transplantation	O	462-477
is	O	478-480
not	O	481-484
yet	O	485-488
understood	O	489-499
,	O	499-500
with	O	501-505
few	O	506-509
literature	O	510-520
citations	O	521-530
reporting	O	531-540
contradictory	O	541-554
results	O	555-562
.	O	562-563

The	O	564-567
aim	O	568-571
of	O	572-574
our	O	575-578
study	O	579-584
was	O	585-588
to	O	589-591
demonstrate	O	592-603
the	O	604-607
perioperative	O	608-621
course	O	622-628
of	O	629-631
thrombocytopenia	B	632-648
after	O	649-654
liver	O	655-660
transplantation	O	661-676
and	O	677-680
determine	O	681-690
the	O	691-694
occurrence	O	695-705
of	O	706-708
clinical	O	709-717
HIT	B	718-721
type	I	722-726
II	I	727-729
.	O	729-730

METHOD	O	731-737
:	O	737-738
We	O	739-741
retrospectively	O	742-757
evaluated	O	758-767
the	O	768-771
medical	O	772-779
records	O	780-787
of	O	788-790
205	O	791-794
consecutive	O	795-806
adult	O	807-812
patients	O	813-821
who	O	822-825
underwent	O	826-835
full	O	836-840
-	O	840-841
size	O	841-845
liver	O	846-851
transplantation	O	852-867
between	O	868-875
January	O	876-883
2006	O	884-888
and	O	889-892
December	O	893-901
2010	O	902-906
due	O	907-910
to	O	911-913
end	B	914-917
-	I	917-918
stage	I	918-923
or	I	924-926
malignant	I	927-936
liver	I	937-942
disease	I	943-950
.	O	950-951

Preoperative	O	952-964
platelet	O	965-973
count	O	974-979
,	O	979-980
postoperative	O	981-994
course	O	995-1001
of	O	1002-1004
platelets	O	1005-1014
,	O	1014-1015
and	O	1016-1019
clinical	O	1020-1028
signs	O	1029-1034
of	O	1035-1037
HIT	B	1038-1041
type	I	1042-1046
II	I	1047-1049
were	O	1050-1054
analyzed	O	1055-1063
.	O	1063-1064

RESULTS	O	1065-1072
:	O	1072-1073
A	O	1074-1075
total	O	1076-1081
of	O	1082-1084
155	O	1085-1088
(	O	1089-1090
75	O	1090-1092
.	O	1092-1093
6	O	1093-1094
%	O	1094-1095
)	O	1095-1096
of	O	1097-1099
205	O	1100-1103
patients	O	1104-1112
had	O	1113-1116
thrombocytopenia	B	1117-1133
before	O	1134-1140
transplantation	O	1141-1156
,	O	1156-1157
significantly	O	1158-1171
influenced	O	1172-1182
by	O	1183-1185
Model	O	1186-1191
of	O	1192-1194
End	B	1195-1198
-	I	1198-1199
Stage	I	1199-1204
Liver	I	1205-1210
Disease	I	1211-1218
score	O	1219-1224
and	O	1225-1228
liver	B	1229-1234
cirrhosis	I	1235-1244
.	O	1244-1245

The	O	1246-1249
platelet	O	1250-1258
count	O	1259-1264
exceeded	O	1265-1273
100	O	1274-1277
,	O	1277-1278
000	O	1278-1281
/	O	1281-1282
uL	O	1282-1284
in	O	1285-1287
most	O	1288-1292
of	O	1293-1295
the	O	1296-1299
patients	O	1300-1308
(	O	1309-1310
n	O	1310-1311
=	O	1312-1313
193	O	1314-1317
)	O	1317-1318
at	O	1319-1321
a	O	1322-1323
medium	O	1324-1330
of	O	1331-1333
7	O	1334-1335
d	O	1336-1337
.	O	1337-1338

Regarding	O	1339-1348
HIT	B	1349-1352
II	I	1353-1355
,	O	1355-1356
there	O	1357-1362
were	O	1363-1367
four	O	1368-1372
(	O	1373-1374
1	O	1374-1375
.	O	1375-1376
95	O	1376-1378
%	O	1378-1379
)	O	1379-1380
patients	O	1381-1389
with	O	1390-1394
a	O	1395-1396
background	O	1397-1407
of	O	1408-1410
HIT	B	1411-1414
type	I	1415-1419
II	I	1420-1422
.	O	1422-1423

CONCLUSIONS	O	1424-1435
:	O	1435-1436
The	O	1437-1440
incidence	O	1441-1450
of	O	1451-1453
HIT	B	1454-1457
in	O	1458-1460
patients	O	1461-1469
with	O	1470-1474
end	B	1475-1478
-	I	1478-1479
stage	I	1479-1484
hepatic	I	1485-1492
failure	I	1493-1500
is	O	1501-1503
,	O	1503-1504
with	O	1505-1509
about	O	1510-1515
1	O	1516-1517
.	O	1517-1518
95	O	1518-1520
%	O	1520-1521
,	O	1521-1522
rare	O	1523-1527
.	O	1527-1528

For	O	1529-1532
further	O	1533-1540
reduction	O	1541-1550
of	O	1551-1553
HIT	B	1554-1557
type	I	1558-1562
II	I	1563-1565
,	O	1565-1566
the	O	1567-1570
use	O	1571-1574
of	O	1575-1577
intravenous	O	1578-1589
heparin	O	1590-1597
should	O	1598-1604
be	O	1605-1607
avoided	O	1608-1615
and	O	1616-1619
the	O	1620-1623
prophylactic	O	1624-1636
anticoagulation	O	1637-1652
should	O	1653-1659
be	O	1660-1662
performed	O	1663-1672
with	O	1673-1677
low	O	1678-1681
-	O	1681-1682
molecular	O	1682-1691
-	O	1681-1682
weight	O	1692-1698
heparin	O	1699-1706
after	O	1707-1712
normalization	O	1713-1726
of	O	1727-1729
platelet	O	1730-1738
count	O	1739-1744
.	O	1744-1745

Takotsubo	B	0-9
syndrome	I	10-18
(	O	19-20
or	O	20-22
apical	B	23-29
ballooning	I	30-40
syndrome	I	41-49
)	O	49-50
secondary	O	51-60
to	O	61-63
Zolmitriptan	O	64-76
.	O	76-77

Takotsubo	B	78-87
syndrome	I	88-96
(	O	97-98
TS	B	98-100
)	O	100-101
,	O	101-102
also	O	103-107
known	O	108-113
as	O	114-116
broken	B	117-123
heart	I	124-129
syndrome	I	130-138
,	O	138-139
is	O	140-142
characterized	O	143-156
by	O	157-159
left	O	160-164
ventricle	O	165-174
apical	O	175-181
ballooning	O	182-192
with	O	193-197
elevated	O	198-206
cardiac	O	207-214
biomarkers	O	215-225
and	O	226-229
electrocardiographic	O	230-250
changes	O	251-258
suggestive	O	259-269
of	O	270-272
an	O	273-275
acute	B	276-281
coronary	I	282-290
syndrome	I	291-299
(	O	300-301
ie	O	301-303
,	O	303-304
ST	O	305-307
-	O	307-308
segment	O	308-315
elevation	O	316-325
,	O	325-326
T	O	327-328
wave	O	329-333
inversions	O	334-344
,	O	344-345
and	O	346-349
pathologic	O	350-360
Q	O	361-362
waves	O	363-368
)	O	368-369
.	O	369-370

We	O	371-373
report	O	374-380
a	O	381-382
case	O	383-387
of	O	388-390
54	O	391-393
-	O	393-394
year	O	394-398
-	O	393-394
old	O	399-402
woman	O	403-408
with	O	409-413
medical	O	414-421
history	O	422-429
of	O	430-432
mitral	B	433-439
valve	I	440-445
prolapse	I	446-454
and	O	455-458
migraines	B	459-468
,	O	468-469
who	O	470-473
was	O	474-477
admitted	O	478-486
to	O	487-489
the	O	490-493
hospital	O	494-502
for	O	503-506
substernal	O	507-517
chest	B	518-523
pain	I	524-528
and	O	529-532
electrocardiogram	O	533-550
demonstrated	O	551-563
1	O	564-565
/	O	565-566
2	O	566-567
mm	O	568-570
ST	O	571-573
-	O	573-574
segment	O	574-581
elevation	O	582-591
in	O	592-594
leads	O	595-600
II	O	601-603
,	O	603-604
III	O	605-608
,	O	608-609
aVF	O	610-613
,	O	613-614
V5	O	615-617
,	O	617-618
and	O	619-622
V6	O	623-625
and	O	626-629
positive	O	630-638
troponin	O	639-647
I	O	648-649
.	O	649-650
Emergent	O	651-659
coronary	O	660-668
angiogram	O	669-678
revealed	O	679-687
normal	O	688-694
coronary	O	695-703
arteries	O	704-712
with	O	713-717
moderately	O	718-728
reduced	O	729-736
left	O	737-741
ventricular	O	742-753
ejection	O	754-762
fraction	O	763-771
with	O	772-776
wall	O	777-781
motion	O	782-788
abnormalities	O	789-802
consistent	O	803-813
with	O	814-818
TS	B	819-821
.	O	821-822

Detailed	O	823-831
history	O	832-839
obtained	O	840-848
retrospectively	O	849-864
revealed	O	865-873
that	O	874-878
the	O	879-882
patient	O	883-890
took	O	891-895
zolmitriptan	O	896-908
sparingly	O	909-918
only	O	919-923
when	O	924-928
she	O	929-932
had	O	933-936
migraines	B	937-946
.	O	946-947

But	O	948-951
before	O	952-958
this	O	959-963
event	O	964-969
,	O	969-970
she	O	971-974
was	O	975-978
taking	O	979-985
zolmitriptan	O	986-998
2	O	999-1000
-	O	1000-1001
3	O	1001-1002
times	O	1003-1008
daily	O	1009-1014
for	O	1015-1018
several	O	1019-1026
days	O	1027-1031
because	O	1032-1039
of	O	1040-1042
a	O	1043-1044
persistent	O	1045-1055
migraine	B	1056-1064
headache	I	1065-1073
.	O	1073-1074

She	O	1075-1078
otherwise	O	1079-1088
reported	O	1089-1097
that	O	1098-1102
she	O	1103-1106
is	O	1107-1109
quite	O	1110-1115
active	O	1116-1122
,	O	1122-1123
rides	O	1124-1129
horses	O	1130-1136
,	O	1136-1137
and	O	1138-1141
does	O	1142-1146
show	O	1147-1151
jumping	O	1152-1159
without	O	1160-1167
any	O	1168-1171
limitations	O	1172-1183
in	O	1184-1186
her	O	1187-1190
physical	O	1191-1199
activity	O	1200-1208
.	O	1208-1209

There	O	1210-1215
was	O	1216-1219
no	O	1220-1222
evidence	O	1223-1231
of	O	1232-1234
any	O	1235-1238
recent	O	1239-1245
stress	O	1246-1252
or	O	1253-1255
status	B	1256-1262
migrainosus	I	1263-1274
.	O	1274-1275

Extensive	O	1276-1285
literature	O	1286-1296
search	O	1297-1303
revealed	O	1304-1312
multiple	O	1313-1321
cases	O	1322-1327
of	O	1328-1330
coronary	B	1331-1339
artery	I	1340-1346
vasospasm	I	1347-1356
secondary	O	1357-1366
to	O	1367-1369
zolmitriptan	O	1370-1382
,	O	1382-1383
but	O	1384-1387
none	O	1388-1392
of	O	1393-1395
the	O	1396-1399
cases	O	1400-1405
were	O	1406-1410
associated	O	1411-1421
with	O	1422-1426
TS	B	1427-1429
.	O	1429-1430

Depression	B	0-10
,	O	10-11
impulsiveness	B	12-25
,	O	25-26
sleep	O	27-32
,	O	32-33
and	O	34-37
memory	O	38-44
in	O	45-47
past	O	48-52
and	O	53-56
present	O	57-64
polydrug	O	65-73
users	O	74-79
of	O	80-82
3	O	83-84
,	O	84-85
4	O	85-86
-	O	86-87
methylenedioxymethamphetamine	O	87-116
(	O	117-118
MDMA	O	118-122
,	O	122-123
ecstasy	O	124-131
)	O	131-132
.	O	132-133

RATIONALE	O	134-143
:	O	143-144
Ecstasy	O	145-152
(	O	153-154
3	O	154-155
,	O	155-156
4	O	156-157
-	O	157-158
methylenedioxymethamphetamine	O	158-187
,	O	155-156
MDMA	O	189-193
)	O	193-194
is	O	195-197
a	O	198-199
worldwide	O	200-209
recreational	O	210-222
drug	O	223-227
of	O	228-230
abuse	O	231-236
.	O	236-237

Unfortunately	O	238-251
,	O	251-252
the	O	253-256
results	O	257-264
from	O	265-269
human	O	270-275
research	O	276-284
investigating	O	285-298
its	O	299-302
psychological	O	303-316
effects	O	317-324
have	O	325-329
been	O	330-334
inconsistent	O	335-347
.	O	347-348

OBJECTIVES	O	349-359
:	O	359-360
The	O	361-364
present	O	365-372
study	O	373-378
aimed	O	379-384
to	O	385-387
be	O	388-390
the	O	391-394
largest	O	395-402
to	O	403-405
date	O	406-410
in	O	411-413
sample	O	414-420
size	O	421-425
and	O	426-429
5HT	O	430-433
-	O	433-434
related	O	434-441
behaviors	O	442-451
;	O	451-452
the	O	453-456
first	O	457-462
to	O	463-465
compare	O	466-473
present	O	474-481
ecstasy	O	482-489
users	O	490-495
with	O	496-500
past	O	501-505
users	O	506-511
after	O	512-517
an	O	518-520
abstinence	O	521-531
of	O	532-534
4	O	535-536
or	O	537-539
more	O	540-544
years	O	545-550
,	O	550-551
and	O	552-555
the	O	556-559
first	O	560-565
to	O	566-568
include	O	569-576
robust	O	577-583
controls	O	584-592
for	O	593-596
other	O	597-602
recreational	O	603-615
substances	O	616-626
.	O	626-627

METHODS	O	628-635
:	O	635-636
A	O	637-638
sample	O	639-645
of	O	646-648
997	O	649-652
participants	O	653-665
(	O	666-667
52	O	667-669
%	O	670-671
male	O	672-676
)	O	676-677
was	O	678-681
recruited	O	682-691
to	O	692-694
four	O	695-699
control	O	700-707
groups	O	708-714
(	O	715-716
non	O	716-719
-	O	719-720
drug	O	720-724
(	O	725-726
ND	O	726-728
)	O	728-729
,	O	729-730
alcohol	O	731-738
/	O	738-739
nicotine	O	739-747
(	O	748-749
AN	O	749-751
)	O	751-752
,	O	752-753
cannabis	O	754-762
/	O	762-763
alcohol	O	763-770
/	O	762-763
nicotine	O	771-779
(	O	780-781
CAN	O	781-784
)	O	784-785
,	O	785-786
non	O	787-790
-	O	790-791
ecstasy	O	791-798
polydrug	O	799-807
(	O	808-809
PD	O	809-811
)	O	811-812
)	O	811-812
,	O	813-814
and	O	815-818
two	O	819-822
ecstasy	O	823-830
polydrug	O	831-839
groups	O	840-846
(	O	847-848
present	O	848-855
(	O	856-857
MDMA	O	857-861
)	O	861-862
and	O	863-866
past	O	867-871
users	O	872-877
(	O	878-879
EX	O	879-881
-	O	881-882
MDMA	O	882-886
)	O	886-887
.	O	887-888

Participants	O	889-901
completed	O	902-911
a	O	912-913
drug	O	914-918
history	O	919-926
questionnaire	O	927-940
,	O	940-941
Beck	O	942-946
Depression	B	947-957
Inventory	O	958-967
,	O	967-968
Barratt	O	969-976
Impulsiveness	B	977-990
Scale	O	991-996
,	O	996-997
Pittsburgh	O	998-1008
Sleep	O	1009-1014
Quality	O	1015-1022
Index	O	1023-1028
,	O	1028-1029
and	O	1030-1033
Wechsler	O	1034-1042
Memory	O	1043-1049
Scale	O	1050-1055
-	O	1055-1056
Revised	O	1056-1063
which	O	1064-1069
,	O	1069-1070
in	O	1071-1073
total	O	1074-1079
,	O	1079-1080
provided	O	1081-1089
13	O	1090-1092
psychometric	O	1093-1105
measures	O	1106-1114
.	O	1114-1115

RESULTS	O	1116-1123
:	O	1123-1124
While	O	1125-1130
the	O	1131-1134
CAN	O	1135-1138
and	O	1139-1142
PD	O	1143-1145
groups	O	1146-1152
tended	O	1153-1159
to	O	1160-1162
record	O	1163-1169
greater	O	1170-1177
deficits	O	1178-1186
than	O	1187-1191
the	O	1192-1195
non	O	1196-1199
-	O	1199-1200
drug	O	1200-1204
controls	O	1205-1213
,	O	1213-1214
the	O	1215-1218
MDMA	O	1219-1223
and	O	1224-1227
EX	O	1228-1230
-	O	1230-1231
MDMA	O	1231-1235
groups	O	1236-1242
recorded	O	1243-1251
greater	O	1252-1259
deficits	O	1260-1268
than	O	1269-1273
all	O	1274-1277
the	O	1278-1281
control	O	1282-1289
groups	O	1290-1296
on	O	1297-1299
ten	O	1300-1303
of	O	1304-1306
the	O	1307-1310
13	O	1311-1313
psychometric	O	1314-1326
measures	O	1327-1335
.	O	1335-1336

Strikingly	O	1337-1347
,	O	1347-1348
despite	O	1349-1356
prolonged	O	1357-1366
abstinence	O	1367-1377
(	O	1378-1379
mean	O	1379-1383
,	O	1383-1384
4	O	1385-1386
.	O	1386-1387
98	O	1387-1389
;	O	1389-1390
range	O	1391-1396
,	O	1396-1397
4	O	1398-1399
-	O	1399-1400
9	O	1400-1401
years	O	1402-1407
)	O	1407-1408
,	O	1408-1409
past	O	1410-1414
ecstasy	O	1415-1422
users	O	1423-1428
showed	O	1429-1435
few	O	1436-1439
signs	O	1440-1445
of	O	1446-1448
recovery	O	1449-1457
.	O	1457-1458

Compared	O	1459-1467
with	O	1468-1472
present	O	1473-1480
ecstasy	O	1481-1488
users	O	1489-1494
,	O	1494-1495
the	O	1496-1499
past	O	1500-1504
users	O	1505-1510
showed	O	1511-1517
no	O	1518-1520
change	O	1521-1527
for	O	1528-1531
ten	O	1532-1535
measures	O	1536-1544
,	O	1544-1545
increased	O	1546-1555
impairment	O	1556-1566
for	O	1567-1570
two	O	1571-1574
measures	O	1575-1583
,	O	1583-1584
and	O	1585-1588
improvement	O	1589-1600
on	O	1601-1603
just	O	1604-1608
one	O	1609-1612
measure	O	1613-1620
.	O	1620-1621

CONCLUSIONS	O	1622-1633
:	O	1633-1634
Given	O	1635-1640
this	O	1641-1645
record	O	1646-1652
of	O	1653-1655
impaired	B	1656-1664
memory	I	1665-1671
and	O	1672-1675
clinically	O	1676-1686
significant	O	1687-1698
levels	O	1699-1705
of	O	1706-1708
depression	B	1709-1719
,	O	1719-1720
impulsiveness	B	1721-1734
,	O	1734-1735
and	O	1736-1739
sleep	B	1740-1745
disturbance	I	1746-1757
,	O	1757-1758
the	O	1759-1762
prognosis	O	1763-1772
for	O	1773-1776
the	O	1777-1780
current	O	1781-1788
generation	O	1789-1799
of	O	1800-1802
ecstasy	O	1803-1810
users	O	1811-1816
is	O	1817-1819
a	O	1820-1821
major	O	1822-1827
cause	O	1828-1833
for	O	1834-1837
concern	O	1838-1845
.	O	1845-1846

Association	O	0-11
of	O	12-14
common	O	15-21
genetic	O	22-29
variants	O	30-38
of	O	39-41
HOMER1	O	42-48
gene	O	49-53
with	O	54-58
levodopa	O	59-67
adverse	O	68-75
effects	O	76-83
in	O	84-86
Parkinson	B	87-96
'	I	96-97
s	I	93-94
disease	I	99-106
patients	O	107-115
.	O	115-116

Levodopa	O	117-125
is	O	126-128
the	O	129-132
most	O	133-137
effective	O	138-147
symptomatic	O	148-159
therapy	O	160-167
for	O	168-171
Parkinson	B	172-181
'	I	181-182
s	I	178-179
disease	I	184-191
,	O	191-192
but	O	193-196
its	O	197-200
chronic	O	201-208
use	O	209-212
could	O	213-218
lead	O	219-223
to	O	224-226
chronic	O	227-234
adverse	O	235-242
outcomes	O	243-251
,	O	251-252
such	O	253-257
as	O	258-260
motor	O	261-266
fluctuations	O	267-279
,	O	279-280
dyskinesia	B	281-291
and	O	292-295
visual	B	296-302
hallucinations	I	303-317
.	O	317-318

HOMER1	O	319-325
is	O	326-328
a	O	329-330
protein	O	331-338
with	O	339-343
pivotal	O	344-351
function	O	352-360
in	O	361-363
glutamate	O	364-373
transmission	O	374-386
,	O	386-387
which	O	388-393
has	O	394-397
been	O	398-402
related	O	403-410
to	O	411-413
the	O	414-417
pathogenesis	O	418-430
of	O	431-433
these	O	434-439
complications	O	440-453
.	O	453-454

This	O	455-459
study	O	460-465
investigates	O	466-478
whether	O	479-486
polymorphisms	O	487-500
in	O	501-503
the	O	504-507
HOMER1	O	508-514
gene	O	515-519
promoter	O	520-528
region	O	529-535
are	O	536-539
associated	O	540-550
with	O	551-555
the	O	556-559
occurrence	O	560-570
of	O	571-573
the	O	574-577
chronic	O	578-585
complications	O	586-599
of	O	600-602
levodopa	O	603-611
therapy	O	612-619
.	O	619-620

A	O	621-622
total	O	623-628
of	O	629-631
205	O	632-635
patients	O	636-644
with	O	645-649
idiopathic	B	650-660
Parkinson	I	661-670
'	I	670-671
s	I	667-668
disease	I	673-680
were	O	681-685
investigated	O	686-698
.	O	698-699

Patients	O	700-708
were	O	709-713
genotyped	O	714-723
for	O	724-727
rs4704559	O	728-737
,	O	737-738
rs10942891	O	739-749
and	O	750-753
rs4704560	O	754-763
by	O	764-766
allelic	O	767-774
discrimination	O	775-789
with	O	790-794
Taqman	O	795-801
assays	O	802-808
.	O	808-809

The	O	810-813
rs4704559	O	814-823
G	O	824-825
allele	O	826-832
was	O	833-836
associated	O	837-847
with	O	848-852
a	O	853-854
lower	O	855-860
prevalence	O	861-871
of	O	872-874
dyskinesia	B	875-885
(	O	886-887
prevalence	O	887-897
ratio	O	898-903
(	O	904-905
PR	O	905-907
)	O	907-908
=	O	908-909
0	O	909-910
.	O	910-911
615	O	911-914
,	O	914-915

95	O	916-918
%	O	918-919
confidence	O	920-930
interval	O	931-939
(	O	940-941
CI	O	941-943
)	O	943-944
0	O	945-946
.	O	946-947
426	O	947-950
-	O	950-951
0	O	945-946
.	O	946-947
887	O	953-956
,	O	956-957

P	O	958-959
=	O	959-960
0	O	960-961
.	O	961-962
009	O	962-965
)	O	965-966
and	O	967-970
visual	B	971-977
hallucinations	I	978-992
(	O	993-994
PR	O	994-996
=	O	996-997
0	O	997-998
.	O	998-999
515	O	999-1002
,	O	1002-1003

95	O	1004-1006
%	O	1006-1007
CI	O	1008-1010
0	O	1011-1012
.	O	1012-1013
295	O	1013-1016
-	O	1016-1017
0	O	1011-1012
.	O	1012-1013
899	O	1019-1022
,	O	1022-1023

P	O	1024-1025
=	O	1025-1026
0	O	1026-1027
.	O	1027-1028
020	O	1028-1031
)	O	1031-1032
.	O	1027-1028

Our	O	1034-1037
data	O	1038-1042
suggest	O	1043-1050
that	O	1051-1055
HOMER1	O	1056-1062
rs4704559	O	1063-1072
G	O	1073-1074
allele	O	1075-1081
has	O	1082-1085
a	O	1086-1087
protective	O	1088-1098
role	O	1099-1103
for	O	1104-1107
the	O	1108-1111
development	O	1112-1123
of	O	1124-1126
levodopa	O	1127-1135
adverse	O	1136-1143
effects	O	1144-1151
.	O	1151-1152

Crocin	O	0-6
improves	O	7-15
lipid	O	16-21
dysregulation	O	22-35
in	O	36-38
subacute	O	39-47
diazinon	O	48-56
exposure	O	57-65
through	O	66-73
ERK1	O	74-78
/	O	78-79
2	O	79-80
pathway	O	81-88
in	O	89-91
rat	O	92-95
liver	O	96-101
.	O	101-102

INTRODUCTION	O	103-115
:	O	115-116
Diazinon	O	117-125
Yis	O	126-129
one	O	130-133
of	O	134-136
the	O	137-140
most	O	141-145
broadly	O	146-153
used	O	154-158
organophosphorus	O	159-175
insecticides	O	176-188
in	O	189-191
agriculture	O	192-203
.	O	203-204

It	O	205-207
has	O	208-211
been	O	212-216
shown	O	217-222
that	O	223-227
exposure	O	228-236
to	O	237-239
diazinon	O	240-248
may	O	249-252
interfere	O	253-262
with	O	263-267
lipid	O	268-273
metabolism	O	274-284
.	O	284-285

Moreover	O	286-294
,	O	294-295
the	O	296-299
hypolipidemic	O	300-313
effect	O	314-320
of	O	321-323
crocin	O	324-330
has	O	331-334
been	O	335-339
established	O	340-351
.	O	351-352

Earlier	O	353-360
studies	O	361-368
revealed	O	369-377
the	O	378-381
major	O	382-387
role	O	388-392
of	O	393-395
Extracellular	O	396-409
signal	O	410-416
-	O	416-417
regulated	O	417-426
kinase	O	427-433
(	O	434-435
ERK	O	435-438
)	O	438-439
pathways	O	440-448
in	O	449-451
low	O	452-455
-	O	455-456
density	O	456-463
lipoprotein	O	464-475
receptor	O	476-484
(	O	485-486
LDLr	O	486-490
)	O	490-491
expression	O	492-502
.	O	502-503

The	O	504-507
aim	O	508-511
of	O	512-514
this	O	515-519
study	O	520-525
was	O	526-529
to	O	530-532
evaluate	O	533-541
changes	O	542-549
in	O	550-552
the	O	553-556
regulation	O	557-567
of	O	568-570
lipid	O	571-576
metabolism	O	577-587
,	O	587-588
ERK	O	589-592
and	O	593-596
LDLr	O	597-601
expression	O	602-612
in	O	613-615
the	O	616-619
liver	O	620-625
of	O	626-628
rats	O	629-633
exposed	O	634-641
to	O	642-644
subacute	O	645-653
diazinon	O	654-662
.	O	662-663

Furthermore	O	664-675
ameliorating	O	676-688
effect	O	689-695
of	O	696-698
crocin	O	699-705
on	O	706-708
diazinon	O	709-717
induced	O	718-725
disturbed	O	726-735
cholesterol	O	736-747
homeostasis	O	748-759
was	O	760-763
studied	O	764-771
.	O	771-772

METHODS	O	773-780
:	O	780-781
24	O	782-784
Rats	O	785-789
were	O	790-794
divided	O	795-802
into	O	803-807
4	O	808-809
groups	O	810-816
and	O	817-820
received	O	821-829
following	O	830-839
treatments	O	840-850
for	O	851-854
4	O	855-856
weeks	O	857-862
;	O	862-863
Corn	O	864-868
oil	O	869-872
(	O	873-874
control	O	874-881
)	O	881-882
,	O	882-883
diazinon	O	884-892
(	O	893-894
15mg	O	894-898
/	O	898-899
kg	O	899-901
per	O	902-905
day	O	906-909
,	O	909-910
orally	O	911-917
)	O	917-918
and	O	919-922
crocin	O	923-929
(	O	930-931
12	O	931-933
.	O	933-934
5	O	934-935
and	O	936-939
25mg	O	940-944
/	O	944-945
kg	O	945-947
per	O	948-951
day	O	952-955
,	O	955-956
intraperitoneally	O	957-974
)	O	974-975
in	O	976-978
combination	O	979-990
with	O	991-995
diazinon	O	996-1004
(	O	1005-1006
15	O	1006-1008
mg	O	1009-1011
/	O	1011-1012
kg	O	1012-1014
)	O	1014-1015
.	O	1015-1016

The	O	1017-1020
levels	O	1021-1027
of	O	1028-1030
cholesterol	O	1031-1042
,	O	1042-1043
triglyceride	O	1044-1056
and	O	1057-1060
LDL	O	1061-1064
in	O	1065-1067
blood	O	1068-1073
of	O	1074-1076
rats	O	1077-1081
were	O	1082-1086
analyzed	O	1087-1095
.	O	1095-1096

Moreover	O	1097-1105
mRNA	O	1106-1110
levels	O	1111-1117
of	O	1118-1120
LDLr	O	1121-1125
and	O	1126-1129
ERK1	O	1130-1134
/	O	1134-1135
2	O	1135-1136
as	O	1137-1139
well	O	1140-1144
as	O	1145-1147
protein	O	1148-1155
levels	O	1156-1162
of	O	1163-1165
total	O	1166-1171
and	O	1172-1175
activated	O	1176-1185
forms	O	1186-1191
of	O	1192-1194
ERK1	O	1195-1199
/	O	1199-1200
2	O	1200-1201
in	O	1202-1204
rat	O	1205-1208
liver	O	1209-1214
were	O	1215-1219
evaluated	O	1220-1229
by	O	1230-1232
Western	O	1233-1240
blotting	O	1241-1249
and	O	1250-1253
quantitative	O	1254-1266
real	O	1267-1271
time	O	1272-1276
polymerase	O	1277-1287
chain	O	1288-1293
reaction	O	1294-1302
analysis	O	1303-1311
.	O	1311-1312

RESULTS	O	1313-1320
:	O	1320-1321
Our	O	1322-1325
data	O	1326-1330
showed	O	1331-1337
that	O	1338-1342
subacute	O	1343-1351
exposure	O	1352-1360
to	O	1361-1363
diazinon	O	1364-1372
significantly	O	1373-1386
increased	O	1387-1396
concentrations	O	1397-1411
of	O	1412-1414
cholesterol	O	1415-1426
,	O	1426-1427
triglyceride	O	1428-1440
and	O	1441-1444
LDL	O	1445-1448
.	O	1448-1449

Moreover	O	1450-1458
diazinon	O	1459-1467
decreased	O	1468-1477
ERK1	O	1478-1482
/	O	1482-1483
2	O	1483-1484
protein	O	1485-1492
phosphorylation	O	1493-1508
and	O	1509-1512
LDLr	O	1513-1517
transcript	O	1518-1528
.	O	1528-1529

Crocin	O	1530-1536
reduced	O	1537-1544
inhibition	O	1545-1555
of	O	1556-1558
ERK	O	1559-1562
activation	O	1563-1573
and	O	1574-1577
diazinon	O	1578-1586
-	O	1586-1587
induced	O	1587-1594
hyperlipemia	B	1595-1607
and	O	1608-1611
increased	O	1612-1621
levels	O	1622-1628
of	O	1629-1631
LDLr	O	1632-1636
transcript	O	1637-1647
.	O	1647-1648

CONCLUSIONS	O	1649-1660
:	O	1660-1661
Crocin	O	1662-1668
may	O	1669-1672
be	O	1673-1675
considered	O	1676-1686
as	O	1687-1689
a	O	1690-1691
novel	O	1692-1697
protective	O	1698-1708
agent	O	1709-1714
in	O	1715-1717
diazinon	O	1718-1726
-	O	1726-1727
induced	O	1727-1734
hyperlipemia	B	1735-1747
through	O	1748-1755
modulating	O	1756-1766
of	O	1767-1769
ERK	O	1770-1773
pathway	O	1774-1781
and	O	1782-1785
increase	O	1786-1794
of	O	1795-1797
LDLr	O	1798-1802
expression	O	1803-1813
.	O	1813-1814

GEM	O	0-3
-	O	3-4
P	O	4-5
chemotherapy	O	6-18
is	O	19-21
active	O	22-28
in	O	29-31
the	O	32-35
treatment	O	36-45
of	O	46-48
relapsed	O	49-57
Hodgkin	B	58-65
lymphoma	I	66-74
.	O	74-75

Hodgkin	B	76-83
lymphoma	I	84-92
(	O	93-94
HL	B	94-96
)	O	96-97
is	O	98-100
a	O	101-102
relatively	O	103-113
chemosensitive	O	114-128
malignancy	B	129-139
.	O	139-140

However	O	141-148
,	O	148-149
for	O	150-153
those	O	154-159
who	O	160-163
relapse	O	164-171
,	O	171-172
high	O	173-177
-	O	177-178
dose	O	178-182
chemotherapy	O	183-195
with	O	196-200
autologous	O	201-211
stem	O	212-216
cell	O	217-221
transplant	O	222-232
is	O	233-235
the	O	236-239
treatment	O	240-249
of	O	250-252
choice	O	253-259
which	O	260-265
relies	O	266-272
on	O	273-275
adequate	O	276-284
disease	O	285-292
control	O	293-300
with	O	301-305
salvage	O	306-313
chemotherapy	O	314-326
.	O	326-327

Regimens	O	328-336
commonly	O	337-345
used	O	346-350
often	O	351-356
require	O	357-364
inpatient	O	365-374
administration	O	375-389
and	O	390-393
can	O	394-397
be	O	398-400
difficult	O	401-410
to	O	411-413
deliver	O	414-421
due	O	422-425
to	O	426-428
toxicity	B	429-437
.	O	437-438

Gemcitabine	O	439-450
and	O	451-454
cisplatin	O	455-464
have	O	465-469
activity	O	470-478
in	O	479-481
HL	B	482-484
,	O	484-485
non	O	486-489
-	O	489-490
overlapping	O	490-501
toxicity	B	502-510
with	O	511-515
first	O	516-521
-	O	521-522
line	O	522-526
chemotherapeutics	O	527-544
,	O	544-545
and	O	546-549
may	O	550-553
be	O	554-556
delivered	O	557-566
in	O	567-569
an	O	570-572
outpatient	O	573-583
setting	O	584-591
.	O	591-592

In	O	593-595
this	O	596-600
retrospective	O	601-614
single	O	615-621
-	O	621-622
centre	O	622-628
analysis	O	629-637
,	O	637-638
patients	O	639-647
with	O	648-652
relapsed	O	653-661
or	O	662-664
refractory	O	665-675
HL	B	676-678
treated	O	679-686
with	O	687-691
gemcitabine	O	692-703
1	O	704-705
,	O	705-706
000	O	706-709
mg	O	710-712
/	O	712-713
m	O	710-711
(	O	714-715
2	O	715-716
)	O	716-717
day	O	718-721
(	O	722-723
D	O	723-724
)	O	724-725
1	O	725-726
,	O	726-727
D8	O	728-730
and	O	731-734
D15	O	735-738
;	O	738-739
methylprednisolone	O	740-758
1	O	759-760
,	O	760-761
000	O	761-764
mg	O	765-767
D1	O	768-770
-	O	770-771
5	O	771-772
;	O	772-773
and	O	774-777
cisplatin	O	778-787
100	O	788-791
mg	O	792-794
/	O	794-795
m	O	792-793
(	O	796-797
2	O	797-798
)	O	798-799
D15	O	800-803
,	O	803-804
every	O	805-810
28	O	811-813
days	O	814-818
(	O	819-820
GEM	O	820-823
-	O	823-824
P	O	824-825
)	O	825-826
were	O	827-831
included	O	832-840
.	O	840-841

Demographic	O	842-853
,	O	853-854
survival	O	855-863
,	O	863-864
response	O	865-873
and	O	874-877
toxicity	B	878-886
data	O	887-891
were	O	892-896
recorded	O	897-905
.	O	905-906

Forty	O	907-912
-	O	912-913
one	O	913-916
eligible	O	917-925
patients	O	926-934
were	O	935-939
identified	O	940-950
:	O	950-951
median	O	952-958
age	O	959-962
27	O	963-965
.	O	965-966

One	O	967-970
hundred	O	971-978
and	O	979-982
twenty	O	983-989
-	O	989-990
two	O	990-993
cycles	O	994-1000
of	O	1001-1003
GEM	O	1004-1007
-	O	1007-1008
P	O	1008-1009
were	O	1010-1014
administered	O	1015-1027
in	O	1028-1030
total	O	1031-1036
(	O	1037-1038
median	O	1038-1044
3	O	1045-1046
cycles	O	1047-1053
;	O	1053-1054
range	O	1055-1060
1	O	1061-1062
-	O	1062-1063
6	O	1063-1064
)	O	1064-1065
.	O	1065-1066

Twenty	O	1067-1073
of	O	1074-1076
41	O	1077-1079
(	O	1080-1081
48	O	1081-1083
%	O	1084-1085
)	O	1085-1086
patients	O	1087-1095
received	O	1096-1104
GEM	O	1105-1108
-	O	1108-1109
P	O	1109-1110
as	O	1111-1113
second	O	1114-1120
-	O	1120-1121
line	O	1121-1125
treatment	O	1126-1135
and	O	1136-1139
11	O	1140-1142
/	O	1142-1143
41	O	1143-1145
(	O	1146-1147
27	O	1147-1149
%	O	1150-1151
)	O	1151-1152
as	O	1153-1155
third	O	1156-1161
-	O	1161-1162
line	O	1162-1166
therapy	O	1167-1174
.	O	1174-1175

Overall	O	1176-1183
response	O	1184-1192
rate	O	1193-1197
(	O	1198-1199
ORR	O	1199-1202
)	O	1202-1203
to	O	1204-1206
GEM	O	1207-1210
-	O	1210-1211
P	O	1211-1212
in	O	1213-1215
the	O	1216-1219
entire	O	1220-1226
cohort	O	1227-1233
was	O	1234-1237
80	O	1238-1240
%	O	1241-1242
(	O	1243-1244
complete	O	1244-1252
response	O	1253-1261
(	O	1262-1263
CR	O	1263-1265
)	O	1265-1266
37	O	1267-1269
%	O	1270-1271
,	O	1271-1272
partial	O	1273-1280
response	O	1281-1289
44	O	1290-1292
%	O	1293-1294
)	O	1294-1295
with	O	1296-1300
14	O	1301-1303
/	O	1303-1304
15	O	1304-1306
CR	O	1307-1309
confirmed	O	1310-1319
as	O	1320-1322
a	O	1323-1324
metabolic	O	1325-1334
CR	O	1335-1337
on	O	1338-1340
PET	O	1341-1344
and	O	1345-1348
ORR	O	1349-1352
of	O	1353-1355
85	O	1356-1358
%	O	1359-1360
in	O	1361-1363
the	O	1364-1367
20	O	1368-1370
second	O	1371-1377
-	O	1377-1378
line	O	1378-1382
patients	O	1383-1391
.	O	1391-1392

The	O	1393-1396
most	O	1397-1401
common	O	1402-1408
grade	O	1409-1414
3	O	1415-1416
/	O	1416-1417
4	O	1417-1418
toxicities	B	1419-1429
were	O	1430-1434
haematological	O	1435-1449
:	O	1449-1450
neutropenia	B	1451-1462
54	O	1463-1465
%	O	1466-1467
and	O	1468-1471
thrombocytopenia	B	1472-1488
51	O	1489-1491
%	O	1492-1493
.	O	1493-1494

Median	O	1495-1501
follow	O	1502-1508
-	O	1508-1509
up	O	1509-1511
from	O	1512-1516
the	O	1517-1520
start	O	1521-1526
of	O	1527-1529
GEM	O	1530-1533
-	O	1533-1534
P	O	1534-1535
was	O	1536-1539
4	O	1540-1541
.	O	1541-1542
5	O	1542-1543
years	O	1544-1549
.	O	1549-1550

Following	O	1551-1560
GEM	O	1561-1564
-	O	1564-1565
P	O	1565-1566
,	O	1566-1567
5	O	1568-1569
-	O	1569-1570
year	O	1570-1574
progression	O	1575-1586
-	O	1586-1587
free	O	1587-1591
survival	O	1592-1600
was	O	1601-1604
46	O	1605-1607
%	O	1608-1609
(	O	1610-1611
95	O	1611-1613
%	O	1614-1615
confidence	O	1616-1626
interval	O	1627-1635
(	O	1636-1637
CI	O	1637-1639
)	O	1639-1640
,	O	1640-1641
30	O	1642-1644
-	O	1644-1645
62	O	1645-1647
%	O	1648-1649
)	O	1649-1650
and	O	1651-1654
5	O	1655-1656
-	O	1656-1657
year	O	1657-1661
overall	O	1662-1669
survival	O	1670-1678
was	O	1679-1682
59	O	1683-1685
%	O	1686-1687
(	O	1688-1689
95	O	1689-1691
%	O	1692-1693
CI	O	1694-1696
,	O	1696-1697
43	O	1698-1700
-	O	1700-1701
74	O	1701-1703
%	O	1704-1705
)	O	1705-1706
.	O	1706-1707

Fourteen	O	1708-1716
of	O	1717-1719
41	O	1720-1722
patients	O	1723-1731
proceeded	O	1732-1741
directly	O	1742-1750
to	O	1751-1753
autologous	O	1754-1764
transplant	O	1765-1775
.	O	1775-1776

GEM	O	1777-1780
-	O	1780-1781
P	O	1781-1782
is	O	1783-1785
a	O	1786-1787
salvage	O	1788-1795
chemotherapy	O	1796-1808
with	O	1809-1813
relatively	O	1814-1824
high	O	1825-1829
response	O	1830-1838
rates	O	1839-1844
,	O	1844-1845
leading	O	1846-1853
to	O	1854-1856
successful	O	1857-1867
transplantation	O	1868-1883
in	O	1884-1886
appropriate	O	1887-1898
patients	O	1899-1907
,	O	1907-1908
in	O	1909-1911
the	O	1912-1915
treatment	O	1916-1925
of	O	1926-1928
relapsed	O	1929-1937
or	O	1938-1940
refractory	O	1941-1951
HL	B	1952-1954
.	O	1954-1955

Basal	O	0-5
functioning	O	6-17
of	O	18-20
the	O	21-24
hypothalamic	O	25-37
-	O	37-38
pituitary	O	38-47
-	O	37-38
adrenal	O	48-55
(	O	56-57
HPA	O	57-60
)	O	60-61
axis	O	62-66
and	O	67-70
psychological	O	71-84
distress	O	85-93
in	O	94-96
recreational	O	97-109
ecstasy	O	110-117
polydrug	O	118-126
users	O	127-132
.	O	132-133

RATIONALE	O	134-143
:	O	143-144
Ecstasy	O	145-152
(	O	153-154
MDMA	O	154-158
)	O	158-159
is	O	160-162
a	O	163-164
psychostimulant	O	165-180
drug	O	181-185
which	O	186-191
is	O	192-194
increasingly	O	195-207
associated	O	208-218
with	O	219-223
psychobiological	B	224-240
dysfunction	I	241-252
.	O	252-253

While	O	254-259
some	O	260-264
recent	O	265-271
studies	O	272-279
suggest	O	280-287
acute	O	288-293
changes	O	294-301
in	O	302-304
neuroendocrine	O	305-319
function	O	320-328
,	O	328-329
less	O	330-334
is	O	335-337
known	O	338-343
about	O	344-349
long	O	350-354
-	O	354-355
term	O	355-359
changes	O	360-367
in	O	368-370
HPA	O	371-374
functionality	O	375-388
in	O	389-391
recreational	O	392-404
users	O	405-410
.	O	410-411

OBJECTIVES	O	412-422
:	O	422-423
The	O	424-427
current	O	428-435
study	O	436-441
is	O	442-444
the	O	445-448
first	O	449-454
to	O	455-457
explore	O	458-465
the	O	466-469
effects	O	470-477
of	O	478-480
ecstasy	O	481-488
-	O	488-489
polydrug	O	489-497
use	O	498-501
on	O	502-504
psychological	O	505-518
distress	O	519-527
and	O	528-531
basal	O	532-537
functioning	O	538-549
of	O	550-552
the	O	553-556
HPA	O	557-560
axis	O	561-565
through	O	566-573
assessing	O	574-583
the	O	584-587
secretion	O	588-597
of	O	598-600
cortisol	O	601-609
across	O	610-616
the	O	617-620
diurnal	O	621-628
period	O	629-635
.	O	635-636

METHOD	O	637-643
:	O	643-644
Seventy	O	645-652
-	O	652-653
six	O	653-656
participants	O	657-669
(	O	670-671
21	O	671-673
nonusers	O	674-682
,	O	682-683
29	O	684-686
light	O	687-692
ecstasy	O	693-700
-	O	700-701
polydrug	O	701-709
users	O	710-715
,	O	715-716
26	O	717-719
heavy	O	720-725
ecstasy	O	726-733
-	O	733-734
polydrug	O	734-742
users	O	743-748
)	O	748-749
completed	O	750-759
a	O	760-761
substance	O	762-771
use	O	772-775
inventory	O	776-785
and	O	786-789
measures	O	790-798
of	O	799-801
psychological	O	802-815
distress	O	816-824
at	O	825-827
baseline	O	828-836
,	O	836-837
then	O	838-842
two	O	843-846
consecutive	O	847-858
days	O	859-863
of	O	864-866
cortisol	O	867-875
sampling	O	876-884
(	O	885-886
on	O	886-888
awakening	O	889-898
,	O	898-899
30	O	900-902
min	O	903-906
post	O	907-911
awakening	O	912-921
,	O	921-922
between	O	923-930
1400	O	931-935
and	O	936-939
1600	O	940-944
hours	O	945-950
and	O	951-954
pre	O	955-958
bedtime	O	959-966
)	O	966-967
.	O	967-968

On	O	969-971
day	O	972-975
2	O	976-977
,	O	977-978
participants	O	979-991
also	O	992-996
attended	O	997-1005
the	O	1006-1009
laboratory	O	1010-1020
to	O	1021-1023
complete	O	1024-1032
a	O	1033-1034
20	O	1035-1037
-	O	1037-1038
min	O	1038-1041
multitasking	O	1042-1054
stressor	O	1055-1063
.	O	1063-1064

RESULTS	O	1065-1072
:	O	1072-1073
Both	O	1074-1078
user	O	1079-1083
groups	O	1084-1090
exhibited	O	1091-1100
significantly	O	1101-1114
greater	O	1115-1122
levels	O	1123-1129
of	O	1130-1132
anxiety	B	1133-1140
and	O	1141-1144
depression	B	1145-1155
than	O	1156-1160
nonusers	O	1161-1169
.	O	1169-1170

On	O	1171-1173
day	O	1174-1177
1	O	1178-1179
,	O	1179-1180
all	O	1181-1184
participants	O	1185-1197
exhibited	O	1198-1207
a	O	1208-1209
typical	O	1210-1217
cortisol	O	1218-1226
profile	O	1227-1234
,	O	1234-1235
though	O	1236-1242
light	O	1243-1248
users	O	1249-1254
had	O	1255-1258
significantly	O	1259-1272
elevated	O	1273-1281
levels	O	1282-1288
pre	O	1289-1292
-	O	1292-1293
bed	O	1293-1296
.	O	1296-1297

On	O	1298-1300
day	O	1301-1304
2	O	1305-1306
,	O	1306-1307
heavy	O	1308-1313
users	O	1314-1319
demonstrated	O	1320-1332
elevated	O	1333-1341
levels	O	1342-1348
upon	O	1349-1353
awakening	O	1354-1363
and	O	1364-1367
all	O	1368-1371
ecstasy	O	1372-1379
-	O	1379-1380
polydrug	O	1380-1388
users	O	1389-1394
demonstrated	O	1395-1407
elevated	O	1408-1416
pre	O	1417-1420
-	O	1420-1421
bed	O	1421-1424
levels	O	1425-1431
compared	O	1432-1440
to	O	1441-1443
non	O	1444-1447
-	O	1447-1448
users	O	1448-1453
.	O	1453-1454

Significant	O	1455-1466
between	O	1467-1474
group	O	1475-1480
differences	O	1481-1492
were	O	1493-1497
also	O	1498-1502
observed	O	1503-1511
in	O	1512-1514
afternoon	O	1515-1524
cortisol	O	1525-1533
levels	O	1534-1540
and	O	1541-1544
in	O	1545-1547
overall	O	1548-1555
cortisol	O	1556-1564
secretion	O	1565-1574
across	O	1575-1581
the	O	1582-1585
day	O	1586-1589
.	O	1589-1590

CONCLUSIONS	O	1591-1602
:	O	1602-1603
The	O	1604-1607
increases	O	1608-1617
in	O	1618-1620
anxiety	B	1621-1628
and	O	1629-1632
depression	B	1633-1643
are	O	1644-1647
in	O	1648-1650
line	O	1651-1655
with	O	1656-1660
previous	O	1661-1669
observations	O	1670-1682
in	O	1683-1685
recreational	O	1686-1698
ecstasy	O	1699-1706
-	O	1706-1707
polydrug	O	1707-1715
users	O	1716-1721
.	O	1721-1722

Dysregulated	O	1723-1735
diurnal	O	1736-1743
cortisol	O	1744-1752
may	O	1753-1756
be	O	1757-1759
indicative	O	1760-1770
of	O	1771-1773
inappropriate	O	1774-1787
anticipation	O	1788-1800
of	O	1801-1803
forthcoming	O	1804-1815
demands	O	1816-1823
and	O	1824-1827
hypersecretion	O	1828-1842
may	O	1843-1846
lead	O	1847-1851
to	O	1852-1854
the	O	1855-1858
increased	O	1859-1868
psychological	O	1869-1882
and	O	1883-1886
physical	O	1887-1895
morbidity	O	1896-1905
associated	O	1906-1916
with	O	1917-1921
heavy	O	1922-1927
recreational	O	1928-1940
use	O	1941-1944
of	O	1945-1947
ecstasy	O	1948-1955
.	O	1955-1956

Ifosfamide	O	0-10
related	O	11-18
encephalopathy	B	19-33
:	O	33-34
the	O	35-38
need	O	39-43
for	O	44-47
a	O	48-49
timely	O	50-56
EEG	O	57-60
evaluation	O	61-71
.	O	71-72

BACKGROUND	O	73-83
:	O	83-84
Ifosfamide	O	85-95
is	O	96-98
an	O	99-101
alkylating	O	102-112
agent	O	113-118
useful	O	119-125
in	O	126-128
the	O	129-132
treatment	O	133-142
of	O	143-145
a	O	146-147
wide	O	148-152
range	O	153-158
of	O	159-161
cancers	B	162-169
including	O	170-179
sarcomas	B	180-188
,	O	188-189
lymphoma	B	190-198
,	O	198-199
gynecologic	B	200-211
and	I	212-215
testicular	I	216-226
cancers	I	227-234
.	O	234-235

Encephalopathy	B	236-250
has	O	251-254
been	O	255-259
reported	O	260-268
in	O	269-271
10	O	272-274
-	O	274-275
40	O	275-277
%	O	277-278
of	O	279-281
patients	O	282-290
receiving	O	291-300
high	O	301-305
-	O	305-306
dose	O	306-310
IV	O	311-313
ifosfamide	O	314-324
.	O	324-325

OBJECTIVE	O	326-335
:	O	335-336
To	O	337-339
highlight	O	340-349
the	O	350-353
role	O	354-358
of	O	359-361
electroencephalogram	O	362-382
(	O	383-384
EEG	O	384-387
)	O	387-388
in	O	389-391
the	O	392-395
early	O	396-401
detection	O	402-411
and	O	412-415
management	O	416-426
of	O	427-429
ifosfamide	O	430-440
related	O	441-448
encephalopathy	B	449-463
.	O	463-464

METHODS	O	465-472
:	O	472-473
Retrospective	O	474-487
chart	O	488-493
review	O	494-500
including	O	501-510
clinical	O	511-519
data	O	520-524
and	O	525-528
EEG	O	529-532
recordings	O	533-543
was	O	544-547
done	O	548-552
on	O	553-555
five	O	556-560
patients	O	561-569
,	O	569-570
admitted	O	571-579
to	O	580-582
MD	O	583-585
Anderson	O	586-594
Cancer	B	595-601
Center	O	602-608
between	O	609-616
years	O	617-622
2009	O	623-627
and	O	628-631
2012	O	632-636
,	O	636-637
who	O	638-641
developed	O	642-651
ifosfamide	O	652-662
related	O	663-670
acute	O	671-676
encephalopathy	B	677-691
.	O	691-692

RESULTS	O	693-700
:	O	700-701
All	O	702-705
five	O	706-710
patients	O	711-719
experienced	O	720-731
symptoms	O	732-740
of	O	741-743
encephalopathy	B	744-758
soon	O	759-763
after	O	764-769
(	O	770-771
within	O	771-777
12	O	778-780
h	O	781-782
-	O	782-783
2	O	783-784
days	O	785-789
)	O	789-790
receiving	O	791-800
ifosfamide	O	801-811
.	O	811-812

Two	O	813-816
patients	O	817-825
developed	O	826-835
generalized	O	836-847
convulsions	B	848-859
while	O	860-865
one	O	866-869
patient	O	870-877
developed	O	878-887
continuous	O	888-898
non	B	899-902
-	I	902-903
convulsive	I	903-913
status	I	914-920
epilepticus	I	921-932
(	O	933-934
NCSE	B	934-938
)	O	938-939
that	O	940-944
required	O	945-953
ICU	O	954-957
admission	O	958-967
and	O	968-971
intubation	O	972-982
.	O	982-983

Initial	O	984-991
EEG	O	992-995
showed	O	996-1002
epileptiform	O	1003-1015
discharges	O	1016-1026
in	O	1027-1029
three	O	1030-1035
patients	O	1036-1044
;	O	1044-1045
run	O	1046-1049
of	O	1050-1052
triphasic	O	1053-1062
waves	O	1063-1068
in	O	1069-1071
one	O	1072-1075
patient	O	1076-1083
and	O	1084-1087
moderate	O	1088-1096
degree	O	1097-1103
diffuse	O	1104-1111
generalized	O	1112-1123
slowing	O	1124-1131
.	O	1131-1132

Mixed	O	1133-1138
pattern	O	1139-1146
with	O	1147-1151
the	O	1152-1155
presence	O	1156-1164
of	O	1165-1167
both	O	1168-1172
sharps	O	1173-1179
and	O	1180-1183
triphasic	O	1184-1193
waves	O	1194-1199
were	O	1200-1204
also	O	1205-1209
noted	O	1210-1215
.	O	1215-1216

Repeat	O	1217-1223
EEGs	O	1224-1228
within	O	1229-1235
24	O	1236-1238
_	O	1238-1239
h	O	1239-1240
of	O	1241-1243
symptom	O	1244-1251
onset	O	1252-1257
showed	O	1258-1264
marked	O	1265-1271
improvement	O	1272-1283
that	O	1284-1288
was	O	1289-1292
correlated	O	1293-1303
with	O	1304-1308
clinical	O	1309-1317
improvement	O	1318-1329
.	O	1329-1330

CONCLUSIONS	O	1331-1342
:	O	1342-1343
Severity	O	1344-1352
of	O	1353-1355
ifosfamide	O	1356-1366
related	O	1367-1374
encephalopathy	B	1375-1389
correlates	O	1390-1400
with	O	1401-1405
EEG	O	1406-1409
changes	O	1410-1417
.	O	1417-1418

We	O	1419-1421
suggest	O	1422-1429
a	O	1430-1431
timely	O	1432-1438
EEG	O	1439-1442
evaluation	O	1443-1453
for	O	1454-1457
patients	O	1458-1466
receiving	O	1467-1476
ifosfamide	O	1477-1487
who	O	1488-1491
develop	O	1492-1499
features	O	1500-1508
of	O	1509-1511
encephalopathy	B	1512-1526
.	O	1526-1527

Incidence	O	0-9
of	O	10-12
contrast	O	13-21
-	O	21-22
induced	O	22-29
nephropathy	B	30-41
in	O	42-44
hospitalised	O	45-57
patients	O	58-66
with	O	67-71
cancer	B	72-78
.	O	78-79

OBJECTIVES	O	80-90
:	O	90-91
To	O	92-94
determine	O	95-104
the	O	105-108
frequency	O	109-118
of	O	119-121
and	O	122-125
possible	O	126-134
factors	O	135-142
related	O	143-150
to	O	151-153
contrast	O	154-162
-	O	162-163
induced	O	163-170
nephropathy	B	171-182
(	O	183-184
CIN	O	184-187
)	O	187-188
in	O	189-191
hospitalised	O	192-204
patients	O	205-213
with	O	214-218
cancer	B	219-225
.	O	225-226

METHODS	O	227-234
:	O	234-235
Ninety	O	236-242
adult	O	243-248
patients	O	249-257
were	O	258-262
enrolled	O	263-271
.	O	271-272

Patients	O	273-281
with	O	282-286
risk	O	287-291
factors	O	292-299
for	O	300-303
acute	B	304-309
renal	I	310-315
failure	I	316-323
were	O	324-328
excluded	O	329-337
.	O	337-338

Blood	O	339-344
samples	O	345-352
were	O	353-357
examined	O	358-366
the	O	367-370
day	O	371-374
before	O	375-381
contrast	O	382-390
-	O	390-391
enhanced	O	391-399
computed	O	400-408
tomography	O	409-419
(	O	420-421
CT	O	421-423
)	O	423-424
and	O	425-428
serially	O	429-437
for	O	438-441
3	O	442-443
days	O	444-448
thereafter	O	449-459
.	O	459-460

CIN	O	461-464
was	O	465-468
defined	O	469-476
as	O	477-479
an	O	480-482
increase	O	483-491
in	O	492-494
serum	O	495-500
creatinine	O	501-511
(	O	512-513
Cr	O	513-515
)	O	515-516
of	O	517-519
0	O	520-521
.	O	521-522
5	O	522-523
mg	O	524-526
/	O	526-527
dl	O	527-529
or	O	530-532
more	O	533-537
,	O	537-538
or	O	539-541
elevation	O	542-551
of	O	552-554
Cr	O	555-557
to	O	558-560
25	O	561-563
%	O	564-565
over	O	566-570
baseline	O	571-579
.	O	579-580

Relationships	O	581-594
between	O	595-602
CIN	O	603-606
and	O	607-610
possible	O	611-619
risk	O	620-624
factors	O	625-632
were	O	633-637
investigated	O	638-650
.	O	650-651

RESULTS	O	652-659
:	O	659-660
CIN	O	661-664
was	O	665-668
detected	O	669-677
in	O	678-680
18	O	681-683
/	O	683-684
90	O	684-686
(	O	687-688
20	O	688-690
%	O	691-692
)	O	692-693
patients	O	694-702
.	O	702-703

CIN	O	704-707
developed	O	708-717
in	O	718-720
25	O	721-723
.	O	723-724
5	O	722-723
%	O	726-727
patients	O	728-736
who	O	737-740
underwent	O	741-750
chemotherapy	O	751-763
and	O	764-767
in	O	768-770
11	O	771-773
%	O	774-775
patients	O	776-784
who	O	785-788
did	O	789-792
not	O	793-796
(	O	797-798
P	O	798-799
=	O	800-801
0	O	802-803
.	O	803-804
1	O	804-805
)	O	805-806
.	O	803-804

CIN	O	808-811
more	O	812-816
frequently	O	817-827
developed	O	828-837
in	O	838-840
patients	O	841-849
who	O	850-853
had	O	854-857
undergone	O	858-867
CT	O	868-870
within	O	871-877
45	O	878-880
days	O	881-885
after	O	886-891
the	O	892-895
last	O	896-900
chemotherapy	O	901-913
(	O	914-915
P	O	915-916
=	O	917-918
0	O	919-920
.	O	920-921
005	O	921-924
)	O	924-925
;	O	925-926
it	O	927-929
was	O	930-933
also	O	934-938
an	O	939-941
independent	O	942-953
risk	O	954-958
factor	O	959-965
(	O	966-967
P	O	967-968
=	O	969-970
0	O	971-972
.	O	972-973
017	O	973-976
)	O	976-977
.	O	972-973

CIN	O	979-982
was	O	983-986
significantly	O	987-1000
more	O	1001-1005
after	O	1006-1011
treatment	O	1012-1021
with	O	1022-1026
bevacizumab	O	1027-1038
/	O	1038-1039
irinotecan	O	1039-1049
(	O	1050-1051
P	O	1051-1052
=	O	1053-1054
0	O	1055-1056
.	O	1056-1057
021	O	1057-1060
)	O	1060-1061
and	O	1062-1065
in	O	1066-1068
patients	O	1069-1077
with	O	1078-1082
hypertension	B	1083-1095
(	O	1096-1097
P	O	1097-1098
=	O	1099-1100
0	O	1101-1102
.	O	1102-1103
044	O	1103-1106
)	O	1106-1107
.	O	1102-1103

CONCLUSIONS	O	1109-1120
:	O	1120-1121
The	O	1122-1125
incidence	O	1126-1135
of	O	1136-1138
CIN	O	1139-1142
after	O	1143-1148
CT	O	1149-1151
in	O	1152-1154
hospitalised	O	1155-1167
oncological	O	1168-1179
patients	O	1180-1188
was	O	1189-1192
20	O	1193-1195
%	O	1196-1197
.	O	1197-1198

CIN	O	1199-1202
developed	O	1203-1212
4	O	1213-1214
.	O	1214-1215
5	O	1215-1216
-	O	1216-1217
times	O	1217-1222
more	O	1223-1227
frequently	O	1228-1238
in	O	1239-1241
patients	O	1242-1250
with	O	1251-1255
cancer	B	1256-1262
who	O	1263-1266
had	O	1267-1270
undergone	O	1271-1280
recent	O	1281-1287
chemotherapy	O	1288-1300
.	O	1300-1301

Hypertension	B	1302-1314
and	O	1315-1318
the	O	1319-1322
combination	O	1323-1334
of	O	1335-1337
bevacizumab	O	1338-1349
/	O	1349-1350
irinotecan	O	1350-1360
may	O	1361-1364
be	O	1365-1367
additional	O	1368-1378
risk	O	1379-1383
factors	O	1384-1391
for	O	1392-1395
CIN	O	1396-1399
development	O	1400-1411
.	O	1411-1412

KEY	O	1413-1416
POINTS	O	1417-1423
:	O	1423-1424
.	O	1425-1426

Contrast	O	1427-1435
-	O	1435-1436
induced	O	1436-1443
nephropathy	B	1444-1455
(	O	1456-1457
CIN	O	1457-1460
)	O	1460-1461
is	O	1462-1464
a	O	1465-1466
concern	O	1467-1474
for	O	1475-1478
oncological	O	1479-1490
patients	O	1491-1499
undergoing	O	1500-1510
CT	O	1511-1513
.	O	1513-1514
.	O	1515-1516

CIN	O	1517-1520
occurs	O	1521-1527
more	O	1528-1532
often	O	1533-1538
when	O	1539-1543
CT	O	1544-1546
is	O	1547-1549
performed	O	1550-1559
<	O	1560-1561
45	O	1561-1563
days	O	1564-1568
after	O	1569-1574
chemotherapy	O	1575-1587
.	O	1587-1588
.	O	1589-1590

Hypertension	B	1591-1603
and	O	1604-1607
treatment	O	1608-1617
with	O	1618-1622
bevacizumab	O	1623-1634
appear	O	1635-1641
to	O	1642-1644
be	O	1645-1647
additional	O	1648-1658
risk	O	1659-1663
factors	O	1664-1671
.	O	1671-1672

Syndrome	B	0-8
of	I	9-11
inappropriate	I	12-25
antidiuretic	I	26-38
hormone	I	39-46
secretion	O	47-56
associated	O	57-67
with	O	68-72
desvenlafaxine	O	73-87
.	O	87-88

OBJECTIVE	O	89-98
:	O	98-99
To	O	100-102
report	O	103-109
a	O	110-111
case	O	112-116
of	O	117-119
syndrome	B	120-128
of	I	129-131
inappropriate	I	132-145
anti	I	146-150
-	I	150-151
diuretic	I	151-159
hormone	I	160-167
(	O	168-169
SIADH	B	169-174
)	O	174-175
secretion	O	176-185
associated	O	186-196
with	O	197-201
desvenlafaxine	O	202-216
.	O	216-217

CASE	O	218-222
SUMMARY	O	223-230
:	O	230-231
A	O	232-233
57	O	234-236
-	O	236-237
year	O	237-241
old	O	242-245
female	O	246-252
with	O	253-257
hyponatraemia	B	258-271
.	O	271-272

Her	O	273-276
medications	O	277-288
included	O	289-297
desvenlafaxine	O	298-312
,	O	312-313
and	O	314-317
symptoms	O	318-326
included	O	327-335
nausea	B	336-342
,	O	342-343
anxiety	B	344-351
and	O	352-355
confusion	B	356-365
.	O	365-366

The	O	367-370
serum	O	371-376
sodium	O	377-383
at	O	384-386
this	O	387-391
time	O	392-396
was	O	397-400
120	O	401-404
mmol	O	405-409
/	O	409-410
L	O	410-411
,	O	411-412
serum	O	413-418
osmolality	O	419-429
was	O	430-433
263	O	434-437
mosmol	O	438-444
/	O	444-445
kg	O	445-447
,	O	447-448
urine	O	449-454
osmolality	O	455-465
410	O	466-469
mosmol	O	470-476
/	O	476-477
kg	O	477-479
and	O	480-483
urine	O	484-489
sodium	O	490-496
63	O	497-499
mmol	O	500-504
/	O	504-505
L	O	505-506
,	O	506-507
consistent	O	508-518
with	O	519-523
a	O	524-525
diagnosis	O	526-535
of	O	536-538
SIADH	B	539-544
.	O	544-545

Desvenlafaxine	O	546-560
was	O	561-564
ceased	O	565-571
and	O	572-575
fluid	O	576-581
restriction	O	582-593
implemented	O	594-605
.	O	605-606

After	O	607-612
4	O	613-614
days	O	615-619
the	O	620-623
sodium	O	624-630
increased	O	631-640
to	O	641-643
128	O	644-647
mmol	O	648-652
/	O	652-653
L	O	653-654
and	O	655-658
fluid	O	659-664
restriction	O	665-676
was	O	677-680
relaxed	O	681-688
.	O	688-689

During	O	690-696
her	O	697-700
further	O	701-708
3	O	709-710
weeks	O	711-716
inpatient	O	717-726
admission	O	727-736
the	O	737-740
serum	O	741-746
sodium	O	747-753
ranged	O	754-760
from	O	761-765
134	O	766-769
to	O	770-772
137	O	773-776
mmol	O	777-781
/	O	781-782
L	O	782-783
during	O	784-790
treatment	O	791-800
with	O	801-805
mirtazapine	O	806-817
.	O	817-818

DISCUSSION	O	819-829
:	O	829-830
SIADH	B	831-836
has	O	837-840
been	O	841-845
widely	O	846-852
reported	O	853-861
with	O	862-866
a	O	867-868
range	O	869-874
of	O	875-877
antidepressants	O	878-893
.	O	893-894

This	O	895-899
case	O	900-904
report	O	905-911
suggests	O	912-920
that	O	921-925
desvenlafaxine	O	926-940
might	O	941-946
cause	O	947-952
clinically	O	953-963
significant	O	964-975
hyponatremia	B	976-988
.	O	988-989

CONCLUSIONS	O	990-1001
:	O	1001-1002
Clinicians	O	1003-1013
should	O	1014-1020
be	O	1021-1023
aware	O	1024-1029
of	O	1030-1032
the	O	1033-1036
potential	O	1037-1046
for	O	1047-1050
antidepressants	O	1051-1066
to	O	1067-1069
cause	O	1070-1075
hyponatremia	B	1076-1088
,	O	1088-1089
and	O	1089-1092
take	O	1093-1097
appropriate	O	1098-1109
corrective	O	1110-1120
action	O	1121-1127
where	O	1128-1133
necessary	O	1134-1143
.	O	1143-1144

Oxidative	O	0-9
stress	O	10-16
on	O	17-19
cardiotoxicity	B	20-34
after	O	35-40
treatment	O	41-50
with	O	51-55
single	O	56-62
and	O	63-66
multiple	O	67-75
doses	O	76-81
of	O	82-84
doxorubicin	O	85-96
.	O	96-97

The	O	98-101
mechanism	O	102-111
of	O	112-114
doxorubicin	O	115-126
(	O	127-128
DOX	O	128-131
)	O	131-132
-	O	132-133
induced	O	133-140
cardiotoxicity	B	141-155
remains	O	156-163
controversial	O	164-177
.	O	177-178

Wistar	O	179-185
rats	O	186-190
(	O	191-192
n	O	192-193
=	O	194-195
66	O	196-198
)	O	198-199
received	O	200-208
DOX	O	209-212
injections	O	213-223
intraperitoneally	O	224-241
and	O	242-245
were	O	246-250
randomly	O	251-259
assigned	O	260-268
to	O	269-271
2	O	272-273
experimental	O	274-286
protocols	O	287-296
:	O	296-297
(	O	298-299
1	O	299-300
)	O	300-301
rats	O	302-306
were	O	307-311
killed	O	312-318
before	O	319-325
(	O	326-327
-	O	327-328
24	O	328-330
h	O	331-332
,	O	332-333
n	O	334-335
=	O	336-337
8	O	338-339
)	O	339-340
and	O	341-344
24	O	345-347
h	O	348-349
after	O	350-355
(	O	356-357
+	O	357-358
24	O	358-360
h	O	361-362
,	O	362-363
n	O	364-365
=	O	366-367
8	O	368-369
)	O	369-370
a	O	371-372
single	O	373-379
dose	O	380-384
of	O	385-387
DOX	O	388-391
(	O	392-393
4	O	393-394
mg	O	395-397
/	O	397-398
kg	O	398-400
body	O	401-405
weight	O	406-412
)	O	412-413
to	O	414-416
determine	O	417-426
the	O	427-430
DOX	O	431-434
acute	O	435-440
effect	O	441-447
and	O	448-451
(	O	452-453
2	O	453-454
)	O	454-455
rats	O	456-460
(	O	461-462
n	O	462-463
=	O	464-465
58	O	466-468
)	O	468-469
received	O	470-478
4	O	479-480
injections	O	481-491
of	O	492-494
DOX	O	495-498
(	O	499-500
4	O	500-501
mg	O	502-504
/	O	504-505
kg	O	505-507
body	O	508-512
weight	O	513-519
/	O	519-520
week	O	520-524
)	O	524-525
and	O	526-529
were	O	530-534
killed	O	535-541
before	O	542-548
the	O	549-552
first	O	553-558
injection	O	559-568
(	O	569-570
M0	O	570-572
)	O	572-573
and	O	574-577
1	O	578-579
week	O	580-584
after	O	585-590
each	O	591-595
injection	O	596-605
(	O	606-607
M1	O	607-609
,	O	609-610
M2	O	611-613
,	O	613-614
M3	O	615-617
,	O	617-618
and	O	619-622
M4	O	623-625
)	O	625-626
to	O	627-629
determine	O	630-639
the	O	640-643
chronological	O	644-657
effects	O	658-665
.	O	665-666

Animals	O	667-674
used	O	675-679
at	O	680-682
M0	O	683-685
(	O	686-687
n	O	687-688
=	O	689-690
8	O	691-692
)	O	692-693
were	O	694-698
also	O	699-703
used	O	704-708
at	O	709-711
moment	O	712-718
-	O	719-720
24	O	720-722
h	O	723-724
of	O	725-727
acute	O	728-733
study	O	734-739
.	O	739-740

Cardiac	O	741-748
total	O	749-754
antioxidant	O	755-766
performance	O	767-778
(	O	779-780
TAP	O	780-783
)	O	783-784
,	O	784-785
DNA	O	786-789
damage	O	790-796
,	O	796-797
and	O	798-801
morphology	O	802-812
analyses	O	813-821
were	O	822-826
carried	O	827-834
out	O	835-838
at	O	839-841
each	O	842-846
time	O	847-851
point	O	852-857
.	O	857-858

Single	O	859-865
dose	O	866-870
of	O	871-873
DOX	O	874-877
was	O	878-881
associated	O	882-892
with	O	893-897
increased	O	898-907
cardiac	B	908-915
disarrangement	I	916-930
,	O	930-931
necrosis	B	932-940
,	O	940-941
and	O	942-945
DNA	O	946-949
damage	O	950-956
(	O	957-958
strand	O	958-964
breaks	O	965-971
(	O	972-973
SBs	O	973-976
)	O	976-977
and	O	978-981
oxidized	O	982-990
pyrimidines	O	991-1002
)	O	1002-1003
and	O	1004-1007
decreased	O	1008-1017
TAP	O	1018-1021
.	O	1021-1022

The	O	1023-1026
chronological	O	1027-1040
study	O	1041-1046
showed	O	1047-1053
an	O	1054-1056
effect	O	1057-1063
of	O	1064-1066
a	O	1067-1068
cumulative	O	1069-1079
dose	O	1080-1084
on	O	1085-1087
body	O	1088-1092
weight	O	1093-1099
(	O	1100-1101
R	O	1101-1102
=	O	1103-1104
-	O	1105-1106
0	O	1106-1107
.	O	1107-1108
99	O	1108-1110
,	O	1110-1111

p	O	1112-1113
=	O	1114-1115
0	O	1116-1117
.	O	1117-1118
011	O	1118-1121
)	O	1121-1122
,	O	1122-1123
necrosis	B	1124-1132
(	O	1133-1134
R	O	1134-1135
=	O	1136-1137
1	O	1138-1139
.	O	1139-1140
00	O	1140-1142
,	O	1142-1143
p	O	1144-1145
=	O	1146-1147
0	O	1148-1149
.	O	1149-1150
004	O	1150-1153
)	O	1153-1154
,	O	1154-1155
TAP	O	1156-1159
(	O	1160-1161
R	O	1161-1162
=	O	1163-1164
0	O	1165-1166
.	O	1166-1167
95	O	1167-1169
,	O	1169-1170
p	O	1171-1172
=	O	1173-1174
0	O	1175-1176
.	O	1176-1177
049	O	1177-1180
)	O	1180-1181
,	O	1181-1182
and	O	1183-1186
DNA	O	1187-1190
SBs	O	1191-1194
(	O	1195-1196
R	O	1196-1197
=	O	1198-1199
-	O	1200-1201
0	O	1201-1202
.	O	1202-1203
95	O	1203-1205
,	O	1205-1206

p	O	1207-1208
=	O	1209-1210
0	O	1211-1212
.	O	1212-1213
049	O	1213-1216
)	O	1216-1217
.	O	1212-1213

DNA	O	1219-1222
SBs	O	1223-1226
damage	O	1227-1233
was	O	1234-1237
negatively	O	1238-1248
associated	O	1249-1259
with	O	1260-1264
TAP	O	1265-1268
(	O	1269-1270
R	O	1270-1271
=	O	1272-1273
-	O	1274-1275
0	O	1275-1276
.	O	1276-1277
98	O	1277-1279
,	O	1279-1280

p	O	1281-1282
=	O	1283-1284
0	O	1285-1286
.	O	1286-1287
018	O	1287-1290
)	O	1290-1291
,	O	1291-1292
and	O	1293-1296
necrosis	B	1297-1305
(	O	1306-1307
R	O	1307-1308
=	O	1309-1310
-	O	1311-1312
0	O	1312-1313
.	O	1313-1314
97	O	1314-1316
,	O	1316-1317

p	O	1318-1319
=	O	1320-1321
0	O	1322-1323
.	O	1323-1324
027	O	1324-1327
)	O	1327-1328
.	O	1323-1324

Our	O	1330-1333
results	O	1334-1341
suggest	O	1342-1349
that	O	1350-1354
oxidative	O	1355-1364
damage	O	1365-1371
is	O	1372-1374
associated	O	1375-1385
with	O	1386-1390
acute	O	1391-1396
cardiotoxicity	B	1397-1411
induced	O	1412-1419
by	O	1420-1422
a	O	1423-1424
single	O	1425-1431
dose	O	1432-1436
of	O	1437-1439
DOX	O	1440-1443
only	O	1444-1448
.	O	1448-1449

Increased	O	1450-1459
resistance	O	1460-1470
to	O	1471-1473
the	O	1474-1477
oxidative	O	1478-1487
stress	O	1488-1494
is	O	1495-1497
plausible	O	1498-1507
for	O	1508-1511
the	O	1512-1515
multiple	O	1516-1524
dose	O	1525-1529
of	O	1530-1532
DOX	O	1533-1536
.	O	1536-1537

Thus	O	1538-1542
,	O	1542-1543
different	O	1544-1553
mechanisms	O	1554-1564
may	O	1565-1568
be	O	1569-1571
involved	O	1572-1580
in	O	1581-1583
acute	O	1584-1589
toxicity	B	1590-1598
versus	O	1599-1605
chronic	O	1606-1613
toxicity	B	1614-1622
.	O	1622-1623

Tacrolimus	O	0-10
-	O	10-11
related	O	11-18
seizure	B	19-26
after	O	27-32
pediatric	O	33-42
liver	O	43-48
transplantation	O	49-64
-	O	64-65
-	O	64-65
a	O	51-52
single	O	68-74
-	O	74-75
center	O	75-81
experience	O	82-92
.	O	92-93

To	O	94-96
identify	O	97-105
the	O	106-109
risk	O	110-114
factors	O	115-122
for	O	123-126
new	O	127-130
-	O	130-131
onset	O	131-136
seizures	B	137-145
after	O	146-151
pediatric	O	152-161
LT	O	162-164
and	O	165-168
to	O	169-171
assess	O	172-178
their	O	179-184
clinical	O	185-193
implications	O	194-206
and	O	207-210
long	O	211-215
-	O	215-216
term	O	216-220
prognosis	O	221-230
.	O	230-231

The	O	232-235
clinical	O	236-244
and	O	245-248
laboratory	O	249-259
data	O	260-264
of	O	265-267
27	O	268-270
consecutive	O	271-282
children	O	283-291
who	O	292-295
underwent	O	296-305
LT	O	306-308
from	O	309-313
January	O	314-321
2007	O	322-326
to	O	327-329
December	O	330-338
2010	O	339-343
in	O	344-346
our	O	347-350
center	O	351-357
were	O	358-362
analyzed	O	363-371
retrospectively	O	372-387
.	O	387-388

Patients	O	389-397
were	O	398-402
divided	O	403-410
into	O	411-415
seizures	B	416-424
group	O	425-430
and	O	431-434
a	O	435-436
non	O	437-440
-	O	440-441
seizures	B	441-449
group	O	450-455
.	O	455-456

Pre	O	457-460
-	O	460-461
operative	O	461-470
,	O	470-471
intra	O	472-477
-	O	477-478
operative	O	478-487
,	O	487-488
and	O	489-492
post	O	493-497
-	O	497-498
operative	O	498-507
data	O	508-512
were	O	513-517
collected	O	518-527
.	O	527-528

Seizures	B	529-537
occurred	O	538-546
in	O	547-549
four	O	550-554
children	O	555-563
,	O	563-564
an	O	565-567
incidence	O	568-577
of	O	578-580
14	O	581-583
.	O	583-584
8	O	584-585
%	O	585-586
.	O	583-584

All	O	588-591
exhibited	O	592-601
generalized	O	602-613
tonic	B	614-619
-	I	619-620
clonic	I	620-626
seizures	I	627-635
within	O	636-642
the	O	643-646
first	O	647-652
two	O	653-656
wk	O	657-659
after	O	660-665
LT	O	666-668
.	O	668-669

Univariate	O	670-680
analysis	O	681-689
showed	O	690-696
that	O	697-701
the	O	702-705
risk	O	706-710
factors	O	711-718
associated	O	719-729
with	O	730-734
seizures	B	735-743
after	O	744-749
pediatric	O	750-759
LT	O	760-762
included	O	763-771
gender	O	772-778
,	O	778-779
pediatric	O	780-789
end	B	790-793
-	I	793-794
stage	I	794-799
liver	I	800-805
disease	I	806-813
score	O	814-819
before	O	820-826
surgery	O	827-834
,	O	834-835
Child	O	836-841
-	O	841-842
Pugh	O	842-846
score	O	847-852
before	O	853-859
surgery	O	860-867
,	O	867-868
serum	O	869-874
total	O	875-880
bilirubin	O	881-890
after	O	891-896
surgery	O	897-904
,	O	904-905
and	O	906-909
trough	O	910-916
TAC	O	917-920
level	O	921-926
.	O	926-927

Multivariate	O	928-940
analysis	O	941-949
showed	O	950-956
that	O	957-961
trough	O	962-968
TAC	O	969-972
level	O	973-978
was	O	979-982
the	O	983-986
only	O	987-991
independent	O	992-1003
risk	O	1004-1008
factor	O	1009-1015
associated	O	1016-1026
with	O	1027-1031
the	O	1032-1035
seizures	B	1036-1044
.	O	1044-1045

All	O	1046-1049
children	O	1050-1058
who	O	1059-1062
experienced	O	1063-1074
seizures	B	1075-1083
survived	O	1084-1092
with	O	1093-1097
good	O	1098-1102
graft	O	1103-1108
function	O	1109-1117
and	O	1118-1121
remained	O	1122-1130
seizure	B	1131-1138
-	O	1138-1139
free	O	1139-1143
without	O	1144-1151
anti	O	1152-1156
-	O	1156-1157
epileptic	B	1157-1166
drugs	O	1167-1172
over	O	1173-1177
a	O	1178-1179
mean	O	1180-1184
follow	O	1185-1191
-	O	1191-1192
up	O	1192-1194
period	O	1195-1201
of	O	1202-1204
33	O	1205-1207
.	O	1207-1208
7	O	1208-1209
+	O	1210-1211
14	O	1212-1214
.	O	1214-1215
6	O	1215-1216
months	O	1217-1223
.	O	1223-1224

High	O	1225-1229
trough	O	1230-1236
TAC	O	1237-1240
level	O	1241-1246
was	O	1247-1250
the	O	1251-1254
predominant	O	1255-1266
factor	O	1267-1273
that	O	1274-1278
contributed	O	1279-1290
to	O	1291-1293
seizures	B	1294-1302
in	O	1303-1305
the	O	1306-1309
early	O	1310-1315
post	O	1316-1320
-	O	1320-1321
operative	O	1321-1330
period	O	1331-1337
after	O	1338-1343
pediatric	O	1344-1353
LT	O	1354-1356
.	O	1356-1357

High	O	1358-1362
PELD	O	1363-1367
and	O	1368-1371
Child	O	1372-1377
-	O	1377-1378
Pugh	O	1378-1382
scores	O	1383-1389
before	O	1390-1396
LT	O	1397-1399
and	O	1400-1403
high	O	1404-1408
post	O	1409-1413
-	O	1413-1414
operative	O	1414-1423
serum	O	1424-1429
Tbil	O	1430-1434
may	O	1435-1438
be	O	1439-1441
contributory	O	1442-1454
risk	O	1455-1459
factors	O	1460-1467
for	O	1468-1471
TAC	O	1472-1475
-	O	1475-1476
related	O	1476-1483
seizures	B	1484-1492
.	O	1492-1493

The	O	0-3
flavonoid	O	4-13
apigenin	O	14-22
delays	O	23-29
forgetting	O	30-40
of	O	41-43
passive	O	44-51
avoidance	O	52-61
conditioning	O	62-74
in	O	75-77
rats	O	78-82
.	O	82-83

The	O	84-87
present	O	88-95
experiments	O	96-107
were	O	108-112
performed	O	113-122
to	O	123-125
study	O	126-131
the	O	132-135
effect	O	136-142
of	O	143-145
the	O	146-149
flavonoid	O	150-159
apigenin	O	160-168
(	O	169-170
20	O	170-172
mg	O	173-175
/	O	175-176
kg	O	176-178
intraperitoneally	O	179-196
(	O	197-198
i	O	198-199
.	O	199-200
p	O	200-201
.	O	199-200
)	O	202-203
,	O	203-204
1	O	205-206
h	O	207-208
before	O	209-215
acquisition	O	216-227
)	O	227-228
,	O	228-229
on	O	230-232
24	O	233-235
h	O	236-237
retention	O	238-247
performance	O	248-259
and	O	260-263
forgetting	O	264-274
of	O	275-277
a	O	278-279
step	O	280-284
-	O	284-285
through	O	285-292
passive	O	293-300
avoidance	O	301-310
task	O	311-315
,	O	315-316
in	O	317-319
young	O	320-325
male	O	326-330
Wistar	O	331-337
rats	O	338-342
.	O	342-343

There	O	344-349
were	O	350-354
no	O	355-357
differences	O	358-369
between	O	370-377
saline	O	378-384
-	O	384-385
and	O	386-389
apigenin	O	390-398
-	O	398-399
treated	O	399-406
groups	O	407-413
in	O	414-416
the	O	417-420
24	O	421-423
h	O	424-425
retention	O	426-435
trial	O	436-441
.	O	441-442

Furthermore	O	443-454
,	O	454-455
apigenin	O	456-464
did	O	465-468
not	O	469-472
prevent	O	473-480
the	O	481-484
amnesia	B	485-492
induced	O	493-500
by	O	501-503
scopolamine	O	504-515
(	O	516-517
1mg	O	517-520
/	O	520-521
kg	O	521-523
,	O	523-524
i	O	525-526
.	O	526-527
p	O	527-528
.	O	526-527
,	O	529-530
30	O	531-533
min	O	534-537
before	O	538-544
the	O	545-548
acquisition	O	549-560
)	O	560-561
.	O	561-562

The	O	563-566
saline	O	567-573
-	O	573-574
and	O	575-578
apigenin	O	579-587
-	O	587-588
treated	O	588-595
rats	O	596-600
that	O	601-605
did	O	606-609
not	O	610-613
step	O	614-618
through	O	619-626
into	O	627-631
the	O	632-635
dark	O	636-640
compartment	O	641-652
during	O	653-659
the	O	660-663
cut	O	664-667
-	O	667-668
off	O	668-671
time	O	672-676
(	O	677-678
540	O	678-681
s	O	682-683
)	O	683-684
were	O	685-689
retested	O	690-698
weekly	O	699-705
for	O	706-709
up	O	710-712
to	O	713-715
eight	O	716-721
weeks	O	722-727
.	O	727-728

In	O	729-731
the	O	732-735
saline	O	736-742
treated	O	743-750
group	O	751-756
,	O	756-757
the	O	758-761
first	O	762-767
significant	O	768-779
decline	O	780-787
in	O	788-790
passive	O	791-798
avoidance	O	799-808
response	O	809-817
was	O	818-821
observed	O	822-830
at	O	831-833
four	O	834-838
weeks	O	839-844
,	O	844-845
and	O	846-849
complete	O	850-858
memory	B	859-865
loss	I	866-870
was	O	871-874
found	O	875-880
five	O	881-885
weeks	O	886-891
after	O	892-897
the	O	898-901
acquisition	O	902-913
of	O	914-916
the	O	917-920
passive	O	921-928
avoidance	O	929-938
task	O	939-943
.	O	943-944

At	O	945-947
the	O	948-951
end	O	952-955
of	O	956-958
the	O	959-962
experimental	O	963-975
period	O	976-982
,	O	982-983
60	O	984-986
%	O	986-987
of	O	988-990
the	O	991-994
animals	O	995-1002
treated	O	1003-1010
with	O	1011-1015
apigenin	O	1016-1024
still	O	1025-1030
did	O	1031-1034
not	O	1035-1038
step	O	1039-1043
through	O	1044-1051
.	O	1051-1052

These	O	1053-1058
data	O	1059-1063
suggest	O	1064-1071
that	O	1072-1076
1	O	1077-1078
)	O	1078-1079
apigenin	O	1080-1088
delays	O	1089-1095
the	O	1096-1099
long	O	1100-1104
-	O	1104-1105
term	O	1105-1109
forgetting	O	1110-1120
but	O	1121-1124
did	O	1125-1128
not	O	1129-1132
modulate	O	1133-1141
the	O	1142-1145
24	O	1146-1148
h	O	1149-1150
retention	O	1151-1160
of	O	1161-1163
fear	O	1164-1168
memory	O	1169-1175
and	O	1176-1179
2	O	1180-1181
)	O	1181-1182
the	O	1183-1186
obtained	O	1187-1195
beneficial	O	1196-1206
effect	O	1207-1213
of	O	1214-1216
apigenin	O	1217-1225
on	O	1226-1228
the	O	1229-1232
passive	O	1233-1240
avoidance	O	1241-1250
conditioning	O	1251-1263
is	O	1264-1266
mediated	O	1267-1275
by	O	1276-1278
mechanisms	O	1279-1289
that	O	1290-1294
do	O	1295-1297
not	O	1298-1301
implicate	O	1302-1311
its	O	1312-1315
action	O	1316-1322
on	O	1323-1325
the	O	1326-1329
muscarinic	O	1330-1340
cholinergic	O	1341-1352
system	O	1353-1359
.	O	1359-1360

Cholecystokinin	O	0-15
-	O	15-16
octapeptide	O	16-27
restored	O	28-36
morphine	O	37-45
-	O	45-46
induced	O	46-53
hippocampal	O	54-65
long	O	66-70
-	O	70-71
term	O	71-75
potentiation	O	76-88
impairment	O	89-99
in	O	100-102
rats	O	103-107
.	O	107-108

Cholecystokinin	O	109-124
-	O	124-125
octapeptide	O	125-136
(	O	137-138
CCK	O	138-141
-	O	141-142
8	O	142-143
)	O	143-144
,	O	144-145
which	O	146-151
is	O	152-154
a	O	155-156
typical	O	157-164
brain	O	165-170
-	O	170-171
gut	O	171-174
peptide	O	175-182
,	O	182-183
exerts	O	184-190
a	O	191-192
wide	O	193-197
range	O	198-203
of	O	204-206
biological	O	207-217
activities	O	218-228
on	O	229-231
the	O	232-235
central	O	236-243
nervous	O	244-251
system	O	252-258
.	O	258-259

We	O	260-262
have	O	263-267
previously	O	268-278
reported	O	279-287
that	O	288-292
CCK	O	293-296
-	O	296-297
8	O	297-298
significantly	O	299-312
alleviated	O	313-323
morphine	O	324-332
-	O	332-333
induced	O	333-340
amnesia	B	341-348
and	O	349-352
reversed	O	353-361
spine	O	362-367
density	O	368-375
decreases	O	376-385
in	O	386-388
the	O	389-392
CA1	O	393-396
region	O	397-403
of	O	404-406
the	O	407-410
hippocampus	O	411-422
in	O	423-425
morphine	O	426-434
-	O	434-435
treated	O	435-442
animals	O	443-450
.	O	450-451

Here	O	452-456
,	O	456-457
we	O	458-460
investigated	O	461-473
the	O	474-477
effects	O	478-485
of	O	486-488
CCK	O	489-492
-	O	492-493
8	O	493-494
on	O	495-497
long	O	498-502
-	O	502-503
term	O	503-507
potentiation	O	508-520
(	O	521-522
LTP	O	522-525
)	O	525-526
in	O	527-529
the	O	530-533
lateral	O	534-541
perforant	O	542-551
path	O	552-556
(	O	557-558
LPP	O	558-561
)	O	561-562
-	O	562-563
granule	O	563-570
cell	O	571-575
synapse	O	576-583
of	O	584-586
rat	O	587-590
dentate	O	591-598
gyrus	O	599-604
(	O	605-606
DG	O	606-608
)	O	608-609
in	O	610-612
acute	O	613-618
saline	O	619-625
or	O	626-628
morphine	O	629-637
-	O	637-638
treated	O	638-645
rats	O	646-650
.	O	650-651

Population	O	652-662
spikes	O	663-669
(	O	670-671
PS	O	671-673
)	O	673-674
,	O	674-675
which	O	676-681
were	O	682-686
evoked	O	687-693
by	O	694-696
stimulation	O	697-708
of	O	709-711
the	O	712-715
LPP	O	716-719
,	O	719-720
were	O	721-725
recorded	O	726-734
in	O	735-737
the	O	738-741
DG	O	742-744
region	O	745-751
.	O	751-752

Acute	O	753-758
morphine	O	759-767
(	O	768-769
30mg	O	769-773
/	O	773-774
kg	O	774-776
,	O	776-777
s	O	778-779
.	O	779-780
c	O	780-781
.	O	779-780
)	O	782-783
treatment	O	784-793
significantly	O	794-807
attenuated	O	808-818
hippocampal	O	819-830
LTP	O	831-834
and	O	835-838
CCK	O	839-842
-	O	842-843
8	O	843-844
(	O	845-846
1ug	O	846-849
,	O	849-850
i	O	851-852
.	O	852-853
c	O	853-854
.	O	852-853
v	O	855-856
.	O	852-853
)	O	857-858
restored	O	859-867
the	O	868-871
amplitude	O	872-881
of	O	882-884
PS	O	885-887
that	O	888-892
was	O	893-896
attenuated	O	897-907
by	O	908-910
morphine	O	911-919
injection	O	920-929
.	O	929-930

Furthermore	O	931-942
,	O	942-943
microinjection	O	944-958
of	O	959-961
CCK	O	962-965
-	O	965-966
8	O	966-967
(	O	968-969
0	O	969-970
.	O	970-971
1	O	971-972
and	O	973-976
1ug	O	977-980
,	O	980-981
i	O	982-983
.	O	983-984
c	O	984-985
.	O	983-984
v	O	986-987
.	O	983-984
)	O	988-989
also	O	990-994
significantly	O	995-1008
augmented	O	1009-1018
hippocampal	O	1019-1030
LTP	O	1031-1034
in	O	1035-1037
saline	O	1038-1044
-	O	1044-1045
treated	O	1045-1052
(	O	1053-1054
1ml	O	1054-1057
/	O	1057-1058
kg	O	1058-1060
,	O	1060-1061
s	O	1062-1063
.	O	1063-1064
c	O	1064-1065
.	O	1063-1064
)	O	1066-1067
rats	O	1068-1072
.	O	1072-1073

Pre	O	1074-1077
-	O	1077-1078
treatment	O	1078-1087
of	O	1088-1090
the	O	1091-1094
CCK2	O	1095-1099
receptor	O	1100-1108
antagonist	O	1109-1119
L	O	1120-1121
-	O	1121-1122
365	O	1122-1125
,	O	1125-1126
260	O	1126-1129
(	O	1130-1131
10ug	O	1131-1135
,	O	1135-1136
i	O	1137-1138
.	O	1138-1139
c	O	1139-1140
.	O	1138-1139
v	O	1141-1142
)	O	1142-1143
reversed	O	1144-1152
the	O	1153-1156
effects	O	1157-1164
of	O	1165-1167
CCK	O	1168-1171
-	O	1171-1172
8	O	1172-1173
,	O	1173-1174
but	O	1175-1178
the	O	1179-1182
CCK1	O	1183-1187
receptor	O	1188-1196
antagonist	O	1197-1207
L	O	1208-1209
-	O	1209-1210
364	O	1210-1213
,	O	1213-1214
718	O	1214-1217
(	O	1218-1219
10ug	O	1219-1223
,	O	1223-1224
i	O	1225-1226
.	O	1226-1227
c	O	1227-1228
.	O	1226-1227
v	O	1229-1230
)	O	1230-1231
did	O	1232-1235
not	O	1236-1239
.	O	1239-1240

The	O	1241-1244
present	O	1245-1252
results	O	1253-1260
demonstrate	O	1261-1272
that	O	1273-1277
CCK	O	1278-1281
-	O	1281-1282
8	O	1282-1283
attenuates	O	1284-1294
the	O	1295-1298
effect	O	1299-1305
of	O	1306-1308
morphine	O	1309-1317
on	O	1318-1320
hippocampal	O	1321-1332
LTP	O	1333-1336
through	O	1337-1344
CCK2	O	1345-1349
receptors	O	1350-1359
and	O	1360-1363
suggest	O	1364-1371
an	O	1372-1374
ameliorative	O	1375-1387
function	O	1388-1396
of	O	1397-1399
CCK	O	1400-1403
-	O	1403-1404
8	O	1404-1405
on	O	1406-1408
morphine	O	1409-1417
-	O	1417-1418
induced	O	1418-1425
memory	B	1426-1432
impairment	I	1433-1443
.	O	1443-1444

Glial	O	0-5
activation	O	6-16
and	O	17-20
post	O	21-25
-	O	25-26
synaptic	O	26-34
neurotoxicity	B	35-48
:	O	48-49
the	O	50-53
key	O	54-57
events	O	58-64
in	O	65-67
Streptozotocin	O	68-82
(	O	83-84
ICV	O	84-87
)	O	87-88
induced	O	89-96
memory	B	97-103
impairment	I	104-114
in	O	115-117
rats	O	118-122
.	O	122-123

In	O	124-126
the	O	127-130
present	O	131-138
study	O	139-144
the	O	145-148
role	O	149-153
of	O	154-156
glial	O	157-162
activation	O	163-173
and	O	174-177
post	O	178-182
synaptic	O	183-191
toxicity	B	192-200
in	O	201-203
ICV	O	204-207
Streptozotocin	O	208-222
(	O	223-224
STZ	O	224-227
)	O	227-228
induced	O	229-236
memory	B	237-243
impaired	I	244-252
rats	O	253-257
was	O	258-261
explored	O	262-270
.	O	270-271

In	O	272-274
experiment	O	275-285
set	O	286-289
up	O	290-292
1	O	293-294
:	O	294-295
Memory	B	296-302
deficit	I	303-310
was	O	311-314
found	O	315-320
in	O	321-323
Morris	O	324-330
water	O	331-336
maze	O	337-341
test	O	342-346
on	O	347-349
14	O	350-352
-	O	352-353
16	O	353-355
days	O	356-360
after	O	361-366
STZ	O	367-370
(	O	371-372
ICV	O	372-375
;	O	375-376
3mg	O	377-380
/	O	380-381
Kg	O	381-383
)	O	383-384
administration	O	385-399
.	O	399-400

STZ	O	401-404
causes	O	405-411
increased	O	412-421
expression	O	422-432
of	O	433-435
GFAP	O	436-440
,	O	440-441
CD11b	O	442-447
and	O	448-451
TNF	O	452-455
-	O	455-456
a	O	456-457
indicating	O	458-468
glial	O	469-474
activation	O	475-485
and	O	486-489
neuroinflammation	B	490-507
.	O	507-508

STZ	O	509-512
also	O	513-517
significantly	O	518-531
increased	O	532-541
the	O	542-545
level	O	546-551
of	O	552-554
ROS	O	555-558
,	O	558-559
nitrite	O	560-567
,	O	567-568
Ca	O	569-571
(	O	571-572
2	O	572-573
+	O	573-574
)	O	574-575
and	O	576-579
reduced	O	580-587
the	O	588-591
mitochondrial	O	592-605
activity	O	606-614
in	O	615-617
synaptosomal	O	618-630
preparation	O	631-642
illustrating	O	643-655
free	O	656-660
radical	O	661-668
generation	O	669-679
and	O	680-683
excitotoxicity	B	684-698
.	O	698-699

Increased	O	700-709
expression	O	710-720
and	O	721-724
activity	O	725-733
of	O	734-736
Caspase	O	737-744
-	O	744-745
3	O	745-746
was	O	747-750
also	O	751-755
observed	O	756-764
in	O	765-767
STZ	O	768-771
treated	O	772-779
rat	O	780-783
which	O	784-789
specify	O	790-797
apoptotic	O	798-807
cell	O	808-812
death	O	813-818
in	O	819-821
hippocampus	O	822-833
and	O	834-837
cortex	O	838-844
.	O	844-845

STZ	O	846-849
treatment	O	850-859
showed	O	860-866
decrease	O	867-875
expression	O	876-886
of	O	887-889
post	O	890-894
synaptic	O	895-903
markers	O	904-911
CaMKIIa	O	912-919
and	O	920-923
PSD	O	924-927
-	O	927-928
95	O	928-930
,	O	930-931
while	O	932-937
,	O	937-938
expression	O	939-949
of	O	950-952
pre	O	953-956
synaptic	O	957-965
markers	O	966-973
(	O	974-975
synaptophysin	O	975-988
and	O	989-992
SNAP	O	993-997
-	O	997-998
25	O	998-1000
)	O	1000-1001
remains	O	1002-1009
unaltered	O	1010-1019
indicating	O	1020-1030
selective	O	1031-1040
post	O	1041-1045
synaptic	O	1046-1054
neurotoxicity	B	1055-1068
.	O	1068-1069

Oral	O	1070-1074
treatment	O	1075-1084
with	O	1085-1089
Memantine	O	1090-1099
(	O	1100-1101
10mg	O	1101-1105
/	O	1105-1106
kg	O	1106-1108
)	O	1108-1109
and	O	1110-1113
Ibuprofen	O	1114-1123
(	O	1124-1125
50	O	1125-1127
mg	O	1128-1130
/	O	1130-1131
kg	O	1131-1133
)	O	1133-1134
daily	O	1135-1140
for	O	1141-1144
13	O	1145-1147
days	O	1148-1152
attenuated	O	1153-1163
STZ	O	1164-1167
induced	O	1168-1175
glial	O	1176-1181
activation	O	1182-1192
,	O	1192-1193
apoptotic	O	1194-1203
cell	O	1204-1208
death	O	1209-1214
and	O	1215-1218
post	O	1219-1223
synaptic	O	1224-1232
neurotoxicity	B	1233-1246
in	O	1247-1249
rat	O	1250-1253
brain	O	1254-1259
.	O	1259-1260

Further	O	1261-1268
,	O	1268-1269
in	O	1270-1272
experiment	O	1273-1283
set	O	1284-1287
up	O	1288-1290
2	O	1291-1292
:	O	1292-1293
where	O	1294-1299
memory	O	1300-1306
function	O	1307-1315
was	O	1316-1319
not	O	1320-1323
affected	O	1324-1332
i	O	1333-1334
.	O	1334-1335
e	O	1335-1336
.	O	1334-1335
7	O	1338-1339
-	O	1339-1340
9	O	1340-1341
days	O	1342-1346
after	O	1347-1352
STZ	O	1353-1356
treatment	O	1357-1366
.	O	1366-1367

The	O	1368-1371
level	O	1372-1377
of	O	1378-1380
GFAP	O	1381-1385
,	O	1385-1386
CD11b	O	1387-1392
,	O	1392-1393
TNF	O	1394-1397
-	O	1397-1398
a	O	1398-1399
,	O	1399-1400
ROS	O	1401-1404
and	O	1405-1408
nitrite	O	1409-1416
levels	O	1417-1423
were	O	1424-1428
increased	O	1429-1438
.	O	1438-1439

On	O	1440-1442
the	O	1443-1446
other	O	1447-1452
hand	O	1453-1457
,	O	1457-1458
apoptotic	O	1459-1468
marker	O	1469-1475
,	O	1475-1476
synaptic	O	1477-1485
markers	O	1486-1493
,	O	1493-1494
mitochondrial	O	1495-1508
activity	O	1509-1517
and	O	1518-1521
Ca	O	1522-1524
(	O	1524-1525
2	O	1525-1526
+	O	1526-1527
)	O	1527-1528
levels	O	1529-1535
remained	O	1536-1544
unaffected	O	1545-1555
.	O	1555-1556

Collective	O	1557-1567
data	O	1568-1572
indicates	O	1573-1582
that	O	1583-1587
neuroinflammatory	B	1588-1605
process	O	1606-1613
and	O	1614-1617
oxidative	O	1618-1627
stress	O	1628-1634
occurs	O	1635-1641
earlier	O	1642-1649
to	O	1650-1652
apoptosis	O	1653-1662
and	O	1663-1666
does	O	1667-1671
not	O	1672-1675
affect	O	1676-1682
memory	O	1683-1689
function	O	1690-1698
.	O	1698-1699

Present	O	1700-1707
study	O	1708-1713
clearly	O	1714-1721
suggests	O	1722-1730
that	O	1731-1735
glial	O	1736-1741
activation	O	1742-1752
and	O	1753-1756
post	O	1757-1761
synaptic	O	1762-1770
neurotoxicity	B	1771-1784
are	O	1785-1788
the	O	1789-1792
key	O	1793-1796
factors	O	1797-1804
in	O	1805-1807
STZ	O	1808-1811
induced	O	1812-1819
memory	B	1820-1826
impairment	I	1827-1837
and	O	1838-1841
neuronal	O	1842-1850
cell	O	1851-1855
death	O	1856-1861
.	O	1861-1862

Comparison	O	0-10
of	O	11-13
effects	O	14-21
of	O	22-24
isotonic	O	25-33
sodium	O	34-40
chloride	O	41-49
with	O	50-54
diltiazem	O	55-64
in	O	65-67
prevention	O	68-78
of	O	79-81
contrast	O	82-90
-	O	90-91
induced	O	91-98
nephropathy	B	99-110
.	O	110-111

INTRODUCTION	O	112-124
AND	O	125-128
OBJECTIVE	O	129-138
:	O	138-139
Contrast	O	140-148
-	O	148-149
induced	O	149-156
nephropathy	B	157-168
(	O	169-170
CIN	O	170-173
)	O	173-174
significantly	O	175-188
increases	O	189-198
the	O	199-202
morbidity	O	203-212
and	O	213-216
mortality	O	217-226
of	O	227-229
patients	O	230-238
.	O	238-239

The	O	240-243
aim	O	244-247
of	O	248-250
this	O	251-255
study	O	256-261
is	O	262-264
to	O	265-267
investigate	O	268-279
and	O	280-283
compare	O	284-291
the	O	292-295
protective	O	296-306
effects	O	307-314
of	O	315-317
isotonic	O	318-326
sodium	O	327-333
chloride	O	334-342
with	O	343-347
sodium	O	348-354
bicarbonate	O	355-366
infusion	O	367-375
and	O	376-379
isotonic	O	380-388
sodium	O	389-395
chloride	O	396-404
infusion	O	405-413
with	O	414-418
diltiazem	O	419-428
,	O	428-429
a	O	430-431
calcium	O	432-439
channel	O	440-447
blocker	O	448-455
,	O	455-456
in	O	457-459
preventing	O	460-470
CIN	O	471-474
.	O	474-475

MATERIALS	O	476-485
AND	O	486-489
METHODS	O	490-497
:	O	497-498
Our	O	499-502
study	O	503-508
included	O	509-517
patients	O	518-526
who	O	527-530
were	O	531-535
administered	O	536-548
30	O	549-551
-	O	551-552
60	O	552-554
mL	O	555-557
of	O	558-560
iodinated	O	561-570
contrast	O	571-579
agent	O	580-585
for	O	586-589
percutaneous	O	590-602
coronary	O	603-611
angiography	O	612-623
(	O	624-625
PCAG	O	625-629
)	O	629-630
,	O	630-631
all	O	632-635
with	O	636-640
creatinine	O	641-651
values	O	652-658
between	O	659-666
1	O	667-668
.	O	668-669
1	O	667-668
and	O	671-674
3	O	675-676
.	O	676-677
1	O	677-678
mg	O	679-681
/	O	681-682
dL	O	682-684
.	O	684-685

Patients	O	686-694
were	O	695-699
divided	O	700-707
into	O	708-712
three	O	713-718
groups	O	719-725
and	O	726-729
each	O	730-734
group	O	735-740
had	O	741-744
20	O	745-747
patients	O	748-756
.	O	756-757

The	O	758-761
first	O	762-767
group	O	768-773
of	O	774-776
patients	O	777-785
was	O	786-789
administered	O	790-802
isotonic	O	803-811
sodium	O	812-818
chloride	O	819-827
;	O	827-828
the	O	829-832
second	O	833-839
group	O	840-845
was	O	846-849
administered	O	850-862
a	O	863-864
solution	O	865-873
that	O	874-878
of	O	879-881
5	O	882-883
%	O	883-884
dextrose	O	885-893
and	O	894-897
sodium	O	898-904
bicarbonate	O	905-916
,	O	916-917
while	O	918-923
the	O	924-927
third	O	928-933
group	O	934-939
was	O	940-943
administered	O	944-956
isotonic	O	957-965
sodium	O	966-972
chloride	O	973-981
before	O	982-988
and	O	989-992
after	O	993-998
the	O	999-1002
contrast	O	1003-1011
injection	O	1012-1021
.	O	1021-1022

The	O	1023-1026
third	O	1027-1032
group	O	1033-1038
received	O	1039-1047
an	O	1048-1050
additional	O	1051-1061
injection	O	1062-1071
of	O	1072-1074
diltiazem	O	1075-1084
the	O	1085-1088
day	O	1089-1092
before	O	1093-1099
and	O	1100-1103
first	O	1104-1109
2	O	1110-1111
days	O	1112-1116
after	O	1117-1122
the	O	1123-1126
contrast	O	1127-1135
injection	O	1136-1145
.	O	1145-1146

All	O	1147-1150
of	O	1151-1153
the	O	1154-1157
patients	O	1158-1166
'	O	1166-1167
plasma	O	1168-1174
blood	O	1175-1180
urea	O	1181-1185
nitrogen	O	1186-1194
(	O	1195-1196
BUN	O	1196-1199
)	O	1199-1200
and	O	1201-1204
creatinine	O	1205-1215
levels	O	1216-1222
were	O	1223-1227
measured	O	1228-1236
on	O	1237-1239
the	O	1240-1243
second	O	1244-1250
and	O	1251-1254
seventh	O	1255-1262
day	O	1263-1266
after	O	1267-1272
the	O	1273-1276
administration	O	1277-1291
of	O	1292-1294
intravenous	O	1295-1306
contrast	O	1307-1315
material	O	1316-1324
.	O	1324-1325

RESULTS	O	1326-1333
:	O	1333-1334
The	O	1335-1338
basal	O	1339-1344
creatinine	O	1345-1355
levels	O	1356-1362
were	O	1363-1367
similar	O	1368-1375
for	O	1376-1379
all	O	1380-1383
three	O	1384-1389
groups	O	1390-1396
(	O	1397-1398
p	O	1398-1399
>	O	1400-1401
0	O	1402-1403
.	O	1403-1404
05	O	1404-1406
)	O	1406-1407
.	O	1403-1404

Among	O	1409-1414
a	O	1415-1416
total	O	1417-1422
of	O	1423-1425
60	O	1426-1428
patients	O	1429-1437
included	O	1438-1446
in	O	1447-1449
the	O	1450-1453
study	O	1454-1459
,	O	1459-1460
16	O	1461-1463
patients	O	1464-1472
developed	O	1473-1482
acute	B	1483-1488
renal	I	1489-1494
failure	I	1495-1502
(	O	1503-1504
ARF	B	1504-1507
)	O	1507-1508
on	O	1509-1511
the	O	1512-1515
second	O	1516-1522
day	O	1523-1526
after	O	1527-1532
contrast	O	1533-1541
material	O	1542-1550
was	O	1551-1554
injected	O	1555-1563
(	O	1564-1565
26	O	1565-1567
.	O	1567-1568
6	O	1566-1567
%	O	1569-1570
)	O	1570-1571
.	O	1567-1568

The	O	1573-1576
number	O	1577-1583
of	O	1584-1586
patients	O	1587-1595
who	O	1596-1599
developed	O	1600-1609
ARF	B	1610-1613
on	O	1614-1616
the	O	1617-1620
second	O	1621-1627
day	O	1628-1631
after	O	1632-1637
the	O	1638-1641
injection	O	1642-1651
in	O	1652-1654
the	O	1655-1658
first	O	1659-1664
group	O	1665-1670
was	O	1671-1674
five	O	1675-1679
(	O	1680-1681
25	O	1681-1683
%	O	1683-1684
)	O	1684-1685
,	O	1685-1686
in	O	1687-1689
the	O	1690-1693
second	O	1694-1700
group	O	1701-1706
was	O	1707-1710
six	O	1711-1714
(	O	1715-1716
30	O	1716-1718
%	O	1718-1719
)	O	1719-1720
and	O	1721-1724
the	O	1725-1728
third	O	1729-1734
group	O	1735-1740
was	O	1741-1744
five	O	1745-1749
(	O	1750-1751
25	O	1751-1753
%	O	1753-1754
)	O	1754-1755
(	O	1756-1757
p	O	1757-1758
>	O	1759-1760
0	O	1761-1762
.	O	1762-1763
05	O	1763-1765
)	O	1765-1766
.	O	1762-1763

CONCLUSION	O	1768-1778
:	O	1778-1779
There	O	1780-1785
was	O	1786-1789
no	O	1790-1792
significant	O	1793-1804
difference	O	1805-1815
between	O	1816-1823
isotonic	O	1824-1832
sodium	O	1833-1839
chloride	O	1840-1848
,	O	1848-1849
sodium	O	1850-1856
bicarbonate	O	1857-1868
and	O	1869-1872
isotonic	O	1873-1881
sodium	O	1882-1888
chloride	O	1889-1897
with	O	1898-1902
diltiazem	O	1903-1912
application	O	1913-1924
in	O	1925-1927
prevention	O	1928-1938
of	O	1939-1941
CIN	O	1942-1945
.	O	1945-1946

Neurocognitive	O	0-14
and	O	15-18
neuroradiologic	O	19-34
central	O	35-42
nervous	O	43-50
system	O	51-57
late	O	58-62
effects	O	63-70
in	O	71-73
children	O	74-82
treated	O	83-90
on	O	91-93
Pediatric	O	94-103
Oncology	O	104-112
Group	O	113-118
(	O	119-120
POG	O	120-123
)	O	123-124
P9605	O	125-130
(	O	131-132
standard	O	132-140
risk	O	141-145
)	O	145-146
and	O	147-150
P9201	O	151-156
(	O	157-158
lesser	O	158-164
risk	O	165-169
)	O	169-170
acute	B	171-176
lymphoblastic	I	177-190
leukemia	I	191-199
protocols	O	200-209
(	O	210-211
ACCL0131	O	211-219
)	O	219-220
:	O	220-221
a	O	222-223
methotrexate	O	224-236
consequence	O	237-248
?	O	248-249

A	O	250-251
report	O	252-258
from	O	259-263
the	O	264-267
Children	O	268-276
'	O	276-277
s	O	277-278
Oncology	O	279-287
Group	O	288-293
.	O	293-294

Concerns	O	295-303
about	O	304-309
long	O	310-314
-	O	314-315
term	O	315-319
methotrexate	O	320-332
(	O	333-334
MTX	O	334-337
)	O	337-338
neurotoxicity	B	339-352
in	O	353-355
the	O	356-359
1990s	O	360-365
led	O	366-369
to	O	370-372
modifications	O	373-386
in	O	387-389
intrathecal	O	390-401
(	O	402-403
IT	O	403-405
)	O	405-406
therapy	O	407-414
,	O	414-415
leucovorin	O	416-426
rescue	O	427-433
,	O	433-434
and	O	435-438
frequency	O	439-448
of	O	449-451
systemic	O	452-460
MTX	O	461-464
administration	O	465-479
in	O	480-482
children	O	483-491
with	O	492-496
acute	B	497-502
lymphoblastic	I	503-516
leukemia	I	517-525
.	O	525-526

In	O	527-529
this	O	530-534
study	O	535-540
,	O	540-541
neurocognitive	O	542-556
outcomes	O	557-565
and	O	566-569
neuroradiologic	O	570-585
evidence	O	586-594
of	O	595-597
leukoencephalopathy	B	598-617
were	O	618-622
compared	O	623-631
in	O	632-634
children	O	635-643
treated	O	644-651
with	O	652-656
intense	O	657-664
central	O	665-672
nervous	O	673-680
system	O	681-687
(	O	688-689
CNS	O	689-692
)	O	692-693
-	O	693-694
directed	O	694-702
therapy	O	703-710
(	O	711-712
P9605	O	712-717
)	O	717-718
versus	O	719-725
those	O	726-731
receiving	O	732-741
fewer	O	742-747
CNS	O	748-751
-	O	751-752
directed	O	752-760
treatment	O	761-770
days	O	771-775
during	O	776-782
intensive	O	783-792
consolidation	O	793-806
(	O	807-808
P9201	O	808-813
)	O	813-814
.	O	814-815

A	O	816-817
total	O	818-823
of	O	824-826
66	O	827-829
children	O	830-838
from	O	839-843
16	O	844-846
Pediatric	O	847-856
Oncology	O	857-865
Group	O	866-871
institutions	O	872-884
with	O	885-889
"	O	890-891
standard	O	891-899
-	O	899-900
risk	O	900-904
"	O	890-891
acute	B	906-911
lymphoblastic	I	912-925
leukemia	I	926-934
,	O	934-935
1	O	936-937
.	O	937-938
00	O	938-940
to	O	941-943
9	O	944-945
.	O	945-946
99	O	946-948
years	O	949-954
at	O	955-957
diagnosis	O	958-967
,	O	967-968
without	O	969-976
evidence	O	977-985
of	O	986-988
CNS	O	989-992
leukemia	B	993-1001
at	O	1002-1004
diagnosis	O	1005-1014
were	O	1015-1019
enrolled	O	1020-1028
on	O	1029-1031
ACCL0131	O	1032-1040
:	O	1040-1041
28	O	1042-1044
from	O	1045-1049
P9201	O	1050-1055
and	O	1056-1059
38	O	1060-1062
from	O	1063-1067
P9605	O	1068-1073
.	O	1073-1074

Magnetic	O	1075-1083
resonance	O	1084-1093
imaging	O	1094-1101
scans	O	1102-1107
and	O	1108-1111
standard	O	1112-1120
neuropsychological	O	1121-1139
tests	O	1140-1145
were	O	1146-1150
performed	O	1151-1160
>	O	1161-1162
2	O	1162-1163
.	O	1163-1164
6	O	1164-1165
years	O	1166-1171
after	O	1172-1177
the	O	1178-1181
end	O	1182-1185
of	O	1186-1188
treatment	O	1189-1198
.	O	1198-1199

Significantly	O	1200-1213
more	O	1214-1218
P9605	O	1219-1224
patients	O	1225-1233
developed	O	1234-1243
leukoencephalopathy	B	1244-1263
compared	O	1264-1272
with	O	1273-1277
P9201	O	1278-1283
patients	O	1284-1292
(	O	1293-1294
68	O	1294-1296
%	O	1296-1297
,	O	1297-1298
95	O	1299-1301
%	O	1301-1302
confidence	O	1303-1313
interval	O	1314-1322
49	O	1323-1325
%	O	1325-1326
-	O	1326-1327
83	O	1327-1329
%	O	1325-1326
vs	O	1331-1333
.	O	1333-1334
22	O	1335-1337
%	O	1337-1338
,	O	1338-1339
95	O	1340-1342
%	O	1342-1343
confidence	O	1344-1354
interval	O	1355-1363
5	O	1364-1365
%	O	1365-1366
-	O	1366-1367
44	O	1367-1369
%	O	1365-1366
;	O	1370-1371
P	O	1372-1373
=	O	1373-1374
0	O	1374-1375
.	O	1375-1376
001	O	1376-1379
)	O	1379-1380
identified	O	1381-1391
as	O	1392-1394
late	O	1395-1399
as	O	1400-1402
7	O	1403-1404
.	O	1404-1405
7	O	1403-1404
years	O	1407-1412
after	O	1413-1418
the	O	1419-1422
end	O	1423-1426
of	O	1427-1429
treatment	O	1430-1439
.	O	1439-1440

Overall	O	1441-1448
,	O	1448-1449
40	O	1450-1452
%	O	1452-1453
of	O	1454-1456
patients	O	1457-1465
scored	O	1466-1472
<	O	1473-1474
85	O	1474-1476
on	O	1477-1479
either	O	1480-1486
Verbal	O	1487-1493
or	O	1494-1496
Performance	O	1497-1508
IQ	O	1509-1511
.	O	1511-1512

Children	O	1513-1521
on	O	1522-1524
both	O	1525-1529
studies	O	1530-1537
had	O	1538-1541
significant	O	1542-1553
attention	B	1554-1563
problems	I	1564-1572
,	O	1572-1573
but	O	1574-1577
P9605	O	1578-1583
children	O	1584-1592
scored	O	1593-1599
below	O	1600-1605
average	O	1606-1613
on	O	1614-1616
more	O	1617-1621
neurocognitive	O	1622-1636
measures	O	1637-1645
than	O	1646-1650
those	O	1651-1656
treated	O	1657-1664
on	O	1665-1667
P9201	O	1668-1673
(	O	1674-1675
82	O	1675-1677
%	O	1677-1678
,	O	1678-1679
14	O	1680-1682
/	O	1682-1683
17	O	1683-1685
measures	O	1686-1694
vs	O	1695-1697
.	O	1697-1698
24	O	1699-1701
%	O	1701-1702
,	O	1702-1703
4	O	1704-1705
/	O	1705-1706
17	O	1706-1708
measures	O	1709-1717
)	O	1717-1718
.	O	1718-1719

This	O	1720-1724
supports	O	1725-1733
ongoing	O	1734-1741
concerns	O	1742-1750
about	O	1751-1756
intensive	O	1757-1766
MTX	O	1767-1770
exposure	O	1771-1779
as	O	1780-1782
a	O	1783-1784
major	O	1785-1790
contributor	O	1791-1802
to	O	1803-1805
CNS	O	1806-1809
late	O	1810-1814
effects	O	1815-1822
.	O	1822-1823

Tranexamic	O	0-10
acid	O	11-15
overdosage	O	16-26
-	O	26-27
induced	O	27-34
generalized	O	35-46
seizure	B	47-54
in	O	55-57
renal	B	58-63
failure	I	64-71
.	O	71-72

We	O	73-75
report	O	76-82
a	O	83-84
45	O	85-87
-	O	87-88
year	O	88-92
-	O	87-88
old	O	93-96
lady	O	97-101
with	O	102-106
chronic	B	107-114
kidney	I	115-121
disease	I	122-129
stage	O	130-135
4	O	136-137
due	O	138-141
to	O	142-144
chronic	O	145-152
tubulointerstial	B	153-169
disease	I	170-177
.	O	177-178

She	O	179-182
was	O	183-186
admitted	O	187-195
to	O	196-198
our	O	199-202
center	O	203-209
for	O	210-213
severe	O	214-220
anemia	B	221-227
due	O	228-231
to	O	232-234
menorrhagia	B	235-246
and	O	247-250
deterioration	B	251-264
of	I	265-267
renal	I	268-273
function	I	274-282
.	O	282-283

She	O	284-287
was	O	288-291
infused	O	292-299
three	O	300-305
units	O	306-311
of	O	312-314
packed	O	315-321
cells	O	322-327
during	O	328-334
a	O	335-336
session	O	337-344
of	O	345-347
hemodialysis	O	348-360
.	O	360-361

Tranexamic	O	362-372
acid	O	373-377
(	O	378-379
TNA	O	379-382
)	O	382-383
1	O	384-385
g	O	386-387
8	O	388-389
-	O	389-390
hourly	O	390-396
was	O	397-400
administered	O	401-413
to	O	414-416
her	O	417-420
to	O	421-423
control	O	424-431
bleeding	B	432-440
per	O	441-444
vaginum	O	445-452
.	O	452-453

Two	O	454-457
hours	O	458-463
after	O	464-469
the	O	470-473
sixth	O	474-479
dose	O	480-484
of	O	485-487
TNA	O	488-491
,	O	491-492
she	O	493-496
had	O	497-500
an	O	501-503
episode	O	504-511
of	O	512-514
generalized	O	515-526
tonic	B	527-532
clonic	I	533-539
convulsions	I	540-551
.	O	551-552

TNA	O	553-556
was	O	557-560
discontinued	O	561-573
.	O	573-574

Investigations	O	575-589
of	O	590-592
the	O	593-596
patient	O	597-604
revealed	O	605-613
no	O	614-616
biochemical	O	617-628
or	O	629-631
structural	O	632-642
central	O	643-650
nervous	B	651-658
system	I	659-665
abnormalities	I	666-679
that	O	680-684
could	O	685-690
have	O	691-695
provoked	O	696-704
the	O	705-708
convulsions	B	709-720
.	O	720-721

She	O	722-725
did	O	726-729
not	O	730-733
require	O	734-741
any	O	742-745
further	O	746-753
dialytic	O	754-762
support	O	763-770
.	O	770-771

She	O	772-775
had	O	776-779
no	O	780-782
further	O	783-790
episodes	O	791-799
of	O	800-802
convulsion	B	803-813
till	O	814-818
dis	O	819-822
-	O	822-823
charge	O	823-829
and	O	830-833
during	O	834-840
the	O	841-844
two	O	845-848
months	O	849-855
of	O	856-858
follow	O	859-865
-	O	865-866
up	O	866-868
.	O	868-869

Thus	O	870-874
,	O	874-875
the	O	876-879
precipitating	O	880-893
cause	O	894-899
of	O	900-902
convulsions	B	903-914
was	O	915-918
believed	O	919-927
to	O	928-930
be	O	931-933
an	O	934-936
overdose	B	937-945
of	O	946-948
TNA	O	949-952
.	O	952-953

Pre	O	0-3
-	O	3-4
treatment	O	4-13
of	O	14-16
bupivacaine	O	17-28
-	O	28-29
induced	O	29-36
cardiovascular	B	37-51
depression	I	52-62
using	O	63-68
different	O	69-78
lipid	O	79-84
formulations	O	85-97
of	O	98-100
propofol	O	101-109
.	O	109-110

BACKGROUND	O	111-121
:	O	121-122
Pre	O	123-126
-	O	126-127
treatment	O	127-136
with	O	137-141
lipid	O	142-147
emulsions	O	148-157
has	O	158-161
been	O	162-166
shown	O	167-172
to	O	173-175
increase	O	176-184
lethal	O	185-191
doses	O	192-197
of	O	198-200
bupivacaine	O	201-212
,	O	212-213
and	O	214-217
the	O	218-221
lipid	O	222-227
content	O	228-235
of	O	236-238
propofol	O	239-247
may	O	248-251
alleviate	O	252-261
bupivacaine	O	262-273
-	O	273-274
induced	O	274-281
cardiotoxicity	B	282-296
.	O	296-297

The	O	298-301
aim	O	302-305
of	O	306-308
this	O	309-313
study	O	314-319
is	O	320-322
to	O	323-325
investigate	O	326-337
the	O	338-341
effects	O	342-349
of	O	350-352
propofol	O	353-361
in	O	362-364
intralipid	O	365-375
or	O	376-378
medialipid	O	379-389
emulsions	O	390-399
on	O	400-402
bupivacaine	O	403-414
-	O	414-415
induced	O	415-422
cardiotoxicity	B	423-437
.	O	437-438

METHODS	O	439-446
:	O	446-447
Rats	O	448-452
were	O	453-457
anaesthetised	O	458-471
with	O	472-476
ketamine	O	477-485
and	O	486-489
were	O	490-494
given	O	495-500
0	O	501-502
.	O	502-503
5	O	503-504
mg	O	505-507
/	O	507-508
kg	O	508-510
/	O	507-508
min	O	511-514
propofol	O	515-523
in	O	524-526
intralipid	O	527-537
(	O	538-539
Group	O	539-544
P	O	545-546
)	O	546-547
,	O	547-548
propofol	O	549-557
in	O	558-560
medialipid	O	561-571
(	O	572-573
Group	O	573-578
L	O	579-580
)	O	580-581
,	O	581-582
or	O	583-585
saline	O	586-592
(	O	593-594
Group	O	594-599
C	O	600-601
)	O	601-602
over	O	603-607
20	O	608-610
min	O	611-614
.	O	614-615

Thereafter	O	616-626
,	O	626-627
2	O	628-629
mg	O	630-632
/	O	632-633
kg	O	633-635
/	O	632-633
min	O	636-639
bupivacaine	O	640-651
0	O	652-653
.	O	653-654
5	O	654-655
%	O	655-656
was	O	657-660
infused	O	661-668
.	O	668-669

We	O	670-672
recorded	O	673-681
time	O	682-686
to	O	687-689
first	O	690-695
dysrhythmia	B	696-707
occurrence	O	708-718
,	O	718-719
respective	O	720-730
times	O	731-736
to	O	737-739
25	O	740-742
%	O	742-743
and	O	744-747
50	O	748-750
%	O	750-751
reduction	O	752-761
of	O	762-764
the	O	765-768
heart	O	769-774
rate	O	775-779
(	O	780-781
HR	O	781-783
)	O	783-784
and	O	785-788
mean	O	789-793
arterial	O	794-802
pressure	O	803-811
,	O	811-812
and	O	813-816
time	O	817-821
to	O	822-824
asystole	B	825-833
and	O	834-837
total	O	838-843
amount	O	844-850
of	O	851-853
bupivacaine	O	854-865
consumption	O	866-877
.	O	877-878

Blood	O	879-884
and	O	885-888
tissue	O	889-895
samples	O	896-903
were	O	904-908
collected	O	909-918
following	O	919-928
asystole	B	929-937
.	O	937-938

RESULTS	O	939-946
:	O	946-947
The	O	948-951
time	O	952-956
to	O	957-959
first	O	960-965
dysrhythmia	B	966-977
occurrence	O	978-988
,	O	988-989
time	O	990-994
to	O	995-997
25	O	998-1000
%	O	1000-1001
and	O	1002-1005
50	O	1006-1008
%	O	1008-1009
reductions	O	1010-1020
in	O	1021-1023
HR	O	1024-1026
,	O	1026-1027
and	O	1028-1031
time	O	1032-1036
to	O	1037-1039
asystole	B	1040-1048
were	O	1049-1053
longer	O	1054-1060
in	O	1061-1063
Group	O	1064-1069
P	O	1070-1071
than	O	1072-1076
the	O	1077-1080
other	O	1081-1086
groups	O	1087-1093
.	O	1093-1094

The	O	1095-1098
cumulative	O	1099-1109
bupivacaine	O	1110-1121
dose	O	1122-1126
given	O	1127-1132
at	O	1133-1135
those	O	1136-1141
time	O	1142-1146
points	O	1147-1153
was	O	1154-1157
higher	O	1158-1164
in	O	1165-1167
Group	O	1168-1173
P	O	1174-1175
.	O	1175-1176
Plasma	O	1177-1183
bupivacaine	O	1184-1195
levels	O	1196-1202
were	O	1203-1207
significantly	O	1208-1221
lower	O	1222-1227
in	O	1228-1230
Group	O	1231-1236
P	O	1237-1238
than	O	1239-1243
in	O	1244-1246
Group	O	1247-1252
C	O	1253-1254
.	O	1254-1255
Bupivacaine	O	1256-1267
levels	O	1268-1274
in	O	1275-1277
the	O	1278-1281
brain	O	1282-1287
and	O	1288-1291
heart	O	1292-1297
were	O	1298-1302
significantly	O	1303-1316
lower	O	1317-1322
in	O	1323-1325
Group	O	1326-1331
P	O	1332-1333
and	O	1334-1337
Group	O	1338-1343
L	O	1344-1345
than	O	1346-1350
in	O	1351-1353
Group	O	1354-1359
C	O	1360-1361
.	O	1361-1362
CONCLUSION	O	1363-1373
:	O	1373-1374
We	O	1375-1377
conclude	O	1378-1386
that	O	1387-1391
pre	O	1392-1395
-	O	1395-1396
treatment	O	1396-1405
with	O	1406-1410
propofol	O	1411-1419
in	O	1420-1422
intralipid	O	1423-1433
,	O	1433-1434
compared	O	1435-1443
with	O	1444-1448
propofol	O	1449-1457
in	O	1458-1460
medialipid	O	1461-1471
or	O	1472-1474
saline	O	1475-1481
,	O	1481-1482
delayed	O	1483-1490
the	O	1491-1494
onset	O	1495-1500
of	O	1501-1503
bupivacaine	O	1504-1515
-	O	1515-1516
induced	O	1516-1523
cardiotoxic	B	1524-1535
effects	O	1536-1543
as	O	1544-1546
well	O	1547-1551
as	O	1552-1554
reduced	O	1555-1562
plasma	O	1563-1569
bupivacaine	O	1570-1581
levels	O	1582-1588
.	O	1588-1589

Further	O	1590-1597
studies	O	1598-1605
are	O	1606-1609
needed	O	1610-1616
to	O	1617-1619
explore	O	1620-1627
tissue	O	1628-1634
bupivacaine	O	1635-1646
levels	O	1647-1653
of	O	1654-1656
propofol	O	1657-1665
in	O	1666-1668
medialipid	O	1669-1679
and	O	1680-1683
adapt	O	1684-1689
these	O	1690-1695
results	O	1696-1703
to	O	1704-1706
clinical	O	1707-1715
practice	O	1716-1724
.	O	1724-1725

Drug	B	0-4
-	I	4-5
Induced	I	5-12
Acute	I	13-18
Liver	I	19-24
Injury	I	25-31
Within	O	32-38
12	O	39-41
Hours	O	42-47
After	O	48-53
Fluvastatin	O	54-65
Therapy	O	66-73
.	O	73-74

Although	O	75-83
statins	O	84-91
are	O	92-95
generally	O	96-105
well	O	106-110
-	O	110-111
tolerated	O	111-120
drugs	O	121-126
,	O	126-127
recent	O	128-134
cases	O	135-140
of	O	141-143
drug	B	144-148
-	I	148-149
induced	I	149-156
liver	I	157-162
injury	I	163-169
associated	O	170-180
with	O	181-185
their	O	186-191
use	O	192-195
have	O	196-200
been	O	201-205
reported	O	206-214
.	O	214-215

A	O	216-217
52	O	218-220
-	O	220-221
year	O	221-225
-	O	220-221
old	O	226-229
Chinese	O	230-237
man	O	238-241
reported	O	242-250
with	O	251-255
liver	B	256-261
damage	I	262-268
,	O	268-269
which	O	270-275
appeared	O	276-284
12	O	285-287
hours	O	288-293
after	O	294-299
beginning	O	300-309
treatment	O	310-319
with	O	320-324
fluvastatin	O	325-336
.	O	336-337

Patient	O	338-345
presented	O	346-355
with	O	356-360
complaints	O	361-371
of	O	372-374
increasing	O	375-385
nausea	B	386-392
,	O	392-393
anorexia	B	394-402
,	O	402-403
and	O	404-407
upper	O	408-413
abdominal	B	414-423
pain	I	424-428
.	O	428-429

His	O	430-433
laboratory	O	434-444
values	O	445-451
showed	O	452-458
elevated	O	459-467
creatine	O	468-476
kinase	O	477-483
and	O	484-487
transaminases	O	488-501
.	O	501-502

Testing	O	503-510
for	O	511-514
autoantibodies	O	515-529
was	O	530-533
also	O	534-538
negative	O	539-547
.	O	547-548

The	O	549-552
liver	O	553-558
biochemistries	O	559-573
eventually	O	574-584
normalized	O	585-595
within	O	596-602
3	O	603-604
weeks	O	605-610
of	O	611-613
stopping	O	614-622
the	O	623-626
fluvastatin	O	627-638
.	O	638-639

Therefore	O	640-649
,	O	649-650
when	O	651-655
prescribing	O	656-667
statins	O	668-675
,	O	675-676
the	O	677-680
possibility	O	681-692
of	O	693-695
hepatic	B	696-703
damage	I	704-710
should	O	711-717
be	O	718-720
taken	O	721-726
into	O	727-731
account	O	732-739
.	O	739-740

Fluconazole	O	0-11
associated	O	12-22
agranulocytosis	B	23-38
and	O	39-42
thrombocytopenia	B	43-59
.	O	59-60

CASE	O	61-65
:	O	65-66
We	O	67-69
describe	O	70-78
a	O	79-80
second	O	81-87
case	O	88-92
of	O	93-95
fluconazole	O	96-107
associated	O	108-118
agranulocytosis	B	119-134
with	O	135-139
thrombocytopenia	B	140-156
and	O	157-160
recovery	O	161-169
upon	O	170-174
discontinuation	O	175-190
of	O	191-193
therapy	O	194-201
.	O	201-202

The	O	203-206
patient	O	207-214
began	O	215-220
to	O	221-223
have	O	224-228
changes	O	229-236
in	O	237-239
white	O	240-245
blood	O	246-251
cells	O	252-257
and	O	258-261
platelets	O	262-271
within	O	272-278
48	O	279-281
h	O	282-283
of	O	284-286
administration	O	287-301
of	O	302-304
fluconazole	O	305-316
and	O	317-320
began	O	321-326
to	O	327-329
recover	O	330-337
with	O	338-342
48	O	343-345
h	O	346-347
of	O	348-350
discontinuation	O	351-366
.	O	366-367

This	O	368-372
case	O	373-377
highlights	O	378-388
that	O	389-393
drug	O	394-398
-	O	398-399
induced	O	399-406
blood	B	407-412
dyscrasias	I	413-423
can	O	424-427
occur	O	428-433
unexpectedly	O	434-446
as	O	447-449
a	O	450-451
result	O	452-458
of	O	459-461
treatment	O	462-471
with	O	472-476
a	O	477-478
commonly	O	479-487
used	O	488-492
drug	O	493-497
thought	O	498-505
to	O	506-508
be	O	509-511
"	O	512-513
safe	O	513-517
"	O	512-513
.	O	518-519

CONCLUSION	O	520-530
:	O	530-531
According	O	532-541
to	O	542-544
Naranjo	O	545-552
'	O	552-553
s	O	553-554
algorithm	O	555-564
the	O	565-568
likelihood	O	569-579
that	O	580-584
our	O	585-588
patient	O	589-596
'	O	596-597
s	O	597-598
agranulocytosis	B	599-614
and	O	615-618
thrombocytopenia	B	619-635
occurred	O	636-644
as	O	645-647
a	O	648-649
result	O	650-656
of	O	657-659
therapy	O	660-667
with	O	668-672
fluconazole	O	673-684
is	O	685-687
probable	O	688-696
,	O	696-697
with	O	698-702
a	O	703-704
total	O	705-710
of	O	711-713
six	O	714-717
points	O	718-724
.	O	724-725

We	O	726-728
feel	O	729-733
that	O	734-738
the	O	739-742
weight	O	743-749
of	O	750-752
the	O	753-756
overall	O	757-764
evidence	O	765-773
of	O	774-776
this	O	777-781
evidence	O	782-790
is	O	791-793
strong	O	794-800
.	O	800-801

In	O	802-804
particular	O	805-815
the	O	816-819
temporal	O	820-828
relationship	O	829-841
of	O	842-844
bone	B	845-849
marrow	I	850-856
suppression	I	857-868
to	O	869-871
the	O	872-875
initiation	O	876-886
of	O	887-889
fluconazole	O	890-901
and	O	902-905
the	O	906-909
abatement	O	910-919
of	O	920-922
symptoms	O	923-931
that	O	932-936
rapidly	O	937-944
reversed	O	945-953
immediately	O	954-965
following	O	966-975
discontinuation	O	976-991
.	O	991-992

Two	O	0-3
-	O	3-4
dimensional	O	4-15
speckle	O	16-23
tracking	O	24-32
echocardiography	O	33-49
combined	O	50-58
with	O	59-63
high	O	64-68
-	O	68-69
sensitive	O	69-78
cardiac	O	79-86
troponin	O	87-95
T	O	96-97
in	O	98-100
early	O	101-106
detection	O	107-116
and	O	117-120
prediction	O	121-131
of	O	132-134
cardiotoxicity	B	135-149
during	O	150-156
epirubicine	O	157-168
-	O	168-169
based	O	169-174
chemotherapy	O	175-187
.	O	187-188

AIMS	O	189-193
:	O	193-194
To	O	195-197
investigate	O	198-209
whether	O	210-217
alterations	O	218-229
of	O	230-232
myocardial	B	233-243
strain	I	244-250
and	O	251-254
high	O	255-259
-	O	259-260
sensitive	O	260-269
cardiac	O	270-277
troponin	O	278-286
T	O	287-288
(	O	289-290
cTnT	O	290-294
)	O	294-295
could	O	296-301
predict	O	302-309
future	O	310-316
cardiac	B	317-324
dysfunction	I	325-336
in	O	337-339
patients	O	340-348
after	O	349-354
epirubicin	O	355-365
exposure	O	366-374
.	O	374-375

METHODS	O	376-383
:	O	383-384
Seventy	O	385-392
-	O	392-393
five	O	393-397
patients	O	398-406
with	O	407-411
non	B	412-415
-	I	415-416
Hodgkin	I	416-423
lymphoma	I	424-432
treated	O	433-440
with	O	441-445
epirubicin	O	446-456
were	O	457-461
studied	O	462-469
.	O	469-470

Blood	O	471-476
collection	O	477-487
and	O	488-491
echocardiography	O	492-508
were	O	509-513
performed	O	514-523
at	O	524-526
baseline	O	527-535
,	O	535-536
1	O	537-538
day	O	539-542
after	O	543-548
the	O	549-552
third	O	553-558
cycle	O	559-564
,	O	564-565
and	O	566-569
1	O	570-571
day	O	572-575
after	O	576-581
completion	O	582-592
of	O	593-595
chemotherapy	O	596-608
.	O	608-609

Patients	O	610-618
were	O	619-623
studied	O	624-631
using	O	632-637
echocardiography	O	638-654
during	O	655-661
follow	O	662-668
-	O	668-669
up	O	669-671
.	O	671-672

Global	O	673-679
longitudinal	O	680-692
(	O	693-694
GLS	O	694-697
)	O	697-698
,	O	698-699
circumferential	O	700-715
(	O	716-717
GCS	O	717-720
)	O	720-721
,	O	721-722
and	O	723-726
radial	O	727-733
strain	O	734-740
(	O	741-742
GRS	O	742-745
)	O	745-746
were	O	747-751
calculated	O	752-762
using	O	763-768
speckle	O	769-776
tracking	O	777-785
echocardiography	O	786-802
.	O	802-803

Left	O	804-808
ventricular	O	809-820
ejection	O	821-829
fraction	O	830-838
was	O	839-842
analysed	O	843-851
by	O	852-854
real	O	855-859
-	O	859-860
time	O	860-864
3D	O	865-867
echocardiography	O	868-884
.	O	884-885

Cardiotoxicity	B	886-900
was	O	901-904
defined	O	905-912
as	O	913-915
a	O	916-917
reduction	O	918-927
of	O	928-930
the	O	931-934
LVEF	O	935-939
of	O	940-942
>	O	943-944
5	O	944-945
%	O	945-946
to	O	947-949
<	O	950-951
55	O	951-953
%	O	953-954
with	O	955-959
symptoms	O	960-968
of	O	969-971
heart	B	972-977
failure	I	978-985
or	O	986-988
an	O	989-991
asymptomatic	O	992-1004
reduction	O	1005-1014
of	O	1015-1017
the	O	1018-1021
LVEF	O	1022-1026
of	O	1027-1029
>	O	1030-1031
10	O	1031-1033
%	O	1033-1034
to	O	1035-1037
<	O	1038-1039
55	O	1039-1041
%	O	1041-1042
.	O	1042-1043

RESULTS	O	1044-1051
:	O	1051-1052
Fourteen	O	1053-1061
patients	O	1062-1070
(	O	1071-1072
18	O	1072-1074
.	O	1074-1075
67	O	1075-1077
%	O	1077-1078
)	O	1078-1079
developed	O	1080-1089
cardiotoxicity	B	1090-1104
after	O	1105-1110
treatment	O	1111-1120
.	O	1120-1121

GLS	O	1122-1125
(	O	1126-1127
-	O	1127-1128
18	O	1128-1130
.	O	1130-1131
48	O	1131-1133
+	O	1134-1135
1	O	1136-1137
.	O	1137-1138
72	O	1138-1140
%	O	1140-1141
vs	O	1142-1144
.	O	1144-1145
-	O	1146-1147
15	O	1147-1149
.	O	1149-1150
96	O	1150-1152

+	O	1153-1154
1	O	1155-1156
.	O	1156-1157
6	O	1157-1158
%	O	1158-1159
)	O	1159-1160
,	O	1160-1161
GCS	O	1162-1165
(	O	1166-1167
-	O	1167-1168
20	O	1168-1170
.	O	1170-1171
93	O	1171-1173
+	O	1174-1175
2	O	1176-1177
.	O	1177-1178
86	O	1178-1180
%	O	1180-1181
vs	O	1182-1184
.	O	1184-1185
-	O	1186-1187
19	O	1187-1189
.	O	1189-1190
20	O	1190-1192
+	O	1193-1194
3	O	1195-1196
.	O	1196-1197
21	O	1197-1199
%	O	1199-1200
)	O	1200-1201
,	O	1201-1202
and	O	1203-1206
GRS	O	1207-1210
(	O	1211-1212
39	O	1212-1214
.	O	1214-1215
23	O	1215-1217
+	O	1218-1219
6	O	1220-1221
.	O	1221-1222
44	O	1222-1224
%	O	1224-1225
vs	O	1226-1228
.	O	1228-1229
34	O	1230-1232
.	O	1232-1233
98	O	1233-1235

+	O	1236-1237
6	O	1238-1239
.	O	1239-1240
2	O	1240-1241
%	O	1241-1242
)	O	1242-1243
were	O	1244-1248
markedly	O	1249-1257
reduced	O	1258-1265
and	O	1266-1269
cTnT	O	1270-1274
was	O	1275-1278
elevated	O	1279-1287
from	O	1288-1292
0	O	1293-1294
.	O	1294-1295
0010	O	1295-1299
+	O	1300-1301
0	O	1302-1303
.	O	1303-1304
0020	O	1304-1308
to	O	1309-1311
0	O	1312-1313
.	O	1313-1314
0073	O	1314-1318
+	O	1319-1320
0	O	1321-1322
.	O	1322-1323
0038	O	1323-1327
ng	O	1328-1330
/	O	1330-1331
mL	O	1331-1333
(	O	1334-1335
P	O	1335-1336
all	O	1337-1340
<	O	1341-1342
0	O	1343-1344
.	O	1344-1345
01	O	1345-1347
)	O	1347-1348
at	O	1349-1351
the	O	1352-1355
completion	O	1356-1366
of	O	1367-1369
chemotherapy	O	1370-1382
compared	O	1383-1391
with	O	1392-1396
baseline	O	1397-1405
values	O	1406-1412
.	O	1412-1413

A	O	1414-1415
>	O	1416-1417
15	O	1417-1419
.	O	1419-1420
9	O	1420-1421
%	O	1421-1422
decrease	O	1423-1431
in	O	1432-1434
GLS	O	1435-1438
[	O	1439-1440
sensitivity	O	1440-1451
,	O	1451-1452
86	O	1453-1455
%	O	1455-1456
;	O	1456-1457
specificity	O	1458-1469
,	O	1469-1470
75	O	1471-1473
%	O	1473-1474
;	O	1474-1475
area	O	1476-1480
under	O	1481-1486
the	O	1487-1490
curve	O	1491-1496
(	O	1497-1498
AUC	O	1498-1501
)	O	1501-1502
=	O	1503-1504
0	O	1505-1506
.	O	1506-1507
815	O	1507-1510
;	O	1510-1511
P	O	1512-1513
=	O	1514-1515
0	O	1516-1517
.	O	1517-1518
001	O	1518-1521
]	O	1521-1522
and	O	1523-1526
a	O	1527-1528
>	O	1529-1530
0	O	1530-1531
.	O	1531-1532
004	O	1532-1535
ng	O	1536-1538
/	O	1538-1539
mL	O	1539-1541
elevation	O	1542-1551
in	O	1552-1554
cTnT	O	1555-1559
(	O	1560-1561
sensitivity	O	1561-1572
,	O	1572-1573
79	O	1574-1576
%	O	1576-1577
;	O	1577-1578
specificity	O	1579-1590
,	O	1590-1591
64	O	1592-1594
%	O	1594-1595
;	O	1595-1596
AUC	O	1597-1600
=	O	1601-1602
0	O	1603-1604
.	O	1604-1605
757	O	1605-1608
;	O	1608-1609
P	O	1610-1611
=	O	1612-1613
0	O	1614-1615
.	O	1615-1616
005	O	1616-1619
)	O	1619-1620
from	O	1621-1625
baseline	O	1626-1634
to	O	1635-1637
the	O	1638-1641
third	O	1642-1647
cycle	O	1648-1653
of	O	1654-1656
chemotherapy	O	1657-1669
predicted	O	1670-1679
later	O	1680-1685
cardiotoxicity	B	1686-1700
.	O	1700-1701

The	O	1702-1705
decrease	O	1706-1714
in	O	1715-1717
GLS	O	1718-1721
remained	O	1722-1730
the	O	1731-1734
only	O	1735-1739
independent	O	1740-1751
predictor	O	1752-1761
of	O	1762-1764
cardiotoxicity	B	1765-1779
(	O	1780-1781
P	O	1781-1782
=	O	1783-1784
0	O	1785-1786
.	O	1786-1787
000	O	1787-1790
)	O	1790-1791
.	O	1786-1787

CONCLUSIONS	O	1793-1804
:	O	1804-1805
GLS	O	1806-1809
combined	O	1810-1818
with	O	1819-1823
cTnT	O	1824-1828
may	O	1829-1832
provide	O	1833-1840
a	O	1841-1842
reliable	O	1843-1851
and	O	1852-1855
non	O	1856-1859
-	O	1859-1860
invasive	O	1860-1868
method	O	1869-1875
to	O	1876-1878
predict	O	1879-1886
cardiac	B	1887-1894
dysfunction	I	1895-1906
in	O	1907-1909
patients	O	1910-1918
receiving	O	1919-1928
anthracycline	O	1929-1942
-	O	1942-1943
based	O	1943-1948
chemotherapy	O	1949-1961
.	O	1961-1962

Prevention	O	0-10
of	O	11-13
etomidate	O	14-23
-	O	23-24
induced	O	24-31
myoclonus	B	32-41
:	O	41-42
which	O	43-48
is	O	49-51
superior	O	52-60
:	O	60-61
Fentanyl	O	62-70
,	O	70-71
midazolam	O	72-81
,	O	81-82
or	O	83-85
a	O	86-87
combination	O	88-99
?	O	99-100

A	O	101-102
Retrospective	O	103-116
comparative	O	117-128
study	O	129-134
.	O	134-135

BACKGROUND	O	136-146
:	O	146-147
In	O	148-150
this	O	151-155
retrospective	O	156-169
comparative	O	170-181
study	O	182-187
,	O	187-188
we	O	189-191
aimed	O	192-197
to	O	198-200
compare	O	201-208
the	O	209-212
effectiveness	O	213-226
of	O	227-229
fentanyl	O	230-238
,	O	238-239
midazolam	O	240-249
,	O	249-250
and	O	251-254
a	O	255-256
combination	O	257-268
of	O	269-271
fentanyl	O	272-280
and	O	281-284
midazolam	O	285-294
to	O	295-297
prevent	O	298-305
etomidate	O	306-315
-	O	315-316
induced	O	316-323
myoclonus	B	324-333
.	O	333-334

MATERIAL	O	335-343
AND	O	344-347
METHODS	O	348-355
:	O	355-356
This	O	357-361
study	O	362-367
was	O	368-371
performed	O	372-381
based	O	382-387
on	O	388-390
anesthesia	O	391-401
records	O	402-409
.	O	409-410

Depending	O	411-420
on	O	421-423
the	O	424-427
drugs	O	428-433
that	O	434-438
would	O	439-444
be	O	445-447
given	O	448-453
before	O	454-460
the	O	461-464
induction	O	465-474
of	O	475-477
anesthesia	O	478-488
with	O	489-493
etomidate	O	494-503
,	O	503-504
the	O	505-508
patients	O	509-517
were	O	518-522
separated	O	523-532
into	O	533-537
4	O	538-539
groups	O	540-546
:	O	546-547
no	O	548-550
pretreatment	O	551-563
(	O	564-565
Group	O	565-570
NP	O	571-573
)	O	573-574
,	O	574-575
fentanyl	O	576-584
1	O	585-586
ug	O	587-589
.	O	589-590
kg	O	590-592
-	O	592-593
1	O	593-594
(	O	595-596
Group	O	596-601
F	O	602-603
)	O	603-604
,	O	604-605
midazolam	O	606-615
0	O	616-617
.	O	617-618
03	O	618-620
mg	O	621-623
.	O	623-624
kg	O	624-626
-	O	626-627
1	O	627-628
(	O	629-630
Group	O	630-635
M	O	636-637
)	O	637-638
,	O	638-639
and	O	640-643
midazolam	O	644-653
0	O	654-655
.	O	655-656
015	O	656-659
mg	O	660-662
.	O	662-663
kg	O	663-665
-	O	665-666
1	O	666-667
+	O	668-669
fentanyl	O	670-678
0	O	679-680
.	O	680-681
5	O	681-682
ug	O	683-685
.	O	685-686
kg	O	686-688
-	O	688-689
1	O	689-690
(	O	691-692
Group	O	692-697
FM	O	698-700
)	O	700-701
.	O	701-702

Patients	O	703-711
who	O	712-715
received	O	716-724
the	O	725-728
same	O	729-733
anesthetic	O	734-744
procedure	O	745-754
were	O	755-759
selected	O	760-768
:	O	768-769
2	O	770-771
minutes	O	772-779
after	O	780-785
intravenous	O	786-797
injections	O	798-808
of	O	809-811
the	O	812-815
pretreatment	O	816-828
drugs	O	829-834
,	O	834-835
anesthesia	O	836-846
is	O	847-849
induced	O	850-857
with	O	858-862
0	O	863-864
.	O	864-865
3	O	865-866
mg	O	867-869
.	O	869-870
kg	O	870-872
-	O	872-873
1	O	873-874
etomidate	O	875-884
injected	O	885-893
intravenously	O	894-907
over	O	908-912
a	O	913-914
period	O	915-921
of	O	922-924
20	O	925-927
-	O	927-928
30	O	928-930
seconds	O	931-938
.	O	938-939

Myoclonic	B	940-949
movements	I	950-959
are	O	960-963
evaluated	O	964-973
,	O	973-974
which	O	975-980
were	O	981-985
observed	O	986-994
and	O	995-998
graded	O	999-1005
according	O	1006-1015
to	O	1016-1018
clinical	O	1019-1027
severity	O	1028-1036
during	O	1037-1043
the	O	1044-1047
2	O	1048-1049
minutes	O	1050-1057
after	O	1058-1063
etomidate	O	1064-1073
injection	O	1074-1083
.	O	1083-1084

The	O	1085-1088
severity	O	1089-1097
of	O	1098-1100
pain	B	1101-1105
due	O	1106-1109
to	O	1110-1112
etomidate	O	1113-1122
injection	O	1123-1132
,	O	1132-1133
mean	O	1134-1138
arterial	O	1139-1147
pressure	O	1148-1156
,	O	1156-1157
heart	O	1158-1163
rate	O	1164-1168
,	O	1168-1169
and	O	1170-1173
adverse	O	1174-1181
effects	O	1182-1189
were	O	1190-1194
also	O	1195-1199
evaluated	O	1200-1209
.	O	1209-1210

RESULTS	O	1211-1218
:	O	1218-1219
Study	O	1220-1225
results	O	1226-1233
showed	O	1234-1240
that	O	1241-1245
myoclonus	B	1246-1255
incidence	O	1256-1265
was	O	1266-1269
85	O	1270-1272
%	O	1272-1273
,	O	1273-1274
40	O	1275-1277
%	O	1277-1278
,	O	1278-1279
70	O	1280-1282
%	O	1282-1283
,	O	1283-1284
and	O	1285-1288
25	O	1289-1291
%	O	1291-1292
in	O	1293-1295
Group	O	1296-1301
NP	O	1302-1304
,	O	1304-1305
Group	O	1306-1311
F	O	1312-1313
,	O	1313-1314
Group	O	1315-1320
M	O	1321-1322
,	O	1322-1323
and	O	1324-1327
Group	O	1328-1333
FM	O	1334-1336
,	O	1336-1337
respectively	O	1338-1350
,	O	1350-1351
and	O	1352-1355
were	O	1356-1360
significantly	O	1361-1374
lower	O	1375-1380
in	O	1381-1383
Group	O	1384-1389
F	O	1390-1391
and	O	1392-1395
Group	O	1396-1401
FM	O	1402-1404
.	O	1404-1405

CONCLUSIONS	O	1406-1417
:	O	1417-1418
We	O	1419-1421
conclude	O	1422-1430
that	O	1431-1435
pretreatment	O	1436-1448
with	O	1449-1453
fentanyl	O	1454-1462
or	O	1463-1465
combination	O	1466-1477
of	O	1478-1480
fentanyl	O	1481-1489
and	O	1490-1493
midazolam	O	1494-1503
was	O	1504-1507
effective	O	1508-1517
in	O	1518-1520
preventing	O	1521-1531
etomidate	O	1532-1541
-	O	1541-1542
induced	O	1542-1549
myoclonus	B	1550-1559
.	O	1559-1560

Cholestatic	B	0-11
presentation	O	12-24
of	O	25-27
yellow	O	28-34
phosphorus	O	35-45
poisoning	B	46-55
.	O	55-56

Yellow	O	57-63
phosphorus	O	64-74
,	O	74-75
a	O	76-77
component	O	78-87
of	O	88-90
certain	O	91-98
pesticide	O	99-108
pastes	O	109-115
and	O	116-119
fireworks	O	120-129
,	O	129-130
is	O	131-133
well	O	134-138
known	O	139-144
to	O	145-147
cause	O	148-153
hepatotoxicity	B	154-168
.	O	168-169

Poisoning	B	170-179
with	O	180-184
yellow	O	185-191
phosphorus	O	192-202
classically	O	203-214
manifests	O	215-224
with	O	225-229
acute	B	230-235
hepatitis	I	236-245
leading	O	246-253
to	O	254-256
acute	B	257-262
liver	I	263-268
failure	I	269-276
which	O	277-282
may	O	283-286
need	O	287-291
liver	O	292-297
transplantation	O	298-313
.	O	313-314

We	O	315-317
present	O	318-325
a	O	326-327
case	O	328-332
of	O	333-335
yellow	O	336-342
phosphorus	O	343-353
poisoning	B	354-363
in	O	364-366
which	O	367-372
a	O	373-374
patient	O	375-382
presented	O	383-392
with	O	393-397
florid	O	398-404
clinical	O	405-413
features	O	414-422
of	O	423-425
cholestasis	B	426-437
highlighting	O	438-450
the	O	451-454
fact	O	455-459
that	O	460-464
cholestasis	B	465-476
can	O	477-480
rarely	O	481-487
be	O	488-490
a	O	491-492
presenting	O	493-503
feature	O	504-511
of	O	512-514
yellow	O	515-521
phosphorus	O	522-532
hepatotoxicity	B	533-547
.	O	547-548

Vasovagal	B	0-9
syncope	I	10-17
and	O	18-21
severe	O	22-28
bradycardia	B	29-40
following	O	41-50
intranasal	O	51-61
dexmedetomidine	O	62-77
for	O	78-81
pediatric	O	82-91
procedural	O	92-102
sedation	O	103-111
.	O	111-112

We	O	113-115
report	O	116-122
syncope	B	123-130
and	O	131-134
bradycardia	B	135-146
in	O	147-149
an	O	150-152
11	O	153-155
-	O	155-156
year	O	156-160
-	O	155-156
old	O	161-164
girl	O	165-169
following	O	170-179
administration	O	180-194
of	O	195-197
intranasal	O	198-208
dexmedetomidine	O	209-224
for	O	225-228
sedation	O	229-237
for	O	238-241
a	O	242-243
voiding	O	244-251
cystourethrogram	O	252-268
.	O	268-269

Following	O	270-279
successful	O	280-290
completion	O	291-301
of	O	302-304
VCUG	O	305-309
and	O	310-313
a	O	314-315
60	O	316-318
-	O	318-319
min	O	319-322
recovery	O	323-331
period	O	332-338
,	O	338-339
the	O	340-343
patient	O	344-351
'	O	351-352
s	O	352-353
level	O	354-359
of	O	360-362
consciousness	O	363-376
and	O	377-380
vital	O	381-386
signs	O	387-392
returned	O	393-401
to	O	402-404
presedation	O	405-416
levels	O	417-423
.	O	423-424

Upon	O	425-429
leaving	O	430-437
the	O	438-441
sedation	O	442-450
area	O	451-455
,	O	455-456
the	O	457-460
patient	O	461-468
collapsed	O	469-478
,	O	478-479
with	O	480-484
no	O	485-487
apparent	O	488-496
inciting	O	497-505
event	O	506-511
.	O	511-512

The	O	513-516
patient	O	517-524
quickly	O	525-532
regained	O	533-541
consciousness	O	542-555
and	O	556-559
no	O	560-562
injury	O	563-569
occurred	O	570-578
.	O	578-579

The	O	580-583
primary	O	584-591
abnormality	O	592-603
found	O	604-609
was	O	610-613
persistent	O	614-624
bradycardia	B	625-636
,	O	636-637
and	O	638-641
she	O	642-645
was	O	646-649
admitted	O	650-658
to	O	659-661
the	O	662-665
hospital	O	666-674
for	O	675-678
telemetric	O	679-689
observation	O	690-701
.	O	701-702

The	O	703-706
bradycardia	B	707-718
lasted	O	719-725
~	O	726-727
2	O	727-728
h	O	729-730
,	O	730-731
and	O	732-735
further	O	736-743
cardiac	O	744-751
workup	O	752-758
revealed	O	759-767
no	O	768-770
underlying	O	771-781
abnormality	O	782-793
.	O	793-794

Unanticipated	O	795-808
and	O	809-812
previously	O	813-823
unreported	O	824-834
outcomes	O	835-843
may	O	844-847
be	O	848-850
witnessed	O	851-860
as	O	861-863
we	O	864-866
expand	O	867-873
the	O	874-877
use	O	878-881
of	O	882-884
certain	O	885-892
sedatives	O	893-902
to	O	903-905
alternative	O	906-917
routes	O	918-924
of	O	925-927
administration	O	928-942
.	O	942-943

Paradoxical	O	0-11
severe	O	12-18
agitation	B	19-28
induced	O	29-36
by	O	37-39
add	O	40-43
-	O	43-44
on	O	44-46
high	O	47-51
-	O	51-52
doses	O	52-57
quetiapine	O	58-68
in	O	69-71
schizo	B	72-78
-	I	78-79
affective	I	79-88
disorder	I	89-97
.	O	97-98

We	O	99-101
report	O	102-108
the	O	109-112
case	O	113-117
of	O	118-120
a	O	121-122
35	O	123-125
-	O	125-126
year	O	126-130
-	O	125-126
old	O	131-134
patient	O	135-142
suffering	O	143-152
from	O	153-157
schizo	B	158-164
-	I	164-165
affective	I	165-174
disorder	I	175-183
since	O	184-189
the	O	190-193
age	O	194-197
of	O	198-200
19	O	201-203
years	O	204-209
,	O	209-210
treated	O	211-218
by	O	219-221
a	O	222-223
combination	O	224-235
of	O	236-238
first	O	239-244
-	O	244-245
generation	O	245-255
antipsychotics	O	256-270
,	O	270-271
zuclopenthixol	O	272-286
(	O	287-288
100	O	288-291
mg	O	292-294
/	O	294-295
day	O	295-298
)	O	298-299
and	O	300-303
lithium	O	304-311
(	O	312-313
1200	O	313-317
mg	O	318-320
/	O	320-321
day	O	321-324
)	O	324-325
(	O	326-327
serum	O	327-332
lithium	O	333-340
=	O	340-341
0	O	341-342
.	O	342-343
85	O	343-345

mEq	O	346-349
/	O	349-350
l	O	350-351
)	O	351-352
.	O	352-353

This	O	354-358
patient	O	359-366
had	O	367-370
no	O	371-373
associated	O	374-384
personality	B	385-396
disorder	I	397-405
(	O	406-407
particularly	O	407-419
no	O	420-422
antisocial	B	423-433
disorder	I	434-442
)	O	442-443
and	O	444-447
no	O	448-450
substance	B	451-460
abuse	I	461-466
disorder	I	467-475
.	O	475-476

Within	O	477-483
the	O	484-487
48	O	488-490
h	O	491-492
following	O	493-502
the	O	503-506
gradual	O	507-514
introduction	O	515-527
of	O	528-530
quetiapine	O	531-541
(	O	542-543
up	O	543-545
to	O	546-548
600	O	549-552
mg	O	553-555
/	O	555-556
day	O	556-559
)	O	559-560
,	O	560-561
the	O	562-565
patient	O	566-573
presented	O	574-583
severe	O	584-590
agitation	B	591-600
without	O	601-608
an	O	609-611
environmental	O	612-625
explanation	O	626-637
,	O	637-638
contrasting	O	639-650
with	O	651-655
the	O	656-659
absence	O	660-667
of	O	668-670
a	O	671-672
history	O	673-680
of	O	681-683
aggressiveness	B	684-698
or	O	699-701
personality	B	702-713
disorder	I	714-722
.	O	722-723

The	O	724-727
diagnoses	O	728-737
of	O	738-740
manic	B	741-746
shift	O	747-752
and	O	753-756
akathisia	B	757-766
were	O	767-771
dismissed	O	772-781
.	O	781-782

The	O	783-786
withdrawal	O	787-797
and	O	798-801
the	O	802-805
gradual	O	806-813
reintroduction	O	814-828
of	O	829-831
quetiapine	O	832-842
2	O	843-844
weeks	O	845-850
later	O	851-856
,	O	856-857
which	O	858-863
led	O	864-867
to	O	868-870
another	O	871-878
severe	O	879-885
agitation	B	886-895
,	O	895-896
enabled	O	897-904
us	O	905-907
to	O	908-910
attribute	O	911-920
the	O	921-924
agitation	B	925-934
specifically	O	935-947
to	O	948-950
quetiapine	O	951-961
.	O	961-962

Antioxidant	O	0-11
effects	O	12-19
of	O	20-22
bovine	O	23-29
lactoferrin	O	30-41
on	O	42-44
dexamethasone	O	45-58
-	O	58-59
induced	O	59-66
hypertension	B	67-79
in	O	80-82
rat	O	83-86
.	O	86-87

Dexamethasone	O	88-101
-	O	101-102
(	O	103-104
Dex	O	104-107
-	O	107-108
)	O	108-109
induced	O	110-117
hypertension	B	118-130
is	O	131-133
associated	O	134-144
with	O	145-149
enhanced	O	150-158
oxidative	O	159-168
stress	O	169-175
.	O	175-176

Lactoferrin	O	177-188
(	O	189-190
LF	O	190-192
)	O	192-193
is	O	194-196
an	O	197-199
iron	O	200-204
-	O	204-205
binding	O	205-212
glycoprotein	O	213-225
with	O	226-230
antihypertensive	O	231-247
properties	O	248-258
.	O	258-259

In	O	260-262
this	O	263-267
study	O	268-273
,	O	273-274
we	O	275-277
investigated	O	278-290
the	O	291-294
effect	O	295-301
of	O	302-304
chronic	O	305-312
administration	O	313-327
of	O	328-330
LF	O	331-333
on	O	334-336
oxidative	O	337-346
stress	O	347-353
and	O	354-357
hypertension	B	358-370
upon	O	371-375
Dex	O	376-379
administration	O	380-394
.	O	394-395

Male	O	396-400
Wistar	O	401-407
rats	O	408-412
were	O	413-417
treated	O	418-425
by	O	426-428
Dex	O	429-432
(	O	433-434
30	O	434-436
u	O	438-439
g	O	440-441
/	O	441-442
kg	O	442-444
/	O	441-442
day	O	445-448
subcutaneously	O	449-463
)	O	463-464
or	O	465-467
saline	O	468-474
for	O	475-478
14	O	479-481
days	O	482-486
.	O	486-487

Oral	O	488-492
bovine	O	493-499
LF	O	500-502
(	O	503-504
30	O	504-506
,	O	506-507
100	O	508-511
,	O	511-512
300	O	513-516
mg	O	517-519
/	O	519-520
kg	O	520-522
)	O	522-523
was	O	524-527
given	O	528-533
from	O	534-538
day	O	539-542
8	O	543-544
to	O	545-547
14	O	548-550
in	O	551-553
a	O	554-555
reversal	O	556-564
study	O	565-570
.	O	570-571

In	O	572-574
a	O	575-576
prevention	O	577-587
study	O	588-593
,	O	593-594
rats	O	595-599
received	O	600-608
4	O	609-610
days	O	611-615
of	O	616-618
LF	O	619-621
treatment	O	622-631
followed	O	632-640
by	O	641-643
Dex	O	644-647
and	O	648-651
continued	O	652-661
during	O	662-668
the	O	669-672
test	O	673-677
period	O	678-684
.	O	684-685

Systolic	O	686-694
blood	O	695-700
pressure	O	701-709
(	O	710-711
SBP	O	711-714
)	O	714-715
was	O	716-719
measured	O	720-728
using	O	729-734
tail	O	735-739
-	O	739-740
cuff	O	740-744
method	O	745-751
.	O	751-752

Thymus	O	753-759
weight	O	760-766
was	O	767-770
used	O	771-775
as	O	776-778
a	O	779-780
marker	O	781-787
of	O	788-790
glucocorticoid	O	791-805
activity	O	806-814
.	O	814-815

Plasma	O	816-822
hydrogen	O	823-831
peroxide	O	832-840
(	O	841-842
H2O2	O	842-846
)	O	846-847
concentration	O	848-861
and	O	862-865
ferric	O	866-872
reducing	O	873-881
antioxidant	O	882-893
power	O	894-899
(	O	900-901
FRAP	O	901-905
)	O	905-906
value	O	907-912
were	O	913-917
determined	O	918-928
.	O	928-929

Dexamethasone	O	930-943
significantly	O	944-957
increased	O	958-967
SBP	O	968-971
and	O	972-975
plasma	O	976-982
H2O2	O	983-987
level	O	988-993
and	O	994-997
decreased	O	998-1007
thymus	O	1008-1014
and	O	1015-1018
body	O	1019-1023
weights	O	1024-1031
.	O	1031-1032

LF	O	1033-1035
lowered	O	1036-1043
(	O	1044-1045
P	O	1045-1046
<	O	1047-1048
0	O	1049-1050
.	O	1050-1051
01	O	1051-1053
)	O	1053-1054
and	O	1055-1058
dose	O	1059-1063
dependently	O	1064-1075
prevented	O	1076-1085
(	O	1086-1087
P	O	1087-1088
<	O	1089-1090
0	O	1091-1092
.	O	1092-1093
001	O	1093-1096
)	O	1096-1097
Dex	O	1098-1101
-	O	1101-1102
induced	O	1102-1109
hypertension	B	1110-1122
.	O	1122-1123

LF	O	1124-1126
prevented	O	1127-1136
body	O	1137-1141
weight	B	1142-1148
loss	I	1149-1153
and	O	1154-1157
significantly	O	1158-1171
reduced	O	1172-1179
the	O	1180-1183
elevated	O	1184-1192
plasma	O	1193-1199
H2O2	O	1200-1204
and	O	1205-1208
increased	O	1209-1218
FRAP	O	1219-1223
values	O	1224-1230
.	O	1230-1231

Chronic	O	1232-1239
administration	O	1240-1254
of	O	1255-1257
LF	O	1258-1260
strongly	O	1261-1269
reduced	O	1270-1277
the	O	1278-1281
blood	O	1282-1287
pressure	O	1288-1296
and	O	1297-1300
production	O	1301-1311
of	O	1312-1314
ROS	O	1315-1318
and	O	1319-1322
improved	O	1323-1331
antioxidant	O	1332-1343
capacity	O	1344-1352
in	O	1353-1355
Dex	O	1356-1359
-	O	1359-1360
induced	O	1360-1367
hypertension	B	1368-1380
,	O	1380-1381
suggesting	O	1382-1392
the	O	1393-1396
role	O	1397-1401
of	O	1402-1404
inhibition	O	1405-1415
of	O	1416-1418
oxidative	O	1419-1428
stress	O	1429-1435
as	O	1436-1438
another	O	1439-1446
mechanism	O	1447-1456
of	O	1457-1459
antihypertensive	O	1460-1476
action	O	1477-1483
of	O	1484-1486
LF	O	1487-1489
.	O	1489-1490

The	O	0-3
association	O	4-15
between	O	16-23
tranexamic	O	24-34
acid	O	35-39
and	O	40-43
convulsive	B	44-54
seizures	B	55-63
after	O	64-69
cardiac	O	70-77
surgery	O	78-85
:	O	85-86
a	O	87-88
multivariate	O	89-101
analysis	O	102-110
in	O	111-113
11	O	114-116
529	O	117-120
patients	O	121-129
.	O	129-130

Because	O	131-138
of	O	139-141
a	O	142-143
lack	O	144-148
of	O	149-151
contemporary	O	152-164
data	O	165-169
regarding	O	170-179
seizures	B	180-188
after	O	189-194
cardiac	O	195-202
surgery	O	203-210
,	O	210-211
we	O	212-214
undertook	O	215-224
a	O	225-226
retrospective	O	227-240
analysis	O	241-249
of	O	250-252
prospectively	O	253-266
collected	O	267-276
data	O	277-281
from	O	282-286
11	O	287-289
529	O	290-293
patients	O	294-302
in	O	303-305
whom	O	306-310
cardiopulmonary	O	311-326
bypass	O	327-333
was	O	334-337
used	O	338-342
from	O	343-347
January	O	348-355
2004	O	356-360
to	O	361-363
December	O	364-372
2010	O	373-377
.	O	377-378

A	O	379-380
convulsive	B	381-391
seizure	B	392-399
was	O	400-403
defined	O	404-411
as	O	412-414
a	O	415-416
transient	O	417-426
episode	O	427-434
of	O	435-437
disturbed	O	438-447
brain	O	448-453
function	O	454-462
characterised	O	463-476
by	O	477-479
abnormal	B	480-488
involuntary	I	489-500
motor	I	501-506
movements	I	507-516
.	O	516-517

Multivariate	O	518-530
regression	O	531-541
analysis	O	542-550
was	O	551-554
performed	O	555-564
to	O	565-567
identify	O	568-576
independent	O	577-588
predictors	O	589-599
of	O	600-602
postoperative	O	603-616
seizures	B	617-625
.	O	625-626

A	O	627-628
total	O	629-634
of	O	635-637
100	O	638-641
(	O	642-643
0	O	643-644
.	O	644-645
9	O	645-646
%	O	646-647
)	O	647-648
patients	O	649-657
developed	O	658-667
postoperative	O	668-681
convulsive	B	682-692
seizures	B	693-701
.	O	701-702

Generalised	B	703-714
and	I	715-718
focal	I	719-724
seizures	I	725-733
were	O	734-738
identified	O	739-749
in	O	750-752
68	O	753-755
and	O	756-759
32	O	760-762
patients	O	763-771
,	O	771-772
respectively	O	773-785
.	O	785-786

The	O	787-790
median	O	791-797
(	O	798-799
IQR	O	799-802
[	O	803-804
range	O	804-809
]	O	809-810
)	O	810-811
time	O	812-816
after	O	817-822
surgery	O	823-830
when	O	831-835
the	O	836-839
seizure	B	840-847
occurred	O	848-856
was	O	857-860
7	O	861-862
(	O	863-864
6	O	864-865
-	O	865-866
12	O	866-868
[	O	869-870
1	O	870-871
-	O	871-872
216	O	872-875
]	O	875-876
)	O	876-877
h	O	878-879
and	O	880-883
8	O	884-885
(	O	886-887
6	O	887-888
-	O	888-889
11	O	889-891
[	O	892-893
4	O	893-894
-	O	894-895
18	O	895-897
]	O	897-898
)	O	898-899
h	O	900-901
,	O	901-902
respectively	O	903-915
.	O	915-916

Epileptiform	O	917-929
findings	O	930-938
on	O	939-941
electroencephalography	O	942-964
were	O	965-969
seen	O	970-974
in	O	975-977
19	O	978-980
patients	O	981-989
.	O	989-990

Independent	O	991-1002
predictors	O	1003-1013
of	O	1014-1016
postoperative	O	1017-1030
seizures	B	1031-1039
included	O	1040-1048
age	O	1049-1052
,	O	1052-1053
female	O	1054-1060
sex	O	1061-1064
,	O	1064-1065
redo	O	1066-1070
cardiac	O	1071-1078
surgery	O	1079-1086
,	O	1086-1087
calcification	O	1088-1101
of	O	1102-1104
ascending	O	1105-1114
aorta	O	1115-1120
,	O	1120-1121
congestive	B	1122-1132
heart	I	1133-1138
failure	I	1139-1146
,	O	1146-1147
deep	O	1148-1152
hypothermic	B	1153-1164
circulatory	O	1165-1176
arrest	O	1177-1183
,	O	1183-1184
duration	O	1185-1193
of	O	1194-1196
aortic	O	1197-1203
cross	O	1204-1209
-	O	1209-1210
clamp	O	1210-1215
and	O	1216-1219
tranexamic	O	1220-1230
acid	O	1231-1235
.	O	1235-1236

When	O	1237-1241
tested	O	1242-1248
in	O	1249-1251
a	O	1252-1253
multivariate	O	1254-1266
regression	O	1267-1277
analysis	O	1278-1286
,	O	1286-1287
tranexamic	O	1288-1298
acid	O	1299-1303
was	O	1304-1307
a	O	1308-1309
strong	O	1310-1316
independent	O	1317-1328
predictor	O	1329-1338
of	O	1339-1341
seizures	B	1342-1350
(	O	1351-1352
OR	O	1352-1354
14	O	1355-1357
.	O	1357-1358
3	O	1358-1359
,	O	1359-1360
95	O	1361-1363
%	O	1363-1364
CI	O	1365-1367
5	O	1368-1369
.	O	1369-1370
5	O	1368-1369
-	O	1371-1372
36	O	1372-1374
.	O	1369-1370
7	O	1375-1376
;	O	1376-1377

p	O	1378-1379
<	O	1380-1381
0	O	1382-1383
.	O	1383-1384
001	O	1384-1387
)	O	1387-1388
.	O	1383-1384

Patients	O	1390-1398
with	O	1399-1403
convulsive	B	1404-1414
seizures	B	1415-1423
had	O	1424-1427
2	O	1428-1429
.	O	1429-1430
5	O	1430-1431
times	O	1432-1437
higher	O	1438-1444
in	O	1445-1447
-	O	1447-1448
hospital	O	1448-1456
mortality	O	1457-1466
rates	O	1467-1472
and	O	1473-1476
twice	O	1477-1482
the	O	1483-1486
length	O	1487-1493
of	O	1494-1496
hospital	O	1497-1505
stay	O	1506-1510
compared	O	1511-1519
with	O	1520-1524
patients	O	1525-1533
without	O	1534-1541
convulsive	B	1542-1552
seizures	B	1553-1561
.	O	1561-1562

Mean	O	1563-1567
(	O	1568-1569
IQR	O	1569-1572
[	O	1573-1574
range	O	1574-1579
]	O	1579-1580
)	O	1580-1581
length	O	1582-1588
of	O	1589-1591
stay	O	1592-1596
in	O	1597-1599
the	O	1600-1603
intensive	O	1604-1613
care	O	1614-1618
unit	O	1619-1623
was	O	1624-1627
115	O	1628-1631
(	O	1632-1633
49	O	1633-1635
-	O	1635-1636
228	O	1636-1639
[	O	1640-1641
32	O	1641-1643
-	O	1643-1644
481	O	1644-1647
]	O	1647-1648
)	O	1648-1649
h	O	1650-1651
in	O	1652-1654
patients	O	1655-1663
with	O	1664-1668
convulsive	B	1669-1679
seizures	B	1680-1688
compared	O	1689-1697
with	O	1698-1702
26	O	1703-1705
(	O	1706-1707
22	O	1707-1709
-	O	1709-1710
69	O	1710-1712
[	O	1713-1714
14	O	1714-1716
-	O	1716-1717
1080	O	1717-1721
]	O	1721-1722
)	O	1722-1723
h	O	1724-1725
in	O	1726-1728
patients	O	1729-1737
without	O	1738-1745
seizures	B	1746-1754
(	O	1755-1756
p	O	1756-1757
<	O	1758-1759
0	O	1760-1761
.	O	1761-1762
001	O	1762-1765
)	O	1765-1766
.	O	1761-1762

Convulsive	B	1768-1778
seizures	B	1779-1787
are	O	1788-1791
a	O	1792-1793
serious	O	1794-1801
postoperative	B	1802-1815
complication	I	1816-1828
after	O	1829-1834
cardiac	O	1835-1842
surgery	O	1843-1850
.	O	1850-1851

As	O	1852-1854
tranexamic	O	1855-1865
acid	O	1866-1870
is	O	1871-1873
the	O	1874-1877
only	O	1878-1882
modifiable	O	1883-1893
factor	O	1894-1900
,	O	1900-1901
its	O	1902-1905
administration	O	1906-1920
,	O	1920-1921
particularly	O	1922-1934
in	O	1935-1937
doses	O	1938-1943
exceeding	O	1944-1953
80	O	1954-1956
mg	O	1957-1959
.	O	1959-1960
kg	O	1960-1962
(	O	1962-1963
-	O	1963-1964
1	O	1964-1965
)	O	1965-1966
,	O	1966-1967
should	O	1968-1974
be	O	1975-1977
weighed	O	1978-1985
against	O	1986-1993
the	O	1994-1997
risk	O	1998-2002
of	O	2003-2005
postoperative	O	2006-2019
seizures	B	2020-2028
.	O	2028-2029

Dysfunctional	B	0-13
overnight	I	14-23
memory	I	24-30
consolidation	O	31-44
in	O	45-47
ecstasy	O	48-55
users	O	56-61
.	O	61-62

Sleep	O	63-68
plays	O	69-74
an	O	75-77
important	O	78-87
role	O	88-92
in	O	93-95
the	O	96-99
consolidation	O	100-113
and	O	114-117
integration	O	118-129
of	O	130-132
memory	O	133-139
in	O	140-142
a	O	143-144
process	O	145-152
called	O	153-159
overnight	O	160-169
memory	O	170-176
consolidation	O	177-190
.	O	190-191

Previous	O	192-200
studies	O	201-208
indicate	O	209-217
that	O	218-222
ecstasy	O	223-230
users	O	231-236
have	O	237-241
marked	O	242-248
and	O	249-252
persistent	O	253-263
neurocognitive	O	264-278
and	O	279-282
sleep	B	283-288
-	I	288-289
related	I	289-296
impairments	I	297-308
.	O	308-309

We	O	310-312
extend	O	313-319
past	O	320-324
research	O	325-333
by	O	334-336
examining	O	337-346
overnight	O	347-356
memory	O	357-363
consolidation	O	364-377
among	O	378-383
regular	O	384-391
ecstasy	O	392-399
users	O	400-405
(	O	406-407
n	O	407-408
=	O	408-409
12	O	409-411
)	O	411-412
and	O	413-416
drug	O	417-421
naive	O	422-427
healthy	O	428-435
controls	O	436-444
(	O	445-446
n	O	446-447
=	O	447-448
26	O	448-450
)	O	450-451
.	O	451-452

Memory	O	453-459
recall	O	460-466
of	O	467-469
word	O	470-474
pairs	O	475-480
was	O	481-484
evaluated	O	485-494
before	O	495-501
and	O	502-505
after	O	506-511
a	O	512-513
period	O	514-520
of	O	521-523
sleep	O	524-529
,	O	529-530
with	O	531-535
and	O	536-539
without	O	540-547
interference	O	548-560
prior	O	561-566
to	O	567-569
testing	O	570-577
.	O	577-578

In	O	579-581
addition	O	582-590
,	O	590-591
we	O	592-594
assessed	O	595-603
neurocognitive	O	604-618
performances	O	619-631
across	O	632-638
tasks	O	639-644
of	O	645-647
learning	O	648-656
,	O	656-657
memory	O	658-664
and	O	665-668
executive	O	669-678
functioning	O	679-690
.	O	690-691

Ecstasy	O	692-699
users	O	700-705
demonstrated	O	706-718
impaired	B	719-727
overnight	I	728-737
memory	I	738-744
consolidation	O	745-758
,	O	758-759
a	O	760-761
finding	O	762-769
that	O	770-774
was	O	775-778
more	O	779-783
pronounced	O	784-794
following	O	795-804
associative	O	805-816
interference	O	817-829
.	O	829-830

Additionally	O	831-843
,	O	843-844
ecstasy	O	845-852
users	O	853-858
demonstrated	O	859-871
impairments	O	872-883
on	O	884-886
tasks	O	887-892
recruiting	O	893-903
frontostriatal	O	904-918
and	O	919-922
hippocampal	O	923-934
neural	O	935-941
circuitry	O	942-951
,	O	951-952
in	O	953-955
the	O	956-959
domains	O	960-967
of	O	968-970
proactive	O	971-980
interference	O	981-993
memory	O	994-1000
,	O	1000-1001
long	O	1002-1006
-	O	1006-1007
term	O	1007-1011
memory	O	1012-1018
,	O	1018-1019
encoding	O	1020-1028
,	O	1028-1029
working	O	1030-1037
memory	O	1038-1044
and	O	1045-1048
complex	O	1049-1056
planning	O	1057-1065
.	O	1065-1066

We	O	1067-1069
suggest	O	1070-1077
that	O	1078-1082
ecstasy	O	1083-1090
-	O	1090-1091
associated	O	1091-1101
dysfunction	O	1102-1113
in	O	1114-1116
fronto	O	1117-1123
-	O	1123-1124
temporal	O	1124-1132
circuitry	O	1133-1142
may	O	1143-1146
underlie	O	1147-1155
overnight	O	1156-1165
consolidation	O	1166-1179
memory	B	1180-1186
impairments	I	1187-1198
in	O	1199-1201
regular	O	1202-1209
ecstasy	O	1210-1217
users	O	1218-1223
.	O	1223-1224

Normoammonemic	O	0-14
encephalopathy	B	15-29
:	O	29-30
solely	O	31-37
valproate	O	38-47
induced	O	48-55
or	O	56-58
multiple	O	59-67
mechanisms	O	68-78
?	O	78-79

A	O	80-81
77	O	82-84
-	O	84-85
year	O	85-89
-	O	84-85
old	O	90-93
woman	O	94-99
presented	O	100-109
with	O	110-114
subacute	O	115-123
onset	O	124-129
progressive	O	130-141
confusion	B	142-151
,	O	151-152
aggression	B	153-163
,	O	163-164
auditory	B	165-173
hallucinations	I	174-188
and	O	189-192
delusions	B	193-202
.	O	202-203

In	O	204-206
the	O	207-210
preceding	O	211-220
months	O	221-227
,	O	227-228
the	O	229-232
patient	O	233-240
had	O	241-244
a	O	245-246
number	O	247-253
of	O	254-256
admissions	O	257-267
with	O	268-272
transient	O	273-282
unilateral	O	283-293
hemiparesis	B	294-305
with	O	306-310
facial	O	311-317
droop	O	318-323
,	O	323-324
and	O	325-328
had	O	329-332
been	O	333-337
started	O	338-345
on	O	346-348
valproate	O	349-358
for	O	359-362
presumed	O	363-371
hemiplegic	B	372-382
migraine	I	383-391
.	O	391-392

Valproate	O	393-402
was	O	403-406
withdrawn	O	407-416
soon	O	417-421
after	O	422-427
admission	O	428-437
and	O	438-441
her	O	442-445
cognitive	O	446-455
abilities	O	456-465
have	O	466-470
gradually	O	471-480
improved	O	481-489
over	O	490-494
3	O	495-496
months	O	497-503
of	O	504-506
follow	O	507-513
-	O	513-514
up	O	514-516
.	O	516-517

Valproate	O	518-527
levels	O	528-534
taken	O	535-540
prior	O	541-546
to	O	547-549
withdrawal	O	550-560
were	O	561-565
subtherapeutic	O	566-580
and	O	581-584
the	O	585-588
patient	O	589-596
was	O	597-600
normoammonaemic	O	601-616
.	O	616-617

EEG	O	618-621
undertaken	O	622-632
during	O	633-639
inpatient	O	640-649
stay	O	650-654
showed	O	655-661
changes	O	662-669
consistent	O	670-680
with	O	681-685
encephalopathy	B	686-700
,	O	700-701
and	O	702-705
low	O	706-709
titre	O	710-715
N	O	716-717
-	O	717-718
methyl	O	718-724
-	O	717-718
D	O	725-726
-	O	717-718
aspartate	O	727-736
(	O	737-738
NMDA	O	738-742
)	O	742-743
receptor	O	744-752
antibodies	O	753-763
were	O	764-768
present	O	769-776
in	O	777-779
this	O	780-784
patient	O	785-792
.	O	792-793

The	O	794-797
possible	O	798-806
aetiologies	O	807-818
of	O	819-821
valproate	O	822-831
-	O	831-832
induced	O	832-839
encephalopathy	B	840-854
and	O	855-858
NMDA	O	859-863
receptor	O	864-872
-	O	872-873
associated	O	873-883
encephalitis	B	884-896
present	O	897-904
a	O	905-906
diagnostic	O	907-917
dilemma	O	918-925
.	O	925-926

We	O	927-929
present	O	930-937
a	O	938-939
putative	O	940-948
combinatorial	O	949-962
hypothesis	O	963-973
to	O	974-976
explain	O	977-984
this	O	985-989
patient	O	990-997
'	O	997-998
s	O	998-999
symptoms	O	1000-1008
.	O	1008-1009

Cerebellar	B	0-10
and	I	11-14
oculomotor	I	15-25
dysfunction	I	26-37
induced	O	38-45
by	O	46-48
rapid	O	49-54
infusion	O	55-63
of	O	64-66
pethidine	O	67-76
.	O	76-77

Pethidine	O	78-87
is	O	88-90
an	O	91-93
opioid	O	94-100
that	O	101-105
gains	O	106-111
its	O	112-115
popularity	O	116-126
for	O	127-130
the	O	131-134
effective	O	135-144
pain	B	145-149
control	O	150-157
through	O	158-165
acting	O	166-172
on	O	173-175
the	O	176-179
opioid	O	180-186
-	O	186-187
receptors	O	187-196
.	O	196-197

However	O	198-205
,	O	205-206
rapid	O	207-212
pain	B	213-217
relief	O	218-224
sometimes	O	225-234
brings	O	235-241
about	O	242-247
unfavourable	O	248-260
side	O	261-265
effects	O	266-273
that	O	274-278
largely	O	279-286
limit	O	287-292
its	O	293-296
clinical	O	297-305
utility	O	306-313
.	O	313-314

Common	O	315-321
side	O	322-326
effects	O	327-334
include	O	335-342
nausea	B	343-349
,	O	349-350
vomiting	B	351-359
and	O	360-363
hypotension	B	364-375
.	O	375-376

In	O	377-379
patients	O	380-388
with	O	389-393
impaired	B	394-402
renal	I	403-408
and	I	409-412
liver	I	413-418
function	I	419-427
,	O	427-428
and	O	429-432
those	O	433-438
who	O	439-442
need	O	443-447
long	O	448-452
-	O	452-453
term	O	453-457
pain	B	458-462
control	O	463-470
,	O	470-471
pethidine	O	472-481
may	O	482-485
cause	O	486-491
excitatory	O	492-502
central	O	503-510
nervous	O	511-518
system	O	519-525
(	O	526-527
CNS	O	527-530
)	O	530-531
effects	O	532-539
through	O	540-547
its	O	548-551
neurotoxic	B	552-562
metabolite	O	563-573
,	O	573-574
norpethidine	O	575-587
,	O	587-588
resulting	O	589-598
in	O	599-601
irritability	B	602-614
and	O	615-618
seizure	B	619-626
attack	O	627-633
.	O	633-634

On	O	635-637
the	O	638-641
contrary	O	642-650
,	O	650-651
though	O	652-658
not	O	659-662
clinically	O	663-673
apparent	O	674-682
,	O	682-683
pethidine	O	684-693
potentially	O	694-705
causes	O	706-712
inhibitory	O	713-723
impacts	O	724-731
on	O	732-734
the	O	735-738
CNS	O	739-742
and	O	743-746
impairs	O	747-754
normal	O	755-761
cerebellar	O	762-772
and	O	773-776
oculomotor	O	777-787
function	O	788-796
in	O	797-799
the	O	800-803
short	O	804-809
term	O	810-814
.	O	814-815

In	O	816-818
this	O	819-823
case	O	824-828
report	O	829-835
,	O	835-836
we	O	837-839
highlight	O	840-849
opioid	O	850-856
'	O	856-857
s	O	857-858
inhibitory	O	859-869
side	O	870-874
effects	O	875-882
on	O	883-885
the	O	886-889
cerebellar	O	890-900
structure	O	901-910
that	O	911-915
causes	O	916-922
dysmetria	B	923-932
,	O	932-933
dysarthria	B	934-944
,	O	944-945
reduced	O	946-953
smooth	O	954-960
pursuit	O	961-968
gain	O	969-973
and	O	974-977
decreased	O	978-987
saccadic	O	988-996
velocity	O	997-1005
.	O	1005-1006

Baboon	B	0-6
syndrome	I	7-15
induced	O	16-23
by	O	24-26
ketoconazole	O	27-39
.	O	39-40

A	O	41-42
27	O	43-45
-	O	45-46
year	O	46-50
-	O	45-46
old	O	51-54
male	O	55-59
patient	O	60-67
presented	O	68-77
with	O	78-82
a	O	83-84
maculopapular	B	85-98
eruption	I	99-107
on	O	108-110
the	O	111-114
flexural	O	115-123
areas	O	124-129
and	O	130-133
buttocks	O	134-142
after	O	143-148
using	O	149-154
oral	O	155-159
ketoconazole	O	160-172
.	O	172-173

The	O	174-177
patient	O	178-185
was	O	186-189
diagnosed	O	190-199
with	O	200-204
drug	O	205-209
-	O	209-210
induced	O	210-217
baboon	B	218-224
syndrome	I	225-233
based	O	234-239
on	O	240-242
his	O	243-246
history	O	247-254
,	O	254-255
which	O	256-261
included	O	262-270
prior	O	271-276
sensitivity	O	277-288
to	O	289-291
topical	O	292-299
ketoconazole	O	300-312
,	O	312-313
a	O	314-315
physical	O	316-324
examination	O	325-336
,	O	336-337
and	O	338-341
histopathological	O	342-359
findings	O	360-368
.	O	368-369

Baboon	B	370-376
syndrome	I	377-385
is	O	386-388
a	O	389-390
drug	O	391-395
-	O	395-396
or	O	397-399
contact	O	400-407
allergen	O	408-416
-	O	416-417
related	O	417-424
maculopapular	B	425-438
eruption	I	439-447
that	O	448-452
typically	O	453-462
involves	O	463-471
the	O	472-475
flexural	O	476-484
and	O	485-488
gluteal	O	489-496
areas	O	497-502
.	O	502-503

To	O	504-506
the	O	507-510
best	O	511-515
of	O	516-518
our	O	519-522
knowledge	O	523-532
,	O	532-533
this	O	534-538
is	O	539-541
the	O	542-545
first	O	546-551
reported	O	552-560
case	O	561-565
of	O	566-568
ketoconazole	O	569-581
-	O	581-582
induced	O	582-589
baboon	B	590-596
syndrome	I	597-605
in	O	606-608
the	O	609-612
English	O	613-620
literature	O	621-631
.	O	631-632

A	O	0-1
Case	O	2-6
of	O	7-9
Sudden	B	10-16
Cardiac	I	17-24
Death	I	25-30
due	O	31-34
to	O	35-37
Pilsicainide	O	38-50
-	O	50-51
Induced	O	51-58
Torsades	B	59-67
de	I	68-70
Pointes	I	71-78
.	O	78-79

An	O	80-82
84	O	83-85
-	O	85-86
year	O	86-90
-	O	85-86
old	O	91-94
male	O	95-99
received	O	100-108
oral	O	109-113
pilsicainide	O	114-126
,	O	126-127
a	O	128-129
pure	O	130-134
sodium	O	135-141
channel	O	142-149
blocker	O	150-157
with	O	158-162
slow	O	163-167
recovery	O	168-176
kinetics	O	177-185
,	O	185-186
to	O	187-189
convert	O	190-197
his	O	198-201
paroxysmal	O	202-212
atrial	B	213-219
fibrillation	I	220-232
to	O	233-235
a	O	236-237
sinus	O	238-243
rhythm	O	244-250
;	O	250-251
the	O	252-255
patient	O	256-263
developed	O	264-273
sudden	B	274-280
cardiac	I	281-288
death	I	289-294
two	O	295-298
days	O	299-303
later	O	304-309
.	O	309-310

The	O	311-314
Holter	O	315-321
electrocardiogram	O	322-339
,	O	339-340
which	O	341-346
was	O	347-350
worn	O	351-355
by	O	356-358
chance	O	359-365
,	O	365-366
revealed	O	367-375
torsade	B	376-383
de	I	384-386
pointes	I	387-394
with	O	395-399
gradually	O	400-409
prolonged	O	410-419
QT	O	420-422
intervals	O	423-432
.	O	432-433

This	O	434-438
drug	O	439-443
is	O	444-446
rapidly	O	447-454
absorbed	O	455-463
from	O	464-468
the	O	469-472
gastrointestinal	O	473-489
tract	O	490-495
,	O	495-496
and	O	497-500
most	O	501-505
of	O	506-508
it	O	509-511
is	O	512-514
excreted	O	515-523
from	O	524-528
the	O	529-532
kidney	O	533-539
.	O	539-540

Although	O	541-549
the	O	550-553
patient	O	554-561
'	O	561-562
s	O	562-563
renal	O	564-569
function	O	570-578
was	O	579-582
not	O	583-586
highly	O	587-593
impaired	O	594-602
and	O	603-606
the	O	607-610
dose	O	611-615
of	O	616-618
pilsicainide	O	619-631
was	O	632-635
low	O	636-639
,	O	639-640
the	O	641-644
plasma	O	645-651
concentration	O	652-665
of	O	666-668
pilsicainide	O	669-681
may	O	682-685
have	O	686-690
been	O	691-695
high	O	696-700
,	O	700-701
which	O	702-707
can	O	708-711
produce	O	712-719
torsades	B	720-728
de	I	729-731
pointes	I	732-739
in	O	740-742
the	O	743-746
octogenarian	O	747-759
.	O	759-760

Although	O	761-769
the	O	770-773
oral	O	774-778
administration	O	779-793
of	O	794-796
class	O	797-802
IC	O	803-805
drugs	O	806-811
,	O	811-812
including	O	813-822
pilsicainide	O	823-835
,	O	835-836
is	O	837-839
effective	O	840-849
to	O	850-852
terminate	O	853-862
atrial	B	863-869
fibrillation	I	870-882
,	O	882-883
careful	O	884-891
consideration	O	892-905
must	O	906-910
be	O	911-913
taken	O	914-919
before	O	920-926
giving	O	927-933
these	O	934-939
drugs	O	940-945
to	O	946-948
octogenarians	O	949-962
.	O	962-963

All	O	0-3
-	O	3-4
trans	O	4-9
retinoic	O	10-18
acid	O	19-23
-	O	23-24
induced	O	24-31
inflammatory	O	32-44
myositis	B	45-53
in	O	54-56
a	O	57-58
patient	O	59-66
with	O	67-71
acute	B	72-77
promyelocytic	I	78-91
leukemia	I	92-100
.	O	100-101

All	O	102-105
-	O	105-106
trans	O	106-111
retinoic	O	112-120
acid	O	121-125
(	O	126-127
ATRA	O	127-131
)	O	131-132
,	O	132-133
a	O	134-135
component	O	136-145
of	O	146-148
standard	O	149-157
therapy	O	158-165
for	O	166-169
acute	B	170-175
promyelocytic	I	176-189
leukemia	I	190-198
(	O	199-200
APL	B	200-203
)	O	203-204
,	O	204-205
is	O	206-208
associated	O	209-219
with	O	220-224
potentially	O	225-236
serious	O	237-244
but	O	245-248
treatable	O	249-258
adverse	O	259-266
effects	O	267-274
involving	O	275-284
numerous	O	285-293
organ	O	294-299
systems	O	300-307
,	O	307-308
including	O	309-318
rare	O	319-323
skeletal	O	324-332
muscle	O	333-339
involvement	O	340-351
.	O	351-352

Only	O	353-357
a	O	358-359
handful	O	360-367
of	O	368-370
cases	O	371-376
of	O	377-379
ATRA	O	380-384
-	O	384-385
induced	O	385-392
myositis	B	393-401
in	O	402-404
children	O	405-413
have	O	414-418
been	O	419-423
reported	O	424-432
,	O	432-433
and	O	434-437
none	O	438-442
in	O	443-445
the	O	446-449
radiology	O	450-459
literature	O	460-470
.	O	470-471

We	O	472-474
present	O	475-482
such	O	483-487
a	O	488-489
case	O	490-494
in	O	495-497
a	O	498-499
15	O	500-502
-	O	502-503
year	O	503-507
-	O	502-503
old	O	508-511
boy	O	512-515
with	O	516-520
APL	B	521-524
,	O	524-525
where	O	526-531
recognition	O	532-543
of	O	544-546
imaging	O	547-554
findings	O	555-563
played	O	564-570
a	O	571-572
crucial	O	573-580
role	O	581-585
in	O	586-588
making	O	589-595
the	O	596-599
diagnosis	O	600-609
and	O	610-613
facilitated	O	614-625
prompt	O	626-632
,	O	632-633
effective	O	634-643
treatment	O	644-653
.	O	653-654

Tolerability	O	0-12
of	O	13-15
lomustine	O	16-25
in	O	26-28
combination	O	29-40
with	O	41-45
cyclophosphamide	O	46-62
in	O	63-65
dogs	O	66-70
with	O	71-75
lymphoma	B	76-84
.	O	84-85

This	O	86-90
retrospective	O	91-104
study	O	105-110
describes	O	111-120
toxicity	B	121-129
associated	O	130-140
with	O	141-145
a	O	146-147
protocol	O	148-156
of	O	157-159
lomustine	O	160-169
(	O	170-171
CCNU	O	171-175
)	O	175-176
and	O	177-180
cyclophosphamide	O	181-197
(	O	198-199
CTX	O	199-202
)	O	202-203
in	O	204-206
dogs	O	207-211
with	O	212-216
lymphoma	B	217-225
.	O	225-226

CCNU	O	227-231
was	O	232-235
administered	O	236-248
per	O	249-252
os	O	253-255
(	O	256-257
PO	O	257-259
)	O	259-260
at	O	261-263
a	O	264-265
targeted	O	266-274
dosage	O	275-281
of	O	282-284
60	O	285-287
mg	O	288-290
/	O	290-291
m	O	288-289
(	O	292-293
2	O	293-294
)	O	294-295
body	O	296-300
surface	O	301-308
area	O	309-313
on	O	314-316
day	O	317-320
0	O	321-322
,	O	322-323
CTX	O	324-327
was	O	328-331
administered	O	332-344
PO	O	345-347
at	O	348-350
a	O	351-352
targeted	O	353-361
dosage	O	362-368
of	O	369-371
250	O	372-375
mg	O	376-378
/	O	378-379
m	O	376-377
(	O	380-381
2	O	381-382
)	O	382-383
divided	O	384-391
over	O	392-396
days	O	397-401
0	O	402-403
through	O	404-411
4	O	412-413
,	O	413-414
and	O	415-418
all	O	419-422
dogs	O	423-427
received	O	428-436
prophylactic	O	437-449
antibiotics	O	450-461
.	O	461-462

Ninety	O	463-469
treatments	O	470-480
were	O	481-485
given	O	486-491
to	O	492-494
the	O	495-498
57	O	499-501
dogs	O	502-506
included	O	507-515
in	O	516-518
the	O	519-522
study	O	523-528
.	O	528-529

Neutropenia	B	530-541
was	O	542-545
the	O	546-549
principal	O	550-559
toxic	O	560-565
effect	O	566-572
,	O	572-573
and	O	574-577
the	O	578-581
overall	O	582-589
frequency	O	590-599
of	O	600-602
grade	O	603-608
4	O	609-610
neutropenia	B	611-622
after	O	623-628
the	O	629-632
first	O	633-638
treatment	O	639-648
of	O	649-651
CCNU	O	652-656
/	O	656-657
CTX	O	657-660
was	O	661-664
30	O	665-667
%	O	667-668
(	O	669-670
95	O	670-672
%	O	672-673
confidence	O	674-684
interval	O	685-693
,	O	693-694
19	O	695-697
-	O	697-698
43	O	698-700
%	O	700-701
)	O	701-702
.	O	702-703

The	O	704-707
mean	O	708-712
body	O	713-717
weight	O	718-724
of	O	725-727
dogs	O	728-732
with	O	733-737
grade	O	738-743
4	O	744-745
neutropenia	B	746-757
(	O	758-759
19	O	759-761
.	O	761-762
7	O	762-763
kg	O	764-766
+	O	767-768
13	O	769-771
.	O	771-772
4	O	772-773
kg	O	774-776
)	O	776-777
was	O	778-781
significantly	O	782-795
less	O	796-800
than	O	801-805
the	O	806-809
mean	O	810-814
body	O	815-819
weight	O	820-826
of	O	827-829
dogs	O	830-834
that	O	835-839
did	O	840-843
not	O	844-847
develop	O	848-855
grade	O	856-861
4	O	862-863
neutropenia	B	864-875
(	O	876-877
31	O	877-879
.	O	879-880
7	O	880-881
kg	O	882-884
+	O	885-886
12	O	887-889
.	O	889-890
4	O	890-891
kg	O	892-894
;	O	894-895
P	O	896-897
=	O	898-899
.	O	900-901
005	O	901-904
)	O	904-905
.	O	900-901

One	O	907-910
dog	O	911-914
(	O	915-916
3	O	916-917
%	O	917-918
)	O	918-919
developed	O	920-929
hematologic	O	930-941
changes	O	942-949
suggestive	O	950-960
of	O	961-963
hepatotoxicity	B	964-978
.	O	978-979

No	O	980-982
dogs	O	983-987
had	O	988-991
evidence	O	992-1000
of	O	1001-1003
either	O	1004-1010
renal	B	1011-1016
toxicity	I	1017-1025
or	O	1026-1028
hemorrhagic	B	1029-1040
cystitis	I	1041-1049
.	O	1049-1050

Adverse	O	1051-1058
gastrointestinal	O	1059-1075
effects	O	1076-1083
were	O	1084-1088
uncommon	O	1089-1097
.	O	1097-1098

On	O	1099-1101
the	O	1102-1105
basis	O	1106-1111
of	O	1112-1114
the	O	1115-1118
findings	O	1119-1127
reported	O	1128-1136
herein	O	1137-1143
,	O	1143-1144
a	O	1145-1146
dose	O	1147-1151
of	O	1152-1154
60	O	1155-1157
mg	O	1158-1160
/	O	1160-1161
m	O	1158-1159
(	O	1162-1163
2	O	1163-1164
)	O	1164-1165
of	O	1166-1168
CCNU	O	1169-1173
combined	O	1174-1182
with	O	1183-1187
250	O	1188-1191
mg	O	1192-1194
/	O	1194-1195
m	O	1192-1193
(	O	1196-1197
2	O	1197-1198
)	O	1198-1199
of	O	1200-1202
CTX	O	1203-1206
(	O	1207-1208
divided	O	1208-1215
over	O	1216-1220
5	O	1221-1222
days	O	1223-1227
)	O	1227-1228
q	O	1229-1230
4	O	1231-1232
wk	O	1233-1235
is	O	1236-1238
tolerable	O	1239-1248
in	O	1249-1251
tumor	B	1252-1257
-	O	1257-1258
bearing	O	1258-1265
dogs	O	1266-1270
.	O	1270-1271

Nelarabine	O	0-10
neurotoxicity	B	11-24
with	O	25-29
concurrent	O	30-40
intrathecal	O	41-52
chemotherapy	O	53-65
:	O	65-66
Case	O	67-71
report	O	72-78
and	O	79-82
review	O	83-89
of	O	90-92
literature	O	93-103
.	O	103-104

Severe	O	105-111
nelarabine	O	112-122
neurotoxicity	B	123-136
in	O	137-139
a	O	140-141
patient	O	142-149
who	O	150-153
received	O	154-162
concurrent	O	163-173
intrathecal	O	174-185
(	O	186-187
IT	O	187-189
)	O	189-190
chemotherapy	O	191-203
is	O	204-206
reported	O	207-215
.	O	215-216

A	O	217-218
37	O	219-221
-	O	221-222
year	O	222-226
-	O	221-222
old	O	227-230
Caucasian	O	231-240
woman	O	241-246
with	O	247-251
a	O	252-253
history	O	254-261
of	O	262-264
T	B	265-266
-	I	266-267
cell	I	267-271
lymphoblastic	I	272-285
lymphoma	I	286-294
was	O	295-298
admitted	O	299-307
for	O	308-311
relapsed	O	312-320
disease	O	321-328
.	O	328-329

She	O	330-333
was	O	334-337
originally	O	338-348
treated	O	349-356
with	O	357-361
induction	O	362-371
chemotherapy	O	372-384
followed	O	385-393
by	O	394-396
an	O	397-399
autologous	O	400-410
transplant	O	411-421
.	O	421-422

She	O	423-426
developed	O	427-436
relapsed	O	437-445
disease	O	446-453
10	O	454-456
months	O	457-463
later	O	464-469
with	O	470-474
leukemic	B	475-483
involvement	O	484-495
.	O	495-496

She	O	497-500
was	O	501-504
re	O	505-507
-	O	507-508
induced	O	508-515
with	O	516-520
nelarabine	O	521-531
1500	O	532-536
mg	O	537-539
/	O	539-540
m	O	537-538
(	O	541-542
2	O	542-543
)	O	543-544
on	O	545-547
days	O	548-552
1	O	553-554
,	O	554-555
3	O	556-557
,	O	557-558
and	O	559-562
5	O	563-564
with	O	565-569
1	O	570-571
dose	O	572-576
of	O	577-579
IT	O	580-582
cytarabine	O	583-593
100	O	594-597
mg	O	598-600
on	O	601-603
day	O	604-607
2	O	608-609
as	O	610-612
central	O	613-620
nervous	O	621-628
system	O	629-635
(	O	636-637
CNS	O	637-640
)	O	640-641
prophylaxis	O	642-653
.	O	653-654

At	O	655-657
the	O	658-661
time	O	662-666
of	O	667-669
treatment	O	670-679
,	O	679-680
she	O	681-684
was	O	685-688
on	O	689-691
continuous	O	692-702
renal	O	703-708
replacement	O	709-720
therapy	O	721-728
due	O	729-732
to	O	733-735
sequelae	O	736-744
of	O	745-747
tumor	B	748-753
lysis	I	754-759
syndrome	I	760-768
(	O	769-770
TLS	B	770-773
)	O	773-774
.	O	774-775

She	O	776-779
tolerated	O	780-789
therapy	O	790-797
well	O	798-802
,	O	802-803
entered	O	804-811
a	O	812-813
complete	O	814-822
remission	O	823-832
,	O	832-833
and	O	834-837
recovered	O	838-847
her	O	848-851
renal	O	852-857
function	O	858-866
.	O	866-867

She	O	868-871
received	O	872-880
a	O	881-882
second	O	883-889
cycle	O	890-895
of	O	896-898
nelarabine	O	899-909
without	O	910-917
additional	O	918-928
IT	O	929-931
prophylaxis	O	932-943
one	O	944-947
month	O	948-953
later	O	954-959
.	O	959-960

A	O	961-962
week	O	963-967
after	O	968-973
this	O	974-978
second	O	979-985
cycle	O	986-991
,	O	991-992
she	O	993-996
noted	O	997-1002
numbness	O	1003-1011
in	O	1012-1014
her	O	1015-1018
lower	O	1019-1024
extremities	O	1025-1036
.	O	1036-1037

Predominantly	O	1038-1051
sensory	O	1052-1059
,	O	1059-1060
though	O	1061-1067
also	O	1068-1072
motor	O	1073-1078
and	O	1079-1082
autonomic	O	1083-1092
,	O	1092-1093
peripheral	B	1094-1104
neuropathy	I	1105-1115
started	O	1116-1123
in	O	1124-1126
her	O	1127-1130
feet	O	1131-1135
,	O	1135-1136
ascended	O	1137-1145
proximally	O	1146-1156
to	O	1157-1159
the	O	1160-1163
mid	O	1164-1167
-	O	1167-1168
thoracic	O	1168-1176
region	O	1177-1183
,	O	1183-1184
and	O	1185-1188
eventually	O	1189-1199
included	O	1200-1208
her	O	1209-1212
distal	O	1213-1219
upper	O	1220-1225
extremities	O	1226-1237
.	O	1237-1238

A	O	1239-1240
magnetic	O	1241-1249
resonance	O	1250-1259
imaging	O	1260-1267
(	O	1268-1269
MRI	O	1269-1272
)	O	1272-1273
of	O	1274-1276
her	O	1277-1280
spine	O	1281-1286
demonstrated	O	1287-1299
changes	O	1300-1307
from	O	1308-1312
C2	O	1313-1315
to	O	1316-1318
C6	O	1319-1321
consistent	O	1322-1332
with	O	1333-1337
subacute	O	1338-1346
combined	O	1347-1355
degeneration	O	1356-1368
.	O	1368-1369

Nelarabine	O	1370-1380
was	O	1381-1384
felt	O	1385-1389
to	O	1390-1392
be	O	1393-1395
the	O	1396-1399
cause	O	1400-1405
of	O	1406-1408
her	O	1409-1412
symptoms	O	1413-1421
.	O	1421-1422

Her	O	1423-1426
neuropathy	B	1427-1437
stabilized	O	1438-1448
and	O	1449-1452
showed	O	1453-1459
slight	O	1460-1466
improvement	O	1467-1478
and	O	1479-1482
ultimately	O	1483-1493
received	O	1494-1502
an	O	1503-1505
unrelated	O	1506-1515
,	O	1515-1516
reduced	O	1517-1524
-	O	1524-1525
intensity	O	1525-1534
allogeneic	O	1535-1545
transplant	O	1546-1556
while	O	1557-1562
in	O	1563-1565
complete	O	1566-1574
remission	O	1575-1584
,	O	1584-1585
but	O	1586-1589
relapsed	O	1590-1598
disease	O	1599-1606
10	O	1607-1609
weeks	O	1610-1615
later	O	1616-1621
.	O	1621-1622

She	O	1623-1626
is	O	1627-1629
currently	O	1630-1639
being	O	1640-1645
treated	O	1646-1653
with	O	1654-1658
best	O	1659-1663
supportive	O	1664-1674
care	O	1675-1679
.	O	1679-1680

To	O	1681-1683
our	O	1684-1687
knowledge	O	1688-1697
,	O	1697-1698
this	O	1699-1703
is	O	1704-1706
the	O	1707-1710
first	O	1711-1716
published	O	1717-1726
case	O	1727-1731
report	O	1732-1738
of	O	1739-1741
severe	O	1742-1748
neurotoxicity	B	1749-1762
caused	O	1763-1769
by	O	1770-1772
nelarabine	O	1773-1783
in	O	1784-1786
a	O	1787-1788
patient	O	1789-1796
who	O	1797-1800
received	O	1801-1809
concurrent	O	1810-1820
IT	O	1821-1823
chemotherapy	O	1824-1836
.	O	1836-1837

Valproate	O	0-9
-	O	9-10
induced	O	10-17
hyperammonemic	B	18-32
encephalopathy	B	33-47
in	O	48-50
a	O	51-52
renal	O	53-58
transplanted	O	59-71
patient	O	72-79
.	O	79-80

Neurological	B	81-93
complications	I	94-107
after	O	108-113
renal	O	114-119
transplantation	O	120-135
constitute	O	136-146
an	O	147-149
important	O	150-159
cause	O	160-165
of	O	166-168
morbidity	O	169-178
and	O	179-182
mortality	O	183-192
.	O	192-193

Their	O	194-199
differential	O	200-212
diagnosis	O	213-222
is	O	223-225
difficult	O	226-235
and	O	236-239
essential	O	240-249
for	O	250-253
subsequent	O	254-264
patient	O	265-272
'	O	272-273
s	O	273-274
management	O	275-285
.	O	285-286

Valproate	O	287-296
-	O	296-297
induced	O	297-304
hyperammonemic	B	305-319
encephalopathy	B	320-334
is	O	335-337
an	O	338-340
uncommon	O	341-349
but	O	350-353
serious	O	354-361
effect	O	362-368
of	O	369-371
valproate	O	372-381
treatment	O	382-391
.	O	391-392

Here	O	393-397
,	O	397-398
we	O	399-401
describe	O	402-410
the	O	411-414
case	O	415-419
of	O	420-422
a	O	423-424
15	O	425-427
-	O	427-428
year	O	428-432
-	O	427-428
old	O	433-436
girl	O	437-441
who	O	442-445
was	O	446-449
on	O	450-452
a	O	453-454
long	O	455-459
-	O	459-460
term	O	460-464
therapy	O	465-472
with	O	473-477
valproate	O	478-487
due	O	488-491
to	O	492-494
epilepsy	B	495-503
and	O	504-507
revealed	O	508-516
impaired	B	517-525
consciousness	I	526-539
with	O	540-544
hyperammonemia	B	545-559
12	O	560-562
days	O	563-567
after	O	568-573
renal	O	574-579
transplantation	O	580-595
.	O	595-596

After	O	597-602
withdraw	O	603-611
of	O	612-614
valproate	O	615-624
,	O	624-625
patients	O	626-634
'	O	634-635
symptoms	O	636-644
resolved	O	645-653
within	O	654-660
24	O	661-663
h	O	664-665
.	O	665-666

Clinicians	O	667-677
should	O	678-684
increase	O	685-693
their	O	694-699
awareness	O	700-709
for	O	710-713
potential	O	714-723
complication	O	724-736
of	O	737-739
valproate	O	740-749
,	O	749-750
especially	O	751-761
in	O	762-764
transplanted	O	765-777
patients	O	778-786
.	O	786-787

Necrotising	B	0-11
fasciitis	I	12-21
after	O	22-27
bortezomib	O	28-38
and	O	39-42
dexamethasone	O	43-56
-	O	56-57
containing	O	57-67
regimen	O	68-75
in	O	76-78
an	O	79-81
elderly	O	82-89
patient	O	90-97
of	O	98-100
Waldenstrom	B	101-112
macroglobulinaemia	I	113-131
.	O	131-132

Bortezomib	O	133-143
and	O	144-147
high	O	148-152
-	O	152-153
dose	O	153-157
dexamethasone	O	158-171
-	O	171-172
containing	O	172-182
regimens	O	183-191
are	O	192-195
considered	O	196-206
to	O	207-209
be	O	210-212
generally	O	213-222
tolerable	O	223-232
with	O	233-237
few	O	238-241
severe	O	242-248
bacterial	B	249-258
infections	I	259-269
in	O	270-272
patients	O	273-281
with	O	282-286
B	O	287-288
-	O	288-289
cell	O	289-293
malignancies	B	294-306
.	O	306-307

However	O	308-315
,	O	315-316
information	O	317-328
is	O	329-331
limited	O	332-339
concerning	O	340-350
the	O	351-354
safety	O	355-361
of	O	362-364
the	O	365-368
regimen	O	369-376
in	O	377-379
elderly	O	380-387
patients	O	388-396
.	O	396-397

We	O	398-400
report	O	401-407
a	O	408-409
case	O	410-414
of	O	415-417
a	O	418-419
76	O	420-422
-	O	422-423
year	O	423-427
-	O	422-423
old	O	428-431
man	O	432-435
with	O	436-440
Waldenstrom	B	441-452
macroglobulinaemia	I	453-471
who	O	472-475
suffered	O	476-484
necrotising	B	485-496
fasciitis	I	497-506
without	O	507-514
neutropenia	B	515-526
after	O	527-532
the	O	533-536
combination	O	537-548
treatment	O	549-558
with	O	559-563
bortezomib	O	564-574
,	O	574-575
high	O	576-580
-	O	580-581
dose	O	581-585
dexamethasone	O	586-599
and	O	600-603
rituximab	O	604-613
.	O	613-614

Despite	O	615-622
immediate	O	623-632
intravenous	O	633-644
antimicrobial	O	645-658
therapy	O	659-666
,	O	666-667
he	O	668-670
succumbed	O	671-680
23	O	681-683
h	O	684-685
after	O	686-691
the	O	692-695
onset	O	696-701
.	O	701-702

Physicians	O	703-713
should	O	714-720
recognise	O	721-730
the	O	731-734
possibility	O	735-746
of	O	747-749
fatal	O	750-755
bacterial	B	756-765
infections	I	766-776
related	O	777-784
to	O	785-787
bortezomib	O	788-798
plus	O	799-803
high	O	804-808
-	O	808-809
dose	O	809-813
dexamethasone	O	814-827
in	O	828-830
elderly	O	831-838
patients	O	839-847
,	O	847-848
and	O	849-852
we	O	853-855
believe	O	856-863
this	O	864-868
case	O	869-873
warrants	O	874-882
further	O	883-890
investigation	O	891-904
.	O	904-905

An	O	0-2
integrated	O	3-13
characterization	O	14-30
of	O	31-33
serological	O	34-45
,	O	45-46
pathological	O	47-59
,	O	59-60
and	O	61-64
functional	O	65-75
events	O	76-82
in	O	83-85
doxorubicin	O	86-97
-	O	97-98
induced	O	98-105
cardiotoxicity	B	106-120
.	O	120-121

Many	O	122-126
efficacious	O	127-138
cancer	B	139-145
treatments	O	146-156
cause	O	157-162
significant	O	163-174
cardiac	O	175-182
morbidity	O	183-192
,	O	192-193
yet	O	194-197
biomarkers	O	198-208
or	O	209-211
functional	O	212-222
indices	O	223-230
of	O	231-233
early	O	234-239
damage	O	240-246
,	O	246-247
which	O	248-253
would	O	254-259
allow	O	260-265
monitoring	O	266-276
and	O	277-280
intervention	O	281-293
,	O	293-294
are	O	295-298
lacking	O	299-306
.	O	306-307

In	O	308-310
this	O	311-315
study	O	316-321
,	O	321-322
we	O	323-325
have	O	326-330
utilized	O	331-339
a	O	340-341
rat	O	342-345
model	O	346-351
of	O	352-354
progressive	O	355-366
doxorubicin	O	367-378
(	O	379-380
DOX	O	380-383
)	O	383-384
-	O	384-385
induced	O	385-392
cardiomyopathy	B	393-407
,	O	407-408
applying	O	409-417
multiple	O	418-426
approaches	O	427-437
,	O	437-438
including	O	439-448
cardiac	O	449-456
magnetic	O	457-465
resonance	O	466-475
imaging	O	476-483
(	O	484-485
MRI	O	485-488
)	O	488-489
,	O	489-490
to	O	491-493
provide	O	494-501
the	O	502-505
most	O	506-510
comprehensive	O	511-524
characterization	O	525-541
to	O	542-544
date	O	545-549
of	O	550-552
the	O	553-556
timecourse	O	557-567
of	O	568-570
serological	O	571-582
,	O	582-583
pathological	O	584-596
,	O	596-597
and	O	598-601
functional	O	602-612
events	O	613-619
underlying	O	620-630
this	O	631-635
toxicity	B	636-644
.	O	644-645

Hannover	O	646-654
Wistar	O	655-661
rats	O	662-666
were	O	667-671
dosed	O	672-677
with	O	678-682
1	O	683-684
.	O	684-685
25	O	685-687
mg	O	688-690
/	O	690-691
kg	O	691-693
DOX	O	694-697
weekly	O	698-704
for	O	705-708
8	O	709-710
weeks	O	711-716
followed	O	717-725
by	O	726-728
a	O	729-730
4	O	731-732
week	O	733-737
off	O	738-741
-	O	741-742
dosing	O	742-748
"	O	749-750
recovery	O	750-758
"	O	749-750
period	O	760-766
.	O	766-767

Electron	O	768-776
microscopy	O	777-787
of	O	788-790
the	O	791-794
myocardium	O	795-805
revealed	O	806-814
subcellular	B	815-826
degeneration	I	827-839
and	O	840-843
marked	O	844-850
mitochondrial	O	851-864
changes	O	865-872
after	O	873-878
a	O	879-880
single	O	881-887
dose	O	888-892
.	O	892-893

Histopathological	O	894-911
analysis	O	912-920
revealed	O	921-929
progressive	O	930-941
cardiomyocyte	B	942-955
degeneration	I	956-968
,	O	968-969
hypertrophy	B	970-981
/	O	981-982
cytomegaly	O	982-992
,	O	992-993
and	O	994-997
extensive	O	998-1007
vacuolation	O	1008-1019
after	O	1020-1025
two	O	1026-1029
doses	O	1030-1035
.	O	1035-1036

Extensive	O	1037-1046
replacement	O	1047-1058
fibrosis	B	1059-1067
(	O	1068-1069
quantified	O	1069-1079
by	O	1080-1082
Sirius	O	1083-1089
red	O	1090-1093
staining	O	1094-1102
)	O	1102-1103
developed	O	1104-1113
during	O	1114-1120
the	O	1121-1124
off	O	1125-1128
-	O	1128-1129
dosing	O	1129-1135
period	O	1136-1142
.	O	1142-1143

Functional	O	1144-1154
indices	O	1155-1162
assessed	O	1163-1171
by	O	1172-1174
cardiac	O	1175-1182
MRI	O	1183-1186
(	O	1187-1188
including	O	1188-1197
left	O	1198-1202
ventricular	O	1203-1214
ejection	O	1215-1223
fraction	O	1224-1232
(	O	1233-1234
LVEF	O	1234-1238
)	O	1238-1239
,	O	1239-1240
cardiac	O	1241-1248
output	O	1249-1255
,	O	1255-1256
and	O	1257-1260
E	O	1261-1262
/	O	1262-1263
A	O	1263-1264
ratio	O	1265-1270
)	O	1270-1271
declined	O	1272-1280
progressively	O	1281-1294
,	O	1294-1295
reaching	O	1296-1304
statistical	O	1305-1316
significance	O	1317-1329
after	O	1330-1335
two	O	1336-1339
doses	O	1340-1345
and	O	1346-1349
culminating	O	1350-1361
in	O	1362-1364
"	O	1365-1366
clinical	O	1366-1374
"	O	1365-1366
LV	B	1376-1378
dysfunction	I	1379-1390
by	O	1391-1393
12	O	1394-1396
weeks	O	1397-1402
.	O	1402-1403

Significant	O	1404-1415
increases	O	1416-1425
in	O	1426-1428
peak	O	1429-1433
myocardial	O	1434-1444
contrast	O	1445-1453
enhancement	O	1454-1465
and	O	1466-1469
serological	O	1470-1481
cardiac	O	1482-1489
troponin	O	1490-1498
I	O	1499-1500
(	O	1501-1502
cTnI	O	1502-1506
)	O	1506-1507
emerged	O	1508-1515
after	O	1516-1521
eight	O	1522-1527
doses	O	1528-1533
,	O	1533-1534
importantly	O	1535-1546
preceding	O	1547-1556
the	O	1557-1560
LVEF	O	1561-1565
decline	O	1566-1573
to	O	1574-1576
<	O	1577-1578
50	O	1578-1580
%	O	1580-1581
.	O	1581-1582

Troponin	O	1583-1591
I	O	1592-1593
levels	O	1594-1600
positively	O	1601-1611
correlated	O	1612-1622
with	O	1623-1627
delayed	O	1628-1635
and	O	1636-1639
peak	O	1640-1644
gadolinium	O	1645-1655
contrast	O	1656-1664
enhancement	O	1665-1676
,	O	1676-1677
histopathological	O	1678-1695
grading	O	1696-1703
,	O	1703-1704
and	O	1705-1708
diastolic	B	1709-1718
dysfunction	I	1719-1730
.	O	1730-1731

In	O	1732-1734
summary	O	1735-1742
,	O	1742-1743
subcellular	O	1744-1755
cardiomyocyte	B	1756-1769
degeneration	I	1770-1782
was	O	1783-1786
the	O	1787-1790
earliest	O	1791-1799
marker	O	1800-1806
,	O	1806-1807
followed	O	1808-1816
by	O	1817-1819
progressive	O	1820-1831
functional	O	1832-1842
decline	O	1843-1850
and	O	1851-1854
histopathological	O	1855-1872
manifestations	O	1873-1887
.	O	1887-1888

Myocardial	O	1889-1899
contrast	O	1900-1908
enhancement	O	1909-1920
and	O	1921-1924
elevations	O	1925-1935
in	O	1936-1938
cTnI	O	1939-1943
occurred	O	1944-1952
later	O	1953-1958
.	O	1958-1959

However	O	1960-1967
,	O	1967-1968
all	O	1969-1972
indices	O	1973-1980
predated	O	1981-1989
"	O	1990-1991
clinical	O	1991-1999
"	O	1990-1991
LV	B	2001-2003
dysfunction	I	2004-2015
and	O	2016-2019
thus	O	2020-2024
warrant	O	2025-2032
further	O	2033-2040
evaluation	O	2041-2051
as	O	2052-2054
predictive	O	2055-2065
biomarkers	O	2066-2076
.	O	2076-2077

Intradermal	O	0-11
glutamate	O	12-21
and	O	22-25
capsaicin	O	26-35
injections	O	36-46
:	O	46-47
intra	O	48-53
-	O	53-54
and	O	55-58
interindividual	O	59-74
variability	O	75-86
of	O	87-89
provoked	O	90-98
hyperalgesia	B	99-111
and	O	112-115
allodynia	B	116-125
.	O	125-126

Intradermal	O	127-138
injections	O	139-149
of	O	150-152
glutamate	O	153-162
and	O	163-166
capsaicin	O	167-176
are	O	177-180
attractive	O	181-191
to	O	192-194
use	O	195-198
in	O	199-201
human	O	202-207
experimental	O	208-220
pain	B	221-225
models	O	226-232
because	O	233-240
hyperalgesia	B	241-253
and	O	254-257
allodynia	B	258-267
mimic	O	268-273
isolated	O	274-282
aspects	O	283-290
of	O	291-293
clinical	O	294-302
pain	B	303-307
disorders	I	308-317
.	O	317-318

The	O	319-322
aim	O	323-326
of	O	327-329
the	O	330-333
present	O	334-341
study	O	342-347
was	O	348-351
to	O	352-354
investigate	O	355-366
the	O	367-370
reproducibility	O	371-386
of	O	387-389
these	O	390-395
models	O	396-402
.	O	402-403

Twenty	O	404-410
healthy	O	411-418
male	O	419-423
volunteers	O	424-434
(	O	435-436
mean	O	436-440
age	O	441-444
24	O	445-447
years	O	448-453
;	O	453-454
range	O	455-460
18	O	461-463
-	O	463-464
38	O	464-466
years	O	467-472
)	O	472-473
received	O	474-482
intradermal	O	483-494
injections	O	495-505
of	O	506-508
glutamate	O	509-518
and	O	519-522
capsaicin	O	523-532
in	O	533-535
the	O	536-539
volar	O	540-545
forearm	O	546-553
.	O	553-554

Magnitudes	O	555-565
of	O	566-568
secondary	O	569-578
pinprick	O	579-587
hyperalgesia	B	588-600
and	O	601-604
brush	O	605-610
-	O	610-611
evoked	O	611-617
allodynia	B	618-627
were	O	628-632
investigated	O	633-645
using	O	646-651
von	O	652-655
Frey	O	656-660
filaments	O	661-670
(	O	671-672
gauges	O	672-678
10	O	679-681
,	O	681-682
15	O	683-685
,	O	685-686
60	O	687-689
and	O	690-693
100	O	694-697
g	O	698-699
)	O	699-700
and	O	701-704
brush	O	705-710
strokes	O	711-718
.	O	718-719

Areas	O	720-725
of	O	726-728
secondary	B	729-738
hyperalgesia	I	739-751
and	O	752-755
allodynia	B	756-765
were	O	766-770
quantified	O	771-781
immediately	O	782-793
after	O	794-799
injection	O	800-809
and	O	810-813
after	O	814-819
15	O	820-822
,	O	822-823
30	O	824-826
and	O	827-830
60	O	831-833
min	O	834-837
.	O	837-838

Two	O	839-842
identical	O	843-852
experiments	O	853-864
separated	O	865-874
by	O	875-877
at	O	878-880
least	O	881-886
7	O	887-888
days	O	889-893
were	O	894-898
performed	O	899-908
.	O	908-909

Reproducibility	O	910-925
across	O	926-932
and	O	933-936
within	O	937-943
volunteers	O	944-954
(	O	955-956
inter	O	956-961
-	O	961-962
and	O	963-966
intra	O	967-972
-	O	972-973
individual	O	973-983
variation	O	984-993
,	O	993-994
respectively	O	995-1007
)	O	1007-1008
was	O	1009-1012
assessed	O	1013-1021
using	O	1022-1027
intraclass	O	1028-1038
correlation	O	1039-1050
coefficient	O	1051-1062
(	O	1063-1064
ICC	O	1064-1067
)	O	1067-1068
and	O	1069-1072
coefficient	O	1073-1084
of	O	1085-1087
variation	O	1088-1097
(	O	1098-1099
CV	O	1099-1101
)	O	1101-1102
.	O	1102-1103

Secondary	O	1104-1113
pinprick	O	1114-1122
hyperalgesia	B	1123-1135
was	O	1136-1139
observed	O	1140-1148
as	O	1149-1151
a	O	1152-1153
marked	O	1154-1160
increase	O	1161-1169
in	O	1170-1172
the	O	1173-1176
visual	O	1177-1183
analogue	O	1184-1192
scale	O	1193-1198
(	O	1199-1200
VAS	O	1200-1203
)	O	1203-1204
response	O	1205-1213
to	O	1214-1216
von	O	1217-1220
Frey	O	1221-1225
gauges	O	1226-1232
60	O	1233-1235
and	O	1236-1239
100	O	1240-1243
g	O	1244-1245
(	O	1246-1247
P	O	1247-1248
<	O	1249-1250
0	O	1251-1252
.	O	1252-1253
001	O	1253-1256
)	O	1256-1257
after	O	1258-1263
glutamate	O	1264-1273
injection	O	1274-1283
.	O	1283-1284

For	O	1285-1288
capsaicin	O	1289-1298
,	O	1298-1299
secondary	O	1300-1309
pinprick	O	1310-1318
hyperalgesia	B	1319-1331
was	O	1332-1335
detected	O	1336-1344
with	O	1345-1349
all	O	1350-1353
von	O	1354-1357
Frey	O	1358-1362
gauges	O	1363-1369
(	O	1370-1371
P	O	1371-1372
<	O	1373-1374
0	O	1375-1376
.	O	1376-1377
001	O	1377-1380
)	O	1380-1381
.	O	1376-1377

Glutamate	O	1383-1392
evoked	O	1393-1399
reproducible	O	1400-1412
VAS	O	1413-1416
response	O	1417-1425
to	O	1426-1428
all	O	1429-1432
von	O	1433-1436
Frey	O	1437-1441
gauges	O	1442-1448
(	O	1449-1450
ICC	O	1450-1453
>	O	1454-1455
0	O	1456-1457
.	O	1457-1458
60	O	1458-1460
)	O	1460-1461
and	O	1462-1465
brush	O	1466-1471
strokes	O	1472-1479
(	O	1480-1481
ICC	O	1481-1484
>	O	1485-1486
0	O	1487-1488
.	O	1488-1489
83	O	1489-1491
)	O	1491-1492
.	O	1488-1489

Capsaicin	O	1494-1503
injection	O	1504-1513
was	O	1514-1517
reproducible	O	1518-1530
for	O	1531-1534
secondary	B	1535-1544
hyperalgesia	I	1545-1557
(	O	1558-1559
ICC	O	1559-1562
>	O	1563-1564
0	O	1565-1566
.	O	1566-1567
70	O	1567-1569
)	O	1569-1570
and	O	1571-1574
allodynia	B	1575-1584
(	O	1585-1586
ICC	O	1586-1589
>	O	1590-1591
0	O	1592-1593
.	O	1593-1594
71	O	1594-1596
)	O	1596-1597
.	O	1593-1594

Intra	O	1599-1604
-	O	1604-1605
individual	O	1605-1615
variability	O	1616-1627
was	O	1628-1631
generally	O	1632-1641
lower	O	1642-1647
for	O	1648-1651
the	O	1652-1655
VAS	O	1656-1659
response	O	1660-1668
to	O	1669-1671
von	O	1672-1675
Frey	O	1676-1680
and	O	1681-1684
brush	O	1685-1690
compared	O	1691-1699
with	O	1700-1704
areas	O	1705-1710
of	O	1711-1713
secondary	B	1714-1723
hyperalgesia	I	1724-1736
and	O	1737-1740
allodynia	B	1741-1750
.	O	1750-1751

In	O	1752-1754
conclusion	O	1755-1765
,	O	1765-1766
glutamate	O	1767-1776
and	O	1777-1780
capsaicin	O	1781-1790
yield	O	1791-1796
reproducible	O	1797-1809
hyperalgesic	B	1810-1822
and	O	1823-1826
allodynic	B	1827-1836
responses	O	1837-1846
,	O	1846-1847
and	O	1848-1851
the	O	1852-1855
present	O	1856-1863
model	O	1864-1869
is	O	1870-1872
well	O	1873-1877
suited	O	1878-1884
for	O	1885-1888
basic	O	1889-1894
research	O	1895-1903
,	O	1903-1904
as	O	1905-1907
well	O	1908-1912
as	O	1913-1915
for	O	1916-1919
assessing	O	1920-1929
the	O	1930-1933
modulation	O	1934-1944
of	O	1945-1947
central	O	1948-1955
phenomena	O	1956-1965
.	O	1965-1966

Ocular	O	0-6
-	O	6-7
specific	O	7-15
ER	O	16-18
stress	O	19-25
reduction	O	26-35
rescues	O	36-43
glaucoma	B	44-52
in	O	53-55
murine	O	56-62
glucocorticoid	O	63-77
-	O	77-78
induced	O	78-85
glaucoma	B	86-94
.	O	94-95

Administration	O	96-110
of	O	111-113
glucocorticoids	O	114-129
induces	O	130-137
ocular	B	138-144
hypertension	I	145-157
in	O	158-160
some	O	161-165
patients	O	166-174
.	O	174-175

If	O	176-178
untreated	O	179-188
,	O	188-189
these	O	190-195
patients	O	196-204
can	O	205-208
develop	O	209-216
a	O	217-218
secondary	O	219-228
glaucoma	B	229-237
that	O	238-242
resembles	O	243-252
primary	B	253-260
open	I	261-265
-	I	265-266
angle	I	266-271
glaucoma	I	272-280
(	O	281-282
POAG	B	282-286
)	O	286-287
.	O	287-288

The	O	289-292
underlying	O	293-303
pathology	O	304-313
of	O	314-316
glucocorticoid	O	317-331
-	O	331-332
induced	O	332-339
glaucoma	B	340-348
is	O	349-351
not	O	352-355
fully	O	356-361
understood	O	362-372
,	O	372-373
due	O	374-377
in	O	378-380
part	O	381-385
to	O	386-388
lack	O	389-393
of	O	394-396
an	O	397-399
appropriate	O	400-411
animal	O	412-418
model	O	419-424
.	O	424-425

Here	O	426-430
,	O	430-431
we	O	432-434
developed	O	435-444
a	O	445-446
murine	O	447-453
model	O	454-459
of	O	460-462
glucocorticoid	O	463-477
-	O	477-478
induced	O	478-485
glaucoma	B	486-494
that	O	495-499
exhibits	O	500-508
glaucoma	B	509-517
features	O	518-526
that	O	527-531
are	O	532-535
observed	O	536-544
in	O	545-547
patients	O	548-556
.	O	556-557

Treatment	O	558-567
of	O	568-570
WT	O	571-573
mice	O	574-578
with	O	579-583
topical	O	584-591
ocular	O	592-598
0	O	599-600
.	O	600-601
1	O	601-602
%	O	602-603
dexamethasone	O	604-617
led	O	618-621
to	O	622-624
elevation	O	625-634
of	O	635-637
intraocular	O	638-649
pressure	O	650-658
(	O	659-660
IOP	O	660-663
)	O	663-664
,	O	664-665
functional	O	666-676
and	O	677-680
structural	O	681-691
loss	O	692-696
of	O	697-699
retinal	B	700-707
ganglion	I	708-716
cells	O	717-722
,	O	722-723
and	O	724-727
axonal	B	728-734
degeneration	I	735-747
,	O	747-748
resembling	O	749-759
glucocorticoid	O	760-774
-	O	774-775
induced	O	775-782
glaucoma	B	783-791
in	O	792-794
human	O	795-800
patients	O	801-809
.	O	809-810

Furthermore	O	811-822
,	O	822-823
dexamethasone	O	824-837
-	O	837-838
induced	O	838-845
ocular	B	846-852
hypertension	I	853-865
was	O	866-869
associated	O	870-880
with	O	881-885
chronic	O	886-893
ER	O	894-896
stress	O	897-903
of	O	904-906
the	O	907-910
trabecular	O	911-921
meshwork	O	922-930
(	O	931-932
TM	O	932-934
)	O	934-935
.	O	935-936

Similar	O	937-944
to	O	945-947
patients	O	948-956
,	O	956-957
withdrawal	O	958-968
of	O	969-971
dexamethasone	O	972-985
treatment	O	986-995
reduced	O	996-1003
elevated	O	1004-1012
IOP	O	1013-1016
and	O	1017-1020
ER	O	1021-1023
stress	O	1024-1030
in	O	1031-1033
this	O	1034-1038
animal	O	1039-1045
model	O	1046-1051
.	O	1051-1052

Dexamethasone	O	1053-1066
induced	O	1067-1074
the	O	1075-1078
transcriptional	O	1079-1094
factor	O	1095-1101
CHOP	O	1102-1106
,	O	1106-1107
a	O	1108-1109
marker	O	1110-1116
for	O	1117-1120
chronic	O	1121-1128
ER	O	1129-1131
stress	O	1132-1138
,	O	1138-1139
in	O	1140-1142
the	O	1143-1146
anterior	O	1147-1155
segment	O	1156-1163
tissues	O	1164-1171
,	O	1171-1172
and	O	1173-1176
Chop	O	1177-1181
deletion	O	1182-1190
reduced	O	1191-1198
ER	O	1199-1201
stress	O	1202-1208
in	O	1209-1211
these	O	1212-1217
tissues	O	1218-1225
and	O	1226-1229
prevented	O	1230-1239
dexamethasone	O	1240-1253
-	O	1253-1254
induced	O	1254-1261
ocular	B	1262-1268
hypertension	I	1269-1281
.	O	1281-1282

Furthermore	O	1283-1294
,	O	1294-1295
reduction	O	1296-1305
of	O	1306-1308
ER	O	1309-1311
stress	O	1312-1318
in	O	1319-1321
the	O	1322-1325
TM	O	1326-1328
with	O	1329-1333
sodium	O	1334-1340
4	O	1341-1342
-	O	1342-1343
phenylbutyrate	O	1343-1357
prevented	O	1358-1367
dexamethasone	O	1368-1381
-	O	1381-1382
induced	O	1382-1389
ocular	B	1390-1396
hypertension	I	1397-1409
in	O	1410-1412
WT	O	1413-1415
mice	O	1416-1420
.	O	1420-1421

Our	O	1422-1425
data	O	1426-1430
indicate	O	1431-1439
that	O	1440-1444
ER	O	1445-1447
stress	O	1448-1454
contributes	O	1455-1466
to	O	1467-1469
glucocorticoid	O	1470-1484
-	O	1484-1485
induced	O	1485-1492
ocular	B	1493-1499
hypertension	I	1500-1512
and	O	1513-1516
suggest	O	1517-1524
that	O	1525-1529
reducing	O	1530-1538
ER	O	1539-1541
stress	O	1542-1548
has	O	1549-1552
potential	O	1553-1562
as	O	1563-1565
a	O	1566-1567
therapeutic	O	1568-1579
strategy	O	1580-1588
for	O	1589-1592
treating	O	1593-1601
glucocorticoid	O	1602-1616
-	O	1616-1617
induced	O	1617-1624
glaucoma	B	1625-1633
.	O	1633-1634

Effects	O	0-7
of	O	8-10
ginsenosides	O	11-23
on	O	24-26
opioid	O	27-33
-	O	33-34
induced	O	34-41
hyperalgesia	B	42-54
in	O	55-57
mice	O	58-62
.	O	62-63

Opioid	O	64-70
-	O	70-71
induced	O	71-78
hyperalgesia	B	79-91
(	O	92-93
OIH	B	93-96
)	O	96-97
is	O	98-100
characterized	O	101-114
by	O	115-117
nociceptive	O	118-129
sensitization	O	130-143
caused	O	144-150
by	O	151-153
the	O	154-157
cessation	O	158-167
of	O	168-170
chronic	O	171-178
opioid	O	179-185
use	O	186-189
.	O	189-190

OIH	B	191-194
can	O	195-198
limit	O	199-204
the	O	205-208
clinical	O	209-217
use	O	218-221
of	O	222-224
opioid	O	225-231
analgesics	O	232-242
and	O	243-246
complicate	O	247-257
withdrawal	O	258-268
from	O	269-273
opioid	B	274-280
addiction	I	281-290
.	O	290-291

In	O	292-294
this	O	295-299
study	O	300-305
,	O	305-306
we	O	307-309
investigated	O	310-322
the	O	323-326
effects	O	327-334
of	O	335-337
Re	O	338-340
,	O	340-341
Rg1	O	342-345
,	O	345-346
and	O	347-350
Rb1	O	351-354
ginsenosides	O	355-367
,	O	367-368
the	O	369-372
bioactive	O	373-382
components	O	383-393
of	O	394-396
ginseng	O	397-404
,	O	404-405
on	O	406-408
OIH	B	409-412
.	O	412-413

OIH	B	414-417
was	O	418-421
achieved	O	422-430
in	O	431-433
mice	O	434-438
after	O	439-444
subcutaneous	O	445-457
administration	O	458-472
of	O	473-475
morphine	O	476-484
for	O	485-488
7	O	489-490
consecutive	O	491-502
days	O	503-507
three	O	508-513
times	O	514-519
per	O	520-523
day	O	524-527
.	O	527-528

During	O	529-535
withdrawal	O	536-546
(	O	547-548
days	O	548-552
8	O	553-554
and	O	555-558
9	O	559-560
)	O	560-561
,	O	561-562
these	O	563-568
mice	O	569-573
were	O	574-578
administered	O	579-591
Re	O	592-594
,	O	594-595
Rg1	O	596-599
,	O	599-600
or	O	601-603
Rb1	O	604-607
intragastrically	O	608-624
two	O	625-628
times	O	629-634
per	O	635-638
day	O	639-642
.	O	642-643

On	O	644-646
the	O	647-650
test	O	651-655
day	O	656-659
(	O	660-661
day	O	661-664
10	O	665-667
)	O	667-668
,	O	668-669
mice	O	670-674
were	O	675-679
subjected	O	680-689
to	O	690-692
the	O	693-696
thermal	O	697-704
sensitivity	O	705-716
test	O	717-721
and	O	722-725
the	O	726-729
acetic	O	730-736
acid	O	737-741
-	O	741-742
induced	O	742-749
writhing	O	750-758
test	O	759-763
.	O	763-764

Re	O	765-767
(	O	768-769
300	O	769-772
mg	O	773-775
/	O	775-776
kg	O	776-778
)	O	778-779
inhibited	O	780-789
OIH	B	790-793
in	O	794-796
both	O	797-801
the	O	802-805
thermal	O	806-813
sensitivity	O	814-825
test	O	826-830
and	O	831-834
the	O	835-838
acetic	O	839-845
acid	O	846-850
-	O	850-851
induced	O	851-858
writhing	O	859-867
test	O	868-872
.	O	872-873

However	O	874-881
,	O	881-882
the	O	883-886
Rg1	O	887-890
and	O	891-894
Rb1	O	895-898
ginsenosides	O	899-911
failed	O	912-918
to	O	919-921
prevent	O	922-929
OIH	B	930-933
in	O	934-936
either	O	937-943
test	O	944-948
.	O	948-949

Furthermore	O	950-961
,	O	961-962
Rg1	O	963-966
showed	O	967-973
a	O	974-975
tendency	O	976-984
to	O	985-987
aggravate	O	988-997
OIH	B	998-1001
in	O	1002-1004
the	O	1005-1008
acetic	O	1009-1015
acid	O	1016-1020
-	O	1020-1021
induced	O	1021-1028
writhing	O	1029-1037
test	O	1038-1042
.	O	1042-1043

Our	O	1044-1047
data	O	1048-1052
suggested	O	1053-1062
that	O	1063-1067
the	O	1068-1071
ginsenoside	O	1072-1083
Re	O	1084-1086
,	O	1086-1087
but	O	1088-1091
not	O	1092-1095
Rg1	O	1096-1099
or	O	1100-1102
Rb1	O	1103-1106
,	O	1106-1107
may	O	1108-1111
contribute	O	1112-1122
toward	O	1123-1129
reversal	O	1130-1138
of	O	1139-1141
OIH	B	1142-1145
.	O	1145-1146

A	O	0-1
comparison	O	2-12
of	O	13-15
severe	O	16-22
hemodynamic	O	23-34
disturbances	O	35-47
between	O	48-55
dexmedetomidine	O	56-71
and	O	72-75
propofol	O	76-84
for	O	85-88
sedation	O	89-97
in	O	98-100
neurocritical	O	101-114
care	O	115-119
patients	O	120-128
.	O	128-129

OBJECTIVE	O	130-139
:	O	139-140
Dexmedetomidine	O	141-156
and	O	157-160
propofol	O	161-169
are	O	170-173
commonly	O	174-182
used	O	183-187
sedatives	O	188-197
in	O	198-200
neurocritical	O	201-214
care	O	215-219
as	O	220-222
they	O	223-227
allow	O	228-233
for	O	234-237
frequent	O	238-246
neurologic	O	247-257
examinations	O	258-270
.	O	270-271

However	O	272-279
,	O	279-280
both	O	281-285
agents	O	286-292
are	O	293-296
associated	O	297-307
with	O	308-312
significant	O	313-324
hemodynamic	O	325-336
side	O	337-341
effects	O	342-349
.	O	349-350

The	O	351-354
primary	O	355-362
objective	O	363-372
of	O	373-375
this	O	376-380
study	O	381-386
is	O	387-389
to	O	390-392
compare	O	393-400
the	O	401-404
prevalence	O	405-415
of	O	416-418
severe	O	419-425
hemodynamic	O	426-437
effects	O	438-445
in	O	446-448
neurocritical	O	449-462
care	O	463-467
patients	O	468-476
receiving	O	477-486
dexmedetomidine	O	487-502
and	O	503-506
propofol	O	507-515
.	O	515-516

DESIGN	O	517-523
:	O	523-524
Multicenter	O	525-536
,	O	536-537
retrospective	O	538-551
,	O	551-552
propensity	O	553-563
-	O	563-564
matched	O	564-571
cohort	O	572-578
study	O	579-584
.	O	584-585

SETTING	O	586-593
:	O	593-594
Neurocritical	O	595-608
care	O	609-613
units	O	614-619
at	O	620-622
two	O	623-626
academic	O	627-635
medical	O	636-643
centers	O	644-651
with	O	652-656
dedicated	O	657-666
neurocritical	O	667-680
care	O	681-685
teams	O	686-691
and	O	692-695
board	O	696-701
-	O	701-702
certified	O	702-711
neurointensivists	O	712-729
.	O	729-730

PATIENTS	O	731-739
:	O	739-740
Neurocritical	O	741-754
care	O	755-759
patients	O	760-768
admitted	O	769-777
between	O	778-785
July	O	786-790
2009	O	791-795
and	O	796-799
September	O	800-809
2012	O	810-814
were	O	815-819
evaluated	O	820-829
and	O	830-833
then	O	834-838
matched	O	839-846
1	O	847-848
:	O	848-849
1	O	847-848
based	O	851-856
on	O	857-859
propensity	O	860-870
scoring	O	871-878
of	O	879-881
baseline	O	882-890
characteristics	O	891-906
.	O	906-907

INTERVENTIONS	O	908-921
:	O	921-922
Continuous	O	923-933
sedation	O	934-942
with	O	943-947
dexmedetomidine	O	948-963
or	O	964-966
propofol	O	967-975
.	O	975-976

MEASUREMENTS	O	977-989
AND	O	990-993
MAIN	O	994-998
RESULTS	O	999-1006
:	O	1006-1007
A	O	1008-1009
total	O	1010-1015
of	O	1016-1018
342	O	1019-1022
patients	O	1023-1031
(	O	1032-1033
105	O	1033-1036
dexmedetomidine	O	1037-1052
and	O	1053-1056
237	O	1057-1060
propofol	O	1061-1069
)	O	1069-1070
were	O	1071-1075
included	O	1076-1084
in	O	1085-1087
the	O	1088-1091
analysis	O	1092-1100
,	O	1100-1101
with	O	1102-1106
190	O	1107-1110
matched	O	1111-1118
(	O	1119-1120
95	O	1120-1122
in	O	1123-1125
each	O	1126-1130
group	O	1131-1136
)	O	1136-1137
by	O	1138-1140
propensity	O	1141-1151
score	O	1152-1157
.	O	1157-1158

The	O	1159-1162
primary	O	1163-1170
outcome	O	1171-1178
of	O	1179-1181
this	O	1182-1186
study	O	1187-1192
was	O	1193-1196
a	O	1197-1198
composite	O	1199-1208
of	O	1209-1211
severe	O	1212-1218
hypotension	B	1219-1230
(	O	1231-1232
mean	O	1232-1236
arterial	O	1237-1245
pressure	O	1246-1254
<	O	1255-1256
60	O	1257-1259
mm	O	1260-1262
Hg	O	1263-1265
)	O	1265-1266
and	O	1267-1270
bradycardia	B	1271-1282
(	O	1283-1284
heart	O	1284-1289
rate	O	1290-1294
<	O	1295-1296
50	O	1297-1299
beats	O	1300-1305
/	O	1305-1306
min	O	1306-1309
)	O	1309-1310
during	O	1311-1317
sedative	O	1318-1326
infusion	O	1327-1335
.	O	1335-1336

No	O	1337-1339
difference	O	1340-1350
in	O	1351-1353
the	O	1354-1357
primary	O	1358-1365
composite	O	1366-1375
outcome	O	1376-1383
in	O	1384-1386
both	O	1387-1391
the	O	1392-1395
unmatched	O	1396-1405
(	O	1406-1407
30	O	1407-1409
%	O	1409-1410
vs	O	1411-1413
30	O	1414-1416
%	O	1416-1417
,	O	1417-1418
p	O	1419-1420
=	O	1421-1422
0	O	1423-1424
.	O	1424-1425
94	O	1425-1427
)	O	1427-1428
or	O	1429-1431
matched	O	1432-1439
cohorts	O	1440-1447
(	O	1448-1449
28	O	1449-1451
%	O	1451-1452
vs	O	1453-1455
34	O	1456-1458
%	O	1458-1459
,	O	1459-1460
p	O	1461-1462
=	O	1463-1464
0	O	1465-1466
.	O	1466-1467
35	O	1467-1469
)	O	1469-1470
could	O	1471-1476
be	O	1477-1479
found	O	1480-1485
.	O	1485-1486

When	O	1487-1491
analyzed	O	1492-1500
separately	O	1501-1511
,	O	1511-1512
no	O	1513-1515
differences	O	1516-1527
could	O	1528-1533
be	O	1534-1536
found	O	1537-1542
in	O	1543-1545
the	O	1546-1549
prevalence	O	1550-1560
of	O	1561-1563
severe	O	1564-1570
hypotension	B	1571-1582
or	O	1583-1585
bradycardia	B	1586-1597
in	O	1598-1600
either	O	1601-1607
the	O	1608-1611
unmatched	O	1612-1621
or	O	1622-1624
matched	O	1625-1632
cohorts	O	1633-1640
.	O	1640-1641

CONCLUSIONS	O	1642-1653
:	O	1653-1654
Severe	O	1655-1661
hypotension	B	1662-1673
and	O	1674-1677
bradycardia	B	1678-1689
occur	O	1690-1695
at	O	1696-1698
similar	O	1699-1706
prevalence	O	1707-1717
in	O	1718-1720
neurocritical	O	1721-1734
care	O	1735-1739
patients	O	1740-1748
who	O	1749-1752
receive	O	1753-1760
dexmedetomidine	O	1761-1776
or	O	1777-1779
propofol	O	1780-1788
.	O	1788-1789

Providers	O	1790-1799
should	O	1800-1806
similarly	O	1807-1816
consider	O	1817-1825
the	O	1826-1829
likelihood	O	1830-1840
of	O	1841-1843
hypotension	B	1844-1855
or	O	1856-1858
bradycardia	B	1859-1870
before	O	1871-1877
starting	O	1878-1886
either	O	1887-1893
sedative	O	1894-1902
.	O	1902-1903

Hydroxytyrosol	O	0-14
ameliorates	O	15-26
oxidative	O	27-36
stress	O	37-43
and	O	44-47
mitochondrial	B	48-61
dysfunction	I	62-73
in	O	74-76
doxorubicin	O	77-88
-	O	88-89
induced	O	89-96
cardiotoxicity	B	97-111
in	O	112-114
rats	O	115-119
with	O	120-124
breast	B	125-131
cancer	I	132-138
.	O	138-139

Oxidative	O	140-149
stress	O	150-156
is	O	157-159
involved	O	160-168
in	O	169-171
several	O	172-179
processes	O	180-189
including	O	190-199
cancer	B	200-206
,	O	206-207
aging	O	208-213
and	O	214-217
cardiovascular	B	218-232
disease	I	233-240
,	O	240-241
and	O	242-245
has	O	246-249
been	O	250-254
shown	O	255-260
to	O	261-263
potentiate	O	264-274
the	O	275-278
therapeutic	O	279-290
effect	O	291-297
of	O	298-300
drugs	O	301-306
such	O	307-311
as	O	312-314
doxorubicin	O	315-326
.	O	326-327

Doxorubicin	O	328-339
causes	O	340-346
significant	O	347-358
cardiotoxicity	B	359-373
characterized	O	374-387
by	O	388-390
marked	O	391-397
increases	O	398-407
in	O	408-410
oxidative	O	411-420
stress	O	421-427
and	O	428-431
mitochondrial	B	432-445
dysfunction	I	446-457
.	O	457-458

Herein	O	459-465
,	O	465-466
we	O	467-469
investigate	O	470-481
whether	O	482-489
doxorubicin	O	490-501
-	O	501-502
associated	O	502-512
chronic	O	513-520
cardiac	B	521-528
toxicity	I	529-537
can	O	538-541
be	O	542-544
ameliorated	O	545-556
with	O	557-561
the	O	562-565
antioxidant	O	566-577
hydroxytyrosol	O	578-592
in	O	593-595
rats	O	596-600
with	O	601-605
breast	B	606-612
cancer	I	613-619
.	O	619-620

Thirty	O	621-627
-	O	627-628
six	O	628-631
rats	O	632-636
bearing	O	637-644
breast	B	645-651
tumors	I	652-658
induced	O	659-666
chemically	O	667-677
were	O	678-682
divided	O	683-690
into	O	691-695
4	O	696-697
groups	O	698-704
:	O	704-705
control	O	706-713
,	O	713-714
hydroxytyrosol	O	715-729
(	O	730-731
0	O	731-732
.	O	732-733
5mg	O	733-736
/	O	736-737
kg	O	737-739
,	O	739-740
5days	O	741-746
/	O	746-747
week	O	747-751
)	O	751-752
,	O	752-753
doxorubicin	O	754-765
(	O	766-767
1mg	O	767-770
/	O	770-771
kg	O	771-773
/	O	770-771
week	O	774-778
)	O	778-779
,	O	779-780
and	O	781-784
doxorubicin	O	785-796
plus	O	797-801
hydroxytyrosol	O	802-816
.	O	816-817

Cardiac	B	818-825
disturbances	I	826-838
at	O	839-841
the	O	842-845
cellular	O	846-854
and	O	855-858
mitochondrial	O	859-872
level	O	873-878
,	O	878-879
mitochondrial	O	880-893
electron	O	894-902
transport	O	903-912
chain	O	913-918
complexes	O	919-928
I	O	929-930
-	O	930-931
IV	O	931-933
and	O	934-937
apoptosis	O	938-947
-	O	947-948
inducing	O	948-956
factor	O	957-963
,	O	963-964
and	O	965-968
oxidative	O	969-978
stress	O	979-985
markers	O	986-993
have	O	994-998
been	O	999-1003
analyzed	O	1004-1012
.	O	1012-1013

Hydroxytyrosol	O	1014-1028
improved	O	1029-1037
the	O	1038-1041
cardiac	B	1042-1049
disturbances	I	1050-1062
enhanced	O	1063-1071
by	O	1072-1074
doxorubicin	O	1075-1086
by	O	1087-1089
significantly	O	1090-1103
reducing	O	1104-1112
the	O	1113-1116
percentage	O	1117-1127
of	O	1128-1130
altered	O	1131-1138
mitochondria	O	1139-1151
and	O	1152-1155
oxidative	O	1156-1165
damage	O	1166-1172
.	O	1172-1173

These	O	1174-1179
results	O	1180-1187
suggest	O	1188-1195
that	O	1196-1200
hydroxytyrosol	O	1201-1215
improve	O	1216-1223
the	O	1224-1227
mitochondrial	O	1228-1241
electron	O	1242-1250
transport	O	1251-1260
chain	O	1261-1266
.	O	1266-1267

This	O	1268-1272
study	O	1273-1278
demonstrates	O	1279-1291
that	O	1292-1296
hydroxytyrosol	O	1297-1311
protect	O	1312-1319
rat	O	1320-1323
heart	B	1324-1329
damage	I	1330-1336
provoked	O	1337-1345
by	O	1346-1348
doxorubicin	O	1349-1360
decreasing	O	1361-1371
oxidative	O	1372-1381
damage	O	1382-1388
and	O	1389-1392
mitochondrial	O	1393-1406
alterations	O	1407-1418
.	O	1418-1419

Amiodarone	O	0-10
-	O	10-11
induced	O	11-18
myxoedema	B	19-28
coma	I	29-33
.	O	33-34

A	O	35-36
62	O	37-39
-	O	39-40
year	O	40-44
-	O	39-40
old	O	45-48
man	O	49-52
was	O	53-56
found	O	57-62
to	O	63-65
have	O	66-70
bradycardia	B	71-82
,	O	82-83
hypothermia	B	84-95
and	O	96-99
respiratory	B	100-111
failure	I	112-119
3	O	120-121
weeks	O	122-127
after	O	128-133
initiation	O	134-144
of	O	145-147
amiodarone	O	148-158
therapy	O	159-166
for	O	167-170
atrial	B	171-177
fibrillation	I	178-190
.	O	190-191

Thyroid	O	192-199
-	O	199-200
stimulating	O	200-211
hormone	O	212-219
was	O	220-223
found	O	224-229
to	O	230-232
be	O	233-235
168	O	236-239
uIU	O	240-243
/	O	243-244
mL	O	244-246
(	O	247-248
nl	O	248-250
.	O	250-251

0	O	252-253
.	O	253-254
3	O	254-255
-	O	255-256
5	O	256-257
uIU	O	258-261
/	O	261-262
mL	O	262-264
)	O	264-265
and	O	266-269
free	O	270-274
thyroxine	O	275-284
(	O	285-286
FT4	O	286-289
)	O	289-290
was	O	291-294
<	O	295-296
0	O	296-297
.	O	297-298
2	O	298-299
ng	O	300-302
/	O	302-303
dL	O	303-305
(	O	306-307
nl	O	307-309
.	O	309-310

0	O	311-312
.	O	312-313
8	O	313-314
-	O	314-315
1	O	315-316
.	O	312-313
8	O	313-314

ng	O	319-321
/	O	321-322
dL	O	322-324
)	O	324-325
.	O	325-326

He	O	327-329
received	O	330-338
intravenous	O	339-350
fluids	O	351-357
,	O	357-358
vasopressor	O	359-370
therapy	O	371-378
and	O	379-382
stress	O	383-389
dose	O	390-394
steroids	O	395-403
;	O	403-404
he	O	405-407
was	O	408-411
intubated	O	412-421
and	O	422-425
admitted	O	426-434
to	O	435-437
the	O	438-441
intensive	O	442-451
care	O	452-456
unit	O	457-461
.	O	461-462

He	O	463-465
received	O	466-474
500	O	475-478
ug	O	479-481
of	O	482-484
intravenous	O	485-496
levothyroxine	O	497-510
in	O	511-513
the	O	514-517
first	O	518-523
18	O	524-526
h	O	527-528
of	O	529-531
therapy	O	532-539
,	O	539-540
and	O	541-544
150	O	545-548
ug	O	549-551
intravenous	O	552-563
daily	O	564-569
thereafter	O	570-580
.	O	580-581

Haemodynamic	O	582-594
improvement	O	595-606
,	O	606-607
along	O	608-613
with	O	614-618
complete	O	619-627
recovery	O	628-636
of	O	637-639
mental	O	640-646
status	O	647-653
,	O	653-654
occurred	O	655-663
after	O	664-669
48	O	670-672
h	O	673-674
.	O	674-675

Twelve	O	676-682
hours	O	683-688
after	O	689-694
the	O	695-698
initiation	O	699-709
of	O	710-712
therapy	O	713-720
,	O	720-721
FT4	O	722-725
was	O	726-729
0	O	730-731
.	O	731-732
96	O	732-734
ng	O	735-737
/	O	737-738
dL	O	738-740
.	O	740-741

The	O	742-745
patient	O	746-753
was	O	754-757
maintained	O	758-768
on	O	769-771
levothyroxine	O	772-785
175	O	786-789
(	O	790-791
g	O	791-792
POorally	O	793-801
daily	O	802-807
.	O	807-808

A	O	809-810
thyroid	O	811-818
ultrasound	O	819-829
showed	O	830-836
diffuse	O	837-844
heterogeneity	O	845-858
.	O	858-859

The	O	860-863
24	O	864-866
hour	O	867-871
excretion	O	872-881
of	O	882-884
iodine	O	885-891
was	O	892-895
3657	O	896-900
(	O	901-902
mcg	O	902-905
(	O	906-907
25	O	907-909
-	O	909-910
756	O	910-913
(	O	914-915
mcg	O	916-919
)	O	919-920
.	O	920-921

The	O	922-925
only	O	926-930
two	O	931-934
cases	O	935-940
of	O	941-943
amiodarone	O	944-954
-	O	954-955
induced	O	955-962
myxoedema	B	963-972
coma	I	973-977
in	O	978-980
the	O	981-984
literature	O	985-995
report	O	996-1002
patient	O	1003-1010
death	O	1011-1016
despite	O	1017-1024
supportive	O	1025-1035
therapy	O	1036-1043
and	O	1044-1047
thyroid	O	1048-1055
hormone	O	1056-1063
replacement	O	1064-1075
.	O	1075-1076

This	O	1077-1081
case	O	1082-1086
represents	O	1087-1097
the	O	1098-1101
most	O	1102-1106
thoroughly	O	1107-1117
investigated	O	1118-1130
case	O	1131-1135
of	O	1136-1138
amiodarone	O	1139-1149
-	O	1149-1150
induced	O	1150-1157
myxoedema	B	1158-1167
coma	I	1168-1172
with	O	1173-1177
a	O	1178-1179
history	O	1180-1187
significant	O	1188-1199
for	O	1200-1203
subclinical	O	1204-1215
thyroid	B	1216-1223
disease	I	1224-1231
.	O	1231-1232

Use	O	0-3
of	O	4-6
argatroban	O	7-17
and	O	18-21
catheter	O	22-30
-	O	30-31
directed	O	31-39
thrombolysis	B	40-52
with	O	53-57
alteplase	O	58-67
in	O	68-70
an	O	71-73
oncology	O	74-82
patient	O	83-90
with	O	91-95
heparin	O	96-103
-	O	103-104
induced	O	104-111
thrombocytopenia	B	112-128
with	O	129-133
thrombosis	B	134-144
.	O	144-145

PURPOSE	O	146-153
:	O	153-154
The	O	155-158
case	O	159-163
of	O	164-166
an	O	167-169
oncology	O	170-178
patient	O	179-186
who	O	187-190
developed	O	191-200
heparin	O	201-208
-	O	208-209
induced	O	209-216
thrombocytopenia	B	217-233
with	O	234-238
thrombosis	B	239-249
(	O	250-251
HITT	B	251-255
)	O	255-256
and	O	257-260
was	O	261-264
treated	O	265-272
with	O	273-277
argatroban	O	278-288
plus	O	289-293
catheter	O	294-302
-	O	302-303
directed	O	303-311
thrombolysis	B	312-324
(	O	325-326
CDT	O	326-329
)	O	329-330
with	O	331-335
alteplase	O	336-345
is	O	346-348
presented	O	349-358
.	O	358-359

SUMMARY	O	360-367
:	O	367-368
A	O	369-370
63	O	371-373
-	O	373-374
year	O	374-378
-	O	373-374
old	O	379-382
Caucasian	O	383-392
man	O	393-396
with	O	397-401
renal	O	402-407
amyloidosis	B	408-419
undergoing	O	420-430
peripheral	O	431-441
blood	O	442-447
stem	O	448-452
cell	O	453-457
collection	O	458-468
for	O	469-472
an	O	473-475
autologous	O	476-486
stem	O	487-491
cell	O	492-496
transplant	O	497-507
developed	O	508-517
extensive	O	518-527
bilateral	O	528-537
upper	B	538-543
-	I	543-544
extremity	I	544-553
deep	I	554-558
venous	I	559-565
thrombosis	I	566-576
(	O	577-578
DVT	B	578-581
)	O	581-582
and	O	583-586
pulmonary	B	587-596
embolism	I	597-605
secondary	O	606-615
to	O	616-618
heparin	O	619-626
-	O	626-627
induced	O	627-634
thrombocytopenia	B	635-651
.	O	651-652

A	O	653-654
continuous	O	655-665
i	O	666-667
.	O	667-668
v	O	668-669
.	O	667-668

infusion	O	671-679
of	O	680-682
argatroban	O	683-693
was	O	694-697
initiated	O	698-707
,	O	707-708
and	O	709-712
the	O	713-716
patient	O	717-724
was	O	725-728
managed	O	729-736
on	O	737-739
the	O	740-743
general	O	744-751
medical	O	752-759
floor	O	760-765
.	O	765-766

After	O	767-772
one	O	773-776
week	O	777-781
of	O	782-784
therapy	O	785-792
,	O	792-793
he	O	794-796
was	O	797-800
transferred	O	801-812
to	O	813-815
the	O	816-819
intensive	O	820-829
care	O	830-834
unit	O	835-839
with	O	840-844
cardiopulmonary	O	845-860
compromise	O	861-871
related	O	872-879
to	O	880-882
superior	B	883-891
vena	I	892-896
cava	I	897-901
(	I	902-903
SVC	I	903-906
)	I	906-907
syndrome	I	908-916
.	O	916-917

A	O	918-919
percutaneous	O	920-932
mechanical	O	933-943
thrombectomy	O	944-956
and	O	957-960
CDT	O	961-964
with	O	965-969
alteplase	O	970-979
were	O	980-984
attempted	O	985-994
,	O	994-995
but	O	996-999
the	O	1000-1003
procedure	O	1004-1013
was	O	1014-1017
aborted	O	1018-1025
due	O	1026-1029
to	O	1030-1032
epistaxis	B	1033-1042
.	O	1042-1043

The	O	1044-1047
epistaxis	B	1048-1057
resolved	O	1058-1066
the	O	1067-1070
next	O	1071-1075
day	O	1076-1079
,	O	1079-1080
and	O	1081-1084
the	O	1085-1088
patient	O	1089-1096
was	O	1097-1100
restarted	O	1101-1110
on	O	1111-1113
argatroban	O	1114-1124
.	O	1124-1125

A	O	1126-1127
second	O	1128-1134
percutaneous	O	1135-1147
mechanical	O	1148-1158
thrombectomy	O	1159-1171
was	O	1172-1175
performed	O	1176-1185
six	O	1186-1189
days	O	1190-1194
later	O	1195-1200
and	O	1201-1204
resulted	O	1205-1213
in	O	1214-1216
partial	O	1217-1224
revascularization	O	1225-1242
of	O	1243-1245
the	O	1246-1249
SVC	O	1250-1253
and	O	1254-1257
central	O	1258-1265
veins	O	1266-1271
.	O	1271-1272

Postthrombectomy	O	1273-1289
continuous	O	1290-1300
CDT	O	1301-1304
with	O	1305-1309
alteplase	O	1310-1319
was	O	1320-1323
commenced	O	1324-1333
while	O	1334-1339
argatroban	O	1340-1350
was	O	1351-1354
withheld	O	1355-1363
,	O	1363-1364
and	O	1365-1368
complete	O	1369-1377
patency	O	1378-1385
of	O	1386-1388
the	O	1389-1392
SVC	O	1393-1396
and	O	1397-1400
central	O	1401-1408
veins	O	1409-1414
was	O	1415-1418
achieved	O	1419-1427
after	O	1428-1433
three	O	1434-1439
days	O	1440-1444
of	O	1445-1447
therapy	O	1448-1455
.	O	1455-1456

Alteplase	O	1457-1466
was	O	1467-1470
discontinued	O	1471-1483
,	O	1483-1484
and	O	1485-1488
the	O	1489-1492
patient	O	1493-1500
was	O	1501-1504
reinitiated	O	1505-1516
on	O	1517-1519
argatroban	O	1520-1530
;	O	1530-1531
ultimately	O	1532-1542
,	O	1542-1543
he	O	1544-1546
was	O	1547-1550
transitioned	O	1551-1563
to	O	1564-1566
warfarin	O	1567-1575
for	O	1576-1579
long	O	1580-1584
-	O	1584-1585
term	O	1585-1589
anticoagulation	O	1590-1605
.	O	1605-1606

Although	O	1607-1615
the	O	1616-1619
patient	O	1620-1627
recovered	O	1628-1637
,	O	1637-1638
he	O	1639-1641
experienced	O	1642-1653
permanent	O	1654-1663
vision	B	1664-1670
and	I	1671-1674
hearing	I	1675-1682
loss	I	1683-1687
,	O	1687-1688
as	O	1689-1691
well	O	1692-1696
as	O	1697-1699
end	B	1700-1703
-	I	1703-1704
stage	I	1704-1709
renal	I	1710-1715
disease	I	1716-1723
.	O	1723-1724

CONCLUSION	O	1725-1735
:	O	1735-1736
A	O	1737-1738
63	O	1739-1741
-	O	1741-1742
year	O	1742-1746
-	O	1741-1742
old	O	1747-1750
man	O	1751-1754
with	O	1755-1759
renal	O	1760-1765
amyloidosis	B	1766-1777
and	O	1778-1781
SVC	B	1782-1785
syndrome	I	1786-1794
secondary	O	1795-1804
to	O	1805-1807
HITT	B	1808-1812
was	O	1813-1816
successfully	O	1817-1829
treated	O	1830-1837
with	O	1838-1842
argatroban	O	1843-1853
and	O	1854-1857
CDT	O	1858-1861
with	O	1862-1866
alteplase	O	1867-1876
.	O	1876-1877

Effects	O	0-7
of	O	8-10
dehydroepiandrosterone	O	11-33
in	O	34-36
amphetamine	O	37-48
-	O	48-49
induced	O	49-56
schizophrenia	B	57-70
models	O	71-77
in	O	78-80
mice	O	81-85
.	O	85-86

OBJECTIVE	O	87-96
:	O	96-97
To	O	98-100
examine	O	101-108
the	O	109-112
effects	O	113-120
of	O	121-123
dehydroepiandrosterone	O	124-146
(	O	147-148
DHEA	O	148-152
)	O	152-153
on	O	154-156
animal	O	157-163
models	O	164-170
of	O	171-173
schizophrenia	B	174-187
.	O	187-188

METHODS	O	189-196
:	O	196-197
Seventy	O	198-205
Swiss	O	206-211
albino	O	212-218
female	O	219-225
mice	O	226-230
(	O	231-232
25	O	232-234
-	O	234-235
35	O	235-237
g	O	238-239
)	O	239-240
were	O	241-245
divided	O	246-253
into	O	254-258
4	O	259-260
groups	O	261-267
:	O	267-268
amphetamine	O	269-280
-	O	280-281
free	O	281-285
(	O	286-287
control	O	287-294
)	O	294-295
,	O	295-296
amphetamine	O	297-308
,	O	308-309
50	O	310-312
,	O	312-313
and	O	314-317
100	O	318-321
mg	O	322-324
/	O	324-325
kg	O	325-327
DHEA	O	328-332
.	O	332-333

The	O	334-337
DHEA	O	338-342
was	O	343-346
administered	O	347-359
intraperitoneally	O	360-377
(	O	378-379
ip	O	379-381
)	O	381-382
for	O	383-386
5	O	387-388
days	O	389-393
.	O	393-394

Amphetamine	O	395-406
(	O	407-408
3	O	408-409
mg	O	410-412
/	O	412-413
kg	O	413-415
ip	O	416-418
)	O	418-419
induced	O	420-427
hyper	B	428-433
locomotion	O	434-444
,	O	444-445
apomorphine	O	446-457
(	O	458-459
1	O	459-460
.	O	460-461
5	O	461-462
mg	O	463-465
/	O	465-466
kg	O	466-468
subcutaneously	O	469-483
[	O	484-485
sc	O	485-487
]	O	487-488
)	O	488-489
induced	O	490-497
climbing	O	498-506
,	O	506-507
and	O	508-511
haloperidol	O	512-523
(	O	524-525
1	O	525-526
.	O	526-527
5	O	527-528
mg	O	529-531
/	O	531-532
kg	O	532-534
sc	O	535-537
)	O	537-538
induced	O	539-546
catalepsy	B	547-556
tests	O	557-562
were	O	563-567
used	O	568-572
as	O	573-575
animal	O	576-582
models	O	583-589
of	O	590-592
schizophrenia	B	593-606
.	O	606-607

The	O	608-611
study	O	612-617
was	O	618-621
conducted	O	622-631
at	O	632-634
the	O	635-638
Animal	O	639-645
Experiment	O	646-656
Laboratories	O	657-669
,	O	669-670
Department	O	671-681
of	O	682-684
Pharmacology	O	685-697
,	O	697-698
Medical	O	699-706
School	O	707-713
,	O	713-714
Eskisehir	O	715-724
Osmangazi	O	725-734
University	O	735-745
,	O	745-746
Eskisehir	O	747-756
,	O	756-757
Turkey	O	758-764
between	O	765-772
March	O	773-778
and	O	779-782
May	O	783-786
2012	O	787-791
.	O	791-792

Statistical	O	793-804
analysis	O	805-813
was	O	814-817
carried	O	818-825
out	O	826-829
using	O	830-835
Kruskal	O	836-843
-	O	843-844
Wallis	O	844-850
test	O	851-855
for	O	856-859
hyper	B	860-865
locomotion	O	866-876
,	O	876-877
and	O	878-881
one	O	882-885
-	O	885-886
way	O	886-889
ANOVA	O	890-895
for	O	896-899
climbing	O	900-908
and	O	909-912
catalepsy	B	913-922
tests	O	923-928
.	O	928-929

RESULTS	O	930-937
:	O	937-938
In	O	939-941
the	O	942-945
amphetamine	O	946-957
-	O	957-958
induced	O	958-965
locomotion	O	966-976
test	O	977-981
,	O	981-982
there	O	983-988
were	O	989-993
significant	O	994-1005
increases	O	1006-1015
in	O	1016-1018
all	O	1019-1022
movements	O	1023-1032
compared	O	1033-1041
with	O	1042-1046
the	O	1047-1050
amphetamine	O	1051-1062
-	O	1062-1063
free	O	1063-1067
group	O	1068-1073
.	O	1073-1074

Both	O	1075-1079
DHEA	O	1080-1084
50	O	1085-1087
mg	O	1088-1090
/	O	1090-1091
kg	O	1091-1093
(	O	1094-1095
p	O	1095-1096
<	O	1096-1097
0	O	1097-1098
.	O	1098-1099
05	O	1099-1101
)	O	1101-1102
,	O	1102-1103
and	O	1104-1107
100	O	1108-1111
mg	O	1112-1114
/	O	1114-1115
kg	O	1115-1117
(	O	1118-1119
p	O	1119-1120
<	O	1120-1121
0	O	1121-1122
.	O	1122-1123
01	O	1123-1125
)	O	1125-1126

significantly	O	1127-1140
decreased	O	1141-1150
all	O	1151-1154
movements	O	1155-1164
compared	O	1165-1173
with	O	1174-1178
the	O	1179-1182
amphetamine	O	1183-1194
-	O	1194-1195
induced	O	1195-1202
locomotion	O	1203-1213
group	O	1214-1219
.	O	1219-1220

There	O	1221-1226
was	O	1227-1230
a	O	1231-1232
significant	O	1233-1244
difference	O	1245-1255
between	O	1256-1263
groups	O	1264-1270
in	O	1271-1273
the	O	1274-1277
haloperidol	O	1278-1289
-	O	1289-1290
induced	O	1290-1297
catalepsy	B	1298-1307
test	O	1308-1312
(	O	1313-1314
p	O	1314-1315
<	O	1315-1316
0	O	1316-1317
.	O	1317-1318
05	O	1318-1320
)	O	1320-1321
.	O	1317-1318

There	O	1323-1328
was	O	1329-1332
no	O	1333-1335
significant	O	1336-1347
difference	O	1348-1358
between	O	1359-1366
groups	O	1367-1373
in	O	1374-1376
terms	O	1377-1382
of	O	1383-1385
total	O	1386-1391
climbing	O	1392-1400
time	O	1401-1405
in	O	1406-1408
the	O	1409-1412
apomorphine	O	1413-1424
-	O	1424-1425
induced	O	1425-1432
climbing	O	1433-1441
test	O	1442-1446
(	O	1447-1448
p	O	1448-1449
>	O	1449-1450
0	O	1450-1451
.	O	1451-1452
05	O	1452-1454
)	O	1454-1455
.	O	1451-1452

CONCLUSION	O	1457-1467
:	O	1467-1468
We	O	1469-1471
observed	O	1472-1480
that	O	1481-1485
DHEA	O	1486-1490
reduced	O	1491-1498
locomotor	O	1499-1508
activity	O	1509-1517
and	O	1518-1521
increased	O	1522-1531
catalepsy	B	1532-1541
at	O	1542-1544
both	O	1545-1549
doses	O	1550-1555
,	O	1555-1556
while	O	1557-1562
it	O	1563-1565
had	O	1566-1569
no	O	1570-1572
effect	O	1573-1579
on	O	1580-1582
climbing	O	1583-1591
behavior	O	1592-1600
.	O	1600-1601

We	O	1602-1604
suggest	O	1605-1612
that	O	1613-1617
DHEA	O	1618-1622
displays	O	1623-1631
typical	O	1632-1639
neuroleptic	O	1640-1651
-	O	1651-1652
like	O	1652-1656
effects	O	1657-1664
,	O	1664-1665
and	O	1666-1669
may	O	1670-1673
be	O	1674-1676
used	O	1677-1681
in	O	1682-1684
the	O	1685-1688
treatment	O	1689-1698
of	O	1699-1701
schizophrenia	B	1702-1715
.	O	1715-1716

Availability	O	0-12
of	O	13-15
human	O	16-21
induced	O	22-29
pluripotent	O	30-41
stem	O	42-46
cell	O	47-51
-	O	51-52
derived	O	52-59
cardiomyocytes	O	60-74
in	O	75-77
assessment	O	78-88
of	O	89-91
drug	O	92-96
potential	O	97-106
for	O	107-110
QT	B	111-113
prolongation	I	114-126
.	O	126-127

Field	O	128-133
potential	O	134-143
duration	O	144-152
(	O	153-154
FPD	O	154-157
)	O	157-158
in	O	159-161
human	O	162-167
-	O	167-168
induced	O	168-175
pluripotent	O	176-187
stem	O	188-192
cell	O	193-197
-	O	197-198
derived	O	198-205
cardiomyocytes	O	206-220
(	O	221-222
hiPS	O	222-226
-	O	226-227
CMs	O	227-230
)	O	230-231
,	O	231-232
which	O	233-238
can	O	239-242
express	O	243-250
QT	O	251-253
interval	O	254-262
in	O	263-265
an	O	266-268
electrocardiogram	O	269-286
,	O	286-287
is	O	288-290
reported	O	291-299
to	O	300-302
be	O	303-305
a	O	306-307
useful	O	308-314
tool	O	315-319
to	O	320-322
predict	O	323-330
K	O	331-332
(	O	332-333
+	O	333-334
)	O	334-335
channel	O	336-343
and	O	344-347
Ca	O	348-350
(	O	350-351
2	O	351-352
+	O	352-353
)	O	353-354
channel	O	355-362
blocker	O	363-370
effects	O	371-378
on	O	379-381
QT	O	382-384
interval	O	385-393
.	O	393-394

However	O	395-402
,	O	402-403
there	O	404-409
is	O	410-412
no	O	413-415
report	O	416-422
showing	O	423-430
that	O	431-435
this	O	436-440
technique	O	441-450
can	O	451-454
be	O	455-457
used	O	458-462
to	O	463-465
predict	O	466-473
multichannel	O	474-486
blocker	O	487-494
potential	O	495-504
for	O	505-508
QT	B	509-511
prolongation	I	512-524
.	O	524-525

The	O	526-529
aim	O	530-533
of	O	534-536
this	O	537-541
study	O	542-547
is	O	548-550
to	O	551-553
show	O	554-558
that	O	559-563
FPD	O	564-567
from	O	568-572
MEA	O	573-576
(	O	577-578
Multielectrode	O	578-592
array	O	593-598
)	O	598-599
of	O	600-602
hiPS	O	603-607
-	O	607-608
CMs	O	608-611
can	O	612-615
detect	O	616-622
QT	B	623-625
prolongation	I	626-638
induced	O	639-646
by	O	647-649
multichannel	O	650-662
blockers	O	663-671
.	O	671-672

hiPS	O	673-677
-	O	677-678
CMs	O	678-681
were	O	682-686
seeded	O	687-693
onto	O	694-698
MEA	O	699-702
and	O	703-706
FPD	O	707-710
was	O	711-714
measured	O	715-723
for	O	724-727
2min	O	728-732
every	O	733-738
10min	O	739-744
for	O	745-748
30min	O	749-754
after	O	755-760
drug	O	761-765
exposure	O	766-774
for	O	775-778
the	O	779-782
vehicle	O	783-790
and	O	791-794
each	O	795-799
drug	O	800-804
concentration	O	805-818
.	O	818-819

IKr	O	820-823
and	O	824-827
IKs	O	828-831
blockers	O	832-840
concentration	O	841-854
-	O	854-855
dependently	O	855-866
prolonged	O	867-876
corrected	O	877-886
FPD	O	887-890
(	O	891-892
FPDc	O	892-896
)	O	896-897
,	O	897-898
whereas	O	899-906
Ca	O	907-909
(	O	909-910
2	O	910-911
+	O	911-912
)	O	912-913
channel	O	914-921
blockers	O	922-930
concentration	O	931-944
-	O	944-945
dependently	O	945-956
shortened	O	957-966
FPDc	O	967-971
.	O	971-972

Also	O	973-977
,	O	977-978
the	O	979-982
multichannel	O	983-995
blockers	O	996-1004
Amiodarone	O	1005-1015
,	O	1015-1016
Paroxetine	O	1017-1027
,	O	1027-1028
Terfenadine	O	1029-1040
and	O	1041-1044
Citalopram	O	1045-1055
prolonged	O	1056-1065
FPDc	O	1066-1070
in	O	1071-1073
a	O	1074-1075
concentration	O	1076-1089
dependent	O	1090-1099
manner	O	1100-1106
.	O	1106-1107

Finally	O	1108-1115
,	O	1115-1116
the	O	1117-1120
IKr	O	1121-1124
blockers	O	1125-1133
,	O	1133-1134
Terfenadine	O	1135-1146
and	O	1147-1150
Citalopram	O	1151-1161
,	O	1161-1162
which	O	1163-1168
are	O	1169-1172
reported	O	1173-1181
to	O	1182-1184
cause	O	1185-1190
Torsade	B	1191-1198
de	I	1199-1201
Pointes	I	1202-1209
(	O	1210-1211
TdP	B	1211-1214
)	O	1214-1215
in	O	1216-1218
clinical	O	1219-1227
practice	O	1228-1236
,	O	1236-1237
produced	O	1238-1246
early	O	1247-1252
afterdepolarization	O	1253-1272
(	O	1273-1274
EAD	O	1274-1277
)	O	1277-1278
.	O	1278-1279

hiPS	O	1280-1284
-	O	1284-1285
CMs	O	1285-1288
using	O	1289-1294
MEA	O	1295-1298
system	O	1299-1305
and	O	1306-1309
FPDc	O	1310-1314
can	O	1315-1318
predict	O	1319-1326
the	O	1327-1330
effects	O	1331-1338
of	O	1339-1341
drug	O	1342-1346
candidates	O	1347-1357
on	O	1358-1360
QT	O	1361-1363
interval	O	1364-1372
.	O	1372-1373

This	O	1374-1378
study	O	1379-1384
also	O	1385-1389
shows	O	1390-1395
that	O	1396-1400
this	O	1401-1405
assay	O	1406-1411
can	O	1412-1415
help	O	1416-1420
detect	O	1421-1427
EAD	O	1428-1431
for	O	1432-1435
drugs	O	1436-1441
with	O	1442-1446
TdP	B	1447-1450
potential	O	1451-1460
.	O	1460-1461

Dermal	O	0-6
developmental	O	7-20
toxicity	B	21-29
of	O	30-32
N	O	33-34
-	O	34-35
phenylimide	O	35-46
herbicides	O	47-57
in	O	58-60
rats	O	61-65
.	O	65-66

BACKGROUND	O	67-77
:	O	77-78
S	O	79-80
-	O	80-81
53482	O	81-86
and	O	87-90
S	O	91-92
-	O	92-93
23121	O	93-98
are	O	99-102
N	O	103-104
-	O	104-105
phenylimide	O	105-116
herbicides	O	117-127
and	O	128-131
produced	O	132-140
embryolethality	B	141-156
,	O	156-157
teratogenicity	B	158-172
(	O	173-174
mainly	O	174-180
ventricular	B	181-192
septal	I	193-199
defects	I	200-207
and	O	208-211
wavy	O	212-216
ribs	O	217-221
)	O	221-222
,	O	222-223
and	O	224-227
growth	B	228-234
retardation	I	235-246
in	O	247-249
rats	O	250-254
in	O	255-257
conventional	O	258-270
oral	O	271-275
developmental	O	276-289
toxicity	B	290-298
studies	O	299-306
.	O	306-307

Our	O	308-311
objective	O	312-321
in	O	322-324
this	O	325-329
study	O	330-335
was	O	336-339
to	O	340-342
investigate	O	343-354
whether	O	355-362
the	O	363-366
compounds	O	367-376
induce	O	377-383
developmental	O	384-397
toxicity	B	398-406
via	O	407-410
the	O	411-414
dermal	O	415-421
route	O	422-427
,	O	427-428
which	O	429-434
is	O	435-437
more	O	438-442
relevant	O	443-451
to	O	452-454
occupational	O	455-467
exposure	O	468-476
,	O	476-477
hence	O	478-483
better	O	484-490
addressing	O	491-501
human	O	502-507
health	O	508-514
risks	O	515-520
.	O	520-521

METHODS	O	522-529
:	O	529-530
S	O	531-532
-	O	532-533
53482	O	533-538
was	O	539-542
administered	O	543-555
dermally	O	556-564
to	O	565-567
rats	O	568-572
at	O	573-575
30	O	576-578
,	O	578-579
100	O	580-583
,	O	583-584
and	O	585-588
300	O	589-592
mg	O	593-595
/	O	595-596
kg	O	596-598
during	O	599-605
organogenesis	O	606-619
,	O	619-620
and	O	621-624
S	O	625-626
-	O	626-627
23121	O	627-632
was	O	633-636
administered	O	637-649
at	O	650-652
200	O	653-656
,	O	656-657
400	O	658-661
,	O	661-662
and	O	663-666
800	O	667-670
mg	O	671-673
/	O	673-674
kg	O	674-676
(	O	677-678
the	O	678-681
maximum	O	682-689
applicable	O	690-700
dose	O	701-705
level	O	706-711
)	O	711-712
.	O	712-713

Fetuses	O	714-721
were	O	722-726
obtained	O	727-735
by	O	736-738
a	O	739-740
Cesarean	O	741-749
section	O	750-757
and	O	758-761
examined	O	762-770
for	O	771-774
external	O	775-783
,	O	783-784
visceral	O	785-793
,	O	793-794
and	O	795-798
skeletal	O	799-807
alterations	O	808-819
.	O	819-820

RESULTS	O	821-828
:	O	828-829
Dermal	O	830-836
exposure	O	837-845
of	O	846-848
rats	O	849-853
to	O	854-856
S	O	857-858
-	O	858-859
53482	O	859-864
at	O	865-867
300	O	868-871
mg	O	872-874
/	O	874-875
kg	O	875-877
produced	O	878-886
patterns	O	887-895
of	O	896-898
developmental	O	899-912
toxicity	B	913-921
similar	O	922-929
to	O	930-932
those	O	933-938
resulting	O	939-948
from	O	949-953
oral	O	954-958
exposure	O	959-967
.	O	967-968

Toxicity	B	969-977
included	O	978-986
embryolethality	B	987-1002
,	O	1002-1003
teratogenicity	B	1004-1018
,	O	1018-1019
and	O	1020-1023
growth	B	1024-1030
retardation	I	1031-1042
.	O	1042-1043

Dermal	O	1044-1050
administration	O	1051-1065
of	O	1066-1068
S	O	1069-1070
-	O	1070-1071
23121	O	1071-1076
at	O	1077-1079
800	O	1080-1083
mg	O	1084-1086
/	O	1086-1087
kg	O	1087-1089
resulted	O	1090-1098
in	O	1099-1101
an	O	1102-1104
increased	O	1105-1114
incidence	O	1115-1124
of	O	1125-1127
embryonic	B	1128-1137
death	I	1138-1143
and	O	1144-1147
ventricular	B	1148-1159
septal	I	1160-1166
defect	I	1167-1173
,	O	1173-1174
but	O	1175-1178
retarded	O	1179-1187
fetal	O	1188-1193
growth	O	1194-1200
was	O	1201-1204
not	O	1205-1208
observed	O	1209-1217
as	O	1218-1220
it	O	1221-1223
was	O	1224-1227
following	O	1228-1237
oral	O	1238-1242
exposure	O	1243-1251
to	O	1252-1254
S	O	1255-1256
-	O	1256-1257
23121	O	1257-1262
.	O	1262-1263

CONCLUSIONS	O	1264-1275
:	O	1275-1276
Based	O	1277-1282
on	O	1283-1285
the	O	1286-1289
results	O	1290-1297
,	O	1297-1298
S	O	1299-1300
-	O	1300-1301
53482	O	1301-1306
and	O	1307-1310
S	O	1311-1312
-	O	1312-1313
23121	O	1313-1318
were	O	1319-1323
teratogenic	B	1324-1335
when	O	1336-1340
administered	O	1341-1353
dermally	O	1354-1362
to	O	1363-1365
pregnant	O	1366-1374
rats	O	1375-1379
as	O	1380-1382
were	O	1383-1387
the	O	1388-1391
compounds	O	1392-1401
administered	O	1402-1414
orally	O	1415-1421
.	O	1421-1422

Thus	O	1423-1427
,	O	1427-1428
investigation	O	1429-1442
of	O	1443-1445
the	O	1446-1449
mechanism	O	1450-1459
and	O	1460-1463
its	O	1464-1467
human	O	1468-1473
relevancy	O	1474-1483
become	O	1484-1490
more	O	1491-1495
important	O	1496-1505
.	O	1505-1506

Rates	O	0-5
of	O	6-8
Renal	B	9-14
Toxicity	I	15-23
in	O	24-26
Cancer	B	27-33
Patients	O	34-42
Receiving	O	43-52
Cisplatin	O	53-62
With	O	63-67
and	O	68-71
Without	O	72-79
Mannitol	O	80-88
.	O	88-89

BACKGROUND	O	90-100
:	O	100-101
Cisplatin	O	102-111
is	O	112-114
a	O	115-116
widely	O	117-123
used	O	124-128
antineoplastic	O	129-143
.	O	143-144

One	O	145-148
of	O	149-151
the	O	152-155
major	O	156-161
complications	O	162-175
of	O	176-178
cisplatin	O	179-188
use	O	189-192
is	O	193-195
dose	O	196-200
-	O	200-201
limiting	O	201-209
nephrotoxicity	B	210-224
.	O	224-225

There	O	226-231
are	O	232-235
many	O	236-240
strategies	O	241-251
to	O	252-254
prevent	O	255-262
this	O	263-267
toxicity	B	268-276
,	O	276-277
including	O	278-287
the	O	288-291
use	O	292-295
of	O	296-298
mannitol	O	299-307
as	O	308-310
a	O	311-312
nephroprotectant	O	313-329
in	O	330-332
combination	O	333-344
with	O	345-349
hydration	O	350-359
.	O	359-360

OBJECTIVE	O	361-370
:	O	370-371
We	O	372-374
aimed	O	375-380
to	O	381-383
evaluate	O	384-392
the	O	393-396
rates	O	397-402
of	O	403-405
cisplatin	O	406-415
-	O	415-416
induced	O	416-423
nephrotoxicity	B	424-438
in	O	439-441
cancer	B	442-448
patients	O	449-457
receiving	O	458-467
single	O	468-474
-	O	474-475
agent	O	475-480
cisplatin	O	481-490
with	O	491-495
and	O	496-499
without	O	500-507
mannitol	O	508-516
.	O	516-517

METHODS	O	518-525
:	O	525-526
This	O	527-531
single	O	532-538
-	O	538-539
center	O	539-545
retrospective	O	546-559
analysis	O	560-568
was	O	569-572
a	O	573-574
quasi	O	575-580
experiment	O	581-591
created	O	592-599
by	O	600-602
the	O	603-606
national	O	607-615
mannitol	O	616-624
shortage	O	625-633
.	O	633-634

Data	O	635-639
were	O	640-644
collected	O	645-654
on	O	655-657
adult	O	658-663
cancer	B	664-670
patients	O	671-679
receiving	O	680-689
single	O	690-696
-	O	696-697
agent	O	697-702
cisplatin	O	703-712
as	O	713-715
an	O	716-718
outpatient	O	719-729
from	O	730-734
January	O	735-742
2011	O	743-747
to	O	748-750
September	O	751-760
2012	O	761-765
.	O	765-766

The	O	767-770
primary	O	771-778
outcome	O	779-786
was	O	787-790
acute	B	791-796
kidney	I	797-803
injury	I	804-810
(	O	811-812
AKI	B	812-815
)	O	815-816
.	O	816-817

RESULTS	O	818-825
:	O	825-826
We	O	827-829
evaluated	O	830-839
143	O	840-843
patients	O	844-852
who	O	853-856
received	O	857-865
single	O	866-872
-	O	872-873
agent	O	873-878
cisplatin	O	879-888
;	O	888-889
97	O	890-892
.	O	892-893
2	O	893-894
%	O	894-895
of	O	896-898
patients	O	899-907
had	O	908-911
head	B	912-916
and	I	917-920
neck	I	921-925
cancer	I	926-932
as	O	933-935
their	O	936-941
primary	O	942-949
malignancy	B	950-960
.	O	960-961

Patients	O	962-970
who	O	971-974
did	O	975-978
not	O	979-982
receive	O	983-990
mannitol	O	991-999
were	O	1000-1004
more	O	1005-1009
likely	O	1010-1016
to	O	1017-1019
develop	O	1020-1027
nephrotoxicity	B	1028-1042
:	O	1042-1043
odds	O	1044-1048
ratio	O	1049-1054
[	O	1055-1056
OR	O	1056-1058
]	O	1058-1059
=	O	1060-1061
2	O	1062-1063
.	O	1063-1064
646	O	1064-1067
(	O	1068-1069
95	O	1069-1071
%	O	1071-1072
CI	O	1073-1075
=	O	1076-1077
1	O	1078-1079
.	O	1079-1080
008	O	1080-1083
,	O	1083-1084
6	O	1085-1086
.	O	1086-1087
944	O	1087-1090
;	O	1090-1091
P	O	1092-1093
=	O	1094-1095
0	O	1096-1097
.	O	1097-1098
048	O	1098-1101
)	O	1101-1102
.	O	1097-1098

Patients	O	1104-1112
who	O	1113-1116
received	O	1117-1125
the	O	1126-1129
100	O	1130-1133
mg	O	1134-1136
/	O	1136-1137
m	O	1134-1135
(	O	1138-1139
2	O	1139-1140
)	O	1140-1141
dosing	O	1142-1148
and	O	1149-1152
patients	O	1153-1161
who	O	1162-1165
had	O	1166-1169
a	O	1170-1171
history	O	1172-1179
of	O	1180-1182
hypertension	B	1183-1195
also	O	1196-1200
had	O	1201-1204
a	O	1205-1206
higher	O	1207-1213
likelihood	O	1214-1224
of	O	1225-1227
developing	O	1228-1238
nephrotoxicity	B	1239-1253
:	O	1253-1254
OR	O	1255-1257
=	O	1258-1259
11	O	1260-1262
.	O	1262-1263
494	O	1263-1266

(	O	1267-1268
95	O	1268-1270
%	O	1270-1271
CI	O	1272-1274
=	O	1275-1276
4	O	1277-1278
.	O	1278-1279
149	O	1279-1282
,	O	1282-1283
32	O	1284-1286
.	O	1286-1287
258	O	1287-1290
;	O	1290-1291
P	O	1292-1293
<	O	1294-1295
0	O	1296-1297
.	O	1297-1298
0001	O	1298-1302
)	O	1302-1303
and	O	1304-1307
OR	O	1308-1310
=	O	1311-1312
3	O	1313-1314
.	O	1314-1315
219	O	1315-1318
(	O	1319-1320
95	O	1320-1322
%	O	1322-1323
CI	O	1324-1326
=	O	1327-1328
1	O	1329-1330
.	O	1330-1331
228	O	1331-1334
,	O	1334-1335
8	O	1336-1337
.	O	1337-1338
439	O	1338-1341
;	O	1341-1342
P	O	1343-1344
=	O	1345-1346
0	O	1347-1348
.	O	1348-1349
017	O	1349-1352
)	O	1352-1353
,	O	1353-1354
respectively	O	1355-1367
.	O	1367-1368

CONCLUSIONS	O	1369-1380
:	O	1380-1381
When	O	1382-1386
limited	O	1387-1394
quantities	O	1395-1405
of	O	1406-1408
mannitol	O	1409-1417
are	O	1418-1421
available	O	1422-1431
,	O	1431-1432
it	O	1433-1435
should	O	1436-1442
preferentially	O	1443-1457
be	O	1458-1460
given	O	1461-1466
to	O	1467-1469
patients	O	1470-1478
at	O	1479-1481
particularly	O	1482-1494
high	O	1495-1499
risk	O	1500-1504
of	O	1505-1507
nephrotoxicity	B	1508-1522
.	O	1522-1523

Our	O	1524-1527
analysis	O	1528-1536
suggests	O	1537-1545
that	O	1546-1550
those	O	1551-1556
patients	O	1557-1565
receiving	O	1566-1575
the	O	1576-1579
dosing	O	1580-1586
schedule	O	1587-1595
of	O	1596-1598
100	O	1599-1602
mg	O	1603-1605
/	O	1605-1606
m	O	1603-1604
(	O	1607-1608
2	O	1608-1609
)	O	1609-1610
cisplatin	O	1611-1620
every	O	1621-1626
3	O	1627-1628
weeks	O	1629-1634
and	O	1635-1638
those	O	1639-1644
with	O	1645-1649
hypertension	B	1650-1662
are	O	1663-1666
at	O	1667-1669
the	O	1670-1673
greatest	O	1674-1682
risk	O	1683-1687
of	O	1688-1690
nephrotoxicity	B	1691-1705
and	O	1706-1709
would	O	1710-1715
benefit	O	1716-1723
from	O	1724-1728
the	O	1729-1732
addition	O	1733-1741
of	O	1742-1744
mannitol	O	1745-1753
.	O	1753-1754

Metformin	O	0-9
protects	O	10-18
against	O	19-26
seizures	B	27-35
,	O	35-36
learning	B	37-45
and	I	46-49
memory	I	50-56
impairments	I	57-68
and	O	69-72
oxidative	O	73-82
damage	O	83-89
induced	O	90-97
by	O	98-100
pentylenetetrazole	O	101-119
-	O	119-120
induced	O	120-127
kindling	O	128-136
in	O	137-139
mice	O	140-144
.	O	144-145

Cognitive	B	146-155
impairment	I	156-166
,	O	166-167
the	O	168-171
most	O	172-176
common	O	177-183
and	O	184-187
severe	O	188-194
comorbidity	O	195-206
of	O	207-209
epilepsy	B	210-218
,	O	218-219
greatly	O	220-227
diminishes	O	228-238
the	O	239-242
quality	O	243-250
of	O	251-253
life	O	254-258
.	O	258-259

However	O	260-267
,	O	267-268
current	O	269-276
therapeutic	O	277-288
interventions	O	289-302
for	O	303-306
epilepsy	B	307-315
can	O	316-319
also	O	320-324
cause	O	325-330
untoward	O	331-339
cognitive	O	340-349
effects	O	350-357
.	O	357-358

Thus	O	359-363
,	O	363-364
there	O	365-370
is	O	371-373
an	O	374-376
urgent	O	377-383
need	O	384-388
for	O	389-392
new	O	393-396
kinds	O	397-402
of	O	403-405
agents	O	406-412
targeting	O	413-422
both	O	423-427
seizures	B	428-436
and	O	437-440
cognition	B	441-450
deficits	I	451-459
.	O	459-460

Oxidative	O	461-470
stress	O	471-477
is	O	478-480
considered	O	481-491
to	O	492-494
play	O	495-499
an	O	500-502
important	O	503-512
role	O	513-517
in	O	518-520
epileptogenesis	O	521-536
and	O	537-540
cognitive	B	541-550
deficits	I	551-559
,	O	559-560
and	O	561-564
antioxidants	O	565-577
have	O	578-582
a	O	583-584
putative	O	585-593
antiepileptic	O	594-607
potential	O	608-617
.	O	617-618

Metformin	O	619-628
,	O	628-629
the	O	630-633
most	O	634-638
commonly	O	639-647
prescribed	O	648-658
antidiabetic	O	659-671
oral	O	672-676
drug	O	677-681
,	O	681-682
has	O	683-686
antioxidant	O	687-698
properties	O	699-709
.	O	709-710

This	O	711-715
study	O	716-721
was	O	722-725
designed	O	726-734
to	O	735-737
evaluate	O	738-746
the	O	747-750
ameliorative	O	751-763
effects	O	764-771
of	O	772-774
metformin	O	775-784
on	O	785-787
seizures	B	788-796
,	O	796-797
cognitive	B	798-807
impairment	I	808-818
and	O	819-822
brain	O	823-828
oxidative	O	829-838
stress	O	839-845
markers	O	846-853
observed	O	854-862
in	O	863-865
pentylenetetrazole	O	866-884
-	O	884-885
induced	O	885-892
kindling	O	893-901
animals	O	902-909
.	O	909-910

Male	O	911-915
C57BL	O	916-921
/	O	921-922
6	O	922-923
mice	O	924-928
were	O	929-933
administered	O	934-946
with	O	947-951
subconvulsive	O	952-965
dose	O	966-970
of	O	971-973
pentylenetetrazole	O	974-992
(	O	993-994
37	O	994-996
mg	O	997-999
/	O	999-1000
kg	O	1000-1002
,	O	1002-1003
i	O	1004-1005
.	O	1005-1006
p	O	1006-1007
.	O	1005-1006
)	O	1008-1009
every	O	1010-1015
other	O	1016-1021
day	O	1022-1025
for	O	1026-1029
14	O	1030-1032
injections	O	1033-1043
.	O	1043-1044

Metformin	O	1045-1054
was	O	1055-1058
injected	O	1059-1067
intraperitoneally	O	1068-1085
in	O	1086-1088
dose	O	1089-1093
of	O	1094-1096
200mg	O	1097-1102
/	O	1102-1103
kg	O	1103-1105
along	O	1106-1111
with	O	1112-1116
alternate	O	1117-1126
-	O	1126-1127
day	O	1127-1130
PTZ	O	1131-1134
.	O	1134-1135

We	O	1136-1138
found	O	1139-1144
that	O	1145-1149
metformin	O	1150-1159
suppressed	O	1160-1170
the	O	1171-1174
progression	O	1175-1186
of	O	1187-1189
kindling	O	1190-1198
,	O	1198-1199
ameliorated	O	1200-1211
the	O	1212-1215
cognitive	B	1216-1225
impairment	I	1226-1236
and	O	1237-1240
decreased	O	1241-1250
brain	O	1251-1256
oxidative	O	1257-1266
stress	O	1267-1273
.	O	1273-1274

Thus	O	1275-1279
the	O	1280-1283
present	O	1284-1291
study	O	1292-1297
concluded	O	1298-1307
that	O	1308-1312
metformin	O	1313-1322
may	O	1323-1326
be	O	1327-1329
a	O	1330-1331
potential	O	1332-1341
agent	O	1342-1347
for	O	1348-1351
the	O	1352-1355
treatment	O	1356-1365
of	O	1366-1368
epilepsy	B	1369-1377
as	O	1378-1380
well	O	1381-1385
as	O	1386-1388
a	O	1389-1390
protective	O	1391-1401
medicine	O	1402-1410
against	O	1411-1418
cognitive	B	1419-1428
impairment	I	1429-1439
induced	O	1440-1447
by	O	1448-1450
seizures	B	1451-1459
.	O	1459-1460

P53	O	0-3
inhibition	O	4-14
exacerbates	O	15-26
late	O	27-31
-	O	31-32
stage	O	32-37
anthracycline	O	38-51
cardiotoxicity	B	52-66
.	O	66-67

AIMS	O	68-72
:	O	72-73
Doxorubicin	O	74-85
(	O	86-87
DOX	O	87-90
)	O	90-91
is	O	92-94
an	O	95-97
effective	O	98-107
anti	O	108-112
-	O	112-113
cancer	B	113-119
therapeutic	O	120-131
,	O	131-132
but	O	133-136
is	O	137-139
associated	O	140-150
with	O	151-155
both	O	156-160
acute	O	161-166
and	O	167-170
late	O	171-175
-	O	175-176
stage	O	176-181
cardiotoxicity	B	182-196
.	O	196-197

Children	O	198-206
are	O	207-210
particularly	O	211-223
sensitive	O	224-233
to	O	234-236
DOX	O	237-240
-	O	240-241
induced	O	241-248
heart	B	249-254
failure	I	255-262
.	O	262-263

Here	O	264-268
,	O	268-269
the	O	270-273
impact	O	274-280
of	O	281-283
p53	O	284-287
inhibition	O	288-298
on	O	299-301
acute	O	302-307
vs	O	308-310
.	O	310-311
late	O	312-316
-	O	316-317
stage	O	317-322
DOX	O	323-326
cardiotoxicity	B	327-341
was	O	342-345
examined	O	346-354
in	O	355-357
a	O	358-359
juvenile	O	360-368
model	O	369-374
.	O	374-375

METHODS	O	376-383
AND	O	384-387
RESULTS	O	388-395
:	O	395-396
Two	O	397-400
-	O	400-401
week	O	401-405
-	O	400-401
old	O	406-409
MHC	O	410-413
-	O	413-414
CB7	O	414-417
mice	O	418-422
(	O	423-424
which	O	424-429
express	O	430-437
dominant	O	438-446
-	O	446-447
interfering	O	447-458
p53	O	459-462
in	O	463-465
cardiomyocytes	O	466-480
)	O	480-481
and	O	482-485
their	O	486-491
non	O	492-495
-	O	495-496
transgenic	O	496-506
(	O	507-508
NON	O	508-511
-	O	511-512
TXG	O	512-515
)	O	515-516
littermates	O	517-528
received	O	529-537
weekly	O	538-544
DOX	O	545-548
injections	O	549-559
for	O	560-563
5	O	564-565
weeks	O	566-571
(	O	572-573
25	O	573-575
mg	O	576-578
/	O	578-579
kg	O	579-581
cumulative	O	582-592
dose	O	593-597
)	O	597-598
.	O	598-599

One	O	600-603
week	O	604-608
after	O	609-614
the	O	615-618
last	O	619-623
DOX	O	624-627
treatment	O	628-637
(	O	638-639
acute	O	639-644
stage	O	645-650
)	O	650-651
,	O	651-652
MHC	O	653-656
-	O	656-657
CB7	O	657-660
mice	O	661-665
exhibited	O	666-675
improved	O	676-684
cardiac	O	685-692
function	O	693-701
and	O	702-705
lower	O	706-711
levels	O	712-718
of	O	719-721
cardiomyocyte	O	722-735
apoptosis	O	736-745
when	O	746-750
compared	O	751-759
with	O	760-764
the	O	765-768
NON	O	769-772
-	O	772-773
TXG	O	773-776
mice	O	777-781
.	O	781-782

Surprisingly	O	783-795
,	O	795-796
by	O	797-799
13	O	800-802
weeks	O	803-808
following	O	809-818
the	O	819-822
last	O	823-827
DOX	O	828-831
treatment	O	832-841
(	O	842-843
late	O	843-847
stage	O	848-853
)	O	853-854
,	O	854-855
MHC	O	856-859
-	O	859-860
CB7	O	860-863
exhibited	O	864-873
a	O	874-875
progressive	O	876-887
decrease	O	888-896
in	O	897-899
cardiac	O	900-907
function	O	908-916
and	O	917-920
higher	O	921-927
rates	O	928-933
of	O	934-936
cardiomyocyte	O	937-950
apoptosis	O	951-960
when	O	961-965
compared	O	966-974
with	O	975-979
NON	O	980-983
-	O	983-984
TXG	O	984-987
mice	O	988-992
.	O	992-993

p53	O	994-997
inhibition	O	998-1008
blocked	O	1009-1016
transient	O	1017-1026
DOX	O	1027-1030
-	O	1030-1031
induced	O	1031-1038
STAT3	O	1039-1044
activation	O	1045-1055
in	O	1056-1058
MHC	O	1059-1062
-	O	1062-1063
CB7	O	1063-1066
mice	O	1067-1071
,	O	1071-1072
which	O	1073-1078
was	O	1079-1082
associated	O	1083-1093
with	O	1094-1098
enhanced	O	1099-1107
induction	O	1108-1117
of	O	1118-1120
the	O	1121-1124
DNA	O	1125-1128
repair	O	1129-1135
proteins	O	1136-1144
Ku70	O	1145-1149
and	O	1150-1153
Ku80	O	1154-1158
.	O	1158-1159

Mice	O	1160-1164
with	O	1165-1169
cardiomyocyte	O	1170-1183
-	O	1183-1184
restricted	O	1184-1194
deletion	O	1195-1203
of	O	1204-1206
STAT3	O	1207-1212
exhibited	O	1213-1222
worse	O	1223-1228
cardiac	O	1229-1236
function	O	1237-1245
,	O	1245-1246
higher	O	1247-1253
levels	O	1254-1260
of	O	1261-1263
cardiomyocyte	O	1264-1277
apoptosis	O	1278-1287
,	O	1287-1288
and	O	1289-1292
a	O	1293-1294
greater	O	1295-1302
induction	O	1303-1312
of	O	1313-1315
Ku70	O	1316-1320
and	O	1321-1324
Ku80	O	1325-1329
in	O	1330-1332
response	O	1333-1341
to	O	1342-1344
DOX	O	1345-1348
treatment	O	1349-1358
during	O	1359-1365
the	O	1366-1369
acute	O	1370-1375
stage	O	1376-1381
when	O	1382-1386
compared	O	1387-1395
with	O	1396-1400
control	O	1401-1408
animals	O	1409-1416
.	O	1416-1417

CONCLUSION	O	1418-1428
:	O	1428-1429
These	O	1430-1435
data	O	1436-1440
support	O	1441-1448
a	O	1449-1450
model	O	1451-1456
wherein	O	1457-1464
a	O	1465-1466
p53	O	1467-1470
-	O	1470-1471
dependent	O	1471-1480
cardioprotective	O	1481-1497
pathway	O	1498-1505
,	O	1505-1506
mediated	O	1507-1515
via	O	1516-1519
STAT3	O	1520-1525
activation	O	1526-1536
,	O	1536-1537
mitigates	O	1538-1547
DOX	O	1548-1551
-	O	1551-1552
induced	O	1552-1559
myocardial	O	1560-1570
stress	O	1571-1577
during	O	1578-1584
drug	O	1585-1589
delivery	O	1590-1598
.	O	1598-1599

Furthermore	O	1600-1611
,	O	1611-1612
these	O	1613-1618
data	O	1619-1623
suggest	O	1624-1631
an	O	1632-1634
explanation	O	1635-1646
as	O	1647-1649
to	O	1650-1652
how	O	1653-1656
p53	O	1657-1660
inhibition	O	1661-1671
can	O	1672-1675
result	O	1676-1682
in	O	1683-1685
cardioprotection	O	1686-1702
during	O	1703-1709
drug	O	1710-1714
treatment	O	1715-1724
and	O	1725-1728
,	O	1728-1729
paradoxically	O	1730-1743
,	O	1743-1744
enhanced	O	1745-1753
cardiotoxicity	B	1754-1768
long	O	1769-1773
after	O	1774-1779
the	O	1780-1783
cessation	O	1784-1793
of	O	1794-1796
drug	O	1797-1801
treatment	O	1802-1811
.	O	1811-1812

Metronidazole	O	0-13
-	O	13-14
induced	O	14-21
encephalopathy	B	22-36
:	O	36-37
an	O	38-40
uncommon	O	41-49
scenario	O	50-58
.	O	58-59

Metronidazole	O	60-73
can	O	74-77
produce	O	78-85
neurological	O	86-98
complications	O	99-112
although	O	113-121
it	O	122-124
is	O	125-127
not	O	128-131
a	O	132-133
common	O	134-140
scenario	O	141-149
.	O	149-150

We	O	151-153
present	O	154-161
a	O	162-163
case	O	164-168
where	O	169-174
a	O	175-176
patient	O	177-184
developed	O	185-194
features	O	195-203
of	O	204-206
encephalopathy	B	207-221
following	O	222-231
prolonged	O	232-241
metronidazole	O	242-255
intake	O	256-262
.	O	262-263

Magnetic	O	264-272
resonance	O	273-282
imaging	O	283-290
(	O	291-292
MRI	O	292-295
)	O	295-296
brain	O	297-302
showed	O	303-309
abnormal	O	310-318
signal	O	319-325
intensity	O	326-335
involving	O	336-345
both	O	346-350
dentate	O	351-358
nuclei	O	359-365
of	O	366-368
cerebellum	O	369-379
and	O	380-383
splenium	O	384-392
of	O	393-395
corpus	O	396-402
callosum	O	403-411
.	O	411-412

The	O	413-416
diagnosis	O	417-426
of	O	427-429
metronidazole	O	430-443
toxicity	B	444-452
was	O	453-456
made	O	457-461
by	O	462-464
the	O	465-468
MRI	O	469-472
findings	O	473-481
and	O	482-485
supported	O	486-495
clinically	O	496-506
.	O	506-507

Aconitine	O	0-9
-	O	9-10
induced	O	10-17
Ca2	O	18-21
+	O	21-22
overload	O	23-31
causes	O	32-38
arrhythmia	B	39-49
and	O	50-53
triggers	O	54-62
apoptosis	O	63-72
through	O	73-80
p38	O	81-84
MAPK	O	85-89
signaling	O	90-99
pathway	O	100-107
in	O	108-110
rats	O	111-115
.	O	115-116

Aconitine	O	117-126
is	O	127-129
a	O	130-131
major	O	132-137
bioactive	O	138-147
diterpenoid	O	148-159
alkaloid	O	160-168
with	O	169-173
high	O	174-178
content	O	179-186
derived	O	187-194
from	O	195-199
herbal	O	200-206
aconitum	O	207-215
plants	O	216-222
.	O	222-223

Emerging	O	224-232
evidence	O	233-241
indicates	O	242-251
that	O	252-256
voltage	O	257-264
-	O	264-265
dependent	O	265-274
Na	O	275-277
(	O	277-278
+	O	278-279
)	O	279-280
channels	O	281-289
have	O	290-294
pivotal	O	295-302
roles	O	303-308
in	O	309-311
the	O	312-315
cardiotoxicity	B	316-330
of	O	331-333
aconitine	O	334-343
.	O	343-344

However	O	345-352
,	O	352-353
no	O	354-356
reports	O	357-364
are	O	365-368
available	O	369-378
on	O	379-381
the	O	382-385
role	O	386-390
of	O	391-393
Ca	O	394-396
(	O	396-397
2	O	397-398
+	O	398-399
)	O	399-400
in	O	401-403
aconitine	O	404-413
poisoning	B	414-423
.	O	423-424

In	O	425-427
this	O	428-432
study	O	433-438
,	O	438-439
we	O	440-442
explored	O	443-451
the	O	452-455
importance	O	456-466
of	O	467-469
pathological	O	470-482
Ca	O	483-485
(	O	485-486
2	O	486-487
+	O	487-488
)	O	488-489
signaling	O	490-499
in	O	500-502
aconitine	O	503-512
poisoning	B	513-522
in	O	523-525
vitro	O	526-531
and	O	532-535
in	O	536-538
vivo	O	539-543
.	O	543-544

We	O	545-547
found	O	548-553
that	O	554-558
Ca	O	559-561
(	O	561-562
2	O	562-563
+	O	563-564
)	O	564-565
overload	O	566-574
lead	O	575-579
to	O	580-582
accelerated	O	583-594
beating	O	595-602
rhythm	O	603-609
in	O	610-612
adult	O	613-618
rat	O	619-622
ventricular	O	623-634
myocytes	O	635-643
and	O	644-647
caused	O	648-654
arrhythmia	B	655-665
in	O	666-668
conscious	O	669-678
freely	O	679-685
moving	O	686-692
rats	O	693-697
.	O	697-698

To	O	699-701
investigate	O	702-713
effects	O	714-721
of	O	722-724
aconitine	O	725-734
on	O	735-737
myocardial	B	738-748
injury	I	749-755
,	O	755-756
we	O	757-759
performed	O	760-769
cytotoxicity	B	770-782
assay	O	783-788
in	O	789-791
neonatal	O	792-800
rat	O	801-804
ventricular	O	805-816
myocytes	O	817-825
(	O	826-827
NRVMs	O	827-832
)	O	832-833
,	O	833-834
as	O	835-837
well	O	838-842
as	O	843-845
measured	O	846-854
lactate	O	855-862
dehydrogenase	O	863-876
level	O	877-882
in	O	883-885
the	O	886-889
culture	O	890-897
medium	O	898-904
of	O	905-907
NRVMs	O	908-913
and	O	914-917
activities	O	918-928
of	O	929-931
serum	O	932-937
cardiac	O	938-945
enzymes	O	946-953
in	O	954-956
rats	O	957-961
.	O	961-962

The	O	963-966
results	O	967-974
showed	O	975-981
that	O	982-986
aconitine	O	987-996
resulted	O	997-1005
in	O	1006-1008
myocardial	B	1009-1019
injury	I	1020-1026
and	O	1027-1030
reduced	O	1031-1038
NRVMs	O	1039-1044
viability	O	1045-1054
dose	O	1055-1059
-	O	1059-1060
dependently	O	1060-1071
.	O	1071-1072

To	O	1073-1075
confirm	O	1076-1083
the	O	1084-1087
pro	O	1088-1091
-	O	1091-1092
apoptotic	O	1092-1101
effects	O	1102-1109
,	O	1109-1110
we	O	1111-1113
performed	O	1114-1123
flow	O	1124-1128
cytometric	O	1129-1139
detection	O	1140-1149
,	O	1149-1150
cardiac	O	1151-1158
histology	O	1159-1168
,	O	1168-1169
transmission	O	1170-1182
electron	O	1183-1191
microscopy	O	1192-1202
and	O	1203-1206
terminal	O	1207-1215
deoxynucleotidyl	O	1216-1232
transferase	O	1233-1244
-	O	1244-1245
mediated	O	1245-1253
dUTP	O	1254-1258
-	O	1258-1259
biotin	O	1259-1265
nick	O	1266-1270
end	O	1271-1274
labeling	O	1275-1283
assay	O	1284-1289
.	O	1289-1290

The	O	1291-1294
results	O	1295-1302
showed	O	1303-1309
that	O	1310-1314
aconitine	O	1315-1324
stimulated	O	1325-1335
apoptosis	O	1336-1345
time	O	1346-1350
-	O	1350-1351
dependently	O	1351-1362
.	O	1362-1363

The	O	1364-1367
expression	O	1368-1378
analysis	O	1379-1387
of	O	1388-1390
Ca	O	1391-1393
(	O	1393-1394
2	O	1394-1395
+	O	1395-1396
)	O	1396-1397
handling	O	1398-1406
proteins	O	1407-1415
demonstrated	O	1416-1428
that	O	1429-1433
aconitine	O	1434-1443
promoted	O	1444-1452
Ca	O	1453-1455
(	O	1455-1456
2	O	1456-1457
+	O	1457-1458
)	O	1458-1459
overload	O	1460-1468
through	O	1469-1476
the	O	1477-1480
expression	O	1481-1491
regulation	O	1492-1502
of	O	1503-1505
Ca	O	1506-1508
(	O	1508-1509
2	O	1509-1510
+	O	1510-1511
)	O	1511-1512
handling	O	1513-1521
proteins	O	1522-1530
.	O	1530-1531

The	O	1532-1535
expression	O	1536-1546
analysis	O	1547-1555
of	O	1556-1558
apoptosis	O	1559-1568
-	O	1568-1569
related	O	1569-1576
proteins	O	1577-1585
revealed	O	1586-1594
that	O	1595-1599
pro	O	1600-1603
-	O	1603-1604
apoptotic	O	1604-1613
protein	O	1614-1621
expression	O	1622-1632
was	O	1633-1636
upregulated	O	1637-1648
,	O	1648-1649
and	O	1650-1653
anti	O	1654-1658
-	O	1658-1659
apoptotic	O	1659-1668
protein	O	1669-1676
BCL	O	1677-1680
-	O	1680-1681
2	O	1681-1682
expression	O	1683-1693
was	O	1694-1697
downregulated	O	1698-1711
.	O	1711-1712

Furthermore	O	1713-1724
,	O	1724-1725
increased	O	1726-1735
phosphorylation	O	1736-1751
of	O	1752-1754
MAPK	O	1755-1759
family	O	1760-1766
members	O	1767-1774
,	O	1774-1775
especially	O	1776-1786
the	O	1787-1790
P	O	1791-1792
-	O	1792-1793
P38	O	1793-1796
/	O	1796-1797
P38	O	1793-1796
ratio	O	1801-1806
was	O	1807-1810
found	O	1811-1816
in	O	1817-1819
cardiac	O	1820-1827
tissues	O	1828-1835
.	O	1835-1836

Hence	O	1837-1842
,	O	1842-1843
our	O	1844-1847
results	O	1848-1855
suggest	O	1856-1863
that	O	1864-1868
aconitine	O	1869-1878
significantly	O	1879-1892
aggravates	O	1893-1903
Ca	O	1904-1906
(	O	1906-1907
2	O	1907-1908
+	O	1908-1909
)	O	1909-1910
overload	O	1911-1919
and	O	1920-1923
causes	O	1924-1930
arrhythmia	B	1931-1941
and	O	1942-1945
finally	O	1946-1953
promotes	O	1954-1962
apoptotic	O	1963-1972
development	O	1973-1984
via	O	1985-1988
phosphorylation	O	1989-2004
of	O	2005-2007
P38	O	2008-2011
mitogen	O	2012-2019
-	O	2019-2020
activated	O	2020-2029
protein	O	2030-2037
kinase	O	2038-2044
.	O	2044-2045

Chronic	O	0-7
treatment	O	8-17
with	O	18-22
metformin	O	23-32
suppresses	O	33-43
toll	O	44-48
-	O	48-49
like	O	49-53
receptor	O	54-62
4	O	63-64
signaling	O	65-74
and	O	75-78
attenuates	O	79-89
left	B	90-94
ventricular	I	95-106
dysfunction	I	107-118
following	O	119-128
myocardial	B	129-139
infarction	I	140-150
.	O	150-151

Acute	O	152-157
treatment	O	158-167
with	O	168-172
metformin	O	173-182
has	O	183-186
a	O	187-188
protective	O	189-199
effect	O	200-206
in	O	207-209
myocardial	B	210-220
infarction	I	221-231
by	O	232-234
suppression	O	235-246
of	O	247-249
inflammatory	O	250-262
responses	O	263-272
due	O	273-276
to	O	277-279
activation	O	280-290
of	O	291-293
AMP	O	294-297
-	O	297-298
activated	O	298-307
protein	O	308-315
kinase	O	316-322
(	O	323-324
AMPK	O	324-328
)	O	328-329
.	O	329-330

In	O	331-333
the	O	334-337
present	O	338-345
study	O	346-351
,	O	351-352
the	O	353-356
effect	O	357-363
of	O	364-366
chronic	O	367-374
pre	O	375-378
-	O	378-379
treatment	O	379-388
with	O	389-393
metformin	O	394-403
on	O	404-406
cardiac	B	407-414
dysfunction	I	415-426
and	O	427-430
toll	O	431-435
-	O	435-436
like	O	436-440
receptor	O	441-449
4	O	450-451
(	O	452-453
TLR4	O	453-457
)	O	457-458
activities	O	459-469
following	O	470-479
myocardial	B	480-490
infarction	I	491-501
and	O	502-505
their	O	506-511
relation	O	512-520
with	O	521-525
AMPK	O	526-530
were	O	531-535
assessed	O	536-544
.	O	544-545

Male	O	546-550
Wistar	O	551-557
rats	O	558-562
were	O	563-567
randomly	O	568-576
assigned	O	577-585
to	O	586-588
one	O	589-592
of	O	593-595
5	O	596-597
groups	O	598-604
(	O	605-606
n	O	606-607
=	O	607-608
6	O	608-609
)	O	609-610
:	O	610-611
normal	O	612-618
control	O	619-626
and	O	627-630
groups	O	631-637
were	O	638-642
injected	O	643-651
isoproterenol	O	652-665
after	O	666-671
chronic	O	672-679
pre	O	680-683
-	O	683-684
treatment	O	684-693
with	O	694-698
0	O	699-700
,	O	700-701
25	O	702-704
,	O	704-705
50	O	706-708
,	O	708-709
or	O	710-712
100mg	O	713-718
/	O	718-719
kg	O	719-721
of	O	722-724
metformin	O	725-734
twice	O	735-740
daily	O	741-746
for	O	747-750
14	O	751-753
days	O	754-758
.	O	758-759

Isoproterenol	O	760-773
(	O	774-775
100mg	O	775-780
/	O	780-781
kg	O	781-783
)	O	783-784
was	O	785-788
injected	O	789-797
subcutaneously	O	798-812
on	O	813-815
the	O	816-819
13th	O	820-824
and	O	825-828
14th	O	829-833
days	O	834-838
to	O	839-841
induce	O	842-848
acute	B	849-854
myocardial	I	855-865
infarction	I	866-876
.	O	876-877

Isoproterenol	O	878-891
alone	O	892-897
decreased	O	898-907
left	O	908-912
ventricular	O	913-924
systolic	O	925-933
pressure	O	934-942
and	O	943-946
myocardial	O	947-957
contractility	O	958-971
indexed	O	972-979
as	O	980-982
LVdp	O	983-987
/	O	987-988
dtmax	O	988-993
and	O	994-997
LVdp	O	998-1002
/	O	1002-1003
dtmin	O	1003-1008
.	O	1008-1009

The	O	1010-1013
left	B	1014-1018
ventricular	I	1019-1030
dysfunction	I	1031-1042
was	O	1043-1046
significantly	O	1047-1060
lower	O	1061-1066
in	O	1067-1069
the	O	1070-1073
groups	O	1074-1080
treated	O	1081-1088
with	O	1089-1093
25	O	1094-1096
and	O	1097-1100
50mg	O	1101-1105
/	O	1105-1106
kg	O	1106-1108
of	O	1109-1111
metformin	O	1112-1121
.	O	1121-1122

Metfromin	O	1123-1132
markedly	O	1133-1141
lowered	O	1142-1149
isoproterenol	O	1150-1163
-	O	1163-1164
induced	O	1164-1171
elevation	O	1172-1181
in	O	1182-1184
the	O	1185-1188
levels	O	1189-1195
of	O	1196-1198
TLR4	O	1199-1203
mRNA	O	1204-1208
,	O	1208-1209
myeloid	O	1210-1217
differentiation	O	1218-1233
protein	O	1234-1241
88	O	1242-1244
(	O	1245-1246
MyD88	O	1246-1251
)	O	1251-1252
,	O	1252-1253
tumor	B	1254-1259
necrosis	B	1260-1268
factor	O	1269-1275
-	O	1275-1276
alpha	O	1276-1281
(	O	1282-1283
TNF	O	1283-1286
-	O	1286-1287
a	O	1287-1288
)	O	1288-1289
,	O	1289-1290
and	O	1291-1294
interleukin	O	1295-1306
6	O	1307-1308
(	O	1309-1310
IL	O	1310-1312
-	O	1312-1313
6	O	1313-1314
)	O	1314-1315
in	O	1316-1318
the	O	1319-1322
heart	O	1323-1328
tissues	O	1329-1336
.	O	1336-1337

Similar	O	1338-1345
changes	O	1346-1353
were	O	1354-1358
also	O	1359-1363
seen	O	1364-1368
in	O	1369-1371
the	O	1372-1375
serum	O	1376-1381
levels	O	1382-1388
of	O	1389-1391
TNF	O	1392-1395
-	O	1395-1396
a	O	1396-1397
and	O	1398-1401
IL	O	1402-1404
-	O	1404-1405
6	O	1405-1406
.	O	1406-1407

However	O	1408-1415
,	O	1415-1416
the	O	1417-1420
lower	O	1421-1426
doses	O	1427-1432
of	O	1433-1435
25	O	1436-1438
and	O	1439-1442
50mg	O	1443-1447
/	O	1447-1448
kg	O	1448-1450
were	O	1451-1455
more	O	1456-1460
effective	O	1461-1470
than	O	1471-1475
100mg	O	1476-1481
/	O	1481-1482
kg	O	1482-1484
.	O	1484-1485

Phosphorylated	O	1486-1500
AMPKa	O	1501-1506
(	O	1507-1508
p	O	1508-1509
-	O	1509-1510
AMPK	O	1510-1514
)	O	1514-1515
in	O	1516-1518
the	O	1519-1522
myocardium	O	1523-1533
was	O	1534-1537
significantly	O	1538-1551
elevated	O	1552-1560
by	O	1561-1563
25mg	O	1564-1568
/	O	1568-1569
kg	O	1569-1571
of	O	1572-1574
metformin	O	1575-1584
,	O	1584-1585
slightly	O	1586-1594
by	O	1595-1597
50mg	O	1598-1602
/	O	1602-1603
kg	O	1603-1605
,	O	1605-1606
but	O	1607-1610
not	O	1611-1614
by	O	1615-1617
100mg	O	1618-1623
/	O	1623-1624
kg	O	1624-1626
.	O	1626-1627

Chronic	O	1628-1635
pre	O	1636-1639
-	O	1639-1640
treatment	O	1640-1649
with	O	1650-1654
metformin	O	1655-1664
reduces	O	1665-1672
post	O	1673-1677
-	O	1677-1678
myocardial	B	1678-1688
infarction	I	1689-1699
cardiac	O	1700-1707
dysfunction	O	1708-1719
and	O	1720-1723
suppresses	O	1724-1734
inflammatory	O	1735-1747
responses	O	1748-1757
,	O	1757-1758
possibly	O	1759-1767
through	O	1768-1775
inhibition	O	1776-1786
of	O	1787-1789
TLR4	O	1790-1794
activities	O	1795-1805
.	O	1805-1806

This	O	1807-1811
mechanism	O	1812-1821
can	O	1822-1825
be	O	1826-1828
considered	O	1829-1839
as	O	1840-1842
a	O	1843-1844
target	O	1845-1851
to	O	1852-1854
protect	O	1855-1862
infarcted	O	1863-1872
myocardium	O	1873-1883
.	O	1883-1884

Neuroleptic	B	0-11
malignant	I	12-21
syndrome	I	22-30
induced	O	31-38
by	O	39-41
combination	O	42-53
therapy	O	54-61
with	O	62-66
tetrabenazine	O	67-80
and	O	81-84
tiapride	O	85-93
in	O	94-96
a	O	97-98
Japanese	O	99-107
patient	O	108-115
with	O	116-120
Huntington	B	121-131
'	I	131-132
s	I	132-133
disease	I	134-141
at	O	142-144
the	O	145-148
terminal	O	149-157
stage	O	158-163
of	O	164-166
recurrent	O	167-176
breast	B	177-183
cancer	I	184-190
.	O	190-191

We	O	192-194
herein	O	195-201
describe	O	202-210
the	O	211-214
case	O	215-219
of	O	220-222
an	O	223-225
81	O	226-228
-	O	228-229
year	O	229-233
-	O	228-229
old	O	234-237
Japanese	O	238-246
woman	O	247-252
with	O	253-257
neuroleptic	B	258-269
malignant	I	270-279
syndrome	I	280-288
that	O	289-293
occurred	O	294-302
36	O	303-305
days	O	306-310
after	O	311-316
the	O	317-320
initiation	O	321-331
of	O	332-334
combination	O	335-346
therapy	O	347-354
with	O	355-359
tiapride	O	360-368
(	O	369-370
75	O	370-372
mg	O	373-375
/	O	375-376
day	O	376-379
)	O	379-380
and	O	381-384
tetrabenazine	O	385-398
(	O	399-400
12	O	400-402
.	O	402-403
5	O	403-404
mg	O	405-407
/	O	407-408
day	O	408-411
)	O	411-412
for	O	413-416
Huntington	B	417-427
'	I	427-428
s	I	428-429
disease	I	430-437
.	O	437-438

The	O	439-442
patient	O	443-450
had	O	451-454
been	O	455-459
treated	O	460-467
with	O	468-472
tiapride	O	473-481
or	O	482-484
tetrabenazine	O	485-498
alone	O	499-504
without	O	505-512
any	O	513-516
adverse	O	517-524
effects	O	525-532
before	O	533-539
the	O	540-543
administration	O	544-558
of	O	559-561
the	O	562-565
combination	O	566-577
therapy	O	578-585
.	O	585-586

She	O	587-590
also	O	591-595
had	O	596-599
advanced	O	600-608
breast	B	609-615
cancer	I	616-622
when	O	623-627
the	O	628-631
combination	O	632-643
therapy	O	644-651
was	O	652-655
initiated	O	656-665
.	O	665-666

To	O	667-669
the	O	670-673
best	O	674-678
of	O	679-681
our	O	682-685
knowledge	O	686-695
,	O	695-696
the	O	697-700
occurrence	O	701-711
of	O	712-714
neuroleptic	B	715-726
malignant	I	727-736
syndrome	I	737-745
due	O	746-749
to	O	750-752
combination	O	753-764
therapy	O	765-772
with	O	773-777
tetrabenazine	O	778-791
and	O	792-795
tiapride	O	796-804
has	O	805-808
not	O	809-812
been	O	813-817
previously	O	818-828
reported	O	829-837
.	O	837-838

Tetrabenazine	O	839-852
should	O	853-859
be	O	860-862
administered	O	863-875
very	O	876-880
carefully	O	881-890
in	O	891-893
combination	O	894-905
with	O	906-910
other	O	911-916
neuroleptic	O	917-928
drugs	O	929-934
,	O	934-935
particularly	O	936-948
in	O	949-951
patients	O	952-960
with	O	961-965
a	O	966-967
worsening	O	968-977
general	O	978-985
condition	O	986-995
.	O	995-996

A	O	0-1
metoprolol	O	2-12
-	O	12-13
terbinafine	O	13-24
combination	O	25-36
induced	O	37-44
bradycardia	B	45-56
.	O	56-57

To	O	58-60
report	O	61-67
a	O	68-69
sinus	B	70-75
bradycardia	I	76-87
induced	O	88-95
by	O	96-98
metoprolol	O	99-109
and	O	110-113
terbinafine	O	114-125
drug	O	126-130
-	O	130-131
drug	O	126-130
interaction	O	136-147
and	O	148-151
its	O	152-155
management	O	156-166
.	O	166-167

A	O	168-169
63	O	170-172
year	O	173-177
-	O	177-178
old	O	178-181
Caucasian	O	182-191
man	O	192-195
on	O	196-198
metoprolol	O	199-209
200	O	210-213
mg	O	214-216
/	O	216-217
day	O	217-220
for	O	221-224
stable	O	225-231
coronary	B	232-240
artery	I	241-247
disease	I	248-255
was	O	256-259
prescribed	O	260-270
a	O	271-272
90	O	273-275
-	O	275-276
day	O	276-279
course	O	280-286
of	O	287-289
oral	O	290-294
terbinafine	O	295-306
250	O	307-310
mg	O	311-313
/	O	313-314
day	O	314-317
for	O	318-321
onychomycosis	B	322-335
.	O	335-336

On	O	337-339
the	O	340-343
49th	O	344-348
day	O	349-352
of	O	353-355
terbinafine	O	356-367
therapy	O	368-375
,	O	375-376
he	O	377-379
was	O	380-383
brought	O	384-391
to	O	392-394
the	O	395-398
emergency	O	399-408
room	O	409-413
for	O	414-417
a	O	418-419
decrease	O	420-428
of	O	429-431
his	O	432-435
global	O	436-442
health	O	443-449
status	O	450-456
,	O	456-457
confusion	B	458-467
and	O	468-471
falls	O	472-477
.	O	477-478

The	O	479-482
electrocardiogram	O	483-500
revealed	O	501-509
a	O	510-511
37	O	512-514
beats	O	515-520
/	O	520-521
min	O	521-524
sinus	B	525-530
bradycardia	I	531-542
.	O	542-543

A	O	544-545
score	O	546-551
of	O	552-554
7	O	555-556
on	O	557-559
the	O	560-563
Naranjo	O	564-571
adverse	B	572-579
drug	I	580-584
reaction	I	585-593
probability	O	594-605
scale	O	606-611
indicates	O	612-621
a	O	622-623
probable	O	624-632
relationship	O	633-645
between	O	646-653
the	O	654-657
patient	O	658-665
'	O	665-666
s	O	666-667
sinus	B	668-673
bradycardia	I	674-685
and	O	686-689
the	O	690-693
drug	O	694-698
interaction	O	699-710
between	O	711-718
metoprolol	O	719-729
and	O	730-733
terbinafine	O	734-745
.	O	745-746

The	O	747-750
heart	O	751-756
rate	O	757-761
ameliorated	O	762-773
first	O	774-779
with	O	780-784
a	O	785-786
decrease	O	787-795
in	O	796-798
the	O	799-802
dose	O	803-807
of	O	808-810
metoprolol	O	811-821
.	O	821-822

It	O	823-825
was	O	826-829
subsequently	O	830-842
changed	O	843-850
to	O	851-853
bisoprolol	O	854-864
and	O	865-868
the	O	869-872
heart	O	873-878
rate	O	879-883
remained	O	884-892
normal	O	893-899
.	O	899-900

By	O	901-903
inhibiting	O	904-914
the	O	915-918
cytochrome	O	919-929
P450	O	930-934
2D6	O	935-938
,	O	938-939
terbinafine	O	940-951
had	O	952-955
decreased	O	956-965
metoprolol	O	966-976
'	O	976-977
s	O	977-978
clearance	O	979-988
,	O	988-989
leading	O	990-997
in	O	998-1000
metoprolol	O	1001-1011
accumulation	O	1012-1024
which	O	1025-1030
has	O	1031-1034
resulted	O	1035-1043
in	O	1044-1046
clinically	O	1047-1057
significant	O	1058-1069
sinus	B	1070-1075
bradycardia	I	1076-1087
.	O	1087-1088

Optochiasmatic	O	0-14
and	O	15-18
peripheral	B	19-29
neuropathy	I	30-40
due	O	41-44
to	O	45-47
ethambutol	O	48-58
overtreatment	O	59-72
.	O	72-73

Ethambutol	O	74-84
is	O	85-87
known	O	88-93
to	O	94-96
cause	O	97-102
optic	B	103-108
neuropathy	I	109-119
and	O	120-123
,	O	123-124
more	O	125-129
rarely	O	130-136
,	O	136-137
axonal	O	138-144
polyneuropathy	B	145-159
.	O	159-160

We	O	161-163
characterize	O	164-176
the	O	177-180
clinical	O	181-189
,	O	189-190
neurophysiological	O	191-209
,	O	209-210
and	O	211-214
neuroimaging	O	215-227
findings	O	228-236
in	O	237-239
a	O	240-241
72	O	242-244
-	O	244-245
year	O	245-249
-	O	244-245
old	O	250-253
man	O	254-257
who	O	258-261
developed	O	262-271
visual	B	272-278
loss	I	279-283
and	O	284-287
paresthesias	B	288-300
after	O	301-306
11	O	307-309
weeks	O	310-315
of	O	316-318
exposure	O	319-327
to	O	328-330
a	O	331-332
supratherapeutic	O	333-349
dose	O	350-354
of	O	355-357
ethambutol	O	358-368
.	O	368-369

This	O	370-374
case	O	375-379
demonstrates	O	380-392
the	O	393-396
selective	O	397-406
vulnerability	O	407-420
of	O	421-423
the	O	424-427
anterior	O	428-436
visual	O	437-443
pathways	O	444-452
and	O	453-456
peripheral	O	457-467
nerves	O	468-474
to	O	475-477
ethambutol	O	478-488
toxicity	B	489-497
.	O	497-498

Testosterone	O	0-12
ameliorates	O	13-24
streptozotocin	O	25-39
-	O	39-40
induced	O	40-47
memory	B	48-54
impairment	I	55-65
in	O	66-68
male	O	69-73
rats	O	74-78
.	O	78-79

AIM	O	80-83
:	O	83-84
To	O	85-87
study	O	88-93
the	O	94-97
effects	O	98-105
of	O	106-108
testosterone	O	109-121
on	O	122-124
streptozotocin	O	125-139
(	O	140-141
STZ	O	141-144
)	O	144-145
-	O	145-146
induced	O	146-153
memory	B	154-160
impairment	I	161-171
in	O	172-174
male	O	175-179
rats	O	180-184
.	O	184-185

METHODS	O	186-193
:	O	193-194
Adult	O	195-200
male	O	201-205
Wistar	O	206-212
rats	O	213-217
were	O	218-222
intracerebroventricularly	O	223-248
(	O	249-250
icv	O	250-253
)	O	253-254
infused	O	255-262
with	O	263-267
STZ	O	268-271
(	O	272-273
750	O	273-276
ug	O	277-279
)	O	279-280
on	O	281-283
d	O	284-285
1	O	286-287
and	O	288-291
d	O	292-293
3	O	294-295
,	O	295-296
and	O	297-300
a	O	301-302
passive	O	303-310
avoidance	O	311-320
task	O	321-325
was	O	326-329
assessed	O	330-338
2	O	339-340
weeks	O	341-346
after	O	347-352
the	O	353-356
first	O	357-362
injection	O	363-372
of	O	373-375
STZ	O	376-379
.	O	379-380

Castration	O	381-391
surgery	O	392-399
was	O	400-403
performed	O	404-413
in	O	414-416
another	O	417-424
group	O	425-430
of	O	431-433
rats	O	434-438
,	O	438-439
and	O	440-443
the	O	444-447
passive	O	448-455
avoidance	O	456-465
task	O	466-470
was	O	471-474
assessed	O	475-483
4	O	484-485
weeks	O	486-491
after	O	492-497
the	O	498-501
operation	O	502-511
.	O	511-512

Testosterone	O	513-525
(	O	526-527
1	O	527-528
mg	O	529-531
.	O	531-532
kg	O	532-534
(	O	534-535
-	O	535-536
1	O	536-537
)	O	537-538
.	O	531-532
d	O	539-540
(	O	534-535
-	O	535-536
1	O	536-537
)	O	537-538
,	O	544-545

sc	O	546-548
)	O	548-549
,	O	549-550
the	O	551-554
androgen	O	555-563
receptor	O	564-572
antagonist	O	573-583
flutamide	O	584-593
(	O	594-595
10	O	595-597
mg	O	598-600
.	O	600-601
kg	O	601-603
(	O	603-604
-	O	604-605
1	O	605-606
)	O	606-607
.	O	600-601
d	O	608-609
(	O	603-604
-	O	604-605
1	O	605-606
)	O	606-607
,	O	613-614

ip	O	615-617
)	O	617-618
,	O	618-619
the	O	620-623
estrogen	O	624-632
receptor	O	633-641
antagonist	O	642-652
tamoxifen	O	653-662
(	O	663-664
1	O	664-665
mg	O	666-668
.	O	668-669
kg	O	669-671
(	O	671-672
-	O	672-673
1	O	673-674
)	O	674-675
.	O	668-669
d	O	676-677
(	O	671-672
-	O	672-673
1	O	673-674
)	O	674-675
,	O	681-682

ip	O	683-685
)	O	685-686
or	O	687-689
the	O	690-693
aromatase	O	694-703
inhibitor	O	704-713
letrozole	O	714-723
(	O	724-725
4	O	725-726
mg	O	727-729
.	O	729-730
kg	O	730-732
(	O	732-733
-	O	733-734
1	O	734-735
)	O	735-736
.	O	729-730
d	O	737-738
(	O	732-733
-	O	733-734
1	O	734-735
)	O	735-736
,	O	742-743

ip	O	744-746
)	O	746-747
were	O	748-752
administered	O	753-765
for	O	766-769
6	O	770-771
d	O	772-773
after	O	774-779
the	O	780-783
first	O	784-789
injection	O	790-799
of	O	800-802
STZ	O	803-806
.	O	806-807

RESULTS	O	808-815
:	O	815-816
STZ	O	817-820
administration	O	821-835
and	O	836-839
castration	O	840-850
markedly	O	851-859
decreased	O	860-869
both	O	870-874
STL1	O	875-879
(	O	880-881
the	O	881-884
short	O	885-890
memory	O	891-897
)	O	897-898
and	O	899-902
STL2	O	903-907
(	O	908-909
the	O	909-912
long	O	913-917
memory	O	918-924
)	O	924-925
in	O	926-928
passive	O	929-936
avoidance	O	937-946
tests	O	947-952
.	O	952-953

Testosterone	O	954-966
replacement	O	967-978
almost	O	979-985
restored	O	986-994
the	O	995-998
STL1	O	999-1003
and	O	1004-1007
STL2	O	1008-1012
in	O	1013-1015
castrated	O	1016-1025
rats	O	1026-1030
,	O	1030-1031
and	O	1032-1035
significantly	O	1036-1049
prolonged	O	1050-1059
the	O	1060-1063
STL1	O	1064-1068
and	O	1069-1072
STL2	O	1073-1077
in	O	1078-1080
STZ	O	1081-1084
-	O	1084-1085
treated	O	1085-1092
rats	O	1093-1097
.	O	1097-1098

Administration	O	1099-1113
of	O	1114-1116
flutamide	O	1117-1126
,	O	1126-1127
letrozole	O	1128-1137
or	O	1138-1140
tamoxifen	O	1141-1150
significantly	O	1151-1164
impaired	B	1165-1173
the	I	1174-1177
memory	I	1178-1184
in	O	1185-1187
intact	O	1188-1194
rats	O	1195-1199
,	O	1199-1200
and	O	1201-1204
significantly	O	1205-1218
attenuated	O	1219-1229
the	O	1230-1233
testosterone	O	1234-1246
replacement	O	1247-1258
in	O	1259-1261
improving	O	1262-1271
STZ	O	1272-1275
-	O	1275-1276
and	O	1277-1280
castration	O	1281-1291
-	O	1291-1292
induced	O	1292-1299
memory	B	1300-1306
impairment	I	1307-1317
.	O	1317-1318

CONCLUSION	O	1319-1329
:	O	1329-1330
Testosterone	O	1331-1343
administration	O	1344-1358
ameliorates	O	1359-1370
STZ	O	1371-1374
-	O	1374-1375
and	O	1376-1379
castration	O	1380-1390
-	O	1390-1391
induced	O	1391-1398
memory	B	1399-1405
impairment	I	1406-1416
in	O	1417-1419
male	O	1420-1424
Wistar	O	1425-1431
rats	O	1432-1436
.	O	1436-1437

Behavioral	O	0-10
and	O	11-14
neurochemical	O	15-28
studies	O	29-36
in	O	37-39
mice	O	40-44
pretreated	O	45-55
with	O	56-60
garcinielliptone	O	61-77
FC	O	78-80
in	O	81-83
pilocarpine	O	84-95
-	O	95-96
induced	O	96-103
seizures	B	104-112
.	O	112-113

Garcinielliptone	O	114-130
FC	O	131-133
(	O	134-135
GFC	O	135-138
)	O	138-139
isolated	O	140-148
from	O	149-153
hexanic	O	154-161
fraction	O	162-170
seed	O	171-175
extract	O	176-183
of	O	184-186
species	O	187-194
Platonia	O	195-203
insignis	O	204-212
Mart	O	213-217
.	O	217-218

It	O	219-221
is	O	222-224
widely	O	225-231
used	O	232-236
in	O	237-239
folk	O	240-244
medicine	O	245-253
to	O	254-256
treat	O	257-262
skin	B	263-267
diseases	I	268-276
in	O	277-279
both	O	280-284
humans	O	285-291
and	O	292-295
animals	O	296-303
as	O	304-306
well	O	307-311
as	O	312-314
the	O	315-318
seed	O	319-323
decoction	O	324-333
has	O	334-337
been	O	338-342
used	O	343-347
to	O	348-350
treat	O	351-356
diarrheas	B	357-366
and	O	367-370
inflammatory	B	371-383
diseases	I	384-392
.	O	392-393

However	O	394-401
,	O	401-402
there	O	403-408
is	O	409-411
no	O	412-414
research	O	415-423
on	O	424-426
GFC	O	427-430
effects	O	431-438
in	O	439-441
the	O	442-445
central	O	446-453
nervous	O	454-461
system	O	462-468
of	O	469-471
rodents	O	472-479
.	O	479-480

The	O	481-484
present	O	485-492
study	O	493-498
aimed	O	499-504
to	O	505-507
evaluate	O	508-516
the	O	517-520
GFC	O	521-524
effects	O	525-532
at	O	533-535
doses	O	536-541
of	O	542-544
25	O	545-547
,	O	547-548
50	O	549-551
or	O	552-554
75	O	555-557
mg	O	558-560
/	O	560-561
kg	O	561-563
on	O	564-566
seizure	B	567-574
parameters	O	575-585
to	O	586-588
determine	O	589-598
their	O	599-604
anticonvulsant	O	605-619
activity	O	620-628
and	O	629-632
its	O	633-636
effects	O	637-644
on	O	645-647
amino	O	648-653
acid	O	654-658
(	O	659-660
r	O	660-661
-	O	661-662
aminobutyric	O	662-674
acid	O	675-679
(	O	680-681
GABA	O	681-685
)	O	685-686
,	O	686-687
glutamine	O	688-697
,	O	697-698
aspartate	O	699-708
and	O	709-712
glutathione	O	713-724
)	O	724-725
levels	O	726-732
as	O	733-735
well	O	736-740
as	O	741-743
on	O	744-746
acetylcholinesterase	O	747-767
(	O	768-769
AChE	O	769-773
)	O	773-774
activity	O	775-783
in	O	784-786
mice	O	787-791
hippocampus	O	792-803
after	O	804-809
seizures	B	810-818
.	O	818-819

GFC	O	820-823
produced	O	824-832
an	O	833-835
increased	O	836-845
latency	O	846-853
to	O	854-856
first	O	857-862
seizure	B	863-870
,	O	870-871
at	O	872-874
doses	O	875-880
25mg	O	881-885
/	O	885-886
kg	O	886-888
(	O	889-890
20	O	890-892
.	O	892-893
12	O	893-895
+	O	896-897
2	O	898-899
.	O	899-900
20	O	900-902
min	O	903-906
)	O	906-907
,	O	907-908
50mg	O	909-913
/	O	913-914
kg	O	914-916
(	O	917-918
20	O	918-920
.	O	920-921
95	O	921-923
+	O	924-925
2	O	926-927
.	O	927-928
21	O	928-930
min	O	931-934
)	O	934-935
or	O	936-938
75	O	939-941
mg	O	942-944
/	O	944-945
kg	O	945-947
(	O	948-949
23	O	949-951
.	O	951-952
43	O	952-954
+	O	955-956
1	O	957-958
.	O	958-959
99	O	959-961
min	O	962-965
)	O	965-966
when	O	967-971
compared	O	972-980
with	O	981-985
seized	O	986-992
mice	O	993-997
.	O	997-998

In	O	999-1001
addition	O	1002-1010
,	O	1010-1011
GABA	O	1012-1016
content	O	1017-1024
of	O	1025-1027
mice	O	1028-1032
hippocampus	O	1033-1044
treated	O	1045-1052
with	O	1053-1057
GFC75	O	1058-1063
plus	O	1064-1068
P400	O	1069-1073
showed	O	1074-1080
an	O	1081-1083
increase	O	1084-1092
of	O	1093-1095
46	O	1096-1098
.	O	1098-1099
90	O	1099-1101
%	O	1101-1102
when	O	1103-1107
compared	O	1108-1116
with	O	1117-1121
seized	O	1122-1128
mice	O	1129-1133
.	O	1133-1134

In	O	1135-1137
aspartate	O	1138-1147
,	O	1147-1148
glutamine	O	1149-1158
and	O	1159-1162
glutamate	O	1163-1172
levels	O	1173-1179
detected	O	1180-1188
a	O	1189-1190
decrease	O	1191-1199
of	O	1200-1202
5	O	1203-1204
.	O	1204-1205
21	O	1205-1207
%	O	1207-1208
,	O	1208-1209
13	O	1210-1212
.	O	1212-1213
55	O	1213-1215
%	O	1215-1216
and	O	1217-1220
21	O	1221-1223
.	O	1223-1224
80	O	1224-1226
%	O	1226-1227
,	O	1227-1228
respectively	O	1229-1241
in	O	1242-1244
mice	O	1245-1249
hippocampus	O	1250-1261
treated	O	1262-1269
with	O	1270-1274
GFC75	O	1275-1280
plus	O	1281-1285
P400	O	1286-1290
when	O	1291-1295
compared	O	1296-1304
with	O	1305-1309
seized	O	1310-1316
mice	O	1317-1321
.	O	1321-1322

Hippocampus	O	1323-1334
mice	O	1335-1339
treated	O	1340-1347
with	O	1348-1352
GFC75	O	1353-1358
plus	O	1359-1363
P400	O	1364-1368
showed	O	1369-1375
an	O	1376-1378
increase	O	1379-1387
in	O	1388-1390
AChE	O	1391-1395
activity	O	1396-1404
(	O	1405-1406
63	O	1406-1408
.	O	1408-1409
30	O	1409-1411
%	O	1411-1412
)	O	1412-1413
when	O	1414-1418
compared	O	1419-1427
with	O	1428-1432
seized	O	1433-1439
mice	O	1440-1444
.	O	1444-1445

The	O	1446-1449
results	O	1450-1457
indicate	O	1458-1466
that	O	1467-1471
GFC	O	1472-1475
can	O	1476-1479
exert	O	1480-1485
anticonvulsant	O	1486-1500
activity	O	1501-1509
and	O	1510-1513
reduce	O	1514-1520
the	O	1521-1524
frequency	O	1525-1534
of	O	1535-1537
installation	O	1538-1550
of	O	1551-1553
pilocarpine	O	1554-1565
-	O	1565-1566
induced	O	1566-1573
status	B	1574-1580
epilepticus	I	1581-1592
,	O	1592-1593
as	O	1594-1596
demonstrated	O	1597-1609
by	O	1610-1612
increase	O	1613-1621
in	O	1622-1624
latency	O	1625-1632
to	O	1633-1635
first	O	1636-1641
seizure	B	1642-1649
and	O	1650-1653
decrease	O	1654-1662
in	O	1663-1665
mortality	O	1666-1675
rate	O	1676-1680
of	O	1681-1683
animals	O	1684-1691
.	O	1691-1692

In	O	1693-1695
conclusion	O	1696-1706
,	O	1706-1707
our	O	1708-1711
data	O	1712-1716
suggest	O	1717-1724
that	O	1725-1729
GFC	O	1730-1733
may	O	1734-1737
influence	O	1738-1747
in	O	1748-1750
epileptogenesis	O	1751-1766
and	O	1767-1770
promote	O	1771-1778
anticonvulsant	O	1779-1793
actions	O	1794-1801
in	O	1802-1804
pilocarpine	O	1805-1816
model	O	1817-1822
by	O	1823-1825
modulating	O	1826-1836
the	O	1837-1840
GABA	O	1841-1845
and	O	1846-1849
glutamate	O	1850-1859
contents	O	1860-1868
and	O	1869-1872
of	O	1873-1875
AChE	O	1876-1880
activity	O	1881-1889
in	O	1890-1892
seized	O	1893-1899
mice	O	1900-1904
hippocampus	O	1905-1916
.	O	1916-1917

This	O	1918-1922
compound	O	1923-1931
may	O	1932-1935
be	O	1936-1938
useful	O	1939-1945
to	O	1946-1948
produce	O	1949-1956
neuronal	O	1957-1965
protection	O	1966-1976
and	O	1977-1980
it	O	1981-1983
can	O	1984-1987
be	O	1988-1990
considered	O	1991-2001
as	O	2002-2004
an	O	2005-2007
anticonvulsant	O	2008-2022
agent	O	2023-2028
.	O	2028-2029

Standard	O	0-8
operating	O	9-18
procedures	O	19-29
for	O	30-33
antibiotic	O	34-44
therapy	O	45-52
and	O	53-56
the	O	57-60
occurrence	O	61-71
of	O	72-74
acute	B	75-80
kidney	I	81-87
injury	I	88-94
:	O	94-95
a	O	96-97
prospective	O	98-109
,	O	109-110
clinical	O	111-119
,	O	119-120
non	O	121-124
-	O	124-125
interventional	O	125-139
,	O	139-140
observational	O	141-154
study	O	155-160
.	O	160-161

INTRODUCTION	O	162-174
:	O	174-175
Acute	B	176-181
kidney	I	182-188
injury	I	189-195
(	O	196-197
AKI	B	197-200
)	O	200-201
occurs	O	202-208
in	O	209-211
7	O	212-213
%	O	213-214
of	O	215-217
hospitalized	O	218-230
and	O	231-234
66	O	235-237
%	O	237-238
of	O	239-241
Intensive	O	242-251
Care	O	252-256
Unit	O	257-261
(	O	262-263
ICU	O	263-266
)	O	266-267
patients	O	268-276
.	O	276-277

It	O	278-280
increases	O	281-290
mortality	O	291-300
,	O	300-301
hospital	O	302-310
length	O	311-317
of	O	318-320
stay	O	321-325
,	O	325-326
and	O	327-330
costs	O	331-336
.	O	336-337

The	O	338-341
aim	O	342-345
of	O	346-348
this	O	349-353
study	O	354-359
was	O	360-363
to	O	364-366
investigate	O	367-378
,	O	378-379
whether	O	380-387
there	O	388-393
is	O	394-396
an	O	397-399
association	O	400-411
between	O	412-419
adherence	O	420-429
to	O	430-432
guidelines	O	433-443
(	O	444-445
standard	O	445-453
operating	O	454-463
procedures	O	464-474
(	O	475-476
SOP	O	476-479
)	O	479-480
)	O	479-480
for	O	482-485
potentially	O	486-497
nephrotoxic	B	498-509
antibiotics	O	510-521
and	O	522-525
the	O	526-529
occurrence	O	530-540
of	O	541-543
AKI	B	544-547
.	O	547-548

METHODS	O	549-556
:	O	556-557
This	O	558-562
study	O	563-568
was	O	569-572
carried	O	573-580
out	O	581-584
as	O	585-587
a	O	588-589
prospective	O	590-601
,	O	601-602
clinical	O	603-611
,	O	611-612
non	O	613-616
-	O	616-617
interventional	O	617-631
,	O	631-632
observational	O	633-646
study	O	647-652
.	O	652-653

Data	O	654-658
collection	O	659-669
was	O	670-673
performed	O	674-683
over	O	684-688
a	O	689-690
total	O	691-696
of	O	697-699
170	O	700-703
days	O	704-708
in	O	709-711
three	O	712-717
ICUs	O	718-722
at	O	723-725
Charite	O	726-733
-	O	734-735
Universitaetsmedizin	O	736-756
Berlin	O	757-763
.	O	763-764

A	O	765-766
total	O	767-772
of	O	773-775
675	O	776-779
patients	O	780-788
were	O	789-793
included	O	794-802
;	O	802-803
163	O	804-807
of	O	808-810
these	O	811-816
had	O	817-820
therapy	O	821-828
with	O	829-833
vancomycin	O	834-844
,	O	844-845
gentamicin	O	846-856
,	O	856-857
or	O	858-860
tobramycin	O	861-871
;	O	871-872
were	O	873-877
>	O	878-879
18	O	879-881
years	O	882-887
;	O	887-888
and	O	889-892
treated	O	893-900
in	O	901-903
the	O	904-907
ICU	O	908-911
for	O	912-915
>	O	916-917
24	O	917-919
hours	O	920-925
.	O	925-926

Patients	O	927-935
with	O	936-940
an	O	941-943
adherence	O	944-953
to	O	954-956
SOP	O	957-960
>	O	961-962
70	O	962-964
%	O	964-965
were	O	966-970
classified	O	971-981
into	O	982-986
the	O	987-990
high	O	991-995
adherence	O	996-1005
group	O	1006-1011
(	O	1012-1013
HAG	O	1013-1016
)	O	1016-1017
and	O	1018-1021
patients	O	1022-1030
with	O	1031-1035
an	O	1036-1038
adherence	O	1039-1048
of	O	1049-1051
<	O	1052-1053
70	O	1053-1055
%	O	1055-1056
into	O	1057-1061
the	O	1062-1065
low	O	1066-1069
adherence	O	1070-1079
group	O	1080-1085
(	O	1086-1087
LAG	O	1087-1090
)	O	1090-1091
.	O	1091-1092

AKI	B	1093-1096
was	O	1097-1100
defined	O	1101-1108
according	O	1109-1118
to	O	1119-1121
RIFLE	O	1122-1127
criteria	O	1128-1136
.	O	1136-1137

Adherence	O	1138-1147
to	O	1148-1150
SOPs	O	1151-1155
was	O	1156-1159
evaluated	O	1160-1169
by	O	1170-1172
retrospective	O	1173-1186
expert	O	1187-1193
audit	O	1194-1199
.	O	1199-1200

Development	O	1201-1212
of	O	1213-1215
AKI	B	1216-1219
was	O	1220-1223
compared	O	1224-1232
between	O	1233-1240
groups	O	1241-1247
with	O	1248-1252
exact	O	1253-1258
Chi2	O	1259-1263
-	O	1263-1264
test	O	1264-1268
and	O	1269-1272
multivariate	O	1273-1285
logistic	O	1286-1294
regression	O	1295-1305
analysis	O	1306-1314
(	O	1315-1316
two	O	1316-1319
-	O	1319-1320
sided	O	1320-1325
P	O	1326-1327
<	O	1328-1329
0	O	1329-1330
.	O	1330-1331
05	O	1331-1333
)	O	1333-1334
.	O	1330-1331

RESULTS	O	1336-1343
:	O	1343-1344
LAG	O	1345-1348
consisted	O	1349-1358
of	O	1359-1361
75	O	1362-1364
patients	O	1365-1373
(	O	1374-1375
46	O	1375-1377
%	O	1377-1378
)	O	1378-1379
versus	O	1380-1386
88	O	1387-1389
HAG	O	1390-1393
patients	O	1394-1402
(	O	1403-1404
54	O	1404-1406
%	O	1406-1407
)	O	1407-1408
.	O	1408-1409

AKI	B	1410-1413
occurred	O	1414-1422
significantly	O	1423-1436
more	O	1437-1441
often	O	1442-1447
in	O	1448-1450
LAG	O	1451-1454
with	O	1455-1459
36	O	1460-1462
%	O	1462-1463
versus	O	1464-1470
21	O	1471-1473
%	O	1473-1474
in	O	1475-1477
HAG	O	1478-1481
(	O	1482-1483
P	O	1483-1484
=	O	1485-1486
0	O	1487-1488
.	O	1488-1489
035	O	1489-1492
)	O	1492-1493
.	O	1488-1489

Basic	O	1495-1500
characteristics	O	1501-1516
were	O	1517-1521
comparable	O	1522-1532
,	O	1532-1533
except	O	1534-1540
an	O	1541-1543
increased	O	1544-1553
rate	O	1554-1558
of	O	1559-1561
soft	O	1562-1566
tissue	O	1567-1573
infections	B	1574-1584
in	O	1585-1587
LAG	O	1588-1591
.	O	1591-1592

Multivariate	O	1593-1605
analysis	O	1606-1614
revealed	O	1615-1623
an	O	1624-1626
odds	O	1627-1631
ratio	O	1632-1637
of	O	1638-1640
2	O	1641-1642
.	O	1642-1643
5	O	1643-1644
-	O	1644-1645
fold	O	1645-1649
for	O	1650-1653
LAG	O	1654-1657
to	O	1658-1660
develop	O	1661-1668
AKI	B	1669-1672
compared	O	1673-1681
with	O	1682-1686
HAG	O	1687-1690
(	O	1691-1692
95	O	1692-1694
%	O	1694-1695
confidence	O	1696-1706
interval	O	1707-1715
1	O	1716-1717
.	O	1717-1718
195	O	1718-1721
to	O	1722-1724
5	O	1725-1726
.	O	1726-1727
124	O	1727-1730
,	O	1730-1731
P	O	1732-1733
=	O	1734-1735
0	O	1736-1737
.	O	1737-1738
039	O	1738-1741
)	O	1741-1742
.	O	1737-1738

CONCLUSION	O	1744-1754
:	O	1754-1755
Low	O	1756-1759
adherence	O	1760-1769
to	O	1770-1772
SOPs	O	1773-1777
for	O	1778-1781
potentially	O	1782-1793
nephrotoxic	B	1794-1805
antibiotics	O	1806-1817
was	O	1818-1821
associated	O	1822-1832
with	O	1833-1837
a	O	1838-1839
higher	O	1840-1846
occurrence	O	1847-1857
of	O	1858-1860
AKI	B	1861-1864
.	O	1864-1865

TRIAL	O	1866-1871
REGISTRATION	O	1872-1884
:	O	1884-1885
Current	O	1886-1893
Controlled	O	1894-1904
Trials	O	1905-1911
ISRCTN54598675	O	1912-1926
.	O	1926-1927

Registered	O	1928-1938
17	O	1939-1941
August	O	1942-1948
2007	O	1949-1953
.	O	1953-1954

Rhabdomyolysis	B	0-14
in	O	15-17
a	O	18-19
hepatitis	B	20-29
C	I	30-31
virus	I	32-37
infected	I	38-46
patient	O	47-54
treated	O	55-62
with	O	63-67
telaprevir	O	68-78
and	O	79-82
simvastatin	O	83-94
.	O	94-95

A	O	96-97
46	O	98-100
-	O	100-101
year	O	101-105
old	O	106-109
man	O	110-113
with	O	114-118
a	O	119-120
chronic	O	121-128
hepatitis	B	129-138
C	I	139-140
virus	I	141-146
infection	I	147-156
received	O	157-165
triple	O	166-172
therapy	O	173-180
with	O	181-185
ribavirin	O	186-195
,	O	195-196
pegylated	O	197-206
interferon	O	207-217
and	O	218-221
telaprevir	O	222-232
.	O	232-233

The	O	234-237
patient	O	238-245
also	O	246-250
received	O	251-259
simvastatin	O	260-271
.	O	271-272

One	O	273-276
month	O	277-282
after	O	283-288
starting	O	289-297
the	O	298-301
antiviral	O	302-311
therapy	O	312-319
,	O	319-320
the	O	321-324
patient	O	325-332
was	O	333-336
admitted	O	337-345
to	O	346-348
the	O	349-352
hospital	O	353-361
because	O	362-369
he	O	370-372
developed	O	373-382
rhabdomyolysis	B	383-397
.	O	397-398

At	O	399-401
admission	O	402-411
simvastatin	O	412-423
and	O	424-427
all	O	428-431
antiviral	O	432-441
drugs	O	442-447
were	O	448-452
discontinued	O	453-465
because	O	466-473
toxicity	B	474-482
due	O	483-486
to	O	487-489
a	O	490-491
drug	O	492-496
-	O	496-497
drug	O	492-496
interaction	O	502-513
was	O	514-517
suspected	O	518-527
.	O	527-528

The	O	529-532
creatine	O	533-541
kinase	O	542-548
peaked	O	549-555
at	O	556-558
62	O	559-561
,	O	561-562
246	O	562-565
IU	O	566-568
/	O	568-569
L	O	569-570
and	O	571-574
the	O	575-578
patient	O	579-586
was	O	587-590
treated	O	591-598
with	O	599-603
intravenous	O	604-615
normal	O	616-622
saline	O	623-629
.	O	629-630

The	O	631-634
patient	O	635-642
'	O	642-643
s	O	643-644
renal	O	645-650
function	O	651-659
remained	O	660-668
unaffected	O	669-679
.	O	679-680

Fourteen	O	681-689
days	O	690-694
after	O	695-700
hospitalization	O	701-716
,	O	716-717
creatine	O	718-726
kinase	O	727-733
level	O	734-739
had	O	740-743
returned	O	744-752
to	O	753-755
230	O	756-759
IU	O	760-762
/	O	762-763
L	O	763-764
and	O	765-768
the	O	769-772
patient	O	773-780
was	O	781-784
discharged	O	785-795
.	O	795-796

Telaprevir	O	797-807
was	O	808-811
considered	O	812-822
the	O	823-826
probable	O	827-835
causative	O	836-845
agent	O	846-851
of	O	852-854
an	O	855-857
interaction	O	858-869
with	O	870-874
simvastatin	O	875-886
according	O	887-896
to	O	897-899
the	O	900-903
Drug	O	904-908
Interaction	O	909-920
Probability	O	921-932
Scale	O	933-938
.	O	938-939

The	O	940-943
interaction	O	944-955
is	O	956-958
due	O	959-962
to	O	963-965
inhibition	O	966-976
of	O	977-979
CYP3A4	O	980-986
-	O	986-987
mediated	O	987-995
simvastatin	O	996-1007
clearance	O	1008-1017
.	O	1017-1018

Simvastatin	O	1019-1030
plasma	O	1031-1037
concentration	O	1038-1051
increased	O	1052-1061
30	O	1062-1064
times	O	1065-1070
in	O	1071-1073
this	O	1074-1078
patient	O	1079-1086
and	O	1087-1090
statin	O	1091-1097
induced	O	1098-1105
muscle	B	1106-1112
toxicity	I	1113-1121
is	O	1122-1124
related	O	1125-1132
to	O	1133-1135
the	O	1136-1139
concentration	O	1140-1153
of	O	1154-1156
the	O	1157-1160
statin	O	1161-1167
in	O	1168-1170
blood	O	1171-1176
.	O	1176-1177

In	O	1178-1180
conclusion	O	1181-1191
,	O	1191-1192
with	O	1193-1197
this	O	1198-1202
case	O	1203-1207
we	O	1208-1210
illustrate	O	1211-1221
that	O	1222-1226
telaprevir	O	1227-1237
as	O	1238-1240
well	O	1241-1245
as	O	1246-1248
statins	O	1249-1256
are	O	1257-1260
susceptible	O	1261-1272
to	O	1273-1275
clinical	O	1276-1284
relevant	O	1285-1293
drug	O	1294-1298
-	O	1298-1299
drug	O	1294-1298
interactions	O	1304-1316
.	O	1316-1317

Combination	O	0-11
of	O	12-14
bortezomib	O	15-25
,	O	25-26
thalidomide	O	27-38
,	O	38-39
and	O	40-43
dexamethasone	O	44-57
(	O	58-59
VTD	O	59-62
)	O	62-63
as	O	64-66
a	O	67-68
consolidation	O	69-82
therapy	O	83-90
after	O	91-96
autologous	O	97-107
stem	O	108-112
cell	O	113-117
transplantation	O	118-133
for	O	134-137
symptomatic	O	138-149
multiple	B	150-158
myeloma	I	159-166
in	O	167-169
Japanese	O	170-178
patients	O	179-187
.	O	187-188

Consolidation	O	189-202
therapy	O	203-210
for	O	211-214
patients	O	215-223
with	O	224-228
multiple	B	229-237
myeloma	I	238-245
(	O	246-247
MM	B	247-249
)	O	249-250
has	O	251-254
been	O	255-259
widely	O	260-266
adopted	O	267-274
to	O	275-277
improve	O	278-285
treatment	O	286-295
response	O	296-304
following	O	305-314
autologous	O	315-325
stem	O	326-330
cell	O	331-335
transplantation	O	336-351
.	O	351-352

In	O	353-355
this	O	356-360
study	O	361-366
,	O	366-367
we	O	368-370
retrospectively	O	371-386
analyzed	O	387-395
the	O	396-399
safety	O	400-406
and	O	407-410
efficacy	O	411-419
of	O	420-422
combination	O	423-434
regimen	O	435-442
of	O	443-445
bortezomib	O	446-456
,	O	456-457
thalidomide	O	458-469
,	O	469-470
and	O	471-474
dexamethasone	O	475-488
(	O	489-490
VTD	O	490-493
)	O	493-494
as	O	495-497
consolidation	O	498-511
therapy	O	512-519
in	O	520-522
24	O	523-525
Japanese	O	526-534
patients	O	535-543
with	O	544-548
newly	O	549-554
diagnosed	O	555-564
MM	B	565-567
.	O	567-568

VTD	O	569-572
consisted	O	573-582
of	O	583-585
bortezomib	O	586-596
at	O	597-599
a	O	600-601
dose	O	602-606
of	O	607-609
1	O	610-611
.	O	611-612
3	O	612-613
mg	O	614-616
/	O	616-617
m	O	614-615
(	O	618-619
2	O	619-620
)	O	620-621
and	O	622-625
dexamethasone	O	626-639
at	O	640-642
a	O	643-644
dose	O	645-649
of	O	650-652
40	O	653-655
mg	O	656-658
/	O	658-659
day	O	659-662
on	O	663-665
days	O	666-670
1	O	671-672
,	O	672-673
8	O	674-675
,	O	675-676
15	O	677-679
,	O	679-680
and	O	681-684
22	O	685-687
of	O	688-690
a	O	691-692
35	O	693-695
-	O	695-696
day	O	696-699
cycle	O	700-705
,	O	705-706
with	O	707-711
daily	O	712-717
oral	O	718-722
thalidomide	O	723-734
at	O	735-737
a	O	738-739
dose	O	740-744
of	O	745-747
100	O	748-751
mg	O	752-754
/	O	754-755
day	O	755-758
.	O	758-759

Grade	O	760-765
3	O	766-767
-	O	767-768
4	O	768-769
neutropenia	B	770-781
and	O	782-785
thrombocytopenia	B	786-802
were	O	803-807
documented	O	808-818
in	O	819-821
four	O	822-826
and	O	827-830
three	O	831-836
patients	O	837-845
(	O	846-847
17	O	847-849
and	O	850-853
13	O	854-856
%	O	857-858
)	O	858-859
,	O	859-860
respectively	O	861-873
,	O	873-874
but	O	875-878
drug	O	879-883
dose	O	884-888
reduction	O	889-898
due	O	899-902
to	O	903-905
cytopenia	B	906-915
was	O	916-919
not	O	920-923
required	O	924-932
in	O	933-935
any	O	936-939
case	O	940-944
.	O	944-945

Peripheral	B	946-956
neuropathy	I	957-967
was	O	968-971
common	O	972-978
(	O	979-980
63	O	980-982
%	O	983-984
)	O	984-985
,	O	985-986
but	O	987-990
severe	O	991-997
grade	O	998-1003
3	O	1004-1005
-	O	1005-1006
4	O	1006-1007
peripheral	B	1008-1018
neuropathy	I	1019-1029
was	O	1030-1033
not	O	1034-1037
observed	O	1038-1046
.	O	1046-1047

Very	O	1048-1052
good	O	1053-1057
partial	O	1058-1065
response	O	1066-1074
or	O	1075-1077
better	O	1078-1084
response	O	1085-1093
(	O	1094-1095
>	O	1095-1096
VGPR	O	1096-1100
)	O	1100-1101
rates	O	1102-1107
before	O	1108-1114
and	O	1115-1118
after	O	1119-1124
consolidation	O	1125-1138
therapy	O	1139-1146
were	O	1147-1151
54	O	1152-1154
and	O	1155-1158
79	O	1159-1161
%	O	1162-1163
,	O	1163-1164
respectively	O	1165-1177
.	O	1177-1178

Patients	O	1179-1187
had	O	1188-1191
a	O	1192-1193
significant	O	1194-1205
probability	O	1206-1217
of	O	1218-1220
improving	O	1221-1230
from	O	1231-1235
<	O	1236-1237
VGPR	O	1237-1241
before	O	1242-1248
consolidation	O	1249-1262
therapy	O	1263-1270
to	O	1271-1273
>	O	1274-1275
VGPR	O	1275-1279
after	O	1280-1285
consolidation	O	1286-1299
therapy	O	1300-1307
(	O	1308-1309
p	O	1309-1310
=	O	1311-1312
0	O	1313-1314
.	O	1314-1315
041	O	1315-1318
)	O	1318-1319
.	O	1314-1315

The	O	1321-1324
VTD	O	1325-1328
regimen	O	1329-1336
may	O	1337-1340
be	O	1341-1343
safe	O	1344-1348
and	O	1349-1352
effective	O	1353-1362
as	O	1363-1365
a	O	1366-1367
consolidation	O	1368-1381
therapy	O	1382-1389
in	O	1390-1392
the	O	1393-1396
treatment	O	1397-1406
of	O	1407-1409
MM	O	1410-1412
in	O	1413-1415
Japanese	O	1416-1424
population	O	1425-1435
.	O	1435-1436

Conversion	O	0-10
to	O	11-13
sirolimus	O	14-23
ameliorates	O	24-35
cyclosporine	O	36-48
-	O	48-49
induced	O	49-56
nephropathy	B	57-68
in	O	69-71
the	O	72-75
rat	O	76-79
:	O	79-80
focus	O	81-86
on	O	87-89
serum	O	90-95
,	O	95-96
urine	O	97-102
,	O	102-103
gene	O	104-108
,	O	108-109
and	O	110-113
protein	O	114-121
renal	O	122-127
expression	O	128-138
biomarkers	O	139-149
.	O	149-150

Protocols	O	151-160
of	O	161-163
conversion	O	164-174
from	O	175-179
cyclosporin	O	180-191
A	O	192-193
(	O	194-195
CsA	O	195-198
)	O	198-199
to	O	200-202
sirolimus	O	203-212
(	O	213-214
SRL	O	214-217
)	O	217-218
have	O	219-223
been	O	224-228
widely	O	229-235
used	O	236-240
in	O	241-243
immunotherapy	O	244-257
after	O	258-263
transplantation	O	264-279
to	O	280-282
prevent	O	283-290
CsA	O	291-294
-	O	294-295
induced	O	295-302
nephropathy	B	303-314
,	O	314-315
but	O	316-319
the	O	320-323
molecular	O	324-333
mechanisms	O	334-344
underlying	O	345-355
these	O	356-361
protocols	O	362-371
remain	O	372-378
nuclear	O	379-386
.	O	386-387

This	O	388-392
study	O	393-398
aimed	O	399-404
to	O	405-407
identify	O	408-416
the	O	417-420
molecular	O	421-430
pathways	O	431-439
and	O	440-443
putative	O	444-452
biomarkers	O	453-463
of	O	464-466
CsA	O	467-470
-	O	470-471
to	O	471-473
-	O	470-471
SRL	O	474-477
conversion	O	478-488
in	O	489-491
a	O	492-493
rat	O	494-497
model	O	498-503
.	O	503-504

Four	O	505-509
animal	O	510-516
groups	O	517-523
(	O	524-525
n	O	525-526
=	O	527-528
6	O	529-530
)	O	530-531
were	O	532-536
tested	O	537-543
during	O	544-550
9	O	551-552
weeks	O	553-558
:	O	558-559
control	O	560-567
,	O	567-568
CsA	O	569-572
,	O	572-573
SRL	O	574-577
,	O	577-578
and	O	579-582
conversion	O	583-593
(	O	594-595
CsA	O	595-598
for	O	599-602
3	O	603-604
weeks	O	605-610
followed	O	611-619
by	O	620-622
SRL	O	623-626
for	O	627-630
6	O	631-632
weeks	O	633-638
)	O	638-639
.	O	639-640

Classical	O	641-650
and	O	651-654
emergent	O	655-663
serum	O	664-669
,	O	669-670
urinary	O	671-678
,	O	678-679
and	O	680-683
kidney	O	684-690
tissue	O	691-697
(	O	698-699
gene	O	699-703
and	O	704-707
protein	O	708-715
expression	O	716-726
)	O	726-727
markers	O	728-735
were	O	736-740
assessed	O	741-749
.	O	749-750

Renal	B	751-756
lesions	I	757-764
were	O	765-769
analyzed	O	770-778
in	O	779-781
hematoxylin	O	782-793
and	O	794-797
eosin	O	798-803
,	O	803-804
periodic	O	805-813
acid	O	814-818
-	O	818-819
Schiff	O	819-825
,	O	825-826
and	O	827-830
Masson	O	831-837
'	O	837-838
s	O	833-834
trichrome	O	840-849
stains	O	850-856
.	O	856-857

SRL	O	858-861
-	O	861-862
treated	O	862-869
rats	O	870-874
presented	O	875-884
proteinuria	B	885-896
and	O	897-900
NGAL	O	901-905
(	O	906-907
serum	O	907-912
and	O	913-916
urinary	O	917-924
)	O	924-925
as	O	926-928
the	O	929-932
best	O	933-937
markers	O	938-945
of	O	946-948
renal	B	949-954
impairment	I	955-965
.	O	965-966

Short	O	967-972
CsA	O	973-976
treatment	O	977-986
presented	O	987-996
slight	O	997-1003
or	O	1004-1006
even	O	1007-1011
absent	O	1012-1018
kidney	B	1019-1025
lesions	I	1026-1033
and	O	1034-1037
TGF	O	1038-1041
-	O	1041-1042
b	O	1042-1043
,	O	1043-1044
NF	O	1045-1047
-	O	1047-1048
kb	O	1049-1051
,	O	1051-1052
mTOR	O	1053-1057
,	O	1057-1058
PCNA	O	1059-1063
,	O	1063-1064
TP53	O	1065-1069
,	O	1069-1070
KIM	O	1071-1074
-	O	1074-1075
1	O	1075-1076
,	O	1076-1077
and	O	1078-1081
CTGF	O	1082-1086
as	O	1087-1089
relevant	O	1090-1098
gene	O	1099-1103
and	O	1104-1107
protein	O	1108-1115
changes	O	1116-1123
.	O	1123-1124

Prolonged	O	1125-1134
CsA	O	1135-1138
exposure	O	1139-1147
aggravated	O	1148-1158
renal	B	1159-1164
damage	I	1165-1171
,	O	1171-1172
without	O	1173-1180
clear	O	1181-1186
changes	O	1187-1194
on	O	1195-1197
the	O	1198-1201
traditional	O	1202-1213
markers	O	1214-1221
,	O	1221-1222
but	O	1223-1226
with	O	1227-1231
changes	O	1232-1239
in	O	1240-1242
serums	O	1243-1249
TGF	O	1250-1253
-	O	1253-1254
b	O	1255-1256
and	O	1257-1260
IL	O	1261-1263
-	O	1263-1264
7	O	1264-1265
,	O	1265-1266
TBARs	O	1267-1272
clearance	O	1273-1282
,	O	1282-1283
and	O	1284-1287
kidney	O	1288-1294
TGF	O	1295-1298
-	O	1298-1299
b	O	1299-1300
and	O	1301-1304
mTOR	O	1305-1309
.	O	1309-1310

Conversion	O	1311-1321
to	O	1322-1324
SRL	O	1325-1328
prevented	O	1329-1338
CsA	O	1339-1342
-	O	1342-1343
induced	O	1343-1350
renal	B	1351-1356
damage	I	1357-1363
evolution	O	1364-1373
(	O	1374-1375
absent	O	1375-1381
/	O	1381-1382
mild	O	1382-1386
grade	O	1387-1392
lesions	O	1393-1400
)	O	1400-1401
,	O	1401-1402
while	O	1403-1408
NGAL	O	1409-1413
(	O	1414-1415
serum	O	1415-1420
versus	O	1421-1427
urine	O	1428-1433
)	O	1433-1434
seems	O	1435-1440
to	O	1441-1443
be	O	1444-1446
a	O	1447-1448
feasible	O	1449-1457
biomarker	O	1458-1467
of	O	1468-1470
CsA	O	1471-1474
replacement	O	1475-1486
to	O	1487-1489
SRL	O	1490-1493
.	O	1493-1494

Kinin	O	0-5
B2	O	6-8
receptor	O	9-17
deletion	O	18-26
and	O	27-30
blockage	O	31-39
ameliorates	O	40-51
cisplatin	O	52-61
-	O	61-62
induced	O	62-69
acute	B	70-75
renal	I	76-81
injury	I	82-88
.	O	88-89

Cisplatin	O	90-99
treatment	O	100-109
has	O	110-113
been	O	114-118
adopted	O	119-126
in	O	127-129
some	O	130-134
chemotherapies	O	135-149
;	O	149-150
however	O	151-158
,	O	158-159
this	O	160-164
drug	O	165-169
can	O	170-173
induce	O	174-180
acute	B	181-186
kidney	I	187-193
injury	I	194-200
due	O	201-204
its	O	205-208
ability	O	209-216
to	O	217-219
negatively	O	220-230
affect	O	231-237
renal	O	238-243
function	O	244-252
,	O	252-253
augment	O	254-261
serum	O	262-267
levels	O	268-274
of	O	275-277
creatinine	O	278-288
and	O	289-292
urea	O	293-297
,	O	297-298
increase	O	299-307
the	O	308-311
acute	B	312-317
tubular	I	318-325
necrosis	I	326-334
score	O	335-340
and	O	341-344
up	O	345-347
-	O	347-348
regulate	O	348-356
cytokines	O	357-366
(	O	367-368
e	O	368-369
.	O	369-370
g	O	370-371
.	O	369-370
,	O	372-373
IL	O	374-376
-	O	376-377
1b	O	377-379
and	O	380-383
TNF	O	384-387
-	O	387-388
a	O	388-389
)	O	389-390
.	O	390-391

The	O	392-395
kinin	O	396-401
B2	O	402-404
receptor	O	405-413
has	O	414-417
been	O	418-422
associated	O	423-433
with	O	434-438
the	O	439-442
inflammation	B	443-455
process	O	456-463
,	O	463-464
as	O	465-467
well	O	468-472
as	O	473-475
the	O	476-479
regulation	O	480-490
of	O	491-493
cytokine	O	494-502
expression	O	503-513
,	O	513-514
and	O	515-518
its	O	519-522
deletion	O	523-531
resulted	O	532-540
in	O	541-543
an	O	544-546
improvement	O	547-558
in	O	559-561
the	O	562-565
diabetic	B	566-574
nephropathy	I	575-586
status	O	587-593
.	O	593-594

To	O	595-597
examine	O	598-605
the	O	606-609
role	O	610-614
of	O	615-617
the	O	618-621
kinin	O	622-627
B2	O	628-630
receptor	O	631-639
in	O	640-642
cisplatin	O	643-652
-	O	652-653
induced	O	653-660
acute	B	661-666
kidney	I	667-673
injury	I	674-680
,	O	680-681
kinin	O	682-687
B2	O	688-690
receptor	O	691-699
knockout	O	700-708
mice	O	709-713
were	O	714-718
challenged	O	719-729
with	O	730-734
cisplatin	O	735-744
.	O	744-745

Additionally	O	746-758
,	O	758-759
WT	O	760-762
mice	O	763-767
were	O	768-772
treated	O	773-780
with	O	781-785
a	O	786-787
B2	O	788-790
receptor	O	791-799
antagonist	O	800-810
after	O	811-816
cisplatin	O	817-826
administration	O	827-841
.	O	841-842

B2	O	843-845
receptor	O	846-854
-	O	854-855
deficient	O	855-864
mice	O	865-869
were	O	870-874
less	O	875-879
sensitive	O	880-889
to	O	890-892
this	O	893-897
drug	O	898-902
than	O	903-907
the	O	908-911
WT	O	912-914
mice	O	915-919
,	O	919-920
as	O	921-923
shown	O	924-929
by	O	930-932
reduced	O	933-940
weight	B	941-947
loss	I	948-952
,	O	952-953
better	O	954-960
preservation	O	961-973
of	O	974-976
kidney	O	977-983
function	O	984-992
,	O	992-993
down	O	994-998
regulation	O	999-1009
of	O	1010-1012
inflammatory	O	1013-1025
cytokines	O	1026-1035
and	O	1036-1039
less	O	1040-1044
acute	B	1045-1050
tubular	I	1051-1058
necrosis	I	1059-1067
.	O	1067-1068

Moreover	O	1069-1077
,	O	1077-1078
treatment	O	1079-1088
with	O	1089-1093
the	O	1094-1097
kinin	O	1098-1103
B2	O	1104-1106
receptor	O	1107-1115
antagonist	O	1116-1126
effectively	O	1127-1138
reduced	O	1139-1146
the	O	1147-1150
levels	O	1151-1157
of	O	1158-1160
serum	O	1161-1166
creatinine	O	1167-1177
and	O	1178-1181
blood	O	1182-1187
urea	O	1188-1192
after	O	1193-1198
cisplatin	O	1199-1208
administration	O	1209-1223
.	O	1223-1224

Thus	O	1225-1229
,	O	1229-1230
our	O	1231-1234
data	O	1235-1239
suggest	O	1240-1247
that	O	1248-1252
the	O	1253-1256
kinin	O	1257-1262
B2	O	1263-1265
receptor	O	1266-1274
is	O	1275-1277
involved	O	1278-1286
in	O	1287-1289
cisplatin	O	1290-1299
-	O	1299-1300
induced	O	1300-1307
acute	B	1308-1313
kidney	I	1314-1320
injury	I	1321-1327
by	O	1328-1330
mediating	O	1331-1340
the	O	1341-1344
necrotic	B	1345-1353
process	O	1354-1361
and	O	1362-1365
the	O	1366-1369
expression	O	1370-1380
of	O	1381-1383
inflammatory	O	1384-1396
cytokines	O	1397-1406
,	O	1406-1407
thus	O	1408-1412
resulting	O	1413-1422
in	O	1423-1425
declined	O	1426-1434
renal	O	1435-1440
function	O	1441-1449
.	O	1449-1450

These	O	1451-1456
results	O	1457-1464
highlight	O	1465-1474
the	O	1475-1478
kinin	O	1479-1484
B2	O	1485-1487
receptor	O	1488-1496
antagonist	O	1497-1507
treatment	O	1508-1517
in	O	1518-1520
amelioration	O	1521-1533
of	O	1534-1536
nephrotoxicity	B	1537-1551
induced	O	1552-1559
by	O	1560-1562
cisplatin	O	1563-1572
therapy	O	1573-1580
.	O	1580-1581

Safety	O	0-6
and	O	7-10
efficacy	O	11-19
of	O	20-22
fluocinolone	O	23-35
acetonide	O	36-45
intravitreal	O	46-58
implant	O	59-66
(	O	67-68
0	O	68-69
.	O	69-70
59	O	70-72
mg	O	73-75
)	O	75-76
in	O	77-79
birdshot	B	80-88
retinochoroidopathy	I	89-108
.	O	108-109

PURPOSE	O	110-117
:	O	117-118
To	O	119-121
report	O	122-128
the	O	129-132
treatment	O	133-142
outcomes	O	143-151
of	O	152-154
the	O	155-158
fluocinolone	O	159-171
acetonide	O	172-181
intravitreal	O	182-194
implant	O	195-202
(	O	203-204
0	O	204-205
.	O	205-206
59	O	206-208
mg	O	209-211
)	O	211-212
in	O	213-215
patients	O	216-224
with	O	225-229
birdshot	B	230-238
retinochoroidopathy	I	239-258
whose	O	259-264
disease	O	265-272
is	O	273-275
refractory	O	276-286
or	O	287-289
intolerant	O	290-300
to	O	301-303
conventional	O	304-316
immunomodulatory	O	317-333
therapy	O	334-341
.	O	341-342

METHODS	O	343-350
:	O	350-351
A	O	352-353
retrospective	O	354-367
case	O	368-372
series	O	373-379
involving	O	380-389
11	O	390-392
birdshot	B	393-401
retinochoroidopathy	I	402-421
patients	O	422-430
(	O	431-432
11	O	432-434
eyes	O	435-439
)	O	439-440
.	O	440-441

Eleven	O	442-448
patients	O	449-457
(	O	458-459
11	O	459-461
eyes	O	462-466
)	O	466-467
underwent	O	468-477
surgery	O	478-485
for	O	486-489
fluocinolone	O	490-502
acetonide	O	503-512
implant	O	513-520
(	O	521-522
0	O	522-523
.	O	523-524
59	O	524-526
mg	O	527-529
)	O	529-530
.	O	530-531

Treatment	O	532-541
outcomes	O	542-550
of	O	551-553
interest	O	554-562
were	O	563-567
noted	O	568-573
at	O	574-576
baseline	O	577-585
,	O	585-586
before	O	587-593
fluocinolone	O	594-606
acetonide	O	607-616
implant	O	617-624
,	O	624-625
and	O	626-629
then	O	630-634
at	O	635-637
6	O	638-639
months	O	640-646
,	O	646-647
1	O	648-649
year	O	650-654
,	O	654-655
2	O	656-657
years	O	658-663
,	O	663-664
3	O	665-666
years	O	667-672
,	O	672-673
and	O	674-677
beyond	O	678-684
3	O	685-686
years	O	687-692
.	O	692-693

Disease	O	694-701
activity	O	702-710
markers	O	711-718
,	O	718-719
including	O	720-729
signs	O	730-735
of	O	736-738
ocular	O	739-745
inflammation	B	746-758
,	O	758-759
evidence	O	760-768
of	O	769-771
retinal	B	772-779
vasculitis	I	780-790
,	O	790-791
Swedish	O	792-799
interactive	O	800-811
threshold	O	812-821
algorithm	O	822-831
-	O	831-832
short	O	832-837
wavelength	O	838-848
automated	O	849-858
perimetry	O	859-868
Humphrey	O	869-877
visual	O	878-884
field	O	885-890
analysis	O	891-899
,	O	899-900
electroretinographic	O	901-921
parameters	O	922-932
,	O	932-933
and	O	934-937
optical	O	938-945
coherence	O	946-955
tomography	O	956-966
were	O	967-971
recorded	O	972-980
.	O	980-981

Data	O	982-986
on	O	987-989
occurrence	O	990-1000
of	O	1001-1003
cataract	B	1004-1012
and	O	1013-1016
raised	B	1017-1023
intraocular	I	1024-1035
pressure	I	1036-1044
were	O	1045-1049
collected	O	1050-1059
in	O	1060-1062
all	O	1063-1066
eyes	O	1067-1071
.	O	1071-1072

RESULTS	O	1073-1080
:	O	1080-1081
Intraocular	O	1082-1093
inflammation	B	1094-1106
was	O	1107-1110
present	O	1111-1118
in	O	1119-1121
54	O	1122-1124
.	O	1124-1125
5	O	1122-1123
,	O	1126-1127
9	O	1128-1129
.	O	1129-1130
9	O	1128-1129
,	O	1131-1132
11	O	1133-1135
.	O	1135-1136
1	O	1133-1134
,	O	1137-1138
and	O	1139-1142
0	O	1143-1144
%	O	1144-1145
of	O	1146-1148
patients	O	1149-1157
at	O	1158-1160
baseline	O	1161-1169
,	O	1169-1170
6	O	1171-1172
months	O	1173-1179
,	O	1179-1180
1	O	1181-1182
year	O	1183-1187
,	O	1187-1188
2	O	1189-1190
years	O	1191-1196
,	O	1196-1197
3	O	1198-1199
years	O	1200-1205
,	O	1205-1206
and	O	1207-1210
beyond	O	1211-1217
3	O	1218-1219
years	O	1220-1225
after	O	1226-1231
receiving	O	1232-1241
the	O	1242-1245
implant	O	1246-1253
,	O	1253-1254
respectively	O	1255-1267
.	O	1267-1268

Active	O	1269-1275
vasculitis	B	1276-1286
was	O	1287-1290
noted	O	1291-1296
in	O	1297-1299
36	O	1300-1302
.	O	1302-1303
3	O	1300-1301
%	O	1304-1305
patients	O	1306-1314
at	O	1315-1317
baseline	O	1318-1326
and	O	1327-1330
0	O	1331-1332
%	O	1332-1333
at	O	1334-1336
3	O	1337-1338
years	O	1339-1344
of	O	1345-1347
follow	O	1348-1354
-	O	1354-1355
up	O	1355-1357
.	O	1357-1358

More	O	1359-1363
than	O	1364-1368
20	O	1369-1371
%	O	1371-1372
(	O	1373-1374
47	O	1374-1376
.	O	1376-1377
61	O	1377-1379
-	O	1379-1380
67	O	1380-1382
.	O	1376-1377
2	O	1383-1384
%	O	1384-1385
)	O	1385-1386

reduction	O	1387-1396
in	O	1397-1399
central	O	1400-1407
retinal	O	1408-1415
thickness	O	1416-1425
was	O	1426-1429
noted	O	1430-1435
in	O	1436-1438
all	O	1439-1442
patients	O	1443-1451
with	O	1452-1456
cystoid	B	1457-1464
macular	I	1465-1472
edema	I	1473-1478
at	O	1479-1481
6	O	1482-1483
months	O	1484-1490
,	O	1490-1491
1	O	1492-1493
year	O	1494-1498
,	O	1498-1499
2	O	1500-1501
years	O	1502-1507
,	O	1507-1508
and	O	1509-1512
3	O	1513-1514
years	O	1515-1520
postimplant	O	1521-1532
.	O	1532-1533

At	O	1534-1536
baseline	O	1537-1545
,	O	1545-1546
54	O	1547-1549
.	O	1549-1550
5	O	1547-1548
%	O	1551-1552
patients	O	1553-1561
were	O	1562-1566
on	O	1567-1569
immunomodulatory	O	1570-1586
agents	O	1587-1593
.	O	1593-1594

This	O	1595-1599
percentage	O	1600-1610
decreased	O	1611-1620
to	O	1621-1623
45	O	1624-1626
.	O	1626-1627
45	O	1624-1626
,	O	1629-1630
44	O	1631-1633
.	O	1633-1634
4	O	1631-1632
,	O	1635-1636
and	O	1637-1640
14	O	1641-1643
.	O	1643-1644
28	O	1644-1646
%	O	1646-1647
at	O	1648-1650
1	O	1651-1652
year	O	1653-1657
,	O	1657-1658
2	O	1659-1660
years	O	1661-1666
,	O	1666-1667
and	O	1668-1671
3	O	1672-1673
years	O	1674-1679
postimplant	O	1680-1691
,	O	1691-1692
respectively	O	1693-1705
.	O	1705-1706

Adverse	O	1707-1714
events	O	1715-1721
included	O	1722-1730
increased	B	1731-1740
intraocular	I	1741-1752
pressure	I	1753-1761
(	O	1762-1763
54	O	1763-1765
.	O	1765-1766
5	O	1763-1764
%	O	1767-1768
)	O	1768-1769
and	O	1770-1773
cataract	B	1774-1782
formation	O	1783-1792
(	O	1793-1794
100	O	1794-1797
%	O	1797-1798
)	O	1798-1799
.	O	1799-1800

CONCLUSION	O	1801-1811
:	O	1811-1812
The	O	1813-1816
data	O	1817-1821
suggest	O	1822-1829
that	O	1830-1834
fluocinolone	O	1835-1847
acetonide	O	1848-1857
implant	O	1858-1865
(	O	1866-1867
0	O	1867-1868
.	O	1868-1869
59	O	1869-1871
mg	O	1872-1874
)	O	1874-1875
helps	O	1876-1881
to	O	1882-1884
control	O	1885-1892
inflammation	B	1893-1905
in	O	1906-1908
otherwise	O	1909-1918
treatment	O	1919-1928
-	O	1928-1929
refractory	O	1929-1939
cases	O	1940-1945
of	O	1946-1948
birdshot	B	1949-1957
retinochoroidopathy	I	1958-1977
.	O	1977-1978

It	O	1979-1981
is	O	1982-1984
associated	O	1985-1995
with	O	1996-2000
significant	O	2001-2012
side	O	2013-2017
effects	O	2018-2025
of	O	2026-2028
cataract	B	2029-2037
and	O	2038-2041
ocular	B	2042-2048
hypertension	I	2049-2061
requiring	O	2062-2071
treatment	O	2072-2081
.	O	2081-2082

Optimal	O	0-7
precurarizing	O	8-21
dose	O	22-26
of	O	27-29
rocuronium	O	30-40
to	O	41-43
decrease	O	44-52
fasciculation	B	53-66
and	O	67-70
myalgia	B	71-78
following	O	79-88
succinylcholine	O	89-104
administration	O	105-119
.	O	119-120

BACKGROUND	O	121-131
:	O	131-132
Succinylcholine	O	133-148
commonly	O	149-157
produces	O	158-166
frequent	O	167-175
adverse	O	176-183
effects	O	184-191
,	O	191-192
including	O	193-202
muscle	B	203-209
fasciculation	I	210-223
and	O	224-227
myalgia	B	228-235
.	O	235-236

The	O	237-240
current	O	241-248
study	O	249-254
identified	O	255-265
the	O	266-269
optimal	O	270-277
dose	O	278-282
of	O	283-285
rocuronium	O	286-296
to	O	297-299
prevent	O	300-307
succinylcholine	O	308-323
-	O	323-324
induced	O	324-331
fasciculation	B	332-345
and	O	346-349
myalgia	B	350-357
and	O	358-361
evaluated	O	362-371
the	O	372-375
influence	O	376-385
of	O	386-388
rocuronium	O	389-399
on	O	400-402
the	O	403-406
speed	O	407-412
of	O	413-415
onset	O	416-421
produced	O	422-430
by	O	431-433
succinylcholine	O	434-449
.	O	449-450

METHODS	O	451-458
:	O	458-459
This	O	460-464
randomized	O	465-475
,	O	475-476
double	O	477-483
-	O	483-484
blinded	O	484-491
study	O	492-497
was	O	498-501
conducted	O	502-511
in	O	512-514
100	O	515-518
patients	O	519-527
randomly	O	528-536
allocated	O	537-546
into	O	547-551
five	O	552-556
groups	O	557-563
of	O	564-566
20	O	567-569
patients	O	570-578
each	O	579-583
.	O	583-584

Patients	O	585-593
were	O	594-598
randomized	O	599-609
to	O	610-612
receive	O	613-620
0	O	621-622
.	O	622-623
02	O	623-625
,	O	625-626
0	O	627-628
.	O	628-629
03	O	629-631
,	O	631-632
0	O	633-634
.	O	634-635
04	O	635-637
,	O	637-638
0	O	639-640
.	O	640-641
05	O	641-643
and	O	644-647
0	O	648-649
.	O	649-650
06	O	650-652
mg	O	653-655
/	O	655-656
kg	O	656-658
rocuronium	O	659-669
as	O	670-672
a	O	673-674
precurarizing	O	675-688
dose	O	689-693
.	O	693-694

Neuromuscular	O	695-708
monitoring	O	709-719
after	O	720-725
each	O	726-730
precurarizing	O	731-744
dose	O	745-749
was	O	750-753
recorded	O	754-762
from	O	763-767
the	O	768-771
adductor	O	772-780
pollicis	O	781-789
muscle	O	790-796
using	O	797-802
acceleromyography	O	803-820
with	O	821-825
train	O	826-831
-	O	831-832
of	O	832-834
-	O	831-832
four	O	835-839
stimulation	O	840-851
of	O	852-854
the	O	855-858
ulnar	O	859-864
nerve	O	865-870
.	O	870-871

All	O	872-875
patients	O	876-884
received	O	885-893
succinylcholine	O	894-909
1	O	910-911
.	O	911-912
5	O	912-913
mg	O	914-916
/	O	916-917
kg	O	917-919
at	O	920-922
2	O	923-924
minutes	O	925-932
after	O	933-938
the	O	939-942
precurarization	O	943-958
,	O	958-959
and	O	960-963
were	O	964-968
assessed	O	969-977
the	O	978-981
incidence	O	982-991
and	O	992-995
severity	O	996-1004
of	O	1005-1007
fasciculations	B	1008-1022
,	O	1022-1023
while	O	1024-1029
myalgia	B	1030-1037
was	O	1038-1041
assessed	O	1042-1050
at	O	1051-1053
24	O	1054-1056
hours	O	1057-1062
after	O	1063-1068
surgery	O	1069-1076
.	O	1076-1077

RESULTS	O	1078-1085
:	O	1085-1086
The	O	1087-1090
incidence	O	1091-1100
and	O	1101-1104
severity	O	1105-1113
of	O	1114-1116
visible	O	1117-1124
muscle	B	1125-1131
fasciculation	I	1132-1145
was	O	1146-1149
significantly	O	1150-1163
less	O	1164-1168
with	O	1169-1173
increasing	O	1174-1184
the	O	1185-1188
amount	O	1189-1195
of	O	1196-1198
precurarizing	O	1199-1212
dose	O	1213-1217
of	O	1218-1220
rocuronium	O	1221-1231
(	O	1232-1233
P	O	1233-1234
<	O	1235-1236
0	O	1237-1238
.	O	1238-1239
001	O	1239-1242
)	O	1242-1243
.	O	1238-1239

Those	O	1245-1250
of	O	1251-1253
myalgia	B	1254-1261
tend	O	1262-1266
to	O	1267-1269
decrease	O	1270-1278
according	O	1279-1288
to	O	1289-1291
increasing	O	1292-1302
the	O	1303-1306
amount	O	1307-1313
of	O	1314-1316
precurarizing	O	1317-1330
dose	O	1331-1335
of	O	1336-1338
rocuronium	O	1339-1349
,	O	1349-1350
but	O	1351-1354
there	O	1355-1360
was	O	1361-1364
no	O	1365-1367
significance	O	1368-1380
(	O	1381-1382
P	O	1382-1383
=	O	1384-1385
0	O	1386-1387
.	O	1387-1388
072	O	1388-1391
)	O	1391-1392
.	O	1387-1388

The	O	1394-1397
onset	O	1398-1403
time	O	1404-1408
of	O	1409-1411
succinylcholine	O	1412-1427
was	O	1428-1431
significantly	O	1432-1445
longer	O	1446-1452
with	O	1453-1457
increasing	O	1458-1468
the	O	1469-1472
amount	O	1473-1479
of	O	1480-1482
precurarizing	O	1483-1496
dose	O	1497-1501
of	O	1502-1504
rocuronium	O	1505-1515
(	O	1516-1517
P	O	1517-1518
<	O	1519-1520
0	O	1521-1522
.	O	1522-1523
001	O	1523-1526
)	O	1526-1527
.	O	1522-1523

CONCLUSIONS	O	1529-1540
:	O	1540-1541
Precurarization	O	1542-1557
with	O	1558-1562
0	O	1563-1564
.	O	1564-1565
04	O	1565-1567
mg	O	1568-1570
/	O	1570-1571
kg	O	1571-1573
rocuronium	O	1574-1584
was	O	1585-1588
the	O	1589-1592
optimal	O	1593-1600
dose	O	1601-1605
considering	O	1606-1617
the	O	1618-1621
reduction	O	1622-1631
in	O	1632-1634
the	O	1635-1638
incidence	O	1639-1648
and	O	1649-1652
severity	O	1653-1661
of	O	1662-1664
fasciculation	B	1665-1678
and	O	1679-1682
myalgia	B	1683-1690
with	O	1691-1695
acceptable	O	1696-1706
onset	O	1707-1712
time	O	1713-1717
,	O	1717-1718
and	O	1719-1722
the	O	1723-1726
safe	O	1727-1731
and	O	1732-1735
effective	O	1736-1745
precurarization	O	1746-1761
.	O	1761-1762

Absence	O	0-7
of	O	8-10
PKC	O	11-14
-	O	14-15
alpha	O	15-20
attenuates	O	21-31
lithium	O	32-39
-	O	39-40
induced	O	40-47
nephrogenic	B	48-59
diabetes	I	60-68
insipidus	I	69-78
.	O	78-79

Lithium	O	80-87
,	O	87-88
an	O	89-91
effective	O	92-101
antipsychotic	O	102-115
,	O	115-116
induces	O	117-124
nephrogenic	B	125-136
diabetes	I	137-145
insipidus	I	146-155
(	O	156-157
NDI	B	157-160
)	O	160-161
in	O	162-164
40	O	166-168
%	O	168-169
of	O	170-172
patients	O	173-181
.	O	181-182

The	O	183-186
decreased	O	187-196
capacity	O	197-205
to	O	206-208
concentrate	O	209-220
urine	O	221-226
is	O	227-229
likely	O	230-236
due	O	237-240
to	O	241-243
lithium	O	244-251
acutely	O	252-259
disrupting	O	260-270
the	O	271-274
cAMP	O	275-279
pathway	O	280-287
and	O	288-291
chronically	O	292-303
reducing	O	304-312
urea	O	313-317
transporter	O	318-329
(	O	330-331
UT	O	331-333
-	O	333-334
A1	O	334-336
)	O	336-337
and	O	338-341
water	O	342-347
channel	O	348-355
(	O	356-357
AQP2	O	357-361
)	O	361-362
expression	O	363-373
in	O	374-376
the	O	377-380
inner	O	381-386
medulla	O	387-394
.	O	394-395

Targeting	O	396-405
an	O	406-408
alternative	O	409-420
signaling	O	421-430
pathway	O	431-438
,	O	438-439
such	O	440-444
as	O	445-447
PKC	O	448-451
-	O	451-452
mediated	O	452-460
signaling	O	461-470
,	O	470-471
may	O	472-475
be	O	476-478
an	O	479-481
effective	O	482-491
method	O	492-498
of	O	499-501
treating	O	502-510
lithium	O	511-518
-	O	518-519
induced	O	519-526
polyuria	B	527-535
.	O	535-536

PKC	O	537-540
-	O	540-541
alpha	O	541-546
null	O	547-551
mice	O	552-556
(	O	557-558
PKCa	O	558-562
KO	O	563-565
)	O	565-566
and	O	567-570
strain	O	571-577
-	O	577-578
matched	O	578-585
wild	O	586-590
type	O	591-595
(	O	596-597
WT	O	597-599
)	O	599-600
controls	O	601-609
were	O	610-614
treated	O	615-622
with	O	623-627
lithium	O	628-635
for	O	636-639
0	O	640-641
,	O	641-642
3	O	643-644
or	O	645-647
5	O	648-649
days	O	650-654
.	O	654-655

WT	O	656-658
mice	O	659-663
had	O	664-667
increased	O	668-677
urine	O	678-683
output	O	684-690
and	O	691-694
lowered	O	695-702
urine	O	703-708
osmolality	O	709-719
after	O	720-725
3	O	726-727
and	O	728-731
5	O	732-733
days	O	734-738
of	O	739-741
treatment	O	742-751
whereas	O	752-759
PKCa	O	760-764
KO	O	765-767
mice	O	768-772
had	O	773-776
no	O	777-779
change	O	780-786
in	O	787-789
urine	O	790-795
output	O	796-802
or	O	803-805
concentration	O	806-819
.	O	819-820

Western	O	821-828
blot	O	829-833
analysis	O	834-842
revealed	O	843-851
that	O	852-856
AQP2	O	857-861
expression	O	862-872
in	O	873-875
medullary	O	876-885
tissues	O	886-893
was	O	894-897
lowered	O	898-905
after	O	906-911
3	O	912-913
and	O	914-917
5	O	918-919
days	O	920-924
in	O	925-927
WT	O	928-930
mice	O	931-935
;	O	935-936
however	O	937-944
,	O	944-945
AQP2	O	946-950
was	O	951-954
unchanged	O	955-964
in	O	965-967
PKCa	O	968-972
KO	O	973-975
.	O	975-976

Similar	O	977-984
results	O	985-992
were	O	993-997
observed	O	998-1006
with	O	1007-1011
UT	O	1012-1014
-	O	1014-1015
A1	O	1015-1017
expression	O	1018-1028
.	O	1028-1029

Animals	O	1030-1037
were	O	1038-1042
also	O	1043-1047
treated	O	1048-1055
with	O	1056-1060
lithium	O	1061-1068
for	O	1069-1072
6	O	1073-1074
weeks	O	1075-1080
.	O	1080-1081

Lithium	O	1082-1089
-	O	1089-1090
treated	O	1090-1097
WT	O	1098-1100
mice	O	1101-1105
had	O	1106-1109
19	O	1110-1112
-	O	1112-1113
fold	O	1113-1117
increased	O	1118-1127
urine	O	1128-1133
output	O	1134-1140
whereas	O	1141-1148
treated	O	1149-1156
PKCa	O	1157-1161
KO	O	1162-1164
animals	O	1165-1172
had	O	1173-1176
a	O	1177-1178
4	O	1179-1180
-	O	1180-1181
fold	O	1181-1185
increase	O	1186-1194
in	O	1195-1197
output	O	1198-1204
.	O	1204-1205

AQP2	O	1206-1210
and	O	1211-1214
UT	O	1215-1217
-	O	1217-1218
A1	O	1218-1220
expression	O	1221-1231
was	O	1232-1235
lowered	O	1236-1243
in	O	1244-1246
6	O	1247-1248
week	O	1249-1253
lithium	O	1254-1261
-	O	1261-1262
treated	O	1262-1269
WT	O	1270-1272
animals	O	1273-1280
whereas	O	1281-1288
in	O	1289-1291
treated	O	1292-1299
PKCa	O	1300-1304
KO	O	1305-1307
mice	O	1308-1312
,	O	1312-1313
AQP2	O	1314-1318
was	O	1319-1322
only	O	1323-1327
reduced	O	1328-1335
by	O	1336-1338
2	O	1339-1340
-	O	1340-1341
fold	O	1341-1345
and	O	1346-1349
UT	O	1350-1352
-	O	1352-1353
A1	O	1353-1355
expression	O	1356-1366
was	O	1367-1370
unaffected	O	1371-1381
.	O	1381-1382

Urinary	O	1383-1390
sodium	O	1391-1397
,	O	1397-1398
potassium	O	1399-1408
and	O	1409-1412
calcium	O	1413-1420
were	O	1421-1425
elevated	O	1426-1434
in	O	1435-1437
lithium	O	1438-1445
-	O	1445-1446
fed	O	1446-1449
WT	O	1450-1452
but	O	1453-1456
not	O	1457-1460
in	O	1461-1463
lithium	O	1464-1471
-	O	1471-1472
fed	O	1472-1475
PKCa	O	1476-1480
KO	O	1481-1483
mice	O	1484-1488
.	O	1488-1489

Our	O	1490-1493
data	O	1494-1498
show	O	1499-1503
that	O	1504-1508
ablation	O	1509-1517
of	O	1518-1520
PKCa	O	1521-1525
preserves	O	1526-1535
AQP2	O	1536-1540
and	O	1541-1544
UT	O	1545-1547
-	O	1547-1548
A1	O	1548-1550
protein	O	1551-1558
expression	O	1559-1569
and	O	1570-1573
localization	O	1574-1586
in	O	1587-1589
lithium	O	1590-1597
-	O	1597-1598
induced	O	1598-1605
NDI	B	1606-1609
,	O	1609-1610
and	O	1611-1614
prevents	O	1615-1623
the	O	1624-1627
development	O	1628-1639
of	O	1640-1642
the	O	1643-1646
severe	O	1647-1653
polyuria	B	1654-1662
associated	O	1663-1673
with	O	1674-1678
lithium	O	1679-1686
therapy	O	1687-1694
.	O	1694-1695

Is	O	0-2
Dysguesia	B	3-12
Going	O	13-18
to	O	19-21
be	O	22-24
a	O	25-26
Rare	O	27-31
or	O	32-34
a	O	35-36
Common	O	37-43
Side	O	44-48
-	O	48-49
effect	O	49-55
of	O	56-58
Amlodipine	O	59-69
?	O	69-70

A	O	71-72
very	O	73-77
rare	O	78-82
side	O	83-87
-	O	87-88
effect	O	88-94
of	O	95-97
amlodipine	O	98-108
is	O	109-111
dysguesia	B	112-121
.	O	121-122

A	O	123-124
review	O	125-131
of	O	132-134
the	O	135-138
literature	O	139-149
produced	O	150-158
only	O	159-163
one	O	164-167
case	O	168-172
.	O	172-173

We	O	174-176
report	O	177-183
a	O	184-185
case	O	186-190
about	O	191-196
a	O	197-198
female	O	199-205
with	O	206-210
essential	O	211-220
hypertension	B	221-233
on	O	234-236
drug	O	237-241
treatment	O	242-251
with	O	252-256
amlodipine	O	257-267
developed	O	268-277
loss	B	278-282
of	I	283-285
taste	I	286-291
sensation	I	292-301
.	O	301-302

Condition	O	303-312
moderately	O	313-323
improved	O	324-332
on	O	333-335
stoppage	O	336-344
of	O	345-347
the	O	348-351
drug	O	352-356
for	O	357-360
25	O	361-363
days	O	364-368
.	O	368-369

We	O	370-372
conclude	O	373-381
that	O	382-386
amlodipine	O	387-397
can	O	398-401
cause	O	402-407
dysguesia	B	408-417
.	O	417-418

Here	O	419-423
,	O	423-424
we	O	425-427
describe	O	428-436
the	O	437-440
clinical	O	441-449
presentation	O	450-462
and	O	463-466
review	O	467-473
the	O	474-477
relevant	O	478-486
literature	O	487-497
on	O	498-500
amlodipine	O	501-511
and	O	512-515
dysguesia	B	516-525
.	O	525-526

Rhabdomyolysis	B	0-14
in	O	15-17
association	O	18-29
with	O	30-34
simvastatin	O	35-46
and	O	47-50
dosage	O	51-57
increment	O	58-67
in	O	68-70
clarithromycin	O	71-85
.	O	85-86

Clarithromycin	O	87-101
is	O	102-104
the	O	105-108
most	O	109-113
documented	O	114-124
cytochrome	O	125-135
P450	O	136-140
3A4	O	141-144
(	O	145-146
CYP3A4	O	146-152
)	O	152-153
inhibitor	O	154-163
to	O	164-166
cause	O	167-172
an	O	173-175
adverse	O	176-183
interaction	O	184-195
with	O	196-200
simvastatin	O	201-212
.	O	212-213

This	O	214-218
particular	O	219-229
case	O	230-234
is	O	235-237
of	O	238-240
interest	O	241-249
as	O	250-252
rhabdomyolysis	B	253-267
only	O	268-272
occurred	O	273-281
after	O	282-287
an	O	288-290
increase	O	291-299
in	O	300-302
the	O	303-306
dose	O	307-311
of	O	312-314
clarithromycin	O	315-329
.	O	329-330

The	O	331-334
patient	O	335-342
developed	O	343-352
raised	O	353-359
cardiac	O	360-367
biomarkers	O	368-378
without	O	379-386
any	O	387-390
obvious	O	391-398
cardiac	O	399-406
issues	O	407-413
,	O	413-414
a	O	415-416
phenomenon	O	417-427
that	O	428-432
has	O	433-436
been	O	437-441
linked	O	442-448
to	O	449-451
rhabdomyolysis	B	452-466
previously	O	467-477
.	O	477-478

To	O	479-481
date	O	482-486
,	O	486-487
there	O	488-493
has	O	494-497
been	O	498-502
no	O	503-505
reported	O	506-514
effect	O	515-521
of	O	522-524
rhabdomyolysis	B	525-539
on	O	540-542
the	O	543-546
structure	O	547-556
and	O	557-560
function	O	561-569
of	O	570-572
cardiac	O	573-580
muscle	O	581-587
.	O	587-588

Clinicians	O	589-599
need	O	600-604
to	O	605-607
be	O	608-610
aware	O	611-616
of	O	617-619
prescribing	O	620-631
concomitant	O	632-643
medications	O	644-655
that	O	656-660
increase	O	661-669
the	O	670-673
risk	O	674-678
of	O	679-681
myopathy	B	682-690
or	O	691-693
inhibit	O	694-701
the	O	702-705
CYP3A4	O	706-712
enzyme	O	713-719
.	O	719-720

Our	O	721-724
case	O	725-729
suggests	O	730-738
that	O	739-743
troponin	O	744-752
elevation	O	753-762
could	O	763-768
be	O	769-771
associated	O	772-782
with	O	783-787
statin	O	788-794
induced	O	795-802
rhabdomyolysis	B	803-817
,	O	817-818
which	O	819-824
may	O	825-828
warrant	O	829-836
further	O	837-844
studies	O	845-852
.	O	852-853

Characterization	O	0-16
of	O	17-19
a	O	20-21
novel	O	22-27
BCHE	O	28-32
"	O	33-34
silent	O	34-40
"	O	33-34
allele	O	42-48
:	O	48-49
point	O	50-55
mutation	O	56-64
(	O	65-66
p	O	66-67
.	O	67-68
Val204Asp	O	68-77
)	O	77-78
causes	O	79-85
loss	O	86-90
of	O	91-93
activity	O	94-102
and	O	103-106
prolonged	O	107-116
apnea	B	117-122
with	O	123-127
suxamethonium	O	128-141
.	O	141-142

Butyrylcholinesterase	B	143-164
deficiency	I	165-175
is	O	176-178
characterized	O	179-192
by	O	193-195
prolonged	O	196-205
apnea	B	206-211
after	O	212-217
the	O	218-221
use	O	222-225
of	O	226-228
muscle	O	229-235
relaxants	O	236-245
(	O	246-247
suxamethonium	O	247-260
or	O	261-263
mivacurium	O	264-274
)	O	274-275
in	O	276-278
patients	O	279-287
who	O	288-291
have	O	292-296
mutations	O	297-306
in	O	307-309
the	O	310-313
BCHE	O	314-318
gene	O	319-323
.	O	323-324

Here	O	325-329
,	O	329-330
we	O	331-333
report	O	334-340
a	O	341-342
case	O	343-347
of	O	348-350
prolonged	O	351-360
neuromuscular	O	361-374
block	O	375-380
after	O	381-386
administration	O	387-401
of	O	402-404
suxamethonium	O	405-418
leading	O	419-426
to	O	427-429
the	O	430-433
discovery	O	434-443
of	O	444-446
a	O	447-448
novel	O	449-454
BCHE	O	455-459
variant	O	460-467
(	O	468-469
c	O	469-470
.	O	470-471
695T	O	471-475
>	O	475-476
A	O	476-477
,	O	477-478
p	O	479-480
.	O	480-481
Val204Asp	O	481-490
)	O	490-491
.	O	480-481

Inhibition	O	493-503
studies	O	504-511
,	O	511-512
kinetic	O	513-520
analysis	O	521-529
and	O	530-533
molecular	O	534-543
dynamics	O	544-552
were	O	553-557
undertaken	O	558-568
to	O	569-571
understand	O	572-582
how	O	583-586
this	O	587-591
mutation	O	592-600
disrupts	O	601-609
the	O	610-613
catalytic	O	614-623
triad	O	624-629
and	O	630-633
determines	O	634-644
a	O	645-646
"	O	647-648
silent	O	648-654
"	O	647-648
phenotype	O	656-665
.	O	665-666

Low	O	667-670
activity	O	671-679
of	O	680-682
patient	O	683-690
plasma	O	691-697
butyrylcholinesterase	O	698-719
with	O	720-724
butyrylthiocholine	O	725-743
(	O	744-745
BTC	O	745-748
)	O	748-749
and	O	750-753
benzoylcholine	O	754-768
,	O	768-769
and	O	770-773
values	O	774-780
of	O	781-783
dibucaine	O	784-793
and	O	794-797
fluoride	O	798-806
numbers	O	807-814
fit	O	815-818
with	O	819-823
heterozygous	O	824-836
atypical	O	837-845
silent	O	846-852
genotype	O	853-861
.	O	861-862

Electrophoretic	O	863-878
analysis	O	879-887
of	O	888-890
plasma	O	891-897
BChE	O	898-902
of	O	903-905
the	O	906-909
proband	O	910-917
and	O	918-921
his	O	922-925
mother	O	926-932
showed	O	933-939
that	O	940-944
patient	O	945-952
has	O	953-956
a	O	957-958
reduced	O	959-966
amount	O	967-973
of	O	974-976
tetrameric	O	977-987
enzyme	O	988-994
in	O	995-997
plasma	O	998-1004
and	O	1005-1008
that	O	1009-1013
minor	O	1014-1019
fast	O	1020-1024
-	O	1024-1025
moving	O	1025-1031
BChE	O	1032-1036
components	O	1037-1047
:	O	1047-1048
monomer	O	1049-1056
,	O	1056-1057
dimer	O	1058-1063
,	O	1063-1064
and	O	1065-1068
monomer	O	1069-1076
-	O	1076-1077
albumin	O	1077-1084
conjugate	O	1085-1094
are	O	1095-1098
missing	O	1099-1106
.	O	1106-1107

Kinetic	O	1108-1115
analysis	O	1116-1124
showed	O	1125-1131
that	O	1132-1136
the	O	1137-1140
p	O	1141-1142
.	O	1142-1143
Val204Asp	O	1143-1152
/	O	1152-1153
p	O	1141-1142
.	O	1142-1143
Asp70Gly	O	1155-1163
-	O	1163-1164
p	O	1141-1142
.	O	1142-1143
Ala539Thr	O	1166-1175
BChE	O	1176-1180
displays	O	1181-1189
a	O	1190-1191
pure	O	1192-1196
Michaelian	O	1197-1207
behavior	O	1208-1216
with	O	1217-1221
BTC	O	1222-1225
as	O	1226-1228
the	O	1229-1232
substrate	O	1233-1242
.	O	1242-1243

Both	O	1244-1248
catalytic	O	1249-1258
parameters	O	1259-1269
Km	O	1270-1272
=	O	1273-1274
265	O	1275-1278
uM	O	1279-1281
for	O	1282-1285
BTC	O	1286-1289
,	O	1289-1290
two	O	1291-1294
times	O	1295-1300
higher	O	1301-1307
than	O	1308-1312
that	O	1313-1317
of	O	1318-1320
the	O	1321-1324
atypical	O	1325-1333
enzyme	O	1334-1340
,	O	1340-1341
and	O	1342-1345
a	O	1346-1347
low	O	1348-1351
Vmax	O	1352-1356
are	O	1357-1360
consistent	O	1361-1371
with	O	1372-1376
the	O	1377-1380
absence	O	1381-1388
of	O	1389-1391
activity	O	1392-1400
against	O	1401-1408
suxamethonium	O	1409-1422
.	O	1422-1423

Molecular	O	1424-1433
dynamic	O	1434-1441
(	O	1442-1443
MD	O	1443-1445
)	O	1445-1446
simulations	O	1447-1458
showed	O	1459-1465
that	O	1466-1470
the	O	1471-1474
overall	O	1475-1482
effect	O	1483-1489
of	O	1490-1492
the	O	1493-1496
mutation	O	1497-1505
p	O	1506-1507
.	O	1507-1508
Val204Asp	O	1508-1517
is	O	1518-1520
disruption	O	1521-1531
of	O	1532-1534
hydrogen	O	1535-1543
bonding	O	1544-1551
between	O	1552-1559
Gln223	O	1560-1566
and	O	1567-1570
Glu441	O	1571-1577
,	O	1577-1578
leading	O	1579-1586
Ser198	O	1587-1593
and	O	1594-1597
His438	O	1598-1604
to	O	1605-1607
move	O	1608-1612
away	O	1613-1617
from	O	1618-1622
each	O	1623-1627
other	O	1628-1633
with	O	1634-1638
subsequent	O	1639-1649
disruption	O	1650-1660
of	O	1661-1663
the	O	1664-1667
catalytic	O	1668-1677
triad	O	1678-1683
functionality	O	1684-1697
regardless	O	1698-1708
of	O	1709-1711
the	O	1712-1715
type	O	1716-1720
of	O	1721-1723
substrate	O	1724-1733
.	O	1733-1734

MD	O	1735-1737
also	O	1738-1742
showed	O	1743-1749
that	O	1750-1754
the	O	1755-1758
enzyme	O	1759-1765
volume	O	1766-1772
is	O	1773-1775
increased	O	1776-1785
,	O	1785-1786
suggesting	O	1787-1797
a	O	1798-1799
pre	O	1800-1803
-	O	1803-1804
denaturation	O	1804-1816
state	O	1817-1822
.	O	1822-1823

This	O	1824-1828
fits	O	1829-1833
with	O	1834-1838
the	O	1839-1842
reduced	O	1843-1850
concentration	O	1851-1864
of	O	1865-1867
p	O	1868-1869
.	O	1869-1870
Ala204Asp	O	1870-1879
/	O	1879-1880
p	O	1868-1869
.	O	1869-1870
Asp70Gly	O	1882-1890
-	O	1890-1891
p	O	1868-1869
.	O	1869-1870
Ala539Thr	O	1893-1902
tetrameric	O	1903-1913
enzyme	O	1914-1920
in	O	1921-1923
the	O	1924-1927
plasma	O	1928-1934
and	O	1935-1938
non	O	1939-1942
-	O	1942-1943
detectable	O	1943-1953
fast	O	1954-1958
moving	O	1959-1965
-	O	1965-1966
bands	O	1966-1971
on	O	1972-1974
electrophoresis	O	1975-1990
gels	O	1991-1995
.	O	1995-1996

Delayed	O	0-7
anemia	B	8-14
after	O	15-20
treatment	O	21-30
with	O	31-35
injectable	O	36-46
artesunate	O	47-57
in	O	58-60
the	O	61-64
Democratic	O	65-75
Republic	O	76-84
of	O	85-87
the	O	88-91
Congo	O	92-97
:	O	97-98
a	O	99-100
manageable	O	101-111
issue	O	112-117
.	O	117-118

Cases	O	119-124
of	O	125-127
delayed	O	128-135
hemolytic	B	136-145
anemia	I	146-152
have	O	153-157
been	O	158-162
described	O	163-172
after	O	173-178
treatment	O	179-188
with	O	189-193
injectable	O	194-204
artesunate	O	205-215
,	O	215-216
the	O	217-220
current	O	221-228
World	O	229-234
Health	O	235-241
Organization	O	242-254
(	O	255-256
WHO	O	256-259
)	O	259-260
-	O	260-261
recommended	O	261-272
first	O	273-278
-	O	278-279
line	O	279-283
drug	O	284-288
for	O	289-292
the	O	293-296
treatment	O	297-306
of	O	307-309
severe	O	310-316
malaria	B	317-324
.	O	324-325

A	O	326-327
total	O	328-333
of	O	334-336
350	O	337-340
patients	O	341-349
(	O	350-351
215	O	351-354
[	O	355-356
61	O	356-358
.	O	358-359
4	O	359-360
%	O	360-361
]	O	361-362
<	O	363-364
5	O	365-366
years	O	367-372
of	O	373-375
age	O	376-379
and	O	380-383
135	O	384-387
[	O	388-389
38	O	389-391
.	O	391-392
6	O	392-393
%	O	393-394
]	O	394-395
>	O	396-397
5	O	398-399
years	O	400-405
of	O	406-408
age	O	409-412
)	O	412-413
were	O	414-418
followed	O	419-427
-	O	427-428
up	O	428-430
after	O	431-436
treatment	O	437-446
with	O	447-451
injectable	O	452-462
artesunate	O	463-473
for	O	474-477
severe	O	478-484
malaria	B	485-492
in	O	493-495
hospitals	O	496-505
and	O	506-509
health	O	510-516
centers	O	517-524
of	O	525-527
the	O	528-531
Democratic	O	532-542
Republic	O	543-551
of	O	552-554
the	O	555-558
Congo	O	559-564
.	O	564-565

Complete	O	566-574
series	O	575-581
of	O	582-584
hemoglobin	O	585-595
(	O	596-597
Hb	O	597-599
)	O	599-600
measurements	O	601-613
were	O	614-618
available	O	619-628
for	O	629-632
201	O	633-636
patients	O	637-645
.	O	645-646

A	O	647-648
decrease	O	649-657
in	O	658-660
Hb	O	661-663
levels	O	664-670
between	O	671-678
2	O	679-680
and	O	681-684
5	O	685-686
g	O	687-688
/	O	688-689
dL	O	689-691
was	O	692-695
detected	O	696-704
in	O	705-707
23	O	708-710
(	O	711-712
11	O	712-714
.	O	714-715
4	O	715-716
%	O	716-717
)	O	717-718
patients	O	719-727
during	O	728-734
the	O	735-738
follow	O	739-745
-	O	745-746
up	O	746-748
period	O	749-755
.	O	755-756

For	O	757-760
five	O	761-765
patients	O	766-774
,	O	774-775
Hb	O	776-778
levels	O	779-785
decreased	O	786-795
below	O	796-801
5	O	802-803
g	O	804-805
/	O	805-806
dL	O	806-808
during	O	809-815
at	O	816-818
least	O	819-824
one	O	825-828
follow	O	829-835
-	O	835-836
up	O	836-838
visit	O	839-844
.	O	844-845

All	O	846-849
cases	O	850-855
of	O	856-858
delayed	O	859-866
anemia	B	867-873
were	O	874-878
clinically	O	879-889
manageable	O	890-900
and	O	901-904
resolved	O	905-913
within	O	914-920
one	O	921-924
month	O	925-930
.	O	930-931

Regulation	O	0-10
of	O	11-13
signal	O	14-20
transducer	O	21-31
and	O	32-35
activator	O	36-45
of	O	46-48
transcription	O	49-62
3	O	63-64
and	O	65-68
apoptotic	O	69-78
pathways	O	79-87
by	O	88-90
betaine	O	91-98
attenuates	O	99-109
isoproterenol	O	110-123
-	O	123-124
induced	O	124-131
acute	O	132-137
myocardial	B	138-148
injury	I	149-155
in	O	156-158
rats	O	159-163
.	O	163-164

The	O	165-168
present	O	169-176
study	O	177-182
was	O	183-186
designed	O	187-195
to	O	196-198
investigate	O	199-210
the	O	211-214
cardioprotective	O	215-231
effects	O	232-239
of	O	240-242
betaine	O	243-250
on	O	251-253
acute	O	254-259
myocardial	B	260-270
ischemia	I	271-279
induced	O	280-287
experimentally	O	288-302
in	O	303-305
rats	O	306-310
focusing	O	311-319
on	O	320-322
regulation	O	323-333
of	O	334-336
signal	O	337-343
transducer	O	344-354
and	O	355-358
activator	O	359-368
of	O	369-371
transcription	O	372-385
3	O	386-387
(	O	388-389
STAT3	O	389-394
)	O	394-395
and	O	396-399
apoptotic	O	400-409
pathways	O	410-418
as	O	419-421
the	O	422-425
potential	O	426-435
mechanism	O	436-445
underlying	O	446-456
the	O	457-460
drug	O	461-465
effect	O	466-472
.	O	472-473

Male	O	474-478
Sprague	O	479-486
Dawley	O	487-493
rats	O	494-498
were	O	499-503
treated	O	504-511
with	O	512-516
betaine	O	517-524
(	O	525-526
100	O	526-529
,	O	529-530
200	O	531-534
,	O	534-535
and	O	536-539
400	O	540-543
mg	O	544-546
/	O	546-547
kg	O	547-549
)	O	549-550
orally	O	551-557
for	O	558-561
40	O	562-564
days	O	565-569
.	O	569-570

Acute	O	571-576
myocardial	B	577-587
ischemic	I	588-596
injury	I	597-603
was	O	604-607
induced	O	608-615
in	O	616-618
rats	O	619-623
by	O	624-626
subcutaneous	O	627-639
injection	O	640-649
of	O	650-652
isoproterenol	O	653-666
(	O	667-668
85	O	668-670
mg	O	671-673
/	O	673-674
kg	O	674-676
)	O	676-677
,	O	677-678
for	O	679-682
two	O	683-686
consecutive	O	687-698
days	O	699-703
.	O	703-704

Serum	O	705-710
cardiac	O	711-718
marker	O	719-725
enzyme	O	726-732
,	O	732-733
histopathological	O	734-751
variables	O	752-761
and	O	762-765
expression	O	766-776
of	O	777-779
protein	O	780-787
levels	O	788-794
were	O	795-799
analyzed	O	800-808
.	O	808-809

Oral	O	810-814
administration	O	815-829
of	O	830-832
betaine	O	833-840
(	O	841-842
200	O	842-845
and	O	846-849
400	O	850-853
mg	O	854-856
/	O	856-857
kg	O	857-859
)	O	859-860
significantly	O	861-874
reduced	O	875-882
the	O	883-886
level	O	887-892
of	O	893-895
cardiac	O	896-903
marker	O	904-910
enzyme	O	911-917
in	O	918-920
the	O	921-924
serum	O	925-930
and	O	931-934
prevented	O	935-944
left	O	945-949
ventricular	B	950-961
remodeling	I	962-972
.	O	972-973

Western	O	974-981
blot	O	982-986
analysis	O	987-995
showed	O	996-1002
that	O	1003-1007
isoproterenol	O	1008-1021
-	O	1021-1022
induced	O	1022-1029
phosphorylation	O	1030-1045
of	O	1046-1048
STAT3	O	1049-1054
was	O	1055-1058
maintained	O	1059-1069
or	O	1070-1072
further	O	1073-1080
enhanced	O	1081-1089
by	O	1090-1092
betaine	O	1093-1100
treatment	O	1101-1110
in	O	1111-1113
myocardium	O	1114-1124
.	O	1124-1125

Furthermore	O	1126-1137
,	O	1137-1138
betaine	O	1139-1146
(	O	1147-1148
200	O	1148-1151
and	O	1152-1155
400	O	1156-1159
mg	O	1160-1162
/	O	1162-1163
kg	O	1163-1165
)	O	1165-1166
treatment	O	1167-1176
increased	O	1177-1186
the	O	1187-1190
ventricular	O	1191-1202
expression	O	1203-1213
of	O	1214-1216
Bcl	O	1217-1220
-	O	1220-1221
2	O	1221-1222
and	O	1223-1226
reduced	O	1227-1234
the	O	1235-1238
level	O	1239-1244
of	O	1245-1247
Bax	O	1248-1251
,	O	1251-1252
therefore	O	1253-1262
causing	O	1263-1270
a	O	1271-1272
significant	O	1273-1284
increase	O	1285-1293
in	O	1294-1296
the	O	1297-1300
ratio	O	1301-1306
of	O	1307-1309
Bcl	O	1310-1313
-	O	1313-1314
2	O	1314-1315
/	O	1315-1316
Bax	O	1316-1319
.	O	1319-1320

The	O	1321-1324
protective	O	1325-1335
role	O	1336-1340
of	O	1341-1343
betaine	O	1344-1351
on	O	1352-1354
myocardial	B	1355-1365
damage	I	1366-1372
was	O	1373-1376
further	O	1377-1384
confirmed	O	1385-1394
by	O	1395-1397
histopathological	O	1398-1415
examination	O	1416-1427
.	O	1427-1428

In	O	1429-1431
summary	O	1432-1439
,	O	1439-1440
our	O	1441-1444
results	O	1445-1452
showed	O	1453-1459
that	O	1460-1464
betaine	O	1465-1472
pretreatment	O	1473-1485
attenuated	O	1486-1496
isoproterenol	O	1497-1510
-	O	1510-1511
induced	O	1511-1518
acute	O	1519-1524
myocardial	B	1525-1535
ischemia	I	1536-1544
via	O	1545-1548
the	O	1549-1552
regulation	O	1553-1563
of	O	1564-1566
STAT3	O	1567-1572
and	O	1573-1576
apoptotic	O	1577-1586
pathways	O	1587-1595
.	O	1595-1596

Quetiapine	O	0-10
-	O	10-11
induced	O	11-18
neutropenia	B	19-30
in	O	31-33
a	O	34-35
bipolar	B	36-43
patient	O	44-51
with	O	52-56
hepatocellular	B	57-71
carcinoma	I	72-81
.	O	81-82

OBJECTIVE	O	83-92
:	O	92-93
Quetiapine	O	94-104
is	O	105-107
a	O	108-109
dibenzothiazepine	O	110-127
derivative	O	128-138
,	O	138-139
similar	O	140-147
to	O	148-150
clozapine	O	151-160
,	O	160-161
which	O	162-167
has	O	168-171
the	O	172-175
highest	O	176-183
risk	O	184-188
of	O	189-191
causing	O	192-199
blood	B	200-205
dyscrasias	I	206-216
,	O	216-217
especially	O	218-228
neutropenia	B	229-240
.	O	240-241

There	O	242-247
are	O	248-251
some	O	252-256
case	O	257-261
reports	O	262-269
about	O	270-275
this	O	276-280
side	O	281-285
effect	O	286-292
of	O	293-295
quetiapine	O	296-306
,	O	306-307
but	O	308-311
possible	O	312-320
risk	O	321-325
factors	O	326-333
are	O	334-337
seldom	O	338-344
discussed	O	345-354
and	O	355-358
identified	O	359-369
.	O	369-370

A	O	371-372
case	O	373-377
of	O	378-380
a	O	381-382
patient	O	383-390
with	O	391-395
hepatocellular	B	396-410
carcinoma	I	411-420
that	O	421-425
developed	O	426-435
neutropenia	B	436-447
after	O	448-453
treatment	O	454-463
with	O	464-468
quetiapine	O	469-479
is	O	480-482
described	O	483-492
here	O	493-497
.	O	497-498

CASE	O	499-503
REPORT	O	504-510
:	O	510-511
A	O	512-513
62	O	514-516
-	O	516-517
year	O	517-521
-	O	516-517
old	O	522-525
Taiwanese	O	526-535
widow	O	536-541
with	O	542-546
bipolar	B	547-554
disorder	I	555-563
was	O	564-567
diagnosed	O	568-577
with	O	578-582
hepatocellular	B	583-597
carcinoma	I	598-607
at	O	608-610
age	O	611-614
60	O	615-617
.	O	617-618

She	O	619-622
developed	O	623-632
leucopenia	B	633-643
after	O	644-649
being	O	650-655
treated	O	656-663
with	O	664-668
quetiapine	O	669-679
.	O	679-680

After	O	681-686
quetiapine	O	687-697
was	O	698-701
discontinued	O	702-714
,	O	714-715
her	O	716-719
white	O	720-725
blood	O	726-731
cell	O	732-736
count	O	737-742
returned	O	743-751
to	O	752-754
normal	O	755-761
.	O	761-762

CONCLUSIONS	O	763-774
:	O	774-775
Although	O	776-784
neutropenia	B	785-796
is	O	797-799
not	O	800-803
a	O	804-805
common	O	806-812
side	O	813-817
effect	O	818-824
of	O	825-827
quetiapine	O	828-838
,	O	838-839
physicians	O	840-850
should	O	851-857
be	O	858-860
cautious	O	861-869
about	O	870-875
its	O	876-879
presentation	O	880-892
and	O	893-896
associated	O	897-907
risk	O	908-912
factors	O	913-920
.	O	920-921

Hepatic	B	922-929
dysfunction	I	930-941
may	O	942-945
be	O	946-948
one	O	949-952
of	O	953-955
the	O	956-959
possible	O	960-968
risk	O	969-973
factors	O	974-981
,	O	981-982
and	O	983-986
concomitant	O	987-998
fever	B	999-1004
may	O	1005-1008
be	O	1009-1011
a	O	1012-1013
diagnostic	O	1014-1024
marker	O	1025-1031
for	O	1032-1035
adverse	O	1036-1043
reaction	O	1044-1052
to	O	1053-1055
quetiapine	O	1056-1066
.	O	1066-1067

Lateral	O	0-7
antebrachial	O	8-20
cutaneous	O	21-30
neuropathy	B	31-41
after	O	42-47
steroid	O	48-55
injection	O	56-65
at	O	66-68
lateral	O	69-76
epicondyle	O	77-87
.	O	87-88

BACKGROUND	O	89-99
AND	O	100-103
OBJECTIVES	O	104-114
:	O	114-115
This	O	116-120
report	O	121-127
aimed	O	128-133
to	O	134-136
present	O	137-144
a	O	145-146
case	O	147-151
of	O	152-154
lateral	O	155-162
antebrachial	O	163-175
cutaneous	O	176-185
neuropathy	B	186-196
(	O	197-198
LACNP	O	198-203
)	O	203-204
that	O	205-209
occurred	O	210-218
after	O	219-224
a	O	225-226
steroid	O	227-234
injection	O	235-244
in	O	245-247
the	O	248-251
lateral	O	252-259
epicondyle	O	260-270
to	O	271-273
treat	O	274-279
lateral	B	280-287
epicondylitis	I	288-301
in	O	302-304
a	O	305-306
40	O	307-309
-	O	309-310
year	O	310-314
-	O	309-310
old	O	315-318
woman	O	319-324
.	O	324-325

MATERIAL	O	326-334
AND	O	335-338
METHOD	O	339-345
:	O	345-346
A	O	347-348
40	O	349-351
-	O	351-352
year	O	352-356
-	O	351-352
old	O	357-360
woman	O	361-366
presented	O	367-376
with	O	377-381
decreased	O	382-391
sensation	O	392-401
and	O	402-405
paresthesia	B	406-417
over	O	418-422
her	O	423-426
right	O	427-432
lateral	O	433-440
forearm	O	441-448
;	O	448-449
the	O	450-453
paresthesia	B	454-465
had	O	466-469
occurred	O	470-478
after	O	479-484
a	O	485-486
steroid	O	487-494
injection	O	495-504
in	O	505-507
the	O	508-511
right	O	512-517
lateral	O	518-525
epicondyle	O	526-536
3	O	537-538
months	O	539-545
before	O	546-552
.	O	552-553

Her	O	554-557
sensation	O	558-567
of	O	568-570
light	O	571-576
touch	O	577-582
and	O	583-586
pain	B	587-591
was	O	592-595
diminished	O	596-606
over	O	607-611
the	O	612-615
lateral	O	616-623
side	O	624-628
of	O	629-631
the	O	632-635
right	O	636-641
forearm	O	642-649
and	O	650-653
wrist	O	654-659
area	O	660-664
.	O	664-665

RESULTS	O	666-673
:	O	673-674
The	O	675-678
sensory	O	679-686
action	O	687-693
potential	O	694-703
amplitude	O	704-713
of	O	714-716
the	O	717-720
right	O	721-726
lateral	O	727-734
antebrachial	O	735-747
cutaneous	O	748-757
nerve	O	758-763
(	O	764-765
LACN	O	765-769
)	O	769-770
(	O	771-772
6	O	772-773
.	O	773-774
2	O	774-775
uV	O	776-778
)	O	778-779
was	O	780-783
lower	O	784-789
than	O	790-794
that	O	795-799
of	O	800-802
the	O	803-806
left	O	807-811
(	O	812-813
13	O	813-815
.	O	815-816
1	O	813-814
uV	O	818-820
)	O	820-821
.	O	821-822

The	O	823-826
difference	O	827-837
of	O	838-840
amplitude	O	841-850
between	O	851-858
both	O	859-863
sides	O	864-869
was	O	870-873
significant	O	874-885
because	O	886-893
there	O	894-899
was	O	900-903
more	O	904-908
than	O	909-913
a	O	914-915
50	O	916-918
%	O	918-919
reduction	O	920-929
.	O	929-930

She	O	931-934
was	O	935-938
diagnosed	O	939-948
with	O	949-953
right	O	954-959
LACNP	O	960-965
(	O	966-967
mainly	O	967-973
axonal	O	974-980
involvement	O	981-992
)	O	992-993
on	O	994-996
the	O	997-1000
basis	O	1001-1006
of	O	1007-1009
the	O	1010-1013
clinical	O	1014-1022
manifestation	O	1023-1036
and	O	1037-1040
the	O	1041-1044
electrodiagnostic	O	1045-1062
findings	O	1063-1071
.	O	1071-1072

Her	O	1073-1076
symptoms	O	1077-1085
improved	O	1086-1094
through	O	1095-1102
physical	O	1103-1111
therapy	O	1112-1119
but	O	1120-1123
persisted	O	1124-1133
to	O	1134-1136
some	O	1137-1141
degree	O	1142-1148
.	O	1148-1149

CONCLUSION	O	1150-1160
:	O	1160-1161
This	O	1162-1166
report	O	1167-1173
describes	O	1174-1183
the	O	1184-1187
case	O	1188-1192
of	O	1193-1195
a	O	1196-1197
woman	O	1198-1203
with	O	1204-1208
LACNP	O	1209-1214
that	O	1215-1219
developed	O	1220-1229
after	O	1230-1235
a	O	1236-1237
steroid	O	1238-1245
injection	O	1246-1255
for	O	1256-1259
the	O	1260-1263
treatment	O	1264-1273
of	O	1274-1276
lateral	B	1277-1284
epicondylitis	I	1285-1298
.	O	1298-1299

An	O	1300-1302
electrodiagnostic	O	1303-1320
study	O	1321-1326
,	O	1326-1327
including	O	1328-1337
a	O	1338-1339
nerve	O	1340-1345
conduction	O	1346-1356
study	O	1357-1362
of	O	1363-1365
the	O	1366-1369
LACN	O	1370-1374
,	O	1374-1375
was	O	1376-1379
helpful	O	1380-1387
to	O	1388-1390
diagnose	O	1391-1399
right	O	1400-1405
LACNP	O	1406-1411
and	O	1412-1415
to	O	1416-1418
find	O	1419-1423
the	O	1424-1427
passage	O	1428-1435
of	O	1436-1438
the	O	1439-1442
LACN	O	1443-1447
on	O	1448-1450
the	O	1451-1454
lateral	O	1455-1462
epicondyle	O	1463-1473
.	O	1473-1474

Curcumin	O	0-8
prevents	O	9-17
maleate	O	18-25
-	O	25-26
induced	O	26-33
nephrotoxicity	B	34-48
:	O	48-49
relation	O	50-58
to	O	59-61
hemodynamic	O	62-73
alterations	O	74-85
,	O	85-86
oxidative	O	87-96
stress	O	97-103
,	O	103-104
mitochondrial	O	105-118
oxygen	O	119-125
consumption	O	126-137
and	O	138-141
activity	O	142-150
of	O	151-153
respiratory	O	154-165
complex	O	166-173
I	O	174-175
.	O	175-176

The	O	177-180
potential	O	181-190
protective	O	191-201
effect	O	202-208
of	O	209-211
the	O	212-215
dietary	O	216-223
antioxidant	O	224-235
curcumin	O	236-244
(	O	245-246
120	O	246-249
mg	O	250-252
/	O	252-253
Kg	O	253-255
/	O	252-253
day	O	256-259
for	O	260-263
6	O	264-265
days	O	266-270
)	O	270-271
against	O	272-279
the	O	280-283
renal	B	284-289
injury	I	290-296
induced	O	297-304
by	O	305-307
maleate	O	308-315
was	O	316-319
evaluated	O	320-329
.	O	329-330

Tubular	O	331-338
proteinuria	B	339-350
and	O	351-354
oxidative	O	355-364
stress	O	365-371
were	O	372-376
induced	O	377-384
by	O	385-387
a	O	388-389
single	O	390-396
injection	O	397-406
of	O	407-409
maleate	O	410-417
(	O	418-419
400	O	419-422
mg	O	423-425
/	O	425-426
kg	O	426-428
)	O	428-429
in	O	430-432
rats	O	433-437
.	O	437-438

Maleate	O	439-446
-	O	446-447
induced	O	447-454
renal	B	455-460
injury	I	461-467
included	O	468-476
increase	O	477-485
in	O	486-488
renal	O	489-494
vascular	O	495-503
resistance	O	504-514
and	O	515-518
in	O	519-521
the	O	522-525
urinary	O	526-533
excretion	O	534-543
of	O	544-546
total	O	547-552
protein	O	553-560
,	O	560-561
glucose	O	562-569
,	O	569-570
sodium	O	571-577
,	O	577-578
neutrophil	O	579-589
gelatinase	O	590-600
-	O	600-601
associated	O	601-611
lipocalin	O	612-621
(	O	622-623
NGAL	O	623-627
)	O	627-628
and	O	629-632
N	O	633-634
-	O	634-635
acetyl	O	635-641
b	O	642-643
-	O	643-644
D	O	644-645
-	O	643-644
glucosaminidase	O	646-661
(	O	662-663
NAG	O	663-666
)	O	666-667
,	O	667-668
upregulation	O	669-681
of	O	682-684
kidney	B	685-691
injury	I	692-698
molecule	O	699-707
(	O	708-709
KIM	O	709-712
)	O	712-713
-	O	713-714
1	O	714-715
,	O	715-716
decrease	O	717-725
in	O	726-728
renal	O	729-734
blood	O	735-740
flow	O	741-745
and	O	746-749
claudin	O	750-757
-	O	757-758
2	O	758-759
expression	O	760-770
besides	O	771-778
of	O	779-781
necrosis	B	782-790
and	O	791-794
apoptosis	O	795-804
of	O	805-807
tubular	O	808-815
cells	O	816-821
on	O	822-824
24	O	825-827
h	O	828-829
.	O	829-830

Oxidative	O	831-840
stress	O	841-847
was	O	848-851
determined	O	852-862
by	O	863-865
measuring	O	866-875
the	O	876-879
oxidation	O	880-889
of	O	890-892
lipids	O	893-899
and	O	900-903
proteins	O	904-912
and	O	913-916
diminution	O	917-927
in	O	928-930
renal	O	931-936
Nrf2	O	937-941
levels	O	942-948
.	O	948-949

Studies	O	950-957
were	O	958-962
also	O	963-967
conducted	O	968-977
in	O	978-980
renal	O	981-986
epithelial	O	987-997
LLC	O	998-1001
-	O	1001-1002
PK1	O	1002-1005
cells	O	1006-1011
and	O	1012-1015
in	O	1016-1018
mitochondria	O	1019-1031
isolated	O	1032-1040
from	O	1041-1045
kidneys	O	1046-1053
of	O	1054-1056
all	O	1057-1060
the	O	1061-1064
experimental	O	1065-1077
groups	O	1078-1084
.	O	1084-1085

Maleate	O	1086-1093
induced	O	1094-1101
cell	O	1102-1106
damage	O	1107-1113
and	O	1114-1117
reactive	O	1118-1126
oxygen	O	1127-1133
species	O	1134-1141
(	O	1142-1143
ROS	O	1143-1146
)	O	1146-1147
production	O	1148-1158
in	O	1159-1161
LLC	O	1162-1165
-	O	1165-1166
PK1	O	1166-1169
cells	O	1170-1175
in	O	1176-1178
culture	O	1179-1186
.	O	1186-1187

In	O	1188-1190
addition	O	1191-1199
,	O	1199-1200
maleate	O	1201-1208
treatment	O	1209-1218
reduced	O	1219-1226
oxygen	O	1227-1233
consumption	O	1234-1245
in	O	1246-1248
ADP	O	1249-1252
-	O	1252-1253
stimulated	O	1253-1263
mitochondria	O	1264-1276
and	O	1277-1280
diminished	O	1281-1291
respiratory	O	1292-1303
control	O	1304-1311
index	O	1312-1317
when	O	1318-1322
using	O	1323-1328
malate	O	1329-1335
/	O	1335-1336
glutamate	O	1336-1345
as	O	1346-1348
substrate	O	1349-1358
.	O	1358-1359

The	O	1360-1363
activities	O	1364-1374
of	O	1375-1377
both	O	1378-1382
complex	O	1383-1390
I	O	1391-1392
and	O	1393-1396
aconitase	O	1397-1406
were	O	1407-1411
also	O	1412-1416
diminished	O	1417-1427
.	O	1427-1428

All	O	1429-1432
the	O	1433-1436
above	O	1437-1442
-	O	1442-1443
described	O	1443-1452
alterations	O	1453-1464
were	O	1465-1469
prevented	O	1470-1479
by	O	1480-1482
curcumin	O	1483-1491
.	O	1491-1492

It	O	1493-1495
is	O	1496-1498
concluded	O	1499-1508
that	O	1509-1513
curcumin	O	1514-1522
is	O	1523-1525
able	O	1526-1530
to	O	1531-1533
attenuate	O	1534-1543
in	O	1544-1546
vivo	O	1547-1551
maleate	O	1552-1559
-	O	1559-1560
induced	O	1560-1567
nephropathy	B	1568-1579
and	O	1580-1583
in	O	1584-1586
vitro	O	1587-1592
cell	O	1593-1597
damage	O	1598-1604
.	O	1604-1605

The	O	1606-1609
in	O	1610-1612
vivo	O	1613-1617
protection	O	1618-1628
was	O	1629-1632
associated	O	1633-1643
to	O	1644-1646
the	O	1647-1650
prevention	O	1651-1661
of	O	1662-1664
oxidative	O	1665-1674
stress	O	1675-1681
and	O	1682-1685
preservation	O	1686-1698
of	O	1699-1701
mitochondrial	O	1702-1715
oxygen	O	1716-1722
consumption	O	1723-1734
and	O	1735-1738
activity	O	1739-1747
of	O	1748-1750
respiratory	O	1751-1762
complex	O	1763-1770
I	O	1771-1772
,	O	1772-1773
and	O	1774-1777
the	O	1778-1781
in	O	1782-1784
vitro	O	1785-1790
protection	O	1791-1801
was	O	1802-1805
associated	O	1806-1816
to	O	1817-1819
the	O	1820-1823
prevention	O	1824-1834
of	O	1835-1837
ROS	O	1838-1841
production	O	1842-1852
.	O	1852-1853

Incidence	O	0-9
of	O	10-12
solid	O	13-18
tumours	B	19-26
among	O	27-32
pesticide	O	33-42
applicators	O	43-54
exposed	O	55-62
to	O	63-65
the	O	66-69
organophosphate	O	70-85
insecticide	O	86-97
diazinon	O	98-106
in	O	107-109
the	O	110-113
Agricultural	O	114-126
Health	O	127-133
Study	O	134-139
:	O	139-140
an	O	141-143
updated	O	144-151
analysis	O	152-160
.	O	160-161

OBJECTIVE	O	162-171
:	O	171-172
Diazinon	O	173-181
,	O	181-182
a	O	183-184
common	O	185-191
organophosphate	O	192-207
insecticide	O	208-219
with	O	220-224
genotoxic	O	225-234
properties	O	235-245
,	O	245-246
was	O	247-250
previously	O	251-261
associated	O	262-272
with	O	273-277
lung	B	278-282
cancer	I	283-289
in	O	290-292
the	O	293-296
Agricultural	O	297-309
Health	O	310-316
Study	O	317-322
(	O	323-324
AHS	O	324-327
)	O	327-328
cohort	O	329-335
,	O	335-336
but	O	337-340
few	O	341-344
other	O	345-350
epidemiological	O	351-366
studies	O	367-374
have	O	375-379
examined	O	380-388
diazinon	O	389-397
-	O	397-398
associated	O	398-408
cancer	B	409-415
risk	O	416-420
.	O	420-421

We	O	422-424
used	O	425-429
updated	O	430-437
diazinon	O	438-446
exposure	O	447-455
and	O	456-459
cancer	B	460-466
incidence	O	467-476
information	O	477-488
to	O	489-491
evaluate	O	492-500
solid	O	501-506
tumour	B	507-513
risk	O	514-518
in	O	519-521
the	O	522-525
AHS	O	526-529
.	O	529-530

METHODS	O	531-538
:	O	538-539
Male	O	540-544
pesticide	O	545-554
applicators	O	555-566
in	O	567-569
Iowa	O	570-574
and	O	575-578
North	O	579-584
Carolina	O	585-593
reported	O	594-602
lifetime	O	603-611
diazinon	O	612-620
use	O	621-624
at	O	625-627
enrolment	O	628-637
(	O	638-639
1993	O	639-643
-	O	643-644
1997	O	644-648
)	O	648-649
and	O	650-653
follow	O	654-660
-	O	660-661
up	O	661-663
(	O	664-665
1998	O	665-669
-	O	669-670
2005	O	670-674
)	O	674-675
;	O	675-676
cancer	B	677-683
incidence	O	684-693
was	O	694-697
assessed	O	698-706
through	O	707-714
2010	O	715-719
(	O	719-720
North	O	720-725
Carolina	O	726-734
)	O	734-735
/	O	735-736
2011	O	736-740
(	O	740-741
Iowa	O	741-745
)	O	734-735
.	O	746-747

Among	O	748-753
applicators	O	754-765
with	O	766-770
usage	O	771-776
information	O	777-788
sufficient	O	789-799
to	O	800-802
evaluate	O	803-811
exposure	O	812-820
-	O	820-821
response	O	821-829
patterns	O	830-838
,	O	838-839
we	O	840-842
used	O	843-847
Poisson	O	848-855
regression	O	856-866
to	O	867-869
estimate	O	870-878
adjusted	O	879-887
rate	O	888-892
ratios	O	893-899
(	O	900-901
RRs	O	901-904
)	O	904-905
and	O	906-909
95	O	910-912
%	O	912-913
CI	O	914-916
for	O	917-920
cancer	B	921-927
sites	O	928-933
with	O	934-938
>	O	939-940
10	O	940-942
exposed	O	943-950
cases	O	951-956
for	O	957-960
both	O	961-965
lifetime	O	966-974
(	O	975-976
LT	O	976-978
)	O	978-979
exposure	O	980-988
days	O	989-993
and	O	994-997
intensity	O	998-1007
-	O	1007-1008
weighted	O	1008-1016
(	O	1017-1018
IW	O	1018-1020
)	O	1020-1021
lifetime	O	1022-1030
exposure	O	1031-1039
days	O	1040-1044
(	O	1045-1046
accounting	O	1046-1056
for	O	1057-1060
factors	O	1061-1068
impacting	O	1069-1078
exposure	O	1079-1087
)	O	1087-1088
.	O	1088-1089

RESULTS	O	1090-1097
:	O	1097-1098
We	O	1099-1101
observed	O	1102-1110
elevated	O	1111-1119
lung	B	1120-1124
cancer	I	1125-1131
risks	O	1132-1137
(	O	1138-1139
N	O	1139-1140
=	O	1140-1141
283	O	1141-1144
)	O	1144-1145
among	O	1146-1151
applicators	O	1152-1163
with	O	1164-1168
the	O	1169-1172
greatest	O	1173-1181
number	O	1182-1188
of	O	1189-1191
LT	O	1192-1194
(	O	1195-1196
RR	O	1196-1198
=	O	1198-1199
1	O	1199-1200
.	O	1200-1201
60	O	1201-1203
;	O	1203-1204

95	O	1205-1207
%	O	1207-1208
CI	O	1209-1211
1	O	1212-1213
.	O	1213-1214
11	O	1214-1216
to	O	1217-1219
2	O	1220-1221
.	O	1221-1222
31	O	1222-1224
;	O	1224-1225
Ptrend	O	1226-1232
=	O	1232-1233
0	O	1233-1234
.	O	1234-1235
02	O	1235-1237
)	O	1237-1238

and	O	1239-1242
IW	O	1243-1245
days	O	1246-1250
of	O	1251-1253
diazinon	O	1254-1262
use	O	1263-1266
(	O	1267-1268
RR	O	1268-1270
=	O	1270-1271
1	O	1271-1272
.	O	1272-1273
41	O	1273-1275
;	O	1275-1276

95	O	1277-1279
%	O	1279-1280
CI	O	1281-1283
0	O	1284-1285
.	O	1285-1286
98	O	1286-1288
to	O	1289-1291
2	O	1292-1293
.	O	1293-1294
04	O	1294-1296
;	O	1296-1297
Ptrend	O	1298-1304
=	O	1304-1305
0	O	1305-1306
.	O	1306-1307
08	O	1307-1309
)	O	1309-1310
.	O	1306-1307

Kidney	B	1312-1318
cancer	I	1319-1325
(	O	1326-1327
N	O	1327-1328
=	O	1328-1329
94	O	1329-1331
)	O	1331-1332
risks	O	1333-1338
were	O	1339-1343
non	O	1344-1347
-	O	1347-1348
significantly	O	1348-1361
elevated	O	1362-1370
(	O	1371-1372
RRLT	O	1372-1376
days	O	1377-1381
=	O	1381-1382
1	O	1382-1383
.	O	1383-1384
77	O	1384-1386
;	O	1386-1387

95	O	1388-1390
%	O	1390-1391
CI	O	1392-1394
0	O	1395-1396
.	O	1396-1397
90	O	1397-1399
to	O	1400-1402
3	O	1403-1404
.	O	1404-1405
51	O	1405-1407
;	O	1407-1408
Ptrend	O	1409-1415
=	O	1415-1416
0	O	1416-1417
.	O	1417-1418
09	O	1418-1420
;	O	1420-1421

RRIW	O	1422-1426
days	O	1427-1431
1	O	1432-1433
.	O	1433-1434
37	O	1434-1436
;	O	1436-1437
95	O	1438-1440
%	O	1440-1441
CI	O	1442-1444
0	O	1445-1446
.	O	1446-1447
64	O	1447-1449
to	O	1450-1452
2	O	1453-1454
.	O	1454-1455
92	O	1455-1457
;	O	1457-1458
Ptrend	O	1459-1465
=	O	1465-1466
0	O	1466-1467
.	O	1467-1468
50	O	1468-1470
)	O	1470-1471
,	O	1471-1472

as	O	1473-1475
were	O	1476-1480
risks	O	1481-1486
for	O	1487-1490
aggressive	O	1491-1501
prostate	B	1502-1510
cancer	I	1511-1517
(	O	1518-1519
N	O	1519-1520
=	O	1520-1521
656	O	1521-1524
)	O	1524-1525
.	O	1525-1526

CONCLUSIONS	O	1527-1538
:	O	1538-1539
Our	O	1540-1543
updated	O	1544-1551
evaluation	O	1552-1562
of	O	1563-1565
diazinon	O	1566-1574
provides	O	1575-1583
additional	O	1584-1594
evidence	O	1595-1603
of	O	1604-1606
an	O	1607-1609
association	O	1610-1621
with	O	1622-1626
lung	B	1627-1631
cancer	I	1632-1638
risk	O	1639-1643
.	O	1643-1644

Newly	O	1645-1650
identified	O	1651-1661
links	O	1662-1667
to	O	1668-1670
kidney	B	1671-1677
cancer	I	1678-1684
and	O	1685-1688
associations	O	1689-1701
with	O	1702-1706
aggressive	O	1707-1717
prostate	B	1718-1726
cancer	I	1727-1733
require	O	1734-1741
further	O	1742-1749
evaluation	O	1750-1760
.	O	1760-1761

Associations	O	0-12
of	O	13-15
Ozone	O	16-21
and	O	22-25
PM2	O	26-29
.	O	29-30
5	O	30-31
Concentrations	O	32-46
With	O	47-51
Parkinson	B	52-61
'	I	61-62
s	I	58-59
Disease	I	64-71
Among	O	72-77
Participants	O	78-90
in	O	91-93
the	O	94-97
Agricultural	O	98-110
Health	O	111-117
Study	O	118-123
.	O	123-124

OBJECTIVE	O	125-134
:	O	134-135
This	O	136-140
study	O	141-146
describes	O	147-156
associations	O	157-169
of	O	170-172
ozone	O	173-178
and	O	179-182
fine	O	183-187
particulate	O	188-199
matter	O	200-206
with	O	207-211
Parkinson	B	212-221
'	I	221-222
s	I	218-219
disease	I	224-231
observed	O	232-240
among	O	241-246
farmers	O	247-254
in	O	255-257
North	O	258-263
Carolina	O	264-272
and	O	273-276
Iowa	O	277-281
.	O	281-282

METHODS	O	283-290
:	O	290-291
We	O	292-294
used	O	295-299
logistic	O	300-308
regression	O	309-319
to	O	320-322
determine	O	323-332
the	O	333-336
associations	O	337-349
of	O	350-352
these	O	353-358
pollutants	O	359-369
with	O	370-374
self	O	375-379
-	O	379-380
reported	O	380-388
,	O	388-389
doctor	O	390-396
-	O	396-397
diagnosed	O	397-406
Parkinson	B	407-416
'	I	416-417
s	I	413-414
disease	I	419-426
.	O	426-427

Daily	O	428-433
predicted	O	434-443
pollutant	O	444-453
concentrations	O	454-468
were	O	469-473
used	O	474-478
to	O	479-481
derive	O	482-488
surrogates	O	489-499
of	O	500-502
long	O	503-507
-	O	507-508
term	O	508-512
exposure	O	513-521
and	O	522-525
link	O	526-530
them	O	531-535
to	O	536-538
study	O	539-544
participants	O	545-557
'	O	557-558
geocoded	O	559-567
addresses	O	568-577
.	O	577-578

RESULTS	O	579-586
:	O	586-587
We	O	588-590
observed	O	591-599
positive	O	600-608
associations	O	609-621
of	O	622-624
Parkinson	B	625-634
'	I	634-635
s	I	631-632
disease	I	637-644
with	O	645-649
ozone	O	650-655
(	O	656-657
odds	O	657-661
ratio	O	662-667
=	O	668-669
1	O	670-671
.	O	671-672
39	O	672-674
;	O	674-675
95	O	676-678
%	O	678-679
CI	O	680-682
:	O	682-683
0	O	684-685
.	O	685-686
98	O	686-688
to	O	689-691
1	O	692-693
.	O	693-694
98	O	694-696
)	O	696-697
and	O	698-701
fine	O	702-706
particulate	O	707-718
matter	O	719-725
(	O	726-727
odds	O	727-731
ratio	O	732-737
=	O	738-739
1	O	740-741
.	O	741-742
34	O	742-744
;	O	744-745
95	O	746-748
%	O	748-749
CI	O	750-752
:	O	752-753
0	O	754-755
.	O	755-756
93	O	756-758
to	O	759-761
1	O	762-763
.	O	763-764
93	O	764-766
)	O	766-767
in	O	768-770
North	O	771-776
Carolina	O	777-785
but	O	786-789
not	O	790-793
in	O	794-796
Iowa	O	797-801
.	O	801-802

CONCLUSIONS	O	803-814
:	O	814-815
The	O	816-819
plausibility	O	820-832
of	O	833-835
an	O	836-838
effect	O	839-845
of	O	846-848
ambient	O	849-856
concentrations	O	857-871
of	O	872-874
these	O	875-880
pollutants	O	881-891
on	O	892-894
Parkinson	B	895-904
'	I	904-905
s	I	901-902
disease	I	907-914
risk	O	915-919
is	O	920-922
supported	O	923-932
by	O	933-935
experimental	O	936-948
data	O	949-953
demonstrating	O	954-967
damage	O	968-974
to	O	975-977
dopaminergic	O	978-990
neurons	O	991-998
at	O	999-1001
relevant	O	1002-1010
concentrations	O	1011-1025
.	O	1025-1026

Additional	O	1027-1037
studies	O	1038-1045
are	O	1046-1049
needed	O	1050-1056
to	O	1057-1059
address	O	1060-1067
uncertainties	O	1068-1081
related	O	1082-1089
to	O	1090-1092
confounding	O	1093-1104
and	O	1105-1108
to	O	1109-1111
examine	O	1112-1119
temporal	O	1120-1128
aspects	O	1129-1136
of	O	1137-1139
the	O	1140-1143
associations	O	1144-1156
we	O	1157-1159
observed	O	1160-1168
.	O	1168-1169

Low	O	0-3
functional	O	4-14
programming	O	15-26
of	O	27-29
renal	O	30-35
AT2R	O	36-40
mediates	O	41-49
the	O	50-53
developmental	O	54-67
origin	O	68-74
of	O	75-77
glomerulosclerosis	B	78-96
in	O	97-99
adult	O	100-105
offspring	O	106-115
induced	O	116-123
by	O	124-126
prenatal	O	127-135
caffeine	O	136-144
exposure	O	145-153
.	O	153-154

UNASSIGNED	O	155-165
:	O	165-166
Our	O	167-170
previous	O	171-179
study	O	180-185
has	O	186-189
indicated	O	190-199
that	O	200-204
prenatal	O	205-213
caffeine	O	214-222
exposure	O	223-231
(	O	232-233
PCE	O	233-236
)	O	236-237
could	O	238-243
induce	O	244-250
intrauterine	B	251-263
growth	I	264-270
retardation	I	271-282
(	O	283-284
IUGR	B	284-288
)	O	288-289
of	O	290-292
offspring	O	293-302
.	O	302-303

Recent	O	304-310
research	O	311-319
suggested	O	320-329
that	O	330-334
IUGR	B	335-339
is	O	340-342
a	O	343-344
risk	O	345-349
factor	O	350-356
for	O	357-360
glomerulosclerosis	B	361-379
.	O	379-380

However	O	381-388
,	O	388-389
whether	O	390-397
PCE	O	398-401
could	O	402-407
induce	O	408-414
glomerulosclerosis	B	415-433
and	O	434-437
its	O	438-441
underlying	O	442-452
mechanisms	O	453-463
remain	O	464-470
unknown	O	471-478
.	O	478-479

This	O	480-484
study	O	485-490
aimed	O	491-496
to	O	497-499
demonstrate	O	500-511
the	O	512-515
induction	O	516-525
to	O	526-528
glomerulosclerosis	B	529-547
in	O	548-550
adult	O	551-556
offspring	O	557-566
by	O	567-569
PCE	O	570-573
and	O	574-577
its	O	578-581
intrauterine	O	582-594
programming	O	595-606
mechanisms	O	607-617
.	O	617-618

A	O	619-620
rat	O	621-624
model	O	625-630
of	O	631-633
IUGR	B	634-638
was	O	639-642
established	O	643-654
by	O	655-657
PCE	O	658-661
,	O	661-662
male	O	663-667
fetuses	O	668-675
and	O	676-679
adult	O	680-685
offspring	O	686-695
at	O	696-698
the	O	699-702
age	O	703-706
of	O	707-709
postnatal	O	710-719
week	O	720-724
24	O	725-727
were	O	728-732
euthanized	O	733-743
.	O	743-744

The	O	745-748
results	O	749-756
revealed	O	757-765
that	O	766-770
the	O	771-774
adult	O	775-780
offspring	O	781-790
kidneys	O	791-798
in	O	799-801
the	O	802-805
PCE	O	806-809
group	O	810-815
exhibited	O	816-825
glomerulosclerosis	B	826-844
as	O	845-847
well	O	848-852
as	O	853-855
interstitial	B	856-868
fibrosis	I	869-877
,	O	877-878
accompanied	O	879-890
by	O	891-893
elevated	O	894-902
levels	O	903-909
of	O	910-912
serum	O	913-918
creatinine	O	919-929
and	O	930-933
urine	O	934-939
protein	O	940-947
.	O	947-948

Renal	O	949-954
angiotensin	O	955-966
II	O	967-969
receptor	O	970-978
type	O	979-983
2	O	984-985
(	O	986-987
AT2R	O	987-991
)	O	991-992
gene	O	993-997
expression	O	998-1008
in	O	1009-1011
adult	O	1012-1017
offspring	O	1018-1027
was	O	1028-1031
reduced	O	1032-1039
by	O	1040-1042
PCE	O	1043-1046
,	O	1046-1047
whereas	O	1048-1055
the	O	1056-1059
renal	O	1060-1065
angiotensin	O	1066-1077
II	O	1078-1080
receptor	O	1081-1089
type	O	1090-1094
1a	O	1095-1097
(	O	1098-1099
AT1aR	O	1099-1104
)	O	1104-1105
/	O	1105-1106
AT2R	O	1106-1110
expression	O	1111-1121
ratio	O	1122-1127
was	O	1128-1131
increased	O	1132-1141
.	O	1141-1142

The	O	1143-1146
fetal	O	1147-1152
kidneys	O	1153-1160
in	O	1161-1163
the	O	1164-1167
PCE	O	1168-1171
group	O	1172-1177
displayed	O	1178-1187
an	O	1188-1190
enlarged	O	1191-1199
Bowman	O	1200-1206
'	O	1206-1207
s	O	1207-1208
space	O	1209-1214
and	O	1215-1218
a	O	1219-1220
shrunken	O	1221-1229
glomerular	O	1230-1240
tuft	O	1241-1245
,	O	1245-1246
accompanied	O	1247-1258
by	O	1259-1261
a	O	1262-1263
reduced	O	1264-1271
cortex	O	1272-1278
width	O	1279-1284
and	O	1285-1288
an	O	1289-1291
increase	O	1292-1300
in	O	1301-1303
the	O	1304-1307
nephrogenic	O	1308-1319
zone	O	1320-1324
/	O	1324-1325
cortical	O	1325-1333
zone	O	1334-1338
ratio	O	1339-1344
.	O	1344-1345

Observation	O	1346-1357
by	O	1358-1360
electronic	O	1361-1371
microscope	O	1372-1382
revealed	O	1383-1391
structural	O	1392-1402
damage	O	1403-1409
of	O	1410-1412
podocytes	O	1413-1422
;	O	1422-1423
the	O	1424-1427
reduced	O	1428-1435
expression	O	1436-1446
level	O	1447-1452
of	O	1453-1455
podocyte	O	1456-1464
marker	O	1465-1471
genes	O	1472-1477
,	O	1477-1478
nephrin	O	1479-1486
and	O	1487-1490
podocin	O	1491-1498
,	O	1498-1499
was	O	1500-1503
also	O	1504-1508
detected	O	1509-1517
by	O	1518-1520
q	O	1521-1522
-	O	1522-1523
PCR	O	1523-1526
.	O	1526-1527

Moreover	O	1528-1536
,	O	1536-1537
AT2R	O	1538-1542
gene	O	1543-1547
and	O	1548-1551
protein	O	1552-1559
expressions	O	1560-1571
in	O	1572-1574
fetal	O	1575-1580
kidneys	O	1581-1588
were	O	1589-1593
inhibited	O	1594-1603
by	O	1604-1606
PCE	O	1607-1610
,	O	1610-1611
associated	O	1612-1622
with	O	1623-1627
the	O	1628-1631
repression	O	1632-1642
of	O	1643-1645
the	O	1646-1649
gene	O	1650-1654
expression	O	1655-1665
of	O	1666-1668
glial	O	1669-1674
-	O	1674-1675
cell	O	1675-1679
-	O	1674-1675
line	O	1680-1684
-	O	1674-1675
derived	O	1685-1692
neurotrophic	O	1693-1705
factor	O	1706-1712
(	O	1713-1714
GDNF	O	1714-1718
)	O	1718-1719
/	O	1719-1720
tyrosine	O	1720-1728
kinase	O	1729-1735
receptor	O	1736-1744
(	O	1745-1746
c	O	1746-1747
-	O	1747-1748
Ret	O	1748-1751
)	O	1751-1752
signaling	O	1753-1762
pathway	O	1763-1770
.	O	1770-1771

These	O	1772-1777
results	O	1778-1785
demonstrated	O	1786-1798
that	O	1799-1803
PCE	O	1804-1807
could	O	1808-1813
induce	O	1814-1820
dysplasia	B	1821-1830
of	I	1831-1833
fetal	I	1834-1839
kidneys	I	1840-1847
as	O	1848-1850
well	O	1851-1855
as	O	1856-1858
glomerulosclerosis	B	1859-1877
of	O	1878-1880
adult	O	1881-1886
offspring	O	1887-1896
,	O	1896-1897
and	O	1898-1901
the	O	1902-1905
low	O	1906-1909
functional	O	1910-1920
programming	O	1921-1932
of	O	1933-1935
renal	O	1936-1941
AT2R	O	1942-1946
might	O	1947-1952
mediate	O	1953-1960
the	O	1961-1964
developmental	O	1965-1978
origin	O	1979-1985
of	O	1986-1988
adult	O	1989-1994
glomerulosclerosis	B	1995-2013
.	O	2013-2014

1	O	0-1
,	O	1-2
3	O	2-3
-	O	3-4
Butadiene	O	4-13
,	O	1-2
CML	B	15-18
and	O	19-22
the	O	23-26
t	O	27-28
(	O	28-29
9	O	29-30
:	O	30-31
22	O	31-33
)	O	33-34
translocation	O	35-48
:	O	48-49
A	O	50-51
reality	O	52-59
check	O	60-65
.	O	65-66

UNASSIGNED	O	67-77
:	O	77-78
Epidemiological	O	79-94
studies	O	95-102
of	O	103-105
1	O	106-107
,	O	107-108
3	O	108-109
-	O	109-110
butadiene	O	110-119
have	O	120-124
suggest	O	125-132
that	O	133-137
exposures	O	138-147
to	O	148-150
humans	O	151-157
are	O	158-161
associated	O	162-172
with	O	173-177
chronic	B	178-185
myeloid	I	186-193
leukemia	I	194-202
(	O	203-204
CML	B	204-207
)	O	207-208
.	O	208-209

CML	B	210-213
has	O	214-217
a	O	218-219
well	O	220-224
-	O	224-225
documented	O	225-235
association	O	236-247
with	O	248-252
ionizing	O	253-261
radiation	O	262-271
,	O	271-272
but	O	273-276
reports	O	277-284
of	O	285-287
associations	O	288-300
with	O	301-305
chemical	O	306-314
exposures	O	315-324
have	O	325-329
been	O	330-334
questioned	O	335-345
.	O	345-346

Ionizing	O	347-355
radiation	O	356-365
is	O	366-368
capable	O	369-376
of	O	377-379
inducing	O	380-388
the	O	389-392
requisite	O	393-402
CML	B	403-406
-	O	406-407
associated	O	407-417
t	O	418-419
(	O	419-420
9	O	420-421
:	O	421-422
22	O	422-424
)	O	424-425
translocation	O	426-439
(	O	440-441
Philadelphia	B	441-453
chromosome	I	454-464
)	O	464-465
in	O	466-468
appropriate	O	469-480
cells	O	481-486
in	O	487-489
vitro	O	490-495
but	O	496-499
,	O	499-500
thus	O	501-505
far	O	506-509
,	O	509-510
chemicals	O	511-520
have	O	521-525
not	O	526-529
shown	O	530-535
this	O	536-540
capacity	O	541-549
.	O	549-550

We	O	551-553
have	O	554-558
proposed	O	559-567
that	O	568-572
1	O	573-574
,	O	574-575
3	O	575-576
-	O	576-577
butadiene	O	577-586
metabolites	O	587-598
be	O	599-601
so	O	602-604
tested	O	605-611
as	O	612-614
a	O	615-616
reality	O	617-624
check	O	625-630
on	O	631-633
the	O	634-637
epidemiological	O	638-653
reports	O	654-661
.	O	661-662

In	O	663-665
order	O	666-671
to	O	672-674
conduct	O	675-682
reliable	O	683-691
testing	O	692-699
in	O	700-702
this	O	703-707
regard	O	708-714
,	O	714-715
it	O	716-718
is	O	719-721
essential	O	722-731
that	O	732-736
a	O	737-738
positive	O	739-747
control	O	748-755
for	O	756-759
induction	O	760-769
be	O	770-772
available	O	773-782
.	O	782-783

We	O	784-786
have	O	787-791
used	O	792-796
ionizing	O	797-805
radiation	O	806-815
to	O	816-818
develop	O	819-826
such	O	827-831
a	O	832-833
control	O	834-841
.	O	841-842

Results	O	843-850
described	O	851-860
here	O	861-865
demonstrate	O	866-877
that	O	878-882
this	O	883-887
agent	O	888-893
does	O	894-898
in	O	899-901
fact	O	902-906
induce	O	907-913
pathogenic	O	914-924
t	O	925-926
(	O	926-927
9	O	927-928
:	O	928-929
22	O	929-931
)	O	931-932
translocations	O	933-947
in	O	948-950
a	O	951-952
human	O	953-958
myeloid	O	959-966
cell	O	967-971
line	O	972-976
in	O	977-979
vitro	O	980-985
,	O	985-986
but	O	987-990
does	O	991-995
so	O	996-998
at	O	999-1001
low	O	1002-1005
frequencies	O	1006-1017
.	O	1017-1018

Conditions	O	1019-1029
that	O	1030-1034
will	O	1035-1039
be	O	1040-1042
required	O	1043-1051
for	O	1052-1055
studies	O	1056-1063
of	O	1064-1066
1	O	1067-1068
,	O	1068-1069
3	O	1069-1070
-	O	1070-1071
butadiene	O	1071-1080
are	O	1081-1084
discussed	O	1085-1094
.	O	1094-1095

Cancer	B	0-6
incidence	O	7-16
and	O	17-20
metolachlor	O	21-32
use	O	33-36
in	O	37-39
the	O	40-43
Agricultural	O	44-56
Health	O	57-63
Study	O	64-69
:	O	69-70
An	O	71-73
update	O	74-80
.	O	80-81

UNASSIGNED	O	82-92
:	O	92-93
Metolachlor	O	94-105
,	O	105-106
a	O	107-108
widely	O	109-115
used	O	116-120
herbicide	O	121-130
,	O	130-131
is	O	132-134
classified	O	135-145
as	O	146-148
a	O	149-150
Group	O	151-156
C	O	157-158
carcinogen	O	159-169
by	O	170-172
the	O	173-176
U	O	177-178
.	O	178-179
S	O	179-180
.	O	178-179
Environmental	O	182-195
Protection	O	196-206
Agency	O	207-213
based	O	214-219
on	O	220-222
increased	O	223-232
liver	B	233-238
neoplasms	I	239-248
in	O	249-251
female	O	252-258
rats	O	259-263
.	O	263-264

Epidemiologic	O	265-278
studies	O	279-286
of	O	287-289
the	O	290-293
health	O	294-300
effects	O	301-308
of	O	309-311
metolachlor	O	312-323
have	O	324-328
been	O	329-333
limited	O	334-341
.	O	341-342

The	O	343-346
Agricultural	O	347-359
Health	O	360-366
Study	O	367-372
(	O	373-374
AHS	O	374-377
)	O	377-378
is	O	379-381
a	O	382-383
prospective	O	384-395
cohort	O	396-402
study	O	403-408
including	O	409-418
licensed	O	419-427
private	O	428-435
and	O	436-439
commercial	O	440-450
pesticide	O	451-460
applicators	O	461-472
in	O	473-475
Iowa	O	476-480
and	O	481-484
North	O	485-490
Carolina	O	491-499
enrolled	O	500-508
1993	O	509-513
-	O	513-514
1997	O	514-518
.	O	518-519

We	O	520-522
evaluated	O	523-532
cancer	B	533-539
incidence	O	540-549
through	O	550-557
2010	O	558-562
/	O	562-563
2011	O	563-567
(	O	568-569
NC	O	569-571
/	O	571-572
IA	O	572-574
)	O	574-575
for	O	576-579
49	O	580-582
,	O	582-583
616	O	583-586
applicators	O	587-598
,	O	598-599
53	O	600-602
%	O	602-603
of	O	604-606
whom	O	607-611
reported	O	612-620
ever	O	621-625
using	O	626-631
metolachlor	O	632-643
.	O	643-644

We	O	645-647
used	O	648-652
Poisson	O	653-660
regression	O	661-671
to	O	672-674
evaluate	O	675-683
relations	O	684-693
between	O	694-701
two	O	702-705
metrics	O	706-713
of	O	714-716
metolachlor	O	717-728
use	O	729-732
(	O	733-734
lifetime	O	734-742
days	O	743-747
,	O	747-748
intensity	O	749-758
-	O	758-759
weighted	O	759-767
lifetime	O	768-776
days	O	777-781
)	O	781-782
and	O	783-786
cancer	B	787-793
incidence	O	794-803
.	O	803-804

We	O	805-807
saw	O	808-811
no	O	812-814
association	O	815-826
between	O	827-834
metolachlor	O	835-846
use	O	847-850
and	O	851-854
incidence	O	855-864
of	O	865-867
all	O	868-871
cancers	B	872-879
combined	O	880-888
(	O	889-890
n	O	890-891
=	O	892-893
5	O	894-895
,	O	895-896
701	O	896-899
with	O	900-904
a	O	905-906
5	O	907-908
-	O	908-909
year	O	909-913
lag	O	914-917
)	O	917-918
or	O	919-921
most	O	922-926
site	O	927-931
-	O	931-932
specific	O	932-940
cancers	B	941-948
.	O	948-949

For	O	950-953
liver	B	954-959
cancer	I	960-966
,	O	966-967
in	O	968-970
analyses	O	971-979
restricted	O	980-990
to	O	991-993
exposed	O	994-1001
workers	O	1002-1009
,	O	1009-1010
elevations	O	1011-1021
observed	O	1022-1030
at	O	1031-1033
higher	O	1034-1040
categories	O	1041-1051
of	O	1052-1054
use	O	1055-1058
were	O	1059-1063
not	O	1064-1067
statistically	O	1068-1081
significant	O	1082-1093
.	O	1093-1094

However	O	1095-1102
,	O	1102-1103
trends	O	1104-1110
for	O	1111-1114
both	O	1115-1119
lifetime	O	1120-1128
and	O	1129-1132
intensity	O	1133-1142
-	O	1142-1143
weighted	O	1143-1151
lifetime	O	1152-1160
days	O	1161-1165
of	O	1166-1168
metolachor	O	1169-1179
use	O	1180-1183
were	O	1184-1188
positive	O	1189-1197
and	O	1198-1201
statistically	O	1202-1215
significant	O	1216-1227
with	O	1228-1232
an	O	1233-1235
unexposed	O	1236-1245
reference	O	1246-1255
group	O	1256-1261
.	O	1261-1262

A	O	1263-1264
similar	O	1265-1272
pattern	O	1273-1280
was	O	1281-1284
observed	O	1285-1293
for	O	1294-1297
follicular	B	1298-1308
cell	I	1309-1313
lymphoma	I	1314-1322
,	O	1322-1323
but	O	1324-1327
no	O	1328-1330
other	O	1331-1336
lymphoma	B	1337-1345
subtypes	O	1346-1354
.	O	1354-1355

An	O	1356-1358
earlier	O	1359-1366
suggestion	O	1367-1377
of	O	1378-1380
increased	O	1381-1390
lung	B	1391-1395
cancer	I	1396-1402
risk	O	1403-1407
at	O	1408-1410
high	O	1411-1415
levels	O	1416-1422
of	O	1423-1425
metolachlor	O	1426-1437
use	O	1438-1441
in	O	1442-1444
this	O	1445-1449
cohort	O	1450-1456
was	O	1457-1460
not	O	1461-1464
confirmed	O	1465-1474
in	O	1475-1477
this	O	1478-1482
update	O	1483-1489
.	O	1489-1490

This	O	1491-1495
suggestion	O	1496-1506
of	O	1507-1509
an	O	1510-1512
association	O	1513-1524
between	O	1525-1532
metolachlor	O	1533-1544
and	O	1545-1548
liver	B	1549-1554
cancer	I	1555-1561
among	O	1562-1567
pesticide	O	1568-1577
applicators	O	1578-1589
is	O	1590-1592
a	O	1593-1594
novel	O	1595-1600
finding	O	1601-1608
and	O	1609-1612
echoes	O	1613-1619
observation	O	1620-1631
of	O	1632-1634
increased	O	1635-1644
liver	B	1645-1650
neoplasms	I	1651-1660
in	O	1661-1663
some	O	1664-1668
animal	O	1669-1675
studies	O	1676-1683
.	O	1683-1684

However	O	1685-1692
,	O	1692-1693
our	O	1694-1697
findings	O	1698-1706
for	O	1707-1710
both	O	1711-1715
liver	B	1716-1721
cancer	I	1722-1728
and	O	1729-1732
follicular	O	1733-1743
cell	O	1744-1748
lymphoma	B	1749-1757
warrant	O	1758-1765
follow	O	1766-1772
-	O	1772-1773
up	O	1773-1775
to	O	1776-1778
better	O	1779-1785
differentiate	O	1786-1799
effects	O	1800-1807
of	O	1808-1810
metolachlor	O	1811-1822
use	O	1823-1826
from	O	1827-1831
other	O	1832-1837
factors	O	1838-1845
.	O	1845-1846

Mechanisms	O	0-10
Underlying	O	11-21
Latent	O	22-28
Disease	O	29-36
Risk	O	37-41
Associated	O	42-52
with	O	53-57
Early	O	58-63
-	O	63-64
Life	O	64-68
Arsenic	O	69-76
Exposure	O	77-85
:	O	85-86
Current	O	87-94
Research	O	95-103
Trends	O	104-110
and	O	111-114
Scientific	O	115-125
Gaps	O	126-130
.	O	130-131

BACKGROUND	O	132-142
:	O	142-143
Millions	O	144-152
of	O	153-155
individuals	O	156-167
worldwide	O	168-177
,	O	177-178
particularly	O	179-191
those	O	192-197
living	O	198-204
in	O	205-207
rural	O	208-213
and	O	214-217
developing	O	218-228
areas	O	229-234
,	O	234-235
are	O	236-239
exposed	O	240-247
to	O	248-250
harmful	O	251-258
levels	O	259-265
of	O	266-268
inorganic	O	269-278
arsenic	O	279-286
(	O	287-288
iAs	O	288-291
)	O	291-292
in	O	293-295
their	O	296-301
drinking	O	302-310
water	O	311-316
.	O	316-317

Inorganic	O	318-327
As	O	328-330
exposure	O	331-339
during	O	340-346
key	O	347-350
developmental	O	351-364
periods	O	365-372
is	O	373-375
associated	O	376-386
with	O	387-391
a	O	392-393
variety	O	394-401
of	O	402-404
adverse	O	405-412
health	O	413-419
effects	O	420-427
including	O	428-437
those	O	438-443
that	O	444-448
are	O	449-452
evident	O	453-460
in	O	461-463
adulthood	O	464-473
.	O	473-474

There	O	475-480
is	O	481-483
considerable	O	484-496
interest	O	497-505
in	O	506-508
identifying	O	509-520
the	O	521-524
molecular	O	525-534
mechanisms	O	535-545
that	O	546-550
relate	O	551-557
early	O	558-563
-	O	563-564
life	O	564-568
iAs	O	569-572
exposure	O	573-581
to	O	582-584
the	O	585-588
development	O	589-600
of	O	601-603
these	O	604-609
latent	O	610-616
diseases	O	617-625
,	O	625-626
particularly	O	627-639
in	O	640-642
relationship	O	643-655
to	O	656-658
cancer	B	659-665
.	O	665-666

OBJECTIVES	O	667-677
:	O	677-678
This	O	679-683
work	O	684-688
summarizes	O	689-699
research	O	700-708
on	O	709-711
the	O	712-715
molecular	O	716-725
mechanisms	O	726-736
that	O	737-741
underlie	O	742-750
the	O	751-754
increased	O	755-764
risk	O	765-769
of	O	770-772
cancer	B	773-779
development	O	780-791
in	O	792-794
adulthood	O	795-804
that	O	805-809
is	O	810-812
associated	O	813-823
with	O	824-828
early	O	829-834
-	O	834-835
life	O	835-839
iAs	O	840-843
exposure	O	844-852
.	O	852-853

DISCUSSION	O	854-864
:	O	864-865
Epigenetic	O	866-876
reprogramming	O	877-890
that	O	891-895
imparts	O	896-903
functional	O	904-914
changes	O	915-922
in	O	923-925
gene	O	926-930
expression	O	931-941
,	O	941-942
the	O	943-946
development	O	947-958
of	O	959-961
cancer	B	962-968
stem	O	969-973
cells	O	974-979
,	O	979-980
and	O	981-984
immunomodulation	O	985-1001
are	O	1002-1005
plausible	O	1006-1015
underlying	O	1016-1026
mechanisms	O	1027-1037
by	O	1038-1040
which	O	1041-1046
early	O	1047-1052
-	O	1052-1053
life	O	1053-1057
iAs	O	1058-1061
exposure	O	1062-1070
elicits	O	1071-1078
latent	O	1079-1085
carcinogenic	O	1086-1098
effects	O	1099-1106
.	O	1106-1107

CONCLUSIONS	O	1108-1119
:	O	1119-1120
Evidence	O	1121-1129
is	O	1130-1132
mounting	O	1133-1141
that	O	1142-1146
relates	O	1147-1154
early	O	1155-1160
-	O	1160-1161
life	O	1161-1165
iAs	O	1166-1169
exposure	O	1170-1178
and	O	1179-1182
cancer	B	1183-1189
development	O	1190-1201
later	O	1202-1207
in	O	1208-1210
life	O	1211-1215
.	O	1215-1216

Future	O	1217-1223
research	O	1224-1232
should	O	1233-1239
include	O	1240-1247
animal	O	1248-1254
studies	O	1255-1262
that	O	1263-1267
address	O	1268-1275
mechanistic	O	1276-1287
hypotheses	O	1288-1298
and	O	1299-1302
studies	O	1303-1310
of	O	1311-1313
human	O	1314-1319
populations	O	1320-1331
that	O	1332-1336
integrate	O	1337-1346
early	O	1347-1352
-	O	1352-1353
life	O	1353-1357
exposure	O	1358-1366
,	O	1366-1367
molecular	O	1368-1377
alterations	O	1378-1389
,	O	1389-1390
and	O	1391-1394
latent	O	1395-1401
disease	O	1402-1409
outcomes	O	1410-1418
.	O	1418-1419

On	O	0-2
the	O	3-6
antiarrhythmic	O	7-21
activity	O	22-30
of	O	31-33
one	O	34-37
N	O	38-39
-	O	39-40
substituted	O	40-51
piperazine	O	52-62
derivative	O	63-73
of	O	74-76
trans	O	77-82
-	O	82-83
2	O	83-84
-	O	82-83
amino	O	85-90
-	O	82-83
3	O	91-92
-	O	82-83
hydroxy	O	93-100
-	O	82-83
1	O	101-102
,	O	102-103
2	O	104-105
,	O	105-106
3	O	107-108
,	O	108-109
4	O	110-111
-	O	111-112
tetrahydroanaphthalene	O	112-134
.	O	134-135

The	O	136-139
antiarrhythmic	O	140-154
activity	O	155-163
of	O	164-166
the	O	167-170
compound	O	171-179
N	O	180-181
-	O	181-182
(	O	182-183
trans	O	183-188
-	O	181-182
3	O	189-190
-	O	181-182
hydroxy	O	191-198
-	O	181-182
1	O	199-200
,	O	200-201
2	O	201-202
,	O	200-201
3	O	189-190
,	O	200-201
4	O	205-206
-	O	181-182
tetrahydro	O	207-217
-	O	181-182
2	O	201-202
-	O	181-182
naphthyl	O	220-228
)	O	228-229
-	O	181-182
N	O	180-181
-	O	181-182
(	O	182-183
3	O	189-190
-	O	181-182
oxo	O	235-238
-	O	181-182
3	O	189-190
-	O	181-182
phenyl	O	241-247
-	O	181-182
2	O	201-202
-	O	181-182
methylpropyl	O	250-262
)	O	228-229
-	O	181-182
piperazine	O	264-274
hydrochloride	O	275-288
,	O	288-289
referred	O	290-298
to	O	299-301
as	O	302-304
P11	O	305-308
,	O	308-309
is	O	310-312
studied	O	313-320
on	O	321-323
anaesthesized	O	324-337
cats	O	338-342
and	O	343-346
Wistar	O	347-353
albino	O	354-360
rats	O	361-365
,	O	365-366
as	O	367-369
well	O	370-374
as	O	375-377
on	O	378-380
non	O	381-384
-	O	384-385
anaesthesized	O	385-398
rabbits	O	399-406
.	O	406-407

Four	O	408-412
types	O	413-418
of	O	419-421
experimental	O	422-434
arrhythmia	B	435-445
are	O	446-449
used	O	450-454
-	O	454-455
-	O	454-455
with	O	456-460
BaCl2	O	461-466
,	O	466-467
with	O	468-472
chloroform	O	473-483
-	O	483-484
adrenaline	O	484-494
,	O	494-495
with	O	496-500
strophantine	O	501-513
G	O	514-515
and	O	516-519
with	O	520-524
aconitine	O	525-534
.	O	534-535

The	O	536-539
compound	O	540-548
P11	O	549-552
is	O	553-555
introduced	O	556-566
in	O	567-569
doses	O	570-575
of	O	576-578
0	O	579-580
.	O	580-581
25	O	581-583
and	O	584-587
0	O	588-589
.	O	589-590
50	O	590-592
mg	O	593-595
/	O	595-596
kg	O	596-598
intravenously	O	599-612
and	O	613-616
10	O	617-619
mg	O	620-622
/	O	622-623
kg	O	623-625
orally	O	626-632
.	O	632-633

The	O	634-637
compound	O	638-646
manifests	O	647-656
antiarrhythmic	O	657-671
activity	O	672-680
in	O	681-683
all	O	684-687
models	O	688-694
of	O	695-697
experimental	O	698-710
arrhythmia	B	711-721
used	O	722-726
,	O	726-727
causing	O	728-735
greatest	O	736-744
inhibition	O	745-755
on	O	756-758
the	O	759-762
arrhythmia	B	763-773
induced	O	774-781
by	O	782-784
chloroform	O	785-795
-	O	795-796
adrenaline	O	796-806
(	O	807-808
in	O	808-810
90	O	811-813
per	O	814-817
cent	O	818-822
)	O	822-823
and	O	824-827
with	O	828-832
BaCl2	O	833-838
(	O	839-840
in	O	840-842
84	O	843-845
per	O	846-849
cent	O	850-854
)	O	854-855
.	O	855-856

The	O	857-860
results	O	861-868
obtained	O	869-877
are	O	878-881
associated	O	882-892
with	O	893-897
the	O	898-901
beta	O	902-906
-	O	906-907
adrenoblocking	O	907-921
and	O	922-925
with	O	926-930
the	O	931-934
membrane	O	935-943
-	O	943-944
stabilizing	O	944-955
action	O	956-962
of	O	963-965
the	O	966-969
compound	O	970-978
.	O	978-979

Experimental	O	0-12
progressive	O	13-24
muscular	B	25-33
dystrophy	I	34-43
and	O	44-47
its	O	48-51
treatment	O	52-61
with	O	62-66
high	O	67-71
doses	O	72-77
anabolizing	O	78-89
agents	O	90-96
.	O	96-97

We	O	98-100
are	O	101-104
still	O	105-110
a	O	111-112
long	O	113-117
way	O	118-121
from	O	122-126
discovering	O	127-138
an	O	139-141
unequivocal	O	142-153
pathogenetic	O	154-166
interpretation	O	167-181
of	O	182-184
progressive	O	185-196
muscular	B	197-205
dystrophy	I	206-215
in	O	216-218
man	O	219-222
.	O	222-223

Noteworthy	O	224-234
efforts	O	235-242
have	O	243-247
been	O	248-252
made	O	253-257
in	O	258-260
the	O	261-264
experimental	O	265-277
field	O	278-283
;	O	283-284
a	O	285-286
recessive	O	287-296
autosomic	O	297-306
form	O	307-311
found	O	312-317
in	O	318-320
the	O	321-324
mouse	O	325-330
seems	O	331-336
to	O	337-339
bear	O	340-344
the	O	345-348
closest	O	349-356
resemblance	O	357-368
to	O	369-371
the	O	372-375
human	O	376-381
form	O	382-386
from	O	387-391
the	O	392-395
genetic	O	396-403
point	O	404-409
of	O	410-412
view	O	413-417
.	O	417-418

Myopathy	B	419-427
due	O	428-431
to	O	432-434
lack	O	435-439
of	O	440-442
vitamin	O	443-450
E	O	451-452
and	O	453-456
myopathy	B	457-465
induced	O	466-473
by	O	474-476
certain	O	477-484
viruses	O	485-492
have	O	493-497
much	O	498-502
in	O	503-505
common	O	506-512
anatomically	O	513-525
and	O	526-529
pathologically	O	530-544
with	O	545-549
the	O	550-553
human	O	554-559
form	O	560-564
.	O	564-565

The	O	566-569
authors	O	570-577
induced	O	578-585
myodystrophy	B	586-598
in	O	599-601
the	O	602-605
rat	O	606-609
by	O	610-612
giving	O	613-619
it	O	620-622
a	O	623-624
diet	O	625-629
lacking	O	630-637
in	O	638-640
vitamin	O	641-648
E	O	649-650
.	O	650-651
The	O	652-655
pharmacological	O	656-671
characteristics	O	672-687
of	O	688-690
vitamin	O	691-698
E	O	699-700
and	O	701-704
the	O	705-708
degenerative	O	709-721
changes	O	722-729
brought	O	730-737
about	O	738-743
by	O	744-746
its	O	747-750
deficiency	O	751-761
,	O	761-762
especially	O	763-773
in	O	774-776
the	O	777-780
muscles	O	781-788
,	O	788-789
are	O	790-793
illustrated	O	794-805
.	O	805-806

It	O	807-809
is	O	810-812
thus	O	813-817
confirmed	O	818-827
that	O	828-832
the	O	833-836
histological	O	837-849
characteristics	O	850-865
of	O	866-868
myopathic	B	869-878
rat	O	879-882
muscle	O	883-889
induced	O	890-897
experimentally	O	898-912
are	O	913-916
extraordinarily	O	917-932
similar	O	933-940
to	O	941-943
those	O	944-949
of	O	950-952
human	O	953-958
myopathy	B	959-967
as	O	968-970
confirmed	O	971-980
during	O	981-987
biopsies	O	988-996
performed	O	997-1006
at	O	1007-1009
the	O	1010-1013
Orthopaedic	O	1014-1025
Traumatological	O	1026-1041
Centre	O	1042-1048
,	O	1048-1049
Florence	O	1050-1058
.	O	1058-1059

The	O	1060-1063
encouraging	O	1064-1075
results	O	1076-1083
obtained	O	1084-1092
in	O	1093-1095
various	O	1096-1103
authoratative	O	1104-1117
departments	O	1118-1129
in	O	1130-1132
myopathic	B	1133-1142
patients	O	1143-1151
by	O	1152-1154
using	O	1155-1160
anabolizing	O	1161-1172
steroids	O	1173-1181
have	O	1182-1186
encouraged	O	1187-1197
the	O	1198-1201
authors	O	1202-1209
to	O	1210-1212
investigate	O	1213-1224
the	O	1225-1228
beneficial	O	1229-1239
effects	O	1240-1247
of	O	1248-1250
one	O	1251-1254
anabolizing	O	1255-1266
agent	O	1267-1272
(	O	1273-1274
Dianabol	O	1274-1282
,	O	1282-1283
CIBA	O	1284-1288
)	O	1288-1289
at	O	1290-1292
high	O	1293-1297
doses	O	1298-1303
in	O	1304-1306
rats	O	1307-1311
rendered	O	1312-1320
myopathic	B	1321-1330
by	O	1331-1333
a	O	1334-1335
diet	O	1336-1340
deficient	O	1341-1350
in	O	1351-1353
vitamin	O	1354-1361
E	O	1362-1363
.	O	1363-1364
In	O	1365-1367
this	O	1368-1372
way	O	1373-1376
they	O	1377-1381
obtained	O	1382-1390
appreciable	O	1391-1402
changes	O	1403-1410
in	O	1411-1413
body	O	1414-1418
weight	O	1419-1425
(	O	1426-1427
increased	O	1427-1436
from	O	1437-1441
50	O	1442-1444
to	O	1445-1447
70	O	1448-1450
g	O	1451-1452
after	O	1453-1458
forty	O	1459-1464
days	O	1465-1469
at	O	1470-1472
a	O	1473-1474
dose	O	1475-1479
of	O	1480-1482
5	O	1483-1484
mg	O	1485-1487
per	O	1488-1491
day	O	1492-1495
of	O	1496-1498
anabolizing	O	1499-1510
agent	O	1511-1516
)	O	1516-1517
,	O	1517-1518
but	O	1519-1522
most	O	1523-1527
of	O	1528-1530
all	O	1531-1534
they	O	1535-1539
found	O	1540-1545
histological	O	1546-1558
changes	O	1559-1566
due	O	1567-1570
to	O	1571-1573
"	O	1574-1575
regenerative	O	1575-1587
"	O	1574-1575
changes	O	1589-1596
in	O	1597-1599
the	O	1600-1603
muscle	O	1604-1610
tissue	O	1611-1617
,	O	1617-1618
which	O	1619-1624
however	O	1625-1632
maintained	O	1633-1643
its	O	1644-1647
myopathic	B	1648-1657
characteristics	O	1658-1673
in	O	1674-1676
the	O	1677-1680
control	O	1681-1688
animals	O	1689-1696
that	O	1697-1701
were	O	1702-1706
not	O	1707-1710
treated	O	1711-1718
with	O	1719-1723
the	O	1724-1727
anabolizing	O	1728-1739
agent	O	1740-1745
.	O	1745-1746

The	O	1747-1750
authors	O	1751-1758
conclude	O	1759-1767
by	O	1768-1770
affirming	O	1771-1780
the	O	1781-1784
undoubted	O	1785-1794
efficacy	O	1795-1803
of	O	1804-1806
the	O	1807-1810
anabolizing	O	1811-1822
steroids	O	1823-1831
in	O	1832-1834
experimental	O	1835-1847
myopathic	B	1848-1857
disease	I	1858-1865
,	O	1865-1866
but	O	1867-1870
they	O	1871-1875
have	O	1876-1880
reservations	O	1881-1893
as	O	1894-1896
to	O	1897-1899
the	O	1900-1903
transfer	O	1904-1912
of	O	1913-1915
the	O	1916-1919
results	O	1920-1927
into	O	1928-1932
the	O	1933-1936
human	O	1937-1942
field	O	1943-1948
,	O	1948-1949
where	O	1950-1955
high	O	1956-1960
dosage	O	1961-1967
cannot	O	1968-1974
be	O	1975-1977
carried	O	1978-1985
out	O	1986-1989
continuously	O	1990-2002
because	O	2003-2010
of	O	2011-2013
the	O	2014-2017
effects	O	2018-2025
of	O	2026-2028
the	O	2029-2032
drug	O	2033-2037
on	O	2038-2040
virility	O	2041-2049
;	O	2049-2050
because	O	2051-2058
the	O	2059-2062
tissue	O	2063-2069
injury	O	2070-2076
too	O	2077-2080
often	O	2081-2086
occurs	O	2087-2093
at	O	2094-2096
an	O	2097-2099
irreversible	O	2100-2112
stage	O	2113-2118
vis	O	2119-2122
-	O	2122-2123
a	O	2123-2124
-	O	2122-2123
vis	O	2119-2122
the	O	2129-2132
"	O	2133-2134
regeneration	O	2134-2146
"	O	2133-2134
of	O	2148-2150
the	O	2151-2154
muscle	O	2155-2161
tissue	O	2162-2168
;	O	2168-2169
and	O	2170-2173
finally	O	2174-2181
because	O	2182-2189
the	O	2190-2193
dystrophic	O	2194-2204
injurious	O	2205-2214
agent	O	2215-2220
is	O	2221-2223
certainly	O	2224-2233
not	O	2234-2237
the	O	2238-2241
lack	O	2242-2246
of	O	2247-2249
vitamin	O	2250-2257
E	O	2258-2259
but	O	2260-2263
something	O	2264-2273
as	O	2274-2276
yet	O	2277-2280
unknown	O	2281-2288
.	O	2288-2289

Fetal	O	0-5
risks	O	6-11
due	O	12-15
to	O	16-18
warfarin	O	19-27
therapy	O	28-35
during	O	36-42
pregnancy	O	43-52
.	O	52-53

Two	O	54-57
mothers	O	58-65
with	O	66-70
heart	O	71-76
valve	O	77-82
prosthesis	O	83-93
were	O	94-98
treated	O	99-106
with	O	107-111
warfarin	O	112-120
during	O	121-127
pregnancy	O	128-137
.	O	137-138

In	O	139-141
the	O	142-145
first	O	146-151
case	O	152-156
a	O	157-158
caesarean	O	159-168
section	O	169-176
was	O	177-180
done	O	181-185
one	O	186-189
week	O	190-194
after	O	195-200
replacement	O	201-212
of	O	213-215
warfarin	O	216-224
with	O	225-229
heparin	O	230-237
.	O	237-238

The	O	239-242
baby	O	243-247
died	O	248-252
of	O	253-255
cerebral	B	256-264
and	I	265-268
pulmonary	I	269-278
hemorrhage	I	279-289
.	O	289-290

The	O	291-294
second	O	295-301
mother	O	302-308
had	O	309-312
a	O	313-314
male	O	315-319
infant	O	320-326
by	O	327-329
caesarean	O	330-339
section	O	340-347
.	O	347-348

The	O	349-352
baby	O	353-357
showed	O	358-364
warfarin	O	365-373
-	O	373-374
induced	O	374-381
embryopathy	B	382-393
with	O	394-398
nasal	B	399-404
hypoplasia	I	405-415
and	O	416-419
stippled	B	420-428
epiphyses	I	429-438
(	O	439-440
chondrodysplasia	B	440-456
punctata	I	457-465
)	O	465-466
.	O	466-467

Nasal	B	468-473
hypoplasia	I	474-484
with	O	485-489
or	O	490-492
without	O	493-500
stippled	B	501-509
epiphyses	I	510-519
has	O	520-523
now	O	524-527
been	O	528-532
reported	O	533-541
in	O	542-544
11	O	545-547
infants	O	548-555
born	O	556-560
to	O	561-563
mothers	O	564-571
treated	O	572-579
with	O	580-584
warfarin	O	585-593
during	O	594-600
the	O	601-604
first	O	605-610
trimester	O	611-620
,	O	620-621
and	O	622-625
a	O	626-627
causal	O	628-634
association	O	635-646
is	O	647-649
probable	O	650-658
.	O	658-659

In	O	660-662
view	O	663-667
of	O	668-670
the	O	671-674
risks	O	675-680
to	O	681-683
both	O	684-688
mother	O	689-695
and	O	696-699
fetus	O	700-705
in	O	706-708
women	O	709-714
with	O	715-719
prosthetic	O	720-730
cardiac	O	731-738
valves	O	739-745
it	O	746-748
is	O	749-751
recommended	O	752-763
that	O	764-768
therapeutic	O	769-780
abortion	O	781-789
be	O	790-792
advised	O	793-800
as	O	801-803
the	O	804-807
first	O	808-813
alternative	O	814-825
.	O	825-826

Isradipine	O	0-10
treatment	O	11-20
for	O	21-24
hypertension	B	25-37
in	O	38-40
general	O	41-48
practice	O	49-57
in	O	58-60
Hong	O	61-65
Kong	O	66-70
.	O	70-71

A	O	72-73
6	O	74-75
-	O	75-76
week	O	76-80
open	O	81-85
study	O	86-91
of	O	92-94
the	O	95-98
introduction	O	99-111
of	O	112-114
isradipine	O	115-125
treatment	O	126-135
was	O	136-139
conducted	O	140-149
in	O	150-152
general	O	153-160
practice	O	161-169
in	O	170-172
Hong	O	173-177
Kong	O	178-182
.	O	182-183

303	O	184-187
Chinese	O	188-195
patients	O	196-204
with	O	205-209
mild	O	210-214
to	O	215-217
moderate	O	218-226
hypertension	B	227-239
entered	O	240-247
the	O	248-251
study	O	252-257
.	O	257-258

Side	O	259-263
effects	O	264-271
were	O	272-276
reported	O	277-285
in	O	286-288
21	O	289-291
%	O	291-292
of	O	293-295
patients	O	296-304
and	O	305-308
caused	O	309-315
withdrawal	O	316-326
from	O	327-331
the	O	332-335
study	O	336-341
in	O	342-344
3	O	345-346
patients	O	347-355
.	O	355-356

The	O	357-360
main	O	361-365
side	O	366-370
-	O	370-371
effects	O	371-378
were	O	379-383
headache	B	384-392
,	O	392-393
dizziness	B	394-403
,	O	403-404
palpitation	B	405-416
and	O	417-420
flushing	B	421-429
and	O	430-433
these	O	434-439
were	O	440-444
not	O	445-448
more	O	449-453
frequent	O	454-462
than	O	463-467
reported	O	468-476
in	O	477-479
other	O	480-485
studies	O	486-493
with	O	494-498
isradipine	O	499-509
or	O	510-512
with	O	513-517
placebo	O	518-525
.	O	525-526

Supine	O	527-533
blood	O	534-539
pressure	O	540-548
was	O	549-552
reduced	O	553-560
(	O	561-562
P	O	562-563
less	O	564-568
than	O	569-573
0	O	574-575
.	O	575-576
01	O	576-578
)	O	578-579
from	O	580-584
170	O	585-588
+	O	589-590
/	O	590-591
-	O	591-592
20	O	593-595
/	O	595-596
102	O	596-599
+	O	600-601
/	O	601-602
-	O	602-603
6	O	604-605
mmHg	O	606-610
to	O	611-613
153	O	614-617
+	O	618-619
/	O	619-620
-	O	620-621
19	O	622-624
/	O	624-625
92	O	625-627
+	O	628-629
/	O	629-630
-	O	630-631
8	O	632-633
,	O	633-634
147	O	635-638
+	O	639-640
/	O	640-641
-	O	641-642
18	O	643-645
/	O	645-646
88	O	646-648
+	O	649-650
/	O	650-651
-	O	651-652
7	O	653-654
and	O	655-658
144	O	659-662
+	O	663-664
/	O	664-665
-	O	665-666
14	O	667-669
/	O	669-670
87	O	670-672
+	O	673-674
/	O	674-675
-	O	675-676
6	O	677-678
mmHg	O	679-683
at	O	684-686
2	O	687-688
,	O	688-689
4	O	690-691
and	O	692-695
6	O	696-697
weeks	O	698-703
respectively	O	704-716
in	O	717-719
evaluable	O	720-729
patients	O	730-738
.	O	738-739

Similar	O	740-747
reductions	O	748-758
occurred	O	759-767
in	O	768-770
standing	O	771-779
blood	O	780-785
pressure	O	786-794
and	O	795-798
there	O	799-804
was	O	805-808
no	O	809-811
evidence	O	812-820
of	O	821-823
postural	B	824-832
hypotension	I	833-844
.	O	844-845

Normalization	O	846-859
and	O	860-863
responder	O	864-873
rates	O	874-879
at	O	880-882
6	O	883-884
weeks	O	885-890
were	O	891-895
86	O	896-898
%	O	898-899
and	O	900-903
69	O	904-906
%	O	906-907
respectively	O	908-920
.	O	920-921

Dosage	O	922-928
was	O	929-932
increased	O	933-942
from	O	943-947
2	O	948-949
.	O	949-950
5	O	950-951
mg	O	952-954
b	O	955-956
.	O	956-957
d	O	957-958
.	O	956-957
to	O	960-962
5	O	963-964
mg	O	965-967
b	O	968-969
.	O	969-970
d	O	970-971
.	O	969-970
at	O	973-975
4	O	976-977
weeks	O	978-983
in	O	984-986
patients	O	987-995
with	O	996-1000
diastolic	O	1001-1010
blood	O	1011-1016
pressure	O	1017-1025
greater	O	1026-1033
than	O	1034-1038
90	O	1039-1041
mmHg	O	1042-1046
and	O	1047-1050
their	O	1051-1056
further	O	1057-1064
response	O	1065-1073
was	O	1074-1077
greater	O	1078-1085
than	O	1086-1090
those	O	1091-1096
remaining	O	1097-1106
on	O	1107-1109
2	O	1110-1111
.	O	1111-1112
5	O	1112-1113
mg	O	1114-1116
b	O	1117-1118
.	O	1118-1119
d	O	1119-1120
.	O	1118-1119

Tachyphylaxis	O	0-13
to	O	14-16
systemic	O	17-25
but	O	26-29
not	O	30-33
to	O	34-36
airway	O	37-43
responses	O	44-53
during	O	54-60
prolonged	O	61-70
therapy	O	71-78
with	O	79-83
high	O	84-88
dose	O	89-93
inhaled	O	94-101
salbutamol	O	102-112
in	O	113-115
asthmatics	B	116-126
.	O	126-127

High	O	128-132
doses	O	133-138
of	O	139-141
inhaled	O	142-149
salbutamol	O	150-160
produce	O	161-168
substantial	O	169-180
improvements	O	181-193
in	O	194-196
airway	O	197-203
response	O	204-212
in	O	213-215
patients	O	216-224
with	O	225-229
asthma	B	230-236
,	O	236-237
and	O	238-241
are	O	242-245
associated	O	246-256
with	O	257-261
dose	O	262-266
-	O	266-267
dependent	O	267-276
systemic	O	277-285
beta	O	286-290
-	O	290-291
adrenoceptor	O	291-303
responses	O	304-313
.	O	313-314

The	O	315-318
purpose	O	319-326
of	O	327-329
the	O	330-333
present	O	334-341
study	O	342-347
was	O	348-351
to	O	352-354
investigate	O	355-366
whether	O	367-374
tachyphylaxis	O	375-388
occurs	O	389-395
during	O	396-402
prolonged	O	403-412
treatment	O	413-422
with	O	423-427
high	O	428-432
dose	O	433-437
inhaled	O	438-445
salbutamol	O	446-456
.	O	456-457

Twelve	O	458-464
asthmatic	B	465-474
patients	O	475-483
(	O	484-485
FEV1	O	485-489
,	O	489-490
81	O	491-493
+	O	494-495
/	O	495-496
-	O	496-497
4	O	498-499
%	O	499-500
predicted	O	501-510
)	O	510-511
,	O	511-512
requiring	O	513-522
only	O	523-527
occasional	O	528-538
inhaled	O	539-546
beta	O	547-551
-	O	551-552
agonists	O	552-560
as	O	561-563
their	O	564-569
sole	O	570-574
therapy	O	575-582
,	O	582-583
were	O	584-588
given	O	589-594
a	O	595-596
14	O	597-599
-	O	599-600
day	O	600-603
treatment	O	604-613
with	O	614-618
high	O	619-623
dose	O	624-628
inhaled	O	629-636
salbutamol	O	637-647
(	O	648-649
HDS	O	649-652
)	O	652-653
,	O	653-654
4	O	655-656
,	O	656-657
000	O	657-660
micrograms	O	661-671
daily	O	672-677
,	O	677-678
low	O	679-682
dose	O	683-687
inhaled	O	688-695
salbutamol	O	696-706
(	O	707-708
LDS	O	708-711
)	O	711-712
,	O	712-713
800	O	714-717
micrograms	O	718-728
daily	O	729-734
,	O	734-735
or	O	736-738
placebo	O	739-746
(	O	747-748
PI	O	748-750
)	O	750-751
by	O	752-754
metered	O	755-762
-	O	762-763
dose	O	763-767
inhaler	O	768-775
in	O	776-778
a	O	779-780
double	O	781-787
-	O	787-788
blind	O	788-793
,	O	793-794
randomized	O	795-805
crossover	O	806-815
design	O	816-822
.	O	822-823

During	O	824-830
the	O	831-834
14	O	835-837
-	O	837-838
day	O	838-841
run	O	842-845
-	O	845-846
in	O	846-848
and	O	849-852
during	O	853-859
washout	O	860-867
periods	O	868-875
,	O	875-876
inhaled	O	877-884
beta	O	885-889
-	O	889-890
agonists	O	890-898
were	O	899-903
withheld	O	904-912
and	O	913-916
ipratropium	O	917-928
bromide	O	929-936
was	O	937-940
substituted	O	941-952
for	O	953-956
rescue	O	957-963
purposes	O	964-972
.	O	972-973

At	O	974-976
the	O	977-980
end	O	981-984
of	O	985-987
each	O	988-992
14	O	993-995
-	O	995-996
day	O	996-999
treatment	O	1000-1009
,	O	1009-1010
a	O	1011-1012
dose	O	1013-1017
-	O	1017-1018
response	O	1018-1026
curve	O	1027-1032
(	O	1033-1034
DRC	O	1034-1037
)	O	1037-1038
was	O	1039-1042
performed	O	1043-1052
,	O	1052-1053
and	O	1054-1057
airway	O	1058-1064
(	O	1065-1066
FEV1	O	1066-1070
,	O	1070-1071
FEF25	O	1072-1077
-	O	1077-1078
75	O	1078-1080
)	O	1080-1081
chronotropic	O	1082-1094
(	O	1095-1096
HR	O	1096-1098
)	O	1098-1099
,	O	1099-1100
tremor	B	1101-1107
,	O	1107-1108
and	O	1109-1112
metabolic	O	1113-1122
(	O	1123-1124
K	O	1124-1125
,	O	1125-1126
Glu	O	1127-1130
)	O	1130-1131
responses	O	1132-1141
were	O	1142-1146
measured	O	1147-1155
at	O	1156-1158
each	O	1159-1163
step	O	1164-1168
(	O	1169-1170
from	O	1170-1174
100	O	1175-1178
to	O	1179-1181
4	O	1182-1183
,	O	1183-1184
000	O	1184-1187
micrograms	O	1188-1198
)	O	1198-1199
.	O	1199-1200

Treatment	O	1201-1210
had	O	1211-1214
no	O	1215-1217
significant	O	1218-1229
effect	O	1230-1236
on	O	1237-1239
baseline	O	1240-1248
values	O	1249-1255
.	O	1255-1256

There	O	1257-1262
were	O	1263-1267
dose	O	1268-1272
-	O	1272-1273
dependent	O	1273-1282
increases	O	1283-1292
in	O	1293-1295
FEV1	O	1296-1300
and	O	1301-1304
FEF25	O	1305-1310
-	O	1310-1311
75	O	1311-1313
(	O	1314-1315
p	O	1315-1316
less	O	1317-1321
than	O	1322-1326
0	O	1327-1328
.	O	1328-1329
001	O	1329-1332
)	O	1332-1333
,	O	1333-1334
and	O	1335-1338
pretreatment	O	1339-1351
with	O	1352-1356
HDS	O	1357-1360
did	O	1361-1364
not	O	1365-1368
displace	O	1369-1377
the	O	1378-1381
DRC	O	1382-1385
to	O	1386-1388
the	O	1389-1392
right	O	1393-1398
.	O	1398-1399

DRC	O	1400-1403
for	O	1404-1407
HR	O	1408-1410
(	O	1411-1412
p	O	1412-1413
less	O	1414-1418
than	O	1419-1423
0	O	1424-1425
.	O	1425-1426
001	O	1426-1429
)	O	1429-1430
,	O	1430-1431
K	O	1432-1433
(	O	1434-1435
p	O	1435-1436
less	O	1437-1441
than	O	1442-1446
0	O	1447-1448
.	O	1448-1449
001	O	1449-1452
)	O	1452-1453
,	O	1453-1454
and	O	1455-1458
Glu	O	1459-1462
(	O	1463-1464
p	O	1464-1465
less	O	1466-1470
than	O	1471-1475
0	O	1476-1477
.	O	1477-1478
005	O	1478-1481
)	O	1481-1482
were	O	1483-1487
attenuated	O	1488-1498
after	O	1499-1504
treatment	O	1505-1514
with	O	1515-1519
HDS	O	1520-1523
compared	O	1524-1532
with	O	1533-1537
PI	O	1538-1540
.	O	1540-1541

There	O	1542-1547
were	O	1548-1552
also	O	1553-1557
differences	O	1558-1569
between	O	1570-1577
HDS	O	1578-1581
and	O	1582-1585
LDS	O	1586-1589
for	O	1590-1593
HR	O	1594-1596
(	O	1597-1598
p	O	1598-1599
less	O	1600-1604
than	O	1605-1609
0	O	1610-1611
.	O	1611-1612
001	O	1612-1615
)	O	1615-1616
and	O	1617-1620
Glu	O	1621-1624
(	O	1625-1626
p	O	1626-1627
less	O	1628-1632
than	O	1633-1637
0	O	1638-1639
.	O	1639-1640
05	O	1640-1642
)	O	1642-1643
responses	O	1644-1653
.	O	1653-1654

Frequency	O	1655-1664
and	O	1665-1668
severity	O	1669-1677
of	O	1678-1680
subjective	O	1681-1691
adverse	O	1692-1699
effects	O	1700-1707
were	O	1708-1712
also	O	1713-1717
reduced	O	1718-1725
after	O	1726-1731
HDS	O	1732-1735
:	O	1735-1736
tremor	B	1737-1743
(	O	1744-1745
p	O	1745-1746
less	O	1747-1751
than	O	1752-1756
0	O	1757-1758
.	O	1758-1759
001	O	1759-1762
)	O	1762-1763
,	O	1763-1764
palpitations	B	1765-1777
(	O	1778-1779
p	O	1779-1780
less	O	1781-1785
than	O	1786-1790
0	O	1791-1792
.	O	1792-1793
001	O	1793-1796
)	O	1796-1797
.	O	1792-1793
(	O	1798-1799
ABSTRACT	O	1799-1807

TRUNCATED	O	1808-1817
AT	O	1818-1820
250	O	1821-1824
WORDS	O	1825-1830
)	O	1830-1831

Increased	O	0-9
anxiogenic	O	10-20
effects	O	21-28
of	O	29-31
caffeine	O	32-40
in	O	41-43
panic	B	44-49
disorders	I	50-59
.	O	59-60

The	O	61-64
effects	O	65-72
of	O	73-75
oral	O	76-80
administration	O	81-95
of	O	96-98
caffeine	O	99-107
(	O	108-109
10	O	109-111
mg	O	112-114
/	O	114-115
kg	O	115-117
)	O	117-118
on	O	119-121
behavioral	O	122-132
ratings	O	133-140
,	O	140-141
somatic	O	142-149
symptoms	O	150-158
,	O	158-159
blood	O	160-165
pressure	O	166-174
and	O	175-178
plasma	O	179-185
levels	O	186-192
of	O	193-195
3	O	196-197
-	O	197-198
methoxy	O	198-205
-	O	197-198
4	O	206-207
-	O	197-198
hydroxyphenethyleneglycol	O	208-233
(	O	234-235
MHPG	O	235-239
)	O	239-240
and	O	241-244
cortisol	O	245-253
were	O	254-258
determined	O	259-269
in	O	270-272
17	O	273-275
healthy	O	276-283
subjects	O	284-292
and	O	293-296
21	O	297-299
patients	O	300-308
meeting	O	309-316
DSM	O	317-320
-	O	320-321
III	O	321-324
criteria	O	325-333
for	O	334-337
agoraphobia	B	338-349
with	O	350-354
panic	B	355-360
attacks	I	361-368
or	O	369-371
panic	B	372-377
disorder	I	378-386
.	O	386-387

Caffeine	O	388-396
produced	O	397-405
significantly	O	406-419
greater	O	420-427
increases	O	428-437
in	O	438-440
subject	O	441-448
-	O	448-449
rated	O	449-454
anxiety	B	455-462
,	O	462-463
nervousness	O	464-475
,	O	475-476
fear	O	477-481
,	O	481-482
nausea	B	483-489
,	O	489-490
palpitations	B	491-503
,	O	503-504
restlessness	B	505-517
,	O	517-518
and	O	519-522
tremors	B	523-530
in	O	531-533
the	O	534-537
patients	O	538-546
compared	O	547-555
with	O	556-560
healthy	O	561-568
subjects	O	569-577
.	O	577-578

In	O	579-581
the	O	582-585
patients	O	586-594
,	O	594-595
but	O	596-599
not	O	600-603
the	O	604-607
healthy	O	608-615
subjects	O	616-624
,	O	624-625
these	O	626-631
symptoms	O	632-640
were	O	641-645
significantly	O	646-659
correlated	O	660-670
with	O	671-675
plasma	O	676-682
caffeine	O	683-691
levels	O	692-698
.	O	698-699

Seventy	O	700-707
-	O	707-708
one	O	708-711
percent	O	712-719
of	O	720-722
the	O	723-726
patients	O	727-735
reported	O	736-744
that	O	745-749
the	O	750-753
behavioral	O	754-764
effects	O	765-772
of	O	773-775
caffeine	O	776-784
were	O	785-789
similar	O	790-797
to	O	798-800
those	O	801-806
experienced	O	807-818
during	O	819-825
panic	B	826-831
attacks	I	832-839
.	O	839-840

Caffeine	O	841-849
did	O	850-853
not	O	854-857
alter	O	858-863
plasma	O	864-870
MHPG	O	871-875
levels	O	876-882
in	O	883-885
either	O	886-892
the	O	893-896
healthy	O	897-904
subjects	O	905-913
or	O	914-916
patients	O	917-925
.	O	925-926

Caffeine	O	927-935
increased	O	936-945
plasma	O	946-952
cortisol	O	953-961
levels	O	962-968
equally	O	969-976
in	O	977-979
the	O	980-983
patient	O	984-991
and	O	992-995
healthy	O	996-1003
groups	O	1004-1010
.	O	1010-1011

Because	O	1012-1019
caffeine	O	1020-1028
is	O	1029-1031
an	O	1032-1034
adenosine	O	1035-1044
receptor	O	1045-1053
antagonist	O	1054-1064
,	O	1064-1065
these	O	1066-1071
results	O	1072-1079
suggest	O	1080-1087
that	O	1088-1092
some	O	1093-1097
panic	B	1098-1103
disorder	I	1104-1112
patients	O	1113-1121
may	O	1122-1125
have	O	1126-1130
abnormalities	B	1131-1144
in	I	1145-1147
neuronal	I	1148-1156
systems	I	1157-1164
involving	O	1165-1174
adenosine	O	1175-1184
.	O	1184-1185

Patients	O	1186-1194
with	O	1195-1199
anxiety	B	1200-1207
disorders	I	1208-1217
may	O	1218-1221
benefit	O	1222-1229
by	O	1230-1232
avoiding	O	1233-1241
caffeine	O	1242-1250
-	O	1250-1251
containing	O	1251-1261
foods	O	1262-1267
and	O	1268-1271
beverages	O	1272-1281
.	O	1281-1282

Human	O	0-5
and	O	6-9
canine	O	10-16
ventricular	O	17-28
vasoactive	O	29-39
intestinal	O	40-50
polypeptide	O	51-62
:	O	62-63
decrease	O	64-72
with	O	73-77
heart	B	78-83
failure	I	84-91
.	O	91-92

Vasoactive	O	93-103
intestinal	O	104-114
polypeptide	O	115-126
(	O	127-128
VIP	O	128-131
)	O	131-132
is	O	133-135
a	O	136-137
systemic	O	138-146
and	O	147-150
coronary	O	151-159
vasodilator	O	160-171
that	O	172-176
may	O	177-180
have	O	181-185
positive	O	186-194
inotropic	O	195-204
properties	O	205-215
.	O	215-216

Myocardial	O	217-227
levels	O	228-234
of	O	235-237
VIP	O	238-241
were	O	242-246
assayed	O	247-254
before	O	255-261
and	O	262-265
after	O	266-271
the	O	272-275
development	O	276-287
of	O	288-290
heart	B	291-296
failure	I	297-304
in	O	305-307
two	O	308-311
canine	O	312-318
models	O	319-325
.	O	325-326

In	O	327-329
the	O	330-333
first	O	334-339
,	O	339-340
cobalt	O	341-347
cardiomyopathy	B	348-362
was	O	363-366
induced	O	367-374
in	O	375-377
eight	O	378-383
dogs	O	384-388
;	O	388-389
VIP	O	390-393
(	O	394-395
by	O	395-397
radioimmunoassay	O	398-414
)	O	414-415
decreased	O	416-425
from	O	426-430
35	O	431-433
+	O	434-435
/	O	435-436
-	O	436-437
11	O	438-440
pg	O	441-443
/	O	443-444
mg	O	444-446
protein	O	447-454
(	O	455-456
mean	O	456-460
+	O	461-462
/	O	462-463
-	O	463-464
SD	O	465-467
)	O	467-468
to	O	469-471
5	O	472-473
+	O	474-475
/	O	475-476
-	O	476-477
4	O	478-479
pg	O	480-482
/	O	482-483
mg	O	483-485
protein	O	486-493
(	O	494-495
P	O	495-496
less	O	497-501
than	O	502-506
0	O	507-508
.	O	508-509
05	O	509-511
)	O	511-512
.	O	508-509

In	O	514-516
six	O	517-520
dogs	O	521-525
with	O	526-530
doxorubicin	O	531-542
-	O	542-543
induced	O	543-550
heart	B	551-556
failure	I	557-564
,	O	564-565
VIP	O	566-569
decreased	O	570-579
from	O	580-584
31	O	585-587
+	O	588-589
/	O	589-590
-	O	590-591
7	O	592-593
to	O	594-596
11	O	597-599
+	O	600-601
/	O	601-602
-	O	602-603
4	O	604-605
pg	O	606-608
/	O	608-609
mg	O	609-611
protein	O	612-619
(	O	620-621
P	O	621-622
less	O	623-627
than	O	628-632
0	O	633-634
.	O	634-635
05	O	635-637
)	O	637-638
.	O	634-635

In	O	640-642
addition	O	643-651
,	O	651-652
VIP	O	653-656
content	O	657-664
of	O	665-667
left	O	668-672
ventricular	O	673-684
muscle	O	685-691
of	O	692-694
resected	O	695-703
failing	O	704-711
hearts	O	712-718
in	O	719-721
10	O	722-724
patients	O	725-733
receiving	O	734-743
a	O	744-745
heart	O	746-751
transplant	O	752-762
was	O	763-766
compared	O	767-775
with	O	776-780
the	O	781-784
papillary	O	785-794
muscles	O	795-802
in	O	803-805
14	O	806-808
patients	O	809-817
(	O	818-819
five	O	819-823
with	O	824-828
rheumatic	B	829-838
disease	I	839-846
,	O	846-847
nine	O	848-852
with	O	853-857
myxomatous	B	858-868
degeneration	I	869-881
)	O	881-882
receiving	O	883-892
mitral	O	893-899
valve	O	900-905
prostheses	O	906-916
.	O	916-917

The	O	918-921
lowest	O	922-928
myocardial	O	929-939
VIP	O	940-943
concentration	O	944-957
was	O	958-961
found	O	962-967
in	O	968-970
the	O	971-974
hearts	O	975-981
of	O	982-984
patients	O	985-993
with	O	994-998
coronary	B	999-1007
disease	I	1008-1015
(	O	1016-1017
one	O	1017-1020
patient	O	1021-1028
receiving	O	1029-1038
a	O	1039-1040
transplant	O	1041-1051
and	O	1052-1055
three	O	1056-1061
receiving	O	1062-1071
mitral	O	1072-1078
prostheses	O	1079-1089
)	O	1089-1090
(	O	1091-1092
6	O	1092-1093
.	O	1093-1094
3	O	1094-1095
+	O	1096-1097
/	O	1097-1098
-	O	1098-1099
1	O	1100-1101
.	O	1101-1102
9	O	1102-1103
pg	O	1104-1106
/	O	1106-1107
mg	O	1107-1109
protein	O	1110-1117
)	O	1117-1118
.	O	1118-1119

The	O	1120-1123
other	O	1124-1129
patients	O	1130-1138
undergoing	O	1139-1149
transplantation	O	1150-1165
had	O	1166-1169
an	O	1170-1172
average	O	1173-1180
ejection	O	1181-1189
fraction	O	1190-1198
of	O	1199-1201
17	O	1202-1204
%	O	1204-1205
+	O	1206-1207
/	O	1207-1208
-	O	1208-1209
6	O	1210-1211
%	O	1211-1212
and	O	1213-1216
a	O	1217-1218
VIP	O	1219-1222
level	O	1223-1228
of	O	1229-1231
8	O	1232-1233
.	O	1233-1234
8	O	1232-1233
+	O	1236-1237
/	O	1237-1238
-	O	1238-1239
3	O	1240-1241
.	O	1241-1242
9	O	1242-1243
pg	O	1244-1246
/	O	1246-1247
mg	O	1247-1249
protein	O	1250-1257
.	O	1257-1258

The	O	1259-1262
hearts	O	1263-1269
without	O	1270-1277
coronary	B	1278-1286
artery	I	1287-1293
disease	I	1294-1301
(	O	1302-1303
average	O	1303-1310
ejection	O	1311-1319
fraction	O	1320-1328
of	O	1329-1331
this	O	1332-1336
group	O	1337-1342
62	O	1343-1345
%	O	1345-1346
+	O	1347-1348
/	O	1348-1349
-	O	1349-1350
10	O	1351-1353
%	O	1353-1354
)	O	1354-1355
had	O	1356-1359
a	O	1360-1361
VIP	O	1362-1365
concentration	O	1366-1379
of	O	1380-1382
14	O	1383-1385
.	O	1385-1386
1	O	1383-1384
+	O	1388-1389
/	O	1389-1390
-	O	1390-1391
7	O	1392-1393
.	O	1393-1394
9	O	1394-1395
pg	O	1396-1398
/	O	1398-1399
mg	O	1399-1401
protein	O	1402-1409
,	O	1409-1410
and	O	1411-1414
this	O	1415-1419
was	O	1420-1423
greater	O	1424-1431
than	O	1432-1436
in	O	1437-1439
hearts	O	1440-1446
of	O	1447-1449
the	O	1450-1453
patients	O	1454-1462
with	O	1463-1467
coronary	B	1468-1476
disease	I	1477-1484
and	O	1485-1488
the	O	1489-1492
hearts	O	1493-1499
of	O	1500-1502
patients	O	1503-1511
receiving	O	1512-1521
a	O	1522-1523
transplant	O	1524-1534
(	O	1535-1536
P	O	1536-1537
less	O	1538-1542
than	O	1543-1547
0	O	1548-1549
.	O	1549-1550
05	O	1550-1552
)	O	1552-1553
.	O	1549-1550

Myocardial	O	1555-1565
catecholamines	O	1566-1580
were	O	1581-1585
also	O	1586-1590
determined	O	1591-1601
in	O	1602-1604
14	O	1605-1607
subjects	O	1608-1616
;	O	1616-1617
a	O	1618-1619
weak	O	1620-1624
correlation	O	1625-1636
(	O	1637-1638
r	O	1638-1639
=	O	1640-1641
0	O	1642-1643
.	O	1643-1644
57	O	1644-1646
,	O	1646-1647
P	O	1648-1649
less	O	1650-1654
than	O	1655-1659
0	O	1660-1661
.	O	1661-1662
05	O	1662-1664
)	O	1664-1665
between	O	1666-1673
the	O	1674-1677
tissue	O	1678-1684
concentrations	O	1685-1699
of	O	1700-1702
VIP	O	1703-1706
and	O	1707-1710
norepinephrine	O	1711-1725
was	O	1726-1729
noted	O	1730-1735
.	O	1735-1736
(	O	1736-1737
ABSTRACT	O	1737-1745

TRUNCATED	O	1746-1755
AT	O	1756-1758
250	O	1759-1762
WORDS	O	1763-1768
)	O	1768-1769

Interstrain	O	0-11
variation	O	12-21
in	O	22-24
acute	O	25-30
toxic	O	31-36
response	O	37-45
to	O	46-48
caffeine	O	49-57
among	O	58-63
inbred	O	64-70
mice	O	71-75
.	O	75-76

Acute	O	77-82
toxic	O	83-88
dosage	O	89-95
-	O	95-96
dependent	O	96-105
behavioral	O	106-116
effects	O	117-124
of	O	125-127
caffeine	O	128-136
were	O	137-141
compared	O	142-150
in	O	151-153
adult	O	154-159
males	O	160-165
from	O	166-170
seven	O	171-176
inbred	O	177-183
mouse	O	184-189
strains	O	190-197
(	O	198-199
A	O	199-200
/	O	200-201
J	O	201-202
,	O	202-203
BALB	O	204-208
/	O	208-209
cJ	O	209-211
,	O	211-212
CBA	O	213-216
/	O	216-217
J	O	217-218
,	O	218-219
C3H	O	220-223
/	O	223-224
HeJ	O	224-227
,	O	227-228
C57BL	O	229-234
/	O	234-235
6J	O	235-237
,	O	237-238
DBA	O	239-242
/	O	242-243
2J	O	243-245
,	O	245-246
SWR	O	247-250
/	O	250-251
J	O	251-252
)	O	252-253
.	O	253-254

C57BL	O	255-260
/	O	260-261
6J	O	261-263
,	O	263-264
chosen	O	265-271
as	O	272-274
a	O	275-276
"	O	277-278
prototypic	O	278-288
"	O	277-278
mouse	O	290-295
strain	O	296-302
,	O	302-303
was	O	304-307
used	O	308-312
to	O	313-315
determine	O	316-325
behavioral	O	326-336
responses	O	337-346
to	O	347-349
a	O	350-351
broad	O	352-357
range	O	358-363
(	O	364-365
5	O	365-366
-	O	366-367
500	O	367-370
mg	O	371-373
/	O	373-374
kg	O	374-376
)	O	376-377
of	O	378-380
caffeine	O	381-389
doses	O	390-395
.	O	395-396

Five	O	397-401
phenotypic	O	402-412
characteristics	O	413-428
-	O	428-429
-	O	428-429
locomotor	O	430-439
activity	O	440-448
,	O	448-449
righting	O	450-458
ability	O	459-466
,	O	466-467
clonic	B	468-474
seizure	I	475-482
induction	O	483-492
,	O	492-493
stress	O	494-500
-	O	500-501
induced	O	501-508
lethality	O	509-518
,	O	518-519
death	O	520-525
without	O	526-533
external	O	534-542
stress	O	543-549
-	O	549-550
-	O	549-550
were	O	551-555
scored	O	556-562
at	O	563-565
various	O	566-573
caffeine	O	574-582
doses	O	583-588
in	O	589-591
drug	O	592-596
-	O	596-597
naive	O	597-602
animals	O	603-610
under	O	611-616
empirically	O	617-628
optimized	O	629-638
,	O	638-639
rigidly	O	640-647
constant	O	648-656
experimental	O	657-669
conditions	O	670-680
.	O	680-681

Mice	O	682-686
(	O	687-688
n	O	688-689
=	O	690-691
12	O	692-694
for	O	695-698
each	O	699-703
point	O	704-709
)	O	709-710
received	O	711-719
single	O	720-726
IP	O	727-729
injections	O	730-740
of	O	741-743
a	O	744-745
fixed	O	746-751
volume	O	752-758
/	O	758-759
g	O	759-760
body	O	761-765
weight	O	766-772
of	O	773-775
physiological	O	776-789
saline	O	790-796
carrier	O	797-804
with	O	805-809
or	O	810-812
without	O	813-820
caffeine	O	821-829
in	O	830-832
doses	O	833-838
ranging	O	839-846
from	O	847-851
125	O	852-855
-	O	855-856
500	O	856-859
mg	O	860-862
/	O	862-863
kg	O	863-865
.	O	865-866

Loss	O	867-871
of	O	872-874
righting	O	875-883
ability	O	884-891
was	O	892-895
scored	O	896-902
at	O	903-905
1	O	906-907
,	O	907-908
3	O	909-910
,	O	910-911
5	O	912-913
min	O	914-917
post	O	918-922
dosing	O	923-929
and	O	930-933
at	O	934-936
5	O	937-938
min	O	939-942
intervals	O	943-952
thereafter	O	953-963
for	O	964-967
20	O	968-970
min	O	971-974
.	O	974-975

In	O	976-978
the	O	979-982
same	O	983-987
animals	O	988-995
the	O	996-999
occurrence	O	1000-1010
of	O	1011-1013
clonic	B	1014-1020
seizures	I	1021-1029
was	O	1030-1033
scored	O	1034-1040
as	O	1041-1043
to	O	1044-1046
time	O	1047-1051
of	O	1052-1054
onset	O	1055-1060
and	O	1061-1064
severity	O	1065-1073
for	O	1074-1077
20	O	1078-1080
min	O	1081-1084
after	O	1085-1090
drug	O	1091-1095
administration	O	1096-1110
.	O	1110-1111

When	O	1112-1116
these	O	1117-1122
proceeded	O	1123-1132
to	O	1133-1135
tonic	B	1136-1141
seizures	I	1142-1150
,	O	1150-1151
death	O	1152-1157
occurred	O	1158-1166
in	O	1167-1169
less	O	1170-1174
than	O	1175-1179
20	O	1180-1182
min	O	1183-1186
.	O	1186-1187

Animals	O	1188-1195
surviving	O	1196-1205
for	O	1206-1209
20	O	1210-1212
min	O	1213-1216
were	O	1217-1221
immediately	O	1222-1233
stressed	O	1234-1242
by	O	1243-1245
a	O	1246-1247
swim	O	1248-1252
test	O	1253-1257
in	O	1258-1260
25	O	1261-1263
degrees	O	1264-1271
C	O	1272-1273
water	O	1274-1279
,	O	1279-1280
and	O	1281-1284
death	O	1285-1290
-	O	1290-1291
producing	O	1291-1300
tonic	B	1301-1306
seizures	I	1307-1315
were	O	1316-1320
scored	O	1321-1327
for	O	1328-1331
2	O	1332-1333
min	O	1334-1337
.	O	1337-1338

In	O	1339-1341
other	O	1342-1347
animals	O	1348-1355
locomotor	O	1356-1365
activity	O	1366-1374
was	O	1375-1378
measured	O	1379-1387
15	O	1388-1390
or	O	1391-1393
60	O	1394-1396
min	O	1397-1400
after	O	1401-1406
caffeine	O	1407-1415
administration	O	1416-1430
.	O	1430-1431

By	O	1432-1434
any	O	1435-1438
single	O	1439-1445
behavioral	O	1446-1456
criterion	O	1457-1466
or	O	1467-1469
a	O	1470-1471
combination	O	1472-1483
of	O	1484-1486
these	O	1487-1492
criteria	O	1493-1501
,	O	1501-1502
marked	O	1503-1509
differences	O	1510-1521
in	O	1522-1524
response	O	1525-1533
to	O	1534-1536
toxic	O	1537-1542
caffeine	O	1543-1551
doses	O	1552-1557
were	O	1558-1562
observed	O	1563-1571
between	O	1572-1579
strains	O	1580-1587
.	O	1587-1588

These	O	1589-1594
results	O	1595-1602
indicate	O	1603-1611
that	O	1612-1616
behavioral	O	1617-1627
toxicity	B	1628-1636
testing	O	1637-1644
of	O	1645-1647
alkylxanthines	O	1648-1662
in	O	1663-1665
a	O	1666-1667
single	O	1668-1674
mouse	O	1675-1680
strain	O	1681-1687
may	O	1688-1691
be	O	1692-1694
misleading	O	1695-1705
and	O	1706-1709
suggest	O	1710-1717
that	O	1718-1722
toxic	O	1723-1728
responses	O	1729-1738
of	O	1739-1741
the	O	1742-1745
central	O	1746-1753
nervous	O	1754-1761
system	O	1762-1768
to	O	1769-1771
this	O	1772-1776
class	O	1777-1782
of	O	1783-1785
compounds	O	1786-1795
are	O	1796-1799
genetically	O	1800-1811
influenced	O	1812-1822
in	O	1823-1825
mammals	O	1826-1833
.	O	1833-1834

Invasive	O	0-8
carcinoma	B	9-18
of	I	19-21
the	I	22-25
renal	I	26-31
pelvis	I	32-38
following	O	39-48
cyclophosphamide	O	49-65
therapy	O	66-73
for	O	74-77
nonmalignant	O	78-90
disease	O	91-98
.	O	98-99

A	O	100-101
47	O	102-104
-	O	104-105
year	O	105-109
-	O	104-105
old	O	110-113
woman	O	114-119
with	O	120-124
right	O	125-130
hydroureteronephrosis	B	131-152
due	O	153-156
to	O	157-159
ureterovesical	O	160-174
junction	O	175-183
obstruction	O	184-195
had	O	196-199
gross	O	200-205
hematuria	B	206-215
after	O	216-221
being	O	222-227
treated	O	228-235
for	O	236-239
five	O	240-244
years	O	245-250
wtih	O	251-255
cyclophosphamide	O	256-272
for	O	273-276
cerebral	B	277-285
vasculitis	I	286-296
.	O	296-297

A	O	298-299
right	O	300-305
nephroureterectomy	O	306-324
was	O	325-328
required	O	329-337
for	O	338-341
control	O	342-349
of	O	350-352
bleeding	B	353-361
.	O	361-362

The	O	363-366
pathology	O	367-376
specimen	O	377-385
contained	O	386-395
clinically	O	396-406
occult	O	407-413
invasive	O	414-422
carcinoma	B	423-432
of	I	433-435
the	I	436-439
renal	I	440-445
pelvis	I	446-452
.	O	452-453

Although	O	454-462
the	O	463-466
ability	O	467-474
of	O	475-477
cyclophosphamide	O	478-494
to	O	495-497
cause	O	498-503
hemorrhagic	B	504-515
cystitis	I	516-524
and	O	525-528
urine	O	529-534
cytologic	O	535-544
abnormalities	O	545-558
indistinguishable	O	559-576
from	O	577-581
high	O	582-586
grade	O	587-592
carcinoma	B	593-602
is	O	603-605
well	O	606-610
known	O	611-616
,	O	616-617
it	O	618-620
is	O	621-623
less	O	624-628
widely	O	629-635
appreciated	O	636-647
that	O	648-652
it	O	653-655
is	O	656-658
also	O	659-663
associated	O	664-674
with	O	675-679
carcinoma	B	680-689
of	I	690-692
the	I	693-696
urinary	I	697-704
tract	I	705-710
.	O	710-711

Twenty	O	712-718
carcinomas	B	719-729
of	I	730-732
the	I	733-736
urinary	I	737-744
bladder	I	745-752
and	O	753-756
one	O	757-760
carcinoma	B	761-770
of	I	771-773
the	I	774-777
prostate	I	778-786
have	O	787-791
been	O	792-796
reported	O	797-805
in	O	806-808
association	O	809-820
with	O	821-825
its	O	826-829
use	O	830-833
.	O	833-834

The	O	835-838
present	O	839-846
case	O	847-851
is	O	852-854
the	O	855-858
first	O	859-864
carcinoma	B	865-874
of	I	875-877
the	I	878-881
renal	I	882-887
pelvis	I	888-894
reported	O	895-903
in	O	904-906
association	O	907-918
with	O	919-923
cyclophosphamide	O	924-940
treatment	O	941-950
.	O	950-951

It	O	952-954
is	O	955-957
the	O	958-961
third	O	962-967
urinary	B	968-975
tract	I	976-981
cancer	I	982-988
reported	O	989-997
in	O	998-1000
association	O	1001-1012
with	O	1013-1017
cyclophosphamide	O	1018-1034
treatment	O	1035-1044
for	O	1045-1048
nonmalignant	O	1049-1061
disease	O	1062-1069
.	O	1069-1070

The	O	1071-1074
association	O	1075-1086
of	O	1087-1089
the	O	1090-1093
tumor	B	1094-1099
with	O	1100-1104
preexisting	O	1105-1116
hydroureteronephrosis	B	1117-1138
suggests	O	1139-1147
that	O	1148-1152
stasis	O	1153-1159
prolonged	O	1160-1169
and	O	1170-1173
intensified	O	1174-1185
exposure	O	1186-1194
of	O	1195-1197
upper	O	1198-1203
urinary	O	1204-1211
tract	O	1212-1217
epithelium	O	1218-1228
to	O	1229-1231
cyclophosphamide	O	1232-1248
.	O	1248-1249

Patients	O	1250-1258
who	O	1259-1262
are	O	1263-1266
candidates	O	1267-1277
for	O	1278-1281
long	O	1282-1286
-	O	1286-1287
term	O	1287-1291
cyclophosphamide	O	1292-1308
treatment	O	1309-1318
should	O	1319-1325
be	O	1326-1328
routinely	O	1329-1338
evaluated	O	1339-1348
for	O	1349-1352
obstructive	B	1353-1364
uropathy	I	1365-1373
.	O	1373-1374

Ascending	O	0-9
dose	O	10-14
tolerance	O	15-24
study	O	25-30
of	O	31-33
intramuscular	O	34-47
carbetocin	O	48-58
administered	O	59-71
after	O	72-77
normal	O	78-84
vaginal	O	85-92
birth	O	93-98
.	O	98-99

OBJECTIVE	O	100-109
:	O	109-110
To	O	111-113
determine	O	114-123
the	O	124-127
maximum	O	128-135
tolerated	O	136-145
dose	O	146-150
(	O	151-152
MTD	O	152-155
)	O	155-156
of	O	157-159
carbetocin	O	160-170
(	O	171-172
a	O	172-173
long	O	174-178
-	O	178-179
acting	O	179-185
synthetic	O	186-195
analogue	O	196-204
of	O	205-207
oxytocin	O	208-216
)	O	216-217
,	O	217-218
when	O	219-223
administered	O	224-236
immediately	O	237-248
after	O	249-254
vaginal	O	255-262
delivery	O	263-271
at	O	272-274
term	O	275-279
.	O	279-280

MATERIALS	O	281-290
AND	O	291-294
METHODS	O	295-302
:	O	302-303
Carbetocin	O	304-314
was	O	315-318
given	O	319-324
as	O	325-327
an	O	328-330
intramuscular	O	331-344
injection	O	345-354
immediately	O	355-366
after	O	367-372
the	O	373-376
birth	O	377-382
of	O	383-385
the	O	386-389
infant	O	390-396
in	O	397-399
45	O	400-402
healthy	O	403-410
women	O	411-416
with	O	417-421
normal	O	422-428
singleton	O	429-438
pregnancies	O	439-450
who	O	451-454
delivered	O	455-464
vaginally	O	465-474
at	O	475-477
term	O	478-482
.	O	482-483

Dosage	O	484-490
groups	O	491-497
of	O	498-500
15	O	501-503
,	O	503-504
30	O	505-507
,	O	507-508
50	O	509-511
,	O	511-512
75	O	513-515
,	O	515-516
100	O	517-520
,	O	520-521
125	O	522-525
,	O	525-526
150	O	527-530
,	O	530-531
175	O	532-535
or	O	536-538
200	O	539-542
microg	O	543-549
carbetocin	O	550-560
were	O	561-565
assigned	O	566-574
to	O	575-577
blocks	O	578-584
of	O	585-587
three	O	588-593
women	O	594-599
according	O	600-609
to	O	610-612
the	O	613-616
continual	O	617-626
reassessment	O	627-639
method	O	640-646
(	O	647-648
CRM	O	648-651
)	O	651-652
.	O	652-653

RESULTS	O	654-661
:	O	661-662
All	O	663-666
dosage	O	667-673
groups	O	674-680
consisted	O	681-690
of	O	691-693
three	O	694-699
women	O	700-705
,	O	705-706
except	O	707-713
those	O	714-719
with	O	720-724
100	O	725-728
microg	O	729-735
(	O	736-737
n	O	737-738
=	O	738-739
6	O	739-740
)	O	740-741
and	O	742-745
200	O	746-749
microg	O	750-756
(	O	757-758
n	O	758-759
=	O	759-760
18	O	760-762
)	O	762-763
.	O	763-764

Recorded	O	765-773
were	O	774-778
dose	O	779-783
-	O	783-784
limiting	O	784-792
adverse	O	793-800
events	O	801-807
:	O	807-808
hyper	B	809-814
-	I	814-815
or	I	816-818
hypotension	I	819-830
(	O	831-832
three	O	832-837
)	O	837-838
,	O	838-839
severe	O	840-846
abdominal	B	847-856
pain	I	857-861
(	O	862-863
0	O	863-864
)	O	864-865
,	O	865-866
vomiting	B	867-875
(	O	876-877
0	O	877-878
)	O	878-879
and	O	880-883
retained	B	884-892
placenta	I	893-901
(	O	902-903
four	O	903-907
)	O	907-908
.	O	908-909

Serious	O	910-917
adverse	O	918-925
events	O	926-932
occurred	O	933-941
in	O	942-944
seven	O	945-950
women	O	951-956
:	O	956-957
six	O	958-961
cases	O	962-967
with	O	968-972
blood	B	973-978
loss	I	979-983
>	O	984-985
or	O	986-988
=	O	989-990
1000	O	991-995
ml	O	996-998
,	O	998-999
four	O	1000-1004
cases	O	1005-1010
of	O	1011-1013
manual	O	1014-1020
placenta	O	1021-1029
removal	O	1030-1037
,	O	1037-1038
five	O	1039-1043
cases	O	1044-1049
of	O	1050-1052
additional	O	1053-1063
oxytocics	O	1064-1073
administration	O	1074-1088
and	O	1089-1092
five	O	1093-1097
cases	O	1098-1103
of	O	1104-1106
blood	O	1107-1112
transfusion	O	1113-1124
.	O	1124-1125

Maximum	O	1126-1133
blood	B	1134-1139
loss	I	1140-1144
was	O	1145-1148
greatest	O	1149-1157
at	O	1158-1160
the	O	1161-1164
upper	O	1165-1170
and	O	1171-1174
lower	O	1175-1180
dose	O	1181-1185
levels	O	1186-1192
,	O	1192-1193
and	O	1194-1197
lowest	O	1198-1204
in	O	1205-1207
the	O	1208-1211
70	O	1212-1214
-	O	1214-1215
125	O	1215-1218
microg	O	1219-1225
dose	O	1226-1230
range	O	1231-1236
.	O	1236-1237

Four	O	1238-1242
out	O	1243-1246
of	O	1247-1249
six	O	1250-1253
cases	O	1254-1259
with	O	1260-1264
blood	B	1265-1270
loss	I	1271-1275
>	O	1276-1277
or	O	1278-1280
=	O	1281-1282
1000	O	1283-1287
ml	O	1288-1290
occurred	O	1291-1299
in	O	1300-1302
the	O	1303-1306
200	O	1307-1310
microg	O	1311-1317
group	O	1318-1323
.	O	1323-1324

The	O	1325-1328
majority	O	1329-1337
of	O	1338-1340
additional	O	1341-1351
administration	O	1352-1366
of	O	1367-1369
oxytocics	O	1370-1379
(	O	1380-1381
4	O	1381-1382
/	O	1382-1383
5	O	1383-1384
)	O	1384-1385
and	O	1386-1389
blood	O	1390-1395
transfusion	O	1396-1407
(	O	1408-1409
3	O	1409-1410
/	O	1410-1411
5	O	1411-1412
)	O	1412-1413
occurred	O	1414-1422
in	O	1423-1425
the	O	1426-1429
dose	O	1430-1434
groups	O	1435-1441
of	O	1442-1444
200	O	1445-1448
microg	O	1449-1455
.	O	1455-1456

All	O	1457-1460
retained	O	1461-1469
placentae	O	1470-1479
were	O	1480-1484
found	O	1485-1490
in	O	1491-1493
the	O	1494-1497
group	O	1498-1503
of	O	1504-1506
200	O	1507-1510
microg	O	1511-1517
.	O	1517-1518

CONCLUSION	O	1519-1529
:	O	1529-1530
The	O	1531-1534
MTD	O	1535-1538
was	O	1539-1542
calculated	O	1543-1553
to	O	1554-1556
be	O	1557-1559
at	O	1560-1562
200	O	1563-1566
microg	O	1567-1573
carbetocin	O	1574-1584
.	O	1584-1585

A	O	0-1
pilot	O	2-7
study	O	8-13
to	O	14-16
assess	O	17-23
the	O	24-27
safety	O	28-34
of	O	35-37
dobutamine	O	38-48
stress	O	49-55
echocardiography	O	56-72
in	O	73-75
the	O	76-79
emergency	O	80-89
department	O	90-100
evaluation	O	101-111
of	O	112-114
cocaine	O	115-122
-	O	122-123
associated	O	123-133
chest	B	134-139
pain	I	140-144
.	O	144-145

STUDY	O	146-151
OBJECTIVE	O	152-161
:	O	161-162
Chest	B	163-168
pain	I	169-173
in	O	174-176
the	O	177-180
setting	O	181-188
of	O	189-191
cocaine	O	192-199
use	O	200-203
poses	O	204-209
a	O	210-211
diagnostic	O	212-222
dilemma	O	223-230
.	O	230-231

Dobutamine	O	232-242
stress	O	243-249
echocardiography	O	250-266
(	O	267-268
DSE	O	268-271
)	O	271-272
is	O	273-275
a	O	276-277
widely	O	278-284
available	O	285-294
and	O	295-298
sensitive	O	299-308
test	O	309-313
for	O	314-317
evaluating	O	318-328
cardiac	O	329-336
ischemia	B	337-345
.	O	345-346

Because	O	347-354
of	O	355-357
the	O	358-361
theoretical	O	362-373
concern	O	374-381
regarding	O	382-391
administration	O	392-406
of	O	407-409
dobutamine	O	410-420
in	O	421-423
the	O	424-427
setting	O	428-435
of	O	436-438
cocaine	O	439-446
use	O	447-450
,	O	450-451
we	O	452-454
conducted	O	455-464
a	O	465-466
pilot	O	467-472
study	O	473-478
to	O	479-481
assess	O	482-488
the	O	489-492
safety	O	493-499
of	O	500-502
DSE	O	503-506
in	O	507-509
emergency	O	510-519
department	O	520-530
patients	O	531-539
with	O	540-544
cocaine	O	545-552
-	O	552-553
associated	O	553-563
chest	B	564-569
pain	I	570-574
.	O	574-575

METHODS	O	576-583
:	O	583-584
A	O	585-586
prospective	O	587-598
case	O	599-603
series	O	604-610
was	O	611-614
conducted	O	615-624
in	O	625-627
the	O	628-631
intensive	O	632-641
diagnostic	O	642-652
and	O	653-656
treatment	O	657-666
unit	O	667-671
in	O	672-674
the	O	675-678
ED	O	679-681
of	O	682-684
an	O	685-687
urban	O	688-693
tertiary	O	694-702
-	O	702-703
care	O	703-707
teaching	O	708-716
hospital	O	717-725
.	O	725-726

Patients	O	727-735
were	O	736-740
eligible	O	741-749
for	O	750-753
DSE	O	754-757
if	O	758-760
they	O	761-765
had	O	766-769
used	O	770-774
cocaine	O	775-782
within	O	783-789
24	O	790-792
hours	O	793-798
preceding	O	799-808
the	O	809-812
onset	O	813-818
of	O	819-821
chest	B	822-827
pain	I	828-832
and	O	833-836
had	O	837-840
a	O	841-842
normal	O	843-849
ECG	O	850-853
and	O	854-857
tropinin	O	858-866
I	O	867-868
level	O	869-874
.	O	874-875

Patients	O	876-884
exhibiting	O	885-895
signs	O	896-901
of	O	902-904
continuing	O	905-915
cocaine	O	916-923
toxicity	B	924-932
were	O	933-937
excluded	O	938-946
from	O	947-951
the	O	952-955
study	O	956-961
.	O	961-962

All	O	963-966
patients	O	967-975
were	O	976-980
admitted	O	981-989
to	O	990-992
the	O	993-996
hospital	O	997-1005
for	O	1006-1009
serial	O	1010-1016
testing	O	1017-1024
after	O	1025-1030
the	O	1031-1034
DSE	O	1035-1038
testing	O	1039-1046
in	O	1047-1049
the	O	1050-1053
intensive	O	1054-1063
diagnostic	O	1064-1074
and	O	1075-1078
treatment	O	1079-1088
unit	O	1089-1093
.	O	1093-1094

RESULTS	O	1095-1102
:	O	1102-1103
Twenty	O	1104-1110
-	O	1110-1111
four	O	1111-1115
patients	O	1116-1124
were	O	1125-1129
enrolled	O	1130-1138
.	O	1138-1139

Two	O	1140-1143
patients	O	1144-1152
had	O	1153-1156
inadequate	O	1157-1167
resting	O	1168-1175
images	O	1176-1182
,	O	1182-1183
one	O	1184-1187
DSE	O	1188-1191
was	O	1192-1195
terminated	O	1196-1206
because	O	1207-1214
of	O	1215-1217
inferior	O	1218-1226
hypokinesis	B	1227-1238
,	O	1238-1239
another	O	1240-1247
DSE	O	1248-1251
was	O	1252-1255
terminated	O	1256-1266
because	O	1267-1274
of	O	1275-1277
a	O	1278-1279
rate	O	1280-1284
-	O	1284-1285
related	O	1285-1292
atrial	O	1293-1299
conduction	O	1300-1310
deficit	O	1311-1318
,	O	1318-1319
and	O	1320-1323
1	O	1324-1325
patient	O	1326-1333
did	O	1334-1337
not	O	1338-1341
reach	O	1342-1347
the	O	1348-1351
target	O	1352-1358
heart	O	1359-1364
rate	O	1365-1369
.	O	1369-1370

Thus	O	1371-1375
,	O	1375-1376
19	O	1377-1379
patients	O	1380-1388
completed	O	1389-1398
a	O	1399-1400
DSE	O	1401-1404
and	O	1405-1408
reached	O	1409-1416
their	O	1417-1422
target	O	1423-1429
heart	O	1430-1435
rates	O	1436-1441
.	O	1441-1442

None	O	1443-1447
of	O	1448-1450
the	O	1451-1454
patients	O	1455-1463
experienced	O	1464-1475
signs	O	1476-1481
of	O	1482-1484
exaggerated	O	1485-1496
adrenergic	O	1497-1507
response	O	1508-1516
,	O	1516-1517
which	O	1518-1523
was	O	1524-1527
defined	O	1528-1535
as	O	1536-1538
a	O	1539-1540
systolic	O	1541-1549
blood	O	1550-1555
pressure	O	1556-1564
of	O	1565-1567
greater	O	1568-1575
than	O	1576-1580
200	O	1581-1584
mm	O	1585-1587
Hg	O	1588-1590
or	O	1591-1593
the	O	1594-1597
occurrence	O	1598-1608
of	O	1609-1611
tachydysrhythmias	B	1612-1629
(	O	1630-1631
excluding	O	1631-1640
sinus	B	1641-1646
tachycardia	I	1647-1658
)	O	1658-1659
.	O	1659-1660

Further	O	1661-1668
suggesting	O	1669-1679
lack	O	1680-1684
of	O	1685-1687
exaggerated	O	1688-1699
adrenergic	O	1700-1710
response	O	1711-1719
,	O	1719-1720
13	O	1721-1723
(	O	1724-1725
65	O	1725-1727
%	O	1727-1728
)	O	1728-1729
of	O	1730-1732
20	O	1733-1735
patients	O	1736-1744
required	O	1745-1753
supplemental	O	1754-1766
atropine	O	1767-1775
to	O	1776-1778
reach	O	1779-1784
their	O	1785-1790
target	O	1791-1797
heart	O	1798-1803
rates	O	1804-1809
.	O	1809-1810

CONCLUSION	O	1811-1821
:	O	1821-1822
No	O	1823-1825
exaggerated	O	1826-1837
adrenergic	O	1838-1848
response	O	1849-1857
was	O	1858-1861
detected	O	1862-1870
when	O	1871-1875
dobutamine	O	1876-1886
was	O	1887-1890
administered	O	1891-1903
to	O	1904-1906
patients	O	1907-1915
with	O	1916-1920
cocaine	O	1921-1928
-	O	1928-1929
related	O	1929-1936
chest	B	1937-1942
pain	I	1943-1947
.	O	1947-1948

Amiodarone	O	0-10
-	O	10-11
induced	O	11-18
torsade	B	19-26
de	I	27-29
pointes	I	30-37
during	O	38-44
bladder	O	45-52
irrigation	O	53-63
:	O	63-64
an	O	65-67
unusual	O	68-75
presentation	O	76-88
-	O	88-89
-	O	88-89
a	O	83-84
case	O	92-96
report	O	97-103
.	O	103-104

The	O	105-108
authors	O	109-116
present	O	117-124
a	O	125-126
case	O	127-131
of	O	132-134
early	O	135-140
(	O	141-142
within	O	142-148
4	O	149-150
days	O	151-155
)	O	155-156
development	O	157-168
of	O	169-171
torsade	B	172-179
de	I	180-182
pointes	I	183-190
(	O	191-192
TdP	B	192-195
)	O	195-196
associated	O	197-207
with	O	208-212
oral	O	213-217
amiodarone	O	218-228
therapy	O	229-236
.	O	236-237

Consistent	O	238-248
with	O	249-253
other	O	254-259
reports	O	260-267
this	O	268-272
case	O	273-277
of	O	278-280
TdP	B	281-284
occurred	O	285-293
in	O	294-296
the	O	297-300
context	O	301-308
of	O	309-311
multiple	O	312-320
exacerbating	O	321-333
factors	O	334-341
including	O	342-351
hypokalemia	B	352-363
and	O	364-367
digoxin	O	368-375
excess	O	376-382
.	O	382-383

Transient	O	384-393
prolongation	O	394-406
of	O	407-409
the	O	410-413
QT	O	414-416
during	O	417-423
bladder	O	424-431
irrigation	O	432-442
prompted	O	443-451
the	O	452-455
episode	O	456-463
of	O	464-466
TdP	B	467-470
.	O	470-471

It	O	472-474
is	O	475-477
well	O	478-482
known	O	483-488
that	O	489-493
bradycardia	B	494-505
exacerbates	O	506-517
acquired	O	518-526
TdP	B	527-530
.	O	530-531

The	O	532-535
authors	O	536-543
speculate	O	544-553
that	O	554-558
the	O	559-562
increased	O	563-572
vagal	O	573-578
tone	O	579-583
during	O	584-590
bladder	O	591-598
irrigation	O	599-609
,	O	609-610
a	O	611-612
vagal	O	613-618
maneuver	O	619-627
,	O	627-628
in	O	629-631
the	O	632-635
context	O	636-643
of	O	644-646
amiodarone	O	647-657
therapy	O	658-665
resulted	O	666-674
in	O	675-677
amiodarone	O	678-688
-	O	688-689
induced	O	689-696
proarrhythmia	B	697-710
.	O	710-711

In	O	712-714
the	O	715-718
absence	O	719-726
of	O	727-729
amiodarone	O	730-740
therapy	O	741-748
,	O	748-749
a	O	750-751
second	O	752-758
bladder	O	759-766
irrigation	O	767-777
did	O	778-781
not	O	782-785
induce	O	786-792
TdP	B	793-796
despite	O	797-804
hypokalemia	B	805-816
and	O	817-820
hypomagnesemia	B	821-835
.	O	835-836

Acute	B	0-5
renal	I	6-11
insufficiency	I	12-25
after	O	26-31
high	O	32-36
-	O	36-37
dose	O	37-41
melphalan	O	42-51
in	O	52-54
patients	O	55-63
with	O	64-68
primary	B	69-76
systemic	I	77-85
amyloidosis	I	86-97
during	O	98-104
stem	O	105-109
cell	O	110-114
transplantation	O	115-130
.	O	130-131

BACKGROUND	O	132-142
:	O	142-143
Patients	O	144-152
with	O	153-157
primary	B	158-165
systemic	I	166-174
amyloidosis	I	175-186
(	O	187-188
AL	B	188-190
)	O	190-191
have	O	192-196
a	O	197-198
poor	O	199-203
prognosis	O	204-213
.	O	213-214

Median	O	215-221
survival	O	222-230
time	O	231-235
from	O	236-240
standard	O	241-249
treatments	O	250-260
is	O	261-263
only	O	264-268
17	O	269-271
months	O	272-278
.	O	278-279

High	O	280-284
-	O	284-285
dose	O	285-289
intravenous	O	290-301
melphalan	O	302-311
followed	O	312-320
by	O	321-323
peripheral	O	324-334
blood	O	335-340
stem	O	341-345
cell	O	346-350
transplant	O	351-361
(	O	362-363
PBSCT	O	363-368
)	O	368-369
appears	O	370-377
to	O	378-380
be	O	381-383
the	O	384-387
most	O	388-392
promising	O	393-402
therapy	O	403-410
,	O	410-411
but	O	412-415
treatment	O	416-425
mortality	O	426-435
can	O	436-439
be	O	440-442
high	O	443-447
.	O	447-448

The	O	449-452
authors	O	453-460
have	O	461-465
noted	O	466-471
the	O	472-475
development	O	476-487
of	O	488-490
acute	B	491-496
renal	I	497-502
insufficiency	I	503-516
immediately	O	517-528
after	O	529-534
melphalan	O	535-544
conditioning	O	545-557
.	O	557-558

This	O	559-563
study	O	564-569
was	O	570-573
undertaken	O	574-584
to	O	585-587
further	O	588-595
examine	O	596-603
its	O	604-607
risk	O	608-612
factors	O	613-620
and	O	621-624
impact	O	625-631
on	O	632-634
posttransplant	O	635-649
mortality	O	650-659
.	O	659-660

METHODS	O	661-668
:	O	668-669
Consecutive	O	670-681
AL	B	682-684
patients	O	685-693
who	O	694-697
underwent	O	698-707
PBSCT	O	708-713
were	O	714-718
studied	O	719-726
retrospectively	O	727-742
.	O	742-743

Acute	B	744-749
renal	I	750-755
insufficiency	I	756-769
(	O	770-771
ARI	B	771-774
)	O	774-775
after	O	776-781
high	O	782-786
-	O	786-787
dose	O	787-791
melphalan	O	792-801
was	O	802-805
defined	O	806-813
by	O	814-816
a	O	817-818
minimum	O	819-826
increase	O	827-835
of	O	836-838
0	O	839-840
.	O	840-841
5	O	841-842
mg	O	843-845
/	O	845-846
dL	O	846-848
(	O	849-850
44	O	850-852
micromol	O	853-861
/	O	861-862
L	O	862-863
)	O	863-864
in	O	865-867
the	O	868-871
serum	O	872-877
creatinine	O	878-888
level	O	889-894
that	O	895-899
is	O	900-902
greater	O	903-910
than	O	911-915
50	O	916-918
%	O	918-919
of	O	920-922
baseline	O	923-931
immediately	O	932-943
after	O	944-949
conditioning	O	950-962
.	O	962-963

Urine	O	964-969
sediment	O	970-978
score	O	979-984
was	O	985-988
the	O	989-992
sum	O	993-996
of	O	997-999
the	O	1000-1003
individual	O	1004-1014
types	O	1015-1020
of	O	1021-1023
sediment	O	1024-1032
identified	O	1033-1043
on	O	1044-1046
urine	O	1047-1052
microscopy	O	1053-1063
.	O	1063-1064

RESULTS	O	1065-1072
:	O	1072-1073
Of	O	1074-1076
the	O	1077-1080
80	O	1081-1083
patients	O	1084-1092
studied	O	1093-1100
,	O	1100-1101
ARI	B	1102-1105
developed	O	1106-1115
in	O	1116-1118
18	O	1119-1121
.	O	1121-1122
8	O	1120-1121
%	O	1123-1124
of	O	1125-1127
the	O	1128-1131
patients	O	1132-1140
after	O	1141-1146
high	O	1147-1151
-	O	1151-1152
dose	O	1152-1156
melphalan	O	1157-1166
.	O	1166-1167

Univariate	O	1168-1178
analysis	O	1179-1187
identified	O	1188-1198
age	O	1199-1202
,	O	1202-1203
hypoalbuminemia	B	1204-1219
,	O	1219-1220
heavy	O	1221-1226
proteinuria	B	1227-1238
,	O	1238-1239
diuretic	O	1240-1248
use	O	1249-1252
,	O	1252-1253
and	O	1254-1257
urine	O	1258-1263
sediment	O	1264-1272
score	O	1273-1278
(	O	1279-1280
>	O	1280-1281
3	O	1281-1282
)	O	1282-1283
as	O	1284-1286
risk	O	1287-1291
factors	O	1292-1299
.	O	1299-1300

Age	O	1301-1304
and	O	1305-1308
urine	O	1309-1314
sediment	O	1315-1323
score	O	1324-1329
remained	O	1330-1338
independently	O	1339-1352
significant	O	1353-1364
risk	O	1365-1369
factors	O	1370-1377
in	O	1378-1380
the	O	1381-1384
multivariate	O	1385-1397
analysis	O	1398-1406
.	O	1406-1407

Patients	O	1408-1416
who	O	1417-1420
had	O	1421-1424
ARI	B	1425-1428
after	O	1429-1434
high	O	1435-1439
-	O	1439-1440
dose	O	1440-1444
melphalan	O	1445-1454
underwent	O	1455-1464
dialysis	O	1465-1473
more	O	1474-1478
often	O	1479-1484
(	O	1485-1486
P	O	1486-1487
=	O	1488-1489
0	O	1490-1491
.	O	1491-1492
007	O	1492-1495
)	O	1495-1496
,	O	1496-1497
and	O	1498-1501
had	O	1502-1505
a	O	1506-1507
worse	O	1508-1513
1	O	1514-1515
-	O	1515-1516
year	O	1516-1520
survival	O	1521-1529
(	O	1530-1531
P	O	1531-1532
=	O	1533-1534
0	O	1535-1536
.	O	1536-1537
03	O	1537-1539
)	O	1539-1540
.	O	1536-1537

CONCLUSION	O	1542-1552
:	O	1552-1553
The	O	1554-1557
timing	O	1558-1564
of	O	1565-1567
renal	B	1568-1573
injury	I	1574-1580
strongly	O	1581-1589
suggests	O	1590-1598
melphalan	O	1599-1608
as	O	1609-1611
the	O	1612-1615
causative	O	1616-1625
agent	O	1626-1631
.	O	1631-1632

Ongoing	O	1633-1640
tubular	B	1641-1648
injury	I	1649-1655
may	O	1656-1659
be	O	1660-1662
a	O	1663-1664
prerequisite	O	1665-1677
for	O	1678-1681
renal	B	1682-1687
injury	I	1688-1694
by	O	1695-1697
melphalan	O	1698-1707
as	O	1708-1710
evidenced	O	1711-1720
by	O	1721-1723
the	O	1724-1727
active	O	1728-1734
urinary	O	1735-1742
sediment	O	1743-1751
.	O	1751-1752

Development	O	1753-1764
of	O	1765-1767
ARI	B	1768-1771
adversely	O	1772-1781
affected	O	1782-1790
the	O	1791-1794
outcome	O	1795-1802
after	O	1803-1808
PBSCT	O	1809-1814
.	O	1814-1815

Effective	O	1816-1825
preventive	O	1826-1836
measures	O	1837-1845
may	O	1846-1849
help	O	1850-1854
decrease	O	1855-1863
the	O	1864-1867
treatment	O	1868-1877
mortality	O	1878-1887
of	O	1888-1890
PBSCT	O	1891-1896
in	O	1897-1899
AL	B	1900-1902
patients	O	1903-1911
.	O	1911-1912

Impaired	B	0-8
fear	I	9-13
recognition	I	14-25
in	O	26-28
regular	O	29-36
recreational	O	37-49
cocaine	O	50-57
users	O	58-63
.	O	63-64

INTRODUCTION	O	65-77
:	O	77-78
The	O	79-82
ability	O	83-90
to	O	91-93
read	O	94-98
facial	O	99-105
expressions	O	106-117
is	O	118-120
essential	O	121-130
for	O	131-134
normal	O	135-141
human	O	142-147
social	O	148-154
interaction	O	155-166
.	O	166-167

The	O	168-171
aim	O	172-175
of	O	176-178
the	O	179-182
present	O	183-190
study	O	191-196
was	O	197-200
to	O	201-203
conduct	O	204-211
the	O	212-215
first	O	216-221
investigation	O	222-235
of	O	236-238
facial	O	239-245
expression	O	246-256
recognition	O	257-268
performance	O	269-280
in	O	281-283
recreational	O	284-296
cocaine	O	297-304
users	O	305-310
.	O	310-311

MATERIALS	O	312-321
AND	O	322-325
METHODS	O	326-333
:	O	333-334
Three	O	335-340
groups	O	341-347
,	O	347-348
comprised	O	349-358
of	O	359-361
21	O	362-364
cocaine	O	365-372
naive	O	373-378
participants	O	379-391
(	O	392-393
CN	O	393-395
)	O	395-396
,	O	396-397
30	O	399-401
occasional	O	402-412
cocaine	O	413-420
(	O	421-422
OC	O	422-424
)	O	424-425
,	O	425-426
and	O	427-430
48	O	431-433
regular	O	434-441
recreational	O	442-454
cocaine	O	455-462
(	O	463-464
RC	O	464-466
)	O	466-467
users	O	468-473
,	O	473-474
were	O	475-479
compared	O	480-488
.	O	488-489

An	O	490-492
emotional	O	493-502
facial	O	503-509
expression	O	510-520
(	O	521-522
EFE	O	522-525
)	O	525-526
task	O	527-531
consisting	O	532-542
of	O	543-545
a	O	546-547
male	O	548-552
and	O	553-556
female	O	557-563
face	O	564-568
expressing	O	569-579
six	O	580-583
basic	O	584-589
emotions	O	590-598
(	O	599-600
happiness	O	600-609
,	O	609-610
surprise	O	611-619
,	O	619-620
sadness	O	621-628
,	O	628-629
anger	O	630-635
,	O	635-636
fear	O	637-641
,	O	641-642
and	O	643-646
disgust	O	647-654
)	O	654-655
was	O	656-659
administered	O	660-672
.	O	672-673

Mean	O	674-678
percent	O	679-686
accuracy	O	687-695
and	O	696-699
latencies	O	700-709
for	O	710-713
correct	O	714-721
responses	O	722-731
across	O	732-738
eight	O	739-744
presentations	O	745-758
of	O	759-761
each	O	762-766
basic	O	767-772
emotion	O	773-780
were	O	781-785
derived	O	786-793
.	O	793-794

Participants	O	795-807
were	O	808-812
also	O	813-817
assessed	O	818-826
with	O	827-831
the	O	832-835
"	O	836-837
Eyes	O	837-841
task	O	842-846
"	O	846-847
to	O	848-850
investigate	O	851-862
their	O	863-868
ability	O	869-876
to	O	877-879
recognize	O	880-889
more	O	890-894
complex	O	895-902
emotional	O	903-912
states	O	913-919
and	O	920-923
the	O	924-927
Symptom	O	928-935
CheckList	O	936-945
-	O	945-946
90	O	946-948
-	O	945-946
Revised	O	949-956
to	O	957-959
measure	O	960-967
psychopathology	O	968-983
.	O	983-984

RESULTS	O	985-992
:	O	992-993
There	O	994-999
were	O	1000-1004
no	O	1005-1007
group	O	1008-1013
differences	O	1014-1025
in	O	1026-1028
psychopathology	O	1029-1044
or	O	1045-1047
"	O	1048-1049
eyes	O	1049-1053
task	O	1054-1058
"	O	1058-1059
performance	O	1060-1071
,	O	1071-1072
but	O	1073-1076
the	O	1077-1080
RC	O	1081-1083
group	O	1084-1089
,	O	1089-1090
who	O	1091-1094
otherwise	O	1095-1104
had	O	1105-1108
similar	O	1109-1116
illicit	O	1117-1124
substance	O	1125-1134
use	O	1135-1138
histories	O	1139-1148
to	O	1149-1151
the	O	1152-1155
OC	O	1156-1158
group	O	1159-1164
,	O	1164-1165
exhibited	O	1166-1175
impaired	B	1176-1184
fear	I	1185-1189
recognition	I	1190-1201
accuracy	O	1202-1210
compared	O	1211-1219
to	O	1220-1222
the	O	1223-1226
OC	O	1227-1229
and	O	1230-1233
CN	O	1234-1236
groups	O	1237-1243
.	O	1243-1244

The	O	1245-1248
RC	O	1249-1251
group	O	1252-1257
also	O	1258-1262
correctly	O	1263-1272
identified	O	1273-1283
anger	O	1284-1289
,	O	1289-1290
fear	O	1291-1295
,	O	1295-1296
happiness	O	1297-1306
,	O	1306-1307
and	O	1308-1311
surprise	O	1312-1320
,	O	1320-1321
more	O	1322-1326
slowly	O	1327-1333
than	O	1334-1338
CN	O	1339-1341
,	O	1341-1342
but	O	1343-1346
not	O	1347-1350
OC	O	1351-1353
participants	O	1354-1366
.	O	1366-1367

The	O	1368-1371
OC	O	1372-1374
group	O	1375-1380
was	O	1381-1384
slower	O	1385-1391
than	O	1392-1396
CN	O	1397-1399
when	O	1400-1404
correctly	O	1405-1414
identifying	O	1415-1426
disgust	O	1427-1434
.	O	1434-1435

The	O	1436-1439
selective	O	1440-1449
deficit	B	1450-1457
in	I	1458-1460
fear	I	1461-1465
recognition	I	1466-1477
accuracy	O	1478-1486
manifested	O	1487-1497
by	O	1498-1500
the	O	1501-1504
RC	O	1505-1507
group	O	1508-1513
cannot	O	1514-1520
be	O	1521-1523
explained	O	1524-1533
by	O	1534-1536
the	O	1537-1540
subacute	O	1541-1549
effects	O	1550-1557
of	O	1558-1560
cocaine	O	1561-1568
,	O	1568-1569
or	O	1570-1572
ecstasy	O	1573-1580
,	O	1580-1581
because	O	1582-1589
recent	O	1590-1596
and	O	1597-1600
less	O	1601-1605
recent	O	1606-1612
users	O	1613-1618
of	O	1619-1621
these	O	1622-1627
drugs	O	1628-1633
within	O	1634-1640
this	O	1641-1645
group	O	1646-1651
were	O	1652-1656
similarly	O	1657-1666
impaired	O	1667-1675
.	O	1675-1676

Possible	O	1677-1685
parallels	O	1686-1695
between	O	1696-1703
RC	O	1704-1706
users	O	1707-1712
and	O	1713-1716
psychopaths	B	1717-1728
with	O	1729-1733
respect	O	1734-1741
to	O	1742-1744
impaired	B	1745-1753
fear	I	1754-1758
recognition	I	1759-1770
,	O	1770-1771
amygdala	B	1772-1780
dysfunction	I	1781-1792
,	O	1792-1793
and	O	1794-1797
etiology	O	1798-1806
are	O	1807-1810
discussed	O	1811-1820
.	O	1820-1821

Corneal	B	0-7
ulcers	I	8-14
associated	O	15-25
with	O	26-30
aerosolized	O	31-42
crack	O	43-48
cocaine	O	49-56
use	O	57-60
.	O	60-61

PURPOSE	O	62-69
:	O	69-70
We	O	71-73
report	O	74-80
4	O	81-82
cases	O	83-88
of	O	89-91
corneal	B	92-99
ulcers	I	100-106
associated	O	107-117
with	O	118-122
drug	B	123-127
abuse	I	128-133
.	O	133-134

The	O	135-138
pathogenesis	O	139-151
of	O	152-154
these	O	155-160
ulcers	B	161-167
and	O	168-171
management	O	172-182
of	O	183-185
these	O	186-191
patients	O	192-200
are	O	201-204
also	O	205-209
reviewed	O	210-218
.	O	218-219

METHODS	O	220-227
:	O	227-228
Review	O	229-235
of	O	236-238
all	O	239-242
cases	O	243-248
of	O	249-251
corneal	B	252-259
ulcers	I	260-266
associated	O	267-277
with	O	278-282
drug	B	283-287
abuse	I	288-293
seen	O	294-298
at	O	299-301
our	O	302-305
institution	O	306-317
from	O	318-322
July	O	323-327
2006	O	328-332
to	O	333-335
December	O	336-344
2006	O	345-349
.	O	349-350

RESULTS	O	351-358
:	O	358-359
Four	O	360-364
patients	O	365-373
with	O	374-378
corneal	B	379-386
ulcers	I	387-393
associated	O	394-404
with	O	405-409
crack	O	410-415
cocaine	O	416-423
use	O	424-427
were	O	428-432
reviewed	O	433-441
.	O	441-442

All	O	443-446
corneal	B	447-454
ulcers	I	455-461
were	O	462-466
cultured	O	467-475
,	O	475-476
and	O	477-480
the	O	481-484
patients	O	485-493
were	O	494-498
admitted	O	499-507
to	O	508-510
the	O	511-514
hospital	O	515-523
for	O	524-527
intensive	O	528-537
topical	O	538-545
antibiotic	O	546-556
treatment	O	557-566
.	O	566-567

Each	O	568-572
patient	O	573-580
received	O	581-589
comprehensive	O	590-603
health	O	604-610
care	O	611-615
,	O	615-616
including	O	617-626
medical	O	627-634
and	O	635-638
substance	B	639-648
abuse	I	649-654
consultations	O	655-668
.	O	668-669

Streptococcal	O	670-683
organisms	O	684-693
were	O	694-698
found	O	699-704
in	O	705-707
3	O	708-709
cases	O	710-715
and	O	716-719
Capnocytophaga	O	720-734
and	O	735-738
Brevibacterium	O	739-753
casei	O	754-759
in	O	760-762
1	O	763-764
patient	O	765-772
.	O	772-773

The	O	774-777
infections	B	778-788
responded	O	789-798
to	O	799-801
antibiotic	O	802-812
treatment	O	813-822
.	O	822-823

Two	O	824-827
patients	O	828-836
needed	O	837-843
a	O	844-845
lateral	O	846-853
tarsorrhaphy	O	854-866
for	O	867-870
persistent	O	871-881
epithelial	B	882-892
defects	I	893-900
.	O	900-901

CONCLUSIONS	O	902-913
:	O	913-914
Aerosolized	O	915-926
crack	O	927-932
cocaine	O	933-940
use	O	941-944
can	O	945-948
be	O	949-951
associated	O	952-962
with	O	963-967
the	O	968-971
development	O	972-983
of	O	984-986
corneal	B	987-994
ulcers	I	995-1001
.	O	1001-1002

Drug	B	1003-1007
abuse	I	1008-1013
provides	O	1014-1022
additional	O	1023-1033
challenges	O	1034-1044
for	O	1045-1048
management	O	1049-1059
.	O	1059-1060

Not	O	1061-1064
only	O	1065-1069
treatment	O	1070-1079
of	O	1080-1082
their	O	1083-1088
infections	B	1089-1099
but	O	1100-1103
also	O	1104-1108
the	O	1109-1112
overall	O	1113-1120
poor	O	1121-1125
health	O	1126-1132
of	O	1133-1135
the	O	1136-1139
patients	O	1140-1148
and	O	1149-1152
increased	O	1153-1162
risk	O	1163-1167
of	O	1168-1170
noncompliance	O	1171-1184
need	O	1185-1189
to	O	1190-1192
be	O	1193-1195
addressed	O	1196-1205
.	O	1205-1206

Comprehensive	O	1207-1220
care	O	1221-1225
may	O	1226-1229
provide	O	1230-1237
the	O	1238-1241
patient	O	1242-1249
the	O	1250-1253
opportunity	O	1254-1265
to	O	1266-1268
discontinue	O	1269-1280
their	O	1281-1286
substance	B	1287-1296
abuse	I	1297-1302
,	O	1302-1303
improve	O	1304-1311
their	O	1312-1317
overall	O	1318-1325
health	O	1326-1332
,	O	1332-1333
and	O	1334-1337
prevent	O	1338-1345
future	O	1346-1352
corneal	O	1353-1360
complications	O	1361-1374
.	O	1374-1375

Levetiracetam	O	0-13
as	O	14-16
an	O	17-19
adjunct	O	20-27
to	O	28-30
phenobarbital	O	31-44
treatment	O	45-54
in	O	55-57
cats	O	58-62
with	O	63-67
suspected	O	68-77
idiopathic	B	78-88
epilepsy	I	89-97
.	O	97-98

OBJECTIVE	O	99-108
:	O	108-109
To	O	110-112
assess	O	113-119
pharmacokinetics	O	120-136
,	O	136-137
efficacy	O	138-146
,	O	146-147
and	O	148-151
tolerability	O	152-164
of	O	165-167
oral	O	168-172
levetiracetam	O	173-186
administered	O	187-199
as	O	200-202
an	O	203-205
adjunct	O	206-213
to	O	214-216
phenobarbital	O	217-230
treatment	O	231-240
in	O	241-243
cats	O	244-248
with	O	249-253
poorly	O	254-260
controlled	O	261-271
suspected	O	272-281
idiopathic	B	282-292
epilepsy	I	293-301
.	O	301-302

DESIGN	O	303-309
-	O	309-310
Open	O	310-314
-	O	309-310
label	O	315-320
,	O	320-321
noncomparative	O	322-336
clinical	O	337-345
trial	O	346-351
.	O	351-352

ANIMALS	O	353-360
:	O	360-361
12	O	362-364
cats	O	365-369
suspected	O	370-379
to	O	380-382
have	O	383-387
idiopathic	B	388-398
epilepsy	I	399-407
that	O	408-412
was	O	413-416
poorly	O	417-423
controlled	O	424-434
with	O	435-439
phenobarbital	O	440-453
or	O	454-456
that	O	457-461
had	O	462-465
unacceptable	O	466-478
adverse	O	479-486
effects	O	487-494
when	O	495-499
treated	O	500-507
with	O	508-512
phenobarbital	O	513-526
.	O	526-527

PROCEDURES	O	528-538
:	O	538-539
Cats	O	540-544
were	O	545-549
treated	O	550-557
with	O	558-562
levetiracetam	O	563-576
(	O	577-578
20	O	578-580
mg	O	581-583
/	O	583-584
kg	O	584-586
[	O	587-588
9	O	588-589
.	O	589-590
1	O	590-591
mg	O	592-594
/	O	594-595
lb	O	595-597
]	O	597-598
,	O	598-599
PO	O	600-602
,	O	602-603
q	O	604-605
8	O	606-607
h	O	608-609
)	O	609-610
.	O	610-611

After	O	612-617
a	O	618-619
minimum	O	620-627
of	O	628-630
1	O	631-632
week	O	633-637
of	O	638-640
treatment	O	641-650
,	O	650-651
serum	O	652-657
levetiracetam	O	658-671
concentrations	O	672-686
were	O	687-691
measured	O	692-700
before	O	701-707
and	O	708-711
2	O	712-713
,	O	713-714
4	O	715-716
,	O	716-717
and	O	718-721
6	O	722-723
hours	O	724-729
after	O	730-735
drug	O	736-740
administration	O	741-755
,	O	755-756
and	O	757-760
maximum	O	761-768
and	O	769-772
minimum	O	773-780
serum	O	781-786
concentrations	O	787-801
and	O	802-805
elimination	O	806-817
half	O	818-822
-	O	822-823
life	O	823-827
were	O	828-832
calculated	O	833-843
.	O	843-844

Seizure	B	845-852
frequencies	O	853-864
before	O	865-871
and	O	872-875
after	O	876-881
initiation	O	882-892
of	O	893-895
levetiracetam	O	896-909
treatment	O	910-919
were	O	920-924
compared	O	925-933
,	O	933-934
and	O	935-938
adverse	O	939-946
effects	O	947-954
were	O	955-959
recorded	O	960-968
.	O	968-969

RESULTS	O	970-977
:	O	977-978
Median	O	979-985
maximum	O	986-993
serum	O	994-999
levetiracetam	O	1000-1013
concentration	O	1014-1027
was	O	1028-1031
25	O	1032-1034
.	O	1034-1035
5	O	1033-1034
microg	O	1037-1043
/	O	1043-1044
mL	O	1044-1046
,	O	1046-1047
median	O	1048-1054
minimum	O	1055-1062
serum	O	1063-1068
levetiracetam	O	1069-1082
concentration	O	1083-1096
was	O	1097-1100
8	O	1101-1102
.	O	1102-1103
3	O	1103-1104
microg	O	1105-1111
/	O	1111-1112
mL	O	1112-1114
,	O	1114-1115
and	O	1116-1119
median	O	1120-1126
elimination	O	1127-1138
half	O	1139-1143
-	O	1143-1144
life	O	1144-1148
was	O	1149-1152
2	O	1153-1154
.	O	1154-1155
9	O	1155-1156
hours	O	1157-1162
.	O	1162-1163

Median	O	1164-1170
seizure	B	1171-1178
frequency	O	1179-1188
prior	O	1189-1194
to	O	1195-1197
treatment	O	1198-1207
with	O	1208-1212
levetiracetam	O	1213-1226
(	O	1227-1228
2	O	1228-1229
.	O	1229-1230
1	O	1230-1231
seizures	B	1232-1240
/	O	1240-1241
mo	O	1241-1243
)	O	1243-1244
was	O	1245-1248
significantly	O	1249-1262
higher	O	1263-1269
than	O	1270-1274
median	O	1275-1281
seizure	B	1282-1289
frequency	O	1290-1299
after	O	1300-1305
initiation	O	1306-1316
of	O	1317-1319
levetiracetam	O	1320-1333
treatment	O	1334-1343
(	O	1344-1345
0	O	1345-1346
.	O	1346-1347
42	O	1347-1349
seizures	B	1350-1358
/	O	1358-1359
mo	O	1359-1361
)	O	1361-1362
,	O	1362-1363
and	O	1364-1367
7	O	1368-1369
of	O	1370-1372
10	O	1373-1375
cats	O	1376-1380
were	O	1381-1385
classified	O	1386-1396
as	O	1397-1399
having	O	1400-1406
responded	O	1407-1416
to	O	1417-1419
levetiracetam	O	1420-1433
treatment	O	1434-1443
(	O	1444-1445
ie	O	1445-1447
,	O	1447-1448
reduction	O	1449-1458
in	O	1459-1461
seizure	B	1462-1469
frequency	O	1470-1479
of	O	1480-1482
>	O	1483-1484
or	O	1484-1486
=	O	1486-1487
50	O	1487-1489
%	O	1489-1490
)	O	1490-1491
.	O	1491-1492

Two	O	1493-1496
cats	O	1497-1501
had	O	1502-1505
transient	O	1506-1515
lethargy	B	1516-1524
and	O	1525-1528
inappetence	B	1529-1540
.	O	1540-1541

CONCLUSIONS	O	1542-1553
AND	O	1554-1557
CLINICAL	O	1558-1566
RELEVANCE	O	1567-1576
:	O	1576-1577
Results	O	1578-1585
suggested	O	1586-1595
that	O	1596-1600
levetiracetam	O	1601-1614
is	O	1615-1617
well	O	1618-1622
tolerated	O	1623-1632
in	O	1633-1635
cats	O	1636-1640
and	O	1641-1644
may	O	1645-1648
be	O	1649-1651
useful	O	1652-1658
as	O	1659-1661
an	O	1662-1664
adjunct	O	1665-1672
to	O	1673-1675
phenobarbital	O	1676-1689
treatment	O	1690-1699
in	O	1700-1702
cats	O	1703-1707
with	O	1708-1712
idiopathic	B	1713-1723
epilepsy	I	1724-1732
.	O	1732-1733

Bilateral	O	0-9
haemorrhagic	B	10-22
infarction	I	23-33
of	I	34-36
the	I	37-40
globus	I	41-47
pallidus	I	48-56
after	O	57-62
cocaine	O	63-70
and	O	71-74
alcohol	O	75-82
intoxication	O	83-95
.	O	95-96

Cocaine	O	97-104
is	O	105-107
a	O	108-109
risk	O	110-114
factor	O	115-121
for	O	122-125
both	O	126-130
ischemic	B	131-139
and	I	140-143
haemorrhagic	I	144-156
stroke	I	157-163
.	O	163-164

We	O	165-167
present	O	168-175
the	O	176-179
case	O	180-184
of	O	185-187
a	O	188-189
31	O	190-192
-	O	192-193
year	O	193-197
-	O	192-193
old	O	198-201
man	O	202-205
with	O	206-210
bilateral	O	211-220
ischemia	B	221-229
of	I	230-232
the	I	233-236
globus	I	237-243
pallidus	I	244-252
after	O	253-258
excessive	O	259-268
alcohol	O	269-276
and	O	277-280
intranasal	O	281-291
cocaine	O	292-299
use	O	300-303
.	O	303-304

Drug	O	305-309
-	O	309-310
related	O	310-317
globus	B	318-324
pallidus	I	325-333
infarctions	I	334-345
are	O	346-349
most	O	350-354
often	O	355-360
associated	O	361-371
with	O	372-376
heroin	O	377-383
.	O	383-384

Bilateral	O	385-394
basal	B	395-400
ganglia	I	401-408
infarcts	I	409-417
after	O	418-423
the	O	424-427
use	O	428-431
of	O	432-434
cocaine	O	435-442
,	O	442-443
without	O	444-451
concurrent	O	452-462
heroin	O	463-469
use	O	470-473
,	O	473-474
have	O	475-479
never	O	480-485
been	O	486-490
reported	O	491-499
.	O	499-500

In	O	501-503
our	O	504-507
patient	O	508-515
,	O	515-516
transient	O	517-526
cardiac	B	527-534
arrhythmia	I	535-545
or	O	546-548
respiratory	B	549-560
dysfunction	I	561-572
related	O	573-580
to	O	581-583
cocaine	O	584-591
and	O	592-595
/	O	595-596
or	O	596-598
ethanol	O	599-606
use	O	607-610
were	O	611-615
the	O	616-619
most	O	620-624
likely	O	625-631
causes	O	632-638
of	O	639-641
cerebral	B	642-650
hypoperfusion	I	651-664
.	O	664-665

Acute	B	0-5
renal	I	6-11
failure	I	12-19
after	O	20-25
high	O	26-30
-	O	30-31
dose	O	31-35
methotrexate	O	36-48
therapy	O	49-56
in	O	57-59
a	O	60-61
patient	O	62-69
with	O	70-74
ileostomy	O	75-84
.	O	84-85

High	O	86-90
-	O	90-91
dose	O	91-95
methotrexate	O	96-108
(	O	109-110
HD	O	110-112
-	O	112-113
MTX	O	113-116
)	O	116-117
is	O	118-120
an	O	121-123
important	O	124-133
treatment	O	134-143
for	O	144-147
Burkitt	B	148-155
lymphoma	I	156-164
,	O	164-165
but	O	166-169
can	O	170-173
cause	O	174-179
hepatic	B	180-187
and	I	188-191
renal	I	192-197
toxicity	I	198-206
when	O	207-211
its	O	212-215
clearance	O	216-225
is	O	226-228
delayed	O	229-236
.	O	236-237

We	O	238-240
report	O	241-247
a	O	248-249
case	O	250-254
of	O	255-257
acute	B	258-263
renal	I	264-269
failure	I	270-277
after	O	278-283
HD	O	284-286
-	O	286-287
MTX	O	287-290
therapy	O	291-298
in	O	299-301
a	O	302-303
patient	O	304-311
with	O	312-316
ileostomy	O	317-326
,	O	326-327
The	O	328-331
patient	O	332-339
was	O	340-343
a	O	344-345
3	O	346-347
-	O	347-348
year	O	348-352
-	O	347-348
old	O	353-356
boy	O	357-360
who	O	361-364
had	O	365-368
received	O	369-377
a	O	378-379
living	O	380-386
-	O	386-387
related	O	387-394
liver	O	395-400
transplantation	O	401-416
for	O	417-420
congenital	O	421-431
biliary	B	432-439
atresia	I	440-447
.	O	447-448

At	O	449-451
day	O	452-455
833	O	456-459
after	O	460-465
the	O	466-469
transplantation	O	470-485
,	O	485-486
he	O	487-489
was	O	490-493
diagnosed	O	494-503
with	O	504-508
PTLD	B	509-513
(	O	514-515
post	B	515-519
-	I	519-520
transplantation	I	520-535
lymphoproliferative	I	536-555
disorder	I	556-564
,	O	564-565
Burkitt	B	566-573
-	I	573-574
type	I	574-578
malignant	I	579-588
lymphoma	I	589-597
)	O	597-598
.	O	598-599

During	O	600-606
induction	O	607-616
therapy	O	617-624
,	O	624-625
he	O	626-628
suffered	O	629-637
ileal	O	638-643
perforation	O	644-655
and	O	656-659
ileostomy	O	660-669
was	O	670-673
performed	O	674-683
.	O	683-684

Subsequent	O	685-695
HD	O	696-698
-	O	698-699
MTX	O	699-702
therapy	O	703-710
caused	O	711-717
acute	B	718-723
renal	I	724-729
failure	I	730-737
that	O	738-742
required	O	743-751
continuous	O	752-762
hemodialysis	O	763-775
.	O	775-776

We	O	777-779
supposed	O	780-788
that	O	789-793
intravascular	O	794-807
hypovolemia	B	808-819
due	O	820-823
to	O	824-826
substantial	O	827-838
drainage	O	839-847
from	O	848-852
the	O	853-856
ileostoma	O	857-866
caused	O	867-873
acute	B	874-879
prerenal	I	880-888
failure	I	889-896
.	O	896-897

After	O	898-903
recovery	O	904-912
of	O	913-915
his	O	916-919
renal	O	920-925
function	O	926-934
,	O	934-935
we	O	936-938
could	O	939-944
safely	O	945-951
treat	O	952-957
the	O	958-961
patient	O	962-969
with	O	970-974
HD	O	975-977
-	O	977-978
MTX	O	978-981
therapy	O	982-989
by	O	990-992
controlling	O	993-1004
drainage	O	1005-1013
from	O	1014-1018
ileostoma	O	1019-1028
with	O	1029-1033
total	O	1034-1039
parenteral	O	1040-1050
nutrition	O	1051-1060
.	O	1060-1061

Antithrombotic	O	0-14
drug	O	15-19
use	O	20-23
,	O	23-24
cerebral	B	25-33
microbleeds	I	34-45
,	O	45-46
and	O	47-50
intracerebral	B	51-64
hemorrhage	I	65-75
:	O	75-76
a	O	77-78
systematic	O	79-89
review	O	90-96
of	O	97-99
published	O	100-109
and	O	110-113
unpublished	O	114-125
studies	O	126-133
.	O	133-134

BACKGROUND	O	135-145
AND	O	146-149
PURPOSE	O	150-157
:	O	157-158
Cerebral	B	159-167
microbleeds	I	168-179
(	O	180-181
MB	B	181-183
)	O	183-184
are	O	185-188
potential	O	189-198
risk	O	199-203
factors	O	204-211
for	O	212-215
intracerebral	B	216-229
hemorrhage	I	230-240
(	O	241-242
ICH	B	242-245
)	O	245-246
,	O	246-247
but	O	248-251
it	O	252-254
is	O	255-257
unclear	O	258-265
if	O	266-268
they	O	269-273
are	O	274-277
a	O	278-279
contraindication	O	280-296
to	O	297-299
using	O	300-305
antithrombotic	O	306-320
drugs	O	321-326
.	O	326-327

Insights	O	328-336
could	O	337-342
be	O	343-345
gained	O	346-352
by	O	353-355
pooling	O	356-363
data	O	364-368
on	O	369-371
MB	B	372-374
frequency	O	375-384
stratified	O	385-395
by	O	396-398
antithrombotic	O	399-413
use	O	414-417
in	O	418-420
cohorts	O	421-428
with	O	429-433
ICH	B	434-437
and	O	438-441
ischemic	B	442-450
stroke	I	451-457
(	O	458-459
IS	B	459-461
)	O	461-462
/	O	462-463
transient	B	463-472
ischemic	I	473-481
attack	I	482-488
(	O	489-490
TIA	B	490-493
)	O	493-494
.	O	494-495

METHODS	O	496-503
:	O	503-504
We	O	505-507
performed	O	508-517
a	O	518-519
systematic	O	520-530
review	O	531-537
of	O	538-540
published	O	541-550
and	O	551-554
unpublished	O	555-566
data	O	567-571
from	O	572-576
cohorts	O	577-584
with	O	585-589
stroke	B	590-596
or	O	597-599
TIA	B	600-603
to	O	604-606
compare	O	607-614
the	O	615-618
presence	O	619-627
of	O	628-630
MB	B	631-633
in	O	634-636
:	O	636-637
(	O	638-639
1	O	639-640
)	O	640-641
antithrombotic	O	642-656
users	O	657-662
vs	O	663-665
nonantithrombotic	O	666-683
users	O	684-689
with	O	690-694
ICH	B	695-698
;	O	698-699
(	O	700-701
2	O	701-702
)	O	702-703
antithrombotic	O	704-718
users	O	719-724
vs	O	725-727
nonusers	O	728-736
with	O	737-741
IS	B	742-744
/	O	744-745
TIA	B	745-748
;	O	748-749
and	O	750-753
(	O	754-755
3	O	755-756
)	O	756-757
ICH	B	758-761
vs	O	762-764
ischemic	B	765-773
events	O	774-780
stratified	O	781-791
by	O	792-794
antithrombotic	O	795-809
use	O	810-813
.	O	813-814

We	O	815-817
also	O	818-822
analyzed	O	823-831
published	O	832-841
and	O	842-845
unpublished	O	846-857
follow	O	858-864
-	O	864-865
up	O	865-867
data	O	868-872
to	O	873-875
determine	O	876-885
the	O	886-889
risk	O	890-894
of	O	895-897
ICH	B	898-901
in	O	902-904
antithrombotic	O	905-919
users	O	920-925
with	O	926-930
MB	B	931-933
.	O	933-934

RESULTS	O	935-942
:	O	942-943
In	O	944-946
a	O	947-948
pooled	O	949-955
analysis	O	956-964
of	O	965-967
1460	O	968-972
ICH	B	973-976
and	O	977-980
3817	O	981-985
IS	B	986-988
/	O	988-989
TIA	B	989-992
,	O	992-993
MB	B	994-996
were	O	997-1001
more	O	1002-1006
frequent	O	1007-1015
in	O	1016-1018
ICH	B	1019-1022
vs	O	1023-1025
IS	B	1026-1028
/	O	1028-1029
TIA	B	1029-1032
in	O	1033-1035
all	O	1036-1039
treatment	O	1040-1049
groups	O	1050-1056
,	O	1056-1057
but	O	1058-1061
the	O	1062-1065
excess	O	1066-1072
increased	O	1073-1082
from	O	1083-1087
2	O	1088-1089
.	O	1089-1090
8	O	1090-1091
(	O	1092-1093
odds	O	1093-1097
ratio	O	1098-1103
;	O	1103-1104
range	O	1105-1110
,	O	1110-1111
2	O	1112-1113
.	O	1113-1114
3	O	1114-1115
-	O	1115-1116
3	O	1114-1115
.	O	1113-1114
5	O	1118-1119
)	O	1119-1120
in	O	1121-1123
nonantithrombotic	O	1124-1141
users	O	1142-1147
to	O	1148-1150
5	O	1151-1152
.	O	1152-1153
7	O	1153-1154
(	O	1155-1156
range	O	1156-1161
,	O	1161-1162
3	O	1163-1164
.	O	1164-1165
4	O	1165-1166
-	O	1166-1167
9	O	1167-1168
.	O	1164-1165
7	O	1169-1170
)	O	1170-1171
in	O	1172-1174
antiplatelet	O	1175-1187
users	O	1188-1193
and	O	1194-1197
8	O	1198-1199
.	O	1199-1200
0	O	1200-1201
(	O	1202-1203
range	O	1203-1208
,	O	1208-1209
3	O	1210-1211
.	O	1211-1212
5	O	1212-1213
-	O	1213-1214
17	O	1214-1216
.	O	1211-1212
8	O	1217-1218
)	O	1218-1219

in	O	1220-1222
warfarin	O	1223-1231
users	O	1232-1237
(	O	1238-1239
P	O	1239-1240
difference	O	1241-1251
=	O	1251-1252
0	O	1252-1253
.	O	1253-1254
01	O	1254-1256
)	O	1256-1257
.	O	1253-1254

There	O	1259-1264
was	O	1265-1268
also	O	1269-1273
an	O	1274-1276
excess	O	1277-1283
of	O	1284-1286
MB	B	1287-1289
in	O	1290-1292
warfarin	O	1293-1301
users	O	1302-1307
vs	O	1308-1310
nonusers	O	1311-1319
with	O	1320-1324
ICH	B	1325-1328
(	O	1329-1330
OR	O	1330-1332
,	O	1332-1333
2	O	1334-1335
.	O	1335-1336
7	O	1336-1337
;	O	1337-1338
95	O	1339-1341
%	O	1341-1342
CI	O	1343-1345
,	O	1345-1346
1	O	1347-1348
.	O	1348-1349
6	O	1349-1350
-	O	1350-1351
4	O	1351-1352
.	O	1348-1349
4	O	1351-1352
;	O	1354-1355

P	O	1356-1357
<	O	1357-1358
0	O	1358-1359
.	O	1359-1360
001	O	1360-1363
)	O	1363-1364
but	O	1365-1368
none	O	1369-1373
in	O	1374-1376
warfarin	O	1377-1385
users	O	1386-1391
with	O	1392-1396
IS	B	1397-1399
/	O	1399-1400
TIA	B	1400-1403
(	O	1404-1405
OR	O	1405-1407
,	O	1407-1408
1	O	1409-1410
.	O	1410-1411
3	O	1411-1412
;	O	1412-1413
95	O	1414-1416
%	O	1416-1417
CI	O	1418-1420
,	O	1420-1421
0	O	1422-1423
.	O	1423-1424
9	O	1424-1425
-	O	1425-1426
1	O	1426-1427
.	O	1423-1424
7	O	1428-1429
;	O	1429-1430

P	O	1431-1432
=	O	1432-1433
0	O	1433-1434
.	O	1434-1435
33	O	1435-1437
;	O	1437-1438
P	O	1439-1440
difference	O	1441-1451
=	O	1451-1452
0	O	1452-1453
.	O	1453-1454
01	O	1454-1456
)	O	1456-1457
.	O	1453-1454

There	O	1459-1464
was	O	1465-1468
a	O	1469-1470
smaller	O	1471-1478
excess	O	1479-1485
of	O	1486-1488
MB	B	1489-1491
in	O	1492-1494
antiplatelet	O	1495-1507
users	O	1508-1513
vs	O	1514-1516
nonusers	O	1517-1525
with	O	1526-1530
ICH	B	1531-1534
(	O	1535-1536
OR	O	1536-1538
,	O	1538-1539
1	O	1540-1541
.	O	1541-1542
7	O	1542-1543
;	O	1543-1544
95	O	1545-1547
%	O	1547-1548
CI	O	1549-1551
,	O	1551-1552
1	O	1553-1554
.	O	1554-1555
3	O	1555-1556
-	O	1556-1557
2	O	1557-1558
.	O	1554-1555
3	O	1555-1556
;	O	1560-1561

P	O	1562-1563
<	O	1563-1564
0	O	1564-1565
.	O	1565-1566
001	O	1566-1569
)	O	1569-1570
,	O	1570-1571
but	O	1572-1575
findings	O	1576-1584
were	O	1585-1589
similar	O	1590-1597
for	O	1598-1601
antiplatelet	O	1602-1614
users	O	1615-1620
with	O	1621-1625
IS	B	1626-1628
/	O	1628-1629
TIA	B	1629-1632
(	O	1633-1634
OR	O	1634-1636
,	O	1636-1637
1	O	1638-1639
.	O	1639-1640
4	O	1640-1641
;	O	1641-1642
95	O	1643-1645
%	O	1645-1646
CI	O	1647-1649
,	O	1649-1650
1	O	1651-1652
.	O	1652-1653
2	O	1653-1654
-	O	1654-1655
1	O	1651-1652
.	O	1652-1653
7	O	1657-1658
;	O	1658-1659

P	O	1660-1661
<	O	1661-1662
0	O	1662-1663
.	O	1663-1664
001	O	1664-1667
;	O	1667-1668
P	O	1669-1670
difference	O	1671-1681
=	O	1681-1682
0	O	1682-1683
.	O	1683-1684
25	O	1684-1686
)	O	1686-1687
.	O	1683-1684

In	O	1689-1691
pooled	O	1692-1698
follow	O	1699-1705
-	O	1705-1706
up	O	1706-1708
data	O	1709-1713
for	O	1714-1717
768	O	1718-1721
antithrombotic	O	1722-1736
users	O	1737-1742
,	O	1742-1743
presence	O	1744-1752
of	O	1753-1755
MB	B	1756-1758
at	O	1759-1761
baseline	O	1762-1770
was	O	1771-1774
associated	O	1775-1785
with	O	1786-1790
a	O	1791-1792
substantially	O	1793-1806
increased	O	1807-1816
risk	O	1817-1821
of	O	1822-1824
subsequent	O	1825-1835
ICH	B	1836-1839
(	O	1840-1841
OR	O	1841-1843
,	O	1843-1844
12	O	1845-1847
.	O	1847-1848
1	O	1845-1846
;	O	1849-1850
95	O	1851-1853
%	O	1853-1854
CI	O	1855-1857
,	O	1857-1858
3	O	1859-1860
.	O	1860-1861
4	O	1861-1862
-	O	1862-1863
42	O	1863-1865
.	O	1860-1861
5	O	1866-1867
;	O	1867-1868

P	O	1869-1870
<	O	1870-1871
0	O	1871-1872
.	O	1872-1873
001	O	1873-1876
)	O	1876-1877
.	O	1872-1873

CONCLUSIONS	O	1879-1890
:	O	1890-1891
The	O	1892-1895
excess	O	1896-1902
of	O	1903-1905
MB	B	1906-1908
in	O	1909-1911
warfarin	O	1912-1920
users	O	1921-1926
with	O	1927-1931
ICH	B	1932-1935
compared	O	1936-1944
to	O	1945-1947
other	O	1948-1953
groups	O	1954-1960
suggests	O	1961-1969
that	O	1970-1974
MB	B	1975-1977
increase	O	1978-1986
the	O	1987-1990
risk	O	1991-1995
of	O	1996-1998
warfarin	O	1999-2007
-	O	2007-2008
associated	O	2008-2018
ICH	B	2019-2022
.	O	2022-2023

Limited	O	2024-2031
prospective	O	2032-2043
data	O	2044-2048
corroborate	O	2049-2060
these	O	2061-2066
findings	O	2067-2075
,	O	2075-2076
but	O	2077-2080
larger	O	2081-2087
prospective	O	2088-2099
studies	O	2100-2107
are	O	2108-2111
urgently	O	2112-2120
required	O	2121-2129
.	O	2129-2130

Verapamil	O	0-9
stimulation	O	10-21
test	O	22-26
in	O	27-29
hyperprolactinemia	B	30-48
:	O	48-49
loss	O	50-54
of	O	55-57
prolactin	O	58-67
response	O	68-76
in	O	77-79
anatomic	O	80-88
or	O	89-91
functional	O	92-102
stalk	O	103-108
effect	O	109-115
.	O	115-116

AIM	O	117-120
:	O	120-121
Verapamil	O	122-131
stimulation	O	132-143
test	O	144-148
was	O	149-152
previously	O	153-163
investigated	O	164-176
as	O	177-179
a	O	180-181
tool	O	182-186
for	O	187-190
differential	O	191-203
diagnosis	O	204-213
of	O	214-216
hyperprolactinemia	B	217-235
,	O	235-236
but	O	237-240
with	O	241-245
conflicting	O	246-257
results	O	258-265
.	O	265-266

Macroprolactinemia	B	267-285
was	O	286-289
never	O	290-295
considered	O	296-306
in	O	307-309
those	O	310-315
previous	O	316-324
studies	O	325-332
.	O	332-333

Here	O	334-338
,	O	338-339
we	O	340-342
aimed	O	343-348
to	O	349-351
re	O	352-354
-	O	354-355
investigate	O	355-366
the	O	367-370
diagnostic	O	371-381
value	O	382-387
of	O	388-390
verapamil	O	391-400
in	O	401-403
a	O	404-405
population	O	406-416
who	O	417-420
were	O	421-425
all	O	426-429
screened	O	430-438
for	O	439-442
macroprolactinemia	B	443-461
.	O	461-462

Prolactin	O	463-472
responses	O	473-482
to	O	483-485
verapamil	O	486-495
in	O	496-498
65	O	499-501
female	O	502-508
patients	O	509-517
(	O	518-519
age	O	519-522
:	O	522-523
29	O	524-526
.	O	526-527
9	O	525-526
+	O	529-530
/	O	530-531
-	O	531-532
8	O	533-534
.	O	534-535
1	O	535-536
years	O	537-542
)	O	542-543
with	O	544-548
hyperprolactinemia	B	549-567
were	O	568-572
tested	O	573-579
in	O	580-582
a	O	583-584
descriptive	O	585-596
,	O	596-597
matched	O	598-605
case	O	606-610
-	O	610-611
control	O	611-618
study	O	619-624
.	O	624-625

METHODS	O	626-633
:	O	633-634
Verapamil	O	635-644
80	O	645-647
mg	O	648-650
,	O	650-651
p	O	652-653
.	O	653-654
o	O	654-655
.	O	653-654
was	O	657-660
administered	O	661-673
,	O	673-674
and	O	675-678
then	O	679-683
PRL	O	684-687
levels	O	688-694
were	O	695-699
measured	O	700-708
at	O	709-711
8th	O	712-715
and	O	716-719
16th	O	720-724
hours	O	725-730
,	O	730-731
by	O	732-734
immunometric	O	735-747
chemiluminescence	O	748-765
.	O	765-766

Verapamil	O	767-776
responsiveness	O	777-791
was	O	792-795
determined	O	796-806
by	O	807-809
peak	O	810-814
percent	O	815-822
change	O	823-829
in	O	830-832
basal	O	833-838
prolactin	O	839-848
levels	O	849-855
(	O	856-857
PRL	O	857-860
)	O	860-861
.	O	861-862

RESULTS	O	863-870
:	O	870-871
Verapamil	O	872-881
significantly	O	882-895
increased	O	896-905
PRL	O	906-909
levels	O	910-916
in	O	917-919
healthy	O	920-927
controls	O	928-936
(	O	937-938
N	O	938-939
.	O	939-940

8	O	941-942
,	O	942-943
PRL	O	944-947
:	O	947-948
183	O	949-952
%	O	952-953
)	O	953-954
,	O	954-955
macroprolactinoma	B	956-973
(	O	974-975
N	O	975-976
.	O	976-977
8	O	978-979
,	O	979-980
PRL	O	981-984
:	O	984-985
7	O	986-987
%	O	987-988
)	O	988-989
,	O	989-990
microprolactinoma	B	991-1008
(	O	1009-1010
N	O	1010-1011
.	O	1011-1012

19	O	1013-1015
,	O	1015-1016
PRL	O	1017-1020
:	O	1020-1021
21	O	1022-1024
%	O	1024-1025
)	O	1025-1026
,	O	1026-1027
macroprolactinemia	B	1028-1046
(	O	1047-1048
N	O	1048-1049
.	O	1049-1050

23	O	1051-1053
,	O	1053-1054
PRL	O	1055-1058
:	O	1058-1059
126	O	1060-1063
%	O	1063-1064
)	O	1064-1065
,	O	1065-1066
but	O	1067-1070
not	O	1071-1074
in	O	1075-1077
pseudoprolactinoma	B	1078-1096
(	O	1097-1098
N	O	1098-1099
.	O	1099-1100
8	O	1101-1102
,	O	1102-1103
PRL	O	1104-1107
:	O	1107-1108
0	O	1109-1110
.	O	1110-1111
8	O	1111-1112
%	O	1112-1113
)	O	1113-1114
,	O	1114-1115
and	O	1116-1119
risperidone	O	1120-1131
-	O	1131-1132
induced	O	1132-1139
hyperprolactinemia	B	1140-1158
(	O	1159-1160
N	O	1160-1161
.	O	1161-1162
7	O	1163-1164
,	O	1164-1165
PRL	O	1166-1169
:	O	1169-1170
3	O	1171-1172
%	O	1172-1173
)	O	1173-1174
.	O	1174-1175

ROC	O	1176-1179
curve	O	1180-1185
analysis	O	1186-1194
revealed	O	1195-1203
that	O	1204-1208
unresponsiveness	O	1209-1225
to	O	1226-1228
verapamil	O	1229-1238
defined	O	1239-1246
as	O	1247-1249
PRL	O	1250-1253
<	O	1254-1255
7	O	1255-1256
%	O	1256-1257
,	O	1257-1258
discriminated	O	1259-1272
anatomical	O	1273-1283
or	O	1284-1286
functional	O	1287-1297
stalk	O	1298-1303
effect	O	1304-1310
(	O	1311-1312
sensitivity	O	1312-1323
:	O	1323-1324
74	O	1325-1327
%	O	1327-1328
,	O	1328-1329
specificity	O	1330-1341
:	O	1341-1342
73	O	1343-1345
%	O	1345-1346
,	O	1346-1347
AUC	O	1348-1351
:	O	1351-1352
0	O	1353-1354
.	O	1354-1355
855	O	1355-1358
+	O	1358-1359
/	O	1359-1360
-	O	1360-1361
0	O	1353-1354
.	O	1354-1355
04	O	1363-1365
,	O	1365-1366

P	O	1367-1368
<	O	1369-1370
0	O	1370-1371
.	O	1371-1372
001	O	1372-1375
,	O	1375-1376
CI	O	1377-1379
:	O	1379-1380
0	O	1381-1382
.	O	1382-1383
768	O	1383-1386
-	O	1386-1387
0	O	1381-1382
.	O	1382-1383
942	O	1389-1392
)	O	1392-1393

associated	O	1394-1404
with	O	1405-1409
pseudoprolactinoma	B	1410-1428
or	O	1429-1431
risperidone	O	1432-1443
-	O	1443-1444
induced	O	1444-1451
hyperprolactinemia	B	1452-1470
,	O	1470-1471
respectively	O	1472-1484
.	O	1484-1485

CONCLUSION	O	1486-1496
:	O	1496-1497
Verapamil	O	1498-1507
responsiveness	O	1508-1522
is	O	1523-1525
not	O	1526-1529
a	O	1530-1531
reliable	O	1532-1540
finding	O	1541-1548
for	O	1549-1552
the	O	1553-1556
differential	O	1557-1569
diagnosis	O	1570-1579
of	O	1580-1582
hyperprolactinemia	B	1583-1601
.	O	1601-1602

However	O	1603-1610
,	O	1610-1611
verapamil	O	1612-1621
unresponsiveness	O	1622-1638
discriminates	O	1639-1652
stalk	O	1653-1658
effect	O	1659-1665
(	O	1666-1667
i	O	1667-1668
.	O	1668-1669
e	O	1669-1670
.	O	1668-1669
,	O	1671-1672
anatomically	O	1673-1685
or	O	1686-1688
functionally	O	1689-1701
inhibited	O	1702-1711
dopaminergic	O	1712-1724
tonus	O	1725-1730
)	O	1730-1731
from	O	1732-1736
other	O	1737-1742
causes	O	1743-1749
of	O	1750-1752
hyperprolactinemia	B	1753-1771
with	O	1772-1776
varying	O	1777-1784
degrees	O	1785-1792
of	O	1793-1795
responsiveness	O	1796-1810
.	O	1810-1811

Central	O	0-7
action	O	8-14
of	O	15-17
narcotic	O	18-26
analgesics	O	27-37
.	O	37-38

Part	O	39-43
IV	O	44-46
.	O	46-47

Noradrenergic	O	48-61
influences	O	62-72
on	O	73-75
the	O	76-79
activity	O	80-88
of	O	89-91
analgesics	O	92-102
in	O	103-105
rats	O	106-110
.	O	110-111

The	O	112-115
effect	O	116-122
of	O	123-125
clonidine	O	126-135
,	O	135-136
naphazoline	O	137-148
and	O	149-152
xylometazoline	O	153-167
on	O	168-170
analgesia	O	171-180
induced	O	181-188
by	O	189-191
morphine	O	192-200
,	O	200-201
codeine	O	202-209
,	O	209-210
fentanyl	O	211-219
and	O	220-223
pentazocine	O	224-235
,	O	235-236
and	O	237-240
on	O	241-243
cataleptic	B	244-254
effect	O	255-261
of	O	262-264
morphine	O	265-273
,	O	273-274
codine	O	275-281
and	O	282-285
fentanyl	O	286-294
was	O	295-298
studied	O	299-306
in	O	307-309
rats	O	310-314
.	O	314-315

The	O	316-319
biochemical	O	320-331
assays	O	332-338
on	O	339-341
the	O	342-345
influence	O	346-355
of	O	356-358
four	O	359-363
analgesics	O	364-374
on	O	375-377
the	O	378-381
brain	O	382-387
concentration	O	388-401
and	O	402-405
turnover	O	406-414
of	O	415-417
noradrenaline	O	418-431
(	O	432-433
NA	O	433-435
)	O	435-436
were	O	437-441
also	O	442-446
performed	O	447-456
.	O	456-457

It	O	458-460
was	O	461-464
found	O	465-470
that	O	471-475
three	O	476-481
drugs	O	482-487
stimulating	O	488-499
central	O	500-507
NA	O	508-510
receptors	O	511-520
failed	O	521-527
to	O	528-530
affect	O	531-537
the	O	538-541
analgesic	O	542-551
ED50	O	552-556
of	O	557-559
all	O	560-563
antinociceptive	O	564-579
agents	O	580-586
and	O	587-590
they	O	591-595
enhanced	O	596-604
catalepsy	B	605-614
induced	O	615-622
by	O	623-625
morphine	O	626-634
and	O	635-638
fentanyl	O	639-647
.	O	647-648

Codeine	O	649-656
catalepsy	B	657-666
was	O	667-670
increased	O	671-680
by	O	681-683
clonidine	O	684-693
and	O	694-697
decreased	O	698-707
by	O	708-710
naphazoline	O	711-722
and	O	723-726
xylometazoline	O	727-741
.	O	741-742

The	O	743-746
brain	O	747-752
concentration	O	753-766
of	O	767-769
NA	O	770-772
was	O	773-776
not	O	777-780
changed	O	781-788
by	O	789-791
morphine	O	792-800
and	O	801-804
fentanyl	O	805-813
,	O	813-814
but	O	815-818
one	O	819-822
of	O	823-825
the	O	826-829
doses	O	830-835
of	O	836-838
codeine	O	839-846
(	O	847-848
45	O	848-850
mg	O	851-853
/	O	853-854
kg	O	854-856
)	O	856-857
slightly	O	858-866
enhanced	O	867-875
it	O	876-878
.	O	878-879

Pentazocine	O	880-891
dose	O	892-896
-	O	896-897
dependently	O	897-908
decreased	O	909-918
the	O	919-922
brain	O	923-928
level	O	929-934
of	O	935-937
NA	O	938-940
.	O	940-941

The	O	942-945
rate	O	946-950
of	O	951-953
NA	O	954-956
turnover	O	957-965
was	O	966-969
not	O	970-973
altered	O	974-981
by	O	982-984
analgesics	O	985-995
except	O	996-1002
for	O	1003-1006
the	O	1007-1010
higher	O	1011-1017
dose	O	1018-1022
of	O	1023-1025
fentanyl	O	1026-1034
(	O	1035-1036
0	O	1036-1037
.	O	1037-1038
2	O	1038-1039
mg	O	1040-1042
/	O	1042-1043
kg	O	1043-1045
)	O	1045-1046
following	O	1047-1056
which	O	1057-1062
the	O	1063-1066
disappearance	O	1067-1080
of	O	1081-1083
NA	O	1084-1086
from	O	1087-1091
the	O	1092-1095
brain	O	1096-1101
was	O	1102-1105
diminished	O	1106-1116
.	O	1116-1117

The	O	1118-1121
results	O	1122-1129
are	O	1130-1133
discussed	O	1134-1143
in	O	1144-1146
the	O	1147-1150
light	O	1151-1156
of	O	1157-1159
various	O	1160-1167
and	O	1168-1171
non	O	1172-1175
-	O	1175-1176
uniform	O	1176-1183
data	O	1184-1188
from	O	1189-1193
the	O	1194-1197
literature	O	1198-1208
.	O	1208-1209

It	O	1210-1212
is	O	1213-1215
suggested	O	1216-1225
that	O	1226-1230
in	O	1231-1233
rats	O	1234-1238
the	O	1239-1242
brain	O	1243-1248
NA	O	1249-1251
plays	O	1252-1257
a	O	1258-1259
less	O	1260-1264
important	O	1265-1274
function	O	1275-1283
than	O	1284-1288
the	O	1289-1292
other	O	1293-1298
monoamines	O	1299-1309
in	O	1310-1312
the	O	1313-1316
behavioural	O	1317-1328
activity	O	1329-1337
of	O	1338-1340
potent	O	1341-1347
analgesics	O	1348-1358
.	O	1358-1359

Modification	O	0-12
by	O	13-15
propranolol	O	16-27
of	O	28-30
cardiovascular	O	31-45
effects	O	46-53
of	O	54-56
induced	O	57-64
hypoglycaemia	B	65-78
.	O	78-79

The	O	80-83
cardiovascular	O	84-98
effects	O	99-106
of	O	107-109
hypoglycaemia	B	110-123
,	O	123-124
with	O	125-129
and	O	130-133
without	O	134-141
beta	O	142-146
-	O	146-147
blockade	O	147-155
,	O	155-156
were	O	157-161
compared	O	162-170
in	O	171-173
fourteen	O	174-182
healthy	O	183-190
men	O	191-194
.	O	194-195

Eight	O	196-201
received	O	202-210
insulin	O	211-218
alone	O	219-224
,	O	224-225
and	O	226-229
eight	O	230-235
,	O	235-236
including	O	237-246
two	O	247-250
of	O	251-253
the	O	254-257
original	O	258-266
insulin	O	267-274
-	O	274-275
only	O	275-279
group	O	280-285
,	O	285-286
were	O	287-291
given	O	292-297
propranolol	O	298-309
and	O	310-313
insulin	O	314-321
.	O	321-322

In	O	323-325
the	O	326-329
insulin	O	330-337
-	O	337-338
group	O	338-343
the	O	344-347
period	O	348-354
of	O	355-357
hypoglycaemia	B	358-371
was	O	372-375
associated	O	376-386
with	O	387-391
an	O	392-394
increase	O	395-403
in	O	404-406
heart	O	407-412
-	O	412-413
rate	O	413-417
and	O	418-421
a	O	422-423
fall	O	424-428
in	O	429-431
diastolic	O	432-441
blood	O	442-447
-	O	447-448
pressure	O	448-456
.	O	456-457

In	O	458-460
the	O	461-464
propranolol	O	465-476
-	O	476-477
insulin	O	477-484
group	O	485-490
there	O	491-496
was	O	497-500
a	O	501-502
significant	O	503-514
fall	O	515-519
in	O	520-522
heart	O	523-528
-	O	528-529
rate	O	529-533
in	O	534-536
most	O	537-541
subjects	O	542-550
and	O	551-554
an	O	555-557
increase	O	558-566
in	O	567-569
diastolic	O	570-579
pressure	O	580-588
.	O	588-589

Typical	O	590-597
S	O	598-599
-	O	599-600
T	O	600-601
/	O	601-602
T	O	600-601
changes	O	604-611
occurred	O	612-620
in	O	621-623
the	O	624-627
insulin	O	628-635
-	O	635-636
group	O	636-641
but	O	642-645
in	O	646-648
none	O	649-653
of	O	654-656
the	O	657-660
propranolol	O	661-672
-	O	672-673
insulin	O	673-680
group	O	681-686
.	O	686-687

Hypertension	B	688-700
in	O	701-703
diabetics	B	704-713
prone	O	714-719
to	O	720-722
hypoglycaemia	B	723-736
attacks	O	737-744
should	O	745-751
not	O	752-755
be	O	756-758
treated	O	759-766
with	O	767-771
beta	O	772-776
-	O	776-777
blockers	O	777-785
because	O	786-793
these	O	794-799
drugs	O	800-805
may	O	806-809
cause	O	810-815
a	O	816-817
sharp	O	818-823
rise	O	824-828
in	O	829-831
blood	O	832-837
-	O	837-838
pressure	O	838-846
in	O	847-849
such	O	850-854
patients	O	855-863
.	O	863-864

Prevention	O	0-10
and	O	11-14
treatment	O	15-24
of	O	25-27
endometrial	B	28-39
disease	I	40-47
in	O	48-50
climacteric	O	51-62
women	O	63-68
receiving	O	69-78
oestrogen	O	79-88
therapy	O	89-96
.	O	96-97

The	O	98-101
treatment	O	102-111
regimens	O	112-120
are	O	121-124
described	O	125-134
in	O	135-137
74	O	138-140
patients	O	141-149
with	O	150-154
endometrial	B	155-166
disease	I	167-174
among	O	175-180
850	O	181-184
climacteric	O	185-196
women	O	197-202
receiving	O	203-212
oestrogen	O	213-222
therapy	O	223-230
.	O	230-231

Cystic	O	232-238
hyperplasia	B	239-250
was	O	251-254
associated	O	255-265
with	O	266-270
unopposed	O	271-280
oestrogen	O	281-290
therapy	O	291-298
without	O	299-306
progestagen	O	307-318
.	O	318-319

Two	O	320-323
courses	O	324-331
of	O	332-334
21	O	335-337
days	O	338-342
of	O	343-345
5	O	346-347
mg	O	348-350
norethisterone	O	351-365
daily	O	366-371
caused	O	372-378
reversion	O	379-388
to	O	389-391
normal	O	392-398
in	O	399-401
all	O	402-405
57	O	406-408
cases	O	409-414
of	O	415-417
cystic	O	418-424
hyperplasia	B	425-436
and	O	437-440
6	O	441-442
of	O	443-445
the	O	446-449
8	O	450-451
cases	O	452-457
of	O	458-460
atypical	O	461-469
hyperplasia	B	470-481
.	O	481-482

4	O	483-484
cases	O	485-490
of	O	491-493
endometrial	B	494-505
carcinoma	I	506-515
referred	O	516-524
from	O	525-529
elsewhere	O	530-539
demonstrated	O	540-552
the	O	553-556
problems	O	557-565
of	O	566-568
inappropriate	O	569-582
and	O	583-586
unsupervised	O	587-599
unopposed	O	600-609
oestrogen	O	610-619
therapy	O	620-627
and	O	628-631
the	O	632-635
difficulty	O	636-646
in	O	647-649
distinguishing	O	650-664
severe	O	665-671
hyperplasia	B	672-683
from	O	684-688
malignancy	B	689-699
.	O	699-700

Cyclical	O	701-709
low	O	710-713
-	O	713-714
dose	O	714-718
oestrogen	O	719-728
therapy	O	729-736
with	O	737-741
7	O	742-743
-	O	743-744
-	O	743-744
13	O	745-747
days	O	748-752
of	O	753-755
progestagen	O	756-767
does	O	768-772
not	O	773-776
seem	O	777-781
to	O	782-784
increase	O	785-793
the	O	794-797
risk	O	798-802
of	O	803-805
endometrial	B	806-817
hyperplasia	I	818-829
or	O	830-832
carcinoma	B	833-842
.	O	842-843

Pure	B	0-4
red	I	5-8
cell	I	9-13
aplasia	I	14-21
,	O	21-22
toxic	B	23-28
dermatitis	I	29-39
and	O	40-43
lymphadenopathy	B	44-59
in	O	60-62
a	O	63-64
patient	O	65-72
taking	O	73-79
diphenylhydantoin	O	80-97
.	O	97-98

A	O	99-100
patient	O	101-108
taking	O	109-115
diphenylhydantoin	O	116-133
for	O	134-137
3	O	138-139
weeks	O	140-145
developed	O	146-155
a	O	156-157
generalized	O	158-169
skin	B	170-174
rash	I	175-179
,	O	179-180
lymphadenopathy	B	181-196
and	O	197-200
pure	B	201-205
red	I	206-209
cell	I	210-214
aplasia	I	215-222
.	O	222-223

After	O	224-229
withdrawal	O	230-240
of	O	241-243
the	O	244-247
pharmacon	O	248-257
all	O	258-261
symptoms	O	262-270
disappeared	O	271-282
spontaneously	O	283-296
.	O	296-297

Skin	B	298-302
rash	I	303-307
is	O	308-310
a	O	311-312
well	O	313-317
-	O	317-318
known	O	318-323
complication	O	324-336
of	O	337-339
diphenylhydantoin	O	340-357
treatment	O	358-367
as	O	368-370
is	O	371-373
benign	O	374-380
and	O	381-384
malignant	O	385-394
lymphadenopathy	B	395-410
.	O	410-411

Pure	B	412-416
red	I	417-420
cell	I	421-425
aplasia	I	426-433
associated	O	434-444
with	O	445-449
diphenylhydantoin	O	450-467
medication	O	468-478
has	O	479-482
been	O	483-487
reported	O	488-496
in	O	497-499
3	O	500-501
patients	O	502-510
.	O	510-511

The	O	512-515
exact	O	516-521
mechanism	O	522-531
by	O	532-534
which	O	535-540
diphenylhydantoin	O	541-558
exerts	O	559-565
its	O	566-569
toxic	O	570-575
effects	O	576-583
is	O	584-586
not	O	587-590
known	O	591-596
.	O	596-597

In	O	598-600
this	O	601-605
patient	O	606-613
the	O	614-617
time	O	618-622
relation	O	623-631
between	O	632-639
the	O	640-643
ingestion	O	644-653
of	O	654-656
diphenylhydantoin	O	657-674
and	O	675-678
the	O	679-682
occurrence	O	683-693
of	O	694-696
the	O	697-700
skin	B	701-705
rash	I	706-710
,	O	710-711
lymphadenopathy	B	712-727
and	O	728-731
pure	B	732-736
red	I	737-740
cell	I	741-745
aplasia	I	746-753
is	O	754-756
very	O	757-761
suggestive	O	762-772
of	O	773-775
a	O	776-777
direct	O	778-784
connection	O	785-795
.	O	795-796

Continuous	O	0-10
infusion	O	11-19
tobramycin	O	20-30
combined	O	31-39
with	O	40-44
carbenicillin	O	45-58
for	O	59-62
infections	B	63-73
in	O	74-76
cancer	B	77-83
patients	O	84-92
.	O	92-93

The	O	94-97
cure	O	98-102
rate	O	103-107
of	O	108-110
infections	B	111-121
in	O	122-124
cancer	B	125-131
patients	O	132-140
is	O	141-143
adversely	O	144-153
affected	O	154-162
by	O	163-165
neutropenia	B	166-177
(	O	178-179
less	O	179-183
than	O	184-188
1	O	189-190
,	O	190-191
000	O	191-194
/	O	194-195
mm3	O	195-198
)	O	198-199
.	O	199-200

In	O	201-203
particular	O	204-214
,	O	214-215
patients	O	216-224
with	O	225-229
severe	O	230-236
neutropenia	B	237-248
(	O	249-250
less	O	250-254
than	O	255-259
100	O	260-263
/	O	263-264
mm3	O	264-267
)	O	267-268
have	O	269-273
shown	O	274-279
a	O	280-281
poor	O	282-286
response	O	287-295
to	O	296-298
antibiotics	O	299-310
.	O	310-311

To	O	312-314
overcome	O	315-323
the	O	324-327
adverse	O	328-335
effects	O	336-343
of	O	344-346
neutropenia	B	347-358
,	O	358-359
tobramycin	O	360-370
was	O	371-374
given	O	375-380
by	O	381-383
continuous	O	384-394
infusion	O	395-403
and	O	404-407
combined	O	408-416
with	O	417-421
intermittent	O	422-434
carbenicillin	O	435-448
.	O	448-449

Tobramycin	O	450-460
was	O	461-464
given	O	465-470
to	O	471-473
a	O	474-475
total	O	476-481
daily	O	482-487
dose	O	488-492
of	O	493-495
300	O	496-499
mg	O	500-502
/	O	502-503
m2	O	503-505
and	O	506-509
carbenicillin	O	510-523
was	O	524-527
given	O	528-533
at	O	534-536
a	O	537-538
dose	O	539-543
of	O	544-546
5	O	547-548
gm	O	549-551
every	O	552-557
four	O	558-562
hours	O	563-568
.	O	568-569

There	O	570-575
were	O	576-580
125	O	581-584
infectious	O	585-595
episodes	O	596-604
in	O	605-607
116	O	608-611
cancer	B	612-618
patients	O	619-627
receiving	O	628-637
myelosuppressive	O	638-654
chemotherapy	O	655-667
.	O	667-668

The	O	669-672
overall	O	673-680
cure	O	681-685
rate	O	686-690
was	O	691-694
70	O	695-697
%	O	697-698
.	O	698-699

Pneumonia	B	700-709
was	O	710-713
the	O	714-717
most	O	718-722
common	O	723-729
infection	B	730-739
and	O	740-743
61	O	744-746
%	O	746-747
of	O	748-750
59	O	751-753
episodes	O	754-762
were	O	763-767
cured	O	768-773
.	O	773-774

Gram	O	775-779
-	O	779-780
negative	O	780-788
bacilli	O	789-796
were	O	797-801
the	O	802-805
most	O	806-810
common	O	811-817
causative	O	818-827
organisms	O	828-837
and	O	838-841
69	O	842-844
%	O	844-845
of	O	846-848
these	O	849-854
infections	B	855-865
were	O	866-870
cured	O	871-876
.	O	876-877

The	O	878-881
most	O	882-886
common	O	887-893
pathogen	O	894-902
was	O	903-906
Klebsiella	O	907-917
pneumoniae	B	918-928
and	O	929-932
this	O	933-937
,	O	937-938
together	O	939-947
with	O	948-952
Escherichia	O	953-964
coli	O	965-969
and	O	970-973
Pseudomonas	O	974-985
aeruginosa	O	986-996
,	O	996-997
accounted	O	998-1007
for	O	1008-1011
74	O	1012-1014
%	O	1014-1015
of	O	1016-1018
all	O	1019-1022
gram	B	1023-1027
-	I	1027-1028
negative	I	1028-1036
bacillary	I	1037-1046
infections	I	1047-1057
.	O	1057-1058

Response	O	1059-1067
was	O	1068-1071
not	O	1072-1075
influenced	O	1076-1086
by	O	1087-1089
the	O	1090-1093
initial	O	1094-1101
neutrophil	O	1102-1112
count	O	1113-1118
,	O	1118-1119
with	O	1120-1124
a	O	1125-1126
62	O	1127-1129
%	O	1129-1130
cure	O	1131-1135
rate	O	1136-1140
for	O	1141-1144
39	O	1145-1147
episodes	O	1148-1156
associated	O	1157-1167
with	O	1168-1172
severe	O	1173-1179
neutropenia	B	1180-1191
.	O	1191-1192

However	O	1193-1200
,	O	1200-1201
failure	O	1202-1209
of	O	1210-1212
the	O	1213-1216
neutrophil	O	1217-1227
count	O	1228-1233
to	O	1234-1236
increase	O	1237-1245
during	O	1246-1252
therapy	O	1253-1260
adversely	O	1261-1270
affected	O	1271-1279
response	O	1280-1288
.	O	1288-1289

Azotemia	B	1290-1298
was	O	1299-1302
the	O	1303-1306
major	O	1307-1312
side	O	1313-1317
effect	O	1318-1324
recognized	O	1325-1335
,	O	1335-1336
and	O	1337-1340
it	O	1341-1343
occurred	O	1344-1352
in	O	1353-1355
11	O	1356-1358
%	O	1358-1359
of	O	1360-1362
episodes	O	1363-1371
.	O	1371-1372

Major	O	1373-1378
azotemia	B	1379-1387
(	O	1388-1389
serum	O	1389-1394
creatinine	O	1395-1405
greater	O	1406-1413
than	O	1414-1418
2	O	1419-1420
.	O	1420-1421
5	O	1421-1422
mg	O	1423-1425
/	O	1425-1426
dl	O	1426-1428
or	O	1429-1431
BUN	O	1432-1435
greater	O	1436-1443
than	O	1444-1448
50	O	1449-1451
mg	O	1452-1454
/	O	1454-1455
dl	O	1455-1457
)	O	1457-1458
occurred	O	1459-1467
in	O	1468-1470
only	O	1471-1475
2	O	1476-1477
%	O	1477-1478
.	O	1478-1479

Azotemia	B	1480-1488
was	O	1489-1492
not	O	1493-1496
related	O	1497-1504
to	O	1505-1507
duration	O	1508-1516
of	O	1517-1519
therapy	O	1520-1527
or	O	1528-1530
serum	O	1531-1536
tobramycin	O	1537-1547
concentration	O	1548-1561
.	O	1561-1562

This	O	1563-1567
antibiotic	O	1568-1578
regimen	O	1579-1586
showed	O	1587-1593
both	O	1594-1598
therapeutic	O	1599-1610
efficacy	O	1611-1619
and	O	1620-1623
acceptable	O	1624-1634
renal	B	1635-1640
toxicity	I	1641-1649
for	O	1650-1653
these	O	1654-1659
patients	O	1660-1668
.	O	1668-1669

Recurrent	O	0-9
subarachnoid	B	10-22
hemorrhage	I	23-33
associated	O	34-44
with	O	45-49
aminocaproic	O	50-62
acid	O	63-67
therapy	O	68-75
and	O	76-79
acute	B	80-85
renal	I	86-91
artery	I	92-98
thrombosis	I	99-109
.	O	109-110

Case	O	111-115
report	O	116-122
.	O	122-123

Epsilon	O	124-131
aminocaproic	O	132-144
acid	O	145-149
(	O	150-151
EACA	O	151-155
)	O	155-156
has	O	157-160
been	O	161-165
used	O	166-170
to	O	171-173
prevent	O	174-181
rebleeding	O	182-192
in	O	193-195
patients	O	196-204
with	O	205-209
subarachnoid	B	210-222
hemorrhage	I	223-233
(	O	234-235
SAH	B	235-238
)	O	238-239
.	O	239-240

Although	O	241-249
this	O	250-254
agent	O	255-260
does	O	261-265
decrease	O	266-274
the	O	275-278
frequency	O	279-288
of	O	289-291
rebleeding	O	292-302
,	O	302-303
several	O	304-311
reports	O	312-319
have	O	320-324
described	O	325-334
thrombotic	B	335-345
complications	O	346-359
of	O	360-362
EACA	O	363-367
therapy	O	368-375
.	O	375-376

These	O	377-382
complications	O	383-396
have	O	397-401
included	O	402-410
clinical	O	411-419
deterioration	O	420-433
and	O	434-437
intracranial	B	438-450
vascular	I	451-459
thrombosis	I	460-470
in	O	471-473
patients	O	474-482
with	O	483-487
SAH	B	488-491
,	O	491-492
arteriolar	O	493-503
and	O	504-507
capillary	O	508-517
fibrin	O	518-524
thrombi	B	525-532
in	O	533-535
patients	O	536-544
with	O	545-549
fibrinolytic	O	550-562
syndromes	O	563-572
treated	O	573-580
with	O	581-585
EACA	O	586-590
,	O	590-591
or	O	592-594
other	O	595-600
thromboembolic	B	601-615
phenomena	I	616-625
.	O	625-626

Since	O	627-632
intravascular	O	633-646
fibrin	O	647-653
thrombi	B	654-661
are	O	662-665
often	O	666-671
observed	O	672-680
in	O	681-683
patients	O	684-692
with	O	693-697
fibrinolytic	O	698-710
disorders	O	711-720
,	O	720-721
EACA	O	722-726
should	O	727-733
not	O	734-737
be	O	738-740
implicated	O	741-751
in	O	752-754
the	O	755-758
pathogenesis	O	759-771
of	O	772-774
fibrin	O	775-781
thrombi	B	782-789
in	O	790-792
patients	O	793-801
with	O	802-806
disseminated	B	807-819
intravascular	I	820-833
coagulation	I	834-845
or	O	846-848
other	O	849-854
"	O	855-856
consumption	B	856-867
coagulopathies	I	868-882
.	O	882-883
"	O	883-884

This	O	885-889
report	O	890-896
describes	O	897-906
subtotal	O	907-915
infarction	B	916-926
of	O	927-929
the	O	930-933
kidney	O	934-940
due	O	941-944
to	O	945-947
thrombosis	B	948-958
of	I	959-961
a	I	962-963
normal	I	964-970
renal	I	971-976
artery	I	977-983
.	O	983-984

This	O	985-989
occlusion	O	990-999
occurred	O	1000-1008
after	O	1009-1014
EACA	O	1015-1019
therapy	O	1020-1027
in	O	1028-1030
a	O	1031-1032
patient	O	1033-1040
with	O	1041-1045
SAH	B	1046-1049
and	O	1050-1053
histopathological	O	1054-1071
documentation	O	1072-1085
of	O	1086-1088
recurrent	O	1089-1098
SAH	B	1099-1102
.	O	1102-1103

The	O	1104-1107
corresponding	O	1108-1121
clinical	O	1122-1130
event	O	1131-1136
was	O	1137-1140
characterized	O	1141-1154
by	O	1155-1157
marked	O	1158-1164
hypertension	B	1165-1177
and	O	1178-1181
abrupt	O	1182-1188
neurological	O	1189-1201
deterioration	O	1202-1215
.	O	1215-1216

Long	O	0-4
-	O	4-5
term	O	5-9
propranolol	O	10-21
therapy	O	22-29
in	O	30-32
pregnancy	O	33-42
:	O	42-43
maternal	O	44-52
and	O	53-56
fetal	O	57-62
outcome	O	63-70
.	O	70-71

Propranolol	O	72-83
,	O	83-84
a	O	85-86
beta	O	87-91
-	O	91-92
adrenergic	O	92-102
blocking	O	103-111
agent	O	112-117
,	O	117-118
has	O	119-122
found	O	123-128
an	O	129-131
important	O	132-141
position	O	142-150
in	O	151-153
the	O	154-157
practice	O	158-166
of	O	167-169
medicine	O	170-178
.	O	178-179

Its	O	180-183
use	O	184-187
in	O	188-190
pregnancy	O	191-200
,	O	200-201
however	O	202-209
,	O	209-210
is	O	211-213
an	O	214-216
open	O	217-221
question	O	222-230
as	O	231-233
a	O	234-235
number	O	236-242
of	O	243-245
detrimental	O	246-257
side	O	258-262
effects	O	263-270
have	O	271-275
been	O	276-280
reported	O	281-289
in	O	290-292
the	O	293-296
fetus	O	297-302
and	O	303-306
neonate	O	307-314
.	O	314-315

Ten	O	316-319
patients	O	320-328
and	O	329-332
12	O	333-335
pregnancies	O	336-347
are	O	348-351
reported	O	352-360
where	O	361-366
chronic	O	367-374
propranolol	O	375-386
has	O	387-390
been	O	391-395
administered	O	396-408
.	O	408-409

Five	O	410-414
patients	O	415-423
with	O	424-428
serial	O	429-435
pregnancies	O	436-447
with	O	448-452
and	O	453-456
without	O	457-464
propranolol	O	465-476
therapy	O	477-484
are	O	485-488
also	O	489-493
examined	O	494-502
.	O	502-503

Maternal	O	504-512
,	O	512-513
fetal	O	514-519
,	O	519-520
and	O	521-524
neonatal	O	525-533
complications	O	534-547
are	O	548-551
examined	O	552-560
.	O	560-561

An	O	562-564
attempt	O	565-572
is	O	573-575
made	O	576-580
to	O	581-583
differentiate	O	584-597
drug	O	598-602
-	O	602-603
related	O	603-610
complications	O	611-624
from	O	625-629
maternal	O	630-638
disease	O	639-646
-	O	646-647
-	O	646-647
related	O	648-655
complications	O	656-669
.	O	669-670

We	O	671-673
conclude	O	674-682
that	O	683-687
previously	O	688-698
reported	O	699-707
hypoglycemia	B	708-720
,	O	720-721
hyperbilirubinemia	B	722-740
,	O	740-741
polycythemia	B	742-754
,	O	754-755
neonatal	B	756-764
apnea	I	765-770
,	O	770-771
and	O	772-775
bradycardia	B	776-787
are	O	788-791
not	O	792-795
invariable	O	796-806
and	O	807-810
cannot	O	811-817
be	O	818-820
statistically	O	821-834
correlated	O	835-845
with	O	846-850
chronic	O	851-858
propranolol	O	859-870
therapy	O	871-878
.	O	878-879

Growth	B	880-886
retardation	I	887-898
,	O	898-899
however	O	900-907
,	O	907-908
appears	O	909-916
to	O	917-919
be	O	920-922
significant	O	923-934
in	O	935-937
both	O	938-942
of	O	943-945
our	O	946-949
series	O	950-956
.	O	956-957

Use	O	0-3
of	O	4-6
propranolol	O	7-18
in	O	19-21
the	O	22-25
treatment	O	26-35
of	O	36-38
idiopathic	B	39-49
orthostatic	I	50-61
hypotension	I	62-73
.	O	73-74

Five	O	75-79
patients	O	80-88
with	O	89-93
idiopathic	B	94-104
orthostatic	I	105-116
hypotension	I	117-128
who	O	129-132
had	O	133-136
physiologic	O	137-148
and	O	149-152
biochemical	O	153-164
evidence	O	165-173
of	O	174-176
severe	O	177-183
autonomic	O	184-193
dysfunction	O	194-205
were	O	206-210
included	O	211-219
in	O	220-222
the	O	223-226
study	O	227-232
.	O	232-233

They	O	234-238
all	O	239-242
exhibited	O	243-252
markedly	O	253-261
reduced	O	262-269
plasma	O	270-276
catecholamines	O	277-291
and	O	292-295
plasma	O	296-302
renin	O	303-308
activity	O	309-317
in	O	318-320
both	O	321-325
recumbent	O	326-335
and	O	336-339
upright	O	340-347
positions	O	348-357
and	O	358-361
had	O	362-365
marked	O	366-372
hypersensitivity	B	373-389
to	O	390-392
the	O	393-396
pressor	O	397-404
effects	O	405-412
of	O	413-415
infused	O	416-423
norepinephrine	O	424-438
.	O	438-439

Treatment	O	440-449
with	O	450-454
propanolol	O	455-465
administered	O	466-478
intravenously	O	479-492
(	O	493-494
1	O	494-495
-	O	495-496
5	O	496-497
mg	O	498-500
)	O	500-501
produced	O	502-510
increases	O	511-520
in	O	521-523
supine	O	524-530
and	O	531-534
upright	O	535-542
blood	O	543-548
pressure	O	549-557
in	O	558-560
4	O	561-562
of	O	563-565
the	O	566-569
5	O	570-571
individuals	O	572-583
with	O	584-588
rises	O	589-594
ranging	O	595-602
from	O	603-607
11	O	608-610
/	O	610-611
6	O	611-612
to	O	613-615
22	O	616-618
/	O	618-619
11	O	619-621
mmHg	O	622-626
.	O	626-627

Chronic	O	628-635
oral	O	636-640
administration	O	641-655
of	O	656-658
propranolol	O	659-670
(	O	671-672
40	O	672-674
-	O	674-675
160	O	675-678
mg	O	679-681
/	O	681-682
day	O	682-685
)	O	685-686
also	O	687-691
elevated	O	692-700
the	O	701-704
blood	O	705-710
pressures	O	711-720
of	O	721-723
these	O	724-729
individuals	O	730-741
with	O	742-746
increases	O	747-756
in	O	757-759
the	O	760-763
order	O	764-769
of	O	770-772
20	O	773-775
-	O	775-776
35	O	776-778
/	O	778-779
15	O	779-781
-	O	775-776
25	O	782-784
mmg	O	785-788
being	O	789-794
observed	O	795-803
.	O	803-804

In	O	805-807
1	O	808-809
patient	O	810-817
,	O	817-818
marked	O	819-825
hypertension	B	826-838
was	O	839-842
induced	O	843-850
by	O	851-853
propranolol	O	854-865
and	O	866-869
the	O	870-873
drug	O	874-878
had	O	879-882
to	O	883-885
be	O	886-888
withdrawn	O	889-898
.	O	898-899

It	O	900-902
otherwise	O	903-912
was	O	913-916
well	O	917-921
tolerated	O	922-931
and	O	932-935
no	O	936-938
important	O	939-948
side	O	949-953
effects	O	954-961
were	O	962-966
observed	O	967-975
.	O	975-976

Treatment	O	977-986
has	O	987-990
been	O	991-995
continued	O	996-1005
in	O	1006-1008
3	O	1009-1010
individuals	O	1011-1022
for	O	1023-1026
6	O	1027-1028
-	O	1028-1029
13	O	1029-1031
months	O	1032-1038
with	O	1039-1043
persistence	O	1044-1055
of	O	1056-1058
the	O	1059-1062
pressor	O	1063-1070
effect	O	1071-1077
,	O	1077-1078
although	O	1079-1087
there	O	1088-1093
appears	O	1094-1101
to	O	1102-1104
have	O	1105-1109
been	O	1110-1114
some	O	1115-1119
decrease	O	1120-1128
in	O	1129-1131
the	O	1132-1135
degree	O	1136-1142
of	O	1143-1145
response	O	1146-1154
with	O	1155-1159
time	O	1160-1164
.	O	1164-1165

Hemodynamic	O	1166-1177
measurements	O	1178-1190
in	O	1191-1193
1	O	1194-1195
of	O	1196-1198
the	O	1199-1202
patients	O	1203-1211
demonstrated	O	1212-1224
an	O	1225-1227
increase	O	1228-1236
in	O	1237-1239
total	O	1240-1245
peripheral	O	1246-1256
resistance	O	1257-1267
and	O	1268-1271
essentially	O	1272-1283
no	O	1284-1286
change	O	1287-1293
in	O	1294-1296
cardiac	O	1297-1304
output	O	1305-1311
following	O	1312-1321
propranolol	O	1322-1333
therapy	O	1334-1341
.	O	1341-1342

The	O	1343-1346
studies	O	1347-1354
suggest	O	1355-1362
that	O	1363-1367
propranolol	O	1368-1379
is	O	1380-1382
a	O	1383-1384
useful	O	1385-1391
drug	O	1392-1396
in	O	1397-1399
selected	O	1400-1408
patients	O	1409-1417
with	O	1418-1422
severe	O	1423-1429
idiopathic	B	1430-1440
orthostatic	I	1441-1452
hypotension	I	1453-1464
.	O	1464-1465

Total	O	0-5
intravenous	O	6-17
anesthesia	O	18-28
with	O	29-33
etomidate	O	34-43
.	O	43-44

III	O	45-48
.	O	48-49

Some	O	50-54
observations	O	55-67
in	O	68-70
adults	O	71-77
.	O	77-78

An	O	79-81
investigation	O	82-95
was	O	96-99
undertaken	O	100-110
to	O	111-113
determine	O	114-123
the	O	124-127
dosage	O	128-134
of	O	135-137
etomidate	O	138-147
required	O	148-156
to	O	157-159
maintain	O	160-168
sleep	O	169-174
in	O	175-177
adults	O	178-184
undergoing	O	185-195
surgery	O	196-203
under	O	204-209
regional	O	210-218
local	O	219-224
anesthesia	O	225-235
.	O	235-236

Premedication	O	237-250
of	O	251-253
diazepam	O	254-262
10	O	263-265
mg	O	266-268
and	O	269-272
atropine	O	273-281
0	O	282-283
.	O	283-284
5	O	284-285
mg	O	286-288
was	O	289-292
given	O	293-298
,	O	298-299
and	O	300-303
sleep	O	304-309
was	O	310-313
induced	O	314-321
and	O	322-325
maintained	O	326-336
by	O	337-339
intermittent	O	340-352
intravenous	O	353-364
injections	O	365-375
of	O	376-378
etomidate	O	379-388
0	O	389-390
.	O	390-391
1	O	391-392
/	O	392-393
mg	O	393-395
/	O	392-393
kg	O	396-398
,	O	398-399
given	O	400-405
whenever	O	406-414
the	O	415-418
patient	O	419-426
would	O	427-432
open	O	433-437
his	O	438-441
eyes	O	442-446
on	O	447-449
request	O	450-457
.	O	457-458

A	O	459-460
mean	O	461-465
overall	O	466-473
dose	O	474-478
of	O	479-481
etomidate	O	482-491
17	O	492-494
.	O	494-495
4	O	495-496
microgram	O	497-506
/	O	506-507
kg	O	507-509
/	O	506-507
min	O	510-513
.	O	513-514

was	O	515-518
required	O	519-527
to	O	528-530
maintain	O	531-539
sleep	O	540-545
,	O	545-546
but	O	547-550
great	O	551-556
individual	O	557-567
variation	O	568-577
occurred	O	578-586
,	O	586-587
with	O	588-592
older	O	593-598
patients	O	599-607
requiring	O	608-617
less	O	618-622
drug	O	623-627
.	O	627-628

The	O	629-632
investigation	O	633-646
was	O	647-650
discontinued	O	651-663
after	O	664-669
18	O	670-672
patients	O	673-681
because	O	682-689
of	O	690-692
the	O	693-696
frequency	O	697-706
and	O	707-710
intensity	O	711-720
of	O	721-723
side	O	724-728
-	O	728-729
effects	O	729-736
,	O	736-737
particularly	O	738-750
pain	B	751-755
and	O	756-759
myoclonia	B	760-769
,	O	769-770
which	O	771-776
caused	O	777-783
the	O	784-787
technique	O	788-797
to	O	798-800
be	O	801-803
abandoned	O	804-813
in	O	814-816
two	O	817-820
cases	O	821-826
.	O	826-827

It	O	828-830
is	O	831-833
considered	O	834-844
unlikely	O	845-853
that	O	854-858
etomidate	O	859-868
will	O	869-873
prove	O	874-879
to	O	880-882
be	O	883-885
the	O	886-889
hypnotic	O	890-898
of	O	899-901
choice	O	902-908
for	O	909-912
a	O	913-914
totally	O	915-922
intravenous	O	923-934
anesthetic	O	935-945
technique	O	946-955
in	O	956-958
adults	O	959-965
because	O	966-973
of	O	974-976
the	O	977-980
high	O	981-985
incidence	O	986-995
of	O	996-998
myoclonia	B	999-1008
after	O	1009-1014
prolonged	O	1015-1024
administration	O	1025-1039
.	O	1039-1040

In	O	1041-1043
several	O	1044-1051
patients	O	1052-1060
uncontrollable	O	1061-1075
muscle	O	1076-1082
movements	O	1083-1092
persisted	O	1093-1102
for	O	1103-1106
many	O	1107-1111
minutes	O	1112-1119
after	O	1120-1125
complete	O	1126-1134
recovery	O	1135-1143
of	O	1144-1146
consciousness	O	1147-1160
.	O	1160-1161

A	O	0-1
method	O	2-8
for	O	9-12
the	O	13-16
measurement	O	17-28
of	O	29-31
tremor	B	32-38
,	O	38-39
and	O	40-43
a	O	44-45
comparison	O	46-56
of	O	57-59
the	O	60-63
effects	O	64-71
of	O	72-74
tocolytic	O	75-84
beta	O	85-89
-	O	89-90
mimetics	O	90-98
.	O	98-99

A	O	100-101
method	O	102-108
permitting	O	109-119
measurement	O	120-131
of	O	132-134
finger	O	135-141
tremor	B	142-148
as	O	149-151
a	O	152-153
displacement	O	154-166
-	O	166-167
time	O	167-171
curve	O	172-177
is	O	178-180
described	O	181-190
,	O	190-191
using	O	192-197
a	O	198-199
test	O	200-204
system	O	205-211
with	O	212-216
simple	O	217-223
amplitude	O	224-233
calibration	O	234-245
.	O	245-246

The	O	247-250
coordinates	O	251-262
of	O	263-265
the	O	266-269
inversion	O	270-279
points	O	280-286
of	O	287-289
the	O	290-293
displacement	O	294-306
-	O	306-307
time	O	307-311
curves	O	312-318
were	O	319-323
transferred	O	324-335
through	O	336-343
graphical	O	344-353
input	O	354-359
equipment	O	360-369
to	O	370-372
punched	O	373-380
tape	O	381-385
.	O	385-386

By	O	387-389
means	O	390-395
of	O	396-398
a	O	399-400
computer	O	401-409
program	O	410-417
,	O	417-418
periods	O	419-426
and	O	427-430
amplitudes	O	431-441
of	O	442-444
tremor	B	445-451
oscillations	O	452-464
were	O	465-469
calculated	O	470-480
and	O	481-484
classified	O	485-495
.	O	495-496

The	O	497-500
event	O	501-506
frequency	O	507-516
for	O	517-520
each	O	521-525
class	O	526-531
of	O	532-534
periods	O	535-542
and	O	543-546
amplitudes	O	547-557
was	O	558-561
determined	O	562-572
.	O	572-573

The	O	574-577
actions	O	578-585
of	O	586-588
fenoterol	O	589-598
-	O	598-599
hydrobromide	O	599-611
,	O	611-612
ritodrin	O	613-621
-	O	621-622
HCl	O	622-625
and	O	626-629
placebo	O	630-637
given	O	638-643
to	O	644-646
10	O	647-649
healthy	O	650-657
subjects	O	658-666
by	O	667-669
intravenous	O	670-681
infusion	O	682-690
in	O	691-693
a	O	694-695
double	O	696-702
-	O	702-703
blind	O	703-708
crossover	O	709-718
study	O	719-724
were	O	725-729
tested	O	730-736
by	O	737-739
this	O	740-744
method	O	745-751
.	O	751-752

At	O	753-755
therapeutic	O	756-767
doses	O	768-773
both	O	774-778
substances	O	779-789
raised	O	790-796
the	O	797-800
mean	O	801-805
tremor	B	806-812
amplitude	O	813-822
to	O	823-825
about	O	826-831
three	O	832-837
times	O	838-843
the	O	844-847
control	O	848-855
level	O	856-861
.	O	861-862

At	O	863-865
the	O	866-869
same	O	870-874
time	O	875-879
,	O	879-880
the	O	881-884
mean	O	885-889
period	O	890-896
within	O	897-903
each	O	904-908
class	O	909-914
of	O	915-917
amplitudes	O	918-928
shortened	O	929-938
by	O	939-941
10	O	942-944
-	O	944-945
-	O	944-945
20	O	946-948
ms	O	949-951
,	O	951-952
whereas	O	953-960
the	O	961-964
mean	O	965-969
periods	O	970-977
calculated	O	978-988
from	O	989-993
all	O	994-997
oscillations	O	998-1010
together	O	1011-1019
did	O	1020-1023
not	O	1024-1027
change	O	1028-1034
significantly	O	1035-1048
.	O	1048-1049

After	O	1050-1055
the	O	1056-1059
end	O	1060-1063
of	O	1064-1066
fenoterol	O	1067-1076
-	O	1076-1077
hydrobromide	O	1077-1089
infusion	O	1090-1098
,	O	1098-1099
tremor	B	1100-1106
amplitudes	O	1107-1117
decreased	O	1118-1127
significantly	O	1128-1141
faster	O	1142-1148
than	O	1149-1153
those	O	1154-1159
following	O	1160-1169
ritodrin	O	1170-1178
-	O	1178-1179
HCl	O	1179-1182
infusion	O	1183-1191
.	O	1191-1192

Bilateral	O	0-9
retinal	B	10-17
artery	I	18-24
and	I	25-28
choriocapillaris	I	29-45
occlusion	I	46-55
following	O	56-65
the	O	66-69
injection	O	70-79
of	O	80-82
long	O	83-87
-	O	87-88
acting	O	88-94
corticosteroid	O	95-109
suspensions	O	110-121
in	O	122-124
combination	O	125-136
with	O	137-141
other	O	142-147
drugs	O	148-153
:	O	153-154
I	O	155-156
.	O	156-157
Clinical	O	158-166
studies	O	167-174
.	O	174-175

Two	O	176-179
well	O	180-184
-	O	184-185
documented	O	185-195
cases	O	196-201
of	O	202-204
bilateral	O	205-214
retinal	B	215-222
artery	I	223-229
and	I	230-233
choriocapillaris	I	234-250
occlusions	I	251-261
with	O	262-266
blindness	B	267-276
following	O	277-286
head	O	287-291
and	O	292-295
neck	O	296-300
soft	O	301-305
-	O	305-306
tissue	O	306-312
injection	O	313-322
with	O	323-327
methylprednisolone	O	328-346
acetate	O	347-354
in	O	355-357
combination	O	358-369
with	O	370-374
lidocaine	O	375-384
,	O	384-385
epinephrine	O	386-397
,	O	397-398
or	O	399-401
penicillin	O	402-412
are	O	413-416
reported	O	417-425
.	O	425-426

One	O	427-430
case	O	431-435
had	O	436-439
only	O	440-444
a	O	445-446
unilateral	O	447-457
injection	O	458-467
.	O	467-468

The	O	469-472
acute	O	473-478
observations	O	479-491
included	O	492-500
hazy	O	501-505
sensorium	O	506-515
,	O	515-516
superior	O	517-525
gaze	O	526-530
palsy	B	531-536
,	O	536-537
pupillary	B	538-547
abnormalities	I	548-561
,	O	561-562
and	O	563-566
conjunctival	O	567-579
hemorrhages	B	580-591
with	O	592-596
edema	B	597-602
.	O	602-603

Follow	O	604-610
-	O	610-611
up	O	611-613
changes	O	614-621
showed	O	622-628
marked	O	629-635
visual	B	636-642
loss	I	643-647
,	O	647-648
constricted	O	649-660
visual	O	661-667
fields	O	668-674
,	O	674-675
optic	O	676-681
nerve	O	682-687
pallor	O	688-694
,	O	694-695
vascular	O	696-704
attenuation	O	705-716
,	O	716-717
and	O	718-721
chorioretinal	B	722-735
atrophy	I	736-743
.	O	743-744

The	O	745-748
literature	O	749-759
is	O	760-762
reviewed	O	763-771
,	O	771-772
and	O	773-776
possible	O	777-785
causes	O	786-792
are	O	793-796
discussed	O	797-806
.	O	806-807

Cephalothin	O	0-11
-	O	11-12
induced	O	12-19
immune	O	20-26
hemolytic	B	27-36
anemia	I	37-43
.	O	43-44

A	O	45-46
patient	O	47-54
with	O	55-59
renal	B	60-65
disease	I	66-73
developed	O	74-83
Coombs	O	84-90
-	O	90-91
positive	O	91-99
hemolytic	B	100-109
anemia	I	110-116
while	O	117-122
receiving	O	123-132
cephalothin	O	133-144
therapy	O	145-152
.	O	152-153

An	O	154-156
anti	O	157-161
-	O	161-162
cephalothin	O	162-173
IgG	O	174-177
antibody	O	178-186
was	O	187-190
detected	O	191-199
in	O	200-202
the	O	203-206
patient	O	207-214
'	O	214-215
s	O	215-216
serum	O	217-222
and	O	223-226
in	O	227-229
the	O	230-233
eluates	O	234-241
from	O	242-246
her	O	247-250
erythrocytes	O	251-263
.	O	263-264

In	O	265-267
addition	O	268-276
,	O	276-277
nonimmunologic	O	278-292
binding	O	293-300
of	O	301-303
normal	O	304-310
and	O	311-314
patient	O	315-322
'	O	322-323
s	O	323-324
serum	O	325-330
proteins	O	331-339
to	O	340-342
her	O	343-346
own	O	347-350
and	O	351-354
cephalothin	O	355-366
-	O	366-367
coated	O	367-373
normal	O	374-380
red	O	381-384
cells	O	385-390
was	O	391-394
demonstrated	O	395-407
.	O	407-408

Skin	O	409-413
tests	O	414-419
and	O	420-423
in	O	424-426
vitro	O	427-432
lymphocyte	O	433-443
stimulation	O	444-455
revealed	O	456-464
that	O	465-469
the	O	470-473
patient	O	474-481
was	O	482-485
sensitized	O	486-496
to	O	497-499
cephalothin	O	500-511
and	O	512-515
also	O	516-520
to	O	521-523
ampicillin	O	524-534
.	O	534-535

Careful	O	536-543
investigation	O	544-557
of	O	558-560
drug	O	561-565
-	O	565-566
induced	O	566-573
hemolytic	B	574-583
anemias	I	584-591
reveals	O	592-599
the	O	600-603
complexity	O	604-614
of	O	615-617
the	O	618-621
immune	O	622-628
mechanisms	O	629-639
involved	O	640-648
.	O	648-649

Kaliuretic	O	0-10
effect	O	11-17
of	O	18-20
L	O	21-22
-	O	22-23
dopa	O	23-27
treatment	O	28-37
in	O	38-40
parkinsonian	B	41-53
patients	O	54-62
.	O	62-63

Hypokalemia	B	64-75
,	O	75-76
sometimes	O	77-86
severe	O	87-93
,	O	93-94
was	O	95-98
observed	O	99-107
in	O	108-110
some	O	111-115
L	O	116-117
-	O	117-118
dopa	O	118-122
-	O	117-118
treated	O	123-130
parkinsonian	B	131-143
patients	O	144-152
.	O	152-153

The	O	154-157
influence	O	158-167
of	O	168-170
L	O	171-172
-	O	172-173
dopa	O	173-177
on	O	178-180
the	O	181-184
renal	O	185-190
excretion	O	191-200
of	O	201-203
potassium	O	204-213
was	O	214-217
studied	O	218-225
in	O	226-228
3	O	229-230
patients	O	231-239
with	O	240-244
hypokalemia	B	245-256
and	O	257-260
in	O	261-263
5	O	264-265
normokalemic	O	266-278
patients	O	279-287
by	O	288-290
determination	O	291-304
of	O	305-307
renal	O	308-313
plasma	O	314-320
flow	O	321-325
,	O	325-326
glomerular	O	327-337
filtration	O	338-348
rate	O	349-353
,	O	353-354
plasma	O	355-361
concentration	O	362-375
of	O	376-378
potassium	O	379-388
and	O	389-392
sodium	O	393-399
as	O	400-402
well	O	403-407
as	O	408-410
urinary	O	411-418
excretion	O	419-428
of	O	429-431
potassium	O	432-441
,	O	441-442
sodium	O	443-449
and	O	450-453
aldosterone	O	454-465
.	O	465-466

L	O	467-468
-	O	468-469
Dopa	O	469-473
intake	O	474-480
was	O	481-484
found	O	485-490
to	O	491-493
cause	O	494-499
an	O	500-502
increased	O	503-512
excretion	O	513-522
of	O	523-525
potassium	O	526-535
,	O	535-536
and	O	537-540
sometimes	O	541-550
also	O	551-555
of	O	556-558
sodium	O	559-565
,	O	565-566
in	O	567-569
the	O	570-573
hypokalemic	O	574-585
but	O	586-589
not	O	590-593
in	O	594-596
the	O	597-600
normokalemic	O	601-613
patients	O	614-622
.	O	622-623

This	O	624-628
effect	O	629-635
on	O	636-638
the	O	639-642
renal	O	643-648
function	O	649-657
could	O	658-663
be	O	664-666
prohibited	O	667-677
by	O	678-680
the	O	681-684
administration	O	685-699
of	O	700-702
a	O	703-704
peripheral	O	705-715
dopa	O	716-720
decarbodylase	O	721-734
inhibitor	O	735-744
.	O	744-745

It	O	746-748
is	O	749-751
not	O	752-755
known	O	756-761
why	O	762-765
this	O	766-770
effect	O	771-777
occurred	O	778-786
in	O	787-789
some	O	790-794
individuals	O	795-806
but	O	807-810
not	O	811-814
in	O	815-817
others	O	818-824
,	O	824-825
but	O	826-829
our	O	830-833
results	O	834-841
indicate	O	842-850
a	O	851-852
correlation	O	853-864
between	O	865-872
aldosterone	O	873-884
production	O	885-895
and	O	896-899
this	O	900-904
renal	O	905-910
effect	O	911-917
of	O	918-920
L	O	921-922
-	O	922-923
dopa	O	923-927
.	O	927-928

Phenytoin	O	0-9
encephalopathy	B	10-24
as	O	25-27
probable	O	28-36
idiosyncratic	O	37-50
reaction	O	51-59
:	O	59-60
case	O	61-65
report	O	66-72
.	O	72-73

A	O	74-75
case	O	76-80
of	O	81-83
phenytoin	O	84-93
(	O	94-95
DPH	O	95-98
)	O	98-99
encephalopathy	B	100-114
with	O	115-119
increasing	O	120-130
seizures	B	131-139
and	O	140-143
EEG	O	144-147
and	O	148-151
mental	O	152-158
changes	O	159-166
is	O	167-169
described	O	170-179
.	O	179-180

Despite	O	181-188
adequate	O	189-197
oral	O	198-202
dosage	O	203-209
of	O	210-212
DPH	O	213-216
(	O	217-218
5	O	218-219
mg	O	220-222
/	O	222-223
kg	O	223-225
/	O	222-223
daily	O	226-231
)	O	231-232
the	O	233-236
plasma	O	237-243
level	O	244-249
was	O	250-253
very	O	254-258
low	O	259-262
(	O	263-264
2	O	264-265
.	O	265-266
8	O	266-267
microgramg	O	268-278
/	O	278-279
ml	O	279-281
)	O	281-282
.	O	282-283

The	O	284-287
encephalopathy	B	288-302
was	O	303-306
probably	O	307-315
an	O	316-318
idiosyncratic	O	319-332
and	O	333-336
not	O	337-340
toxic	O	341-346
or	O	347-349
allergic	O	350-358
reaction	O	359-367
.	O	367-368

In	O	369-371
fact	O	372-376
the	O	377-380
concentration	O	381-394
of	O	395-397
free	O	398-402
DPH	O	403-406
was	O	407-410
normal	O	411-417
,	O	417-418
the	O	419-422
patient	O	423-430
presented	O	431-440
a	O	441-442
retarded	O	443-451
morbilliform	O	452-464
rash	B	465-469
during	O	470-476
DPH	O	477-480
treatment	O	481-490
,	O	490-491
the	O	492-495
protidogram	O	496-507
was	O	508-511
normal	O	512-518
,	O	518-519
and	O	520-523
an	O	524-526
intradermic	O	527-538
DPH	O	539-542
injection	O	543-552
had	O	553-556
no	O	557-559
local	O	560-565
effect	O	566-572
.	O	572-573

The	O	574-577
authors	O	578-585
conclude	O	586-594
that	O	595-599
in	O	600-602
a	O	603-604
patient	O	605-612
starting	O	613-621
DPH	O	622-625
treatment	O	626-635
an	O	636-638
unexpected	O	639-649
increase	O	650-658
in	O	659-661
seizures	B	662-670
,	O	670-671
with	O	672-676
EEG	O	677-680
and	O	681-684
mental	O	685-691
changes	O	692-699
occurring	O	700-709
simultaneously	O	710-724
,	O	724-725
should	O	726-732
alert	O	733-738
the	O	739-742
physician	O	743-752
to	O	753-755
the	O	756-759
possible	O	760-768
need	O	769-773
for	O	774-777
eliminating	O	778-789
DPH	O	790-793
from	O	794-798
the	O	799-802
therapeutic	O	803-814
regimen	O	815-822
,	O	822-823
even	O	824-828
if	O	829-831
plasma	O	832-838
concentrations	O	839-853
are	O	854-857
low	O	858-861
.	O	861-862

Effects	O	0-7
of	O	8-10
exercise	O	11-19
on	O	20-22
the	O	23-26
severity	O	27-35
of	O	36-38
isoproterenol	O	39-52
-	O	52-53
induced	O	53-60
myocardial	B	61-71
infarction	I	72-82
.	O	82-83

The	O	84-87
effect	O	88-94
of	O	95-97
exercise	O	98-106
on	O	107-109
the	O	110-113
severity	O	114-122
of	O	123-125
isoproterenol	O	126-139
-	O	139-140
induced	O	140-147
myocardial	B	148-158
infarction	I	159-169
was	O	170-173
studied	O	174-181
in	O	182-184
male	O	185-189
rats	O	190-194
.	O	194-195

Ninety	O	196-202
-	O	202-203
three	O	203-208
rats	O	209-213
were	O	214-218
randomly	O	219-227
divided	O	228-235
into	O	236-240
three	O	241-246
groups	O	247-253
.	O	253-254

The	O	255-258
exercise	O	259-267
-	O	267-268
isoproterenol	O	268-281
(	O	282-283
E	O	283-284
-	O	284-285
1	O	285-286
)	O	286-287
and	O	288-291
exercise	O	292-300
control	O	301-308
(	O	309-310
EC	O	310-312
)	O	312-313
groups	O	314-320
exercised	O	321-330
daily	O	331-336
for	O	337-340
thirty	O	341-347
days	O	348-352
on	O	353-355
a	O	356-357
treadmill	O	358-367
at	O	368-370
1	O	371-372
mph	O	373-376
,	O	376-377
2	O	378-379
%	O	379-380
grade	O	381-386
while	O	387-392
animals	O	393-400
of	O	401-403
the	O	404-407
sedentary	O	408-417
-	O	417-418
isoproterenol	O	418-431
(	O	432-433
S	O	433-434
-	O	434-435
I	O	435-436
)	O	436-437
group	O	438-443
remained	O	444-452
sedentary	O	453-462
.	O	462-463

Eight	O	464-469
animals	O	470-477
were	O	478-482
assigned	O	483-491
to	O	492-494
the	O	495-498
sedentary	O	499-508
control	O	509-516
(	O	517-518
SC	O	518-520
)	O	520-521
group	O	522-527
which	O	528-533
remained	O	534-542
sedentary	O	543-552
throughout	O	553-563
the	O	564-567
experimental	O	568-580
period	O	581-587
.	O	587-588

Forty	O	589-594
-	O	594-595
eight	O	595-600
hours	O	601-606
after	O	607-612
the	O	613-616
final	O	617-622
exercise	O	623-631
period	O	632-638
,	O	638-639
S	O	640-641
-	O	641-642
I	O	642-643
and	O	644-647
E	O	648-649
-	O	649-650
I	O	650-651
animals	O	652-659
received	O	660-668
a	O	669-670
single	O	671-677
subcutaneous	O	678-690
injection	O	691-700
of	O	701-703
isoproterenol	O	704-717
(	O	718-719
250	O	719-722
mg	O	723-725
/	O	725-726
kg	O	726-728
body	O	729-733
weight	O	734-740
)	O	740-741
.	O	741-742

Animals	O	743-750
of	O	751-753
the	O	754-757
S	O	758-759
-	O	759-760
I	O	760-761
group	O	762-767
exhibited	O	768-777
significantly	O	778-791
(	O	792-793
Pp	O	793-795
less	O	796-800
than	O	801-805
0	O	806-807
.	O	807-808
05	O	808-810
)	O	810-811
greater	O	812-819
mortality	O	820-829
from	O	830-834
the	O	835-838
effects	O	839-846
of	O	847-849
isoproterenol	O	850-863
than	O	864-868
animals	O	869-876
of	O	877-879
the	O	880-883
E	O	884-885
-	O	885-886
I	O	886-887
group	O	888-893
.	O	893-894

Serum	O	895-900
CPK	O	901-904
activity	O	905-913
for	O	914-917
E	O	918-919
-	O	919-920
I	O	920-921
animals	O	922-929
was	O	930-933
significantly	O	934-947
(	O	948-949
p	O	949-950
less	O	951-955
than	O	956-960
0	O	961-962
.	O	962-963
05	O	963-965
)	O	965-966
greater	O	967-974
than	O	975-979
for	O	980-983
animals	O	984-991
in	O	992-994
the	O	995-998
S	O	999-1000
-	O	1000-1001
I	O	1001-1002
and	O	1003-1006
EC	O	1007-1009
groups	O	1010-1016
twenty	O	1017-1023
hours	O	1024-1029
following	O	1030-1039
isoproterenol	O	1040-1053
injection	O	1054-1063
.	O	1063-1064

No	O	1065-1067
statistically	O	1068-1081
significant	O	1082-1093
differences	O	1094-1105
were	O	1106-1110
observed	O	1111-1119
between	O	1120-1127
the	O	1128-1131
two	O	1132-1135
isoproterenol	O	1136-1149
treated	O	1150-1157
groups	O	1158-1164
for	O	1165-1168
severity	O	1169-1177
of	O	1178-1180
the	O	1181-1184
induced	O	1185-1192
lesions	O	1193-1200
,	O	1200-1201
changes	O	1202-1209
in	O	1210-1212
heart	O	1213-1218
weight	O	1219-1225
,	O	1225-1226
or	O	1227-1229
heart	O	1230-1235
weight	O	1236-1242
to	O	1243-1245
body	O	1246-1250
weight	O	1251-1257
ratios	O	1258-1264
.	O	1264-1265

The	O	1266-1269
results	O	1270-1277
indicated	O	1278-1287
that	O	1288-1292
exercise	O	1293-1301
reduced	O	1302-1309
the	O	1310-1313
mortality	O	1314-1323
associated	O	1324-1334
with	O	1335-1339
the	O	1340-1343
effects	O	1344-1351
of	O	1352-1354
large	O	1355-1360
dosages	O	1361-1368
of	O	1369-1371
isoproterenol	O	1372-1385
but	O	1386-1389
had	O	1390-1393
little	O	1394-1400
on	O	1401-1403
the	O	1404-1407
severity	O	1408-1416
of	O	1417-1419
the	O	1420-1423
infarction	B	1424-1434
.	O	1434-1435

Effect	O	0-6
of	O	7-9
D	O	10-11
-	O	11-12
Glucarates	O	12-22
on	O	23-25
basic	O	26-31
antibiotic	O	32-42
-	O	42-43
induced	O	43-50
renal	B	51-56
damage	I	57-63
in	O	64-66
rats	O	67-71
.	O	71-72

Dehydrated	B	73-83
rats	O	84-88
regularly	O	89-98
develop	O	99-106
acute	B	107-112
renal	I	113-118
failure	I	119-126
following	O	127-136
single	O	137-143
injection	O	144-153
of	O	154-156
aminoglycoside	O	157-171
antibiotics	O	172-183
combined	O	184-192
with	O	193-197
dextran	O	198-205
or	O	206-208
of	O	209-211
antibiotics	O	212-223
only	O	224-228
.	O	228-229

Oral	O	230-234
administration	O	235-249
of	O	250-252
2	O	253-254
,	O	254-255
5	O	255-256
-	O	256-257
di	O	257-259
-	O	256-257
O	O	260-261
-	O	256-257
acetyl	O	262-268
-	O	256-257
D	O	269-270
-	O	256-257
glucaro	O	271-278
-	O	256-257
1	O	279-280
,	O	254-255
4	O	281-282
-	O	256-257
6	O	283-284
,	O	254-255
3	O	285-286
-	O	256-257
dilactone	O	287-296
protected	O	297-306
rats	O	307-311
against	O	312-319
renal	B	320-325
failure	I	326-333
induced	O	334-341
by	O	342-344
kanamycin	O	345-354
-	O	354-355
dextran	O	355-362
.	O	362-363

The	O	364-367
protective	O	368-378
effect	O	379-385
was	O	386-389
prevalent	O	390-399
among	O	400-405
D	O	406-407
-	O	407-408
glucarates	O	408-418
,	O	418-419
and	O	420-423
also	O	424-428
to	O	429-431
other	O	432-437
saccharic	O	438-447
acid	O	448-452
,	O	452-453
hexauronic	O	454-464
acids	O	465-470
and	O	471-474
hexaaldonic	O	475-486
acids	O	487-492
,	O	492-493
although	O	494-502
to	O	503-505
a	O	506-507
lesser	O	508-514
degree	O	515-521
,	O	521-522
but	O	523-526
not	O	527-530
to	O	531-533
a	O	534-535
hexaaldose	O	536-546
,	O	546-547
sugar	O	548-553
alcohols	O	554-562
,	O	562-563
substances	O	564-574
inthe	O	575-580
TCA	O	581-584
cycle	O	585-590
and	O	591-594
other	O	595-600
acidic	O	601-607
compounds	O	608-617
.	O	617-618

D	O	619-620
-	O	620-621
Glucarates	O	621-631
were	O	632-636
effective	O	637-646
against	O	647-654
renal	B	655-660
damage	I	661-667
induced	O	668-675
by	O	676-678
peptide	O	679-686
antibiotics	O	687-698
as	O	699-701
well	O	702-706
as	O	707-709
various	O	710-717
aminoglycoside	O	718-732
antibitocis	O	733-744
.	O	744-745

Dose	O	746-750
-	O	750-751
responses	O	751-760
were	O	761-765
observed	O	766-774
in	O	775-777
the	O	778-781
protective	O	782-792
effect	O	793-799
of	O	800-802
D	O	803-804
-	O	804-805
Glucarates	O	805-815
.	O	815-816

With	O	817-821
a	O	822-823
D	O	824-825
-	O	825-826
glucarate	O	826-835
of	O	836-838
a	O	839-840
fixed	O	841-846
size	O	847-851
of	O	852-854
dose	O	855-859
,	O	859-860
approximately	O	861-874
the	O	875-878
same	O	879-883
degree	O	884-890
of	O	891-893
protection	O	894-904
was	O	905-908
obtained	O	909-917
against	O	918-925
renal	B	926-931
damages	I	932-939
induced	O	940-947
by	O	948-950
different	O	951-960
basic	O	961-966
antibiotics	O	967-978
despite	O	979-986
large	O	987-992
disparities	O	993-1004
in	O	1005-1007
administration	O	1008-1022
doses	O	1023-1028
of	O	1029-1031
different	O	1032-1041
antibiotics	O	1042-1053
.	O	1053-1054

D	O	1055-1056
-	O	1056-1057
Glucarates	O	1057-1067
had	O	1068-1071
the	O	1072-1075
ability	O	1076-1083
to	O	1084-1086
prevent	O	1087-1094
renal	B	1095-1100
damage	I	1101-1107
but	O	1108-1111
not	O	1112-1115
to	O	1116-1118
cure	O	1119-1123
it	O	1124-1126
.	O	1126-1127

Rats	O	1128-1132
excreted	O	1133-1141
acidic	O	1142-1148
urine	O	1149-1154
when	O	1155-1159
they	O	1160-1164
were	O	1165-1169
spared	O	1170-1176
from	O	1177-1181
renal	B	1182-1187
lesions	I	1188-1195
by	O	1196-1198
monosaccharides	O	1199-1214
.	O	1214-1215

The	O	1216-1219
reduction	O	1220-1229
effect	O	1230-1236
of	O	1237-1239
D	O	1240-1241
-	O	1241-1242
glucarates	O	1242-1252
against	O	1253-1260
nephrotoxicity	B	1261-1275
of	O	1276-1278
basic	O	1279-1284
antibiotics	O	1285-1296
was	O	1297-1300
discussed	O	1301-1310
.	O	1310-1311

Paraplegia	B	0-10
following	O	11-20
intrathecal	O	21-32
methotrexate	O	33-45
:	O	45-46
report	O	47-53
of	O	54-56
a	O	57-58
case	O	59-63
and	O	64-67
review	O	68-74
of	O	75-77
the	O	78-81
literature	O	82-92
.	O	92-93

A	O	94-95
patient	O	96-103
who	O	104-107
developed	O	108-117
paraplegia	B	118-128
following	O	129-138
the	O	139-142
intrathecal	O	143-154
instillation	O	155-167
of	O	168-170
methotrexate	O	171-183
is	O	184-186
discribed	O	187-196
.	O	196-197

The	O	198-201
ten	O	202-205
previously	O	206-216
reported	O	217-225
cases	O	226-231
of	O	232-234
this	O	235-239
unusual	O	240-247
complication	O	248-260
are	O	261-264
reviewed	O	265-273
.	O	273-274

The	O	275-278
following	O	279-288
factors	O	289-296
appear	O	297-303
to	O	304-306
predispose	O	307-317
to	O	318-320
the	O	321-324
development	O	325-336
of	O	337-339
this	O	340-344
complication	O	345-357
:	O	357-358
abnormal	O	359-367
cerebrospinal	O	368-381
dynamics	O	382-390
related	O	391-398
to	O	399-401
the	O	402-405
presence	O	406-414
of	O	415-417
central	B	418-425
nervous	I	426-433
system	I	434-440
leukemia	I	441-449
,	O	449-450
and	O	451-454
epidural	O	455-463
cerebrospinal	O	464-477
leakage	O	478-485
;	O	485-486
elevated	O	487-495
cerebrospinal	O	496-509
fluid	O	510-515
methothexate	O	516-528
concentration	O	529-542
related	O	543-550
to	O	551-553
abnormal	O	554-562
cerebrospinal	O	563-576
fluid	O	577-582
dynamics	O	583-591
and	O	592-595
to	O	596-598
inappropriately	O	599-614
high	O	615-619
methotrexate	O	620-632
doses	O	633-638
based	O	639-644
on	O	645-647
body	O	648-652
surface	O	653-660
area	O	661-665
calculations	O	666-678
in	O	679-681
older	O	682-687
children	O	688-696
and	O	697-700
adults	O	701-707
;	O	707-708
the	O	709-712
presence	O	713-721
of	O	722-724
neurotoxic	B	725-735
preservatives	O	736-749
in	O	750-752
commercially	O	753-765
available	O	766-775
methotrexate	O	776-788
preparations	O	789-801
and	O	802-805
diluents	O	806-814
;	O	814-815
and	O	816-819
the	O	820-823
use	O	824-827
of	O	828-830
methotrexate	O	831-843
diluents	O	844-852
of	O	853-855
unphysiologic	O	856-869
pH	O	870-872
,	O	872-873
ionic	O	874-879
content	O	880-887
and	O	888-891
osmolarity	O	892-902
.	O	902-903

The	O	904-907
role	O	908-912
of	O	913-915
methotrexate	O	916-928
contaminants	O	929-941
,	O	941-942
local	O	943-948
folate	B	949-955
deficiency	I	956-966
,	O	966-967
and	O	968-971
cranial	O	972-979
irradiation	O	980-991
in	O	992-994
the	O	995-998
pathogenesis	O	999-1011
of	O	1012-1014
intrathecal	O	1015-1026
methotrexate	O	1027-1039
toxicity	B	1040-1048
is	O	1049-1051
unclear	O	1052-1059
.	O	1059-1060

The	O	1061-1064
incidence	O	1065-1074
of	O	1075-1077
neurotoxicity	B	1078-1091
may	O	1092-1095
be	O	1096-1098
reduced	O	1099-1106
by	O	1107-1109
employing	O	1110-1119
lower	O	1120-1125
doses	O	1126-1131
of	O	1132-1134
methotrexate	O	1135-1147
in	O	1148-1150
the	O	1151-1154
presence	O	1155-1163
of	O	1164-1166
central	B	1167-1174
nervous	I	1175-1182
system	I	1183-1189
leukemia	I	1190-1198
,	O	1198-1199
in	O	1200-1202
older	O	1203-1208
children	O	1209-1217
and	O	1218-1221
adults	O	1222-1228
,	O	1228-1229
and	O	1230-1233
in	O	1234-1236
the	O	1237-1240
presence	O	1241-1249
of	O	1250-1252
epidural	O	1253-1261
leakage	O	1262-1269
.	O	1269-1270

Only	O	1271-1275
preservative	O	1276-1288
-	O	1288-1289
free	O	1289-1293
methotrexate	O	1294-1306
in	O	1307-1309
Elliott	O	1310-1317
'	O	1317-1318
s	O	1318-1319
B	O	1320-1321
Solution	O	1322-1330
at	O	1331-1333
a	O	1334-1335
concentration	O	1336-1349
of	O	1350-1352
not	O	1353-1356
more	O	1357-1361
than	O	1362-1366
1	O	1367-1368
mg	O	1369-1371
/	O	1371-1372
ml	O	1372-1374
should	O	1375-1381
be	O	1382-1384
used	O	1385-1389
for	O	1390-1393
intrathecal	O	1394-1405
administration	O	1406-1420
.	O	1420-1421

Periodic	O	1422-1430
monitoring	O	1431-1441
of	O	1442-1444
cerebruspinal	O	1445-1458
fluid	O	1459-1464
methotrexate	O	1465-1477
levels	O	1478-1484
may	O	1485-1488
be	O	1489-1491
predictive	O	1492-1502
of	O	1503-1505
the	O	1506-1509
development	O	1510-1521
of	O	1522-1524
serious	O	1525-1532
neurotoxicity	B	1533-1546
.	O	1546-1547

Centrally	O	0-9
mediated	O	10-18
cardiovascular	O	19-33
effects	O	34-41
of	O	42-44
intracisternal	O	45-59
application	O	60-71
of	O	72-74
carbachol	O	75-84
in	O	85-87
anesthetized	O	88-100
rats	O	101-105
.	O	105-106

The	O	107-110
pressor	O	111-118
response	O	119-127
to	O	128-130
the	O	131-134
intracisternal	O	135-149
(	O	150-151
i	O	151-152
.	O	152-153
c	O	153-154
.	O	152-153
)	O	155-156
injection	O	157-166
of	O	167-169
carbachol	O	170-179
(	O	180-181
1	O	181-182
mug	O	183-186
)	O	186-187
in	O	188-190
anesthetized	O	191-203
rats	O	204-208
was	O	209-212
analyzed	O	213-221
.	O	221-222

This	O	223-227
response	O	228-236
was	O	237-240
significantly	O	241-254
reduced	O	255-262
by	O	263-265
the	O	266-269
intravenous	O	270-281
(	O	282-283
i	O	283-284
.	O	284-285
v	O	285-286
.	O	284-285
)	O	287-288
injection	O	289-298
of	O	299-301
guanethidine	O	302-314
(	O	315-316
5	O	316-317
mg	O	318-320
)	O	320-321
,	O	321-322
hexamethonium	O	323-336
(	O	337-338
10	O	338-340
mg	O	341-343
)	O	343-344
or	O	345-347
phentolamine	O	348-360
(	O	361-362
5	O	362-363
mg	O	364-366
)	O	366-367
,	O	367-368
and	O	369-372
conversely	O	373-383
,	O	383-384
potentiated	O	385-396
by	O	397-399
i	O	400-401
.	O	401-402
v	O	402-403
.	O	401-402

desmethylimipramine	O	405-424
(	O	425-426
0	O	426-427
.	O	427-428
3	O	428-429
mg	O	430-432
)	O	432-433
,	O	433-434
while	O	435-440
propranolol	O	441-452
(	O	453-454
0	O	454-455
.	O	455-456
5	O	456-457
mg	O	458-460
)	O	460-461
i	O	462-463
.	O	463-464
v	O	464-465
.	O	463-464

selectively	O	467-478
inhibited	O	479-488
the	O	489-492
enlargement	B	493-504
of	I	505-507
pulse	I	508-513
pressure	I	514-522
and	O	523-526
the	O	527-530
tachycardia	B	531-542
following	O	543-552
i	O	553-554
.	O	554-555
c	O	555-556
.	O	554-555

carbachol	O	558-567
(	O	568-569
1	O	569-570
mug	O	571-574
)	O	574-575
.	O	575-576

On	O	577-579
the	O	580-583
other	O	584-589
hand	O	590-594
,	O	594-595
the	O	596-599
pressor	O	600-607
response	O	608-616
to	O	617-619
i	O	620-621
.	O	621-622
c	O	622-623
.	O	621-622

carbachol	O	625-634
(	O	635-636
1	O	636-637
mug	O	638-641
)	O	641-642
was	O	643-646
almost	O	647-653
completely	O	654-664
blocked	O	665-672
by	O	673-675
i	O	676-677
.	O	677-678
c	O	678-679
.	O	677-678

atropine	O	681-689
(	O	690-691
3	O	691-692
mug	O	693-696
)	O	696-697
or	O	698-700
hexamethonium	O	701-714
(	O	715-716
500	O	716-719
mug	O	720-723
)	O	723-724
,	O	724-725
and	O	726-729
significantly	O	730-743
reduced	O	744-751
by	O	752-754
i	O	755-756
.	O	756-757
c	O	757-758
.	O	756-757

chlorpromazine	O	760-774
(	O	775-776
50	O	776-778
mug	O	779-782
)	O	782-783
but	O	784-787
significantly	O	788-801
potentiated	O	802-813
by	O	814-816
i	O	817-818
.	O	818-819
c	O	819-820
.	O	818-819

desmethylimipramine	O	822-841
(	O	842-843
30	O	843-845
mug	O	846-849
)	O	849-850
.	O	850-851

The	O	852-855
pressor	O	856-863
response	O	864-872
to	O	873-875
i	O	876-877
.	O	877-878
c	O	878-879
.	O	877-878

carbachol	O	881-890
(	O	891-892
1	O	892-893
mug	O	894-897
)	O	897-898
remained	O	899-907
unchanged	O	908-917
after	O	918-923
sectioning	O	924-934
of	O	935-937
the	O	938-941
bilateral	O	942-951
cervical	O	952-960
vagal	O	961-966
nerves	O	967-973
but	O	974-977
disappeared	O	978-989
after	O	990-995
sectioning	O	996-1006
of	O	1007-1009
the	O	1010-1013
spinal	O	1014-1020
cord	O	1021-1025
(	O	1026-1027
C7	O	1027-1029
-	O	1029-1030
C8	O	1030-1032
)	O	1032-1033
.	O	1033-1034

From	O	1035-1039
the	O	1040-1043
above	O	1044-1049
result	O	1050-1056
it	O	1057-1059
is	O	1060-1062
suggested	O	1063-1072
that	O	1073-1077
the	O	1078-1081
pressor	O	1082-1089
response	O	1090-1098
to	O	1099-1101
i	O	1102-1103
.	O	1103-1104
c	O	1104-1105
.	O	1103-1104

carbachol	O	1107-1116
ortral	O	1117-1123
and	O	1124-1127
peripheral	O	1128-1138
adrenergic	O	1139-1149
mechanisms	O	1150-1160
,	O	1160-1161
and	O	1162-1165
that	O	1166-1170
the	O	1171-1174
sympathetic	O	1175-1186
trunk	O	1187-1192
is	O	1193-1195
the	O	1196-1199
main	O	1200-1204
pathway	O	1205-1212
.	O	1212-1213

Hyperglycemic	B	0-13
effect	O	14-20
of	O	21-23
amino	O	24-29
compounds	O	30-39
structurally	O	40-52
related	O	53-60
to	O	61-63
caproate	O	64-72
in	O	73-75
rats	O	76-80
.	O	80-81

The	O	82-85
chronic	O	86-93
feeding	O	94-101
of	O	102-104
small	O	105-110
amounts	O	111-118
(	O	119-120
0	O	120-121
.	O	121-122
3	O	122-123
-	O	123-124
3	O	122-123
%	O	125-126
of	O	127-129
diet	O	130-134
weight	O	135-141
)	O	141-142
of	O	143-145
certain	O	146-153
amino	O	154-159
derivatives	O	160-171
of	O	172-174
caproate	O	175-183
resulted	O	184-192
in	O	193-195
hyperglycemia	B	196-209
,	O	209-210
an	O	211-213
elevated	O	214-222
glucose	O	223-230
tolerance	O	231-240
curve	O	241-246
and	O	247-250
,	O	250-251
occasionally	O	252-264
,	O	264-265
glucosuria	B	266-276
.	O	276-277

Effective	O	278-287
compounds	O	288-297
included	O	298-306
norleucine	O	307-317
,	O	317-318
norvaline	O	319-328
,	O	328-329
glutamate	O	330-339
,	O	339-340
epsilon	O	341-348
-	O	348-349
aminocaproate	O	349-362
,	O	362-363
methionine	O	364-374
,	O	374-375
and	O	376-379
leucine	O	380-387
.	O	387-388

Fatty	B	0-5
liver	I	6-11
induced	O	12-19
by	O	20-22
tetracycline	O	23-35
in	O	36-38
the	O	39-42
rat	O	43-46
.	O	46-47

Dose	O	48-52
-	O	52-53
response	O	53-61
relationships	O	62-75
and	O	76-79
effect	O	80-86
of	O	87-89
sex	O	90-93
.	O	93-94

Dose	O	95-99
-	O	99-100
response	O	100-108
relationships	O	109-122
,	O	122-123
biochemical	O	124-135
mechanisms	O	136-146
,	O	146-147
and	O	148-151
sex	O	152-155
differences	O	156-167
in	O	168-170
the	O	171-174
experimental	O	175-187
fatty	B	188-193
liver	I	194-199
induced	O	200-207
by	O	208-210
tetracycline	O	211-223
were	O	224-228
studied	O	229-236
in	O	237-239
the	O	240-243
intact	O	244-250
rat	O	251-254
and	O	255-258
with	O	259-263
the	O	264-267
isolated	O	268-276
perfused	O	277-285
rat	O	286-289
liver	O	290-295
in	O	296-298
vitro	O	299-304
.	O	304-305

In	O	306-308
the	O	309-312
intact	O	313-319
male	O	320-324
and	O	325-328
female	O	329-335
rat	O	336-339
,	O	339-340
no	O	341-343
direct	O	344-350
relationship	O	351-363
was	O	364-367
observed	O	368-376
between	O	377-384
dose	O	385-389
of	O	390-392
tetracycline	O	393-405
and	O	406-409
hepatic	O	410-417
accumulation	O	418-430
of	O	431-433
triglyceride	O	434-446
.	O	446-447

With	O	448-452
provision	O	453-462
of	O	463-465
adequate	O	466-474
oleic	O	475-480
acid	O	481-485
as	O	486-488
a	O	489-490
substrate	O	491-500
for	O	501-504
the	O	505-508
isolated	O	509-517
perfused	O	518-526
liver	O	527-532
,	O	532-533
a	O	534-535
direct	O	536-542
relationship	O	543-555
was	O	556-559
observed	O	560-568
between	O	569-576
dose	O	577-581
of	O	582-584
tetracycline	O	585-597
and	O	598-601
both	O	602-606
accumulation	O	607-619
of	O	620-622
triglyceride	O	623-635
in	O	636-638
the	O	639-642
liver	O	643-648
and	O	649-652
depression	B	653-663
of	O	664-666
output	O	667-673
of	O	674-676
triglyceride	O	677-689
by	O	690-692
livers	O	693-699
from	O	700-704
male	O	705-709
and	O	710-713
female	O	714-720
rats	O	721-725
.	O	725-726

Marked	O	727-733
differences	O	734-745
were	O	746-750
observed	O	751-759
between	O	760-767
female	O	768-774
and	O	775-778
male	O	779-783
rats	O	784-788
with	O	789-793
regard	O	794-800
to	O	801-803
base	O	804-808
line	O	809-813
(	O	814-815
control	O	815-822
)	O	822-823
hepatic	O	824-831
concentration	O	832-845
of	O	846-848
triglyceride	O	849-861
and	O	862-865
output	O	866-872
of	O	873-875
triglyceride	O	876-888
.	O	888-889

Accumulation	O	890-902
of	O	903-905
hepatic	O	906-913
triglyceride	O	914-926
,	O	926-927
as	O	928-930
a	O	931-932
per	O	933-936
cent	O	937-941
of	O	942-944
control	O	945-952
values	O	953-959
,	O	959-960
in	O	961-963
response	O	964-972
to	O	973-975
graded	O	976-982
doses	O	983-988
of	O	989-991
tetracycline	O	992-1004
,	O	1004-1005
did	O	1006-1009
not	O	1010-1013
differ	O	1014-1020
significantly	O	1021-1034
between	O	1035-1042
male	O	1043-1047
,	O	1047-1048
female	O	1049-1055
and	O	1056-1059
pregnant	O	1060-1068
rat	O	1069-1072
livers	O	1073-1079
.	O	1079-1080

However	O	1081-1088
,	O	1088-1089
livers	O	1090-1096
from	O	1097-1101
female	O	1102-1108
,	O	1108-1109
and	O	1110-1113
especially	O	1114-1124
pregnant	O	1125-1133
female	O	1134-1140
rats	O	1141-1145
,	O	1145-1146
were	O	1147-1151
strikingly	O	1152-1162
resistant	O	1163-1172
to	O	1173-1175
the	O	1176-1179
effects	O	1180-1187
of	O	1188-1190
tetracycline	O	1191-1203
on	O	1204-1206
depression	B	1207-1217
of	O	1218-1220
output	O	1221-1227
of	O	1228-1230
triglyceride	O	1231-1243
under	O	1244-1249
these	O	1250-1255
experimental	O	1256-1268
conditions	O	1269-1279
.	O	1279-1280

These	O	1281-1286
differences	O	1287-1298
between	O	1299-1306
the	O	1307-1310
sexes	O	1311-1316
could	O	1317-1322
not	O	1323-1326
be	O	1327-1329
related	O	1330-1337
to	O	1338-1340
altered	O	1341-1348
disposition	O	1349-1360
of	O	1361-1363
tetracycline	O	1364-1376
or	O	1377-1379
altered	O	1380-1387
uptake	O	1388-1394
of	O	1395-1397
oleic	O	1398-1403
acid	O	1404-1408
.	O	1408-1409

Depressed	O	1410-1419
hepatic	O	1420-1427
secretion	O	1428-1437
of	O	1438-1440
triglyceride	O	1441-1453
accounted	O	1454-1463
only	O	1464-1468
for	O	1469-1472
30	O	1473-1475
to	O	1476-1478
50	O	1479-1481
%	O	1481-1482
of	O	1483-1485
accumulated	O	1486-1497
hepatic	O	1498-1505
triglyceride	O	1506-1518
,	O	1518-1519
indicating	O	1520-1530
that	O	1531-1535
additional	O	1536-1546
mechanisms	O	1547-1557
must	O	1558-1562
be	O	1563-1565
involved	O	1566-1574
in	O	1575-1577
the	O	1578-1581
production	O	1582-1592
of	O	1593-1595
the	O	1596-1599
triglyceride	O	1600-1612
-	O	1612-1613
rich	O	1613-1617
fatty	B	1618-1623
liver	I	1624-1629
in	O	1630-1632
response	O	1633-1641
to	O	1642-1644
tetracycline	O	1645-1657
.	O	1657-1658

Fatal	O	0-5
myeloencephalopathy	B	6-25
due	O	26-29
to	O	30-32
intrathecal	O	33-44
vincristine	O	45-56
administration	O	57-71
.	O	71-72

Vincristine	O	73-84
was	O	85-88
accidentally	O	89-101
given	O	102-107
intrathecally	O	108-121
to	O	122-124
a	O	125-126
child	O	127-132
with	O	133-137
leukaemia	B	138-147
,	O	147-148
producing	O	149-158
sensory	B	159-166
and	I	167-170
motor	I	171-176
dysfunction	I	177-188
followed	O	189-197
by	O	198-200
encephalopathy	B	201-215
and	O	216-219
death	O	220-225
.	O	225-226

Separate	O	227-235
times	O	236-241
for	O	242-245
administering	O	246-259
vincristine	O	260-271
and	O	272-275
intrathecal	O	276-287
therapy	O	288-295
is	O	296-298
recommended	O	299-310
.	O	310-311

Progesterone	O	0-12
potentiation	O	13-25
of	O	26-28
bupivacaine	O	29-40
arrhythmogenicity	O	41-58
in	O	59-61
pentobarbital	O	62-75
-	O	75-76
anesthetized	O	76-88
rats	O	89-93
and	O	94-97
beating	O	98-105
rat	O	106-109
heart	O	110-115
cell	O	116-120
cultures	O	121-129
.	O	129-130

The	O	131-134
effects	O	135-142
of	O	143-145
progesterone	O	146-158
treatment	O	159-168
on	O	169-171
bupivacaine	O	172-183
arrhythmogenicity	O	184-201
in	O	202-204
beating	O	205-212
rat	O	213-216
heart	O	217-222
myocyte	O	223-230
cultures	O	231-239
and	O	240-243
on	O	244-246
anesthetized	O	247-259
rats	O	260-264
were	O	265-269
determined	O	270-280
.	O	280-281

After	O	282-287
determining	O	288-299
the	O	300-303
bupivacaine	O	304-315
AD50	O	316-320
(	O	321-322
the	O	322-325
concentration	O	326-339
of	O	340-342
bupivacaine	O	343-354
that	O	355-359
caused	O	360-366
50	O	367-369
%	O	369-370
of	O	371-373
all	O	374-377
beating	O	378-385
rat	O	386-389
heart	O	390-395
myocyte	O	396-403
cultures	O	404-412
to	O	413-415
become	O	416-422
arrhythmic	B	423-433
)	O	433-434
,	O	434-435
we	O	436-438
determined	O	439-449
the	O	450-453
effect	O	454-460
of	O	461-463
1	O	464-465
-	O	465-466
hour	O	466-470
progesterone	O	471-483
HCl	O	484-487
exposure	O	488-496
on	O	497-499
myocyte	O	500-507
contractile	O	508-519
rhythm	O	520-526
.	O	526-527

Each	O	528-532
concentration	O	533-546
of	O	547-549
progesterone	O	550-562
(	O	563-564
6	O	564-565
.	O	565-566
25	O	566-568
,	O	568-569
12	O	570-572
.	O	572-573
5	O	573-574
,	O	574-575
25	O	576-578
,	O	578-579
and	O	580-583
50	O	584-586
micrograms	O	587-597
/	O	597-598
ml	O	598-600
)	O	600-601
caused	O	602-608
a	O	609-610
significant	O	611-622
and	O	623-626
concentration	O	627-640
-	O	640-641
dependent	O	641-650
reduction	O	651-660
in	O	661-663
the	O	664-667
AD50	O	668-672
for	O	673-676
bupivacaine	O	677-688
.	O	688-689

Estradiol	O	690-699
treatment	O	700-709
also	O	710-714
increased	O	715-724
the	O	725-728
arrhythmogenicity	O	729-746
of	O	747-749
bupivacaine	O	750-761
in	O	762-764
myocyte	O	765-772
cultures	O	773-781
,	O	781-782
but	O	783-786
was	O	787-790
only	O	791-795
one	O	796-799
fourth	O	800-806
as	O	807-809
potent	O	810-816
as	O	817-819
progesterone	O	820-832
.	O	832-833

Neither	O	834-841
progesterone	O	842-854
nor	O	855-858
estradiol	O	859-868
effects	O	869-876
on	O	877-879
bupivacaine	O	880-891
arrhythmogenicity	O	892-909
were	O	910-914
potentiated	O	915-926
by	O	927-929
epinephrine	O	930-941
.	O	941-942

Chronic	O	943-950
progesterone	O	951-963
pretreatment	O	964-976
(	O	977-978
5	O	978-979
mg	O	980-982
/	O	982-983
kg	O	983-985
/	O	982-983
day	O	986-989
for	O	990-993
21	O	994-996
days	O	997-1001
)	O	1001-1002
caused	O	1003-1009
a	O	1010-1011
significant	O	1012-1023
increase	O	1024-1032
in	O	1033-1035
bupivacaine	O	1036-1047
arrhythmogenicity	O	1048-1065
in	O	1066-1068
intact	O	1069-1075
pentobarbital	O	1076-1089
-	O	1089-1090
anesthetized	O	1090-1102
rats	O	1103-1107
.	O	1107-1108

There	O	1109-1114
was	O	1115-1118
a	O	1119-1120
significant	O	1121-1132
decrease	O	1133-1141
in	O	1142-1144
the	O	1145-1148
time	O	1149-1153
to	O	1154-1156
onset	O	1157-1162
of	O	1163-1165
arrhythmia	B	1166-1176
as	O	1177-1179
compared	O	1180-1188
with	O	1189-1193
control	O	1194-1201
nonprogesterone	O	1202-1217
-	O	1217-1218
treated	O	1218-1225
rats	O	1226-1230
(	O	1231-1232
6	O	1232-1233
.	O	1233-1234
2	O	1234-1235
+	O	1236-1237
/	O	1237-1238
-	O	1238-1239
1	O	1240-1241
.	O	1241-1242
3	O	1242-1243
vs	O	1244-1246
.	O	1246-1247
30	O	1248-1250
.	O	1250-1251
8	O	1251-1252

+	O	1253-1254
/	O	1254-1255
-	O	1255-1256
2	O	1257-1258
.	O	1258-1259
5	O	1259-1260
min	O	1261-1264
,	O	1264-1265
mean	O	1266-1270
+	O	1271-1272
/	O	1272-1273
-	O	1273-1274
SE	O	1275-1277
)	O	1277-1278
.	O	1278-1279

The	O	1280-1283
results	O	1284-1291
of	O	1292-1294
this	O	1295-1299
study	O	1300-1305
indicate	O	1306-1314
that	O	1315-1319
progesterone	O	1320-1332
can	O	1333-1336
potentiate	O	1337-1347
bupivacaine	O	1348-1359
arrhythmogenicity	O	1360-1377
both	O	1378-1382
in	O	1383-1385
vivo	O	1386-1390
and	O	1391-1394
in	O	1395-1397
vitro	O	1398-1403
.	O	1403-1404

Potentiation	O	1405-1417
of	O	1418-1420
bupivacaine	O	1421-1432
arrhythmia	B	1433-1443
in	O	1444-1446
myocyte	O	1447-1454
cultures	O	1455-1463
suggests	O	1464-1472
that	O	1473-1477
this	O	1478-1482
effect	O	1483-1489
is	O	1490-1492
at	O	1493-1495
least	O	1496-1501
partly	O	1502-1508
mediated	O	1509-1517
at	O	1518-1520
the	O	1521-1524
myocyte	O	1525-1532
level	O	1533-1538
.	O	1538-1539

Acute	B	0-5
renal	I	6-11
failure	I	12-19
occurring	O	20-29
during	O	30-36
intravenous	O	37-48
desferrioxamine	O	49-64
therapy	O	65-72
:	O	72-73
recovery	O	74-82
after	O	83-88
haemodialysis	O	89-102
.	O	102-103

A	O	104-105
patient	O	106-113
with	O	114-118
transfusion	O	119-130
-	O	130-131
dependent	O	131-140
thalassemia	B	141-152
was	O	153-156
undergoing	O	157-167
home	O	168-172
intravenous	O	173-184
desferrioxamine	O	185-200
(	O	201-202
DFX	O	202-205
)	O	205-206
treatment	O	207-216
by	O	217-219
means	O	220-225
of	O	226-228
a	O	229-230
totally	O	231-238
implanted	O	239-248
system	O	249-255
because	O	256-263
of	O	264-266
his	O	267-270
poor	O	271-275
compliance	O	276-286
with	O	287-291
the	O	292-295
nightly	O	296-303
subcutaneous	O	304-316
therapy	O	317-324
.	O	324-325

Due	O	326-329
to	O	330-332
an	O	333-335
accidental	O	336-346
malfunctioning	O	347-361
of	O	362-364
the	O	365-368
infusion	O	369-377
pump	O	378-382
,	O	382-383
the	O	384-387
patient	O	388-395
was	O	396-399
inadvertently	O	400-413
administered	O	414-426
a	O	427-428
toxic	O	429-434
dosage	O	435-441
of	O	442-444
the	O	445-448
drug	O	449-453
which	O	454-459
caused	O	460-466
renal	B	467-472
insufficiency	I	473-486
.	O	486-487

Given	O	488-493
the	O	494-497
progressive	O	498-509
deterioration	O	510-523
of	O	524-526
the	O	527-530
symptoms	O	531-539
and	O	540-543
of	O	544-546
the	O	547-550
laboratory	O	551-561
values	O	562-568
,	O	568-569
despite	O	570-577
adequate	O	578-586
medical	O	587-594
treatment	O	595-604
,	O	604-605
a	O	606-607
decision	O	608-616
was	O	617-620
made	O	621-625
to	O	626-628
introduce	O	629-638
haemodialytical	O	639-654
therapy	O	655-662
in	O	663-665
order	O	666-671
to	O	672-674
remove	O	675-681
the	O	682-685
drug	O	686-690
and	O	691-694
therapy	O	695-702
reduce	O	703-709
the	O	710-713
nephrotoxicity	B	714-728
.	O	728-729

From	O	730-734
the	O	735-738
results	O	739-746
obtained	O	747-755
,	O	755-756
haemodialysis	O	757-770
can	O	771-774
therefore	O	775-784
be	O	785-787
suggested	O	788-797
as	O	798-800
a	O	801-802
useful	O	803-809
therapy	O	810-817
in	O	818-820
rare	O	821-825
cases	O	826-831
of	O	832-834
progressive	O	835-846
acute	B	847-852
renal	I	853-858
failure	I	859-866
caused	O	867-873
by	O	874-876
desferrioxamine	O	877-892
.	O	892-893

Neuroleptic	O	0-11
-	O	11-12
associated	O	12-22
hyperprolactinemia	B	23-41
.	O	41-42

Can	O	43-46
it	O	47-49
be	O	50-52
treated	O	53-60
with	O	61-65
bromocriptine	O	66-79
?	O	79-80

Six	O	81-84
stable	O	85-91
psychiatric	O	92-103
outpatients	O	104-115
with	O	116-120
hyperprolactinemia	B	121-139
and	O	140-143
amenorrhea	B	144-154
/	O	154-155
oligomenorrhea	B	155-169
associated	O	170-180
with	O	181-185
their	O	186-191
neuroleptic	O	192-203
medications	O	204-215
were	O	216-220
treated	O	221-228
with	O	229-233
bromocriptine	O	234-247
.	O	247-248

Daily	O	249-254
dosages	O	255-262
of	O	263-265
5	O	266-267
-	O	267-268
10	O	268-270
mg	O	271-273
corrected	O	274-283
the	O	284-287
hyperprolactinemia	B	288-306
and	O	307-310
restored	O	311-319
menstruation	O	320-332
in	O	333-335
four	O	336-340
of	O	341-343
the	O	344-347
six	O	348-351
patients	O	352-360
.	O	360-361

One	O	362-365
woman	O	366-371
,	O	371-372
however	O	373-380
,	O	380-381
developed	O	382-391
worsened	O	392-400
psychiatric	B	401-412
symptoms	I	413-421
while	O	422-427
taking	O	428-434
bromocriptine	O	435-448
,	O	448-449
and	O	450-453
it	O	454-456
was	O	457-460
discontinued	O	461-473
.	O	473-474

Thus	O	475-479
,	O	479-480
three	O	481-486
of	O	487-489
six	O	490-493
patients	O	494-502
had	O	503-506
their	O	507-512
menstrual	O	513-522
irregularity	O	523-535
successfully	O	536-548
corrected	O	549-558
with	O	559-563
bromocriptine	O	564-577
.	O	577-578

This	O	579-583
suggests	O	584-592
that	O	593-597
bromocriptine	O	598-611
should	O	612-618
be	O	619-621
further	O	622-629
evaluated	O	630-639
as	O	640-642
potential	O	643-652
therapy	O	653-660
for	O	661-664
neuroleptic	O	665-676
-	O	676-677
associated	O	677-687
hyperprolactinemia	B	688-706
and	O	707-710
amenorrhea	B	711-721
/	O	721-722
galactorrhea	B	722-734
.	O	734-735

Ethacrynic	O	0-10
acid	O	11-15
-	O	15-16
induced	O	16-23
convulsions	B	24-35
and	O	36-39
brain	O	40-45
neurotransmitters	O	46-63
in	O	64-66
mice	O	67-71
.	O	71-72

Intracerebroventricular	O	73-96
injection	O	97-106
of	O	107-109
ethacrynic	O	110-120
acid	O	121-125
(	O	126-127
50	O	127-129
%	O	129-130
convulsive	B	131-141
dose	O	142-146
;	O	146-147
50	O	148-150
micrograms	O	151-161
/	O	161-162
mouse	O	162-167
)	O	167-168
accelerated	O	169-180
the	O	181-184
synthesis	O	185-194
/	O	194-195
turnover	O	195-203
of	O	204-206
5	O	207-208
-	O	208-209
hydroxytryptamine	O	209-226
(	O	227-228
5	O	228-229
-	O	229-230
HT	O	230-232
)	O	232-233
but	O	234-237
suppressed	O	238-248
the	O	249-252
synthesis	O	253-262
of	O	263-265
gamma	O	266-271
-	O	271-272
aminobutyric	O	272-284
acid	O	285-289
and	O	290-293
acetylcholine	O	294-307
in	O	308-310
mouse	O	311-316
brain	O	317-322
.	O	322-323

These	O	324-329
effects	O	330-337
were	O	338-342
completely	O	343-353
antagonized	O	354-365
by	O	366-368
pretreatment	O	369-381
with	O	382-386
a	O	387-388
glutamate	O	389-398
/	O	398-399
N	O	399-400
-	O	400-401
methyl	O	401-407
-	O	400-401
D	O	408-409
-	O	400-401
aspartate	O	410-419
antagonist	O	420-430
,	O	430-431
aminophosphonovaleric	O	432-453
acid	O	454-458
.	O	458-459

In	O	460-462
ethacrynic	O	463-473
acid	O	474-478
-	O	478-479
induced	O	479-486
convulsions	B	487-498
,	O	498-499
these	O	500-505
neurotransmitter	O	506-522
systems	O	523-530
may	O	531-534
be	O	535-537
differentially	O	538-552
modulated	O	553-562
,	O	562-563
probably	O	564-572
through	O	573-580
activation	O	581-591
of	O	592-594
glutaminergic	O	595-608
neurons	O	609-616
in	O	617-619
the	O	620-623
brain	O	624-629
.	O	629-630

Pharmacology	O	0-12
of	O	13-15
gamma	O	16-21
-	O	21-22
aminobutyric	O	22-34
acidA	O	35-40
receptor	O	41-49
complex	O	50-57
after	O	58-63
the	O	64-67
in	O	68-70
vivo	O	71-75
administration	O	76-90
of	O	91-93
the	O	94-97
anxioselective	O	98-112
and	O	113-116
anticonvulsant	O	117-131
beta	O	132-136
-	O	136-137
carboline	O	137-146
derivative	O	147-157
abecarnil	O	158-167
.	O	167-168

In	O	169-171
rodents	O	172-179
,	O	179-180
the	O	181-184
effect	O	185-191
of	O	192-194
the	O	195-198
beta	O	199-203
-	O	203-204
carboline	O	204-213
derivative	O	214-224
isopropyl	O	225-234
-	O	234-235
6	O	235-236
-	O	234-235
benzyloxy	O	238-247
-	O	247-248
4	O	248-249
-	O	247-248
methoxymethyl	O	250-263
-	O	247-248
beta	O	264-268
-	O	247-248
carboline	O	269-278
-	O	247-248
3	O	279-280
-	O	247-248
carboxylate	O	281-292
(	O	293-294
abecarrnil	O	294-304
)	O	304-305
,	O	305-306
a	O	307-308
new	O	309-312
ligand	O	313-319
for	O	320-323
benzodiazepine	O	324-338
receptors	O	339-348
possessing	O	349-359
anxiolytic	O	360-370
and	O	371-374
anticonvulsant	O	375-389
properties	O	390-400
,	O	400-401
was	O	402-405
evaluated	O	406-415
on	O	416-418
the	O	419-422
function	O	423-431
of	O	432-434
central	O	435-442
gamma	O	443-448
-	O	448-449
aminobutyric	O	449-461
acid	O	462-466
(	O	467-468
GABA	O	468-472
)	O	472-473
A	O	469-470
receptor	O	475-483
complex	O	484-491
,	O	491-492
both	O	493-497
in	O	498-500
vitro	O	501-506
and	O	507-510
in	O	511-513
vivo	O	514-518
.	O	518-519

Added	O	520-525
in	O	526-528
vitro	O	529-534
to	O	535-537
rat	O	538-541
cortical	O	542-550
membrane	O	551-559
preparation	O	560-571
,	O	571-572
abecarnil	O	573-582
increased	O	583-592
[	O	593-594
3H	O	594-596
]	O	596-597
GABA	O	597-601
binding	O	602-609
,	O	609-610
enhanced	O	611-619
muscimol	O	620-628
-	O	628-629
stimulated	O	629-639
36Cl	O	640-644
-	O	644-645
uptake	O	646-652
and	O	653-656
reduced	O	657-664
the	O	665-668
binding	O	669-676
of	O	677-679
t	O	680-681
-	O	681-682
[	O	682-683
35S	O	683-686
]	O	686-687
butylbicyclophosphorothionate	O	687-716
(	O	717-718
[	O	718-719
35S	O	719-722
]	O	722-723
TBPS	O	723-727
)	O	727-728
.	O	728-729

These	O	730-735
effects	O	736-743
were	O	744-748
similar	O	749-756
to	O	757-759
those	O	760-765
induced	O	766-773
by	O	774-776
diazepam	O	777-785
,	O	785-786
whereas	O	787-794
the	O	795-798
partial	O	799-806
agonist	O	807-814
Ro	O	815-817
16	O	818-820
-	O	820-821
6028	O	821-825
(	O	826-827
tert	O	827-831
-	O	831-832
butyl	O	832-837
-	O	831-832
(	O	826-827
S	O	839-840
)	O	840-841
-	O	831-832
8	O	842-843
-	O	831-832
bromo	O	844-849
-	O	831-832
11	O	850-852
,	O	852-853
12	O	853-855
,	O	852-853
13	O	856-858
,	O	852-853
13a	O	859-862
-	O	831-832
tetrahydro	O	863-873
-	O	831-832
9	O	874-875
-	O	831-832
oxo	O	876-879
-	O	831-832
9H	O	880-882
-	O	831-832
imidazo	O	884-891
[	O	891-892
1	O	892-893
,	O	893-894
5	O	894-895
-	O	895-896
a	O	888-889
]	O	897-898
-	O	895-896
pyrrolo	O	899-906
-	O	895-896
[	O	891-892
2	O	908-909
,	O	893-894
1	O	892-893
-	O	895-896
c	O	912-913
]	O	897-898
[	O	891-892
1	O	892-893
,	O	893-894
4	O	917-918
]	O	897-898
benzodiazepine	O	919-933
-	O	895-896
1	O	892-893
-	O	895-896
carboxylate	O	936-947
)	O	947-948
showed	O	949-955
very	O	956-960
weak	O	961-965
efficacy	O	966-974
in	O	975-977
these	O	978-983
biochemical	O	984-995
tests	O	996-1001
.	O	1001-1002

After	O	1003-1008
i	O	1009-1010
.	O	1010-1011
p	O	1011-1012
.	O	1010-1011
injection	O	1014-1023
to	O	1024-1026
rats	O	1027-1031
,	O	1031-1032
abecarnil	O	1033-1042
and	O	1043-1046
diazepam	O	1047-1055
decreased	O	1056-1065
in	O	1066-1068
a	O	1069-1070
time	O	1071-1075
-	O	1075-1076
dependent	O	1076-1085
and	O	1086-1089
dose	O	1090-1094
-	O	1094-1095
related	O	1095-1102
(	O	1103-1104
0	O	1104-1105
.	O	1105-1106
25	O	1106-1108
-	O	1108-1109
20	O	1109-1111
mg	O	1112-1114
/	O	1114-1115
kg	O	1115-1117
i	O	1118-1119
.	O	1119-1120
p	O	1120-1121
.	O	1119-1120
)	O	1122-1123
manner	O	1124-1130
[	O	1131-1132
35S	O	1132-1135
]	O	1135-1136
TBPS	O	1136-1140
binding	O	1141-1148
measured	O	1149-1157
ex	O	1158-1160
vivo	O	1161-1165
in	O	1166-1168
the	O	1169-1172
cerebral	O	1173-1181
cortex	O	1182-1188
.	O	1188-1189

Moreover	O	1190-1198
,	O	1198-1199
both	O	1200-1204
drugs	O	1205-1210
at	O	1211-1213
the	O	1214-1217
dose	O	1218-1222
of	O	1223-1225
0	O	1226-1227
.	O	1227-1228
5	O	1228-1229
mg	O	1230-1232
/	O	1232-1233
kg	O	1233-1235
antagonized	O	1236-1247
completely	O	1248-1258
the	O	1259-1262
convulsant	O	1263-1273
activity	O	1274-1282
and	O	1283-1286
the	O	1287-1290
increase	O	1291-1299
of	O	1300-1302
[	O	1303-1304
35S	O	1304-1307
]	O	1307-1308
TBPS	O	1308-1312
binding	O	1313-1320
induced	O	1321-1328
by	O	1329-1331
isoniazide	O	1332-1342
(	O	1343-1344
350	O	1344-1347
mg	O	1348-1350
/	O	1350-1351
kg	O	1351-1353
s	O	1354-1355
.	O	1355-1356
c	O	1356-1357
.	O	1355-1356
)	O	1358-1359
as	O	1360-1362
well	O	1363-1367
as	O	1368-1370
the	O	1371-1374
increase	O	1375-1383
of	O	1384-1386
[	O	1387-1388
35S	O	1388-1391
]	O	1391-1392
TBPS	O	1392-1396
binding	O	1397-1404
induced	O	1405-1412
by	O	1413-1415
foot	O	1416-1420
-	O	1420-1421
shock	O	1421-1426
stress	O	1427-1433
.	O	1433-1434

To	O	1435-1437
better	O	1438-1444
correlate	O	1445-1454
the	O	1455-1458
biochemical	O	1459-1470
and	O	1471-1474
the	O	1475-1478
pharmacological	O	1479-1494
effects	O	1495-1502
,	O	1502-1503
we	O	1504-1506
studied	O	1507-1514
the	O	1515-1518
action	O	1519-1525
of	O	1526-1528
abecarnil	O	1529-1538
on	O	1539-1541
[	O	1542-1543
35S	O	1543-1546
]	O	1546-1547
TBPS	O	1547-1551
binding	O	1552-1559
,	O	1559-1560
exploratory	O	1561-1572
motility	O	1573-1581
and	O	1582-1585
on	O	1586-1588
isoniazid	O	1589-1598
-	O	1598-1599
induced	O	1599-1606
biochemical	O	1607-1618
and	O	1619-1622
pharmacological	O	1623-1638
effects	O	1639-1646
in	O	1647-1649
mice	O	1650-1654
.	O	1654-1655

In	O	1656-1658
these	O	1659-1664
animals	O	1665-1672
,	O	1672-1673
abecarnil	O	1674-1683
produced	O	1684-1692
a	O	1693-1694
paralleled	O	1695-1705
dose	O	1706-1710
-	O	1710-1711
dependent	O	1711-1720
(	O	1721-1722
0	O	1722-1723
.	O	1723-1724
05	O	1724-1726
-	O	1726-1727
1	O	1727-1728
mg	O	1729-1731
/	O	1731-1732
kg	O	1732-1734
i	O	1735-1736
.	O	1736-1737
p	O	1737-1738
.	O	1736-1737
)	O	1739-1740
reduction	O	1741-1750
of	O	1751-1753
both	O	1754-1758
motor	O	1759-1764
behavior	O	1765-1773
and	O	1774-1777
cortical	O	1778-1786
[	O	1787-1788
35S	O	1788-1791
]	O	1791-1792
TBPS	O	1792-1796
binding	O	1797-1804
.	O	1804-1805

Moreover	O	1806-1814
,	O	1814-1815
0	O	1816-1817
.	O	1817-1818
05	O	1818-1820
mg	O	1821-1823
/	O	1823-1824
kg	O	1824-1826
of	O	1827-1829
this	O	1830-1834
beta	O	1835-1839
-	O	1839-1840
carboline	O	1840-1849
reduced	O	1850-1857
markedly	O	1858-1866
the	O	1867-1870
increase	O	1871-1879
of	O	1880-1882
[	O	1883-1884
35S	O	1884-1887
]	O	1887-1888
TBPS	O	1888-1892
binding	O	1893-1900
and	O	1901-1904
the	O	1905-1908
convulsions	B	1909-1920
induced	O	1921-1928
by	O	1929-1931
isoniazid	O	1932-1941
(	O	1942-1943
200	O	1943-1946
mg	O	1947-1949
/	O	1949-1950
kg	O	1950-1952
s	O	1953-1954
.	O	1954-1955
c	O	1955-1956
.	O	1954-1955
)	O	1957-1958
.	O	1954-1955
(	O	1959-1960
ABSTRACT	O	1960-1968

TRUNCATED	O	1969-1978
AT	O	1979-1981
250	O	1982-1985
WORDS	O	1986-1991
)	O	1991-1992

Recurrent	O	0-9
myocardial	B	10-20
infarction	I	21-31
in	O	32-34
a	O	35-36
postpartum	O	37-47
patient	O	48-55
receiving	O	56-65
bromocriptine	O	66-79
.	O	79-80

Myocardial	B	81-91
infarction	I	92-102
in	O	103-105
puerperium	O	106-116
is	O	117-119
infrequently	O	120-132
reported	O	133-141
.	O	141-142

Spasm	B	143-148
,	O	148-149
coronary	O	150-158
dissection	O	159-169
,	O	169-170
or	O	171-173
atheromatous	O	174-186
etiology	O	187-195
has	O	196-199
been	O	200-204
described	O	205-214
.	O	214-215

Bromocriptine	O	216-229
has	O	230-233
been	O	234-238
implicated	O	239-249
in	O	250-252
several	O	253-260
previous	O	261-269
case	O	270-274
reports	O	275-282
of	O	283-285
myocardial	B	286-296
infarction	I	297-307
in	O	308-310
the	O	311-314
puerperium	O	315-325
.	O	325-326

Our	O	327-330
case	O	331-335
(	O	336-337
including	O	337-346
an	O	347-349
inadvertent	O	350-361
rechallenge	O	362-373
)	O	373-374
suggests	O	375-383
such	O	384-388
a	O	389-390
relationship	O	391-403
.	O	403-404

Although	O	405-413
generally	O	414-423
regarded	O	424-432
as	O	433-435
"	O	436-437
safe	O	437-441
,	O	441-442
"	O	436-437
possible	O	444-452
serious	O	453-460
cardiac	O	461-468
effects	O	469-476
of	O	477-479
bromocriptine	O	480-493
should	O	494-500
be	O	501-503
acknowledged	O	504-516
.	O	516-517

Asterixis	B	0-9
induced	O	10-17
by	O	18-20
carbamazepine	O	21-34
therapy	O	35-42
.	O	42-43

There	O	44-49
are	O	50-53
very	O	54-58
few	O	59-62
reports	O	63-70
about	O	71-76
asterixis	B	77-86
as	O	87-89
a	O	90-91
side	O	92-96
effect	O	97-103
of	O	104-106
treatment	O	107-116
with	O	117-121
psychopharmacologic	O	122-141
agents	O	142-148
.	O	148-149

In	O	150-152
this	O	153-157
report	O	158-164
we	O	165-167
present	O	168-175
four	O	176-180
patients	O	181-189
treated	O	190-197
with	O	198-202
a	O	203-204
combination	O	205-216
of	O	217-219
different	O	220-229
psychotropic	O	230-242
drugs	O	243-248
,	O	248-249
in	O	250-252
whom	O	253-257
asterixis	B	258-267
was	O	268-271
triggered	O	272-281
either	O	282-288
by	O	289-291
adding	O	292-298
carbamazepine	O	299-312
(	O	313-314
CBZ	O	314-317
)	O	317-318
to	O	319-321
a	O	322-323
treatment	O	324-333
regimen	O	334-341
,	O	341-342
or	O	343-345
by	O	346-348
increasing	O	349-359
its	O	360-363
dosage	O	364-370
.	O	370-371

Neither	O	372-379
dosage	O	380-386
nor	O	387-390
serum	O	391-396
levels	O	397-403
of	O	404-406
CBZ	O	407-410
were	O	411-415
in	O	416-418
a	O	419-420
higher	O	421-427
range	O	428-433
.	O	433-434

We	O	435-437
consider	O	438-446
asterixis	B	447-456
to	O	457-459
be	O	460-462
an	O	463-465
easily	O	466-472
overlooked	O	473-483
sign	O	484-488
of	O	489-491
neurotoxicity	B	492-505
,	O	505-506
which	O	507-512
may	O	513-516
occur	O	517-522
even	O	523-527
at	O	528-530
low	O	531-534
or	O	535-537
moderate	O	538-546
dosage	O	547-553
levels	O	554-560
,	O	560-561
if	O	562-564
certain	O	565-572
drugs	O	573-578
as	O	579-581
lithium	O	582-589
or	O	590-592
clozapine	O	593-602
are	O	603-606
used	O	607-611
in	O	612-614
combination	O	615-626
with	O	627-631
CBZ	O	632-635
.	O	635-636

Pharmacodynamics	O	0-16
of	O	17-19
the	O	20-23
hypotensive	B	24-35
effect	O	36-42
of	O	43-45
levodopa	O	46-54
in	O	55-57
parkinsonian	B	58-70
patients	O	71-79
.	O	79-80

Blood	O	81-86
pressure	O	87-95
effects	O	96-103
of	O	104-106
i	O	107-108
.	O	108-109
v	O	109-110
.	O	108-109

levodopa	O	112-120
were	O	121-125
examined	O	126-134
in	O	135-137
parkinsonian	B	138-150
patients	O	151-159
with	O	160-164
stable	O	165-171
and	O	172-175
fluctuating	O	176-187
responses	O	188-197
to	O	198-200
levodopa	O	201-209
.	O	209-210

The	O	211-214
magnitude	O	215-224
of	O	225-227
the	O	228-231
hypotensive	B	232-243
effect	O	244-250
of	O	251-253
levodopa	O	254-262
was	O	263-266
concentration	O	267-280
dependent	O	281-290
and	O	291-294
was	O	295-298
fit	O	299-302
to	O	303-305
an	O	306-308
Emax	O	309-313
model	O	314-319
in	O	320-322
fluctuating	O	323-334
responders	O	335-345
.	O	345-346

Stable	O	347-353
responders	O	354-364
demonstrated	O	365-377
a	O	378-379
small	O	380-385
hypotensive	B	386-397
response	O	398-406
.	O	406-407

Baseline	O	408-416
blood	O	417-422
pressures	O	423-432
were	O	433-437
higher	O	438-444
in	O	445-447
fluctuating	O	448-459
patients	O	460-468
;	O	468-469
a	O	470-471
higher	O	472-478
baseline	O	479-487
blood	O	488-493
pressure	O	494-502
correlated	O	503-513
with	O	514-518
greater	O	519-526
hypotensive	B	527-538
effects	O	539-546
.	O	546-547

Antiparkinsonian	O	548-564
effects	O	565-572
of	O	573-575
levodopa	O	576-584
temporally	O	585-595
correlated	O	596-606
with	O	607-611
blood	O	612-617
pressure	O	618-626
changes	O	627-634
.	O	634-635

Phenylalanine	O	636-649
,	O	649-650
a	O	651-652
large	O	653-658
neutral	O	659-666
amino	O	667-672
acid	O	673-677
(	O	678-679
LNAA	O	679-683
)	O	683-684
competing	O	685-694
with	O	695-699
levodopa	O	700-708
for	O	709-712
transport	O	713-722
across	O	723-729
the	O	730-733
blood	O	734-739
-	O	739-740
brain	O	740-745
barrier	O	746-753
,	O	753-754
reduced	O	755-762
the	O	763-766
hypotensive	B	767-778
and	O	779-782
antiparkinsonian	O	783-799
effects	O	800-807
of	O	808-810
levodopa	O	811-819
.	O	819-820

We	O	821-823
conclude	O	824-832
that	O	833-837
levodopa	O	838-846
has	O	847-850
a	O	851-852
central	O	853-860
hypotensive	B	861-872
action	O	873-879
that	O	880-884
parallels	O	885-894
the	O	895-898
motor	O	899-904
effects	O	905-912
in	O	913-915
fluctuating	O	916-927
patients	O	928-936
.	O	936-937

The	O	938-941
hypotensive	B	942-953
effect	O	954-960
appears	O	961-968
to	O	969-971
be	O	972-974
related	O	975-982
to	O	983-985
the	O	986-989
higher	O	990-996
baseline	O	997-1005
blood	O	1006-1011
pressure	O	1012-1020
we	O	1021-1023
observed	O	1024-1032
in	O	1033-1035
fluctuating	O	1036-1047
patients	O	1048-1056
relative	O	1057-1065
to	O	1066-1068
stable	O	1069-1075
patients	O	1076-1084
.	O	1084-1085

Syndrome	B	0-8
of	I	9-11
inappropriate	I	12-25
secretion	I	26-35
of	I	36-38
antidiuretic	I	39-51
hormone	I	52-59
after	O	60-65
infusional	O	66-76
vincristine	O	77-88
.	O	88-89

A	O	90-91
77	O	92-94
-	O	94-95
year	O	95-99
-	O	94-95
old	O	100-103
woman	O	104-109
with	O	110-114
refractory	O	115-125
multiple	B	126-134
myeloma	I	135-142
was	O	143-146
treated	O	147-154
with	O	155-159
a	O	160-161
4	O	162-163
-	O	163-164
day	O	164-167
continuous	O	168-178
intravenous	O	179-190
infusion	O	191-199
of	O	200-202
vincristine	O	203-214
and	O	215-218
doxorubicin	O	219-230
and	O	231-234
4	O	235-236
days	O	237-241
of	O	242-244
oral	O	245-249
dexamethasone	O	250-263
.	O	263-264

Nine	O	265-269
days	O	270-274
after	O	275-280
her	O	281-284
second	O	285-291
cycle	O	292-297
she	O	298-301
presented	O	302-311
with	O	312-316
lethargy	B	317-325
and	O	326-329
weakness	B	330-338
associated	O	339-349
with	O	350-354
hyponatremia	B	355-367
.	O	367-368

Evaluation	O	369-379
revealed	O	380-388
the	O	389-392
syndrome	B	393-401
of	I	402-404
inappropriate	I	405-418
secretion	I	419-428
of	I	429-431
antidiuretic	I	432-444
hormone	I	445-452
,	O	452-453
which	O	454-459
was	O	460-463
attributed	O	464-474
to	O	475-477
the	O	478-481
vincristine	O	482-493
infusion	O	494-502
.	O	502-503

After	O	504-509
normal	O	510-516
serum	O	517-522
sodium	O	523-529
levels	O	530-536
returned	O	537-545
,	O	545-546
further	O	547-554
doxorubicin	O	555-566
and	O	567-570
dexamethasone	O	571-584
chemotherapy	O	585-597
without	O	598-605
vincristine	O	606-617
did	O	618-621
not	O	622-625
produce	O	626-633
this	O	634-638
complication	O	639-651
.	O	651-652

Heart	B	0-5
failure	I	6-13
:	O	13-14
to	O	15-17
digitalise	O	18-28
or	O	29-31
not	O	32-35
?	O	35-36

The	O	37-40
view	O	41-45
against	O	46-53
.	O	53-54

Despite	O	55-62
extensive	O	63-72
clinical	O	73-81
experience	O	82-92
the	O	93-96
role	O	97-101
of	O	102-104
digoxin	O	105-112
is	O	113-115
still	O	116-121
not	O	122-125
well	O	126-130
defined	O	131-138
.	O	138-139

In	O	140-142
patients	O	143-151
with	O	152-156
atrial	B	157-163
fibrillation	I	164-176
digoxin	O	177-184
is	O	185-187
beneficial	O	188-198
for	O	199-202
ventricular	O	203-214
rate	O	215-219
control	O	220-227
.	O	227-228

For	O	229-232
patients	O	233-241
in	O	242-244
sinus	O	245-250
rhythm	O	251-257
and	O	258-261
heart	B	262-267
failure	I	268-275
the	O	276-279
situation	O	280-289
is	O	290-292
less	O	293-297
clear	O	298-303
.	O	303-304

Digoxin	O	305-312
has	O	313-316
a	O	317-318
narrow	O	319-325
therapeutic	O	326-337
:	O	337-338
toxic	O	338-343
ratio	O	344-349
and	O	350-353
concentrations	O	354-368
are	O	369-372
affected	O	373-381
by	O	382-384
a	O	385-386
number	O	387-393
of	O	394-396
drugs	O	397-402
.	O	402-403

Also	O	404-408
,	O	408-409
digoxin	O	410-417
has	O	418-421
undesirable	O	422-433
effects	O	434-441
such	O	442-446
as	O	447-449
increasing	O	450-460
peripheral	O	461-471
resistance	O	472-482
and	O	483-486
myocardial	O	487-497
demands	O	498-505
,	O	505-506
and	O	507-510
causing	O	511-518
arrhythmias	B	519-530
.	O	530-531

There	O	532-537
is	O	538-540
a	O	541-542
paucity	O	543-550
of	O	551-553
data	O	554-558
from	O	559-563
well	O	564-568
-	O	568-569
designed	O	569-577
trials	O	578-584
.	O	584-585

The	O	586-589
trials	O	590-596
that	O	597-601
are	O	602-605
available	O	606-615
are	O	616-619
generally	O	620-629
small	O	630-635
with	O	636-640
limitations	O	641-652
in	O	653-655
design	O	656-662
and	O	663-666
these	O	667-672
show	O	673-677
variation	O	678-687
in	O	688-690
patient	O	691-698
benefit	O	699-706
.	O	706-707

More	O	708-712
convincing	O	713-723
evidence	O	724-732
is	O	733-735
required	O	736-744
showing	O	745-752
that	O	753-757
digoxin	O	758-765
improves	O	766-774
symptoms	O	775-783
or	O	784-786
exercise	O	787-795
capacity	O	796-804
.	O	804-805

Furthermore	O	806-817
,	O	817-818
no	O	819-821
trial	O	822-827
has	O	828-831
had	O	832-835
sufficient	O	836-846
power	O	847-852
to	O	853-855
evaluate	O	856-864
mortality	O	865-874
.	O	874-875

Pooled	O	876-882
analysis	O	883-891
of	O	892-894
the	O	895-898
effects	O	899-906
of	O	907-909
other	O	910-915
inotropic	O	916-925
drugs	O	926-931
shows	O	932-937
an	O	938-940
excess	O	941-947
mortality	O	948-957
and	O	958-961
there	O	962-967
is	O	968-970
a	O	971-972
possibility	O	973-984
that	O	985-989
digoxin	O	990-997
may	O	998-1001
increase	O	1002-1010
mortality	O	1011-1020
after	O	1021-1026
myocardial	B	1027-1037
infarction	I	1038-1048
(	O	1049-1050
MI	B	1050-1052
)	O	1052-1053
.	O	1053-1054

Angiotensin	O	1055-1066
-	O	1066-1067
converting	O	1067-1077
enzyme	O	1078-1084
(	O	1085-1086
ACE	O	1086-1089
)	O	1089-1090
inhibitors	O	1091-1101
should	O	1102-1108
be	O	1109-1111
used	O	1112-1116
first	O	1117-1122
as	O	1123-1125
they	O	1126-1130
are	O	1131-1134
safer	O	1135-1140
,	O	1140-1141
do	O	1142-1144
not	O	1145-1148
require	O	1149-1156
blood	O	1157-1162
level	O	1163-1168
monitoring	O	1169-1179
,	O	1179-1180
modify	O	1181-1187
progression	O	1188-1199
of	O	1200-1202
disease	O	1203-1210
,	O	1210-1211
relieve	O	1212-1219
symptoms	O	1220-1228
,	O	1228-1229
improve	O	1230-1237
exercise	O	1238-1246
tolerance	O	1247-1256
and	O	1257-1260
reduce	O	1261-1267
mortality	O	1268-1277
.	O	1277-1278

Caution	O	1279-1286
should	O	1287-1293
be	O	1294-1296
exercised	O	1297-1306
in	O	1307-1309
using	O	1310-1315
digoxin	O	1316-1323
until	O	1324-1329
large	O	1330-1335
mortality	O	1336-1345
trials	O	1346-1352
are	O	1353-1356
completed	O	1357-1366
showing	O	1367-1374
either	O	1375-1381
benefit	O	1382-1389
or	O	1390-1392
harm	O	1393-1397
.	O	1397-1398

Until	O	1399-1404
then	O	1405-1409
digoxin	O	1410-1417
should	O	1418-1424
be	O	1425-1427
considered	O	1428-1438
a	O	1439-1440
third	O	1441-1446
-	O	1446-1447
line	O	1447-1451
therapy	O	1452-1459
.	O	1459-1460

Intravascular	O	0-13
hemolysis	B	14-23
and	O	24-27
acute	B	28-33
renal	I	34-39
failure	I	40-47
following	O	48-57
intermittent	O	58-70
rifampin	O	71-79
therapy	O	80-87
.	O	87-88

Renal	B	89-94
failure	I	95-102
is	O	103-105
a	O	106-107
rare	O	108-112
complication	O	113-125
associated	O	126-136
with	O	137-141
the	O	142-145
use	O	146-149
of	O	150-152
rifampin	O	153-161
.	O	161-162

Intravascular	O	163-176
hemolysis	B	177-186
leading	O	187-194
to	O	195-197
acute	B	198-203
renal	I	204-209
failure	I	210-217
following	O	218-227
rifampin	O	228-236
therapy	O	237-244
is	O	245-247
extremely	O	248-257
rare	O	258-262
.	O	262-263

Two	O	264-267
patients	O	268-276
with	O	277-281
leprosy	B	282-289
who	O	290-293
developed	O	294-303
hemolysis	B	304-313
and	O	314-317
acute	B	318-323
renal	I	324-329
failure	I	330-337
following	O	338-347
rifampin	O	348-356
are	O	357-360
reported	O	361-369
.	O	369-370

Zidovudine	O	0-10
-	O	10-11
induced	O	11-18
hepatitis	B	19-28
.	O	28-29

A	O	30-31
case	O	32-36
of	O	37-39
acute	O	40-45
hepatitis	B	46-55
induced	O	56-63
by	O	64-66
zidovudine	O	67-77
in	O	78-80
a	O	81-82
38	O	83-85
-	O	85-86
year	O	86-90
-	O	85-86
old	O	91-94
patient	O	95-102
with	O	103-107
AIDS	B	108-112
is	O	113-115
presented	O	116-125
.	O	125-126

The	O	127-130
mechanism	O	131-140
whereby	O	141-148
the	O	149-152
hepatitis	B	153-162
was	O	163-166
induced	O	167-174
is	O	175-177
not	O	178-181
known	O	182-187
.	O	187-188

However	O	189-196
,	O	196-197
the	O	198-201
patient	O	202-209
tolerated	O	210-219
well	O	220-224
an	O	225-227
alternative	O	228-239
reverse	O	240-247
transcriptase	O	248-261
inhibitor	O	262-271
,	O	271-272
2	O	273-274
'	O	274-275
3	O	275-276
'	O	274-275
dideoxyinosine	O	278-292
.	O	292-293

Physicians	O	294-304
caring	O	305-311
for	O	312-315
patients	O	316-324
with	O	325-329
AIDS	B	330-334
should	O	335-341
be	O	342-344
aware	O	345-350
of	O	351-353
this	O	354-358
hitherto	O	359-367
rarely	O	368-374
reported	O	375-383
complication	O	384-396
.	O	396-397

Thoracic	B	0-8
hematomyelia	I	9-21
secondary	O	22-31
to	O	32-34
coumadin	O	35-43
anticoagulant	O	44-57
therapy	O	58-65
:	O	65-66
a	O	67-68
case	O	69-73
report	O	74-80
.	O	80-81

A	O	82-83
case	O	84-88
of	O	89-91
thoracic	B	92-100
hematomyelia	I	101-113
secondary	O	114-123
to	O	124-126
anticoagulant	O	127-140
therapy	O	141-148
is	O	149-151
presented	O	152-161
.	O	161-162

Clinical	O	163-171
features	O	172-180
,	O	180-181
similar	O	182-189
to	O	190-192
2	O	193-194
other	O	195-200
previously	O	201-211
reported	O	212-220
cases	O	221-226
,	O	226-227
are	O	228-231
discussed	O	232-241
.	O	241-242

A	O	243-244
high	O	245-249
index	O	250-255
of	O	256-258
suspicion	O	259-268
may	O	269-272
lead	O	273-277
to	O	278-280
a	O	281-282
quick	O	283-288
diagnostic	O	289-299
procedure	O	300-309
and	O	310-313
successful	O	314-324
decompressive	O	325-338
surgery	O	339-346
.	O	346-347

Mania	B	0-5
associated	O	6-16
with	O	17-21
fluoxetine	O	22-32
treatment	O	33-42
in	O	43-45
adolescents	O	46-57
.	O	57-58

Fluoxetine	O	59-69
,	O	69-70
a	O	71-72
selective	O	73-82
serotonin	O	83-92
reuptake	O	93-101
inhibitor	O	102-111
,	O	111-112
is	O	113-115
gaining	O	116-123
increased	O	124-133
acceptance	O	134-144
in	O	145-147
the	O	148-151
treatment	O	152-161
of	O	162-164
adolescent	O	165-175
depression	B	176-186
.	O	186-187

Generally	O	188-197
safe	O	198-202
and	O	203-206
well	O	207-211
tolerated	O	212-221
by	O	222-224
adults	O	225-231
,	O	231-232
fluoxetine	O	233-243
has	O	244-247
been	O	248-252
reported	O	253-261
to	O	262-264
induce	O	265-271
mania	B	272-277
.	O	277-278

The	O	279-282
cases	O	283-288
of	O	289-291
five	O	292-296
depressed	B	297-306
adolescents	O	307-318
,	O	318-319
14	O	320-322
-	O	322-323
16	O	323-325
years	O	326-331
of	O	332-334
age	O	335-338
,	O	338-339
who	O	340-343
developed	O	344-353
mania	B	354-359
during	O	360-366
pharmacotherapy	O	367-382
with	O	383-387
fluoxetine	O	388-398
,	O	398-399
are	O	400-403
reported	O	404-412
here	O	413-417
.	O	417-418

Apparent	O	419-427
risk	O	428-432
factors	O	433-440
for	O	441-444
the	O	445-448
development	O	449-460
of	O	461-463
mania	B	464-469
or	O	470-472
hypomania	B	473-482
during	O	483-489
fluoxetine	O	490-500
pharmacotherapy	O	501-516
in	O	517-519
this	O	520-524
population	O	525-535
were	O	536-540
the	O	541-544
combination	O	545-556
of	O	557-559
attention	B	560-569
-	I	569-570
deficit	I	570-577
hyperactivity	I	578-591
disorder	I	592-600
and	O	601-604
affective	O	605-614
instability	O	615-626
;	O	626-627
major	O	628-633
depression	B	634-644
with	O	645-649
psychotic	B	650-659
features	O	660-668
;	O	668-669
a	O	670-671
family	O	672-678
history	O	679-686
of	O	687-689
affective	B	690-699
disorder	I	700-708
,	O	708-709
especially	O	710-720
bipolar	B	721-728
disorder	I	729-737
;	O	737-738
and	O	739-742
a	O	743-744
diagnosis	O	745-754
of	O	755-757
bipolar	B	758-765
disorder	I	766-774
.	O	774-775

Further	O	776-783
study	O	784-789
is	O	790-792
needed	O	793-799
to	O	800-802
determine	O	803-812
the	O	813-816
optimal	O	817-824
dosage	O	825-831
and	O	832-835
to	O	836-838
identify	O	839-847
risk	O	848-852
factors	O	853-860
that	O	861-865
increase	O	866-874
individual	O	875-885
vulnerability	O	886-899
to	O	900-902
fluoxetine	O	903-913
induced	O	914-921
mania	B	922-927
in	O	928-930
adolescents	O	931-942
.	O	942-943

Gemfibrozil	O	0-11
-	O	11-12
lovastatin	O	12-22
therapy	O	23-30
for	O	31-34
primary	O	35-42
hyperlipoproteinemias	B	43-64
.	O	64-65

The	O	66-69
specific	O	70-78
aim	O	79-82
of	O	83-85
this	O	86-90
retrospective	O	91-104
,	O	104-105
observational	O	106-119
study	O	120-125
was	O	126-129
to	O	130-132
assess	O	133-139
safety	O	140-146
and	O	147-150
efficacy	O	151-159
of	O	160-162
long	O	163-167
-	O	167-168
term	O	168-172
(	O	173-174
21	O	174-176
months	O	177-183
/	O	183-184
patient	O	184-191
)	O	191-192
,	O	192-193
open	O	194-198
-	O	198-199
label	O	199-204
,	O	204-205
gemfibrozil	O	206-217
-	O	217-218
lovastatin	O	218-228
treatment	O	229-238
in	O	239-241
80	O	242-244
patients	O	245-253
with	O	254-258
primary	O	259-266
mixed	O	267-272
hyperlipidemia	B	273-287
(	O	288-289
68	O	289-291
%	O	291-292
of	O	293-295
whom	O	296-300
had	O	301-304
atherosclerotic	B	305-320
vascular	I	321-329
disease	I	330-337
)	O	337-338
.	O	338-339

Because	O	340-347
ideal	O	348-353
lipid	O	354-359
targets	O	360-367
were	O	368-372
not	O	373-376
reached	O	377-384
(	O	385-386
low	O	386-389
-	O	389-390
density	O	390-397
lipoprotein	O	398-409
(	O	410-411
LDL	O	411-414
)	O	414-415
cholesterol	O	416-427
less	O	428-432
than	O	433-437
130	O	438-441
mg	O	442-444
/	O	444-445
dl	O	445-447
,	O	447-448
high	O	449-453
-	O	453-454
density	O	454-461
lipoprotein	O	462-473
(	O	474-475
HDL	O	475-478
)	O	478-479
cholesterol	O	480-491
greater	O	492-499
than	O	500-504
35	O	505-507
mg	O	508-510
/	O	510-511
dl	O	511-513
,	O	513-514
or	O	515-517
total	O	518-523
cholesterol	O	524-535
/	O	535-536
HDL	O	536-539
cholesterol	O	540-551
less	O	552-556
than	O	557-561
4	O	562-563
.	O	563-564
5	O	564-565
mg	O	566-568
/	O	568-569
dl	O	569-571
)	O	571-572
with	O	573-577
diet	O	578-582
plus	O	583-587
a	O	588-589
single	O	590-596
drug	O	597-601
,	O	601-602
gemfibrozil	O	603-614
(	O	615-616
1	O	616-617
.	O	617-618
2	O	618-619
g	O	620-621
/	O	621-622
day	O	622-625
)	O	625-626
-	O	626-627
lovastatin	O	627-637
(	O	638-639
primarily	O	639-648
20	O	649-651
or	O	652-654
40	O	655-657
mg	O	658-660
)	O	660-661
treatment	O	662-671
was	O	672-675
given	O	676-681
.	O	681-682

Follow	O	683-689
-	O	689-690
up	O	690-692
visits	O	693-699
were	O	700-704
scheduled	O	705-714
with	O	715-719
2	O	720-721
-	O	721-722
drug	O	722-726
therapy	O	727-734
every	O	735-740
6	O	741-742
to	O	743-745
8	O	746-747
weeks	O	748-753
,	O	753-754
an	O	755-757
average	O	758-765
of	O	766-768
10	O	769-771
.	O	771-772
3	O	772-773
visits	O	774-780
per	O	781-784
patient	O	785-792
,	O	792-793
with	O	794-798
741	O	799-802
batteries	O	803-812
of	O	813-815
6	O	816-817
liver	O	818-823
function	O	824-832
tests	O	833-838
and	O	839-842
714	O	843-846
creatine	O	847-855
phosphokinase	O	856-869
levels	O	870-876
measured	O	877-885
.	O	885-886

Only	O	887-891
1	O	892-893
of	O	894-896
the	O	897-900
4	O	901-902
,	O	902-903
446	O	903-906
liver	O	907-912
function	O	913-921
tests	O	922-927
(	O	928-929
0	O	929-930
.	O	930-931
02	O	931-933
%	O	933-934
)	O	934-935
,	O	935-936
a	O	937-938
gamma	O	939-944
glutamyl	O	945-953
transferase	O	954-965
,	O	965-966
was	O	967-970
greater	O	971-978
than	O	979-983
or	O	984-986
equal	O	987-992
to	O	993-995
3	O	996-997
times	O	998-1003
the	O	1004-1007
upper	O	1008-1013
normal	O	1014-1020
limit	O	1021-1026
.	O	1026-1027

Of	O	1028-1030
the	O	1031-1034
714	O	1035-1038
creatine	O	1039-1047
phosphokinase	O	1048-1061
levels	O	1062-1068
,	O	1068-1069
9	O	1070-1071
%	O	1071-1072
were	O	1073-1077
high	O	1078-1082
;	O	1082-1083
only	O	1084-1088
1	O	1089-1090
(	O	1091-1092
0	O	1092-1093
.	O	1093-1094
1	O	1094-1095
%	O	1095-1096
)	O	1096-1097
was	O	1098-1101
greater	O	1102-1109
than	O	1110-1114
or	O	1115-1117
equal	O	1118-1123
to	O	1124-1126
3	O	1127-1128
times	O	1129-1134
the	O	1135-1138
upper	O	1139-1144
normal	O	1145-1151
limit	O	1152-1157
.	O	1157-1158

With	O	1159-1163
2	O	1164-1165
-	O	1165-1166
drug	O	1166-1170
therapy	O	1171-1178
,	O	1178-1179
mean	O	1180-1184
total	O	1185-1190
cholesterol	O	1191-1202
decreased	O	1203-1212
22	O	1213-1215
%	O	1215-1216
from	O	1217-1221
255	O	1222-1225
to	O	1226-1228
200	O	1229-1232
mg	O	1233-1235
/	O	1235-1236
dl	O	1236-1238
,	O	1238-1239
triglyceride	O	1240-1252
levels	O	1253-1259
decreased	O	1260-1269
35	O	1270-1272
%	O	1272-1273
from	O	1274-1278
236	O	1279-1282
to	O	1283-1285
154	O	1286-1289
mg	O	1290-1292
/	O	1292-1293
dl	O	1293-1295
,	O	1295-1296
LDL	O	1297-1300
cholesterol	O	1301-1312
decreased	O	1313-1322
26	O	1323-1325
%	O	1325-1326
from	O	1327-1331
176	O	1332-1335
to	O	1336-1338
131	O	1339-1342
mg	O	1343-1345
/	O	1345-1346
dl	O	1346-1348
,	O	1348-1349
and	O	1350-1353
the	O	1354-1357
total	O	1358-1363
cholesterol	O	1364-1375
/	O	1375-1376
HDL	O	1376-1379
cholesterol	O	1380-1391
ratio	O	1392-1397
decreased	O	1398-1407
24	O	1408-1410
%	O	1410-1411
from	O	1412-1416
7	O	1417-1418
.	O	1418-1419
1	O	1419-1420
to	O	1421-1423
5	O	1424-1425
.	O	1425-1426
4	O	1426-1427
,	O	1427-1428
all	O	1429-1432
p	O	1433-1434
less	O	1435-1439
than	O	1440-1444
or	O	1445-1447
equal	O	1448-1453
to	O	1454-1456
0	O	1457-1458
.	O	1458-1459
0001	O	1459-1463
.	O	1458-1459

Myositis	B	1465-1473
,	O	1473-1474
attributable	O	1475-1487
to	O	1488-1490
the	O	1491-1494
drug	O	1495-1499
combination	O	1500-1511
and	O	1512-1515
symptomatic	O	1516-1527
enough	O	1528-1534
to	O	1535-1537
discontinue	O	1538-1549
it	O	1550-1552
,	O	1552-1553
occurred	O	1554-1562
in	O	1563-1565
3	O	1566-1567
%	O	1567-1568
of	O	1569-1571
patients	O	1572-1580
,	O	1580-1581
and	O	1582-1585
in	O	1586-1588
1	O	1589-1590
%	O	1590-1591
with	O	1592-1596
concurrent	O	1597-1607
high	O	1608-1612
creatine	O	1613-1621
phosphokinase	O	1622-1635
(	O	1636-1637
769	O	1637-1640
U	O	1641-1642
/	O	1642-1643
liter	O	1643-1648
)	O	1648-1649
;	O	1649-1650
no	O	1651-1653
patients	O	1654-1662
had	O	1663-1666
rhabdomyolysis	B	1667-1681
or	O	1682-1684
myoglobinuria	B	1685-1698
.	O	1698-1699
(	O	1699-1700
ABSTRACT	O	1700-1708

TRUNCATED	O	1709-1718
AT	O	1719-1721
250	O	1722-1725
WORDS	O	1726-1731
)	O	1731-1732

Hepatocellular	B	0-14
carcinoma	I	15-24
in	O	25-27
Fanconi	B	28-35
'	I	35-36
s	I	36-37
anemia	I	38-44
treated	O	45-52
with	O	53-57
androgen	O	58-66
and	O	67-70
corticosteroid	O	71-85
.	O	85-86

The	O	87-90
case	O	91-95
of	O	96-98
an	O	99-101
11	O	102-104
-	O	104-105
year	O	105-109
-	O	104-105
old	O	110-113
boy	O	114-117
is	O	118-120
reported	O	121-129
who	O	130-133
was	O	134-137
known	O	138-143
to	O	144-146
have	O	147-151
Fanconi	B	152-159
'	I	159-160
s	I	160-161
anemia	I	162-168
for	O	169-172
3	O	173-174
years	O	175-180
and	O	181-184
was	O	185-188
treated	O	189-196
with	O	197-201
androgens	O	202-211
,	O	211-212
corticosteroids	O	213-228
and	O	229-232
transfusions	O	233-245
.	O	245-246

Two	O	247-250
weeks	O	251-256
before	O	257-263
his	O	264-267
death	O	268-273
he	O	274-276
was	O	277-280
readmitted	O	281-291
because	O	292-299
of	O	300-302
aplastic	O	303-311
crisis	O	312-318
with	O	319-323
septicemia	B	324-334
and	O	335-338
marked	O	339-345
abnormalities	O	346-359
in	O	360-362
liver	O	363-368
function	O	369-377
and	O	378-381
died	O	382-386
of	O	387-389
hemorrhagic	B	390-401
bronchopneumonia	I	402-418
.	O	418-419

At	O	420-422
autopsy	O	423-430
peliosis	B	431-439
and	O	440-443
multiple	O	444-452
hepatic	B	453-460
tumors	I	461-467
were	O	468-472
found	O	473-478
which	O	479-484
histologically	O	485-499
proved	O	500-506
to	O	507-509
be	O	510-512
well	O	513-517
-	O	517-518
differentiated	O	518-532
hepatocellular	B	533-547
carcinoma	I	548-557
.	O	557-558

This	O	559-563
case	O	564-568
contributes	O	569-580
to	O	581-583
the	O	584-587
previous	O	588-596
observations	O	597-609
that	O	610-614
non	O	615-618
-	O	618-619
metastasizing	O	619-632
hepatic	B	633-640
neoplasms	I	641-650
and	O	651-654
peliosis	B	655-663
can	O	664-667
develop	O	668-675
in	O	676-678
patients	O	679-687
with	O	688-692
androgen	O	693-701
-	O	701-702
and	O	703-706
corticosteroid	O	707-721
-	O	721-722
treated	O	722-729
Fanconi	B	730-737
'	I	737-738
s	I	738-739
anemia	I	740-746
.	O	746-747

Chronic	O	0-7
lesion	O	8-14
of	O	15-17
rostral	O	18-25
ventrolateral	O	26-39
medulla	O	40-47
in	O	48-50
spontaneously	O	51-64
hypertensive	B	65-77
rats	O	78-82
.	O	82-83

We	O	84-86
studied	O	87-94
the	O	95-98
effects	O	99-106
of	O	107-109
chronic	O	110-117
selective	O	118-127
neuronal	O	128-136
lesion	O	137-143
of	O	144-146
rostral	O	147-154
ventrolateral	O	155-168
medulla	O	169-176
on	O	177-179
mean	O	180-184
arterial	O	185-193
pressure	O	194-202
,	O	202-203
heart	O	204-209
rate	O	210-214
,	O	214-215
and	O	216-219
neurogenic	O	220-230
tone	O	231-235
in	O	236-238
conscious	O	239-248
,	O	248-249
unrestrained	O	250-262
spontaneously	O	263-276
hypertensive	B	277-289
rats	O	290-294
.	O	294-295

The	O	296-299
lesions	O	300-307
were	O	308-312
placed	O	313-319
via	O	320-323
bilateral	O	324-333
microinjections	O	334-349
of	O	350-352
30	O	353-355
nmol	O	356-360
/	O	360-361
200	O	361-364
nl	O	365-367
N	O	368-369
-	O	369-370
methyl	O	370-376
-	O	369-370
D	O	377-378
-	O	369-370
aspartic	O	379-387
acid	O	388-392
.	O	392-393

The	O	394-397
restimulation	O	398-411
of	O	412-414
this	O	415-419
area	O	420-424
with	O	425-429
N	O	430-431
-	O	431-432
methyl	O	432-438
-	O	431-432
D	O	439-440
-	O	431-432
aspartic	O	441-449
acid	O	450-454
15	O	455-457
days	O	458-462
postlesion	O	463-473
failed	O	474-480
to	O	481-483
produce	O	484-491
a	O	492-493
pressor	O	494-501
response	O	502-510
.	O	510-511

One	O	512-515
day	O	516-519
postlesion	O	520-530
,	O	530-531
the	O	532-535
resting	O	536-543
mean	O	544-548
arterial	O	549-557
pressure	O	558-566
was	O	567-570
significantly	O	571-584
decreased	O	585-594
in	O	595-597
lesioned	O	598-606
rats	O	607-611
when	O	612-616
compared	O	617-625
with	O	626-630
sham	O	631-635
rats	O	636-640
(	O	641-642
100	O	642-645
+	O	646-647
/	O	647-648
-	O	648-649
7	O	650-651
versus	O	652-658
173	O	659-662
+	O	663-664
/	O	664-665
-	O	665-666
4	O	667-668
mm	O	669-671
Hg	O	672-674
,	O	674-675
p	O	676-677
less	O	678-682
than	O	683-687
0	O	688-689
.	O	689-690
05	O	690-692
)	O	692-693
.	O	689-690

Fifteen	O	695-702
days	O	703-707
later	O	708-713
,	O	713-714
the	O	715-718
lesioned	O	719-727
group	O	728-733
still	O	734-739
showed	O	740-746
values	O	747-753
significantly	O	754-767
lower	O	768-773
than	O	774-778
the	O	779-782
sham	O	783-787
group	O	788-793
(	O	794-795
150	O	795-798
+	O	799-800
/	O	800-801
-	O	801-802
6	O	803-804
versus	O	805-811
167	O	812-815
+	O	816-817
/	O	817-818
-	O	818-819
5	O	820-821
mm	O	822-824
Hg	O	825-827
,	O	827-828
p	O	829-830
less	O	831-835
than	O	836-840
0	O	841-842
.	O	842-843
05	O	843-845
)	O	845-846
.	O	842-843

No	O	848-850
significant	O	851-862
heart	O	863-868
rate	O	869-873
differences	O	874-885
were	O	886-890
observed	O	891-899
between	O	900-907
the	O	908-911
sham	O	912-916
and	O	917-920
lesioned	O	921-929
groups	O	930-936
.	O	936-937

The	O	938-941
ganglionic	O	942-952
blocker	O	953-960
trimethaphan	O	961-973
(	O	974-975
5	O	975-976
mg	O	977-979
/	O	979-980
kg	O	980-982
i	O	983-984
.	O	984-985
v	O	985-986
.	O	984-985
)	O	987-988
caused	O	989-995
similar	O	996-1003
reductions	O	1004-1014
in	O	1015-1017
mean	O	1018-1022
arterial	O	1023-1031
pressure	O	1032-1040
in	O	1041-1043
both	O	1044-1048
lesioned	O	1049-1057
and	O	1058-1061
sham	O	1062-1066
groups	O	1067-1073
.	O	1073-1074

The	O	1075-1078
trimethaphan	O	1079-1091
-	O	1091-1092
induced	O	1092-1099
hypotension	B	1100-1111
was	O	1112-1115
accompanied	O	1116-1127
by	O	1128-1130
a	O	1131-1132
significant	O	1133-1144
bradycardia	B	1145-1156
in	O	1157-1159
lesioned	O	1160-1168
rats	O	1169-1173
(	O	1174-1175
-	O	1175-1176
32	O	1176-1178
+	O	1179-1180
/	O	1180-1181
-	O	1181-1182
13	O	1183-1185
beats	O	1186-1191
per	O	1192-1195
minute	O	1196-1202
)	O	1202-1203
but	O	1204-1207
a	O	1208-1209
tachycardia	B	1210-1221
in	O	1222-1224
sham	O	1225-1229
rats	O	1230-1234
(	O	1235-1236
+	O	1236-1237
33	O	1237-1239
+	O	1240-1241
/	O	1241-1242
-	O	1242-1243
12	O	1244-1246
beats	O	1247-1252
per	O	1253-1256
minute	O	1257-1263
)	O	1263-1264
1	O	1265-1266
day	O	1267-1270
postlesion	O	1271-1281
.	O	1281-1282

Therefore	O	1283-1292
,	O	1292-1293
rostral	O	1294-1301
ventrolateral	O	1302-1315
medulla	O	1316-1323
neurons	O	1324-1331
appear	O	1332-1338
to	O	1339-1341
play	O	1342-1346
a	O	1347-1348
significant	O	1349-1360
role	O	1361-1365
in	O	1366-1368
maintaining	O	1369-1380
hypertension	B	1381-1393
in	O	1394-1396
conscious	O	1397-1406
spontaneously	O	1407-1420
hypertensive	B	1421-1433
rats	O	1434-1438
.	O	1438-1439

Spinal	O	1440-1446
or	O	1447-1449
suprabulbar	O	1450-1461
structures	O	1462-1472
could	O	1473-1478
be	O	1479-1481
responsible	O	1482-1493
for	O	1494-1497
the	O	1498-1501
gradual	O	1502-1509
recovery	O	1510-1518
of	O	1519-1521
the	O	1522-1525
hypertension	B	1526-1538
in	O	1539-1541
the	O	1542-1545
lesioned	O	1546-1554
rats	O	1555-1559
.	O	1559-1560

Damage	B	0-6
of	I	7-9
substantia	I	10-20
nigra	I	21-26
pars	I	27-31
reticulata	I	32-42
during	O	43-49
pilocarpine	O	50-61
-	O	61-62
induced	O	62-69
status	B	70-76
epilepticus	I	77-88
in	O	89-91
the	O	92-95
rat	O	96-99
:	O	99-100
immunohistochemical	O	101-120
study	O	121-126
of	O	127-129
neurons	O	130-137
,	O	137-138
astrocytes	O	139-149
and	O	150-153
serum	O	154-159
-	O	159-160
protein	O	160-167
extravasation	O	168-181
.	O	181-182

The	O	183-186
substantia	O	187-197
nigra	O	198-203
has	O	204-207
a	O	208-209
gating	O	210-216
function	O	217-225
controlling	O	226-237
the	O	238-241
spread	O	242-248
of	O	249-251
epileptic	B	252-261
seizure	I	262-269
activity	O	270-278
.	O	278-279

Additionally	O	280-292
,	O	292-293
in	O	294-296
models	O	297-303
of	O	304-306
prolonged	B	307-316
status	I	317-323
epilepticus	I	324-335
the	O	336-339
pars	O	340-344
reticulata	O	345-355
of	O	356-358
substantia	O	359-369
nigra	O	370-375
(	O	376-377
SNR	O	377-380
)	O	380-381
suffers	O	382-389
from	O	390-394
a	O	395-396
massive	O	397-404
lesion	O	405-411
which	O	412-417
may	O	418-421
arise	O	422-427
from	O	428-432
a	O	433-434
massive	O	435-442
metabolic	B	443-452
derangement	I	453-464
and	O	465-468
hyperexcitation	O	469-484
developing	O	485-495
in	O	496-498
the	O	499-502
activated	O	503-512
SNR	O	513-516
.	O	516-517

In	O	518-520
this	O	521-525
study	O	526-531
,	O	531-532
status	B	533-539
epilepticus	I	540-551
was	O	552-555
induced	O	556-563
by	O	564-566
systemic	O	567-575
injection	O	576-585
of	O	586-588
pilocarpine	O	589-600
in	O	601-603
rats	O	604-608
.	O	608-609

The	O	610-613
neuropathology	O	614-628
of	O	629-631
SNR	O	632-635
was	O	636-639
investigated	O	640-652
using	O	653-658
immunohistochemical	O	659-678
techniques	O	679-689
with	O	690-694
the	O	695-698
major	O	699-704
emphasis	O	705-713
on	O	714-716
the	O	717-720
time	O	721-725
-	O	725-726
course	O	726-732
of	O	733-735
changes	O	736-743
in	O	744-746
neurons	O	747-754
and	O	755-758
astrocytes	O	759-769
.	O	769-770

Animals	O	771-778
surviving	O	779-788
20	O	789-791
,	O	791-792
30	O	793-795
,	O	795-796
40	O	797-799
,	O	799-800
60	O	801-803
min	O	804-807
,	O	807-808
2	O	809-810
,	O	810-811
3	O	812-813
,	O	813-814
6	O	815-816
hours	O	817-822
,	O	822-823
1	O	824-825
,	O	825-826
2	O	827-828
,	O	828-829
and	O	830-833
3	O	834-835
days	O	836-840
after	O	841-846
induction	O	847-856
of	O	857-859
status	B	860-866
epilepticus	I	867-878
were	O	879-883
perfusion	O	884-893
-	O	893-894
fixed	O	894-899
,	O	899-900
and	O	901-904
brains	O	905-911
processed	O	912-921
for	O	922-925
immunohistochemical	O	926-945
staining	O	946-954
of	O	955-957
SNR	O	958-961
.	O	961-962

Nissl	O	963-968
-	O	968-969
staining	O	969-977
and	O	978-981
antibodies	O	982-992
against	O	993-1000
the	O	1001-1004
neuron	O	1005-1011
-	O	1011-1012
specific	O	1012-1020
calcium	O	1021-1028
-	O	1028-1029
binding	O	1029-1036
protein	O	1037-1044
,	O	1044-1045
parvalbumin	O	1046-1057
,	O	1057-1058
served	O	1059-1065
to	O	1066-1068
detect	O	1069-1075
neuronal	B	1076-1084
damage	I	1085-1091
in	O	1092-1094
SNR	O	1095-1098
.	O	1098-1099

Antibodies	O	1100-1110
against	O	1111-1118
the	O	1119-1122
astroglia	O	1123-1132
-	O	1132-1133
specific	O	1133-1141
cytoskeletal	O	1142-1154
protein	O	1155-1162
,	O	1162-1163
glial	O	1164-1169
fibrillary	O	1170-1180
acidic	O	1181-1187
protein	O	1188-1195
(	O	1196-1197
GFAP	O	1197-1201
)	O	1201-1202
,	O	1202-1203
and	O	1204-1207
against	O	1208-1215
the	O	1216-1219
glial	O	1220-1225
calcium	O	1226-1233
-	O	1233-1234
binding	O	1234-1241
protein	O	1242-1249
,	O	1249-1250
S	O	1251-1252
-	O	1252-1253
100	O	1253-1256
protein	O	1257-1264
,	O	1264-1265
were	O	1266-1270
used	O	1271-1275
to	O	1276-1278
assess	O	1279-1285
the	O	1286-1289
status	O	1290-1296
of	O	1297-1299
astrocytes	O	1300-1310
.	O	1310-1311

Immunohistochemical	O	1312-1331
staining	O	1332-1340
for	O	1341-1344
serum	O	1345-1350
-	O	1350-1351
albumin	O	1351-1358
and	O	1359-1362
immunoglobulins	O	1363-1378
in	O	1379-1381
brain	O	1382-1387
tissue	O	1388-1394
was	O	1395-1398
taken	O	1399-1404
as	O	1405-1407
indicator	O	1408-1417
of	O	1418-1420
blood	O	1421-1426
-	O	1426-1427
brain	O	1427-1432
barrier	O	1433-1440
disturbances	O	1441-1453
and	O	1454-1457
vasogenic	B	1458-1467
edema	I	1468-1473
formation	O	1474-1483
.	O	1483-1484

Immunohistochemical	O	1485-1504
staining	O	1505-1513
indicated	O	1514-1523
loss	O	1524-1528
of	O	1529-1531
GFAP	O	1532-1536
-	O	1536-1537
staining	O	1537-1545
already	O	1546-1553
at	O	1554-1556
30	O	1557-1559
min	O	1560-1563
after	O	1564-1569
induction	O	1570-1579
of	O	1580-1582
seizures	B	1583-1591
in	O	1592-1594
an	O	1595-1597
oval	O	1598-1602
focus	O	1603-1608
situated	O	1609-1617
in	O	1618-1620
the	O	1621-1624
center	O	1625-1631
of	O	1632-1634
SNR	O	1635-1638
while	O	1639-1644
sparing	O	1645-1652
medial	O	1653-1659
and	O	1660-1663
lateral	O	1664-1671
aspects	O	1672-1679
.	O	1679-1680

At	O	1681-1683
1	O	1684-1685
h	O	1686-1687
there	O	1688-1693
was	O	1694-1697
additional	O	1698-1708
vacuolation	O	1709-1720
in	O	1721-1723
S	O	1724-1725
-	O	1725-1726
100	O	1726-1729
protein	O	1730-1737
staining	O	1738-1746
.	O	1746-1747

By	O	1748-1750
2	O	1751-1752
hours	O	1753-1758
,	O	1758-1759
parvalbumin	O	1760-1771
-	O	1771-1772
staining	O	1772-1780
changed	O	1781-1788
in	O	1789-1791
the	O	1792-1795
central	O	1796-1803
SNR	O	1804-1807
indicating	O	1808-1818
neuronal	B	1819-1827
damage	I	1828-1834
,	O	1834-1835
and	O	1836-1839
Nissl	O	1840-1845
-	O	1845-1846
staining	O	1846-1854
visualized	O	1855-1865
some	O	1866-1870
neuronal	O	1871-1879
distortion	O	1880-1890
.	O	1890-1891

Staining	O	1892-1900
for	O	1901-1904
serum	O	1905-1910
-	O	1910-1911
proteins	O	1911-1919
occurred	O	1920-1928
in	O	1929-1931
a	O	1932-1933
patchy	O	1934-1940
manner	O	1941-1947
throughout	O	1948-1958
the	O	1959-1962
forebrain	O	1963-1972
during	O	1973-1979
the	O	1980-1983
first	O	1984-1989
hours	O	1990-1995
.	O	1995-1996

By	O	1997-1999
6	O	2000-2001
h	O	2002-2003
,	O	2003-2004
vasogenic	B	2005-2014
edema	I	2015-2020
covered	O	2021-2028
the	O	2029-2032
lesioned	B	2033-2041
SNR	I	2042-2045
.	O	2045-2046

By	O	2047-2049
24	O	2050-2052
h	O	2053-2054
,	O	2054-2055
glial	O	2056-2061
and	O	2062-2065
neuronal	O	2066-2074
markers	O	2075-2082
indicated	O	2083-2092
a	O	2093-2094
massive	O	2095-2102
lesion	O	2103-2109
in	O	2110-2112
the	O	2113-2116
center	O	2117-2123
of	O	2124-2126
SNR	O	2127-2130
.	O	2130-2131

By	O	2132-2134
48	O	2135-2137
-	O	2137-2138
72	O	2138-2140
h	O	2141-2142
,	O	2142-2143
astrocytes	O	2144-2154
surrounding	O	2155-2166
the	O	2167-2170
lesion	O	2171-2177
increased	O	2178-2187
in	O	2188-2190
size	O	2191-2195
,	O	2195-2196
and	O	2197-2200
polymorphic	O	2201-2212
phagocytotic	O	2213-2225
cells	O	2226-2231
invaded	O	2232-2239
the	O	2240-2243
damaged	O	2244-2251
area	O	2252-2256
.	O	2256-2257

In	O	2258-2260
a	O	2261-2262
further	O	2263-2270
group	O	2271-2276
of	O	2277-2279
animals	O	2280-2287
surviving	O	2288-2297
1	O	2298-2299
to	O	2300-2302
5	O	2303-2304
days	O	2305-2309
,	O	2309-2310
conventional	O	2311-2323
paraffin	O	2324-2332
-	O	2332-2333
sections	O	2333-2341
confirmed	O	2342-2351
the	O	2352-2355
neuronal	O	2356-2364
and	O	2365-2368
glial	O	2369-2374
damage	B	2375-2381
of	I	2382-2384
SNR	I	2385-2388
.	O	2388-2389

Additional	O	2390-2400
pathology	O	2401-2410
of	O	2411-2413
similar	O	2414-2421
quality	O	2422-2429
was	O	2430-2433
found	O	2434-2439
in	O	2440-2442
the	O	2443-2446
globus	O	2447-2453
pallidus	O	2454-2462
.	O	2462-2463

Since	O	2464-2469
astrocytes	O	2470-2480
were	O	2481-2485
always	O	2486-2492
damaged	O	2493-2500
in	O	2501-2503
parallel	O	2504-2512
with	O	2513-2517
neurons	O	2518-2525
in	O	2526-2528
SNR	O	2529-2532
it	O	2533-2535
is	O	2536-2538
proposed	O	2539-2547
that	O	2548-2552
the	O	2553-2556
anatomical	O	2557-2567
and	O	2568-2571
functional	O	2572-2582
interrelationship	O	2583-2600
between	O	2601-2608
neurons	O	2609-2616
and	O	2617-2620
astrocytes	O	2621-2631
is	O	2632-2634
particularly	O	2635-2647
tight	O	2648-2653
in	O	2654-2656
SNR	O	2657-2660
.	O	2660-2661

Both	O	2662-2666
cell	O	2667-2671
elements	O	2672-2680
may	O	2681-2684
suffer	O	2685-2691
in	O	2692-2694
common	O	2695-2701
from	O	2702-2706
metabolic	O	2707-2716
disturbance	O	2717-2728
and	O	2729-2732
neurotransmitter	B	2733-2749
dysfunction	I	2750-2761
as	O	2762-2764
occur	O	2765-2770
during	O	2771-2777
massive	O	2778-2785
status	B	2786-2792
epilepticus	I	2793-2804
.	O	2804-2805

Reduced	O	0-7
cardiotoxicity	B	8-22
of	O	23-25
doxorubicin	O	26-37
given	O	38-43
in	O	44-46
the	O	47-50
form	O	51-55
of	O	56-58
N	O	59-60
-	O	60-61
(	O	61-62
2	O	62-63
-	O	60-61
hydroxypropyl	O	64-77
)	O	77-78
methacrylamide	O	78-92
conjugates	O	93-103
:	O	103-104
and	O	105-108
experimental	O	109-121
study	O	122-127
in	O	128-130
the	O	131-134
rat	O	135-138
.	O	138-139

A	O	140-141
rat	O	142-145
model	O	146-151
was	O	152-155
used	O	156-160
to	O	161-163
evaluate	O	164-172
the	O	173-176
general	O	177-184
acute	O	185-190
toxicity	B	191-199
and	O	200-203
the	O	204-207
late	O	208-212
cardiotoxicity	B	213-227
of	O	228-230
4	O	231-232
mg	O	233-235
/	O	235-236
kg	O	236-238
doxorubicin	O	239-250
(	O	251-252
DOX	O	252-255
)	O	255-256
given	O	257-262
either	O	263-269
as	O	270-272
free	O	273-277
drug	O	278-282
or	O	283-285
in	O	286-288
the	O	289-292
form	O	293-297
of	O	298-300
three	O	301-306
N	O	307-308
-	O	308-309
(	O	309-310
2	O	310-311
-	O	308-309
hydroxypropyl	O	312-325
)	O	325-326
methacrylamide	O	326-340
(	O	341-342
HPMA	O	342-346
)	O	346-347
copolymer	O	348-357
conjugates	O	358-368
.	O	368-369

In	O	370-372
these	O	373-378
HPMA	O	379-383
copolymers	O	384-394
,	O	394-395
DOX	O	396-399
was	O	400-403
covalently	O	404-414
bound	O	415-420
via	O	421-424
peptide	O	425-432
linkages	O	433-441
that	O	442-446
were	O	447-451
either	O	452-458
non	O	459-462
-	O	462-463
biodegradable	O	463-476
(	O	477-478
Gly	O	478-481
-	O	481-482
Gly	O	478-481
)	O	485-486
or	O	487-489
degradable	O	490-500
by	O	501-503
lysosomal	O	504-513
proteinases	O	514-525
(	O	526-527
Gly	O	527-530
-	O	530-531
Phe	O	531-534
-	O	530-531
Leu	O	535-538
-	O	530-531
Gly	O	527-530
)	O	542-543
.	O	543-544

In	O	545-547
addition	O	548-556
,	O	556-557
one	O	558-561
biodegradable	O	562-575
conjugate	O	576-585
containing	O	586-596
galactosamine	O	597-610
was	O	611-614
used	O	615-619
;	O	619-620
this	O	621-625
residue	O	626-633
was	O	634-637
targeted	O	638-646
to	O	647-649
the	O	650-653
liver	O	654-659
.	O	659-660

Over	O	661-665
the	O	666-669
first	O	670-675
3	O	676-677
weeks	O	678-683
after	O	684-689
the	O	690-693
i	O	694-695
.	O	695-696
v	O	696-697
.	O	695-696

administration	O	699-713
of	O	714-716
free	O	717-721
and	O	722-725
polymer	O	726-733
-	O	733-734
bound	O	734-739
DOX	O	740-743
,	O	743-744
all	O	745-748
animals	O	749-756
showed	O	757-763
a	O	764-765
transient	O	766-775
reduction	O	776-785
in	O	786-788
body	O	789-793
weight	O	794-800
.	O	800-801

However	O	802-809
,	O	809-810
the	O	811-814
maximal	O	815-822
reduction	O	823-832
in	O	833-835
body	O	836-840
weight	O	841-847
seen	O	848-852
in	O	853-855
animals	O	856-863
that	O	864-868
received	O	869-877
polymer	O	878-885
-	O	885-886
bound	O	886-891
DOX	O	892-895
(	O	896-897
4	O	897-898
mg	O	899-901
/	O	901-902
kg	O	902-904
)	O	904-905
was	O	906-909
significantly	O	910-923
lower	O	924-929
than	O	930-934
that	O	935-939
observed	O	940-948
in	O	949-951
those	O	952-957
that	O	958-962
received	O	963-971
free	O	972-976
DOX	O	977-980
(	O	981-982
4	O	982-983
mg	O	984-986
/	O	986-987
kg	O	987-989
)	O	989-990
or	O	991-993
a	O	994-995
mixture	O	996-1003
of	O	1004-1006
the	O	1007-1010
unmodified	O	1011-1021
parent	O	1022-1028
HPMA	O	1029-1033
copolymer	O	1034-1043
and	O	1044-1047
free	O	1048-1052
DOX	O	1053-1056
(	O	1057-1058
4	O	1058-1059
mg	O	1060-1062
/	O	1062-1063
kg	O	1063-1065
;	O	1065-1066
P	O	1067-1068
less	O	1069-1073
than	O	1074-1078
0	O	1079-1080
.	O	1080-1081
01	O	1081-1083
)	O	1083-1084
.	O	1080-1081

Throughout	O	1086-1096
the	O	1097-1100
study	O	1101-1106
(	O	1107-1108
20	O	1108-1110
weeks	O	1111-1116
)	O	1116-1117
,	O	1117-1118
deaths	O	1119-1125
related	O	1126-1133
to	O	1134-1136
cardiotoxicity	B	1137-1151
were	O	1152-1156
observed	O	1157-1165
only	O	1166-1170
in	O	1171-1173
animals	O	1174-1181
that	O	1182-1186
received	O	1187-1195
either	O	1196-1202
free	O	1203-1207
DOX	O	1208-1211
or	O	1212-1214
the	O	1215-1218
mixture	O	1219-1226
of	O	1227-1229
HPMA	O	1230-1234
copolymer	O	1235-1244
and	O	1245-1248
free	O	1249-1253
DOX	O	1254-1257
;	O	1257-1258
in	O	1259-1261
these	O	1262-1267
cases	O	1268-1273
,	O	1273-1274
histological	O	1275-1287
investigations	O	1288-1302
revealed	O	1303-1311
marked	O	1312-1318
changes	O	1319-1326
in	O	1327-1329
the	O	1330-1333
heart	O	1334-1339
that	O	1340-1344
were	O	1345-1349
consistent	O	1350-1360
with	O	1361-1365
DOX	O	1366-1369
-	O	1369-1370
induced	O	1370-1377
cardiotoxicity	B	1378-1392
.	O	1392-1393

Sequential	O	1394-1404
measurements	O	1405-1417
of	O	1418-1420
cardiac	O	1421-1428
output	O	1429-1435
in	O	1436-1438
surviving	O	1439-1448
animals	O	1449-1456
that	O	1457-1461
received	O	1462-1470
either	O	1471-1477
free	O	1478-1482
DOX	O	1483-1486
or	O	1487-1489
the	O	1490-1493
mixture	O	1494-1501
of	O	1502-1504
HPMA	O	1505-1509
copolymer	O	1510-1519
and	O	1520-1523
free	O	1524-1528
DOX	O	1529-1532
showed	O	1533-1539
a	O	1540-1541
reduction	O	1542-1551
of	O	1552-1554
approximately	O	1555-1568
30	O	1569-1571
%	O	1571-1572
in	O	1573-1575
function	O	1576-1584
beginning	O	1585-1594
at	O	1595-1597
the	O	1598-1601
4th	O	1602-1605
week	O	1606-1610
after	O	1611-1616
drug	O	1617-1621
administration	O	1622-1636
.	O	1636-1637

The	O	1638-1641
heart	O	1642-1647
rate	O	1648-1652
in	O	1653-1655
these	O	1656-1661
animals	O	1662-1669
was	O	1670-1673
approximately	O	1674-1687
12	O	1688-1690
%	O	1690-1691
lower	O	1692-1697
than	O	1698-1702
that	O	1703-1707
measured	O	1708-1716
in	O	1717-1719
age	O	1720-1723
-	O	1723-1724
matched	O	1724-1731
control	O	1732-1739
rats	O	1740-1744
(	O	1745-1746
P	O	1746-1747
less	O	1748-1752
than	O	1753-1757
0	O	1758-1759
.	O	1759-1760
05	O	1760-1762
)	O	1762-1763
.	O	1759-1760

Animals	O	1765-1772
that	O	1773-1777
were	O	1778-1782
given	O	1783-1788
the	O	1789-1792
HPMA	O	1793-1797
copolymer	O	1798-1807
conjugates	O	1808-1818
containing	O	1819-1829
DOX	O	1830-1833
exhibited	O	1834-1843
no	O	1844-1846
significant	O	1847-1858
change	O	1859-1865
in	O	1866-1868
cardiac	O	1869-1876
output	O	1877-1883
throughout	O	1884-1894
the	O	1895-1898
study	O	1899-1904
(	O	1905-1906
P	O	1906-1907
less	O	1908-1912
than	O	1913-1917
0	O	1918-1919
.	O	1919-1920
05	O	1920-1922
)	O	1922-1923
.	O	1919-1920

In	O	1925-1927
addition	O	1928-1936
,	O	1936-1937
no	O	1938-1940
significant	O	1941-1952
histological	O	1953-1965
change	O	1966-1972
was	O	1973-1976
observed	O	1977-1985
in	O	1986-1988
the	O	1989-1992
heart	O	1993-1998
of	O	1999-2001
animals	O	2002-2009
that	O	2010-2014
received	O	2015-2023
DOX	O	2024-2027
in	O	2028-2030
the	O	2031-2034
form	O	2035-2039
of	O	2040-2042
HPMA	O	2043-2047
copolymer	O	2048-2057
conjugates	O	2058-2068
and	O	2069-2072
were	O	2073-2077
killed	O	2078-2084
at	O	2085-2087
the	O	2088-2091
end	O	2092-2095
of	O	2096-2098
the	O	2099-2102
study	O	2103-2108
.	O	2108-2109

However	O	2110-2117
,	O	2117-2118
these	O	2119-2124
animals	O	2125-2132
had	O	2133-2136
shown	O	2137-2142
a	O	2143-2144
significant	O	2145-2156
increase	O	2157-2165
in	O	2166-2168
heart	O	2169-2174
rate	O	2175-2179
beginning	O	2180-2189
at	O	2190-2192
8	O	2193-2194
weeks	O	2195-2200
after	O	2201-2206
drug	O	2207-2211
administration	O	2212-2226
(	O	2227-2228
P	O	2228-2229
less	O	2230-2234
than	O	2235-2239
0	O	2240-2241
.	O	2241-2242
01	O	2242-2244
)	O	2244-2245
.	O	2241-2242
(	O	2246-2247
ABSTRACT	O	2247-2255

TRUNCATED	O	2256-2265
AT	O	2266-2268
400	O	2269-2272
WORDS	O	2273-2278
)	O	2278-2279

Topical	O	0-7
0	O	8-9
.	O	9-10
025	O	10-13
%	O	13-14
capsaicin	O	15-24
in	O	25-27
chronic	O	28-35
post	B	36-40
-	I	40-41
herpetic	I	41-49
neuralgia	I	50-59
:	O	59-60
efficacy	O	61-69
,	O	69-70
predictors	O	71-81
of	O	82-84
response	O	85-93
and	O	94-97
long	O	98-102
-	O	102-103
term	O	103-107
course	O	108-114
.	O	114-115

In	O	116-118
order	O	119-124
to	O	125-127
evaluate	O	128-136
the	O	137-140
efficacy	O	141-149
,	O	149-150
time	O	151-155
-	O	155-156
course	O	156-162
of	O	163-165
action	O	166-172
and	O	173-176
predictors	O	177-187
of	O	188-190
response	O	191-199
to	O	200-202
topical	O	203-210
capsaicin	O	211-220
,	O	220-221
39	O	222-224
patients	O	225-233
with	O	234-238
chronic	O	239-246
post	B	247-251
-	I	251-252
herpetic	I	252-260
neuralgia	I	261-270
(	O	271-272
PHN	B	272-275
)	O	275-276
,	O	276-277
median	O	278-284
duration	O	285-293
24	O	294-296
months	O	297-303
,	O	303-304
were	O	305-309
treated	O	310-317
with	O	318-322
0	O	323-324
.	O	324-325
025	O	325-328
%	O	328-329
capsaicin	O	330-339
cream	O	340-345
for	O	346-349
8	O	350-351
weeks	O	352-357
.	O	357-358

During	O	359-365
therapy	O	366-373
the	O	374-377
patients	O	378-386
rated	O	387-392
their	O	393-398
pain	B	399-403
on	O	404-406
a	O	407-408
visual	O	409-415
analogue	O	416-424
scale	O	425-430
(	O	431-432
VAS	O	432-435
)	O	435-436
and	O	437-440
a	O	441-442
verbal	O	443-449
outcome	O	450-457
scale	O	458-463
.	O	463-464

A	O	465-466
follow	O	467-473
-	O	473-474
up	O	474-476
investigation	O	477-490
was	O	491-494
performed	O	495-504
10	O	505-507
-	O	507-508
12	O	508-510
months	O	511-517
after	O	518-523
study	O	524-529
onset	O	530-535
on	O	536-538
the	O	539-542
patients	O	543-551
who	O	552-555
had	O	556-559
improved	O	560-568
.	O	568-569

Nineteen	O	570-578
patients	O	579-587
(	O	588-589
48	O	589-591
.	O	591-592
7	O	592-593
%	O	593-594
)	O	594-595
substantially	O	596-609
improved	O	610-618
after	O	619-624
the	O	625-628
8	O	629-630
-	O	630-631
week	O	631-635
trial	O	636-641
;	O	641-642
5	O	643-644
(	O	645-646
12	O	646-648
.	O	648-649
8	O	649-650
%	O	650-651
)	O	651-652
discontinued	O	653-665
therapy	O	666-673
due	O	674-677
to	O	678-680
side	O	681-685
-	O	685-686
effects	O	686-693
such	O	694-698
as	O	699-701
intolerable	O	702-713
capsaicin	O	714-723
-	O	723-724
induced	O	724-731
burning	O	732-739
sensations	O	740-750
(	O	751-752
4	O	752-753
)	O	753-754
or	O	755-757
mastitis	B	758-766
(	O	767-768
1	O	768-769
)	O	769-770
;	O	770-771
15	O	772-774
(	O	775-776
38	O	776-778
.	O	778-779
5	O	779-780
%	O	780-781
)	O	781-782
reported	O	783-791
no	O	792-794
benefit	O	795-802
.	O	802-803

The	O	804-807
decrease	O	808-816
in	O	817-819
VAS	O	820-823
ratings	O	824-831
was	O	832-835
significant	O	836-847
after	O	848-853
2	O	854-855
weeks	O	856-861
of	O	862-864
continuous	O	865-875
application	O	876-887
.	O	887-888

Of	O	889-891
the	O	892-895
responders	O	896-906
72	O	907-909
.	O	909-910
2	O	908-909
%	O	911-912
were	O	913-917
still	O	918-923
improved	O	924-932
at	O	933-935
the	O	936-939
follow	O	940-946
-	O	946-947
up	O	947-949
;	O	949-950
only	O	951-955
one	O	956-959
-	O	959-960
third	O	960-965
of	O	966-968
them	O	969-973
had	O	974-977
continued	O	978-987
application	O	988-999
irregularly	O	1000-1011
.	O	1011-1012

Treatment	O	1013-1022
effect	O	1023-1029
was	O	1030-1033
not	O	1034-1037
dependent	O	1038-1047
on	O	1048-1050
patient	O	1051-1058
'	O	1058-1059
s	O	1059-1060
age	O	1061-1064
,	O	1064-1065
duration	O	1066-1074
or	O	1075-1077
localization	O	1078-1090
of	O	1091-1093
PHN	B	1094-1097
(	O	1098-1099
trigeminal	O	1099-1109
involvement	O	1110-1121
was	O	1122-1125
excluded	O	1126-1134
)	O	1134-1135
,	O	1135-1136
sensory	B	1137-1144
disturbance	I	1145-1156
or	O	1157-1159
pain	B	1160-1164
character	O	1165-1174
.	O	1174-1175

Treatment	O	1176-1185
response	O	1186-1194
was	O	1195-1198
not	O	1199-1202
correlated	O	1203-1213
with	O	1214-1218
the	O	1219-1222
incidence	O	1223-1232
,	O	1232-1233
time	O	1234-1238
-	O	1238-1239
course	O	1239-1245
or	O	1246-1248
severity	O	1249-1257
of	O	1258-1260
capsaicin	O	1261-1270
-	O	1270-1271
induced	O	1271-1278
burning	O	1279-1286
.	O	1286-1287

If	O	1288-1290
confirmed	O	1291-1300
in	O	1301-1303
controlled	O	1304-1314
trials	O	1315-1321
,	O	1321-1322
the	O	1323-1326
long	O	1327-1331
-	O	1331-1332
term	O	1332-1336
results	O	1337-1344
of	O	1345-1347
this	O	1348-1352
open	O	1353-1357
,	O	1357-1358
non	O	1359-1362
-	O	1362-1363
randomized	O	1363-1373
study	O	1374-1379
might	O	1380-1385
indicate	O	1386-1394
that	O	1395-1399
the	O	1400-1403
analgesic	O	1404-1413
effect	O	1414-1420
of	O	1421-1423
capsaicin	O	1424-1433
in	O	1434-1436
PHN	B	1437-1440
is	O	1441-1443
mediated	O	1444-1452
by	O	1453-1455
both	O	1456-1460
interference	O	1461-1473
with	O	1474-1478
neuropeptide	O	1479-1491
metabolism	O	1492-1502
and	O	1503-1506
morphological	O	1507-1520
changes	O	1521-1528
(	O	1529-1530
perhaps	O	1530-1537
degeneration	O	1538-1550
)	O	1550-1551
of	O	1552-1554
nociceptive	O	1555-1566
afferents	O	1567-1576
.	O	1576-1577

Serotonin	O	0-9
reuptake	O	10-18
inhibitors	O	19-29
,	O	29-30
paranoia	B	31-39
,	O	39-40
and	O	41-44
the	O	45-48
ventral	O	49-56
basal	O	57-62
ganglia	O	63-70
.	O	70-71

Antidepressants	O	72-87
have	O	88-92
previously	O	93-103
been	O	104-108
associated	O	109-119
with	O	120-124
paranoid	B	125-133
reactions	O	134-143
in	O	144-146
psychiatric	O	147-158
patients	O	159-167
.	O	167-168

Five	O	169-173
cases	O	174-179
of	O	180-182
paranoid	B	183-191
exacerbation	O	192-204
with	O	205-209
the	O	210-213
serotonin	O	214-223
reuptake	O	224-232
inhibitors	O	233-243
fluoxetine	O	244-254
and	O	255-258
amitriptyline	O	259-272
are	O	273-276
reported	O	277-285
here	O	286-290
.	O	290-291

Elements	O	292-300
common	O	301-307
to	O	308-310
these	O	311-316
cases	O	317-322
included	O	323-331
a	O	332-333
history	O	334-341
of	O	342-344
paranoid	B	345-353
symptomatology	O	354-368
and	O	369-372
the	O	373-376
concomitant	O	377-388
occurrence	O	389-399
of	O	400-402
depressive	B	403-413
and	I	414-417
psychotic	I	418-427
symptoms	I	428-436
.	O	436-437

Complicated	O	438-449
depressive	B	450-460
disorders	I	461-470
(	O	471-472
including	O	472-481
atypicality	O	482-493
of	O	494-496
course	O	497-503
and	O	504-507
symptomatology	O	508-522
,	O	522-523
chronicity	O	524-534
,	O	534-535
psychosis	B	536-545
,	O	545-546
bipolarity	O	547-557
,	O	557-558
and	O	559-562
secondary	O	563-572
onset	O	573-578
in	O	579-581
the	O	582-585
course	O	586-592
of	O	593-595
a	O	596-597
primary	O	598-605
psychosis	B	606-615
)	O	615-616
may	O	617-620
present	O	621-628
particular	O	629-639
vulnerability	O	640-653
to	O	654-656
paranoid	B	657-665
exacerbations	O	666-679
associated	O	680-690
with	O	691-695
serotonin	O	696-705
reuptake	O	706-714
inhibitors	O	715-725
.	O	725-726

Although	O	727-735
the	O	736-739
pharmacology	O	740-752
and	O	753-756
neurobiology	O	757-769
of	O	770-772
paranoia	B	773-781
remain	O	782-788
cryptic	O	789-796
,	O	796-797
several	O	798-805
mechanisms	O	806-816
,	O	816-817
including	O	818-827
5HT3	O	828-832
receptor	O	833-841
-	O	841-842
mediated	O	842-850
dopamine	O	851-859
release	O	860-867
,	O	867-868
beta	O	869-873
-	O	873-874
noradrenergic	O	874-887
receptor	O	888-896
downregulation	O	897-911
,	O	911-912
or	O	913-915
GABAB	O	916-921
receptor	O	922-930
upregulation	O	931-943
acting	O	944-950
in	O	951-953
the	O	954-957
vicinity	O	958-966
of	O	967-969
the	O	970-973
ventral	O	974-981
basal	O	982-987
ganglia	O	988-995
(	O	996-997
possibly	O	997-1005
in	O	1006-1008
lateral	O	1009-1016
orbitofrontal	O	1017-1030
or	O	1031-1033
anterior	O	1034-1042
cingulate	O	1043-1052
circuits	O	1053-1061
)	O	1061-1062
,	O	1062-1063
might	O	1064-1069
apply	O	1070-1075
to	O	1076-1078
this	O	1079-1083
phenomenon	O	1084-1094
.	O	1094-1095

These	O	1096-1101
cases	O	1102-1107
call	O	1108-1112
attention	O	1113-1122
to	O	1123-1125
possible	O	1126-1134
paranoid	B	1135-1143
exacerbations	O	1144-1157
with	O	1158-1162
serotonin	O	1163-1172
reuptake	O	1173-1181
blockers	O	1182-1190
in	O	1191-1193
select	O	1194-1200
patients	O	1201-1209
and	O	1210-1213
raise	O	1214-1219
neurobiological	O	1220-1235
considerations	O	1236-1250
regarding	O	1251-1260
paranoia	B	1261-1269
.	O	1269-1270

Five	O	0-4
cases	O	5-10
of	O	11-13
encephalitis	B	14-26
during	O	27-33
treatment	O	34-43
of	O	44-46
loiasis	B	47-54
with	O	55-59
diethylcarbamazine	O	60-78
.	O	78-79

Five	O	80-84
cases	O	85-90
of	O	91-93
encephalitis	B	94-106
following	O	107-116
treatment	O	117-126
with	O	127-131
diethylcarbamazine	O	132-150
(	O	151-152
DEC	O	152-155
)	O	155-156
were	O	157-161
observed	O	162-170
in	O	171-173
Congolese	O	174-183
patients	O	184-192
with	O	193-197
Loa	O	198-201
loa	O	202-205
filariasis	B	206-216
.	O	216-217

Two	O	218-221
cases	O	222-227
had	O	228-231
a	O	232-233
fatal	O	234-239
outcome	O	240-247
and	O	248-251
one	O	252-255
resulted	O	256-264
in	O	265-267
severe	O	268-274
sequelae	O	275-283
.	O	283-284

The	O	285-288
notable	O	289-296
fact	O	297-301
was	O	302-305
that	O	306-310
this	O	311-315
complication	O	316-328
occurred	O	329-337
in	O	338-340
three	O	341-346
patients	O	347-355
hospitalized	O	356-368
before	O	369-375
treatment	O	376-385
began	O	386-391
,	O	391-392
with	O	393-397
whom	O	398-402
particularly	O	403-415
strict	O	416-422
therapeutic	O	423-434
precautions	O	435-446
were	O	447-451
taken	O	452-457
,	O	457-458
i	O	459-460
.	O	460-461
e	O	461-462
.	O	460-461
,	O	463-464
initial	O	465-472
dose	O	473-477
less	O	478-482
than	O	483-487
10	O	488-490
mg	O	491-493
of	O	494-496
DEC	O	497-500
,	O	500-501
very	O	502-506
gradual	O	507-514
dose	O	515-519
increases	O	520-529
,	O	529-530
and	O	531-534
associated	O	535-545
anti	O	546-550
-	O	550-551
allergic	O	551-559
treatment	O	560-569
.	O	569-570

This	O	571-575
type	O	576-580
of	O	581-583
drug	O	584-588
-	O	588-589
induced	O	589-596
complication	O	597-609
may	O	610-613
not	O	614-617
be	O	618-620
that	O	621-625
uncommon	O	626-634
in	O	635-637
highly	O	638-644
endemic	O	645-652
regions	O	653-660
.	O	660-661

It	O	662-664
occurs	O	665-671
primarily	O	672-681
,	O	681-682
but	O	683-686
not	O	687-690
exclusively	O	691-702
,	O	702-703
in	O	704-706
subjects	O	707-715
presenting	O	716-726
with	O	727-731
a	O	732-733
high	O	734-738
microfilarial	O	739-752
load	O	753-757
.	O	757-758

The	O	759-762
relationship	O	763-775
between	O	776-783
the	O	784-787
occurrence	O	788-798
of	O	799-801
encephalitis	B	802-814
and	O	815-818
the	O	819-822
decrease	O	823-831
in	O	832-834
microfilaremia	B	835-849
is	O	850-852
evident	O	853-860
.	O	860-861

The	O	862-865
pathophysiological	O	866-884
mechanisms	O	885-895
are	O	896-899
discussed	O	900-909
in	O	910-912
the	O	913-916
light	O	917-922
of	O	923-925
these	O	926-931
observations	O	932-944
and	O	945-948
the	O	949-952
few	O	953-956
other	O	957-962
comments	O	963-971
on	O	972-974
this	O	975-979
subject	O	980-987
published	O	988-997
in	O	998-1000
the	O	1001-1004
literature	O	1005-1015
.	O	1015-1016

Delirium	B	0-8
in	O	9-11
an	O	12-14
elderly	O	15-22
woman	O	23-28
possibly	O	29-37
associated	O	38-48
with	O	49-53
administration	O	54-68
of	O	69-71
misoprostol	O	72-83
.	O	83-84

Misoprostol	O	85-96
has	O	97-100
been	O	101-105
associated	O	106-116
with	O	117-121
adverse	O	122-129
reactions	O	130-139
,	O	139-140
including	O	141-150
gastrointestinal	O	151-167
symptoms	O	168-176
,	O	176-177
gynecologic	O	178-189
problems	O	190-198
,	O	198-199
and	O	200-203
headache	B	204-212
.	O	212-213

Changes	O	214-221
in	O	222-224
mental	O	225-231
status	O	232-238
,	O	238-239
however	O	240-247
,	O	247-248
have	O	249-253
not	O	254-257
been	O	258-262
reported	O	263-271
.	O	271-272

We	O	273-275
present	O	276-283
a	O	284-285
case	O	286-290
in	O	291-293
which	O	294-299
an	O	300-302
89	O	303-305
-	O	305-306
year	O	306-310
-	O	305-306
old	O	311-314
woman	O	315-320
in	O	321-323
a	O	324-325
long	O	326-330
-	O	330-331
term	O	331-335
care	O	336-340
facility	O	341-349
became	O	350-356
confused	O	357-365
after	O	366-371
the	O	372-375
initiation	O	376-386
of	O	387-389
misoprostol	O	390-401
therapy	O	402-409
.	O	409-410

The	O	411-414
patient	O	415-422
'	O	422-423
s	O	423-424
change	O	425-431
in	O	432-434
mental	O	435-441
status	O	442-448
was	O	449-452
first	O	453-458
reported	O	459-467
nine	O	468-472
days	O	473-477
after	O	478-483
the	O	484-487
initiation	O	488-498
of	O	499-501
therapy	O	502-509
.	O	509-510

Her	O	511-514
delirium	B	515-523
significantly	O	524-537
improved	O	538-546
after	O	547-552
misoprostol	O	553-564
was	O	565-568
discontinued	O	569-581
and	O	582-585
her	O	586-589
mental	O	590-596
status	O	597-603
returned	O	604-612
to	O	613-615
normal	O	616-622
within	O	623-629
a	O	630-631
week	O	632-636
.	O	636-637

Because	O	638-645
no	O	646-648
other	O	649-654
factors	O	655-662
related	O	663-670
to	O	671-673
this	O	674-678
patient	O	679-686
changed	O	687-694
significantly	O	695-708
,	O	708-709
the	O	710-713
delirium	B	714-722
experienced	O	723-734
by	O	735-737
this	O	738-742
patient	O	743-750
possibly	O	751-759
resulted	O	760-768
from	O	769-773
misoprostol	O	774-785
therapy	O	786-793
.	O	793-794

Hepatocellular	O	0-14
oxidant	O	15-22
stress	O	23-29
following	O	30-39
intestinal	O	40-50
ischemia	B	51-59
-	O	59-60
reperfusion	B	60-71
injury	I	72-78
.	O	78-79

Reperfusion	O	80-91
of	O	92-94
ischemic	B	95-103
intestine	O	104-113
results	O	114-121
in	O	122-124
acute	O	125-130
liver	B	131-136
dysfunction	I	137-148
characterized	O	149-162
by	O	163-165
hepatocellular	O	166-180
enzyme	O	181-187
release	O	188-195
into	O	196-200
plasma	O	201-207
,	O	207-208
reduction	O	209-218
in	O	219-221
bile	O	222-226
flow	O	227-231
rate	O	232-236
,	O	236-237
and	O	238-241
neutrophil	O	242-252
sequestration	O	253-266
within	O	267-273
the	O	274-277
liver	O	278-283
.	O	283-284

The	O	285-288
pathophysiology	O	289-304
underlying	O	305-315
this	O	316-320
acute	O	321-326
hepatic	B	327-334
injury	I	335-341
is	O	342-344
unknown	O	345-352
.	O	352-353

This	O	354-358
study	O	359-364
was	O	365-368
undertaken	O	369-379
to	O	380-382
determine	O	383-392
whether	O	393-400
oxidants	O	401-409
are	O	410-413
associated	O	414-424
with	O	425-429
the	O	430-433
hepatic	B	434-441
injury	I	442-448
and	O	449-452
to	O	453-455
determine	O	456-465
the	O	466-469
relative	O	470-478
value	O	479-484
of	O	485-487
several	O	488-495
indirect	O	496-504
methods	O	505-512
of	O	513-515
assessing	O	516-525
oxidant	O	526-533
exposure	O	534-542
in	O	543-545
vivo	O	546-550
.	O	550-551

Rats	O	552-556
were	O	557-561
subjected	O	562-571
to	O	572-574
a	O	575-576
standardized	O	577-589
intestinal	O	590-600
ischemia	B	601-609
-	O	609-610
reperfusion	B	610-621
injury	I	622-628
.	O	628-629

Hepatic	O	630-637
tissue	O	638-644
was	O	645-648
assayed	O	649-656
for	O	657-660
lipid	O	661-666
peroxidation	O	667-679
products	O	680-688
and	O	689-692
oxidized	O	693-701
and	O	702-705
reduced	O	706-713
glutathione	O	714-725
.	O	725-726

There	O	727-732
was	O	733-736
no	O	737-739
change	O	740-746
in	O	747-749
hepatic	O	750-757
tissue	O	758-764
total	O	765-770
glutathione	O	771-782
following	O	783-792
intestinal	O	793-803
ischemia	B	804-812
-	O	812-813
reperfusion	B	813-824
injury	I	825-831
.	O	831-832

Oxidized	O	833-841
glutathione	O	842-853
(	O	854-855
GSSG	O	855-859
)	O	859-860
increased	O	861-870
significantly	O	871-884
following	O	885-894
30	O	895-897
and	O	898-901
60	O	902-904
min	O	905-908
of	O	909-911
reperfusion	O	912-923
.	O	923-924

There	O	925-930
was	O	931-934
no	O	935-937
increase	O	938-946
in	O	947-949
any	O	950-953
of	O	954-956
the	O	957-960
products	O	961-969
of	O	970-972
lipid	O	973-978
peroxidation	O	979-991
associated	O	992-1002
with	O	1003-1007
this	O	1008-1012
injury	O	1013-1019
.	O	1019-1020

An	O	1021-1023
increase	O	1024-1032
in	O	1033-1035
GSSG	O	1036-1040
within	O	1041-1047
hepatic	O	1048-1055
tissue	O	1056-1062
during	O	1063-1069
intestinal	O	1070-1080
reperfusion	O	1081-1092
suggests	O	1093-1101
exposure	O	1102-1110
of	O	1111-1113
hepatocytes	O	1114-1125
to	O	1126-1128
an	O	1129-1131
oxidant	O	1132-1139
stress	O	1140-1146
.	O	1146-1147

The	O	1148-1151
lack	O	1152-1156
of	O	1157-1159
a	O	1160-1161
significant	O	1162-1173
increase	O	1174-1182
in	O	1183-1185
products	O	1186-1194
of	O	1195-1197
lipid	O	1198-1203
peroxidation	O	1204-1216
suggests	O	1217-1225
that	O	1226-1230
the	O	1231-1234
oxidant	O	1235-1242
stress	O	1243-1249
is	O	1250-1252
of	O	1253-1255
insufficient	O	1256-1268
magnitude	O	1269-1278
to	O	1279-1281
result	O	1282-1288
in	O	1289-1291
irreversible	O	1292-1304
injury	O	1305-1311
to	O	1312-1314
hepatocyte	O	1315-1325
cell	O	1326-1330
membranes	O	1331-1340
.	O	1340-1341

These	O	1342-1347
data	O	1348-1352
also	O	1353-1357
suggest	O	1358-1365
that	O	1366-1370
the	O	1371-1374
measurement	O	1375-1386
of	O	1387-1389
tissue	O	1390-1396
GSSG	O	1397-1401
may	O	1402-1405
be	O	1406-1408
a	O	1409-1410
more	O	1411-1415
sensitive	O	1416-1425
indicator	O	1426-1435
of	O	1436-1438
oxidant	O	1439-1446
stress	O	1447-1453
than	O	1454-1458
measurement	O	1459-1470
of	O	1471-1473
products	O	1474-1482
of	O	1483-1485
lipid	O	1486-1491
peroxidation	O	1492-1504
.	O	1504-1505

Diphenhydramine	O	0-15
prevents	O	16-24
the	O	25-28
haemodynamic	O	29-41
changes	O	42-49
of	O	50-52
cimetidine	O	53-63
in	O	64-66
ICU	O	67-70
patients	O	71-79
.	O	79-80

Cimetidine	O	81-91
,	O	91-92
a	O	93-94
histamine	O	95-104
2	O	105-106
(	O	107-108
H2	O	108-110
)	O	110-111
antagonist	O	112-122
,	O	122-123
produces	O	124-132
a	O	133-134
decrease	O	135-143
in	O	144-146
arterial	O	147-155
pressure	O	156-164
due	O	165-168
to	O	169-171
vasodilatation	O	172-186
,	O	186-187
especially	O	188-198
in	O	199-201
critically	O	202-212
ill	O	213-216
patients	O	217-225
.	O	225-226

This	O	227-231
may	O	232-235
be	O	236-238
because	O	239-246
cimetidine	O	247-257
acts	O	258-262
as	O	263-265
a	O	266-267
histamine	O	268-277
agonist	O	278-285
.	O	285-286

We	O	287-289
,	O	289-290
therefore	O	291-300
,	O	300-301
investigated	O	302-314
the	O	315-318
effects	O	319-326
of	O	327-329
the	O	330-333
histamine	O	334-343
1	O	344-345
(	O	345-346
H1	O	346-348
)	O	348-349
receptor	O	350-358
antagonist	O	359-369
,	O	369-370
diphenhydramine	O	371-386
,	O	386-387
on	O	388-390
the	O	391-394
haemodynamic	O	395-407
changes	O	408-415
observed	O	416-424
after	O	425-430
cimetidine	O	431-441
in	O	442-444
ICU	O	445-448
patients	O	449-457
.	O	457-458

Each	O	459-463
patient	O	464-471
was	O	472-475
studied	O	476-483
on	O	484-486
two	O	487-490
separate	O	491-499
days	O	500-504
.	O	504-505

In	O	506-508
a	O	509-510
random	O	511-517
fashion	O	518-525
,	O	525-526
they	O	527-531
received	O	532-540
cimetidine	O	541-551
200	O	552-555
mg	O	556-558
iv	O	559-561
on	O	562-564
one	O	565-568
day	O	569-572
,	O	572-573
and	O	574-577
on	O	578-580
the	O	581-584
other	O	585-590
,	O	590-591
a	O	592-593
pretreatment	O	594-606
of	O	607-609
diphenhydramine	O	610-625
40	O	626-628
mg	O	629-631
iv	O	632-634
with	O	635-639
cimetidine	O	640-650
200	O	651-654
mg	O	655-657
iv	O	658-660
.	O	660-661

In	O	662-664
the	O	665-668
non	O	669-672
-	O	672-673
pretreatment	O	673-685
group	O	686-691
,	O	691-692
mean	O	693-697
arterial	O	698-706
pressure	O	707-715
(	O	716-717
MAP	O	717-720
)	O	720-721
decreased	O	722-731
from	O	732-736
107	O	737-740
.	O	740-741
4	O	741-742
+	O	743-744
/	O	744-745
-	O	745-746
8	O	747-748
.	O	748-749
4	O	749-750
mmHg	O	751-755
to	O	756-758
86	O	759-761
.	O	761-762
7	O	762-763
+	O	764-765
/	O	765-766
-	O	766-767
11	O	768-770
.	O	770-771
4	O	771-772
mmHg	O	773-777
(	O	778-779
P	O	779-780
less	O	781-785
than	O	786-790
0	O	791-792
.	O	792-793
01	O	793-795
)	O	795-796
two	O	797-800
minutes	O	801-808
after	O	809-814
cimetidine	O	815-825
.	O	825-826

Also	O	827-831
,	O	831-832
systemic	O	833-841
vascular	O	842-850
resistance	O	851-861
(	O	862-863
SVR	O	863-866
)	O	866-867
decreased	O	868-877
during	O	878-884
the	O	885-888
eight	O	889-894
-	O	894-895
minute	O	895-901
observation	O	902-913
period	O	914-920
(	O	921-922
P	O	922-923
less	O	924-928
than	O	929-933
0	O	934-935
.	O	935-936
01	O	936-938
)	O	938-939
.	O	935-936

In	O	941-943
contrast	O	944-952
,	O	952-953
in	O	954-956
the	O	957-960
pretreatment	O	961-973
group	O	974-979
,	O	979-980
little	O	981-987
haemodynamic	O	988-1000
change	O	1001-1007
was	O	1008-1011
seen	O	1012-1016
.	O	1016-1017

We	O	1018-1020
conclude	O	1021-1029
that	O	1030-1034
an	O	1035-1037
H1	O	1038-1040
antagonist	O	1041-1051
may	O	1052-1055
be	O	1056-1058
useful	O	1059-1065
in	O	1066-1068
preventing	O	1069-1079
hypotension	B	1080-1091
caused	O	1092-1098
by	O	1099-1101
iv	O	1102-1104
cimetidine	O	1105-1115
,	O	1115-1116
since	O	1117-1122
the	O	1123-1126
vasodilating	O	1127-1139
activity	O	1140-1148
of	O	1149-1151
cimetidine	O	1152-1162
is	O	1163-1165
mediated	O	1166-1174
,	O	1174-1175
in	O	1176-1178
part	O	1179-1183
,	O	1183-1184
through	O	1185-1192
the	O	1193-1196
H1	O	1197-1199
receptor	O	1200-1208
.	O	1208-1209

Acute	B	0-5
renal	I	6-11
failure	I	12-19
due	O	20-23
to	O	24-26
rifampicin	O	27-37
.	O	37-38

A	O	39-40
23	O	41-43
-	O	43-44
year	O	44-48
-	O	43-44
old	O	49-52
male	O	53-57
patient	O	58-65
with	O	66-70
bacteriologically	O	71-88
proven	O	89-95
pulmonary	B	96-105
tuberculosis	I	106-118
was	O	119-122
treated	O	123-130
with	O	131-135
the	O	136-139
various	O	140-147
regimens	O	148-156
of	O	157-159
antituberculosis	O	160-176
drugs	O	177-182
for	O	183-186
nearly	O	187-193
15	O	194-196
months	O	197-203
.	O	203-204

Rifampicin	O	205-215
was	O	216-219
administered	O	220-232
thrice	O	233-239
as	O	240-242
one	O	243-246
of	O	247-249
the	O	250-253
3	O	254-255
-	O	255-256
4	O	256-257
drug	O	258-262
regimen	O	263-270
and	O	271-274
each	O	275-279
time	O	280-284
he	O	285-287
developed	O	288-297
untoward	O	298-306
side	O	307-311
effects	O	312-319
like	O	320-324
nausea	B	325-331
,	O	331-332
vomiting	B	333-341
and	O	342-345
fever	B	346-351
with	O	352-356
chills	O	357-363
and	O	364-367
rigors	O	368-374
.	O	374-375

The	O	376-379
last	O	380-384
such	O	385-389
episode	O	390-397
was	O	398-401
of	O	402-404
acute	O	405-410
renal	O	411-416
failure	O	417-424
at	O	425-427
which	O	428-433
stage	O	434-439
the	O	440-443
patient	O	444-451
was	O	452-455
seen	O	456-460
by	O	461-463
the	O	464-467
authors	O	468-475
of	O	476-478
this	O	479-483
report	O	484-490
.	O	490-491

The	O	492-495
patient	O	496-503
,	O	503-504
however	O	505-512
,	O	512-513
made	O	514-518
a	O	519-520
full	O	521-525
recovery	O	526-534
.	O	534-535

Severe	O	0-6
polyneuropathy	B	7-21
and	O	22-25
motor	O	26-31
loss	O	32-36
after	O	37-42
intrathecal	O	43-54
thiotepa	O	55-63
combination	O	64-75
chemotherapy	O	76-88
:	O	88-89
description	O	90-101
of	O	102-104
two	O	105-108
cases	O	109-114
.	O	114-115

Two	O	116-119
cases	O	120-125
of	O	126-128
severe	O	129-135
delayed	O	136-143
neurologic	B	144-154
toxicity	I	155-163
related	O	164-171
to	O	172-174
the	O	175-178
administration	O	179-193
of	O	194-196
intrathecal	O	197-208
(	O	209-210
IT	O	210-212
)	O	212-213
combination	O	214-225
chemotherapy	O	226-238
including	O	239-248
thiotepa	O	249-257
(	O	258-259
TSPA	O	259-263
)	O	263-264
are	O	265-268
presented	O	269-278
.	O	278-279

Both	O	280-284
cases	O	285-290
developed	O	291-300
axonal	B	301-307
neuropathy	I	308-318
with	O	319-323
motor	O	324-329
predominance	O	330-342
in	O	343-345
the	O	346-349
lower	O	350-355
extremities	O	356-367
1	O	368-369
and	O	370-373
6	O	374-375
months	O	376-382
after	O	383-388
IT	O	389-391
chemotherapy	O	392-404
was	O	405-408
administered	O	409-421
.	O	421-422

Neurologic	B	423-433
toxicities	I	434-444
have	O	445-449
been	O	450-454
described	O	455-464
with	O	465-469
IT	O	470-472
-	O	472-473
methotrexate	O	473-485
,	O	485-486
IT	O	487-489
-	O	489-490
cytosine	O	490-498
arabinoside	O	499-510
and	O	511-514
IT	O	515-517
-	O	517-518
TSPA	O	518-522
.	O	522-523

To	O	524-526
our	O	527-530
knowledge	O	531-540
,	O	540-541
however	O	542-549
,	O	549-550
axonal	B	551-557
neuropathy	I	558-568
following	O	569-578
administration	O	579-593
of	O	594-596
these	O	597-602
three	O	603-608
agents	O	609-615
has	O	616-619
not	O	620-623
been	O	624-628
previously	O	629-639
described	O	640-649
.	O	649-650

In	O	651-653
spite	O	654-659
of	O	660-662
the	O	663-666
fact	O	667-671
that	O	672-676
TSPA	O	677-681
is	O	682-684
a	O	685-686
useful	O	687-693
IT	O	694-696
agent	O	697-702
,	O	702-703
its	O	704-707
combination	O	708-719
with	O	720-724
MTX	O	725-728
,	O	728-729
ara	O	730-733
-	O	733-734
C	O	734-735
and	O	736-739
radiotherapy	O	740-752
could	O	753-758
cause	O	759-764
severe	O	765-771
neurotoxicity	B	772-785
.	O	785-786

This	O	787-791
unexpected	O	792-802
complication	O	803-815
indicates	O	816-825
the	O	826-829
need	O	830-834
for	O	835-838
further	O	839-846
toxicology	O	847-857
research	O	858-866
on	O	867-869
IT	O	870-872
-	O	872-873
TSPA	O	873-877
.	O	877-878

Effects	O	0-7
of	O	8-10
cromakalim	O	11-21
and	O	22-25
pinacidil	O	26-35
on	O	36-38
large	O	39-44
epicardial	O	45-55
and	O	56-59
small	O	60-65
coronary	O	66-74
arteries	O	75-83
in	O	84-86
conscious	O	87-96
dogs	O	97-101
.	O	101-102

The	O	103-106
effects	O	107-114
of	O	115-117
i	O	118-119
.	O	119-120
v	O	120-121
.	O	119-120

bolus	O	123-128
administration	O	129-143
of	O	144-146
cromakalim	O	147-157
(	O	158-159
1	O	159-160
-	O	160-161
10	O	161-163
micrograms	O	164-174
/	O	174-175
kg	O	175-177
)	O	177-178
and	O	179-182
pinacidil	O	183-192
(	O	193-194
3	O	194-195
-	O	195-196
100	O	196-199
micrograms	O	200-210
/	O	210-211
kg	O	211-213
)	O	213-214
on	O	215-217
large	O	218-223
(	O	224-225
circumflex	O	225-235
artery	O	236-242
)	O	242-243
and	O	244-247
small	O	248-253
coronary	O	254-262
arteries	O	263-271
and	O	272-275
on	O	276-278
systemic	O	279-287
hemodynamics	O	288-300
were	O	301-305
investigated	O	306-318
in	O	319-321
chronically	O	322-333
instrumented	O	334-346
conscious	O	347-356
dogs	O	357-361
and	O	362-365
compared	O	366-374
to	O	375-377
those	O	378-383
of	O	384-386
nitroglycerin	O	387-400
(	O	401-402
0	O	402-403
.	O	403-404
03	O	404-406
-	O	406-407
10	O	407-409
micrograms	O	410-420
/	O	420-421
kg	O	421-423
)	O	423-424
.	O	424-425

Nitroglycerin	O	426-439
,	O	439-440
up	O	441-443
to	O	444-446
0	O	447-448
.	O	448-449
3	O	449-450
micrograms	O	451-461
/	O	461-462
kg	O	462-464
,	O	464-465
selectively	O	466-477
increased	O	478-487
circumflex	O	488-498
artery	O	499-505
diameter	O	506-514
(	O	515-516
CxAD	O	516-520
)	O	520-521
without	O	522-529
simultaneously	O	530-544
affecting	O	545-554
any	O	555-558
other	O	559-564
cardiac	O	565-572
or	O	573-575
systemic	O	576-584
hemodynamic	O	585-596
parameter	O	597-606
.	O	606-607

In	O	608-610
contrast	O	611-619
,	O	619-620
cromakalim	O	621-631
and	O	632-635
pinacidil	O	636-645
at	O	646-648
all	O	649-652
doses	O	653-658
and	O	659-662
nitroglycerin	O	663-676
at	O	677-679
doses	O	680-685
higher	O	686-692
than	O	693-697
0	O	698-699
.	O	699-700
3	O	700-701
micrograms	O	702-712
/	O	712-713
kg	O	713-715
simultaneously	O	716-730
and	O	731-734
dose	O	735-739
-	O	739-740
dependently	O	740-751
increased	O	752-761
CxAD	O	762-766
,	O	766-767
coronary	O	768-776
blood	O	777-782
flow	O	783-787
and	O	788-791
heart	O	792-797
rate	O	798-802
and	O	803-806
decreased	O	807-816
coronary	O	817-825
vascular	O	826-834
resistance	O	835-845
and	O	846-849
aortic	O	850-856
pressure	O	857-865
.	O	865-866

Cromakalim	O	867-877
was	O	878-881
approximately	O	882-895
8	O	896-897
-	O	897-898
to	O	899-901
9	O	902-903
.	O	903-904
5	O	904-905
-	O	905-906
fold	O	906-910
more	O	911-915
potent	O	916-922
than	O	923-927
pinacidil	O	928-937
in	O	938-940
increasing	O	941-951
CxAD	O	952-956
.	O	956-957

Vasodilation	O	958-970
of	O	971-973
large	O	974-979
and	O	980-983
small	O	984-989
coronary	O	990-998
vessels	O	999-1006
and	O	1007-1010
hypotension	B	1011-1022
induced	O	1023-1030
by	O	1031-1033
cromakalim	O	1034-1044
and	O	1045-1048
pinacidil	O	1049-1058
were	O	1059-1063
not	O	1064-1067
affected	O	1068-1076
by	O	1077-1079
prior	O	1080-1085
combined	O	1086-1094
beta	O	1095-1099
adrenergic	O	1100-1110
and	O	1111-1114
muscarinic	O	1115-1125
receptors	O	1126-1135
blockade	O	1136-1144
but	O	1145-1148
drug	O	1149-1153
-	O	1153-1154
induced	O	1154-1161
tachycardia	B	1162-1173
was	O	1174-1177
abolished	O	1178-1187
.	O	1187-1188

When	O	1189-1193
circumflex	O	1194-1204
artery	O	1205-1211
blood	O	1212-1217
flow	O	1218-1222
was	O	1223-1226
maintained	O	1227-1237
constant	O	1238-1246
,	O	1246-1247
the	O	1248-1251
increases	O	1252-1261
in	O	1262-1264
CxAD	O	1265-1269
induced	O	1270-1277
by	O	1278-1280
cromakalim	O	1281-1291
(	O	1292-1293
10	O	1293-1295
micrograms	O	1296-1306
/	O	1306-1307
kg	O	1307-1309
)	O	1309-1310
,	O	1310-1311
pinacidil	O	1312-1321
(	O	1322-1323
30	O	1323-1325
micrograms	O	1326-1336
/	O	1336-1337
kg	O	1337-1339
)	O	1339-1340
and	O	1341-1344
nitroglycerin	O	1345-1358
(	O	1359-1360
10	O	1360-1362
micrograms	O	1363-1373
/	O	1373-1374
kg	O	1374-1376
)	O	1376-1377
were	O	1378-1382
reduced	O	1383-1390
by	O	1391-1393
68	O	1394-1396
+	O	1397-1398
/	O	1398-1399
-	O	1399-1400
7	O	1401-1402
,	O	1402-1403
54	O	1404-1406
+	O	1407-1408
/	O	1408-1409
-	O	1409-1410
9	O	1411-1412
and	O	1413-1416
1	O	1417-1418
+	O	1419-1420
/	O	1420-1421
-	O	1421-1422
1	O	1423-1424
%	O	1424-1425
,	O	1425-1426
respectively	O	1427-1439
.	O	1439-1440

Thus	O	1441-1445
,	O	1445-1446
whereas	O	1447-1454
nitroglycerin	O	1455-1468
preferentially	O	1469-1483
and	O	1484-1487
flow	O	1488-1492
-	O	1492-1493
independently	O	1493-1506
dilates	O	1507-1514
large	O	1515-1520
coronary	O	1521-1529
arteries	O	1530-1538
,	O	1538-1539
cromakalim	O	1540-1550
and	O	1551-1554
pinacidil	O	1555-1564
dilate	O	1565-1571
both	O	1572-1576
large	O	1577-1582
and	O	1583-1586
small	O	1587-1592
coronary	O	1593-1601
arteries	O	1602-1610
and	O	1611-1614
this	O	1615-1619
effect	O	1620-1626
is	O	1627-1629
not	O	1630-1633
dependent	O	1634-1643
upon	O	1644-1648
the	O	1649-1652
simultaneous	O	1653-1665
beta	O	1666-1670
adrenoceptors	O	1671-1684
-	O	1684-1685
mediated	O	1685-1693
rise	O	1694-1698
in	O	1699-1701
myocardial	O	1702-1712
metabolic	O	1713-1722
demand	O	1723-1729
.	O	1729-1730

Finally	O	1731-1738
,	O	1738-1739
two	O	1740-1743
mechanisms	O	1744-1754
at	O	1755-1757
least	O	1758-1763
,	O	1763-1764
direct	O	1765-1771
vasodilation	O	1772-1784
and	O	1785-1788
flow	O	1789-1793
dependency	O	1794-1804
,	O	1804-1805
are	O	1806-1809
involved	O	1810-1818
in	O	1819-1821
the	O	1822-1825
cromakalim	O	1826-1836
-	O	1836-1837
and	O	1838-1841
pinacidil	O	1842-1851
-	O	1851-1852
induced	O	1852-1859
increase	O	1860-1868
in	O	1869-1871
CxAD	O	1872-1876
.	O	1876-1877

Mefenamic	O	0-9
acid	O	10-14
-	O	14-15
induced	O	15-22
neutropenia	B	23-34
and	O	35-38
renal	B	39-44
failure	I	45-52
in	O	53-55
elderly	O	56-63
females	O	64-71
with	O	72-76
hypothyroidism	B	77-91
.	O	91-92

We	O	93-95
report	O	96-102
mefenamic	O	103-112
acid	O	113-117
-	O	117-118
induced	O	118-125
non	O	126-129
-	O	129-130
oliguric	O	130-138
renal	B	139-144
failure	I	145-152
and	O	153-156
severe	O	157-163
neutropenia	B	164-175
occurring	O	176-185
simultaneously	O	186-200
in	O	201-203
two	O	204-207
elderly	O	208-215
females	O	216-223
.	O	223-224

The	O	225-228
neutropenia	B	229-240
was	O	241-244
due	O	245-248
to	O	249-251
maturation	O	252-262
arrest	O	263-269
of	O	270-272
the	O	273-276
myeloid	O	277-284
series	O	285-291
in	O	292-294
one	O	295-298
patient	O	299-306
.	O	306-307

Both	O	308-312
patients	O	313-321
were	O	322-326
also	O	327-331
hypothyroid	B	332-343
,	O	343-344
but	O	345-348
it	O	349-351
is	O	352-354
not	O	355-358
clear	O	359-364
whether	O	365-372
this	O	373-377
was	O	378-381
a	O	382-383
predisposing	O	384-396
factor	O	397-403
to	O	404-406
the	O	407-410
development	O	411-422
of	O	423-425
these	O	426-431
adverse	O	432-439
reactions	O	440-449
.	O	449-450

However	O	451-458
,	O	458-459
it	O	460-462
would	O	463-468
seem	O	469-473
prudent	O	474-481
not	O	482-485
to	O	486-488
use	O	489-492
mefenamic	O	493-502
acid	O	503-507
in	O	508-510
hypothyroid	B	511-522
patients	O	523-531
until	O	532-537
the	O	538-541
hypothyroidism	B	542-556
has	O	557-560
been	O	561-565
corrected	O	566-575
.	O	575-576

Etiology	O	0-8
of	O	9-11
hypercalcemia	B	12-25
in	O	26-28
hemodialysis	O	29-41
patients	O	42-50
on	O	51-53
calcium	O	54-61
carbonate	O	62-71
therapy	O	72-79
.	O	79-80

Fourteen	O	81-89
of	O	90-92
39	O	93-95
dialysis	O	96-104
patients	O	105-113
(	O	114-115
36	O	115-117
%	O	117-118
)	O	118-119
became	O	120-126
hypercalcemic	B	127-140
after	O	141-146
switching	O	147-156
to	O	157-159
calcium	O	160-167
carbonate	O	168-177
as	O	178-180
their	O	181-186
principal	O	187-196
phosphate	O	197-206
binder	O	207-213
.	O	213-214

In	O	215-217
order	O	218-223
to	O	224-226
identify	O	227-235
risk	O	236-240
factors	O	241-248
associated	O	249-259
with	O	260-264
the	O	265-268
development	O	269-280
of	O	281-283
hypercalcemia	B	284-297
,	O	297-298
indirect	O	299-307
parameters	O	308-318
of	O	319-321
intestinal	O	322-332
calcium	O	333-340
reabsorption	O	341-353
and	O	354-357
bone	O	358-362
turnover	O	363-371
rate	O	372-376
in	O	377-379
these	O	380-385
14	O	386-388
patients	O	389-397
were	O	398-402
compared	O	403-411
with	O	412-416
results	O	417-424
in	O	425-427
14	O	428-430
eucalcemic	O	431-441
patients	O	442-450
matched	O	451-458
for	O	459-462
age	O	463-466
,	O	466-467
sex	O	468-471
,	O	471-472
length	O	473-479
of	O	480-482
time	O	483-487
on	O	488-490
dialysis	O	491-499
,	O	499-500
and	O	501-504
etiology	O	505-513
of	O	514-516
renal	B	517-522
disease	I	523-530
.	O	530-531

In	O	532-534
addition	O	535-543
to	O	544-546
experiencing	O	547-559
hypercalcemic	B	560-573
episodes	O	574-582
with	O	583-587
peak	O	588-592
calcium	O	593-600
values	O	601-607
of	O	608-610
2	O	611-612
.	O	612-613
7	O	613-614
to	O	615-617
3	O	618-619
.	O	619-620
8	O	620-621
mmol	O	622-626
/	O	626-627
L	O	627-628
(	O	629-630
10	O	630-632
.	O	632-633
7	O	633-634
to	O	635-637
15	O	638-640
.	O	640-641
0	O	641-642
mg	O	643-645
/	O	645-646
dL	O	646-648
)	O	648-649
,	O	649-650
patients	O	651-659
in	O	660-662
the	O	663-666
hypercalcemic	B	667-680
group	O	681-686
exhibited	O	687-696
a	O	697-698
significant	O	699-710
increase	O	711-719
in	O	720-722
the	O	723-726
mean	O	727-731
calcium	O	732-739
concentration	O	740-753
obtained	O	754-762
during	O	763-769
6	O	770-771
months	O	772-778
before	O	779-785
the	O	786-789
switch	O	790-796
,	O	796-797
compared	O	798-806
with	O	807-811
the	O	812-815
mean	O	816-820
value	O	821-826
obtained	O	827-835
during	O	836-842
the	O	843-846
7	O	847-848
months	O	849-855
of	O	856-858
observation	O	859-870
after	O	871-876
the	O	877-880
switch	O	881-887
(	O	888-889
2	O	889-890
.	O	890-891
4	O	891-892
+	O	893-894
/	O	894-895
-	O	895-896
0	O	897-898
.	O	898-899
03	O	899-901
to	O	902-904
2	O	905-906
.	O	906-907
5	O	907-908
+	O	909-910
/	O	910-911
-	O	911-912
0	O	913-914
.	O	914-915
03	O	915-917
mmol	O	918-922
/	O	922-923
L	O	923-924
[	O	925-926
9	O	926-927
.	O	927-928
7	O	928-929
+	O	930-931
/	O	931-932
-	O	932-933
0	O	934-935
.	O	935-936
2	O	936-937
to	O	938-940
10	O	941-943
.	O	943-944
2	O	944-945
+	O	946-947
/	O	947-948
-	O	948-949
0	O	950-951
.	O	951-952
1	O	952-953
mg	O	954-956
/	O	956-957
dL	O	957-959
]	O	959-960
,	O	960-961
P	O	962-963
=	O	964-965
0	O	966-967
.	O	967-968
006	O	968-971
)	O	971-972
.	O	967-968

In	O	974-976
contrast	O	977-985
,	O	985-986
eucalcemic	O	987-997
patients	O	998-1006
exhibited	O	1007-1016
no	O	1017-1019
change	O	1020-1026
in	O	1027-1029
mean	O	1030-1034
calcium	O	1035-1042
values	O	1043-1049
over	O	1050-1054
the	O	1055-1058
same	O	1059-1063
time	O	1064-1068
period	O	1069-1075
(	O	1076-1077
2	O	1077-1078
.	O	1078-1079
3	O	1079-1080
+	O	1081-1082
/	O	1082-1083
-	O	1083-1084
0	O	1085-1086
.	O	1086-1087
05	O	1087-1089
to	O	1090-1092
2	O	1093-1094
.	O	1094-1095
3	O	1095-1096
+	O	1097-1098
/	O	1098-1099
-	O	1099-1100
0	O	1101-1102
.	O	1102-1103
05	O	1103-1105
mmol	O	1106-1110
/	O	1110-1111
L	O	1111-1112
[	O	1113-1114
9	O	1114-1115
.	O	1115-1116
2	O	1116-1117
+	O	1118-1119
/	O	1119-1120
-	O	1120-1121
0	O	1122-1123
.	O	1123-1124
2	O	1124-1125
to	O	1126-1128
9	O	1129-1130
.	O	1130-1131
2	O	1131-1132
+	O	1133-1134
/	O	1134-1135
-	O	1135-1136
0	O	1137-1138
.	O	1138-1139
2	O	1139-1140
mg	O	1141-1143
/	O	1143-1144
dL	O	1144-1146
]	O	1146-1147
)	O	1147-1148
.	O	1148-1149

CaCO3	O	1150-1155
dosage	O	1156-1162
,	O	1162-1163
calculated	O	1164-1174
dietary	O	1175-1182
calcium	O	1183-1190
intake	O	1191-1197
,	O	1197-1198
and	O	1199-1202
circulating	O	1203-1214
levels	O	1215-1221
of	O	1222-1224
vitamin	O	1225-1232
D	O	1233-1234
metabolites	O	1235-1246
were	O	1247-1251
similar	O	1252-1259
in	O	1260-1262
both	O	1263-1267
groups	O	1268-1274
.	O	1274-1275

Physical	O	1276-1284
activity	O	1285-1293
index	O	1294-1299
and	O	1300-1303
predialysis	O	1304-1315
serum	O	1316-1321
bicarbonate	O	1322-1333
levels	O	1334-1340
also	O	1341-1345
were	O	1346-1350
similar	O	1351-1358
in	O	1359-1361
both	O	1362-1366
groups	O	1367-1373
.	O	1373-1374

However	O	1375-1382
,	O	1382-1383
there	O	1384-1389
was	O	1390-1393
a	O	1394-1395
significant	O	1396-1407
difference	O	1408-1418
in	O	1419-1421
parameters	O	1422-1432
reflecting	O	1433-1443
bone	O	1444-1448
turnover	O	1449-1457
rates	O	1458-1463
between	O	1464-1471
groups	O	1472-1478
.	O	1478-1479
(	O	1479-1480
ABSTRACT	O	1480-1488

TRUNCATED	O	1489-1498
AT	O	1499-1501
250	O	1502-1505
WORDS	O	1506-1511
)	O	1511-1512

Methyldopa	O	0-10
-	O	10-11
induced	O	11-18
hemolytic	B	19-28
anemia	I	29-35
in	O	36-38
a	O	39-40
15	O	41-43
year	O	44-48
old	O	49-52
presenting	O	53-63
as	O	64-66
near	O	67-71
-	O	71-72
syncope	B	72-79
.	O	79-80

Methyldopa	O	81-91
is	O	92-94
an	O	95-97
antihypertensive	O	98-114
medication	O	115-125
which	O	126-131
is	O	132-134
available	O	135-144
generically	O	145-156
and	O	157-160
under	O	161-166
the	O	167-170
trade	O	171-176
name	O	177-181
Aldomet	O	182-189
that	O	190-194
is	O	195-197
widely	O	198-204
prescribed	O	205-215
in	O	216-218
the	O	219-222
adult	O	223-228
population	O	229-239
and	O	240-243
infrequently	O	244-256
used	O	257-261
in	O	262-264
children	O	265-273
.	O	273-274

Methyldopa	O	275-285
causes	O	286-292
an	O	293-295
autoimmune	B	296-306
hemolytic	I	307-316
anemia	I	317-323
in	O	324-326
a	O	327-328
small	O	329-334
percentage	O	335-345
of	O	346-348
patients	O	349-357
who	O	358-361
take	O	362-366
the	O	367-370
drug	O	371-375
.	O	375-376

We	O	377-379
report	O	380-386
a	O	387-388
case	O	389-393
of	O	394-396
methyldopa	O	397-407
-	O	407-408
induced	O	408-415
hemolytic	B	416-425
anemia	I	426-432
in	O	433-435
a	O	436-437
15	O	438-440
-	O	440-441
year	O	441-445
-	O	440-441
old	O	446-449
boy	O	450-453
who	O	454-457
presented	O	458-467
to	O	468-470
the	O	471-474
emergency	B	475-484
department	I	485-495
with	O	496-500
near	O	501-505
-	O	505-506
syncope	B	506-513
.	O	513-514

The	O	515-518
boy	O	519-522
had	O	523-526
been	O	527-531
treated	O	532-539
with	O	540-544
intravenous	O	545-556
methyldopa	O	557-567
during	O	568-574
a	O	575-576
trauma	B	577-583
admission	O	584-593
seven	O	594-599
weeks	O	600-605
prior	O	606-611
to	O	612-614
presentation	O	615-627
.	O	627-628

Evaluation	O	629-639
revealed	O	640-648
a	O	649-650
hemoglobin	O	651-661
of	O	662-664
three	O	665-670
grams	O	671-676
,	O	676-677
3	O	678-679
+	O	679-680
Coombs	O	681-687
'	O	687-688
test	O	689-693
with	O	694-698
polyspecific	O	699-711
anti	O	712-716
-	O	716-717
human	O	717-722
globulin	O	723-731
and	O	732-735
monospecific	O	736-748
IgG	O	749-752
reagents	O	753-761
,	O	761-762
and	O	763-766
a	O	767-768
warm	O	769-773
reacting	O	774-782
autoantibody	O	783-795
.	O	795-796

Transfusion	O	797-808
and	O	809-812
corticosteroid	O	813-827
therapy	O	828-835
resulted	O	836-844
in	O	845-847
a	O	848-849
complete	O	850-858
recovery	O	859-867
of	O	868-870
the	O	871-874
patient	O	875-882
.	O	882-883

Emergency	O	884-893
physicians	O	894-904
treating	O	905-913
children	O	914-922
must	O	923-927
be	O	928-930
aware	O	931-936
of	O	937-939
this	O	940-944
syndrome	O	945-953
in	O	954-956
order	O	957-962
to	O	963-965
diagnose	O	966-974
and	O	975-978
treat	O	979-984
it	O	985-987
correctly	O	988-997
.	O	997-998

A	O	999-1000
brief	O	1001-1006
review	O	1007-1013
of	O	1014-1016
autoimmune	O	1017-1027
and	O	1028-1031
drug	O	1032-1036
-	O	1036-1037
induced	O	1037-1044
hemolytic	B	1045-1054
anemias	I	1055-1062
is	O	1063-1065
provided	O	1066-1074
.	O	1074-1075

The	O	0-3
long	O	4-8
-	O	8-9
term	O	9-13
safety	O	14-20
of	O	21-23
danazol	O	24-31
in	O	32-34
women	O	35-40
with	O	41-45
hereditary	B	46-56
angioedema	I	57-67
.	O	67-68

Although	O	69-77
the	O	78-81
short	O	82-87
-	O	87-88
term	O	88-92
safety	O	93-99
(	O	100-101
less	O	101-105
than	O	106-110
or	O	111-113
equal	O	114-119
to	O	120-122
6	O	123-124
months	O	125-131
)	O	131-132
of	O	133-135
danazol	O	136-143
has	O	144-147
been	O	148-152
established	O	153-164
in	O	165-167
a	O	168-169
variety	O	170-177
of	O	178-180
settings	O	181-189
,	O	189-190
no	O	191-193
information	O	194-205
exists	O	206-212
as	O	213-215
to	O	216-218
its	O	219-222
long	O	223-227
-	O	227-228
term	O	228-232
safety	O	233-239
.	O	239-240

We	O	241-243
therefore	O	244-253
investigated	O	254-266
the	O	267-270
long	O	271-275
-	O	275-276
term	O	276-280
safety	O	281-287
of	O	288-290
danazol	O	291-298
by	O	299-301
performing	O	302-312
a	O	313-314
retrospective	O	315-328
chart	O	329-334
review	O	335-341
of	O	342-344
60	O	345-347
female	O	348-354
patients	O	355-363
with	O	364-368
hereditary	B	369-379
angioedema	I	380-390
treated	O	391-398
with	O	399-403
danazol	O	404-411
for	O	412-415
a	O	416-417
continuous	O	418-428
period	O	429-435
of	O	436-438
6	O	439-440
months	O	441-447
or	O	448-450
longer	O	451-457
.	O	457-458

The	O	459-462
mean	O	463-467
age	O	468-471
of	O	472-474
the	O	475-478
patients	O	479-487
was	O	488-491
35	O	492-494
.	O	494-495
2	O	495-496
years	O	497-502
and	O	503-506
the	O	507-510
mean	O	511-515
duration	O	516-524
of	O	525-527
therapy	O	528-535
was	O	536-539
59	O	540-542
.	O	542-543
7	O	543-544
months	O	545-551
.	O	551-552

Virtually	O	553-562
all	O	563-566
patients	O	567-575
experienced	O	576-587
one	O	588-591
or	O	592-594
more	O	595-599
adverse	O	600-607
reactions	O	608-617
.	O	617-618

Menstrual	B	619-628
abnormalities	I	629-642
(	O	643-644
79	O	644-646
%	O	646-647
)	O	647-648
,	O	648-649
weight	B	650-656
gain	I	657-661
(	O	662-663
60	O	663-665
%	O	665-666
)	O	666-667
,	O	667-668
muscle	B	669-675
cramps	I	676-682
/	O	682-683
myalgias	B	683-691
(	O	692-693
40	O	693-695
%	O	695-696
)	O	696-697
,	O	697-698
and	O	699-702
transaminase	O	703-715
elevations	O	716-726
(	O	727-728
40	O	728-730
%	O	730-731
)	O	731-732
were	O	733-737
the	O	738-741
most	O	742-746
common	O	747-753
adverse	O	754-761
reactions	O	762-771
.	O	771-772

The	O	773-776
drug	O	777-781
was	O	782-785
discontinued	O	786-798
due	O	799-802
to	O	803-805
adverse	O	806-813
reactions	O	814-823
in	O	824-826
8	O	827-828
patients	O	829-837
.	O	837-838

No	O	839-841
patient	O	842-849
has	O	850-853
died	O	854-858
or	O	859-861
suffered	O	862-870
any	O	871-874
apparent	O	875-883
long	O	884-888
-	O	888-889
term	O	889-893
sequelae	O	894-902
that	O	903-907
were	O	908-912
directly	O	913-921
attributable	O	922-934
to	O	935-937
the	O	938-941
drug	O	942-946
.	O	946-947

We	O	948-950
conclude	O	951-959
that	O	960-964
,	O	964-965
despite	O	966-973
a	O	974-975
relatively	O	976-986
high	O	987-991
incidence	O	992-1001
of	O	1002-1004
adverse	O	1005-1012
reactions	O	1013-1022
,	O	1022-1023
danazol	O	1024-1031
has	O	1032-1035
proven	O	1036-1042
to	O	1043-1045
be	O	1046-1048
remarkably	O	1049-1059
safe	O	1060-1064
over	O	1065-1069
the	O	1070-1073
long	O	1074-1078
-	O	1078-1079
term	O	1079-1083
in	O	1084-1086
this	O	1087-1091
group	O	1092-1097
of	O	1098-1100
patients	O	1101-1109
.	O	1109-1110

Patient	O	0-7
tolerance	O	8-17
study	O	18-23
of	O	24-26
topical	O	27-34
chlorhexidine	O	35-48
diphosphanilate	O	49-64
:	O	64-65
a	O	66-67
new	O	68-71
topical	O	72-79
agent	O	80-85
for	O	86-89
burns	B	90-95
.	O	95-96

Effective	O	97-106
topical	O	107-114
antimicrobial	O	115-128
agents	O	129-135
decrease	O	136-144
infection	B	145-154
and	O	155-158
mortality	O	159-168
in	O	169-171
burn	B	172-176
patients	O	177-185
.	O	185-186

Chlorhexidine	O	187-200
phosphanilate	O	201-214
(	O	215-216
CHP	O	216-219
)	O	219-220
,	O	220-221
a	O	222-223
new	O	224-227
broad	O	228-233
-	O	233-234
spectrum	O	234-242
antimicrobial	O	243-256
agent	O	257-262
,	O	262-263
has	O	264-267
been	O	268-272
evaluated	O	273-282
as	O	283-285
a	O	286-287
topical	O	288-295
burn	B	296-300
wound	O	301-306
dressing	O	307-315
in	O	316-318
cream	O	319-324
form	O	325-329
,	O	329-330
but	O	331-334
preliminary	O	335-346
clinical	O	347-355
trials	O	356-362
reported	O	363-371
that	O	372-376
it	O	377-379
was	O	380-383
painful	O	384-391
upon	O	392-396
application	O	397-408
.	O	408-409

This	O	410-414
study	O	415-420
compared	O	421-429
various	O	430-437
concentrations	O	438-452
of	O	453-455
CHP	O	456-459
to	O	460-462
determine	O	463-472
if	O	473-475
a	O	476-477
tolerable	O	478-487
concentration	O	488-501
could	O	502-507
be	O	508-510
identified	O	511-521
with	O	522-526
retention	O	527-536
of	O	537-539
antimicrobial	O	540-553
efficacy	O	554-562
.	O	562-563

Twenty	O	564-570
-	O	570-571
nine	O	571-575
burn	B	576-580
patients	O	581-589
,	O	589-590
each	O	591-595
with	O	596-600
two	O	601-604
similar	O	605-612
burns	B	613-618
which	O	619-624
could	O	625-630
be	O	631-633
separately	O	634-644
treated	O	645-652
,	O	652-653
were	O	654-658
given	O	659-664
pairs	O	665-670
of	O	671-673
treatments	O	674-684
at	O	685-687
successive	O	688-698
12	O	699-701
-	O	701-702
h	O	702-703
intervals	O	704-713
over	O	714-718
a	O	719-720
3	O	721-722
-	O	722-723
day	O	723-726
period	O	727-733
.	O	733-734

One	O	735-738
burn	B	739-743
site	O	744-748
was	O	749-752
treated	O	753-760
with	O	761-765
each	O	766-770
of	O	771-773
four	O	774-778
different	O	779-788
CHP	O	789-792
concentrations	O	793-807
,	O	807-808
from	O	809-813
0	O	814-815
.	O	815-816
25	O	816-818
per	O	819-822
cent	O	823-827
to	O	828-830
2	O	831-832
per	O	833-836
cent	O	837-841
,	O	841-842
their	O	843-848
vehicle	O	849-856
,	O	856-857
and	O	858-861
1	O	862-863
per	O	864-867
cent	O	868-872
silver	O	873-879
sulphadiazine	O	880-893
(	O	894-895
AgSD	O	895-899
)	O	899-900
cream	O	901-906
,	O	906-907
an	O	908-910
antimicrobial	O	911-924
agent	O	925-930
frequently	O	931-941
used	O	942-946
for	O	947-950
topical	O	951-958
treatment	O	959-968
of	O	969-971
burn	B	972-976
wounds	O	977-983
.	O	983-984

The	O	985-988
other	O	989-994
site	O	995-999
was	O	1000-1003
always	O	1004-1010
treated	O	1011-1018
with	O	1019-1023
AgSD	O	1024-1028
cream	O	1029-1034
.	O	1034-1035

There	O	1036-1041
was	O	1042-1045
a	O	1046-1047
direct	O	1048-1054
relationship	O	1055-1067
between	O	1068-1075
CHP	O	1076-1079
concentration	O	1080-1093
and	O	1094-1097
patients	O	1098-1106
'	O	1106-1107
ratings	O	1108-1115
of	O	1116-1118
pain	B	1119-1123
on	O	1124-1126
an	O	1127-1129
analogue	O	1130-1138
scale	O	1139-1144
.	O	1144-1145

The	O	1146-1149
0	O	1150-1151
.	O	1151-1152
25	O	1152-1154
per	O	1155-1158
cent	O	1159-1163
CHP	O	1164-1167
cream	O	1168-1173
was	O	1174-1177
closest	O	1178-1185
to	O	1186-1188
AgSD	O	1189-1193
in	O	1194-1196
pain	B	1197-1201
tolerance	O	1202-1211
;	O	1211-1212
however	O	1213-1220
,	O	1220-1221
none	O	1222-1226
of	O	1227-1229
the	O	1230-1233
treatments	O	1234-1244
differed	O	1245-1253
statistically	O	1254-1267
from	O	1268-1272
AgSD	O	1273-1277
or	O	1278-1280
from	O	1281-1285
each	O	1286-1290
other	O	1291-1296
.	O	1296-1297

In	O	1298-1300
addition	O	1301-1309
,	O	1309-1310
ease	O	1311-1315
of	O	1316-1318
application	O	1319-1330
of	O	1331-1333
CHP	O	1334-1337
creams	O	1338-1344
was	O	1345-1348
less	O	1349-1353
satisfactory	O	1354-1366
than	O	1367-1371
that	O	1372-1376
of	O	1377-1379
AgSD	O	1380-1384
.	O	1384-1385

It	O	1386-1388
was	O	1389-1392
concluded	O	1393-1402
that	O	1403-1407
formulations	O	1408-1420
at	O	1421-1423
or	O	1424-1426
below	O	1427-1432
0	O	1433-1434
.	O	1434-1435
5	O	1435-1436
per	O	1437-1440
cent	O	1441-1445
CHP	O	1446-1449
may	O	1450-1453
prove	O	1454-1459
acceptable	O	1460-1470
for	O	1471-1474
wound	O	1475-1480
care	O	1481-1485
,	O	1485-1486
but	O	1487-1490
the	O	1491-1494
vehicle	O	1495-1502
system	O	1503-1509
needs	O	1510-1515
pharmaceutical	O	1516-1530
improvement	O	1531-1542
to	O	1543-1545
render	O	1546-1552
it	O	1553-1555
more	O	1556-1560
tolerable	O	1561-1570
and	O	1571-1574
easier	O	1575-1581
to	O	1582-1584
use	O	1585-1588
.	O	1588-1589

Dose	O	0-4
-	O	4-5
dependent	O	5-14
neurotoxicity	B	15-28
of	O	29-31
high	O	32-36
-	O	36-37
dose	O	37-41
busulfan	O	42-50
in	O	51-53
children	O	54-62
:	O	62-63
a	O	64-65
clinical	O	66-74
and	O	75-78
pharmacological	O	79-94
study	O	95-100
.	O	100-101

Busulfan	O	102-110
is	O	111-113
known	O	114-119
to	O	120-122
be	O	123-125
neurotoxic	B	126-136
in	O	137-139
animals	O	140-147
and	O	148-151
humans	O	152-158
,	O	158-159
but	O	160-163
its	O	164-167
acute	O	168-173
neurotoxicity	B	174-187
remains	O	188-195
poorly	O	196-202
characterized	O	203-216
in	O	217-219
children	O	220-228
.	O	228-229

We	O	230-232
report	O	233-239
here	O	240-244
a	O	245-246
retrospective	O	247-260
study	O	261-266
of	O	267-269
123	O	270-273
children	O	274-282
(	O	283-284
median	O	284-290
age	O	291-294
,	O	294-295
6	O	296-297
.	O	297-298
5	O	298-299
years	O	300-305
)	O	305-306
receiving	O	307-316
high	O	317-321
-	O	321-322
dose	O	322-326
busulfan	O	327-335
in	O	336-338
combined	O	339-347
chemotherapy	O	348-360
before	O	361-367
bone	O	368-372
marrow	O	373-379
transplantation	O	380-395
for	O	396-399
malignant	O	400-409
solid	O	410-415
tumors	B	416-422
,	O	422-423
brain	B	424-429
tumors	I	430-436
excluded	O	437-445
.	O	445-446

Busulfan	O	447-455
was	O	456-459
given	O	460-465
p	O	466-467
.	O	467-468
o	O	468-469
.	O	467-468
,	O	470-471
every	O	472-477
6	O	478-479
hours	O	480-485
for	O	486-489
16	O	490-492
doses	O	493-498
over	O	499-503
4	O	504-505
days	O	506-510
.	O	510-511

Two	O	512-515
total	O	516-521
doses	O	522-527
were	O	528-532
consecutively	O	533-546
used	O	547-551
:	O	551-552
16	O	553-555
mg	O	556-558
/	O	558-559
kg	O	559-561
,	O	561-562
then	O	563-567
600	O	568-571
mg	O	572-574
/	O	574-575
m2	O	575-577
.	O	577-578

The	O	579-582
dose	O	583-587
calculation	O	588-599
on	O	600-602
the	O	603-606
basis	O	607-612
of	O	613-615
body	O	616-620
surface	O	621-628
area	O	629-633
results	O	634-641
in	O	642-644
higher	O	645-651
doses	O	652-657
in	O	658-660
young	O	661-666
children	O	667-675
than	O	676-680
in	O	681-683
older	O	684-689
patients	O	690-698
(	O	699-700
16	O	700-702
to	O	703-705
28	O	706-708
mg	O	709-711
/	O	711-712
kg	O	712-714
)	O	714-715
.	O	715-716

Ninety	O	717-723
-	O	723-724
six	O	724-727
patients	O	728-736
were	O	737-741
not	O	742-745
given	O	746-751
anticonvulsive	O	752-766
prophylaxis	O	767-778
;	O	778-779
7	O	780-781
(	O	782-783
7	O	783-784
.	O	784-785
5	O	785-786
%	O	786-787
)	O	787-788

developed	O	789-798
seizures	B	799-807
during	O	808-814
the	O	815-818
4	O	819-820
days	O	821-825
of	O	826-828
the	O	829-832
busulfan	O	833-841
course	O	842-848
or	O	849-851
within	O	852-858
24	O	859-861
h	O	862-863
after	O	864-869
the	O	870-873
last	O	874-878
dosing	O	879-885
.	O	885-886

When	O	887-891
the	O	892-895
total	O	896-901
busulfan	O	902-910
dose	O	911-915
was	O	916-919
taken	O	920-925
into	O	926-930
account	O	931-938
,	O	938-939
there	O	940-945
was	O	946-949
a	O	950-951
significant	O	952-963
difference	O	964-974
in	O	975-977
terms	O	978-983
of	O	984-986
neurotoxicity	B	987-1000
incidence	O	1001-1010
among	O	1011-1016
patients	O	1017-1025
under	O	1026-1031
16	O	1032-1034
mg	O	1035-1037
/	O	1037-1038
kg	O	1038-1040
(	O	1041-1042
1	O	1042-1043
of	O	1044-1046
57	O	1047-1049
,	O	1049-1050
1	O	1051-1052
.	O	1052-1053
7	O	1053-1054
%	O	1054-1055
)	O	1055-1056
and	O	1057-1060
patients	O	1061-1069
under	O	1070-1075
600	O	1076-1079
mg	O	1080-1082
/	O	1082-1083
m2	O	1083-1085
(	O	1086-1087
6	O	1087-1088
of	O	1089-1091
39	O	1092-1094
,	O	1094-1095
15	O	1096-1098
.	O	1098-1099
4	O	1099-1100
%	O	1100-1101
)	O	1101-1102
(	O	1103-1104
P	O	1104-1105
less	O	1106-1110
than	O	1111-1115
0	O	1116-1117
.	O	1117-1118
02	O	1118-1120
)	O	1120-1121
.	O	1117-1118

Twenty	O	1123-1129
-	O	1129-1130
seven	O	1130-1135
patients	O	1136-1144
were	O	1145-1149
given	O	1150-1155
a	O	1156-1157
600	O	1158-1161
-	O	1161-1162
mg	O	1162-1164
/	O	1164-1165
m2	O	1165-1167
busulfan	O	1168-1176
total	O	1177-1182
dose	O	1183-1187
with	O	1188-1192
continuous	O	1193-1203
i	O	1204-1205
.	O	1205-1206
v	O	1206-1207
.	O	1205-1206

infusion	O	1209-1217
of	O	1218-1220
clonazepam	O	1221-1231
;	O	1231-1232
none	O	1233-1237
had	O	1238-1241
any	O	1242-1245
neurological	B	1246-1258
symptoms	I	1259-1267
.	O	1267-1268

Busulfan	O	1269-1277
levels	O	1278-1284
were	O	1285-1289
measured	O	1290-1298
by	O	1299-1301
a	O	1302-1303
gas	O	1304-1307
chromatographic	O	1308-1323
-	O	1323-1324
mass	O	1324-1328
spectrometry	O	1329-1341
assay	O	1342-1347
in	O	1348-1350
the	O	1351-1354
plasma	O	1355-1361
and	O	1362-1365
cerebrospinal	O	1366-1379
fluid	O	1380-1385
of	O	1386-1388
9	O	1389-1390
children	O	1391-1399
without	O	1400-1407
central	B	1408-1415
nervous	I	1416-1423
system	I	1424-1430
disease	I	1431-1438
under	O	1439-1444
600	O	1445-1448
mg	O	1449-1451
/	O	1451-1452
m2	O	1452-1454
busulfan	O	1455-1463
with	O	1464-1468
clonazepam	O	1469-1479
:	O	1479-1480
busulfan	O	1480-1488
cerebrospinal	O	1489-1502
fluid	O	1503-1508
:	O	1508-1509
plasma	O	1509-1515
ratio	O	1516-1521
was	O	1522-1525
1	O	1526-1527
.	O	1527-1528
39	O	1528-1530
.	O	1527-1528

This	O	1532-1536
was	O	1537-1540
significantly	O	1541-1554
different	O	1555-1564
(	O	1565-1566
P	O	1566-1567
less	O	1568-1572
than	O	1573-1577
0	O	1578-1579
.	O	1579-1580
02	O	1580-1582
)	O	1582-1583
from	O	1584-1588
the	O	1589-1592
cerebrospinal	O	1593-1606
fluid	O	1607-1612
:	O	1612-1613
plasma	O	1613-1619
ratio	O	1620-1625
previously	O	1626-1636
defined	O	1637-1644
in	O	1645-1647
children	O	1648-1656
receiving	O	1657-1666
a	O	1667-1668
16	O	1669-1671
-	O	1671-1672
mg	O	1672-1674
/	O	1674-1675
kg	O	1675-1677
total	O	1678-1683
dose	O	1684-1688
of	O	1689-1691
busulfan	O	1692-1700
.	O	1700-1701

This	O	1702-1706
study	O	1707-1712
shows	O	1713-1718
that	O	1719-1723
busulfan	O	1724-1732
neurotoxicity	B	1733-1746
is	O	1747-1749
dose	O	1750-1754
-	O	1754-1755
dependent	O	1755-1764
in	O	1765-1767
children	O	1768-1776
and	O	1777-1780
efficiently	O	1781-1792
prevented	O	1793-1802
by	O	1803-1805
clonazepam	O	1806-1816
.	O	1816-1817

A	O	1818-1819
busulfan	O	1820-1828
dose	O	1829-1833
calculated	O	1834-1844
on	O	1845-1847
the	O	1848-1851
basis	O	1852-1857
of	O	1858-1860
body	O	1861-1865
surface	O	1866-1873
area	O	1874-1878
,	O	1878-1879
resulting	O	1880-1889
in	O	1890-1892
higher	O	1893-1899
doses	O	1900-1905
in	O	1906-1908
young	O	1909-1914
children	O	1915-1923
,	O	1923-1924
was	O	1925-1928
followed	O	1929-1937
by	O	1938-1940
increased	O	1941-1950
neurotoxicity	B	1951-1964
,	O	1964-1965
close	O	1966-1971
to	O	1972-1974
neurotoxicity	B	1975-1988
incidence	O	1989-1998
observed	O	1999-2007
in	O	2008-2010
adults	O	2011-2017
.	O	2017-2018

Since	O	2019-2024
plasma	O	2025-2031
pharmacokinetic	O	2032-2047
studies	O	2048-2055
showed	O	2056-2062
a	O	2063-2064
faster	O	2065-2071
busulfan	O	2072-2080
clearance	O	2081-2090
in	O	2091-2093
children	O	2094-2102
than	O	2103-2107
in	O	2108-2110
adults	O	2111-2117
,	O	2117-2118
this	O	2119-2123
new	O	2124-2127
dose	O	2128-2132
may	O	2133-2136
approximate	O	2137-2148
more	O	2149-2153
closely	O	2154-2161
the	O	2162-2165
adult	O	2166-2171
systemic	O	2172-2180
exposure	O	2181-2189
obtained	O	2190-2198
after	O	2199-2204
the	O	2205-2208
usual	O	2209-2214
16	O	2215-2217
-	O	2217-2218
mg	O	2218-2220
/	O	2220-2221
kg	O	2221-2223
total	O	2224-2229
dose	O	2230-2234
,	O	2234-2235
with	O	2236-2240
potential	O	2241-2250
inferences	O	2251-2261
in	O	2262-2264
terms	O	2265-2270
of	O	2271-2273
anticancer	O	2274-2284
or	O	2285-2287
myeloablative	O	2288-2301
effects	O	2302-2309
.	O	2309-2310

The	O	2311-2314
busulfan	O	2315-2323
dose	O	2324-2328
in	O	2329-2331
children	O	2332-2340
and	O	2341-2344
infants	O	2345-2352
undergoing	O	2353-2363
bone	O	2364-2368
marrow	O	2369-2375
transplantation	O	2376-2391
should	O	2392-2398
be	O	2399-2401
reconsidered	O	2402-2414
on	O	2415-2417
the	O	2418-2421
basis	O	2422-2427
of	O	2428-2430
pharmacokinetic	O	2431-2446
studies	O	2447-2454
.	O	2454-2455

Histamine	O	0-9
antagonists	O	10-21
and	O	22-25
d	O	26-27
-	O	27-28
tubocurarine	O	28-40
-	O	27-28
induced	O	41-48
hypotension	B	49-60
in	O	61-63
cardiac	O	64-71
surgical	O	72-80
patients	O	81-89
.	O	89-90

Hemodynamic	O	91-102
effects	O	103-110
and	O	111-114
histamine	O	115-124
release	O	125-132
by	O	133-135
bolus	O	136-141
injection	O	142-151
of	O	152-154
0	O	155-156
.	O	156-157
35	O	157-159
mg	O	160-162
/	O	162-163
kg	O	163-165
of	O	166-168
d	O	169-170
-	O	170-171
tubocurarine	O	171-183
were	O	184-188
studied	O	189-196
in	O	197-199
24	O	200-202
patients	O	203-211
.	O	211-212

H1	O	213-215
-	O	215-216
and	O	217-220
H2	O	221-223
-	O	223-224
histamine	O	224-233
antagonists	O	234-245
or	O	246-248
placebo	O	249-256
were	O	257-261
given	O	262-267
before	O	268-274
dosing	O	275-281
with	O	282-286
d	O	287-288
-	O	288-289
tubocurarine	O	289-301
in	O	302-304
a	O	305-306
randomized	O	307-317
double	O	318-324
-	O	324-325
blind	O	325-330
fashion	O	331-338
to	O	339-341
four	O	342-346
groups	O	347-353
:	O	353-354
group	O	355-360
1	O	361-362
-	O	362-363
-	O	362-363
placebo	O	364-371
;	O	371-372
group	O	373-378
2	O	379-380
-	O	380-381
-	O	380-381
cimetidine	O	382-392
,	O	392-393
4	O	394-395
mg	O	396-398
/	O	398-399
kg	O	399-401
,	O	401-402
plus	O	403-407
placebo	O	408-415
;	O	415-416
group	O	417-422
3	O	423-424
-	O	424-425
-	O	424-425
chlorpheniramine	O	426-442
,	O	442-443
0	O	444-445
.	O	445-446
1	O	446-447
mg	O	448-450
/	O	450-451
kg	O	451-453
,	O	453-454
plus	O	455-459
placebo	O	460-467
;	O	467-468
and	O	469-472
group	O	473-478
4	O	479-480
-	O	480-481
-	O	480-481
cimetidine	O	482-492
plus	O	493-497
chlorpheniramine	O	498-514
.	O	514-515

Histamine	O	516-525
release	O	526-533
occurred	O	534-542
in	O	543-545
most	O	546-550
patients	O	551-559
,	O	559-560
the	O	561-564
highest	O	565-572
level	O	573-578
2	O	579-580
minutes	O	581-588
after	O	589-594
d	O	595-596
-	O	596-597
tubocurarine	O	597-609
dosing	O	610-616
.	O	616-617

Group	O	618-623
1	O	624-625
had	O	626-629
a	O	630-631
moderate	O	632-640
negative	O	641-649
correlation	O	650-661
between	O	662-669
plasma	O	670-676
histamine	O	677-686
change	O	687-693
and	O	694-697
systemic	O	698-706
vascular	O	707-715
resistance	O	716-726
(	O	727-728
r	O	728-729
=	O	730-731
0	O	732-733
.	O	733-734
58	O	734-736
;	O	736-737
P	O	738-739
less	O	740-744
than	O	745-749
0	O	750-751
.	O	751-752
05	O	752-754
)	O	754-755
not	O	756-759
present	O	760-767
in	O	768-770
group	O	771-776
4	O	777-778
.	O	778-779
Prior	O	780-785
dosing	O	786-792
with	O	793-797
antagonists	O	798-809
partially	O	810-819
prevented	O	820-829
the	O	830-833
fall	O	834-838
in	O	839-841
systemic	O	842-850
vascular	O	851-859
resistance	O	860-870
.	O	870-871

These	O	872-877
data	O	878-882
demonstrate	O	883-894
that	O	895-899
the	O	900-903
hemodynamic	O	904-915
changes	O	916-923
associated	O	924-934
with	O	935-939
d	O	940-941
-	O	941-942
tubocurarine	O	942-954
dosing	O	955-961
are	O	962-965
only	O	966-970
partially	O	971-980
explained	O	981-990
by	O	991-993
histamine	O	994-1003
release	O	1004-1011
.	O	1011-1012

Thus	O	1013-1017
prior	O	1018-1023
dosing	O	1024-1030
with	O	1031-1035
H1	O	1036-1038
-	O	1038-1039
and	O	1040-1043
H2	O	1044-1046
-	O	1046-1047
antagonists	O	1047-1058
provides	O	1059-1067
only	O	1068-1072
partial	O	1073-1080
protection	O	1081-1091
.	O	1091-1092

Convulsant	O	0-10
effect	O	11-17
of	O	18-20
lindane	O	21-28
and	O	29-32
regional	O	33-41
brain	O	42-47
concentration	O	48-61
of	O	62-64
GABA	O	65-69
and	O	70-73
dopamine	O	74-82
.	O	82-83

Lindane	O	84-91
(	O	92-93
gamma	O	93-98
-	O	98-99
hexachlorocyclohexane	O	99-120
)	O	120-121
is	O	122-124
an	O	125-127
organochlorine	O	128-142
insecticide	O	143-154
with	O	155-159
known	O	160-165
neurotoxic	B	166-176
effects	O	177-184
.	O	184-185

Its	O	186-189
mechanism	O	190-199
of	O	200-202
action	O	203-209
is	O	210-212
not	O	213-216
well	O	217-221
understood	O	222-232
although	O	233-241
it	O	242-244
has	O	245-248
been	O	249-253
proposed	O	254-262
that	O	263-267
lindane	O	268-275
acts	O	276-280
as	O	281-283
a	O	284-285
non	O	286-289
-	O	289-290
competitive	O	290-301
antagonist	O	302-312
at	O	313-315
the	O	316-319
gamma	O	320-325
-	O	325-326
aminobutyric	O	326-338
acid	O	339-343
(	O	344-345
GABA	O	345-349
)	O	349-350
-	O	350-351
A	O	346-347
receptor	O	353-361
.	O	361-362

We	O	363-365
studied	O	366-373
the	O	374-377
effect	O	378-384
of	O	385-387
lindane	O	388-395
(	O	396-397
150	O	397-400
mg	O	401-403
/	O	403-404
kg	O	404-406
)	O	406-407
on	O	408-410
the	O	411-414
GABAergic	O	415-424
and	O	425-428
dopaminergic	O	429-441
systems	O	442-449
by	O	450-452
measuring	O	453-462
the	O	463-466
concentration	O	467-480
of	O	481-483
GABA	O	484-488
,	O	488-489
dopamine	O	490-498
and	O	499-502
its	O	503-506
metabolites	O	507-518
in	O	519-521
7	O	522-523
brain	O	524-529
areas	O	530-535
at	O	536-538
the	O	539-542
onset	O	543-548
of	O	549-551
seizures	B	552-560
.	O	560-561

All	O	562-565
animals	O	566-573
suffered	O	574-582
tonic	O	583-588
convulsions	B	589-600
at	O	601-603
18	O	604-606
.	O	606-607
3	O	607-608
+	O	609-610
/	O	610-611
-	O	611-612
1	O	613-614
.	O	614-615
4	O	615-616
min	O	617-620
after	O	621-626
lindane	O	627-634
administration	O	635-649
.	O	649-650

The	O	651-654
concentration	O	655-668
of	O	669-671
GABA	O	672-676
was	O	677-680
only	O	681-685
slightly	O	686-694
but	O	695-698
significantly	O	699-712
decreased	O	713-722
in	O	723-725
the	O	726-729
colliculi	O	730-739
without	O	740-747
modifications	O	748-761
in	O	762-764
the	O	765-768
other	O	769-774
areas	O	775-780
.	O	780-781

The	O	782-785
concentration	O	786-799
of	O	800-802
dopamine	O	803-811
was	O	812-815
increased	O	816-825
in	O	826-828
the	O	829-832
mesencephalon	O	833-846
and	O	847-850
that	O	851-855
of	O	856-858
its	O	859-862
metabolite	O	863-873
DOPAC	O	874-879
was	O	880-883
also	O	884-888
increased	O	889-898
in	O	899-901
the	O	902-905
mesencephalon	O	906-919
and	O	920-923
the	O	924-927
striatum	O	928-936
.	O	936-937

Unusual	O	0-7
complications	O	8-21
of	O	22-24
antithyroid	O	25-36
drug	O	37-41
therapy	O	42-49
:	O	49-50
four	O	51-55
case	O	56-60
reports	O	61-68
and	O	69-72
review	O	73-79
of	O	80-82
literature	O	83-93
.	O	93-94

Two	O	95-98
cases	O	99-104
of	O	105-107
propylthiouracil	O	108-124
-	O	124-125
associated	O	125-135
acute	O	136-141
hepatitis	B	142-151
,	O	151-152
one	O	153-156
case	O	157-161
of	O	162-164
fatal	O	165-170
methimazole	O	171-182
-	O	182-183
associated	O	183-193
hepatocellular	B	194-208
necrosis	I	209-217
and	O	218-221
one	O	222-225
case	O	226-230
of	O	231-233
propylthiouracil	O	234-250
-	O	250-251
associated	O	251-261
lupus	B	262-267
-	I	267-268
like	I	268-272
syndrome	I	273-281
are	O	282-285
described	O	286-295
.	O	295-296

The	O	297-300
literature	O	301-311
related	O	312-319
to	O	320-322
antithyroid	O	323-334
drug	O	335-339
side	O	340-344
effects	O	345-352
and	O	353-356
the	O	357-360
mechanisms	O	361-371
for	O	372-375
their	O	376-381
occurrence	O	382-392
are	O	393-396
reviewed	O	397-405
and	O	406-409
the	O	410-413
efficacy	O	414-422
and	O	423-426
complications	O	427-440
of	O	441-443
thyroidectomy	O	444-457
and	O	458-461
radioiodine	O	462-473
compared	O	474-482
to	O	483-485
those	O	486-491
of	O	492-494
antithyroid	O	495-506
drugs	O	507-512
.	O	512-513

It	O	514-516
is	O	517-519
concluded	O	520-529
that	O	530-534
in	O	535-537
most	O	538-542
circumstances	O	543-556
131I	O	557-561
is	O	562-564
the	O	565-568
therapy	O	569-576
of	O	577-579
choice	O	580-586
for	O	587-590
hyperthyroidism	B	591-606
.	O	606-607

Anticonvulsant	O	0-14
actions	O	15-22
of	O	23-25
MK	O	26-28
-	O	28-29
801	O	29-32
on	O	33-35
the	O	36-39
lithium	O	40-47
-	O	47-48
pilocarpine	O	48-59
model	O	60-65
of	O	66-68
status	B	69-75
epilepticus	I	76-87
in	O	88-90
rats	O	91-95
.	O	95-96

MK	O	97-99
-	O	99-100
801	O	100-103
,	O	103-104
a	O	105-106
noncompetitive	O	107-121
N	O	122-123
-	O	123-124
methyl	O	124-130
-	O	123-124
D	O	131-132
-	O	123-124
aspartate	O	133-142
(	O	143-144
NMDA	O	144-148
)	O	148-149
receptor	O	150-158
antagonist	O	159-169
,	O	169-170
was	O	171-174
tested	O	175-181
for	O	182-185
anticonvulsant	O	186-200
effects	O	201-208
in	O	209-211
rats	O	212-216
using	O	217-222
two	O	223-226
seizure	B	227-234
models	O	235-241
,	O	241-242
coadministration	O	243-259
of	O	260-262
lithium	O	263-270
and	O	271-274
pilocarpine	O	275-286
and	O	287-290
administration	O	291-305
of	O	306-308
a	O	309-310
high	O	311-315
dose	O	316-320
of	O	321-323
pilocarpine	O	324-335
alone	O	336-341
.	O	341-342

Three	O	343-348
major	O	349-354
results	O	355-362
are	O	363-366
reported	O	367-375
.	O	375-376

First	O	377-382
,	O	382-383
pretreatment	O	384-396
with	O	397-401
MK	O	402-404
-	O	404-405
801	O	405-408
produced	O	409-417
an	O	418-420
effective	O	421-430
and	O	431-434
dose	O	435-439
-	O	439-440
dependent	O	440-449
anticonvulsant	O	450-464
action	O	465-471
with	O	472-476
the	O	477-480
lithium	O	481-488
-	O	488-489
pilocarpine	O	489-500
model	O	501-506
but	O	507-510
not	O	511-514
with	O	515-519
rats	O	520-524
treated	O	525-532
with	O	533-537
pilocarpine	O	538-549
alone	O	550-555
,	O	555-556
suggesting	O	557-567
that	O	568-572
different	O	573-582
biochemical	O	583-594
mechanisms	O	595-605
control	O	606-613
seizures	B	614-622
in	O	623-625
these	O	626-631
two	O	632-635
models	O	636-642
.	O	642-643

Second	O	644-650
,	O	650-651
the	O	652-655
anticonvulsant	O	656-670
effect	O	671-677
of	O	678-680
MK	O	681-683
-	O	683-684
801	O	684-687
in	O	688-690
the	O	691-694
lithium	O	695-702
-	O	702-703
pilocarpine	O	703-714
model	O	715-720
only	O	721-725
occurred	O	726-734
after	O	735-740
initial	O	741-748
periods	O	749-756
of	O	757-759
seizure	B	760-767
activity	O	768-776
.	O	776-777

This	O	778-782
observation	O	783-794
is	O	795-797
suggested	O	798-807
to	O	808-810
be	O	811-813
an	O	814-816
in	O	817-819
vivo	O	820-824
demonstration	O	825-838
of	O	839-841
the	O	842-845
conclusion	O	846-856
derived	O	857-864
from	O	865-869
in	O	870-872
vitro	O	873-878
experiments	O	879-890
that	O	891-895
MK	O	896-898
-	O	898-899
801	O	899-902
binding	O	903-910
requires	O	911-919
agonist	O	920-927
-	O	927-928
induced	O	928-935
opening	O	936-943
of	O	944-946
the	O	947-950
channel	O	951-958
sites	O	959-964
of	O	965-967
the	O	968-971
NMDA	O	972-976
receptor	O	977-985
.	O	985-986

Third	O	987-992
,	O	992-993
although	O	994-1002
it	O	1003-1005
is	O	1006-1008
relatively	O	1009-1019
easy	O	1020-1024
to	O	1025-1027
block	O	1028-1033
seizures	B	1034-1042
induced	O	1043-1050
by	O	1051-1053
lithium	O	1054-1061
and	O	1062-1065
pilocarpine	O	1066-1077
by	O	1078-1080
administration	O	1081-1095
of	O	1096-1098
anticonvulsants	O	1099-1114
prior	O	1115-1120
to	O	1121-1123
pilocarpine	O	1124-1135
,	O	1135-1136
it	O	1137-1139
is	O	1140-1142
more	O	1143-1147
difficult	O	1148-1157
to	O	1158-1160
terminate	O	1161-1170
ongoing	O	1171-1178
status	B	1179-1185
epilepticus	I	1186-1197
and	O	1198-1201
block	O	1202-1207
the	O	1208-1211
lethality	O	1212-1221
of	O	1222-1224
the	O	1225-1228
seizures	B	1229-1237
.	O	1237-1238

Administration	O	1239-1253
of	O	1254-1256
MK	O	1257-1259
-	O	1259-1260
801	O	1260-1263
30	O	1264-1266
or	O	1267-1269
60	O	1270-1272
min	O	1273-1276
after	O	1277-1282
pilocarpine	O	1283-1294
,	O	1294-1295
i	O	1296-1297
.	O	1297-1298
e	O	1298-1299
.	O	1297-1298
,	O	1300-1301
during	O	1302-1308
status	B	1309-1315
epilepticus	I	1316-1327
,	O	1327-1328
gradually	O	1329-1338
reduced	O	1339-1346
electrical	O	1347-1357
and	O	1358-1361
behavioral	O	1362-1372
seizure	B	1373-1380
activity	O	1381-1389
and	O	1390-1393
greatly	O	1394-1401
enhanced	O	1402-1410
the	O	1411-1414
survival	O	1415-1423
rate	O	1424-1428
.	O	1428-1429

These	O	1430-1435
results	O	1436-1443
suggest	O	1444-1451
that	O	1452-1456
activation	O	1457-1467
of	O	1468-1470
NMDA	O	1471-1475
receptors	O	1476-1485
plays	O	1486-1491
an	O	1492-1494
important	O	1495-1504
role	O	1505-1509
in	O	1510-1512
status	B	1513-1519
epilepticus	I	1520-1531
and	O	1532-1535
brain	B	1536-1541
damage	I	1542-1548
in	O	1549-1551
the	O	1552-1555
lithium	O	1556-1563
-	O	1563-1564
pilocarpine	O	1564-1575
model	O	1576-1581
.	O	1581-1582

This	O	1583-1587
was	O	1588-1591
further	O	1592-1599
supported	O	1600-1609
by	O	1610-1612
results	O	1613-1620
showing	O	1621-1628
that	O	1629-1633
nonconvulsive	O	1634-1647
doses	O	1648-1653
of	O	1654-1656
NMDA	O	1657-1661
and	O	1662-1665
pilocarpine	O	1666-1677
were	O	1678-1682
synergistic	O	1683-1694
,	O	1694-1695
resulting	O	1696-1705
in	O	1706-1708
status	B	1709-1715
epilepticus	I	1716-1727
and	O	1728-1731
subsequent	O	1732-1742
mortality	O	1743-1752
.	O	1752-1753

Nifedipine	O	0-10
induced	O	11-18
bradycardia	B	19-30
in	O	31-33
a	O	34-35
patient	O	36-43
with	O	44-48
autonomic	B	49-58
neuropathy	I	59-69
.	O	69-70

An	O	71-73
80	O	74-76
year	O	77-81
old	O	82-85
diabetic	B	86-94
male	O	95-99
with	O	100-104
evidence	O	105-113
of	O	114-116
peripheral	B	117-127
and	I	128-131
autonomic	I	132-141
neuropathy	I	142-152
was	O	153-156
admitted	O	157-165
with	O	166-170
chest	B	171-176
pain	I	177-181
.	O	181-182

He	O	183-185
was	O	186-189
found	O	190-195
to	O	196-198
have	O	199-203
atrial	B	204-210
flutter	I	211-218
at	O	219-221
a	O	222-223
ventricular	O	224-235
rate	O	236-240
of	O	241-243
70	O	244-246
/	O	246-247
min	O	247-250
which	O	251-256
slowed	O	257-263
down	O	264-268
to	O	269-271
30	O	272-274
-	O	274-275
40	O	275-277
/	O	277-278
min	O	278-281
when	O	282-286
nifedipine	O	287-297
(	O	298-299
60	O	299-301
mg	O	302-304
)	O	304-305
in	O	306-308
3	O	309-310
divided	O	311-318
doses	O	319-324
,	O	324-325
during	O	326-332
which	O	333-338
he	O	339-341
was	O	342-345
paced	O	346-351
at	O	352-354
a	O	355-356
rate	O	357-361
of	O	362-364
70	O	365-367
/	O	367-368
min	O	368-371
.	O	371-372

This	O	373-377
is	O	378-380
inconsistent	O	381-393
with	O	394-398
the	O	399-402
well	O	403-407
-	O	407-408
established	O	408-419
finding	O	420-427
that	O	428-432
nifedipine	O	433-443
induces	O	444-451
tachycardia	B	452-463
in	O	464-466
normally	O	467-475
innervated	O	476-486
hearts	O	487-493
.	O	493-494

However	O	495-502
,	O	502-503
in	O	504-506
hearts	O	507-513
deprived	O	514-522
of	O	523-525
compensatory	O	526-538
sympathetic	O	539-550
drive	O	551-556
,	O	556-557
it	O	558-560
may	O	561-564
lead	O	565-569
to	O	570-572
bradycardia	B	573-584
.	O	584-585

The	O	0-3
effect	O	4-10
of	O	11-13
haloperidol	O	14-25
in	O	26-28
cocaine	O	29-36
and	O	37-40
amphetamine	O	41-52
intoxication	O	53-65
.	O	65-66

The	O	67-70
effectiveness	O	71-84
of	O	85-87
haloperidol	O	88-99
pretreatment	O	100-112
in	O	113-115
preventing	O	116-126
the	O	127-130
toxic	O	131-136
effects	O	137-144
of	O	145-147
high	O	148-152
doses	O	153-158
of	O	159-161
amphetamine	O	162-173
and	O	174-177
cocaine	O	178-185
was	O	186-189
studied	O	190-197
in	O	198-200
rats	O	201-205
.	O	205-206

In	O	207-209
this	O	210-214
model	O	215-220
,	O	220-221
toxic	O	222-227
effects	O	228-235
were	O	236-240
induced	O	241-248
by	O	249-251
intraperitoneal	O	252-267
(	O	268-269
i	O	269-270
.	O	270-271
p	O	271-272
.	O	270-271
)	O	273-274
injection	O	275-284
of	O	285-287
amphetamine	O	288-299
75	O	300-302
mg	O	303-305
/	O	305-306
kg	O	306-308
(	O	309-310
100	O	310-313
%	O	313-314
death	O	315-320
rate	O	321-325
)	O	325-326
or	O	327-329
cocaine	O	330-337
70	O	338-340
mg	O	341-343
/	O	343-344
kg	O	344-346
(	O	347-348
82	O	348-350
%	O	350-351
death	O	352-357
rate	O	358-362
)	O	362-363
.	O	363-364

Haloperidol	O	365-376
failed	O	377-383
to	O	384-386
prevent	O	387-394
amphetamine	O	395-406
-	O	406-407
induced	O	407-414
seizures	B	415-423
,	O	423-424
but	O	425-428
did	O	429-432
lower	O	433-438
the	O	439-442
mortality	O	443-452
rate	O	453-457
at	O	458-460
most	O	461-465
doses	O	466-471
tested	O	472-478
.	O	478-479

Haloperidol	O	480-491
decreased	O	492-501
the	O	502-505
incidence	O	506-515
of	O	516-518
cocaine	O	519-526
-	O	526-527
induced	O	527-534
seizures	B	535-543
at	O	544-546
the	O	547-550
two	O	551-554
highest	O	555-562
doses	O	563-568
,	O	568-569
but	O	570-573
the	O	574-577
lowering	O	578-586
of	O	587-589
the	O	590-593
mortality	O	594-603
rate	O	604-608
did	O	609-612
not	O	613-616
reach	O	617-622
statistical	O	623-634
significance	O	635-647
at	O	648-650
any	O	651-654
dose	O	655-659
.	O	659-660

These	O	661-666
data	O	667-671
suggest	O	672-679
a	O	680-681
protective	O	682-692
role	O	693-697
for	O	698-701
the	O	702-705
central	O	706-713
dopamine	O	714-722
blocker	O	723-730
haloperidol	O	731-742
against	O	743-750
death	O	751-756
from	O	757-761
high	O	762-766
-	O	766-767
dose	O	767-771
amphetamine	O	772-783
exposure	O	784-792
without	O	793-800
reducing	O	801-809
the	O	810-813
incidence	O	814-823
of	O	824-826
seizures	B	827-835
.	O	835-836

In	O	837-839
contrast	O	840-848
,	O	848-849
haloperidol	O	850-861
demonstrated	O	862-874
an	O	875-877
ability	O	878-885
to	O	886-888
reduce	O	889-895
cocaine	O	896-903
-	O	903-904
induced	O	904-911
seizures	B	912-920
without	O	921-928
significantly	O	929-942
reducing	O	943-951
mortality	O	952-961
.	O	961-962

Autoradiographic	O	0-16
evidence	O	17-25
of	O	26-28
estrogen	O	29-37
binding	O	38-45
sites	O	46-51
in	O	52-54
nuclei	O	55-61
of	O	62-64
diethylstilbesterol	O	65-84
induced	O	85-92
hamster	O	93-100
renal	B	101-106
carcinomas	I	107-117
.	O	117-118

Estrogen	O	119-127
binding	O	128-135
sites	O	136-141
were	O	142-146
demonstrated	O	147-159
by	O	160-162
autoradiography	O	163-178
in	O	179-181
one	O	182-185
transplantable	O	186-200
and	O	201-204
five	O	205-209
primary	O	210-217
diethylstilbesterol	O	218-237
induced	O	238-245
renal	B	246-251
carcinomas	I	252-262
in	O	263-265
three	O	266-271
hamsters	O	272-280
.	O	280-281

Radiolabelling	O	282-296
,	O	296-297
following	O	298-307
the	O	308-311
in	O	312-314
vivo	O	315-319
injection	O	320-329
of	O	330-332
3H	O	333-335
-	O	335-336
17	O	336-338
beta	O	339-343
estradiol	O	344-353
,	O	353-354
was	O	355-358
increased	O	359-368
only	O	369-373
over	O	374-378
the	O	379-382
nuclei	O	383-389
of	O	390-392
tumor	B	393-398
cells	O	399-404
;	O	404-405
stereologic	O	406-417
analysis	O	418-426
revealed	O	427-435
a	O	436-437
4	O	438-439
.	O	439-440
5	O	440-441
-	O	441-442
to	O	443-445
6	O	446-447
.	O	447-448
7	O	448-449
-	O	449-450
times	O	450-455
higher	O	456-462
concentration	O	463-476
of	O	477-479
reduced	O	480-487
silver	O	488-494
grains	O	495-501
over	O	502-506
nuclei	O	507-513
than	O	514-518
cytoplasm	O	519-528
of	O	529-531
these	O	532-537
cells	O	538-543
.	O	543-544

Despite	O	545-552
rapid	O	553-558
tubular	O	559-566
excretion	O	567-576
of	O	577-579
estradiol	O	580-589
which	O	590-595
peaked	O	596-602
in	O	603-605
less	O	606-610
than	O	611-615
1	O	616-617
h	O	618-619
,	O	619-620
the	O	621-624
normal	O	625-631
cells	O	632-637
did	O	638-641
not	O	642-645
appear	O	646-652
to	O	653-655
bind	O	656-660
the	O	661-664
ligand	O	665-671
.	O	671-672

This	O	673-677
is	O	678-680
the	O	681-684
first	O	685-690
published	O	691-700
report	O	701-707
documenting	O	708-719
the	O	720-723
preferential	O	724-736
in	O	737-739
vivo	O	740-744
binding	O	745-752
of	O	753-755
estrogen	O	756-764
to	O	765-767
nuclei	O	768-774
of	O	775-777
cells	O	778-783
in	O	784-786
estrogen	O	787-795
induced	O	796-803
hamster	O	804-811
renal	B	812-817
carcinomas	I	818-828
.	O	828-829

Bradycardia	B	0-11
due	O	12-15
to	O	16-18
biperiden	O	19-28
.	O	28-29

In	O	30-32
a	O	33-34
38	O	35-37
-	O	37-38
year	O	38-42
-	O	37-38
old	O	43-46
male	O	47-51
patient	O	52-59
suffering	O	60-69
from	O	70-74
a	O	75-76
severe	O	77-83
postzosteric	B	84-96
trigeminal	B	97-107
neuralgia	I	108-117
,	O	117-118
intravenous	O	119-130
application	O	131-142
of	O	143-145
10	O	146-148
mg	O	149-151
biperiden	O	152-161
lactate	O	162-169
led	O	170-173
to	O	174-176
a	O	177-178
long	O	179-183
-	O	183-184
lasting	O	184-191
paradoxical	O	192-203
reaction	O	204-212
characterized	O	213-226
by	O	227-229
considerable	O	230-242
bradycardia	B	243-254
,	O	254-255
dysarthria	B	256-266
,	O	266-267
and	O	268-271
dysphagia	B	272-281
.	O	281-282

The	O	283-286
heart	O	287-292
rate	O	293-297
was	O	298-301
back	O	302-306
to	O	307-309
normal	O	310-316
within	O	317-323
12	O	324-326
hours	O	327-332
upon	O	333-337
administration	O	338-352
of	O	353-355
orciprenaline	O	356-369
under	O	370-375
cardiac	O	376-383
monitoring	O	384-394
in	O	395-397
an	O	398-400
intensive	O	401-410
care	O	411-415
unit	O	416-420
.	O	420-421

Bradycardia	B	422-433
induced	O	434-441
by	O	442-444
biperiden	O	445-454
is	O	455-457
attributed	O	458-468
to	O	469-471
the	O	472-475
speed	O	476-481
of	O	482-484
injection	O	485-494
and	O	495-498
to	O	499-501
a	O	502-503
dose	O	504-508
-	O	508-509
related	O	509-516
dual	O	517-521
effect	O	522-528
of	O	529-531
atropine	O	532-540
-	O	540-541
like	O	541-545
drugs	O	546-551
on	O	552-554
muscarine	O	555-564
receptors	O	565-574
.	O	574-575

Deliberate	O	0-10
hypotension	B	11-22
induced	O	23-30
by	O	31-33
labetalol	O	34-43
with	O	44-48
halothane	O	49-58
,	O	58-59
enflurane	O	60-69
or	O	70-72
isoflurane	O	73-83
for	O	84-87
middle	O	88-94
-	O	94-95
ear	O	95-98
surgery	O	99-106
.	O	106-107

The	O	108-111
feasibility	O	112-123
of	O	124-126
using	O	127-132
labetalol	O	133-142
,	O	142-143
an	O	144-146
alpha	O	147-152
-	O	152-153
and	O	154-157
beta	O	158-162
-	O	162-163
adrenergic	O	163-173
blocking	O	174-182
agent	O	183-188
,	O	188-189
as	O	190-192
a	O	193-194
hypotensive	B	195-206
agent	O	207-212
in	O	213-215
combination	O	216-227
with	O	228-232
inhalation	O	233-243
anaesthetics	O	244-256
(	O	257-258
halothane	O	258-267
,	O	267-268
enflurane	O	269-278
or	O	279-281
isoflurane	O	282-292
)	O	292-293
was	O	294-297
studied	O	298-305
in	O	306-308
23	O	309-311
adult	O	312-317
patients	O	318-326
undergoing	O	327-337
middle	O	338-344
-	O	344-345
ear	O	345-348
surgery	O	349-356
.	O	356-357

The	O	358-361
mean	O	362-366
arterial	O	367-375
pressure	O	376-384
was	O	385-388
decreased	O	389-398
from	O	399-403
86	O	404-406
+	O	407-408
/	O	408-409
-	O	409-410
5	O	411-412
(	O	413-414
s	O	414-415
.	O	415-416
e	O	416-417
.	O	415-416

mean	O	419-423
)	O	423-424
mmHg	O	425-429
to	O	430-432
52	O	433-435
+	O	436-437
/	O	437-438
-	O	438-439
1	O	440-441
mmHg	O	442-446
(	O	447-448
11	O	448-450
.	O	450-451
5	O	451-452
+	O	453-454
/	O	454-455
-	O	455-456
0	O	457-458
.	O	458-459
7	O	459-460
to	O	461-463
6	O	464-465
.	O	465-466
9	O	466-467
+	O	468-469
/	O	469-470
-	O	470-471
0	O	472-473
.	O	473-474
1	O	474-475
kPa	O	476-479
)	O	479-480
for	O	481-484
98	O	485-487
+	O	488-489
/	O	489-490
-	O	490-491
10	O	492-494
min	O	495-498
in	O	499-501
the	O	502-505
halothane	O	506-515
(	O	516-517
H	O	517-518
)	O	518-519
group	O	520-525
,	O	525-526
from	O	527-531
79	O	532-534
+	O	535-536
/	O	536-537
-	O	537-538
5	O	539-540
to	O	541-543
53	O	544-546
+	O	547-548
/	O	548-549
-	O	549-550
1	O	551-552
mmHg	O	553-557
(	O	558-559
10	O	559-561
.	O	561-562
5	O	562-563
+	O	564-565
/	O	565-566
-	O	566-567
0	O	568-569
.	O	569-570
7	O	570-571
to	O	572-574
7	O	575-576
.	O	576-577
1	O	577-578
+	O	579-580
/	O	580-581
-	O	581-582
0	O	583-584
.	O	584-585
1	O	585-586
kPa	O	587-590
)	O	590-591
for	O	592-595
129	O	596-599
+	O	600-601
/	O	601-602
-	O	602-603
11	O	604-606
min	O	607-610
in	O	611-613
the	O	614-617
enflurane	O	618-627
(	O	628-629
E	O	629-630
)	O	630-631
group	O	632-637
,	O	637-638
and	O	639-642
from	O	643-647
80	O	648-650
+	O	651-652
/	O	652-653
-	O	653-654
4	O	655-656
to	O	657-659
49	O	660-662
+	O	663-664
/	O	664-665
-	O	665-666
1	O	667-668
mmHg	O	669-673
(	O	674-675
10	O	675-677
.	O	677-678
7	O	678-679
+	O	680-681
/	O	681-682
-	O	682-683
0	O	684-685
.	O	685-686
5	O	686-687
to	O	688-690
6	O	691-692
.	O	692-693
5	O	693-694
+	O	695-696
/	O	696-697
-	O	697-698
0	O	699-700
.	O	700-701
1	O	701-702
kPa	O	703-706
)	O	706-707
for	O	708-711
135	O	712-715
+	O	716-717
/	O	717-718
-	O	718-719
15	O	720-722
min	O	723-726
in	O	727-729
the	O	730-733
isoflurane	O	734-744
(	O	745-746
I	O	746-747
)	O	747-748
group	O	749-754
.	O	754-755

The	O	756-759
mean	O	760-764
H	O	765-766
concentration	O	767-780
during	O	781-787
hypotension	B	788-799
in	O	800-802
the	O	803-806
inspiratory	O	807-818
gas	O	819-822
was	O	823-826
0	O	827-828
.	O	828-829
7	O	829-830
+	O	831-832
/	O	832-833
-	O	833-834
0	O	835-836
.	O	836-837
1	O	837-838
vol	O	839-842
%	O	842-843
,	O	843-844
the	O	845-848
mean	O	849-853
E	O	854-855
concentration	O	856-869
1	O	870-871
.	O	871-872
6	O	872-873
+	O	874-875
/	O	875-876
-	O	876-877
0	O	878-879
.	O	879-880
2	O	880-881
vol	O	882-885
%	O	885-886
,	O	886-887
and	O	888-891
the	O	892-895
mean	O	896-900
I	O	901-902
concentration	O	903-916
1	O	917-918
.	O	918-919
0	O	919-920
+	O	921-922
/	O	922-923
-	O	923-924
0	O	925-926
.	O	926-927
1	O	927-928
vol	O	929-932
%	O	932-933
.	O	933-934

In	O	935-937
addition	O	938-946
,	O	946-947
the	O	948-951
patients	O	952-960
received	O	961-969
fentanyl	O	970-978
and	O	979-982
d	O	983-984
-	O	984-985
tubocurarine	O	985-997
.	O	997-998

The	O	999-1002
initial	O	1003-1010
dose	O	1011-1015
of	O	1016-1018
labetalol	O	1019-1028
for	O	1029-1032
lowering	O	1033-1041
blood	O	1042-1047
pressure	O	1048-1056
was	O	1057-1060
similar	O	1061-1068
,	O	1068-1069
0	O	1070-1071
.	O	1071-1072
52	O	1072-1074
-	O	1074-1075
0	O	1070-1071
.	O	1071-1072
59	O	1077-1079

mg	O	1080-1082
/	O	1082-1083
kg	O	1083-1085
,	O	1085-1086
in	O	1087-1089
all	O	1090-1093
the	O	1094-1097
groups	O	1098-1104
.	O	1104-1105

During	O	1106-1112
hypotension	B	1113-1124
,	O	1124-1125
the	O	1126-1129
heart	O	1130-1135
rate	O	1136-1140
was	O	1141-1144
stable	O	1145-1151
without	O	1152-1159
tachy	B	1160-1165
-	I	1165-1166
or	I	1167-1169
bradycardia	I	1170-1181
.	O	1181-1182

The	O	1183-1186
operating	O	1187-1196
conditions	O	1197-1207
regarding	O	1208-1217
bleeding	B	1218-1226
were	O	1227-1231
estimated	O	1232-1241
in	O	1242-1244
a	O	1245-1246
double	O	1247-1253
-	O	1253-1254
blind	O	1254-1259
manner	O	1260-1266
,	O	1266-1267
and	O	1268-1271
did	O	1272-1275
not	O	1276-1279
differ	O	1280-1286
significantly	O	1287-1300
between	O	1301-1308
the	O	1309-1312
groups	O	1313-1319
.	O	1319-1320

During	O	1321-1327
hypotension	B	1328-1339
,	O	1339-1340
the	O	1341-1344
serum	O	1345-1350
creatinine	O	1351-1361
concentration	O	1362-1375
rose	O	1376-1380
significantly	O	1381-1394
in	O	1395-1397
all	O	1398-1401
groups	O	1402-1408
from	O	1409-1413
the	O	1414-1417
values	O	1418-1424
before	O	1425-1431
hypotension	B	1432-1443
and	O	1444-1447
returned	O	1448-1456
postoperatively	O	1457-1472
to	O	1473-1475
the	O	1476-1479
initial	O	1480-1487
level	O	1488-1493
in	O	1494-1496
the	O	1497-1500
other	O	1501-1506
groups	O	1507-1513
,	O	1513-1514
except	O	1515-1521
the	O	1522-1525
isoflurane	O	1526-1536
group	O	1537-1542
.	O	1542-1543

After	O	1544-1549
hypotension	B	1550-1561
there	O	1562-1567
was	O	1568-1571
no	O	1572-1574
rebound	O	1575-1582
phenomenon	O	1583-1593
in	O	1594-1596
either	O	1597-1603
blood	O	1604-1609
pressure	O	1610-1618
or	O	1619-1621
heart	O	1622-1627
rate	O	1628-1632
.	O	1632-1633

These	O	1634-1639
results	O	1640-1647
indicate	O	1648-1656
that	O	1657-1661
labetalol	O	1662-1671
induces	O	1672-1679
easily	O	1680-1686
adjustable	O	1687-1697
hypotension	B	1698-1709
without	O	1710-1717
compensatory	O	1718-1730
tachycardia	B	1731-1742
and	O	1743-1746
rebound	O	1747-1754
hypertension	B	1755-1767
.	O	1767-1768

Convulsion	B	0-10
following	O	11-20
intravenous	O	21-32
fluorescein	O	33-44
angiography	O	45-56
.	O	56-57

Tonic	B	58-63
-	I	63-64
clonic	I	64-70
seizures	I	71-79
followed	O	80-88
intravenous	O	89-100
fluorescein	O	101-112
injection	O	113-122
for	O	123-126
fundus	O	127-133
angiography	O	134-145
in	O	146-148
a	O	149-150
47	O	151-153
-	O	153-154
year	O	154-158
-	O	153-154
old	O	159-162
male	O	163-167
.	O	167-168

Despite	O	169-176
precautions	O	177-188
this	O	189-193
adverse	O	194-201
reaction	O	202-210
recurred	O	211-219
on	O	220-222
re	O	223-225
-	O	225-226
exposure	O	226-234
to	O	235-237
intravenous	O	238-249
fluorescein	O	250-261
.	O	261-262

Pharmacology	O	0-12
of	O	13-15
ACC	O	16-19
-	O	19-20
9653	O	20-24
(	O	25-26
phenytoin	O	26-35
prodrug	O	36-43
)	O	43-44
.	O	44-45

ACC	O	46-49
-	O	49-50
9653	O	50-54
,	O	54-55
the	O	56-59
disodium	O	60-68
phosphate	O	69-78
ester	O	79-84
of	O	85-87
3	O	88-89
-	O	89-90
hydroxymethyl	O	90-103
-	O	89-90
5	O	104-105
,	O	105-106
5	O	104-105
-	O	89-90
diphenylhydantoin	O	108-125
,	O	105-106
is	O	127-129
a	O	130-131
prodrug	O	132-139
of	O	140-142
phenytoin	O	143-152
with	O	153-157
advantageous	O	158-170
physicochemical	O	171-186
properties	O	187-197
.	O	197-198

ACC	O	199-202
-	O	202-203
9653	O	203-207
is	O	208-210
rapidly	O	211-218
converted	O	219-228
enzymatically	O	229-242
to	O	243-245
phenytoin	O	246-255
in	O	256-258
vivo	O	259-263
.	O	263-264

ACC	O	265-268
-	O	268-269
9653	O	269-273
and	O	274-277
phenytoin	O	278-287
sodium	O	288-294
have	O	295-299
equivalent	O	300-310
anticonvulsant	O	311-325
activity	O	326-334
against	O	335-342
seizures	B	343-351
induced	O	352-359
by	O	360-362
maximal	O	363-370
electroshock	O	371-383
(	O	384-385
MES	O	385-388
)	O	388-389
in	O	390-392
mice	O	393-397
following	O	398-407
i	O	408-409
.	O	409-410
p	O	410-411
.	O	409-410
,	O	412-413
oral	O	414-418
,	O	418-419
or	O	420-422
i	O	423-424
.	O	424-425
v	O	425-426
.	O	424-425

administration	O	428-442
.	O	442-443

The	O	444-447
ED50	O	448-452
doses	O	453-458
were	O	459-463
16	O	464-466
mg	O	467-469
/	O	469-470
kg	O	470-472
for	O	473-476
i	O	477-478
.	O	478-479
v	O	479-480
.	O	478-479

ACC	O	482-485
-	O	485-486
9653	O	486-490
and	O	491-494
8	O	495-496
mg	O	497-499
/	O	499-500
kg	O	500-502
for	O	503-506
i	O	507-508
.	O	508-509
v	O	509-510
.	O	508-509

phenytoin	O	512-521
sodium	O	522-528
.	O	528-529

ACC	O	530-533
-	O	533-534
9653	O	534-538
and	O	539-542
phenytoin	O	543-552
sodium	O	553-559
have	O	560-564
similar	O	565-572
antiarrhythmic	O	573-587
activity	O	588-596
against	O	597-604
ouabain	O	605-612
-	O	612-613
induced	O	613-620
ventricular	B	621-632
tachycardia	I	633-644
in	O	645-647
anesthetized	O	648-660
dogs	O	661-665
.	O	665-666

The	O	667-670
total	O	671-676
doses	O	677-682
of	O	683-685
ACC	O	686-689
-	O	689-690
9653	O	690-694
or	O	695-697
phenytoin	O	698-707
sodium	O	708-714
necessary	O	715-724
to	O	725-727
convert	O	728-735
the	O	736-739
arrhythmia	B	740-750
to	O	751-753
a	O	754-755
normal	O	756-762
sinus	O	763-768
rhythm	O	769-775
were	O	776-780
24	O	781-783
+	O	784-785
/	O	785-786
-	O	786-787
6	O	788-789
and	O	790-793
14	O	794-796
+	O	797-798
/	O	798-799
-	O	799-800
3	O	801-802
mg	O	803-805
/	O	805-806
kg	O	806-808
,	O	808-809
respectively	O	810-822
.	O	822-823

Only	O	824-828
phenytoin	O	829-838
sodium	O	839-845
displayed	O	846-855
in	O	856-858
vitro	O	859-864
antiarrhythmic	O	865-879
activity	O	880-888
against	O	889-896
strophanthidin	O	897-911
-	O	911-912
induced	O	912-919
arrhythmias	B	920-931
in	O	932-934
guinea	O	935-941
pig	O	942-945
right	O	946-951
atria	O	952-957
.	O	957-958

In	O	959-961
anesthetized	O	962-974
dogs	O	975-979
,	O	979-980
a	O	981-982
high	O	983-987
dose	O	988-992
of	O	993-995
ACC	O	996-999
-	O	999-1000
9653	O	1000-1004
(	O	1005-1006
31	O	1006-1008
mg	O	1009-1011
/	O	1011-1012
kg	O	1012-1014
)	O	1014-1015
was	O	1016-1019
infused	O	1020-1027
over	O	1028-1032
15	O	1033-1035
,	O	1035-1036
20	O	1037-1039
,	O	1039-1040
and	O	1041-1044
30	O	1045-1047
min	O	1048-1051
and	O	1052-1055
the	O	1056-1059
responses	O	1060-1069
were	O	1070-1074
compared	O	1075-1083
to	O	1084-1086
an	O	1087-1089
equimolar	O	1090-1099
dose	O	1100-1104
of	O	1105-1107
phenytoin	O	1108-1117
sodium	O	1118-1124
(	O	1125-1126
21	O	1126-1128
mg	O	1129-1131
/	O	1131-1132
kg	O	1132-1134
)	O	1134-1135
.	O	1135-1136

The	O	1137-1140
ACC	O	1141-1144
-	O	1144-1145
9653	O	1145-1149
and	O	1150-1153
phenytoin	O	1154-1163
sodium	O	1164-1170
treatments	O	1171-1181
produced	O	1182-1190
similar	O	1191-1198
marked	O	1199-1205
reductions	O	1206-1216
in	O	1217-1219
diastolic	O	1220-1229
blood	O	1230-1235
pressure	O	1236-1244
and	O	1245-1248
contractile	O	1249-1260
force	O	1261-1266
(	O	1267-1268
LVdP	O	1268-1272
/	O	1272-1273
dt	O	1273-1275
)	O	1275-1276
.	O	1276-1277

The	O	1278-1281
maximum	O	1282-1289
effects	O	1290-1297
of	O	1298-1300
each	O	1301-1305
treatment	O	1306-1315
occurred	O	1316-1324
at	O	1325-1327
the	O	1328-1331
time	O	1332-1336
of	O	1337-1339
maximum	O	1340-1347
phenytoin	O	1348-1357
sodium	O	1358-1364
levels	O	1365-1371
.	O	1371-1372

Acute	O	1373-1378
toxicity	B	1379-1387
studies	O	1388-1395
of	O	1396-1398
ACC	O	1399-1402
-	O	1402-1403
9653	O	1403-1407
and	O	1408-1411
phenytoin	O	1412-1421
sodium	O	1422-1428
were	O	1429-1433
carried	O	1434-1441
out	O	1442-1445
in	O	1446-1448
mice	O	1449-1453
,	O	1453-1454
rats	O	1455-1459
,	O	1459-1460
rabbits	O	1461-1468
,	O	1468-1469
and	O	1470-1473
dogs	O	1474-1478
by	O	1479-1481
i	O	1482-1483
.	O	1483-1484
v	O	1484-1485
.	O	1483-1484
,	O	1486-1487
i	O	1488-1489
.	O	1489-1490
m	O	1490-1491
.	O	1489-1490
,	O	1492-1493
and	O	1494-1497
i	O	1498-1499
.	O	1499-1500
p	O	1500-1501
.	O	1499-1500
routes	O	1503-1509
of	O	1510-1512
administration	O	1513-1527
.	O	1527-1528

The	O	1529-1532
systemic	O	1533-1541
toxic	O	1542-1547
signs	O	1548-1553
of	O	1554-1556
both	O	1557-1561
agents	O	1562-1568
were	O	1569-1573
similar	O	1574-1581
and	O	1582-1585
occurred	O	1586-1594
at	O	1595-1597
approximately	O	1598-1611
equivalent	O	1612-1622
doses	O	1623-1628
.	O	1628-1629

Importantly	O	1630-1641
,	O	1641-1642
the	O	1643-1646
local	O	1647-1652
irritation	O	1653-1663
of	O	1664-1666
ACC	O	1667-1670
-	O	1670-1671
9653	O	1671-1675
was	O	1676-1679
markedly	O	1680-1688
less	O	1689-1693
than	O	1694-1698
phenytoin	O	1699-1708
sodium	O	1709-1715
following	O	1716-1725
i	O	1726-1727
.	O	1727-1728
m	O	1728-1729
.	O	1727-1728
administration	O	1731-1745
.	O	1745-1746
(	O	1746-1747
ABSTRACT	O	1747-1755

TRUNCATED	O	1756-1765
AT	O	1766-1768
250	O	1769-1772
WORDS	O	1773-1778
)	O	1778-1779

Phenytoin	O	0-9
induced	O	10-17
fatal	O	18-23
hepatic	B	24-31
injury	I	32-38
.	O	38-39

A	O	40-41
61	O	42-44
year	O	45-49
old	O	50-53
female	O	54-60
developed	O	61-70
fatal	O	71-76
hepatic	B	77-84
failure	I	85-92
after	O	93-98
phenytoin	O	99-108
administration	O	109-123
.	O	123-124

A	O	125-126
typical	O	127-134
multisystem	O	135-146
clinical	O	147-155
pattern	O	156-163
precedes	O	164-172
the	O	173-176
manifestations	O	177-191
of	O	192-194
hepatic	B	195-202
injury	I	203-209
.	O	209-210

The	O	211-214
hematologic	O	215-226
,	O	226-227
biochemical	O	228-239
and	O	240-243
pathologic	O	244-254
features	O	255-263
indicate	O	264-272
a	O	273-274
mixed	O	275-280
hepatocellular	B	281-295
damage	I	296-302
due	O	303-306
to	O	307-309
drug	B	310-314
hypersensitivity	I	315-331
.	O	331-332

In	O	333-335
a	O	336-337
patient	O	338-345
receiving	O	346-355
phenytoin	O	356-365
who	O	366-369
presents	O	370-378
a	O	379-380
viral	O	381-386
-	O	386-387
like	O	387-391
illness	O	392-399
,	O	399-400
early	O	401-406
recognition	O	407-418
and	O	419-422
discontinuation	O	423-438
of	O	439-441
the	O	442-445
drug	O	446-450
are	O	451-454
mandatory	O	455-464
.	O	464-465

Treatment	O	0-9
of	O	10-12
lethal	O	13-19
pertussis	O	20-29
vaccine	O	30-37
reaction	O	38-46
with	O	47-51
histamine	O	52-61
H1	O	62-64
antagonists	O	65-76
.	O	76-77

We	O	78-80
studied	O	81-88
mortality	O	89-98
after	O	99-104
pertussis	B	105-114
immunization	O	115-127
in	O	128-130
the	O	131-134
mouse	O	135-140
.	O	140-141

Without	O	142-149
treatment	O	150-159
,	O	159-160
73	O	161-163
of	O	164-166
92	O	167-169
animals	O	170-177
(	O	178-179
80	O	179-181
%	O	181-182
)	O	182-183
died	O	184-188
after	O	189-194
injection	O	195-204
of	O	205-207
bovine	O	208-214
serum	O	215-220
albumin	O	221-228
(	O	229-230
BSA	O	230-233
)	O	233-234
on	O	235-237
day	O	238-241
+	O	242-243
7	O	243-244
of	O	245-247
pertussis	B	248-257
immunization	O	258-270
.	O	270-271

After	O	272-277
pretreatment	O	278-290
with	O	291-295
3	O	296-297
mg	O	298-300
of	O	301-303
cyproheptadine	O	304-318
,	O	318-319
2	O	320-321
mg	O	322-324
mianserin	O	325-334
,	O	334-335
or	O	336-338
2	O	339-340
mg	O	341-343
chlorpheniramine	O	344-360
,	O	360-361
only	O	362-366
5	O	367-368
of	O	369-371
105	O	372-375
animals	O	376-383
(	O	384-385
5	O	385-386
%	O	386-387
)	O	387-388
died	O	389-393
after	O	394-399
receiving	O	400-409
BSA	O	410-413
on	O	414-416
day	O	417-420
+	O	421-422
7	O	422-423
(	O	424-425
p	O	425-426
less	O	427-431
than	O	432-436
0	O	437-438
.	O	438-439
001	O	439-442
)	O	442-443
.	O	438-439

Blockade	O	445-453
of	O	454-456
histamine	O	457-466
H1	O	467-469
receptors	O	470-479
may	O	480-483
reduce	O	484-490
mortality	O	491-500
in	O	501-503
pertussis	B	504-513
immunization	O	514-526
-	O	526-527
induced	O	527-534
encephalopathy	B	535-549
in	O	550-552
mice	O	553-557
.	O	557-558

Support	O	0-7
for	O	8-11
adrenaline	O	12-22
-	O	22-23
hypertension	B	23-35
hypothesis	O	36-46
:	O	46-47
18	O	48-50
hour	O	51-55
pressor	O	56-63
effect	O	64-70
after	O	71-76
6	O	77-78
hours	O	79-84
adrenaline	O	85-95
infusion	O	96-104
.	O	104-105

In	O	106-108
a	O	109-110
double	O	111-117
blind	O	118-123
,	O	123-124
crossover	O	125-134
study	O	135-140
6	O	141-142
h	O	143-144
infusions	O	145-154
of	O	155-157
adrenaline	O	158-168
(	O	169-170
15	O	170-172
ng	O	173-175
/	O	175-176
kg	O	176-178
/	O	175-176
min	O	179-182
;	O	182-183
1	O	184-185
ng	O	186-188
=	O	189-190
5	O	191-192
.	O	192-193
458	O	193-196
pmol	O	197-201
)	O	201-202
,	O	202-203
noradrenaline	O	204-217
(	O	218-219
30	O	219-221
ng	O	222-224
/	O	224-225
kg	O	225-227
/	O	224-225
min	O	228-231
;	O	231-232
1	O	233-234
ng	O	235-237
=	O	238-239
5	O	240-241
.	O	241-242
911	O	242-245
pmol	O	246-250
)	O	250-251
,	O	251-252
and	O	253-256
a	O	257-258
5	O	259-260
%	O	260-261
dextrose	O	262-270
solution	O	271-279
(	O	280-281
5	O	281-282
.	O	282-283
4	O	283-284
ml	O	285-287
/	O	287-288
h	O	288-289
)	O	289-290
,	O	290-291
were	O	292-296
given	O	297-302
to	O	303-305
ten	O	306-309
healthy	O	310-317
volunteers	O	318-328
in	O	329-331
random	O	332-338
order	O	339-344
2	O	345-346
weeks	O	347-352
apart	O	353-358
.	O	358-359

By	O	360-362
means	O	363-368
of	O	369-371
intra	O	372-377
-	O	377-378
arterial	O	378-386
ambulatory	O	387-397
monitoring	O	398-408
the	O	409-412
haemodynamic	O	413-425
effects	O	426-433
were	O	434-438
followed	O	439-447
for	O	448-451
18	O	452-454
h	O	455-456
after	O	457-462
the	O	463-466
infusions	O	467-476
were	O	477-481
stopped	O	482-489
.	O	489-490

Adrenaline	O	491-501
,	O	501-502
but	O	503-506
not	O	507-510
noradrenaline	O	511-524
,	O	524-525
caused	O	526-532
a	O	533-534
delayed	O	535-542
and	O	543-546
protracted	O	547-557
pressor	O	558-565
effect	O	566-572
.	O	572-573

Over	O	574-578
the	O	579-582
total	O	583-588
postinfusion	O	589-601
period	O	602-608
systolic	O	609-617
and	O	618-621
diastolic	O	622-631
arterial	O	632-640
pressure	O	641-649
were	O	650-654
6	O	655-656
(	O	657-658
SEM	O	658-661
2	O	662-663
)	O	663-664
%	O	664-665
and	O	666-669
7	O	670-671
(	O	672-673
2	O	673-674
)	O	674-675
%	O	675-676
,	O	676-677
respectively	O	678-690
,	O	690-691
higher	O	692-698
than	O	699-703
after	O	704-709
dextrose	O	710-718
infusion	O	719-727
(	O	728-729
ANOVA	O	729-734
,	O	734-735
p	O	736-737
less	O	738-742
than	O	743-747
0	O	748-749
.	O	749-750
001	O	750-753
)	O	753-754
.	O	749-750

Thus	O	756-760
,	O	760-761
"	O	762-763
stress	O	763-769
"	O	762-763
levels	O	771-777
of	O	778-780
adrenaline	O	781-791
(	O	792-793
230	O	793-796
pg	O	797-799
/	O	799-800
ml	O	800-802
)	O	802-803
for	O	804-807
6	O	808-809
h	O	810-811
cause	O	812-817
a	O	818-819
delayed	O	820-827
and	O	828-831
protracted	O	832-842
pressor	O	843-850
effect	O	851-857
.	O	857-858

These	O	859-864
findings	O	865-873
are	O	874-877
strong	O	878-884
support	O	885-892
for	O	893-896
the	O	897-900
adrenaline	O	901-911
-	O	911-912
hypertension	B	912-924
hypothesis	O	925-935
in	O	936-938
man	O	939-942
.	O	942-943

Effect	O	0-6
of	O	7-9
alkylxanthines	O	10-24
on	O	25-27
gentamicin	O	28-38
-	O	38-39
induced	O	39-46
acute	B	47-52
renal	I	53-58
failure	I	59-66
in	O	67-69
the	O	70-73
rat	O	74-77
.	O	77-78

Adenosine	O	79-88
antagonists	O	89-100
have	O	101-105
been	O	106-110
previously	O	111-121
shown	O	122-127
to	O	128-130
be	O	131-133
of	O	134-136
benefit	O	137-144
in	O	145-147
some	O	148-152
ischaemic	B	153-162
and	O	163-166
nephrotoxic	B	167-178
models	O	179-185
of	O	186-188
acute	B	189-194
renal	I	195-200
failure	I	201-208
(	O	209-210
ARF	B	210-213
)	O	213-214
.	O	214-215

In	O	216-218
the	O	219-222
present	O	223-230
study	O	231-236
,	O	236-237
the	O	238-241
effects	O	242-249
of	O	250-252
three	O	253-258
alkylxanthines	O	259-273
with	O	274-278
different	O	279-288
potencies	O	289-298
as	O	299-301
adenosine	O	302-311
antagonists	O	312-323
8	O	324-325
-	O	325-326
phenyltheophylline	O	326-344
,	O	344-345
theophylline	O	346-358
and	O	359-362
enprofylline	O	363-375
,	O	375-376
were	O	377-381
examined	O	382-390
in	O	391-393
rats	O	394-398
developing	O	399-409
acute	B	410-415
renal	I	416-421
failure	I	422-429
after	O	430-435
4	O	436-437
daily	O	438-443
injections	O	444-454
of	O	455-457
gentamicin	O	458-468
(	O	469-470
200	O	470-473
mg	O	474-476
kg	O	477-479
-	O	479-480
1	O	480-481
)	O	481-482
.	O	482-483

Renal	O	484-489
function	O	490-498
was	O	499-502
assessed	O	503-511
by	O	512-514
biochemical	O	515-526
(	O	527-528
plasma	O	528-534
urea	O	535-539
and	O	540-543
creatinine	O	544-554
)	O	554-555
,	O	555-556
functional	O	557-567
(	O	568-569
urine	O	569-574
analysis	O	575-583
and	O	584-587
[	O	588-589
3H	O	589-591
]	O	591-592
inulin	O	592-598
and	O	599-602
[	O	603-604
14C	O	604-607
]	O	607-608
p	O	608-609
-	O	609-610
aminohippuric	O	610-623
acid	O	624-628
clearances	O	629-639
)	O	639-640
and	O	641-644
morphological	O	645-658
(	O	659-660
degree	O	660-666
of	O	667-669
necrosis	B	670-678
)	O	678-679
indices	O	680-687
.	O	687-688

The	O	689-692
various	O	693-700
drug	O	701-705
treatments	O	706-716
produced	O	717-725
improvements	O	726-738
in	O	739-741
some	O	742-746
,	O	746-747
but	O	748-751
not	O	752-755
all	O	756-759
,	O	759-760
measurements	O	761-773
of	O	774-776
renal	O	777-782
function	O	783-791
.	O	791-792

However	O	793-800
,	O	800-801
any	O	802-805
improvement	O	806-817
produced	O	818-826
by	O	827-829
drug	O	830-834
treatment	O	835-844
was	O	845-848
largely	O	849-856
a	O	857-858
result	O	859-865
of	O	866-868
a	O	869-870
beneficial	O	871-881
effect	O	882-888
exerted	O	889-896
by	O	897-899
its	O	900-903
vehicle	O	904-911
(	O	912-913
polyethylene	O	913-925
glycol	O	926-932
and	O	933-936
NaOH	O	937-941
)	O	941-942
.	O	942-943

The	O	944-947
lack	O	948-952
of	O	953-955
any	O	956-959
consistent	O	960-970
protective	O	971-981
effect	O	982-988
noted	O	989-994
with	O	995-999
the	O	1000-1003
alkylxanthines	O	1004-1018
tested	O	1019-1025
in	O	1026-1028
the	O	1029-1032
present	O	1033-1040
study	O	1041-1046
indicates	O	1047-1056
that	O	1057-1061
adenosine	O	1062-1071
plays	O	1072-1077
little	O	1078-1084
,	O	1084-1085
if	O	1086-1088
any	O	1089-1092
,	O	1092-1093
pathophysiological	O	1094-1112
role	O	1113-1117
in	O	1118-1120
gentamicin	O	1121-1131
-	O	1131-1132
induced	O	1132-1139
ARF	B	1140-1143
.	O	1143-1144

Adverse	O	0-7
ocular	O	8-14
reactions	O	15-24
possibly	O	25-33
associated	O	34-44
with	O	45-49
isotretinoin	O	50-62
.	O	62-63

A	O	64-65
total	O	66-71
of	O	72-74
261	O	75-78
adverse	O	79-86
ocular	O	87-93
reactions	O	94-103
occurred	O	104-112
in	O	113-115
237	O	116-119
patients	O	120-128
who	O	129-132
received	O	133-141
isotretinoin	O	142-154
,	O	154-155
a	O	156-157
commonly	O	158-166
used	O	167-171
drug	O	172-176
in	O	177-179
the	O	180-183
treatment	O	184-193
of	O	194-196
severe	O	197-203
cystic	O	204-210
acne	B	211-215
.	O	215-216

Blepharoconjunctivitis	B	217-239
,	O	239-240
subjective	O	241-251
complaints	O	252-262
of	O	263-265
dry	B	266-269
eyes	I	270-274
,	O	274-275
blurred	B	276-283
vision	I	284-290
,	O	290-291
contact	O	292-299
lens	O	300-304
intolerance	O	305-316
,	O	316-317
and	O	318-321
photodermatitis	B	322-337
are	O	338-341
reversible	O	342-352
side	O	353-357
effects	O	358-365
.	O	365-366

More	O	367-371
serious	O	372-379
ocular	O	380-386
adverse	O	387-394
reactions	O	395-404
include	O	405-412
papilledema	B	413-424
,	O	424-425
pseudotumor	B	426-437
cerebri	I	438-445
,	O	445-446
and	O	447-450
white	O	451-456
or	O	457-459
gray	O	460-464
subepithelial	O	465-478
corneal	B	479-486
opacities	I	487-496
;	O	496-497
all	O	498-501
of	O	502-504
these	O	505-510
are	O	511-514
reversible	O	515-525
if	O	526-528
the	O	529-532
drug	O	533-537
is	O	538-540
discontinued	O	541-553
.	O	553-554

Reported	O	555-563
cases	O	564-569
of	O	570-572
decreased	O	573-582
dark	O	583-587
adaptation	O	588-598
are	O	599-602
under	O	603-608
investigation	O	609-622
.	O	622-623

Isotretinoin	O	624-636
is	O	637-639
contraindicated	O	640-655
in	O	656-658
pregnancy	O	659-668
because	O	669-676
of	O	677-679
the	O	680-683
many	O	684-688
reported	O	689-697
congenital	B	698-708
abnormalities	I	709-722
after	O	723-728
maternal	O	729-737
use	O	738-741
(	O	742-743
including	O	743-752
microphthalmos	B	753-767
,	O	767-768
orbital	O	769-776
hypertelorism	B	777-790
,	O	790-791
and	O	792-795
optic	B	796-801
nerve	I	802-807
hypoplasia	I	808-818
)	O	818-819
.	O	819-820

Procaterol	O	0-10
and	O	11-14
terbutaline	O	15-26
in	O	27-29
bronchial	B	30-39
asthma	I	40-46
.	O	46-47

A	O	48-49
double	O	50-56
-	O	56-57
blind	O	57-62
,	O	62-63
placebo	O	64-71
-	O	71-72
controlled	O	72-82
,	O	82-83
cross	O	84-89
-	O	89-90
over	O	90-94
study	O	95-100
.	O	100-101

Procaterol	O	102-112
,	O	112-113
a	O	114-115
new	O	116-119
beta	O	120-124
-	O	124-125
2	O	125-126
adrenoceptor	O	127-139
stimulant	O	140-149
,	O	149-150
was	O	151-154
studied	O	155-162
in	O	163-165
a	O	166-167
double	O	168-174
-	O	174-175
blind	O	175-180
,	O	180-181
placebo	O	182-189
-	O	189-190
controlled	O	190-200
,	O	200-201
cross	O	202-207
-	O	207-208
over	O	208-212
trial	O	213-218
in	O	219-221
patients	O	222-230
with	O	231-235
bronchial	B	236-245
asthma	I	246-252
.	O	252-253

Oral	O	254-258
procaterol	O	259-269
50	O	270-272
micrograms	O	273-283
b	O	284-285
.	O	285-286
d	O	286-287
.	O	285-286
,	O	288-289
procaterol	O	290-300
100	O	301-304
micrograms	O	305-315
b	O	316-317
.	O	317-318
d	O	318-319
.	O	317-318
,	O	320-321
and	O	322-325
terbutaline	O	326-337
5	O	338-339
mg	O	340-342
t	O	343-344
.	O	344-345
i	O	345-346
.	O	344-345
d	O	347-348
.	O	344-345
,	O	349-350
were	O	351-355
compared	O	356-364
when	O	365-369
given	O	370-375
randomly	O	376-384
in	O	385-387
1	O	388-389
-	O	389-390
week	O	390-394
treatment	O	395-404
periods	O	405-412
.	O	412-413

The	O	414-417
best	O	418-422
clinical	O	423-431
effect	O	432-438
was	O	439-442
found	O	443-448
with	O	449-453
terbutaline	O	454-465
.	O	465-466

Both	O	467-471
anti	O	472-476
-	O	476-477
asthmatic	B	477-486
and	O	487-490
tremorgenic	B	491-502
effects	O	503-510
of	O	511-513
procaterol	O	514-524
were	O	525-529
dose	O	530-534
-	O	534-535
related	O	535-542
.	O	542-543

Procaterol	O	544-554
appeared	O	555-563
effective	O	564-573
in	O	574-576
the	O	577-580
doses	O	581-586
tested	O	587-593
,	O	593-594
and	O	595-598
a	O	599-600
twice	O	601-606
daily	O	607-612
regimen	O	613-620
would	O	621-626
appear	O	627-633
to	O	634-636
be	O	637-639
suitable	O	640-648
with	O	649-653
this	O	654-658
drug	O	659-663
.	O	663-664

Subacute	O	0-8
effects	O	9-16
of	O	17-19
propranolol	O	20-31
and	O	32-35
B	O	36-37
24	O	38-40
/	O	40-41
76	O	41-43
on	O	44-46
isoproterenol	O	47-60
-	O	60-61
induced	O	61-68
rat	O	69-72
heart	B	73-78
hypertrophy	I	79-90
in	O	91-93
correlation	O	94-105
with	O	106-110
blood	O	111-116
pressure	O	117-125
.	O	125-126

We	O	127-129
compared	O	130-138
the	O	139-142
potential	O	143-152
beta	O	153-157
-	O	157-158
receptor	O	158-166
blocker	O	167-174
,	O	174-175
B	O	176-177
24	O	178-180
/	O	180-181
76	O	181-183
i	O	184-185
.	O	185-186
e	O	186-187
.	O	185-186
1	O	189-190
-	O	190-191
(	O	191-192
2	O	192-193
,	O	193-194
4	O	194-195
-	O	190-191
dichlorophenoxy	O	196-211
)	O	211-212
-	O	190-191
3	O	213-214
[	O	214-215
2	O	192-193
-	O	190-191
3	O	213-214
,	O	193-194
4	O	194-195
-	O	190-191
dimethoxyphenyl	O	221-236
)	O	211-212
ethanolamino	O	237-249
]	O	249-250
-	O	190-191
prop	O	251-255
an	O	256-258
-	O	258-259
2	O	259-260
-	O	258-259
ol	O	261-263
,	O	263-264
which	O	265-270
is	O	271-273
characterized	O	274-287
by	O	288-290
beta	O	291-295
1	O	296-297
-	O	297-298
adrenoceptor	O	298-310
blocking	O	311-319
and	O	320-323
beta	O	324-328
2	O	329-330
-	O	330-331
adrenoceptor	O	331-343
stimulating	O	344-355
properties	O	356-366
with	O	367-371
propranolol	O	372-383
.	O	383-384

The	O	385-388
studies	O	389-396
were	O	397-401
performed	O	402-411
using	O	412-417
an	O	418-420
experimental	O	421-433
model	O	434-439
of	O	440-442
isoproterenol	O	443-456
-	O	456-457
induced	O	457-464
heart	B	465-470
hypertrophy	I	471-482
in	O	483-485
rats	O	486-490
.	O	490-491

A	O	492-493
correlation	O	494-505
of	O	506-508
the	O	509-512
blood	O	513-518
pressure	O	519-527
was	O	528-531
neither	O	532-539
found	O	540-545
in	O	546-548
the	O	549-552
development	O	553-564
nor	O	565-568
in	O	569-571
the	O	572-575
attempt	O	576-583
to	O	584-586
suppress	O	587-595
the	O	596-599
development	O	600-611
of	O	612-614
heart	B	615-620
hypertrophy	I	621-632
with	O	633-637
the	O	638-641
two	O	642-645
beta	O	646-650
-	O	650-651
receptor	O	651-659
blockers	O	660-668
.	O	668-669

Both	O	670-674
beta	O	675-679
-	O	679-680
blockers	O	680-688
influenced	O	689-699
the	O	700-703
development	O	704-715
of	O	716-718
hypertrophy	B	719-730
to	O	731-733
a	O	734-735
different	O	736-745
,	O	745-746
but	O	747-750
not	O	751-754
reproducible	O	755-767
extent	O	768-774
.	O	774-775

It	O	776-778
was	O	779-782
possible	O	783-791
to	O	792-794
suppress	O	795-803
the	O	804-807
increased	O	808-817
ornithine	O	818-827
decarboxylase	O	828-841
activity	O	842-850
with	O	851-855
both	O	856-860
beta	O	861-865
-	O	865-866
blockers	O	866-874
in	O	875-877
hypertrophied	B	878-891
hearts	I	892-898
,	O	898-899
but	O	900-903
there	O	904-909
was	O	910-913
no	O	914-916
effect	O	917-923
on	O	924-926
the	O	927-930
heart	O	931-936
mass	O	937-941
.	O	941-942

Neither	O	943-950
propranolol	O	951-962
nor	O	963-966
B	O	967-968
24	O	969-971
/	O	971-972
76	O	972-974
could	O	975-980
stop	O	981-985
the	O	986-989
changes	O	990-997
in	O	998-1000
the	O	1001-1004
characteristic	O	1005-1019
myosin	O	1020-1026
isoenzyme	O	1027-1036
pattern	O	1037-1044
of	O	1045-1047
the	O	1048-1051
hypertrophied	B	1052-1065
rat	O	1066-1069
heart	O	1070-1075
.	O	1075-1076

Thus	O	1077-1081
,	O	1081-1082
the	O	1083-1086
investigations	O	1087-1101
did	O	1102-1105
not	O	1106-1109
provide	O	1110-1117
any	O	1118-1121
evidence	O	1122-1130
that	O	1131-1135
the	O	1136-1139
beta	O	1140-1144
-	O	1144-1145
receptor	O	1145-1153
blockers	O	1154-1162
propranolol	O	1163-1174
and	O	1175-1178
B	O	1179-1180
24	O	1181-1183
/	O	1183-1184
76	O	1184-1186
have	O	1187-1191
the	O	1192-1195
potency	O	1196-1203
to	O	1204-1206
prevent	O	1207-1214
isoproterenol	O	1215-1228
from	O	1229-1233
producing	O	1234-1243
heart	B	1244-1249
hypertrophy	I	1250-1261
.	O	1261-1262

Comparison	O	0-10
of	O	11-13
the	O	14-17
effect	O	18-24
of	O	25-27
oxitropium	O	28-38
bromide	O	39-46
and	O	47-50
of	O	51-53
slow	O	54-58
-	O	58-59
release	O	59-66
theophylline	O	67-79
on	O	80-82
nocturnal	O	83-92
asthma	B	93-99
.	O	99-100

The	O	101-104
effects	O	105-112
of	O	113-115
a	O	116-117
new	O	118-121
inhaled	O	122-129
antimuscarinic	O	130-144
drug	O	145-149
,	O	149-150
oxitropium	O	151-161
bromide	O	162-169
,	O	169-170
and	O	171-174
of	O	175-177
a	O	178-179
slow	O	180-184
-	O	184-185
release	O	185-192
theophylline	O	193-205
preparation	O	206-217
upon	O	218-222
nocturnal	O	223-232
asthma	B	233-239
were	O	240-244
compared	O	245-253
in	O	254-256
a	O	257-258
placebo	O	259-266
-	O	266-267
controlled	O	267-277
double	O	278-284
-	O	284-285
blind	O	285-290
study	O	291-296
.	O	296-297

Two	O	298-301
samples	O	302-309
were	O	310-314
studied	O	315-322
:	O	322-323
12	O	324-326
patients	O	327-335
received	O	336-344
oxitropium	O	345-355
at	O	356-358
600	O	359-362
micrograms	O	363-373
(	O	374-375
6	O	375-376
subjects	O	377-385
)	O	385-386
or	O	387-389
at	O	390-392
400	O	393-396
micrograms	O	397-407
t	O	408-409
.	O	409-410
i	O	410-411
.	O	409-410
d	O	412-413
.	O	409-410

(	O	415-416
6	O	416-417
subjects	O	418-426
)	O	426-427
whereas	O	428-435
11	O	436-438
received	O	439-447
theophylline	O	448-460
at	O	461-463
300	O	464-467
mg	O	468-470
b	O	471-472
.	O	472-473
i	O	473-474
.	O	472-473
d	O	475-476
.	O	472-473

Morning	O	478-485
dipping	O	486-493
,	O	493-494
assessed	O	495-503
by	O	504-506
the	O	507-510
fall	O	511-515
in	O	516-518
peak	O	519-523
flow	O	524-528
overnight	O	529-538
,	O	538-539
was	O	540-543
significantly	O	544-557
reduced	O	558-565
in	O	566-568
the	O	569-572
periods	O	573-580
when	O	581-585
either	O	586-592
active	O	593-599
drug	O	600-604
was	O	605-608
taken	O	609-614
,	O	614-615
whereas	O	616-623
no	O	624-626
difference	O	627-637
was	O	638-641
noticed	O	642-649
during	O	650-656
the	O	657-660
placebo	O	661-668
administration	O	669-683
.	O	683-684

No	O	685-687
significant	O	688-699
difference	O	700-710
was	O	711-714
noticed	O	715-722
between	O	723-730
results	O	731-738
obtained	O	739-747
with	O	748-752
either	O	753-759
active	O	760-766
drug	O	767-771
,	O	771-772
as	O	773-775
well	O	776-780
as	O	781-783
with	O	784-788
either	O	789-795
dosage	O	796-802
of	O	803-805
oxitropium	O	806-816
.	O	816-817

No	O	818-820
subject	O	821-828
reported	O	829-837
side	O	838-842
effects	O	843-850
of	O	851-853
oxitropium	O	854-864
,	O	864-865
as	O	866-868
compared	O	869-877
to	O	878-880
three	O	881-886
subjects	O	887-895
reporting	O	896-905
nausea	B	906-912
,	O	912-913
vomiting	B	914-922
and	O	923-926
tremors	B	927-934
after	O	935-940
theophylline	O	941-953
.	O	953-954

Oxitropium	O	955-965
proves	O	966-972
to	O	973-975
be	O	976-978
a	O	979-980
valuable	O	981-989
alternative	O	990-1001
to	O	1002-1004
theophylline	O	1005-1017
in	O	1018-1020
nocturnal	O	1021-1030
asthma	B	1031-1037
,	O	1037-1038
since	O	1039-1044
it	O	1045-1047
is	O	1048-1050
equally	O	1051-1058
potent	O	1059-1065
,	O	1065-1066
safer	O	1067-1072
and	O	1073-1076
does	O	1077-1081
not	O	1082-1085
require	O	1086-1093
the	O	1094-1097
titration	O	1098-1107
of	O	1108-1110
dosage	O	1111-1117
.	O	1117-1118

Penicillin	O	0-10
anaphylaxis	B	11-22
.	O	22-23

A	O	24-25
case	O	26-30
of	O	31-33
oral	O	34-38
penicillin	O	39-49
anaphylaxis	B	50-61
is	O	62-64
described	O	65-74
,	O	74-75
and	O	76-79
the	O	80-83
terminology	O	84-95
,	O	95-96
occurrence	O	97-107
,	O	107-108
clinical	O	109-117
manifestations	O	118-132
,	O	132-133
pathogenesis	O	134-146
,	O	146-147
prevention	O	148-158
,	O	158-159
and	O	160-163
treatment	O	164-173
of	O	174-176
anaphylaxis	B	177-188
are	O	189-192
reviewed	O	193-201
.	O	201-202

Emergency	O	203-212
physicians	O	213-223
should	O	224-230
be	O	231-233
aware	O	234-239
of	O	240-242
oral	O	243-247
penicillin	O	248-258
anaphylaxis	B	259-270
in	O	271-273
order	O	274-279
to	O	280-282
prevent	O	283-290
its	O	291-294
occurrence	O	295-305
by	O	306-308
prescribing	O	309-320
the	O	321-324
antibiotic	O	325-335
judiciously	O	336-347
and	O	348-351
knowledgeably	O	352-365
and	O	366-369
to	O	370-372
offer	O	373-378
optimal	O	379-386
medical	O	387-394
therapy	O	395-402
once	O	403-407
this	O	408-412
life	O	413-417
-	O	417-418
threatening	O	418-429
reaction	O	430-438
has	O	439-442
begun	O	443-448
.	O	448-449

Reversible	O	0-10
valproic	O	11-19
acid	O	20-24
-	O	24-25
induced	O	25-32
dementia	B	33-41
:	O	41-42
a	O	43-44
case	O	45-49
report	O	50-56
.	O	56-57

Reversible	O	58-68
valproic	O	69-77
acid	O	78-82
-	O	82-83
induced	O	83-90
dementia	B	91-99
was	O	100-103
documented	O	104-114
in	O	115-117
a	O	118-119
21	O	120-122
-	O	122-123
year	O	123-127
-	O	122-123
old	O	128-131
man	O	132-135
with	O	136-140
epilepsy	B	141-149
who	O	150-153
had	O	154-157
a	O	158-159
3	O	160-161
-	O	161-162
year	O	162-166
history	O	167-174
of	O	175-177
insidious	O	178-187
progressive	O	188-199
decline	O	200-207
in	O	208-210
global	O	211-217
cognitive	O	218-227
abilities	O	228-237
documented	O	238-248
by	O	249-251
serial	O	252-258
neuropsychological	O	259-277
studies	O	278-285
.	O	285-286

Repeat	O	287-293
neuropsychological	O	294-312
testing	O	313-320
7	O	321-322
weeks	O	323-328
after	O	329-334
discontinuation	O	335-350
of	O	351-353
the	O	354-357
drug	O	358-362
revealed	O	363-371
dramatic	O	372-380
improvement	O	381-392
in	O	393-395
IQ	O	396-398
,	O	398-399
memory	O	400-406
,	O	406-407
naming	O	408-414
,	O	414-415
and	O	416-419
other	O	420-425
tasks	O	426-431
commensurate	O	432-444
with	O	445-449
clinical	O	450-458
recovery	O	459-467
in	O	468-470
his	O	471-474
intellectual	O	475-487
capacity	O	488-496
.	O	496-497

Possible	O	498-506
pathophysiological	O	507-525
mechanisms	O	526-536
which	O	537-542
may	O	543-546
have	O	547-551
been	O	552-556
operative	O	557-566
in	O	567-569
this	O	570-574
case	O	575-579
include	O	580-587
:	O	587-588
a	O	589-590
direct	O	591-597
central	O	598-605
nervous	O	606-613
system	O	614-620
(	O	621-622
CNS	O	622-625
)	O	625-626
toxic	O	627-632
effect	O	633-639
of	O	640-642
valproic	O	643-651
acid	O	652-656
;	O	656-657
a	O	658-659
paradoxical	O	660-671
epileptogenic	O	672-685
effect	O	686-692
secondary	O	693-702
to	O	703-705
the	O	706-709
drug	O	710-714
;	O	714-715
and	O	716-719
an	O	720-722
indirect	O	723-731
CNS	O	732-735
toxic	O	736-741
effect	O	742-748
mediated	O	749-757
through	O	758-765
valproic	O	766-774
acid	O	775-779
-	O	779-780
induced	O	780-787
hyperammonemia	B	788-802
.	O	802-803

Reversal	O	0-8
of	O	9-11
scopolamine	O	12-23
-	O	23-24
induced	O	24-31
amnesia	B	32-39
of	O	40-42
passive	O	43-50
avoidance	O	51-60
by	O	61-63
pre	O	64-67
-	O	67-68
and	O	69-72
post	O	73-77
-	O	77-78
training	O	78-86
naloxone	O	87-95
.	O	95-96

In	O	97-99
a	O	100-101
series	O	102-108
of	O	109-111
five	O	112-116
experiments	O	117-128
,	O	128-129
the	O	130-133
modulating	O	134-144
role	O	145-149
of	O	150-152
naloxone	O	153-161
on	O	162-164
a	O	165-166
scopolamine	O	167-178
-	O	178-179
induced	O	179-186
retention	B	187-196
deficit	I	197-204
in	O	205-207
a	O	208-209
passive	O	210-217
avoidance	O	218-227
paradigm	O	228-236
was	O	237-240
investigated	O	241-253
in	O	254-256
mice	O	257-261
.	O	261-262

Scopolamine	O	263-274
,	O	274-275
but	O	276-279
not	O	280-283
methyl	O	284-290
scopolamine	O	291-302
(	O	303-304
1	O	304-305
and	O	306-309
3	O	310-311
mg	O	312-314
/	O	314-315
kg	O	315-317
)	O	317-318
,	O	318-319
induced	O	320-327
an	O	328-330
amnesia	B	331-338
as	O	339-341
measured	O	342-350
by	O	351-353
latency	O	354-361
and	O	362-365
duration	O	366-374
parameters	O	375-385
.	O	385-386

Naloxone	O	387-395
(	O	396-397
0	O	397-398
.	O	398-399
3	O	399-400
,	O	400-401
1	O	402-403
,	O	403-404
3	O	405-406
,	O	406-407
and	O	408-411
10	O	412-414
mg	O	415-417
/	O	417-418
kg	O	418-420
)	O	420-421
injected	O	422-430
prior	O	431-436
to	O	437-439
training	O	440-448
attenuated	O	449-459
the	O	460-463
retention	B	464-473
deficit	I	474-481
with	O	482-486
a	O	487-488
peak	O	489-493
of	O	494-496
activity	O	497-505
at	O	506-508
3	O	509-510
mg	O	511-513
/	O	513-514
kg	O	514-516
.	O	516-517

The	O	518-521
effect	O	522-528
of	O	529-531
naloxone	O	532-540
could	O	541-546
be	O	547-549
antagonized	O	550-561
with	O	562-566
morphine	O	567-575
(	O	576-577
1	O	577-578
,	O	578-579
3	O	580-581
,	O	581-582
and	O	583-586
10	O	587-589
mg	O	590-592
/	O	592-593
kg	O	593-595
)	O	595-596
,	O	596-597
demonstrating	O	598-611
the	O	612-615
opioid	O	616-622
specificity	O	623-634
of	O	635-637
the	O	638-641
naloxone	O	642-650
effect	O	651-657
.	O	657-658

Post	O	659-663
-	O	663-664
training	O	664-672
administration	O	673-687
of	O	688-690
naloxone	O	691-699
(	O	700-701
3	O	701-702
mg	O	703-705
/	O	705-706
kg	O	706-708
)	O	708-709
as	O	710-712
a	O	713-714
single	O	715-721
or	O	722-724
as	O	725-727
a	O	728-729
split	O	730-735
dose	O	736-740
also	O	741-745
attenuated	O	746-756
the	O	757-760
scopolamine	O	761-772
-	O	772-773
induced	O	773-780
amnesia	B	781-788
.	O	788-789

Control	O	790-797
experiments	O	798-809
indicated	O	810-819
that	O	820-824
neither	O	825-832
an	O	833-835
increase	O	836-844
in	O	845-847
pain	B	848-852
sensitivity	O	853-864
(	O	865-866
pre	O	866-869
-	O	869-870
training	O	870-878
naloxone	O	879-887
)	O	887-888
nor	O	889-892
an	O	893-895
induced	O	896-903
aversive	O	904-912
state	O	913-918
(	O	919-920
post	O	920-924
-	O	924-925
training	O	925-933
naloxone	O	934-942
)	O	942-943
appear	O	944-950
to	O	951-953
be	O	954-956
responsible	O	957-968
for	O	969-972
the	O	973-976
influence	O	977-986
of	O	987-989
naloxone	O	990-998
on	O	999-1001
the	O	1002-1005
scopolamine	O	1006-1017
-	O	1017-1018
induced	O	1018-1025
retention	B	1026-1035
deficit	I	1036-1043
.	O	1043-1044

These	O	1045-1050
results	O	1051-1058
extend	O	1059-1065
previous	O	1066-1074
findings	O	1075-1083
implicating	O	1084-1095
a	O	1096-1097
cholinergic	O	1098-1109
-	O	1109-1110
opioid	O	1110-1116
interaction	O	1117-1128
in	O	1129-1131
memory	O	1132-1138
processes	O	1139-1148
.	O	1148-1149

A	O	1150-1151
possible	O	1152-1160
mechanism	O	1161-1170
for	O	1171-1174
this	O	1175-1179
interaction	O	1180-1191
involving	O	1192-1201
the	O	1202-1205
septo	O	1206-1211
-	O	1211-1212
hippocampal	O	1212-1223
cholinergic	O	1224-1235
pathway	O	1236-1243
is	O	1244-1246
discussed	O	1247-1256
.	O	1256-1257

Electron	O	0-8
microscopic	O	9-20
investigations	O	21-35
of	O	36-38
the	O	39-42
cyclophosphamide	O	43-59
-	O	59-60
induced	O	60-67
lesions	B	68-75
of	I	76-78
the	I	79-82
urinary	I	83-90
bladder	I	91-98
of	O	99-101
the	O	102-105
rat	O	106-109
and	O	110-113
their	O	114-119
prevention	O	120-130
by	O	131-133
mesna	O	134-139
.	O	139-140

Fully	O	141-146
developed	O	147-156
cyclophosphamide	O	157-173
-	O	173-174
induced	O	174-181
cystitis	B	182-190
is	O	191-193
characterized	O	194-207
by	O	208-210
nearly	O	211-217
complete	O	218-226
detachment	O	227-237
of	O	238-240
the	O	241-244
urothelium	O	245-255
,	O	255-256
severe	O	257-263
submucosal	O	264-274
edema	B	275-280
owing	O	281-286
to	O	287-289
damage	O	290-296
to	O	297-299
the	O	300-303
microvascular	O	304-317
bed	O	318-321
and	O	322-325
focal	O	326-331
muscle	O	332-338
necroses	B	339-347
.	O	347-348

The	O	349-352
initial	O	353-360
response	O	361-369
to	O	370-372
the	O	373-376
primary	O	377-384
attack	O	385-391
by	O	392-394
the	O	395-398
cyclophosphamide	O	399-415
metabolites	O	416-427
seems	O	428-433
to	O	434-436
be	O	437-439
fragmentation	O	440-453
of	O	454-456
the	O	457-460
luminal	O	461-468
membrane	O	469-477
.	O	477-478

This	O	479-483
damages	O	484-491
the	O	492-495
cellular	O	496-504
barrier	O	505-512
against	O	513-520
the	O	521-524
hypertonic	O	525-535
urine	O	536-541
.	O	541-542

Subsequent	O	543-553
breaks	O	554-560
in	O	561-563
the	O	564-567
lateral	O	568-575
cell	O	576-580
membranes	O	581-590
of	O	591-593
the	O	594-597
superficial	O	598-609
cells	O	610-615
and	O	616-619
in	O	620-622
all	O	623-626
the	O	627-630
plasma	O	631-637
membranes	O	638-647
of	O	648-650
the	O	651-654
intermediate	O	655-667
and	O	668-671
basal	O	672-677
cells	O	678-683
,	O	683-684
intercellular	O	685-698
and	O	699-702
intracellular	O	703-716
edema	B	717-722
and	O	723-726
disintegration	O	727-741
of	O	742-744
the	O	745-748
desmosomes	O	749-759
and	O	760-763
hemidesmosomes	O	764-778
lead	O	779-783
to	O	784-786
progressive	O	787-798
degeneration	O	799-811
and	O	812-815
detachment	O	816-826
of	O	827-829
the	O	830-833
epithelial	O	834-844
cells	O	845-850
with	O	851-855
exposure	O	856-864
and	O	865-868
splitting	O	869-878
of	O	879-881
the	O	882-885
basal	O	886-891
membrane	O	892-900
.	O	900-901

The	O	902-905
morphological	O	906-919
changes	O	920-927
of	O	928-930
the	O	931-934
endothelial	O	935-946
cells	O	947-952
,	O	952-953
which	O	954-959
become	O	960-966
more	O	967-971
pronounced	O	972-982
in	O	983-985
the	O	986-989
later	O	990-995
stages	O	996-1002
of	O	1003-1005
the	O	1006-1009
experiment	O	1010-1020
,	O	1020-1021
the	O	1022-1025
involvement	O	1026-1037
of	O	1038-1040
blood	O	1041-1046
vessels	O	1047-1054
regardless	O	1055-1065
of	O	1066-1068
their	O	1069-1074
diameter	O	1075-1083
and	O	1084-1087
the	O	1088-1091
location	O	1092-1100
-	O	1100-1101
dependent	O	1101-1110
extent	O	1111-1117
of	O	1118-1120
the	O	1121-1124
damage	O	1125-1131
indicate	O	1132-1140
a	O	1141-1142
direct	O	1143-1149
type	O	1150-1154
of	O	1155-1157
damage	O	1158-1164
which	O	1165-1170
is	O	1171-1173
preceded	O	1174-1182
by	O	1183-1185
a	O	1186-1187
mediator	O	1188-1196
-	O	1196-1197
induced	O	1197-1204
increase	O	1205-1213
in	O	1214-1216
permeability	O	1217-1229
,	O	1229-1230
the	O	1231-1234
morphological	O	1235-1248
correlate	O	1249-1258
of	O	1259-1261
which	O	1262-1267
is	O	1268-1270
the	O	1271-1274
formation	O	1275-1284
of	O	1285-1287
gaps	O	1288-1292
in	O	1293-1295
the	O	1296-1299
interendothelial	O	1300-1316
cell	O	1317-1321
connections	O	1322-1333
on	O	1334-1336
the	O	1337-1340
venules	O	1341-1348
.	O	1348-1349

These	O	1350-1355
changes	O	1356-1363
can	O	1364-1367
be	O	1368-1370
effectively	O	1371-1382
prevented	O	1383-1392
by	O	1393-1395
mesna	O	1396-1401
.	O	1401-1402

The	O	1403-1406
only	O	1407-1411
sign	O	1412-1416
of	O	1417-1419
a	O	1420-1421
possible	O	1422-1430
involvement	O	1431-1442
is	O	1443-1445
the	O	1446-1449
increase	O	1450-1458
in	O	1459-1461
the	O	1462-1465
number	O	1466-1472
of	O	1473-1475
specific	O	1476-1484
granules	O	1485-1493
with	O	1494-1498
a	O	1499-1500
presumed	O	1501-1509
lysosomal	O	1510-1519
function	O	1520-1528
in	O	1529-1531
the	O	1532-1535
superficial	O	1536-1547
cells	O	1548-1553
.	O	1553-1554

Increase	O	0-8
in	O	9-11
intragastric	O	12-24
pressure	O	25-33
during	O	34-40
suxamethonium	O	41-54
-	O	54-55
induced	O	55-62
muscle	B	63-69
fasciculations	I	70-84
in	O	85-87
children	O	88-96
:	O	96-97
inhibition	O	98-108
by	O	109-111
alfentanil	O	112-122
.	O	122-123

Changes	O	124-131
in	O	132-134
intragastric	O	135-147
pressure	O	148-156
after	O	157-162
the	O	163-166
administration	O	167-181
of	O	182-184
suxamethonium	O	185-198
1	O	199-200
.	O	200-201
5	O	201-202
mg	O	203-205
kg	O	206-208
-	O	208-209
1	O	209-210
i	O	211-212
.	O	212-213
v	O	213-214
.	O	212-213
were	O	216-220
studied	O	221-228
in	O	229-231
32	O	232-234
children	O	235-243
(	O	244-245
mean	O	245-249
age	O	250-253
6	O	254-255
.	O	255-256
9	O	256-257
yr	O	258-260
)	O	260-261
pretreated	O	262-272
with	O	273-277
either	O	278-284
physiological	O	285-298
saline	O	299-305
or	O	306-308
alfentanil	O	309-319
50	O	320-322
micrograms	O	323-333
kg	O	334-336
-	O	336-337
1	O	337-338
.	O	338-339

Anaesthesia	O	340-351
was	O	352-355
induced	O	356-363
with	O	364-368
thiopentone	O	369-380
5	O	381-382
mg	O	383-385
kg	O	386-388
-	O	388-389
1	O	389-390
.	O	390-391

The	O	392-395
incidence	O	396-405
and	O	406-409
intensity	O	410-419
of	O	420-422
muscle	B	423-429
fasciculations	I	430-444
caused	O	445-451
by	O	452-454
suxamethonium	O	455-468
were	O	469-473
significantly	O	474-487
greater	O	488-495
in	O	496-498
the	O	499-502
control	O	503-510
than	O	511-515
in	O	516-518
the	O	519-522
alfentanil	O	523-533
group	O	534-539
.	O	539-540

The	O	541-544
intragastric	O	545-557
pressure	O	558-566
during	O	567-573
muscle	B	574-580
fasciculations	I	581-595
was	O	596-599
significantly	O	600-613
higher	O	614-620
in	O	621-623
the	O	624-627
control	O	628-635
group	O	636-641
(	O	642-643
16	O	643-645
+	O	646-647
/	O	647-648
-	O	648-649
0	O	650-651
.	O	651-652
7	O	652-653
(	O	654-655
SEM	O	655-658
)	O	658-659
cm	O	660-662
H2O	O	663-666
)	O	666-667
than	O	668-672
in	O	673-675
the	O	676-679
alfentanil	O	680-690
group	O	691-696
(	O	697-698
7	O	698-699
.	O	699-700
7	O	698-699
+	O	702-703
/	O	703-704
-	O	704-705
1	O	706-707
.	O	707-708
5	O	708-709
(	O	710-711
SEM	O	711-714
)	O	714-715
cm	O	716-718
H2O	O	719-722
)	O	722-723
.	O	723-724

The	O	725-728
increase	O	729-737
in	O	738-740
intragastric	O	741-753
pressure	O	754-762
was	O	763-766
directly	O	767-775
related	O	776-783
to	O	784-786
the	O	787-790
intensity	O	791-800
of	O	801-803
muscle	B	804-810
fasciculations	I	811-825
(	O	826-827
regression	O	827-837
line	O	838-842
:	O	842-843
y	O	844-845
=	O	846-847
0	O	848-849
.	O	849-850
5	O	850-851
+	O	852-853
4	O	854-855
.	O	855-856
78x	O	856-859
with	O	860-864
r	O	865-866
of	O	867-869
0	O	870-871
.	O	871-872
78	O	872-874
)	O	874-875
.	O	871-872

It	O	877-879
is	O	880-882
concluded	O	883-892
that	O	893-897
intragastric	O	898-910
pressure	O	911-919
increases	O	920-929
significantly	O	930-943
during	O	944-950
muscle	B	951-957
fasciculations	I	958-972
caused	O	973-979
by	O	980-982
suxamethonium	O	983-996
in	O	997-999
healthy	O	1000-1007
children	O	1008-1016
.	O	1016-1017

Alfentanil	O	1018-1028
50	O	1029-1031
micrograms	O	1032-1042
kg	O	1043-1045
-	O	1045-1046
1	O	1046-1047
effectively	O	1048-1059
inhibits	O	1060-1068
the	O	1069-1072
incidence	O	1073-1082
and	O	1083-1086
intensity	O	1087-1096
of	O	1097-1099
suxamethonium	O	1100-1113
-	O	1113-1114
induced	O	1114-1121
muscle	B	1122-1128
fasciculations	I	1129-1143
;	O	1143-1144
moreover	O	1145-1153
,	O	1153-1154
intragastric	O	1155-1167
pressure	O	1168-1176
remains	O	1177-1184
at	O	1185-1187
its	O	1188-1191
control	O	1192-1199
value	O	1200-1205
.	O	1205-1206

Acute	O	0-5
insulin	O	6-13
treatment	O	14-23
normalizes	O	24-34
the	O	35-38
resistance	O	39-49
to	O	50-52
the	O	53-56
cardiotoxic	B	57-68
effect	O	69-75
of	O	76-78
isoproterenol	O	79-92
in	O	93-95
streptozotocin	O	96-110
diabetic	B	111-119
rats	O	120-124
.	O	124-125

A	O	126-127
morphometric	O	128-140
study	O	141-146
of	O	147-149
isoproterenol	O	150-163
induced	O	164-171
myocardial	O	172-182
fibrosis	B	183-191
.	O	191-192

The	O	193-196
acute	O	197-202
effect	O	203-209
of	O	210-212
insulin	O	213-220
treatment	O	221-230
on	O	231-233
the	O	234-237
earlier	O	238-245
reported	O	246-254
protective	O	255-265
effect	O	266-272
of	O	273-275
streptozotocin	O	276-290
diabetes	B	291-299
against	O	300-307
the	O	308-311
cardiotoxic	B	312-323
effect	O	324-330
of	O	331-333
high	O	334-338
doses	O	339-344
of	O	345-347
isoproterenol	O	348-361
(	O	362-363
ISO	O	363-366
)	O	366-367
was	O	368-371
investigated	O	372-384
in	O	385-387
rats	O	388-392
.	O	392-393

Thirty	O	394-400
to	O	401-403
135	O	404-407
min	O	408-411
after	O	412-417
the	O	418-421
injection	O	422-431
of	O	432-434
crystalline	O	435-446
insulin	O	447-454
,	O	454-455
ISO	O	456-459
was	O	460-463
given	O	464-469
subcutaneously	O	470-484
and	O	485-488
when	O	489-493
ISO	O	494-497
induced	O	498-505
fibrosis	B	506-514
in	O	515-517
the	O	518-521
myocardium	O	522-532
was	O	533-536
morphometrically	O	537-553
analyzed	O	554-562
7	O	563-564
days	O	565-569
later	O	570-575
,	O	575-576
a	O	577-578
highly	O	579-585
significant	O	586-597
correlation	O	598-609
(	O	610-611
r	O	611-612
=	O	613-614
0	O	615-616
.	O	616-617
83	O	617-619
,	O	619-620
2	O	621-622
p	O	623-624
=	O	625-626
0	O	627-628
.	O	628-629
006	O	629-632
)	O	632-633
to	O	634-636
the	O	637-640
slope	O	641-646
of	O	647-649
the	O	650-653
fall	O	654-658
in	O	659-661
blood	O	662-667
glucose	O	668-675
after	O	676-681
insulin	O	682-689
treatment	O	690-699
appeared	O	700-708
.	O	708-709

The	O	710-713
myocardial	O	714-724
content	O	725-732
of	O	733-735
catecholamines	O	736-750
was	O	751-754
estimated	O	755-764
in	O	765-767
these	O	768-773
8	O	774-775
day	O	776-779
diabetic	B	780-788
rats	O	789-793
.	O	793-794

The	O	795-798
norepinephrine	O	799-813
content	O	814-821
was	O	822-825
significantly	O	826-839
increased	O	840-849
while	O	850-855
epinephrine	O	856-867
remained	O	868-876
unchanged	O	877-886
.	O	886-887

An	O	888-890
enhanced	O	891-899
sympathetic	O	900-911
nervous	O	912-919
system	O	920-926
activity	O	927-935
with	O	936-940
a	O	941-942
consequent	O	943-953
down	O	954-958
regulation	O	959-969
of	O	970-972
the	O	973-976
myocardial	O	977-987
beta	O	988-992
-	O	992-993
adrenergic	O	993-1003
receptors	O	1004-1013
could	O	1014-1019
,	O	1019-1020
therefore	O	1021-1030
,	O	1030-1031
explain	O	1032-1039
this	O	1040-1044
catecholamine	O	1045-1058
resistance	O	1059-1069
.	O	1069-1070

The	O	1071-1074
rapid	O	1075-1080
reversion	O	1081-1090
after	O	1091-1096
insulin	O	1097-1104
treatment	O	1105-1114
excludes	O	1115-1123
the	O	1124-1127
possibility	O	1128-1139
that	O	1140-1144
streptozotocin	O	1145-1159
in	O	1160-1162
itself	O	1163-1169
causes	O	1170-1176
the	O	1177-1180
ISO	O	1181-1184
resistance	O	1185-1195
and	O	1196-1199
points	O	1200-1206
towards	O	1207-1214
a	O	1215-1216
direct	O	1217-1223
insulin	O	1224-1231
effect	O	1232-1238
on	O	1239-1241
myocardial	O	1242-1252
catecholamine	O	1253-1266
sensitivity	O	1267-1278
in	O	1279-1281
diabetic	B	1282-1290
rats	O	1291-1295
.	O	1295-1296

The	O	1297-1300
phenomenon	O	1301-1311
described	O	1312-1321
might	O	1322-1327
elucidate	O	1328-1337
pathogenetic	O	1338-1350
mechanisms	O	1351-1361
behind	O	1362-1368
toxic	O	1369-1374
myocardial	O	1375-1385
cell	O	1386-1390
degeneration	O	1391-1403
and	O	1404-1407
may	O	1408-1411
possibly	O	1412-1420
have	O	1421-1425
relevance	O	1426-1435
for	O	1436-1439
acute	O	1440-1445
cardiovascular	O	1446-1460
complications	O	1461-1474
in	O	1475-1477
diabetic	B	1478-1486
patients	O	1487-1495
.	O	1495-1496

Differential	O	0-12
effects	O	13-20
of	O	21-23
non	O	24-27
-	O	27-28
steroidal	O	28-37
anti	O	38-42
-	O	42-43
inflammatory	O	43-55
drugs	O	56-61
on	O	62-64
seizures	B	65-73
produced	O	74-82
by	O	83-85
pilocarpine	O	86-97
in	O	98-100
rats	O	101-105
.	O	105-106

The	O	107-110
muscarinic	O	111-121
cholinergic	O	122-133
agonist	O	134-141
pilocarpine	O	142-153
induces	O	154-161
in	O	162-164
rats	O	165-169
seizures	B	170-178
and	O	179-182
status	B	183-189
epilepticus	I	190-201
followed	O	202-210
by	O	211-213
widespread	O	214-224
damage	O	225-231
to	O	232-234
the	O	235-238
forebrain	O	239-248
.	O	248-249

The	O	250-253
present	O	254-261
study	O	262-267
was	O	268-271
designed	O	272-280
to	O	281-283
investigate	O	284-295
the	O	296-299
effect	O	300-306
of	O	307-309
5	O	310-311
non	O	312-315
-	O	315-316
steroidal	O	316-325
anti	O	326-330
-	O	330-331
inflammatory	O	331-343
drugs	O	344-349
,	O	349-350
sodium	O	351-357
salicylate	O	358-368
,	O	368-369
phenylbutazone	O	370-384
,	O	384-385
indomethacin	O	386-398
,	O	398-399
ibuprofen	O	400-409
and	O	410-413
mefenamic	O	414-423
acid	O	424-428
,	O	428-429
on	O	430-432
seizures	B	433-441
produced	O	442-450
by	O	451-453
pilocarpine	O	454-465
.	O	465-466

Pretreatment	O	467-479
of	O	480-482
rats	O	483-487
with	O	488-492
sodium	O	493-499
salicylate	O	500-510
,	O	510-511
ED50	O	512-516
103	O	517-520
mg	O	521-523
/	O	523-524
kg	O	524-526
(	O	527-528
60	O	528-530
-	O	530-531
174	O	531-534
)	O	534-535
,	O	535-536
and	O	537-540
phenylbutazone	O	541-555
,	O	555-556
59	O	557-559
mg	O	560-562
/	O	562-563
kg	O	563-565
(	O	566-567
50	O	567-569
-	O	569-570
70	O	570-572
)	O	572-573
converted	O	574-583
the	O	584-587
non	O	588-591
-	O	591-592
convulsant	O	592-602
dose	O	603-607
of	O	608-610
pilocarpine	O	611-622
,	O	622-623
200	O	624-627
mg	O	628-630
/	O	630-631
kg	O	631-633
,	O	633-634
to	O	635-637
a	O	638-639
convulsant	O	640-650
one	O	651-654
.	O	654-655

Indomethacin	O	656-668
,	O	668-669
1	O	670-671
-	O	671-672
10	O	672-674
mg	O	675-677
/	O	677-678
kg	O	678-680
,	O	680-681
and	O	682-685
ibuprofen	O	686-695
,	O	695-696
10	O	697-699
-	O	699-700
100	O	700-703
mg	O	704-706
/	O	706-707
kg	O	707-709
,	O	709-710
failed	O	711-717
to	O	718-720
modulate	O	721-729
seizures	B	730-738
produced	O	739-747
by	O	748-750
pilocarpine	O	751-762
.	O	762-763

Mefenamic	O	764-773
acid	O	774-778
,	O	778-779
26	O	780-782
(	O	783-784
22	O	784-786
-	O	786-787
30	O	787-789
)	O	789-790
mg	O	791-793
/	O	793-794
kg	O	794-796
,	O	796-797
prevented	O	798-807
seizures	B	808-816
and	O	817-820
protected	O	821-830
rats	O	831-835
from	O	836-840
seizure	B	841-848
-	O	848-849
related	O	849-856
brain	B	857-862
damage	I	863-869
induced	O	870-877
by	O	878-880
pilocarpine	O	881-892
,	O	892-893
380	O	894-897
mg	O	898-900
/	O	900-901
kg	O	901-903
.	O	903-904

These	O	905-910
results	O	911-918
indicate	O	919-927
that	O	928-932
non	O	933-936
-	O	936-937
steroidal	O	937-946
anti	O	947-951
-	O	951-952
inflammatory	O	952-964
drugs	O	965-970
differentially	O	971-985
modulate	O	986-994
the	O	995-998
threshold	O	999-1008
for	O	1009-1012
pilocarpine	O	1013-1024
-	O	1024-1025
induced	O	1025-1032
seizures	B	1033-1041
.	O	1041-1042

Acute	B	0-5
neurologic	I	6-16
dysfunction	I	17-28
after	O	29-34
high	O	35-39
-	O	39-40
dose	O	40-44
etoposide	O	45-54
therapy	O	55-62
for	O	63-66
malignant	B	67-76
glioma	I	77-83
.	O	83-84

Etoposide	O	85-94
(	O	95-96
VP	O	96-98
-	O	98-99
16	O	99-101
-	O	98-99
213	O	102-105
)	O	105-106
has	O	107-110
been	O	111-115
used	O	116-120
in	O	121-123
the	O	124-127
treatment	O	128-137
of	O	138-140
many	O	141-145
solid	O	146-151
tumors	B	152-158
and	O	159-162
hematologic	B	163-174
malignancies	I	175-187
.	O	187-188

When	O	189-193
used	O	194-198
in	O	199-201
high	O	202-206
doses	O	207-212
and	O	213-216
in	O	217-219
conjunction	O	220-231
with	O	232-236
autologous	O	237-247
bone	O	248-252
marrow	O	253-259
transplantation	O	260-275
,	O	275-276
this	O	277-281
agent	O	282-287
has	O	288-291
activity	O	292-300
against	O	301-308
several	O	309-316
treatment	O	317-326
-	O	326-327
resistant	O	327-336
cancers	B	337-344
including	O	345-354
malignant	B	355-364
glioma	I	365-371
.	O	371-372

In	O	373-375
six	O	376-379
of	O	380-382
eight	O	383-388
patients	O	389-397
(	O	398-399
75	O	399-401
%	O	401-402
)	O	402-403
who	O	404-407
we	O	408-410
treated	O	411-418
for	O	419-422
recurrent	O	423-432
or	O	433-435
resistant	O	436-445
glioma	B	446-452
,	O	452-453
sudden	O	454-460
severe	O	461-467
neurologic	B	468-478
deterioration	I	479-492
occurred	O	493-501
.	O	501-502

This	O	503-507
developed	O	508-517
a	O	518-519
median	O	520-526
of	O	527-529
9	O	530-531
days	O	532-536
after	O	537-542
initiation	O	543-553
of	O	554-556
high	O	557-561
-	O	561-562
dose	O	562-566
etoposide	O	567-576
therapy	O	577-584
.	O	584-585

Significant	O	586-597
clinical	O	598-606
manifestations	O	607-621
have	O	622-626
included	O	627-635
confusion	B	636-645
,	O	645-646
papilledema	B	647-658
,	O	658-659
somnolence	B	660-670
,	O	670-671
exacerbation	O	672-684
of	O	685-687
motor	B	688-693
deficits	I	694-702
,	O	702-703
and	O	704-707
sharp	O	708-713
increase	O	714-722
in	O	723-725
seizure	B	726-733
activity	O	734-742
.	O	742-743

These	O	744-749
abnormalities	O	750-763
resolved	O	764-772
rapidly	O	773-780
after	O	781-786
initiation	O	787-797
of	O	798-800
high	O	801-805
-	O	805-806
dose	O	806-810
intravenous	O	811-822
dexamethasone	O	823-836
therapy	O	837-844
.	O	844-845

In	O	846-848
all	O	849-852
patients	O	853-861
,	O	861-862
computerized	O	863-875
tomographic	O	876-887
(	O	888-889
CT	O	889-891
)	O	891-892
brain	O	893-898
scans	O	899-904
demonstrated	O	905-917
stability	O	918-927
in	O	928-930
tumor	B	931-936
size	O	937-941
and	O	942-945
peritumor	O	946-955
edema	B	956-961
when	O	962-966
compared	O	967-975
with	O	976-980
pretransplant	O	981-994
scans	O	995-1000
.	O	1000-1001

This	O	1002-1006
complication	O	1007-1019
appears	O	1020-1027
to	O	1028-1030
represent	O	1031-1040
a	O	1041-1042
significant	O	1043-1054
new	O	1055-1058
toxicity	B	1059-1067
of	O	1068-1070
high	O	1071-1075
-	O	1075-1076
dose	O	1076-1080
etoposide	O	1081-1090
therapy	O	1091-1098
for	O	1099-1102
malignant	B	1103-1112
glioma	I	1113-1119
.	O	1119-1120

Progressive	O	0-11
bile	B	12-16
duct	I	17-21
injury	I	22-28
after	O	29-34
thiabendazole	O	35-48
administration	O	49-63
.	O	63-64

A	O	65-66
27	O	67-69
-	O	69-70
yr	O	70-72
-	O	69-70
old	O	73-76
man	O	77-80
developed	O	81-90
jaundice	B	91-99
2	O	100-101
wk	O	102-104
after	O	105-110
exposure	O	111-119
to	O	120-122
thiabendazole	O	123-136
.	O	136-137

Cholestasis	B	138-149
persisted	O	150-159
for	O	160-163
3	O	164-165
yr	O	166-168
,	O	168-169
at	O	170-172
which	O	173-178
time	O	179-183
a	O	184-185
liver	O	186-191
transplant	O	192-202
was	O	203-206
performed	O	207-216
.	O	216-217

Two	O	218-221
liver	O	222-227
biopsy	O	228-234
specimens	O	235-244
and	O	245-248
the	O	249-252
hepatectomy	O	253-264
specimen	O	265-273
were	O	274-278
remarkable	O	279-289
for	O	290-293
almost	O	294-300
complete	O	301-309
disappearance	O	310-323
of	O	324-326
interlobular	O	327-339
bile	O	340-344
ducts	O	345-350
.	O	350-351

Prominent	O	352-361
fibrosis	B	362-370
and	O	371-374
hepatocellular	O	375-389
regeneration	O	390-402
were	O	403-407
also	O	408-412
present	O	413-420
;	O	420-421
however	O	422-429
,	O	429-430
the	O	431-434
lobular	O	435-442
architecture	O	443-455
was	O	456-459
preserved	O	460-469
.	O	469-470

This	O	471-475
case	O	476-480
represents	O	481-491
an	O	492-494
example	O	495-502
of	O	503-505
"	O	506-507
idiosyncratic	O	507-520
"	O	506-507
drug	B	522-526
-	I	526-527
induced	I	527-534
liver	I	535-540
damage	I	541-547
in	O	548-550
which	O	551-556
the	O	557-560
primary	O	561-568
target	O	569-575
of	O	576-578
injury	O	579-585
is	O	586-588
the	O	589-592
bile	O	593-597
duct	O	598-602
.	O	602-603

An	O	604-606
autoimmune	O	607-617
pathogenesis	O	618-630
of	O	631-633
the	O	634-637
bile	B	638-642
duct	I	643-647
destruction	I	648-659
is	O	660-662
suggested	O	663-672
.	O	672-673

Differential	O	0-12
effects	O	13-20
of	O	21-23
1	O	24-25
,	O	25-26
4	O	26-27
-	O	27-28
dihydropyridine	O	28-43
calcium	O	44-51
channel	O	52-59
blockers	O	60-68
:	O	68-69
therapeutic	O	70-81
implications	O	82-94
.	O	94-95

Increasing	O	96-106
recognition	O	107-118
of	O	119-121
the	O	122-125
importance	O	126-136
of	O	137-139
calcium	O	140-147
in	O	148-150
the	O	151-154
pathogenesis	O	155-167
of	O	168-170
cardiovascular	B	171-185
disease	I	186-193
has	O	194-197
stimulated	O	198-208
research	O	209-217
into	O	218-222
the	O	223-226
use	O	227-230
of	O	231-233
calcium	O	234-241
channel	O	242-249
blocking	O	250-258
agents	O	259-265
for	O	266-269
treatment	O	270-279
of	O	280-282
a	O	283-284
variety	O	285-292
of	O	293-295
cardiovascular	B	296-310
diseases	I	311-319
.	O	319-320

The	O	321-324
favorable	O	325-334
efficacy	O	335-343
and	O	344-347
tolerability	O	348-360
profiles	O	361-369
of	O	370-372
these	O	373-378
agents	O	379-385
make	O	386-390
them	O	391-395
attractive	O	396-406
therapeutic	O	407-418
modalities	O	419-429
.	O	429-430

Clinical	O	431-439
applications	O	440-452
of	O	453-455
calcium	O	456-463
channel	O	464-471
blockers	O	472-480
parallel	O	481-489
their	O	490-495
tissue	O	496-502
selectivity	O	503-514
.	O	514-515

In	O	516-518
contrast	O	519-527
to	O	528-530
verapamil	O	531-540
and	O	541-544
diltiazem	O	545-554
,	O	554-555
which	O	556-561
are	O	562-565
roughly	O	566-573
equipotent	O	574-584
in	O	585-587
their	O	588-593
actions	O	594-601
on	O	602-604
the	O	605-608
heart	O	609-614
and	O	615-618
vascular	O	619-627
smooth	O	628-634
muscle	O	635-641
,	O	641-642
the	O	643-646
dihydropyridine	O	647-662
calcium	O	663-670
channel	O	671-678
blockers	O	679-687
are	O	688-691
a	O	692-693
group	O	694-699
of	O	700-702
potent	O	703-709
peripheral	O	710-720
vasodilator	O	721-732
agents	O	733-739
that	O	740-744
exert	O	745-750
minimal	O	751-758
electrophysiologic	O	759-777
effects	O	778-785
on	O	786-788
cardiac	O	789-796
nodal	O	797-802
or	O	803-805
conduction	O	806-816
tissue	O	817-823
.	O	823-824

As	O	825-827
the	O	828-831
first	O	832-837
dihydropyridine	O	838-853
available	O	854-863
for	O	864-867
use	O	868-871
in	O	872-874
the	O	875-878
United	O	879-885
States	O	886-892
,	O	892-893
nifedipine	O	894-904
controls	O	905-913
angina	B	914-920
and	O	921-924
hypertension	B	925-937
with	O	938-942
minimal	O	943-950
depression	O	951-961
of	O	962-964
cardiac	O	965-972
function	O	973-981
.	O	981-982

Additional	O	983-993
members	O	994-1001
of	O	1002-1004
this	O	1005-1009
group	O	1010-1015
of	O	1016-1018
calcium	O	1019-1026
channel	O	1027-1034
blockers	O	1035-1043
have	O	1044-1048
been	O	1049-1053
studied	O	1054-1061
for	O	1062-1065
a	O	1066-1067
variety	O	1068-1075
of	O	1076-1078
indications	O	1079-1090
for	O	1091-1094
which	O	1095-1100
they	O	1101-1105
may	O	1106-1109
offer	O	1110-1115
advantages	O	1116-1126
over	O	1127-1131
current	O	1132-1139
therapy	O	1140-1147
.	O	1147-1148

Once	O	1149-1153
or	O	1154-1156
twice	O	1157-1162
daily	O	1163-1168
dosage	O	1169-1175
possible	O	1176-1184
with	O	1185-1189
nitrendipine	O	1190-1202
and	O	1203-1206
nisoldipine	O	1207-1218
offers	O	1219-1225
a	O	1226-1227
convenient	O	1228-1238
administration	O	1239-1253
schedule	O	1254-1262
,	O	1262-1263
which	O	1264-1269
encourages	O	1270-1280
patient	O	1281-1288
compliance	O	1289-1299
in	O	1300-1302
long	O	1303-1307
-	O	1307-1308
term	O	1308-1312
therapy	O	1313-1320
of	O	1321-1323
hypertension	B	1324-1336
.	O	1336-1337

The	O	1338-1341
coronary	O	1342-1350
vasodilating	O	1351-1363
properties	O	1364-1374
of	O	1375-1377
nisoldipine	O	1378-1389
have	O	1390-1394
led	O	1395-1398
to	O	1399-1401
the	O	1402-1405
investigation	O	1406-1419
of	O	1420-1422
this	O	1423-1427
agent	O	1428-1433
for	O	1434-1437
use	O	1438-1441
in	O	1442-1444
angina	B	1445-1451
.	O	1451-1452

Selectivity	O	1453-1464
for	O	1465-1468
the	O	1469-1472
cerebrovascular	O	1473-1488
bed	O	1489-1492
makes	O	1493-1498
nimodipine	O	1499-1509
potentially	O	1510-1521
useful	O	1522-1528
in	O	1529-1531
the	O	1532-1535
treatment	O	1536-1545
of	O	1546-1548
subarachnoid	B	1549-1561
hemorrhage	I	1562-1572
,	O	1572-1573
migraine	B	1574-1582
headache	I	1583-1591
,	O	1591-1592
dementia	B	1593-1601
,	O	1601-1602
and	O	1603-1606
stroke	B	1607-1613
.	O	1613-1614

In	O	1615-1617
general	O	1618-1625
,	O	1625-1626
the	O	1627-1630
dihydropyridine	O	1631-1646
calcium	O	1647-1654
channel	O	1655-1662
blockers	O	1663-1671
are	O	1672-1675
usually	O	1676-1683
well	O	1684-1688
tolerated	O	1689-1698
,	O	1698-1699
with	O	1700-1704
headache	B	1705-1713
,	O	1713-1714
facial	O	1715-1721
flushing	B	1722-1730
,	O	1730-1731
palpitations	B	1732-1744
,	O	1744-1745
edema	B	1746-1751
,	O	1751-1752
nausea	B	1753-1759
,	O	1759-1760
anorexia	B	1761-1769
,	O	1769-1770
and	O	1771-1774
dizziness	B	1775-1784
being	O	1785-1790
the	O	1791-1794
more	O	1795-1799
common	O	1800-1806
adverse	O	1807-1814
effects	O	1815-1822
.	O	1822-1823

The	O	0-3
enhancement	O	4-15
of	O	16-18
aminonucleoside	O	19-34
nephrosis	B	35-44
by	O	45-47
the	O	48-51
co	O	52-54
-	O	54-55
administration	O	55-69
of	O	70-72
protamine	O	73-82
.	O	82-83

An	O	84-86
experimental	O	87-99
model	O	100-105
of	O	106-108
focal	B	109-114
segmental	I	115-124
glomerular	I	125-135
sclerosis	I	136-145
(	O	146-147
FSGS	B	147-151
)	O	151-152
was	O	153-156
developed	O	157-166
in	O	167-169
rats	O	170-174
by	O	175-177
the	O	178-181
combined	O	182-190
administration	O	191-205
of	O	206-208
puromycin	O	209-218
-	O	218-219
aminonucleoside	O	219-234
(	O	235-236
AMNS	O	236-240
)	O	240-241
and	O	242-245
protamine	O	246-255
sulfate	O	256-263
(	O	264-265
PS	O	265-267
)	O	267-268
.	O	268-269

Male	O	270-274
Sprague	O	275-282
-	O	282-283
Dawley	O	283-289
rats	O	290-294
,	O	294-295
uninephrectomized	O	296-313
three	O	314-319
weeks	O	320-325
before	O	326-332
,	O	332-333
received	O	334-342
daily	O	343-348
injections	O	349-359
of	O	360-362
subcutaneous	O	363-375
AMNS	O	376-380
(	O	381-382
1	O	382-383
mg	O	384-386
/	O	386-387
100	O	387-390
g	O	391-392
body	O	393-397
wt	O	398-400
)	O	400-401
and	O	402-405
intravenous	O	406-417
PS	O	418-420
(	O	421-422
2	O	422-423
separated	O	424-433
doses	O	434-439
of	O	440-442
2	O	443-444
.	O	444-445
5	O	445-446
mg	O	447-449
/	O	449-450
100	O	450-453
g	O	454-455
body	O	456-460
wt	O	461-463
)	O	463-464
for	O	465-468
four	O	469-473
days	O	474-478
.	O	478-479

The	O	480-483
series	O	484-490
of	O	491-493
injections	O	494-504
were	O	505-509
repeated	O	510-518
another	O	519-526
three	O	527-532
times	O	533-538
at	O	539-541
10	O	542-544
day	O	545-548
intervals	O	549-558
.	O	558-559

The	O	560-563
animals	O	564-571
were	O	572-576
sacrificed	O	577-587
on	O	588-590
days	O	591-595
24	O	596-598
,	O	598-599
52	O	600-602
,	O	602-603
and	O	604-607
80	O	608-610
.	O	610-611

They	O	612-616
developed	O	617-626
nephrotic	B	627-636
syndrome	I	637-645
and	O	646-649
finally	O	650-657
renal	B	658-663
failure	I	664-671
.	O	671-672

The	O	673-676
time	O	677-681
-	O	681-682
course	O	682-688
curve	O	689-694
of	O	695-697
creatinine	O	698-708
clearance	O	709-718
dropped	O	719-726
and	O	727-730
showed	O	731-737
significant	O	738-749
difference	O	750-760
(	O	761-762
P	O	762-763
less	O	764-768
than	O	769-773
0	O	774-775
.	O	775-776
01	O	776-778
)	O	778-779
from	O	780-784
that	O	785-789
of	O	790-792
each	O	793-797
control	O	798-805
group	O	806-811
,	O	811-812
such	O	813-817
as	O	818-820
,	O	820-821
AMNS	O	822-826
alone	O	827-832
,	O	832-833
PS	O	834-836
alone	O	837-842
or	O	843-845
saline	O	846-852
injected	O	853-861
.	O	861-862

Their	O	863-868
glomeruli	O	869-878
showed	O	879-885
changes	O	886-893
of	O	894-896
progressive	O	897-908
FSGS	B	909-913
.	O	913-914

The	O	915-918
ultrastructural	O	919-934
studies	O	935-942
in	O	943-945
the	O	946-949
initial	O	950-957
stage	O	958-963
revealed	O	964-972
significant	O	973-984
lack	O	985-989
of	O	990-992
particles	O	993-1002
of	O	1003-1005
perfused	O	1006-1014
ruthenium	O	1015-1024
red	O	1025-1028
on	O	1029-1031
the	O	1032-1035
lamina	O	1036-1042
rara	O	1043-1047
externa	O	1048-1055
and	O	1056-1059
marked	O	1060-1066
changes	O	1067-1074
in	O	1075-1077
epithelial	O	1078-1088
cell	O	1089-1093
cytoplasm	O	1094-1103
.	O	1103-1104

Therefore	O	1105-1114
,	O	1114-1115
it	O	1116-1118
is	O	1119-1121
suggested	O	1122-1131
that	O	1132-1136
the	O	1137-1140
administration	O	1141-1155
of	O	1156-1158
PS	O	1159-1161
enhances	O	1162-1170
the	O	1171-1174
toxicity	B	1175-1183
of	O	1184-1186
AMNS	O	1187-1191
on	O	1192-1194
the	O	1195-1198
glomerulus	O	1199-1209
and	O	1210-1213
readily	O	1214-1221
produces	O	1222-1230
progressive	O	1231-1242
FSGS	B	1243-1247
in	O	1248-1250
rats	O	1251-1255
resulting	O	1256-1265
in	O	1266-1268
the	O	1269-1272
end	B	1273-1276
-	I	1276-1277
stage	I	1277-1282
renal	I	1283-1288
disease	I	1289-1296
.	O	1296-1297

Theophylline	O	0-12
neurotoxicity	B	13-26
in	O	27-29
pregnant	O	30-38
rats	O	39-43
.	O	43-44

The	O	45-48
purpose	O	49-56
of	O	57-59
this	O	60-64
investigation	O	65-78
was	O	79-82
to	O	83-85
determine	O	86-95
whether	O	96-103
the	O	104-107
neurotoxicity	B	108-121
of	O	122-124
theophylline	O	125-137
is	O	138-140
altered	O	141-148
in	O	149-151
advanced	O	152-160
pregnancy	O	161-170
.	O	170-171

Sprague	O	172-179
-	O	179-180
Dawley	O	180-186
rats	O	187-191
that	O	192-196
were	O	197-201
20	O	202-204
days	O	205-209
pregnant	O	210-218
and	O	219-222
nonpregnant	O	223-234
rats	O	235-239
of	O	240-242
the	O	243-246
same	O	247-251
age	O	252-255
and	O	256-259
strain	O	260-266
received	O	267-275
infusions	O	276-285
of	O	286-288
aminophylline	O	289-302
until	O	303-308
onset	O	309-314
of	O	315-317
maximal	O	318-325
seizures	B	326-334
which	O	335-340
occurred	O	341-349
after	O	350-355
28	O	356-358
and	O	359-362
30	O	363-365
minutes	O	366-373
respectively	O	374-386
.	O	386-387

Theophylline	O	388-400
concentrations	O	401-415
at	O	416-418
this	O	419-423
endpoint	O	424-432
in	O	433-435
serum	O	436-441
(	O	442-443
total	O	443-448
)	O	448-449
and	O	450-453
CSF	O	454-457
were	O	458-462
similar	O	463-470
but	O	471-474
serum	O	475-480
(	O	481-482
free	O	482-486
)	O	486-487
and	O	488-491
brain	O	492-497
concentrations	O	498-512
were	O	513-517
slightly	O	518-526
different	O	527-536
in	O	537-539
pregnant	O	540-548
rats	O	549-553
.	O	553-554

Theophylline	O	555-567
serum	O	568-573
protein	O	574-581
binding	O	582-589
determined	O	590-600
by	O	601-603
equilibrium	O	604-615
dialysis	O	616-624
was	O	625-628
lower	O	629-634
in	O	635-637
pregnant	O	638-646
rats	O	647-651
.	O	651-652

Fetal	O	653-658
serum	O	659-664
concentrations	O	665-679
at	O	680-682
onset	O	683-688
of	O	689-691
seizures	B	692-700
in	O	701-703
the	O	704-707
mother	O	708-714
were	O	715-719
similar	O	720-727
to	O	728-730
maternal	O	731-739
brain	O	740-745
and	O	746-749
CSF	O	750-753
concentrations	O	754-768
and	O	769-772
correlated	O	773-783
significantly	O	784-797
with	O	798-802
the	O	803-806
former	O	807-813
.	O	813-814

It	O	815-817
is	O	818-820
concluded	O	821-830
that	O	831-835
advanced	O	836-844
pregnancy	O	845-854
has	O	855-858
a	O	859-860
negligible	O	861-871
effect	O	872-878
on	O	879-881
the	O	882-885
neurotoxic	B	886-896
response	O	897-905
to	O	906-908
theophylline	O	909-921
in	O	922-924
rats	O	925-929
.	O	929-930

Hyperkalemia	B	0-12
induced	O	13-20
by	O	21-23
indomethacin	O	24-36
and	O	37-40
naproxen	O	41-49
and	O	50-53
reversed	O	54-62
by	O	63-65
fludrocortisone	O	66-81
.	O	81-82

We	O	83-85
have	O	86-90
described	O	91-100
a	O	101-102
patient	O	103-110
with	O	111-115
severe	O	116-122
rheumatoid	B	123-133
arthritis	I	134-143
and	O	144-147
a	O	148-149
history	O	150-157
of	O	158-160
mefenamic	O	161-170
acid	O	171-175
nephropathy	B	176-187
in	O	188-190
whom	O	191-195
hyperkalemia	B	196-208
and	O	209-212
inappropriate	O	213-226
hypoaldosteronism	B	227-244
were	O	245-249
caused	O	250-256
by	O	257-259
both	O	260-264
indomethacin	O	265-277
and	O	278-281
naproxen	O	282-290
,	O	290-291
without	O	292-299
major	O	300-305
decline	O	306-313
in	O	314-316
renal	O	317-322
function	O	323-331
.	O	331-332

It	O	333-335
is	O	336-338
likely	O	339-345
that	O	346-350
preexisting	O	351-362
renal	B	363-368
disease	I	369-376
predisposed	O	377-388
this	O	389-393
patient	O	394-401
to	O	402-404
type	B	405-409
IV	I	410-412
renal	I	413-418
tubular	I	419-426
acidosis	I	427-435
with	O	436-440
prostaglandin	O	441-454
synthetase	O	455-465
inhibitors	O	466-476
.	O	476-477

Because	O	478-485
he	O	486-488
was	O	489-492
unable	O	493-499
to	O	500-502
discontinue	O	503-514
nonsteroidal	O	515-527
anti	O	528-532
-	O	532-533
inflammatory	O	533-545
drug	O	546-550
therapy	O	551-558
,	O	558-559
fludrocortisone	O	560-575
was	O	576-579
added	O	580-585
,	O	585-586
correcting	O	587-597
the	O	598-601
hyperkalemia	B	602-614
and	O	615-618
allowing	O	619-627
indomethacin	O	628-640
therapy	O	641-648
to	O	649-651
be	O	652-654
continued	O	655-664
safely	O	665-671
.	O	671-672

Hypotension	B	0-11
as	O	12-14
a	O	15-16
manifestation	O	17-30
of	O	31-33
cardiotoxicity	B	34-48
in	O	49-51
three	O	52-57
patients	O	58-66
receiving	O	67-76
cisplatin	O	77-86
and	O	87-90
5	O	91-92
-	O	92-93
fluorouracil	O	93-105
.	O	105-106

Cardiac	O	107-114
symptoms	O	115-123
,	O	123-124
including	O	125-134
hypotension	B	135-146
,	O	146-147
developed	O	148-157
in	O	158-160
three	O	161-166
patients	O	167-175
with	O	176-180
advanced	O	181-189
colorectal	B	190-200
carcinoma	I	201-210
while	O	211-216
being	O	217-222
treated	O	223-230
with	O	231-235
cisplatin	O	236-245
(	O	246-247
CDDP	O	247-251
)	O	251-252
and	O	253-256
5	O	257-258
-	O	258-259
fluorouracil	O	259-271
(	O	272-273
5	O	273-274
-	O	274-275
FU	O	275-277
)	O	277-278
.	O	278-279

In	O	280-282
two	O	283-286
patients	O	287-295
,	O	295-296
hypotension	B	297-308
was	O	309-312
associated	O	313-323
with	O	324-328
severe	O	329-335
left	B	336-340
ventricular	I	341-352
dysfunction	I	353-364
.	O	364-365

All	O	366-369
three	O	370-375
patients	O	376-384
required	O	385-393
therapy	O	394-401
discontinuation	O	402-417
.	O	417-418

Cardiac	O	419-426
enzymes	O	427-434
remained	O	435-443
normal	O	444-450
despite	O	451-458
transient	O	459-468
electrocardiographic	O	469-489
(	O	490-491
EKG	O	491-494
)	O	494-495
changes	O	496-503
.	O	503-504

The	O	505-508
presentation	O	509-521
and	O	522-525
cardiac	O	526-533
evaluation	O	534-544
(	O	545-546
hemodynamic	O	546-557
,	O	557-558
echocardiographic	O	559-576
,	O	576-577
and	O	578-581
scintigraphic	O	582-595
)	O	595-596
of	O	597-599
these	O	600-605
patients	O	606-614
suggest	O	615-622
new	O	623-626
manifestations	O	627-641
of	O	642-644
5	O	645-646
-	O	646-647
FU	O	647-649
cardiotoxicity	B	650-664
that	O	665-669
may	O	670-673
be	O	674-676
influenced	O	677-687
by	O	688-690
CDDP	O	691-695
.	O	695-696

The	O	697-700
possible	O	701-709
pathophysiologic	O	710-726
mechanisms	O	727-737
are	O	738-741
discussed	O	742-751
.	O	751-752

Fatal	O	0-5
aplastic	B	6-14
anemia	I	15-21
in	O	22-24
a	O	25-26
patient	O	27-34
treated	O	35-42
with	O	43-47
carbamazepine	O	48-61
.	O	61-62

A	O	63-64
case	O	65-69
of	O	70-72
fatal	O	73-78
aplastic	B	79-87
anemia	I	88-94
due	O	95-98
to	O	99-101
carbamazepine	O	102-115
treatment	O	116-125
in	O	126-128
an	O	129-131
epileptic	B	132-141
woman	O	142-147
is	O	148-150
reported	O	151-159
.	O	159-160

Despite	O	161-168
concerns	O	169-177
of	O	178-180
fatal	O	181-186
bone	B	187-191
marrow	I	192-198
toxicity	I	199-207
due	O	208-211
to	O	212-214
carbamazepine	O	215-228
,	O	228-229
this	O	230-234
is	O	235-237
only	O	238-242
the	O	243-246
fourth	O	247-253
documented	O	254-264
and	O	265-268
published	O	269-278
report	O	279-285
.	O	285-286

Carbamazepine	O	287-300
is	O	301-303
a	O	304-305
safe	O	306-310
drug	O	311-315
,	O	315-316
but	O	317-320
physicians	O	321-331
and	O	332-335
patients	O	336-344
should	O	345-351
be	O	352-354
aware	O	355-360
of	O	361-363
the	O	364-367
exceedingly	O	368-379
rare	O	380-384
but	O	385-388
potentially	O	389-400
fatal	O	401-406
side	O	407-411
effects	O	412-419
,	O	419-420
better	O	421-427
prevented	O	428-437
by	O	438-440
clinical	O	441-449
than	O	450-454
by	O	455-457
laboratory	O	458-468
monitoring	O	469-479
.	O	479-480

Participation	O	0-13
of	O	14-16
a	O	17-18
bulbospinal	O	19-30
serotonergic	O	31-43
pathway	O	44-51
in	O	52-54
the	O	55-58
rat	O	59-62
brain	O	63-68
in	O	69-71
clonidine	O	72-81
-	O	81-82
induced	O	82-89
hypotension	B	90-101
and	O	102-105
bradycardia	B	106-117
.	O	117-118

The	O	119-122
effects	O	123-130
of	O	131-133
microinjection	O	134-148
of	O	149-151
clonidine	O	152-161
(	O	162-163
1	O	163-164
-	O	164-165
10	O	165-167
micrograms	O	168-178
in	O	179-181
1	O	182-183
microliter	O	184-194
)	O	194-195
into	O	196-200
a	O	201-202
region	O	203-209
adjacent	O	210-218
to	O	219-221
the	O	222-225
ventrolateral	O	226-239
surface	O	240-247
of	O	248-250
the	O	251-254
medulla	O	255-262
oblongata	O	263-272
on	O	273-275
cardiovascular	O	276-290
function	O	291-299
were	O	300-304
assessed	O	305-313
in	O	314-316
urethane	O	317-325
-	O	325-326
anesthetized	O	326-338
rats	O	339-343
.	O	343-344

Intramedullary	O	345-359
administration	O	360-374
of	O	375-377
clonidine	O	378-387
,	O	387-388
but	O	389-392
not	O	393-396
saline	O	397-403
vehicle	O	404-411
,	O	411-412
caused	O	413-419
a	O	420-421
dose	O	422-426
-	O	426-427
dependent	O	427-436
decrease	O	437-445
in	O	446-448
both	O	449-453
the	O	454-457
mean	O	458-462
arterial	O	463-471
pressure	O	472-480
and	O	481-484
the	O	485-488
heart	O	489-494
rate	O	495-499
.	O	499-500

The	O	501-504
clonidine	O	505-514
-	O	514-515
induced	O	515-522
hypotension	B	523-534
was	O	535-538
antagonized	O	539-550
by	O	551-553
prior	O	554-559
spinal	O	560-566
transection	O	567-578
,	O	578-579
but	O	580-583
not	O	584-587
bilateral	O	588-597
vagotomy	O	598-606
.	O	606-607

On	O	608-610
the	O	611-614
other	O	615-620
hand	O	621-625
,	O	625-626
the	O	627-630
clonidine	O	631-640
-	O	640-641
induced	O	641-648
bradycardia	B	649-660
was	O	661-664
antagonized	O	665-676
by	O	677-679
prior	O	680-685
bilateral	O	686-695
vagotomy	O	696-704
,	O	704-705
but	O	706-709
not	O	710-713
spinal	O	714-720
transection	O	721-732
.	O	732-733

Furthermore	O	734-745
,	O	745-746
selective	O	747-756
destruction	O	757-768
of	O	769-771
the	O	772-775
spinal	O	776-782
5	O	783-784
-	O	784-785
HT	O	785-787
nerves	O	788-794
,	O	794-795
produced	O	796-804
by	O	805-807
bilateral	O	808-817
spinal	O	818-824
injection	O	825-834
of	O	835-837
5	O	838-839
,	O	839-840
7	O	840-841
-	O	841-842
dihydroxytryptamine	O	842-861
,	O	839-840
reduced	O	863-870
the	O	871-874
magnitude	O	875-884
of	O	885-887
the	O	888-891
vasodepressor	O	892-905
or	O	906-908
the	O	909-912
bradycardiac	B	913-925
responses	O	926-935
to	O	936-938
clonidine	O	939-948
microinjected	O	949-962
into	O	963-967
the	O	968-971
area	O	972-976
near	O	977-981
the	O	982-985
ventrolateral	O	986-999
surface	O	1000-1007
of	O	1008-1010
the	O	1011-1014
medulla	O	1015-1022
oblongata	O	1023-1032
in	O	1033-1035
rats	O	1036-1040
.	O	1040-1041

The	O	1042-1045
data	O	1046-1050
indicate	O	1051-1059
that	O	1060-1064
a	O	1065-1066
bulbospinal	O	1067-1078
serotonergic	O	1079-1091
pathway	O	1092-1099
is	O	1100-1102
involved	O	1103-1111
in	O	1112-1114
development	O	1115-1126
of	O	1127-1129
clonidine	O	1130-1139
-	O	1139-1140
induced	O	1140-1147
hypotension	B	1148-1159
and	O	1160-1163
bradycardia	B	1164-1175
.	O	1175-1176

The	O	1177-1180
induced	O	1181-1188
hypotension	B	1189-1200
is	O	1201-1203
brought	O	1204-1211
about	O	1212-1217
by	O	1218-1220
a	O	1221-1222
decrease	O	1223-1231
in	O	1232-1234
sympathetic	O	1235-1246
efferent	O	1247-1255
activity	O	1256-1264
,	O	1264-1265
whereas	O	1266-1273
the	O	1274-1277
induced	O	1278-1285
bradycardia	B	1286-1297
was	O	1298-1301
due	O	1302-1305
to	O	1306-1308
an	O	1309-1311
increase	O	1312-1320
in	O	1321-1323
vagal	O	1324-1329
efferent	O	1330-1338
activity	O	1339-1347
.	O	1347-1348

Hypertension	B	0-12
in	O	13-15
neuroblastoma	B	16-29
induced	O	30-37
by	O	38-40
imipramine	O	41-51
.	O	51-52

Hypertension	B	53-65
is	O	66-68
a	O	69-70
well	O	71-75
-	O	75-76
known	O	76-81
finding	O	82-89
in	O	90-92
some	O	93-97
patients	O	98-106
with	O	107-111
neuroblastoma	B	112-125
.	O	125-126

However	O	127-134
,	O	134-135
it	O	136-138
has	O	139-142
not	O	143-146
previously	O	147-157
been	O	158-162
described	O	163-172
in	O	173-175
association	O	176-187
with	O	188-192
the	O	193-196
use	O	197-200
of	O	201-203
Imipramine	O	204-214
.	O	214-215

We	O	216-218
report	O	219-225
the	O	226-229
occurrence	O	230-240
of	O	241-243
severe	O	244-250
hypertension	B	251-263
(	O	264-265
blood	O	265-270
pressure	O	271-279
190	O	280-283
/	O	283-284
160	O	284-287
)	O	287-288
in	O	289-291
a	O	292-293
4	O	294-295
-	O	295-296
year	O	296-300
-	O	295-296
old	O	301-304
girl	O	305-309
with	O	310-314
neuroblastoma	B	315-328
who	O	329-332
was	O	333-336
given	O	337-342
Imipramine	O	343-353
to	O	354-356
control	O	357-364
a	O	365-366
behavior	B	367-375
disorder	I	376-384
.	O	384-385

It	O	386-388
was	O	389-392
determined	O	393-403
later	O	404-409
that	O	410-414
this	O	415-419
patient	O	420-427
'	O	427-428
s	O	428-429
tumor	B	430-435
was	O	436-439
recurring	O	440-449
at	O	450-452
the	O	453-456
time	O	457-461
of	O	462-464
her	O	465-468
hypertensive	B	469-481
episode	O	482-489
.	O	489-490

Since	O	491-496
she	O	497-500
had	O	501-504
no	O	505-507
blood	O	508-513
pressure	O	514-522
elevation	O	523-532
at	O	533-535
initial	O	536-543
diagnosis	O	544-553
and	O	554-557
none	O	558-562
following	O	563-572
discontinuation	O	573-588
of	O	589-591
the	O	592-595
Imipramine	O	596-606
(	O	607-608
when	O	608-612
she	O	613-616
was	O	617-620
in	O	621-623
florid	O	624-630
relapse	O	631-638
)	O	638-639
,	O	639-640
we	O	641-643
believe	O	644-651
that	O	652-656
this	O	657-661
drug	O	662-666
rather	O	667-673
than	O	674-678
her	O	679-682
underlying	O	683-693
disease	O	694-701
alone	O	702-707
caused	O	708-714
her	O	715-718
hypertension	B	719-731
.	O	731-732

The	O	733-736
mechanism	O	737-746
for	O	747-750
this	O	751-755
reaction	O	756-764
is	O	765-767
believed	O	768-776
to	O	777-779
be	O	780-782
increased	O	783-792
levels	O	793-799
of	O	800-802
vasoactive	O	803-813
catecholamines	O	814-828
due	O	829-832
to	O	833-835
interference	O	836-848
of	O	849-851
their	O	852-857
physiologic	O	858-869
inactivation	O	870-882
by	O	883-885
Imipramine	O	886-896
.	O	896-897

From	O	898-902
this	O	903-907
experience	O	908-918
,	O	918-919
we	O	920-922
urge	O	923-927
extreme	O	928-935
caution	O	936-943
in	O	944-946
the	O	947-950
use	O	951-954
of	O	955-957
tricyclic	O	958-967
antidepressants	O	968-983
in	O	984-986
children	O	987-995
with	O	996-1000
active	O	1001-1007
neuroblastoma	B	1008-1021
.	O	1021-1022

Rechallenge	O	0-11
of	O	12-14
patients	O	15-23
who	O	24-27
developed	O	28-37
oral	B	38-42
candidiasis	I	43-54
or	O	55-57
hoarseness	B	58-68
with	O	69-73
beclomethasone	O	74-88
dipropionate	O	89-101
.	O	101-102

Of	O	103-105
158	O	106-109
asthmatic	B	110-119
patients	O	120-128
who	O	129-132
were	O	133-137
placed	O	138-144
on	O	145-147
inhaled	O	148-155
beclomethasone	O	156-170
,	O	170-171
15	O	172-174
(	O	175-176
9	O	176-177
.	O	177-178
5	O	178-179
%	O	179-180
)	O	180-181
developed	O	182-191
either	O	192-198
hoarseness	B	199-209
(	O	210-211
8	O	211-212
)	O	212-213
,	O	213-214
oral	O	215-219
thrush	B	220-226
(	O	227-228
6	O	228-229
)	O	229-230
,	O	230-231
or	O	232-234
both	O	235-239
(	O	240-241
1	O	241-242
)	O	242-243
.	O	243-244

When	O	245-249
their	O	250-255
adverse	O	256-263
reactions	O	264-273
subsided	O	274-282
,	O	282-283
seven	O	284-289
of	O	290-292
these	O	293-298
15	O	299-301
patients	O	302-310
were	O	311-315
rechallenged	O	316-328
with	O	329-333
inhaled	O	334-341
beclomethasone	O	342-356
.	O	356-357

These	O	358-363
included	O	364-372
five	O	373-377
cases	O	378-383
who	O	384-387
developed	O	388-397
hoarseness	B	398-408
and	O	409-412
three	O	413-418
who	O	419-422
developed	O	423-432
Candidiasis	B	433-444
.	O	444-445

One	O	446-449
patient	O	450-457
had	O	458-461
both	O	462-466
.	O	466-467

Oral	O	468-472
thrush	B	473-479
did	O	480-483
not	O	484-487
recur	O	488-493
,	O	493-494
but	O	495-498
60	O	499-501
%	O	501-502
(	O	503-504
3	O	504-505
/	O	505-506
5	O	506-507
)	O	507-508
of	O	509-511
patients	O	512-520
with	O	521-525
hoarseness	B	526-536
had	O	537-540
recurrence	O	541-551
.	O	551-552

We	O	553-555
conclude	O	556-564
that	O	565-569
patients	O	570-578
may	O	579-582
be	O	583-585
restarted	O	586-595
on	O	596-598
inhaled	O	599-606
beclomethasone	O	607-621
when	O	622-626
clinically	O	627-637
indicated	O	638-647
;	O	647-648
however	O	649-656
,	O	656-657
because	O	658-665
of	O	666-668
the	O	669-672
high	O	673-677
recurrence	O	678-688
rate	O	689-693
,	O	693-694
patients	O	695-703
who	O	704-707
develop	O	708-715
hoarseness	B	716-726
should	O	727-733
not	O	734-737
be	O	738-740
re	O	741-743
-	O	743-744
challenged	O	744-754
.	O	754-755

Concomitant	O	756-767
use	O	768-771
of	O	772-774
oral	O	775-779
prednisone	O	780-790
and	O	791-794
topical	O	795-802
beclomethasone	O	803-817
may	O	818-821
increase	O	822-830
the	O	831-834
risk	O	835-839
of	O	840-842
developing	O	843-853
hoarseness	B	854-864
or	O	865-867
candidiasis	B	868-879
.	O	879-880

Cyclophosphamide	O	0-16
cardiotoxicity	B	17-31
:	O	31-32
an	O	33-35
analysis	O	36-44
of	O	45-47
dosing	O	48-54
as	O	55-57
a	O	58-59
risk	O	60-64
factor	O	65-71
.	O	71-72

Patients	O	73-81
who	O	82-85
undergo	O	86-93
bone	O	94-98
marrow	O	99-105
transplantation	O	106-121
are	O	122-125
generally	O	126-135
immunosuppressed	O	136-152
with	O	153-157
a	O	158-159
dose	O	160-164
of	O	165-167
cyclophosphamide	O	168-184
(	O	185-186
CYA	O	186-189
)	O	189-190
which	O	191-196
is	O	197-199
usually	O	200-207
calculated	O	208-218
based	O	219-224
on	O	225-227
the	O	228-231
patient	O	232-239
'	O	239-240
s	O	240-241
weight	O	242-248
.	O	248-249

At	O	250-252
these	O	253-258
high	O	259-263
doses	O	264-269
of	O	270-272
CYA	O	273-276
,	O	276-277
serious	O	278-285
cardiotoxicity	B	286-300
may	O	301-304
occur	O	305-310
,	O	310-311
but	O	312-315
definitive	O	316-326
risk	O	327-331
factors	O	332-339
for	O	340-343
the	O	344-347
development	O	348-359
of	O	360-362
such	O	363-367
cardiotoxicity	B	368-382
have	O	383-387
not	O	388-391
been	O	392-396
described	O	397-406
.	O	406-407

Since	O	408-413
chemotherapeutic	O	414-430
agent	O	431-436
toxicity	B	437-445
generally	O	446-455
correlates	O	456-466
with	O	467-471
dose	O	472-476
per	O	477-480
body	O	481-485
surface	O	486-493
area	O	494-498
,	O	498-499
we	O	500-502
retrospectively	O	503-518
calculated	O	519-529
the	O	530-533
dose	O	534-538
of	O	539-541
CYA	O	542-545
in	O	546-548
patients	O	549-557
transplanted	O	558-570
at	O	571-573
our	O	574-577
institution	O	578-589
to	O	590-592
determine	O	593-602
whether	O	603-610
the	O	611-614
incidence	O	615-624
of	O	625-627
CYA	O	628-631
cardiotoxicity	B	632-646
correlated	O	647-657
with	O	658-662
the	O	663-666
dose	O	667-671
per	O	672-675
body	O	676-680
surface	O	681-688
area	O	689-693
.	O	693-694

Eighty	O	695-701
patients	O	702-710
who	O	711-714
were	O	715-719
to	O	720-722
receive	O	723-730
CYA	O	731-734
50	O	735-737
mg	O	738-740
/	O	740-741
kg	O	741-743
/	O	740-741
d	O	744-745
for	O	746-749
four	O	750-754
days	O	755-759
as	O	760-762
preparation	O	763-774
for	O	775-778
marrow	O	779-785
grafting	O	786-794
underwent	O	795-804
a	O	805-806
total	O	807-812
of	O	813-815
84	O	816-818
transplants	O	819-830
for	O	831-834
aplastic	B	835-843
anemia	I	844-850
,	O	850-851
Wiskott	B	852-859
-	I	859-860
Aldrich	I	860-867
syndrome	I	868-876
,	O	876-877
or	O	878-880
severe	B	881-887
combined	I	888-896
immunodeficiency	I	897-913
syndrome	I	914-922
.	O	922-923

Fourteen	O	924-932
of	O	933-935
84	O	936-938
(	O	939-940
17	O	940-942
%	O	942-943
)	O	943-944
patients	O	945-953
had	O	954-957
symptoms	O	958-966
and	O	967-970
signs	O	971-976
consistent	O	977-987
with	O	988-992
CYA	O	993-996
cardiotoxicity	B	997-1011
within	O	1012-1018
ten	O	1019-1022
days	O	1023-1027
of	O	1028-1030
receiving	O	1031-1040
1	O	1041-1042
to	O	1043-1045
4	O	1046-1047
doses	O	1048-1053
of	O	1054-1056
CYA	O	1057-1060
.	O	1060-1061

Six	O	1062-1065
of	O	1066-1068
the	O	1069-1072
14	O	1073-1075
patients	O	1076-1084
died	O	1085-1089
with	O	1090-1094
congestive	B	1095-1105
heart	I	1106-1111
failure	I	1112-1119
.	O	1119-1120

The	O	1121-1124
dose	O	1125-1129
of	O	1130-1132
CYA	O	1133-1136
per	O	1137-1140
body	O	1141-1145
surface	O	1146-1153
area	O	1154-1158
was	O	1159-1162
calculated	O	1163-1173
for	O	1174-1177
all	O	1178-1181
patients	O	1182-1190
and	O	1191-1194
the	O	1195-1198
patients	O	1199-1207
were	O	1208-1212
divided	O	1213-1220
into	O	1221-1225
two	O	1226-1229
groups	O	1230-1236
based	O	1237-1242
on	O	1243-1245
daily	O	1246-1251
CYA	O	1252-1255
dose	O	1256-1260
:	O	1260-1261
Group	O	1262-1267
1	O	1268-1269
,	O	1269-1270
CYA	O	1271-1274
less	O	1275-1279
than	O	1280-1284
or	O	1285-1287
equal	O	1288-1293
to	O	1294-1296
1	O	1297-1298
.	O	1298-1299
55	O	1299-1301
g	O	1302-1303
/	O	1303-1304
m2	O	1304-1306
/	O	1303-1304
d	O	1307-1308
;	O	1308-1309
Group	O	1310-1315
2	O	1316-1317
,	O	1317-1318
CYA	O	1319-1322
greater	O	1323-1330
than	O	1331-1335
1	O	1336-1337
.	O	1337-1338
55	O	1338-1340
g	O	1341-1342
/	O	1342-1343
m2	O	1343-1345
/	O	1342-1343
d	O	1346-1347
.	O	1347-1348

Cardiotoxicity	B	1349-1363
that	O	1364-1368
was	O	1369-1372
thought	O	1373-1380
to	O	1381-1383
be	O	1384-1386
related	O	1387-1394
to	O	1395-1397
CYA	O	1398-1401
occurred	O	1402-1410
in	O	1411-1413
1	O	1414-1415
/	O	1415-1416
32	O	1416-1418
(	O	1419-1420
3	O	1420-1421
%	O	1421-1422
)	O	1422-1423
of	O	1424-1426
patients	O	1427-1435
in	O	1436-1438
Group	O	1439-1444
1	O	1445-1446
and	O	1447-1450
in	O	1451-1453
13	O	1454-1456
/	O	1456-1457
52	O	1457-1459
(	O	1460-1461
25	O	1461-1463
%	O	1463-1464
)	O	1464-1465
patients	O	1466-1474
in	O	1475-1477
Group	O	1478-1483
2	O	1484-1485
(	O	1486-1487
P	O	1487-1488
less	O	1489-1493
than	O	1494-1498
0	O	1499-1500
.	O	1500-1501
025	O	1501-1504
)	O	1504-1505
.	O	1500-1501

Congestive	B	1507-1517
heart	I	1518-1523
failure	I	1524-1531
caused	O	1532-1538
or	O	1539-1541
contributed	O	1542-1553
to	O	1554-1556
death	O	1557-1562
in	O	1563-1565
0	O	1566-1567
/	O	1567-1568
32	O	1568-1570
patients	O	1571-1579
in	O	1580-1582
Group	O	1583-1588
1	O	1589-1590
v	O	1591-1592
6	O	1593-1594
/	O	1594-1595
52	O	1595-1597
(	O	1598-1599
12	O	1599-1601
%	O	1601-1602
)	O	1602-1603
of	O	1604-1606
patients	O	1607-1615
in	O	1616-1618
Group	O	1619-1624
2	O	1625-1626
(	O	1627-1628
P	O	1628-1629
less	O	1630-1634
than	O	1635-1639
0	O	1640-1641
.	O	1641-1642
25	O	1642-1644
)	O	1644-1645
.	O	1641-1642

There	O	1647-1652
was	O	1653-1656
no	O	1657-1659
difference	O	1660-1670
in	O	1671-1673
the	O	1674-1677
rate	O	1678-1682
of	O	1683-1685
engraftment	O	1686-1697
of	O	1698-1700
evaluable	O	1701-1710
patients	O	1711-1719
in	O	1720-1722
the	O	1723-1726
two	O	1727-1730
groups	O	1731-1737
(	O	1738-1739
P	O	1739-1740
greater	O	1741-1748
than	O	1749-1753
0	O	1754-1755
.	O	1755-1756
5	O	1756-1757
)	O	1757-1758
.	O	1755-1756

We	O	1760-1762
conclude	O	1763-1771
that	O	1772-1776
the	O	1777-1780
CYA	O	1781-1784
cardiotoxicity	B	1785-1799
correlates	O	1800-1810
with	O	1811-1815
CYA	O	1816-1819
dosage	O	1820-1826
as	O	1827-1829
calculated	O	1830-1840
by	O	1841-1843
body	O	1844-1848
surface	O	1849-1856
area	O	1857-1861
,	O	1861-1862
and	O	1863-1866
that	O	1867-1871
patients	O	1872-1880
with	O	1881-1885
aplastic	B	1886-1894
anemia	I	1895-1901
and	O	1902-1905
immunodeficiencies	B	1906-1924
can	O	1925-1928
be	O	1929-1931
effectively	O	1932-1943
prepared	O	1944-1952
for	O	1953-1956
bone	O	1957-1961
marrow	O	1962-1968
grafting	O	1969-1977
at	O	1978-1980
a	O	1981-1982
CYA	O	1983-1986
dose	O	1987-1991
of	O	1992-1994
1	O	1995-1996
.	O	1996-1997
55	O	1997-1999
g	O	2000-2001
/	O	2001-2002
m2	O	2002-2004
/	O	2001-2002
d	O	2005-2006
for	O	2007-2010
four	O	2011-2015
days	O	2016-2020
with	O	2021-2025
a	O	2026-2027
lower	O	2028-2033
incidence	O	2034-2043
of	O	2044-2046
cardiotoxicity	B	2047-2061
than	O	2062-2066
patients	O	2067-2075
whose	O	2076-2081
CYA	O	2082-2085
dosage	O	2086-2092
is	O	2093-2095
calculated	O	2096-2106
based	O	2107-2112
on	O	2113-2115
weight	O	2116-2122
.	O	2122-2123

This	O	2124-2128
study	O	2129-2134
reaffirms	O	2135-2144
the	O	2145-2148
principle	O	2149-2158
that	O	2159-2163
drug	O	2164-2168
toxicity	B	2169-2177
correlates	O	2178-2188
with	O	2189-2193
dose	O	2194-2198
per	O	2199-2202
body	O	2203-2207
surface	O	2208-2215
area	O	2216-2220
.	O	2220-2221

Studies	O	0-7
of	O	8-10
risk	O	11-15
factors	O	16-23
for	O	24-27
aminoglycoside	O	28-42
nephrotoxicity	B	43-57
.	O	57-58

The	O	59-62
epidemiology	O	63-75
of	O	76-78
aminoglycoside	O	79-93
-	O	93-94
induced	O	94-101
nephrotoxicity	B	102-116
is	O	117-119
not	O	120-123
fully	O	124-129
understood	O	130-140
.	O	140-141

Experimental	O	142-154
studies	O	155-162
in	O	163-165
healthy	O	166-173
human	O	174-179
volunteers	O	180-190
indicate	O	191-199
aminoglycosides	O	200-215
cause	O	216-221
proximal	O	222-230
tubular	O	231-238
damage	O	239-245
in	O	246-248
most	O	249-253
patients	O	254-262
,	O	262-263
but	O	264-267
rarely	O	268-274
,	O	274-275
if	O	276-278
ever	O	279-283
,	O	283-284
cause	O	285-290
glomerular	B	291-301
or	I	302-304
tubular	I	305-312
dysfunction	I	313-324
.	O	324-325

Clinical	O	326-334
trials	O	335-341
of	O	342-344
aminoglycosides	O	345-360
in	O	361-363
seriously	O	364-373
ill	O	374-377
patients	O	378-386
indicate	O	387-395
that	O	396-400
the	O	401-404
relative	O	405-413
risk	O	414-418
for	O	419-422
developing	O	423-433
acute	B	434-439
renal	I	440-445
failure	I	446-453
during	O	454-460
therapy	O	461-468
ranges	O	469-475
from	O	476-480
8	O	481-482
to	O	483-485
10	O	486-488
and	O	489-492
that	O	493-497
the	O	498-501
attributable	O	502-514
risk	O	515-519
is	O	520-522
70	O	523-525
%	O	525-526
to	O	527-529
80	O	530-532
%	O	532-533
.	O	533-534

Further	O	535-542
analysis	O	543-551
of	O	552-554
these	O	555-560
data	O	561-565
suggests	O	566-574
that	O	575-579
the	O	580-583
duration	O	584-592
of	O	593-595
therapy	O	596-603
,	O	603-604
plasma	O	605-611
aminoglycoside	O	612-626
levels	O	627-633
,	O	633-634
liver	B	635-640
disease	I	641-648
,	O	648-649
advanced	O	650-658
age	O	659-662
,	O	662-663
high	O	664-668
initial	O	669-676
estimated	O	677-686
creatinine	O	687-697
clearance	O	698-707
and	O	708-711
,	O	711-712
possibly	O	713-721
,	O	721-722
female	O	723-729
gender	O	730-736
all	O	737-740
increase	O	741-749
the	O	750-753
risk	O	754-758
for	O	759-762
nephrotoxicity	B	763-777
.	O	777-778

Other	O	779-784
causes	O	785-791
of	O	792-794
acute	B	795-800
renal	I	801-806
failure	I	807-814
,	O	814-815
such	O	816-820
as	O	821-823
shock	B	824-829
,	O	829-830
appear	O	831-837
to	O	838-840
have	O	841-845
an	O	846-848
additive	O	849-857
effect	O	858-864
.	O	864-865

Predictive	O	866-876
models	O	877-883
have	O	884-888
been	O	889-893
developed	O	894-903
from	O	904-908
these	O	909-914
analyses	O	915-923
that	O	924-928
should	O	929-935
be	O	936-938
useful	O	939-945
for	O	946-949
identifying	O	950-961
patients	O	962-970
at	O	971-973
high	O	974-978
risk	O	979-983
.	O	983-984

These	O	985-990
models	O	991-997
may	O	998-1001
also	O	1002-1006
be	O	1007-1009
useful	O	1010-1016
in	O	1017-1019
developing	O	1020-1030
insights	O	1031-1039
into	O	1040-1044
the	O	1045-1048
pathophysiology	O	1049-1064
of	O	1065-1067
aminoglycoside	O	1068-1082
-	O	1082-1083
induced	O	1083-1090
nephrotoxicity	B	1091-1105
.	O	1105-1106

Flurothyl	O	0-9
seizure	B	10-17
thresholds	O	18-28
in	O	29-31
mice	O	32-36
treated	O	37-44
neonatally	O	45-55
with	O	56-60
a	O	61-62
single	O	63-69
injection	O	70-79
of	O	80-82
monosodium	O	83-93
glutamate	O	94-103
(	O	104-105
MSG	O	105-108
)	O	108-109
:	O	109-110
evaluation	O	111-121
of	O	122-124
experimental	O	125-137
parameters	O	138-148
in	O	149-151
flurothyl	O	152-161
seizure	B	162-169
testing	O	170-177
.	O	177-178

Monosodium	O	179-189
glutamate	O	190-199
(	O	200-201
MSG	O	201-204
)	O	204-205
administration	O	206-220
to	O	221-223
neonatal	O	224-232
rodents	O	233-240
produces	O	241-249
convulsions	B	250-261
and	O	262-265
results	O	266-273
in	O	274-276
numerous	O	277-285
biochemical	O	286-297
and	O	298-301
behavioral	O	302-312
deficits	O	313-321
.	O	321-322

These	O	323-328
studies	O	329-336
were	O	337-341
undertaken	O	342-352
to	O	353-355
determine	O	356-365
if	O	366-368
neonatal	O	369-377
administration	O	378-392
of	O	393-395
MSG	O	396-399
produced	O	400-408
permanent	O	409-418
alterations	O	419-430
in	O	431-433
seizure	B	434-441
susceptibility	O	442-456
,	O	456-457
since	O	458-463
previous	O	464-472
investigations	O	473-487
were	O	488-492
inconclusive	O	493-505
.	O	505-506

A	O	507-508
flurothyl	O	509-518
ether	O	519-524
seizure	B	525-532
screening	O	533-542
technique	O	543-552
was	O	553-556
used	O	557-561
to	O	562-564
evaluate	O	565-573
seizure	B	574-581
susceptibility	O	582-596
in	O	597-599
adult	O	600-605
mice	O	606-610
that	O	611-615
received	O	616-624
neonatal	O	625-633
injections	O	634-644
of	O	645-647
MSG	O	648-651
(	O	652-653
4	O	653-654
mg	O	655-657
/	O	657-658
g	O	656-657
and	O	660-663
1	O	664-665
mg	O	666-668
/	O	668-669
g	O	667-668
)	O	670-671
.	O	671-672

MSG	O	673-676
treatment	O	677-686
resulted	O	687-695
in	O	696-698
significant	O	699-710
reductions	O	711-721
in	O	722-724
whole	O	725-730
brain	O	731-736
weight	O	737-743
but	O	744-747
did	O	748-751
not	O	752-755
alter	O	756-761
seizure	B	762-769
threshold	O	770-779
.	O	779-780

A	O	781-782
naloxone	O	783-791
(	O	792-793
5	O	793-794
mg	O	795-797
/	O	797-798
kg	O	798-800
)	O	800-801
challenge	O	802-811
was	O	812-815
also	O	816-820
ineffective	O	821-832
in	O	833-835
altering	O	836-844
the	O	845-848
seizure	B	849-856
thresholds	O	857-867
of	O	868-870
either	O	871-877
control	O	878-885
of	O	886-888
MSG	O	889-892
-	O	892-893
treated	O	893-900
mice	O	901-905
.	O	905-906

Flurothyl	O	907-916
ether	O	917-922
produced	O	923-931
hypothermia	B	932-943
which	O	944-949
was	O	950-953
correlated	O	954-964
with	O	965-969
the	O	970-973
duration	O	974-982
of	O	983-985
flurothyl	O	986-995
exposure	O	996-1004
;	O	1004-1005
however	O	1006-1013
,	O	1013-1014
the	O	1015-1018
relationship	O	1019-1031
of	O	1032-1034
hypothermia	B	1035-1046
to	O	1047-1049
seizure	B	1050-1057
induction	O	1058-1067
was	O	1068-1071
unclear	O	1072-1079
.	O	1079-1080

Flurothyl	O	1081-1090
seizure	B	1091-1098
testing	O	1099-1106
proved	O	1107-1113
to	O	1114-1116
be	O	1117-1119
a	O	1120-1121
rapid	O	1122-1127
and	O	1128-1131
reliable	O	1132-1140
technique	O	1141-1150
with	O	1151-1155
which	O	1156-1161
to	O	1162-1164
evaluate	O	1165-1173
seizure	B	1174-1181
susceptibility	O	1182-1196
.	O	1196-1197

Susceptibility	O	0-14
to	O	15-17
seizures	B	18-26
produced	O	27-35
by	O	36-38
pilocarpine	O	39-50
in	O	51-53
rats	O	54-58
after	O	59-64
microinjection	O	65-79
of	O	80-82
isoniazid	O	83-92
or	O	93-95
gamma	O	96-101
-	O	101-102
vinyl	O	102-107
-	O	101-102
GABA	O	108-112
into	O	113-117
the	O	118-121
substantia	O	122-132
nigra	O	133-138
.	O	138-139

Pilocarpine	O	140-151
,	O	151-152
given	O	153-158
intraperitoneally	O	159-176
to	O	177-179
rats	O	180-184
,	O	184-185
reproduces	O	186-196
the	O	197-200
neuropathological	O	201-218
sequelae	O	219-227
of	O	228-230
temporal	B	231-239
lobe	I	240-244
epilepsy	I	245-253
and	O	254-257
provides	O	258-266
a	O	267-268
relevant	O	269-277
animal	O	278-284
model	O	285-290
for	O	291-294
studying	O	295-303
mechanisms	O	304-314
of	O	315-317
buildup	O	318-325
of	O	326-328
convulsive	B	329-339
activity	O	340-348
and	O	349-352
pathways	O	353-361
operative	O	362-371
in	O	372-374
the	O	375-378
generalization	O	379-393
and	O	394-397
propagation	O	398-409
of	O	410-412
seizures	B	413-421
within	O	422-428
the	O	429-432
forebrain	O	433-442
.	O	442-443

In	O	444-446
the	O	447-450
present	O	451-458
study	O	459-464
,	O	464-465
the	O	466-469
effects	O	470-477
of	O	478-480
manipulating	O	481-493
the	O	494-497
activity	O	498-506
of	O	507-509
the	O	510-513
gamma	O	514-519
-	O	519-520
aminobutyric	O	520-532
acid	O	533-537
(	O	538-539
GABA	O	539-543
)	O	543-544
-	O	544-545
mediated	O	545-553
synaptic	O	554-562
inhibition	O	563-573
within	O	574-580
the	O	581-584
substantia	O	585-595
nigra	O	596-601
on	O	602-604
seizures	B	605-613
produced	O	614-622
by	O	623-625
pilocarpine	O	626-637
in	O	638-640
rats	O	641-645
,	O	645-646
were	O	647-651
investigated	O	652-664
.	O	664-665

In	O	666-668
animals	O	669-676
pretreated	O	677-687
with	O	688-692
microinjections	O	693-708
of	O	709-711
isoniazid	O	712-721
,	O	721-722
150	O	723-726
micrograms	O	727-737
,	O	737-738
an	O	739-741
inhibitor	O	742-751
of	O	752-754
activity	O	755-763
of	O	764-766
the	O	767-770
GABA	O	771-775
-	O	775-776
synthesizing	O	776-788
enzyme	O	789-795
,	O	795-796
L	O	797-798
-	O	798-799
glutamic	O	799-807
acid	O	808-812
decarboxylase	O	813-826
,	O	826-827
into	O	828-832
the	O	833-836
substantia	O	837-847
nigra	O	848-853
pars	O	854-858
reticulata	O	859-869
(	O	870-871
SNR	O	871-874
)	O	874-875
,	O	875-876
bilaterally	O	877-888
,	O	888-889
non	O	890-893
-	O	893-894
convulsant	O	894-904
doses	O	905-910
of	O	911-913
pilocarpine	O	914-925
,	O	925-926
100	O	927-930
and	O	931-934
200	O	935-938
mg	O	939-941
/	O	941-942
kg	O	942-944
,	O	944-945
resulted	O	946-954
in	O	955-957
severe	O	958-964
motor	O	965-970
limbic	O	971-977
seizures	B	978-986
and	O	987-990
status	B	991-997
epilepticus	I	998-1009
.	O	1009-1010

Electroencephalographic	O	1011-1034
and	O	1035-1038
behavioral	O	1039-1049
monitoring	O	1050-1060
revealed	O	1061-1069
a	O	1070-1071
profound	O	1072-1080
reduction	O	1081-1090
of	O	1091-1093
the	O	1094-1097
threshold	O	1098-1107
for	O	1108-1111
pilocarpine	O	1112-1123
-	O	1123-1124
induced	O	1124-1131
convulsions	B	1132-1143
.	O	1143-1144

Morphological	O	1145-1158
analysis	O	1159-1167
of	O	1168-1170
frontal	O	1171-1178
forebrain	O	1179-1188
sections	O	1189-1197
with	O	1198-1202
light	O	1203-1208
microscopy	O	1209-1219
revealed	O	1220-1228
seizure	B	1229-1236
-	O	1236-1237
related	O	1237-1244
damage	O	1245-1251
to	O	1252-1254
the	O	1255-1258
hippocampal	O	1259-1270
formation	O	1271-1280
,	O	1280-1281
thalamus	O	1282-1290
,	O	1290-1291
amygdala	O	1292-1300
,	O	1300-1301
olfactory	O	1302-1311
cortex	O	1312-1318
,	O	1318-1319
substantia	O	1320-1330
nigra	O	1331-1336
and	O	1337-1340
neocortex	O	1341-1350
,	O	1350-1351
which	O	1352-1357
is	O	1358-1360
typically	O	1361-1370
observed	O	1371-1379
with	O	1380-1384
pilocarpine	O	1385-1396
in	O	1397-1399
doses	O	1400-1405
exceeding	O	1406-1415
350	O	1416-1419
mg	O	1420-1422
/	O	1422-1423
kg	O	1423-1425
.	O	1425-1426

Bilateral	O	1427-1436
intrastriatal	O	1437-1450
injections	O	1451-1461
of	O	1462-1464
isoniazid	O	1465-1474
did	O	1475-1478
not	O	1479-1482
augment	O	1483-1490
seizures	B	1491-1499
produced	O	1500-1508
by	O	1509-1511
pilocarpine	O	1512-1523
,	O	1523-1524
200	O	1525-1528
mg	O	1529-1531
/	O	1531-1532
kg	O	1532-1534
.	O	1534-1535

Application	O	1536-1547
of	O	1548-1550
an	O	1551-1553
irreversible	O	1554-1566
inhibitor	O	1567-1576
of	O	1577-1579
GABA	O	1580-1584
transaminase	O	1585-1597
,	O	1597-1598
gamma	O	1599-1604
-	O	1604-1605
vinyl	O	1605-1610
-	O	1604-1605
GABA	O	1611-1615
(	O	1616-1617
D	O	1617-1618
,	O	1618-1619
L	O	1619-1620
-	O	1620-1621
4	O	1621-1622
-	O	1620-1621
amino	O	1623-1628
-	O	1620-1621
hex	O	1629-1632
-	O	1620-1621
5	O	1633-1634
-	O	1620-1621
enoic	O	1635-1640
acid	O	1641-1645
)	O	1645-1646
,	O	1646-1647
5	O	1648-1649
micrograms	O	1650-1660
,	O	1660-1661
into	O	1662-1666
the	O	1667-1670
SNR	O	1671-1674
,	O	1674-1675
bilaterally	O	1676-1687
,	O	1687-1688
suppressed	O	1689-1699
the	O	1700-1703
appearance	O	1704-1714
of	O	1715-1717
electrographic	O	1718-1732
and	O	1733-1736
behavioral	O	1737-1747
seizures	B	1748-1756
produced	O	1757-1765
by	O	1766-1768
pilocarpine	O	1769-1780
,	O	1780-1781
380	O	1782-1785
mg	O	1786-1788
/	O	1788-1789
kg	O	1789-1791
.	O	1791-1792

This	O	1793-1797
treatment	O	1798-1807
was	O	1808-1811
also	O	1812-1816
sufficient	O	1817-1827
to	O	1828-1830
protect	O	1831-1838
animals	O	1839-1846
from	O	1847-1851
the	O	1852-1855
occurrence	O	1856-1866
of	O	1867-1869
brain	B	1870-1875
damage	I	1876-1882
.	O	1882-1883

Microinjections	O	1884-1899
of	O	1900-1902
gamma	O	1903-1908
-	O	1908-1909
vinyl	O	1909-1914
-	O	1908-1909
GABA	O	1915-1919
,	O	1919-1920
5	O	1921-1922
micrograms	O	1923-1933
,	O	1933-1934
into	O	1935-1939
the	O	1940-1943
dorsal	O	1944-1950
striatum	O	1951-1959
,	O	1959-1960
bilaterally	O	1961-1972
,	O	1972-1973
failed	O	1974-1980
to	O	1981-1983
prevent	O	1984-1991
the	O	1992-1995
development	O	1996-2007
of	O	2008-2010
convulsions	B	2011-2022
produced	O	2023-2031
by	O	2032-2034
pilocarpine	O	2035-2046
,	O	2046-2047
380	O	2048-2051
mg	O	2052-2054
/	O	2054-2055
kg	O	2055-2057
.	O	2057-2058

The	O	2059-2062
results	O	2063-2070
demonstrate	O	2071-2082
that	O	2083-2087
the	O	2088-2091
threshold	O	2092-2101
for	O	2102-2105
pilocarpine	O	2106-2117
-	O	2117-2118
induced	O	2118-2125
seizures	B	2126-2134
in	O	2135-2137
rats	O	2138-2142
is	O	2143-2145
subjected	O	2146-2155
to	O	2156-2158
the	O	2159-2162
regulation	O	2163-2173
of	O	2174-2176
the	O	2177-2180
GABA	O	2181-2185
-	O	2185-2186
mediated	O	2186-2194
synaptic	O	2195-2203
inhibition	O	2204-2214
within	O	2215-2221
the	O	2222-2225
substantia	O	2226-2236
nigra	O	2237-2242
.	O	2242-2243

Non	O	0-3
-	O	3-4
invasive	O	4-12
detection	O	13-22
of	O	23-25
coronary	B	26-34
artery	I	35-41
disease	I	42-49
by	O	50-52
body	O	53-57
surface	O	58-65
electrocardiographic	O	66-86
mapping	O	87-94
after	O	95-100
dipyridamole	O	101-113
infusion	O	114-122
.	O	122-123

Electrocardiographic	O	124-144
changes	O	145-152
after	O	153-158
dipyridamole	O	159-171
infusion	O	172-180
(	O	181-182
0	O	182-183
.	O	183-184
568	O	184-187
mg	O	188-190
/	O	190-191
kg	O	191-193
/	O	190-191
4	O	194-195
min	O	196-199
)	O	199-200
were	O	201-205
studied	O	206-213
in	O	214-216
41	O	217-219
patients	O	220-228
with	O	229-233
coronary	B	234-242
artery	I	243-249
disease	I	250-257
and	O	258-261
compared	O	262-270
with	O	271-275
those	O	276-281
after	O	282-287
submaximal	O	288-298
treadmill	O	299-308
exercise	O	309-317
by	O	318-320
use	O	321-324
of	O	325-327
the	O	328-331
body	O	332-336
surface	O	337-344
mapping	O	345-352
technique	O	353-362
.	O	362-363

Patients	O	364-372
were	O	373-377
divided	O	378-385
into	O	386-390
three	O	391-396
groups	O	397-403
;	O	403-404
19	O	405-407
patients	O	408-416
without	O	417-424
myocardial	B	425-435
infarction	I	436-446
(	O	447-448
non	O	448-451
-	O	451-452
MI	B	452-454
group	O	455-460
)	O	460-461
,	O	461-462
14	O	463-465
with	O	466-470
anterior	B	471-479
infarction	I	480-490
(	O	491-492
ANT	B	492-495
-	I	495-496
MI	I	496-498
)	O	498-499
and	O	500-503
eight	O	504-509
with	O	510-514
inferior	B	515-523
infarction	I	524-534
(	O	535-536
INF	B	536-539
-	I	539-540
MI	I	540-542
)	O	542-543
.	O	543-544

Eighty	O	545-551
-	O	551-552
seven	O	552-557
unipolar	O	558-566
electrocardiograms	O	567-585
(	O	586-587
ECGs	O	587-591
)	O	591-592
distributed	O	593-604
over	O	605-609
the	O	610-613
entire	O	614-620
thoracic	O	621-629
surface	O	630-637
were	O	638-642
simultaneously	O	643-657
recorded	O	658-666
.	O	666-667

After	O	668-673
dipyridamole	O	674-686
,	O	686-687
ischemic	B	688-696
ST	O	697-699
-	O	699-700
segment	O	700-707
depression	B	708-718
(	O	719-720
0	O	720-721
.	O	721-722
05	O	722-724
mV	O	725-727
or	O	728-730
more	O	731-735
)	O	735-736
was	O	737-740
observed	O	741-749
in	O	750-752
84	O	753-755
%	O	755-756
of	O	757-759
the	O	760-763
non	O	764-767
-	O	767-768
MI	B	768-770
group	O	771-776
,	O	776-777
29	O	778-780
%	O	780-781
of	O	782-784
the	O	785-788
ANT	B	789-792
-	I	792-793
MI	I	793-795
group	O	796-801
,	O	801-802
63	O	803-805
%	O	805-806
of	O	807-809
the	O	810-813
INF	B	814-817
-	I	817-818
MI	I	818-820
group	O	821-826
and	O	827-830
61	O	831-833
%	O	833-834
of	O	835-837
the	O	838-841
total	O	842-847
population	O	848-858
.	O	858-859

Exercise	O	860-868
-	O	868-869
induced	O	869-876
ST	O	877-879
depression	B	880-890
was	O	891-894
observed	O	895-903
in	O	904-906
84	O	907-909
%	O	909-910
of	O	911-913
the	O	914-917
non	O	918-921
-	O	921-922
MI	B	922-924
group	O	925-930
,	O	930-931
43	O	932-934
%	O	934-935
of	O	936-938
the	O	939-942
ANT	B	943-946
-	I	946-947
MI	I	947-949
group	O	950-955
,	O	955-956
38	O	957-959
%	O	959-960
of	O	961-963
the	O	964-967
INF	B	968-971
-	I	971-972
MI	I	972-974
group	O	975-980
and	O	981-984
61	O	985-987
%	O	987-988
of	O	989-991
the	O	992-995
total	O	996-1001
.	O	1001-1002

For	O	1003-1006
individual	O	1007-1017
patients	O	1018-1026
,	O	1026-1027
there	O	1028-1033
were	O	1034-1038
no	O	1039-1041
obvious	O	1042-1049
differences	O	1050-1061
between	O	1062-1069
the	O	1070-1073
body	O	1074-1078
surface	O	1079-1086
distribution	O	1087-1099
of	O	1100-1102
ST	O	1103-1105
depression	B	1106-1116
in	O	1117-1119
both	O	1120-1124
tests	O	1125-1130
.	O	1130-1131

The	O	1132-1135
increase	O	1136-1144
in	O	1145-1147
pressure	O	1148-1156
rate	O	1157-1161
product	O	1162-1169
after	O	1170-1175
dipyridamole	O	1176-1188
was	O	1189-1192
significantly	O	1193-1206
less	O	1207-1211
than	O	1212-1216
that	O	1217-1221
during	O	1222-1228
the	O	1229-1232
treadmill	O	1233-1242
exercise	O	1243-1251
.	O	1251-1252

The	O	1253-1256
data	O	1257-1261
suggest	O	1262-1269
that	O	1270-1274
the	O	1275-1278
dipyridamole	O	1279-1291
-	O	1291-1292
induced	O	1292-1299
myocardial	B	1300-1310
ischemia	I	1311-1319
is	O	1320-1322
caused	O	1323-1329
by	O	1330-1332
the	O	1333-1336
inhomogenous	O	1337-1349
distribution	O	1350-1362
of	O	1363-1365
myocardial	O	1366-1376
blood	O	1377-1382
flow	O	1383-1387
.	O	1387-1388

We	O	1389-1391
conclude	O	1392-1400
that	O	1401-1405
the	O	1406-1409
dipyridamole	O	1410-1422
ECG	O	1423-1426
test	O	1427-1431
is	O	1432-1434
as	O	1435-1437
useful	O	1438-1444
as	O	1445-1447
the	O	1448-1451
exercise	O	1452-1460
ECG	O	1461-1464
test	O	1465-1469
for	O	1470-1473
the	O	1474-1477
assessment	O	1478-1488
of	O	1489-1491
coronary	B	1492-1500
artery	I	1501-1507
disease	I	1508-1515
.	O	1515-1516

Bradycardia	B	0-11
after	O	12-17
high	O	18-22
-	O	22-23
dose	O	23-27
intravenous	O	28-39
methylprednisolone	O	40-58
therapy	O	59-66
.	O	66-67

In	O	68-70
5	O	71-72
consecutive	O	73-84
patients	O	85-93
with	O	94-98
rheumatoid	B	99-109
arthritis	I	110-119
who	O	120-123
received	O	124-132
intravenous	O	133-144
high	O	145-149
-	O	149-150
dose	O	150-154
methylprednisolone	O	155-173
(	O	174-175
MP	O	175-177
)	O	177-178
therapy	O	179-186
(	O	187-188
1	O	188-189
g	O	190-191
daily	O	192-197
for	O	198-201
2	O	202-203
or	O	204-206
3	O	207-208
consecutive	O	209-220
days	O	221-225
)	O	225-226
,	O	226-227
a	O	228-229
decline	O	230-237
in	O	238-240
pulse	O	241-246
rate	O	247-251
was	O	252-255
observed	O	256-264
,	O	264-265
most	O	266-270
pronounced	O	271-281
on	O	282-284
day	O	285-288
4	O	289-290
.	O	290-291

In	O	292-294
one	O	295-298
of	O	299-301
the	O	302-305
5	O	306-307
patients	O	308-316
the	O	317-320
bradycardia	B	321-332
was	O	333-336
associated	O	337-347
with	O	348-352
complaints	O	353-363
of	O	364-366
substernal	O	367-377
pressure	O	378-386
.	O	386-387

Reversal	O	388-396
to	O	397-399
normal	O	400-406
heart	O	407-412
rate	O	413-417
was	O	418-421
found	O	422-427
on	O	428-430
day	O	431-434
7	O	435-436
.	O	436-437
Electrocardiographic	O	438-458
registrations	O	459-472
showed	O	473-479
sinus	B	480-485
bradycardia	I	486-497
in	O	498-500
all	O	501-504
cases	O	505-510
.	O	510-511

No	O	512-514
significant	O	515-526
changes	O	527-534
in	O	535-537
plasma	O	538-544
concentrations	O	545-559
of	O	560-562
electrolytes	O	563-575
were	O	576-580
found	O	581-586
.	O	586-587

Careful	O	588-595
observation	O	596-607
of	O	608-610
patients	O	611-619
receiving	O	620-629
high	O	630-634
-	O	634-635
dose	O	635-639
MP	O	640-642
is	O	643-645
recommended	O	646-657
.	O	657-658

High	O	659-663
-	O	663-664
dose	O	664-668
MP	O	669-671
may	O	672-675
be	O	676-678
contraindicated	O	679-694
in	O	695-697
patients	O	698-706
with	O	707-711
known	O	712-717
heart	B	718-723
disease	I	724-731
.	O	731-732

Two	O	0-3
cases	O	4-9
of	O	10-12
downbeat	B	13-21
nystagmus	I	22-31
and	O	32-35
oscillopsia	B	36-47
associated	O	48-58
with	O	59-63
carbamazepine	O	64-77
.	O	77-78

Downbeat	B	79-87
nystagmus	I	88-97
is	O	98-100
often	O	101-106
associated	O	107-117
with	O	118-122
structural	O	123-133
lesions	O	134-141
at	O	142-144
the	O	145-148
craniocervical	O	149-163
junction	O	164-172
,	O	172-173
but	O	174-177
has	O	178-181
occasionally	O	182-194
been	O	195-199
reported	O	200-208
as	O	209-211
a	O	212-213
manifestation	O	214-227
of	O	228-230
metabolic	O	231-240
imbalance	O	241-250
or	O	251-253
drug	O	254-258
intoxication	O	259-271
.	O	271-272

We	O	273-275
recorded	O	276-284
the	O	285-288
eye	O	289-292
movements	O	293-302
of	O	303-305
two	O	306-309
patients	O	310-318
with	O	319-323
reversible	O	324-334
downbeat	B	335-343
nystagmus	I	344-353
related	O	354-361
to	O	362-364
carbamazepine	O	365-378
therapy	O	379-386
.	O	386-387

The	O	388-391
nystagmus	B	392-401
of	O	402-404
both	O	405-409
patients	O	410-418
resolved	O	419-427
after	O	428-433
reduction	O	434-443
of	O	444-446
the	O	447-450
serum	O	451-456
carbamazepine	O	457-470
levels	O	471-477
.	O	477-478

Neuroradiologic	O	479-494
investigations	O	495-509
including	O	510-519
magnetic	O	520-528
resonance	O	529-538
imaging	O	539-546
scans	O	547-552
in	O	553-555
both	O	556-560
patients	O	561-569
showed	O	570-576
no	O	577-579
evidence	O	580-588
of	O	589-591
intracranial	O	592-604
abnormality	O	605-616
.	O	616-617

In	O	618-620
patients	O	621-629
with	O	630-634
downbeat	B	635-643
nystagmus	I	644-653
who	O	654-657
are	O	658-661
taking	O	662-668
anticonvulsant	O	669-683
medications	O	684-695
,	O	695-696
consideration	O	697-710
should	O	711-717
be	O	718-720
given	O	721-726
to	O	727-729
reduction	O	730-739
in	O	740-742
dose	O	743-747
before	O	748-754
further	O	755-762
investigation	O	763-776
is	O	777-779
undertaken	O	780-790
.	O	790-791

Improvement	O	0-11
by	O	12-14
denopamine	O	15-25
(	O	26-27
TA	O	27-29
-	O	29-30
064	O	30-33
)	O	33-34
of	O	35-37
pentobarbital	O	38-51
-	O	51-52
induced	O	52-59
cardiac	B	60-67
failure	I	68-75
in	O	76-78
the	O	79-82
dog	O	83-86
heart	O	87-92
-	O	92-93
lung	O	93-97
preparation	O	98-109
.	O	109-110

The	O	111-114
efficacy	O	115-123
of	O	124-126
denopamine	O	127-137
,	O	137-138
an	O	139-141
orally	O	142-148
active	O	149-155
beta	O	156-160
1	O	161-162
-	O	162-163
adrenoceptor	O	163-175
agonist	O	176-183
,	O	183-184
in	O	185-187
improving	O	188-197
cardiac	B	198-205
failure	I	206-213
was	O	214-217
assessed	O	218-226
in	O	227-229
dog	O	230-233
heart	O	234-239
-	O	239-240
lung	O	240-244
preparations	O	245-257
.	O	257-258

Cardiac	O	259-266
functions	O	267-276
depressed	O	277-286
by	O	287-289
pentobarbital	O	290-303
(	O	304-305
118	O	305-308
+	O	309-310
/	O	310-311
-	O	311-312
28	O	313-315
mg	O	316-318
;	O	318-319
mean	O	320-324
value	O	325-330
+	O	331-332
/	O	332-333
-	O	333-334
SD	O	335-337
)	O	337-338
such	O	339-343
that	O	344-348
cardiac	O	349-356
output	O	357-363
and	O	364-367
maximum	O	368-375
rate	O	376-380
of	O	381-383
rise	O	384-388
of	O	389-391
left	O	392-396
ventricular	O	397-408
pressure	O	409-417
(	O	418-419
LV	O	419-421
dP	O	422-424
/	O	424-425
dt	O	425-427
max	O	428-431
)	O	431-432
had	O	433-436
been	O	437-441
reduced	O	442-449
by	O	450-452
about	O	453-458
35	O	459-461
%	O	461-462
and	O	463-466
26	O	467-469
%	O	469-470
of	O	471-473
the	O	474-477
respective	O	478-488
controls	O	489-497
were	O	498-502
improved	O	503-511
by	O	512-514
denopamine	O	515-525
(	O	526-527
10	O	527-529
-	O	529-530
300	O	530-533
micrograms	O	534-544
)	O	544-545
in	O	546-548
a	O	549-550
dose	O	551-555
-	O	555-556
dependent	O	556-565
manner	O	566-572
.	O	572-573

With	O	574-578
100	O	579-582
micrograms	O	583-593
denopamine	O	594-604
,	O	604-605
almost	O	606-612
complete	O	613-621
restoration	O	622-633
of	O	634-636
cardiac	O	637-644
performance	O	645-656
was	O	657-660
attained	O	661-669
,	O	669-670
associated	O	671-681
with	O	682-686
a	O	687-688
slight	O	689-695
increase	O	696-704
in	O	705-707
heart	O	708-713
rate	O	714-718
.	O	718-719

No	O	720-722
arrhythmias	B	723-734
were	O	735-739
induced	O	740-747
by	O	748-750
these	O	751-756
doses	O	757-762
of	O	763-765
denopamine	O	766-776
.	O	776-777

The	O	778-781
results	O	782-789
warrant	O	790-797
clinical	O	798-806
trials	O	807-813
of	O	814-816
denopamine	O	817-827
in	O	828-830
the	O	831-834
treatment	O	835-844
of	O	845-847
cardiac	B	848-855
failure	I	856-863
.	O	863-864

Clonazepam	O	0-10
monotherapy	O	11-22
for	O	23-26
epilepsy	B	27-35
in	O	36-38
childhood	O	39-48
.	O	48-49

Sixty	O	50-55
patients	O	56-64
(	O	65-66
age	O	66-69
-	O	69-70
range	O	70-75
one	O	76-79
month	O	80-85
to	O	86-88
14	O	89-91
years	O	92-97
)	O	97-98
with	O	99-103
other	O	104-109
types	O	110-115
of	O	116-118
epilepsy	B	119-127
than	O	128-132
infantile	B	133-142
spasms	I	143-149
were	O	150-154
treated	O	155-162
with	O	163-167
clonazepam	O	168-178
.	O	178-179

Disappearance	O	180-193
of	O	194-196
seizures	B	197-205
and	O	206-209
normalization	O	210-223
of	O	224-226
abnormal	O	227-235
EEG	O	236-239
with	O	240-244
disappearance	O	245-258
of	O	259-261
seizures	B	262-270
were	O	271-275
recognized	O	276-286
in	O	287-289
77	O	290-292
%	O	292-293
and	O	294-297
50	O	298-300
%	O	300-301
,	O	301-302
respectively	O	303-315
.	O	315-316

Seizures	B	317-325
disappeared	O	326-337
in	O	338-340
71	O	341-343
%	O	343-344
of	O	345-347
the	O	348-351
patients	O	352-360
with	O	361-365
generalized	O	366-377
seizures	B	378-386
and	O	387-390
89	O	391-393
%	O	393-394
of	O	395-397
partial	O	398-405
seizures	B	406-414
.	O	414-415

Improvement	O	416-427
of	O	428-430
abnormal	O	431-439
EEG	O	440-443
was	O	444-447
noticed	O	448-455
in	O	456-458
76	O	459-461
%	O	461-462
of	O	463-465
diffuse	O	466-473
paroxysms	O	474-483
and	O	484-487
in	O	488-490
67	O	491-493
%	O	493-494
of	O	495-497
focal	O	498-503
paroxysms	O	504-513
.	O	513-514

In	O	515-517
excellent	O	518-527
cases	O	528-533
,	O	533-534
mean	O	535-539
effective	O	540-549
dosages	O	550-557
were	O	558-562
0	O	563-564
.	O	564-565
086	O	565-568
+	O	569-570
/	O	570-571
-	O	571-572
0	O	573-574
.	O	574-575
021	O	575-578
mg	O	579-581
/	O	581-582
kg	O	582-584
/	O	581-582
day	O	585-588
in	O	589-591
infants	O	592-599
and	O	600-603
0	O	604-605
.	O	605-606
057	O	606-609
+	O	610-611
/	O	611-612
-	O	612-613
0	O	614-615
.	O	615-616
022	O	616-619
mg	O	620-622
/	O	622-623
kg	O	623-625
/	O	622-623
day	O	626-629
in	O	630-632
schoolchildren	O	633-647
,	O	647-648
this	O	649-653
difference	O	654-664
was	O	665-668
statistically	O	669-682
significant	O	683-694
(	O	695-696
p	O	696-697
less	O	698-702
than	O	703-707
0	O	708-709
.	O	709-710
005	O	710-713
)	O	713-714
.	O	709-710

The	O	716-719
incidence	O	720-729
of	O	730-732
side	O	733-737
effects	O	738-745
such	O	746-750
as	O	751-753
drowsiness	B	754-764
and	O	765-768
ataxia	B	769-775
was	O	776-779
only	O	780-784
5	O	785-786
%	O	786-787
.	O	787-788

Postmarketing	O	0-13
study	O	14-19
of	O	20-22
timolol	O	23-30
-	O	30-31
hydrochlorothiazide	O	31-50
antihypertensive	O	51-67
therapy	O	68-75
.	O	75-76

A	O	77-78
postmarketing	O	79-92
surveillance	O	93-105
study	O	106-111
was	O	112-115
conducted	O	116-125
to	O	126-128
determine	O	129-138
the	O	139-142
safety	O	143-149
and	O	150-153
efficacy	O	154-162
of	O	163-165
a	O	166-167
fixed	O	168-173
-	O	173-174
ratio	O	174-179
combination	O	180-191
containing	O	192-202
10	O	203-205
mg	O	206-208
of	O	209-211
timolol	O	212-219
maleate	O	220-227
and	O	228-231
25	O	232-234
mg	O	235-237
of	O	238-240
hydrochlorothiazide	O	241-260
,	O	260-261
administered	O	262-274
twice	O	275-280
daily	O	281-286
for	O	287-290
one	O	291-294
month	O	295-300
to	O	301-303
hypertensive	B	304-316
patients	O	317-325
.	O	325-326

Data	O	327-331
on	O	332-334
9	O	335-336
,	O	336-337
037	O	337-340
patients	O	341-349
were	O	350-354
collected	O	355-364
by	O	365-367
1	O	368-369
,	O	369-370
455	O	370-373
participating	O	374-387
physicians	O	388-398
.	O	398-399

Mean	O	400-404
systolic	O	405-413
blood	O	414-419
pressure	O	420-428
decreased	O	429-438
25	O	439-441
mmHg	O	442-446
and	O	447-450
mean	O	451-455
diastolic	O	456-465
blood	O	466-471
pressure	O	472-480
declined	O	481-489
15	O	490-492
mmHg	O	493-497
after	O	498-503
one	O	504-507
month	O	508-513
of	O	514-516
timolol	O	517-524
-	O	524-525
hydrochlorothiazide	O	525-544
therapy	O	545-552
(	O	553-554
P	O	554-555
less	O	556-560
than	O	561-565
0	O	566-567
.	O	567-568
01	O	568-570
,	O	570-571
both	O	572-576
comparisons	O	577-588
)	O	588-589
.	O	589-590

Age	O	591-594
,	O	594-595
race	O	596-600
,	O	600-601
and	O	602-605
sex	O	606-609
appeared	O	610-618
to	O	619-621
have	O	622-626
no	O	627-629
influence	O	630-639
on	O	640-642
the	O	643-646
decrease	O	647-655
in	O	656-658
blood	O	659-664
pressure	O	665-673
.	O	673-674

The	O	675-678
antihypertensive	O	679-695
effect	O	696-702
of	O	703-705
the	O	706-709
drug	O	710-714
was	O	715-718
greater	O	719-726
in	O	727-729
patients	O	730-738
with	O	739-743
more	O	744-748
severe	O	749-755
hypertension	B	756-768
.	O	768-769

Overall	O	770-777
,	O	777-778
1	O	779-780
,	O	780-781
453	O	781-784
patients	O	785-793
experienced	O	794-805
a	O	806-807
total	O	808-813
of	O	814-816
2	O	817-818
,	O	818-819
658	O	819-822
adverse	O	823-830
events	O	831-837
,	O	837-838
the	O	839-842
most	O	843-847
common	O	848-854
being	O	855-860
fatigue	B	861-868
,	O	868-869
dizziness	B	870-879
,	O	879-880
and	O	881-884
weakness	B	885-893
.	O	893-894

Treatment	O	895-904
in	O	905-907
590	O	908-911
patients	O	912-920
was	O	921-924
discontinued	O	925-937
because	O	938-945
of	O	946-948
adverse	O	949-956
events	O	957-963
.	O	963-964

Salicylate	O	0-10
nephropathy	B	11-22
in	O	23-25
the	O	26-29
Gunn	O	30-34
rat	O	35-38
:	O	38-39
potential	O	40-49
role	O	50-54
of	O	55-57
prostaglandins	O	58-72
.	O	72-73

We	O	74-76
examined	O	77-85
the	O	86-89
potential	O	90-99
role	O	100-104
of	O	105-107
prostaglandins	O	108-122
in	O	123-125
the	O	126-129
development	O	130-141
of	O	142-144
analgesic	O	145-154
nephropathy	B	155-166
in	O	167-169
the	O	170-173
Gunn	O	174-178
strain	O	179-185
of	O	186-188
rat	O	189-192
.	O	192-193

The	O	194-197
homozygous	O	198-208
Gunn	O	209-213
rats	O	214-218
have	O	219-223
unconjugated	O	224-236
hyperbilirubinemia	B	237-255
due	O	256-259
to	O	260-262
the	O	263-266
absence	O	267-274
of	O	275-277
glucuronyl	O	278-288
transferase	O	289-300
,	O	300-301
leading	O	302-309
to	O	310-312
marked	O	313-319
bilirubin	O	320-329
deposition	O	330-340
in	O	341-343
renal	O	344-349
medulla	O	350-357
and	O	358-361
papilla	O	362-369
.	O	369-370

These	O	371-376
rats	O	377-381
are	O	382-385
also	O	386-390
highly	O	391-397
susceptible	O	398-409
to	O	410-412
develop	O	413-420
papillary	B	421-430
necrosis	I	431-439
with	O	440-444
analgesic	O	445-454
administration	O	455-469
.	O	469-470

We	O	471-473
used	O	474-478
homozygous	O	479-489
(	O	490-491
jj	O	491-493
)	O	493-494
and	O	495-498
phenotypically	O	499-513
normal	O	514-520
heterozygous	O	521-533
(	O	534-535
jJ	O	535-537
)	O	537-538
animals	O	539-546
.	O	546-547

Four	O	548-552
groups	O	553-559
of	O	560-562
rats	O	563-567
(	O	568-569
n	O	569-570
=	O	571-572
7	O	573-574
)	O	574-575
were	O	576-580
studied	O	581-588
:	O	588-589
jj	O	590-592
and	O	593-596
jJ	O	597-599
rats	O	600-604
treated	O	605-612
either	O	613-619
with	O	620-624
aspirin	O	625-632
300	O	633-636
mg	O	637-639
/	O	639-640
kg	O	640-642
every	O	643-648
other	O	649-654
day	O	655-658
or	O	659-661
sham	O	662-666
-	O	666-667
treated	O	667-674
.	O	674-675

After	O	676-681
one	O	682-685
week	O	686-690
,	O	690-691
slices	O	692-698
of	O	699-701
cortex	O	702-708
,	O	708-709
outer	O	710-715
and	O	716-719
inner	O	720-725
medulla	O	726-733
from	O	734-738
one	O	739-742
kidney	O	743-749
were	O	750-754
incubated	O	755-764
in	O	765-767
buffer	O	768-774
and	O	775-778
prostaglandin	O	779-792
synthesis	O	793-802
was	O	803-806
determined	O	807-817
by	O	818-820
radioimmunoassay	O	821-837
.	O	837-838

The	O	839-842
other	O	843-848
kidney	O	849-855
was	O	856-859
examined	O	860-868
histologically	O	869-883
.	O	883-884

A	O	885-886
marked	O	887-893
corticomedullary	O	894-910
gradient	O	911-919
of	O	920-922
prostaglandin	O	923-936
synthesis	O	937-946
was	O	947-950
observed	O	951-959
in	O	960-962
all	O	963-966
groups	O	967-973
.	O	973-974

PGE2	O	975-979
synthesis	O	980-989
was	O	990-993
significantly	O	994-1007
higher	O	1008-1014
in	O	1015-1017
outer	O	1018-1023
medulla	O	1024-1031
,	O	1031-1032
but	O	1033-1036
not	O	1037-1040
cortex	O	1041-1047
or	O	1048-1050
inner	O	1051-1056
medulla	O	1057-1064
,	O	1064-1065
of	O	1066-1068
jj	O	1069-1071
(	O	1072-1073
38	O	1073-1075
+	O	1076-1077
/	O	1077-1078
-	O	1078-1079
6	O	1080-1081
ng	O	1082-1084
/	O	1084-1085
mg	O	1085-1087
prot	O	1088-1092
)	O	1092-1093
than	O	1094-1098
jJ	O	1099-1101
rats	O	1102-1106
(	O	1107-1108
15	O	1108-1110
+	O	1111-1112
/	O	1112-1113
-	O	1113-1114
3	O	1115-1116
)	O	1116-1117
(	O	1118-1119
p	O	1119-1120
less	O	1121-1125
than	O	1126-1130
0	O	1131-1132
.	O	1132-1133
01	O	1133-1135
)	O	1135-1136
.	O	1132-1133

Aspirin	O	1138-1145
treatment	O	1146-1155
reduced	O	1156-1163
PGE2	O	1164-1168
synthesis	O	1169-1178
in	O	1179-1181
all	O	1182-1185
regions	O	1186-1193
,	O	1193-1194
but	O	1195-1198
outer	O	1199-1204
medullary	O	1205-1214
PGE2	O	1215-1219
remained	O	1220-1228
higher	O	1229-1235
in	O	1236-1238
jj	O	1239-1241
(	O	1242-1243
18	O	1243-1245
+	O	1246-1247
/	O	1247-1248
-	O	1248-1249
3	O	1250-1251
)	O	1251-1252
than	O	1253-1257
jJ	O	1258-1260
rats	O	1261-1265
(	O	1266-1267
9	O	1267-1268
+	O	1269-1270
/	O	1270-1271
-	O	1271-1272
2	O	1273-1274
)	O	1274-1275
(	O	1276-1277
p	O	1277-1278
less	O	1279-1283
than	O	1284-1288
0	O	1289-1290
.	O	1290-1291
05	O	1291-1293
)	O	1293-1294
.	O	1290-1291

PGF2	O	1296-1300
alpha	O	1301-1306
was	O	1307-1310
also	O	1311-1315
significantly	O	1316-1329
higher	O	1330-1336
in	O	1337-1339
the	O	1340-1343
outer	O	1344-1349
medulla	O	1350-1357
of	O	1358-1360
jj	O	1361-1363
rats	O	1364-1368
with	O	1369-1373
and	O	1374-1377
without	O	1378-1385
aspirin	O	1386-1393
administration	O	1394-1408
(	O	1409-1410
p	O	1410-1411
less	O	1412-1416
than	O	1417-1421
0	O	1422-1423
.	O	1423-1424
05	O	1424-1426
)	O	1426-1427
.	O	1423-1424

The	O	1429-1432
changes	O	1433-1440
in	O	1441-1443
renal	O	1444-1449
prostaglandin	O	1450-1463
synthesis	O	1464-1473
were	O	1474-1478
accompanied	O	1479-1490
by	O	1491-1493
evidence	O	1494-1502
of	O	1503-1505
renal	B	1506-1511
damage	I	1512-1518
in	O	1519-1521
aspirin	O	1522-1529
-	O	1529-1530
treated	O	1530-1537
jj	O	1538-1540
but	O	1541-1544
not	O	1545-1548
jJ	O	1549-1551
rats	O	1552-1556
as	O	1557-1559
evidenced	O	1560-1569
by	O	1570-1572
:	O	1572-1573
increased	O	1574-1583
incidence	O	1584-1593
and	O	1594-1597
severity	O	1598-1606
of	O	1607-1609
hematuria	B	1610-1619
(	O	1620-1621
p	O	1621-1622
less	O	1623-1627
than	O	1628-1632
0	O	1633-1634
.	O	1634-1635
01	O	1635-1637
)	O	1637-1638
;	O	1638-1639
increased	O	1640-1649
serum	O	1650-1655
creatinine	O	1656-1666
(	O	1667-1668
p	O	1668-1669
less	O	1670-1674
than	O	1675-1679
0	O	1680-1681
.	O	1681-1682
05	O	1682-1684
)	O	1684-1685
;	O	1685-1686
and	O	1687-1690
increase	O	1691-1699
in	O	1700-1702
outer	O	1703-1708
medullary	O	1709-1718
histopathologic	O	1719-1734
lesions	O	1735-1742
(	O	1743-1744
p	O	1744-1745
less	O	1746-1750
than	O	1751-1755
0	O	1756-1757
.	O	1757-1758
005	O	1758-1761
compared	O	1762-1770
to	O	1771-1773
either	O	1774-1780
sham	O	1781-1785
-	O	1785-1786
treated	O	1786-1793
jj	O	1794-1796
or	O	1797-1799
aspirin	O	1800-1807
-	O	1807-1808
treated	O	1808-1815
jJ	O	1816-1818
)	O	1818-1819
.	O	1819-1820

These	O	1821-1826
results	O	1827-1834
suggest	O	1835-1842
that	O	1843-1847
enhanced	O	1848-1856
prostaglandin	O	1857-1870
synthesis	O	1871-1880
contributes	O	1881-1892
to	O	1893-1895
maintenance	O	1896-1907
of	O	1908-1910
renal	O	1911-1916
function	O	1917-1925
and	O	1926-1929
morphological	O	1930-1943
integrity	O	1944-1953
,	O	1953-1954
and	O	1955-1958
that	O	1959-1963
inhibition	O	1964-1974
of	O	1975-1977
prostaglandin	O	1978-1991
synthesis	O	1992-2001
may	O	2002-2005
lead	O	2006-2010
to	O	2011-2013
pathological	B	2014-2026
renal	I	2027-2032
medullary	I	2033-2042
lesions	I	2043-2050
and	O	2051-2054
deterioration	B	2055-2068
of	I	2069-2071
renal	I	2072-2077
function	I	2078-2086
.	O	2086-2087

Prophylactic	O	0-12
lidocaine	O	13-22
in	O	23-25
the	O	26-29
early	O	30-35
phase	O	36-41
of	O	42-44
suspected	O	45-54
myocardial	B	55-65
infarction	I	66-76
.	O	76-77

Four	O	78-82
hundred	O	83-90
two	O	91-94
patients	O	95-103
with	O	104-108
suspected	O	109-118
myocardial	B	119-129
infarction	I	130-140
seen	O	141-145
within	O	146-152
6	O	153-154
hours	O	155-160
of	O	161-163
the	O	164-167
onset	O	168-173
of	O	174-176
symptoms	O	177-185
entered	O	186-193
a	O	194-195
double	O	196-202
-	O	202-203
blind	O	203-208
randomized	O	209-219
trial	O	220-225
of	O	226-228
lidocaine	O	229-238
vs	O	239-241
placebo	O	242-249
.	O	249-250

During	O	251-257
the	O	258-261
1	O	262-263
hour	O	264-268
after	O	269-274
administration	O	275-289
of	O	290-292
the	O	293-296
drug	O	297-301
the	O	302-305
incidence	O	306-315
of	O	316-318
ventricular	B	319-330
fibrillation	I	331-343
or	O	344-346
sustained	O	347-356
ventricular	B	357-368
tachycardia	I	369-380
among	O	381-386
the	O	387-390
204	O	391-394
patients	O	395-403
with	O	404-408
acute	O	409-414
myocardial	B	415-425
infarction	I	426-436
was	O	437-440
low	O	441-444
,	O	444-445
1	O	446-447
.	O	447-448
5	O	448-449
%	O	449-450
.	O	447-448

Lidocaine	O	452-461
,	O	461-462
given	O	463-468
in	O	469-471
a	O	472-473
300	O	474-477
mg	O	478-480
dose	O	481-485
intramuscularly	O	486-501
followed	O	502-510
by	O	511-513
100	O	514-517
mg	O	518-520
intravenously	O	521-534
,	O	534-535
did	O	536-539
not	O	540-543
prevent	O	544-551
sustained	O	552-561
ventricular	B	562-573
tachycardia	I	574-585
,	O	585-586
although	O	587-595
there	O	596-601
was	O	602-605
a	O	606-607
significant	O	608-619
reduction	O	620-629
in	O	630-632
the	O	633-636
number	O	637-643
of	O	644-646
patients	O	647-655
with	O	656-660
warning	O	661-668
arrhythmias	B	669-680
between	O	681-688
15	O	689-691
and	O	692-695
45	O	696-698
minutes	O	699-706
after	O	707-712
the	O	713-716
administration	O	717-731
of	O	732-734
lidocaine	O	735-744
(	O	745-746
p	O	746-747
less	O	748-752
than	O	753-757
0	O	758-759
.	O	759-760
05	O	760-762
)	O	762-763
.	O	759-760

The	O	765-768
average	O	769-776
plasma	O	777-783
lidocaine	O	784-793
level	O	794-799
10	O	800-802
minutes	O	803-810
after	O	811-816
administration	O	817-831
for	O	832-835
patients	O	836-844
without	O	845-852
a	O	853-854
myocardial	B	855-865
infarction	I	866-876
was	O	877-880
significantly	O	881-894
higher	O	895-901
than	O	902-906
that	O	907-911
for	O	912-915
patients	O	916-924
with	O	925-929
an	O	930-932
acute	O	933-938
infarction	B	939-949
.	O	949-950

The	O	951-954
mean	O	955-959
plasma	O	960-966
lidocaine	O	967-976
level	O	977-982
of	O	983-985
patients	O	986-994
on	O	995-997
beta	O	998-1002
-	O	1002-1003
blocking	O	1003-1011
agents	O	1012-1018
was	O	1019-1022
no	O	1023-1025
different	O	1026-1035
from	O	1036-1040
that	O	1041-1045
in	O	1046-1048
patients	O	1049-1057
not	O	1058-1061
on	O	1062-1064
beta	O	1065-1069
blocking	O	1070-1078
agents	O	1079-1085
.	O	1085-1086

During	O	1087-1093
the	O	1094-1097
1	O	1098-1099
-	O	1099-1100
hour	O	1100-1104
study	O	1105-1110
period	O	1111-1117
,	O	1117-1118
the	O	1119-1122
incidence	O	1123-1132
of	O	1133-1135
central	O	1136-1143
nervous	O	1144-1151
system	O	1152-1158
side	O	1159-1163
effects	O	1164-1171
was	O	1172-1175
significantly	O	1176-1189
greater	O	1190-1197
in	O	1198-1200
the	O	1201-1204
lidocaine	O	1205-1214
group	O	1215-1220
,	O	1220-1221
hypotension	B	1222-1233
occurred	O	1234-1242
in	O	1243-1245
11	O	1246-1248
patients	O	1249-1257
,	O	1257-1258
nine	O	1259-1263
of	O	1264-1266
whom	O	1267-1271
had	O	1272-1275
received	O	1276-1284
lidocaine	O	1285-1294
,	O	1294-1295
and	O	1296-1299
four	O	1300-1304
patients	O	1305-1313
died	O	1314-1318
from	O	1319-1323
asystole	B	1324-1332
,	O	1332-1333
three	O	1334-1339
of	O	1340-1342
whom	O	1343-1347
had	O	1348-1351
had	O	1352-1355
lidocaine	O	1356-1365
.	O	1365-1366

We	O	1367-1369
cannot	O	1370-1376
advocate	O	1377-1385
the	O	1386-1389
administration	O	1390-1404
of	O	1405-1407
lidocaine	O	1408-1417
prophylactically	O	1418-1434
in	O	1435-1437
the	O	1438-1441
early	O	1442-1447
hours	O	1448-1453
of	O	1454-1456
suspected	O	1457-1466
myocardial	B	1467-1477
infarction	I	1478-1488
.	O	1488-1489

Evidence	O	0-8
for	O	9-12
a	O	13-14
cholinergic	O	15-26
role	O	27-31
in	O	32-34
haloperidol	O	35-46
-	O	46-47
induced	O	47-54
catalepsy	B	55-64
.	O	64-65

Experiments	O	66-77
in	O	78-80
mice	O	81-85
tested	O	86-92
previous	O	93-101
evidence	O	102-110
that	O	111-115
activation	O	116-126
of	O	127-129
cholinergic	O	130-141
systems	O	142-149
promotes	O	150-158
catalepsy	B	159-168
and	O	169-172
that	O	173-177
cholinergic	O	178-189
mechanisms	O	190-200
need	O	201-205
to	O	206-208
be	O	209-211
intact	O	212-218
for	O	219-222
full	O	223-227
expression	O	228-238
of	O	239-241
neuroleptic	O	242-253
-	O	253-254
induced	O	254-261
catalepsy	B	262-271
.	O	271-272

Large	O	273-278
doses	O	279-284
of	O	285-287
the	O	288-291
cholinomimetic	O	292-306
,	O	306-307
pilocarpine	O	308-319
,	O	319-320
could	O	321-326
induce	O	327-333
catalepsy	B	334-343
when	O	344-348
peripheral	O	349-359
cholinergic	O	360-371
receptors	O	372-381
were	O	382-386
blocked	O	387-394
.	O	394-395

Low	O	396-399
doses	O	400-405
of	O	406-408
pilocarpine	O	409-420
caused	O	421-427
a	O	428-429
pronounced	O	430-440
enhancement	O	441-452
of	O	453-455
the	O	456-459
catalepsy	B	460-469
that	O	470-474
was	O	475-478
induced	O	479-486
by	O	487-489
the	O	490-493
dopaminergic	O	494-506
blocker	O	507-514
,	O	514-515
haloperidol	O	516-527
.	O	527-528

A	O	529-530
muscarinic	O	531-541
receptor	O	542-550
blocker	O	551-558
,	O	558-559
atropine	O	560-568
,	O	568-569
disrupted	O	570-579
haloperidol	O	580-591
-	O	591-592
induced	O	592-599
catalepsy	B	600-609
.	O	609-610

Intracranial	O	611-623
injection	O	624-633
of	O	634-636
an	O	637-639
acetylcholine	O	640-653
-	O	653-654
synthesis	O	654-663
inhibitor	O	664-673
,	O	673-674
hemicholinium	O	675-688
,	O	688-689
prevented	O	690-699
the	O	700-703
catalepsy	B	704-713
that	O	714-718
is	O	719-721
usually	O	722-729
induced	O	730-737
by	O	738-740
haloperidol	O	741-752
.	O	752-753

These	O	754-759
findings	O	760-768
suggest	O	769-776
the	O	777-780
hypothesis	O	781-791
that	O	792-796
the	O	797-800
catalepsy	B	801-810
that	O	811-815
is	O	816-818
produced	O	819-827
by	O	828-830
neuroleptics	O	831-843
such	O	844-848
as	O	849-851
haloperidol	O	852-863
is	O	864-866
actually	O	867-875
mediated	O	876-884
by	O	885-887
intrinsic	O	888-897
central	O	898-905
cholinergic	O	906-917
systems	O	918-925
.	O	925-926

Alternatively	O	927-940
,	O	940-941
activation	O	942-952
of	O	953-955
central	O	956-963
cholinergic	O	964-975
systems	O	976-983
could	O	984-989
promote	O	990-997
catalepsy	B	998-1007
by	O	1008-1010
suppression	O	1011-1022
of	O	1023-1025
dopaminergic	O	1026-1038
systems	O	1039-1046
.	O	1046-1047

Cardiovascular	B	0-14
dysfunction	I	15-26
and	O	27-30
hypersensitivity	B	31-47
to	O	48-50
sodium	O	51-57
pentobarbital	O	58-71
induced	O	72-79
by	O	80-82
chronic	O	83-90
barium	O	91-97
chloride	O	98-106
ingestion	O	107-116
.	O	116-117

Barium	O	118-124
-	O	124-125
supplemented	O	125-137
Long	O	138-142
-	O	142-143
Evans	O	143-148
hooded	O	149-155
rats	O	156-160
were	O	161-165
characterized	O	166-179
by	O	180-182
a	O	183-184
persistent	O	185-195
hypertension	B	196-208
that	O	209-213
was	O	214-217
evident	O	218-225
after	O	226-231
1	O	232-233
month	O	234-239
of	O	240-242
barium	O	243-249
(	O	250-251
100	O	251-254
micrograms	O	255-265
/	O	265-266
ml	O	266-268
mineral	O	269-276
fortified	O	277-286
water	O	287-292
)	O	292-293
treatment	O	294-303
.	O	303-304

Analysis	O	305-313
of	O	314-316
in	O	317-319
vivo	O	320-324
myocardial	O	325-335
excitability	O	336-348
,	O	348-349
contractility	O	350-363
,	O	363-364
and	O	365-368
metabolic	O	369-378
characteristics	O	379-394
at	O	395-397
16	O	398-400
months	O	401-407
revealed	O	408-416
other	O	417-422
significant	O	423-434
barium	O	435-441
-	O	441-442
induced	O	442-449
disturbances	B	450-462
within	I	463-469
the	I	470-473
cardiovascular	I	474-488
system	I	489-495
.	O	495-496

The	O	497-500
most	O	501-505
distinctive	O	506-517
aspect	O	518-524
of	O	525-527
the	O	528-531
barium	O	532-538
effect	O	539-545
was	O	546-549
a	O	550-551
demonstrated	O	552-564
hypersensitivity	B	565-581
of	O	582-584
the	O	585-588
cardiovascular	O	589-603
system	O	604-610
to	O	611-613
sodium	O	614-620
pentobarbital	O	621-634
.	O	634-635

Under	O	636-641
barbiturate	O	642-653
anesthesia	O	654-664
,	O	664-665
virtually	O	666-675
all	O	676-679
of	O	680-682
the	O	683-686
myocardial	O	687-697
contractile	O	698-709
indices	O	710-717
were	O	718-722
depressed	O	723-732
significantly	O	733-746
in	O	747-749
barium	O	750-756
-	O	756-757
exposed	O	757-764
rats	O	765-769
relative	O	770-778
to	O	779-781
the	O	782-785
corresponding	O	786-799
control	O	800-807
-	O	807-808
fed	O	808-811
rats	O	812-816
.	O	816-817

The	O	818-821
lack	O	822-826
of	O	827-829
a	O	830-831
similar	O	832-839
response	O	840-848
to	O	849-851
ketamine	O	852-860
and	O	861-864
xylazine	O	865-873
anesthesia	O	874-884
revealed	O	885-893
that	O	894-898
the	O	899-902
cardiovascular	O	903-917
actions	O	918-925
of	O	926-928
sodium	O	929-935
pentobarbital	O	936-949
in	O	950-952
barium	O	953-959
-	O	959-960
treated	O	960-967
rats	O	968-972
were	O	973-977
linked	O	978-984
specifically	O	985-997
to	O	998-1000
this	O	1001-1005
anesthetic	O	1006-1016
,	O	1016-1017
and	O	1018-1021
were	O	1022-1026
not	O	1027-1030
representative	O	1031-1045
of	O	1046-1048
a	O	1049-1050
generalized	O	1051-1062
anesthetic	O	1063-1073
response	O	1074-1082
.	O	1082-1083

Other	O	1084-1089
myocardial	O	1090-1100
pathophysiologic	O	1101-1117
and	O	1118-1121
metabolic	O	1122-1131
changes	O	1132-1139
induced	O	1140-1147
by	O	1148-1150
barium	O	1151-1157
were	O	1158-1162
manifest	O	1163-1171
,	O	1171-1172
irrespective	O	1173-1185
of	O	1186-1188
the	O	1189-1192
anesthetic	O	1193-1203
employed	O	1204-1212
.	O	1212-1213

The	O	1214-1217
contractile	O	1218-1229
element	O	1230-1237
shortening	O	1238-1248
velocity	O	1249-1257
of	O	1258-1260
the	O	1261-1264
cardiac	O	1265-1272
muscle	O	1273-1279
fibers	O	1280-1286
was	O	1287-1290
significantly	O	1291-1304
slower	O	1305-1311
in	O	1312-1314
both	O	1315-1319
groups	O	1320-1326
of	O	1327-1329
barium	O	1330-1336
-	O	1336-1337
treated	O	1337-1344
rats	O	1345-1349
relative	O	1350-1358
to	O	1359-1361
the	O	1362-1365
control	O	1366-1373
groups	O	1374-1380
,	O	1380-1381
irrespective	O	1382-1394
of	O	1395-1397
the	O	1398-1401
anesthetic	O	1402-1412
regimen	O	1413-1420
.	O	1420-1421

Similarly	O	1422-1431
,	O	1431-1432
significant	O	1433-1444
disturbances	O	1445-1457
in	O	1458-1460
myocardial	O	1461-1471
energy	O	1472-1478
metabolism	O	1479-1489
were	O	1490-1494
detected	O	1495-1503
in	O	1504-1506
the	O	1507-1510
barium	O	1511-1517
-	O	1517-1518
exposed	O	1518-1525
rats	O	1526-1530
which	O	1531-1536
were	O	1537-1541
consistent	O	1542-1552
with	O	1553-1557
the	O	1558-1561
reduced	O	1562-1569
contractile	O	1570-1581
element	O	1582-1589
shortening	O	1590-1600
velocity	O	1601-1609
.	O	1609-1610

In	O	1611-1613
addition	O	1614-1622
,	O	1622-1623
the	O	1624-1627
excitability	O	1628-1640
of	O	1641-1643
the	O	1644-1647
cardiac	O	1648-1655
conduction	O	1656-1666
system	O	1667-1673
was	O	1674-1677
depressed	O	1678-1687
preferentially	O	1688-1702
in	O	1703-1705
the	O	1706-1709
atrioventricular	O	1710-1726
nodal	O	1727-1732
region	O	1733-1739
of	O	1740-1742
hearts	O	1743-1749
from	O	1750-1754
barium	O	1755-1761
-	O	1761-1762
exposed	O	1762-1769
rats	O	1770-1774
.	O	1774-1775

Overall	O	1776-1783
,	O	1783-1784
the	O	1785-1788
altered	O	1789-1796
cardiac	O	1797-1804
contractility	O	1805-1818
and	O	1819-1822
excitability	O	1823-1835
characteristics	O	1836-1851
,	O	1851-1852
the	O	1853-1856
myocardial	O	1857-1867
metabolic	B	1868-1877
disturbances	I	1878-1890
,	O	1890-1891
and	O	1892-1895
the	O	1896-1899
hypersensitivity	B	1900-1916
of	O	1917-1919
the	O	1920-1923
cardiovascular	O	1924-1938
system	O	1939-1945
to	O	1946-1948
sodium	O	1949-1955
pentobarbital	O	1956-1969
suggest	O	1970-1977
the	O	1978-1981
existence	O	1982-1991
of	O	1992-1994
a	O	1995-1996
heretofore	O	1997-2007
undescribed	O	2008-2019
cardiomyopathic	B	2020-2035
disorder	I	2036-2044
induced	O	2045-2052
by	O	2053-2055
chronic	O	2056-2063
barium	O	2064-2070
exposure	O	2071-2079
.	O	2079-2080

These	O	2081-2086
experimental	O	2087-2099
findings	O	2100-2108
represent	O	2109-2118
the	O	2119-2122
first	O	2123-2128
indication	O	2129-2139
that	O	2140-2144
life	O	2145-2149
-	O	2149-2150
long	O	2150-2154
barium	O	2155-2161
ingestion	O	2162-2171
may	O	2172-2175
have	O	2176-2180
significant	O	2181-2192
adverse	O	2193-2200
effects	O	2201-2208
on	O	2209-2211
the	O	2212-2215
mammalian	O	2216-2225
cardiovascular	O	2226-2240
system	O	2241-2247
.	O	2247-2248

Propranolol	O	0-11
antagonism	O	12-22
of	O	23-25
phenylpropanolamine	O	26-45
-	O	45-46
induced	O	46-53
hypertension	B	54-66
.	O	66-67

Phenylpropanolamine	O	68-87
(	O	88-89
PPA	O	89-92
)	O	92-93
overdose	B	94-102
can	O	103-106
cause	O	107-112
severe	O	113-119
hypertension	B	120-132
,	O	132-133
intracerebral	B	134-147
hemorrhage	I	148-158
,	O	158-159
and	O	160-163
death	O	164-169
.	O	169-170

We	O	171-173
studied	O	174-181
the	O	182-185
efficacy	O	186-194
and	O	195-198
safety	O	199-205
of	O	206-208
propranolol	O	209-220
in	O	221-223
the	O	224-227
treatment	O	228-237
of	O	238-240
PPA	O	241-244
-	O	244-245
induced	O	245-252
hypertension	B	253-265
.	O	265-266

Subjects	O	267-275
received	O	276-284
propranolol	O	285-296
either	O	297-303
by	O	304-306
mouth	O	307-312
for	O	313-316
48	O	317-319
hours	O	320-325
before	O	326-332
PPA	O	333-336
or	O	337-339
as	O	340-342
a	O	343-344
rapid	O	345-350
intravenous	O	351-362
infusion	O	363-371
after	O	372-377
PPA	O	378-381
.	O	381-382

PPA	O	383-386
,	O	386-387
75	O	388-390
mg	O	391-393
alone	O	394-399
,	O	399-400
increased	O	401-410
blood	O	411-416
pressure	O	417-425
(	O	426-427
31	O	427-429
+	O	430-431
/	O	431-432
-	O	432-433
14	O	434-436
mm	O	437-439
Hg	O	440-442
systolic	O	443-451
,	O	451-452
20	O	453-455
+	O	456-457
/	O	457-458
-	O	458-459
5	O	460-461
mm	O	462-464
Hg	O	465-467
diastolic	O	468-477
)	O	477-478
,	O	478-479
and	O	480-483
propranolol	O	484-495
pretreatment	O	496-508
antagonized	O	509-520
this	O	521-525
increase	O	526-534
(	O	535-536
12	O	536-538
+	O	539-540
/	O	540-541
-	O	541-542
10	O	543-545
mm	O	546-548
Hg	O	549-551
systolic	O	552-560
,	O	560-561
10	O	562-564
+	O	565-566
/	O	566-567
-	O	567-568
7	O	569-570
mm	O	571-573
Hg	O	574-576
diastolic	O	577-586
)	O	586-587
.	O	587-588

Intravenous	O	589-600
propranolol	O	601-612
after	O	613-618
PPA	O	619-622
also	O	623-627
decreased	O	628-637
blood	O	638-643
pressure	O	644-652
.	O	652-653

Left	O	654-658
ventricular	O	659-670
function	O	671-679
(	O	680-681
assessed	O	681-689
by	O	690-692
echocardiography	O	693-709
)	O	709-710
showed	O	711-717
that	O	718-722
PPA	O	723-726
increased	O	727-736
the	O	737-740
stroke	B	741-747
volume	O	748-754
30	O	755-757
%	O	757-758
(	O	759-760
from	O	760-764
62	O	765-767
.	O	767-768
5	O	768-769
+	O	770-771
/	O	771-772
-	O	772-773
20	O	774-776
.	O	776-777
9	O	777-778
to	O	779-781
80	O	782-784
.	O	784-785
8	O	782-783
+	O	787-788
/	O	788-789
-	O	789-790
22	O	791-793
.	O	793-794
4	O	794-795
ml	O	796-798
)	O	798-799
,	O	799-800
the	O	801-804
ejection	O	805-813
fraction	O	814-822
9	O	823-824
%	O	824-825
(	O	826-827
from	O	827-831
64	O	832-834
%	O	834-835
+	O	836-837
/	O	837-838
-	O	838-839
10	O	840-842
%	O	842-843
to	O	844-846
70	O	847-849
%	O	849-850
+	O	851-852
/	O	852-853
-	O	853-854
7	O	855-856
%	O	856-857
)	O	857-858
,	O	858-859
and	O	860-863
cardiac	O	864-871
output	O	872-878
14	O	879-881
%	O	881-882
(	O	883-884
from	O	884-888
3	O	889-890
.	O	890-891
6	O	891-892
+	O	893-894
/	O	894-895
-	O	895-896
0	O	897-898
.	O	898-899
6	O	899-900
to	O	901-903
4	O	904-905
.	O	905-906
1	O	906-907
+	O	908-909
/	O	909-910
-	O	910-911
1	O	912-913
.	O	913-914
0	O	914-915
L	O	916-917
/	O	917-918
min	O	918-921
)	O	921-922
.	O	922-923

Intravenous	O	924-935
propranolol	O	936-947
reversed	O	948-956
these	O	957-962
effects	O	963-970
.	O	970-971

Systemic	O	972-980
vascular	O	981-989
resistance	O	990-1000
was	O	1001-1004
increased	O	1005-1014
by	O	1015-1017
PPA	O	1018-1021
28	O	1022-1024
%	O	1024-1025
(	O	1026-1027
from	O	1027-1031
1710	O	1032-1036
+	O	1037-1038
/	O	1038-1039
-	O	1039-1040
200	O	1041-1044
to	O	1045-1047
2190	O	1048-1052
+	O	1053-1054
/	O	1054-1055
-	O	1055-1056
700	O	1057-1060
dyne	O	1061-1065
X	O	1066-1067
sec	O	1068-1071
/	O	1071-1072
cm5	O	1072-1075
)	O	1075-1076
and	O	1077-1080
was	O	1081-1084
further	O	1085-1092
increased	O	1093-1102
by	O	1103-1105
propranolol	O	1106-1117
22	O	1118-1120
%	O	1120-1121
(	O	1122-1123
to	O	1123-1125
2660	O	1126-1130
+	O	1131-1132
/	O	1132-1133
-	O	1133-1134
1200	O	1135-1139
dyne	O	1140-1144
X	O	1145-1146
sec	O	1147-1150
/	O	1150-1151
cm5	O	1151-1154
)	O	1154-1155
.	O	1155-1156

We	O	1157-1159
conclude	O	1160-1168
that	O	1169-1173
PPA	O	1174-1177
increases	O	1178-1187
blood	O	1188-1193
pressure	O	1194-1202
by	O	1203-1205
increasing	O	1206-1216
systemic	O	1217-1225
vascular	O	1226-1234
resistance	O	1235-1245
and	O	1246-1249
cardiac	O	1250-1257
output	O	1258-1264
,	O	1264-1265
and	O	1266-1269
that	O	1270-1274
propranolol	O	1275-1286
antagonizes	O	1287-1298
this	O	1299-1303
increase	O	1304-1312
by	O	1313-1315
reversing	O	1316-1325
the	O	1326-1329
effect	O	1330-1336
of	O	1337-1339
PPA	O	1340-1343
on	O	1344-1346
cardiac	O	1347-1354
output	O	1355-1361
.	O	1361-1362

That	O	1363-1367
propranolol	O	1368-1379
antagonizes	O	1380-1391
the	O	1392-1395
pressor	O	1396-1403
effect	O	1404-1410
of	O	1411-1413
PPA	O	1414-1417
is	O	1418-1420
in	O	1421-1423
contrast	O	1424-1432
to	O	1433-1435
the	O	1436-1439
interaction	O	1440-1451
in	O	1452-1454
which	O	1455-1460
propranolol	O	1461-1472
enhances	O	1473-1481
the	O	1482-1485
pressor	O	1486-1493
effect	O	1494-1500
of	O	1501-1503
norepinephrine	O	1504-1518
.	O	1518-1519

This	O	1520-1524
is	O	1525-1527
probably	O	1528-1536
because	O	1537-1544
PPA	O	1545-1548
has	O	1549-1552
less	O	1553-1557
beta	O	1558-1562
2	O	1563-1564
activity	O	1565-1573
than	O	1574-1578
does	O	1579-1583
norepinephrine	O	1584-1598
.	O	1598-1599

Mesangial	O	0-9
function	O	10-18
and	O	19-22
glomerular	B	23-33
sclerosis	I	34-43
in	O	44-46
rats	O	47-51
with	O	52-56
aminonucleoside	O	57-72
nephrosis	B	73-82
.	O	82-83

The	O	84-87
possible	O	88-96
relationship	O	97-109
between	O	110-117
mesangial	B	118-127
dysfunction	I	128-139
and	O	140-143
development	O	144-155
of	O	156-158
glomerular	B	159-169
sclerosis	I	170-179
was	O	180-183
studied	O	184-191
in	O	192-194
the	O	195-198
puromycin	O	199-208
aminonucleoside	O	209-224
(	O	225-226
PAN	O	226-229
)	O	229-230
model	O	231-236
.	O	236-237

Five	O	238-242
male	O	243-247
Wistar	O	248-254
rats	O	255-259
received	O	260-268
repeated	O	269-277
subcutaneous	O	278-290
PAN	O	291-294
injections	O	295-305
;	O	305-306
five	O	307-311
controls	O	312-320
received	O	321-329
saline	O	330-336
only	O	337-341
.	O	341-342

After	O	343-348
4	O	349-350
weeks	O	351-356
the	O	357-360
PAN	O	361-364
rats	O	365-369
were	O	370-374
severely	O	375-383
proteinuric	B	384-395
(	O	396-397
190	O	397-400
+	O	401-402
/	O	402-403
-	O	403-404
80	O	405-407
mg	O	408-410
/	O	410-411
24	O	411-413
hr	O	414-416
)	O	416-417
,	O	417-418
and	O	419-422
all	O	423-426
rats	O	427-431
were	O	432-436
given	O	437-442
colloidal	O	443-452
carbon	O	453-459
(	O	460-461
CC	O	461-463
)	O	463-464
intravenously	O	465-478
.	O	478-479

At	O	480-482
5	O	483-484
months	O	485-491
glomerular	B	492-502
sclerosis	I	503-512
was	O	513-516
found	O	517-522
in	O	523-525
7	O	526-527
.	O	527-528
6	O	528-529
+	O	530-531
/	O	531-532
-	O	532-533
3	O	534-535
.	O	535-536
4	O	536-537
%	O	537-538
of	O	539-541
the	O	542-545
glomeruli	O	546-555
of	O	556-558
PAN	O	559-562
rats	O	563-567
;	O	567-568
glomeruli	O	569-578
of	O	579-581
the	O	582-585
controls	O	586-594
were	O	595-599
normal	O	600-606
.	O	606-607

Glomeruli	O	608-617
of	O	618-620
PAN	O	621-624
rats	O	625-629
contained	O	630-639
significantly	O	640-653
more	O	654-658
CC	O	659-661
than	O	662-666
glomeruli	O	667-676
of	O	677-679
controls	O	680-688
.	O	688-689

Glomeruli	O	690-699
with	O	700-704
sclerosis	B	705-714
contained	O	715-724
significantly	O	725-738
more	O	739-743
CC	O	744-746
than	O	747-751
non	O	752-755
-	O	755-756
sclerotic	O	756-765
glomeruli	O	766-775
in	O	776-778
the	O	779-782
same	O	783-787
kidneys	O	788-795
.	O	795-796

CC	O	797-799
was	O	800-803
preferentially	O	804-818
localized	O	819-828
within	O	829-835
the	O	836-839
sclerotic	O	840-849
areas	O	850-855
of	O	856-858
the	O	859-862
affected	O	863-871
glomeruli	O	872-881
.	O	881-882

Since	O	883-888
mesangial	O	889-898
CC	O	899-901
clearance	O	902-911
from	O	912-916
the	O	917-920
mesangium	O	921-930
did	O	931-934
not	O	935-938
change	O	939-945
during	O	946-952
chronic	O	953-960
PAN	O	961-964
treatment	O	965-974
,	O	974-975
we	O	976-978
conclude	O	979-987
that	O	988-992
this	O	993-997
preferential	O	998-1010
CC	O	1011-1013
localization	O	1014-1026
within	O	1027-1033
the	O	1034-1037
lesions	O	1038-1045
is	O	1046-1048
caused	O	1049-1055
by	O	1056-1058
an	O	1059-1061
increased	O	1062-1071
CC	O	1072-1074
uptake	O	1075-1081
shortly	O	1082-1089
after	O	1090-1095
injection	O	1096-1105
in	O	1106-1108
apparent	O	1109-1117
vulnerable	O	1118-1128
areas	O	1129-1134
where	O	1135-1140
sclerosis	B	1141-1150
will	O	1151-1155
develop	O	1156-1163
subsequently	O	1164-1176
.	O	1176-1177

Cluster	O	1178-1185
analysis	O	1186-1194
showed	O	1195-1201
a	O	1202-1203
random	O	1204-1210
distribution	O	1211-1223
of	O	1224-1226
lesions	O	1227-1234
in	O	1235-1237
the	O	1238-1241
PAN	O	1242-1245
glomeruli	O	1246-1255
in	O	1256-1258
concordance	O	1259-1270
with	O	1271-1275
the	O	1276-1279
random	O	1280-1286
localization	O	1287-1299
of	O	1300-1302
mesangial	O	1303-1312
areas	O	1313-1318
with	O	1319-1323
dysfunction	O	1324-1335
in	O	1336-1338
this	O	1339-1343
model	O	1344-1349
.	O	1349-1350

Similar	O	1351-1358
to	O	1359-1361
the	O	1362-1365
remnant	O	1366-1373
kidney	O	1374-1380
model	O	1381-1386
in	O	1387-1389
PAN	O	1390-1393
nephrosis	B	1394-1403
the	O	1404-1407
development	O	1408-1419
of	O	1420-1422
glomerular	B	1423-1433
sclerosis	I	1434-1443
may	O	1444-1447
be	O	1448-1450
related	O	1451-1458
to	O	1459-1461
"	O	1462-1463
mesangial	O	1463-1472
overloading	O	1473-1484
.	O	1484-1485
"	O	1485-1486

Relationship	O	0-12
between	O	13-20
nicotine	O	21-29
-	O	29-30
induced	O	30-37
seizures	B	38-46
and	O	47-50
hippocampal	O	51-62
nicotinic	O	63-72
receptors	O	73-82
.	O	82-83

A	O	84-85
controversy	O	86-97
has	O	98-101
existed	O	102-109
for	O	110-113
several	O	114-121
years	O	122-127
concerning	O	128-138
the	O	139-142
physiological	O	143-156
relevance	O	157-166
of	O	167-169
the	O	170-173
nicotinic	O	174-183
receptor	O	184-192
measured	O	193-201
by	O	202-204
alpha	O	205-210
-	O	210-211
bungarotoxin	O	211-223
binding	O	224-231
.	O	231-232

Using	O	233-238
mice	O	239-243
derived	O	244-251
from	O	252-256
a	O	257-258
classical	O	259-268
F2	O	269-271
and	O	272-275
backcross	O	276-285
genetic	O	286-293
design	O	294-300
,	O	300-301
a	O	302-303
relationship	O	304-316
between	O	317-324
nicotine	O	325-333
-	O	333-334
induced	O	334-341
seizures	B	342-350
and	O	351-354
alpha	O	355-360
-	O	360-361
bungarotoxin	O	361-373
nicotinic	O	374-383
receptor	O	384-392
concentration	O	393-406
was	O	407-410
found	O	411-416
.	O	416-417

Mice	O	418-422
sensitive	O	423-432
to	O	433-435
the	O	436-439
convulsant	O	440-450
effects	O	451-458
of	O	459-461
nicotine	O	462-470
had	O	471-474
greater	O	475-482
alpha	O	483-488
-	O	488-489
bungarotoxin	O	489-501
binding	O	502-509
in	O	510-512
the	O	513-516
hippocampus	O	517-528
than	O	529-533
seizure	B	534-541
insensitive	O	542-553
mice	O	554-558
.	O	558-559

The	O	560-563
binding	O	564-571
sites	O	572-577
from	O	578-582
seizure	B	583-590
sensitive	O	591-600
and	O	601-604
resistant	O	605-614
mice	O	615-619
were	O	620-624
equally	O	625-632
affected	O	633-641
by	O	642-644
treatment	O	645-654
with	O	655-659
dithiothreitol	O	660-674
,	O	674-675
trypsin	O	676-683
or	O	684-686
heat	O	687-691
.	O	691-692

Thus	O	693-697
it	O	698-700
appears	O	701-708
that	O	709-713
the	O	714-717
difference	O	718-728
between	O	729-736
seizure	B	737-744
sensitive	O	745-754
and	O	755-758
insensitive	O	759-770
animals	O	771-778
may	O	779-782
be	O	783-785
due	O	786-789
to	O	790-792
a	O	793-794
difference	O	795-805
in	O	806-808
hippocampal	O	809-820
nicotinic	O	821-830
receptor	O	831-839
concentration	O	840-853
as	O	854-856
measured	O	857-865
with	O	866-870
alpha	O	871-876
-	O	876-877
bungarotoxin	O	877-889
binding	O	890-897
.	O	897-898

The	O	0-3
role	O	4-8
of	O	9-11
p	O	12-13
-	O	13-14
aminophenol	O	14-25
in	O	26-28
acetaminophen	O	29-42
-	O	42-43
induced	O	43-50
nephrotoxicity	B	51-65
:	O	65-66
effect	O	67-73
of	O	74-76
bis	O	77-80
(	O	80-81
p	O	81-82
-	O	82-83
nitrophenyl	O	83-94
)	O	94-95
phosphate	O	96-105
on	O	106-108
acetaminophen	O	109-122
and	O	123-126
p	O	127-128
-	O	128-129
aminophenol	O	129-140
nephrotoxicity	B	141-155
and	O	156-159
metabolism	O	160-170
in	O	171-173
Fischer	O	174-181
344	O	182-185
rats	O	186-190
.	O	190-191

Acetaminophen	O	192-205
(	O	206-207
APAP	O	207-211
)	O	211-212
produces	O	213-221
proximal	O	222-230
tubular	B	231-238
necrosis	I	239-247
in	O	248-250
Fischer	O	251-258
344	O	259-262
(	O	263-264
F344	O	264-268
)	O	268-269
rats	O	270-274
.	O	274-275

Recently	O	276-284
,	O	284-285
p	O	286-287
-	O	287-288
aminophenol	O	288-299
(	O	300-301
PAP	O	301-304
)	O	304-305
,	O	305-306
a	O	307-308
known	O	309-314
potent	O	315-321
nephrotoxicant	O	322-336
,	O	336-337
was	O	338-341
identified	O	342-352
as	O	353-355
a	O	356-357
metabolite	O	358-368
of	O	369-371
APAP	O	372-376
in	O	377-379
F344	O	380-384
rats	O	385-389
.	O	389-390

The	O	391-394
purpose	O	395-402
of	O	403-405
this	O	406-410
study	O	411-416
was	O	417-420
to	O	421-423
determine	O	424-433
if	O	434-436
PAP	O	437-440
formation	O	441-450
is	O	451-453
a	O	454-455
requisite	O	456-465
step	O	466-470
in	O	471-473
APAP	O	474-478
-	O	478-479
induced	O	479-486
nephrotoxicity	B	487-501
.	O	501-502

Therefore	O	503-512
,	O	512-513
the	O	514-517
effect	O	518-524
of	O	525-527
bis	O	528-531
(	O	531-532
p	O	532-533
-	O	533-534
nitrophenyl	O	534-545
)	O	545-546
phosphate	O	547-556
(	O	557-558
BNPP	O	558-562
)	O	562-563
,	O	563-564
an	O	565-567
acylamidase	O	568-579
inhibitor	O	580-589
,	O	589-590
on	O	591-593
APAP	O	594-598
and	O	599-602
PAP	O	603-606
nephrotoxicity	B	607-621
and	O	622-625
metabolism	O	626-636
was	O	637-640
determined	O	641-651
.	O	651-652

BNPP	O	653-657
(	O	658-659
1	O	659-660
to	O	661-663
8	O	664-665
mM	O	666-668
)	O	668-669
reduced	O	670-677
APAP	O	678-682
deacetylation	O	683-696
and	O	697-700
covalent	O	701-709
binding	O	710-717
in	O	718-720
F344	O	721-725
renal	O	726-731
cortical	O	732-740
homogenates	O	741-752
in	O	753-755
a	O	756-757
concentration	O	758-771
-	O	771-772
dependent	O	772-781
manner	O	782-788
.	O	788-789

Pretreatment	O	790-802
of	O	803-805
animals	O	806-813
with	O	814-818
BNPP	O	819-823
prior	O	824-829
to	O	830-832
APAP	O	833-837
or	O	838-840
PAP	O	841-844
administration	O	845-859
resulted	O	860-868
in	O	869-871
marked	O	872-878
reduction	O	879-888
of	O	889-891
APAP	O	892-896
(	O	897-898
900	O	898-901
mg	O	902-904
/	O	904-905
kg	O	905-907
)	O	907-908
nephrotoxicity	B	909-923
but	O	924-927
not	O	928-931
PAP	O	932-935
nephrotoxicity	B	936-950
.	O	950-951

This	O	952-956
result	O	957-963
was	O	964-967
not	O	968-971
due	O	972-975
to	O	976-978
altered	O	979-986
disposition	O	987-998
of	O	999-1001
either	O	1002-1008
APAP	O	1009-1013
or	O	1014-1016
acetylated	O	1017-1027
metabolites	O	1028-1039
in	O	1040-1042
plasma	O	1043-1049
or	O	1050-1052
renal	O	1053-1058
cortical	O	1059-1067
and	O	1068-1071
hepatic	O	1072-1079
tissue	O	1080-1086
.	O	1086-1087

Rather	O	1088-1094
,	O	1094-1095
BNPP	O	1096-1100
pretreatment	O	1101-1113
reduced	O	1114-1121
the	O	1122-1125
fraction	O	1126-1134
of	O	1135-1137
APAP	O	1138-1142
excreted	O	1143-1151
as	O	1152-1154
PAP	O	1155-1158
by	O	1159-1161
64	O	1162-1164
and	O	1165-1168
75	O	1169-1171
%	O	1171-1172
after	O	1173-1178
APAP	O	1179-1183
doses	O	1184-1189
of	O	1190-1192
750	O	1193-1196
and	O	1197-1200
900	O	1201-1204
mg	O	1205-1207
/	O	1207-1208
kg	O	1208-1210
.	O	1210-1211

BNPP	O	1212-1216
did	O	1217-1220
not	O	1221-1224
alter	O	1225-1230
the	O	1231-1234
excretion	O	1235-1244
of	O	1245-1247
APAP	O	1248-1252
or	O	1253-1255
any	O	1256-1259
of	O	1260-1262
its	O	1263-1266
non	O	1267-1270
-	O	1270-1271
deacetylated	O	1271-1283
metabolites	O	1284-1295
nor	O	1296-1299
did	O	1300-1303
BNPP	O	1304-1308
alter	O	1309-1314
excretion	O	1315-1324
of	O	1325-1327
PAP	O	1328-1331
or	O	1332-1334
its	O	1335-1338
metabolites	O	1339-1350
after	O	1351-1356
PAP	O	1357-1360
doses	O	1361-1366
of	O	1367-1369
150	O	1370-1373
and	O	1374-1377
300	O	1378-1381
mg	O	1382-1384
/	O	1384-1385
kg	O	1385-1387
.	O	1387-1388

Therefore	O	1389-1398
,	O	1398-1399
the	O	1400-1403
BNPP	O	1404-1408
-	O	1408-1409
induced	O	1409-1416
reduction	O	1417-1426
in	O	1427-1429
APAP	O	1430-1434
-	O	1434-1435
induced	O	1435-1442
nephrotoxicity	B	1443-1457
appears	O	1458-1465
to	O	1466-1468
be	O	1469-1471
due	O	1472-1475
to	O	1476-1478
inhibition	O	1479-1489
of	O	1490-1492
APAP	O	1493-1497
deacetylation	O	1498-1511
.	O	1511-1512

It	O	1513-1515
is	O	1516-1518
concluded	O	1519-1528
that	O	1529-1533
PAP	O	1534-1537
formation	O	1538-1547
,	O	1547-1548
in	O	1549-1551
vivo	O	1552-1556
,	O	1556-1557
accounts	O	1558-1566
,	O	1566-1567
at	O	1568-1570
least	O	1571-1576
in	O	1577-1579
part	O	1580-1584
,	O	1584-1585
for	O	1586-1589
APAP	O	1590-1594
-	O	1594-1595
induced	O	1595-1602
renal	B	1603-1608
tubular	I	1609-1616
necrosis	I	1617-1625
.	O	1625-1626

Morphine	O	0-8
-	O	8-9
induced	O	9-16
seizures	B	17-25
in	O	26-28
newborn	O	29-36
infants	O	37-44
.	O	44-45

Two	O	46-49
neonates	O	50-58
suffered	O	59-67
from	O	68-72
generalized	O	73-84
seizures	B	85-93
during	O	94-100
the	O	101-104
course	O	105-111
of	O	112-114
intravenous	O	115-126
morphine	O	127-135
sulfate	O	136-143
for	O	144-147
post	O	148-152
-	O	152-153
operative	O	153-162
analgesia	O	163-172
.	O	172-173

They	O	174-178
received	O	179-187
morphine	O	188-196
in	O	197-199
doses	O	200-205
of	O	206-208
32	O	209-211
micrograms	O	212-222
/	O	222-223
kg	O	223-225
/	O	222-223
hr	O	226-228
and	O	229-232
40	O	233-235
micrograms	O	236-246
/	O	246-247
kg	O	247-249
/	O	246-247
hr	O	250-252
larger	O	253-259
than	O	260-264
a	O	265-266
group	O	267-272
of	O	273-275
10	O	276-278
neonates	O	279-287
who	O	288-291
received	O	292-300
6	O	301-302
-	O	302-303
24	O	303-305
micrograms	O	306-316
/	O	316-317
kg	O	317-319
/	O	316-317
hr	O	320-322
and	O	323-326
had	O	327-330
no	O	331-333
seizures	B	334-342
.	O	342-343

Plasma	O	344-350
concentrations	O	351-365
of	O	366-368
morphine	O	369-377
in	O	378-380
these	O	381-386
neonates	O	387-395
was	O	396-399
excessive	O	400-409
(	O	410-411
60	O	411-413
and	O	414-417
90	O	418-420
mg	O	421-423
/	O	423-424
ml	O	424-426
)	O	426-427
.	O	427-428

Other	O	429-434
known	O	435-440
reasons	O	441-448
for	O	449-452
seizures	B	453-461
were	O	462-466
ruled	O	467-472
out	O	473-476
and	O	477-480
the	O	481-484
convulsions	B	485-496
stopped	O	497-504
a	O	505-506
few	O	507-510
hours	O	511-516
after	O	517-522
cessation	O	523-532
of	O	533-535
morphine	O	536-544
and	O	545-548
did	O	549-552
not	O	553-556
reoccur	O	557-564
in	O	565-567
the	O	568-571
subsequent	O	572-582
8	O	583-584
months	O	585-591
.	O	591-592

It	O	593-595
is	O	596-598
suggested	O	599-608
that	O	609-613
post	O	614-618
-	O	618-619
operative	O	619-628
intravenous	O	629-640
morphine	O	641-649
should	O	650-656
not	O	657-660
exceed	O	661-667
20	O	668-670
micrograms	O	671-681
/	O	681-682
kg	O	682-684
/	O	681-682
ml	O	685-687
in	O	688-690
neonates	O	691-699
.	O	699-700

Effect	O	0-6
of	O	7-9
vincristine	O	10-21
sulfate	O	22-29
on	O	30-32
Pseudomonas	B	33-44
infections	I	45-55
in	O	56-58
monkeys	O	59-66
.	O	66-67

In	O	68-70
rhesus	O	71-77
monkeys	O	78-85
,	O	85-86
intravenous	O	87-98
challenge	O	99-108
with	O	109-113
0	O	114-115
.	O	115-116
6	O	116-117
x	O	118-119
10	O	120-122
(	O	122-123
10	O	120-122
)	O	125-126
to	O	127-129
2	O	130-131
.	O	131-132
2	O	130-131
x	O	134-135
10	O	136-138
(	O	138-139
10	O	136-138
)	O	141-142
Pseudomonas	O	142-153
aeruginosa	O	154-164
organisms	O	165-174
caused	O	175-181
acute	O	182-187
illness	O	188-195
of	O	196-198
4	O	199-200
to	O	201-203
5	O	204-205
days	O	206-210
'	O	210-211
duration	O	212-220
with	O	221-225
spontaneous	O	226-237
recovery	O	238-246
in	O	247-249
13	O	250-252
of	O	253-255
15	O	256-258
monkeys	O	259-266
;	O	266-267
blood	O	268-273
cultures	O	274-282
became	O	283-289
negative	O	290-298
3	O	299-300
to	O	301-303
17	O	304-306
days	O	307-311
after	O	312-317
challenge	O	318-327
.	O	327-328

Leukocytosis	B	329-341
was	O	342-345
observed	O	346-354
in	O	355-357
all	O	358-361
monkeys	O	362-369
.	O	369-370

Intravenous	O	371-382
or	O	383-385
intratracheal	O	386-399
inoculation	O	400-411
of	O	412-414
2	O	415-416
.	O	416-417
0	O	417-418
to	O	419-421
2	O	422-423
.	O	423-424
5	O	424-425
mg	O	426-428
of	O	429-431
vincristine	O	432-443
sulfate	O	444-451
was	O	452-455
followed	O	456-464
by	O	465-467
leukopenia	B	468-478
in	O	479-481
4	O	482-483
to	O	484-486
5	O	487-488
days	O	489-493
.	O	493-494

Intravenous	O	495-506
inoculation	O	507-518
of	O	519-521
4	O	522-523
.	O	523-524
2	O	524-525
x	O	526-527
10	O	528-530
(	O	530-531
10	O	528-530
)	O	533-534
to	O	535-537
7	O	538-539
.	O	539-540
8	O	540-541
x	O	542-543
10	O	544-546
(	O	546-547
10	O	544-546
)	O	549-550
pyocin	O	551-557
type	O	558-562
6	O	563-564
Pseudomonas	O	565-576
organisms	O	577-586
in	O	587-589
monkeys	O	590-597
given	O	598-603
vincristine	O	604-615
sulfate	O	616-623
4	O	624-625
days	O	626-630
previously	O	631-641
resulted	O	642-650
in	O	651-653
fatal	O	654-659
infection	B	660-669
in	O	670-672
11	O	673-675
of	O	676-678
14	O	679-681
monkeys	O	682-689
,	O	689-690
whereas	O	691-698
none	O	699-703
of	O	704-706
four	O	707-711
receiving	O	712-721
Pseudomonas	O	722-733
alone	O	734-739
died	O	740-744
.	O	744-745

These	O	746-751
studies	O	752-759
suggest	O	760-767
that	O	768-772
an	O	773-775
antimetabolite	O	776-790
-	O	790-791
induced	O	791-798
leukopenia	B	799-809
predisposes	O	810-821
to	O	822-824
severe	O	825-831
Pseudomonas	O	832-843
sepsis	B	844-850
and	O	851-854
that	O	855-859
such	O	860-864
monkeys	O	865-872
may	O	873-876
serve	O	877-882
as	O	883-885
a	O	886-887
biological	O	888-898
model	O	899-904
for	O	905-908
study	O	909-914
of	O	915-917
comparative	O	918-929
efficacy	O	930-938
of	O	939-941
antimicrobial	O	942-955
agents	O	956-962
.	O	962-963

Central	O	0-7
excitatory	O	8-18
actions	O	19-26
of	O	27-29
flurazepam	O	30-40
.	O	40-41

Toxic	O	42-47
actions	O	48-55
of	O	56-58
flurazepam	O	59-69
(	O	70-71
FZP	O	71-74
)	O	74-75
were	O	76-80
studied	O	81-88
in	O	89-91
cats	O	92-96
,	O	96-97
mice	O	98-102
and	O	103-106
rats	O	107-111
.	O	111-112

High	O	113-117
doses	O	118-123
caused	O	124-130
an	O	131-133
apparent	O	134-142
central	O	143-150
excitation	O	151-161
,	O	161-162
most	O	163-167
clearly	O	168-175
seen	O	176-180
as	O	181-183
clonic	O	184-190
convulsions	B	191-202
,	O	202-203
superimposed	O	204-216
on	O	217-219
general	O	220-227
depression	B	228-238
.	O	238-239

Following	O	240-249
a	O	250-251
lethal	O	252-258
dose	O	259-263
,	O	263-264
death	O	265-270
was	O	271-274
always	O	275-281
associated	O	282-292
with	O	293-297
convulsions	B	298-309
.	O	309-310

Comparing	O	311-320
the	O	321-324
relative	O	325-333
sensitivity	O	334-345
to	O	346-348
central	O	349-356
depression	B	357-367
and	O	368-371
excitation	O	372-382
revealed	O	383-391
that	O	392-396
rats	O	397-401
were	O	402-406
least	O	407-412
likely	O	413-419
to	O	420-422
have	O	423-427
convulsions	B	428-439
at	O	440-442
doses	O	443-448
that	O	449-453
did	O	454-457
not	O	458-461
first	O	462-467
cause	O	468-473
loss	B	474-478
of	I	479-481
consciousness	I	482-495
,	O	495-496
while	O	497-502
cats	O	503-507
most	O	508-512
clearly	O	513-520
showed	O	521-527
marked	O	528-534
central	O	535-542
excitatory	O	543-553
actions	O	554-561
.	O	561-562

Signs	O	563-568
of	O	569-571
FZP	O	572-575
toxocity	B	576-584
in	O	585-587
cats	O	588-592
included	O	593-601
excessive	O	602-611
salivation	B	612-622
,	O	622-623
extreme	O	624-631
apprehensive	O	632-644
behavior	O	645-653
,	O	653-654
retching	O	655-663
,	O	663-664
muscle	B	665-671
tremors	I	672-679
and	O	680-683
convulsions	B	684-695
.	O	695-696

An	O	697-699
interaction	O	700-711
between	O	712-719
FZP	O	720-723
and	O	724-727
pentylenetetrazol	O	728-745
(	O	746-747
PTZ	O	747-750
)	O	750-751
was	O	752-755
shown	O	756-761
by	O	762-764
pretreating	O	765-776
mice	O	777-781
with	O	782-786
FZP	O	787-790
before	O	791-797
PTZ	O	798-801
challenge	O	802-811
.	O	811-812

As	O	813-815
a	O	816-817
function	O	818-826
of	O	827-829
dose	O	830-834
,	O	834-835
FZP	O	836-839
first	O	840-845
protected	O	846-855
against	O	856-863
convulsions	B	864-875
and	O	876-879
death	O	880-885
.	O	885-886

At	O	887-889
higher	O	890-896
doses	O	897-902
,	O	902-903
however	O	904-911
,	O	911-912
convulsions	B	913-924
again	O	925-930
emerged	O	931-938
.	O	938-939

These	O	940-945
doses	O	946-951
of	O	952-954
FZP	O	955-958
were	O	959-963
lower	O	964-969
than	O	970-974
those	O	975-980
that	O	981-985
would	O	986-991
alone	O	992-997
cause	O	998-1003
convulsions	B	1004-1015
.	O	1015-1016

These	O	1017-1022
results	O	1023-1030
may	O	1031-1034
be	O	1035-1037
relevant	O	1038-1046
to	O	1047-1049
the	O	1050-1053
use	O	1054-1057
of	O	1058-1060
FZP	O	1061-1064
in	O	1065-1067
clinical	O	1068-1076
situations	O	1077-1087
in	O	1088-1090
which	O	1091-1096
there	O	1097-1102
is	O	1103-1105
increased	O	1106-1115
neural	O	1116-1122
excitability	O	1123-1135
,	O	1135-1136
such	O	1137-1141
as	O	1142-1144
epilepsy	B	1145-1153
or	O	1154-1156
sedative	O	1157-1165
-	O	1165-1166
hypnotic	O	1166-1174
drug	O	1175-1179
withdrawal	O	1180-1190
.	O	1190-1191

Evidence	O	0-8
for	O	9-12
cardiac	O	13-20
beta	O	21-25
2	O	26-27
-	O	27-28
adrenoceptors	O	28-41
in	O	42-44
man	O	45-48
.	O	48-49

We	O	50-52
compared	O	53-61
the	O	62-65
effects	O	66-73
of	O	74-76
single	O	77-83
doses	O	84-89
of	O	90-92
50	O	93-95
mg	O	96-98
atenolol	O	99-107
(	O	108-109
cardioselective	O	109-124
)	O	124-125
,	O	125-126
40	O	127-129
mg	O	130-132
propranolol	O	133-144
(	O	145-146
nonselective	O	146-158
)	O	158-159
,	O	159-160
and	O	161-164
placebo	O	165-172
on	O	173-175
both	O	176-180
exercise	O	181-189
-	O	189-190
and	O	191-194
isoproterenol	O	195-208
-	O	208-209
induced	O	209-216
tachycardia	B	217-228
in	O	229-231
two	O	232-235
experiments	O	236-247
involving	O	248-257
nine	O	258-262
normal	O	263-269
subjects	O	270-278
.	O	278-279

Maximal	O	280-287
exercise	O	288-296
heart	O	297-302
rate	O	303-307
was	O	308-311
reduced	O	312-319
from	O	320-324
187	O	325-328
+	O	329-330
/	O	330-331
-	O	331-332
4	O	333-334
(	O	334-335
SEM	O	335-338
)	O	338-339
after	O	340-345
placebo	O	346-353
to	O	354-356
146	O	357-360
+	O	361-362
/	O	362-363
-	O	363-364
7	O	365-366
bpm	O	367-370
after	O	371-376
atenolol	O	377-385
and	O	386-389
138	O	390-393
+	O	394-395
/	O	395-396
-	O	396-397
6	O	398-399
bpm	O	400-403
after	O	404-409
propranolol	O	410-421
,	O	421-422
but	O	423-426
there	O	427-432
were	O	433-437
no	O	438-440
differences	O	441-452
between	O	453-460
the	O	461-464
drugs	O	465-470
.	O	470-471

The	O	472-475
effects	O	476-483
on	O	484-486
isoproterenol	O	487-500
tachycardia	B	501-512
were	O	513-517
determined	O	518-528
before	O	529-535
and	O	536-539
after	O	540-545
atropine	O	546-554
(	O	555-556
0	O	556-557
.	O	557-558
04	O	558-560
mg	O	561-563
/	O	563-564
kg	O	564-566
IV	O	567-569
)	O	569-570
.	O	570-571

Isoproterenol	O	572-585
sensitivity	O	586-597
was	O	598-601
determined	O	602-612
as	O	613-615
the	O	616-619
intravenous	O	620-631
dose	O	632-636
that	O	637-641
increased	O	642-651
heart	O	652-657
rate	O	658-662
by	O	663-665
25	O	666-668
bpm	O	669-672
(	O	673-674
CD25	O	674-678
)	O	678-679
and	O	680-683
this	O	684-688
was	O	689-692
increased	O	693-702
from	O	703-707
1	O	708-709
.	O	709-710
8	O	710-711
+	O	712-713
/	O	713-714
-	O	714-715
0	O	716-717
.	O	717-718
3	O	718-719
micrograms	O	720-730
after	O	731-736
placebo	O	737-744
to	O	745-747
38	O	748-750
.	O	750-751
9	O	751-752
+	O	753-754
/	O	754-755
-	O	755-756
8	O	757-758
.	O	758-759
3	O	759-760
micrograms	O	761-771
after	O	772-777
propranolol	O	778-789
and	O	790-793
8	O	794-795
.	O	795-796
3	O	796-797
+	O	798-799
/	O	799-800
-	O	800-801
1	O	802-803
.	O	803-804
7	O	804-805
micrograms	O	806-816
after	O	817-822
atenolol	O	823-831
.	O	831-832

The	O	833-836
difference	O	837-847
in	O	848-850
the	O	851-854
effects	O	855-862
of	O	863-865
the	O	866-869
two	O	870-873
was	O	874-877
significant	O	878-889
.	O	889-890

After	O	891-896
atropine	O	897-905
the	O	906-909
CD25	O	910-914
was	O	915-918
unchanged	O	919-928
after	O	929-934
placebo	O	935-942
(	O	943-944
2	O	944-945
.	O	945-946
3	O	946-947
+	O	948-949
/	O	949-950
-	O	950-951
0	O	952-953
.	O	953-954
3	O	954-955
micrograms	O	956-966
)	O	966-967
and	O	968-971
atenolol	O	972-980
(	O	981-982
7	O	982-983
.	O	983-984
7	O	982-983
+	O	986-987
/	O	987-988
-	O	988-989
1	O	990-991
.	O	991-992
3	O	992-993
micrograms	O	994-1004
)	O	1004-1005
;	O	1005-1006
it	O	1007-1009
was	O	1010-1013
reduced	O	1014-1021
after	O	1022-1027
propranolol	O	1028-1039
(	O	1040-1041
24	O	1041-1043
.	O	1043-1044
8	O	1044-1045
+	O	1046-1047
/	O	1047-1048
-	O	1048-1049
5	O	1050-1051
.	O	1051-1052
0	O	1052-1053
micrograms	O	1054-1064
)	O	1064-1065
,	O	1065-1066
but	O	1067-1070
remained	O	1071-1079
different	O	1080-1089
from	O	1090-1094
atenolol	O	1095-1103
.	O	1103-1104

This	O	1105-1109
change	O	1110-1116
with	O	1117-1121
propranolol	O	1122-1133
sensitivity	O	1134-1145
was	O	1146-1149
calculated	O	1150-1160
as	O	1161-1163
the	O	1164-1167
apparent	O	1168-1176
Ka	O	1177-1179
,	O	1179-1180
this	O	1181-1185
was	O	1186-1189
unchanged	O	1190-1199
by	O	1200-1202
atropine	O	1203-1211
(	O	1212-1213
11	O	1213-1215
.	O	1215-1216
7	O	1216-1217
+	O	1218-1219
/	O	1219-1220
-	O	1220-1221
2	O	1222-1223
.	O	1223-1224
1	O	1224-1225
and	O	1226-1229
10	O	1230-1232
.	O	1232-1233
1	O	1230-1231
+	O	1235-1236
/	O	1236-1237
-	O	1237-1238
2	O	1239-1240
.	O	1240-1241
5	O	1241-1242
ml	O	1243-1245
/	O	1245-1246
ng	O	1246-1248
)	O	1248-1249
.	O	1249-1250

These	O	1251-1256
data	O	1257-1261
are	O	1262-1265
consistent	O	1266-1276
with	O	1277-1281
the	O	1282-1285
hypothesis	O	1286-1296
that	O	1297-1301
exercise	O	1302-1310
-	O	1310-1311
induced	O	1311-1318
tachycardia	B	1319-1330
results	O	1331-1338
largely	O	1339-1346
from	O	1347-1351
beta	O	1352-1356
1	O	1357-1358
-	O	1358-1359
receptor	O	1359-1367
activation	O	1368-1378
that	O	1379-1383
is	O	1384-1386
blocked	O	1387-1394
by	O	1395-1397
both	O	1398-1402
cardioselective	O	1403-1418
and	O	1419-1422
nonselective	O	1423-1435
drugs	O	1436-1441
,	O	1441-1442
whereas	O	1443-1450
isoproterenol	O	1451-1464
activates	O	1465-1474
both	O	1475-1479
beta	O	1480-1484
1	O	1485-1486
-	O	1486-1487
and	O	1488-1491
beta	O	1492-1496
2	O	1497-1498
-	O	1498-1499
receptors	O	1499-1508
so	O	1509-1511
that	O	1512-1516
after	O	1517-1522
cardioselective	O	1523-1538
blockade	O	1539-1547
there	O	1548-1553
remains	O	1554-1561
a	O	1562-1563
beta	O	1564-1568
2	O	1569-1570
-	O	1570-1571
component	O	1571-1580
that	O	1581-1585
can	O	1586-1589
be	O	1590-1592
blocked	O	1593-1600
with	O	1601-1605
a	O	1606-1607
nonselective	O	1608-1620
drug	O	1621-1625
.	O	1625-1626

While	O	1627-1632
there	O	1633-1638
appear	O	1639-1645
to	O	1646-1648
be	O	1649-1651
beta	O	1652-1656
2	O	1657-1658
-	O	1658-1659
receptors	O	1659-1668
in	O	1669-1671
the	O	1672-1675
human	O	1676-1681
heart	O	1682-1687
,	O	1687-1688
their	O	1689-1694
physiologic	O	1695-1706
or	O	1707-1709
pathologic	O	1710-1720
roles	O	1721-1726
remain	O	1727-1733
to	O	1734-1736
be	O	1737-1739
defined	O	1740-1747
.	O	1747-1748

Hormones	O	0-8
and	O	9-12
risk	O	13-17
of	O	18-20
breast	B	21-27
cancer	I	28-34
.	O	34-35

This	O	36-40
paper	O	41-46
reports	O	47-54
the	O	55-58
results	O	59-66
of	O	67-69
a	O	70-71
study	O	72-77
of	O	78-80
50	O	81-83
menopausal	O	84-94
women	O	95-100
receiving	O	101-110
hormonal	O	111-119
replacement	O	120-131
therapy	O	132-139
.	O	139-140

The	O	141-144
majority	O	145-153
(	O	154-155
29	O	155-157
)	O	157-158
had	O	159-162
surgical	O	163-171
menopause	O	172-181
;	O	181-182
their	O	183-188
mean	O	189-193
age	O	194-197
was	O	198-201
45	O	202-204
.	O	204-205
7	O	205-206
years	O	207-212
.	O	212-213

It	O	214-216
was	O	217-220
hypothesized	O	221-233
that	O	234-238
progestins	O	239-249
could	O	250-255
equilibrate	O	256-267
the	O	268-271
effects	O	272-279
of	O	280-282
the	O	283-286
estrogenic	O	287-297
stimulation	O	298-309
on	O	310-312
the	O	313-316
mammary	O	317-324
and	O	325-328
endometrial	O	329-340
target	O	341-347
tissues	O	348-355
of	O	356-358
women	O	359-364
on	O	365-367
hormonal	O	368-376
replacement	O	377-388
therapy	O	389-396
.	O	396-397

The	O	398-401
treatment	O	402-411
schedule	O	412-420
consisted	O	421-430
of	O	431-433
conjugated	O	434-444
estrogens	O	445-454
(	O	455-456
Premarin	O	456-464
)	O	464-465
1	O	466-467
.	O	467-468
25	O	468-470
mg	O	471-473
/	O	473-474
day	O	474-477
for	O	478-481
21	O	482-484
days	O	485-489
and	O	490-493
Medroxyprogesterone	O	494-513
acetate	O	514-521
10	O	522-524
mg	O	525-527
/	O	527-528
day	O	528-531
for	O	532-535
10	O	536-538
days	O	539-543
in	O	544-546
each	O	547-551
month	O	552-557
.	O	557-558

The	O	559-562
mean	O	563-567
treatment	O	568-577
period	O	578-584
was	O	585-588
18	O	589-591
months	O	592-598
.	O	598-599

During	O	600-606
the	O	607-610
follow	O	611-617
-	O	617-618
up	O	618-620
period	O	621-627
,	O	627-628
attention	O	629-638
was	O	639-642
paid	O	643-647
to	O	648-650
breast	O	651-657
modifications	O	658-671
as	O	672-674
evidenced	O	675-684
by	O	685-687
symptomatology	O	688-702
,	O	702-703
physical	O	704-712
examination	O	713-724
,	O	724-725
and	O	726-729
plate	O	730-735
thermography	O	736-748
.	O	748-749

Mastodynia	B	750-760
was	O	761-764
reported	O	765-773
by	O	774-776
21	O	777-779
patients	O	780-788
,	O	788-789
and	O	790-793
physical	O	794-802
examination	O	803-814
revealed	O	815-823
a	O	824-825
light	O	826-831
increase	O	832-840
in	O	841-843
breast	O	844-850
firmness	O	851-859
in	O	860-862
12	O	863-865
women	O	866-871
and	O	872-875
a	O	876-877
moderate	O	878-886
increase	O	887-895
in	O	896-898
breast	O	899-905
nodularity	O	906-916
in	O	917-919
2	O	920-921
women	O	922-927
.	O	927-928

Themography	O	929-940
confirmed	O	941-950
the	O	951-954
existence	O	955-964
of	O	965-967
an	O	968-970
excessive	O	971-980
breast	O	981-987
stimulation	O	988-999
in	O	1000-1002
1	O	1003-1004
women	O	1005-1010
who	O	1011-1014
complained	O	1015-1025
of	O	1026-1028
moderate	O	1029-1037
mastodynia	B	1038-1048
and	O	1049-1052
in	O	1053-1055
5	O	1056-1057
of	O	1058-1060
the	O	1061-1064
7	O	1065-1066
women	O	1067-1072
who	O	1073-1076
complained	O	1077-1087
of	O	1088-1090
severe	O	1091-1097
mastodynia	B	1098-1108
.	O	1108-1109

Normalization	O	1110-1123
was	O	1124-1127
obtained	O	1128-1136
by	O	1137-1139
halving	O	1140-1147
the	O	1148-1151
estrogen	O	1152-1160
dose	O	1161-1165
.	O	1165-1166

These	O	1167-1172
results	O	1173-1180
suggest	O	1181-1188
that	O	1189-1193
hormonal	O	1194-1202
replacement	O	1203-1214
therapy	O	1215-1222
can	O	1223-1226
be	O	1227-1229
safely	O	1230-1236
prescribed	O	1237-1247
if	O	1248-1250
the	O	1251-1254
following	O	1255-1264
criteria	O	1265-1273
are	O	1274-1277
satisfied	O	1278-1287
:	O	1287-1288
1	O	1289-1290
)	O	1290-1291
preliminary	O	1292-1303
evaluation	O	1304-1314
of	O	1315-1317
patients	O	1318-1326
from	O	1327-1331
a	O	1332-1333
clinical	O	1334-1342
,	O	1342-1343
metabolic	O	1344-1353
,	O	1353-1354
cytologic	O	1355-1364
,	O	1364-1365
and	O	1366-1369
mammographic	O	1370-1382
perspective	O	1383-1394
;	O	1394-1395
2	O	1396-1397
)	O	1397-1398
cyclic	O	1399-1405
treatment	O	1406-1415
schedule	O	1416-1424
,	O	1424-1425
with	O	1426-1430
a	O	1431-1432
progestative	O	1433-1445
phase	O	1446-1451
of	O	1452-1454
10	O	1455-1457
days	O	1458-1462
;	O	1462-1463
and	O	1464-1467
3	O	1468-1469
)	O	1469-1470
periodic	O	1471-1479
complete	O	1480-1488
follow	O	1489-1495
-	O	1495-1496
up	O	1496-1498
,	O	1498-1499
with	O	1500-1504
accurate	O	1505-1513
thermographic	O	1514-1527
evaluation	O	1528-1538
of	O	1539-1541
the	O	1542-1545
breast	O	1546-1552
target	O	1553-1559
tissues	O	1560-1567
.	O	1567-1568

Early	O	0-5
infections	B	6-16
in	O	17-19
kidney	O	20-26
,	O	26-27
heart	O	28-33
,	O	33-34
and	O	35-38
liver	O	39-44
transplant	O	45-55
recipients	O	56-66
on	O	67-69
cyclosporine	O	70-82
.	O	82-83

Eighty	O	84-90
-	O	90-91
one	O	91-94
renal	O	95-100
,	O	100-101
seventeen	O	102-111
heart	O	112-117
,	O	117-118
and	O	119-122
twenty	O	123-129
-	O	129-130
four	O	130-134
liver	O	135-140
transplant	O	141-151
patients	O	152-160
were	O	161-165
followed	O	166-174
for	O	175-178
infection	B	179-188
.	O	188-189

Seventeen	O	190-199
renal	O	200-205
patients	O	206-214
received	O	215-223
azathioprine	O	224-236
(	O	237-238
Aza	O	238-241
)	O	241-242
and	O	243-246
prednisone	O	247-257
as	O	258-260
part	O	261-265
of	O	266-268
a	O	269-270
randomized	O	271-281
trial	O	282-287
of	O	288-290
immunosuppression	O	291-308
with	O	309-313
21	O	314-316
cyclosporine	O	317-329
-	O	329-330
and	O	330-333
-	O	329-330
prednisone	O	334-344
-	O	329-330
treated	O	345-352
renal	O	353-358
transplant	O	359-369
patients	O	370-378
.	O	378-379

All	O	380-383
others	O	384-390
received	O	391-399
cyclosporine	O	400-412
and	O	413-416
prednisone	O	417-427
.	O	427-428

The	O	429-432
randomized	O	433-443
Aza	O	444-447
patients	O	448-456
had	O	457-460
more	O	461-465
overall	O	466-473
infections	B	474-484
(	O	485-486
P	O	486-487
less	O	488-492
than	O	493-497
0	O	498-499
.	O	499-500
05	O	500-502
)	O	502-503
and	O	504-507
more	O	508-512
nonviral	O	513-521
infections	B	522-532
(	O	533-534
P	O	534-535
less	O	536-540
than	O	541-545
0	O	546-547
.	O	547-548
02	O	548-550
)	O	550-551
than	O	552-556
the	O	557-560
randomized	O	561-571
cyclosporine	O	572-584
patients	O	585-593
.	O	593-594

Heart	O	595-600
and	O	601-604
liver	O	605-610
patients	O	611-619
had	O	620-623
more	O	624-628
infections	B	629-639
than	O	640-644
cyclosporine	O	645-657
renal	O	658-663
patients	O	664-672
but	O	673-676
fewer	O	677-682
infections	B	683-693
than	O	694-698
the	O	699-702
Aza	O	703-706
renal	O	707-712
patients	O	713-721
.	O	721-722

There	O	723-728
were	O	729-733
no	O	734-736
infectious	O	737-747
deaths	O	748-754
in	O	755-757
renal	O	758-763
transplant	O	764-774
patients	O	775-783
on	O	784-786
cyclosporine	O	787-799
or	O	800-802
Aza	O	803-806
,	O	806-807
but	O	808-811
infection	B	812-821
played	O	822-828
a	O	829-830
major	O	831-836
role	O	837-841
in	O	842-844
3	O	845-846
out	O	847-850
of	O	851-853
6	O	854-855
cardiac	O	856-863
transplant	O	864-874
deaths	O	875-881
and	O	882-885
in	O	886-888
8	O	889-890
out	O	891-894
of	O	895-897
9	O	898-899
liver	O	900-905
transplant	O	906-916
deaths	O	917-923
.	O	923-924

Renal	O	925-930
patients	O	931-939
on	O	940-942
cyclosporine	O	943-955
had	O	956-959
the	O	960-963
fewest	O	964-970
bacteremias	B	971-982
.	O	982-983

Analysis	O	984-992
of	O	993-995
site	O	996-1000
of	O	1001-1003
infection	B	1004-1013
showed	O	1014-1020
a	O	1021-1022
preponderance	O	1023-1036
of	O	1037-1039
abdominal	B	1040-1049
infections	I	1050-1060
in	O	1061-1063
liver	O	1064-1069
patients	O	1070-1078
,	O	1078-1079
intrathoracic	O	1080-1093
infections	B	1094-1104
in	O	1105-1107
heart	O	1108-1113
patients	O	1114-1122
,	O	1122-1123
and	O	1124-1127
urinary	B	1128-1135
tract	I	1136-1141
infections	I	1142-1152
in	O	1153-1155
renal	O	1156-1161
patients	O	1162-1170
.	O	1170-1171

Pulmonary	O	1172-1181
infections	B	1182-1192
were	O	1193-1197
less	O	1198-1202
common	O	1203-1209
in	O	1210-1212
cyclosporine	O	1213-1225
-	O	1225-1226
treated	O	1226-1233
renal	O	1234-1239
patients	O	1240-1248
than	O	1249-1253
in	O	1254-1256
Aza	O	1257-1260
-	O	1260-1261
treated	O	1261-1268
patients	O	1269-1277
(	O	1278-1279
P	O	1279-1280
less	O	1281-1285
than	O	1286-1290
0	O	1291-1292
.	O	1292-1293
05	O	1293-1295
)	O	1295-1296
.	O	1292-1293

Aza	O	1298-1301
patients	O	1302-1310
had	O	1311-1314
significantly	O	1315-1328
more	O	1329-1333
staphylococcal	B	1334-1348
infections	I	1349-1359
than	O	1360-1364
all	O	1365-1368
other	O	1369-1374
transplant	O	1375-1385
groups	O	1386-1392
(	O	1393-1394
P	O	1394-1395
less	O	1396-1400
than	O	1401-1405
0	O	1406-1407
.	O	1407-1408
005	O	1408-1411
)	O	1411-1412
,	O	1412-1413
and	O	1414-1417
systemic	O	1418-1426
fungal	B	1427-1433
infections	I	1434-1444
occurred	O	1445-1453
only	O	1454-1458
in	O	1459-1461
the	O	1462-1465
liver	O	1466-1471
transplant	O	1472-1482
group	O	1483-1488
.	O	1488-1489

Cytomegalovirus	O	1490-1505
(	O	1506-1507
CMV	O	1507-1510
)	O	1510-1511
shedding	O	1512-1520
or	O	1521-1523
serological	O	1524-1535
rises	O	1536-1541
in	O	1542-1544
antibody	O	1545-1553
titer	O	1554-1559
,	O	1559-1560
or	O	1561-1563
both	O	1564-1568
occurred	O	1569-1577
in	O	1578-1580
78	O	1581-1583
%	O	1583-1584
of	O	1585-1587
cyclosporine	O	1588-1600
patients	O	1601-1609
and	O	1610-1613
76	O	1614-1616
%	O	1616-1617
of	O	1618-1620
Aza	O	1621-1624
patients	O	1625-1633
.	O	1633-1634

Of	O	1635-1637
the	O	1638-1641
cyclosporine	O	1642-1654
patients	O	1655-1663
,	O	1663-1664
15	O	1665-1667
%	O	1667-1668
had	O	1669-1672
symptoms	O	1673-1681
related	O	1682-1689
to	O	1690-1692
CMV	B	1693-1696
infection	I	1697-1706
.	O	1706-1707

Serological	O	1708-1719
evidence	O	1720-1728
for	O	1729-1732
Epstein	B	1733-1740
Barr	I	1741-1745
Virus	I	1746-1751
infection	I	1752-1761
was	O	1762-1765
found	O	1766-1771
in	O	1772-1774
20	O	1775-1777
%	O	1777-1778
of	O	1779-1781
65	O	1782-1784
cyclosporine	O	1785-1797
patients	O	1798-1806
studied	O	1807-1814
.	O	1814-1815

Three	O	1816-1821
had	O	1822-1825
associated	O	1826-1836
symptoms	O	1837-1845
,	O	1845-1846
and	O	1847-1850
one	O	1851-1854
developed	O	1855-1864
a	O	1865-1866
lymphoma	B	1867-1875
.	O	1875-1876

Structure	O	0-9
-	O	9-10
activity	O	10-18
and	O	19-22
dose	O	23-27
-	O	27-28
effect	O	28-34
relationships	O	35-48
of	O	49-51
the	O	52-55
antagonism	O	56-66
of	O	67-69
picrotoxin	O	70-80
-	O	80-81
induced	O	81-88
seizures	B	89-97
by	O	98-100
cholecystokinin	O	101-116
,	O	116-117
fragments	O	118-127
and	O	128-131
analogues	O	132-141
of	O	142-144
cholecystokinin	O	145-160
in	O	161-163
mice	O	164-168
.	O	168-169

Intraperitoneal	O	170-185
administration	O	186-200
of	O	201-203
cholecystokinin	O	204-219
octapeptide	O	220-231
sulphate	O	232-240
ester	O	241-246
(	O	247-248
CCK	O	248-251
-	O	251-252
8	O	252-253
-	O	251-252
SE	O	254-256
)	O	256-257
and	O	258-261
nonsulphated	O	262-274
cholecystokinin	O	275-290
octapeptide	O	291-302
(	O	303-304
CCK	O	304-307
-	O	307-308
8	O	308-309
-	O	307-308
NS	O	310-312
)	O	312-313
enhanced	O	314-322
the	O	323-326
latency	O	327-334
of	O	335-337
seizures	B	338-346
induced	O	347-354
by	O	355-357
picrotoxin	O	358-368
in	O	369-371
mice	O	372-376
.	O	376-377

Experiments	O	378-389
with	O	390-394
N	O	395-396
-	O	396-397
and	O	398-401
C	O	402-403
-	O	403-404
terminal	O	404-412
fragments	O	413-422
revealed	O	423-431
that	O	432-436
the	O	437-440
C	O	441-442
-	O	442-443
terminal	O	443-451
tetrapeptide	O	452-464
(	O	465-466
CCK	O	466-469
-	O	469-470
5	O	470-471
-	O	469-470
8	O	472-473
)	O	473-474
was	O	475-478
the	O	479-482
active	O	483-489
centre	O	490-496
of	O	497-499
the	O	500-503
CCK	O	504-507
octapeptide	O	508-519
molecule	O	520-528
.	O	528-529

The	O	530-533
analogues	O	534-543
CCK	O	544-547
-	O	547-548
8	O	548-549
-	O	547-548
SE	O	550-552
and	O	553-556
CCK	O	557-560
-	O	560-561
8	O	561-562
-	O	560-561
NS	O	563-565
(	O	566-567
dose	O	567-571
range	O	572-577
0	O	578-579
.	O	579-580
2	O	580-581
-	O	581-582
6	O	582-583
.	O	579-580
4	O	584-585

mumol	O	586-591
/	O	591-592
kg	O	592-594
)	O	594-595
and	O	596-599
caerulein	O	600-609
dose	O	610-614
range	O	615-620
0	O	621-622
.	O	622-623
1	O	623-624
-	O	624-625
0	O	621-622
.	O	622-623
8	O	627-628

mumol	O	629-634
/	O	634-635
kg	O	635-637
)	O	637-638
showed	O	639-645
bell	O	646-650
-	O	650-651
shaped	O	651-657
dose	O	658-662
-	O	662-663
effect	O	663-669
curves	O	670-676
,	O	676-677
with	O	678-682
the	O	683-686
greatest	O	687-695
maximum	O	696-703
inhibition	O	704-714
for	O	715-718
CCK	O	719-722
-	O	722-723
8	O	723-724
-	O	722-723
NS	O	725-727
.	O	727-728

The	O	729-732
peptide	O	733-740
CCK	O	741-744
-	O	744-745
5	O	745-746
-	O	744-745
8	O	747-748
had	O	749-752
weak	O	753-757
anticonvulsant	O	758-772
activity	O	773-781
in	O	782-784
comparison	O	785-795
to	O	796-798
the	O	799-802
octapeptides	O	803-815
,	O	815-816
3	O	817-818
.	O	818-819
2	O	819-820
mumol	O	821-826
/	O	826-827
kg	O	827-829
and	O	830-833
larger	O	834-840
doses	O	841-846
of	O	847-849
the	O	850-853
reference	O	854-863
drug	O	864-868
,	O	868-869
diazepam	O	870-878
,	O	878-879
totally	O	880-887
prevented	O	888-897
picrotoxin	O	898-908
-	O	908-909
induced	O	909-916
seizures	B	917-925
and	O	926-929
mortality	O	930-939
.	O	939-940

The	O	941-944
maximum	O	945-952
effect	O	953-959
of	O	960-962
the	O	963-966
peptides	O	967-975
tested	O	976-982
was	O	983-986
less	O	987-991
than	O	992-996
that	O	997-1001
of	O	1002-1004
diazepam	O	1005-1013
.	O	1013-1014

Experiments	O	1015-1026
with	O	1027-1031
analogues	O	1032-1041
and	O	1042-1045
derivatives	O	1046-1057
of	O	1058-1060
CCK	O	1061-1064
-	O	1064-1065
5	O	1065-1066
-	O	1064-1065
8	O	1067-1068
demonstrated	O	1069-1081
that	O	1082-1086
the	O	1087-1090
effectiveness	O	1091-1104
of	O	1105-1107
the	O	1108-1111
beta	O	1112-1116
-	O	1116-1117
alanyl	O	1117-1123
derivatives	O	1124-1135
of	O	1136-1138
CCK	O	1139-1142
-	O	1142-1143
5	O	1143-1144
-	O	1142-1143
8	O	1145-1146
were	O	1147-1151
enhanced	O	1152-1160
and	O	1161-1164
that	O	1165-1169
they	O	1170-1174
were	O	1175-1179
equipotent	O	1180-1190
with	O	1191-1195
CCK	O	1196-1199
-	O	1199-1200
8	O	1200-1201
-	O	1199-1200
SE	O	1202-1204
.	O	1204-1205

Of	O	1206-1208
the	O	1209-1212
CCK	O	1213-1216
-	O	1216-1217
2	O	1217-1218
-	O	1216-1217
8	O	1219-1220
analogues	O	1221-1230
,	O	1230-1231
Ser	O	1232-1235
(	O	1235-1236
SO3H	O	1236-1240
)	O	1240-1241
7	O	1241-1242
-	O	1242-1243
Ac	O	1243-1245
-	O	1242-1243
CCK	O	1246-1249
-	O	1242-1243
2	O	1250-1251
-	O	1242-1243
8	O	1252-1253
-	O	1242-1243
SE	O	1254-1256
and	O	1257-1260
Thr	O	1261-1264
(	O	1264-1265
SO3H	O	1265-1269
)	O	1269-1270
7	O	1270-1271
-	O	1271-1272
Ac	O	1272-1274
-	O	1271-1272
CCK	O	1275-1278
-	O	1271-1272
2	O	1279-1280
-	O	1271-1272
8	O	1281-1282
-	O	1271-1272
SE	O	1283-1285
and	O	1286-1289
Hyp	O	1290-1293
(	O	1293-1294
SO3H	O	1294-1298
)	O	1298-1299
-	O	1299-1300
Ac	O	1300-1302
-	O	1299-1300
CCK	O	1303-1306
-	O	1299-1300
2	O	1307-1308
-	O	1299-1300
8	O	1309-1310
-	O	1299-1300
SE	O	1311-1313
were	O	1314-1318
slightly	O	1319-1327
more	O	1328-1332
active	O	1333-1339
than	O	1340-1344
CCK	O	1345-1348
-	O	1348-1349
8	O	1349-1350
-	O	1348-1349
SE	O	1351-1353
.	O	1353-1354

Vasopressin	O	0-11
as	O	12-14
a	O	15-16
possible	O	17-25
contributor	O	26-37
to	O	38-40
hypertension	B	41-53
.	O	53-54

The	O	55-58
role	O	59-63
of	O	64-66
vasopressin	O	67-78
as	O	79-81
a	O	82-83
pressor	O	84-91
agent	O	92-97
to	O	98-100
the	O	101-104
hypertensive	B	105-117
process	O	118-125
was	O	126-129
examined	O	130-138
.	O	138-139

Vasopressin	O	140-151
plays	O	152-157
a	O	158-159
major	O	160-165
role	O	166-170
in	O	171-173
the	O	174-177
pathogenesis	O	178-190
of	O	191-193
DOCA	O	194-198
-	O	198-199
salt	O	199-203
hypertension	B	204-216
,	O	216-217
since	O	218-223
the	O	224-227
elevation	O	228-237
of	O	238-240
blood	O	241-246
pressure	O	247-255
was	O	256-259
not	O	260-263
substantial	O	264-275
in	O	276-278
the	O	279-282
rats	O	283-287
with	O	288-292
lithium	O	293-300
-	O	300-301
treated	O	301-308
diabetes	B	309-317
insipidus	I	318-327
after	O	328-333
DOCA	O	334-338
-	O	338-339
salt	O	339-343
treatment	O	344-353
.	O	353-354

Administration	O	355-369
of	O	370-372
DDAVP	O	373-378
which	O	379-384
has	O	385-388
antidiuretic	O	389-401
action	O	402-408
but	O	409-412
minimal	O	413-420
vasopressor	O	421-432
effect	O	433-439
failed	O	440-446
to	O	447-449
increase	O	450-458
blood	O	459-464
pressure	O	465-473
to	O	474-476
the	O	477-480
levels	O	481-487
observed	O	488-496
after	O	497-502
administration	O	503-517
of	O	518-520
AVP	O	521-524
.	O	524-525

Furthermore	O	526-537
,	O	537-538
the	O	539-542
pressor	O	543-550
action	O	551-557
of	O	558-560
vasopressin	O	561-572
appears	O	573-580
to	O	581-583
be	O	584-586
important	O	587-596
in	O	597-599
the	O	600-603
development	O	604-615
of	O	616-618
this	O	619-623
model	O	624-629
of	O	630-632
hypertension	B	633-645
,	O	645-646
since	O	647-652
the	O	653-656
enhanced	O	657-665
pressor	O	666-673
responsiveness	O	674-688
to	O	689-691
the	O	692-695
hormone	O	696-703
was	O	704-707
observed	O	708-716
in	O	717-719
the	O	720-723
initial	O	724-731
stage	O	732-737
of	O	738-740
hypertension	B	741-753
.	O	753-754

Increased	O	755-764
secretion	O	765-774
of	O	775-777
vasopressin	O	778-789
from	O	790-794
neurohypophysis	O	795-810
also	O	811-815
promotes	O	816-824
the	O	825-828
function	O	829-837
of	O	838-840
the	O	841-844
hormone	O	845-852
as	O	853-855
a	O	856-857
pathogenetic	O	858-870
factor	O	871-877
in	O	878-880
hypertension	B	881-893
.	O	893-894

An	O	895-897
unproportional	O	898-912
release	O	913-920
of	O	921-923
vasopressin	O	924-935
compared	O	936-944
to	O	945-947
plasma	O	948-954
osmolality	O	955-965
may	O	966-969
be	O	970-972
induced	O	973-980
by	O	981-983
the	O	984-987
absence	O	988-995
of	O	996-998
an	O	999-1001
adjusting	O	1002-1011
control	O	1012-1019
of	O	1020-1022
angiotensin	O	1023-1034
II	O	1035-1037
forming	O	1038-1045
and	O	1046-1049
receptor	O	1050-1058
binding	O	1059-1066
capacity	O	1067-1075
for	O	1076-1079
sodium	O	1080-1086
balance	O	1087-1094
in	O	1095-1097
the	O	1098-1101
brain	O	1102-1107
.	O	1107-1108

However	O	1109-1116
,	O	1116-1117
the	O	1118-1121
role	O	1122-1126
of	O	1127-1129
vasopressin	O	1130-1141
remains	O	1142-1149
to	O	1150-1152
be	O	1153-1155
determined	O	1156-1166
in	O	1167-1169
human	O	1170-1175
essential	O	1176-1185
hypertension	B	1186-1198
.	O	1198-1199

Toxic	B	0-5
hepatitis	I	6-15
induced	O	16-23
by	O	24-26
disulfiram	O	27-37
in	O	38-40
a	O	41-42
non	O	43-46
-	O	46-47
alcoholic	O	47-56
.	O	56-57

A	O	58-59
reversible	O	60-70
toxic	B	71-76
liver	I	77-82
damage	I	83-89
was	O	90-93
observed	O	94-102
in	O	103-105
a	O	106-107
non	O	108-111
-	O	111-112
alcoholic	O	112-121
woman	O	122-127
treated	O	128-135
with	O	136-140
disulfiram	O	141-151
.	O	151-152

The	O	153-156
causative	O	157-166
relationship	O	167-179
was	O	180-183
proven	O	184-190
by	O	191-193
challenge	O	194-203
.	O	203-204

Atrial	B	0-6
thrombosis	I	7-17
involving	O	18-27
the	O	28-31
heart	O	32-37
of	O	38-40
F	O	41-42
-	O	42-43
344	O	43-46
rats	O	47-51
ingesting	O	52-61
quinacrine	O	62-72
hydrochloride	O	73-86
.	O	86-87

Quinacrine	O	88-98
hydrochloride	O	99-112
is	O	113-115
toxic	O	116-121
for	O	122-125
the	O	126-129
heart	O	130-135
of	O	136-138
F	O	139-140
-	O	140-141
344	O	141-144
rats	O	145-149
.	O	149-150

Rats	O	151-155
treated	O	156-163
with	O	164-168
500	O	169-172
ppm	O	173-176
quinacrine	O	177-187
hydrochloride	O	188-201
in	O	202-204
the	O	205-208
diet	O	209-213
all	O	214-217
developed	O	218-227
a	O	228-229
high	O	230-234
incidence	O	235-244
of	O	245-247
left	O	248-252
atrial	B	253-259
thrombosis	I	260-270
.	O	270-271

The	O	272-275
lesion	O	276-282
was	O	283-286
associated	O	287-297
with	O	298-302
cardiac	B	303-310
hypertrophy	I	311-322
and	O	323-326
dilatation	O	327-337
and	O	338-341
focal	O	342-347
myocardial	B	348-358
degeneration	I	359-371
.	O	371-372

Rats	O	373-377
died	O	378-382
from	O	383-387
cardiac	B	388-395
hypertrophy	I	396-407
with	O	408-412
severe	O	413-419
acute	O	420-425
and	O	426-429
chronic	O	430-437
congestion	O	438-448
of	O	449-451
the	O	452-455
lungs	O	456-461
,	O	461-462
liver	O	463-468
,	O	468-469
and	O	470-473
other	O	474-479
organs	O	480-486
.	O	486-487

Seventy	O	488-495
percent	O	496-503
of	O	504-506
rats	O	507-511
given	O	512-517
250	O	518-521
ppm	O	522-525
quinacrine	O	526-536
hydrochloride	O	537-550
and	O	551-554
1	O	555-556
,	O	556-557
000	O	557-560
ppm	O	561-564
sodium	O	565-571
nitrite	O	572-579
simultaneously	O	580-594
in	O	595-597
the	O	598-601
diet	O	602-606
had	O	607-610
thrombosis	B	611-621
of	O	622-624
the	O	625-628
atria	O	629-634
of	O	635-637
the	O	638-641
heart	O	642-647
,	O	647-648
while	O	649-654
untreated	O	655-664
control	O	665-672
rats	O	673-677
in	O	678-680
this	O	681-685
laboratory	O	686-696
did	O	697-700
not	O	701-704
have	O	705-709
atrial	B	710-716
thrombosis	I	717-727
.	O	727-728

Sodium	O	729-735
nitrite	O	736-743
in	O	744-746
combination	O	747-758
with	O	759-763
quinacrine	O	764-774
hydrochloride	O	775-788
appeared	O	789-797
to	O	798-800
have	O	801-805
no	O	806-808
additional	O	809-819
effect	O	820-826
.	O	826-827

Alternating	B	0-11
sinus	I	12-17
rhythm	I	18-24
and	O	25-28
intermittent	O	29-41
sinoatrial	B	42-52
block	I	53-58
induced	O	59-66
by	O	67-69
propranolol	O	70-81
.	O	81-82

Alternating	B	83-94
sinus	I	95-100
rhythm	I	101-107
and	O	108-111
intermittent	O	112-124
sinoatrial	B	125-135
(	I	136-137
S	I	137-138
-	I	138-139
A	I	139-140
)	I	140-141
block	I	142-147
was	O	148-151
observed	O	152-160
in	O	161-163
a	O	164-165
57	O	166-168
-	O	168-169
year	O	169-173
-	O	168-169
old	O	174-177
woman	O	178-183
,	O	183-184
under	O	185-190
treatment	O	191-200
for	O	201-204
angina	B	205-211
with	O	212-216
80	O	217-219
mg	O	220-222
propranolol	O	223-234
daily	O	235-240
.	O	240-241

The	O	242-245
electrocardiogram	O	246-263
showed	O	264-270
alternation	O	271-282
of	O	283-285
long	O	286-290
and	O	291-294
short	O	295-300
P	O	301-302
-	O	302-303
P	O	301-302
intervals	O	305-314
and	O	315-318
occasional	O	319-329
pauses	O	330-336
.	O	336-337

These	O	338-343
pauses	O	344-350
were	O	351-355
always	O	356-362
preceded	O	363-371
by	O	372-374
the	O	375-378
short	O	379-384
P	O	385-386
-	O	386-387
P	O	385-386
intervals	O	389-398
and	O	399-402
were	O	403-407
usually	O	408-415
followed	O	416-424
by	O	425-427
one	O	428-431
or	O	432-434
two	O	435-438
P	O	439-440
-	O	440-441
P	O	439-440
intervals	O	443-452
of	O	453-455
0	O	456-457
.	O	457-458
92	O	458-460
-	O	460-461
0	O	456-457
.	O	457-458
95	O	463-465

s	O	466-467
representing	O	468-480
the	O	481-484
basic	O	485-490
sinus	O	491-496
cycle	O	497-502
.	O	502-503

Following	O	504-513
these	O	514-519
basic	O	520-525
sinus	O	526-531
cycles	O	532-538
,	O	538-539
alternating	B	540-551
rhythm	I	552-558
started	O	559-566
with	O	567-571
the	O	572-575
longer	O	576-582
P	O	583-584
-	O	584-585
P	O	583-584
interval	O	587-595
.	O	595-596

The	O	597-600
long	O	601-605
P	O	606-607
-	O	607-608
P	O	606-607
intervals	O	610-619
ranged	O	620-626
between	O	627-634
1	O	635-636
.	O	636-637
04	O	637-639
-	O	639-640
1	O	635-636
.	O	636-637
12	O	642-644

s	O	645-646
and	O	647-650
the	O	651-654
short	O	655-660
P	O	661-662
-	O	662-663
P	O	661-662
intervals	O	665-674
between	O	675-682
0	O	683-684
.	O	684-685
80	O	685-687
-	O	687-688
0	O	683-684
.	O	684-685
84	O	690-692

s	O	693-694
,	O	694-695
respectively	O	696-708
.	O	708-709

The	O	710-713
duration	O	714-722
of	O	723-725
the	O	726-729
pauses	O	730-736
were	O	737-741
equal	O	742-747
or	O	748-750
almost	O	751-757
equal	O	758-763
to	O	764-766
one	O	767-770
short	O	771-776
plus	O	777-781
one	O	782-785
long	O	786-790
P	O	791-792
-	O	792-793
P	O	791-792
interval	O	795-803
or	O	804-806
to	O	807-809
twice	O	810-815
the	O	816-819
basic	O	820-825
sinus	O	826-831
cycle	O	832-837
.	O	837-838

In	O	839-841
one	O	842-845
recording	O	846-855
a	O	856-857
short	O	858-863
period	O	864-870
of	O	871-873
regular	O	874-881
sinus	O	882-887
rhythm	O	888-894
with	O	895-899
intermittent	O	900-912
2	O	913-914
/	O	914-915
1	O	915-916
S	B	917-918
-	I	918-919
A	I	919-920
block	I	921-926
was	O	927-930
observed	O	931-939
.	O	939-940

This	O	941-945
short	O	946-951
period	O	952-958
of	O	959-961
sinus	O	962-967
rhythm	O	968-974
was	O	975-978
interrupted	O	979-990
by	O	991-993
sudden	O	994-1000
prolongation	O	1001-1013
of	O	1014-1016
the	O	1017-1020
P	O	1021-1022
-	O	1022-1023
P	O	1021-1022
interval	O	1025-1033
starting	O	1034-1042
the	O	1043-1046
alternative	O	1047-1058
rhythm	O	1059-1065
.	O	1065-1066

There	O	1067-1072
were	O	1073-1077
small	O	1078-1083
changes	O	1084-1091
in	O	1092-1094
the	O	1095-1098
shape	O	1099-1104
of	O	1105-1107
the	O	1108-1111
P	O	1112-1113
waves	O	1114-1119
and	O	1120-1123
P	O	1124-1125
-	O	1125-1126
R	O	1126-1127
intervals	O	1128-1137
.	O	1137-1138

S	O	1139-1140
-	O	1140-1141
A	O	1141-1142
conduction	O	1143-1153
through	O	1154-1161
two	O	1162-1165
pathways	O	1166-1174
,	O	1174-1175
the	O	1176-1179
first	O	1180-1185
with	O	1186-1190
2	O	1191-1192
/	O	1192-1193
1	O	1193-1194
block	O	1195-1200
the	O	1201-1204
second	O	1205-1211
having	O	1212-1218
0	O	1219-1220
.	O	1220-1221
12	O	1221-1223
-	O	1223-1224
0	O	1219-1220
.	O	1220-1221
14	O	1226-1228

s	O	1229-1230
longer	O	1231-1237
conduction	O	1238-1248
time	O	1249-1253
and	O	1254-1257
with	O	1258-1262
occasional	O	1263-1273
2	O	1274-1275
/	O	1275-1276
1	O	1276-1277
block	O	1278-1283
was	O	1284-1287
proposed	O	1288-1296
for	O	1297-1300
the	O	1301-1304
explanation	O	1305-1316
of	O	1317-1319
the	O	1320-1323
alternating	O	1324-1335
P	O	1336-1337
-	O	1337-1338
P	O	1336-1337
interval	O	1340-1348
and	O	1349-1352
other	O	1353-1358
electrocardiographic	O	1359-1379
features	O	1380-1388
seen	O	1389-1393
.	O	1393-1394

Atropine	O	1395-1403
1	O	1404-1405
mg	O	1406-1408
given	O	1409-1414
intravenously	O	1415-1428
resulted	O	1429-1437
in	O	1438-1440
shortening	O	1441-1451
of	O	1452-1454
all	O	1455-1458
P	O	1459-1460
-	O	1460-1461
P	O	1459-1460
intervals	O	1463-1472
without	O	1473-1480
changing	O	1481-1489
the	O	1490-1493
rhythm	O	1494-1500
.	O	1500-1501

The	O	1502-1505
abnormal	O	1506-1514
rhythm	O	1515-1521
disappeared	O	1522-1533
with	O	1534-1538
the	O	1539-1542
withdrawal	O	1543-1553
of	O	1554-1556
propranolol	O	1557-1568
and	O	1569-1572
when	O	1573-1577
the	O	1578-1581
drug	O	1582-1586
was	O	1587-1590
restarted	O	1591-1600
a	O	1601-1602
2	O	1603-1604
/	O	1604-1605
1	O	1605-1606
S	B	1607-1608
-	I	1608-1609
A	I	1609-1610
block	I	1611-1616
was	O	1617-1620
seen	O	1621-1625
.	O	1625-1626

This	O	1627-1631
was	O	1632-1635
accepted	O	1636-1644
as	O	1645-1647
evidence	O	1648-1656
for	O	1657-1660
propranolol	O	1661-1672
being	O	1673-1678
the	O	1679-1682
cause	O	1683-1688
of	O	1689-1691
this	O	1692-1696
conduction	B	1697-1707
disorder	I	1708-1716
.	O	1716-1717

Antitumor	O	0-9
effect	O	10-16
,	O	16-17
cardiotoxicity	B	18-32
,	O	32-33
and	O	34-37
nephrotoxicity	B	38-52
of	O	53-55
doxorubicin	O	56-67
in	O	68-70
the	O	71-74
IgM	O	75-78
solid	O	79-84
immunocytoma	B	85-97
-	O	97-98
bearing	O	98-105
LOU	O	106-109
/	O	109-110
M	O	110-111
/	O	109-110
WSL	O	112-115
rat	O	116-119
.	O	119-120

Antitumor	O	121-130
activity	O	131-139
,	O	139-140
cardiotoxicity	B	141-155
,	O	155-156
and	O	157-160
nephrotoxicity	B	161-175
induced	O	176-183
by	O	184-186
doxorubicin	O	187-198
were	O	199-203
studied	O	204-211
in	O	212-214
LOU	O	215-218
/	O	218-219
M	O	219-220
/	O	218-219
WSL	O	221-224
inbred	O	225-231
rats	O	232-236
each	O	237-241
bearing	O	242-249
a	O	250-251
transplantable	O	252-266
solid	O	267-272
IgM	O	273-276
immunocytoma	B	277-289
.	O	289-290

Animals	O	291-298
with	O	299-303
a	O	304-305
tumor	B	306-311
(	O	312-313
diameter	O	313-321
,	O	321-322
15	O	323-325
.	O	325-326
8	O	326-327
+	O	328-329
/	O	329-330
-	O	330-331
3	O	332-333
.	O	333-334
3	O	332-333
mm	O	336-338
)	O	338-339
were	O	340-344
treated	O	345-352
with	O	353-357
iv	O	358-360
injections	O	361-371
of	O	372-374
doxorubicin	O	375-386
on	O	387-389
5	O	390-391
consecutive	O	392-403
days	O	404-408
,	O	408-409
followed	O	410-418
by	O	419-421
1	O	422-423
weekly	O	424-430
injection	O	431-440
for	O	441-444
7	O	445-446
weeks	O	447-452
(	O	453-454
dose	O	454-458
range	O	459-464
,	O	464-465
0	O	466-467
.	O	467-468
015	O	468-471
-	O	471-472
4	O	472-473
.	O	467-468
0	O	466-467

mg	O	476-478
/	O	478-479
kg	O	479-481
body	O	482-486
wt	O	487-489
)	O	489-490
.	O	490-491

Tumor	B	492-497
regression	O	498-508
was	O	509-512
observed	O	513-521
with	O	522-526
0	O	527-528
.	O	528-529
5	O	529-530
mg	O	531-533
doxorubicin	O	534-545
/	O	545-546
kg	O	546-548
.	O	548-549

Complete	O	550-558
disappearance	O	559-572
of	O	573-575
the	O	576-579
tumor	B	580-585
was	O	586-589
induced	O	590-597
with	O	598-602
1	O	603-604
.	O	604-605
0	O	605-606
mg	O	607-609
doxorubicin	O	610-621
/	O	621-622
kg	O	622-624
.	O	624-625

Histologic	O	626-636
evidence	O	637-645
of	O	646-648
cardiotoxicity	B	649-663
scored	O	664-670
as	O	671-673
grade	O	674-679
III	O	680-683
was	O	684-687
only	O	688-692
observed	O	693-701
at	O	702-704
a	O	705-706
dose	O	707-711
of	O	712-714
1	O	715-716
.	O	716-717
0	O	717-718
mg	O	719-721
doxorubicin	O	722-733
/	O	733-734
kg	O	734-736
.	O	736-737

Light	O	738-743
microscopic	O	744-755
evidence	O	756-764
of	O	765-767
renal	B	768-773
damage	I	774-780
was	O	781-784
seen	O	785-789
above	O	790-795
a	O	796-797
dose	O	798-802
of	O	803-805
0	O	806-807
.	O	807-808
5	O	808-809
mg	O	810-812
doxorubicin	O	813-824
/	O	824-825
kg	O	825-827
,	O	827-828
which	O	829-834
resulted	O	835-843
in	O	844-846
albuminuria	B	847-858
and	O	859-862
very	O	863-867
low	O	868-871
serum	O	872-877
albumin	O	878-885
levels	O	886-892
.	O	892-893

In	O	894-896
the	O	897-900
group	O	901-906
that	O	907-911
received	O	912-920
1	O	921-922
.	O	922-923
0	O	923-924
mg	O	925-927
doxorubicin	O	928-939
/	O	939-940
kg	O	940-942
,	O	942-943
the	O	944-947
serum	O	948-953
albumin	O	954-961
level	O	962-967
decreased	O	968-977
from	O	978-982
33	O	983-985
.	O	985-986
6	O	986-987
+	O	988-989
/	O	989-990
-	O	990-991
4	O	992-993
.	O	993-994
1	O	994-995
to	O	996-998
1	O	999-1000
.	O	1000-1001
5	O	1001-1002
+	O	1003-1004
/	O	1004-1005
-	O	1005-1006
0	O	1007-1008
.	O	1008-1009
5	O	1009-1010
g	O	1011-1012
/	O	1012-1013
liter	O	1013-1018
.	O	1018-1019

Ascites	B	1020-1027
and	O	1028-1031
hydrothorax	B	1032-1043
were	O	1044-1048
observed	O	1049-1057
simultaneously	O	1058-1072
.	O	1072-1073

The	O	1074-1077
same	O	1078-1082
experiments	O	1083-1094
were	O	1095-1099
performed	O	1100-1109
with	O	1110-1114
non	O	1115-1118
-	O	1118-1119
tumor	B	1119-1124
-	O	1118-1119
bearing	O	1125-1132
rats	O	1133-1137
,	O	1137-1138
in	O	1139-1141
which	O	1142-1147
no	O	1148-1150
major	O	1151-1156
differences	O	1157-1168
were	O	1169-1173
observed	O	1174-1182
.	O	1182-1183

In	O	1184-1186
conclusion	O	1187-1197
,	O	1197-1198
antitumor	O	1199-1208
activity	O	1209-1217
,	O	1217-1218
cardiotoxicity	B	1219-1233
,	O	1233-1234
and	O	1235-1238
nephrotoxicity	B	1239-1253
were	O	1254-1258
studied	O	1259-1266
simultaneously	O	1267-1281
in	O	1282-1284
the	O	1285-1288
same	O	1289-1293
LOU	O	1294-1297
/	O	1297-1298
M	O	1298-1299
/	O	1297-1298
WSL	O	1300-1303
rat	O	1304-1307
.	O	1307-1308

Albuminuria	B	1309-1320
due	O	1321-1324
to	O	1325-1327
renal	B	1328-1333
damage	I	1334-1340
led	O	1341-1344
to	O	1345-1347
extremely	O	1348-1357
low	O	1358-1361
serum	O	1362-1367
albumin	O	1368-1375
levels	O	1376-1382
,	O	1382-1383
so	O	1384-1386
ascites	B	1387-1394
and	O	1395-1398
hydrothorax	B	1399-1410
were	O	1411-1415
not	O	1416-1419
necessarily	O	1420-1431
a	O	1432-1433
consequence	O	1434-1445
of	O	1446-1448
the	O	1449-1452
observed	O	1453-1461
cardiomyopathy	B	1462-1476
.	O	1476-1477

Intraoperative	O	0-14
bradycardia	B	15-26
and	O	27-30
hypotension	B	31-42
associated	O	43-53
with	O	54-58
timolol	O	59-66
and	O	67-70
pilocarpine	O	71-82
eye	O	83-86
drops	O	87-92
.	O	92-93

A	O	94-95
69	O	96-98
-	O	98-99
yr	O	99-101
-	O	98-99
old	O	102-105
man	O	106-109
,	O	109-110
who	O	111-114
was	O	115-118
concurrently	O	119-131
being	O	132-137
treated	O	138-145
with	O	146-150
pilocarpine	O	151-162
nitrate	O	163-170
and	O	171-174
timolol	O	175-182
maleate	O	183-190
eye	O	191-194
drops	O	195-200
,	O	200-201
developed	O	202-211
a	O	212-213
bradycardia	B	214-225
and	O	226-229
became	O	230-236
hypotensive	B	237-248
during	O	249-255
halothane	O	256-265
anaesthesia	O	266-277
.	O	277-278

Both	O	279-283
timolol	O	284-291
and	O	292-295
pilocarpine	O	296-307
were	O	308-312
subsequently	O	313-325
identified	O	326-336
in	O	337-339
a	O	340-341
24	O	342-344
-	O	344-345
h	O	345-346
collection	O	347-357
of	O	358-360
urine	O	361-366
.	O	366-367

Timolol	O	368-375
(	O	376-377
but	O	377-380
not	O	381-384
pilocarpine	O	385-396
)	O	396-397
was	O	398-401
detected	O	402-410
in	O	411-413
a	O	414-415
sample	O	416-422
of	O	423-425
plasma	O	426-432
removed	O	433-440
during	O	441-447
surgery	O	448-455
;	O	455-456
the	O	457-460
plasma	O	461-467
concentration	O	468-481
of	O	482-484
timolol	O	485-492
(	O	493-494
2	O	494-495
.	O	495-496
6	O	496-497
ng	O	498-500
ml	O	501-503
-	O	503-504
1	O	504-505
)	O	505-506
was	O	507-510
consistent	O	511-521
with	O	522-526
partial	O	527-534
beta	O	535-539
-	O	539-540
adrenoceptor	O	540-552
blockade	O	553-561
.	O	561-562

It	O	563-565
is	O	566-568
postulated	O	569-579
that	O	580-584
this	O	585-589
action	O	590-596
may	O	597-600
have	O	601-605
been	O	606-610
enhanced	O	611-619
during	O	620-626
halothane	O	627-636
anaesthesia	O	637-648
with	O	649-653
resultant	O	654-663
bradycardia	B	664-675
and	O	676-679
hypotension	B	680-691
.	O	691-692

Pilocarpine	O	693-704
may	O	705-708
have	O	709-713
had	O	714-717
a	O	718-719
contributory	O	720-732
effect	O	733-739
.	O	739-740

Succinylcholine	O	0-15
apnoea	B	16-22
:	O	22-23
attempted	O	24-33
reversal	O	34-42
with	O	43-47
anticholinesterases	O	48-67
.	O	67-68

Anticholinesterases	O	69-88
were	O	89-93
administered	O	94-106
in	O	107-109
an	O	110-112
attempt	O	113-120
to	O	121-123
antagonize	O	124-134
prolonged	O	135-144
neuromuscular	B	145-158
blockade	I	159-167
following	O	168-177
the	O	178-181
administration	O	182-196
of	O	197-199
succinylcholine	O	200-215
in	O	216-218
a	O	219-220
patient	O	221-228
later	O	229-234
found	O	235-240
to	O	241-243
be	O	244-246
homozygous	O	247-257
for	O	258-261
atypical	O	262-270
plasma	O	271-277
cholinesterase	O	278-292
.	O	292-293

Edrophonium	O	294-305
10	O	306-308
mg	O	309-311
,	O	311-312
given	O	313-318
74	O	319-321
min	O	322-325
after	O	326-331
succinylcholine	O	332-347
,	O	347-348
when	O	349-353
train	O	354-359
-	O	359-360
of	O	360-362
-	O	359-360
four	O	363-367
stimulation	O	368-379
was	O	380-383
characteristic	O	384-398
of	O	399-401
phase	O	402-407
II	O	408-410
block	O	411-416
,	O	416-417
produced	O	418-426
partial	O	427-434
antagonism	O	435-445
which	O	446-451
was	O	452-455
not	O	456-459
sustained	O	460-469
.	O	469-470

Repeated	O	471-479
doses	O	480-485
of	O	486-488
edrophonium	O	489-500
to	O	501-503
70	O	504-506
mg	O	507-509
and	O	510-513
neostigmine	O	514-525
to	O	526-528
2	O	529-530
.	O	530-531
5	O	531-532
mg	O	533-535
did	O	536-539
not	O	540-543
antagonize	O	544-554
or	O	555-557
augment	O	558-565
the	O	566-569
block	O	570-575
.	O	575-576

Spontaneous	O	577-588
respiration	O	589-600
recommenced	O	601-612
200	O	613-616
min	O	617-620
after	O	621-626
succinylcholine	O	627-642
administration	O	643-657
.	O	657-658

It	O	659-661
is	O	662-664
concluded	O	665-674
that	O	675-679
anticholinesterases	O	680-699
are	O	700-703
only	O	704-708
partially	O	709-718
effective	O	719-728
in	O	729-731
restoring	O	732-741
neuromuscular	O	742-755
function	O	756-764
in	O	765-767
succinylcholine	O	768-783
apnoea	B	784-790
despite	O	791-798
muscle	O	799-805
twitch	O	806-812
activity	O	813-821
typical	O	822-829
of	O	830-832
phase	O	833-838
II	O	839-841
block	O	842-847
.	O	847-848

Effect	O	0-6
of	O	7-9
doxorubicin	O	10-21
on	O	22-24
[	O	25-26
omega	O	26-31
-	O	31-32
I	O	32-33
-	O	31-32
131	O	34-37
]	O	37-38
heptadecanoic	O	38-51
acid	O	52-56
myocardial	O	57-67
scintigraphy	O	68-80
and	O	81-84
echocardiography	O	85-101
in	O	102-104
dogs	O	105-109
.	O	109-110

The	O	111-114
effects	O	115-122
of	O	123-125
serial	O	126-132
treatment	O	133-142
with	O	143-147
doxorubicin	O	148-159
on	O	160-162
dynamic	O	163-170
myocardial	O	171-181
scintigraphy	O	182-194
with	O	195-199
[	O	200-201
omega	O	201-206
-	O	206-207
I	O	207-208
-	O	206-207
131	O	209-212
]	O	212-213
heptadecanoic	O	213-226
acid	O	227-231
(	O	232-233
I	O	233-234
-	O	234-235
131	O	235-238
HA	O	239-241
)	O	241-242
,	O	242-243
and	O	244-247
on	O	248-250
global	O	251-257
left	O	258-262
-	O	262-263
ventricular	O	263-274
function	O	275-283
determined	O	284-294
echocardiographically	O	295-316
,	O	316-317
were	O	318-322
studied	O	323-330
in	O	331-333
a	O	334-335
group	O	336-341
of	O	342-344
nine	O	345-349
mongrel	O	350-357
dogs	O	358-362
.	O	362-363

Total	O	364-369
extractable	O	370-381
myocardial	O	382-392
lipid	O	393-398
was	O	399-402
compared	O	403-411
postmortem	O	412-422
between	O	423-430
a	O	431-432
group	O	433-438
of	O	439-441
control	O	442-449
dogs	O	450-454
and	O	455-458
doxorubicin	O	459-470
-	O	470-471
treated	O	471-478
dogs	O	479-483
.	O	483-484

A	O	485-486
significant	O	487-498
and	O	499-502
then	O	503-507
progressive	O	508-519
fall	O	520-524
in	O	525-527
global	O	528-534
LV	O	535-537
function	O	538-546
was	O	547-550
observed	O	551-559
at	O	560-562
a	O	563-564
cumulative	O	565-575
doxorubicin	O	576-587
dose	O	588-592
of	O	593-595
4	O	596-597
mg	O	598-600
/	O	600-601
kg	O	601-603
.	O	603-604

A	O	605-606
significant	O	607-618
increase	O	619-627
in	O	628-630
the	O	631-634
myocardial	O	635-645
t1	O	646-648
/	O	648-649
2	O	649-650
of	O	651-653
the	O	654-657
I	O	658-659
-	O	659-660
131	O	660-663
HA	O	664-666
was	O	667-670
observed	O	671-679
only	O	680-684
at	O	685-687
a	O	688-689
higher	O	690-696
cumulative	O	697-707
dose	O	708-712
,	O	712-713
10	O	714-716
mg	O	717-719
/	O	719-720
kg	O	720-722
.	O	722-723

No	O	724-726
significant	O	727-738
alteration	O	739-749
in	O	750-752
total	O	753-758
extractable	O	759-770
myocardial	O	771-781
lipids	O	782-788
was	O	789-792
observed	O	793-801
between	O	802-809
control	O	810-817
dogs	O	818-822
and	O	823-826
those	O	827-832
treated	O	833-840
with	O	841-845
doxorubicin	O	846-857
.	O	857-858

Our	O	859-862
findings	O	863-871
suggest	O	872-879
that	O	880-884
the	O	885-888
changes	O	889-896
leading	O	897-904
to	O	905-907
an	O	908-910
alteration	O	911-921
of	O	922-924
myocardial	O	925-935
dynamic	O	936-943
imaging	O	944-951
with	O	952-956
I	O	957-958
-	O	958-959
131	O	959-962
HA	O	963-965
are	O	966-969
not	O	970-973
the	O	974-977
initiating	O	978-988
factor	O	989-995
in	O	996-998
doxorubicin	O	999-1010
cardiotoxicity	B	1011-1025
.	O	1025-1026

Hemodynamics	O	0-12
and	O	13-16
myocardial	O	17-27
metabolism	O	28-38
under	O	39-44
deliberate	O	45-55
hypotension	B	56-67
.	O	67-68

An	O	69-71
experimental	O	72-84
study	O	85-90
in	O	91-93
dogs	O	94-98
.	O	98-99

Coronary	O	100-108
blood	O	109-114
flow	O	115-119
,	O	119-120
cardiac	O	121-128
work	O	129-133
and	O	134-137
metabolism	O	138-148
were	O	149-153
studied	O	154-161
in	O	162-164
dogs	O	165-169
under	O	170-175
sodium	O	176-182
nitroprusside	O	183-196
(	O	197-198
SNP	O	198-201
)	O	201-202
and	O	203-206
trimetaphan	O	207-218
(	O	219-220
TMP	O	220-223
)	O	223-224
deliberate	O	225-235
hypotension	B	236-247
(	O	248-249
20	O	249-251
%	O	251-252
and	O	253-256
40	O	257-259
%	O	259-260
mean	O	261-265
pressure	O	266-274
decrease	O	275-283
from	O	284-288
baseline	O	289-297
)	O	297-298
.	O	298-299

Regarding	O	300-309
the	O	310-313
effects	O	314-321
of	O	322-324
drug	O	325-329
-	O	329-330
induced	O	330-337
hypotension	B	338-349
on	O	350-352
coronary	O	353-361
blood	O	362-367
flow	O	368-372
,	O	372-373
aortic	O	374-380
and	O	381-384
coronary	O	385-393
sinus	O	394-399
metabolic	O	400-409
data	O	410-414
(	O	415-416
pH	O	416-418
,	O	418-419
pO2	O	420-423
,	O	423-424
pCO2	O	425-429
)	O	429-430
we	O	431-433
could	O	434-439
confirm	O	440-447
that	O	448-452
nitroprusside	O	453-466
hypotension	B	467-478
could	O	479-484
be	O	485-487
safely	O	488-494
used	O	495-499
to	O	500-502
30	O	503-505
%	O	505-506
mean	O	507-511
blood	O	512-517
pressure	O	518-526
decrease	O	527-535
from	O	536-540
control	O	541-548
,	O	548-549
trimetaphan	O	550-561
hypotension	B	562-573
to	O	574-576
20	O	577-579
%	O	579-580
mean	O	581-585
blood	O	586-591
pressure	O	592-600
decrease	O	601-609
.	O	609-610

Cardiac	O	611-618
work	O	619-623
was	O	624-627
significantly	O	628-641
reduced	O	642-649
during	O	650-656
SNP	O	657-660
hypotension	B	661-672
.	O	672-673

Myocardial	O	674-684
O2	O	685-687
consumption	O	688-699
and	O	700-703
O2	O	704-706
availability	O	707-719
were	O	720-724
directly	O	725-733
dependent	O	734-743
on	O	744-746
the	O	747-750
coronary	O	751-759
perfusion	O	760-769
.	O	769-770

Careful	O	771-778
invasive	O	779-787
monitoring	O	788-798
of	O	799-801
the	O	802-805
blood	O	806-811
pressure	O	812-820
,	O	820-821
blood	O	822-827
gases	O	828-833
and	O	834-837
of	O	838-840
the	O	841-844
ECG	O	845-848
ST	O	849-851
-	O	851-852
T	O	850-851
segment	O	854-861
is	O	862-864
mandatory	O	865-874
.	O	874-875

Evidence	O	0-8
for	O	9-12
a	O	13-14
selective	O	15-24
brain	O	25-30
noradrenergic	O	31-44
involvement	O	45-56
in	O	57-59
the	O	60-63
locomotor	O	64-73
stimulant	O	74-83
effects	O	84-91
of	O	92-94
amphetamine	O	95-106
in	O	107-109
the	O	110-113
rat	O	114-117
.	O	117-118

Male	O	119-123
rats	O	124-128
received	O	129-137
the	O	138-141
noradrenaline	O	142-155
neurotoxin	O	156-166
DSP4	O	167-171
(	O	172-173
50	O	173-175
mg	O	176-178
/	O	178-179
kg	O	179-181
)	O	181-182
7	O	183-184
days	O	185-189
prior	O	190-195
to	O	196-198
injection	O	199-208
of	O	209-211
D	O	212-213
-	O	213-214
amphetamine	O	214-225
(	O	226-227
10	O	227-229
or	O	230-232
40	O	233-235
mumol	O	236-241
/	O	241-242
kg	O	242-244
i	O	245-246
.	O	246-247
p	O	247-248
.	O	246-247
)	O	249-250
.	O	246-247

The	O	252-255
hyperactivity	B	256-269
induced	O	270-277
by	O	278-280
D	O	281-282
-	O	282-283
amphetamine	O	283-294
(	O	295-296
10	O	296-298
mumol	O	299-304
/	O	304-305
kg	O	305-307
)	O	307-308
was	O	309-312
significantly	O	313-326
reduced	O	327-334
by	O	335-337
DSP4	O	338-342
pretreatment	O	343-355
.	O	355-356

However	O	357-364
,	O	364-365
the	O	366-369
increased	O	370-379
rearings	O	380-388
and	O	389-392
the	O	393-396
amphetamine	O	397-408
-	O	408-409
induced	O	409-416
stereotypies	B	417-429
were	O	430-434
not	O	435-438
blocked	O	439-446
by	O	447-449
pretreatment	O	450-462
with	O	463-467
DSP4	O	468-472
.	O	472-473

The	O	474-477
reduction	O	478-487
of	O	488-490
amphetamine	O	491-502
hyperactivity	B	503-516
induced	O	517-524
by	O	525-527
DSP4	O	528-532
was	O	533-536
blocked	O	537-544
by	O	545-547
pretreatment	O	548-560
with	O	561-565
the	O	566-569
noradrenaline	O	570-583
-	O	583-584
uptake	O	584-590
blocking	O	591-599
agent	O	600-605
,	O	605-606
desipramine	O	607-618
,	O	618-619
which	O	620-625
prevents	O	626-634
the	O	635-638
neurotoxic	B	639-649
action	O	650-656
of	O	657-659
DSP4	O	660-664
.	O	664-665

The	O	666-669
present	O	670-677
results	O	678-685
suggest	O	686-693
a	O	694-695
selective	O	696-705
involvement	O	706-717
of	O	718-720
central	O	721-728
noradrenergic	O	729-742
neurones	O	743-751
in	O	752-754
the	O	755-758
locomotor	O	759-768
stimulant	O	769-778
effect	O	779-785
of	O	786-788
amphetamine	O	789-800
in	O	801-803
the	O	804-807
rat	O	808-811
.	O	811-812

Accelerated	B	0-11
junctional	I	12-22
rhythms	I	23-30
during	O	31-37
oral	O	38-42
verapamil	O	43-52
therapy	O	53-60
.	O	60-61

This	O	62-66
study	O	67-72
examined	O	73-81
the	O	82-85
frequency	O	86-95
of	O	96-98
atrioventricular	O	99-115
(	O	116-117
AV	O	117-119
)	O	119-120
dissociation	O	121-133
and	O	134-137
accelerated	B	138-149
junctional	I	150-160
rhythms	I	161-168
in	O	169-171
59	O	172-174
patients	O	175-183
receiving	O	184-193
oral	O	194-198
verapamil	O	199-208
.	O	208-209

Accelerated	B	210-221
junctional	I	222-232
rhythms	I	233-240
and	O	241-244
AV	O	245-247
dissociation	O	248-260
were	O	261-265
frequent	O	266-274
in	O	275-277
patients	O	278-286
with	O	287-291
supraventricular	B	292-308
tachyarrhythmias	I	309-325
,	O	325-326
particularly	O	327-339
AV	O	340-342
nodal	O	343-348
reentry	O	349-356
.	O	356-357

Verapamil	O	358-367
administration	O	368-382
to	O	383-385
these	O	386-391
patients	O	392-400
led	O	401-404
to	O	405-407
an	O	408-410
asymptomatic	O	411-423
increase	O	424-432
in	O	433-435
activity	O	436-444
of	O	445-447
these	O	448-453
junctional	O	454-464
pacemakers	O	465-475
.	O	475-476

In	O	477-479
patients	O	480-488
with	O	489-493
various	O	494-501
chest	B	502-507
pain	I	508-512
syndromes	O	513-522
,	O	522-523
verapamil	O	524-533
neither	O	534-541
increased	O	542-551
the	O	552-555
frequency	O	556-565
of	O	566-568
junctional	O	569-579
rhythms	O	580-587
nor	O	588-591
suppressed	O	592-602
their	O	603-608
role	O	609-613
as	O	614-616
escape	O	617-623
rhythms	O	624-631
under	O	632-637
physiologically	O	638-653
appropriate	O	654-665
circumstances	O	666-679
.	O	679-680

Treatment	O	0-9
of	O	10-12
ovarian	B	13-20
cancer	I	21-27
with	O	28-32
a	O	33-34
combination	O	35-46
of	O	47-49
cis	O	50-53
-	O	53-54
platinum	O	54-62
,	O	62-63
adriamycin	O	64-74
,	O	74-75
cyclophosphamide	O	76-92
and	O	93-96
hexamethylmelamine	O	97-115
.	O	115-116

During	O	117-123
the	O	124-127
last	O	128-132
2	O	133-134
1	O	135-136
/	O	136-137
2	O	137-138
years	O	139-144
,	O	144-145
38	O	146-148
patients	O	149-157
with	O	158-162
ovarian	B	163-170
cancer	I	171-177
were	O	178-182
treated	O	183-190
with	O	191-195
a	O	196-197
combination	O	198-209
of	O	210-212
cisplatinum	O	213-224
(	O	225-226
CPDD	O	226-230
)	O	230-231
,	O	231-232
50	O	233-235
mg	O	236-238
/	O	238-239
m2	O	239-241
,	O	241-242
adriamycin	O	243-253
,	O	253-254
30	O	255-257
mg	O	258-260
/	O	260-261
m2	O	261-263
,	O	263-264
cyclophosphamide	O	265-281
,	O	281-282
300	O	283-286
mg	O	287-289
/	O	289-290
m2	O	290-292
,	O	292-293
on	O	294-296
day	O	297-300
1	O	301-302
;	O	302-303
and	O	304-307
hexamethylmelamine	O	308-326
(	O	327-328
HMM	O	328-331
)	O	331-332
,	O	332-333
6	O	334-335
mg	O	336-338
/	O	338-339
kg	O	339-341
daily	O	342-347
,	O	347-348
for	O	349-352
14	O	353-355
days	O	356-360
.	O	360-361

Each	O	362-366
course	O	367-373
was	O	374-377
repeated	O	378-386
monthly	O	387-394
.	O	394-395
2	O	396-397
patients	O	398-406
had	O	407-410
stage	O	411-416
II	O	417-419
,	O	419-420
14	O	421-423
stage	O	424-429
III	O	430-433
and	O	434-437
22	O	438-440
stage	O	441-446
IV	O	447-449
disease	O	450-457
.	O	457-458

14	O	459-461
of	O	462-464
the	O	465-468
38	O	469-471
patients	O	472-480
were	O	481-485
previously	O	486-496
treated	O	497-504
with	O	505-509
chemotherapy	O	510-522
,	O	522-523
1	O	524-525
with	O	526-530
radiation	O	531-540
,	O	540-541
6	O	542-543
with	O	544-548
both	O	549-553
chemotherapy	O	554-566
and	O	567-570
radiation	O	571-580
,	O	580-581
and	O	582-585
17	O	586-588
did	O	589-592
not	O	593-596
have	O	597-601
any	O	602-605
treatment	O	606-615
before	O	616-622
CPDD	O	623-627
combination	O	628-639
.	O	639-640

31	O	641-643
of	O	644-646
the	O	647-650
38	O	651-653
cases	O	654-659
(	O	660-661
81	O	661-663
.	O	663-664
5	O	664-665
%	O	665-666
)	O	666-667
demonstrated	O	668-680
objective	O	681-690
responses	O	691-700
lasting	O	701-708
for	O	709-712
2	O	713-714
months	O	715-721
or	O	722-724
more	O	725-729
.	O	729-730

These	O	731-736
responses	O	737-746
were	O	747-751
partial	O	752-759
in	O	760-762
19	O	763-765
and	O	766-769
complete	O	770-778
in	O	779-781
12	O	782-784
cases	O	785-790
.	O	790-791

Hematologic	B	792-803
toxicity	I	804-812
was	O	813-816
moderate	O	817-825
and	O	826-829
with	O	830-834
reversible	O	835-845
anemia	B	846-852
developing	O	853-863
in	O	864-866
71	O	867-869
%	O	869-870
of	O	871-873
patients	O	874-882
.	O	882-883

Gastrointestinal	O	884-900
side	O	901-905
effects	O	906-913
from	O	914-918
CPDD	O	919-923
were	O	924-928
universal	O	929-938
.	O	938-939

HMM	O	940-943
gastrointestinal	B	944-960
toxicity	I	961-969
necessitated	O	970-982
discontinuation	O	983-998
of	O	999-1001
the	O	1002-1005
drug	O	1006-1010
in	O	1011-1013
5	O	1014-1015
patients	O	1016-1024
.	O	1024-1025

Severe	O	1026-1032
nephrotoxicity	B	1033-1047
was	O	1048-1051
observed	O	1052-1060
in	O	1061-1063
2	O	1064-1065
patients	O	1066-1074
but	O	1075-1078
was	O	1079-1082
reversible	O	1083-1093
.	O	1093-1094

There	O	1095-1100
were	O	1101-1105
no	O	1106-1108
drug	O	1109-1113
-	O	1113-1114
related	O	1114-1121
deaths	O	1122-1128
.	O	1128-1129

Nontraumatic	O	0-12
dissecting	B	13-23
aneurysm	I	24-32
of	O	33-35
the	O	36-39
basilar	O	40-47
artery	O	48-54
.	O	54-55

A	O	56-57
case	O	58-62
of	O	63-65
nontraumatic	O	66-78
dissecting	B	79-89
aneurysm	I	90-98
of	O	99-101
the	O	102-105
basilar	O	106-113
artery	O	114-120
in	O	121-123
association	O	124-135
with	O	136-140
hypertension	B	141-153
,	O	153-154
smoke	O	155-160
,	O	160-161
and	O	162-165
oral	O	166-170
contraceptives	O	171-185
is	O	186-188
reported	O	189-197
in	O	198-200
a	O	201-202
young	O	203-208
female	O	209-215
patient	O	216-223
with	O	224-228
a	O	229-230
locked	B	231-237
-	I	237-238
in	I	238-240
syndrome	I	241-249
.	O	249-250

Propylthiouracil	O	0-16
-	O	16-17
induced	O	17-24
hepatic	B	25-32
damage	I	33-39
.	O	39-40

Two	O	41-44
cases	O	45-50
of	O	51-53
propylthiouracil	O	54-70
-	O	70-71
induced	O	71-78
liver	B	79-84
damage	I	85-91
have	O	92-96
been	O	97-101
observed	O	102-110
.	O	110-111

The	O	112-115
first	O	116-121
case	O	122-126
is	O	127-129
of	O	130-132
an	O	133-135
acute	O	136-141
type	O	142-146
of	O	147-149
damage	O	150-156
,	O	156-157
proven	O	158-164
by	O	165-167
rechallenge	O	168-179
;	O	179-180
the	O	181-184
second	O	185-191
presents	O	192-200
a	O	201-202
clinical	O	203-211
and	O	212-215
histologic	O	216-226
picture	O	227-234
resembling	O	235-245
chronic	B	246-253
active	I	254-260
hepatitis	I	261-270
,	O	270-271
with	O	272-276
spontaneous	O	277-288
remission	O	289-298
.	O	298-299

Studies	O	0-7
on	O	8-10
the	O	11-14
bradycardia	B	15-26
induced	O	27-34
by	O	35-37
bepridil	O	38-46
.	O	46-47

Bepridil	O	48-56
,	O	56-57
a	O	58-59
novel	O	60-65
active	O	66-72
compound	O	73-81
for	O	82-85
prophylactic	O	86-98
treatment	O	99-108
of	O	109-111
anginal	B	112-119
attacks	I	120-127
,	O	127-128
induced	O	129-136
persistent	O	137-147
bradycardia	B	148-159
and	O	160-163
a	O	164-165
non	O	166-169
-	O	169-170
specific	O	170-178
anti	O	179-183
-	O	183-184
tachycardial	B	184-196
effect	O	197-203
,	O	203-204
the	O	205-208
mechanisms	O	209-219
of	O	220-222
which	O	223-228
were	O	229-233
investigated	O	234-246
in	O	247-249
vitro	O	250-255
and	O	256-259
in	O	260-262
vivo	O	263-267
.	O	267-268

In	O	269-271
vitro	O	272-277
perfusion	O	278-287
of	O	288-290
bepridil	O	291-299
in	O	300-302
the	O	303-306
life	O	307-311
-	O	311-312
support	O	312-319
medium	O	320-326
for	O	327-330
isolated	O	331-339
sino	O	340-344
-	O	344-345
atrial	O	345-351
tissue	O	352-358
from	O	359-363
rabbit	O	364-370
heart	O	371-376
,	O	376-377
caused	O	378-384
a	O	385-386
reduction	O	387-396
in	O	397-399
action	O	400-406
potential	O	407-416
(	O	417-418
AP	O	418-420
)	O	420-421
spike	O	422-427
frequency	O	428-437
(	O	438-439
recorded	O	439-447
by	O	448-450
KCl	O	451-454
microelectrodes	O	455-470
)	O	470-471
starting	O	472-480
at	O	481-483
doses	O	484-489
of	O	490-492
5	O	493-494
X	O	495-496
10	O	497-499
(	O	499-500
-	O	500-501
6	O	501-502
)	O	502-503
M	O	504-505
.	O	505-506

This	O	507-511
effect	O	512-518
was	O	519-522
dose	O	523-527
-	O	527-528
dependent	O	528-537
up	O	538-540
to	O	541-543
concentrations	O	544-558
of	O	559-561
5	O	562-563
X	O	564-565
10	O	566-568
(	O	568-569
-	O	569-570
5	O	570-571
)	O	571-572
M	O	573-574
,	O	574-575
whereupon	O	576-585
blockade	O	586-594
of	O	595-597
sinus	O	598-603
activity	O	604-612
set	O	613-616
in	O	617-619
.	O	619-620

Bepridil	O	621-629
at	O	630-632
a	O	633-634
dose	O	635-639
of	O	640-642
5	O	643-644
X	O	645-646
10	O	647-649
(	O	649-650
-	O	650-651
6	O	651-652
)	O	652-653
M	O	654-655
,	O	655-656
induced	O	657-664
a	O	665-666
concomitant	O	667-678
reduction	O	679-688
in	O	689-691
AP	O	692-694
amplitude	O	695-704
(	O	705-706
falling	O	706-713
from	O	714-718
71	O	719-721
+	O	722-723
/	O	723-724
-	O	724-725
8	O	726-727
mV	O	728-730
to	O	731-733
47	O	734-736
+	O	737-738
/	O	738-739
-	O	739-740
6	O	741-742
mV	O	743-745
)	O	745-746
,	O	746-747
maximum	O	748-755
systolic	O	756-764
depolarization	O	765-779
velocity	O	780-788
(	O	789-790
phase	O	790-795
0	O	796-797
)	O	797-798
which	O	799-804
fell	O	805-809
from	O	810-814
1	O	815-816
.	O	816-817
85	O	817-819
+	O	820-821
/	O	821-822
-	O	822-823
0	O	824-825
.	O	825-826
35	O	826-828
V	O	829-830
/	O	830-831
s	O	831-832
to	O	833-835
0	O	836-837
.	O	837-838
84	O	838-840
+	O	841-842
/	O	842-843
-	O	843-844
0	O	845-846
.	O	846-847
28	O	847-849
V	O	850-851
/	O	851-852
s	O	852-853
,	O	853-854
together	O	855-863
with	O	864-868
maximum	O	869-876
diastolic	O	877-886
depolarization	O	887-901
velocity	O	902-910
(	O	911-912
phase	O	912-917
4	O	918-919
)	O	919-920
which	O	921-926
fell	O	927-931
from	O	932-936
38	O	937-939
+	O	940-941
/	O	941-942
-	O	942-943
3	O	944-945
mV	O	946-948
/	O	948-949
s	O	949-950
to	O	951-953
24	O	954-956
+	O	957-958
/	O	958-959
-	O	959-960
5	O	961-962
mV	O	963-965
/	O	965-966
s	O	966-967
.	O	967-968

In	O	969-971
vivo	O	972-976
injection	O	977-986
of	O	987-989
bepridil	O	990-998
at	O	999-1001
a	O	1002-1003
dose	O	1004-1008
of	O	1009-1011
5	O	1012-1013
mg	O	1014-1016
/	O	1016-1017
kg	O	1017-1019
(	O	1020-1021
i	O	1021-1022
.	O	1022-1023
v	O	1023-1024
.	O	1022-1023
)	O	1025-1026
into	O	1027-1031
6	O	1032-1033
anaesthetized	O	1034-1047
dogs	O	1048-1052
which	O	1053-1058
had	O	1059-1062
undergone	O	1063-1072
ablation	O	1073-1081
of	O	1082-1084
all	O	1085-1088
the	O	1089-1092
extrinsic	O	1093-1102
cardiac	O	1103-1110
afferent	O	1111-1119
nerve	O	1120-1125
supply	O	1126-1132
,	O	1132-1133
together	O	1134-1142
with	O	1143-1147
a	O	1148-1149
bilateral	O	1150-1159
medullo	O	1160-1167
-	O	1167-1168
adrenalectomy	O	1168-1181
,	O	1181-1182
caused	O	1183-1189
a	O	1190-1191
marked	O	1192-1198
reduction	O	1199-1208
in	O	1209-1211
heart	O	1212-1217
rate	O	1218-1222
which	O	1223-1228
fell	O	1229-1233
from	O	1234-1238
98	O	1239-1241
.	O	1241-1242
7	O	1242-1243
+	O	1244-1245
/	O	1245-1246
-	O	1246-1247
4	O	1248-1249
.	O	1249-1250
2	O	1250-1251
beats	O	1252-1257
/	O	1257-1258
min	O	1258-1261
to	O	1262-1264
76	O	1265-1267
+	O	1268-1269
/	O	1269-1270
-	O	1270-1271
5	O	1272-1273
.	O	1273-1274
3	O	1274-1275
beats	O	1276-1281
/	O	1281-1282
min	O	1282-1285
sustained	O	1286-1295
for	O	1296-1299
more	O	1300-1304
than	O	1305-1309
45	O	1310-1312
min	O	1313-1316
.	O	1316-1317

It	O	1318-1320
is	O	1321-1323
concluded	O	1324-1333
that	O	1334-1338
bepridil	O	1339-1347
reduces	O	1348-1355
heart	O	1356-1361
rate	O	1362-1366
by	O	1367-1369
acting	O	1370-1376
directly	O	1377-1385
on	O	1386-1388
the	O	1389-1392
sinus	O	1393-1398
node	O	1399-1403
.	O	1403-1404

This	O	1405-1409
effect	O	1410-1416
,	O	1416-1417
which	O	1418-1423
results	O	1424-1431
in	O	1432-1434
a	O	1435-1436
flattening	O	1437-1447
of	O	1448-1450
the	O	1451-1454
phase	O	1455-1460
0	O	1461-1462
and	O	1463-1466
phase	O	1467-1472
4	O	1473-1474
slope	O	1475-1480
,	O	1480-1481
together	O	1482-1490
with	O	1491-1495
a	O	1496-1497
longer	O	1498-1504
AP	O	1505-1507
duration	O	1508-1516
,	O	1516-1517
may	O	1518-1521
be	O	1522-1524
due	O	1525-1528
to	O	1529-1531
an	O	1532-1534
increase	O	1535-1543
in	O	1544-1546
the	O	1547-1550
time	O	1551-1555
constants	O	1556-1565
of	O	1566-1568
slow	O	1569-1573
inward	O	1574-1580
ionic	O	1581-1586
currents	O	1587-1595
(	O	1596-1597
already	O	1597-1604
demonstrated	O	1605-1617
elsewhere	O	1618-1627
)	O	1627-1628
,	O	1628-1629
but	O	1630-1633
also	O	1634-1638
to	O	1639-1641
an	O	1642-1644
increased	O	1645-1654
time	O	1655-1659
constant	O	1660-1668
for	O	1669-1672
deactivation	O	1673-1685
of	O	1686-1688
the	O	1689-1692
outward	O	1693-1700
potassium	O	1701-1710
current	O	1711-1718
(	O	1719-1720
Ip	O	1720-1722
)	O	1722-1723
.	O	1723-1724

Hepatitis	B	0-9
and	O	10-13
renal	B	14-19
tubular	I	20-27
acidosis	I	28-36
after	O	37-42
anesthesia	O	43-53
with	O	54-58
methoxyflurane	O	59-73
.	O	73-74

A	O	75-76
69	O	77-79
-	O	79-80
year	O	80-84
-	O	79-80
old	O	85-88
man	O	89-92
operated	O	93-101
for	O	102-105
acute	B	106-111
cholecystitis	I	112-125
under	O	126-131
methoxyflurane	O	132-146
anesthesia	O	147-157
developed	O	158-167
postoperatively	O	168-183
a	O	184-185
hepatic	B	186-193
insufficiency	I	194-207
syndrome	I	208-216
and	O	217-220
renal	B	221-226
tubular	I	227-234
acidosis	I	235-243
.	O	243-244

Massive	O	245-252
bleeding	B	253-261
appeared	O	262-270
during	O	271-277
surgery	O	278-285
which	O	286-291
lasted	O	292-298
for	O	299-302
six	O	303-306
hours	O	307-312
.	O	312-313

Postoperative	O	314-327
evolution	O	328-337
under	O	338-343
supportive	O	344-354
therapy	O	355-362
was	O	363-366
favourable	O	367-377
.	O	377-378

Complete	O	379-387
recovery	O	388-396
was	O	397-400
confirmed	O	401-410
by	O	411-413
repeated	O	414-422
controls	O	423-431
performed	O	432-441
over	O	442-446
a	O	447-448
period	O	449-455
of	O	456-458
one	O	459-462
year	O	463-467
after	O	468-473
surgery	O	474-481
.	O	481-482

Pituitary	O	0-9
response	O	10-18
to	O	19-21
luteinizing	O	22-33
hormone	O	34-41
-	O	41-42
releasing	O	42-51
hormone	O	52-59
during	O	60-66
haloperidol	O	67-78
-	O	78-79
induced	O	79-86
hyperprolactinemia	B	87-105
.	O	105-106

The	O	107-110
effects	O	111-118
of	O	119-121
a	O	122-123
6	O	124-125
-	O	125-126
hour	O	126-130
infusion	O	131-139
with	O	140-144
haloperidol	O	145-156
on	O	157-159
serum	O	160-165
prolactin	O	166-175
and	O	176-179
luteinizing	O	180-191
hormone	O	192-199
(	O	200-201
LH	O	201-203
)	O	203-204
levels	O	205-211
was	O	212-215
studied	O	216-223
in	O	224-226
a	O	227-228
group	O	229-234
of	O	235-237
male	O	238-242
subjects	O	243-251
.	O	251-252

Five	O	253-257
hours	O	258-263
after	O	264-269
starting	O	270-278
the	O	279-282
infusions	O	283-292
,	O	292-293
a	O	294-295
study	O	296-301
of	O	302-304
the	O	305-308
pituitary	O	309-318
responses	O	319-328
to	O	329-331
LH	O	332-334
-	O	334-335
releasing	O	335-344
hormone	O	345-352
(	O	353-354
LH	O	354-356
-	O	356-357
RH	O	357-359
)	O	359-360
was	O	361-364
carried	O	365-372
out	O	373-376
.	O	376-377

Control	O	378-385
patients	O	386-394
received	O	395-403
infusions	O	404-413
of	O	414-416
0	O	417-418
.	O	418-419
9	O	419-420
%	O	420-421
NaCl	O	422-426
solution	O	427-435
.	O	435-436

During	O	437-443
the	O	444-447
course	O	448-454
of	O	455-457
haloperidol	O	458-469
infusions	O	470-479
,	O	479-480
significant	O	481-492
hyperprolactinemia	B	493-511
was	O	512-515
found	O	516-521
,	O	521-522
together	O	523-531
with	O	532-536
an	O	537-539
abolished	O	540-549
pituitary	O	550-559
response	O	560-568
to	O	569-571
LH	O	572-574
-	O	574-575
RH	O	575-577
,	O	577-578
as	O	579-581
compared	O	582-590
with	O	591-595
responses	O	596-605
of	O	606-608
control	O	609-616
subjects	O	617-625
.	O	625-626

Antirifampicin	O	0-14
antibodies	O	15-25
in	O	26-28
acute	O	29-34
rifampicin	O	35-45
-	O	45-46
associated	O	46-56
renal	B	57-62
failure	I	63-70
.	O	70-71

5	O	72-73
patients	O	74-82
with	O	83-87
acute	B	88-93
renal	I	94-99
failure	I	100-107
(	O	108-109
3	O	109-110
with	O	111-115
thrombopenia	B	116-128
and	O	129-132
hemolysis	B	133-142
)	O	142-143
induced	O	144-151
by	O	152-154
the	O	155-158
reintroduction	O	159-173
of	O	174-176
rifampicin	O	177-187
are	O	188-191
described	O	192-201
.	O	201-202

No	O	203-205
correlation	O	206-217
was	O	218-221
found	O	222-227
between	O	228-235
the	O	236-239
severity	O	240-248
of	O	249-251
clinical	O	252-260
manifestations	O	261-275
and	O	276-279
the	O	280-283
total	O	284-289
dose	O	290-294
taken	O	295-300
by	O	301-303
the	O	304-307
patients	O	308-316
.	O	316-317

In	O	318-320
all	O	321-324
but	O	325-328
1	O	329-330
patient	O	331-338
,	O	338-339
antirifampicin	O	340-354
antibodies	O	355-365
were	O	366-370
detected	O	371-379
.	O	379-380

Antibodies	O	381-391
suggested	O	392-401
to	O	402-404
be	O	405-407
of	O	408-410
the	O	411-414
IgM	O	415-418
class	O	419-424
were	O	425-429
detected	O	430-438
in	O	439-441
all	O	442-445
3	O	446-447
patients	O	448-456
with	O	457-461
hematological	B	462-475
disorders	I	476-485
.	O	485-486

The	O	487-490
pattern	O	491-498
of	O	499-501
non	O	502-505
-	O	505-506
specific	O	506-514
acute	B	515-520
tubular	I	521-528
necrosis	I	529-537
found	O	538-543
in	O	544-546
the	O	547-550
2	O	551-552
biopsied	O	553-561
patients	O	562-570
,	O	570-571
indistinguishable	O	572-589
from	O	590-594
that	O	595-599
of	O	600-602
ischemic	O	603-611
origin	O	612-618
,	O	618-619
raised	O	620-626
the	O	627-630
possibility	O	631-642
of	O	643-645
a	O	646-647
vascular	O	648-656
-	O	656-657
mediated	O	657-665
damage	O	666-672
.	O	672-673

In	O	674-676
3	O	677-678
patients	O	679-687
,	O	687-688
the	O	689-692
possibility	O	693-704
of	O	705-707
a	O	708-709
triggering	O	710-720
immunoallergic	O	721-735
mechanism	O	736-745
is	O	746-748
discussed	O	749-758
.	O	758-759

Cardiovascular	O	0-14
effects	O	15-22
of	O	23-25
hypotension	B	26-37
induced	O	38-45
by	O	46-48
adenosine	O	49-58
triphosphate	O	59-71
and	O	72-75
sodium	O	76-82
nitroprusside	O	83-96
on	O	97-99
dogs	O	100-104
with	O	105-109
denervated	O	110-120
hearts	O	121-127
.	O	127-128

Adenosine	O	129-138
triphosphate	O	139-151
(	O	152-153
ATP	O	153-156
)	O	156-157
and	O	158-161
sodium	O	162-168
nitroprusside	O	169-182
(	O	183-184
SNP	O	184-187
)	O	187-188
are	O	189-192
administered	O	193-205
to	O	206-208
patients	O	209-217
to	O	218-220
induce	O	221-227
and	O	228-231
control	O	232-239
hypotension	B	240-251
during	O	252-258
anesthesia	O	259-269
.	O	269-270

SNP	O	271-274
is	O	275-277
authorized	O	278-288
for	O	289-292
clinical	O	293-301
use	O	302-305
in	O	306-308
USA	O	309-312
and	O	313-316
UK	O	317-319
,	O	319-320
and	O	321-324
ATP	O	325-328
is	O	329-331
clinically	O	332-342
used	O	343-347
in	O	348-350
other	O	351-356
countries	O	357-366
such	O	367-371
as	O	372-374
Japan	O	375-380
.	O	380-381

We	O	382-384
investigated	O	385-397
how	O	398-401
these	O	402-407
two	O	408-411
drugs	O	412-417
act	O	418-421
on	O	422-424
the	O	425-428
cardiovascular	O	429-443
systems	O	444-451
of	O	452-454
20	O	455-457
dogs	O	458-462
whose	O	463-468
hearts	O	469-475
had	O	476-479
been	O	480-484
denervated	O	485-495
by	O	496-498
a	O	499-500
procedure	O	501-510
we	O	511-513
had	O	514-517
devised	O	518-525
.	O	525-526

ATP	O	527-530
(	O	531-532
10	O	532-534
dogs	O	535-539
)	O	539-540
or	O	541-543
SNP	O	544-547
(	O	548-549
10	O	549-551
dogs	O	552-556
)	O	556-557
was	O	558-561
administered	O	562-574
to	O	575-577
reduce	O	578-584
mean	O	585-589
arterial	O	590-598
pressure	O	599-607
by	O	608-610
30	O	611-613
%	O	613-614
to	O	615-617
70	O	618-620
%	O	620-621
of	O	622-624
control	O	625-632
.	O	632-633

Before	O	634-640
,	O	640-641
during	O	642-648
and	O	649-652
after	O	653-658
induced	O	659-666
hypotension	B	667-678
,	O	678-679
we	O	680-682
measured	O	683-691
major	O	692-697
cardiovascular	O	698-712
parameters	O	713-723
.	O	723-724

Hypotension	B	725-736
induced	O	737-744
by	O	745-747
ATP	O	748-751
was	O	752-755
accompanied	O	756-767
by	O	768-770
significant	O	771-782
decreases	O	783-792
in	O	793-795
mean	O	796-800
pulmonary	O	801-810
arterial	O	811-819
pressure	O	820-828
(	O	829-830
p	O	830-831
less	O	832-836
than	O	837-841
0	O	842-843
.	O	843-844
001	O	844-847
)	O	847-848
,	O	848-849
central	O	850-857
venous	O	858-864
pressure	O	865-873
(	O	874-875
p	O	875-876
less	O	877-881
than	O	882-886
0	O	887-888
.	O	888-889
001	O	889-892
)	O	892-893
,	O	893-894
left	O	895-899
ventricular	O	900-911
end	O	912-915
-	O	915-916
diastolic	O	916-925
pressure	O	926-934
(	O	935-936
p	O	936-937
less	O	938-942
than	O	943-947
0	O	948-949
.	O	949-950
001	O	950-953
)	O	953-954
,	O	954-955
total	O	956-961
peripheral	O	962-972
resistance	O	973-983
(	O	984-985
p	O	985-986
less	O	987-991
than	O	992-996
0	O	997-998
.	O	998-999
001	O	999-1002
)	O	1002-1003
,	O	1003-1004
rate	O	1005-1009
pressure	O	1010-1018
product	O	1019-1026
(	O	1027-1028
p	O	1028-1029
less	O	1030-1034
than	O	1035-1039
0	O	1040-1041
.	O	1041-1042
001	O	1042-1045
)	O	1045-1046
,	O	1046-1047
total	O	1048-1053
body	O	1054-1058
oxygen	O	1059-1065
consumption	O	1066-1077
(	O	1078-1079
p	O	1079-1080
less	O	1081-1085
than	O	1086-1090
0	O	1091-1092
.	O	1092-1093
05	O	1093-1095
)	O	1095-1096
,	O	1096-1097
and	O	1098-1101
heart	O	1102-1107
rate	O	1108-1112
(	O	1113-1114
p	O	1114-1115
less	O	1116-1120
than	O	1121-1125
0	O	1126-1127
.	O	1127-1128
001	O	1128-1131
)	O	1131-1132
;	O	1132-1133
all	O	1134-1137
these	O	1138-1143
variables	O	1144-1153
returned	O	1154-1162
normal	O	1163-1169
within	O	1170-1176
30	O	1177-1179
min	O	1180-1183
after	O	1184-1189
ATP	O	1190-1193
was	O	1194-1197
stopped	O	1198-1205
.	O	1205-1206

Cardiac	O	1207-1214
output	O	1215-1221
did	O	1222-1225
not	O	1226-1229
change	O	1230-1236
.	O	1236-1237

During	O	1238-1244
hypotension	B	1245-1256
produced	O	1257-1265
by	O	1266-1268
SNP	O	1269-1272
similar	O	1273-1280
decreases	O	1281-1290
were	O	1291-1295
observed	O	1296-1304
in	O	1305-1307
mean	O	1308-1312
pulmonary	O	1313-1322
arterial	O	1323-1331
pressure	O	1332-1340
(	O	1341-1342
p	O	1342-1343
less	O	1344-1348
than	O	1349-1353
0	O	1354-1355
.	O	1355-1356
01	O	1356-1358
)	O	1358-1359
,	O	1359-1360
central	O	1361-1368
venous	O	1369-1375
pressure	O	1376-1384
(	O	1385-1386
p	O	1386-1387
less	O	1388-1392
than	O	1393-1397
0	O	1398-1399
.	O	1399-1400
001	O	1400-1403
)	O	1403-1404
,	O	1404-1405
left	O	1406-1410
ventricular	O	1411-1422
end	O	1423-1426
-	O	1426-1427
diastolic	O	1427-1436
pressure	O	1437-1445
(	O	1446-1447
p	O	1447-1448
less	O	1449-1453
than	O	1454-1458
0	O	1459-1460
.	O	1460-1461
01	O	1461-1463
)	O	1463-1464
,	O	1464-1465
total	O	1466-1471
peripheral	O	1472-1482
resistance	O	1483-1493
(	O	1494-1495
p	O	1495-1496
less	O	1497-1501
than	O	1502-1506
0	O	1507-1508
.	O	1508-1509
001	O	1509-1512
)	O	1512-1513
,	O	1513-1514
rate	O	1515-1519
pressure	O	1520-1528
product	O	1529-1536
(	O	1537-1538
p	O	1538-1539
less	O	1540-1544
than	O	1545-1549
0	O	1550-1551
.	O	1551-1552
001	O	1552-1555
)	O	1555-1556
,	O	1556-1557
and	O	1558-1561
oxygen	O	1562-1568
content	O	1569-1576
difference	O	1577-1587
between	O	1588-1595
arterial	O	1596-1604
and	O	1605-1608
mixed	O	1609-1614
venous	O	1615-1621
blood	O	1622-1627
(	O	1628-1629
p	O	1629-1630
less	O	1631-1635
than	O	1636-1640
0	O	1641-1642
.	O	1642-1643
05	O	1643-1645
)	O	1645-1646
,	O	1646-1647
while	O	1648-1653
heart	O	1654-1659
rate	O	1660-1664
(	O	1665-1666
p	O	1666-1667
less	O	1668-1672
than	O	1673-1677
0	O	1678-1679
.	O	1679-1680
001	O	1680-1683
)	O	1683-1684
and	O	1685-1688
cardiac	O	1689-1696
output	O	1697-1703
(	O	1704-1705
p	O	1705-1706
less	O	1707-1711
than	O	1712-1716
0	O	1717-1718
.	O	1718-1719
05	O	1719-1721
)	O	1721-1722
were	O	1723-1727
increased	O	1728-1737
.	O	1737-1738

Recoveries	O	1739-1749
of	O	1750-1752
heart	O	1753-1758
rate	O	1759-1763
and	O	1764-1767
left	O	1768-1772
ventricular	O	1773-1784
end	O	1785-1788
-	O	1788-1789
diastolic	O	1789-1798
pressure	O	1799-1807
were	O	1808-1812
not	O	1813-1816
shown	O	1817-1822
within	O	1823-1829
60	O	1830-1832
min	O	1833-1836
after	O	1837-1842
SNP	O	1843-1846
had	O	1847-1850
been	O	1851-1855
stopped	O	1856-1863
.	O	1863-1864

Both	O	1865-1869
ATP	O	1870-1873
and	O	1874-1877
SNP	O	1878-1881
should	O	1882-1888
act	O	1889-1892
on	O	1893-1895
the	O	1896-1899
pacemaker	O	1900-1909
tissue	O	1910-1916
of	O	1917-1919
the	O	1920-1923
heart	O	1924-1929
.	O	1929-1930

Comparative	O	0-11
study	O	12-17
:	O	17-18
Endografine	O	19-30
(	O	31-32
diatrizoate	O	32-43
)	O	43-44
,	O	44-45
Vasurix	O	46-53
polyvidone	O	54-64
(	O	65-66
acetrizoate	O	66-77
)	O	77-78
,	O	78-79
Dimer	O	80-85
-	O	85-86
X	O	86-87
(	O	88-89
iocarmate	O	89-98
)	O	98-99
and	O	100-103
Hexabrix	O	104-112
(	O	113-114
ioxaglate	O	114-123
)	O	123-124
in	O	125-127
hysterosalpingography	O	128-149
.	O	149-150

Side	O	151-155
effects	O	156-163
of	O	164-166
hysterosalpingography	O	167-188
with	O	189-193
Dimer	O	194-199
-	O	199-200
X	O	200-201
,	O	201-202
Hexabrix	O	203-211
,	O	211-212
Vasurix	O	213-220
polyvidone	O	221-231
and	O	232-235
Endografine	O	236-247
in	O	248-250
142	O	251-254
consecutive	O	255-266
patients	O	267-275
,	O	275-276
receiving	O	277-286
one	O	287-290
of	O	291-293
the	O	294-297
four	O	298-302
tested	O	303-309
media	O	310-315
were	O	316-320
evaluated	O	321-330
from	O	331-335
replies	O	336-343
to	O	344-346
postal	O	347-353
questionnaires	O	354-368
.	O	368-369

The	O	370-373
Dimer	O	374-379
-	O	379-380
X	O	380-381
group	O	382-387
had	O	388-391
a	O	392-393
higher	O	394-400
incidence	O	401-410
of	O	411-413
nausea	B	414-420
and	O	421-424
dizziness	B	425-434
.	O	434-435

The	O	436-439
Endografine	O	440-451
group	O	452-457
had	O	458-461
a	O	462-463
higher	O	464-470
incidence	O	471-480
of	O	481-483
abdominal	B	484-493
pain	I	494-498
.	O	498-499

These	O	500-505
differences	O	506-517
occur	O	518-523
especially	O	524-534
in	O	535-537
the	O	538-541
age	O	542-545
groups	O	546-552
under	O	553-558
30	O	559-561
years	O	562-567
.	O	567-568

Hexabrix	O	569-577
and	O	578-581
Vasurix	O	582-589
polyvidone	O	590-600
are	O	601-604
considered	O	605-615
the	O	616-619
best	O	620-624
contrast	O	625-633
media	O	634-639
for	O	640-643
hysterosalpingography	O	644-665
and	O	666-669
perhaps	O	670-677
because	O	678-685
of	O	686-688
its	O	689-692
low	O	693-696
toxicity	B	697-705
Hexabrix	O	706-714
should	O	715-721
be	O	722-724
preferred	O	725-734
.	O	734-735

Post	O	0-4
-	O	4-5
suxamethonium	O	5-18
pains	B	19-24
in	O	25-27
Nigerian	O	28-36
surgical	O	37-45
patients	O	46-54
.	O	54-55

Contrary	O	56-64
to	O	65-67
an	O	68-70
earlier	O	71-78
report	O	79-85
by	O	86-88
Coxon	O	89-94
,	O	94-95
scoline	O	96-103
pain	B	104-108
occurs	O	109-115
in	O	116-118
African	O	119-126
negroes	O	127-134
.	O	134-135

Its	O	136-139
incidence	O	140-149
was	O	150-153
determined	O	154-164
in	O	165-167
a	O	168-169
prospective	O	170-181
study	O	182-187
involving	O	188-197
a	O	198-199
total	O	200-205
of	O	206-208
100	O	209-212
Nigerian	O	213-221
patients	O	222-230
(	O	231-232
50	O	232-234
out	O	235-238
-	O	238-239
patients	O	239-247
and	O	248-251
50	O	252-254
in	O	255-257
-	O	257-258
patients	O	258-266
)	O	266-267
.	O	267-268

About	O	269-274
62	O	275-277
%	O	277-278
of	O	279-281
the	O	282-285
out	O	286-289
-	O	289-290
patients	O	290-298
developed	O	299-308
scoline	O	309-316
pain	B	317-321
as	O	322-324
compared	O	325-333
with	O	334-338
about	O	339-344
26	O	345-347
%	O	347-348
among	O	349-354
the	O	355-358
in	O	359-361
-	O	361-362
patients	O	362-370
.	O	370-371

The	O	372-375
abolition	O	376-385
of	O	386-388
muscle	O	389-395
fasciculations	B	396-410
(	O	411-412
by	O	412-414
0	O	415-416
.	O	416-417
075mg	O	417-422
/	O	422-423
kg	O	423-425
dose	O	426-430
of	O	431-433
Fazadinium	O	434-444
)	O	444-445
did	O	446-449
not	O	450-453
influence	O	454-463
the	O	464-467
occurrence	O	468-478
of	O	479-481
scoline	O	482-489
pain	B	490-494
.	O	494-495

Neither	O	496-503
the	O	504-507
type	O	508-512
of	O	513-515
induction	O	516-525
agent	O	526-531
(	O	532-533
Althesin	O	533-541
or	O	542-544
Thiopentone	O	545-556
)	O	556-557
nor	O	558-561
the	O	562-565
salt	O	566-570
preparation	O	571-582
of	O	583-585
suxamethonium	O	586-599
used	O	600-604
(	O	605-606
chloride	O	606-614
or	O	615-617
bromide	O	618-625
)	O	625-626
,	O	626-627
affected	O	628-636
the	O	637-640
incidence	O	641-650
of	O	651-653
scoline	O	654-661
pain	B	662-666
.	O	666-667

Medial	O	0-6
changes	O	7-14
in	O	15-17
arterial	O	18-26
spasm	B	27-32
induced	O	33-40
by	O	41-43
L	O	44-45
-	O	45-46
norepinephrine	O	46-60
.	O	60-61

In	O	62-64
normal	O	65-71
rats	O	72-76
,	O	76-77
the	O	78-81
media	O	82-87
of	O	88-90
small	O	91-96
arteries	O	97-105
(	O	106-107
0	O	107-108
.	O	108-109
4	O	109-110
-	O	110-111
-	O	110-111
0	O	107-108
.	O	108-109
2	O	114-115
mm	O	116-118
in	O	119-121
diameter	O	122-130
)	O	130-131
previously	O	132-142
was	O	143-146
shown	O	147-152
to	O	153-155
contain	O	156-163
intracellular	O	164-177
vacuoles	O	178-186
,	O	186-187
identified	O	188-198
ultrastructurally	O	199-216
as	O	217-219
herniations	O	220-231
of	O	232-234
one	O	235-238
smooth	O	239-245
muscle	O	246-252
cell	O	253-257
into	O	258-262
another	O	263-270
.	O	270-271

The	O	272-275
hypothesis	O	276-286
that	O	287-291
intense	O	292-299
vasoconstriction	O	300-316
would	O	317-322
increase	O	323-331
the	O	332-335
number	O	336-342
of	O	343-345
such	O	346-350
vacuoles	O	351-359
has	O	360-363
been	O	364-368
tested	O	369-375
.	O	375-376

In	O	377-379
the	O	380-383
media	O	384-389
of	O	390-392
the	O	393-396
saphenous	O	397-406
artery	O	407-413
and	O	414-417
its	O	418-421
distal	O	422-428
branch	O	429-435
,	O	435-436
vasoconstriction	O	437-453
induced	O	454-461
by	O	462-464
L	O	465-466
-	O	466-467
norepinephrine	O	467-481
produced	O	482-490
many	O	491-495
cell	O	496-500
-	O	500-501
to	O	501-503
-	O	500-501
cell	O	496-500
hernias	B	509-516
within	O	517-523
15	O	524-526
minutes	O	527-534
.	O	534-535

At	O	536-538
1	O	539-540
day	O	541-544
their	O	545-550
number	O	551-557
was	O	558-561
reduced	O	562-569
to	O	570-572
about	O	573-578
1	O	579-580
/	O	580-581
10	O	581-583
of	O	584-586
the	O	587-590
original	O	591-599
number	O	600-606
.	O	606-607

By	O	608-610
7	O	611-612
days	O	613-617
the	O	618-621
vessel	O	622-628
was	O	629-632
almost	O	633-639
restored	O	640-648
to	O	649-651
normal	O	652-658
.	O	658-659

Triple	O	660-666
stimulation	O	667-678
over	O	679-683
1	O	684-685
day	O	686-689
induced	O	690-697
more	O	698-702
severe	O	703-709
changes	O	710-717
in	O	718-720
the	O	721-724
media	O	725-730
.	O	730-731

These	O	732-737
findings	O	738-746
suggest	O	747-754
that	O	755-759
smooth	O	760-766
muscle	O	767-773
cells	O	774-779
are	O	780-783
susceptible	O	784-795
to	O	796-798
damage	O	799-805
in	O	806-808
the	O	809-812
course	O	813-819
of	O	820-822
their	O	823-828
specific	O	829-837
function	O	838-846
.	O	846-847

The	O	848-851
experimental	O	852-864
data	O	865-869
are	O	870-873
discussed	O	874-883
in	O	884-886
relation	O	887-895
to	O	896-898
medial	O	899-905
changes	O	906-913
observed	O	914-922
in	O	923-925
other	O	926-931
instances	O	932-941
of	O	942-944
arterial	O	945-953
spasm	B	954-959
.	O	959-960

Endothelial	O	961-972
changes	O	973-980
that	O	981-985
developed	O	986-995
in	O	996-998
the	O	999-1002
same	O	1003-1007
experimental	O	1008-1020
model	O	1021-1026
were	O	1027-1031
described	O	1032-1041
in	O	1042-1044
a	O	1045-1046
previous	O	1047-1055
paper	O	1056-1061
.	O	1061-1062

Abnormalities	O	0-13
of	O	14-16
the	O	17-20
pupil	O	21-26
and	O	27-30
visual	O	31-37
-	O	37-38
evoked	O	38-44
potential	O	45-54
in	O	55-57
quinine	O	58-65
amblyopia	B	66-75
.	O	75-76

Total	O	77-82
blindness	B	83-92
with	O	93-97
a	O	98-99
transient	O	100-109
tonic	B	110-115
pupillary	I	116-125
response	O	126-134
,	O	134-135
denervation	O	136-147
supersensitivity	O	148-164
,	O	164-165
and	O	166-169
abnormal	O	170-178
visual	O	179-185
-	O	185-186
evoked	O	186-192
potentials	O	193-203
developed	O	204-213
in	O	214-216
a	O	217-218
54	O	219-221
-	O	221-222
year	O	222-226
-	O	221-222
old	O	227-230
man	O	231-234
after	O	235-240
the	O	241-244
use	O	245-248
of	O	249-251
quinine	O	252-259
sulfate	O	260-267
for	O	268-271
leg	B	272-275
cramps	I	276-282
.	O	282-283

He	O	284-286
later	O	287-292
recovered	O	293-302
normal	O	303-309
visual	O	310-316
acuity	O	317-323
.	O	323-324

A	O	325-326
transient	O	327-336
tonic	B	337-342
pupillary	I	343-352
response	O	353-361
,	O	361-362
denervation	O	363-374
supersensitivity	O	375-391
,	O	391-392
and	O	393-396
abnormal	O	397-405
visual	O	406-412
-	O	412-413
evoked	O	413-419
potentials	O	420-430
in	O	431-433
quinine	O	434-441
toxicity	B	442-450
,	O	450-451
to	O	452-454
our	O	455-458
knowledge	O	459-468
,	O	468-469
have	O	470-474
not	O	475-478
been	O	479-483
previously	O	484-494
reported	O	495-503
.	O	503-504

Suxamethonium	O	0-13
-	O	13-14
induced	O	14-21
jaw	B	22-25
stiffness	I	26-35
and	O	36-39
myalgia	B	40-47
associated	O	48-58
with	O	59-63
atypical	O	64-72
cholinesterase	O	73-87
:	O	87-88
case	O	89-93
report	O	94-100
.	O	100-101

An	O	102-104
11	O	105-107
-	O	107-108
year	O	108-112
-	O	107-108
old	O	113-116
boy	O	117-120
was	O	121-124
given	O	125-130
halothane	O	131-140
,	O	140-141
nitrous	O	142-149
oxide	O	150-155
and	O	156-159
oxygen	O	160-166
,	O	166-167
pancuronium	O	168-179
0	O	180-181
.	O	181-182
4	O	182-183
mg	O	184-186
and	O	187-190
suxamethonium	O	191-204
100	O	205-208
mg	O	209-211
for	O	212-215
induction	O	216-225
of	O	226-228
anaesthesia	O	229-240
.	O	240-241

In	O	242-244
response	O	245-253
to	O	254-256
this	O	257-261
a	O	262-263
marked	O	264-270
jaw	B	271-274
stiffness	I	275-284
occurred	O	285-293
which	O	294-299
lasted	O	300-306
for	O	307-310
two	O	311-314
minutes	O	315-322
and	O	323-326
the	O	327-330
anaesthesia	O	331-342
were	O	343-347
terminated	O	348-358
.	O	358-359

Four	O	360-364
hours	O	365-370
of	O	371-373
apnoea	B	374-380
ensued	O	381-387
and	O	388-391
he	O	392-394
suffered	O	395-403
generalized	O	404-415
severe	O	416-422
myalgia	B	423-430
lasting	O	431-438
for	O	439-442
one	O	443-446
week	O	447-451
.	O	451-452

He	O	453-455
was	O	456-459
found	O	460-465
to	O	466-468
have	O	469-473
atypical	O	474-482
plasma	O	483-489
cholinesterase	O	490-504
with	O	505-509
a	O	510-511
dibucaine	O	512-521
number	O	522-528
of	O	529-531
12	O	532-534
,	O	534-535
indicating	O	536-546
homozygocity	O	547-559
.	O	559-560

This	O	561-565
was	O	566-569
verified	O	570-578
by	O	579-581
study	O	582-587
of	O	588-590
the	O	591-594
family	O	595-601
.	O	601-602

The	O	603-606
case	O	607-611
shows	O	612-617
that	O	618-622
prolonged	B	623-632
jaw	I	633-636
rigidity	I	637-645
and	O	646-649
myalgia	B	650-657
may	O	658-661
occur	O	662-667
after	O	668-673
suxamethonium	O	674-687
in	O	688-690
patients	O	691-699
with	O	700-704
atypical	O	705-713
cholinesterase	O	714-728
despite	O	729-736
pretreatment	O	737-749
with	O	750-754
pancuronium	O	755-766
.	O	766-767

Indomethacin	O	0-12
-	O	12-13
induced	O	13-20
hyperkalemia	B	21-33
in	O	34-36
three	O	37-42
patients	O	43-51
with	O	52-56
gouty	B	57-62
arthritis	I	63-72
.	O	72-73

We	O	74-76
describe	O	77-85
three	O	86-91
patients	O	92-100
in	O	101-103
whom	O	104-108
severe	O	109-115
,	O	115-116
life	O	117-121
-	O	121-122
threatening	O	122-133
hyperkalemia	B	134-146
and	O	147-150
renal	B	151-156
insufficiency	I	157-170
developed	O	171-180
after	O	181-186
treatment	O	187-196
of	O	197-199
acute	O	200-205
gouty	B	206-211
arthritis	I	212-221
with	O	222-226
indomethacin	O	227-239
.	O	239-240

This	O	241-245
complication	O	246-258
may	O	259-262
result	O	263-269
from	O	270-274
an	O	275-277
inhibition	O	278-288
of	O	289-291
prostaglandin	O	292-305
synthesis	O	306-315
and	O	316-319
consequent	O	320-330
hyporeninemic	B	331-344
hypoaidosteronism	I	345-362
.	O	362-363

Careful	O	364-371
attention	O	372-381
to	O	382-384
renal	O	385-390
function	O	391-399
and	O	400-403
potassium	O	404-413
balance	O	414-421
in	O	422-424
patients	O	425-433
receiving	O	434-443
indomethacin	O	444-456
or	O	457-459
other	O	460-465
nonsteroidal	O	466-478
anti	O	479-483
-	O	483-484
inflammatory	O	484-496
agents	O	497-503
,	O	503-504
particularly	O	505-517
in	O	518-520
those	O	521-526
patients	O	527-535
with	O	536-540
diabetes	B	541-549
mellitus	I	550-558
or	O	559-561
preexisting	O	562-573
renal	B	574-579
disease	I	580-587
,	O	587-588
will	O	589-593
help	O	594-598
prevent	O	599-606
this	O	607-611
potentially	O	612-623
serious	O	624-631
complication	O	632-644
.	O	644-645

Etomidate	O	0-9
:	O	9-10
a	O	11-12
foreshortened	O	13-26
clinical	O	27-35
trial	O	36-41
.	O	41-42

A	O	43-44
clinical	O	45-53
evaluation	O	54-64
of	O	65-67
etomidate	O	68-77
for	O	78-81
outpatient	O	82-92
cystoscopy	O	93-103
was	O	104-107
embarked	O	108-116
upon	O	117-121
.	O	121-122

Unpremedicated	O	123-137
patients	O	138-146
were	O	147-151
given	O	152-157
fentanyl	O	158-166
1	O	167-168
microgram	O	169-178
/	O	178-179
kg	O	179-181
followed	O	182-190
by	O	191-193
etomidate	O	194-203
0	O	204-205
.	O	205-206
3	O	206-207
mg	O	208-210
/	O	210-211
kg	O	211-213
.	O	213-214

Anaesthesia	O	215-226
was	O	227-230
maintained	O	231-241
with	O	242-246
intermittent	O	247-259
etomidate	O	260-269
in	O	270-272
2	O	273-274
-	O	274-275
4	O	275-276
mg	O	277-279
doses	O	280-285
.	O	285-286

Patients	O	287-295
were	O	296-300
interviewed	O	301-312
personally	O	313-323
later	O	324-329
the	O	330-333
same	O	334-338
day	O	339-342
,	O	342-343
and	O	344-347
by	O	348-350
questionnaire	O	351-364
three	O	365-370
to	O	371-373
four	O	374-378
weeks	O	379-384
later	O	385-390
.	O	390-391

The	O	392-395
trial	O	396-401
was	O	402-405
discontinued	O	406-418
after	O	419-424
20	O	425-427
cases	O	428-433
because	O	434-441
of	O	442-444
an	O	445-447
unacceptable	O	448-460
incidence	O	461-470
of	O	471-473
side	O	474-478
effects	O	479-486
.	O	486-487

Venous	O	488-494
pain	B	495-499
occurred	O	500-508
in	O	509-511
68	O	512-514
%	O	514-515
of	O	516-518
patients	O	519-527
and	O	528-531
50	O	532-534
%	O	534-535
had	O	536-539
redness	O	540-547
,	O	547-548
pain	B	549-553
or	O	554-556
swelling	B	557-565
related	O	566-573
to	O	574-576
the	O	577-580
injection	O	581-590
site	O	591-595
,	O	595-596
in	O	597-599
some	O	600-604
cases	O	605-610
lasting	O	611-618
up	O	619-621
to	O	622-624
three	O	625-630
weeks	O	631-636
after	O	637-642
anaesthesia	O	643-654
.	O	654-655

Skeletal	O	656-664
movements	O	665-674
occurred	O	675-683
in	O	684-686
50	O	687-689
%	O	689-690
of	O	691-693
patients	O	694-702
;	O	702-703
30	O	704-706
%	O	706-707
experienced	O	708-719
respiratory	B	720-731
upset	I	732-737
,	O	737-738
one	O	739-742
sufficiently	O	743-755
severe	O	756-762
to	O	763-765
necessitate	O	766-777
abandoning	O	778-788
the	O	789-792
technique	O	793-802
.	O	802-803

Nausea	B	804-810
and	O	811-814
vomiting	B	815-823
occurred	O	824-832
in	O	833-835
40	O	836-838
%	O	838-839
and	O	840-843
25	O	844-846
%	O	846-847
had	O	848-851
disturbing	O	852-862
emergence	O	863-872
psychoses	B	873-882
.	O	882-883

Levodopa	O	0-8
-	O	8-9
induced	O	9-16
dyskinesias	B	17-28
are	O	29-32
improved	O	33-41
by	O	42-44
fluoxetine	O	45-55
.	O	55-56

We	O	57-59
evaluated	O	60-69
the	O	70-73
severity	O	74-82
of	O	83-85
motor	B	86-91
disability	I	92-102
and	O	103-106
dyskinesias	B	107-118
in	O	119-121
seven	O	122-127
levodopa	O	128-136
-	O	136-137
responsive	O	137-147
patients	O	148-156
with	O	157-161
Parkinson	B	162-171
'	I	171-172
s	I	168-169
disease	I	174-181
after	O	182-187
an	O	188-190
acute	O	191-196
challenge	O	197-206
with	O	207-211
the	O	212-215
mixed	O	216-221
dopamine	O	222-230
agonist	O	231-238
,	O	238-239
apomorphine	O	240-251
,	O	251-252
before	O	253-259
and	O	260-263
after	O	264-269
the	O	270-273
administration	O	274-288
of	O	289-291
fluoxetine	O	292-302
(	O	303-304
20	O	304-306
mg	O	307-309
twice	O	310-315
per	O	316-319
day	O	320-323
)	O	323-324
for	O	325-328
11	O	329-331
+	O	332-333
/	O	333-334
-	O	334-335
1	O	336-337
days	O	338-342
.	O	342-343

After	O	344-349
fluoxetine	O	350-360
treatment	O	361-370
,	O	370-371
there	O	372-377
was	O	378-381
a	O	382-383
significant	O	384-395
47	O	396-398
%	O	398-399
improvement	O	400-411
(	O	412-413
p	O	413-414
<	O	415-416
0	O	417-418
.	O	418-419
05	O	419-421
)	O	421-422
of	O	423-425
apomorphine	O	426-437
-	O	437-438
induced	O	438-445
dyskinesias	B	446-457
without	O	458-465
modification	O	466-478
of	O	479-481
parkinsonian	B	482-494
motor	B	495-500
disability	I	501-511
.	O	511-512

The	O	513-516
dyskinesias	B	517-528
were	O	529-533
reduced	O	534-541
predominantly	O	542-555
in	O	556-558
the	O	559-562
lower	O	563-568
limbs	O	569-574
during	O	575-581
the	O	582-585
onset	O	586-591
and	O	592-595
disappearance	O	596-609
of	O	610-612
dystonic	B	613-621
dyskinesias	I	622-633
(	O	634-635
onset	O	635-640
-	O	640-641
and	O	642-645
end	O	646-649
-	O	649-650
of	O	650-652
-	O	649-650
dose	O	653-657
dyskinesias	B	658-669
)	O	669-670
and	O	671-674
in	O	675-677
the	O	678-681
upper	O	682-687
limbs	O	688-693
during	O	694-700
choreic	B	701-708
mid	I	709-712
-	I	712-713
dose	I	713-717
dyskinesias	I	718-729
.	O	729-730

The	O	731-734
results	O	735-742
suggest	O	743-750
that	O	751-755
increased	O	756-765
brain	O	766-771
serotoninergic	O	772-786
transmission	O	787-799
with	O	800-804
fluoxetine	O	805-815
may	O	816-819
reduce	O	820-826
levodopa	O	827-835
-	O	835-836
or	O	837-839
dopamine	O	840-848
agonist	O	849-856
-	O	856-857
induced	O	857-864
dyskinesias	B	865-876
without	O	877-884
aggravating	O	885-896
parkinsonian	B	897-909
motor	B	910-915
disability	I	916-926
.	O	926-927

A	O	0-1
large	O	2-7
population	O	8-18
-	O	18-19
based	O	19-24
follow	O	25-31
-	O	31-32
up	O	32-34
study	O	35-40
of	O	41-43
trimethoprim	O	44-56
-	O	56-57
sulfamethoxazole	O	57-73
,	O	73-74
trimethoprim	O	75-87
,	O	87-88
and	O	89-92
cephalexin	O	93-103
for	O	104-107
uncommon	O	108-116
serious	O	117-124
drug	B	125-129
toxicity	I	130-138
.	O	138-139

We	O	140-142
conducted	O	143-152
a	O	153-154
population	O	155-165
-	O	165-166
based	O	166-171
45	O	172-174
-	O	174-175
day	O	175-178
follow	O	179-185
-	O	185-186
up	O	186-188
study	O	189-194
of	O	195-197
232	O	198-201
,	O	201-202
390	O	202-205
people	O	206-212
who	O	213-216
were	O	217-221
prescribed	O	222-232
trimethoprim	O	233-245
-	O	245-246
sulfamethoxazole	O	246-262
(	O	263-264
TMP	O	264-267
-	O	267-268
SMZ	O	268-271
)	O	271-272
,	O	272-273
266	O	274-277
,	O	277-278
951	O	278-281
prescribed	O	282-292
trimethoprim	O	293-305
alone	O	306-311
,	O	311-312
and	O	313-316
196	O	317-320
,	O	320-321
397	O	321-324
prescribed	O	325-335
cephalexin	O	336-346
,	O	346-347
to	O	348-350
estimate	O	351-359
the	O	360-363
risk	O	364-368
of	O	369-371
serious	O	372-379
liver	B	380-385
,	I	385-386
blood	I	387-392
,	I	392-393
skin	I	394-398
,	I	398-399
and	I	400-403
renal	I	404-409
disorders	I	410-419
resulting	O	420-429
in	O	430-432
referral	O	433-441
or	O	442-444
hospitalization	O	445-460
associated	O	461-471
with	O	472-476
these	O	477-482
drugs	O	483-488
.	O	488-489

The	O	490-493
results	O	494-501
were	O	502-506
based	O	507-512
on	O	513-515
information	O	516-527
recorded	O	528-536
on	O	537-539
office	O	540-546
computers	O	547-556
by	O	557-559
selected	O	560-568
general	O	569-576
practitioners	O	577-590
in	O	591-593
the	O	594-597
United	O	598-604
Kingdom	O	605-612
,	O	612-613
together	O	614-622
with	O	623-627
a	O	628-629
review	O	630-636
of	O	637-639
clinical	O	640-648
records	O	649-656
.	O	656-657

The	O	658-661
risk	O	662-666
of	O	667-669
clinically	O	670-680
important	O	681-690
idiopathic	O	691-701
liver	B	702-707
disease	I	708-715
was	O	716-719
similar	O	720-727
for	O	728-731
persons	O	732-739
prescribed	O	740-750
TMP	O	751-754
-	O	754-755
SMZ	O	755-758
(	O	759-760
5	O	760-761
.	O	761-762
2	O	762-763
/	O	763-764
100	O	764-767
,	O	767-768
000	O	768-771
)	O	771-772
and	O	773-776
those	O	777-782
prescribed	O	783-793
trimethoprim	O	794-806
alone	O	807-812
(	O	813-814
3	O	814-815
.	O	815-816
8	O	816-817
/	O	817-818
100	O	818-821
,	O	821-822
000	O	822-825
)	O	825-826
.	O	815-816

The	O	828-831
risk	O	832-836
for	O	837-840
those	O	841-846
prescribed	O	847-857
cephalexin	O	858-868
was	O	869-872
somewhat	O	873-881
lower	O	882-887
(	O	888-889
2	O	889-890
.	O	890-891
0	O	891-892
/	O	892-893
100	O	893-896
,	O	896-897
000	O	897-900
)	O	900-901
.	O	890-891

Only	O	903-907
five	O	908-912
patients	O	913-921
experienced	O	922-933
blood	O	934-939
disorders	O	940-949
,	O	949-950
one	O	951-954
of	O	955-957
whom	O	958-962
was	O	963-966
exposed	O	967-974
to	O	975-977
TMP	O	978-981
-	O	981-982
SMZ	O	982-985
;	O	985-986
of	O	987-989
seven	O	990-995
with	O	996-1000
erythema	B	1001-1009
multiforme	I	1010-1020
and	O	1021-1024
Stevens	B	1025-1032
-	I	1032-1033
Johnson	I	1033-1040
syndrome	I	1041-1049
,	O	1049-1050
four	O	1051-1055
were	O	1056-1060
exposed	O	1061-1068
to	O	1069-1071
TMP	O	1072-1075
-	O	1075-1076
SMZ	O	1076-1079
.	O	1079-1080

The	O	1081-1084
one	O	1085-1088
case	O	1089-1093
of	O	1094-1096
toxic	B	1097-1102
epidermal	I	1103-1112
necrolysis	I	1113-1123
occurred	O	1124-1132
in	O	1133-1135
a	O	1136-1137
patient	O	1138-1145
who	O	1146-1149
took	O	1150-1154
cephalexin	O	1155-1165
.	O	1165-1166

Finally	O	1167-1174
,	O	1174-1175
only	O	1176-1180
five	O	1181-1185
cases	O	1186-1191
of	O	1192-1194
acute	O	1195-1200
parenchymal	O	1201-1212
renal	B	1213-1218
disease	I	1219-1226
occurred	O	1227-1235
,	O	1235-1236
none	O	1237-1241
likely	O	1242-1248
to	O	1249-1251
be	O	1252-1254
caused	O	1255-1261
by	O	1262-1264
a	O	1265-1266
study	O	1267-1272
drug	O	1273-1277
.	O	1277-1278

We	O	1279-1281
conclude	O	1282-1290
that	O	1291-1295
the	O	1296-1299
risk	O	1300-1304
of	O	1305-1307
the	O	1308-1311
serious	O	1312-1319
diseases	O	1320-1328
studied	O	1329-1336
is	O	1337-1339
small	O	1340-1345
for	O	1346-1349
the	O	1350-1353
three	O	1354-1359
agents	O	1360-1366
,	O	1366-1367
and	O	1368-1371
compares	O	1372-1380
reasonably	O	1381-1391
with	O	1392-1396
the	O	1397-1400
risk	O	1401-1405
for	O	1406-1409
many	O	1410-1414
other	O	1415-1420
antibiotics	O	1421-1432
.	O	1432-1433

Clinical	O	0-8
safety	O	9-15
of	O	16-18
lidocaine	O	19-28
in	O	29-31
patients	O	32-40
with	O	41-45
cocaine	O	46-53
-	O	53-54
associated	O	54-64
myocardial	B	65-75
infarction	I	76-86
.	O	86-87

STUDY	O	88-93
OBJECTIVE	O	94-103
:	O	103-104
To	O	105-107
evaluate	O	108-116
the	O	117-120
safety	O	121-127
of	O	128-130
lidocaine	O	131-140
in	O	141-143
the	O	144-147
setting	O	148-155
of	O	156-158
cocaine	O	159-166
-	O	166-167
induced	O	167-174
myocardial	B	175-185
infarction	I	186-196
(	O	197-198
MI	B	198-200
)	O	200-201
.	O	201-202

DESIGN	O	203-209
:	O	209-210
A	O	211-212
retrospective	O	213-226
,	O	226-227
multicenter	O	228-239
study	O	240-245
.	O	245-246

SETTING	O	247-254
:	O	254-255
Twenty	O	256-262
-	O	262-263
nine	O	263-267
university	O	268-278
,	O	278-279
university	O	280-290
-	O	290-291
affiliated	O	291-301
,	O	301-302
or	O	303-305
community	O	306-315
hospitals	O	316-325
during	O	326-332
a	O	333-334
6	O	335-336
-	O	336-337
year	O	337-341
period	O	342-348
(	O	349-350
total	O	350-355
of	O	356-358
117	O	359-362
cumulative	O	363-373
hospital	O	374-382
-	O	382-383
years	O	383-388
)	O	388-389
.	O	389-390

PARTICIPANTS	O	391-403
:	O	403-404
Patients	O	405-413
with	O	414-418
cocaine	O	419-426
-	O	426-427
associated	O	427-437
MI	B	438-440
who	O	441-444
received	O	445-453
lidocaine	O	454-463
in	O	464-466
the	O	467-470
emergency	O	471-480
department	O	481-491
.	O	491-492

RESULTS	O	493-500
:	O	500-501
Of	O	502-504
29	O	505-507
patients	O	508-516
who	O	517-520
received	O	521-529
lidocaine	O	530-539
in	O	540-542
the	O	543-546
setting	O	547-554
of	O	555-557
cocaine	O	558-565
-	O	565-566
associated	O	566-576
MI	B	577-579
,	O	579-580
no	O	581-583
patient	O	584-591
died	O	592-596
;	O	596-597
exhibited	O	598-607
bradydysrhythmias	B	608-625
,	O	625-626
ventricular	B	627-638
tachycardia	I	639-650
,	O	650-651
or	O	652-654
ventricular	B	655-666
fibrillation	I	667-679
;	O	679-680
or	O	681-683
experienced	O	684-695
seizures	B	696-704
after	O	705-710
administration	O	711-725
of	O	726-728
lidocaine	O	729-738
(	O	739-740
95	O	740-742
%	O	742-743
confidence	O	744-754
interval	O	755-763
,	O	763-764
0	O	765-766
%	O	766-767
to	O	768-770
11	O	771-773
%	O	773-774
)	O	774-775
.	O	775-776

CONCLUSION	O	777-787
:	O	787-788
Despite	O	789-796
theoretical	O	797-808
concerns	O	809-817
that	O	818-822
lidocaine	O	823-832
may	O	833-836
enhance	O	837-844
cocaine	O	845-852
toxicity	B	853-861
,	O	861-862
the	O	863-866
use	O	867-870
of	O	871-873
lidocaine	O	874-883
in	O	884-886
patients	O	887-895
with	O	896-900
cocaine	O	901-908
-	O	908-909
associated	O	909-919
MI	B	920-922
was	O	923-926
not	O	927-930
associated	O	931-941
with	O	942-946
significant	O	947-958
cardiovascular	B	959-973
or	I	974-976
central	I	977-984
nervous	I	985-992
system	I	993-999
toxicity	I	1000-1008
.	O	1008-1009

Paclitaxel	O	0-10
3	O	11-12
-	O	12-13
hour	O	13-17
infusion	O	18-26
given	O	27-32
alone	O	33-38
and	O	39-42
combined	O	43-51
with	O	52-56
carboplatin	O	57-68
:	O	68-69
preliminary	O	70-81
results	O	82-89
of	O	90-92
dose	O	93-97
-	O	97-98
escalation	O	98-108
trials	O	109-115
.	O	115-116

Paclitaxel	O	117-127
(	O	128-129
Taxol	O	129-134
;	O	134-135
Bristol	O	136-143
-	O	143-144
Myers	O	144-149
Squibb	O	150-156
Company	O	157-164
,	O	164-165
Princeton	O	166-175
,	O	175-176
NJ	O	177-179
)	O	179-180
by	O	181-183
3	O	184-185
-	O	185-186
hour	O	186-190
infusion	O	191-199
was	O	200-203
combined	O	204-212
with	O	213-217
carboplatin	O	218-229
in	O	230-232
a	O	233-234
phase	O	235-240
I	O	241-242
/	O	242-243
II	O	243-245
study	O	246-251
directed	O	252-260
to	O	261-263
patients	O	264-272
with	O	273-277
non	B	278-281
-	I	281-282
small	I	282-287
cell	I	288-292
lung	I	293-297
cancer	I	298-304
.	O	304-305

Carboplatin	O	306-317
was	O	318-321
given	O	322-327
at	O	328-330
a	O	331-332
fixed	O	333-338
target	O	339-345
area	O	346-350
under	O	351-356
the	O	357-360
concentration	O	361-374
-	O	374-375
time	O	375-379
curve	O	380-385
of	O	386-388
6	O	389-390
.	O	390-391
0	O	391-392
by	O	393-395
the	O	396-399
Calvert	O	400-407
formula	O	408-415
,	O	415-416
whereas	O	417-424
paclitaxel	O	425-435
was	O	436-439
escalated	O	440-449
in	O	450-452
patient	O	453-460
cohorts	O	461-468
from	O	469-473
150	O	474-477
mg	O	478-480
/	O	480-481
m2	O	481-483
(	O	484-485
dose	O	485-489
level	O	490-495
I	O	496-497
)	O	497-498
to	O	499-501
175	O	502-505
,	O	505-506
200	O	507-510
,	O	510-511
225	O	512-515
,	O	515-516
and	O	517-520
250	O	521-524
mg	O	525-527
/	O	527-528
m2	O	528-530
.	O	530-531

The	O	532-535
225	O	536-539
mg	O	540-542
/	O	542-543
m2	O	543-545
level	O	546-551
was	O	552-555
expanded	O	556-564
for	O	565-568
the	O	569-572
phase	O	573-578
II	O	579-581
study	O	582-587
since	O	588-593
the	O	594-597
highest	O	598-605
level	O	606-611
achieved	O	612-620
(	O	621-622
250	O	622-625
mg	O	626-628
/	O	628-629
m2	O	629-631
)	O	631-632
required	O	633-641
modification	O	642-654
because	O	655-662
of	O	663-665
nonhematologic	O	666-680
toxicities	B	681-691
(	O	692-693
arthralgia	B	693-703
and	O	704-707
sensory	B	708-715
neuropathy	I	716-726
)	O	726-727
.	O	727-728

Therapeutic	O	729-740
effects	O	741-748
were	O	749-753
noted	O	754-759
at	O	760-762
all	O	763-766
dose	O	767-771
levels	O	772-778
,	O	778-779
with	O	780-784
objective	O	785-794
responses	O	795-804
in	O	805-807
17	O	808-810
(	O	811-812
two	O	812-815
complete	O	816-824
and	O	825-828
15	O	829-831
partial	O	832-839
regressions	O	840-851
)	O	851-852
of	O	853-855
41	O	856-858
previously	O	859-869
untreated	O	870-879
patients	O	880-888
.	O	888-889

Toxicities	B	890-900
were	O	901-905
compared	O	906-914
with	O	915-919
a	O	920-921
cohort	O	922-928
of	O	929-931
patients	O	932-940
in	O	941-943
a	O	944-945
phase	O	946-951
I	O	952-953
trial	O	954-959
of	O	960-962
paclitaxel	O	963-973
alone	O	974-979
at	O	980-982
identical	O	983-992
dose	O	993-997
levels	O	998-1004
.	O	1004-1005

Carboplatin	O	1006-1017
did	O	1018-1021
not	O	1022-1025
appear	O	1026-1032
to	O	1033-1035
add	O	1036-1039
to	O	1040-1042
the	O	1043-1046
hematologic	B	1047-1058
toxicities	I	1059-1069
observed	O	1070-1078
,	O	1078-1079
and	O	1080-1083
the	O	1084-1087
paclitaxel	O	1088-1098
/	O	1098-1099
carboplatin	O	1099-1110
combination	O	1111-1122
could	O	1123-1128
be	O	1129-1131
dosed	O	1132-1137
every	O	1138-1143
3	O	1144-1145
weeks	O	1146-1151
.	O	1151-1152

The	O	0-3
dose	O	4-8
-	O	8-9
dependent	O	9-18
effect	O	19-25
of	O	26-28
misoprostol	O	29-40
on	O	41-43
indomethacin	O	44-56
-	O	56-57
induced	O	57-64
renal	B	65-70
dysfunction	I	71-82
in	O	83-85
well	O	86-90
compensated	O	91-102
cirrhosis	B	103-112
.	O	112-113

Misoprostol	O	114-125
(	O	126-127
200	O	127-130
micrograms	O	131-141
)	O	141-142
has	O	143-146
been	O	147-151
shown	O	152-157
to	O	158-160
acutely	O	161-168
counteract	O	169-179
the	O	180-183
indomethacin	O	184-196
-	O	196-197
induced	O	197-204
renal	B	205-210
dysfunction	I	211-222
in	O	223-225
well	O	226-230
compensated	O	231-242
cirrhotic	B	243-252
patients	O	253-261
.	O	261-262

The	O	263-266
aim	O	267-270
of	O	271-273
this	O	274-278
study	O	279-284
was	O	285-288
to	O	289-291
determine	O	292-301
if	O	302-304
the	O	305-308
prophylactic	O	309-321
value	O	322-327
of	O	328-330
misoprostol	O	331-342
was	O	343-346
dose	O	347-351
-	O	351-352
dependent	O	352-361
.	O	361-362

Parameters	O	363-373
of	O	374-376
renal	O	377-382
hemodynamics	O	383-395
and	O	396-399
tubular	O	400-407
sodium	O	408-414
and	O	415-418
water	O	419-424
handling	O	425-433
were	O	434-438
assessed	O	439-447
by	O	448-450
clearance	O	451-460
techniques	O	461-471
in	O	472-474
26	O	475-477
well	O	478-482
compensated	O	483-494
cirrhotic	B	495-504
patients	O	505-513
before	O	514-520
and	O	521-524
after	O	525-530
an	O	531-533
oral	O	534-538
combination	O	539-550
of	O	551-553
50	O	554-556
mg	O	557-559
of	O	560-562
indomethacin	O	563-575
and	O	576-579
various	O	580-587
doses	O	588-593
of	O	594-596
misoprostol	O	597-608
.	O	608-609

The	O	610-613
200	O	614-617
-	O	617-618
micrograms	O	618-628
dose	O	629-633
was	O	634-637
able	O	638-642
to	O	643-645
totally	O	646-653
abolish	O	654-661
the	O	662-665
deleterious	O	666-677
renal	O	678-683
effects	O	684-691
of	O	692-694
indomethacin	O	695-707
,	O	707-708
whereas	O	709-716
the	O	717-720
800	O	721-724
-	O	724-725
micrograms	O	725-735
dose	O	736-740
resulted	O	741-749
in	O	750-752
significant	O	753-764
worsening	O	765-774
of	O	775-777
renal	O	778-783
hemodynamics	O	784-796
and	O	797-800
sodium	O	801-807
retention	O	808-817
.	O	817-818

These	O	819-824
changes	O	825-832
were	O	833-837
maximal	O	838-845
in	O	846-848
the	O	849-852
hour	O	853-857
immediately	O	858-869
after	O	870-875
medications	O	876-887
and	O	888-891
slowly	O	892-898
returned	O	899-907
toward	O	908-914
base	O	915-919
-	O	919-920
line	O	920-924
levels	O	925-931
thereafter	O	932-942
.	O	942-943

These	O	944-949
results	O	950-957
suggest	O	958-965
that	O	966-970
the	O	971-974
renal	O	975-980
protective	O	981-991
effects	O	992-999
of	O	1000-1002
misoprostol	O	1003-1014
is	O	1015-1017
dose	O	1018-1022
-	O	1022-1023
dependent	O	1023-1032
.	O	1032-1033

However	O	1034-1041
,	O	1041-1042
until	O	1043-1048
this	O	1049-1053
apparent	O	1054-1062
ability	O	1063-1070
of	O	1071-1073
200	O	1074-1077
micrograms	O	1078-1088
of	O	1089-1091
misoprostol	O	1092-1103
to	O	1104-1106
prevent	O	1107-1114
the	O	1115-1118
adverse	O	1119-1126
effects	O	1127-1134
of	O	1135-1137
indomethacin	O	1138-1150
on	O	1151-1153
renal	O	1154-1159
function	O	1160-1168
is	O	1169-1171
confirmed	O	1172-1181
with	O	1182-1186
chronic	O	1187-1194
frequent	O	1195-1203
dosing	O	1204-1210
,	O	1210-1211
it	O	1212-1214
would	O	1215-1220
be	O	1221-1223
prudent	O	1224-1231
to	O	1232-1234
avoid	O	1235-1240
nonsteroidal	O	1241-1253
anti	O	1254-1258
-	O	1258-1259
inflammatory	O	1259-1271
therapy	O	1272-1279
in	O	1280-1282
patients	O	1283-1291
with	O	1292-1296
cirrhosis	B	1297-1306
.	O	1306-1307

Increased	O	0-9
frequency	O	10-19
and	O	20-23
severity	O	24-32
of	O	33-35
angio	B	36-41
-	I	41-42
oedema	I	42-48
related	O	49-56
to	O	57-59
long	O	60-64
-	O	64-65
term	O	65-69
therapy	O	70-77
with	O	78-82
angiotensin	O	83-94
-	O	94-95
converting	O	95-105
enzyme	O	106-112
inhibitor	O	113-122
in	O	123-125
two	O	126-129
patients	O	130-138
.	O	138-139

Adverse	O	140-147
reactions	O	148-157
to	O	158-160
drugs	O	161-166
are	O	167-170
well	O	171-175
recognized	O	176-186
as	O	187-189
a	O	190-191
cause	O	192-197
of	O	198-200
acute	O	201-206
or	O	207-209
chronic	O	210-217
urticaria	B	218-227
,	O	227-228
and	O	229-232
angio	B	233-238
-	I	238-239
oedema	I	239-245
.	O	245-246

Angiotensin	O	247-258
-	O	258-259
converting	O	259-269
enzyme	O	270-276
(	O	277-278
ACE	O	278-281
)	O	281-282
inhibitors	O	283-293
,	O	293-294
used	O	295-299
to	O	300-302
treat	O	303-308
hypertension	B	309-321
and	O	322-325
congestive	B	326-336
heart	I	337-342
failure	I	343-350
,	O	350-351
were	O	352-356
introduced	O	357-367
in	O	368-370
Europe	O	371-377
in	O	378-380
the	O	381-384
middle	O	385-391
of	O	392-394
the	O	395-398
eighties	O	399-407
,	O	407-408
and	O	409-412
the	O	413-416
use	O	417-420
of	O	421-423
these	O	424-429
drugs	O	430-435
has	O	436-439
increased	O	440-449
progressively	O	450-463
.	O	463-464

Soon	O	465-469
after	O	470-475
the	O	476-479
introduction	O	480-492
of	O	493-495
ACE	O	496-499
inhibitors	O	500-510
,	O	510-511
acute	O	512-517
bouts	O	518-523
of	O	524-526
angio	B	527-532
-	I	532-533
oedema	I	533-539
were	O	540-544
reported	O	545-553
in	O	554-556
association	O	557-568
with	O	569-573
the	O	574-577
use	O	578-581
of	O	582-584
these	O	585-590
drugs	O	591-596
.	O	596-597

We	O	598-600
wish	O	601-605
to	O	606-608
draw	O	609-613
attention	O	614-623
to	O	624-626
the	O	627-630
possibility	O	631-642
of	O	643-645
adverse	O	646-653
reactions	O	654-663
to	O	664-666
ACE	O	667-670
inhibitors	O	671-681
after	O	682-687
long	O	688-692
-	O	692-693
term	O	693-697
use	O	698-701
and	O	702-705
in	O	706-708
patients	O	709-717
with	O	718-722
pre	O	723-726
-	O	726-727
existing	O	727-735
angio	B	736-741
-	I	741-742
oedema	I	742-748
.	O	748-749

Myoclonus	B	0-9
associated	O	10-20
with	O	21-25
lorazepam	O	26-35
therapy	O	36-43
in	O	44-46
very	O	47-51
-	O	51-52
low	O	52-55
-	O	51-52
birth	O	56-61
-	O	51-52
weight	O	62-68
infants	O	69-76
.	O	76-77

Lorazepam	O	78-87
is	O	88-90
being	O	91-96
used	O	97-101
with	O	102-106
increasing	O	107-117
frequency	O	118-127
as	O	128-130
a	O	131-132
sedative	O	133-141
in	O	142-144
the	O	145-148
newborn	O	149-156
and	O	157-160
the	O	161-164
young	O	165-170
infant	O	171-177
.	O	177-178

Concern	O	179-186
has	O	187-190
been	O	191-195
raised	O	196-202
with	O	203-207
regard	O	208-214
to	O	215-217
the	O	218-221
safety	O	222-228
of	O	229-231
lorazepam	O	232-241
in	O	242-244
this	O	245-249
age	O	250-253
group	O	254-259
,	O	259-260
especially	O	261-271
in	O	272-274
very	O	275-279
-	O	279-280
low	O	280-283
-	O	279-280
birth	O	284-289
-	O	279-280
weight	O	290-296
(	O	297-298
VLBW	O	298-302
;	O	302-303
<	O	304-305
1	O	306-307
,	O	307-308
500	O	308-311
g	O	312-313
)	O	313-314
infants	O	315-322
.	O	322-323

Three	O	324-329
young	O	330-335
infants	O	336-343
,	O	343-344
all	O	345-348
of	O	349-351
birth	O	352-357
weight	O	358-364
<	O	365-366
1	O	367-368
,	O	368-369
500	O	369-372
g	O	373-374
,	O	374-375
experienced	O	376-387
myoclonus	B	388-397
following	O	398-407
the	O	408-411
intravenous	O	412-423
administration	O	424-438
of	O	439-441
lorazepam	O	442-451
.	O	451-452

The	O	453-456
potential	O	457-466
neurotoxic	B	467-477
effects	O	478-485
of	O	486-488
the	O	489-492
drug	O	493-497
(	O	498-499
and	O	499-502
its	O	503-506
vehicle	O	507-514
)	O	514-515
in	O	516-518
this	O	519-523
population	O	524-534
are	O	535-538
discussed	O	539-548
.	O	548-549

Injectable	O	550-560
lorazepam	O	561-570
should	O	571-577
be	O	578-580
used	O	581-585
with	O	586-590
caution	O	591-598
in	O	599-601
VLBW	O	602-606
infants	O	607-614
.	O	614-615

Transvenous	O	0-11
right	O	12-17
ventricular	O	18-29
pacing	O	30-36
during	O	37-43
cardiopulmonary	O	44-59
resuscitation	O	60-73
of	O	74-76
pediatric	O	77-86
patients	O	87-95
with	O	96-100
acute	O	101-106
cardiomyopathy	B	107-121
.	O	121-122

We	O	123-125
describe	O	126-134
the	O	135-138
cardiopulmonary	O	139-154
resuscitation	O	155-168
efforts	O	169-176
on	O	177-179
five	O	180-184
patients	O	185-193
who	O	194-197
presented	O	198-207
in	O	208-210
acute	O	211-216
circulatory	B	217-228
failure	I	229-236
from	O	237-241
myocardial	B	242-252
dysfunction	I	253-264
.	O	264-265

Three	O	266-271
patients	O	272-280
had	O	281-284
acute	O	285-290
viral	O	291-296
myocarditis	B	297-308
,	O	308-309
one	O	310-313
had	O	314-317
a	O	318-319
carbamazepine	O	320-333
-	O	333-334
induced	O	334-341
acute	O	342-347
eosinophilic	B	348-360
myocarditis	I	361-372
,	O	372-373
and	O	374-377
one	O	378-381
had	O	382-385
cardiac	O	386-393
hemosiderosis	O	394-407
resulting	O	408-417
in	O	418-420
acute	O	421-426
cardiogenic	B	427-438
shock	I	439-444
.	O	444-445

All	O	446-449
patients	O	450-458
were	O	459-463
continuously	O	464-476
monitored	O	477-486
with	O	487-491
central	O	492-499
venous	O	500-506
and	O	507-510
arterial	O	511-519
catheters	O	520-529
in	O	530-532
addition	O	533-541
to	O	542-544
routine	O	545-552
noninvasive	O	553-564
monitoring	O	565-575
.	O	575-576

An	O	577-579
introducer	O	580-590
sheath	O	591-597
,	O	597-598
a	O	599-600
pacemaker	O	601-610
,	O	610-611
and	O	612-615
sterile	O	616-623
pacing	O	624-630
wires	O	631-636
were	O	637-641
made	O	642-646
readily	O	647-654
available	O	655-664
for	O	665-668
the	O	669-672
patients	O	673-681
,	O	681-682
should	O	683-689
the	O	690-693
need	O	694-698
arise	O	699-704
to	O	705-707
terminate	O	708-717
resistant	O	718-727
cardiac	O	728-735
dysrhythmias	B	736-748
.	O	748-749

All	O	750-753
patients	O	754-762
developed	O	763-772
cardiocirculatory	O	773-790
arrest	O	791-797
associated	O	798-808
with	O	809-813
extreme	O	814-821
hypotension	B	822-833
and	O	834-837
dysrhythmias	B	838-850
within	O	851-857
the	O	858-861
first	O	862-867
48	O	868-870
hours	O	871-876
of	O	877-879
their	O	880-885
admission	O	886-895
to	O	896-898
the	O	899-902
pediatric	O	903-912
intensive	O	913-922
care	O	923-927
unit	O	928-932
(	O	933-934
PICU	O	934-938
)	O	938-939
.	O	939-940

Right	O	941-946
ventricular	O	947-958
pacemaker	O	959-968
wires	O	969-974
were	O	975-979
inserted	O	980-988
in	O	989-991
all	O	992-995
of	O	996-998
them	O	999-1003
during	O	1004-1010
cardiopulmonary	O	1011-1026
resuscitation	O	1027-1040
(	O	1041-1042
CPR	O	1042-1045
)	O	1045-1046
.	O	1046-1047

In	O	1048-1050
four	O	1051-1055
patients	O	1056-1064
,	O	1064-1065
cardiac	O	1066-1073
pacing	O	1074-1080
was	O	1081-1084
used	O	1085-1089
,	O	1089-1090
resulting	O	1091-1100
in	O	1101-1103
a	O	1104-1105
temporary	O	1106-1115
captured	O	1116-1124
rhythm	O	1125-1131
and	O	1132-1135
restoration	O	1136-1147
of	O	1148-1150
their	O	1151-1156
cardiac	O	1157-1164
output	O	1165-1171
.	O	1171-1172

These	O	1173-1178
patients	O	1179-1187
had	O	1188-1191
a	O	1192-1193
second	O	1194-1200
event	O	1201-1206
of	O	1207-1209
cardiac	B	1210-1217
arrest	I	1218-1224
,	O	1224-1225
resulting	O	1226-1235
in	O	1236-1238
death	O	1239-1244
,	O	1244-1245
within	O	1246-1252
10	O	1253-1255
to	O	1256-1258
60	O	1259-1261
minutes	O	1262-1269
.	O	1269-1270

In	O	1271-1273
one	O	1274-1277
patient	O	1278-1285
,	O	1285-1286
cardiac	O	1287-1294
pacing	O	1295-1301
was	O	1302-1305
not	O	1306-1309
used	O	1310-1314
,	O	1314-1315
because	O	1316-1323
he	O	1324-1326
converted	O	1327-1336
to	O	1337-1339
normal	O	1340-1346
sinus	O	1347-1352
rhythm	O	1353-1359
by	O	1360-1362
electrical	O	1363-1373
defibrillation	O	1374-1388
within	O	1389-1395
three	O	1396-1401
minutes	O	1402-1409
of	O	1410-1412
initiating	O	1413-1423
CPR	O	1424-1427
.	O	1427-1428

We	O	1429-1431
conclude	O	1432-1440
that	O	1441-1445
cardiac	O	1446-1453
pacing	O	1454-1460
during	O	1461-1467
resuscitative	O	1468-1481
efforts	O	1482-1489
in	O	1490-1492
pediatric	O	1493-1502
patients	O	1503-1511
suffering	O	1512-1521
from	O	1522-1526
acute	O	1527-1532
myocardial	B	1533-1543
dysfunction	I	1544-1555
may	O	1556-1559
not	O	1560-1563
have	O	1564-1568
long	O	1569-1573
-	O	1573-1574
term	O	1574-1578
value	O	1579-1584
in	O	1585-1587
and	O	1588-1591
of	O	1592-1594
itself	O	1595-1601
;	O	1601-1602
however	O	1603-1610
,	O	1610-1611
if	O	1612-1614
temporary	O	1615-1624
hemodynamic	O	1625-1636
stability	O	1637-1646
is	O	1647-1649
achieved	O	1650-1658
by	O	1659-1661
this	O	1662-1666
procedure	O	1667-1676
,	O	1676-1677
it	O	1678-1680
may	O	1681-1684
provide	O	1685-1692
additional	O	1693-1703
time	O	1704-1708
needed	O	1709-1715
to	O	1716-1718
institute	O	1719-1728
other	O	1729-1734
therapeutic	O	1735-1746
modalities	O	1747-1757
.	O	1757-1758

Efficacy	O	0-8
and	O	9-12
safety	O	13-19
of	O	20-22
granisetron	O	23-34
,	O	34-35
a	O	36-37
selective	O	38-47
5	O	48-49
-	O	49-50
hydroxytryptamine	O	50-67
-	O	49-50
3	O	68-69
receptor	O	70-78
antagonist	O	79-89
,	O	89-90
in	O	91-93
the	O	94-97
prevention	O	98-108
of	O	109-111
nausea	B	112-118
and	O	119-122
vomiting	B	123-131
induced	O	132-139
by	O	140-142
high	O	143-147
-	O	147-148
dose	O	148-152
cisplatin	O	153-162
.	O	162-163

PURPOSE	O	164-171
:	O	171-172
To	O	173-175
assess	O	176-182
the	O	183-186
antiemetic	O	187-197
effects	O	198-205
and	O	206-209
safety	O	210-216
profile	O	217-224
of	O	225-227
four	O	228-232
different	O	233-242
doses	O	243-248
of	O	249-251
granisetron	O	252-263
(	O	264-265
Kytril	O	265-271
;	O	271-272
SmithKline	O	273-283
Beecham	O	284-291
Pharmaceuticals	O	292-307
,	O	307-308
Philadelphia	O	309-321
,	O	321-322
PA	O	323-325
)	O	325-326
when	O	327-331
administered	O	332-344
as	O	345-347
a	O	348-349
single	O	350-356
intravenous	O	357-368
(	O	369-370
IV	O	370-372
)	O	372-373
dose	O	374-378
for	O	379-382
prophylaxis	O	383-394
of	O	395-397
cisplatin	O	398-407
-	O	407-408
induced	O	408-415
nausea	B	416-422
and	O	423-426
vomiting	B	427-435
.	O	435-436

PATIENTS	O	437-445
AND	O	446-449
METHODS	O	450-457
:	O	457-458
One	O	459-462
hundred	O	463-470
eighty	O	471-477
-	O	477-478
four	O	478-482
chemotherapy	O	483-495
-	O	495-496
naive	O	496-501
patients	O	502-510
receiving	O	511-520
high	O	521-525
-	O	525-526
dose	O	526-530
cisplatin	O	531-540
(	O	541-542
81	O	542-544
to	O	545-547
120	O	548-551
mg	O	552-554
/	O	554-555
m2	O	555-557
)	O	557-558
were	O	559-563
randomized	O	564-574
to	O	575-577
receive	O	578-585
one	O	586-589
of	O	590-592
four	O	593-597
granisetron	O	598-609
doses	O	610-615
(	O	616-617
5	O	617-618
,	O	618-619
10	O	620-622
,	O	622-623
20	O	624-626
,	O	626-627
or	O	628-630
40	O	631-633
micrograms	O	634-644
/	O	644-645
kg	O	645-647
)	O	647-648
administered	O	649-661
before	O	662-668
chemotherapy	O	669-681
.	O	681-682

Patients	O	683-691
were	O	692-696
observed	O	697-705
on	O	706-708
an	O	709-711
inpatient	O	712-721
basis	O	722-727
for	O	728-731
18	O	732-734
to	O	735-737
24	O	738-740
hours	O	741-746
,	O	746-747
and	O	748-751
vital	O	752-757
signs	O	758-763
,	O	763-764
nausea	B	765-771
,	O	771-772
vomiting	B	773-781
,	O	781-782
retching	O	783-791
,	O	791-792
and	O	793-796
appetite	O	797-805
were	O	806-810
assessed	O	811-819
.	O	819-820

Safety	O	821-827
analyses	O	828-836
included	O	837-845
incidence	O	846-855
of	O	856-858
adverse	O	859-866
experiences	O	867-878
and	O	879-882
laboratory	O	883-893
parameter	O	894-903
changes	O	904-911
.	O	911-912

RESULTS	O	913-920
:	O	920-921
After	O	922-927
granisetron	O	928-939
doses	O	940-945
of	O	946-948
5	O	949-950
,	O	950-951
10	O	952-954
,	O	954-955
20	O	956-958
,	O	958-959
and	O	960-963
40	O	964-966
micrograms	O	967-977
/	O	977-978
kg	O	978-980
,	O	980-981
a	O	982-983
major	O	984-989
response	O	990-998
(	O	999-1000
<	O	1000-1001
or	O	1002-1004
=	O	1005-1006
two	O	1007-1010
vomiting	B	1011-1019
or	O	1020-1022
retching	O	1023-1031
episodes	O	1032-1040
,	O	1040-1041
and	O	1042-1045
no	O	1046-1048
antiemetic	O	1049-1059
rescue	O	1060-1066
)	O	1066-1067
was	O	1068-1071
recorded	O	1072-1080
in	O	1081-1083
23	O	1084-1086
%	O	1086-1087
,	O	1087-1088
57	O	1089-1091
%	O	1091-1092
,	O	1092-1093
58	O	1094-1096
%	O	1096-1097
,	O	1097-1098
and	O	1099-1102
60	O	1103-1105
%	O	1105-1106
of	O	1107-1109
patients	O	1110-1118
,	O	1118-1119
respectively	O	1120-1132
,	O	1132-1133
and	O	1134-1137
a	O	1138-1139
complete	O	1140-1148
response	O	1149-1157
(	O	1158-1159
no	O	1159-1161
vomiting	B	1162-1170
or	O	1171-1173
retching	O	1174-1182
,	O	1182-1183
and	O	1184-1187
no	O	1188-1190
antiemetic	O	1191-1201
rescue	O	1202-1208
)	O	1208-1209
in	O	1210-1212
18	O	1213-1215
%	O	1215-1216
,	O	1216-1217
41	O	1218-1220
%	O	1220-1221
,	O	1221-1222
40	O	1223-1225
%	O	1225-1226
,	O	1226-1227
and	O	1228-1231
47	O	1232-1234
%	O	1234-1235
of	O	1236-1238
patients	O	1239-1247
,	O	1247-1248
respectively	O	1249-1261
.	O	1261-1262

There	O	1263-1268
was	O	1269-1272
a	O	1273-1274
statistically	O	1275-1288
longer	O	1289-1295
time	O	1296-1300
to	O	1301-1303
first	O	1304-1309
episode	O	1310-1317
of	O	1318-1320
nausea	B	1321-1327
(	O	1328-1329
P	O	1329-1330
=	O	1331-1332
.	O	1333-1334
0015	O	1334-1338
)	O	1338-1339

and	O	1340-1343
vomiting	B	1344-1352
(	O	1353-1354
P	O	1354-1355
=	O	1356-1357
.	O	1358-1359
0001	O	1359-1363
)	O	1363-1364
,	O	1364-1365

and	O	1366-1369
fewer	O	1370-1375
patients	O	1376-1384
were	O	1385-1389
administered	O	1390-1402
additional	O	1403-1413
antiemetic	O	1414-1424
medication	O	1425-1435
in	O	1436-1438
the	O	1439-1442
10	O	1443-1445
-	O	1445-1446
micrograms	O	1446-1456
/	O	1456-1457
kg	O	1457-1459
dosing	O	1460-1466
groups	O	1467-1473
than	O	1474-1478
in	O	1479-1481
the	O	1482-1485
5	O	1486-1487
-	O	1487-1488
micrograms	O	1488-1498
/	O	1498-1499
kg	O	1499-1501
dosing	O	1502-1508
group	O	1509-1514
.	O	1514-1515

As	O	1516-1518
granisetron	O	1519-1530
dose	O	1531-1535
increased	O	1536-1545
,	O	1545-1546
appetite	O	1547-1555
return	O	1556-1562
increased	O	1563-1572
(	O	1573-1574
P	O	1574-1575
=	O	1576-1577
.	O	1578-1579
040	O	1579-1582
)	O	1582-1583
.	O	1578-1579

Headache	B	1585-1593
was	O	1594-1597
the	O	1598-1601
most	O	1602-1606
frequently	O	1607-1617
reported	O	1618-1626
adverse	O	1627-1634
event	O	1635-1640
(	O	1641-1642
20	O	1642-1644
%	O	1644-1645
)	O	1645-1646
.	O	1646-1647

CONCLUSION	O	1648-1658
:	O	1658-1659
A	O	1660-1661
single	O	1662-1668
10	O	1669-1671
-	O	1671-1672
,	O	1672-1673
20	O	1674-1676
-	O	1676-1677
,	O	1677-1678
or	O	1679-1681
40	O	1682-1684
-	O	1684-1685
micrograms	O	1685-1695
/	O	1695-1696
kg	O	1696-1698
dose	O	1699-1703
of	O	1704-1706
granisetron	O	1707-1718
was	O	1719-1722
effective	O	1723-1732
in	O	1733-1735
controlling	O	1736-1747
vomiting	B	1748-1756
in	O	1757-1759
57	O	1760-1762
%	O	1762-1763
to	O	1764-1766
60	O	1767-1769
%	O	1769-1770
of	O	1771-1773
patients	O	1774-1782
who	O	1783-1786
received	O	1787-1795
cisplatin	O	1796-1805
at	O	1806-1808
doses	O	1809-1814
greater	O	1815-1822
than	O	1823-1827
81	O	1828-1830
mg	O	1831-1833
/	O	1833-1834
m2	O	1834-1836
and	O	1837-1840
totally	O	1841-1848
prevented	O	1849-1858
vomiting	B	1859-1867
in	O	1868-1870
40	O	1871-1873
%	O	1873-1874
to	O	1875-1877
47	O	1878-1880
%	O	1880-1881
of	O	1882-1884
patients	O	1885-1893
.	O	1893-1894

There	O	1895-1900
were	O	1901-1905
no	O	1906-1908
statistically	O	1909-1922
significant	O	1923-1934
differences	O	1935-1946
in	O	1947-1949
efficacy	O	1950-1958
between	O	1959-1966
the	O	1967-1970
10	O	1971-1973
-	O	1973-1974
micrograms	O	1974-1984
/	O	1984-1985
kg	O	1985-1987
dose	O	1988-1992
and	O	1993-1996
the	O	1997-2000
20	O	2001-2003
-	O	2003-2004
and	O	2005-2008
40	O	2009-2011
-	O	2011-2012
micrograms	O	2012-2022
/	O	2022-2023
kg	O	2023-2025
doses	O	2026-2031
.	O	2031-2032

Granisetron	O	2033-2044
was	O	2045-2048
well	O	2049-2053
tolerated	O	2054-2063
at	O	2064-2066
all	O	2067-2070
doses	O	2071-2076
.	O	2076-2077

Adverse	O	0-7
interaction	O	8-19
between	O	20-27
clonidine	O	28-37
and	O	38-41
verapamil	O	42-51
.	O	51-52

OBJECTIVE	O	53-62
:	O	62-63
To	O	64-66
report	O	67-73
two	O	74-77
cases	O	78-83
of	O	84-86
a	O	87-88
possible	O	89-97
adverse	O	98-105
interaction	O	106-117
between	O	118-125
clonidine	O	126-135
and	O	136-139
verapamil	O	140-149
resulting	O	150-159
in	O	160-162
atrioventricular	B	163-179
(	I	180-181
AV	I	181-183
)	I	183-184
block	I	185-190
in	O	191-193
both	O	194-198
patients	O	199-207
and	O	208-211
severe	O	212-218
hypotension	B	219-230
in	O	231-233
one	O	234-237
patient	O	238-245
.	O	245-246

CASE	O	247-251
SUMMARIES	O	252-261
:	O	261-262
A	O	263-264
54	O	265-267
-	O	267-268
year	O	268-272
-	O	267-268
old	O	273-276
woman	O	277-282
with	O	283-287
hyperaldosteronism	B	288-306
was	O	307-310
treated	O	311-318
with	O	319-323
verapamil	O	324-333
480	O	334-337
mg	O	338-340
/	O	340-341
d	O	341-342
and	O	343-346
spironolactone	O	347-361
100	O	362-365
mg	O	366-368
/	O	368-369
d	O	369-370
.	O	370-371

After	O	372-377
the	O	378-381
addition	O	382-390
of	O	391-393
a	O	394-395
minimal	O	396-403
dose	O	404-408
of	O	409-411
clonidine	O	412-421
(	O	422-423
0	O	423-424
.	O	424-425
15	O	425-427
mg	O	428-430
bid	O	431-434
)	O	434-435
,	O	435-436
she	O	437-440
developed	O	441-450
complete	O	451-459
AV	B	460-462
block	I	463-468
and	O	469-472
severe	O	473-479
hypotension	B	480-491
,	O	491-492
which	O	493-498
resolved	O	499-507
upon	O	508-512
cessation	O	513-522
of	O	523-525
all	O	526-529
medications	O	530-541
.	O	541-542

A	O	543-544
65	O	545-547
-	O	547-548
year	O	548-552
-	O	547-548
old	O	553-556
woman	O	557-562
was	O	563-566
treated	O	567-574
with	O	575-579
extended	O	580-588
-	O	588-589
release	O	589-596
verapamil	O	597-606
240	O	607-610
mg	O	611-613
/	O	613-614
d	O	614-615
.	O	615-616

After	O	617-622
the	O	623-626
addition	O	627-635
of	O	636-638
clonidine	O	639-648
0	O	649-650
.	O	650-651
15	O	651-653
mg	O	654-656
bid	O	657-660
she	O	661-664
developed	O	665-674
complete	O	675-683
AV	B	684-686
block	I	687-692
,	O	692-693
which	O	694-699
resolved	O	700-708
after	O	709-714
all	O	715-718
therapy	O	719-726
was	O	727-730
stopped	O	731-738
.	O	738-739

DISCUSSION	O	740-750
:	O	750-751
An	O	752-754
adverse	O	755-762
interaction	O	763-774
between	O	775-782
clonidine	O	783-792
and	O	793-796
verapamil	O	797-806
has	O	807-810
not	O	811-814
been	O	815-819
reported	O	820-828
previously	O	829-839
.	O	839-840

We	O	841-843
describe	O	844-852
two	O	853-856
such	O	857-861
cases	O	862-867
and	O	868-871
discuss	O	872-879
the	O	880-883
various	O	884-891
mechanisms	O	892-902
that	O	903-907
might	O	908-913
cause	O	914-919
such	O	920-924
an	O	925-927
interaction	O	928-939
.	O	939-940

Clinicians	O	941-951
should	O	952-958
be	O	959-961
acquainted	O	962-972
with	O	973-977
this	O	978-982
possibly	O	983-991
fatal	O	992-997
interaction	O	998-1009
between	O	1010-1017
two	O	1018-1021
commonly	O	1022-1030
used	O	1031-1035
antihypertensive	O	1036-1052
drugs	O	1053-1058
.	O	1058-1059

CONCLUSIONS	O	1060-1071
:	O	1071-1072
Caution	O	1073-1080
is	O	1081-1083
recommended	O	1084-1095
in	O	1096-1098
combining	O	1099-1108
clonidine	O	1109-1118
and	O	1119-1122
verapamil	O	1123-1132
therapy	O	1133-1140
,	O	1140-1141
even	O	1142-1146
in	O	1147-1149
patients	O	1150-1158
who	O	1159-1162
do	O	1163-1165
not	O	1166-1169
have	O	1170-1174
sinus	O	1175-1180
or	O	1181-1183
AV	O	1184-1186
node	O	1187-1191
dysfunction	O	1192-1203
.	O	1203-1204

The	O	1205-1208
two	O	1209-1212
drugs	O	1213-1218
may	O	1219-1222
act	O	1223-1226
synergistically	O	1227-1242
on	O	1243-1245
both	O	1246-1250
the	O	1251-1254
AV	O	1255-1257
node	O	1258-1262
and	O	1263-1266
the	O	1267-1270
peripheral	O	1271-1281
circulation	O	1282-1293
.	O	1293-1294

Pharmacological	O	0-15
studies	O	16-23
on	O	24-26
a	O	27-28
new	O	29-32
dihydrothienopyridine	O	33-54
calcium	O	55-62
antagonist	O	63-73
,	O	73-74
S	O	75-76
-	O	76-77
312	O	77-80
-	O	76-77
d	O	81-82
.	O	82-83

5th	O	84-87
communication	O	88-101
:	O	101-102
anticonvulsant	O	103-117
effects	O	118-125
in	O	126-128
mice	O	129-133
.	O	133-134

S	O	135-136
-	O	136-137
312	O	137-140
,	O	140-141
S	O	142-143
-	O	143-144
312	O	144-147
-	O	143-144
d	O	148-149
,	O	149-150
but	O	151-154
not	O	155-158
S	O	159-160
-	O	160-161
312	O	161-164
-	O	160-161
l	O	165-166
,	O	166-167
L	O	168-169
-	O	169-170
type	O	170-174
calcium	O	175-182
channel	O	183-190
antagonists	O	191-202
,	O	202-203
showed	O	204-210
anticonvulsant	O	211-225
effects	O	226-233
on	O	234-236
the	O	237-240
audiogenic	B	241-251
tonic	I	252-257
convulsions	I	258-269
in	O	270-272
DBA	O	273-276
/	O	276-277
2	O	277-278
mice	O	279-283
;	O	283-284
and	O	285-288
their	O	289-294
ED50	O	295-299
values	O	300-306
were	O	307-311
18	O	312-314
.	O	314-315
4	O	315-316
(	O	317-318
12	O	318-320
.	O	320-321
8	O	321-322
-	O	322-323
27	O	323-325
.	O	320-321
1	O	318-319
)	O	327-328

mg	O	329-331
/	O	331-332
kg	O	332-334
,	O	334-335
p	O	336-337
.	O	337-338
o	O	338-339
.	O	337-338
and	O	341-344
15	O	345-347
.	O	347-348
0	O	348-349
(	O	350-351
10	O	351-353
.	O	353-354
2	O	354-355
-	O	355-356
23	O	356-358
.	O	353-354
7	O	359-360
)	O	360-361

mg	O	362-364
/	O	364-365
kg	O	365-367
,	O	367-368
p	O	369-370
.	O	370-371
o	O	371-372
.	O	370-371
,	O	373-374
respectively	O	375-387
,	O	387-388
while	O	389-394
that	O	395-399
of	O	400-402
flunarizine	O	403-414
was	O	415-418
34	O	419-421
.	O	421-422
0	O	422-423
(	O	424-425
26	O	425-427
.	O	427-428
0	O	428-429
-	O	429-430
44	O	430-432
.	O	427-428
8	O	433-434
)	O	434-435

mg	O	436-438
/	O	438-439
kg	O	439-441
,	O	441-442
p	O	443-444
.	O	444-445
o	O	445-446
.	O	444-445

Although	O	448-456
moderate	O	457-465
anticonvulsant	O	466-480
effects	O	481-488
of	O	489-491
S	O	492-493
-	O	493-494
312	O	494-497
-	O	493-494
d	O	498-499
in	O	500-502
higher	O	503-509
doses	O	510-515
were	O	516-520
observed	O	521-529
against	O	530-537
the	O	538-541
clonic	O	542-548
convulsions	B	549-560
induced	O	561-568
by	O	569-571
pentylenetetrazole	O	572-590
(	O	591-592
85	O	592-594
mg	O	595-597
/	O	597-598
kg	O	598-600
,	O	600-601
s	O	602-603
.	O	603-604
c	O	604-605
.	O	603-604
)	O	606-607
or	O	608-610
bemegride	O	611-620
(	O	621-622
40	O	622-624
mg	O	625-627
/	O	627-628
kg	O	628-630
,	O	630-631
s	O	632-633
.	O	633-634
c	O	634-635
.	O	633-634
)	O	636-637
,	O	637-638
no	O	639-641
effects	O	642-649
were	O	650-654
observed	O	655-663
in	O	664-666
convulsions	B	667-678
induced	O	679-686
by	O	687-689
N	O	690-691
-	O	691-692
methyl	O	692-698
-	O	691-692
D	O	699-700
-	O	691-692
aspartate	O	701-710
,	O	710-711
picrotoxin	O	712-722
,	O	722-723
or	O	724-726
electroshock	O	727-739
in	O	740-742
Slc	O	743-746
:	O	746-747
ddY	O	747-750
mice	O	751-755
.	O	755-756

S	O	757-758
-	O	758-759
312	O	759-762
-	O	758-759
d	O	763-764
may	O	765-768
be	O	769-771
useful	O	772-778
in	O	779-781
the	O	782-785
therapy	O	786-793
of	O	794-796
certain	O	797-804
types	O	805-810
of	O	811-813
human	O	814-819
epilepsy	B	820-828
.	O	828-829

Transmural	O	0-10
myocardial	B	11-21
infarction	I	22-32
with	O	33-37
sumatriptan	O	38-49
.	O	49-50

For	O	51-54
sumatriptan	O	55-66
,	O	66-67
tightness	O	68-77
in	O	78-80
the	O	81-84
chest	O	85-90
caused	O	91-97
by	O	98-100
an	O	101-103
unknown	O	104-111
mechanism	O	112-121
has	O	122-125
been	O	126-130
reported	O	131-139
in	O	140-142
3	O	143-144
-	O	144-145
5	O	145-146
%	O	146-147
of	O	148-150
users	O	151-156
.	O	156-157

We	O	158-160
describe	O	161-169
a	O	170-171
47	O	172-174
-	O	174-175
year	O	175-179
-	O	174-175
old	O	180-183
woman	O	184-189
with	O	190-194
an	O	195-197
acute	O	198-203
myocardial	B	204-214
infarction	I	215-225
after	O	226-231
administration	O	232-246
of	O	247-249
sumatriptan	O	250-261
6	O	262-263
mg	O	264-266
subcutaneously	O	267-281
for	O	282-285
cluster	B	286-293
headache	I	294-302
.	O	302-303

The	O	304-307
patient	O	308-315
had	O	316-319
no	O	320-322
history	O	323-330
of	O	331-333
underlying	O	334-344
ischaemic	B	345-354
heart	I	355-360
disease	I	361-368
or	O	369-371
Prinzmetal	B	372-382
'	I	382-383
s	I	383-384
angina	I	385-391
.	O	391-392

She	O	393-396
recovered	O	397-406
without	O	407-414
complications	O	415-428
.	O	428-429

Flumazenil	O	0-10
induces	O	11-18
seizures	B	19-27
and	O	28-31
death	O	32-37
in	O	38-40
mixed	O	41-46
cocaine	O	47-54
-	O	54-55
diazepam	O	55-63
intoxications	O	64-77
.	O	77-78

STUDY	O	79-84
HYPOTHESIS	O	85-95
:	O	95-96
Administration	O	97-111
of	O	112-114
the	O	115-118
benzodiazepine	O	119-133
antagonist	O	134-144
flumazenil	O	145-155
may	O	156-159
unmask	O	160-166
seizures	B	167-175
in	O	176-178
mixed	O	179-184
cocaine	O	185-192
-	O	192-193
benzodiazepine	O	193-207
intoxication	O	208-220
.	O	220-221

DESIGN	O	222-228
:	O	228-229
Male	O	230-234
Sprague	O	235-242
-	O	242-243
Dawley	O	243-249
rats	O	250-254
received	O	255-263
100	O	264-267
mg	O	268-270
/	O	270-271
kg	O	271-273
cocaine	O	274-281
IP	O	282-284
alone	O	285-290
,	O	290-291
5	O	292-293
mg	O	294-296
/	O	296-297
kg	O	297-299
diazepam	O	300-308
alone	O	309-314
,	O	314-315
or	O	316-318
a	O	319-320
combination	O	321-332
of	O	333-335
diazepam	O	336-344
and	O	345-348
cocaine	O	349-356
.	O	356-357

Three	O	358-363
minutes	O	364-371
later	O	372-377
,	O	377-378
groups	O	379-385
were	O	386-390
challenged	O	391-401
with	O	402-406
vehicle	O	407-414
or	O	415-417
flumazenil	O	418-428
5	O	429-430
or	O	431-433
10	O	434-436
mg	O	437-439
/	O	439-440
kg	O	440-442
IP	O	443-445
.	O	445-446

Animal	O	447-453
behavior	O	454-462
,	O	462-463
seizures	B	464-472
(	O	473-474
time	O	474-478
to	O	479-481
and	O	482-485
incidence	O	486-495
)	O	495-496
,	O	496-497
death	O	498-503
(	O	504-505
time	O	505-509
to	O	510-512
and	O	513-516
incidence	O	517-526
)	O	526-527
,	O	527-528
and	O	529-532
cortical	O	533-541
EEG	O	542-545
tracings	O	546-554
were	O	555-559
recorded	O	560-568
.	O	568-569

INTERVENTIONS	O	570-583
:	O	583-584
Administration	O	585-599
of	O	600-602
flumazenil	O	603-613
to	O	614-616
animals	O	617-624
after	O	625-630
they	O	631-635
had	O	636-639
received	O	640-648
a	O	649-650
combination	O	651-662
dose	O	663-667
of	O	668-670
cocaine	O	671-678
and	O	679-682
diazepam	O	683-691
.	O	691-692

RESULTS	O	693-700
:	O	700-701
In	O	702-704
group	O	705-710
1	O	711-712
,	O	712-713
animals	O	714-721
received	O	722-730
cocaine	O	731-738
followed	O	739-747
by	O	748-750
vehicle	O	751-758
.	O	758-759

This	O	760-764
resulted	O	765-773
in	O	774-776
100	O	777-780
%	O	780-781
developing	O	782-792
seizures	B	793-801
and	O	802-805
death	O	806-811
.	O	811-812

Group	O	813-818
2	O	819-820
received	O	821-829
diazepam	O	830-838
alone	O	839-844
followed	O	845-853
by	O	854-856
vehicle	O	857-864
.	O	864-865

Animals	O	866-873
became	O	874-880
somnolent	O	881-890
and	O	891-894
none	O	895-899
died	O	900-904
.	O	904-905

Group	O	906-911
3	O	912-913
received	O	914-922
diazepam	O	923-931
followed	O	932-940
by	O	941-943
5	O	944-945
mg	O	946-948
/	O	948-949
kg	O	949-951
flumazenil	O	952-962
.	O	962-963

Animals	O	964-971
became	O	972-978
somnolent	O	979-988
after	O	989-994
diazepam	O	995-1003
and	O	1004-1007
then	O	1008-1012
active	O	1013-1019
after	O	1020-1025
flumazenil	O	1026-1036
administration	O	1037-1051
.	O	1051-1052

In	O	1053-1055
group	O	1056-1061
4	O	1062-1063
,	O	1063-1064
a	O	1065-1066
combination	O	1067-1078
of	O	1079-1081
cocaine	O	1082-1089
and	O	1090-1093
diazepam	O	1094-1102
was	O	1103-1106
administered	O	1107-1119
simultaneously	O	1120-1134
.	O	1134-1135

This	O	1136-1140
resulted	O	1141-1149
in	O	1150-1152
no	O	1153-1155
overt	O	1156-1161
or	O	1162-1164
EEG	O	1165-1168
-	O	1168-1169
detectable	O	1169-1179
seizures	B	1180-1188
and	O	1189-1192
a	O	1193-1194
50	O	1195-1197
%	O	1197-1198
incidence	O	1199-1208
of	O	1209-1211
death	O	1212-1217
.	O	1217-1218

Group	O	1219-1224
5	O	1225-1226
received	O	1227-1235
a	O	1236-1237
similar	O	1238-1245
combination	O	1246-1257
of	O	1258-1260
cocaine	O	1261-1268
and	O	1269-1272
diazepam	O	1273-1281
,	O	1281-1282
followed	O	1283-1291
later	O	1292-1297
by	O	1298-1300
5	O	1301-1302
mg	O	1303-1305
/	O	1305-1306
kg	O	1306-1308
flumazenil	O	1309-1319
.	O	1319-1320

This	O	1321-1325
resulted	O	1326-1334
in	O	1335-1337
an	O	1338-1340
increased	O	1341-1350
incidence	O	1351-1360
of	O	1361-1363
seizures	B	1364-1372
,	O	1372-1373
90	O	1374-1376
%	O	1376-1377
(	O	1378-1379
P	O	1379-1380
<	O	1381-1382
.	O	1383-1384
01	O	1384-1386
)	O	1386-1387
,	O	1387-1388

and	O	1389-1392
death	O	1393-1398
,	O	1398-1399
100	O	1400-1403
%	O	1403-1404
(	O	1405-1406
P	O	1406-1407
<	O	1408-1409
or	O	1410-1412
=	O	1413-1414
.	O	1415-1416
01	O	1416-1418
)	O	1418-1419
,	O	1419-1420

compared	O	1421-1429
with	O	1430-1434
group	O	1435-1440
4	O	1441-1442
.	O	1442-1443
Group	O	1444-1449
6	O	1450-1451
received	O	1452-1460
cocaine	O	1461-1468
and	O	1469-1472
diazepam	O	1473-1481
followed	O	1482-1490
by	O	1491-1493
10	O	1494-1496
mg	O	1497-1499
/	O	1499-1500
kg	O	1500-1502
flumazenil	O	1503-1513
.	O	1513-1514

This	O	1515-1519
also	O	1520-1524
resulted	O	1525-1533
in	O	1534-1536
an	O	1537-1539
increased	O	1540-1549
incidence	O	1550-1559
of	O	1560-1562
seizures	B	1563-1571
,	O	1571-1572
90	O	1573-1575
%	O	1575-1576
(	O	1577-1578
P	O	1578-1579
<	O	1580-1581
or	O	1582-1584
=	O	1585-1586
.	O	1587-1588
01	O	1588-1590
)	O	1590-1591
,	O	1591-1592

and	O	1593-1596
death	O	1597-1602
,	O	1602-1603
90	O	1604-1606
%	O	1606-1607
(	O	1608-1609
P	O	1609-1610
<	O	1611-1612
or	O	1613-1615
=	O	1616-1617
.	O	1618-1619
05	O	1619-1621
)	O	1621-1622
,	O	1622-1623

compared	O	1624-1632
with	O	1633-1637
group	O	1638-1643
4	O	1644-1645
.	O	1645-1646
CONCLUSION	O	1647-1657
:	O	1657-1658
Flumazenil	O	1659-1669
can	O	1670-1673
unmask	O	1674-1680
seizures	B	1681-1689
and	O	1690-1693
increase	O	1694-1702
the	O	1703-1706
incidence	O	1707-1716
of	O	1717-1719
death	O	1720-1725
in	O	1726-1728
a	O	1729-1730
model	O	1731-1736
of	O	1737-1739
combined	O	1740-1748
cocaine	O	1749-1756
-	O	1756-1757
diazepam	O	1757-1765
intoxications	O	1766-1779
.	O	1779-1780

Mechanisms	O	0-10
for	O	11-14
protective	O	15-25
effects	O	26-33
of	O	34-36
free	O	37-41
radical	O	42-49
scavengers	O	50-60
on	O	61-63
gentamicin	O	64-74
-	O	74-75
mediated	O	75-83
nephropathy	B	84-95
in	O	96-98
rats	O	99-103
.	O	103-104

Studies	O	105-112
were	O	113-117
performed	O	118-127
to	O	128-130
examine	O	131-138
the	O	139-142
mechanisms	O	143-153
for	O	154-157
the	O	158-161
protective	O	162-172
effects	O	173-180
of	O	181-183
free	O	184-188
radical	O	189-196
scavengers	O	197-207
on	O	208-210
gentamicin	O	211-221
(	O	222-223
GM	O	223-225
)	O	225-226
-	O	226-227
mediated	O	227-235
nephropathy	B	236-247
.	O	247-248

Administration	O	249-263
of	O	264-266
GM	O	267-269
at	O	270-272
40	O	273-275
mg	O	276-278
/	O	278-279
kg	O	279-281
sc	O	282-284
for	O	285-288
13	O	289-291
days	O	292-296
to	O	297-299
rats	O	300-304
induced	O	305-312
a	O	313-314
significant	O	315-326
reduction	O	327-336
in	O	337-339
renal	O	340-345
blood	O	346-351
flow	O	352-356
(	O	357-358
RBF	O	358-361
)	O	361-362
and	O	363-366
inulin	O	367-373
clearance	O	374-383
(	O	384-385
CIn	O	385-388
)	O	388-389
as	O	390-392
well	O	393-397
as	O	398-400
marked	O	401-407
tubular	B	408-415
damage	I	416-422
.	O	422-423

A	O	424-425
significant	O	426-437
reduction	O	438-447
in	O	448-450
urinary	O	451-458
guanosine	O	459-468
3	O	469-470
'	O	470-471
,	O	471-472
5	O	472-473
'	O	470-471
-	O	474-475
cyclic	O	475-481
monophosphate	O	482-495
(	O	496-497
cGMP	O	497-501
)	O	501-502
excretion	O	503-512
and	O	513-516
a	O	517-518
significant	O	519-530
increase	O	531-539
in	O	540-542
renal	O	543-548
cortical	O	549-557
renin	O	558-563
and	O	564-567
endothelin	O	568-578
-	O	578-579
1	O	579-580
contents	O	581-589
were	O	590-594
also	O	595-599
observed	O	600-608
in	O	609-611
GM	O	612-614
-	O	614-615
mediated	O	615-623
nephropathy	B	624-635
.	O	635-636

Superoxide	O	637-647
dismutase	O	648-657
(	O	658-659
SOD	O	659-662
)	O	662-663
or	O	664-666
dimethylthiourea	O	667-683
(	O	684-685
DMTU	O	685-689
)	O	689-690
significantly	O	691-704
lessened	O	705-713
the	O	714-717
GM	O	718-720
-	O	720-721
induced	O	721-728
decrement	O	729-738
in	O	739-741
CIn	O	742-745
.	O	745-746

The	O	747-750
SOD	O	751-754
-	O	754-755
induced	O	755-762
increase	O	763-771
in	O	772-774
glomerular	O	775-785
filtration	O	786-796
rate	O	797-801
was	O	802-805
associated	O	806-816
with	O	817-821
a	O	822-823
marked	O	824-830
improvement	O	831-842
in	O	843-845
RBF	O	846-849
,	O	849-850
an	O	851-853
increase	O	854-862
in	O	863-865
urinary	O	866-873
cGMP	O	874-878
excretion	O	879-888
,	O	888-889
and	O	890-893
a	O	894-895
decrease	O	896-904
in	O	905-907
renal	O	908-913
renin	O	914-919
and	O	920-923
endothelin	O	924-934
-	O	934-935
1	O	935-936
content	O	937-944
.	O	944-945

SOD	O	946-949
did	O	950-953
not	O	954-957
attenuate	O	958-967
the	O	968-971
tubular	B	972-979
damage	I	980-986
.	O	986-987

In	O	988-990
contrast	O	991-999
,	O	999-1000
DMTU	O	1001-1005
significantly	O	1006-1019
reduced	O	1020-1027
the	O	1028-1031
tubular	B	1032-1039
damage	I	1040-1046
and	O	1047-1050
lipid	O	1051-1056
peroxidation	O	1057-1069
,	O	1069-1070
but	O	1071-1074
it	O	1075-1077
did	O	1078-1081
not	O	1082-1085
affect	O	1086-1092
renal	O	1093-1098
hemodynamics	O	1099-1111
and	O	1112-1115
vasoactive	O	1116-1126
substances	O	1127-1137
.	O	1137-1138

Neither	O	1139-1146
SOD	O	1147-1150
nor	O	1151-1154
DMTU	O	1155-1159
affected	O	1160-1168
the	O	1169-1172
renal	O	1173-1178
cortical	O	1179-1187
GM	O	1188-1190
content	O	1191-1198
in	O	1199-1201
GM	O	1202-1204
-	O	1204-1205
treated	O	1205-1212
rats	O	1213-1217
.	O	1217-1218

These	O	1219-1224
results	O	1225-1232
suggest	O	1233-1240
that	O	1241-1245
1	O	1246-1247
)	O	1247-1248
both	O	1249-1253
SOD	O	1254-1257
and	O	1258-1261
DMTU	O	1262-1266
have	O	1267-1271
protective	O	1272-1282
effects	O	1283-1290
on	O	1291-1293
GM	O	1294-1296
-	O	1296-1297
mediated	O	1297-1305
nephropathy	B	1306-1317
,	O	1317-1318
2	O	1319-1320
)	O	1320-1321
the	O	1322-1325
mechanisms	O	1326-1336
for	O	1337-1340
the	O	1341-1344
protective	O	1345-1355
effects	O	1356-1363
differ	O	1364-1370
for	O	1371-1374
SOD	O	1375-1378
and	O	1379-1382
DMTU	O	1383-1387
,	O	1387-1388
and	O	1389-1392
3	O	1393-1394
)	O	1394-1395
superoxide	O	1396-1406
anions	O	1407-1413
play	O	1414-1418
a	O	1419-1420
critical	O	1421-1429
role	O	1430-1434
in	O	1435-1437
GM	O	1438-1440
-	O	1440-1441
induced	O	1441-1448
renal	O	1449-1454
vasoconstriction	O	1455-1471
.	O	1471-1472

Assessment	O	0-10
of	O	11-13
cardiomyocyte	O	14-27
DNA	O	28-31
synthesis	O	32-41
during	O	42-48
hypertrophy	B	49-60
in	O	61-63
adult	O	64-69
mice	O	70-74
.	O	74-75

The	O	76-79
ability	O	80-87
of	O	88-90
cardiomyocytes	O	91-105
to	O	106-108
synthesize	O	109-119
DNA	O	120-123
in	O	124-126
response	O	127-135
to	O	136-138
experimentally	O	139-153
induced	O	154-161
cardiac	B	162-169
hypertrophy	I	170-181
was	O	182-185
assessed	O	186-194
in	O	195-197
adult	O	198-203
mice	O	204-208
.	O	208-209

Isoproterenol	O	210-223
delivered	O	224-233
by	O	234-236
osmotic	O	237-244
minipump	O	245-253
implantation	O	254-266
in	O	267-269
adult	O	270-275
C3Heb	O	276-281
/	O	281-282
FeJ	O	282-285
mice	O	286-290
resulted	O	291-299
in	O	300-302
a	O	303-304
46	O	305-307
%	O	307-308
increase	O	309-317
in	O	318-320
heart	O	321-326
weight	O	327-333
and	O	334-337
a	O	338-339
19	O	340-342
.	O	342-343
3	O	343-344
%	O	344-345
increase	O	346-354
in	O	355-357
cardiomyocyte	O	358-371
area	O	372-376
.	O	376-377

No	O	378-380
DNA	O	381-384
synthesis	O	385-394
,	O	394-395
as	O	396-398
assessed	O	399-407
by	O	408-410
autoradiographic	O	411-427
analysis	O	428-436
of	O	437-439
isolated	O	440-448
cardiomyocytes	O	449-463
,	O	463-464
was	O	465-468
observed	O	469-477
in	O	478-480
control	O	481-488
or	O	489-491
hypertrophic	B	492-504
hearts	I	505-511
.	O	511-512

A	O	513-514
survey	O	515-521
of	O	522-524
15	O	525-527
independent	O	528-539
inbred	O	540-546
strains	O	547-554
of	O	555-557
mice	O	558-562
revealed	O	563-571
that	O	572-576
ventricular	O	577-588
cardiomyocyte	O	589-602
nuclear	O	603-610
number	O	611-617
ranged	O	618-624
from	O	625-629
3	O	630-631
to	O	632-634
13	O	635-637
%	O	637-638
mononucleate	O	639-651
,	O	651-652
suggesting	O	653-663
that	O	664-668
cardiomyocyte	O	669-682
terminal	O	683-691
differentiation	O	692-707
is	O	708-710
influenced	O	711-721
directly	O	722-730
or	O	731-733
indirectly	O	734-744
by	O	745-747
genetic	O	748-755
background	O	756-766
.	O	766-767

To	O	768-770
determine	O	771-780
whether	O	781-788
the	O	789-792
capacity	O	793-801
for	O	802-805
reactive	O	806-814
DNA	O	815-818
synthesis	O	819-828
was	O	829-832
also	O	833-837
subject	O	838-845
to	O	846-848
genetic	O	849-856
regulation	O	857-867
,	O	867-868
cardiac	B	869-876
hypertrophy	I	877-888
was	O	889-892
induced	O	893-900
in	O	901-903
the	O	904-907
strains	O	908-915
of	O	916-918
mice	O	919-923
comprising	O	924-934
the	O	935-938
extremes	O	939-947
of	O	948-950
the	O	951-954
nuclear	O	955-962
number	O	963-969
survey	O	970-976
.	O	976-977

These	O	978-983
data	O	984-988
indicate	O	989-997
that	O	998-1002
adult	O	1003-1008
mouse	O	1009-1014
atrial	O	1015-1021
and	O	1022-1025
ventricular	O	1026-1037
cardiomyocytes	O	1038-1052
do	O	1053-1055
not	O	1056-1059
synthesize	O	1060-1070
DNA	O	1071-1074
in	O	1075-1077
response	O	1078-1086
to	O	1087-1089
isoproterenol	O	1090-1103
-	O	1103-1104
induced	O	1104-1111
cardiac	B	1112-1119
hypertrophy	I	1120-1131
.	O	1131-1132

Central	O	0-7
cardiovascular	O	8-22
effects	O	23-30
of	O	31-33
AVP	O	34-37
and	O	38-41
ANP	O	42-45
in	O	46-48
normotensive	O	49-61
and	O	62-65
spontaneously	O	66-79
hypertensive	B	80-92
rats	O	93-97
.	O	97-98

The	O	99-102
purpose	O	103-110
of	O	111-113
the	O	114-117
present	O	118-125
study	O	126-131
was	O	132-135
to	O	136-138
compare	O	139-146
influence	O	147-156
of	O	157-159
central	O	160-167
arginine	O	168-176
vasopressin	O	177-188
(	O	189-190
AVP	O	190-193
)	O	193-194
and	O	195-198
of	O	199-201
atrial	O	202-208
natriuretic	O	209-220
peptide	O	221-228
(	O	229-230
ANP	O	230-233
)	O	233-234
on	O	235-237
control	O	238-245
of	O	246-248
arterial	O	249-257
blood	O	258-263
pressure	O	264-272
(	O	273-274
MAP	O	274-277
)	O	277-278
and	O	279-282
heart	O	283-288
rate	O	289-293
(	O	294-295
HR	O	295-297
)	O	297-298
in	O	299-301
normotensive	O	302-314
(	O	315-316
WKY	O	316-319
)	O	319-320
and	O	321-324
spontaneously	O	325-338
hypertensive	B	339-351
(	O	352-353
SHR	O	353-356
)	O	356-357
rats	O	358-362
.	O	362-363

Three	O	364-369
series	O	370-376
of	O	377-379
experiments	O	380-391
were	O	392-396
performed	O	397-406
on	O	407-409
30	O	410-412
WKY	O	413-416
and	O	417-420
30	O	421-423
SHR	O	424-427
,	O	427-428
chronically	O	429-440
instrumented	O	441-453
with	O	454-458
guide	O	459-464
tubes	O	465-470
in	O	471-473
the	O	474-477
lateral	O	478-485
ventricle	O	486-495
(	O	496-497
LV	O	497-499
)	O	499-500
and	O	501-504
arterial	O	505-513
and	O	514-517
venous	O	518-524
catheters	O	525-534
.	O	534-535

MAP	O	536-539
and	O	540-543
HR	O	544-546
were	O	547-551
monitored	O	552-561
before	O	562-568
and	O	569-572
after	O	573-578
i	O	579-580
.	O	580-581
v	O	581-582
.	O	580-581

injections	O	584-594
of	O	595-597
either	O	598-604
vehicle	O	605-612
or	O	613-615
1	O	616-617
,	O	617-618
10	O	619-621
and	O	622-625
50	O	626-628
ng	O	629-631
of	O	632-634
AVP	O	635-638
and	O	639-642
25	O	643-645
,	O	645-646
125	O	647-650
and	O	651-654
500	O	655-658
ng	O	659-661
of	O	662-664
ANP	O	665-668
.	O	668-669

Sensitivity	O	670-681
of	O	682-684
cardiac	O	685-692
component	O	693-702
of	O	703-705
baroreflex	O	706-716
(	O	717-718
CCB	O	718-721
)	O	721-722
,	O	722-723
expressed	O	724-733
as	O	734-736
a	O	737-738
slope	O	739-744
of	O	745-747
the	O	748-751
regression	O	752-762
line	O	763-767
was	O	768-771
determined	O	772-782
from	O	783-787
relationships	O	788-801
between	O	802-809
systolic	O	810-818
arterial	O	819-827
pressure	O	828-836
(	O	837-838
SAP	O	838-841
)	O	841-842
and	O	843-846
HR	O	847-849
period	O	850-856
(	O	857-858
HRp	O	858-861
)	O	861-862
during	O	863-869
phenylephrine	O	870-883
(	O	884-885
Phe	O	885-888
)	O	888-889
-	O	889-890
induced	O	890-897
hypertension	B	898-910
and	O	911-914
sodium	O	915-921
nitroprusside	O	922-935
(	O	936-937
SN	O	937-939
)	O	939-940
-	O	940-941
induced	O	941-948
hypotension	B	949-960
.	O	960-961

CCB	O	962-965
was	O	966-969
measured	O	970-978
before	O	979-985
and	O	986-989
after	O	990-995
administration	O	996-1010
of	O	1011-1013
either	O	1014-1020
vehicle	O	1021-1028
,	O	1028-1029
AVP	O	1030-1033
,	O	1033-1034
ANP	O	1035-1038
,	O	1038-1039
or	O	1040-1042
both	O	1043-1047
peptides	O	1048-1056
together	O	1057-1065
.	O	1065-1066

Increases	O	1067-1076
of	O	1077-1079
MAP	O	1080-1083
occurred	O	1084-1092
after	O	1093-1098
LV	O	1099-1101
administration	O	1102-1116
of	O	1117-1119
1	O	1120-1121
,	O	1121-1122
10	O	1123-1125
and	O	1126-1129
50	O	1130-1132
ng	O	1133-1135
of	O	1136-1138
AVP	O	1139-1142
in	O	1143-1145
WKY	O	1146-1149
and	O	1150-1153
of	O	1154-1156
10	O	1157-1159
and	O	1160-1163
50	O	1164-1166
ng	O	1167-1169
in	O	1170-1172
SHR	O	1173-1176
.	O	1176-1177

ANP	O	1178-1181
did	O	1182-1185
not	O	1186-1189
cause	O	1190-1195
significant	O	1196-1207
changes	O	1208-1215
in	O	1216-1218
MAP	O	1219-1222
in	O	1223-1225
both	O	1226-1230
strains	O	1231-1238
as	O	1239-1241
compared	O	1242-1250
to	O	1251-1253
vehicle	O	1254-1261
,	O	1261-1262
but	O	1263-1266
it	O	1267-1269
abolished	O	1270-1279
AVP	O	1280-1283
-	O	1283-1284
induced	O	1284-1291
MAP	O	1292-1295
increase	O	1296-1304
in	O	1305-1307
WKY	O	1308-1311
and	O	1312-1315
SHR	O	1316-1319
.	O	1319-1320

CCB	O	1321-1324
was	O	1325-1328
reduced	O	1329-1336
in	O	1337-1339
WKY	O	1340-1343
and	O	1344-1347
SHR	O	1348-1351
after	O	1352-1357
LV	O	1358-1360
administration	O	1361-1375
of	O	1376-1378
AVP	O	1379-1382
during	O	1383-1389
SN	O	1390-1392
-	O	1392-1393
induced	O	1393-1400
hypotension	B	1401-1412
.	O	1412-1413

In	O	1414-1416
SHR	O	1417-1420
but	O	1421-1424
not	O	1425-1428
in	O	1429-1431
WKY	O	1432-1435
administration	O	1436-1450
of	O	1451-1453
ANP	O	1454-1457
,	O	1457-1458
AVP	O	1459-1462
and	O	1463-1466
ANP	O	1467-1470
+	O	1471-1472
AVP	O	1473-1476
decreased	O	1477-1486
CCB	O	1487-1490
during	O	1491-1497
Phe	O	1498-1501
-	O	1501-1502
induced	O	1502-1509
MAP	O	1510-1513
elevation	O	1514-1523
.	O	1523-1524

The	O	1525-1528
results	O	1529-1536
indicate	O	1537-1545
that	O	1546-1550
centrally	O	1551-1560
applied	O	1561-1568
AVP	O	1569-1572
and	O	1573-1576
ANP	O	1577-1580
exert	O	1581-1586
differential	O	1587-1599
effects	O	1600-1607
on	O	1608-1610
blood	O	1611-1616
pressure	O	1617-1625
and	O	1626-1629
baroreflex	O	1630-1640
control	O	1641-1648
of	O	1649-1651
heart	O	1652-1657
rate	O	1658-1662
in	O	1663-1665
WKY	O	1666-1669
and	O	1670-1673
SHR	O	1674-1677
and	O	1678-1681
suggest	O	1682-1689
interaction	O	1690-1701
of	O	1702-1704
these	O	1705-1710
two	O	1711-1714
peptides	O	1715-1723
in	O	1724-1726
blood	O	1727-1732
pressure	O	1733-1741
regulation	O	1742-1752
at	O	1753-1755
the	O	1756-1759
level	O	1760-1765
of	O	1766-1768
central	O	1769-1776
nervous	O	1777-1784
system	O	1785-1791
.	O	1791-1792

Cutaneous	O	0-9
exposure	O	10-18
to	O	19-21
warfarin	O	22-30
-	O	30-31
like	O	31-35
anticoagulant	O	36-49
causing	O	50-57
an	O	58-60
intracerebral	B	61-74
hemorrhage	I	75-85
:	O	85-86
a	O	87-88
case	O	89-93
report	O	94-100
.	O	100-101

A	O	102-103
case	O	104-108
of	O	109-111
intercerebral	O	112-125
hematoma	B	126-134
due	O	135-138
to	O	139-141
warfarin	O	142-150
-	O	150-151
induced	O	151-158
coagulopathy	B	159-171
is	O	172-174
presented	O	175-184
.	O	184-185

The	O	186-189
39	O	190-192
-	O	192-193
year	O	193-197
-	O	192-193
old	O	198-201
woman	O	202-207
had	O	208-211
spread	O	212-218
a	O	219-220
warfarin	O	221-229
-	O	229-230
type	O	230-234
rat	O	235-238
poison	O	239-245
around	O	246-252
her	O	253-256
house	O	257-262
weekly	O	263-269
using	O	270-275
her	O	276-279
bare	O	280-284
hands	O	285-290
,	O	290-291
with	O	292-296
no	O	297-299
washing	O	300-307
post	O	308-312
application	O	313-324
.	O	324-325

Percutaneous	O	326-338
absorption	O	339-349
of	O	350-352
warfarin	O	353-361
causing	O	362-369
coagulopathy	B	370-382
,	O	382-383
reported	O	384-392
three	O	393-398
times	O	399-404
in	O	405-407
the	O	408-411
past	O	412-416
,	O	416-417
is	O	418-420
a	O	421-422
significant	O	423-434
risk	O	435-439
if	O	440-442
protective	O	443-453
measures	O	454-462
,	O	462-463
such	O	464-468
as	O	469-471
gloves	O	472-478
,	O	478-479
are	O	480-483
not	O	484-487
used	O	488-492
.	O	492-493

An	O	494-496
adverse	O	497-504
drug	O	505-509
interaction	O	510-521
with	O	522-526
piroxicam	O	527-536
,	O	536-537
which	O	538-543
she	O	544-547
took	O	548-552
occasionally	O	553-565
,	O	565-566
may	O	567-570
have	O	571-575
exacerbated	O	576-587
the	O	588-591
coagulopathy	B	592-604
.	O	604-605

Pediatric	O	0-9
heart	O	10-15
transplantation	O	16-31
without	O	32-39
chronic	O	40-47
maintenance	O	48-59
steroids	O	60-68
.	O	68-69

From	O	70-74
1986	O	75-79
to	O	80-82
February	O	83-91
1993	O	92-96
,	O	96-97
40	O	98-100
children	O	101-109
aged	O	110-114
2	O	115-116
months	O	117-123
to	O	124-126
18	O	127-129
years	O	130-135
(	O	136-137
average	O	137-144
age	O	145-148
10	O	149-151
.	O	151-152
4	O	152-153
+	O	154-155
/	O	155-156
-	O	156-157
5	O	158-159
.	O	159-160
8	O	160-161
years	O	162-167
)	O	167-168
underwent	O	169-178
heart	O	179-184
transplantation	O	185-200
.	O	200-201

Indications	O	202-213
for	O	214-217
transplantation	O	218-233
were	O	234-238
idiopathic	B	239-249
cardiomyopathy	I	250-264
(	O	265-266
52	O	266-268
%	O	268-269
)	O	269-270
,	O	270-271
congenital	B	272-282
heart	I	283-288
disease	I	289-296
(	O	297-298
35	O	298-300
%	O	300-301
)	O	301-302
with	O	303-307
and	O	308-311
without	O	312-319
prior	O	320-325
repair	O	326-332
(	O	333-334
71	O	334-336
%	O	336-337
and	O	338-341
29	O	342-344
%	O	344-345
,	O	345-346
respectively	O	347-359
)	O	359-360
,	O	360-361
hypertrophic	B	362-374
cardiomyopathy	I	375-389
(	O	390-391
5	O	391-392
%	O	392-393
)	O	393-394
,	O	394-395
valvular	B	396-404
heart	I	405-410
disease	I	411-418
(	O	419-420
3	O	420-421
%	O	421-422
)	O	422-423
,	O	423-424
and	O	425-428
doxorubicin	O	429-440
cardiomyopathy	B	441-455
(	O	456-457
5	O	457-458
%	O	458-459
)	O	459-460
.	O	460-461

Patients	O	462-470
were	O	471-475
managed	O	476-483
with	O	484-488
cyclosporine	O	489-501
and	O	502-505
azathioprine	O	506-518
.	O	518-519

No	O	520-522
prophylaxis	O	523-534
with	O	535-539
antilymphocyte	O	540-554
globulin	O	555-563
was	O	564-567
used	O	568-572
.	O	572-573

Steroids	O	574-582
were	O	583-587
given	O	588-593
to	O	594-596
39	O	597-599
%	O	599-600
of	O	601-603
patients	O	604-612
for	O	613-616
refractory	O	617-627
rejection	O	628-637
,	O	637-638
but	O	639-642
weaning	O	643-650
was	O	651-654
always	O	655-661
attempted	O	662-671
and	O	672-675
generally	O	676-685
successful	O	686-696
(	O	697-698
64	O	698-700
%	O	700-701
)	O	701-702
.	O	702-703

Five	O	704-708
patients	O	709-717
(	O	718-719
14	O	719-721
%	O	721-722
)	O	722-723
received	O	724-732
maintenance	O	733-744
steroids	O	745-753
.	O	753-754

Four	O	755-759
patients	O	760-768
died	O	769-773
in	O	774-776
the	O	777-780
perioperative	O	781-794
period	O	795-801
and	O	802-805
one	O	806-809
died	O	810-814
4	O	815-816
months	O	817-823
later	O	824-829
.	O	829-830

There	O	831-836
have	O	837-841
been	O	842-846
no	O	847-849
deaths	O	850-856
related	O	857-864
to	O	865-867
rejection	O	868-877
or	O	878-880
infection	B	881-890
.	O	890-891

Average	O	892-899
follow	O	900-906
-	O	906-907
up	O	907-909
was	O	910-913
36	O	914-916
+	O	917-918
/	O	918-919
-	O	919-920
19	O	921-923
months	O	924-930
(	O	931-932
range	O	932-937
1	O	938-939
to	O	940-942
65	O	943-945
months	O	946-952
)	O	952-953
.	O	953-954

Cumulative	O	955-965
survival	O	966-974
is	O	975-977
88	O	978-980
%	O	980-981
at	O	982-984
5	O	985-986
years	O	987-992
.	O	992-993

In	O	994-996
patients	O	997-1005
less	O	1006-1010
than	O	1011-1015
7	O	1016-1017
years	O	1018-1023
of	O	1024-1026
age	O	1027-1030
,	O	1030-1031
rejection	O	1032-1041
was	O	1042-1045
monitored	O	1046-1055
noninvasively	O	1056-1069
.	O	1069-1070

In	O	1071-1073
the	O	1074-1077
first	O	1078-1083
postoperative	O	1084-1097
month	O	1098-1103
,	O	1103-1104
89	O	1105-1107
%	O	1107-1108
of	O	1109-1111
patients	O	1112-1120
were	O	1121-1125
treated	O	1126-1133
for	O	1134-1137
rejection	O	1138-1147
.	O	1147-1148

Freedom	O	1149-1156
from	O	1157-1161
serious	O	1162-1169
infections	B	1170-1180
was	O	1181-1184
83	O	1185-1187
%	O	1187-1188
at	O	1189-1191
1	O	1192-1193
month	O	1194-1199
and	O	1200-1203
65	O	1204-1206
%	O	1206-1207
at	O	1208-1210
1	O	1211-1212
year	O	1213-1217
.	O	1217-1218

Cytomegalovirus	B	1219-1234
infections	I	1235-1245
were	O	1246-1250
treated	O	1251-1258
successfully	O	1259-1271
with	O	1272-1276
ganciclovir	O	1277-1288
in	O	1289-1291
11	O	1292-1294
patients	O	1295-1303
.	O	1303-1304

No	O	1305-1307
impairment	O	1308-1318
of	O	1319-1321
growth	O	1322-1328
was	O	1329-1332
observed	O	1333-1341
in	O	1342-1344
children	O	1345-1353
who	O	1354-1357
underwent	O	1358-1367
transplantation	O	1368-1383
compared	O	1384-1392
with	O	1393-1397
a	O	1398-1399
control	O	1400-1407
population	O	1408-1418
.	O	1418-1419

Twenty	O	1420-1426
-	O	1426-1427
one	O	1427-1430
patients	O	1431-1439
(	O	1440-1441
60	O	1441-1443
%	O	1443-1444
)	O	1444-1445
have	O	1446-1450
undergone	O	1451-1460
annual	O	1461-1467
catheterizations	O	1468-1484
and	O	1485-1488
no	O	1489-1491
sign	O	1492-1496
of	O	1497-1499
graft	O	1500-1505
atherosclerosis	B	1506-1521
has	O	1522-1525
been	O	1526-1530
observed	O	1531-1539
.	O	1539-1540

Seizures	B	1541-1549
occurred	O	1550-1558
in	O	1559-1561
five	O	1562-1566
patients	O	1567-1575
(	O	1576-1577
14	O	1577-1579
%	O	1579-1580
)	O	1580-1581
and	O	1582-1585
hypertension	B	1586-1598
was	O	1599-1602
treated	O	1603-1610
in	O	1611-1613
10	O	1614-1616
patients	O	1617-1625
(	O	1626-1627
28	O	1627-1629
%	O	1629-1630
)	O	1630-1631
.	O	1631-1632

No	O	1633-1635
patient	O	1636-1643
was	O	1644-1647
disabled	O	1648-1656
and	O	1657-1660
no	O	1661-1663
lymphoproliferative	B	1664-1683
disorder	I	1684-1692
was	O	1693-1696
observed	O	1697-1705
.	O	1705-1706
(	O	1706-1707
ABSTRACT	O	1707-1715

TRUNCATED	O	1716-1725
AT	O	1726-1728
250	O	1729-1732
WORDS	O	1733-1738
)	O	1738-1739

Delirium	B	0-8
during	O	9-15
fluoxetine	O	16-26
treatment	O	27-36
.	O	36-37

A	O	38-39
case	O	40-44
report	O	45-51
.	O	51-52

The	O	53-56
correlation	O	57-68
between	O	69-76
high	O	77-81
serum	O	82-87
tricyclic	O	88-97
antidepressant	O	98-112
concentrations	O	113-127
and	O	128-131
central	O	132-139
nervous	O	140-147
system	O	148-154
side	O	155-159
effects	O	160-167
has	O	168-171
been	O	172-176
well	O	177-181
established	O	182-193
.	O	193-194

Only	O	195-199
a	O	200-201
few	O	202-205
reports	O	206-213
exist	O	214-219
,	O	219-220
however	O	221-228
,	O	228-229
on	O	230-232
the	O	233-236
relationship	O	237-249
between	O	250-257
the	O	258-261
serum	O	262-267
concentrations	O	268-282
of	O	283-285
selective	O	286-295
serotonin	O	296-305
reuptake	O	306-314
inhibitors	O	315-325
(	O	326-327
SSRIs	O	327-332
)	O	332-333
and	O	334-337
their	O	338-343
toxic	O	344-349
effects	O	350-357
.	O	357-358

In	O	359-361
some	O	362-366
cases	O	367-372
,	O	372-373
a	O	374-375
high	O	376-380
serum	O	381-386
concentration	O	387-400
of	O	401-403
citalopram	O	404-414
(	O	415-416
>	O	416-417
600	O	418-421
nmol	O	422-426
/	O	426-427
L	O	427-428
)	O	428-429
in	O	430-432
elderly	O	433-440
patients	O	441-449
has	O	450-453
been	O	454-458
associated	O	459-469
with	O	470-474
increased	O	475-484
somnolence	B	485-495
and	O	496-499
movement	B	500-508
difficulties	I	509-521
.	O	521-522

Widespread	O	523-533
cognitive	B	534-543
disorders	I	544-553
,	O	553-554
such	O	555-559
as	O	560-562
delirium	B	563-571
,	O	571-572
have	O	573-577
not	O	578-581
been	O	582-586
previously	O	587-597
linked	O	598-604
with	O	605-609
high	O	610-614
blood	O	615-620
levels	O	621-627
of	O	628-630
SSRIs	O	631-636
.	O	636-637

In	O	638-640
this	O	641-645
report	O	646-652
,	O	652-653
we	O	654-656
describe	O	657-665
a	O	666-667
patient	O	668-675
with	O	676-680
acute	O	681-686
hyperkinetic	B	687-699
delirium	B	700-708
connected	O	709-718
with	O	719-723
a	O	724-725
high	O	726-730
serum	O	731-736
total	O	737-742
fluoxetine	O	743-753
(	O	754-755
fluoxetine	O	755-765
plus	O	766-770
desmethylfluoxetine	O	771-790
)	O	790-791
concentration	O	792-805
.	O	805-806

Pulmonary	B	0-9
edema	I	10-15
and	O	16-19
shock	B	20-25
after	O	26-31
high	O	32-36
-	O	36-37
dose	O	37-41
aracytine	O	42-51
-	O	51-52
C	O	52-53
for	O	54-57
lymphoma	B	58-66
;	O	66-67
possible	O	68-76
role	O	77-81
of	O	82-84
TNF	O	85-88
-	O	88-89
alpha	O	89-94
and	O	95-98
PAF	O	99-102
.	O	102-103

Four	O	104-108
out	O	109-112
of	O	113-115
23	O	116-118
consecutive	O	119-130
patients	O	131-139
treated	O	140-147
with	O	148-152
high	O	153-157
-	O	157-158
dose	O	158-162
Ara	O	163-166
-	O	166-167
C	O	167-168
for	O	169-172
lymphomas	B	173-182
in	O	183-185
our	O	186-189
institution	O	190-201
developed	O	202-211
a	O	212-213
strikingly	O	214-224
similar	O	225-232
syndrome	O	233-241
during	O	242-248
the	O	249-252
perfusion	O	253-262
.	O	262-263

It	O	264-266
was	O	267-270
characterized	O	271-284
by	O	285-287
the	O	288-291
onset	O	292-297
of	O	298-300
fever	B	301-306
,	O	306-307
diarrhea	B	308-316
,	O	316-317
shock	B	318-323
,	O	323-324
pulmonary	B	325-334
edema	I	335-340
,	O	340-341
acute	B	342-347
renal	I	348-353
failure	I	354-361
,	O	361-362
metabolic	B	363-372
acidosis	I	373-381
,	O	381-382
weight	B	383-389
gain	I	390-394
and	O	395-398
leukocytosis	B	399-411
.	O	411-412

Thorough	O	413-421
bacteriological	O	422-437
screening	O	438-447
failed	O	448-454
to	O	455-457
provide	O	458-465
evidence	O	466-474
of	O	475-477
infection	B	478-487
.	O	487-488

Sequential	O	489-499
biological	O	500-510
assays	O	511-517
of	O	518-520
IL	O	521-523
-	O	523-524
1	O	524-525
,	O	525-526
IL	O	527-529
-	O	529-530
2	O	530-531
,	O	531-532
TNF	O	533-536
and	O	537-540
PAF	O	541-544
were	O	545-549
performed	O	550-559
during	O	560-566
Ara	O	567-570
-	O	570-571
C	O	571-572
infusion	O	573-581
to	O	582-584
ten	O	585-588
patients	O	589-597
,	O	597-598
including	O	599-608
the	O	609-612
four	O	613-617
who	O	618-621
developed	O	622-631
the	O	632-635
syndrome	O	636-644
.	O	644-645

TNF	O	646-649
and	O	650-653
PAF	O	654-657
activity	O	658-666
was	O	667-670
found	O	671-676
in	O	677-679
the	O	680-683
serum	O	684-689
of	O	690-692
respectively	O	693-705
two	O	706-709
and	O	710-713
four	O	714-718
of	O	719-721
the	O	722-725
cases	O	726-731
,	O	731-732
but	O	733-736
not	O	737-740
in	O	741-743
the	O	744-747
six	O	748-751
controls	O	752-760
.	O	760-761

As	O	762-764
TNF	O	765-768
and	O	769-772
PAF	O	773-776
are	O	777-780
thought	O	781-788
to	O	789-791
be	O	792-794
involved	O	795-803
in	O	804-806
the	O	807-810
development	O	811-822
of	O	823-825
septic	O	826-832
shock	B	833-838
and	O	839-842
adult	B	843-848
respiratory	I	849-860
distress	I	861-869
syndrome	I	870-878
,	O	878-879
we	O	880-882
hypothesize	O	883-894
that	O	895-899
high	O	900-904
-	O	904-905
dose	O	905-909
Ara	O	910-913
-	O	913-914
C	O	914-915
may	O	916-919
be	O	920-922
associated	O	923-933
with	O	934-938
cytokine	O	939-947
release	O	948-955
.	O	955-956

Protective	O	0-10
effect	O	11-17
of	O	18-20
clentiazem	O	21-31
against	O	32-39
epinephrine	O	40-51
-	O	51-52
induced	O	52-59
cardiac	B	60-67
injury	I	68-74
in	O	75-77
rats	O	78-82
.	O	82-83

We	O	84-86
investigated	O	87-99
the	O	100-103
effects	O	104-111
of	O	112-114
clentiazem	O	115-125
,	O	125-126
a	O	127-128
1	O	129-130
,	O	130-131
5	O	131-132
-	O	132-133
benzothiazepine	O	133-148
calcium	O	149-156
antagonist	O	157-167
,	O	167-168
on	O	169-171
epinephrine	O	172-183
-	O	183-184
induced	O	184-191
cardiomyopathy	B	192-206
in	O	207-209
rats	O	210-214
.	O	214-215

With	O	216-220
2	O	221-222
-	O	222-223
week	O	223-227
chronic	O	228-235
epinephrine	O	236-247
infusion	O	248-256
,	O	256-257
16	O	258-260
of	O	261-263
30	O	264-266
rats	O	267-271
died	O	272-276
within	O	277-283
4	O	284-285
days	O	286-290
,	O	290-291
and	O	292-295
severe	O	296-302
ischemic	B	303-311
lesions	I	312-319
and	O	320-323
fibrosis	B	324-332
of	O	333-335
the	O	336-339
left	O	340-344
ventricles	O	345-355
were	O	356-360
observed	O	361-369
.	O	369-370

In	O	371-373
epinephrine	O	374-385
-	O	385-386
treated	O	386-393
rats	O	394-398
,	O	398-399
left	O	400-404
atrial	O	405-411
and	O	412-415
left	O	416-420
ventricular	O	421-432
papillary	O	433-442
muscle	O	443-449
contractile	O	450-461
responses	O	462-471
to	O	472-474
isoproterenol	O	475-488
were	O	489-493
reduced	O	494-501
,	O	501-502
but	O	503-506
responses	O	507-516
to	O	517-519
calcium	O	520-527
were	O	528-532
normal	O	533-539
or	O	540-542
enhanced	O	543-551
compared	O	552-560
to	O	561-563
controls	O	564-572
.	O	572-573

Left	O	574-578
ventricular	O	579-590
alpha	O	591-596
and	O	597-600
beta	O	601-605
adrenoceptor	O	606-618
densities	O	619-628
were	O	629-633
also	O	634-638
reduced	O	639-646
compared	O	647-655
to	O	656-658
controls	O	659-667
.	O	667-668

Treatment	O	669-678
with	O	679-683
clentiazem	O	684-694
prevented	O	695-704
epinephrine	O	705-716
-	O	716-717
induced	O	717-724
death	O	725-730
(	O	731-732
P	O	732-733
<	O	734-735
.	O	736-737
05	O	737-739
)	O	739-740
,	O	740-741

and	O	742-745
attenuated	O	746-756
the	O	757-760
ventricular	O	761-772
ischemic	B	773-781
lesions	I	782-789
and	O	790-793
fibrosis	B	794-802
,	O	802-803
in	O	804-806
a	O	807-808
dose	O	809-813
-	O	813-814
dependent	O	814-823
manner	O	824-830
.	O	830-831

Left	O	832-836
atrial	O	837-843
and	O	844-847
left	O	848-852
ventricular	O	853-864
papillary	O	865-874
muscle	O	875-881
contractile	O	882-893
responses	O	894-903
to	O	904-906
isoproterenol	O	907-920
were	O	921-925
reduced	O	926-933
compared	O	934-942
to	O	943-945
controls	O	946-954
in	O	955-957
groups	O	958-964
treated	O	965-972
with	O	973-977
clentiazem	O	978-988
alone	O	989-994
,	O	994-995
but	O	996-999
combined	O	1000-1008
with	O	1009-1013
epinephrine	O	1014-1025
,	O	1025-1026
clentiazem	O	1027-1037
restored	O	1038-1046
left	O	1047-1051
atrial	O	1052-1058
responses	O	1059-1068
and	O	1069-1072
enhanced	O	1073-1081
left	O	1082-1086
ventricular	O	1087-1098
papillary	O	1099-1108
responses	O	1109-1118
to	O	1119-1121
isoproterenol	O	1122-1135
.	O	1135-1136

On	O	1137-1139
the	O	1140-1143
other	O	1144-1149
hand	O	1150-1154
clentiazem	O	1155-1165
did	O	1166-1169
not	O	1170-1173
prevent	O	1174-1181
epinephrine	O	1182-1193
-	O	1193-1194
induced	O	1194-1201
down	O	1202-1206
-	O	1206-1207
regulation	O	1207-1217
of	O	1218-1220
alpha	O	1221-1226
and	O	1227-1230
beta	O	1231-1235
adrenoceptors	O	1236-1249
.	O	1249-1250

Interestingly	O	1251-1264
,	O	1264-1265
clentiazem	O	1266-1276
,	O	1276-1277
infused	O	1278-1285
alone	O	1286-1291
,	O	1291-1292
resulted	O	1293-1301
in	O	1302-1304
decreased	O	1305-1314
adrenergic	O	1315-1325
receptor	O	1326-1334
densities	O	1335-1344
in	O	1345-1347
the	O	1348-1351
left	O	1352-1356
ventricle	O	1357-1366
.	O	1366-1367

Clentiazem	O	1368-1378
also	O	1379-1383
did	O	1384-1387
not	O	1388-1391
prevent	O	1392-1399
the	O	1400-1403
enhanced	O	1404-1412
responses	O	1413-1422
to	O	1423-1425
calcium	O	1426-1433
seen	O	1434-1438
in	O	1439-1441
the	O	1442-1445
epinephrine	O	1446-1457
-	O	1457-1458
treated	O	1458-1465
animals	O	1466-1473
,	O	1473-1474
although	O	1475-1483
the	O	1484-1487
high	O	1488-1492
dose	O	1493-1497
of	O	1498-1500
clentiazem	O	1501-1511
partially	O	1512-1521
attenuated	O	1522-1532
the	O	1533-1536
maximal	O	1537-1544
response	O	1545-1553
to	O	1554-1556
calcium	O	1557-1564
compared	O	1565-1573
to	O	1574-1576
epinephrine	O	1577-1588
-	O	1588-1589
treated	O	1589-1596
animals	O	1597-1604
.	O	1604-1605

In	O	1606-1608
conclusion	O	1609-1619
,	O	1619-1620
clentiazem	O	1621-1631
attenuated	O	1632-1642
epinephrine	O	1643-1654
-	O	1654-1655
induced	O	1655-1662
cardiac	B	1663-1670
injury	I	1671-1677
,	O	1677-1678
possibly	O	1679-1687
through	O	1688-1695
its	O	1696-1699
effect	O	1700-1706
on	O	1707-1709
the	O	1710-1713
adrenergic	O	1714-1724
pathway	O	1725-1732
.	O	1732-1733

Cocaine	O	0-7
induced	O	8-15
myocardial	B	16-26
ischemia	I	27-35
.	O	35-36

We	O	37-39
report	O	40-46
a	O	47-48
case	O	49-53
of	O	54-56
myocardial	B	57-67
ischemia	I	68-76
induced	O	77-84
by	O	85-87
cocaine	O	88-95
.	O	95-96

The	O	97-100
ischemia	B	101-109
probably	O	110-118
induced	O	119-126
by	O	127-129
coronary	B	130-138
artery	I	139-145
spasm	I	146-151
was	O	152-155
reversed	O	156-164
by	O	165-167
nitroglycerin	O	168-181
and	O	182-185
calcium	O	186-193
blocking	O	194-202
agents	O	203-209
.	O	209-210

Doxorubicin	O	0-11
-	O	11-12
induced	O	12-19
cardiotoxicity	B	20-34
monitored	O	35-44
by	O	45-47
ECG	O	48-51
in	O	52-54
freely	O	55-61
moving	O	62-68
mice	O	69-73
.	O	73-74

A	O	75-76
new	O	77-80
model	O	81-86
to	O	87-89
test	O	90-94
potential	O	95-104
protectors	O	105-115
.	O	115-116

In	O	117-119
laboratory	O	120-130
animals	O	131-138
,	O	138-139
histology	O	140-149
is	O	150-152
most	O	153-157
commonly	O	158-166
used	O	167-171
to	O	172-174
study	O	175-180
doxorubicin	O	181-192
-	O	192-193
induced	O	193-200
cardiotoxicity	B	201-215
.	O	215-216

However	O	217-224
,	O	224-225
for	O	226-229
monitoring	O	230-240
during	O	241-247
treatment	O	248-257
,	O	257-258
large	O	259-264
numbers	O	265-272
of	O	273-275
animals	O	276-283
are	O	284-287
needed	O	288-294
.	O	294-295

Recently	O	296-304
we	O	305-307
developed	O	308-317
a	O	318-319
new	O	320-323
method	O	324-330
to	O	331-333
measure	O	334-341
ECG	O	342-345
values	O	346-352
in	O	353-355
freely	O	356-362
moving	O	363-369
mice	O	370-374
by	O	375-377
telemetry	O	378-387
.	O	387-388

With	O	389-393
this	O	394-398
model	O	399-404
we	O	405-407
investigated	O	408-420
the	O	421-424
effect	O	425-431
of	O	432-434
chronic	O	435-442
doxorubicin	O	443-454
administration	O	455-469
on	O	470-472
the	O	473-476
ECG	O	477-480
of	O	481-483
freely	O	484-490
moving	O	491-497
BALB	O	498-502
/	O	502-503
c	O	503-504
mice	O	505-509
and	O	510-513
the	O	514-517
efficacy	O	518-526
of	O	527-529
ICRF	O	530-534
-	O	534-535
187	O	535-538
as	O	539-541
a	O	542-543
protective	O	544-554
agent	O	555-560
.	O	560-561

The	O	562-565
ST	O	566-568
interval	O	569-577
significantly	O	578-591
widened	O	592-599
from	O	600-604
15	O	605-607
.	O	607-608
0	O	608-609
+	O	610-611
/	O	611-612
-	O	612-613
1	O	614-615
.	O	615-616
5	O	616-617
to	O	618-620
56	O	621-623
.	O	623-624
8	O	624-625
+	O	626-627
/	O	627-628
-	O	628-629
11	O	630-632
.	O	632-633
8	O	633-634
ms	O	635-637
in	O	638-640
week	O	641-645
10	O	646-648
(	O	649-650
7	O	650-651
weekly	O	652-658
doses	O	659-664
of	O	665-667
4	O	668-669
mg	O	670-672
/	O	672-673
kg	O	673-675
doxorubicin	O	676-687
given	O	688-693
i	O	694-695
.	O	695-696
v	O	696-697
.	O	695-696

plus	O	699-703
3	O	704-705
weeks	O	706-711
of	O	712-714
observation	O	715-726
)	O	726-727
.	O	727-728

The	O	729-732
ECG	O	733-736
of	O	737-739
the	O	740-743
control	O	744-751
animals	O	752-759
did	O	760-763
not	O	764-767
change	O	768-774
during	O	775-781
the	O	782-785
entire	O	786-792
study	O	793-798
.	O	798-799

After	O	800-805
sacrifice	O	806-815
the	O	816-819
hearts	O	820-826
of	O	827-829
doxorubicin	O	830-841
-	O	841-842
treated	O	842-849
animals	O	850-857
were	O	858-862
enlarged	O	863-871
and	O	872-875
the	O	876-879
atria	O	880-885
were	O	886-890
hypertrophic	B	891-903
.	O	903-904

As	O	905-907
this	O	908-912
schedule	O	913-921
exerted	O	922-929
more	O	930-934
toxicity	B	935-943
than	O	944-948
needed	O	949-955
to	O	956-958
investigate	O	959-970
protective	O	971-981
agents	O	982-988
,	O	988-989
the	O	990-993
protection	O	994-1004
of	O	1005-1007
ICRF	O	1008-1012
-	O	1012-1013
187	O	1013-1016
was	O	1017-1020
determined	O	1021-1031
using	O	1032-1037
a	O	1038-1039
dose	O	1040-1044
schedule	O	1045-1053
with	O	1054-1058
lower	O	1059-1064
general	O	1065-1072
toxicity	B	1073-1081
(	O	1082-1083
6	O	1083-1084
weekly	O	1085-1091
doses	O	1092-1097
of	O	1098-1100
4	O	1101-1102
mg	O	1103-1105
/	O	1105-1106
kg	O	1106-1108
doxorubicin	O	1109-1120
given	O	1121-1126
i	O	1127-1128
.	O	1128-1129
v	O	1129-1130
.	O	1128-1129

plus	O	1132-1136
2	O	1137-1138
weeks	O	1139-1144
of	O	1145-1147
observation	O	1148-1159
)	O	1159-1160
.	O	1160-1161

On	O	1162-1164
this	O	1165-1169
schedule	O	1170-1178
,	O	1178-1179
the	O	1180-1183
animals	O	1184-1191
'	O	1191-1192
hearts	O	1193-1199
appeared	O	1200-1208
normal	O	1209-1215
after	O	1216-1221
sacrifice	O	1222-1231
and	O	1232-1235
ICRF	O	1236-1240
-	O	1240-1241
187	O	1241-1244
(	O	1245-1246
50	O	1246-1248
mg	O	1249-1251
/	O	1251-1252
kg	O	1252-1254
given	O	1255-1260
i	O	1261-1262
.	O	1262-1263
p	O	1263-1264
.	O	1262-1263
1	O	1266-1267
h	O	1268-1269
before	O	1270-1276
doxorubicin	O	1277-1288
)	O	1288-1289
provided	O	1290-1298
almost	O	1299-1305
full	O	1306-1310
protection	O	1311-1321
.	O	1321-1322

These	O	1323-1328
data	O	1329-1333
were	O	1334-1338
confirmed	O	1339-1348
by	O	1349-1351
histology	O	1352-1361
.	O	1361-1362

The	O	1363-1366
results	O	1367-1374
indicate	O	1375-1383
that	O	1384-1388
this	O	1389-1393
new	O	1394-1397
model	O	1398-1403
is	O	1404-1406
very	O	1407-1411
sensitive	O	1412-1421
and	O	1422-1425
enables	O	1426-1433
monitoring	O	1434-1444
of	O	1445-1447
the	O	1448-1451
development	O	1452-1463
of	O	1464-1466
cardiotoxicity	B	1467-1481
with	O	1482-1486
time	O	1487-1491
.	O	1491-1492

These	O	1493-1498
findings	O	1499-1507
result	O	1508-1514
in	O	1515-1517
a	O	1518-1519
model	O	1520-1525
that	O	1526-1530
allows	O	1531-1537
the	O	1538-1541
testing	O	1542-1549
of	O	1550-1552
protectors	O	1553-1563
against	O	1564-1571
doxorubicin	O	1572-1583
-	O	1583-1584
induced	O	1584-1591
cardiotoxicity	B	1592-1606
as	O	1607-1609
demonstrated	O	1610-1622
by	O	1623-1625
the	O	1626-1629
protection	O	1630-1640
provided	O	1641-1649
by	O	1650-1652
ICRF	O	1653-1657
-	O	1657-1658
187	O	1658-1661
.	O	1661-1662

Epinephrine	O	0-11
dysrhythmogenicity	O	12-30
is	O	31-33
not	O	34-37
enhanced	O	38-46
by	O	47-49
subtoxic	O	50-58
bupivacaine	O	59-70
in	O	71-73
dogs	O	74-78
.	O	78-79

Since	O	80-85
bupivacaine	O	86-97
and	O	98-101
epinephrine	O	102-113
may	O	114-117
both	O	118-122
precipitate	O	123-134
dysrhythmias	B	135-147
,	O	147-148
circulating	O	149-160
bupivacaine	O	161-172
during	O	173-179
regional	O	180-188
anesthesia	O	189-199
could	O	200-205
potentiate	O	206-216
dysrhythmogenic	O	217-232
effects	O	233-240
of	O	241-243
epinephrine	O	244-255
.	O	255-256

We	O	257-259
therefore	O	260-269
examined	O	270-278
whether	O	279-286
bupivacaine	O	287-298
alters	O	299-305
the	O	306-309
dysrhythmogenicity	O	310-328
of	O	329-331
subsequent	O	332-342
administration	O	343-357
of	O	358-360
epinephrine	O	361-372
in	O	373-375
conscious	O	376-385
,	O	385-386
healthy	O	387-394
dogs	O	395-399
and	O	400-403
in	O	404-406
anesthetized	O	407-419
dogs	O	420-424
with	O	425-429
myocardial	B	430-440
infarction	I	441-451
.	O	451-452

Forty	O	453-458
-	O	458-459
one	O	459-462
conscious	O	463-472
dogs	O	473-477
received	O	478-486
10	O	487-489
micrograms	O	490-500
.	O	500-501
kg	O	501-503
-	O	503-504
1	O	504-505
.	O	500-501
min	O	506-509
-	O	503-504
1	O	504-505

epinephrine	O	512-523
.	O	523-524

Seventeen	O	525-534
animals	O	535-542
responded	O	543-552
with	O	553-557
ventricular	B	558-569
tachycardia	I	570-581
(	O	582-583
VT	B	583-585
)	O	585-586
within	O	587-593
3	O	594-595
min	O	596-599
.	O	599-600

After	O	601-606
3	O	607-608
h	O	609-610
,	O	610-611
these	O	612-617
responders	O	618-628
randomly	O	629-637
received	O	638-646
1	O	647-648
or	O	649-651
2	O	652-653
mg	O	654-656
/	O	656-657
kg	O	657-659
bupivacaine	O	660-671
or	O	672-674
saline	O	675-681
over	O	682-686
5	O	687-688
min	O	689-692
,	O	692-693
followed	O	694-702
by	O	703-705
10	O	706-708
micrograms	O	709-719
.	O	719-720
kg	O	720-722
-	O	722-723
1	O	723-724
.	O	719-720
min	O	725-728
-	O	722-723
1	O	723-724

epinephrine	O	731-742
.	O	742-743

In	O	744-746
the	O	747-750
bupivacaine	O	751-762
groups	O	763-769
,	O	769-770
epinephrine	O	771-782
caused	O	783-789
fewer	O	790-795
prodysrhythmic	O	796-810
effects	O	811-818
than	O	819-823
without	O	824-831
bupivacaine	O	832-843
.	O	843-844

VT	B	845-847
appeared	O	848-856
in	O	857-859
fewer	O	860-865
dogs	O	866-870
and	O	871-874
at	O	875-877
a	O	878-879
later	O	880-885
time	O	886-890
,	O	890-891
and	O	892-895
there	O	896-901
were	O	902-906
more	O	907-911
sinoatrial	O	912-922
beats	O	923-928
and	O	929-932
less	O	933-937
ectopies	O	938-946
.	O	946-947

Epinephrine	O	948-959
shortened	O	960-969
QT	O	970-972
less	O	973-977
after	O	978-983
bupivacaine	O	984-995
than	O	996-1000
in	O	1001-1003
control	O	1004-1011
animals	O	1012-1019
.	O	1019-1020

One	O	1021-1024
day	O	1025-1028
after	O	1029-1034
experimental	O	1035-1047
myocardial	B	1048-1058
infarction	I	1059-1069
,	O	1069-1070
six	O	1071-1074
additional	O	1075-1085
halothane	O	1086-1095
-	O	1095-1096
anesthetized	O	1096-1108
dogs	O	1109-1113
received	O	1114-1122
4	O	1123-1124
micrograms	O	1125-1135
.	O	1135-1136
kg	O	1136-1138
-	O	1138-1139
1	O	1139-1140
.	O	1135-1136
min	O	1141-1144
-	O	1138-1139
1	O	1139-1140

epinephrine	O	1147-1158
until	O	1159-1164
VT	B	1165-1167
appeared	O	1168-1176
.	O	1176-1177

After	O	1178-1183
45	O	1184-1186
min	O	1187-1190
,	O	1190-1191
1	O	1192-1193
mg	O	1194-1196
/	O	1196-1197
kg	O	1197-1199
bupivacaine	O	1200-1211
was	O	1212-1215
injected	O	1216-1224
over	O	1225-1229
5	O	1230-1231
min	O	1232-1235
,	O	1235-1236
again	O	1237-1242
followed	O	1243-1251
by	O	1252-1254
4	O	1255-1256
micrograms	O	1257-1267
.	O	1267-1268
kg	O	1268-1270
-	O	1270-1271
1	O	1271-1272
.	O	1267-1268
min	O	1273-1276
-	O	1270-1271
1	O	1271-1272

epinephrine	O	1279-1290
.	O	1290-1291

In	O	1292-1294
these	O	1295-1300
dogs	O	1301-1305
,	O	1305-1306
the	O	1307-1310
prodysrhythmic	O	1311-1325
response	O	1326-1334
to	O	1335-1337
epinephrine	O	1338-1349
was	O	1350-1353
also	O	1354-1358
mitigated	O	1359-1368
by	O	1369-1371
preceding	O	1372-1381
bupivacaine	O	1382-1393
.	O	1393-1394

Bupivacaine	O	1395-1406
antagonizes	O	1407-1418
epinephrine	O	1419-1430
dysrhythmogenicity	O	1431-1449
in	O	1450-1452
conscious	O	1453-1462
dogs	O	1463-1467
susceptible	O	1468-1479
to	O	1480-1482
VT	B	1483-1485
and	O	1486-1489
in	O	1490-1492
anesthetized	O	1493-1505
dogs	O	1506-1510
with	O	1511-1515
spontaneous	O	1516-1527
postinfarct	O	1528-1539
dysrhythmias	B	1540-1552
.	O	1552-1553

There	O	1554-1559
is	O	1560-1562
no	O	1563-1565
evidence	O	1566-1574
that	O	1575-1579
systemic	O	1580-1588
subtoxic	O	1589-1597
bupivacaine	O	1598-1609
administration	O	1610-1624
enhances	O	1625-1633
the	O	1634-1637
dysrhythmogenicity	O	1638-1656
of	O	1657-1659
subsequent	O	1660-1670
epinephrine	O	1671-1682
.	O	1682-1683

Milk	B	0-4
-	I	4-5
alkali	I	5-11
syndrome	I	12-20
induced	O	21-28
by	O	29-31
1	O	32-33
,	O	33-34
25	O	34-36
(	O	36-37
OH	O	37-39
)	O	39-40
2D	O	40-42
in	O	43-45
a	O	46-47
patient	O	48-55
with	O	56-60
hypoparathyroidism	B	61-79
.	O	79-80

Milk	B	81-85
-	I	85-86
alkali	I	86-92
syndrome	I	93-101
was	O	102-105
first	O	106-111
described	O	112-121
70	O	122-124
years	O	125-130
ago	O	131-134
in	O	135-137
the	O	138-141
context	O	142-149
of	O	150-152
the	O	153-156
treatment	O	157-166
of	O	167-169
peptic	B	170-176
ulcer	I	177-182
disease	I	183-190
with	O	191-195
large	O	196-201
amounts	O	202-209
of	O	210-212
calcium	O	213-220
and	O	221-224
alkali	O	225-231
.	O	231-232

Although	O	233-241
with	O	242-246
current	O	247-254
ulcer	B	255-260
therapy	O	261-268
(	O	269-270
H	O	270-271
-	O	271-272
2	O	272-273
blockers	O	274-282
,	O	282-283
omeprazole	O	284-294
,	O	294-295
and	O	296-299
sucralfate	O	300-310
)	O	310-311
,	O	311-312
the	O	313-316
frequency	O	317-326
of	O	327-329
milk	B	330-334
-	I	334-335
alkali	I	335-341
syndrome	I	342-350
has	O	351-354
decreased	O	355-364
significantly	O	365-378
,	O	378-379
the	O	380-383
classic	O	384-391
triad	O	392-397
of	O	398-400
hypercalcemia	B	401-414
,	O	414-415
alkalosis	B	416-425
,	O	425-426
and	O	427-430
renal	B	431-436
impairment	I	437-447
remains	O	448-455
the	O	456-459
hallmark	O	460-468
of	O	469-471
the	O	472-475
syndrome	O	476-484
.	O	484-485

Milk	B	486-490
-	I	490-491
alkali	I	491-497
syndrome	I	498-506
can	O	507-510
present	O	511-518
serious	O	519-526
and	O	527-530
occasionally	O	531-543
life	O	544-548
-	O	548-549
threatening	O	549-560
illness	O	561-568
unless	O	569-575
diagnosed	O	576-585
and	O	586-589
treated	O	590-597
appropriately	O	598-611
.	O	611-612

This	O	613-617
article	O	618-625
presents	O	626-634
a	O	635-636
patient	O	637-644
with	O	645-649
hypoparathyroidism	B	650-668
who	O	669-672
was	O	673-676
treated	O	677-684
with	O	685-689
calcium	O	690-697
carbonate	O	698-707
and	O	708-711
calcitriol	O	712-722
resulting	O	723-732
in	O	733-735
two	O	736-739
admissions	O	740-750
to	O	751-753
the	O	754-757
hospital	O	758-766
for	O	767-770
milk	B	771-775
-	I	775-776
alkali	I	776-782
syndrome	I	783-791
.	O	791-792

The	O	793-796
patient	O	797-804
was	O	805-808
successfully	O	809-821
treated	O	822-829
with	O	830-834
intravenous	O	835-846
pamidronate	O	847-858
on	O	859-861
his	O	862-865
first	O	866-871
admission	O	872-881
and	O	882-885
with	O	886-890
hydrocortisone	O	891-905
on	O	906-908
the	O	909-912
second	O	913-919
.	O	919-920

This	O	921-925
illustrates	O	926-937
intravenous	O	938-949
pamidronate	O	950-961
as	O	962-964
a	O	965-966
valuable	O	967-975
therapeutic	O	976-987
tool	O	988-992
when	O	993-997
milk	B	998-1002
-	I	1002-1003
alkali	I	1003-1009
syndrome	I	1010-1018
presents	O	1019-1027
as	O	1028-1030
hypercalcemic	B	1031-1044
emergency	I	1045-1054
.	O	1054-1055

Encephalopathy	B	0-14
during	O	15-21
amitriptyline	O	22-35
therapy	O	36-43
:	O	43-44
are	O	45-48
neuroleptic	B	49-60
malignant	I	61-70
syndrome	I	71-79
and	O	80-83
serotonin	B	84-93
syndrome	I	94-102
spectrum	O	103-111
disorders	O	112-121
?	O	121-122

This	O	123-127
report	O	128-134
describes	O	135-144
a	O	145-146
case	O	147-151
of	O	152-154
encephalopathy	B	155-169
developed	O	170-179
in	O	180-182
the	O	183-186
course	O	187-193
of	O	194-196
amitriptyline	O	197-210
therapy	O	211-218
,	O	218-219
during	O	220-226
a	O	227-228
remission	O	229-238
of	O	239-241
unipolar	B	242-250
depression	I	251-261
.	O	261-262

This	O	263-267
patient	O	268-275
could	O	276-281
have	O	282-286
been	O	287-291
diagnosed	O	292-301
as	O	302-304
having	O	305-311
either	O	312-318
neuroleptic	B	319-330
malignant	I	331-340
syndrome	I	341-349
(	O	350-351
NMS	B	351-354
)	O	354-355
or	O	356-358
serotonin	B	359-368
syndrome	I	369-377
(	O	378-379
SS	B	379-381
)	O	381-382
.	O	382-383

The	O	384-387
major	O	388-393
determinant	O	394-405
of	O	406-408
the	O	409-412
symptoms	O	413-421
may	O	422-425
have	O	426-430
been	O	431-435
dopamine	O	436-444
/	O	444-445
serotonin	O	445-454
imbalance	O	455-464
in	O	465-467
the	O	468-471
central	O	472-479
nervous	O	480-487
system	O	488-494
.	O	494-495

The	O	496-499
NMS	B	500-503
-	O	503-504
like	O	504-508
encephalopathy	B	509-523
that	O	524-528
develops	O	529-537
in	O	538-540
association	O	541-552
with	O	553-557
the	O	558-561
use	O	562-565
of	O	566-568
antidepressants	O	569-584
indicates	O	585-594
that	O	595-599
NMS	B	600-603
and	O	604-607
SS	B	608-610
are	O	611-614
spectrum	O	615-623
disorders	O	624-633
induced	O	634-641
by	O	642-644
drugs	O	645-650
with	O	651-655
both	O	656-660
antidopaminergic	O	661-677
and	O	678-681
serotonergic	O	682-694
effects	O	695-702
.	O	702-703

Genetic	O	0-7
separation	O	8-18
of	O	19-21
tumor	B	22-27
growth	O	28-34
and	O	35-38
hemorrhagic	B	39-50
phenotypes	O	51-61
in	O	62-64
an	O	65-67
estrogen	O	68-76
-	O	76-77
induced	O	77-84
tumor	B	85-90
.	O	90-91

Chronic	O	92-99
administration	O	100-114
of	O	115-117
estrogen	O	118-126
to	O	127-129
the	O	130-133
Fischer	O	134-141
344	O	142-145
(	O	146-147
F344	O	147-151
)	O	151-152
rat	O	153-156
induces	O	157-164
growth	O	165-171
of	O	172-174
large	O	175-180
,	O	180-181
hemorrhagic	B	182-193
pituitary	B	194-203
tumors	I	204-210
.	O	210-211

Ten	O	212-215
weeks	O	216-221
of	O	222-224
diethylstilbestrol	O	225-243
(	O	244-245
DES	O	245-248
)	O	248-249
treatment	O	250-259
caused	O	260-266
female	O	267-273
F344	O	274-278
rat	O	279-282
pituitaries	O	283-294
to	O	295-297
grow	O	298-302
to	O	303-305
an	O	306-308
average	O	309-316
of	O	317-319
109	O	320-323
.	O	323-324
2	O	324-325
+	O	326-327
/	O	327-328
-	O	328-329
6	O	330-331
.	O	331-332
3	O	332-333
mg	O	334-336
(	O	337-338
mean	O	338-342
+	O	343-344
/	O	344-345
-	O	345-346
SE	O	347-349
)	O	349-350
versus	O	351-357
11	O	358-360
.	O	360-361
3	O	361-362
+	O	363-364
/	O	364-365
-	O	365-366
1	O	367-368
.	O	368-369
4	O	369-370
mg	O	371-373
for	O	374-377
untreated	O	378-387
rats	O	388-392
,	O	392-393
and	O	394-397
to	O	398-400
become	O	401-407
highly	O	408-414
hemorrhagic	B	415-426
.	O	426-427

The	O	428-431
same	O	432-436
DES	O	437-440
treatment	O	441-450
produced	O	451-459
no	O	460-462
significant	O	463-474
growth	O	475-481
(	O	482-483
8	O	483-484
.	O	484-485
9	O	485-486
+	O	487-488
/	O	488-489
-	O	489-490
0	O	491-492
.	O	492-493
5	O	493-494
mg	O	495-497
for	O	498-501
treated	O	502-509
females	O	510-517
versus	O	518-524
8	O	525-526
.	O	526-527
7	O	527-528
+	O	529-530
/	O	530-531
-	O	531-532
1	O	533-534
.	O	534-535
1	O	533-534
for	O	537-540
untreated	O	541-550
females	O	551-558
)	O	558-559
or	O	560-562
morphological	O	563-576
changes	O	577-584
in	O	585-587
Brown	O	588-593
Norway	O	594-600
(	O	601-602
BN	O	602-604
)	O	604-605
rat	O	606-609
pituitaries	O	610-621
.	O	621-622

An	O	623-625
F1	O	626-628
hybrid	O	629-635
of	O	636-638
F344	O	639-643
and	O	644-647
BN	O	648-650
exhibited	O	651-660
significant	O	661-672
pituitary	O	673-682
growth	O	683-689
after	O	690-695
10	O	696-698
weeks	O	699-704
of	O	705-707
DES	O	708-711
treatment	O	712-721
with	O	722-726
an	O	727-729
average	O	730-737
mass	O	738-742
of	O	743-745
26	O	746-748
.	O	748-749
3	O	749-750
+	O	751-752
/	O	752-753
-	O	753-754
0	O	755-756
.	O	756-757
7	O	757-758
mg	O	759-761
compared	O	762-770
with	O	771-775
8	O	776-777
.	O	777-778
6	O	778-779
+	O	780-781
/	O	781-782
-	O	782-783
0	O	784-785
.	O	785-786
9	O	786-787
mg	O	788-790
for	O	791-794
untreated	O	795-804
rats	O	805-809
.	O	809-810

Surprisingly	O	811-823
,	O	823-824
the	O	825-828
F1	O	829-831
hybrid	O	832-838
tumors	B	839-845
were	O	846-850
not	O	851-854
hemorrhagic	B	855-866
and	O	867-870
had	O	871-874
hemoglobin	O	875-885
content	O	886-893
and	O	894-897
outward	O	898-905
appearance	O	906-916
identical	O	917-926
to	O	927-929
that	O	930-934
of	O	935-937
BN	O	938-940
.	O	940-941

Expression	O	942-952
of	O	953-955
both	O	956-960
growth	O	961-967
and	O	968-971
morphological	O	972-985
changes	O	986-993
is	O	994-996
due	O	997-1000
to	O	1001-1003
multiple	O	1004-1012
genes	O	1013-1018
.	O	1018-1019

However	O	1020-1027
,	O	1027-1028
while	O	1029-1034
DES	O	1035-1038
-	O	1038-1039
induced	O	1039-1046
pituitary	O	1047-1056
growth	O	1057-1063
exhibited	O	1064-1073
quantitative	O	1074-1086
,	O	1086-1087
additive	O	1088-1096
inheritance	O	1097-1108
,	O	1108-1109
the	O	1110-1113
hemorrhagic	B	1114-1125
phenotype	O	1126-1135
exhibited	O	1136-1145
recessive	O	1146-1155
,	O	1155-1156
epistatic	O	1157-1166
inheritance	O	1167-1178
.	O	1178-1179

Only	O	1180-1184
5	O	1185-1186
of	O	1187-1189
the	O	1190-1193
160	O	1194-1197
F2	O	1198-1200
pituitaries	O	1201-1212
exhibited	O	1213-1222
the	O	1223-1226
hemorrhagic	B	1227-1238
phenotype	O	1239-1248
;	O	1248-1249
36	O	1250-1252
of	O	1253-1255
the	O	1256-1259
160	O	1260-1263
F2	O	1264-1266
pituitaries	O	1267-1278
were	O	1279-1283
in	O	1284-1286
the	O	1287-1290
F344	O	1291-1295
range	O	1296-1301
of	O	1302-1304
mass	O	1305-1309
,	O	1309-1310
but	O	1311-1314
31	O	1315-1317
of	O	1318-1320
these	O	1321-1326
were	O	1327-1331
not	O	1332-1335
hemorrhagic	B	1336-1347
,	O	1347-1348
indicating	O	1349-1359
that	O	1360-1364
the	O	1365-1368
hemorrhagic	B	1369-1380
phenotype	O	1381-1390
is	O	1391-1393
not	O	1394-1397
merely	O	1398-1404
a	O	1405-1406
consequence	O	1407-1418
of	O	1419-1421
extensive	O	1422-1431
growth	O	1432-1438
.	O	1438-1439

The	O	1440-1443
hemorrhagic	B	1444-1455
F2	O	1456-1458
pituitaries	O	1459-1470
were	O	1471-1475
all	O	1476-1479
among	O	1480-1485
the	O	1486-1489
most	O	1490-1494
massive	O	1495-1502
,	O	1502-1503
indicating	O	1504-1514
that	O	1515-1519
some	O	1520-1524
of	O	1525-1527
the	O	1528-1531
genes	O	1532-1537
regulate	O	1538-1546
both	O	1547-1551
phenotypes	O	1552-1562
.	O	1562-1563

Increased	O	0-9
expression	O	10-20
of	O	21-23
neuronal	O	24-32
nitric	O	33-39
oxide	O	40-45
synthase	O	46-54
in	O	55-57
bladder	O	58-65
afferent	O	66-74
pathways	O	75-83
following	O	84-93
chronic	O	94-101
bladder	B	102-109
irritation	I	110-120
.	O	120-121

Immunocytochemical	O	122-140
techniques	O	141-151
were	O	152-156
used	O	157-161
to	O	162-164
examine	O	165-172
alterations	O	173-184
in	O	185-187
the	O	188-191
expression	O	192-202
of	O	203-205
neuronal	O	206-214
nitric	O	215-221
oxide	O	222-227
synthase	O	228-236
(	O	237-238
NOS	O	238-241
)	O	241-242
in	O	243-245
bladder	O	246-253
pathways	O	254-262
following	O	263-272
acute	O	273-278
and	O	279-282
chronic	O	283-290
irritation	B	291-301
of	I	302-304
the	I	305-308
urinary	I	309-316
tract	I	317-322
of	O	323-325
the	O	326-329
rat	O	330-333
.	O	333-334

Chemical	O	335-343
cystitis	B	344-352
was	O	353-356
induced	O	357-364
by	O	365-367
cyclophosphamide	O	368-384
(	O	385-386
CYP	O	386-389
)	O	389-390
which	O	391-396
is	O	397-399
metabolized	O	400-411
to	O	412-414
acrolein	O	415-423
,	O	423-424
an	O	425-427
irritant	O	428-436
eliminated	O	437-447
in	O	448-450
the	O	451-454
urine	O	455-460
.	O	460-461

Injection	O	462-471
of	O	472-474
CYP	O	475-478
(	O	479-480
n	O	480-481
=	O	482-483
10	O	484-486
,	O	486-487
75	O	488-490
mg	O	491-493
/	O	493-494
kg	O	494-496
,	O	496-497
i	O	498-499
.	O	499-500
p	O	500-501
.	O	499-500
)	O	502-503
2	O	504-505
hours	O	506-511
prior	O	512-517
to	O	518-520
perfusion	O	521-530
(	O	531-532
acute	O	532-537
treatment	O	538-547
)	O	547-548
of	O	549-551
the	O	552-555
animals	O	556-563
increased	O	564-573
Fos	O	574-577
-	O	577-578
immunoreactivity	O	578-594
(	O	595-596
IR	O	596-598
)	O	598-599
in	O	600-602
neurons	O	603-610
in	O	611-613
the	O	614-617
dorsal	O	618-624
commissure	O	625-635
,	O	635-636
dorsal	O	637-643
horn	O	644-648
,	O	648-649
and	O	650-653
autonomic	O	654-663
regions	O	664-671
of	O	672-674
spinal	O	675-681
segments	O	682-690
(	O	691-692
L1	O	692-694
-	O	694-695
L2	O	695-697
and	O	698-701
L6	O	702-704
-	O	704-705
S1	O	705-707
)	O	707-708
which	O	709-714
receive	O	715-722
afferent	O	723-731
inputs	O	732-738
from	O	739-743
the	O	744-747
bladder	O	748-755
,	O	755-756
urethra	O	757-764
,	O	764-765
and	O	766-769
ureter	O	770-776
.	O	776-777

Fos	O	778-781
-	O	781-782
IR	O	782-784
in	O	785-787
the	O	788-791
spinal	O	792-798
cord	O	799-803
was	O	804-807
not	O	808-811
changed	O	812-819
in	O	820-822
rats	O	823-827
receiving	O	828-837
chronic	O	838-845
CYP	O	846-849
treatment	O	850-859
(	O	860-861
n	O	861-862
=	O	863-864
15	O	865-867
,	O	867-868
75	O	869-871
mg	O	872-874
/	O	874-875
kg	O	875-877
,	O	877-878
i	O	879-880
.	O	880-881
p	O	881-882
.	O	880-881
,	O	883-884
every	O	885-890
3rd	O	891-894
day	O	895-898
for	O	899-902
2	O	903-904
weeks	O	905-910
)	O	910-911
.	O	911-912

In	O	913-915
control	O	916-923
animals	O	924-931
and	O	932-935
in	O	936-938
animals	O	939-946
treated	O	947-954
acutely	O	955-962
with	O	963-967
CYP	O	968-971
,	O	971-972
only	O	973-977
small	O	978-983
numbers	O	984-991
of	O	992-994
NOS	O	995-998
-	O	998-999
IR	O	999-1001
cells	O	1002-1007
(	O	1008-1009
0	O	1009-1010
.	O	1010-1011
5	O	1011-1012
-	O	1012-1013
0	O	1009-1010
.	O	1010-1011
7	O	1015-1016
cell	O	1017-1021
profiles	O	1022-1030
/	O	1030-1031
sections	O	1031-1039
)	O	1039-1040
were	O	1041-1045
detected	O	1046-1054
in	O	1055-1057
the	O	1058-1061
L6	O	1062-1064
-	O	1064-1065
S1	O	1065-1067
dorsal	O	1068-1074
root	O	1075-1079
ganglia	O	1080-1087
(	O	1088-1089
DRG	O	1089-1092
)	O	1092-1093
.	O	1093-1094

Chronic	O	1095-1102
CYP	O	1103-1106
administration	O	1107-1121
significantly	O	1122-1135
(	O	1136-1137
P	O	1137-1138
<	O	1139-1140
or	O	1141-1143
=	O	1144-1145
.	O	1146-1147
002	O	1147-1150
)	O	1150-1151

increased	O	1152-1161
bladder	O	1162-1169
weight	O	1170-1176
by	O	1177-1179
60	O	1180-1182
%	O	1182-1183
and	O	1184-1187
increased	O	1188-1197
(	O	1198-1199
7	O	1199-1200
-	O	1200-1201
to	O	1202-1204
11	O	1205-1207
-	O	1207-1208
fold	O	1208-1212
)	O	1212-1213
the	O	1214-1217
numbers	O	1218-1225
of	O	1226-1228
NOS	O	1229-1232
-	O	1232-1233
immunoreactive	O	1233-1247
(	O	1248-1249
IR	O	1249-1251
)	O	1251-1252
afferent	O	1253-1261
neurons	O	1262-1269
in	O	1270-1272
the	O	1273-1276
L6	O	1277-1279
-	O	1279-1280
S1	O	1280-1282
DRG	O	1283-1286
.	O	1286-1287

A	O	1288-1289
small	O	1290-1295
increase	O	1296-1304
(	O	1305-1306
1	O	1306-1307
.	O	1307-1308
5	O	1308-1309
-	O	1309-1310
fold	O	1310-1314
)	O	1314-1315
also	O	1316-1320
occurred	O	1321-1329
in	O	1330-1332
the	O	1333-1336
L1	O	1337-1339
DRG	O	1340-1343
,	O	1343-1344
but	O	1345-1348
no	O	1349-1351
change	O	1352-1358
was	O	1359-1362
detected	O	1363-1371
in	O	1372-1374
the	O	1375-1378
L2	O	1379-1381
and	O	1382-1385
L5	O	1386-1388
DRG	O	1389-1392
.	O	1392-1393

Bladder	O	1394-1401
afferent	O	1402-1410
cells	O	1411-1416
in	O	1417-1419
the	O	1420-1423
L6	O	1424-1426
-	O	1426-1427
S1	O	1427-1429
DRG	O	1430-1433
labeled	O	1434-1441
by	O	1442-1444
Fluorogold	O	1445-1455
(	O	1456-1457
40	O	1457-1459
microliters	O	1460-1471
)	O	1471-1472
injected	O	1473-1481
into	O	1482-1486
the	O	1487-1490
bladder	O	1491-1498
wall	O	1499-1503
did	O	1504-1507
not	O	1508-1511
exhibit	O	1512-1519
NOS	O	1520-1523
-	O	1523-1524
IR	O	1524-1526
in	O	1527-1529
control	O	1530-1537
animals	O	1538-1545
;	O	1545-1546
however	O	1547-1554
,	O	1554-1555
following	O	1556-1565
chronic	O	1566-1573
CYP	O	1574-1577
administration	O	1578-1592
,	O	1592-1593
a	O	1594-1595
significant	O	1596-1607
percentage	O	1608-1618
of	O	1619-1621
bladder	O	1622-1629
afferent	O	1630-1638
neurons	O	1639-1646
were	O	1647-1651
NOS	O	1652-1655
-	O	1655-1656
IR	O	1656-1658
:	O	1658-1659
L6	O	1660-1662
(	O	1663-1664
19	O	1664-1666
.	O	1666-1667
8	O	1667-1668
+	O	1669-1670
/	O	1670-1671
-	O	1671-1672
4	O	1673-1674
.	O	1674-1675
6	O	1675-1676
%	O	1676-1677
)	O	1677-1678
and	O	1679-1682
S1	O	1683-1685
(	O	1686-1687
25	O	1687-1689
.	O	1689-1690
3	O	1690-1691
+	O	1692-1693
/	O	1693-1694
-	O	1694-1695
2	O	1696-1697
.	O	1697-1698
9	O	1698-1699
%	O	1699-1700
)	O	1700-1701
.	O	1697-1698

These	O	1703-1708
results	O	1709-1716
indicate	O	1717-1725
that	O	1726-1730
neuronal	O	1731-1739
gene	O	1740-1744
expression	O	1745-1755
in	O	1756-1758
visceral	O	1759-1767
sensory	O	1768-1775
pathways	O	1776-1784
can	O	1785-1788
be	O	1789-1791
upregulated	O	1792-1803
by	O	1804-1806
chemical	O	1807-1815
irritation	O	1816-1826
of	O	1827-1829
afferent	O	1830-1838
receptors	O	1839-1848
in	O	1849-1851
the	O	1852-1855
urinary	O	1856-1863
tract	O	1864-1869
and	O	1870-1873
/	O	1873-1874
or	O	1874-1876
that	O	1877-1881
pathological	O	1882-1894
changes	O	1895-1902
in	O	1903-1905
the	O	1906-1909
urinary	O	1910-1917
tract	O	1918-1923
can	O	1924-1927
initiate	O	1928-1936
chemical	O	1937-1945
signals	O	1946-1953
that	O	1954-1958
alter	O	1959-1964
the	O	1965-1968
chemical	O	1969-1977
properties	O	1978-1988
of	O	1989-1991
visceral	O	1992-2000
afferent	O	2001-2009
neurons	O	2010-2017
.	O	2017-2018

Effects	O	0-7
of	O	8-10
a	O	11-12
new	O	13-16
calcium	O	17-24
antagonist	O	25-35
,	O	35-36
CD	O	37-39
-	O	39-40
832	O	40-43
,	O	43-44
on	O	45-47
isoproterenol	O	48-61
-	O	61-62
induced	O	62-69
myocardial	B	70-80
ischemia	I	81-89
in	O	90-92
dogs	O	93-97
with	O	98-102
partial	O	103-110
coronary	B	111-119
stenosis	I	120-128
.	O	128-129

Effects	O	130-137
of	O	138-140
CD	O	141-143
-	O	143-144
832	O	144-147
on	O	148-150
isoproterenol	O	151-164
(	O	165-166
ISO	O	166-169
)	O	169-170
-	O	170-171
induced	O	171-178
myocardial	B	179-189
ischemia	I	190-198
were	O	199-203
studied	O	204-211
in	O	212-214
dogs	O	215-219
with	O	220-224
partial	O	225-232
coronary	B	233-241
stenosis	I	242-250
of	O	251-253
the	O	254-257
left	O	258-262
circumflex	O	263-273
coronary	O	274-282
artery	O	283-289
and	O	290-293
findings	O	294-302
were	O	303-307
compared	O	308-316
with	O	317-321
those	O	322-327
for	O	328-331
nifedipine	O	332-342
or	O	343-345
diltiazem	O	346-355
.	O	355-356

In	O	357-359
the	O	360-363
presence	O	364-372
of	O	373-375
coronary	B	376-384
artery	I	385-391
stenosis	I	392-400
,	O	400-401
3	O	402-403
-	O	403-404
min	O	404-407
periods	O	408-415
of	O	416-418
intracoronary	O	419-432
ISO	O	433-436
infusion	O	437-445
(	O	446-447
10	O	447-449
ng	O	450-452
/	O	452-453
kg	O	453-455
/	O	452-453
min	O	456-459
)	O	459-460
increased	O	461-470
heart	O	471-476
rate	O	477-481
and	O	482-485
maximal	O	486-493
rate	O	494-498
of	O	499-501
left	O	502-506
ventricular	O	507-518
pressure	O	519-527
rise	O	528-532
,	O	532-533
which	O	534-539
resulted	O	540-548
in	O	549-551
a	O	552-553
decrease	O	554-562
in	O	563-565
percentage	O	566-576
segmental	O	577-586
shortening	O	587-597
and	O	598-601
ST	O	602-604
-	O	604-605
segment	O	605-612
elevation	O	613-622
of	O	623-625
the	O	626-629
epicardial	O	630-640
electrocardiogram	O	641-658
.	O	658-659

After	O	660-665
the	O	666-669
control	O	670-677
ISO	O	678-681
infusion	O	682-690
with	O	691-695
stenosis	B	696-704
was	O	705-708
performed	O	709-718
,	O	718-719
equihypotensive	O	720-735
doses	O	736-741
of	O	742-744
CD	O	745-747
-	O	747-748
832	O	748-751
(	O	752-753
3	O	753-754
and	O	755-758
10	O	759-761
micrograms	O	762-772
/	O	772-773
kg	O	773-775
/	O	772-773
min	O	776-779
,	O	779-780
n	O	781-782
=	O	783-784
7	O	785-786
)	O	786-787
,	O	787-788
nifedipine	O	789-799
(	O	800-801
1	O	801-802
and	O	803-806
3	O	807-808
micrograms	O	809-819
/	O	819-820
kg	O	820-822
/	O	819-820
min	O	823-826
,	O	826-827
n	O	828-829
=	O	830-831
9	O	832-833
)	O	833-834
or	O	835-837
diltiazem	O	838-847
(	O	848-849
10	O	849-851
and	O	852-855
30	O	856-858
micrograms	O	859-869
/	O	869-870
kg	O	870-872
/	O	869-870
min	O	873-876
,	O	876-877
n	O	878-879
=	O	880-881
7	O	882-883
)	O	883-884
were	O	885-889
infused	O	890-897
5	O	898-899
min	O	900-903
before	O	904-910
and	O	911-914
during	O	915-921
the	O	922-925
second	O	926-932
and	O	933-936
third	O	937-942
ISO	O	943-946
infusion	O	947-955
.	O	955-956

Both	O	957-961
CD	O	962-964
-	O	964-965
832	O	965-968
and	O	969-972
diltiazem	O	973-982
,	O	982-983
but	O	984-987
not	O	988-991
nifedipine	O	992-1002
,	O	1002-1003
significantly	O	1004-1017
reduced	O	1018-1025
the	O	1026-1029
increase	O	1030-1038
in	O	1039-1041
heart	O	1042-1047
rate	O	1048-1052
induced	O	1053-1060
by	O	1061-1063
ISO	O	1064-1067
infusion	O	1068-1076
.	O	1076-1077

In	O	1078-1080
contrast	O	1081-1089
to	O	1090-1092
nifedipine	O	1093-1103
,	O	1103-1104
CD	O	1105-1107
-	O	1107-1108
832	O	1108-1111
(	O	1112-1113
10	O	1113-1115
micrograms	O	1116-1126
/	O	1126-1127
kg	O	1127-1129
/	O	1126-1127
min	O	1130-1133
)	O	1133-1134
prevented	O	1135-1144
the	O	1145-1148
decrease	O	1149-1157
in	O	1158-1160
percentage	O	1161-1171
segmental	O	1172-1181
shortening	O	1182-1192
from	O	1193-1197
32	O	1198-1200
+	O	1201-1202
/	O	1202-1203
-	O	1203-1204
12	O	1205-1207
%	O	1207-1208
to	O	1209-1211
115	O	1212-1215
+	O	1216-1217
/	O	1217-1218
-	O	1218-1219
26	O	1220-1222
%	O	1222-1223
of	O	1224-1226
the	O	1227-1230
control	O	1231-1238
value	O	1239-1244
(	O	1245-1246
P	O	1246-1247
<	O	1248-1249
.	O	1250-1251
01	O	1251-1253
)	O	1253-1254

and	O	1255-1258
ST	O	1259-1261
-	O	1261-1262
segment	O	1262-1269
elevation	O	1270-1279
from	O	1280-1284
5	O	1285-1286
.	O	1286-1287
6	O	1287-1288
+	O	1289-1290
/	O	1290-1291
-	O	1291-1292
1	O	1293-1294
.	O	1294-1295
0	O	1295-1296
mV	O	1297-1299
to	O	1300-1302
1	O	1303-1304
.	O	1304-1305
6	O	1305-1306
+	O	1307-1308
/	O	1308-1309
-	O	1309-1310
1	O	1311-1312
.	O	1312-1313
3	O	1313-1314
mV	O	1315-1317
(	O	1318-1319
P	O	1319-1320
<	O	1321-1322
.	O	1323-1324
01	O	1324-1326
)	O	1326-1327

at	O	1328-1330
3	O	1331-1332
min	O	1333-1336
after	O	1337-1342
ISO	O	1343-1346
infusion	O	1347-1355
with	O	1356-1360
stenosis	B	1361-1369
.	O	1369-1370

Diltiazem	O	1371-1380
(	O	1381-1382
30	O	1382-1384
micrograms	O	1385-1395
/	O	1395-1396
kg	O	1396-1398
/	O	1395-1396
min	O	1399-1402
)	O	1402-1403
also	O	1404-1408
prevented	O	1409-1418
the	O	1419-1422
decrease	O	1423-1431
in	O	1432-1434
percentage	O	1435-1445
segmental	O	1446-1455
shortening	O	1456-1466
from	O	1467-1471
34	O	1472-1474
+	O	1475-1476
/	O	1476-1477
-	O	1477-1478
14	O	1479-1481
%	O	1481-1482
to	O	1483-1485
63	O	1486-1488
+	O	1489-1490
/	O	1490-1491
-	O	1491-1492
18	O	1493-1495
%	O	1495-1496
of	O	1497-1499
the	O	1500-1503
control	O	1504-1511
value	O	1512-1517
(	O	1518-1519
P	O	1519-1520
<	O	1521-1522
.	O	1523-1524
05	O	1524-1526
)	O	1526-1527

and	O	1528-1531
ST	O	1532-1534
-	O	1534-1535
segment	O	1535-1542
elevation	O	1543-1552
from	O	1553-1557
4	O	1558-1559
.	O	1559-1560
7	O	1560-1561
+	O	1562-1563
/	O	1563-1564
-	O	1564-1565
0	O	1566-1567
.	O	1567-1568
7	O	1568-1569
mV	O	1570-1572
to	O	1573-1575
2	O	1576-1577
.	O	1577-1578
1	O	1578-1579
+	O	1580-1581
/	O	1581-1582
-	O	1582-1583
0	O	1584-1585
.	O	1585-1586
7	O	1586-1587
mV	O	1588-1590
(	O	1591-1592
P	O	1592-1593
<	O	1594-1595
.	O	1596-1597
01	O	1597-1599
)	O	1599-1600

at	O	1601-1603
3	O	1604-1605
min	O	1606-1609
after	O	1610-1615
ISO	O	1616-1619
infusion	O	1620-1628
with	O	1629-1633
stenosis	B	1634-1642
.	O	1642-1643

These	O	1644-1649
data	O	1650-1654
show	O	1655-1659
that	O	1660-1664
CD	O	1665-1667
-	O	1667-1668
832	O	1668-1671
improves	O	1672-1680
myocardial	B	1681-1691
ischemia	I	1692-1700
during	O	1701-1707
ISO	O	1708-1711
infusion	O	1712-1720
with	O	1721-1725
stenosis	B	1726-1734
and	O	1735-1738
suggest	O	1739-1746
that	O	1747-1751
the	O	1752-1755
negative	O	1756-1764
chronotropic	O	1765-1777
property	O	1778-1786
of	O	1787-1789
CD	O	1790-1792
-	O	1792-1793
832	O	1793-1796
plays	O	1797-1802
a	O	1803-1804
major	O	1805-1810
role	O	1811-1815
in	O	1816-1818
the	O	1819-1822
beneficial	O	1823-1833
effects	O	1834-1841
of	O	1842-1844
CD	O	1845-1847
-	O	1847-1848
832	O	1848-1851
.	O	1851-1852

The	O	0-3
effect	O	4-10
of	O	11-13
recombinant	O	14-25
human	O	26-31
insulin	O	32-39
-	O	39-40
like	O	40-44
growth	O	45-51
factor	O	52-58
-	O	58-59
I	O	59-60
on	O	61-63
chronic	O	64-71
puromycin	O	72-81
aminonucleoside	O	82-97
nephropathy	B	98-109
in	O	110-112
rats	O	113-117
.	O	117-118

We	O	119-121
recently	O	122-130
demonstrated	O	131-143
that	O	144-148
recombinant	O	149-160
hGH	O	161-164
exacerbates	O	165-176
renal	O	177-182
functional	O	183-193
and	O	194-197
structural	O	198-208
injury	O	209-215
in	O	216-218
chronic	O	219-226
puromycin	O	227-236
aminonucleoside	O	237-252
(	O	253-254
PAN	O	254-257
)	O	257-258
nephropathy	B	259-270
,	O	270-271
an	O	272-274
experimental	O	275-287
model	O	288-293
of	O	294-296
glomerular	B	297-307
disease	I	308-315
.	O	315-316

Therefore	O	317-326
,	O	326-327
we	O	328-330
examined	O	331-339
whether	O	340-347
recombinant	O	348-359
human	O	360-365
(	O	366-367
rh	O	367-369
)	O	369-370
IGF	O	371-374
-	O	374-375
I	O	371-372
is	O	377-379
a	O	380-381
safer	O	382-387
alternative	O	388-399
for	O	400-403
the	O	404-407
treatment	O	408-417
of	O	418-420
growth	B	421-427
failure	I	428-435
in	O	436-438
rats	O	439-443
with	O	444-448
chronic	O	449-456
PAN	O	457-460
nephropathy	B	461-472
.	O	472-473

The	O	474-477
glomerulopathy	B	478-492
was	O	493-496
induced	O	497-504
by	O	505-507
seven	O	508-513
serial	O	514-520
injections	O	521-531
of	O	532-534
PAN	O	535-538
over	O	539-543
12	O	544-546
wk	O	547-549
.	O	549-550

Experimental	O	551-563
animals	O	564-571
(	O	572-573
n	O	573-574
=	O	575-576
6	O	577-578
)	O	578-579
received	O	580-588
rhIGF	O	589-594
-	O	594-595
I	O	591-592
,	O	596-597
400	O	598-601
micrograms	O	602-612
/	O	612-613
d	O	613-614
,	O	614-615
whereas	O	616-623
control	O	624-631
rats	O	632-636
(	O	637-638
n	O	638-639
=	O	640-641
6	O	642-643
)	O	643-644
received	O	645-653
the	O	654-657
vehicle	O	658-665
.	O	665-666

rhIGF	O	667-672
-	O	672-673
I	O	669-670
improved	O	675-683
weight	O	684-690
gain	O	691-695
by	O	696-698
14	O	699-701
%	O	701-702
(	O	703-704
p	O	704-705
<	O	706-707
0	O	708-709
.	O	709-710
05	O	710-712
)	O	712-713
,	O	713-714
without	O	715-722
altering	O	723-731
hematocrit	O	732-742
or	O	743-745
blood	O	746-751
pressure	O	752-760
in	O	761-763
rats	O	764-768
with	O	769-773
renal	B	774-779
disease	I	780-787
.	O	787-788

Urinary	O	789-796
protein	O	797-804
excretion	O	805-814
was	O	815-818
unaltered	O	819-828
by	O	829-831
rhIGF	O	832-837
-	O	837-838
I	O	834-835
treatment	O	840-849
in	O	850-852
rats	O	853-857
with	O	858-862
chronic	O	863-870
PAN	O	871-874
nephropathy	B	875-886
.	O	886-887

After	O	888-893
12	O	894-896
wk	O	897-899
,	O	899-900
the	O	901-904
inulin	O	905-911
clearance	O	912-921
was	O	922-925
higher	O	926-932
in	O	933-935
rhIGF	O	936-941
-	O	941-942
I	O	938-939
-	O	941-942
treated	O	944-951
rats	O	952-956
,	O	956-957
0	O	958-959
.	O	959-960
48	O	960-962
+	O	963-964
/	O	964-965
-	O	965-966
0	O	967-968
.	O	968-969
08	O	969-971
versus	O	972-978
0	O	979-980
.	O	980-981
24	O	981-983
+	O	984-985
/	O	985-986
-	O	986-987
0	O	988-989
.	O	989-990
06	O	990-992
mL	O	993-995
/	O	995-996
min	O	996-999
/	O	995-996
100	O	1000-1003
g	O	1004-1005
of	O	1006-1008
body	O	1009-1013
weight	O	1014-1020
in	O	1021-1023
untreated	O	1024-1033
PAN	O	1034-1037
nephropathy	B	1038-1049
animals	O	1050-1057
,	O	1057-1058
p	O	1059-1060
<	O	1061-1062
0	O	1063-1064
.	O	1064-1065
05	O	1065-1067
.	O	1064-1065

The	O	1069-1072
improvement	O	1073-1084
in	O	1085-1087
GFR	O	1088-1091
was	O	1092-1095
not	O	1096-1099
associated	O	1100-1110
with	O	1111-1115
enhanced	O	1116-1124
glomerular	B	1125-1135
hypertrophy	I	1136-1147
or	O	1148-1150
increased	O	1151-1160
segmental	O	1161-1170
glomerulosclerosis	B	1171-1189
,	O	1189-1190
tubulointerstitial	B	1191-1209
injury	I	1210-1216
,	O	1216-1217
or	O	1218-1220
renal	O	1221-1226
cortical	O	1227-1235
malondialdehyde	O	1236-1251
content	O	1252-1259
.	O	1259-1260

In	O	1261-1263
rats	O	1264-1268
with	O	1269-1273
PAN	O	1274-1277
nephropathy	B	1278-1289
,	O	1289-1290
administration	O	1291-1305
of	O	1306-1308
rhIGF	O	1309-1314
-	O	1314-1315
I	O	1311-1312
increased	O	1317-1326
IGF	O	1327-1330
-	O	1330-1331
I	O	1327-1328
and	O	1333-1336
GH	O	1337-1339
receptor	O	1340-1348
gene	O	1349-1353
expression	O	1354-1364
,	O	1364-1365
without	O	1366-1373
altering	O	1374-1382
the	O	1383-1386
steady	O	1387-1393
state	O	1394-1399
level	O	1400-1405
of	O	1406-1408
IGF	O	1409-1412
-	O	1412-1413
I	O	1409-1410
receptor	O	1415-1423
mRNA	O	1424-1428
.	O	1428-1429

In	O	1430-1432
normal	O	1433-1439
rats	O	1440-1444
with	O	1445-1449
intact	O	1450-1456
kidneys	O	1457-1464
,	O	1464-1465
rhIGF	O	1466-1471
-	O	1471-1472
I	O	1468-1469
administration	O	1474-1488
(	O	1489-1490
n	O	1490-1491
=	O	1492-1493
4	O	1494-1495
)	O	1495-1496
did	O	1497-1500
not	O	1501-1504
alter	O	1505-1510
weight	O	1511-1517
gain	O	1518-1522
,	O	1522-1523
blood	O	1524-1529
pressure	O	1530-1538
,	O	1538-1539
proteinuria	B	1540-1551
,	O	1551-1552
GFR	O	1553-1556
,	O	1556-1557
glomerular	O	1558-1568
planar	O	1569-1575
area	O	1576-1580
,	O	1580-1581
renal	O	1582-1587
cortical	O	1588-1596
malondialdehyde	O	1597-1612
content	O	1613-1620
,	O	1620-1621
or	O	1622-1624
glomerular	O	1625-1635
or	O	1636-1638
tubulointerstitial	B	1639-1657
damage	I	1658-1664
,	O	1664-1665
compared	O	1666-1674
with	O	1675-1679
untreated	O	1680-1689
animals	O	1690-1697
(	O	1698-1699
n	O	1699-1700
=	O	1701-1702
4	O	1703-1704
)	O	1704-1705
.	O	1705-1706

rhIGF	O	1707-1712
-	O	1712-1713
I	O	1709-1710
treatment	O	1715-1724
reduced	O	1725-1732
the	O	1733-1736
steady	O	1737-1743
state	O	1744-1749
renal	O	1750-1755
IGF	O	1756-1759
-	O	1759-1760
I	O	1756-1757
mRNA	O	1762-1766
level	O	1767-1772
but	O	1773-1776
did	O	1777-1780
not	O	1781-1784
modify	O	1785-1791
gene	O	1792-1796
expression	O	1797-1807
of	O	1808-1810
the	O	1811-1814
IGF	O	1815-1818
-	O	1818-1819
I	O	1815-1816
or	O	1821-1823
GH	O	1824-1826
receptors	O	1827-1836
.	O	1836-1837

We	O	1838-1840
conclude	O	1841-1849
that	O	1850-1854
:	O	1854-1855
1	O	1856-1857
)	O	1857-1858
administration	O	1859-1873
of	O	1874-1876
rhIGF	O	1877-1882
-	O	1882-1883
I	O	1879-1880
improves	O	1885-1893
growth	O	1894-1900
and	O	1901-1904
GFR	O	1905-1908
in	O	1909-1911
rats	O	1912-1916
with	O	1917-1921
chronic	O	1922-1929
PAN	O	1930-1933
nephropathy	B	1934-1945
and	O	1946-1949
2	O	1950-1951
)	O	1951-1952
unlike	O	1953-1959
rhGH	O	1960-1964
,	O	1964-1965
long	O	1966-1970
-	O	1970-1971
term	O	1971-1975
use	O	1976-1979
of	O	1980-1982
rhIGF	O	1983-1988
-	O	1988-1989
I	O	1985-1986
does	O	1991-1995
not	O	1996-1999
worsen	O	2000-2006
renal	O	2007-2012
functional	O	2013-2023
and	O	2024-2027
structural	O	2028-2038
injury	O	2039-2045
in	O	2046-2048
this	O	2049-2053
disease	O	2054-2061
model	O	2062-2067
.	O	2067-2068

Nefiracetam	O	0-11
(	O	12-13
DM	O	13-15
-	O	15-16
9384	O	16-20
)	O	20-21
reverses	O	22-30
apomorphine	O	31-42
-	O	42-43
induced	O	43-50
amnesia	B	51-58
of	O	59-61
a	O	62-63
passive	O	64-71
avoidance	O	72-81
response	O	82-90
:	O	90-91
delayed	O	92-99
emergence	O	100-109
of	O	110-112
the	O	113-116
memory	O	117-123
retention	O	124-133
effects	O	134-141
.	O	141-142

Nefiracetam	O	143-154
is	O	155-157
a	O	158-159
novel	O	160-165
pyrrolidone	O	166-177
derivative	O	178-188
which	O	189-194
attenuates	O	195-205
scopolamine	O	206-217
-	O	217-218
induced	O	218-225
learning	B	226-234
and	I	235-238
post	I	239-243
-	I	243-244
training	I	244-252
consolidation	I	253-266
deficits	I	267-275
.	O	275-276

Given	O	277-282
that	O	283-287
apomorphine	O	288-299
inhibits	O	300-308
passive	O	309-316
avoidance	O	317-326
retention	O	327-336
when	O	337-341
given	O	342-347
during	O	348-354
training	O	355-363
or	O	364-366
in	O	367-369
a	O	370-371
defined	O	372-379
10	O	380-382
-	O	382-383
12h	O	383-386
post	O	387-391
-	O	391-392
training	O	392-400
period	O	401-407
,	O	407-408
we	O	409-411
evaluated	O	412-421
the	O	422-425
ability	O	426-433
of	O	434-436
nefiracetam	O	437-448
to	O	449-451
attenuate	O	452-461
amnesia	B	462-469
induced	O	470-477
by	O	478-480
dopaminergic	O	481-493
agonism	O	494-501
.	O	501-502

A	O	503-504
step	O	505-509
-	O	509-510
down	O	510-514
passive	O	515-522
avoidance	O	523-532
paradigm	O	533-541
was	O	542-545
employed	O	546-554
and	O	555-558
nefiracetam	O	559-570
(	O	571-572
3	O	572-573
mg	O	574-576
/	O	576-577
kg	O	577-579
)	O	579-580
and	O	581-584
apomorphine	O	585-596
(	O	597-598
0	O	598-599
.	O	599-600
5	O	600-601
mg	O	602-604
/	O	604-605
kg	O	605-607
)	O	607-608
were	O	609-613
given	O	614-619
alone	O	620-625
or	O	626-628
in	O	629-631
combination	O	632-643
during	O	644-650
training	O	651-659
and	O	660-663
at	O	664-666
the	O	667-670
10	O	671-673
-	O	673-674
12h	O	674-677
post	O	678-682
-	O	682-683
training	O	683-691
period	O	692-698
of	O	699-701
consolidation	O	702-715
.	O	715-716

Co	O	717-719
-	O	719-720
administration	O	720-734
of	O	735-737
nefiracetam	O	738-749
and	O	750-753
apomorphine	O	754-765
during	O	766-772
training	O	773-781
or	O	782-784
10h	O	785-788
thereafter	O	789-799
produced	O	800-808
no	O	809-811
significant	O	812-823
anti	O	824-828
-	O	828-829
amnesic	O	829-836
effect	O	837-843
.	O	843-844

However	O	845-852
,	O	852-853
administration	O	854-868
of	O	869-871
nefiracetam	O	872-883
during	O	884-890
training	O	891-899
completely	O	900-910
reversed	O	911-919
the	O	920-923
amnesia	B	924-931
induced	O	932-939
by	O	940-942
apomorphine	O	943-954
at	O	955-957
the	O	958-961
10h	O	962-965
post	O	966-970
-	O	970-971
training	O	971-979
time	O	980-984
and	O	985-988
the	O	989-992
converse	O	993-1001
was	O	1002-1005
also	O	1006-1010
true	O	1011-1015
.	O	1015-1016

These	O	1017-1022
effects	O	1023-1030
were	O	1031-1035
not	O	1036-1039
mediated	O	1040-1048
by	O	1049-1051
a	O	1052-1053
dopaminergic	O	1054-1066
mechanism	O	1067-1076
as	O	1077-1079
nefiracetam	O	1080-1091
,	O	1091-1092
at	O	1093-1095
millimolar	O	1096-1106
concentrations	O	1107-1121
,	O	1121-1122
failed	O	1123-1129
to	O	1130-1132
displace	O	1133-1141
either	O	1142-1148
[	O	1149-1150
3H	O	1150-1152
]	O	1152-1153
SCH	O	1153-1156
23390	O	1157-1162
or	O	1163-1165
[	O	1166-1167
3H	O	1167-1169
]	O	1169-1170
spiperone	O	1170-1179
binding	O	1180-1187
from	O	1188-1192
D1	O	1193-1195
or	O	1196-1198
D2	O	1199-1201
dopamine	O	1202-1210
receptor	O	1211-1219
subtypes	O	1220-1228
,	O	1228-1229
respectively	O	1230-1242
.	O	1242-1243

It	O	1244-1246
is	O	1247-1249
suggested	O	1250-1259
that	O	1260-1264
nefiracetam	O	1265-1276
augments	O	1277-1285
molecular	O	1286-1295
processes	O	1296-1305
in	O	1306-1308
the	O	1309-1312
early	O	1313-1318
stages	O	1319-1325
of	O	1326-1328
events	O	1329-1335
which	O	1336-1341
ultimately	O	1342-1352
lead	O	1353-1357
to	O	1358-1360
consolidation	O	1361-1374
of	O	1375-1377
memory	O	1378-1384
.	O	1384-1385

Human	O	0-5
corticotropin	O	6-19
-	O	19-20
releasing	O	20-29
hormone	O	30-37
and	O	38-41
thyrotropin	O	42-53
-	O	53-54
releasing	O	54-63
hormone	O	64-71
modulate	O	72-80
the	O	81-84
hypercapnic	B	85-96
ventilatory	O	97-108
response	O	109-117
in	O	118-120
humans	O	121-127
.	O	127-128

Human	O	129-134
corticotropin	O	135-148
-	O	148-149
releasing	O	149-158
hormone	O	159-166
(	O	167-168
hCRH	O	168-172
)	O	172-173
and	O	174-177
thyrotropin	O	178-189
-	O	189-190
releasing	O	190-199
hormone	O	200-207
(	O	208-209
TRH	O	209-212
)	O	212-213
are	O	214-217
known	O	218-223
to	O	224-226
stimulate	O	227-236
ventilation	O	237-248
after	O	249-254
i	O	255-256
.	O	256-257
v	O	257-258
.	O	256-257

administration	O	260-274
in	O	275-277
humans	O	278-284
.	O	284-285

In	O	286-288
a	O	289-290
placebo	O	291-298
-	O	298-299
controlled	O	299-309
,	O	309-310
single	O	311-317
-	O	317-318
blind	O	318-323
study	O	324-329
we	O	330-332
aimed	O	333-338
to	O	339-341
clarify	O	342-349
if	O	350-352
both	O	353-357
peptides	O	358-366
act	O	367-370
by	O	371-373
altering	O	374-382
central	O	383-390
chemosensitivity	O	391-407
.	O	407-408

Two	O	409-412
subsequent	O	413-423
CO2	O	424-427
-	O	427-428
rebreathing	O	428-439
tests	O	440-445
were	O	446-450
performed	O	451-460
in	O	461-463
healthy	O	464-471
young	O	472-477
volunteers	O	478-488
.	O	488-489

During	O	490-496
the	O	497-500
first	O	501-506
test	O	507-511
0	O	512-513
.	O	513-514
9	O	514-515
%	O	515-516
NaCl	O	517-521
was	O	522-525
given	O	526-531
i	O	532-533
.	O	533-534
v	O	534-535
.	O	533-534
;	O	536-537
during	O	538-544
the	O	545-548
second	O	549-555
test	O	556-560
200	O	561-564
micrograms	O	565-575
of	O	576-578
hCRH	O	579-583
(	O	584-585
n	O	585-586
=	O	587-588
12	O	589-591
)	O	591-592
or	O	593-595
400	O	596-599
micrograms	O	600-610
of	O	611-613
TRH	O	614-617
(	O	618-619
n	O	619-620
=	O	621-622
6	O	623-624
)	O	624-625
was	O	626-629
administered	O	630-642
i	O	643-644
.	O	644-645
v	O	645-646
.	O	644-645

Nine	O	648-652
subjects	O	653-661
received	O	662-670
0	O	671-672
.	O	672-673
9	O	673-674
%	O	674-675
NaCl	O	676-680
i	O	681-682
.	O	682-683
v	O	683-684
.	O	682-683

during	O	686-692
both	O	693-697
rebreathing	O	698-709
manoeuvres	O	710-720
.	O	720-721

The	O	722-725
CO2	O	726-729
-	O	729-730
response	O	730-738
curves	O	739-745
for	O	746-749
the	O	750-753
two	O	754-757
tests	O	758-763
were	O	764-768
compared	O	769-777
within	O	778-784
the	O	785-788
same	O	789-793
subject	O	794-801
.	O	801-802

In	O	803-805
the	O	806-809
hCRH	O	810-814
group	O	815-820
a	O	821-822
marked	O	823-829
parallel	O	830-838
shift	O	839-844
of	O	845-847
the	O	848-851
CO2	O	852-855
-	O	855-856
response	O	856-864
curve	O	865-870
to	O	871-873
the	O	874-877
left	O	878-882
was	O	883-886
observed	O	887-895
after	O	896-901
hCRH	O	902-906
(	O	907-908
P	O	908-909
<	O	910-911
0	O	912-913
.	O	913-914
01	O	914-916
)	O	916-917
.	O	913-914

The	O	919-922
same	O	923-927
effect	O	928-934
occurred	O	935-943
following	O	944-953
TRH	O	954-957
but	O	958-961
was	O	962-965
less	O	966-970
striking	O	971-979
(	O	980-981
P	O	981-982
=	O	983-984
0	O	985-986
.	O	986-987
05	O	987-989
)	O	989-990
.	O	986-987

hCRH	O	992-996
and	O	997-1000
TRH	O	1001-1004
caused	O	1005-1011
a	O	1012-1013
reduction	O	1014-1023
in	O	1024-1026
the	O	1027-1030
CO2	O	1031-1034
threshold	O	1035-1044
.	O	1044-1045

The	O	1046-1049
CO2	O	1050-1053
-	O	1053-1054
response	O	1054-1062
curves	O	1063-1069
in	O	1070-1072
the	O	1073-1076
control	O	1077-1084
group	O	1085-1090
were	O	1091-1095
nearly	O	1096-1102
identical	O	1103-1112
.	O	1112-1113

The	O	1114-1117
results	O	1118-1125
indicate	O	1126-1134
an	O	1135-1137
additive	O	1138-1146
effect	O	1147-1153
of	O	1154-1156
both	O	1157-1161
releasing	O	1162-1171
hormones	O	1172-1180
on	O	1181-1183
the	O	1184-1187
hypercapnic	B	1188-1199
ventilatory	O	1200-1211
response	O	1212-1220
in	O	1221-1223
humans	O	1224-1230
,	O	1230-1231
presumably	O	1232-1242
independent	O	1243-1254
of	O	1255-1257
central	O	1258-1265
chemosensitivity	O	1266-1282
.	O	1282-1283

Lamivudine	O	0-10
is	O	11-13
effective	O	14-23
in	O	24-26
suppressing	O	27-38
hepatitis	B	39-48
B	I	49-50
virus	O	51-56
DNA	O	57-60
in	O	61-63
Chinese	O	64-71
hepatitis	O	72-81
B	O	82-83
surface	O	84-91
antigen	O	92-99
carriers	O	100-108
:	O	108-109
a	O	110-111
placebo	O	112-119
-	O	119-120
controlled	O	120-130
trial	O	131-136
.	O	136-137

Lamivudine	O	138-148
is	O	149-151
a	O	152-153
novel	O	154-159
2	O	160-161
'	O	161-162
,	O	162-163
3	O	163-164
'	O	161-162
-	O	165-166
dideoxy	O	166-173
cytosine	O	174-182
analogue	O	183-191
that	O	192-196
has	O	197-200
potent	O	201-207
inhibitory	O	208-218
effects	O	219-226
on	O	227-229
hepatitis	B	230-239
B	I	240-241
virus	O	242-247
replication	O	248-259
in	O	260-262
vitro	O	263-268
and	O	269-272
in	O	273-275
vivo	O	276-280
.	O	280-281

We	O	282-284
performed	O	285-294
a	O	295-296
single	O	297-303
-	O	303-304
blind	O	304-309
,	O	309-310
placebo	O	311-318
-	O	318-319
controlled	O	319-329
study	O	330-335
to	O	336-338
assess	O	339-345
its	O	346-349
effectiveness	O	350-363
and	O	364-367
safety	O	368-374
in	O	375-377
Chinese	O	378-385
hepatitis	O	386-395
B	O	396-397
surface	O	398-405
antigen	O	406-413
(	O	414-415
HBsAg	O	415-420
)	O	420-421
carriers	O	422-430
.	O	430-431

Forty	O	432-437
-	O	437-438
two	O	438-441
Chinese	O	442-449
HBsAg	O	450-455
carriers	O	456-464
were	O	465-469
randomized	O	470-480
to	O	481-483
receive	O	484-491
placebo	O	492-499
(	O	500-501
6	O	501-502
patients	O	503-511
)	O	511-512
or	O	513-515
lamivudine	O	516-526
orally	O	527-533
in	O	534-536
dosages	O	537-544
of	O	545-547
25	O	548-550
mg	O	551-553
,	O	553-554
100	O	555-558
mg	O	559-561
,	O	561-562
or	O	563-565
300	O	566-569
mg	O	570-572
daily	O	573-578
(	O	579-580
12	O	580-582
patients	O	583-591
for	O	592-595
each	O	596-600
dosage	O	601-607
)	O	607-608
.	O	608-609

The	O	610-613
drug	O	614-618
was	O	619-622
given	O	623-628
for	O	629-632
4	O	633-634
weeks	O	635-640
.	O	640-641

The	O	642-645
patients	O	646-654
were	O	655-659
closely	O	660-667
monitored	O	668-677
clinically	O	678-688
,	O	688-689
biochemically	O	690-703
,	O	703-704
and	O	705-708
serologically	O	709-722
up	O	723-725
to	O	726-728
4	O	729-730
weeks	O	731-736
after	O	737-742
drug	O	743-747
treatment	O	748-757
.	O	757-758

All	O	759-762
36	O	763-765
patients	O	766-774
receiving	O	775-784
lamivudine	O	785-795
had	O	796-799
a	O	800-801
decrease	O	802-810
in	O	811-813
hepatitis	B	814-823
B	I	824-825
virus	O	826-831
(	O	832-833
HBV	O	833-836
)	O	836-837
DNA	O	838-841
values	O	842-848
of	O	849-851
>	O	852-853
90	O	853-855
%	O	855-856
(	O	857-858
P	O	858-859
<	O	860-861
.	O	862-863
001	O	863-866

compared	O	867-875
with	O	876-880
placebo	O	881-888
)	O	888-889
.	O	889-890

Although	O	891-899
25	O	900-902
mg	O	903-905
of	O	906-908
lamivudine	O	909-919
was	O	920-923
slightly	O	924-932
less	O	933-937
effective	O	938-947
than	O	948-952
100	O	953-956
mg	O	957-959
(	O	960-961
P	O	961-962
=	O	963-964
.	O	965-966
011	O	966-969
)	O	969-970

and	O	971-974
300	O	975-978
mg	O	979-981
(	O	982-983
P	O	983-984
=	O	985-986
.	O	987-988
005	O	988-991
)	O	991-992
,	O	992-993

it	O	994-996
still	O	997-1002
induced	O	1003-1010
94	O	1011-1013
%	O	1013-1014
suppression	O	1015-1026
of	O	1027-1029
HBV	O	1030-1033
DNA	O	1034-1037
after	O	1038-1043
the	O	1044-1047
fourth	O	1048-1054
week	O	1055-1059
of	O	1060-1062
therapy	O	1063-1070
.	O	1070-1071

HBV	O	1072-1075
DNA	O	1076-1079
values	O	1080-1086
returned	O	1087-1095
to	O	1096-1098
pretreatment	O	1099-1111
levels	O	1112-1118
within	O	1119-1125
4	O	1126-1127
weeks	O	1128-1133
of	O	1134-1136
cessation	O	1137-1146
of	O	1147-1149
therapy	O	1150-1157
.	O	1157-1158

There	O	1159-1164
was	O	1165-1168
no	O	1169-1171
change	O	1172-1178
in	O	1179-1181
the	O	1182-1185
hepatitis	B	1186-1195
B	I	1196-1197
e	O	1198-1199
antigen	O	1200-1207
status	O	1208-1214
or	O	1215-1217
in	O	1218-1220
aminotransferase	O	1221-1237
levels	O	1238-1244
.	O	1244-1245

No	O	1246-1248
serious	O	1249-1256
adverse	O	1257-1264
events	O	1265-1271
were	O	1272-1276
observed	O	1277-1285
.	O	1285-1286

In	O	1287-1289
conclusion	O	1290-1300
,	O	1300-1301
a	O	1302-1303
4	O	1304-1305
-	O	1305-1306
week	O	1306-1310
course	O	1311-1317
of	O	1318-1320
lamivudine	O	1321-1331
was	O	1332-1335
safe	O	1336-1340
and	O	1341-1344
effective	O	1345-1354
in	O	1355-1357
suppression	O	1358-1369
of	O	1370-1372
HBV	O	1373-1376
DNA	O	1377-1380
in	O	1381-1383
Chinese	O	1384-1391
HBsAg	O	1392-1397
carriers	O	1398-1406
.	O	1406-1407

The	O	1408-1411
suppression	O	1412-1423
was	O	1424-1427
>	O	1428-1429
90	O	1429-1431
%	O	1431-1432
but	O	1433-1436
reversible	O	1437-1447
.	O	1447-1448

Studies	O	1449-1456
with	O	1457-1461
long	O	1462-1466
-	O	1466-1467
term	O	1467-1471
lamivudine	O	1472-1482
administration	O	1483-1497
should	O	1498-1504
be	O	1505-1507
performed	O	1508-1517
to	O	1518-1520
determine	O	1521-1530
if	O	1531-1533
prolonged	O	1534-1543
suppression	O	1544-1555
of	O	1556-1558
HBV	O	1559-1562
DNA	O	1563-1566
can	O	1567-1570
be	O	1571-1573
achieved	O	1574-1582
.	O	1582-1583

Population	O	0-10
-	O	10-11
based	O	11-16
study	O	17-22
of	O	23-25
risk	O	26-30
of	O	31-33
venous	B	34-40
thromboembolism	I	41-56
associated	O	57-67
with	O	68-72
various	O	73-80
oral	O	81-85
contraceptives	O	86-100
.	O	100-101

BACKGROUND	O	102-112
:	O	112-113
Four	O	114-118
studies	O	119-126
published	O	127-136
since	O	137-142
December	O	143-151
,	O	151-152
1995	O	153-157
,	O	157-158
reported	O	159-167
that	O	168-172
the	O	173-176
incidence	O	177-186
of	O	187-189
venous	B	190-196
thromboembolism	I	197-212
(	O	213-214
VTE	B	214-217
)	O	217-218
was	O	219-222
higher	O	223-229
in	O	230-232
women	O	233-238
who	O	239-242
used	O	243-247
oral	O	248-252
contraceptives	O	253-267
(	O	268-269
OCs	O	269-272
)	O	272-273
containing	O	274-284
the	O	285-288
third	O	289-294
-	O	294-295
generation	O	295-305
progestagens	O	306-318
gestodene	O	319-328
or	O	329-331
desogestrel	O	332-343
than	O	344-348
in	O	349-351
users	O	352-357
of	O	358-360
OCs	O	361-364
containing	O	365-375
second	O	376-382
-	O	382-383
generation	O	383-393
progestagens	O	394-406
.	O	406-407

However	O	408-415
,	O	415-416
confounding	O	417-428
and	O	429-432
bias	O	433-437
in	O	438-440
the	O	441-444
design	O	445-451
of	O	452-454
these	O	455-460
studies	O	461-468
may	O	469-472
have	O	473-477
affected	O	478-486
the	O	487-490
findings	O	491-499
.	O	499-500

The	O	501-504
aim	O	505-508
of	O	509-511
our	O	512-515
study	O	516-521
was	O	522-525
to	O	526-528
re	O	529-531
-	O	531-532
examine	O	532-539
the	O	540-543
association	O	544-555
between	O	556-563
risk	O	564-568
of	O	569-571
VTE	B	572-575
and	O	576-579
OC	O	580-582
use	O	583-586
with	O	587-591
a	O	592-593
different	O	594-603
study	O	604-609
design	O	610-616
and	O	617-620
analysis	O	621-629
to	O	630-632
avoid	O	633-638
some	O	639-643
of	O	644-646
the	O	647-650
bias	O	651-655
and	O	656-659
confounding	O	660-671
of	O	672-674
the	O	675-678
earlier	O	679-686
studies	O	687-694
.	O	694-695

METHODS	O	696-703
:	O	703-704
We	O	705-707
used	O	708-712
computer	O	713-721
records	O	722-729
of	O	730-732
patients	O	733-741
from	O	742-746
143	O	747-750
general	O	751-758
practices	O	759-768
in	O	769-771
the	O	772-775
UK	O	776-778
.	O	778-779

The	O	780-783
study	O	784-789
was	O	790-793
based	O	794-799
on	O	800-802
the	O	803-806
medical	O	807-814
records	O	815-822
of	O	823-825
about	O	826-831
540	O	832-835
,	O	835-836
000	O	836-839
women	O	840-845
born	O	846-850
between	O	851-858
1941	O	859-863
and	O	864-867
1981	O	868-872
.	O	872-873

All	O	874-877
women	O	878-883
who	O	884-887
had	O	888-891
a	O	892-893
recorded	O	894-902
diagnosis	O	903-912
of	O	913-915
deep	B	916-920
-	I	920-921
vein	I	921-925
thrombosis	I	926-936
,	O	936-937
venous	B	938-944
thrombosis	I	945-955
not	O	956-959
otherwise	O	960-969
specified	O	970-979
,	O	979-980
or	O	981-983
pulmonary	O	984-993
embolus	O	994-1001
during	O	1002-1008
the	O	1009-1012
study	O	1013-1018
period	O	1019-1025
,	O	1025-1026
and	O	1027-1030
who	O	1031-1034
had	O	1035-1038
been	O	1039-1043
treated	O	1044-1051
with	O	1052-1056
an	O	1057-1059
anticoagulant	O	1060-1073
were	O	1074-1078
identified	O	1079-1089
as	O	1090-1092
potential	O	1093-1102
cases	O	1103-1108
of	O	1109-1111
VTE	B	1112-1115
.	O	1115-1116

We	O	1117-1119
did	O	1120-1123
a	O	1124-1125
cohort	O	1126-1132
analysis	O	1133-1141
to	O	1142-1144
estimate	O	1145-1153
and	O	1154-1157
compare	O	1158-1165
incidence	O	1166-1175
of	O	1176-1178
VTE	B	1179-1182
in	O	1183-1185
users	O	1186-1191
of	O	1192-1194
the	O	1195-1198
main	O	1199-1203
OC	O	1204-1206
preparations	O	1207-1219
,	O	1219-1220
and	O	1221-1224
a	O	1225-1226
nested	O	1227-1233
case	O	1234-1238
-	O	1238-1239
control	O	1239-1246
study	O	1247-1252
to	O	1253-1255
calculate	O	1256-1265
the	O	1266-1269
odds	O	1270-1274
ratios	O	1275-1281
of	O	1282-1284
VTE	B	1285-1288
associated	O	1289-1299
with	O	1300-1304
use	O	1305-1308
of	O	1309-1311
different	O	1312-1321
types	O	1322-1327
of	O	1328-1330
OC	O	1331-1333
,	O	1333-1334
after	O	1335-1340
adjustment	O	1341-1351
for	O	1352-1355
potential	O	1356-1365
confounding	O	1366-1377
factors	O	1378-1385
.	O	1385-1386

In	O	1387-1389
the	O	1390-1393
case	O	1394-1398
-	O	1398-1399
control	O	1399-1406
study	O	1407-1412
,	O	1412-1413
we	O	1414-1416
matched	O	1417-1424
cases	O	1425-1430
to	O	1431-1433
controls	O	1434-1442
by	O	1443-1445
exact	O	1446-1451
year	O	1452-1456
of	O	1457-1459
birth	O	1460-1465
,	O	1465-1466
practice	O	1467-1475
,	O	1475-1476
and	O	1477-1480
current	O	1481-1488
use	O	1489-1492
of	O	1493-1495
OCs	O	1496-1499
.	O	1499-1500

We	O	1501-1503
used	O	1504-1508
a	O	1509-1510
multiple	O	1511-1519
logistic	O	1520-1528
regression	O	1529-1539
model	O	1540-1545
that	O	1546-1550
included	O	1551-1559
body	O	1560-1564
-	O	1564-1565
mass	O	1565-1569
index	O	1570-1575
,	O	1575-1576
number	O	1577-1583
of	O	1584-1586
cycles	O	1587-1593
,	O	1593-1594
change	O	1595-1601
in	O	1602-1604
type	O	1605-1609
of	O	1610-1612
OC	O	1613-1615
prescribed	O	1616-1626
within	O	1627-1633
3	O	1634-1635
months	O	1636-1642
of	O	1643-1645
the	O	1646-1649
event	O	1650-1655
,	O	1655-1656
previous	O	1657-1665
pregnancy	O	1666-1675
,	O	1675-1676
and	O	1677-1680
concurrent	O	1681-1691
disease	O	1692-1699
.	O	1699-1700

FINDINGS	O	1701-1709
:	O	1709-1710
85	O	1711-1713
women	O	1714-1719
met	O	1720-1723
the	O	1724-1727
inclusion	O	1728-1737
criteria	O	1738-1746
for	O	1747-1750
VTE	B	1751-1754
,	O	1754-1755
two	O	1756-1759
of	O	1760-1762
whom	O	1763-1767
were	O	1768-1772
users	O	1773-1778
of	O	1779-1781
progestagen	O	1782-1793
-	O	1793-1794
only	O	1794-1798
OCs	O	1799-1802
.	O	1802-1803

Of	O	1804-1806
the	O	1807-1810
83	O	1811-1813
cases	O	1814-1819
of	O	1820-1822
VTE	B	1823-1826
associated	O	1827-1837
with	O	1838-1842
use	O	1843-1846
of	O	1847-1849
combined	O	1850-1858
OCs	O	1859-1862
,	O	1862-1863
43	O	1864-1866
were	O	1867-1871
recorded	O	1872-1880
as	O	1881-1883
deep	B	1884-1888
-	I	1888-1889
vein	I	1889-1893
thrombosis	I	1894-1904
,	O	1904-1905
35	O	1906-1908
as	O	1909-1911
pulmonary	O	1912-1921
thrombosis	B	1922-1932
,	O	1932-1933
and	O	1934-1937
five	O	1938-1942
as	O	1943-1945
venous	B	1946-1952
thrombosis	I	1953-1963
not	O	1964-1967
otherwise	O	1968-1977
specified	O	1978-1987
.	O	1987-1988

The	O	1989-1992
crude	O	1993-1998
rate	O	1999-2003
of	O	2004-2006
VTE	B	2007-2010
per	O	2011-2014
10	O	2015-2017
,	O	2017-2018
000	O	2018-2021
woman	O	2022-2027
-	O	2027-2028
years	O	2028-2033
was	O	2034-2037
4	O	2038-2039
.	O	2039-2040
10	O	2040-2042
in	O	2043-2045
current	O	2046-2053
users	O	2054-2059
of	O	2060-2062
any	O	2063-2066
OC	O	2067-2069
,	O	2069-2070
3	O	2071-2072
.	O	2072-2073
10	O	2073-2075
in	O	2076-2078
users	O	2079-2084
of	O	2085-2087
second	O	2088-2094
-	O	2094-2095
generation	O	2095-2105
OCs	O	2106-2109
,	O	2109-2110
and	O	2111-2114
4	O	2115-2116
.	O	2116-2117
96	O	2117-2119
in	O	2120-2122
users	O	2123-2128
of	O	2129-2131
third	O	2132-2137
-	O	2137-2138
generation	O	2138-2148
preparations	O	2149-2161
.	O	2161-2162

After	O	2163-2168
adjustment	O	2169-2179
for	O	2180-2183
age	O	2184-2187
,	O	2187-2188
the	O	2189-2192
rate	O	2193-2197
ratio	O	2198-2203
of	O	2204-2206
VTE	B	2207-2210
in	O	2211-2213
users	O	2214-2219
of	O	2220-2222
third	O	2223-2228
-	O	2228-2229
generation	O	2229-2239
relative	O	2240-2248
to	O	2249-2251
second	O	2252-2258
-	O	2258-2259
generation	O	2259-2269
OCs	O	2270-2273
was	O	2274-2277
1	O	2278-2279
.	O	2279-2280
68	O	2280-2282
(	O	2283-2284
95	O	2284-2286
%	O	2286-2287
CI	O	2288-2290
1	O	2291-2292
.	O	2292-2293
04	O	2293-2295
-	O	2295-2296
2	O	2296-2297
.	O	2292-2293
75	O	2298-2300
)	O	2300-2301
.	O	2292-2293

Logistic	O	2303-2311
regression	O	2312-2322
showed	O	2323-2329
no	O	2330-2332
significant	O	2333-2344
difference	O	2345-2355
in	O	2356-2358
the	O	2359-2362
risk	O	2363-2367
of	O	2368-2370
VTE	B	2371-2374
between	O	2375-2382
users	O	2383-2388
of	O	2389-2391
third	O	2392-2397
-	O	2397-2398
generation	O	2398-2408
and	O	2409-2412
second	O	2413-2419
-	O	2419-2420
generation	O	2420-2430
OCs	O	2431-2434
.	O	2434-2435

Among	O	2436-2441
users	O	2442-2447
of	O	2448-2450
third	O	2451-2456
-	O	2456-2457
generation	O	2457-2467
progestagens	O	2468-2480
,	O	2480-2481
the	O	2482-2485
risk	O	2486-2490
of	O	2491-2493
VTE	B	2494-2497
was	O	2498-2501
higher	O	2502-2508
in	O	2509-2511
users	O	2512-2517
of	O	2518-2520
desogestrel	O	2521-2532
with	O	2533-2537
20	O	2538-2540
g	O	2541-2542
ethinyloestradiol	O	2543-2560
than	O	2561-2565
in	O	2566-2568
users	O	2569-2574
of	O	2575-2577
gestodene	O	2578-2587
or	O	2588-2590
desogestrel	O	2591-2602
with	O	2603-2607
30	O	2608-2610
g	O	2611-2612
ethinyloestradiol	O	2613-2630
.	O	2630-2631

With	O	2632-2636
all	O	2637-2640
second	O	2641-2647
-	O	2647-2648
generation	O	2648-2658
OCs	O	2659-2662
as	O	2663-2665
the	O	2666-2669
reference	O	2670-2679
,	O	2679-2680
the	O	2681-2684
odds	O	2685-2689
ratios	O	2690-2696
for	O	2697-2700
VTE	B	2701-2704
were	O	2705-2709
3	O	2710-2711
.	O	2711-2712
49	O	2712-2714
(	O	2715-2716
1	O	2716-2717
.	O	2717-2718
21	O	2718-2720
-	O	2720-2721
10	O	2721-2723
.	O	2717-2718
12	O	2724-2726
)	O	2726-2727

for	O	2728-2731
desogestrel	O	2732-2743
plus	O	2744-2748
20	O	2749-2751
g	O	2752-2753
ethinyloestradiol	O	2754-2771
and	O	2772-2775
1	O	2776-2777
.	O	2777-2778
18	O	2778-2780
(	O	2781-2782
0	O	2782-2783
.	O	2783-2784
66	O	2784-2786
-	O	2786-2787
2	O	2787-2788
.	O	2783-2784
17	O	2789-2791
)	O	2791-2792
for	O	2793-2796
the	O	2797-2800
other	O	2801-2806
third	O	2807-2812
-	O	2812-2813
generation	O	2813-2823
progestagens	O	2824-2836
.	O	2836-2837

INTERPRETATION	O	2838-2852
:	O	2852-2853
The	O	2854-2857
previously	O	2858-2868
reported	O	2869-2877
increase	O	2878-2886
in	O	2887-2889
odds	O	2890-2894
ratio	O	2895-2900
associated	O	2901-2911
with	O	2912-2916
third	O	2917-2922
-	O	2922-2923
generation	O	2923-2933
OCs	O	2934-2937
when	O	2938-2942
compared	O	2943-2951
with	O	2952-2956
second	O	2957-2963
-	O	2963-2964
generation	O	2964-2974
products	O	2975-2983
is	O	2984-2986
likely	O	2987-2993
to	O	2994-2996
have	O	2997-3001
been	O	3002-3006
the	O	3007-3010
result	O	3011-3017
of	O	3018-3020
residual	O	3021-3029
confounding	O	3030-3041
by	O	3042-3044
age	O	3045-3048
.	O	3048-3049

The	O	3050-3053
increased	O	3054-3063
odds	O	3064-3068
ratio	O	3069-3074
associated	O	3075-3085
with	O	3086-3090
products	O	3091-3099
containing	O	3100-3110
20	O	3111-3113
micrograms	O	3114-3124
ethinyloestradiol	O	3125-3142
and	O	3143-3146
desogestrel	O	3147-3158
compared	O	3159-3167
with	O	3168-3172
the	O	3173-3176
30	O	3177-3179
micrograms	O	3180-3190
product	O	3191-3198
is	O	3199-3201
biologically	O	3202-3214
implausible	O	3215-3226
,	O	3226-3227
and	O	3228-3231
is	O	3232-3234
likely	O	3235-3241
to	O	3242-3244
be	O	3245-3247
the	O	3248-3251
result	O	3252-3258
of	O	3259-3261
preferential	O	3262-3274
prescribing	O	3275-3286
and	O	3287-3290
,	O	3290-3291
thus	O	3292-3296
,	O	3296-3297
confounding	O	3298-3309
.	O	3309-3310

MK	O	0-2
-	O	2-3
801	O	3-6
augments	O	7-15
pilocarpine	O	16-27
-	O	27-28
induced	O	28-35
electrographic	O	36-50
seizure	B	51-58
but	O	59-62
protects	O	63-71
against	O	72-79
brain	B	80-85
damage	I	86-92
in	O	93-95
rats	O	96-100
.	O	100-101
1	O	102-103
.	O	103-104

The	O	105-108
authors	O	109-116
examined	O	117-125
the	O	126-129
anticonvulsant	O	130-144
effects	O	145-152
of	O	153-155
MK	O	156-158
-	O	158-159
801	O	159-162
on	O	163-165
the	O	166-169
pilocarpine	O	170-181
-	O	181-182
induced	O	182-189
seizure	B	190-197
model	O	198-203
.	O	203-204

Intraperitoneal	O	205-220
injection	O	221-230
of	O	231-233
pilocarpine	O	234-245
(	O	246-247
400	O	247-250
mg	O	251-253
/	O	253-254
kg	O	254-256
)	O	256-257
induced	O	258-265
tonic	B	266-271
and	I	272-275
clonic	I	276-282
seizure	I	283-290
.	O	290-291

Scopolamine	O	292-303
(	O	304-305
10	O	305-307
mg	O	308-310
/	O	310-311
kg	O	311-313
)	O	313-314
and	O	315-318
pentobarbital	O	319-332
(	O	333-334
5	O	334-335
mg	O	336-338
/	O	338-339
kg	O	339-341
)	O	341-342
prevented	O	343-352
development	O	353-364
of	O	365-367
pilocarpine	O	368-379
-	O	379-380
induced	O	380-387
behavioral	O	388-398
seizure	B	399-406
but	O	407-410
MK	O	411-413
-	O	413-414
801	O	414-417
(	O	418-419
0	O	419-420
.	O	420-421
5	O	421-422
mg	O	423-425
/	O	425-426
kg	O	426-428
)	O	428-429
did	O	430-433
not	O	434-437
.	O	437-438

2	O	439-440
.	O	440-441

An	O	442-444
electrical	O	445-455
seizure	B	456-463
measured	O	464-472
with	O	473-477
hippocampal	O	478-489
EEG	O	490-493
appeared	O	494-502
in	O	503-505
the	O	506-509
pilocarpine	O	510-521
-	O	521-522
treated	O	522-529
group	O	530-535
.	O	535-536

Scopolamine	O	537-548
and	O	549-552
pentobarbital	O	553-566
blocked	O	567-574
the	O	575-578
pilocarpine	O	579-590
-	O	590-591
induced	O	591-598
electrographic	O	599-613
seizure	B	614-621
,	O	621-622
MK	O	623-625
-	O	625-626
801	O	626-629
treatment	O	630-639
augmented	O	640-649
the	O	650-653
electrographic	O	654-668
seizure	B	669-676
induced	O	677-684
by	O	685-687
pilocarpine	O	688-699
.	O	699-700

3	O	701-702
.	O	702-703
Brain	B	704-709
damage	I	710-716
was	O	717-720
assessed	O	721-729
by	O	730-732
examining	O	733-742
the	O	743-746
hippocampus	O	747-758
microscopically	O	759-774
.	O	774-775

Pilocarpine	O	776-787
produced	O	788-796
neuronal	B	797-805
death	I	806-811
in	O	812-814
the	O	815-818
hippocampus	O	819-830
,	O	830-831
which	O	832-837
showed	O	838-844
pyknotic	O	845-853
changes	O	854-861
.	O	861-862

Pentobarbital	O	863-876
,	O	876-877
scopolamine	O	878-889
and	O	890-893
MK	O	894-896
-	O	896-897
801	O	897-900
protected	O	901-910
the	O	911-914
brain	B	915-920
damage	I	921-927
by	O	928-930
pilocarpine	O	931-942
,	O	942-943
though	O	944-950
in	O	951-953
the	O	954-957
MK	O	958-960
-	O	960-961
801	O	961-964
-	O	960-961
treated	O	965-972
group	O	973-978
,	O	978-979
the	O	980-983
pyramidal	O	984-993
cells	O	994-999
of	O	1000-1002
hippocampus	O	1003-1014
appeared	O	1015-1023
darker	O	1024-1030
than	O	1031-1035
normal	O	1036-1042
.	O	1042-1043

In	O	1044-1046
all	O	1047-1050
treatments	O	1051-1061
,	O	1061-1062
granule	O	1063-1070
cells	O	1071-1076
of	O	1077-1079
the	O	1080-1083
dentate	O	1084-1091
gyrus	O	1092-1097
were	O	1098-1102
not	O	1103-1106
affected	O	1107-1115
.	O	1115-1116

4	O	1117-1118
.	O	1118-1119

These	O	1120-1125
results	O	1126-1133
indicate	O	1134-1142
that	O	1143-1147
status	B	1148-1154
epilepticus	I	1155-1166
induced	O	1167-1174
by	O	1175-1177
pilocarpine	O	1178-1189
is	O	1190-1192
initiated	O	1193-1202
by	O	1203-1205
cholinergic	O	1206-1217
overstimulation	O	1218-1233
and	O	1234-1237
propagated	O	1238-1248
by	O	1249-1251
glutamatergic	O	1252-1265
transmission	O	1266-1278
,	O	1278-1279
the	O	1280-1283
elevation	O	1284-1293
of	O	1294-1296
which	O	1297-1302
may	O	1303-1306
cause	O	1307-1312
brain	B	1313-1318
damage	I	1319-1325
through	O	1326-1333
an	O	1334-1336
excitatory	O	1337-1347
NMDA	O	1348-1352
receptor	O	1353-1361
-	O	1361-1362
mediated	O	1362-1370
mechanism	O	1371-1380
.	O	1380-1381

Paclitaxel	O	0-10
,	O	10-11
5	O	12-13
-	O	13-14
fluorouracil	O	14-26
,	O	26-27
and	O	28-31
folinic	O	32-39
acid	O	40-44
in	O	45-47
metastatic	O	48-58
breast	B	59-65
cancer	I	66-72
:	O	72-73
BRE	O	74-77
-	O	77-78
26	O	78-80
,	O	80-81
a	O	82-83
phase	O	84-89
II	O	90-92
trial	O	93-98
.	O	98-99

5	O	100-101
-	O	101-102
Fluorouracil	O	102-114
plus	O	115-119
folinic	O	120-127
acid	O	128-132
and	O	133-136
paclitaxel	O	137-147
(	O	148-149
Taxol	O	149-154
;	O	154-155
Bristol	O	156-163
-	O	163-164
Myers	O	164-169
Squibb	O	170-176
Company	O	177-184
,	O	184-185
Princeton	O	186-195
,	O	195-196
NJ	O	197-199
)	O	199-200
are	O	201-204
effective	O	205-214
salvage	O	215-222
therapies	O	223-232
for	O	233-236
metastatic	O	237-247
breast	B	248-254
cancer	I	255-261
patients	O	262-270
.	O	270-271

Paclitaxel	O	272-282
and	O	283-286
5	O	287-288
-	O	288-289
fluorouracil	O	289-301
have	O	302-306
additive	O	307-315
cytotoxicity	B	316-328
in	O	329-331
MCF	O	332-335
-	O	335-336
7	O	336-337
cell	O	338-342
lines	O	343-348
.	O	348-349

We	O	350-352
performed	O	353-362
a	O	363-364
phase	O	365-370
II	O	371-373
trial	O	374-379
of	O	380-382
paclitaxel	O	383-393
175	O	394-397
mg	O	398-400
/	O	400-401
m2	O	401-403
over	O	404-408
3	O	409-410
hours	O	411-416
on	O	417-419
day	O	420-423
I	O	424-425
followed	O	426-434
by	O	435-437
folinic	O	438-445
acid	O	446-450
300	O	451-454
mg	O	455-457
over	O	458-462
1	O	463-464
hour	O	465-469
before	O	470-476
5	O	477-478
-	O	478-479
fluorouracil	O	479-491
350	O	492-495
mg	O	496-498
/	O	498-499
m2	O	499-501
on	O	502-504
days	O	505-509
1	O	510-511
to	O	512-514
3	O	515-516
every	O	517-522
28	O	523-525
days	O	526-530
(	O	531-532
TFL	O	532-535
)	O	535-536
in	O	537-539
women	O	540-545
with	O	546-550
metastatic	O	551-561
breast	B	562-568
cancer	I	569-575
.	O	575-576

Analysis	O	577-585
is	O	586-588
reported	O	589-597
on	O	598-600
37	O	601-603
patients	O	604-612
with	O	613-617
a	O	618-619
minimum	O	620-627
of	O	628-630
6	O	631-632
months	O	633-639
follow	O	640-646
-	O	646-647
up	O	647-649
who	O	650-653
received	O	654-662
a	O	663-664
total	O	665-670
of	O	671-673
192	O	674-677
cycles	O	678-684
of	O	685-687
TFL	O	688-691
:	O	691-692
nine	O	693-697
cycles	O	698-704
(	O	705-706
5	O	706-707
%	O	707-708
)	O	708-709
were	O	710-714
associated	O	715-725
with	O	726-730
grade	O	731-736
3	O	737-738
/	O	738-739
4	O	739-740
neutropenia	B	741-752
requiring	O	753-762
hospitalization	O	763-778
;	O	778-779
seven	O	780-785
(	O	786-787
4	O	787-788
%	O	788-789
)	O	789-790
cycles	O	791-797
in	O	798-800
two	O	801-804
patients	O	805-813
required	O	814-822
granulocyte	O	823-834
colony	O	835-841
-	O	841-842
stimulating	O	842-853
factor	O	854-860
due	O	861-864
to	O	865-867
neutropenia	B	868-879
;	O	879-880
no	O	881-883
patient	O	884-891
required	O	892-900
platelet	O	901-909
transfusions	O	910-922
.	O	922-923

Grade	O	924-929
3	O	930-931
/	O	931-932
4	O	932-933
nonhematologic	O	934-948
toxicities	B	949-959
were	O	960-964
uncommon	O	965-973
.	O	973-974

Among	O	975-980
the	O	981-984
34	O	985-987
patients	O	988-996
evaluable	O	997-1006
for	O	1007-1010
response	O	1011-1019
,	O	1019-1020
there	O	1021-1026
were	O	1027-1031
three	O	1032-1037
complete	O	1038-1046
responses	O	1047-1056
(	O	1057-1058
9	O	1058-1059
%	O	1059-1060
)	O	1060-1061
and	O	1062-1065
18	O	1066-1068
partial	O	1069-1076
responses	O	1077-1086
(	O	1087-1088
53	O	1088-1090
%	O	1090-1091
)	O	1091-1092
for	O	1093-1096
an	O	1097-1099
overall	O	1100-1107
response	O	1108-1116
rate	O	1117-1121
of	O	1122-1124
62	O	1125-1127
%	O	1127-1128
.	O	1128-1129

Of	O	1130-1132
the	O	1133-1136
19	O	1137-1139
evaluable	O	1140-1149
patients	O	1150-1158
with	O	1159-1163
prior	O	1164-1169
doxorubicin	O	1170-1181
exposure	O	1182-1190
,	O	1190-1191
11	O	1192-1194
(	O	1195-1196
58	O	1196-1198
%	O	1198-1199
)	O	1199-1200
responded	O	1201-1210
compared	O	1211-1219
with	O	1220-1224
nine	O	1225-1229
of	O	1230-1232
15	O	1233-1235
(	O	1236-1237
60	O	1237-1239
%	O	1239-1240
)	O	1240-1241
without	O	1242-1249
prior	O	1250-1255
doxorubicin	O	1256-1267
.	O	1267-1268

Plasma	O	1269-1275
paclitaxel	O	1276-1286
concentrations	O	1287-1301
were	O	1302-1306
measured	O	1307-1315
at	O	1316-1318
the	O	1319-1322
completion	O	1323-1333
of	O	1334-1336
paclitaxel	O	1337-1347
infusion	O	1348-1356
and	O	1357-1360
at	O	1361-1363
24	O	1364-1366
hours	O	1367-1372
in	O	1373-1375
19	O	1376-1378
patients	O	1379-1387
.	O	1387-1388

TFL	O	1389-1392
is	O	1393-1395
an	O	1396-1398
active	O	1399-1405
,	O	1405-1406
well	O	1407-1411
-	O	1411-1412
tolerated	O	1412-1421
regimen	O	1422-1429
in	O	1430-1432
metastatic	O	1433-1443
breast	B	1444-1450
cancer	I	1451-1457
.	O	1457-1458

Efficacy	O	0-8
and	O	9-12
proarrhythmia	B	13-26
with	O	27-31
the	O	32-35
use	O	36-39
of	O	40-42
d	O	43-44
,	O	44-45
l	O	45-46
-	O	46-47
sotalol	O	47-54
for	O	55-58
sustained	O	59-68
ventricular	B	69-80
tachyarrhythmias	I	81-97
.	O	97-98

This	O	99-103
study	O	104-109
prospectively	O	110-123
evaluated	O	124-133
the	O	134-137
clinical	O	138-146
efficacy	O	147-155
,	O	155-156
the	O	157-160
incidence	O	161-170
of	O	171-173
torsades	B	174-182
de	I	183-185
pointes	I	186-193
,	O	193-194
and	O	195-198
the	O	199-202
presumable	O	203-213
risk	O	214-218
factors	O	219-226
for	O	227-230
torsades	B	231-239
de	I	240-242
pointes	I	243-250
in	O	251-253
patients	O	254-262
treated	O	263-270
with	O	271-275
d	O	276-277
,	O	277-278
l	O	278-279
-	O	279-280
sotalol	O	280-287
for	O	288-291
sustained	O	292-301
ventricular	B	302-313
tachyarrhythmias	I	314-330
.	O	330-331

Eighty	O	332-338
-	O	338-339
one	O	339-342
consecutive	O	343-354
patients	O	355-363
(	O	364-365
54	O	365-367
with	O	368-372
coronary	B	373-381
artery	I	382-388
disease	I	389-396
,	O	396-397
and	O	398-401
20	O	402-404
with	O	405-409
dilated	B	410-417
cardiomyopathy	I	418-432
)	O	432-433
with	O	434-438
inducible	O	439-448
sustained	O	449-458
ventricular	B	459-470
tachycardia	I	471-482
or	O	483-485
ventricular	B	486-497
fibrillation	I	498-510
received	O	511-519
oral	O	520-524
d	O	525-526
,	O	526-527
l	O	527-528
-	O	528-529
sotalol	O	529-536
to	O	537-539
prevent	O	540-547
induction	O	548-557
of	O	558-560
the	O	561-564
ventricular	B	565-576
tachyarrhythmia	I	577-592
.	O	592-593

During	O	594-600
oral	O	601-605
loading	O	606-613
with	O	614-618
d	O	619-620
,	O	620-621
l	O	621-622
-	O	622-623
sotalol	O	623-630
,	O	620-621
continuous	O	632-642
electrocardiographic	O	643-663
(	O	664-665
ECG	O	665-668
)	O	668-669
monitoring	O	670-680
was	O	681-684
performed	O	685-694
.	O	694-695

Those	O	696-701
patients	O	702-710
in	O	711-713
whom	O	714-718
d	O	719-720
,	O	720-721
l	O	721-722
-	O	722-723
sotalol	O	723-730
prevented	O	731-740
induction	O	741-750
of	O	751-753
ventricular	B	754-765
tachycardia	I	766-777
or	O	778-780
ventricular	B	781-792
fibrillation	I	793-805
were	O	806-810
discharged	O	811-821
with	O	822-826
the	O	827-830
drug	O	831-835
and	O	836-839
followed	O	840-848
up	O	849-851
on	O	852-854
an	O	855-857
outpatient	O	858-868
basis	O	869-874
for	O	875-878
21	O	879-881
+	O	882-883
/	O	883-884
-	O	884-885
18	O	886-888
months	O	889-895
.	O	895-896

Induction	O	897-906
of	O	907-909
the	O	910-913
ventricular	B	914-925
tachyarrhythmia	I	926-941
was	O	942-945
prevented	O	946-955
by	O	956-958
oral	O	959-963
d	O	964-965
,	O	965-966
l	O	966-967
-	O	967-968
sotalol	O	968-975
in	O	976-978
35	O	979-981
(	O	982-983
43	O	983-985
%	O	985-986
)	O	986-987
patients	O	988-996
;	O	996-997
the	O	998-1001
ventricular	B	1002-1013
tachyarrhythmia	I	1014-1029
remained	O	1030-1038
inducible	O	1039-1048
in	O	1049-1051
40	O	1052-1054
(	O	1055-1056
49	O	1056-1058
%	O	1058-1059
)	O	1059-1060
patients	O	1061-1069
;	O	1069-1070
and	O	1071-1074
two	O	1075-1078
(	O	1079-1080
2	O	1080-1081
.	O	1081-1082
5	O	1082-1083
%	O	1083-1084
)	O	1084-1085
patients	O	1086-1094
did	O	1095-1098
not	O	1099-1102
tolerate	O	1103-1111
even	O	1112-1116
40	O	1117-1119
mg	O	1120-1122
of	O	1123-1125
d	O	1126-1127
,	O	1127-1128
l	O	1128-1129
-	O	1129-1130
sotalol	O	1130-1137
once	O	1138-1142
daily	O	1143-1148
.	O	1148-1149

Four	O	1150-1154
(	O	1155-1156
5	O	1156-1157
%	O	1157-1158
)	O	1158-1159
patients	O	1160-1168
had	O	1169-1172
from	O	1173-1177
torsades	B	1178-1186
de	I	1187-1189
pointes	I	1190-1197
during	O	1198-1204
the	O	1205-1208
initial	O	1209-1216
oral	O	1217-1221
treatment	O	1222-1231
with	O	1232-1236
d	O	1237-1238
,	O	1238-1239
l	O	1239-1240
-	O	1240-1241
sotalol	O	1241-1248
.	O	1248-1249

Neither	O	1250-1257
ECG	O	1258-1261
[	O	1262-1263
sinus	O	1263-1268
-	O	1268-1269
cycle	O	1269-1274
length	O	1275-1281
(	O	1282-1283
SCL	O	1283-1286
)	O	1286-1287
,	O	1287-1288
QT	O	1289-1291
or	O	1292-1294
QTc	O	1295-1298
interval	O	1299-1307
,	O	1307-1308
or	O	1309-1311
U	O	1312-1313
wave	O	1314-1318
]	O	1318-1319
nor	O	1320-1323
clinical	O	1324-1332
parameters	O	1333-1343
identified	O	1344-1354
patients	O	1355-1363
at	O	1364-1366
risk	O	1367-1371
for	O	1372-1375
torsades	B	1376-1384
de	I	1385-1387
pointes	I	1388-1395
.	O	1395-1396

However	O	1397-1404
,	O	1404-1405
the	O	1406-1409
oral	O	1410-1414
dose	O	1415-1419
of	O	1420-1422
d	O	1423-1424
,	O	1424-1425
l	O	1425-1426
-	O	1426-1427
sotalol	O	1427-1434
was	O	1435-1438
significantly	O	1439-1452
lower	O	1453-1458
in	O	1459-1461
patients	O	1462-1470
with	O	1471-1475
torsades	B	1476-1484
de	I	1485-1487
pointes	I	1488-1495
(	O	1496-1497
200	O	1497-1500
+	O	1501-1502
/	O	1502-1503
-	O	1503-1504
46	O	1505-1507
vs	O	1508-1510
.	O	1510-1511
328	O	1512-1515
+	O	1516-1517
/	O	1517-1518
-	O	1518-1519
53	O	1520-1522
mg	O	1523-1525
/	O	1525-1526
day	O	1526-1529
;	O	1529-1530
p	O	1531-1532
=	O	1533-1534
0	O	1535-1536
.	O	1536-1537
0017	O	1537-1541
)	O	1541-1542
.	O	1536-1537

Risk	O	1544-1548
factors	O	1549-1556
associated	O	1557-1567
with	O	1568-1572
the	O	1573-1576
development	O	1577-1588
of	O	1589-1591
torsades	B	1592-1600
de	I	1601-1603
pointes	I	1604-1611
were	O	1612-1616
the	O	1617-1620
appearance	O	1621-1631
of	O	1632-1634
an	O	1635-1637
U	O	1638-1639
wave	O	1640-1644
(	O	1645-1646
p	O	1646-1647
=	O	1648-1649
0	O	1650-1651
.	O	1651-1652
049	O	1652-1655
)	O	1655-1656
,	O	1656-1657
female	O	1658-1664
gender	O	1665-1671
(	O	1672-1673
p	O	1673-1674
=	O	1675-1676
0	O	1677-1678
.	O	1678-1679
015	O	1679-1682
)	O	1682-1683
,	O	1683-1684
and	O	1685-1688
significant	O	1689-1700
dose	O	1701-1705
-	O	1705-1706
corrected	O	1706-1715
changes	O	1716-1723
of	O	1724-1726
SCL	O	1727-1730
,	O	1730-1731
QT	O	1732-1734
interval	O	1735-1743
,	O	1743-1744
and	O	1745-1748
QTc	O	1749-1752
interval	O	1753-1761
(	O	1762-1763
p	O	1763-1764
<	O	1765-1766
0	O	1767-1768
.	O	1768-1769
05	O	1769-1771
)	O	1771-1772
.	O	1768-1769

During	O	1774-1780
follow	O	1781-1787
-	O	1787-1788
up	O	1788-1790
,	O	1790-1791
seven	O	1792-1797
(	O	1798-1799
20	O	1799-1801
%	O	1801-1802
)	O	1802-1803
patients	O	1804-1812
had	O	1813-1816
a	O	1817-1818
nonfatal	O	1819-1827
ventricular	B	1828-1839
tachycardia	I	1840-1851
recurrence	O	1852-1862
,	O	1862-1863
and	O	1864-1867
two	O	1868-1871
(	O	1872-1873
6	O	1873-1874
%	O	1874-1875
)	O	1875-1876
patients	O	1877-1885
died	O	1886-1890
suddenly	O	1891-1899
.	O	1899-1900

One	O	1901-1904
female	O	1905-1911
patient	O	1912-1919
with	O	1920-1924
stable	O	1925-1931
cardiac	B	1932-1939
disease	I	1940-1947
had	O	1948-1951
recurrent	O	1952-1961
torsades	B	1962-1970
de	I	1971-1973
pointes	I	1974-1981
after	O	1982-1987
2	O	1988-1989
years	O	1990-1995
of	O	1996-1998
successful	O	1999-2009
treatment	O	2010-2019
with	O	2020-2024
d	O	2025-2026
,	O	2026-2027
l	O	2027-2028
-	O	2028-2029
sotalol	O	2029-2036
.	O	2036-2037

Torsades	B	2038-2046
de	I	2047-2049
pointes	I	2050-2057
occurred	O	2058-2066
early	O	2067-2072
during	O	2073-2079
treatment	O	2080-2089
even	O	2090-2094
with	O	2095-2099
low	O	2100-2103
doses	O	2104-2109
of	O	2110-2112
oral	O	2113-2117
d	O	2118-2119
,	O	2119-2120
l	O	2120-2121
-	O	2121-2122
sotalol	O	2122-2129
.	O	2129-2130

Pronounced	O	2131-2141
changes	O	2142-2149
in	O	2150-2152
the	O	2153-2156
surface	O	2157-2164
ECG	O	2165-2168
(	O	2169-2170
cycle	O	2170-2175
length	O	2176-2182
,	O	2182-2183
QT	O	2184-2186
,	O	2186-2187
and	O	2188-2191
QTc	O	2192-2195
)	O	2195-2196
in	O	2197-2199
relation	O	2200-2208
to	O	2209-2211
the	O	2212-2215
dose	O	2216-2220
of	O	2221-2223
oral	O	2224-2228
d	O	2229-2230
,	O	2230-2231
l	O	2231-2232
-	O	2232-2233
sotalol	O	2233-2240
might	O	2241-2246
identify	O	2247-2255
a	O	2256-2257
subgroup	O	2258-2266
of	O	2267-2269
patients	O	2270-2278
with	O	2279-2283
an	O	2284-2286
increased	O	2287-2296
risk	O	2297-2301
for	O	2302-2305
torsades	B	2306-2314
de	I	2315-2317
pointes	I	2318-2325
.	O	2325-2326

Other	O	2327-2332
ECG	O	2333-2336
parameters	O	2337-2347
before	O	2348-2354
the	O	2355-2358
application	O	2359-2370
of	O	2371-2373
d	O	2374-2375
,	O	2375-2376
l	O	2376-2377
-	O	2377-2378
sotalol	O	2378-2385
did	O	2386-2389
not	O	2390-2393
identify	O	2394-2402
patients	O	2403-2411
at	O	2412-2414
increased	O	2415-2424
risk	O	2425-2429
for	O	2430-2433
torsades	B	2434-2442
de	I	2443-2445
pointes	I	2446-2453
.	O	2453-2454

Recurrence	O	2455-2465
rates	O	2466-2471
of	O	2472-2474
ventricular	B	2475-2486
tachyarrhythmias	I	2487-2503
are	O	2504-2507
high	O	2508-2512
despite	O	2513-2520
complete	O	2521-2529
suppression	O	2530-2541
of	O	2542-2544
the	O	2545-2548
arrhythmia	B	2549-2559
during	O	2560-2566
programmed	O	2567-2577
stimulation	O	2578-2589
.	O	2589-2590

Therefore	O	2591-2600
programmed	O	2601-2611
electrical	O	2612-2622
stimulation	O	2623-2634
in	O	2635-2637
the	O	2638-2641
case	O	2642-2646
of	O	2647-2649
d	O	2650-2651
,	O	2651-2652
l	O	2652-2653
-	O	2653-2654
sotalol	O	2654-2661
seems	O	2662-2667
to	O	2668-2670
be	O	2671-2673
of	O	2674-2676
limited	O	2677-2684
prognostic	O	2685-2695
value	O	2696-2701
.	O	2701-2702

Chronic	O	0-7
hyperprolactinemia	B	8-26
and	O	27-30
changes	O	31-38
in	O	39-41
dopamine	O	42-50
neurons	O	51-58
.	O	58-59

The	O	60-63
tuberoinfundibular	O	64-82
dopaminergic	O	83-95
(	O	96-97
TIDA	O	97-101
)	O	101-102
system	O	103-109
is	O	110-112
known	O	113-118
to	O	119-121
inhibit	O	122-129
prolactin	O	130-139
(	O	140-141
PRL	O	141-144
)	O	144-145
secretion	O	146-155
.	O	155-156

In	O	157-159
young	O	160-165
animals	O	166-173
this	O	174-178
system	O	179-185
responds	O	186-194
to	O	195-197
acute	O	198-203
elevations	O	204-214
in	O	215-217
serum	O	218-223
PRL	O	224-227
by	O	228-230
increasing	O	231-241
its	O	242-245
activity	O	246-254
.	O	254-255

However	O	256-263
,	O	263-264
this	O	265-269
responsiveness	O	270-284
is	O	285-287
lost	O	288-292
in	O	293-295
aging	O	296-301
rats	O	302-306
with	O	307-311
chronically	O	312-323
high	O	324-328
serum	O	329-334
PRL	O	335-338
levels	O	339-345
.	O	345-346

The	O	347-350
purpose	O	351-358
of	O	359-361
this	O	362-366
study	O	367-372
was	O	373-376
to	O	377-379
induce	O	380-386
hyperprolactinemia	B	387-405
in	O	406-408
rats	O	409-413
for	O	414-417
extended	O	418-426
periods	O	427-434
of	O	435-437
time	O	438-442
and	O	443-446
examine	O	447-454
its	O	455-458
effects	O	459-466
on	O	467-469
dopaminergic	O	470-482
systems	O	483-490
in	O	491-493
the	O	494-497
brain	O	498-503
.	O	503-504

Hyperprolactinemia	B	505-523
was	O	524-527
induced	O	528-535
by	O	536-538
treatment	O	539-548
with	O	549-553
haloperidol	O	554-565
,	O	565-566
a	O	567-568
dopamine	O	569-577
receptor	O	578-586
antagonist	O	587-597
,	O	597-598
and	O	599-602
Palkovits	O	603-612
'	O	612-613
microdissection	O	614-629
technique	O	630-639
in	O	640-642
combination	O	643-654
with	O	655-659
high	O	660-664
-	O	664-665
performance	O	665-676
liquid	O	677-683
chromatography	O	684-698
was	O	699-702
used	O	703-707
to	O	708-710
measure	O	711-718
neurotransmitter	O	719-735
concentrations	O	736-750
in	O	751-753
several	O	754-761
areas	O	762-767
of	O	768-770
the	O	771-774
brain	O	775-780
.	O	780-781

After	O	782-787
6	O	788-789
months	O	790-796
of	O	797-799
hyperprolactinemia	B	800-818
,	O	818-819
dopamine	O	820-828
(	O	829-830
DA	O	830-832
)	O	832-833
concentrations	O	834-848
in	O	849-851
the	O	852-855
median	O	856-862
eminence	O	863-871
(	O	872-873
ME	O	873-875
)	O	875-876
increased	O	877-886
by	O	887-889
84	O	890-892
%	O	892-893
over	O	894-898
the	O	899-902
control	O	903-910
group	O	911-916
.	O	916-917

Nine	O	918-922
months	O	923-929
of	O	930-932
hyperprolactinemia	B	933-951
produced	O	952-960
a	O	961-962
50	O	963-965
%	O	965-966
increase	O	967-975
in	O	976-978
DA	O	979-981
concentrations	O	982-996
in	O	997-999
the	O	1000-1003
ME	O	1004-1006
over	O	1007-1011
the	O	1012-1015
control	O	1016-1023
group	O	1024-1029
.	O	1029-1030

However	O	1031-1038
,	O	1038-1039
DA	O	1040-1042
response	O	1043-1051
was	O	1052-1055
lost	O	1056-1060
if	O	1061-1063
a	O	1064-1065
9	O	1066-1067
-	O	1067-1068
month	O	1068-1073
long	O	1074-1078
haloperidol	O	1079-1090
-	O	1090-1091
induced	O	1091-1098
hyperprolactinemia	B	1099-1117
was	O	1118-1121
followed	O	1122-1130
by	O	1131-1133
a	O	1134-1135
1	O	1136-1137
1	O	1138-1139
/	O	1139-1140
2	O	1140-1141
month	O	1142-1147
-	O	1147-1148
long	O	1148-1152
extremely	O	1153-1162
high	O	1163-1167
increase	O	1168-1176
in	O	1177-1179
serum	O	1180-1185
PRL	O	1186-1189
levels	O	1190-1196
produced	O	1197-1205
by	O	1206-1208
implantation	O	1209-1221
of	O	1222-1224
MMQ	O	1225-1228
cells	O	1229-1234
under	O	1235-1240
the	O	1241-1244
kidney	O	1245-1251
capsule	O	1252-1259
.	O	1259-1260

There	O	1261-1266
was	O	1267-1270
no	O	1271-1273
change	O	1274-1280
in	O	1281-1283
the	O	1284-1287
levels	O	1288-1294
of	O	1295-1297
DA	O	1298-1300
,	O	1300-1301
norepinephrine	O	1302-1316
(	O	1317-1318
NE	O	1318-1320
)	O	1320-1321
,	O	1321-1322
serotonin	O	1323-1332
(	O	1333-1334
5	O	1334-1335
-	O	1335-1336
HT	O	1336-1338
)	O	1338-1339
,	O	1339-1340
or	O	1341-1343
their	O	1344-1349
metabolites	O	1350-1361
in	O	1362-1364
the	O	1365-1368
arcuate	O	1369-1376
nucleus	O	1377-1384
(	O	1385-1386
AN	O	1386-1388
)	O	1388-1389
,	O	1389-1390
medial	O	1391-1397
preoptic	O	1398-1406
area	O	1407-1411
(	O	1412-1413
MPA	O	1413-1416
)	O	1416-1417
,	O	1417-1418
caudate	O	1419-1426
putamen	O	1427-1434
(	O	1435-1436
CP	O	1436-1438
)	O	1438-1439
,	O	1439-1440
substantia	O	1441-1451
nigra	O	1452-1457
(	O	1458-1459
SN	O	1459-1461
)	O	1461-1462
,	O	1462-1463
and	O	1464-1467
zona	O	1468-1472
incerta	O	1473-1480
(	O	1481-1482
ZI	O	1482-1484
)	O	1484-1485
,	O	1485-1486
except	O	1487-1493
for	O	1494-1497
a	O	1498-1499
decrease	O	1500-1508
in	O	1509-1511
5	O	1512-1513
-	O	1513-1514
hydroxyindoleacetic	O	1514-1533
acid	O	1534-1538
(	O	1539-1540
5	O	1540-1541
-	O	1541-1542
HIAA	O	1542-1546
)	O	1546-1547
in	O	1548-1550
the	O	1551-1554
AN	O	1555-1557
after	O	1558-1563
6	O	1564-1565
-	O	1565-1566
months	O	1566-1572
of	O	1573-1575
hyperprolactinemia	B	1576-1594
and	O	1595-1598
an	O	1599-1601
increase	O	1602-1610
in	O	1611-1613
DA	O	1614-1616
concentrations	O	1617-1631
in	O	1632-1634
the	O	1635-1638
AN	O	1639-1641
after	O	1642-1647
9	O	1648-1649
-	O	1649-1650
months	O	1650-1656
of	O	1657-1659
hyperprolactinemia	B	1660-1678
.	O	1678-1679

These	O	1680-1685
results	O	1686-1693
demonstrate	O	1694-1705
that	O	1706-1710
hyperprolactinemia	B	1711-1729
specifically	O	1730-1742
affects	O	1743-1750
TIDA	O	1751-1755
neurons	O	1756-1763
and	O	1764-1767
these	O	1768-1773
effects	O	1774-1781
vary	O	1782-1786
,	O	1786-1787
depending	O	1788-1797
on	O	1798-1800
the	O	1801-1804
duration	O	1805-1813
and	O	1814-1817
intensity	O	1818-1827
of	O	1828-1830
hyperprolactinemia	B	1831-1849
.	O	1849-1850

The	O	1851-1854
age	O	1855-1858
-	O	1858-1859
related	O	1859-1866
decrease	O	1867-1875
in	O	1876-1878
hypothalamic	O	1879-1891
dopamine	O	1892-1900
function	O	1901-1909
may	O	1910-1913
be	O	1914-1916
associated	O	1917-1927
with	O	1928-1932
increases	O	1933-1942
in	O	1943-1945
PRL	O	1946-1949
secretion	O	1950-1959
.	O	1959-1960

Treatment	O	0-9
-	O	9-10
related	O	10-17
disseminated	O	18-30
necrotizing	O	31-42
leukoencephalopathy	B	43-62
with	O	63-67
characteristic	O	68-82
contrast	O	83-91
enhancement	O	92-103
of	O	104-106
the	O	107-110
white	O	111-116
matter	O	117-123
.	O	123-124

This	O	125-129
report	O	130-136
describes	O	137-146
unique	O	147-153
contrast	O	154-162
enhancement	O	163-174
of	O	175-177
the	O	178-181
white	O	182-187
matter	O	188-194
on	O	195-197
T1	O	198-200
-	O	200-201
weighted	O	201-209
magnetic	O	210-218
resonance	O	219-228
images	O	229-235
of	O	236-238
two	O	239-242
patients	O	243-251
with	O	252-256
disseminated	O	257-269
necrotizing	O	270-281
leukoencephalopathy	B	282-301
,	O	301-302
which	O	303-308
developed	O	309-318
from	O	319-323
acute	B	324-329
lymphoblastic	I	330-343
leukemia	I	344-352
treated	O	353-360
with	O	361-365
high	O	366-370
-	O	370-371
dose	O	371-375
methotrexate	O	376-388
.	O	388-389

In	O	390-392
both	O	393-397
patients	O	398-406
,	O	406-407
the	O	408-411
enhancement	O	412-423
was	O	424-427
more	O	428-432
pronounced	O	433-443
near	O	444-448
the	O	449-452
base	O	453-457
of	O	458-460
the	O	461-464
brain	O	465-470
than	O	471-475
at	O	476-478
the	O	479-482
vertex	O	483-489
.	O	489-490

Necropsy	O	491-499
of	O	500-502
the	O	503-506
first	O	507-512
case	O	513-517
revealed	O	518-526
loss	B	527-531
of	I	532-534
myelination	I	535-546
and	O	547-550
necrosis	B	551-559
of	O	560-562
the	O	563-566
white	O	567-572
matter	O	573-579
.	O	579-580

Possible	O	581-589
mechanisms	O	590-600
causing	O	601-608
such	O	609-613
a	O	614-615
leukoencephalopathy	B	616-635
are	O	636-639
discussed	O	640-649
.	O	649-650

Thrombotic	B	0-10
complications	O	11-24
in	O	25-27
acute	B	28-33
promyelocytic	I	34-47
leukemia	I	48-56
during	O	57-63
all	O	64-67
-	O	67-68
trans	O	68-73
-	O	67-68
retinoic	O	74-82
acid	O	83-87
therapy	O	88-95
.	O	95-96

A	O	97-98
case	O	99-103
of	O	104-106
acute	B	107-112
renal	I	113-118
failure	I	119-126
,	O	126-127
due	O	128-131
to	O	132-134
occlusion	B	135-144
of	I	145-147
renal	I	148-153
vessels	I	154-161
in	O	162-164
a	O	165-166
patient	O	167-174
with	O	175-179
acute	B	180-185
promyelocytic	I	186-199
leukemia	I	200-208
(	O	209-210
APL	B	210-213
)	O	213-214
treated	O	215-222
with	O	223-227
all	O	228-231
-	O	231-232
trans	O	232-237
-	O	231-232
retinoic	O	238-246
acid	O	247-251
(	O	252-253
ATRA	O	253-257
)	O	257-258
and	O	259-262
tranexamic	O	263-273
acid	O	274-278
has	O	279-282
been	O	283-287
described	O	288-297
recently	O	298-306
.	O	306-307

We	O	308-310
report	O	311-317
a	O	318-319
case	O	320-324
of	O	325-327
acute	B	328-333
renal	I	334-339
failure	I	340-347
in	O	348-350
an	O	351-353
APL	B	354-357
patient	O	358-365
treated	O	366-373
with	O	374-378
ATRA	O	379-383
alone	O	384-389
.	O	389-390

This	O	391-395
case	O	396-400
further	O	401-408
supports	O	409-417
the	O	418-421
concern	O	422-429
about	O	430-435
thromboembolic	B	436-450
complications	O	451-464
associated	O	465-475
with	O	476-480
ATRA	O	481-485
therapy	O	486-493
in	O	494-496
APL	B	497-500
patients	O	501-509
.	O	509-510

The	O	511-514
patients	O	515-523
,	O	523-524
a	O	525-526
43	O	527-529
-	O	529-530
year	O	530-534
-	O	529-530
old	O	535-538
man	O	539-542
,	O	542-543
presented	O	544-553
all	O	554-557
the	O	558-561
signs	O	562-567
and	O	568-571
symptoms	O	572-580
of	O	581-583
APL	B	584-587
and	O	588-591
was	O	592-595
included	O	596-604
in	O	605-607
a	O	608-609
treatment	O	610-619
protocol	O	620-628
with	O	629-633
ATRA	O	634-638
.	O	638-639

After	O	640-645
10	O	646-648
days	O	649-653
of	O	654-656
treatment	O	657-666
,	O	666-667
he	O	668-670
developed	O	671-680
acute	B	681-686
renal	I	687-692
failure	I	693-700
that	O	701-705
was	O	706-709
completely	O	710-720
reversible	O	721-731
after	O	732-737
complete	O	738-746
remission	O	747-756
of	O	757-759
APL	B	760-763
was	O	764-767
achieved	O	768-776
and	O	777-780
therapy	O	781-788
discontinued	O	789-801
.	O	801-802

We	O	803-805
conclude	O	806-814
that	O	815-819
ATRA	O	820-824
is	O	825-827
a	O	828-829
valid	O	830-835
therapeutic	O	836-847
choice	O	848-854
for	O	855-858
patients	O	859-867
with	O	868-872
APL	B	873-876
,	O	876-877
although	O	878-886
the	O	887-890
procoagulant	O	891-903
tendency	O	904-912
is	O	913-915
not	O	916-919
completely	O	920-930
corrected	O	931-940
.	O	940-941

Thrombotic	B	942-952
events	O	953-959
,	O	959-960
however	O	961-968
,	O	968-969
could	O	970-975
be	O	976-978
avoided	O	979-986
by	O	987-989
using	O	990-995
low	O	996-999
-	O	999-1000
dose	O	1000-1004
heparin	O	1005-1012
.	O	1012-1013

Pupillary	O	0-9
changes	O	10-17
associated	O	18-28
with	O	29-33
the	O	34-37
development	O	38-49
of	O	50-52
stimulant	O	53-62
-	O	62-63
induced	O	63-70
mania	B	71-76
:	O	76-77
a	O	78-79
case	O	80-84
report	O	85-91
.	O	91-92

A	O	93-94
30	O	95-97
-	O	97-98
year	O	98-102
-	O	97-98
old	O	103-106
cocaine	O	107-114
-	O	114-115
dependent	O	115-124
man	O	125-128
who	O	129-132
was	O	133-136
a	O	137-138
subject	O	139-146
in	O	147-149
a	O	150-151
study	O	152-157
evaluating	O	158-168
the	O	169-172
anticraving	O	173-184
efficacy	O	185-193
of	O	194-196
the	O	197-200
stimulant	O	201-210
medication	O	211-221
diethylpropion	O	222-236
(	O	237-238
DEP	O	238-241
)	O	241-242
became	O	243-249
manic	B	250-255
during	O	256-262
his	O	263-266
second	O	267-273
week	O	274-278
on	O	279-281
the	O	282-285
study	O	286-291
drug	O	292-296
.	O	296-297

Pupillometric	O	298-311
changes	O	312-319
while	O	320-325
on	O	326-328
DEP	O	329-332
,	O	332-333
especially	O	334-344
changes	O	345-352
in	O	353-355
the	O	356-359
total	O	360-365
power	O	366-371
of	O	372-374
pupillary	B	375-384
oscillation	I	385-396
,	O	396-397
were	O	398-402
dramatically	O	403-415
different	O	416-425
than	O	426-430
those	O	431-436
observed	O	437-445
in	O	446-448
the	O	449-452
eight	O	453-458
other	O	459-464
study	O	465-470
subjects	O	471-479
who	O	480-483
did	O	484-487
not	O	488-491
become	O	492-498
manic	B	499-504
.	O	504-505

The	O	506-509
large	O	510-515
changes	O	516-523
in	O	524-526
total	O	527-532
power	O	533-538
of	O	539-541
pupillary	B	542-551
oscillation	I	552-563
occurred	O	564-572
a	O	573-574
few	O	575-578
days	O	579-583
before	O	584-590
the	O	591-594
patient	O	595-602
became	O	603-609
fully	O	610-615
manic	B	616-621
.	O	621-622

Such	O	623-627
medication	O	628-638
-	O	638-639
associated	O	639-649
changes	O	650-657
in	O	658-660
the	O	661-664
total	O	665-670
power	O	671-676
of	O	677-679
pupillary	B	680-689
oscillation	I	690-701
might	O	702-707
be	O	708-710
of	O	711-713
utility	O	714-721
in	O	722-724
identifying	O	725-736
persons	O	737-744
at	O	745-747
risk	O	748-752
for	O	753-756
manic	B	757-762
-	O	762-763
like	O	763-767
adverse	O	768-775
effects	O	776-783
during	O	784-790
the	O	791-794
medical	O	795-802
use	O	803-806
of	O	807-809
psychomotor	O	810-821
stimulants	O	822-832
or	O	833-835
sympathomimetic	O	836-851
agents	O	852-858
.	O	858-859

The	O	0-3
negative	O	4-12
mucosal	O	13-20
potential	O	21-30
:	O	30-31
separating	O	32-42
central	O	43-50
and	O	51-54
peripheral	O	55-65
effects	O	66-73
of	O	74-76
NSAIDs	O	77-83
in	O	84-86
man	O	87-90
.	O	90-91

OBJECTIVE	O	92-101
:	O	101-102
We	O	103-105
wanted	O	106-112
to	O	113-115
test	O	116-120
whether	O	121-128
assessment	O	129-139
of	O	140-142
both	O	143-147
a	O	148-149
central	O	150-157
pain	B	158-162
-	O	162-163
related	O	163-170
signal	O	171-177
(	O	178-179
chemo	O	179-184
-	O	184-185
somatosensory	O	185-198
evoked	O	199-205
potential	O	206-215
,	O	215-216
CSSEP	O	217-222
)	O	222-223
and	O	224-227
a	O	228-229
concomitantly	O	230-243
recorded	O	244-252
peripheral	O	253-263
signal	O	264-270
(	O	271-272
negative	O	272-280
mucosal	O	281-288
potential	O	289-298
,	O	298-299
NMP	O	300-303
)	O	303-304
allows	O	305-311
for	O	312-315
separation	O	316-326
of	O	327-329
central	O	330-337
and	O	338-341
peripheral	O	342-352
effects	O	353-360
of	O	361-363
NSAIDs	O	364-370
.	O	370-371

For	O	372-375
this	O	376-380
purpose	O	381-388
,	O	388-389
experimental	O	390-402
conditions	O	403-413
were	O	414-418
created	O	419-426
in	O	427-429
which	O	430-435
NSAIDs	O	436-442
had	O	443-446
previously	O	447-457
been	O	458-462
observed	O	463-471
to	O	472-474
produce	O	475-482
effects	O	483-490
on	O	491-493
phasic	O	494-500
and	O	501-504
tonic	O	505-510
pain	B	511-515
by	O	516-518
either	O	519-525
central	O	526-533
or	O	534-536
peripheral	O	537-547
mechanisms	O	548-558
.	O	558-559

METHODS	O	560-567
:	O	567-568
According	O	569-578
to	O	579-581
a	O	582-583
double	O	584-590
-	O	590-591
blind	O	591-596
,	O	596-597
randomised	O	598-608
,	O	608-609
controlled	O	610-620
,	O	620-621
threefold	O	622-631
cross	O	632-637
-	O	637-638
over	O	638-642
design	O	643-649
,	O	649-650
18	O	651-653
healthy	O	654-661
subjects	O	662-670
(	O	671-672
11	O	672-674
males	O	675-680
,	O	680-681
7	O	682-683
females	O	684-691
;	O	691-692
mean	O	693-697
age	O	698-701
26	O	702-704
years	O	705-710
)	O	710-711
received	O	712-720
either	O	721-727
placebo	O	728-735
,	O	735-736
400	O	737-740
mg	O	741-743
ibuprofen	O	744-753
,	O	753-754
or	O	755-757
800	O	758-761
mg	O	762-764
ibuprofen	O	765-774
.	O	774-775

Phasic	O	776-782
pain	B	783-787
was	O	788-791
applied	O	792-799
by	O	800-802
means	O	803-808
of	O	809-811
short	O	812-817
pulses	O	818-824
of	O	825-827
CO2	O	828-831
to	O	832-834
the	O	835-838
nasal	O	839-844
mucosa	O	845-851
(	O	852-853
stimulus	O	853-861
duration	O	862-870
500	O	871-874
ms	O	875-877
,	O	877-878
interval	O	879-887
approximately	O	888-901
60	O	902-904
s	O	905-906
)	O	906-907
,	O	907-908
and	O	909-912
tonic	O	913-918
pain	B	919-923
was	O	924-927
induced	O	928-935
in	O	936-938
the	O	939-942
nasal	O	943-948
cavity	O	949-955
by	O	956-958
means	O	959-964
of	O	965-967
dry	O	968-971
air	O	972-975
of	O	976-978
controlled	O	979-989
temperature	O	990-1001
,	O	1001-1002
humidity	O	1003-1011
and	O	1012-1015
flow	O	1016-1020
rate	O	1021-1025
(	O	1026-1027
22	O	1027-1029
degrees	O	1030-1037
C	O	1038-1039
,	O	1039-1040
0	O	1041-1042
%	O	1042-1043
relative	O	1044-1052
humidity	O	1053-1061
,	O	1061-1062
145	O	1063-1066
ml	O	1067-1069
.	O	1069-1070
s	O	1070-1071
-	O	1071-1072
1	O	1072-1073
)	O	1073-1074
.	O	1069-1070

Both	O	1076-1080
CSSEPs	O	1081-1087
as	O	1088-1090
central	O	1091-1098
and	O	1099-1102
NMPs	O	1103-1107
as	O	1108-1110
peripheral	O	1111-1121
correlates	O	1122-1132
of	O	1133-1135
pain	B	1136-1140
were	O	1141-1145
obtained	O	1146-1154
in	O	1155-1157
response	O	1158-1166
to	O	1167-1169
the	O	1170-1173
CO2	O	1174-1177
stimuli	O	1178-1185
.	O	1185-1186

Additionally	O	1187-1199
,	O	1199-1200
the	O	1201-1204
subjects	O	1205-1213
rated	O	1214-1219
the	O	1220-1223
intensity	O	1224-1233
of	O	1234-1236
both	O	1237-1241
phasic	O	1242-1248
and	O	1249-1252
tonic	O	1253-1258
pain	B	1259-1263
by	O	1264-1266
means	O	1267-1272
of	O	1273-1275
visual	O	1276-1282
analogue	O	1283-1291
scales	O	1292-1298
.	O	1298-1299

RESULTS	O	1300-1307
:	O	1307-1308
As	O	1309-1311
described	O	1312-1321
earlier	O	1322-1329
,	O	1329-1330
administration	O	1331-1345
of	O	1346-1348
ibuprofen	O	1349-1358
was	O	1359-1362
followed	O	1363-1371
by	O	1372-1374
a	O	1375-1376
decrease	O	1377-1385
in	O	1386-1388
tonic	O	1389-1394
pain	B	1395-1399
but	O	1400-1403
-	O	1403-1404
relative	O	1404-1412
to	O	1413-1415
placebo	O	1416-1423
-	O	1423-1424
an	O	1424-1426
increase	O	1427-1435
in	O	1436-1438
correlates	O	1439-1449
of	O	1450-1452
phasic	O	1453-1459
pain	B	1460-1464
,	O	1464-1465
indicating	O	1466-1476
a	O	1477-1478
specific	O	1479-1487
effect	O	1488-1494
of	O	1495-1497
ibuprofen	O	1498-1507
on	O	1508-1510
the	O	1511-1514
interaction	O	1515-1526
between	O	1527-1534
the	O	1535-1538
pain	B	1539-1543
stimuli	O	1544-1551
under	O	1552-1557
these	O	1558-1563
special	O	1564-1571
experimental	O	1572-1584
conditions	O	1585-1595
.	O	1595-1596

Based	O	1597-1602
on	O	1603-1605
the	O	1606-1609
similar	O	1610-1617
behaviour	O	1618-1627
of	O	1628-1630
CSSEP	O	1631-1636
and	O	1637-1640
NMP	O	1641-1644
,	O	1644-1645
it	O	1646-1648
was	O	1649-1652
concluded	O	1653-1662
that	O	1663-1667
the	O	1668-1671
pharmacological	O	1672-1687
process	O	1688-1695
underlying	O	1696-1706
this	O	1707-1711
phenomenon	O	1712-1722
was	O	1723-1726
localised	O	1727-1736
in	O	1737-1739
the	O	1740-1743
periphery	O	1744-1753
.	O	1753-1754

By	O	1755-1757
means	O	1758-1763
of	O	1764-1766
the	O	1767-1770
simultaneous	O	1771-1783
recording	O	1784-1793
of	O	1794-1796
interrelated	O	1797-1809
peripheral	O	1810-1820
and	O	1821-1824
central	O	1825-1832
electrophysiologic	O	1833-1851
correlates	O	1852-1862
of	O	1863-1865
nociception	O	1866-1877
,	O	1877-1878
it	O	1879-1881
was	O	1882-1885
possible	O	1886-1894
to	O	1895-1897
separate	O	1898-1906
central	O	1907-1914
and	O	1915-1918
peripheral	O	1919-1929
effects	O	1930-1937
of	O	1938-1940
an	O	1941-1943
NSAID	O	1944-1949
.	O	1949-1950

The	O	1951-1954
major	O	1955-1960
advantage	O	1961-1970
of	O	1971-1973
this	O	1974-1978
pain	B	1979-1983
model	O	1984-1989
is	O	1990-1992
the	O	1993-1996
possibility	O	1997-2008
of	O	2009-2011
obtaining	O	2012-2021
peripheral	O	2022-2032
pain	B	2033-2037
-	O	2037-2038
related	O	2038-2045
activity	O	2046-2054
directly	O	2055-2063
using	O	2064-2069
a	O	2070-2071
non	O	2072-2075
-	O	2075-2076
invasive	O	2076-2084
technique	O	2085-2094
in	O	2095-2097
humans	O	2098-2104
.	O	2104-2105

Acute	O	0-5
severe	O	6-12
depression	B	13-23
following	O	24-33
peri	O	34-38
-	O	38-39
operative	O	39-48
ondansetron	O	49-60
.	O	60-61

A	O	62-63
41	O	64-66
-	O	66-67
year	O	67-71
-	O	66-67
old	O	72-75
woman	O	76-81
with	O	82-86
a	O	87-88
strong	O	89-95
history	O	96-103
of	O	104-106
postoperative	B	107-120
nausea	I	121-127
and	I	128-131
vomiting	I	132-140
presented	O	141-150
for	O	151-154
abdominal	O	155-164
hysterectomy	O	165-177
3	O	178-179
months	O	180-186
after	O	187-192
a	O	193-194
previous	O	195-203
anaesthetic	O	204-215
where	O	216-221
ondansetron	O	222-233
prophylaxis	O	234-245
had	O	246-249
been	O	250-254
used	O	255-259
.	O	259-260

She	O	261-264
had	O	265-268
developed	O	269-278
a	O	279-280
severe	O	281-287
acute	O	288-293
major	B	294-299
depression	I	300-310
disorder	I	311-319
almost	O	320-326
immediately	O	327-338
thereafter	O	339-349
,	O	349-350
possibly	O	351-359
related	O	360-367
to	O	368-370
the	O	371-374
use	O	375-378
of	O	379-381
a	O	382-383
serotonin	O	384-393
antagonist	O	394-404
.	O	404-405

Nine	O	406-410
years	O	411-416
before	O	417-423
she	O	424-427
had	O	428-431
experienced	O	432-443
a	O	444-445
self	O	446-450
-	O	450-451
limited	O	451-458
puerperal	O	459-468
depressive	B	469-479
episode	I	480-487
.	O	487-488

Anaesthesia	O	489-500
with	O	501-505
a	O	506-507
propofol	O	508-516
infusion	O	517-525
and	O	526-529
avoidance	O	530-539
of	O	540-542
serotonin	O	543-552
antagonists	O	553-564
provided	O	565-573
a	O	574-575
nausea	B	576-582
-	O	582-583
free	O	583-587
postoperative	O	588-601
course	O	602-608
without	O	609-616
exacerbation	O	617-629
of	O	630-632
the	O	633-636
depression	B	637-647
disorder	I	648-656
.	O	656-657

Hypertensive	B	0-12
response	O	13-21
during	O	22-28
dobutamine	O	29-39
stress	O	40-46
echocardiography	O	47-63
.	O	63-64

Among	O	65-70
3	O	71-72
,	O	72-73
129	O	73-76
dobutamine	O	77-87
stress	O	88-94
echocardiographic	O	95-112
studies	O	113-120
,	O	120-121
a	O	122-123
hypertensive	B	124-136
response	O	137-145
,	O	145-146
defined	O	147-154
as	O	155-157
systolic	O	158-166
blood	O	167-172
pressure	O	173-181
(	O	182-183
BP	O	183-185
)	O	185-186
>	O	187-188
or	O	189-191
=	O	192-193
220	O	194-197
mm	O	198-200
Hg	O	201-203
and	O	204-207
/	O	207-208
or	O	208-210
diastolic	O	211-220
BP	O	221-223
>	O	224-225
or	O	226-228
=	O	229-230
110	O	231-234
mm	O	235-237
Hg	O	238-240
,	O	240-241
occurred	O	242-250
in	O	251-253
30	O	254-256
patients	O	257-265
(	O	266-267
1	O	267-268
%	O	268-269
)	O	269-270
.	O	270-271

Patients	O	272-280
with	O	281-285
this	O	286-290
response	O	291-299
more	O	300-304
often	O	305-310
had	O	311-314
a	O	315-316
history	O	317-324
of	O	325-327
hypertension	B	328-340
and	O	341-344
had	O	345-348
higher	O	349-355
resting	O	356-363
systolic	O	364-372
and	O	373-376
diastolic	O	377-386
BP	O	387-389
before	O	390-396
dobutamine	O	397-407
infusion	O	408-416
.	O	416-417

Continuously	O	0-12
nebulized	O	13-22
albuterol	O	23-32
in	O	33-35
severe	O	36-42
exacerbations	O	43-56
of	O	57-59
asthma	B	60-66
in	O	67-69
adults	O	70-76
:	O	76-77
a	O	78-79
case	O	80-84
-	O	84-85
controlled	O	85-95
study	O	96-101
.	O	101-102

A	O	103-104
retrospective	O	105-118
,	O	118-119
case	O	120-124
-	O	124-125
controlled	O	125-135
analysis	O	136-144
comparing	O	145-154
patients	O	155-163
admitted	O	164-172
to	O	173-175
a	O	176-177
medical	O	178-185
intensive	O	186-195
care	O	196-200
unit	O	201-205
with	O	206-210
severe	O	211-217
exacerbations	O	218-231
of	O	232-234
asthma	B	235-241
who	O	242-245
received	O	246-254
continuously	O	255-267
nebulized	O	268-277
albuterol	O	278-287
(	O	288-289
CNA	O	289-292
)	O	292-293
versus	O	294-300
intermittent	O	301-313
albuterol	O	314-323
(	O	324-325
INA	O	325-328
)	O	328-329
treatments	O	330-340
is	O	341-343
reported	O	344-352
.	O	352-353

Forty	O	354-359
matched	O	360-367
pairs	O	368-373
of	O	374-376
patients	O	377-385
with	O	386-390
asthma	B	391-397
are	O	398-401
compared	O	402-410
.	O	410-411

CNA	O	412-415
was	O	416-419
administered	O	420-432
for	O	433-436
a	O	437-438
mean	O	439-443
of	O	444-446
11	O	447-449
+	O	450-451
/	O	451-452
-	O	452-453
10	O	454-456
hr	O	457-459
.	O	459-460

The	O	461-464
incidence	O	465-474
of	O	475-477
cardiac	B	478-485
dysrhythmias	I	486-498
was	O	499-502
similar	O	503-510
between	O	511-518
groups	O	519-525
.	O	525-526

Symptomatic	O	527-538
hypokalemia	B	539-550
did	O	551-554
not	O	555-558
occur	O	559-564
.	O	564-565

CNA	O	566-569
patients	O	570-578
had	O	579-582
higher	O	583-589
heart	O	590-595
rates	O	596-601
during	O	602-608
treatment	O	609-618
,	O	618-619
which	O	620-625
may	O	626-629
reflect	O	630-637
severity	O	638-646
of	O	647-649
illness	O	650-657
.	O	657-658

The	O	659-662
incidence	O	663-672
of	O	673-675
intubation	O	676-686
was	O	687-690
similar	O	691-698
.	O	698-699

We	O	700-702
conclude	O	703-711
that	O	712-716
CNA	O	717-720
and	O	721-724
INA	O	725-728
demonstrated	O	729-741
similar	O	742-749
profiles	O	750-758
with	O	759-763
regard	O	764-770
to	O	771-773
safety	O	774-780
,	O	780-781
morbidity	O	782-791
,	O	791-792
and	O	793-796
mortality	O	797-806
.	O	806-807

Hyperosmolar	B	0-12
nonketotic	I	13-23
coma	I	24-28
precipitated	O	29-41
by	O	42-44
lithium	O	45-52
-	O	52-53
induced	O	53-60
nephrogenic	B	61-72
diabetes	I	73-81
insipidus	I	82-91
.	O	91-92

A	O	93-94
45	O	95-97
-	O	97-98
year	O	98-102
-	O	97-98
old	O	103-106
man	O	107-110
,	O	110-111
with	O	112-116
a	O	117-118
10	O	119-121
-	O	121-122
year	O	122-126
history	O	127-134
of	O	135-137
manic	B	138-143
depression	I	144-154
treated	O	155-162
with	O	163-167
lithium	O	168-175
,	O	175-176
was	O	177-180
admitted	O	181-189
with	O	190-194
hyperosmolar	B	195-207
,	I	207-208
nonketotic	I	209-219
coma	I	220-224
.	O	224-225

He	O	226-228
gave	O	229-233
a	O	234-235
five	O	236-240
-	O	240-241
year	O	241-245
history	O	246-253
of	O	254-256
polyuria	B	257-265
and	O	266-269
polydipsia	B	270-280
,	O	280-281
during	O	282-288
which	O	289-294
time	O	295-299
urinalysis	O	300-310
had	O	311-314
been	O	315-319
negative	O	320-328
for	O	329-332
glucose	O	333-340
.	O	340-341

After	O	342-347
recovery	O	348-356
from	O	357-361
hyperglycaemia	B	362-376
,	O	376-377
he	O	378-380
remained	O	381-389
polyuric	B	390-398
despite	O	399-406
normal	O	407-413
blood	O	414-419
glucose	O	420-427
concentrations	O	428-442
;	O	442-443
water	O	444-449
deprivation	O	450-461
testing	O	462-469
indicated	O	470-479
nephrogenic	B	480-491
diabetes	I	492-500
insipidus	I	501-510
,	O	510-511
likely	O	512-518
to	O	519-521
be	O	522-524
lithium	O	525-532
-	O	532-533
induced	O	533-540
.	O	540-541

We	O	542-544
hypothesize	O	545-556
that	O	557-561
when	O	562-566
this	O	567-571
man	O	572-575
developed	O	576-585
type	B	586-590
2	I	591-592
diabetes	I	593-601
,	O	601-602
chronic	O	603-610
polyuria	B	611-619
due	O	620-623
to	O	624-626
nephrogenic	B	627-638
diabetes	I	639-647
insipidus	I	648-657
was	O	658-661
sufficient	O	662-672
to	O	673-675
precipitate	O	676-687
hyperosmolar	O	688-700
dehydration	B	701-712
.	O	712-713

Effects	O	0-7
of	O	8-10
the	O	11-14
intracoronary	O	15-28
infusion	O	29-37
of	O	38-40
cocaine	O	41-48
on	O	49-51
left	O	52-56
ventricular	O	57-68
systolic	O	69-77
and	O	78-81
diastolic	O	82-91
function	O	92-100
in	O	101-103
humans	O	104-110
.	O	110-111

BACKGROUND	O	112-122
:	O	122-123
In	O	124-126
dogs	O	127-131
,	O	131-132
a	O	133-134
large	O	135-140
amount	O	141-147
of	O	148-150
intravenous	O	151-162
cocaine	O	163-170
causes	O	171-177
a	O	178-179
profound	O	180-188
deterioration	B	189-202
of	I	203-205
left	I	206-210
ventricular	I	211-222
(	I	223-224
LV	I	224-226
)	I	226-227
systolic	I	228-236
function	I	237-245
and	O	246-249
an	O	250-252
increase	O	253-261
in	O	262-264
LV	O	265-267
end	O	268-271
-	O	271-272
diastolic	O	272-281
pressure	O	282-290
.	O	290-291

This	O	292-296
study	O	297-302
was	O	303-306
done	O	307-311
to	O	312-314
assess	O	315-321
the	O	322-325
influence	O	326-335
of	O	336-338
a	O	339-340
high	O	341-345
intracoronary	O	346-359
cocaine	O	360-367
concentration	O	368-381
on	O	382-384
LV	O	385-387
systolic	O	388-396
and	O	397-400
diastolic	O	401-410
function	O	411-419
in	O	420-422
humans	O	423-429
.	O	429-430

METHODS	O	431-438
AND	O	439-442
RESULTS	O	443-450
:	O	450-451
In	O	452-454
20	O	455-457
patients	O	458-466
(	O	467-468
14	O	468-470
men	O	471-474
and	O	475-478
6	O	479-480
women	O	481-486
aged	O	487-491
39	O	492-494
to	O	495-497
72	O	498-500
years	O	501-506
)	O	506-507
referred	O	508-516
for	O	517-520
cardiac	O	521-528
catheterization	O	529-544
for	O	545-548
the	O	549-552
evaluation	O	553-563
of	O	564-566
chest	B	567-572
pain	I	573-577
,	O	577-578
we	O	579-581
measured	O	582-590
heart	O	591-596
rate	O	597-601
,	O	601-602
systemic	O	603-611
arterial	O	612-620
pressure	O	621-629
,	O	629-630
LV	O	631-633
pressure	O	634-642
and	O	643-646
its	O	647-650
first	O	651-656
derivative	O	657-667
(	O	668-669
dP	O	669-671
/	O	671-672
dt	O	672-674
)	O	674-675
,	O	675-676
and	O	677-680
LV	O	681-683
volumes	O	684-691
and	O	692-695
ejection	O	696-704
fraction	O	705-713
before	O	714-720
and	O	721-724
during	O	725-731
the	O	732-735
final	O	736-741
2	O	742-743
to	O	744-746
3	O	747-748
minutes	O	749-756
of	O	757-759
a	O	760-761
15	O	762-764
-	O	764-765
minute	O	765-771
intracoronary	O	772-785
infusion	O	786-794
of	O	795-797
saline	O	798-804
(	O	805-806
n	O	806-807
=	O	807-808
10	O	808-810
,	O	810-811
control	O	812-819
subjects	O	820-828
)	O	828-829
or	O	830-832
cocaine	O	833-840
hydrochloride	O	841-854
1	O	855-856
mg	O	857-859
/	O	859-860
min	O	860-863
(	O	864-865
n	O	865-866
=	O	866-867
10	O	867-869
)	O	869-870
.	O	870-871

No	O	872-874
variable	O	875-883
changed	O	884-891
with	O	892-896
saline	O	897-903
.	O	903-904

With	O	905-909
cocaine	O	910-917
,	O	917-918
the	O	919-922
drug	O	923-927
concentration	O	928-941
in	O	942-944
blood	O	945-950
obtained	O	951-959
from	O	960-964
the	O	965-968
coronary	O	969-977
sinus	O	978-983
was	O	984-987
3	O	988-989
.	O	989-990
0	O	990-991
+	O	991-992
/	O	992-993
-	O	993-994
0	O	990-991
.	O	989-990
4	O	996-997

(	O	998-999
mean	O	999-1003
+	O	1003-1004
/	O	1004-1005
-	O	1005-1006
SD	O	1006-1008
)	O	1008-1009
mg	O	1010-1012
/	O	1012-1013
L	O	1013-1014
,	O	1014-1015
similar	O	1016-1023
in	O	1024-1026
magnitude	O	1027-1036
to	O	1037-1039
the	O	1040-1043
blood	O	1044-1049
cocaine	O	1050-1057
concentration	O	1058-1071
reported	O	1072-1080
in	O	1081-1083
abusers	O	1084-1091
dying	O	1092-1097
of	O	1098-1100
cocaine	O	1101-1108
intoxication	O	1109-1121
.	O	1121-1122

Cocaine	O	1123-1130
induced	O	1131-1138
no	O	1139-1141
significant	O	1142-1153
change	O	1154-1160
in	O	1161-1163
heart	O	1164-1169
rate	O	1170-1174
,	O	1174-1175
LV	O	1176-1178
dP	O	1179-1181
/	O	1181-1182
dt	O	1182-1184
(	O	1185-1186
positive	O	1186-1194
or	O	1195-1197
negative	O	1198-1206
)	O	1206-1207
,	O	1207-1208
or	O	1209-1211
LV	O	1212-1214
end	O	1215-1218
-	O	1218-1219
diastolic	O	1219-1228
volume	O	1229-1235
,	O	1235-1236
but	O	1237-1240
it	O	1241-1243
caused	O	1244-1250
an	O	1251-1253
increase	O	1254-1262
in	O	1263-1265
systolic	O	1266-1274
and	O	1275-1278
mean	O	1279-1283
arterial	O	1284-1292
pressures	O	1293-1302
,	O	1302-1303
LV	O	1304-1306
end	O	1307-1310
-	O	1310-1311
diastolic	O	1311-1320
pressure	O	1321-1329
,	O	1329-1330
and	O	1331-1334
LV	O	1335-1337
end	O	1338-1341
-	O	1341-1342
systolic	O	1342-1350
volume	O	1351-1357
,	O	1357-1358
as	O	1359-1361
well	O	1362-1366
as	O	1367-1369
a	O	1370-1371
decrease	O	1372-1380
in	O	1381-1383
LV	O	1384-1386
ejection	O	1387-1395
fraction	O	1396-1404
.	O	1404-1405

CONCLUSIONS	O	1406-1417
:	O	1417-1418
In	O	1419-1421
humans	O	1422-1428
,	O	1428-1429
the	O	1430-1433
intracoronary	O	1434-1447
infusion	O	1448-1456
of	O	1457-1459
cocaine	O	1460-1467
sufficient	O	1468-1478
in	O	1479-1481
amount	O	1482-1488
to	O	1489-1491
achieve	O	1492-1499
a	O	1500-1501
high	O	1502-1506
drug	O	1507-1511
concentration	O	1512-1525
in	O	1526-1528
coronary	O	1529-1537
sinus	O	1538-1543
blood	O	1544-1549
causes	O	1550-1556
a	O	1557-1558
deterioration	B	1559-1572
of	I	1573-1575
LV	I	1576-1578
systolic	I	1579-1587
and	I	1588-1591
diastolic	I	1592-1601
performance	I	1602-1613
.	O	1613-1614

Heparin	O	0-7
-	O	7-8
induced	O	8-15
thrombocytopenia	B	16-32
,	O	32-33
paradoxical	O	34-45
thromboembolism	B	46-61
,	O	61-62
and	O	63-66
other	O	67-72
side	O	73-77
effects	O	78-85
of	O	86-88
heparin	O	89-96
therapy	O	97-104
.	O	104-105

Although	O	106-114
several	O	115-122
new	O	123-126
anticoagulant	O	127-140
drugs	O	141-146
are	O	147-150
in	O	151-153
development	O	154-165
,	O	165-166
heparin	O	167-174
remains	O	175-182
the	O	183-186
drug	O	187-191
of	O	192-194
choice	O	195-201
for	O	202-205
most	O	206-210
anticoagulation	O	211-226
needs	O	227-232
.	O	232-233

The	O	234-237
clinical	O	238-246
effects	O	247-254
of	O	255-257
heparin	O	258-265
are	O	266-269
meritorious	O	270-281
,	O	281-282
but	O	283-286
side	O	287-291
effects	O	292-299
do	O	300-302
exist	O	303-308
.	O	308-309

Important	O	310-319
untoward	O	320-328
effects	O	329-336
of	O	337-339
heparin	O	340-347
therapy	O	348-355
including	O	356-365
heparin	O	366-373
-	O	373-374
induced	O	374-381
thrombocytopenia	B	382-398
,	O	398-399
heparin	O	400-407
-	O	407-408
associated	O	408-418
osteoporosis	B	419-431
,	O	431-432
eosinophilia	B	433-445
,	O	445-446
skin	B	447-451
reactions	I	452-461
,	O	461-462
allergic	B	463-471
reactions	I	472-481
other	O	482-487
than	O	488-492
thrombocytopenia	B	493-509
and	O	510-513
alopecia	B	514-522
will	O	523-527
be	O	528-530
discussed	O	531-540
in	O	541-543
this	O	544-548
article	O	549-556
.	O	556-557

Nonopaque	O	0-9
crystal	O	10-17
deposition	O	18-28
causing	O	29-36
ureteric	B	37-45
obstruction	I	46-57
in	O	58-60
patients	O	61-69
with	O	70-74
HIV	O	75-78
undergoing	O	79-89
indinavir	O	90-99
therapy	O	100-107
.	O	107-108

OBJECTIVE	O	109-118
:	O	118-119
We	O	120-122
describe	O	123-131
the	O	132-135
unique	O	136-142
CT	O	143-145
features	O	146-154
of	O	155-157
ureteric	B	158-166
calculi	I	167-174
in	O	175-177
six	O	178-181
HIV	B	182-185
-	I	185-186
infected	I	186-194
patients	O	195-203
receiving	O	204-213
indinavir	O	214-223
,	O	223-224
the	O	225-228
most	O	229-233
commonly	O	234-242
used	O	243-247
HIV	O	248-251
protease	O	252-260
inhibitor	O	261-270
,	O	270-271
which	O	272-277
is	O	278-280
associated	O	281-291
with	O	292-296
an	O	297-299
increased	O	300-309
incidence	O	310-319
of	O	320-322
urolithiasis	B	323-335
.	O	335-336

CONCLUSION	O	337-347
:	O	347-348
Ureteric	B	349-357
obstruction	I	358-369
caused	O	370-376
by	O	377-379
precipitated	O	380-392
indinavir	O	393-402
crystals	O	403-411
may	O	412-415
be	O	416-418
difficult	O	419-428
to	O	429-431
diagnose	O	432-440
with	O	441-445
unenhanced	O	446-456
CT	O	457-459
.	O	459-460

The	O	461-464
calculi	O	465-472
are	O	473-476
not	O	477-480
opaque	O	481-487
,	O	487-488
and	O	489-492
secondary	O	493-502
signs	O	503-508
of	O	509-511
obstruction	O	512-523
may	O	524-527
be	O	528-530
absent	O	531-537
or	O	538-540
minimal	O	541-548
and	O	549-552
should	O	553-559
be	O	560-562
sought	O	563-569
carefully	O	570-579
.	O	579-580

Images	O	581-587
may	O	588-591
need	O	592-596
to	O	597-599
be	O	600-602
obtained	O	603-611
using	O	612-617
i	O	618-619
.	O	619-620
v	O	620-621
.	O	619-620

contrast	O	623-631
material	O	632-640
to	O	641-643
enable	O	644-650
diagnosis	O	651-660
of	O	661-663
ureteric	B	664-672
stones	I	673-679
or	I	680-682
obstruction	I	683-694
in	O	695-697
patients	O	698-706
with	O	707-711
HIV	B	712-715
infection	I	716-725
who	O	726-729
receive	O	730-737
indinavir	O	738-747
therapy	O	748-755
.	O	755-756

Ischemic	B	0-8
colitis	I	9-16
and	O	17-20
sumatriptan	O	21-32
use	O	33-36
.	O	36-37

Sumatriptan	O	38-49
succinate	O	50-59
,	O	59-60
a	O	61-62
serotonin	O	63-72
-	O	72-73
1	O	73-74
(	O	75-76
5	O	76-77
-	O	77-78
hydroxytryptamine	O	78-95
-	O	77-78
1	O	96-97
)	O	97-98
receptor	O	99-107
agonist	O	108-115
,	O	115-116
is	O	117-119
an	O	120-122
antimigraine	O	123-135
drug	O	136-140
that	O	141-145
is	O	146-148
reported	O	149-157
to	O	158-160
act	O	161-164
by	O	165-167
selectively	O	168-179
constricting	O	180-192
intracranial	O	193-205
arteries	O	206-214
.	O	214-215

Recently	O	216-224
,	O	224-225
vasopressor	O	226-237
responses	O	238-247
that	O	248-252
are	O	253-256
distinct	O	257-265
from	O	266-270
the	O	271-274
cranial	O	275-282
circulation	O	283-294
have	O	295-299
been	O	300-304
demonstrated	O	305-317
to	O	318-320
occur	O	321-326
in	O	327-329
the	O	330-333
systemic	O	334-342
,	O	342-343
pulmonary	O	344-353
,	O	353-354
and	O	355-358
coronary	O	359-367
circulations	O	368-380
.	O	380-381

Cases	O	382-387
have	O	388-392
been	O	393-397
published	O	398-407
of	O	408-410
coronary	B	411-419
vasospasm	I	420-429
,	O	429-430
myocardial	B	431-441
ischemia	I	442-450
,	O	450-451
and	O	452-455
myocardial	B	456-466
infarction	I	467-477
occurring	O	478-487
after	O	488-493
sumatriptan	O	494-505
use	O	506-509
.	O	509-510

We	O	511-513
report	O	514-520
on	O	521-523
the	O	524-527
development	O	528-539
of	O	540-542
8	O	543-544
serious	O	545-552
cases	O	553-558
of	O	559-561
ischemic	B	562-570
colitis	I	571-578
in	O	579-581
patients	O	582-590
with	O	591-595
migraine	B	596-604
treated	O	605-612
with	O	613-617
sumatriptan	O	618-629
.	O	629-630

Pallidotomy	O	0-11
with	O	12-16
the	O	17-20
gamma	O	21-26
knife	O	27-32
:	O	32-33
a	O	34-35
positive	O	36-44
experience	O	45-55
.	O	55-56

51	O	57-59
patients	O	60-68
with	O	69-73
medically	O	74-83
refractory	O	84-94
Parkinson	B	95-104
'	I	104-105
s	I	101-102
disease	I	107-114
underwent	O	115-124
stereotactic	O	125-137
posteromedial	O	138-151
pallidotomy	O	152-163
between	O	164-171
August	O	172-178
1993	O	179-183
and	O	184-187
February	O	188-196
1997	O	197-201
for	O	202-205
treatment	O	206-215
of	O	216-218
bradykinesia	B	219-231
,	O	231-232
rigidity	B	233-241
,	O	241-242
and	O	243-246
L	O	247-248
-	O	248-249
DOPA	O	249-253
-	O	248-249
induced	O	254-261
dyskinesias	B	262-273
.	O	273-274

In	O	275-277
29	O	278-280
patients	O	281-289
,	O	289-290
the	O	291-294
pallidotomies	O	295-308
were	O	309-313
performed	O	314-323
with	O	324-328
the	O	329-332
Leksell	O	333-340
Gamma	O	341-346
Knife	O	347-352
and	O	353-356
in	O	357-359
22	O	360-362
they	O	363-367
were	O	368-372
performed	O	373-382
with	O	383-387
the	O	388-391
standard	O	392-400
radiofrequency	O	401-415
(	O	416-417
RF	O	417-419
)	O	419-420
method	O	421-427
.	O	427-428

Clinical	O	429-437
assessment	O	438-448
as	O	449-451
well	O	452-456
as	O	457-459
blinded	O	460-467
ratings	O	468-475
of	O	476-478
Unified	O	479-486
Parkinson	B	487-496
'	I	496-497
s	I	493-494
Disease	I	499-506
Rating	O	507-513
Scale	O	514-519
(	O	520-521
UPDRS	O	521-526
)	O	526-527
scores	O	528-534
were	O	535-539
carried	O	540-547
out	O	548-551
pre	O	552-555
-	O	555-556
and	O	557-560
postoperatively	O	561-576
.	O	576-577

Mean	O	578-582
follow	O	583-589
-	O	589-590
up	O	590-592
time	O	593-597
is	O	598-600
20	O	601-603
.	O	603-604
6	O	604-605
months	O	606-612
(	O	613-614
range	O	614-619
6	O	620-621
-	O	621-622
48	O	622-624
)	O	624-625
and	O	626-629
all	O	630-633
except	O	634-640
4	O	641-642
patients	O	643-651
have	O	652-656
been	O	657-661
followed	O	662-670
more	O	671-675
than	O	676-680
one	O	681-684
year	O	685-689
.	O	689-690

85	O	691-693
percent	O	694-701
of	O	702-704
patients	O	705-713
with	O	714-718
dyskinesias	B	719-730
were	O	731-735
relieved	O	736-744
of	O	745-747
symptoms	O	748-756
,	O	756-757
regardless	O	758-768
of	O	769-771
whether	O	772-779
the	O	780-783
pallidotomies	O	784-797
were	O	798-802
performed	O	803-812
with	O	813-817
the	O	818-821
Gamma	O	822-827
Knife	O	828-833
or	O	834-836
radiofrequency	O	837-851
methods	O	852-859
.	O	859-860

About	O	861-866
2	O	867-868
/	O	868-869
3	O	869-870
of	O	871-873
the	O	874-877
patients	O	878-886
in	O	887-889
both	O	890-894
Gamma	O	895-900
Knife	O	901-906
and	O	907-910
radiofrequency	O	911-925
groups	O	926-932
showed	O	933-939
improvements	O	940-952
in	O	953-955
bradykinesia	B	956-968
and	O	969-972
rigidity	B	973-981
,	O	981-982
although	O	983-991
when	O	992-996
considered	O	997-1007
as	O	1008-1010
a	O	1011-1012
group	O	1013-1018
neither	O	1019-1026
the	O	1027-1030
Gamma	O	1031-1036
Knife	O	1037-1042
nor	O	1043-1046
the	O	1047-1050
radiofrequency	O	1051-1065
group	O	1066-1071
showed	O	1072-1078
statistically	O	1079-1092
significant	O	1093-1104
improvements	O	1105-1117
in	O	1118-1120
UPDRS	O	1121-1126
scores	O	1127-1133
.	O	1133-1134

One	O	1135-1138
patient	O	1139-1146
in	O	1147-1149
the	O	1150-1153
Gamma	O	1154-1159
Knife	O	1160-1165
group	O	1166-1171
(	O	1172-1173
3	O	1173-1174
.	O	1174-1175
4	O	1175-1176
%	O	1176-1177
)	O	1177-1178
developed	O	1179-1188
a	O	1189-1190
homonymous	B	1191-1201
hemianopsia	I	1202-1213
9	O	1214-1215
months	O	1216-1222
following	O	1223-1232
treatment	O	1233-1242
and	O	1243-1246
5	O	1247-1248
patients	O	1249-1257
(	O	1258-1259
27	O	1259-1261
.	O	1261-1262
7	O	1260-1261
%	O	1263-1264
)	O	1264-1265
in	O	1266-1268
the	O	1269-1272
radiofrequency	O	1273-1287
group	O	1288-1293
became	O	1294-1300
transiently	O	1301-1312
confused	O	1313-1321
postoperatively	O	1322-1337
.	O	1337-1338

No	O	1339-1341
other	O	1342-1347
complications	O	1348-1361
were	O	1362-1366
seen	O	1367-1371
.	O	1371-1372

Gamma	O	1373-1378
Knife	O	1379-1384
pallidotomy	O	1385-1396
is	O	1397-1399
as	O	1400-1402
effective	O	1403-1412
as	O	1413-1415
radiofrequency	O	1416-1430
pallidotomy	O	1431-1442
in	O	1443-1445
controlling	O	1446-1457
certain	O	1458-1465
of	O	1466-1468
the	O	1469-1472
symptoms	O	1473-1481
of	O	1482-1484
Parkinson	B	1485-1494
'	I	1494-1495
s	I	1491-1492
disease	I	1497-1504
.	O	1504-1505

It	O	1506-1508
may	O	1509-1512
be	O	1513-1515
the	O	1516-1519
only	O	1520-1524
practical	O	1525-1534
technique	O	1535-1544
available	O	1545-1554
in	O	1555-1557
certain	O	1558-1565
patients	O	1566-1574
,	O	1574-1575
such	O	1576-1580
as	O	1581-1583
those	O	1584-1589
who	O	1590-1593
take	O	1594-1598
anticoagulants	O	1599-1613
,	O	1613-1614
have	O	1615-1619
bleeding	B	1620-1628
diatheses	O	1629-1638
or	O	1639-1641
serious	O	1642-1649
systemic	O	1650-1658
medical	O	1659-1666
illnesses	O	1667-1676
.	O	1676-1677

It	O	1678-1680
is	O	1681-1683
a	O	1684-1685
viable	O	1686-1692
option	O	1693-1699
for	O	1700-1703
other	O	1704-1709
patients	O	1710-1718
as	O	1719-1721
well	O	1722-1726
.	O	1726-1727

Neuroleptic	B	0-11
malignant	I	12-21
syndrome	I	22-30
and	O	31-34
methylphenidate	O	35-50
.	O	50-51

A	O	52-53
1	O	54-55
-	O	55-56
year	O	56-60
-	O	55-56
old	O	61-64
female	O	65-71
presented	O	72-81
with	O	82-86
neuroleptic	B	87-98
malignant	I	99-108
syndrome	I	109-117
probably	O	118-126
caused	O	127-133
by	O	134-136
methylphenidate	O	137-152
.	O	152-153

She	O	154-157
had	O	158-161
defects	O	162-169
in	O	170-172
the	O	173-176
supratentorial	O	177-191
brain	O	192-197
including	O	198-207
the	O	208-211
basal	O	212-217
ganglia	O	218-225
and	O	226-229
the	O	230-233
striatum	O	234-242
(	O	243-244
multicystic	B	244-255
encephalomalacia	I	256-272
)	O	272-273
due	O	274-277
to	O	278-280
severe	O	281-287
perinatal	O	288-297
hypoxic	B	298-305
-	I	305-306
ischemic	I	306-314
encephalopathy	I	315-329
,	O	329-330
which	O	331-336
was	O	337-340
considered	O	341-351
to	O	352-354
be	O	355-357
a	O	358-359
possible	O	360-368
predisposing	O	369-381
factor	O	382-388
causing	O	389-396
neuroleptic	B	397-408
malignant	I	409-418
syndrome	I	419-427
.	O	427-428

A	O	429-430
dopaminergic	O	431-443
blockade	O	444-452
mechanism	O	453-462
generally	O	463-472
is	O	473-475
accepted	O	476-484
as	O	485-487
the	O	488-491
pathogenesis	O	492-504
of	O	505-507
this	O	508-512
syndrome	O	513-521
.	O	521-522

However	O	523-530
,	O	530-531
methylphenidate	O	532-547
is	O	548-550
a	O	551-552
dopamine	O	553-561
agonist	O	562-569
via	O	570-573
the	O	574-577
inhibition	O	578-588
of	O	589-591
uptake	O	592-598
of	O	599-601
dopamine	O	602-610
,	O	610-611
and	O	612-615
therefore	O	616-625
dopaminergic	O	626-638
systems	O	639-646
in	O	647-649
the	O	650-653
brainstem	O	654-663
(	O	664-665
mainly	O	665-671
the	O	672-675
midbrain	O	676-684
)	O	684-685
and	O	686-689
the	O	690-693
spinal	O	694-700
cord	O	701-705
were	O	706-710
unlikely	O	711-719
to	O	720-722
participate	O	723-734
in	O	735-737
the	O	738-741
onset	O	742-747
of	O	748-750
this	O	751-755
syndrome	O	756-764
.	O	764-765

A	O	766-767
relative	O	768-776
gamma	O	777-782
-	O	782-783
aminobutyric	O	783-795
acid	O	796-800
-	O	800-801
ergic	O	801-806
deficiency	O	807-817
might	O	818-823
occur	O	824-829
because	O	830-837
diazepam	O	838-846
,	O	846-847
a	O	848-849
gamma	O	850-855
-	O	855-856
aminobutyric	O	856-868
acid	O	869-873
-	O	873-874
mimetic	O	874-881
agent	O	882-887
,	O	887-888
was	O	889-892
strikingly	O	893-903
effective	O	904-913
.	O	913-914

This	O	915-919
is	O	920-922
the	O	923-926
first	O	927-932
reported	O	933-941
patient	O	942-949
with	O	950-954
neuroleptic	B	955-966
malignant	I	967-976
syndrome	I	977-985
probably	O	986-994
caused	O	995-1001
by	O	1002-1004
methylphenidate	O	1005-1020
.	O	1020-1021

Differential	O	0-12
effects	O	13-20
of	O	21-23
17alpha	O	24-31
-	O	31-32
ethinylestradiol	O	32-48
on	O	49-51
the	O	52-55
neutral	O	56-63
and	O	64-67
acidic	O	68-74
pathways	O	75-83
of	O	84-86
bile	O	87-91
salt	O	92-96
synthesis	O	97-106
in	O	107-109
the	O	110-113
rat	O	114-117
.	O	117-118

Effects	O	119-126
of	O	127-129
17alpha	O	130-137
-	O	137-138
ethinylestradiol	O	138-154
(	O	155-156
EE	O	156-158
)	O	158-159
on	O	160-162
the	O	163-166
neutral	O	167-174
and	O	175-178
acidic	O	179-185
biosynthetic	O	186-198
pathways	O	199-207
of	O	208-210
bile	O	211-215
salt	O	216-220
(	O	221-222
BS	O	222-224
)	O	224-225
synthesis	O	226-235
were	O	236-240
evaluated	O	241-250
in	O	251-253
rats	O	254-258
with	O	259-263
an	O	264-266
intact	O	267-273
enterohepatic	O	274-287
circulation	O	288-299
and	O	300-303
in	O	304-306
rats	O	307-311
with	O	312-316
long	O	317-321
-	O	321-322
term	O	322-326
bile	O	327-331
diversion	O	332-341
to	O	342-344
induce	O	345-351
BS	O	352-354
synthesis	O	355-364
.	O	364-365

For	O	366-369
this	O	370-374
purpose	O	375-382
,	O	382-383
bile	O	384-388
salt	O	389-393
pool	O	394-398
composition	O	399-410
,	O	410-411
synthesis	O	412-421
of	O	422-424
individual	O	425-435
BS	O	436-438
in	O	439-441
vivo	O	442-446
,	O	446-447
hepatic	O	448-455
activities	O	456-466
,	O	466-467
and	O	468-471
expression	O	472-482
levels	O	483-489
of	O	490-492
cholesterol	O	493-504
7alpha	O	505-511
-	O	511-512
hydroxylase	O	512-523
(	O	524-525
CYP7A	O	525-530
)	O	530-531
,	O	531-532
and	O	533-536
sterol	O	537-543
27	O	544-546
-	O	546-547
hydroxylase	O	547-558
(	O	559-560
CYP27	O	560-565
)	O	565-566
,	O	566-567
as	O	568-570
well	O	571-575
as	O	576-578
of	O	579-581
other	O	582-587
enzymes	O	588-595
involved	O	596-604
in	O	605-607
BS	O	608-610
synthesis	O	611-620
,	O	620-621
were	O	622-626
analyzed	O	627-635
in	O	636-638
rats	O	639-643
treated	O	644-651
with	O	652-656
EE	O	657-659
(	O	660-661
5	O	661-662
mg	O	663-665
/	O	665-666
kg	O	666-668
,	O	668-669
3	O	670-671
days	O	672-676
)	O	676-677
or	O	678-680
its	O	681-684
vehicle	O	685-692
.	O	692-693

BS	O	694-696
pool	O	697-701
size	O	702-706
was	O	707-710
decreased	O	711-720
by	O	721-723
27	O	724-726
%	O	726-727
but	O	728-731
total	O	732-737
BS	O	738-740
synthesis	O	741-750
was	O	751-754
not	O	755-758
affected	O	759-767
by	O	768-770
EE	O	771-773
in	O	774-776
intact	O	777-783
rats	O	784-788
.	O	788-789

Synthesis	O	790-799
of	O	800-802
cholate	O	803-810
was	O	811-814
reduced	O	815-822
by	O	823-825
68	O	826-828
%	O	828-829
in	O	830-832
EE	O	833-835
-	O	835-836
treated	O	836-843
rats	O	844-848
,	O	848-849
while	O	850-855
that	O	856-860
of	O	861-863
chenodeoxycholate	O	864-881
was	O	882-885
increased	O	886-895
by	O	896-898
60	O	899-901
%	O	901-902
.	O	902-903

The	O	904-907
recently	O	908-916
identified	O	917-927
Delta22	O	928-935
-	O	935-936
isomer	O	936-942
of	O	943-945
beta	O	946-950
-	O	950-951
muricholate	O	951-962
contributed	O	963-974
for	O	975-978
5	O	979-980
.	O	980-981
4	O	981-982
%	O	982-983
and	O	984-987
18	O	988-990
.	O	990-991
3	O	991-992
%	O	993-994
(	O	995-996
P	O	996-997
<	O	998-999
0	O	1000-1001
.	O	1001-1002
01	O	1002-1004
)	O	1004-1005
to	O	1006-1008
the	O	1009-1012
pool	O	1013-1017
in	O	1018-1020
control	O	1021-1028
and	O	1029-1032
EE	O	1033-1035
-	O	1035-1036
treated	O	1036-1043
rats	O	1044-1048
,	O	1048-1049
respectively	O	1050-1062
,	O	1062-1063
but	O	1064-1067
could	O	1068-1073
not	O	1074-1077
be	O	1078-1080
detected	O	1081-1089
in	O	1090-1092
bile	O	1093-1097
after	O	1098-1103
exhaustion	O	1104-1114
of	O	1115-1117
the	O	1118-1121
pool	O	1122-1126
.	O	1126-1127

A	O	1128-1129
clear	O	1130-1135
reduction	O	1136-1145
of	O	1146-1148
BS	O	1149-1151
synthesis	O	1152-1161
was	O	1162-1165
found	O	1166-1171
in	O	1172-1174
bile	O	1175-1179
-	O	1179-1180
diverted	O	1180-1188
rats	O	1189-1193
treated	O	1194-1201
with	O	1202-1206
EE	O	1207-1209
,	O	1209-1210
yet	O	1211-1214
biliary	O	1215-1222
BS	O	1223-1225
composition	O	1226-1237
was	O	1238-1241
only	O	1242-1246
minimally	O	1247-1256
affected	O	1257-1265
.	O	1265-1266

Activity	O	1267-1275
of	O	1276-1278
CYP7A	O	1279-1284
was	O	1285-1288
decreased	O	1289-1298
by	O	1299-1301
EE	O	1302-1304
in	O	1305-1307
both	O	1308-1312
intact	O	1313-1319
and	O	1320-1323
bile	O	1324-1328
-	O	1328-1329
diverted	O	1329-1337
rats	O	1338-1342
,	O	1342-1343
whereas	O	1344-1351
the	O	1352-1355
activity	O	1356-1364
of	O	1365-1367
the	O	1368-1371
CYP27	O	1372-1377
was	O	1378-1381
not	O	1382-1385
affected	O	1386-1394
.	O	1394-1395

Hepatic	O	1396-1403
mRNA	O	1404-1408
levels	O	1409-1415
of	O	1416-1418
CYP7A	O	1419-1424
were	O	1425-1429
significantly	O	1430-1443
reduced	O	1444-1451
by	O	1452-1454
EE	O	1455-1457
in	O	1458-1460
bile	O	1461-1465
-	O	1465-1466
diverted	O	1466-1474
rats	O	1475-1479
only	O	1480-1484
;	O	1484-1485
CYP27	O	1486-1491
mRNA	O	1492-1496
levels	O	1497-1503
were	O	1504-1508
not	O	1509-1512
affected	O	1513-1521
by	O	1522-1524
EE	O	1525-1527
.	O	1527-1528

In	O	1529-1531
addition	O	1532-1540
,	O	1540-1541
mRNA	O	1542-1546
levels	O	1547-1553
of	O	1554-1556
sterol	O	1557-1563
12alpha	O	1564-1571
-	O	1571-1572
hydroxylase	O	1572-1583
and	O	1584-1587
lithocholate	O	1588-1600
6beta	O	1601-1606
-	O	1606-1607
hydroxylase	O	1607-1618
were	O	1619-1623
increased	O	1624-1633
by	O	1634-1636
bile	O	1637-1641
diversion	O	1642-1651
and	O	1652-1655
suppressed	O	1656-1666
by	O	1667-1669
EE	O	1670-1672
.	O	1672-1673

This	O	1674-1678
study	O	1679-1684
shows	O	1685-1690
that	O	1691-1695
17alpha	O	1696-1703
-	O	1703-1704
ethinylestradiol	O	1704-1720
(	O	1721-1722
EE	O	1722-1724
)	O	1724-1725
-	O	1725-1726
induced	O	1726-1733
intrahepatic	B	1734-1746
cholestasis	I	1747-1758
in	O	1759-1761
rats	O	1762-1766
is	O	1767-1769
associated	O	1770-1780
with	O	1781-1785
selective	O	1786-1795
inhibition	O	1796-1806
of	O	1807-1809
the	O	1810-1813
neutral	O	1814-1821
pathway	O	1822-1829
of	O	1830-1832
bile	O	1833-1837
salt	O	1838-1842
(	O	1843-1844
BS	O	1844-1846
)	O	1846-1847
synthesis	O	1848-1857
.	O	1857-1858

Simultaneous	O	1859-1871
impairment	O	1872-1882
of	O	1883-1885
other	O	1886-1891
enzymes	O	1892-1899
in	O	1900-1902
the	O	1903-1906
BS	O	1907-1909
biosynthetic	O	1910-1922
pathways	O	1923-1931
may	O	1932-1935
contribute	O	1936-1946
to	O	1947-1949
overall	O	1950-1957
effects	O	1958-1965
of	O	1966-1968
EE	O	1969-1971
on	O	1972-1974
BS	O	1975-1977
synthesis	O	1978-1987
.	O	1987-1988

Glibenclamide	O	0-13
-	O	13-14
sensitive	O	14-23
hypotension	B	24-35
produced	O	36-44
by	O	45-47
helodermin	O	48-58
assessed	O	59-67
in	O	68-70
the	O	71-74
rat	O	75-78
.	O	78-79

The	O	80-83
effects	O	84-91
of	O	92-94
helodermin	O	95-105
,	O	105-106
a	O	107-108
basic	O	109-114
35	O	115-117
-	O	117-118
amino	O	118-123
acid	O	124-128
peptide	O	129-136
isolated	O	137-145
from	O	146-150
the	O	151-154
venom	O	155-160
of	O	161-163
a	O	164-165
lizard	O	166-172
salivary	O	173-181
gland	O	182-187
,	O	187-188
on	O	189-191
arterial	O	192-200
blood	O	201-206
pressure	O	207-215
and	O	216-219
heart	O	220-225
rate	O	226-230
were	O	231-235
examined	O	236-244
in	O	245-247
the	O	248-251
rat	O	252-255
,	O	255-256
focusing	O	257-265
on	O	266-268
the	O	269-272
possibility	O	273-284
that	O	285-289
activation	O	290-300
of	O	301-303
ATP	O	304-307
sensitive	O	308-317
K	O	318-319
+	O	319-320
(	O	321-322
K	O	322-323
(	O	321-322
ATP	O	324-327
)	O	327-328
)	O	327-328
channels	O	330-338
is	O	339-341
involved	O	342-350
in	O	351-353
the	O	354-357
responses	O	358-367
.	O	367-368

The	O	369-372
results	O	373-380
were	O	381-385
also	O	386-390
compared	O	391-399
with	O	400-404
those	O	405-410
of	O	411-413
vasoactive	O	414-424
intestinal	O	425-435
polypeptide	O	436-447
(	O	448-449
VIP	O	449-452
)	O	452-453
.	O	453-454

Helodermin	O	455-465
produced	O	466-474
hypotension	B	475-486
in	O	487-489
a	O	490-491
dose	O	492-496
-	O	496-497
dependent	O	497-506
manner	O	507-513
with	O	514-518
approximately	O	519-532
similar	O	533-540
potency	O	541-548
and	O	549-552
duration	O	553-561
to	O	562-564
VIP	O	565-568
.	O	568-569

Hypotension	B	570-581
induced	O	582-589
by	O	590-592
both	O	593-597
peptides	O	598-606
was	O	607-610
significantly	O	611-624
attenuated	O	625-635
by	O	636-638
glibenclamide	O	639-652
,	O	652-653
which	O	654-659
abolished	O	660-669
a	O	670-671
levcromakalim	O	672-685
-	O	685-686
produced	O	686-694
decrease	O	695-703
in	O	704-706
arterial	O	707-715
blood	O	716-721
pressure	O	722-730
.	O	730-731

Oxyhemoglobin	O	732-745
did	O	746-749
not	O	750-753
affect	O	754-760
helodermin	O	761-771
-	O	771-772
induced	O	772-779
hypotension	B	780-791
,	O	791-792
whereas	O	793-800
it	O	801-803
shortened	O	804-813
the	O	814-817
duration	O	818-826
of	O	827-829
acetylcholine	O	830-843
(	O	844-845
ACh	O	845-848
)	O	848-849
-	O	849-850
produced	O	850-858
hypotension	B	859-870
.	O	870-871

These	O	872-877
findings	O	878-886
suggest	O	887-894
that	O	895-899
helodermin	O	900-910
-	O	910-911
produced	O	911-919
hypotension	B	920-931
is	O	932-934
partly	O	935-941
attributable	O	942-954
to	O	955-957
the	O	958-961
activation	O	962-972
of	O	973-975
glibenclamide	O	976-989
-	O	989-990
sensitive	O	990-999
K	O	1000-1001
+	O	1001-1002
channels	O	1003-1011
(	O	1012-1013
K	O	1013-1014
(	O	1012-1013
ATP	O	1015-1018
)	O	1018-1019
channels	O	1020-1028
)	O	1028-1029
,	O	1029-1030
which	O	1031-1036
presumably	O	1037-1047
exist	O	1048-1053
on	O	1054-1056
arterial	O	1057-1065
smooth	O	1066-1072
muscle	O	1073-1079
cells	O	1080-1085
.	O	1085-1086

EDRF	O	1087-1091
(	O	1092-1093
endothelium	O	1093-1104
-	O	1104-1105
derived	O	1105-1112
relaxing	O	1113-1121
factor	O	1122-1128
)	O	1128-1129
/	O	1129-1130
nitric	O	1130-1136
oxide	O	1137-1142
does	O	1143-1147
not	O	1148-1151
seem	O	1152-1156
to	O	1157-1159
play	O	1160-1164
an	O	1165-1167
important	O	1168-1177
role	O	1178-1182
in	O	1183-1185
the	O	1186-1189
peptide	O	1190-1197
-	O	1197-1198
produced	O	1198-1206
hypotension	B	1207-1218
.	O	1218-1219

Long	O	0-4
-	O	4-5
term	O	5-9
efficacy	O	10-18
and	O	19-22
adverse	O	23-30
event	O	31-36
of	O	37-39
nifedipine	O	40-50
sustained	O	51-60
-	O	60-61
release	O	61-68
tablets	O	69-76
for	O	77-80
cyclosporin	O	81-92
A	O	93-94
-	O	94-95
induced	O	95-102
hypertension	B	103-115
in	O	116-118
patients	O	119-127
with	O	128-132
psoriasis	B	133-142
.	O	142-143

Thirteen	O	144-152
psoriatic	B	153-162
patients	O	163-171
with	O	172-176
hypertension	B	177-189
during	O	190-196
the	O	197-200
course	O	201-207
of	O	208-210
cyclosporin	O	211-222
A	O	223-224
therapy	O	225-232
were	O	233-237
treated	O	238-245
for	O	246-249
25	O	250-252
months	O	253-259
with	O	260-264
a	O	265-266
calcium	O	267-274
channel	O	275-282
blocker	O	283-290
,	O	290-291
sustained	O	292-301
-	O	301-302
release	O	302-309
nifedipine	O	310-320
,	O	320-321
to	O	322-324
study	O	325-330
the	O	331-334
clinical	O	335-343
antihypertensive	O	344-360
effects	O	361-368
and	O	369-372
adverse	O	373-380
events	O	381-387
during	O	388-394
treatment	O	395-404
with	O	405-409
both	O	410-414
drugs	O	415-420
.	O	420-421

Seven	O	422-427
of	O	428-430
the	O	431-434
13	O	435-437
patients	O	438-446
had	O	447-450
exhibited	O	451-460
a	O	461-462
subclinical	O	463-474
hypertensive	B	475-487
state	O	488-493
before	O	494-500
cyclosporin	O	501-512
A	O	513-514
therapy	O	515-522
.	O	522-523

Both	O	524-528
systolic	O	529-537
and	O	538-541
diastolic	O	542-551
blood	O	552-557
pressures	O	558-567
of	O	568-570
these	O	571-576
13	O	577-579
patients	O	580-588
were	O	589-593
decreased	O	594-603
significantly	O	604-617
after	O	618-623
4	O	624-625
weeks	O	626-631
of	O	632-634
nifedipine	O	635-645
therapy	O	646-653
,	O	653-654
and	O	655-658
blood	O	659-664
pressure	O	665-673
was	O	674-677
maintained	O	678-688
within	O	689-695
the	O	696-699
normal	O	700-706
range	O	707-712
thereafter	O	713-723
for	O	724-727
25	O	728-730
months	O	731-737
.	O	737-738

The	O	739-742
adverse	O	743-750
events	O	751-757
during	O	758-764
combined	O	765-773
therapy	O	774-781
with	O	782-786
cyclosporin	O	787-798
A	O	799-800
and	O	801-804
nifedipine	O	805-815
included	O	816-824
an	O	825-827
increase	O	828-836
in	O	837-839
blood	O	840-845
urea	O	846-850
nitrogen	O	851-859
levels	O	860-866
in	O	867-869
9	O	870-871
of	O	872-874
the	O	875-878
13	O	879-881
patients	O	882-890
and	O	891-894
development	O	895-906
of	O	907-909
gingival	B	910-918
hyperplasia	I	919-930
in	O	931-933
2	O	934-935
of	O	936-938
the	O	939-942
13	O	943-945
patients	O	946-954
.	O	954-955

Our	O	956-959
findings	O	960-968
indicate	O	969-977
that	O	978-982
sustained	O	983-992
-	O	992-993
release	O	993-1000
nifedipine	O	1001-1011
is	O	1012-1014
useful	O	1015-1021
for	O	1022-1025
hypertensive	B	1026-1038
psoriatic	B	1039-1048
patients	O	1049-1057
under	O	1058-1063
long	O	1064-1068
-	O	1068-1069
term	O	1069-1073
treatment	O	1074-1083
with	O	1084-1088
cyclosporin	O	1089-1100
A	O	1101-1102
,	O	1102-1103
but	O	1104-1107
that	O	1108-1112
these	O	1113-1118
patients	O	1119-1127
should	O	1128-1134
be	O	1135-1137
monitored	O	1138-1147
for	O	1148-1151
gingival	B	1152-1160
hyperplasia	I	1161-1172
.	O	1172-1173

Torsade	B	0-7
de	I	8-10
pointes	I	11-18
ventricular	B	19-30
tachycardia	I	31-42
during	O	43-49
low	O	50-53
dose	O	54-58
intermittent	O	59-71
dobutamine	O	72-82
treatment	O	83-92
in	O	93-95
a	O	96-97
patient	O	98-105
with	O	106-110
dilated	B	111-118
cardiomyopathy	I	119-133
and	O	134-137
congestive	B	138-148
heart	I	149-154
failure	I	155-162
.	O	162-163

The	O	164-167
authors	O	168-175
describe	O	176-184
the	O	185-188
case	O	189-193
of	O	194-196
a	O	197-198
56	O	199-201
-	O	201-202
year	O	202-206
-	O	201-202
old	O	207-210
woman	O	211-216
with	O	217-221
chronic	O	222-229
,	O	229-230
severe	O	231-237
heart	B	238-243
failure	I	244-251
secondary	O	252-261
to	O	262-264
dilated	B	265-272
cardiomyopathy	I	273-287
and	O	288-291
absence	O	292-299
of	O	300-302
significant	O	303-314
ventricular	B	315-326
arrhythmias	I	327-338
who	O	339-342
developed	O	343-352
QT	B	353-355
prolongation	I	356-368
and	O	369-372
torsade	B	373-380
de	I	381-383
pointes	I	384-391
ventricular	B	392-403
tachycardia	I	404-415
during	O	416-422
one	O	423-426
cycle	O	427-432
of	O	433-435
intermittent	O	436-448
low	O	449-452
dose	O	453-457
(	O	458-459
2	O	459-460
.	O	460-461
5	O	461-462
mcg	O	463-466
/	O	466-467
kg	O	467-469
per	O	470-473
min	O	474-477
)	O	477-478
dobutamine	O	479-489
.	O	489-490

This	O	491-495
report	O	496-502
of	O	503-505
torsade	B	506-513
de	I	514-516
pointes	I	517-524
ventricular	B	525-536
tachycardia	I	537-548
during	O	549-555
intermittent	O	556-568
dobutamine	O	569-579
supports	O	580-588
the	O	589-592
hypothesis	O	593-603
that	O	604-608
unpredictable	O	609-622
fatal	O	623-628
arrhythmias	B	629-640
may	O	641-644
occur	O	645-650
even	O	651-655
with	O	656-660
low	O	661-664
doses	O	665-670
and	O	671-674
in	O	675-677
patients	O	678-686
with	O	687-691
no	O	692-694
history	O	695-702
of	O	703-705
significant	O	706-717
rhythm	O	718-724
disturbances	O	725-737
.	O	737-738

The	O	739-742
mechanisms	O	743-753
of	O	754-756
proarrhythmic	O	757-770
effects	O	771-778
of	O	779-781
Dubutamine	O	782-792
are	O	793-796
discussed	O	797-806
.	O	806-807

Positive	O	0-8
skin	O	9-13
tests	O	14-19
in	O	20-22
late	O	23-27
reactions	O	28-37
to	O	38-40
radiographic	O	41-53
contrast	O	54-62
media	O	63-68
.	O	68-69

In	O	70-72
the	O	73-76
last	O	77-81
few	O	82-85
years	O	86-91
delayed	O	92-99
reactions	O	100-109
several	O	110-117
hours	O	118-123
after	O	124-129
the	O	130-133
injection	O	134-143
of	O	144-146
radiographic	O	147-159
and	O	160-163
contrast	O	164-172
materials	O	173-182
(	O	183-184
PRC	O	184-187
)	O	187-188
have	O	189-193
been	O	194-198
described	O	199-208
with	O	209-213
increasing	O	214-224
frequency	O	225-234
.	O	234-235

The	O	236-239
authors	O	240-247
report	O	248-254
two	O	255-258
observations	O	259-271
on	O	272-274
patients	O	275-283
with	O	284-288
delayed	O	289-296
reactions	O	297-306
in	O	307-309
whom	O	310-314
intradermoreactions	O	315-334
(	O	335-336
IDR	O	336-339
)	O	339-340
and	O	341-344
patch	O	345-350
tests	O	351-356
to	O	357-359
a	O	360-361
series	O	362-368
of	O	369-371
ionic	O	372-377
and	O	378-381
non	O	382-385
ionic	O	386-391
PRC	O	392-395
were	O	396-400
studied	O	401-408
.	O	408-409

After	O	410-415
angiography	O	416-427
by	O	428-430
the	O	431-434
venous	O	435-441
route	O	442-447
in	O	448-450
patient	O	451-458
n	O	459-460
degree	O	461-467
1	O	468-469
a	O	470-471
biphasic	O	472-480
reaction	O	481-489
with	O	490-494
an	O	495-497
immediate	O	498-507
reaction	O	508-516
(	O	517-518
dyspnea	B	518-525
,	O	525-526
loss	B	527-531
of	I	532-534
consciousness	I	535-548
)	O	548-549
and	O	550-553
delayed	O	554-561
macro	B	562-567
-	I	567-568
papular	I	568-575
rash	I	576-580
appeared	O	581-589
,	O	589-590
whilst	O	591-597
patient	O	598-605
n	O	606-607
degree	O	608-614
2	O	615-616
developed	O	617-626
a	O	627-628
generalised	O	629-640
sensation	O	641-650
of	O	651-653
heat	O	654-658
,	O	658-659
persistent	O	660-670
pain	B	671-675
at	O	676-678
the	O	679-682
site	O	683-687
of	O	688-690
injection	O	691-700
immediately	O	701-712
and	O	713-716
a	O	717-718
generalised	O	719-730
macro	O	731-736
-	O	736-737
papular	O	737-744
reaction	O	745-753
after	O	754-759
24	O	760-762
hours	O	763-768
.	O	768-769

The	O	770-773
skin	O	774-778
tests	O	779-784
revealed	O	785-793
positive	O	794-802
delayed	O	803-810
reactions	O	811-820
of	O	821-823
24	O	824-826
hours	O	827-832
and	O	833-836
48	O	837-839
hours	O	840-845
by	O	846-848
IDR	O	849-852
and	O	853-856
patch	O	857-862
tests	O	863-868
to	O	869-871
only	O	872-876
some	O	877-881
PRC	O	882-885
with	O	886-890
common	O	891-897
chains	O	898-904
in	O	905-907
their	O	908-913
structures	O	914-924
.	O	924-925

The	O	926-929
positive	O	930-938
skin	O	939-943
tests	O	944-949
are	O	950-953
in	O	954-956
favour	O	957-963
of	O	964-966
immunological	O	967-980
reactions	O	981-990
and	O	991-994
may	O	995-998
help	O	999-1003
in	O	1004-1006
diagnosis	O	1007-1016
of	O	1017-1019
allergy	B	1020-1027
in	O	1028-1030
the	O	1031-1034
patients	O	1035-1043
.	O	1043-1044

Risk	O	0-4
of	O	5-7
transient	O	8-17
hyperammonemic	B	18-32
encephalopathy	I	33-47
in	O	48-50
cancer	B	51-57
patients	O	58-66
who	O	67-70
received	O	71-79
continuous	O	80-90
infusion	O	91-99
of	O	100-102
5	O	103-104
-	O	104-105
fluorouracil	O	105-117
with	O	118-122
the	O	123-126
complication	O	127-139
of	O	140-142
dehydration	B	143-154
and	O	155-158
infection	B	159-168
.	O	168-169

From	O	170-174
1986	O	175-179
to	O	180-182
1998	O	183-187
,	O	187-188
29	O	189-191
cancer	B	192-198
patients	O	199-207
who	O	208-211
had	O	212-215
32	O	216-218
episodes	O	219-227
of	O	228-230
transient	O	231-240
hyperammonemic	B	241-255
encephalopathy	I	256-270
related	O	271-278
to	O	279-281
continuous	O	282-292
infusion	O	293-301
of	O	302-304
5	O	305-306
-	O	306-307
fluorouracil	O	307-319
(	O	320-321
5	O	321-322
-	O	322-323
FU	O	323-325
)	O	325-326
were	O	327-331
identified	O	332-342
.	O	342-343

None	O	344-348
of	O	349-351
the	O	352-355
patients	O	356-364
had	O	365-368
decompensated	O	369-382
liver	B	383-388
disease	I	389-396
.	O	396-397

Onset	O	398-403
of	O	404-406
hyperammonemic	B	407-421
encephalopathy	I	422-436
varied	O	437-443
from	O	444-448
0	O	449-450
.	O	450-451
5	O	451-452
to	O	453-455
5	O	456-457
days	O	458-462
(	O	463-464
mean	O	464-468
:	O	468-469
2	O	470-471
.	O	471-472
6	O	472-473
+	O	474-475
/	O	475-476
-	O	476-477
1	O	478-479
.	O	479-480
3	O	480-481
days	O	482-486
)	O	486-487
after	O	488-493
the	O	494-497
initiation	O	498-508
of	O	509-511
chemotherapy	O	512-524
.	O	524-525

Plasma	O	526-532
ammonium	O	533-541
level	O	542-547
ranged	O	548-554
from	O	555-559
248	O	560-563
to	O	564-566
2387	O	567-571
microg	O	572-578
%	O	578-579
(	O	580-581
mean	O	581-585
:	O	585-586
626	O	587-590
+	O	591-592
/	O	592-593
-	O	593-594
431	O	595-598
microg	O	599-605
%	O	605-606
)	O	606-607
.	O	607-608

Among	O	609-614
the	O	615-618
32	O	619-621
episodes	O	622-630
,	O	630-631
26	O	632-634
(	O	635-636
81	O	636-638
%	O	638-639
)	O	639-640
had	O	641-644
various	O	645-652
degrees	O	653-660
of	O	661-663
azotemia	B	664-672
,	O	672-673
18	O	674-676
(	O	677-678
56	O	678-680
%	O	680-681
)	O	681-682
occurred	O	683-691
during	O	692-698
bacterial	B	699-708
infections	I	709-719
and	O	720-723
14	O	724-726
(	O	727-728
44	O	728-730
%	O	730-731
)	O	731-732
without	O	733-740
infection	B	741-750
occurred	O	751-759
during	O	760-766
periods	O	767-774
of	O	775-777
dehydration	B	778-789
.	O	789-790

Higher	O	791-797
plasma	O	798-804
ammonium	O	805-813
levels	O	814-820
and	O	821-824
more	O	825-829
rapid	O	830-835
onset	O	836-841
of	O	842-844
hyperammonemia	B	845-859
were	O	860-864
seen	O	865-869
in	O	870-872
18	O	873-875
patients	O	876-884
with	O	885-889
bacterial	B	890-899
infections	I	900-910
(	O	911-912
p	O	912-913
=	O	913-914
0	O	914-915
.	O	915-916
003	O	916-919
and	O	920-923
0	O	924-925
.	O	925-926
0006	O	926-930
,	O	930-931
respectively	O	932-944
)	O	944-945
and	O	946-949
in	O	950-952
nine	O	953-957
patients	O	958-966
receiving	O	967-976
high	O	977-981
daily	O	982-987
doses	O	988-993
(	O	994-995
2600	O	995-999
or	O	1000-1002
1800	O	1003-1007
mg	O	1008-1010
/	O	1010-1011
m2	O	1011-1013
)	O	1013-1014
of	O	1015-1017
5	O	1018-1019
-	O	1019-1020
FU	O	1020-1022
(	O	1023-1024
p	O	1024-1025
=	O	1025-1026
0	O	1026-1027
.	O	1027-1028
0001	O	1028-1032
and	O	1033-1036
<	O	1037-1038
0	O	1039-1040
.	O	1040-1041
0001	O	1041-1045
,	O	1045-1046
respectively	O	1047-1059
)	O	1059-1060
.	O	1060-1061

In	O	1062-1064
25	O	1065-1067
out	O	1068-1071
of	O	1072-1074
32	O	1075-1077
episodes	O	1078-1086
(	O	1087-1088
78	O	1088-1090
%	O	1090-1091
)	O	1091-1092
,	O	1092-1093
plasma	O	1094-1100
ammonium	O	1101-1109
levels	O	1110-1116
and	O	1117-1120
mental	O	1121-1127
status	O	1128-1134
returned	O	1135-1143
to	O	1144-1146
normal	O	1147-1153
within	O	1154-1160
2	O	1161-1162
days	O	1163-1167
after	O	1168-1173
adequate	O	1174-1182
management	O	1183-1193
.	O	1193-1194

In	O	1195-1197
conclusion	O	1198-1208
,	O	1208-1209
hyperammonemic	B	1210-1224
encephalopathy	I	1225-1239
can	O	1240-1243
occur	O	1244-1249
in	O	1250-1252
patients	O	1253-1261
receiving	O	1262-1271
continuous	O	1272-1282
infusion	O	1283-1291
of	O	1292-1294
5	O	1295-1296
-	O	1296-1297
FU	O	1297-1299
.	O	1299-1300

Azotemia	B	1301-1309
,	O	1309-1310
body	O	1311-1315
fluid	O	1316-1321
insufficiency	O	1322-1335
and	O	1336-1339
bacterial	B	1340-1349
infections	I	1350-1360
were	O	1361-1365
frequently	O	1366-1376
found	O	1377-1382
in	O	1383-1385
these	O	1386-1391
patients	O	1392-1400
.	O	1400-1401

It	O	1402-1404
is	O	1405-1407
therefore	O	1408-1417
important	O	1418-1427
to	O	1428-1430
recognize	O	1431-1440
this	O	1441-1445
condition	O	1446-1455
in	O	1456-1458
patients	O	1459-1467
receiving	O	1468-1477
continuous	O	1478-1488
infusion	O	1489-1497
of	O	1498-1500
5	O	1501-1502
-	O	1502-1503
FU	O	1503-1505
.	O	1505-1506

The	O	0-3
effects	O	4-11
of	O	12-14
quinine	O	15-22
and	O	23-26
4	O	27-28
-	O	28-29
aminopyridine	O	29-42
on	O	43-45
conditioned	O	46-57
place	O	58-63
preference	O	64-74
and	O	75-78
changes	O	79-86
in	O	87-89
motor	O	90-95
activity	O	96-104
induced	O	105-112
by	O	113-115
morphine	O	116-124
in	O	125-127
rats	O	128-132
.	O	132-133
1	O	134-135
.	O	135-136

The	O	137-140
effects	O	141-148
of	O	149-151
two	O	152-155
unselective	O	156-167
potassium	O	168-177
(	O	178-179
K	O	179-180
(	O	178-179
+	O	181-182
)	O	182-183
-	O	183-184
)	O	182-183
channel	O	186-193
blockers	O	194-202
,	O	202-203
quinine	O	204-211
(	O	212-213
12	O	213-215
.	O	215-216
5	O	216-217
,	O	217-218
25	O	219-221
and	O	222-225
50	O	226-228
mg	O	229-231
/	O	231-232
kg	O	232-234
)	O	234-235
and	O	236-239
4	O	240-241
-	O	241-242
aminopyridine	O	242-255
(	O	256-257
1	O	257-258
and	O	259-262
2	O	263-264
mg	O	265-267
/	O	267-268
kg	O	268-270
)	O	270-271
,	O	271-272
on	O	273-275
conditioned	O	276-287
place	O	288-293
preference	O	294-304
and	O	305-308
biphasic	O	309-317
changes	O	318-325
in	O	326-328
motor	O	329-334
activity	O	335-343
induced	O	344-351
by	O	352-354
morphine	O	355-363
(	O	364-365
10	O	365-367
mg	O	368-370
/	O	370-371
kg	O	371-373
)	O	373-374
were	O	375-379
tested	O	380-386
in	O	387-389
Wistar	O	390-396
rats	O	397-401
.	O	401-402

Quinine	O	403-410
is	O	411-413
known	O	414-419
to	O	420-422
block	O	423-428
voltage	O	429-436
-	O	436-437
,	O	437-438
calcium	O	439-446
-	O	446-447
and	O	448-451
ATP	O	452-455
-	O	455-456
sensitive	O	456-465
K	O	466-467
(	O	467-468
+	O	468-469
)	O	469-470
-	O	470-471
channels	O	471-479
while	O	480-485
4	O	486-487
-	O	487-488
aminopyridine	O	488-501
is	O	502-504
known	O	505-510
to	O	511-513
block	O	514-519
voltage	O	520-527
-	O	527-528
sensitive	O	528-537
K	O	538-539
(	O	539-540
+	O	540-541
)	O	541-542
-	O	542-543
channels	O	543-551
.	O	551-552
2	O	553-554
.	O	554-555
In	O	556-558
the	O	559-562
counterbalanced	O	563-578
method	O	579-585
,	O	585-586
quinine	O	587-594
attenuated	O	595-605
morphine	O	606-614
-	O	614-615
induced	O	615-622
place	O	623-628
preference	O	629-639
,	O	639-640
whereas	O	641-648
4	O	649-650
-	O	650-651
aminopyridine	O	651-664
was	O	665-668
ineffective	O	669-680
.	O	680-681

In	O	682-684
the	O	685-688
motor	O	689-694
activity	O	695-703
test	O	704-708
measured	O	709-717
with	O	718-722
an	O	723-725
Animex	O	726-732
-	O	732-733
activity	O	733-741
meter	O	742-747
neither	O	748-755
of	O	756-758
the	O	759-762
K	O	763-764
(	O	764-765
+	O	765-766
)	O	766-767
-	O	767-768
channel	O	768-775
blockers	O	776-784
affected	O	785-793
morphine	O	794-802
-	O	802-803
induced	O	803-810
hypoactivity	B	811-823
,	O	823-824
but	O	825-828
both	O	829-833
K	O	834-835
(	O	835-836
+	O	836-837
)	O	837-838
-	O	838-839
channel	O	839-846
blockers	O	847-855
prevented	O	856-865
morphine	O	866-874
-	O	874-875
induced	O	875-882
secondary	O	883-892
hyperactivity	B	893-906
.	O	906-907

3	O	908-909
.	O	909-910

These	O	911-916
results	O	917-924
suggest	O	925-932
the	O	933-936
involvement	O	937-948
of	O	949-951
quinine	O	952-959
-	O	959-960
sensitive	O	960-969
but	O	970-973
not	O	974-977
4	O	978-979
-	O	979-980
aminopyridine	O	980-993
-	O	979-980
sensitive	O	994-1003
K	O	1004-1005
(	O	1005-1006
+	O	1006-1007
)	O	1007-1008
-	O	1008-1009
channels	O	1009-1017
in	O	1018-1020
morphine	O	1021-1029
reward	O	1030-1036
.	O	1036-1037

It	O	1038-1040
is	O	1041-1043
also	O	1044-1048
suggested	O	1049-1058
that	O	1059-1063
the	O	1064-1067
blockade	O	1068-1076
of	O	1077-1079
K	O	1080-1081
(	O	1081-1082
+	O	1082-1083
)	O	1083-1084
-	O	1084-1085
channels	O	1085-1093
sensitive	O	1094-1103
to	O	1104-1106
these	O	1107-1112
blockers	O	1113-1121
is	O	1122-1124
not	O	1125-1128
sufficient	O	1129-1139
to	O	1140-1142
prevent	O	1143-1150
morphine	O	1151-1159
-	O	1159-1160
induced	O	1160-1167
hypoactivity	B	1168-1180
whereas	O	1181-1188
morphine	O	1189-1197
-	O	1197-1198
induced	O	1198-1205
hyperactivity	B	1206-1219
seems	O	1220-1225
to	O	1226-1228
be	O	1229-1231
connected	O	1232-1241
to	O	1242-1244
both	O	1245-1249
quinine	O	1250-1257
-	O	1257-1258
and	O	1259-1262
4	O	1263-1264
-	O	1264-1265
aminopyridine	O	1265-1278
-	O	1264-1265
sensitive	O	1279-1288
K	O	1289-1290
(	O	1290-1291
+	O	1291-1292
)	O	1292-1293
-	O	1293-1294
channels	O	1294-1302
.	O	1302-1303

Nociceptin	O	0-10
/	O	10-11
orphanin	O	11-19
FQ	O	20-22
and	O	23-26
nocistatin	O	27-37
on	O	38-40
learning	B	41-49
and	I	50-53
memory	I	54-60
impairment	I	61-71
induced	O	72-79
by	O	80-82
scopolamine	O	83-94
in	O	95-97
mice	O	98-102
.	O	102-103
1	O	104-105
.	O	105-106
Nociceptin	O	107-117
,	O	117-118
also	O	119-123
known	O	124-129
as	O	130-132
orphanin	O	133-141
FQ	O	142-144
,	O	144-145
is	O	146-148
an	O	149-151
endogenous	O	152-162
ligand	O	163-169
for	O	170-173
the	O	174-177
orphan	O	178-184
opioid	O	185-191
receptor	O	192-200
-	O	200-201
like	O	201-205
receptor	O	206-214
1	O	215-216
(	O	217-218
ORL1	O	218-222
)	O	222-223
and	O	224-227
involves	O	228-236
in	O	237-239
various	O	240-247
functions	O	248-257
in	O	258-260
the	O	261-264
central	O	265-272
nervous	O	273-280
system	O	281-287
(	O	288-289
CNS	O	289-292
)	O	292-293
.	O	293-294

On	O	295-297
the	O	298-301
other	O	302-307
hand	O	308-312
,	O	312-313
nocistatin	O	314-324
is	O	325-327
recently	O	328-336
isolated	O	337-345
from	O	346-350
the	O	351-354
same	O	355-359
precursor	O	360-369
as	O	370-372
nociceptin	O	373-383
and	O	384-387
blocks	O	388-394
nociceptin	O	395-405
-	O	405-406
induced	O	406-413
allodynia	B	414-423
and	O	424-427
hyperalgesia	B	428-440
.	O	440-441

2	O	442-443
.	O	443-444
Although	O	445-453
ORL1	O	454-458
receptors	O	459-468
which	O	469-474
display	O	475-482
a	O	483-484
high	O	485-489
degree	O	490-496
of	O	497-499
sequence	O	500-508
homology	O	509-517
with	O	518-522
classical	O	523-532
opioid	O	533-539
receptors	O	540-549
are	O	550-553
abundant	O	554-562
in	O	563-565
the	O	566-569
hippocampus	O	570-581
,	O	581-582
little	O	583-589
is	O	590-592
known	O	593-598
regarding	O	599-608
their	O	609-614
role	O	615-619
in	O	620-622
learning	O	623-631
and	O	632-635
memory	O	636-642
.	O	642-643

3	O	644-645
.	O	645-646
The	O	647-650
present	O	651-658
study	O	659-664
was	O	665-668
designed	O	669-677
to	O	678-680
investigate	O	681-692
whether	O	693-700
nociceptin	O	701-711
/	O	711-712
orphanin	O	712-720
FQ	O	721-723
and	O	724-727
nocistatin	O	728-738
could	O	739-744
modulate	O	745-753
impairment	B	754-764
of	I	765-767
learning	I	768-776
and	I	777-780
memory	I	781-787
induced	O	788-795
by	O	796-798
scopolamine	O	799-810
,	O	810-811
a	O	812-813
muscarinic	O	814-824
cholinergic	O	825-836
receptor	O	837-845
antagonist	O	846-856
,	O	856-857
using	O	858-863
spontaneous	O	864-875
alternation	O	876-887
of	O	888-890
Y	O	891-892
-	O	892-893
maze	O	893-897
and	O	898-901
step	O	902-906
-	O	906-907
down	O	907-911
type	O	912-916
passive	O	917-924
avoidance	O	925-934
tasks	O	935-940
in	O	941-943
mice	O	944-948
.	O	948-949

4	O	950-951
.	O	951-952
While	O	953-958
nocistatin	O	959-969
(	O	970-971
0	O	971-972
.	O	972-973
5	O	973-974
-	O	974-975
5	O	973-974
.	O	972-973
0	O	971-972
nmol	O	979-983
mouse	O	984-989
-	O	989-990
1	O	990-991
,	O	991-992
i	O	993-994
.	O	994-995
c	O	995-996
.	O	994-995
v	O	997-998
.	O	994-995
)	O	999-1000
administered	O	1001-1013
30	O	1014-1016
min	O	1017-1020
before	O	1021-1027
spontaneous	O	1028-1039
alternation	O	1040-1051
performance	O	1052-1063
or	O	1064-1066
the	O	1067-1070
training	O	1071-1079
session	O	1080-1087
of	O	1088-1090
the	O	1091-1094
passive	O	1095-1102
avoidance	O	1103-1112
task	O	1113-1117
,	O	1117-1118
had	O	1119-1122
no	O	1123-1125
effect	O	1126-1132
on	O	1133-1135
spontaneous	O	1136-1147
alternation	O	1148-1159
or	O	1160-1162
passive	O	1163-1170
avoidance	O	1171-1180
behaviours	O	1181-1191
,	O	1191-1192
a	O	1193-1194
lower	O	1195-1200
per	O	1201-1204
cent	O	1205-1209
alternation	O	1210-1221
and	O	1222-1225
shorter	O	1226-1233
median	O	1234-1240
step	O	1241-1245
-	O	1245-1246
down	O	1246-1250
latency	O	1251-1258
in	O	1259-1261
the	O	1262-1265
retention	O	1266-1275
test	O	1276-1280
were	O	1281-1285
obtained	O	1286-1294
in	O	1295-1297
nociceptin	O	1298-1308
(	O	1309-1310
1	O	1310-1311
.	O	1311-1312
5	O	1312-1313
and	O	1314-1317
/	O	1317-1318
or	O	1318-1320
5	O	1321-1322
.	O	1322-1323
0	O	1323-1324
nmol	O	1325-1329
mouse	O	1330-1335
-	O	1335-1336
1	O	1336-1337
,	O	1337-1338
i	O	1339-1340
.	O	1340-1341
c	O	1341-1342
.	O	1340-1341
v	O	1343-1344
.	O	1340-1341
)	O	1345-1346
-	O	1346-1347
treated	O	1347-1354
normal	O	1355-1361
mice	O	1362-1366
.	O	1366-1367
5	O	1368-1369
.	O	1369-1370
Administration	O	1371-1385
of	O	1386-1388
nocistatin	O	1389-1399
(	O	1400-1401
1	O	1401-1402
.	O	1402-1403
5	O	1403-1404
and	O	1405-1408
/	O	1408-1409
or	O	1409-1411
5	O	1412-1413
.	O	1413-1414
0	O	1414-1415
nmol	O	1416-1420
mouse	O	1421-1426
-	O	1426-1427
1	O	1427-1428
,	O	1428-1429
i	O	1430-1431
.	O	1431-1432
c	O	1432-1433
.	O	1431-1432
v	O	1434-1435
.	O	1431-1432
)	O	1436-1437
30	O	1438-1440
min	O	1441-1444
before	O	1445-1451
spontaneous	O	1452-1463
alternation	O	1464-1475
performance	O	1476-1487
or	O	1488-1490
the	O	1491-1494
training	O	1495-1503
session	O	1504-1511
of	O	1512-1514
the	O	1515-1518
passive	O	1519-1526
avoidance	O	1527-1536
task	O	1537-1541
,	O	1541-1542
attenuated	O	1543-1553
the	O	1554-1557
scopolamine	O	1558-1569
-	O	1569-1570
induced	O	1570-1577
impairment	O	1578-1588
of	O	1589-1591
spontaneous	O	1592-1603
alternation	O	1604-1615
and	O	1616-1619
passive	O	1620-1627
avoidance	O	1628-1637
behaviours	O	1638-1648
.	O	1648-1649

6	O	1650-1651
.	O	1651-1652

These	O	1653-1658
results	O	1659-1666
indicated	O	1667-1676
that	O	1677-1681
nocistatin	O	1682-1692
,	O	1692-1693
a	O	1694-1695
new	O	1696-1699
biologically	O	1700-1712
active	O	1713-1719
peptide	O	1720-1727
,	O	1727-1728
ameliorates	O	1729-1740
impairments	O	1741-1752
of	O	1753-1755
spontaneous	O	1756-1767
alternation	O	1768-1779
and	O	1780-1783
passive	O	1784-1791
avoidance	O	1792-1801
induced	O	1802-1809
by	O	1810-1812
scopolamine	O	1813-1824
,	O	1824-1825
and	O	1826-1829
suggested	O	1830-1839
that	O	1840-1844
these	O	1845-1850
peptides	O	1851-1859
play	O	1860-1864
opposite	O	1865-1873
roles	O	1874-1879
in	O	1880-1882
learning	O	1883-1891
and	O	1892-1895
memory	O	1896-1902
.	O	1902-1903

Meloxicam	O	0-9
-	O	9-10
induced	O	10-17
liver	B	18-23
toxicity	I	24-32
.	O	32-33

We	O	34-36
report	O	37-43
the	O	44-47
case	O	48-52
of	O	53-55
a	O	56-57
female	O	58-64
patient	O	65-72
with	O	73-77
rheumatoid	B	78-88
arthritis	I	89-98
who	O	99-102
developed	O	103-112
acute	O	113-118
cytolytic	O	119-128
hepatitis	B	129-138
due	O	139-142
to	O	143-145
meloxicam	O	146-155
.	O	155-156

Recently	O	157-165
introduced	O	166-176
in	O	177-179
Belgium	O	180-187
,	O	187-188
meloxicam	O	189-198
is	O	199-201
the	O	202-205
first	O	206-211
nonsteroidal	O	212-224
antiinflammatory	O	225-241
drug	O	242-246
with	O	247-251
selective	O	252-261
action	O	262-268
on	O	269-271
the	O	272-275
inducible	O	276-285
form	O	286-290
of	O	291-293
cyclooxygenase	O	294-308
2	O	309-310
.	O	310-311
The	O	312-315
acute	O	316-321
cytolytic	O	322-331
hepatitis	B	332-341
occurred	O	342-350
rapidly	O	351-358
after	O	359-364
meloxicam	O	365-374
administration	O	375-389
and	O	390-393
was	O	394-397
associated	O	398-408
with	O	409-413
the	O	414-417
development	O	418-429
of	O	430-432
antinuclear	O	433-444
antibodies	O	445-455
suggesting	O	456-466
a	O	467-468
hypersensitivity	B	469-485
mechanism	O	486-495
.	O	495-496

This	O	497-501
first	O	502-507
case	O	508-512
of	O	513-515
meloxicam	O	516-525
related	O	526-533
liver	B	534-539
toxicity	I	540-548
demonstrates	O	549-561
the	O	562-565
potential	O	566-575
of	O	576-578
this	O	579-583
drug	O	584-588
to	O	589-591
induce	O	592-598
hepatic	B	599-606
damage	I	607-613
.	O	613-614

Induction	O	0-9
of	O	10-12
apoptosis	O	13-22
by	O	23-25
remoxipride	O	26-37
metabolites	O	38-49
in	O	50-52
HL60	O	53-57
and	O	58-61
CD34	O	62-66
+	O	66-67
/	O	67-68
CD19	O	68-72
-	O	72-73
human	O	74-79
bone	O	80-84
marrow	O	85-91
progenitor	O	92-102
cells	O	103-108
:	O	108-109
potential	O	110-119
relevance	O	120-129
to	O	130-132
remoxipride	O	133-144
-	O	144-145
induced	O	145-152
aplastic	B	153-161
anemia	I	162-168
.	O	168-169

The	O	170-173
antipsychotic	O	174-187
agent	O	188-193
,	O	193-194
remoxipride	O	195-206
[	O	207-208
(	O	208-209
S	O	209-210
)	O	210-211
-	O	211-212
(	O	208-209
-	O	211-212
)	O	210-211
-	O	211-212
3	O	216-217
-	O	211-212
bromo	O	218-223
-	O	211-212
N	O	224-225
-	O	211-212
[	O	207-208
(	O	208-209
1	O	228-229
-	O	211-212
ethyl	O	230-235
-	O	211-212
2	O	236-237
-	O	211-212
pyrrolidinyl	O	238-250
)	O	210-211
methyl	O	251-257
]	O	257-258
-	O	211-212
2	O	236-237
,	O	260-261
6	O	261-262
-	O	211-212
dimethoxybenz	O	263-276
amide	O	277-282
]	O	282-283
has	O	284-287
been	O	288-292
associated	O	293-303
with	O	304-308
acquired	O	309-317
aplastic	B	318-326
anemia	I	327-333
.	O	333-334

We	O	335-337
have	O	338-342
examined	O	343-351
the	O	352-355
ability	O	356-363
of	O	364-366
remoxipride	O	367-378
,	O	378-379
three	O	380-385
pyrrolidine	O	386-397
ring	O	398-402
metabolites	O	403-414
and	O	415-418
five	O	419-423
aromatic	O	424-432
ring	O	433-437
metabolites	O	438-449
of	O	450-452
the	O	453-456
parent	O	457-463
compound	O	464-472
to	O	473-475
induce	O	476-482
apoptosis	O	483-492
in	O	493-495
HL60	O	496-500
cells	O	501-506
and	O	507-510
human	O	511-516
bone	O	517-521
marrow	O	522-528
progenitor	O	529-539
(	O	540-541
HBMP	O	541-545
)	O	545-546
cells	O	547-552
.	O	552-553

Cells	O	554-559
were	O	560-564
treated	O	565-572
for	O	573-576
0	O	577-578
-	O	578-579
24	O	579-581
h	O	582-583
with	O	584-588
each	O	589-593
compound	O	594-602
(	O	603-604
0	O	604-605
-	O	605-606
200	O	606-609
microM	O	610-616
)	O	616-617
.	O	617-618

Apoptosis	O	619-628
was	O	629-632
assessed	O	633-641
by	O	642-644
fluorescence	O	645-657
microscopy	O	658-668
in	O	669-671
Hoechst	O	672-679
33342	O	680-685
-	O	685-686
and	O	687-690
propidium	O	691-700
iodide	O	701-707
stained	O	708-715
cell	O	716-720
samples	O	721-728
.	O	728-729

Results	O	730-737
were	O	738-742
confirmed	O	743-752
by	O	753-755
determination	O	756-769
of	O	770-772
internucleosomal	O	773-789
DNA	O	790-793
fragmentation	O	794-807
using	O	808-813
gel	O	814-817
electrophoresis	O	818-833
for	O	834-837
HL60	O	838-842
cell	O	843-847
samples	O	848-855
and	O	856-859
terminal	O	860-868
deoxynucleotidyl	O	869-885
transferase	O	886-897
assay	O	898-903
in	O	904-906
HBMP	O	907-911
cells	O	912-917
.	O	917-918

The	O	919-922
catechol	O	923-931
and	O	932-935
hydroquinone	O	936-948
metabolites	O	949-960
,	O	960-961
NCQ436	O	962-968
and	O	969-972
NCQ344	O	973-979
,	O	979-980
induced	O	981-988
apoptosis	O	989-998
in	O	999-1001
HL60	O	1002-1006
and	O	1007-1010
HBMP	O	1011-1015
cells	O	1016-1021
in	O	1022-1024
a	O	1025-1026
time	O	1027-1031
-	O	1031-1032
and	O	1033-1036
concentration	O	1037-1050
dependent	O	1051-1060
manner	O	1061-1067
,	O	1067-1068
while	O	1069-1074
the	O	1075-1078
phenols	O	1079-1086
,	O	1086-1087
NCR181	O	1088-1094
,	O	1094-1095
FLA873	O	1096-1102
,	O	1102-1103
and	O	1104-1107
FLA797	O	1108-1114
,	O	1114-1115
and	O	1116-1119
the	O	1120-1123
derivatives	O	1124-1135
formed	O	1136-1142
by	O	1143-1145
oxidation	O	1146-1155
of	O	1156-1158
the	O	1159-1162
pyrrolidine	O	1163-1174
ring	O	1175-1179
,	O	1179-1180
FLA838	O	1181-1187
,	O	1187-1188
NCM001	O	1189-1195
,	O	1195-1196
and	O	1197-1200
NCL118	O	1201-1207
,	O	1207-1208
had	O	1209-1212
no	O	1213-1215
effect	O	1216-1222
.	O	1222-1223

No	O	1224-1226
necrosis	B	1227-1235
was	O	1236-1239
observed	O	1240-1248
in	O	1249-1251
cells	O	1252-1257
treated	O	1258-1265
with	O	1266-1270
NCQ436	O	1271-1277
but	O	1278-1281
NCQ344	O	1282-1288
had	O	1289-1292
a	O	1293-1294
biphasic	O	1295-1303
effect	O	1304-1310
in	O	1311-1313
both	O	1314-1318
cell	O	1319-1323
types	O	1324-1329
,	O	1329-1330
inducing	O	1331-1339
apoptosis	O	1340-1349
at	O	1350-1352
lower	O	1353-1358
concentrations	O	1359-1373
and	O	1374-1377
necrosis	B	1378-1386
at	O	1387-1389
higher	O	1390-1396
concentrations	O	1397-1411
.	O	1411-1412

These	O	1413-1418
data	O	1419-1423
show	O	1424-1428
that	O	1429-1433
the	O	1434-1437
catechol	O	1438-1446
and	O	1447-1450
hydroquinone	O	1451-1463
metabolites	O	1464-1475
of	O	1476-1478
remoxipride	O	1479-1490
have	O	1491-1495
direct	O	1496-1502
toxic	O	1503-1508
effects	O	1509-1516
in	O	1517-1519
HL60	O	1520-1524
and	O	1525-1528
HBMP	O	1529-1533
cells	O	1534-1539
,	O	1539-1540
leading	O	1541-1548
to	O	1549-1551
apoptosis	O	1552-1561
,	O	1561-1562
while	O	1563-1568
the	O	1569-1572
phenol	O	1573-1579
metabolites	O	1580-1591
were	O	1592-1596
inactive	O	1597-1605
.	O	1605-1606

Similarly	O	1607-1616
,	O	1616-1617
benzene	O	1618-1625
-	O	1625-1626
derived	O	1626-1633
catechol	O	1634-1642
and	O	1643-1646
hydroquinone	O	1647-1659
,	O	1659-1660
but	O	1661-1664
not	O	1665-1668
phenol	O	1669-1675
,	O	1675-1676
induce	O	1677-1683
apoptosis	O	1684-1693
in	O	1694-1696
HBMP	O	1697-1701
cells	O	1702-1707
[	O	1708-1709
Moran	O	1709-1714
et	O	1715-1717
al	O	1718-1720
.	O	1720-1721
,	O	1721-1722
Mol	O	1723-1726
.	O	1726-1727

Pharmacol	O	1728-1737
.	O	1737-1738
,	O	1738-1739
50	O	1740-1742
(	O	1743-1744
1996	O	1744-1748
)	O	1748-1749
610	O	1750-1753
-	O	1753-1754
615	O	1754-1757
]	O	1757-1758
.	O	1758-1759

We	O	1760-1762
propose	O	1763-1770
that	O	1771-1775
remoxipride	O	1776-1787
and	O	1788-1791
benzene	O	1792-1799
may	O	1800-1803
induce	O	1804-1810
aplastic	B	1811-1819
anemia	I	1820-1826
via	O	1827-1830
production	O	1831-1841
of	O	1842-1844
similar	O	1845-1852
reactive	O	1853-1861
metabolites	O	1862-1873
and	O	1874-1877
that	O	1878-1882
the	O	1883-1886
ability	O	1887-1894
of	O	1895-1897
NCQ436	O	1898-1904
and	O	1905-1908
NCQ344	O	1909-1915
to	O	1916-1918
induce	O	1919-1925
apoptosis	O	1926-1935
in	O	1936-1938
HBMP	O	1939-1943
cells	O	1944-1949
may	O	1950-1953
contribute	O	1954-1964
to	O	1965-1967
the	O	1968-1971
mechanism	O	1972-1981
underlying	O	1982-1992
acquired	O	1993-2001
aplastic	B	2002-2010
anemia	I	2011-2017
that	O	2018-2022
has	O	2023-2026
been	O	2027-2031
associated	O	2032-2042
with	O	2043-2047
remoxipride	O	2048-2059
.	O	2059-2060

Synthesis	O	0-9
and	O	10-13
preliminary	O	14-25
pharmacological	O	26-41
investigations	O	42-56
of	O	57-59
1	O	60-61
-	O	61-62
(	O	62-63
1	O	60-61
,	O	64-65
2	O	65-66
-	O	61-62
dihydro	O	67-74
-	O	61-62
2	O	65-66
-	O	61-62
acenaphthylenyl	O	77-92
)	O	92-93
piperazine	O	93-103
derivatives	O	104-115
as	O	116-118
potential	O	119-128
atypical	O	129-137
antipsychotic	O	138-151
agents	O	152-158
in	O	159-161
mice	O	162-166
.	O	166-167

In	O	168-170
research	O	171-179
towards	O	180-187
the	O	188-191
development	O	192-203
of	O	204-206
new	O	207-210
atypical	O	211-219
antipsychotic	O	220-233
agents	O	234-240
,	O	240-241
one	O	242-245
strategy	O	246-254
is	O	255-257
that	O	258-262
the	O	263-266
dopaminergic	O	267-279
system	O	280-286
can	O	287-290
be	O	291-293
modulated	O	294-303
through	O	304-311
manipulation	O	312-324
of	O	325-327
the	O	328-331
serotonergic	O	332-344
system	O	345-351
.	O	351-352

The	O	353-356
synthesis	O	357-366
and	O	367-370
preliminary	O	371-382
pharmacological	O	383-398
evaluation	O	399-409
of	O	410-412
a	O	413-414
series	O	415-421
of	O	422-424
potential	O	425-434
atypical	O	435-443
antipsychotic	O	444-457
agents	O	458-464
based	O	465-470
on	O	471-473
the	O	474-477
structure	O	478-487
of	O	488-490
1	O	491-492
-	O	492-493
(	O	493-494
1	O	491-492
,	O	495-496
2	O	496-497
-	O	492-493
dihydro	O	498-505
-	O	492-493
2	O	496-497
-	O	492-493
acenaphthylenyl	O	508-523
)	O	523-524
piperazine	O	524-534
(	O	535-536
7	O	536-537
)	O	537-538
is	O	539-541
described	O	542-551
.	O	551-552

Compound	O	553-561
7e	O	562-564
,	O	564-565
5	O	566-567
-	O	567-568
{	O	568-569
2	O	569-570
-	O	567-568
[	O	571-572
4	O	572-573
-	O	567-568
(	O	574-575
1	O	575-576
,	O	576-577
2	O	569-570
-	O	567-568
dihydro	O	579-586
-	O	567-568
2	O	569-570
-	O	567-568
acenaphthylenyl	O	589-604
)	O	604-605
piperazinyl	O	605-616
]	O	616-617
ethyl	O	617-622
}	O	622-623
-	O	567-568
2	O	569-570
,	O	576-577
3	O	626-627
-	O	567-568
dihy	O	579-583
dro	O	633-636
-	O	636-637
1H	O	637-639
-	O	636-637
indol	O	641-646
-	O	646-647
2	O	647-648
-	O	646-647
one	O	649-652
,	O	652-653
from	O	654-658
this	O	659-663
series	O	664-670
showed	O	671-677
significant	O	678-689
affinities	O	690-700
at	O	701-703
the	O	704-707
5	O	708-709
-	O	709-710
HT1A	O	710-714
and	O	715-718
5	O	719-720
-	O	720-721
HT2A	O	721-725
receptors	O	726-735
and	O	736-739
moderate	O	740-748
affinity	O	749-757
at	O	758-760
the	O	761-764
D2	O	765-767
receptor	O	768-776
.	O	776-777

7e	O	778-780
exhibits	O	781-789
a	O	790-791
high	O	792-796
reversal	O	797-805
of	O	806-808
catalepsy	B	809-818
induced	O	819-826
by	O	827-829
haloperidol	O	830-841
indicating	O	842-852
its	O	853-856
atypical	O	857-865
antipsychotic	O	866-879
nature	O	880-886
.	O	886-887

Sub	O	0-3
-	O	3-4
chronic	O	4-11
inhibition	O	12-22
of	O	23-25
nitric	O	26-32
-	O	32-33
oxide	O	33-38
synthesis	O	39-48
modifies	O	49-57
haloperidol	O	58-69
-	O	69-70
induced	O	70-77
catalepsy	B	78-87
and	O	88-91
the	O	92-95
number	O	96-102
of	O	103-105
NADPH	O	106-111
-	O	111-112
diaphorase	O	112-122
neurons	O	123-130
in	O	131-133
mice	O	134-138
.	O	138-139

RATIONALE	O	140-149
:	O	149-150
NG	O	151-153
-	O	153-154
nitro	O	154-159
-	O	153-154
L	O	160-161
-	O	153-154
arginine	O	162-170
(	O	171-172
L	O	172-173
-	O	173-174
NOARG	O	174-179
)	O	179-180
,	O	180-181
an	O	182-184
inhibitor	O	185-194
of	O	195-197
nitric	O	198-204
-	O	204-205
oxide	O	205-210
synthase	O	211-219
(	O	220-221
NOS	O	221-224
)	O	224-225
,	O	225-226
induces	O	227-234
catalepsy	B	235-244
in	O	245-247
mice	O	248-252
.	O	252-253

This	O	254-258
effect	O	259-265
undergoes	O	266-275
rapid	O	276-281
tolerance	O	282-291
,	O	291-292
showing	O	293-300
a	O	301-302
significant	O	303-314
decrease	O	315-323
after	O	324-329
2	O	330-331
days	O	332-336
of	O	337-339
sub	O	340-343
-	O	343-344
chronic	O	344-351
L	O	352-353
-	O	353-354
NOARG	O	354-359
treatment	O	360-369
.	O	369-370

Nitric	O	371-377
oxide	O	378-383
(	O	384-385
NO	O	385-387
)	O	387-388
has	O	389-392
been	O	393-397
shown	O	398-403
to	O	404-406
influence	O	407-416
dopaminergic	O	417-429
neurotransmission	O	430-447
in	O	448-450
the	O	451-454
striatum	O	455-463
.	O	463-464

Neuroleptic	O	465-476
drugs	O	477-482
such	O	483-487
as	O	488-490
haloperidol	O	491-502
,	O	502-503
which	O	504-509
block	O	510-515
dopamine	O	516-524
receptors	O	525-534
,	O	534-535
also	O	536-540
cause	O	541-546
catalepsy	B	547-556
in	O	557-559
rodents	O	560-567
.	O	567-568

OBJECTIVES	O	569-579
:	O	579-580
To	O	581-583
investigate	O	584-595
the	O	596-599
effects	O	600-607
of	O	608-610
subchronic	O	611-621
L	O	622-623
-	O	623-624
NOARG	O	624-629
treatment	O	630-639
in	O	640-642
haloperidol	O	643-654
-	O	654-655
induced	O	655-662
catalepsy	B	663-672
and	O	673-676
the	O	677-680
number	O	681-687
of	O	688-690
NOS	O	691-694
neurons	O	695-702
in	O	703-705
areas	O	706-711
related	O	712-719
to	O	720-722
motor	O	723-728
control	O	729-736
.	O	736-737

METHODS	O	738-745
:	O	745-746
Male	O	747-751
albino	O	752-758
Swiss	O	759-764
mice	O	765-769
were	O	770-774
treated	O	775-782
sub	O	783-786
-	O	786-787
chronically	O	787-798
(	O	799-800
twice	O	800-805
a	O	806-807
day	O	808-811
for	O	812-815
4	O	816-817
days	O	818-822
)	O	822-823
with	O	824-828
L	O	829-830
-	O	830-831
NOARG	O	831-836
(	O	837-838
40	O	838-840
mg	O	841-843
/	O	843-844
kg	O	844-846
i	O	847-848
.	O	848-849
p	O	849-850
.	O	848-849
)	O	851-852
or	O	853-855
haloperidol	O	856-867
(	O	868-869
1	O	869-870
mg	O	871-873
/	O	873-874
kg	O	874-876
i	O	877-878
.	O	878-879
p	O	879-880
.	O	878-879
)	O	881-882
.	O	878-879

Catalepsy	B	884-893
was	O	894-897
evaluated	O	898-907
at	O	908-910
the	O	911-914
beginning	O	915-924
and	O	925-928
the	O	929-932
end	O	933-936
of	O	937-939
the	O	940-943
treatments	O	944-954
.	O	954-955

Reduced	O	956-963
nicotinamide	O	964-976
adenine	O	977-984
dinucleotide	O	985-997
phosphate	O	998-1007
-	O	1007-1008
diaphorase	O	1008-1018
(	O	1019-1020
NADPH	O	1020-1025
-	O	1025-1026
d	O	1026-1027
)	O	1027-1028
histochemistry	O	1029-1043
was	O	1044-1047
also	O	1048-1052
employed	O	1053-1061
to	O	1062-1064
visualize	O	1065-1074
NOS	O	1075-1078
as	O	1079-1081
an	O	1082-1084
index	O	1085-1090
of	O	1091-1093
enzyme	O	1094-1100
expression	O	1101-1111
in	O	1112-1114
mice	O	1115-1119
brain	O	1120-1125
regions	O	1126-1133
related	O	1134-1141
to	O	1142-1144
motor	O	1145-1150
control	O	1151-1158
.	O	1158-1159

RESULTS	O	1160-1167
:	O	1167-1168
L	O	1169-1170
-	O	1170-1171
NOARG	O	1171-1176
sub	O	1177-1180
-	O	1180-1181
chronic	O	1181-1188
administration	O	1189-1203
produced	O	1204-1212
tolerance	O	1213-1222
of	O	1223-1225
L	O	1226-1227
-	O	1227-1228
NOARG	O	1228-1233
and	O	1234-1237
of	O	1238-1240
haloperidol	O	1241-1252
-	O	1252-1253
induced	O	1253-1260
catalepsy	B	1261-1270
.	O	1270-1271

It	O	1272-1274
also	O	1275-1279
induced	O	1280-1287
an	O	1288-1290
increase	O	1291-1299
in	O	1300-1302
the	O	1303-1306
number	O	1307-1313
of	O	1314-1316
NADPH	O	1317-1322
-	O	1322-1323
d	O	1323-1324
-	O	1322-1323
positive	O	1325-1333
cells	O	1334-1339
in	O	1340-1342
the	O	1343-1346
dorsal	O	1347-1353
part	O	1354-1358
of	O	1359-1361
the	O	1362-1365
caudate	O	1366-1373
and	O	1374-1377
accumbens	O	1378-1387
nuclei	O	1388-1394
compared	O	1395-1403
with	O	1404-1408
haloperidol	O	1409-1420
and	O	1421-1424
in	O	1425-1427
the	O	1428-1431
pedunculopontine	O	1432-1448
tegmental	O	1449-1458
nucleus	O	1459-1466
compared	O	1467-1475
with	O	1476-1480
saline	O	1481-1487
.	O	1487-1488

In	O	1489-1491
contrast	O	1492-1500
,	O	1500-1501
there	O	1502-1507
was	O	1508-1511
a	O	1512-1513
decrease	O	1514-1522
in	O	1523-1525
NADPH	O	1526-1531
-	O	1531-1532
d	O	1532-1533
neuron	O	1534-1540
number	O	1541-1547
in	O	1548-1550
the	O	1551-1554
substantia	O	1555-1565
nigra	O	1566-1571
,	O	1571-1572
pars	O	1573-1577
compacta	O	1578-1586
in	O	1587-1589
both	O	1590-1594
haloperidol	O	1595-1606
-	O	1606-1607
treated	O	1607-1614
and	O	1615-1618
L	O	1619-1620
-	O	1620-1621
NOARG	O	1621-1626
-	O	1620-1621
treated	O	1627-1634
animals	O	1635-1642
.	O	1642-1643

CONCLUSIONS	O	1644-1655
:	O	1655-1656
The	O	1657-1660
results	O	1661-1668
give	O	1669-1673
further	O	1674-1681
support	O	1682-1689
to	O	1690-1692
the	O	1693-1696
hypothesis	O	1697-1707
that	O	1708-1712
NO	O	1713-1715
plays	O	1716-1721
a	O	1722-1723
role	O	1724-1728
in	O	1729-1731
motor	O	1732-1737
behavior	O	1738-1746
control	O	1747-1754
and	O	1755-1758
suggest	O	1759-1766
that	O	1767-1771
it	O	1772-1774
may	O	1775-1778
take	O	1779-1783
part	O	1784-1788
in	O	1789-1791
the	O	1792-1795
synaptic	O	1796-1804
changes	O	1805-1812
produced	O	1813-1821
by	O	1822-1824
antipsychotic	O	1825-1838
treatment	O	1839-1848
.	O	1848-1849

Prolonged	O	0-9
left	B	10-14
ventricular	I	15-26
dysfunction	I	27-38
occurs	O	39-45
in	O	46-48
patients	O	49-57
with	O	58-62
coronary	B	63-71
artery	I	72-78
disease	I	79-86
after	O	87-92
both	O	93-97
dobutamine	O	98-108
and	O	109-112
exercise	O	113-121
induced	O	122-129
myocardial	B	130-140
ischaemia	I	141-150
.	O	150-151

OBJECTIVE	O	152-161
:	O	161-162
To	O	163-165
determine	O	166-175
whether	O	176-183
pharmacological	O	184-199
stress	O	200-206
leads	O	207-212
to	O	213-215
prolonged	O	216-225
but	O	226-229
reversible	O	230-240
left	B	241-245
ventricular	I	246-257
dysfunction	I	258-269
in	O	270-272
patients	O	273-281
with	O	282-286
coronary	B	287-295
artery	I	296-302
disease	I	303-310
,	O	310-311
similar	O	312-319
to	O	320-322
that	O	323-327
seen	O	328-332
after	O	333-338
exercise	O	339-347
.	O	347-348

DESIGN	O	349-355
:	O	355-356
A	O	357-358
randomised	O	359-369
crossover	O	370-379
study	O	380-385
of	O	386-388
recovery	O	389-397
time	O	398-402
of	O	403-405
systolic	O	406-414
and	O	415-418
diastolic	O	419-428
left	O	429-433
ventricular	O	434-445
function	O	446-454
after	O	455-460
exercise	O	461-469
and	O	470-473
dobutamine	O	474-484
induced	O	485-492
ischaemia	B	493-502
.	O	502-503

SUBJECTS	O	504-512
:	O	512-513
10	O	514-516
patients	O	517-525
with	O	526-530
stable	B	531-537
angina	I	538-544
,	O	544-545
angiographically	O	546-562
proven	O	563-569
coronary	B	570-578
artery	I	579-585
disease	I	586-593
,	O	593-594
and	O	595-598
normal	O	599-605
left	O	606-610
ventricular	O	611-622
function	O	623-631
.	O	631-632

INTERVENTIONS	O	633-646
:	O	646-647
Treadmill	O	648-657
exercise	O	658-666
and	O	667-670
dobutamine	O	671-681
stress	O	682-688
were	O	689-693
performed	O	694-703
on	O	704-706
different	O	707-716
days	O	717-721
.	O	721-722

Quantitative	O	723-735
assessment	O	736-746
of	O	747-749
systolic	O	750-758
and	O	759-762
diastolic	O	763-772
left	O	773-777
ventricular	O	778-789
function	O	790-798
was	O	799-802
performed	O	803-812
using	O	813-818
transthoracic	O	819-832
echocardiography	O	833-849
at	O	850-852
baseline	O	853-861
and	O	862-865
at	O	866-868
regular	O	869-876
intervals	O	877-886
after	O	887-892
each	O	893-897
test	O	898-902
.	O	902-903

RESULTS	O	904-911
:	O	911-912
Both	O	913-917
forms	O	918-923
of	O	924-926
stress	O	927-933
led	O	934-937
to	O	938-940
prolonged	O	941-950
but	O	951-954
reversible	O	955-965
systolic	O	966-974
and	O	975-978
diastolic	O	979-988
dysfunction	O	989-1000
.	O	1000-1001

There	O	1002-1007
was	O	1008-1011
no	O	1012-1014
difference	O	1015-1025
in	O	1026-1028
the	O	1029-1032
maximum	O	1033-1040
double	O	1041-1047
product	O	1048-1055
(	O	1056-1057
p	O	1057-1058
=	O	1059-1060
0	O	1061-1062
.	O	1062-1063
53	O	1063-1065
)	O	1065-1066
or	O	1067-1069
ST	O	1070-1072
depression	B	1073-1083
(	O	1084-1085
p	O	1085-1086
=	O	1087-1088
0	O	1089-1090
.	O	1090-1091
63	O	1091-1093
)	O	1093-1094
with	O	1095-1099
either	O	1100-1106
form	O	1107-1111
of	O	1112-1114
stress	O	1115-1121
.	O	1121-1122

After	O	1123-1128
exercise	O	1129-1137
,	O	1137-1138
ejection	O	1139-1147
fraction	O	1148-1156
was	O	1157-1160
reduced	O	1161-1168
at	O	1169-1171
15	O	1172-1174
and	O	1175-1178
30	O	1179-1181
minutes	O	1182-1189
compared	O	1190-1198
with	O	1199-1203
baseline	O	1204-1212
(	O	1213-1214
mean	O	1214-1218
(	O	1219-1220
SEM	O	1220-1223
)	O	1223-1224
,	O	1224-1225
-	O	1226-1227
5	O	1227-1228
.	O	1228-1229
6	O	1229-1230
(	O	1231-1232
1	O	1232-1233
.	O	1233-1234
5	O	1234-1235
)	O	1235-1236
%	O	1236-1237
,	O	1237-1238
p	O	1239-1240
<	O	1241-1242
0	O	1243-1244
.	O	1244-1245
05	O	1245-1247
;	O	1247-1248
and	O	1249-1252
-	O	1253-1254
6	O	1254-1255
.	O	1255-1256
1	O	1256-1257
(	O	1258-1259
2	O	1259-1260
.	O	1260-1261
2	O	1259-1260
)	O	1262-1263
%	O	1263-1264
,	O	1264-1265
p	O	1266-1267
<	O	1268-1269
0	O	1270-1271
.	O	1271-1272
01	O	1273-1275
)	O	1275-1276
,	O	1276-1277
and	O	1278-1281
at	O	1282-1284
30	O	1285-1287
and	O	1288-1291
45	O	1292-1294
minutes	O	1295-1302
after	O	1303-1308
dobutamine	O	1309-1319
(	O	1320-1321
-	O	1321-1322
10	O	1322-1324
.	O	1324-1325
8	O	1325-1326
(	O	1327-1328
1	O	1328-1329
.	O	1329-1330
8	O	1330-1331
)	O	1331-1332
%	O	1332-1333
and	O	1334-1337
-	O	1338-1339
5	O	1339-1340
.	O	1340-1341
5	O	1342-1343
(	O	1344-1345
1	O	1345-1346
.	O	1346-1347
8	O	1347-1348
)	O	1348-1349
%	O	1349-1350
,	O	1350-1351
both	O	1352-1356
p	O	1357-1358
<	O	1359-1360
0	O	1361-1362
.	O	1362-1363
01	O	1363-1365
)	O	1365-1366
.	O	1362-1363

Regional	O	1368-1376
analysis	O	1377-1385
showed	O	1386-1392
a	O	1393-1394
reduction	O	1395-1404
in	O	1405-1407
the	O	1408-1411
worst	O	1412-1417
affected	O	1418-1426
segment	O	1427-1434
15	O	1435-1437
and	O	1438-1441
30	O	1442-1444
minutes	O	1445-1452
after	O	1453-1458
exercise	O	1459-1467
(	O	1468-1469
-	O	1469-1470
27	O	1470-1472
.	O	1472-1473
9	O	1473-1474
(	O	1475-1476
7	O	1476-1477
.	O	1477-1478
2	O	1478-1479
)	O	1479-1480
%	O	1480-1481
and	O	1482-1485
-	O	1486-1487
28	O	1487-1489
.	O	1489-1490
6	O	1490-1491
(	O	1492-1493
5	O	1493-1494
.	O	1494-1495
7	O	1495-1496
)	O	1496-1497
%	O	1497-1498
,	O	1498-1499
both	O	1500-1504
p	O	1505-1506
<	O	1507-1508
0	O	1509-1510
.	O	1510-1511
01	O	1511-1513
)	O	1513-1514
,	O	1514-1515
and	O	1516-1519
at	O	1520-1522
30	O	1523-1525
minutes	O	1526-1533
after	O	1534-1539
dobutamine	O	1540-1550
(	O	1551-1552
-	O	1552-1553
32	O	1553-1555
(	O	1556-1557
5	O	1557-1558
.	O	1558-1559
3	O	1559-1560
)	O	1560-1561
%	O	1561-1562
,	O	1562-1563
p	O	1564-1565
<	O	1566-1567
0	O	1568-1569
.	O	1569-1570
01	O	1570-1572
)	O	1572-1573
.	O	1569-1570

The	O	1575-1578
isovolumic	O	1579-1589
relaxation	O	1590-1600
period	O	1601-1607
was	O	1608-1611
prolonged	O	1612-1621
45	O	1622-1624
minutes	O	1625-1632
after	O	1633-1638
each	O	1639-1643
form	O	1644-1648
of	O	1649-1651
stress	O	1652-1658
(	O	1659-1660
p	O	1660-1661
<	O	1662-1663
0	O	1664-1665
.	O	1665-1666
05	O	1666-1668
)	O	1668-1669
.	O	1665-1666

CONCLUSIONS	O	1671-1682
:	O	1682-1683
In	O	1684-1686
patients	O	1687-1695
with	O	1696-1700
coronary	B	1701-1709
artery	I	1710-1716
disease	I	1717-1724
,	O	1724-1725
dobutamine	O	1726-1736
induced	O	1737-1744
ischaemia	B	1745-1754
results	O	1755-1762
in	O	1763-1765
prolonged	O	1766-1775
reversible	O	1776-1786
left	B	1787-1791
ventricular	I	1792-1803
dysfunction	I	1804-1815
,	O	1815-1816
presumed	O	1817-1825
to	O	1826-1828
be	O	1829-1831
myocardial	B	1832-1842
stunning	I	1843-1851
,	O	1851-1852
similar	O	1853-1860
to	O	1861-1863
that	O	1864-1868
seen	O	1869-1873
after	O	1874-1879
exercise	O	1880-1888
.	O	1888-1889

Dobutamine	O	1890-1900
induced	O	1901-1908
ischaemia	B	1909-1918
could	O	1919-1924
therefore	O	1925-1934
be	O	1935-1937
used	O	1938-1942
to	O	1943-1945
study	O	1946-1951
the	O	1952-1955
pathophysiology	O	1956-1971
of	O	1972-1974
this	O	1975-1979
phenomenon	O	1980-1990
further	O	1991-1998
in	O	1999-2001
patients	O	2002-2010
with	O	2011-2015
coronary	B	2016-2024
artery	I	2025-2031
disease	I	2032-2039
.	O	2039-2040

Anorexigens	O	0-11
and	O	12-15
pulmonary	B	16-25
hypertension	I	26-38
in	O	39-41
the	O	42-45
United	O	46-52
States	O	53-59
:	O	59-60
results	O	61-68
from	O	69-73
the	O	74-77
surveillance	O	78-90
of	O	91-93
North	O	94-99
American	O	100-108
pulmonary	B	109-118
hypertension	I	119-131
.	O	131-132

BACKGROUND	O	133-143
:	O	143-144
The	O	145-148
use	O	149-152
of	O	153-155
appetite	O	156-164
suppressants	O	165-177
in	O	178-180
Europe	O	181-187
has	O	188-191
been	O	192-196
associated	O	197-207
with	O	208-212
the	O	213-216
development	O	217-228
of	O	229-231
primary	B	232-239
pulmonary	I	240-249
hypertension	I	250-262
(	O	263-264
PPH	B	264-267
)	O	267-268
.	O	268-269

Recently	O	270-278
,	O	278-279
fenfluramine	O	280-292
appetite	O	293-301
suppressants	O	302-314
became	O	315-321
widely	O	322-328
used	O	329-333
in	O	334-336
the	O	337-340
United	O	341-347
States	O	348-354
but	O	355-358
were	O	359-363
withdrawn	O	364-373
in	O	374-376
September	O	377-386
1997	O	387-391
because	O	392-399
of	O	400-402
concerns	O	403-411
over	O	412-416
adverse	O	417-424
effects	O	425-432
.	O	432-433

MATERIALS	O	434-443
AND	O	444-447
METHODS	O	448-455
:	O	455-456
We	O	457-459
conducted	O	460-469
a	O	470-471
prospective	O	472-483
surveillance	O	484-496
study	O	497-502
on	O	503-505
patients	O	506-514
diagnosed	O	515-524
with	O	525-529
pulmonary	B	530-539
hypertension	I	540-552
at	O	553-555
12	O	556-558
large	O	559-564
referral	O	565-573
centers	O	574-581
in	O	582-584
North	O	585-590
America	O	591-598
.	O	598-599

Data	O	600-604
collected	O	605-614
on	O	615-617
patients	O	618-626
seen	O	627-631
from	O	632-636
September	O	637-646
1	O	647-648
,	O	648-649
1996	O	650-654
,	O	654-655
to	O	656-658
December	O	659-667
31	O	668-670
,	O	670-671
1997	O	672-676
,	O	676-677
included	O	678-686
the	O	687-690
cause	O	691-696
of	O	697-699
the	O	700-703
pulmonary	B	704-713
hypertension	I	714-726
and	O	727-730
its	O	731-734
severity	O	735-743
.	O	743-744

Patients	O	745-753
with	O	754-758
no	O	759-761
identifiable	O	762-774
cause	O	775-780
of	O	781-783
pulmonary	B	784-793
hypertension	I	794-806
were	O	807-811
classed	O	812-819
as	O	820-822
PPH	B	823-826
.	O	826-827

A	O	828-829
history	O	830-837
of	O	838-840
drug	O	841-845
exposure	O	846-854
also	O	855-859
was	O	860-863
taken	O	864-869
with	O	870-874
special	O	875-882
attention	O	883-892
on	O	893-895
the	O	896-899
use	O	900-903
of	O	904-906
antidepressants	O	907-922
,	O	922-923
anorexigens	O	924-935
,	O	935-936
and	O	937-940
amphetamines	O	941-953
.	O	953-954

RESULTS	O	955-962
:	O	962-963
Five	O	964-968
hundred	O	969-976
seventy	O	977-984
-	O	984-985
nine	O	985-989
patients	O	990-998
were	O	999-1003
studied	O	1004-1011
,	O	1011-1012
205	O	1013-1016
with	O	1017-1021
PPH	B	1022-1025
and	O	1026-1029
374	O	1030-1033
with	O	1034-1038
pulmonary	B	1039-1048
hypertension	I	1049-1061
from	O	1062-1066
other	O	1067-1072
causes	O	1073-1079
(	O	1080-1081
secondary	O	1081-1090
pulmonary	B	1091-1100
hypertension	I	1101-1113
[	O	1114-1115
SPH	O	1115-1118
]	O	1118-1119
)	O	1119-1120
.	O	1120-1121

The	O	1122-1125
use	O	1126-1129
of	O	1130-1132
anorexigens	O	1133-1144
was	O	1145-1148
common	O	1149-1155
in	O	1156-1158
both	O	1159-1163
groups	O	1164-1170
.	O	1170-1171

However	O	1172-1179
,	O	1179-1180
of	O	1181-1183
the	O	1184-1187
medications	O	1188-1199
surveyed	O	1200-1208
,	O	1208-1209
only	O	1210-1214
the	O	1215-1218
fenfluramines	O	1219-1232
had	O	1233-1236
a	O	1237-1238
significant	O	1239-1250
preferential	O	1251-1263
association	O	1264-1275
with	O	1276-1280
PPH	B	1281-1284
as	O	1285-1287
compared	O	1288-1296
with	O	1297-1301
SPH	O	1302-1305
(	O	1306-1307
adjusted	O	1307-1315
odds	O	1316-1320
ratio	O	1321-1326
for	O	1327-1330
use	O	1331-1334
>	O	1335-1336
6	O	1337-1338
months	O	1339-1345
,	O	1345-1346
7	O	1347-1348
.	O	1348-1349
5	O	1349-1350
;	O	1350-1351
95	O	1352-1354
%	O	1354-1355
confidence	O	1356-1366
interval	O	1367-1375
,	O	1375-1376
1	O	1377-1378
.	O	1378-1379
7	O	1379-1380
to	O	1381-1383
32	O	1384-1386
.	O	1386-1387
4	O	1387-1388
)	O	1388-1389
.	O	1386-1387

The	O	1391-1394
association	O	1395-1406
was	O	1407-1410
stronger	O	1411-1419
with	O	1420-1424
longer	O	1425-1431
duration	O	1432-1440
of	O	1441-1443
use	O	1444-1447
when	O	1448-1452
compared	O	1453-1461
to	O	1462-1464
shorter	O	1465-1472
duration	O	1473-1481
of	O	1482-1484
use	O	1485-1488
and	O	1489-1492
was	O	1493-1496
more	O	1497-1501
pronounced	O	1502-1512
in	O	1513-1515
recent	O	1516-1522
users	O	1523-1528
than	O	1529-1533
in	O	1534-1536
remote	O	1537-1543
users	O	1544-1549
.	O	1549-1550

An	O	1551-1553
unexpectedly	O	1554-1566
high	O	1567-1571
(	O	1572-1573
11	O	1573-1575
.	O	1575-1576
4	O	1576-1577
%	O	1577-1578
)	O	1578-1579

number	O	1580-1586
of	O	1587-1589
patients	O	1590-1598
with	O	1599-1603
SPH	O	1604-1607
had	O	1608-1611
used	O	1612-1616
anorexigens	O	1617-1628
.	O	1628-1629

CONCLUSION	O	1630-1640
:	O	1640-1641
The	O	1642-1645
magnitude	O	1646-1655
of	O	1656-1658
the	O	1659-1662
association	O	1663-1674
with	O	1675-1679
PPH	B	1680-1683
,	O	1683-1684
the	O	1685-1688
increase	O	1689-1697
of	O	1698-1700
association	O	1701-1712
with	O	1713-1717
increasing	O	1718-1728
duration	O	1729-1737
of	O	1738-1740
use	O	1741-1744
,	O	1744-1745
and	O	1746-1749
the	O	1750-1753
specificity	O	1754-1765
for	O	1766-1769
fenfluramines	O	1770-1783
are	O	1784-1787
consistent	O	1788-1798
with	O	1799-1803
previous	O	1804-1812
studies	O	1813-1820
indicating	O	1821-1831
that	O	1832-1836
fenfluramines	O	1837-1850
are	O	1851-1854
causally	O	1855-1863
related	O	1864-1871
to	O	1872-1874
PPH	B	1875-1878
.	O	1878-1879

The	O	1880-1883
high	O	1884-1888
prevalence	O	1889-1899
of	O	1900-1902
anorexigen	O	1903-1913
use	O	1914-1917
in	O	1918-1920
patients	O	1921-1929
with	O	1930-1934
SPH	O	1935-1938
also	O	1939-1943
raises	O	1944-1950
the	O	1951-1954
possibility	O	1955-1966
that	O	1967-1971
these	O	1972-1977
drugs	O	1978-1983
precipitate	O	1984-1995
pulmonary	B	1996-2005
hypertension	I	2006-2018
in	O	2019-2021
patients	O	2022-2030
with	O	2031-2035
underlying	O	2036-2046
conditions	O	2047-2057
associated	O	2058-2068
with	O	2069-2073
SPH	O	2074-2077
.	O	2077-2078

Clinical	O	0-8
aspects	O	9-16
of	O	17-19
heparin	O	20-27
-	O	27-28
induced	O	28-35
thrombocytopenia	B	36-52
and	O	53-56
thrombosis	B	57-67
and	O	68-71
other	O	72-77
side	O	78-82
effects	O	83-90
of	O	91-93
heparin	O	94-101
therapy	O	102-109
.	O	109-110

Heparin	O	111-118
,	O	118-119
first	O	120-125
used	O	126-130
to	O	131-133
prevent	O	134-141
the	O	142-145
clotting	O	146-154
of	O	155-157
blood	O	158-163
in	O	164-166
vitro	O	167-172
,	O	172-173
has	O	174-177
been	O	178-182
clinically	O	183-193
used	O	194-198
to	O	199-201
treat	O	202-207
thrombosis	B	208-218
for	O	219-222
more	O	223-227
than	O	228-232
50	O	233-235
years	O	236-241
.	O	241-242

Although	O	243-251
several	O	252-259
new	O	260-263
anticoagulant	O	264-277
drugs	O	278-283
are	O	284-287
in	O	288-290
development	O	291-302
,	O	302-303
heparin	O	304-311
remains	O	312-319
the	O	320-323
anticoagulant	O	324-337
of	O	338-340
choice	O	341-347
to	O	348-350
treat	O	351-356
acute	O	357-362
thrombotic	B	363-373
episodes	O	374-382
.	O	382-383

The	O	384-387
clinical	O	388-396
effects	O	397-404
of	O	405-407
heparin	O	408-415
are	O	416-419
meritorious	O	420-431
,	O	431-432
but	O	433-436
side	O	437-441
effects	O	442-449
do	O	450-452
exist	O	453-458
.	O	458-459

Bleeding	B	460-468
is	O	469-471
the	O	472-475
primary	O	476-483
untoward	O	484-492
effect	O	493-499
of	O	500-502
heparin	O	503-510
.	O	510-511

Major	O	512-517
bleeding	B	518-526
is	O	527-529
of	O	530-532
primary	O	533-540
concern	O	541-548
in	O	549-551
patients	O	552-560
receiving	O	561-570
heparin	O	571-578
therapy	O	579-586
.	O	586-587

However	O	588-595
,	O	595-596
additional	O	597-607
important	O	608-617
untoward	O	618-626
effects	O	627-634
of	O	635-637
heparin	O	638-645
therapy	O	646-653
include	O	654-661
heparin	O	662-669
-	O	669-670
induced	O	670-677
thrombocytopenia	B	678-694
,	O	694-695
heparin	O	696-703
-	O	703-704
associated	O	704-714
osteoporosis	B	715-727
,	O	727-728
eosinophilia	B	729-741
,	O	741-742
skin	B	743-747
reactions	I	748-757
,	O	757-758
allergic	B	759-767
reactions	I	768-777
other	O	778-783
than	O	784-788
thrombocytopenia	B	789-805
,	O	805-806
alopecia	B	807-815
,	O	815-816
transaminasemia	O	817-832
,	O	832-833
hyperkalemia	B	834-846
,	O	846-847
hypoaldosteronism	B	848-865
,	O	865-866
and	O	867-870
priapism	B	871-879
.	O	879-880

These	O	881-886
side	O	887-891
effects	O	892-899
are	O	900-903
relatively	O	904-914
rare	O	915-919
in	O	920-922
a	O	923-924
given	O	925-930
individual	O	931-941
,	O	941-942
but	O	943-946
given	O	947-952
the	O	953-956
extremely	O	957-966
widespread	O	967-977
use	O	978-981
of	O	982-984
heparin	O	985-992
,	O	992-993
some	O	994-998
are	O	999-1002
quite	O	1003-1008
common	O	1009-1015
,	O	1015-1016
particularly	O	1017-1029
HITT	B	1030-1034
and	O	1035-1038
osteoporosis	B	1039-1051
.	O	1051-1052

Although	O	1053-1061
reasonable	O	1062-1072
incidences	O	1073-1083
of	O	1084-1086
many	O	1087-1091
of	O	1092-1094
these	O	1095-1100
side	O	1101-1105
effects	O	1106-1113
can	O	1114-1117
be	O	1118-1120
"	O	1121-1122
softly	O	1122-1128
"	O	1121-1122
deduced	O	1130-1137
from	O	1138-1142
current	O	1143-1150
reports	O	1151-1158
dealing	O	1159-1166
with	O	1167-1171
unfractionated	O	1172-1186
heparin	O	1187-1194
,	O	1194-1195
at	O	1196-1198
present	O	1199-1206
the	O	1207-1210
incidences	O	1211-1221
of	O	1222-1224
these	O	1225-1230
side	O	1231-1235
effects	O	1236-1243
with	O	1244-1248
newer	O	1249-1254
low	O	1255-1258
molecular	O	1259-1268
weight	O	1269-1275
heparins	O	1276-1284
appear	O	1285-1291
to	O	1292-1294
be	O	1295-1297
much	O	1298-1302
less	O	1303-1307
common	O	1308-1314
.	O	1314-1315

However	O	1316-1323
,	O	1323-1324
only	O	1325-1329
longer	O	1330-1336
experience	O	1337-1347
will	O	1348-1352
more	O	1353-1357
clearly	O	1358-1365
define	O	1366-1372
the	O	1373-1376
incidence	O	1377-1386
of	O	1387-1389
each	O	1390-1394
side	O	1395-1399
effect	O	1400-1406
with	O	1407-1411
low	O	1412-1415
molecular	O	1416-1425
weight	O	1426-1432
preparations	O	1433-1445
.	O	1445-1446

A	O	0-1
case	O	2-6
of	O	7-9
bilateral	O	10-19
optic	B	20-25
neuropathy	I	26-36
in	O	37-39
a	O	40-41
patient	O	42-49
on	O	50-52
tacrolimus	O	53-63
(	O	64-65
FK506	O	65-70
)	O	70-71
therapy	O	72-79
after	O	80-85
liver	O	86-91
transplantation	O	92-107
.	O	107-108

PURPOSE	O	109-116
:	O	116-117
To	O	118-120
report	O	121-127
a	O	128-129
case	O	130-134
of	O	135-137
bilateral	O	138-147
optic	B	148-153
neuropathy	I	154-164
in	O	165-167
a	O	168-169
patient	O	170-177
receiving	O	178-187
tacrolimus	O	188-198
(	O	199-200
FK	O	200-202
506	O	203-206
,	O	206-207
Prograf	O	208-215
;	O	215-216
Fujisawa	O	217-225
USA	O	226-229
,	O	229-230
Inc	O	231-234
,	O	234-235
Deerfield	O	236-245
,	O	245-246
Illinois	O	247-255
)	O	255-256
for	O	257-260
immunosuppression	O	261-278
after	O	279-284
orthotropic	O	285-296
liver	O	297-302
transplantation	O	303-318
.	O	318-319

METHOD	O	320-326
:	O	326-327
Case	O	328-332
report	O	333-339
.	O	339-340

In	O	341-343
a	O	344-345
58	O	346-348
-	O	348-349
year	O	349-353
-	O	348-349
old	O	354-357
man	O	358-361
receiving	O	362-371
tacrolimus	O	372-382
after	O	383-388
orthotropic	O	389-400
liver	O	401-406
transplantation	O	407-422
,	O	422-423
serial	O	424-430
neuro	O	431-436
-	O	436-437
ophthalmologic	O	437-451
examinations	O	452-464
and	O	465-468
laboratory	O	469-479
studies	O	480-487
were	O	488-492
performed	O	493-502
.	O	502-503

RESULTS	O	504-511
:	O	511-512
The	O	513-516
patient	O	517-524
had	O	525-528
episodic	O	529-537
deterioration	O	538-551
of	O	552-554
vision	O	555-561
in	O	562-564
both	O	565-569
eyes	O	570-574
,	O	574-575
with	O	576-580
clinical	O	581-589
features	O	590-598
resembling	O	599-609
ischemic	B	610-618
optic	I	619-624
neuropathies	I	625-637
.	O	637-638

Deterioration	B	639-652
of	I	653-655
vision	I	656-662
occurred	O	663-671
despite	O	672-679
discontinuation	O	680-695
of	O	696-698
the	O	699-702
tacrolimus	O	703-713
.	O	713-714

CONCLUSION	O	715-725
:	O	725-726
Tacrolimus	O	727-737
and	O	738-741
other	O	742-747
immunosuppressive	O	748-765
agents	O	766-772
may	O	773-776
be	O	777-779
associated	O	780-790
with	O	791-795
optic	B	796-801
nerve	I	802-807
toxicity	I	808-816
.	O	816-817

Hypercalcemia	B	0-13
,	O	13-14
arrhythmia	B	15-25
,	O	25-26
and	O	27-30
mood	O	31-35
stabilizers	O	36-47
.	O	47-48

Recent	O	49-55
findings	O	56-64
in	O	65-67
a	O	68-69
bipolar	B	70-77
patient	O	78-85
receiving	O	86-95
maintenance	O	96-107
lithium	O	108-115
therapy	O	116-123
who	O	124-127
developed	O	128-137
hypercalcemia	B	138-151
and	O	152-155
severe	O	156-162
bradyarrhythmia	B	163-178
prompted	O	179-187
the	O	188-191
authors	O	192-199
to	O	200-202
conduct	O	203-210
a	O	211-212
retrospective	O	213-226
study	O	227-232
of	O	233-235
bipolar	B	236-243
patients	O	244-252
with	O	253-257
lithium	O	258-265
-	O	265-266
associated	O	266-276
hypercalcemia	B	277-290
.	O	290-291

A	O	292-293
printout	O	294-302
of	O	303-305
all	O	306-309
cases	O	310-315
of	O	316-318
hypercalcemia	B	319-332
that	O	333-337
presented	O	338-347
during	O	348-354
a	O	355-356
1	O	357-358
-	O	358-359
year	O	359-363
period	O	364-370
was	O	371-374
generated	O	375-384
.	O	384-385

After	O	386-391
eliminating	O	392-403
spurious	O	404-412
hypercalcemias	B	413-427
or	O	428-430
those	O	431-436
associated	O	437-447
with	O	448-452
intravenous	O	453-464
fluids	O	465-471
,	O	471-472
the	O	473-476
authors	O	477-484
identified	O	485-495
18	O	496-498
non	O	499-502
-	O	502-503
lithium	O	503-510
-	O	502-503
treated	O	511-518
patients	O	519-527
with	O	528-532
hypercalcemias	B	533-547
related	O	548-555
to	O	556-558
malignancies	B	559-571
and	O	572-575
other	O	576-581
medical	O	582-589
conditions	O	590-600
(	O	601-602
group	O	602-607
A	O	608-609
)	O	609-610
and	O	611-614
12	O	615-617
patients	O	618-626
with	O	627-631
lithium	O	632-639
-	O	639-640
associated	O	640-650
hypercalcemia	B	651-664
(	O	665-666
group	O	666-671
B	O	672-673
)	O	673-674
.	O	674-675

Patients	O	676-684
in	O	685-687
group	O	688-693
B	O	694-695
were	O	696-700
not	O	701-704
comparable	O	705-715
to	O	716-718
those	O	719-724
in	O	725-727
group	O	728-733
A	O	734-735
,	O	735-736
as	O	737-739
the	O	740-743
latter	O	744-750
were	O	751-755
medically	O	756-765
compromised	O	766-777
and	O	778-781
were	O	782-786
receiving	O	787-796
multiple	O	797-805
pharmacotherapies	O	806-823
.	O	823-824

Thus	O	825-829
,	O	829-830
two	O	831-834
control	O	835-842
groups	O	843-849
were	O	850-854
generated	O	855-864
:	O	864-865
group	O	866-871
C1	O	872-874
,	O	874-875
which	O	876-881
included	O	882-890
age	O	891-894
-	O	894-895
and	O	896-899
sex	O	900-903
-	O	903-904
comparable	O	904-914
lithium	O	915-922
-	O	922-923
treated	O	923-930
bipolar	B	931-938
normocalcemic	O	939-952
patients	O	953-961
,	O	961-962
and	O	963-966
group	O	967-972
C2	O	973-975
,	O	975-976
which	O	977-982
included	O	983-991
bipolar	B	992-999
normocalcemic	O	1000-1013
patients	O	1014-1022
treated	O	1023-1030
with	O	1031-1035
anticonvulsant	O	1036-1050
mood	O	1051-1055
stabilizers	O	1056-1067
.	O	1067-1068

The	O	1069-1072
electrocardiographic	O	1073-1093
(	O	1094-1095
ECG	O	1095-1098
)	O	1098-1099
findings	O	1100-1108
for	O	1109-1112
patients	O	1113-1121
in	O	1122-1124
group	O	1125-1130
B	O	1131-1132
were	O	1133-1137
compared	O	1138-1146
with	O	1147-1151
those	O	1152-1157
of	O	1158-1160
patients	O	1161-1169
in	O	1170-1172
groups	O	1173-1179
C1	O	1180-1182
and	O	1183-1186
C2	O	1187-1189
.	O	1189-1190

It	O	1191-1193
was	O	1194-1197
found	O	1198-1203
that	O	1204-1208
these	O	1209-1214
groups	O	1215-1221
did	O	1222-1225
not	O	1226-1229
differ	O	1230-1236
in	O	1237-1239
their	O	1240-1245
overall	O	1246-1253
frequency	O	1254-1263
of	O	1264-1266
ECG	O	1267-1270
abnormalities	O	1271-1284
;	O	1284-1285
however	O	1286-1293
,	O	1293-1294
there	O	1295-1300
were	O	1301-1305
significant	O	1306-1317
differences	O	1318-1329
in	O	1330-1332
the	O	1333-1336
frequency	O	1337-1346
of	O	1347-1349
conduction	O	1350-1360
defects	O	1361-1368
.	O	1368-1369

Patients	O	1370-1378
with	O	1379-1383
hypercalcemia	B	1384-1397
resulting	O	1398-1407
from	O	1408-1412
medical	O	1413-1420
diseases	O	1421-1429
and	O	1430-1433
bipolar	B	1434-1441
patients	O	1442-1450
with	O	1451-1455
lithium	O	1456-1463
-	O	1463-1464
associated	O	1464-1474
hypercalcemia	B	1475-1488
had	O	1489-1492
significantly	O	1493-1506
higher	O	1507-1513
frequencies	O	1514-1525
of	O	1526-1528
conduction	O	1529-1539
defects	O	1540-1547
.	O	1547-1548

Patients	O	1549-1557
in	O	1558-1560
group	O	1561-1566
A	O	1567-1568
had	O	1569-1572
significant	O	1573-1584
mortality	O	1585-1594
at	O	1595-1597
2	O	1598-1599
-	O	1599-1600
year	O	1600-1604
follow	O	1605-1611
-	O	1611-1612
up	O	1612-1614
(	O	1615-1616
28	O	1616-1618
%	O	1618-1619
)	O	1619-1620
,	O	1620-1621
in	O	1622-1624
contrast	O	1625-1633
to	O	1634-1636
zero	O	1637-1641
mortality	O	1642-1651
in	O	1652-1654
the	O	1655-1658
other	O	1659-1664
three	O	1665-1670
groups	O	1671-1677
.	O	1677-1678

The	O	1679-1682
clinical	O	1683-1691
implications	O	1692-1704
of	O	1705-1707
these	O	1708-1713
findings	O	1714-1722
are	O	1723-1726
discussed	O	1727-1736
.	O	1736-1737

Attenuation	O	0-11
of	O	12-14
nephrotoxicity	B	15-29
by	O	30-32
a	O	33-34
novel	O	35-40
lipid	O	41-46
nanosphere	O	47-57
(	O	58-59
NS	O	59-61
-	O	61-62
718	O	62-65
)	O	65-66
incorporating	O	67-80
amphotericin	O	81-93
B	O	94-95
.	O	95-96
NS	O	97-99
-	O	99-100
718	O	100-103
,	O	103-104
a	O	105-106
lipid	O	107-112
nanosphere	O	113-123
incorporating	O	124-137
amphotericin	O	138-150
B	O	151-152
,	O	152-153
is	O	154-156
effective	O	157-166
against	O	167-174
pathogenic	O	175-185
fungi	O	186-191
and	O	192-195
has	O	196-199
low	O	200-203
toxicity	B	204-212
.	O	212-213

We	O	214-216
compared	O	217-225
the	O	226-229
toxicity	B	230-238
of	O	239-241
NS	O	242-244
-	O	244-245
718	O	245-248
with	O	249-253
that	O	254-258
of	O	259-261
Fungizone	O	262-271
(	O	272-273
amphotericin	O	273-285
B	O	286-287
-	O	287-288
sodium	O	288-294
deoxycholate	O	295-307
;	O	307-308
D	O	309-310
-	O	310-311
AmB	O	311-314
)	O	314-315
in	O	316-318
vitro	O	319-324
using	O	325-330
renal	O	331-336
cell	O	337-341
cultures	O	342-350
and	O	351-354
in	O	355-357
vivo	O	358-362
by	O	363-365
biochemical	O	366-377
analysis	O	378-386
,	O	386-387
histopathological	O	388-405
study	O	406-411
of	O	412-414
the	O	415-418
kidney	O	419-425
and	O	426-429
pharmacokinetic	O	430-445
study	O	446-451
of	O	452-454
amphotericin	O	455-467
B	O	468-469
following	O	470-479
intravenous	O	480-491
infusion	O	492-500
of	O	501-503
the	O	504-507
formulation	O	508-519
in	O	520-522
rats	O	523-527
.	O	527-528

Incubation	O	529-539
with	O	540-544
NS	O	545-547
-	O	547-548
718	O	548-551
resulted	O	552-560
in	O	561-563
significantly	O	564-577
less	O	578-582
damage	O	583-589
of	O	590-592
cultured	O	593-601
human	O	602-607
renal	O	608-613
proximal	O	614-622
tubular	O	623-630
epithelial	O	631-641
cells	O	642-647
compared	O	648-656
with	O	657-661
D	O	662-663
-	O	663-664
AmB	O	664-667
.	O	667-668

Serum	O	669-674
blood	O	675-680
urea	O	681-685
and	O	686-689
creatinine	O	690-700
concentrations	O	701-715
increased	O	716-725
significantly	O	726-739
in	O	740-742
rats	O	743-747
given	O	748-753
an	O	754-756
iv	O	757-759
infusion	O	760-768
of	O	769-771
D	O	772-773
-	O	773-774
AmB	O	774-777
3	O	778-779
mg	O	780-782
/	O	782-783
kg	O	783-785
but	O	786-789
not	O	790-793
in	O	794-796
those	O	797-802
given	O	803-808
the	O	809-812
same	O	813-817
dose	O	818-822
of	O	823-825
NS	O	826-828
-	O	828-829
718	O	829-832
.	O	832-833

Histopathological	O	834-851
examination	O	852-863
of	O	864-866
the	O	867-870
kidney	O	871-877
showed	O	878-884
tubular	B	885-892
necrosis	I	893-901
in	O	902-904
D	O	905-906
-	O	906-907
AmB	O	907-910
-	O	906-907
treated	O	911-918
rats	O	919-923
but	O	924-927
no	O	928-930
change	O	931-937
in	O	938-940
NS	O	941-943
-	O	943-944
718	O	944-947
-	O	943-944
treated	O	948-955
rats	O	956-960
.	O	960-961

Amphotericin	O	962-974
B	O	975-976
concentrations	O	977-991
in	O	992-994
the	O	995-998
kidney	O	999-1005
in	O	1006-1008
NS	O	1009-1011
-	O	1011-1012
718	O	1012-1015
-	O	1011-1012
treated	O	1016-1023
rats	O	1024-1028
were	O	1029-1033
higher	O	1034-1040
than	O	1041-1045
those	O	1046-1051
in	O	1052-1054
D	O	1055-1056
-	O	1056-1057
AmB	O	1057-1060
-	O	1056-1057
treated	O	1061-1068
rats	O	1069-1073
.	O	1073-1074

Our	O	1075-1078
in	O	1079-1081
vitro	O	1082-1087
and	O	1088-1091
in	O	1092-1094
vivo	O	1095-1099
results	O	1100-1107
suggest	O	1108-1115
that	O	1116-1120
incorporation	O	1121-1134
of	O	1135-1137
amphotericin	O	1138-1150
B	O	1151-1152
into	O	1153-1157
lipid	O	1158-1163
nanospheres	O	1164-1175
of	O	1176-1178
NS	O	1179-1181
-	O	1181-1182
718	O	1182-1185
attenuates	O	1186-1196
the	O	1197-1200
nephrotoxicity	B	1201-1215
of	O	1216-1218
amphotericin	O	1219-1231
B	O	1232-1233
.	O	1233-1234

Patterns	O	0-8
of	O	9-11
sulfadiazine	O	12-24
acute	B	25-30
nephrotoxicity	I	31-45
.	O	45-46

Sulfadiazine	O	47-59
acute	B	60-65
nephrotoxicity	I	66-80
is	O	81-83
reviving	O	84-92
specially	O	93-102
because	O	103-110
of	O	111-113
its	O	114-117
use	O	118-121
in	O	122-124
toxoplasmosis	B	125-138
in	O	139-141
HIV	O	142-145
-	O	145-146
positive	O	146-154
patients	O	155-163
.	O	163-164

We	O	165-167
report	O	168-174
4	O	175-176
cases	O	177-182
,	O	182-183
one	O	184-187
of	O	188-190
them	O	191-195
in	O	196-198
a	O	199-200
previously	O	201-211
healthy	O	212-219
person	O	220-226
.	O	226-227

Under	O	228-233
treatment	O	234-243
with	O	244-248
sulfadiazine	O	249-261
they	O	262-266
developed	O	267-276
oliguria	B	277-285
,	O	285-286
abdominal	B	287-296
pain	I	297-301
,	O	301-302
renal	B	303-308
failure	I	309-316
and	O	317-320
showed	O	321-327
multiple	O	328-336
radiolucent	O	337-348
renal	B	349-354
calculi	I	355-362
in	O	363-365
echography	O	366-376
.	O	376-377

All	O	378-381
patients	O	382-390
recovered	O	391-400
their	O	401-406
previous	O	407-415
normal	O	416-422
renal	O	423-428
function	O	429-437
after	O	438-443
adequate	O	444-452
hydration	O	453-462
and	O	463-466
alcalinization	O	467-481
.	O	481-482

A	O	483-484
nephrostomy	O	485-496
tube	O	497-501
had	O	502-505
to	O	506-508
be	O	509-511
placed	O	512-518
in	O	519-521
one	O	522-525
of	O	526-528
the	O	529-532
patients	O	533-541
for	O	542-545
ureteral	B	546-554
lithiasis	I	555-564
in	O	565-567
a	O	568-569
single	O	570-576
functional	O	577-587
kidney	O	588-594
.	O	594-595

None	O	596-600
of	O	601-603
them	O	604-608
needed	O	609-615
dialysis	O	616-624
or	O	625-627
a	O	628-629
renal	O	630-635
biopsy	O	636-642
because	O	643-650
of	O	651-653
a	O	654-655
typical	O	656-663
benign	O	664-670
course	O	671-677
.	O	677-678

Treatment	O	679-688
with	O	689-693
sulfadiazine	O	694-706
requires	O	707-715
exquisite	O	716-725
control	O	726-733
of	O	734-736
renal	O	737-742
function	O	743-751
,	O	751-752
an	O	753-755
increase	O	756-764
in	O	765-767
water	O	768-773
ingestion	O	774-783
and	O	784-787
possibly	O	788-796
the	O	797-800
alcalinization	O	801-815
of	O	816-818
the	O	819-822
urine	O	823-828
.	O	828-829

We	O	830-832
communicate	O	833-844
a	O	845-846
case	O	847-851
in	O	852-854
a	O	855-856
previously	O	857-867
healthy	O	868-875
person	O	876-882
,	O	882-883
a	O	884-885
fact	O	886-890
not	O	891-894
found	O	895-900
in	O	901-903
the	O	904-907
recent	O	908-914
literature	O	915-925
.	O	925-926

Probably	O	927-935
many	O	936-940
more	O	941-945
cases	O	946-951
are	O	952-955
not	O	956-959
detected	O	960-968
.	O	968-969

We	O	970-972
think	O	973-978
that	O	979-983
a	O	984-985
prospective	O	986-997
study	O	998-1003
would	O	1004-1009
be	O	1010-1012
useful	O	1013-1019
.	O	1019-1020

Downbeat	B	0-8
nystagmus	I	9-18
associated	O	19-29
with	O	30-34
intravenous	O	35-46
patient	O	47-54
-	O	54-55
controlled	O	55-65
administration	O	66-80
of	O	81-83
morphine	O	84-92
.	O	92-93

IMPLICATIONS	O	94-106
:	O	106-107
This	O	108-112
case	O	113-117
documents	O	118-127
a	O	128-129
patient	O	130-137
who	O	138-141
developed	O	142-151
dizziness	B	152-161
with	O	162-166
downbeating	B	167-178
nystagmus	I	179-188
while	O	189-194
receiving	O	195-204
a	O	205-206
relatively	O	207-217
large	O	218-223
dose	O	224-228
of	O	229-231
IV	O	232-234
patient	O	235-242
-	O	242-243
controlled	O	243-253
analgesia	O	254-263
morphine	O	264-272
.	O	272-273

Although	O	274-282
there	O	283-288
have	O	289-293
been	O	294-298
case	O	299-303
reports	O	304-311
of	O	312-314
epidural	O	315-323
morphine	O	324-332
with	O	333-337
these	O	338-343
symptoms	O	344-352
and	O	353-356
signs	O	357-362
,	O	362-363
this	O	364-368
has	O	369-372
not	O	373-376
been	O	377-381
previously	O	382-392
documented	O	393-403
with	O	404-408
IV	O	409-411
or	O	412-414
patient	O	415-422
-	O	422-423
controlled	O	423-433
analgesia	O	434-443
morphine	O	444-452
.	O	452-453

Hemodynamic	O	0-11
and	O	12-15
antiadrenergic	O	16-30
effects	O	31-38
of	O	39-41
dronedarone	O	42-53
and	O	54-57
amiodarone	O	58-68
in	O	69-71
animals	O	72-79
with	O	80-84
a	O	85-86
healed	O	87-93
myocardial	B	94-104
infarction	I	105-115
.	O	115-116

The	O	117-120
hemodynamic	O	121-132
and	O	133-136
antiadrenergic	O	137-151
effects	O	152-159
of	O	160-162
dronedarone	O	163-174
,	O	174-175
a	O	176-177
noniodinated	O	178-190
compound	O	191-199
structurally	O	200-212
related	O	213-220
to	O	221-223
amiodarone	O	224-234
,	O	234-235
were	O	236-240
compared	O	241-249
with	O	250-254
those	O	255-260
of	O	261-263
amiodarone	O	264-274
after	O	275-280
prolonged	O	281-290
oral	O	291-295
administration	O	296-310
,	O	310-311
both	O	312-316
at	O	317-319
rest	O	320-324
and	O	325-328
during	O	329-335
sympathetic	O	336-347
stimulation	O	348-359
in	O	360-362
conscious	O	363-372
dogs	O	373-377
with	O	378-382
a	O	383-384
healed	O	385-391
myocardial	B	392-402
infarction	I	403-413
.	O	413-414

All	O	415-418
dogs	O	419-423
(	O	424-425
n	O	425-426
=	O	427-428
6	O	429-430
)	O	430-431
randomly	O	432-440
received	O	441-449
orally	O	450-456
dronedarone	O	457-468
(	O	469-470
10	O	470-472
and	O	473-476
30	O	477-479
mg	O	480-482
/	O	482-483
kg	O	483-485
)	O	485-486
,	O	486-487
amiodarone	O	488-498
(	O	499-500
10	O	500-502
and	O	503-506
30	O	507-509
mg	O	510-512
/	O	512-513
kg	O	513-515
)	O	515-516
,	O	516-517
and	O	518-521
placebo	O	522-529
twice	O	530-535
daily	O	536-541
for	O	542-545
7	O	546-547
days	O	548-552
,	O	552-553
with	O	554-558
a	O	559-560
3	O	561-562
-	O	562-563
week	O	563-567
washout	O	568-575
between	O	576-583
consecutive	O	584-595
treatments	O	596-606
.	O	606-607

Heart	O	608-613
rate	O	614-618
(	O	619-620
HR	O	620-622
)	O	622-623
,	O	623-624
mean	O	625-629
arterial	O	630-638
pressure	O	639-647
(	O	648-649
MBP	O	649-652
)	O	652-653
,	O	653-654
positive	O	655-663
rate	O	664-668
of	O	669-671
increase	O	672-680
of	O	681-683
left	O	684-688
ventricular	O	689-700
pressure	O	701-709
(	O	710-711
+	O	711-712
LVdP	O	712-716
/	O	716-717
dt	O	717-719
)	O	719-720
,	O	720-721
echocardiographically	O	722-743
assessed	O	744-752
left	O	753-757
ventricular	O	758-769
ejection	O	770-778
fraction	O	779-787
(	O	788-789
LVEF	O	789-793
)	O	793-794
,	O	794-795
and	O	796-799
fractional	O	800-810
shortening	O	811-821
(	O	822-823
FS	O	823-825
)	O	825-826
,	O	826-827
as	O	828-830
well	O	831-835
as	O	836-838
chronotropic	O	839-851
response	O	852-860
to	O	861-863
isoproterenol	O	864-877
and	O	878-881
exercise	O	882-890
-	O	890-891
induced	O	891-898
sympathetic	O	899-910
stimulation	O	911-922
were	O	923-927
evaluated	O	928-937
under	O	938-943
baseline	O	944-952
and	O	953-956
posttreatment	O	957-970
conditions	O	971-981
.	O	981-982

Resting	O	983-990
values	O	991-997
of	O	998-1000
LVEF	O	1001-1005
,	O	1005-1006
FS	O	1007-1009
,	O	1009-1010
+	O	1011-1012
LVdP	O	1012-1016
/	O	1016-1017
dt	O	1017-1019
,	O	1019-1020
and	O	1021-1024
MBP	O	1025-1028
remained	O	1029-1037
unchanged	O	1038-1047
whatever	O	1048-1056
the	O	1057-1060
drug	O	1061-1065
and	O	1066-1069
the	O	1070-1073
dosing	O	1074-1080
regimen	O	1081-1088
,	O	1088-1089
whereas	O	1090-1097
resting	O	1098-1105
HR	O	1106-1108
was	O	1109-1112
significantly	O	1113-1126
and	O	1127-1130
dose	O	1131-1135
-	O	1135-1136
dependently	O	1136-1147
lowered	O	1148-1155
after	O	1156-1161
dronedarone	O	1162-1173
and	O	1174-1177
to	O	1178-1180
a	O	1181-1182
lesser	O	1183-1189
extent	O	1190-1196
after	O	1197-1202
amiodarone	O	1203-1213
.	O	1213-1214

Both	O	1215-1219
dronedarone	O	1220-1231
and	O	1232-1235
amiodarone	O	1236-1246
significantly	O	1247-1260
reduced	O	1261-1268
the	O	1269-1272
exercise	O	1273-1281
-	O	1281-1282
induced	O	1282-1289
tachycardia	B	1290-1301
and	O	1302-1305
,	O	1305-1306
at	O	1307-1309
the	O	1310-1313
highest	O	1314-1321
dose	O	1322-1326
,	O	1326-1327
decreased	O	1328-1337
the	O	1338-1341
isoproterenol	O	1342-1355
-	O	1355-1356
induced	O	1356-1363
tachycardia	B	1364-1375
.	O	1375-1376

Thus	O	1377-1381
,	O	1381-1382
dronedarone	O	1383-1394
and	O	1395-1398
amiodarone	O	1399-1409
displayed	O	1410-1419
a	O	1420-1421
similar	O	1422-1429
level	O	1430-1435
of	O	1436-1438
antiadrenergic	O	1439-1453
effect	O	1454-1460
and	O	1461-1464
did	O	1465-1468
not	O	1469-1472
impair	O	1473-1479
the	O	1480-1483
resting	O	1484-1491
left	O	1492-1496
ventricular	O	1497-1508
function	O	1509-1517
.	O	1517-1518

Consequently	O	1519-1531
,	O	1531-1532
dronedarone	O	1533-1544
might	O	1545-1550
be	O	1551-1553
particularly	O	1554-1566
suitable	O	1567-1575
for	O	1576-1579
the	O	1580-1583
treatment	O	1584-1593
and	O	1594-1597
prevention	O	1598-1608
of	O	1609-1611
various	O	1612-1619
clinical	O	1620-1628
arrhythmias	B	1629-1640
,	O	1640-1641
without	O	1642-1649
compromising	O	1650-1662
the	O	1663-1666
left	O	1667-1671
ventricular	O	1672-1683
function	O	1684-1692
.	O	1692-1693

Phase	O	0-5
2	O	6-7
trial	O	8-13
of	O	14-16
liposomal	O	17-26
doxorubicin	O	27-38
(	O	39-40
40	O	40-42
mg	O	43-45
/	O	45-46
m	O	43-44
(	O	47-48
2	O	48-49
)	O	49-50
)	O	49-50
in	O	52-54
platinum	O	55-63
/	O	63-64
paclitaxel	O	64-74
-	O	74-75
refractory	O	75-85
ovarian	B	86-93
and	I	94-97
fallopian	I	98-107
tube	I	108-112
cancers	I	113-120
and	O	121-124
primary	O	125-132
carcinoma	B	133-142
of	I	143-145
the	I	146-149
peritoneum	I	150-160
.	O	160-161

BACKGROUND	O	162-172
:	O	172-173
Several	O	174-181
studies	O	182-189
have	O	190-194
demonstrated	O	195-207
liposomal	O	208-217
doxorubicin	O	218-229
(	O	230-231
Doxil	O	231-236
)	O	236-237
to	O	238-240
be	O	241-243
an	O	244-246
active	O	247-253
antineoplastic	O	254-268
agent	O	269-274
in	O	275-277
platinum	O	278-286
-	O	286-287
resistant	O	287-296
ovarian	B	297-304
cancer	I	305-311
,	O	311-312
with	O	313-317
dose	O	318-322
limiting	O	323-331
toxicity	B	332-340
of	O	341-343
the	O	344-347
standard	O	348-356
dosing	O	357-363
regimen	O	364-371
(	O	372-373
50	O	373-375
mg	O	376-378
/	O	378-379
m	O	376-377
(	O	380-381
2	O	381-382
)	O	382-383
q	O	384-385
4	O	386-387
weeks	O	388-393
)	O	393-394
being	O	395-400
severe	O	401-407
erythrodysesthesia	B	408-426
(	O	427-428
"	O	428-429
hand	B	429-433
-	I	433-434
foot	I	434-438
syndrome	I	439-447
"	O	447-448
)	O	448-449
and	O	450-453
stomatitis	B	454-464
.	O	464-465

We	O	466-468
wished	O	469-475
to	O	476-478
develop	O	479-486
a	O	487-488
more	O	489-493
tolerable	O	494-503
liposomal	O	504-513
doxorubicin	O	514-525
treatment	O	526-535
regimen	O	536-543
and	O	544-547
document	O	548-556
its	O	557-560
level	O	561-566
of	O	567-569
activity	O	570-578
in	O	579-581
a	O	582-583
well	O	584-588
-	O	588-589
defined	O	589-596
patient	O	597-604
population	O	605-615
with	O	616-620
platinum	O	621-629
/	O	629-630
paclitaxel	O	630-640
-	O	640-641
refractory	O	641-651
disease	O	652-659
.	O	659-660

METHODS	O	661-668
AND	O	669-672
MATERIALS	O	673-682
:	O	682-683
Patients	O	684-692
with	O	693-697
ovarian	B	698-705
or	I	706-708
fallopian	I	709-718
tube	I	719-723
cancers	I	724-731
or	O	732-734
primary	O	735-742
peritoneal	B	743-753
carcinoma	I	754-763
with	O	764-768
platinum	O	769-777
/	O	777-778
paclitaxel	O	778-788
-	O	788-789
refractory	O	789-799
disease	O	800-807
(	O	808-809
stable	O	809-815
or	O	816-818
progressive	O	819-830
disease	O	831-838
following	O	839-848
treatment	O	849-858
with	O	859-863
these	O	864-869
agents	O	870-876
or	O	877-879
previous	O	880-888
objective	O	889-898
response	O	899-907
<	O	908-909
3	O	909-910
months	O	911-917
in	O	918-920
duration	O	921-929
)	O	929-930
were	O	931-935
treated	O	936-943
with	O	944-948
liposomal	O	949-958
doxorubicin	O	959-970
at	O	971-973
a	O	974-975
dose	O	976-980
of	O	981-983
40	O	984-986
mg	O	987-989
/	O	989-990
m	O	987-988
(	O	991-992
2	O	992-993
)	O	993-994
q	O	995-996
4	O	997-998
weeks	O	999-1004
.	O	1004-1005

RESULTS	O	1006-1013
:	O	1013-1014
A	O	1015-1016
total	O	1017-1022
of	O	1023-1025
49	O	1026-1028
patients	O	1029-1037
(	O	1038-1039
median	O	1039-1045
age	O	1046-1049
:	O	1049-1050
60	O	1051-1053
;	O	1053-1054
range	O	1055-1060
41	O	1061-1063
-	O	1063-1064
81	O	1064-1066
)	O	1066-1067
entered	O	1068-1075
this	O	1076-1080
phase	O	1081-1086
2	O	1087-1088
trial	O	1089-1094
.	O	1094-1095

The	O	1096-1099
median	O	1100-1106
number	O	1107-1113
of	O	1114-1116
prior	O	1117-1122
regimens	O	1123-1131
was	O	1132-1135
2	O	1136-1137
(	O	1138-1139
range	O	1139-1144
:	O	1144-1145
1	O	1146-1147
-	O	1147-1148
6	O	1148-1149
)	O	1149-1150
.	O	1150-1151

Six	O	1152-1155
(	O	1156-1157
12	O	1157-1159
%	O	1159-1160
)	O	1160-1161
and	O	1162-1165
4	O	1166-1167
(	O	1168-1169
8	O	1169-1170
%	O	1170-1171
)	O	1171-1172
patients	O	1173-1181
experienced	O	1182-1193
grade	O	1194-1199
2	O	1200-1201
hand	B	1202-1206
-	I	1206-1207
foot	I	1207-1211
syndrome	I	1212-1220
and	O	1221-1224
stomatitis	B	1225-1235
,	O	1235-1236
respectively	O	1237-1249
(	O	1250-1251
no	O	1251-1253
episodes	O	1254-1262
of	O	1263-1265
grade	O	1266-1271
3	O	1272-1273
)	O	1273-1274
.	O	1274-1275

One	O	1276-1279
patient	O	1280-1287
developed	O	1288-1297
grade	O	1298-1303
3	O	1304-1305
diarrhea	B	1306-1314
requiring	O	1315-1324
hospitalization	O	1325-1340
for	O	1341-1344
hydration	O	1345-1354
.	O	1354-1355

Six	O	1356-1359
(	O	1360-1361
12	O	1361-1363
%	O	1363-1364
)	O	1364-1365
individuals	O	1366-1377
required	O	1378-1386
dose	O	1387-1391
reductions	O	1392-1402
.	O	1402-1403

The	O	1404-1407
median	O	1408-1414
number	O	1415-1421
of	O	1422-1424
courses	O	1425-1432
of	O	1433-1435
liposomal	O	1436-1445
doxorubicin	O	1446-1457
administered	O	1458-1470
on	O	1471-1473
this	O	1474-1478
protocol	O	1479-1487
was	O	1488-1491
2	O	1492-1493
(	O	1494-1495
range	O	1495-1500
:	O	1500-1501
1	O	1502-1503
-	O	1503-1504
12	O	1504-1506
)	O	1506-1507
.	O	1507-1508

Four	O	1509-1513
of	O	1514-1516
44	O	1517-1519
patients	O	1520-1528
(	O	1529-1530
9	O	1530-1531
%	O	1531-1532
)	O	1532-1533
evaluable	O	1534-1543
for	O	1544-1547
response	O	1548-1556
exhibited	O	1557-1566
objective	O	1567-1576
and	O	1577-1580
subjective	O	1581-1591
evidence	O	1592-1600
of	O	1601-1603
an	O	1604-1606
antineoplastic	O	1607-1621
effect	O	1622-1628
of	O	1629-1631
therapy	O	1632-1639
.	O	1639-1640

CONCLUSION	O	1641-1651
:	O	1651-1652
This	O	1653-1657
modified	O	1658-1666
liposomal	O	1667-1676
doxorubicin	O	1677-1688
regimen	O	1689-1696
results	O	1697-1704
in	O	1705-1707
less	O	1708-1712
toxicity	B	1713-1721
(	O	1722-1723
stomatitis	B	1723-1733
,	O	1733-1734
hand	B	1735-1739
-	I	1739-1740
foot	I	1740-1744
syndrome	I	1745-1753
)	O	1753-1754
than	O	1755-1759
the	O	1760-1763
standard	O	1764-1772
FDA	O	1773-1776
-	O	1776-1777
approved	O	1777-1785
dose	O	1786-1790
schedule	O	1791-1799
.	O	1799-1800

Definite	O	1801-1809
,	O	1809-1810
although	O	1811-1819
limited	O	1820-1827
,	O	1827-1828
antineoplastic	O	1829-1843
activity	O	1844-1852
is	O	1853-1855
observed	O	1856-1864
in	O	1865-1867
patients	O	1868-1876
with	O	1877-1881
well	O	1882-1886
-	O	1886-1887
defined	O	1887-1894
platinum	O	1895-1903
-	O	1903-1904
and	O	1905-1908
paclitaxel	O	1909-1919
-	O	1919-1920
refractory	O	1920-1930
ovarian	B	1931-1938
cancer	I	1939-1945
.	O	1945-1946

Efficacy	O	0-8
of	O	9-11
olanzapine	O	12-22
in	O	23-25
acute	O	26-31
bipolar	B	32-39
mania	I	40-45
:	O	45-46
a	O	47-48
double	O	49-55
-	O	55-56
blind	O	56-61
,	O	61-62
placebo	O	63-70
-	O	70-71
controlled	O	71-81
study	O	82-87
.	O	87-88

The	O	89-92
Olanzipine	O	93-103
HGGW	O	104-108
Study	O	109-114
Group	O	115-120
.	O	120-121

BACKGROUND	O	122-132
:	O	132-133
We	O	134-136
compared	O	137-145
the	O	146-149
efficacy	O	150-158
and	O	159-162
safety	O	163-169
of	O	170-172
olanzapine	O	173-183
vs	O	184-186
placebo	O	187-194
for	O	195-198
the	O	199-202
treatment	O	203-212
of	O	213-215
acute	O	216-221
bipolar	B	222-229
mania	I	230-235
.	O	235-236

METHODS	O	237-244
:	O	244-245
Four	O	246-250
-	O	250-251
week	O	251-255
,	O	255-256
randomized	O	257-267
,	O	267-268
double	O	269-275
-	O	275-276
blind	O	276-281
,	O	281-282
parallel	O	283-291
study	O	292-297
.	O	297-298

A	O	299-300
total	O	301-306
of	O	307-309
115	O	310-313
patients	O	314-322
with	O	323-327
a	O	328-329
DSM	O	330-333
-	O	333-334
IV	O	334-336
diagnosis	O	337-346
of	O	347-349
bipolar	B	350-357
disorder	I	358-366
,	O	366-367
manic	B	368-373
or	O	374-376
mixed	O	377-382
,	O	382-383
were	O	384-388
randomized	O	389-399
to	O	400-402
olanzapine	O	403-413
,	O	413-414
5	O	415-416
to	O	417-419
20	O	420-422
mg	O	423-425
/	O	425-426
d	O	426-427
(	O	428-429
n	O	429-430
=	O	431-432
55	O	433-435
)	O	435-436
,	O	436-437
or	O	438-440
placebo	O	441-448
(	O	449-450
n	O	450-451
=	O	452-453
60	O	454-456
)	O	456-457
.	O	457-458

The	O	459-462
primary	O	463-470
efficacy	O	471-479
measure	O	480-487
was	O	488-491
the	O	492-495
Young	O	496-501
-	O	501-502
Mania	B	502-507
Rating	O	508-514
Scale	O	515-520
(	O	521-522
Y	O	522-523
-	O	523-524
MRS	O	524-527
)	O	527-528
total	O	529-534
score	O	535-540
.	O	540-541

Response	O	542-550
and	O	551-554
euthymia	O	555-563
were	O	564-568
defined	O	569-576
,	O	576-577
a	O	578-579
priori	O	580-586
,	O	586-587
as	O	588-590
at	O	591-593
least	O	594-599
a	O	600-601
50	O	602-604
%	O	604-605
improvement	O	606-617
from	O	618-622
baseline	O	623-631
to	O	632-634
end	O	635-638
point	O	639-644
and	O	645-648
as	O	649-651
a	O	652-653
score	O	654-659
of	O	660-662
no	O	663-665
less	O	666-670
than	O	671-675
12	O	676-678
at	O	679-681
end	O	682-685
point	O	686-691
in	O	692-694
the	O	695-698
Y	O	699-700
-	O	700-701
MRS	O	701-704
total	O	705-710
score	O	711-716
,	O	716-717
respectively	O	718-730
.	O	730-731

Safety	O	732-738
was	O	739-742
assessed	O	743-751
using	O	752-757
adverse	O	758-765
events	O	766-772
,	O	772-773
Extrapyramidal	B	774-788
Symptom	I	789-796
(	O	797-798
EPS	B	798-801
)	O	801-802
rating	O	803-809
scales	O	810-816
,	O	816-817
laboratory	O	818-828
values	O	829-835
,	O	835-836
electrocardiograms	O	837-855
,	O	855-856
vital	O	857-862
signs	O	863-868
,	O	868-869
and	O	870-873
weight	O	874-880
change	O	881-887
.	O	887-888

RESULTS	O	889-896
:	O	896-897
Olanzapine	O	898-908
-	O	908-909
treated	O	909-916
patients	O	917-925
demonstrated	O	926-938
a	O	939-940
statistically	O	941-954
significant	O	955-966
greater	O	967-974
mean	O	975-979
(	O	980-981
+	O	981-982
/	O	982-983
-	O	983-984
SD	O	985-987
)	O	987-988
improvement	O	989-1000
in	O	1001-1003
Y	O	1004-1005
-	O	1005-1006
MRS	O	1006-1009
total	O	1010-1015
score	O	1016-1021
than	O	1022-1026
placebo	O	1027-1034
-	O	1034-1035
treated	O	1035-1042
patients	O	1043-1051
(	O	1052-1053
-	O	1053-1054
14	O	1054-1056
.	O	1056-1057
8	O	1057-1058
+	O	1059-1060
/	O	1060-1061
-	O	1061-1062
12	O	1063-1065
.	O	1065-1066
5	O	1066-1067
and	O	1068-1071
-	O	1072-1073
8	O	1073-1074
.	O	1074-1075
1	O	1075-1076
+	O	1077-1078
/	O	1078-1079
-	O	1079-1080
12	O	1081-1083
.	O	1083-1084
7	O	1084-1085
,	O	1085-1086
respectively	O	1087-1099
;	O	1099-1100
P	O	1101-1102
<	O	1102-1103
.	O	1103-1104
001	O	1104-1107
)	O	1107-1108
,	O	1108-1109
which	O	1110-1115
was	O	1116-1119
evident	O	1120-1127
at	O	1128-1130
the	O	1131-1134
first	O	1135-1140
postbaseline	O	1141-1153
observation	O	1154-1165
1	O	1166-1167
week	O	1168-1172
after	O	1173-1178
randomization	O	1179-1192
and	O	1193-1196
was	O	1197-1200
maintained	O	1201-1211
throughout	O	1212-1222
the	O	1223-1226
study	O	1227-1232
(	O	1233-1234
last	O	1234-1238
observation	O	1239-1250
carried	O	1251-1258
forward	O	1259-1266
)	O	1266-1267
.	O	1267-1268

Olanzapine	O	1269-1279
-	O	1279-1280
treated	O	1280-1287
patients	O	1288-1296
demonstrated	O	1297-1309
a	O	1310-1311
higher	O	1312-1318
rate	O	1319-1323
of	O	1324-1326
response	O	1327-1335
(	O	1336-1337
65	O	1337-1339
%	O	1339-1340
vs	O	1341-1343
43	O	1344-1346
%	O	1346-1347
,	O	1347-1348
respectively	O	1349-1361
;	O	1361-1362
P	O	1363-1364
=	O	1365-1366
.	O	1366-1367
02	O	1367-1369
)	O	1369-1370
and	O	1371-1374
euthymia	O	1375-1383
(	O	1384-1385
61	O	1385-1387
%	O	1387-1388
vs	O	1389-1391
36	O	1392-1394
%	O	1394-1395
,	O	1395-1396
respectively	O	1397-1409
;	O	1409-1410
P	O	1411-1412
=	O	1413-1414
.	O	1414-1415
01	O	1416-1418
)	O	1418-1419
than	O	1420-1424
placebo	O	1425-1432
-	O	1432-1433
treated	O	1433-1440
patients	O	1441-1449
.	O	1449-1450

There	O	1451-1456
were	O	1457-1461
no	O	1462-1464
statistically	O	1465-1478
significant	O	1479-1490
differences	O	1491-1502
in	O	1503-1505
EPSs	B	1506-1510
between	O	1511-1518
groups	O	1519-1525
.	O	1525-1526

However	O	1527-1534
,	O	1534-1535
olanzapine	O	1536-1546
-	O	1546-1547
treated	O	1547-1554
patients	O	1555-1563
had	O	1564-1567
a	O	1568-1569
statistically	O	1570-1583
significant	O	1584-1595
greater	O	1596-1603
mean	O	1604-1608
(	O	1609-1610
+	O	1610-1611
/	O	1611-1612
-	O	1612-1613
SD	O	1614-1616
)	O	1616-1617
weight	B	1618-1624
gain	I	1625-1629
than	O	1630-1634
placebo	O	1635-1642
-	O	1642-1643
treated	O	1643-1650
patients	O	1651-1659
(	O	1660-1661
2	O	1661-1662
.	O	1662-1663
1	O	1663-1664
+	O	1665-1666
/	O	1666-1667
-	O	1667-1668
2	O	1669-1670
.	O	1670-1671
8	O	1671-1672
vs	O	1673-1675
0	O	1676-1677
.	O	1677-1678
45	O	1678-1680
+	O	1681-1682
/	O	1682-1683
-	O	1683-1684
2	O	1685-1686
.	O	1686-1687
3	O	1687-1688
kg	O	1689-1691
,	O	1691-1692
respectively	O	1693-1705
)	O	1705-1706
and	O	1707-1710
also	O	1711-1715
experienced	O	1716-1727
more	O	1728-1732
treatment	O	1733-1742
-	O	1742-1743
emergent	O	1743-1751
somnolence	B	1752-1762
(	O	1763-1764
21	O	1764-1766
patients	O	1767-1775
[	O	1776-1777
38	O	1777-1779
.	O	1779-1780
2	O	1780-1781
%	O	1781-1782
]	O	1782-1783
vs	O	1784-1786
5	O	1787-1788
[	O	1789-1790
8	O	1790-1791
.	O	1791-1792
3	O	1792-1793
%	O	1793-1794
]	O	1795-1796
,	O	1796-1797
respectively	O	1798-1810
)	O	1810-1811
.	O	1811-1812

CONCLUSION	O	1813-1823
:	O	1823-1824
Olanzapine	O	1825-1835
demonstrated	O	1836-1848
greater	O	1849-1856
efficacy	O	1857-1865
than	O	1866-1870
placebo	O	1871-1878
in	O	1879-1881
the	O	1882-1885
treatment	O	1886-1895
of	O	1896-1898
acute	O	1899-1904
bipolar	B	1905-1912
mania	I	1913-1918
and	O	1919-1922
was	O	1923-1926
generally	O	1927-1936
well	O	1937-1941
tolerated	O	1942-1951
.	O	1951-1952

The	O	0-3
effect	O	4-10
of	O	11-13
pupil	B	14-19
dilation	I	20-28
with	O	29-33
tropicamide	O	34-45
on	O	46-48
vision	O	49-55
and	O	56-59
driving	O	60-67
simulator	O	68-77
performance	O	78-89
.	O	89-90

PURPOSE	O	91-98
:	O	98-99
To	O	100-102
assess	O	103-109
the	O	110-113
effect	O	114-120
of	O	121-123
pupil	B	124-129
dilation	I	130-138
on	O	139-141
vision	O	142-148
and	O	149-152
driving	O	153-160
ability	O	161-168
.	O	168-169

METHODS	O	170-177
:	O	177-178
A	O	179-180
series	O	181-187
of	O	188-190
tests	O	191-196
on	O	197-199
various	O	200-207
parameters	O	208-218
of	O	219-221
visual	O	222-228
function	O	229-237
and	O	238-241
driving	O	242-249
simulator	O	250-259
performance	O	260-271
were	O	272-276
performed	O	277-286
on	O	287-289
12	O	290-292
healthy	O	293-300
drivers	O	301-308
,	O	308-309
before	O	310-316
and	O	317-320
after	O	321-326
pupil	B	327-332
dilation	I	333-341
using	O	342-347
guttae	O	348-354
tropicamide	O	355-366
1	O	367-368
%	O	368-369
.	O	369-370

A	O	371-372
driving	O	373-380
simulator	O	381-390
(	O	391-392
Transport	O	392-401
Research	O	402-410
Laboratory	O	411-421
)	O	421-422
was	O	423-426
used	O	427-431
to	O	432-434
measure	O	435-442
reaction	O	443-451
time	O	452-456
(	O	457-458
RT	O	458-460
)	O	460-461
,	O	461-462
speed	O	463-468
maintenance	O	469-480
and	O	481-484
steering	O	485-493
accuracy	O	494-502
.	O	502-503

Tests	O	504-509
of	O	510-512
basic	O	513-518
visual	O	519-525
function	O	526-534
included	O	535-543
high	O	544-548
-	O	548-549
and	O	550-553
low	O	554-557
-	O	557-558
contrast	O	558-566
visual	O	567-573
acuity	O	574-580
(	O	581-582
HCVA	O	582-586
and	O	587-590
LCVA	O	591-595
)	O	595-596
,	O	596-597
Pelli	O	598-603
-	O	603-604
Robson	O	604-610
contrast	O	611-619
threshold	O	620-629
(	O	630-631
CT	O	631-633
)	O	633-634
and	O	635-638
Goldmann	O	639-647
perimetry	O	648-657
(	O	658-659
FIELDS	O	659-665
)	O	665-666
.	O	666-667

Useful	O	668-674
Field	O	675-680
of	O	681-683
View	O	684-688
(	O	689-690
UFOV	O	690-694
-	O	694-695
-	O	694-695
a	O	696-697
test	O	698-702
of	O	703-705
visual	O	706-712
attention	O	713-722
)	O	722-723
was	O	724-727
also	O	728-732
undertaken	O	733-743
.	O	743-744

The	O	745-748
mean	O	749-753
differences	O	754-765
in	O	766-768
the	O	769-772
pre	O	773-776
-	O	776-777
and	O	778-781
post	O	782-786
-	O	786-787
dilatation	O	787-797
measurements	O	798-810
were	O	811-815
tested	O	816-822
for	O	823-826
statistical	O	827-838
significance	O	839-851
at	O	852-854
the	O	855-858
95	O	859-861
%	O	861-862
level	O	863-868
using	O	869-874
one	O	875-878
-	O	878-879
tail	O	879-883
paired	O	884-890
t	O	891-892
-	O	892-893
tests	O	893-898
.	O	898-899

RESULTS	O	900-907
:	O	907-908
Pupillary	B	909-918
dilation	I	919-927
resulted	O	928-936
in	O	937-939
a	O	940-941
statistically	O	942-955
significant	O	956-967
deterioration	O	968-981
in	O	982-984
CT	O	985-987
and	O	988-991
HCVA	O	992-996
only	O	997-1001
.	O	1001-1002

Five	O	1003-1007
of	O	1008-1010
12	O	1011-1013
drivers	O	1014-1021
also	O	1022-1026
exhibited	O	1027-1036
deterioration	O	1037-1050
in	O	1051-1053
LCVA	O	1054-1058
,	O	1058-1059
CT	O	1060-1062
and	O	1063-1066
RT	O	1067-1069
.	O	1069-1070

Little	O	1071-1077
evidence	O	1078-1086
emerged	O	1087-1094
for	O	1095-1098
deterioration	O	1099-1112
in	O	1113-1115
FIELDS	O	1116-1122
and	O	1123-1126
UFOV	O	1127-1131
.	O	1131-1132

Also	O	1133-1137
,	O	1137-1138
7	O	1139-1140
of	O	1141-1143
12	O	1144-1146
drivers	O	1147-1154
appeared	O	1155-1163
to	O	1164-1166
adjust	O	1167-1173
their	O	1174-1179
driving	O	1180-1187
behaviour	O	1188-1197
by	O	1198-1200
reducing	O	1201-1209
their	O	1210-1215
speed	O	1216-1221
on	O	1222-1224
the	O	1225-1228
driving	O	1229-1236
simulator	O	1237-1246
,	O	1246-1247
leading	O	1248-1255
to	O	1256-1258
improved	O	1259-1267
steering	O	1268-1276
accuracy	O	1277-1285
.	O	1285-1286

CONCLUSIONS	O	1287-1298
:	O	1298-1299
Pupillary	B	1300-1309
dilation	I	1310-1318
may	O	1319-1322
lead	O	1323-1327
to	O	1328-1330
a	O	1331-1332
decrease	O	1333-1341
in	O	1342-1344
vision	O	1345-1351
and	O	1352-1355
daylight	O	1356-1364
driving	O	1365-1372
performance	O	1373-1384
in	O	1385-1387
young	O	1388-1393
people	O	1394-1400
.	O	1400-1401

A	O	1402-1403
larger	O	1404-1410
study	O	1411-1416
,	O	1416-1417
including	O	1418-1427
a	O	1428-1429
broader	O	1430-1437
spectrum	O	1438-1446
of	O	1447-1449
subjects	O	1450-1458
,	O	1458-1459
is	O	1460-1462
warranted	O	1463-1472
before	O	1473-1479
guidelines	O	1480-1490
can	O	1491-1494
be	O	1495-1497
recommended	O	1498-1509
.	O	1509-1510

A	O	0-1
case	O	2-6
of	O	7-9
isotretinoin	B	10-22
embryopathy	I	23-34
with	O	35-39
bilateral	O	40-49
anotia	B	50-56
and	O	57-60
Taussig	B	61-68
-	I	68-69
Bing	I	69-73
malformation	I	74-86
.	O	86-87

We	O	88-90
report	O	91-97
a	O	98-99
newborn	O	100-107
infant	O	108-114
with	O	115-119
multiple	O	120-128
congenital	O	129-139
anomalies	O	140-149
(	O	150-151
anotia	B	151-157
and	O	158-161
Taussig	B	162-169
-	I	169-170
Bing	I	170-174
malformation	I	175-187
)	O	187-188
due	O	189-192
to	O	193-195
exposure	O	196-204
to	O	205-207
isotretinoin	O	208-220
within	O	221-227
the	O	228-231
first	O	232-237
trimester	O	238-247
.	O	247-248

In	O	249-251
this	O	252-256
paper	O	257-262
we	O	263-265
aim	O	266-269
to	O	270-272
draw	O	273-277
to	O	278-280
the	O	281-284
fact	O	285-289
that	O	290-294
caution	O	295-302
is	O	303-305
needed	O	306-312
when	O	313-317
prescribing	O	318-329
vitamin	O	330-337
A	O	338-339
-	O	339-340
containing	O	340-350
drugs	O	351-356
to	O	357-359
women	O	360-365
of	O	366-368
childbearing	O	369-381
years	O	382-387
.	O	387-388

Effect	O	0-6
of	O	7-9
methoxamine	O	10-21
on	O	22-24
maximum	O	25-32
urethral	O	33-41
pressure	O	42-50
in	O	51-53
women	O	54-59
with	O	60-64
genuine	O	65-72
stress	B	73-79
incontinence	I	80-92
:	O	92-93
a	O	94-95
placebo	O	96-103
-	O	103-104
controlled	O	104-114
,	O	114-115
double	O	116-122
-	O	122-123
blind	O	123-128
crossover	O	129-138
study	O	139-144
.	O	144-145

The	O	146-149
aim	O	150-153
of	O	154-156
the	O	157-160
study	O	161-166
was	O	167-170
to	O	171-173
evaluate	O	174-182
the	O	183-186
potential	O	187-196
role	O	197-201
for	O	202-205
a	O	206-207
selective	O	208-217
alpha1	O	218-224
-	O	224-225
adrenoceptor	O	225-237
agonist	O	238-245
in	O	246-248
the	O	249-252
treatment	O	253-262
of	O	263-265
urinary	B	266-273
stress	I	274-280
incontinence	I	281-293
.	O	293-294

A	O	295-296
randomised	O	297-307
,	O	307-308
double	O	309-315
-	O	315-316
blind	O	316-321
,	O	321-322
placebo	O	323-330
-	O	330-331
controlled	O	331-341
,	O	341-342
crossover	O	343-352
study	O	353-358
design	O	359-365
was	O	366-369
employed	O	370-378
.	O	378-379

Half	O	380-384
log	O	385-388
incremental	O	389-400
doses	O	401-406
of	O	407-409
intravenous	O	410-421
methoxamine	O	422-433
or	O	434-436
placebo	O	437-444
(	O	445-446
saline	O	446-452
)	O	452-453
were	O	454-458
administered	O	459-471
to	O	472-474
a	O	475-476
group	O	477-482
of	O	483-485
women	O	486-491
with	O	492-496
genuine	O	497-504
stress	B	505-511
incontinence	I	512-524
while	O	525-530
measuring	O	531-540
maximum	O	541-548
urethral	O	549-557
pressure	O	558-566
(	O	567-568
MUP	O	568-571
)	O	571-572
,	O	572-573
blood	O	574-579
pressure	O	580-588
,	O	588-589
heart	O	590-595
rate	O	596-600
,	O	600-601
and	O	602-605
symptomatic	O	606-617
side	O	618-622
effects	O	623-630
.	O	630-631

Methoxamine	O	632-643
evoked	O	644-650
non	O	651-654
-	O	654-655
significant	O	655-666
increases	O	667-676
in	O	677-679
MUP	O	680-683
and	O	684-687
diastolic	O	688-697
blood	O	698-703
pressure	O	704-712
but	O	713-716
caused	O	717-723
a	B	724-725
significant	I	726-737
rise	I	738-742
in	I	743-745
systolic	I	746-754
blood	I	755-760
pressure	I	761-769
and	O	770-773
significant	O	774-785
fall	O	786-790
in	O	791-793
heart	O	794-799
rate	O	800-804
at	O	805-807
maximum	O	808-815
dosage	O	816-822
.	O	822-823

Systemic	O	824-832
side	O	833-837
effects	O	838-845
including	O	846-855
piloerection	O	856-868
,	O	868-869
headache	B	870-878
,	O	878-879
and	O	880-883
cold	O	884-888
extremities	O	889-900
were	O	901-905
experienced	O	906-917
in	O	918-920
all	O	921-924
subjects	O	925-933
.	O	933-934

The	O	935-938
results	O	939-946
indicate	O	947-955
that	O	956-960
the	O	961-964
clinical	O	965-973
usefulness	O	974-984
of	O	985-987
direct	O	988-994
,	O	994-995
peripherally	O	996-1008
acting	O	1009-1015
sub	O	1016-1019
-	O	1019-1020
type	O	1020-1024
-	O	1019-1020
selective	O	1025-1034
alpha1	O	1035-1041
-	O	1041-1042
adrenoceptor	O	1042-1054
agonists	O	1055-1063
in	O	1064-1066
the	O	1067-1070
medical	O	1071-1078
treatment	O	1079-1088
of	O	1089-1091
stress	B	1092-1098
incontinence	I	1099-1111
may	O	1112-1115
be	O	1116-1118
limited	O	1119-1126
by	O	1127-1129
associated	O	1130-1140
piloerection	O	1141-1153
and	O	1154-1157
cardiovascular	O	1158-1172
side	O	1173-1177
effects	O	1178-1185
.	O	1185-1186

Toleration	O	0-10
of	O	11-13
high	O	14-18
doses	O	19-24
of	O	25-27
angiotensin	O	28-39
-	O	39-40
converting	O	40-50
enzyme	O	51-57
inhibitors	O	58-68
in	O	69-71
patients	O	72-80
with	O	81-85
chronic	O	86-93
heart	B	94-99
failure	I	100-107
:	O	107-108
results	O	109-116
from	O	117-121
the	O	122-125
ATLAS	O	126-131
trial	O	132-137
.	O	137-138

The	O	139-142
Assessment	O	143-153
of	O	154-156
Treatment	O	157-166
with	O	167-171
Lisinopril	O	172-182
and	O	183-186
Survival	O	187-195
.	O	195-196

BACKGROUND	O	197-207
:	O	207-208
Treatment	O	209-218
with	O	219-223
angiotensin	O	224-235
-	O	235-236
converting	O	236-246
enzyme	O	247-253
(	O	254-255
ACE	O	255-258
)	O	258-259
inhibitors	O	260-270
reduces	O	271-278
mortality	O	279-288
and	O	289-292
morbidity	O	293-302
in	O	303-305
patients	O	306-314
with	O	315-319
chronic	O	320-327
heart	B	328-333
failure	I	334-341
(	O	342-343
CHF	B	343-346
)	O	346-347
,	O	347-348
but	O	349-352
most	O	353-357
affected	O	358-366
patients	O	367-375
are	O	376-379
not	O	380-383
receiving	O	384-393
these	O	394-399
agents	O	400-406
or	O	407-409
are	O	410-413
being	O	414-419
treated	O	420-427
with	O	428-432
doses	O	433-438
lower	O	439-444
than	O	445-449
those	O	450-455
found	O	456-461
to	O	462-464
be	O	465-467
efficacious	O	468-479
in	O	480-482
trials	O	483-489
,	O	489-490
primarily	O	491-500
because	O	501-508
of	O	509-511
concerns	O	512-520
about	O	521-526
the	O	527-530
safety	O	531-537
and	O	538-541
tolerability	O	542-554
of	O	555-557
these	O	558-563
agents	O	564-570
,	O	570-571
especially	O	572-582
at	O	583-585
the	O	586-589
recommended	O	590-601
doses	O	602-607
.	O	607-608

The	O	609-612
present	O	613-620
study	O	621-626
examines	O	627-635
the	O	636-639
safety	O	640-646
and	O	647-650
tolerability	O	651-663
of	O	664-666
high	O	667-671
-	O	671-672
compared	O	673-681
with	O	682-686
low	O	687-690
-	O	690-691
dose	O	691-695
lisinopril	O	696-706
in	O	707-709
CHF	B	710-713
.	O	713-714

METHODS	O	715-722
:	O	722-723
The	O	724-727
Assessment	O	728-738
of	O	739-741
Lisinopril	O	742-752
and	O	753-756
Survival	O	757-765
study	O	766-771
was	O	772-775
a	O	776-777
multicenter	O	778-789
,	O	789-790
randomized	O	791-801
,	O	801-802
double	O	803-809
-	O	809-810
blind	O	810-815
trial	O	816-821
in	O	822-824
which	O	825-830
patients	O	831-839
with	O	840-844
or	O	845-847
without	O	848-855
previous	O	856-864
ACE	O	865-868
inhibitor	O	869-878
treatment	O	879-888
were	O	889-893
stabilized	O	894-904
receiving	O	905-914
medium	O	915-921
-	O	921-922
dose	O	922-926
lisinopril	O	927-937
(	O	938-939
12	O	939-941
.	O	941-942
5	O	942-943
or	O	944-946
15	O	947-949
.	O	949-950
0	O	950-951
mg	O	952-954
once	O	955-959
daily	O	960-965
[	O	966-967
OD	O	967-969
]	O	969-970
)	O	970-971
for	O	972-975
2	O	976-977
to	O	978-980
4	O	981-982
weeks	O	983-988
and	O	989-992
then	O	993-997
randomized	O	998-1008
to	O	1009-1011
high	O	1012-1016
-	O	1016-1017
(	O	1018-1019
35	O	1019-1021
.	O	1021-1022
0	O	1022-1023
or	O	1024-1026
32	O	1027-1029
.	O	1029-1030
5	O	1030-1031
mg	O	1032-1034
OD	O	1035-1037
)	O	1037-1038
or	O	1039-1041
low	O	1042-1045
-	O	1045-1046
dose	O	1046-1050
(	O	1051-1052
5	O	1052-1053
.	O	1053-1054
0	O	1054-1055
or	O	1056-1058
2	O	1059-1060
.	O	1060-1061
5	O	1061-1062
mg	O	1063-1065
OD	O	1066-1068
)	O	1068-1069
groups	O	1070-1076
.	O	1076-1077

Patients	O	1078-1086
with	O	1087-1091
New	O	1092-1095
York	O	1096-1100
Heart	O	1101-1106
Association	O	1107-1118
classes	O	1119-1126
II	O	1127-1129
to	O	1130-1132
IV	O	1133-1135
CHF	B	1136-1139
and	O	1140-1143
left	O	1144-1148
ventricular	O	1149-1160
ejection	O	1161-1169
fractions	O	1170-1179
of	O	1180-1182
no	O	1183-1185
greater	O	1186-1193
than	O	1194-1198
0	O	1199-1200
.	O	1200-1201
30	O	1201-1203
(	O	1204-1205
n	O	1205-1206
=	O	1207-1208
3164	O	1209-1213
)	O	1213-1214
were	O	1215-1219
randomized	O	1220-1230
and	O	1231-1234
followed	O	1235-1243
up	O	1244-1246
for	O	1247-1250
a	O	1251-1252
median	O	1253-1259
of	O	1260-1262
46	O	1263-1265
months	O	1266-1272
.	O	1272-1273

We	O	1274-1276
examined	O	1277-1285
the	O	1286-1289
occurrence	O	1290-1300
of	O	1301-1303
adverse	O	1304-1311
events	O	1312-1318
and	O	1319-1322
the	O	1323-1326
need	O	1327-1331
for	O	1332-1335
discontinuation	O	1336-1351
and	O	1352-1355
dose	O	1356-1360
reduction	O	1361-1370
during	O	1371-1377
treatment	O	1378-1387
,	O	1387-1388
with	O	1389-1393
a	O	1394-1395
focus	O	1396-1401
on	O	1402-1404
hypotension	B	1405-1416
and	O	1417-1420
renal	B	1421-1426
dysfunction	I	1427-1438
.	O	1438-1439

RESULTS	O	1440-1447
:	O	1447-1448
Of	O	1449-1451
405	O	1452-1455
patients	O	1456-1464
not	O	1465-1468
previously	O	1469-1479
receiving	O	1480-1489
an	O	1490-1492
ACE	O	1493-1496
inhibitor	O	1497-1506
,	O	1506-1507
doses	O	1508-1513
in	O	1514-1516
only	O	1517-1521
4	O	1522-1523
.	O	1523-1524
2	O	1524-1525
%	O	1525-1526
could	O	1527-1532
not	O	1533-1536
be	O	1537-1539
titrated	O	1540-1548
to	O	1549-1551
the	O	1552-1555
medium	O	1556-1562
doses	O	1563-1568
required	O	1569-1577
for	O	1578-1581
randomization	O	1582-1595
because	O	1596-1603
of	O	1604-1606
symptoms	O	1607-1615
possibly	O	1616-1624
related	O	1625-1632
to	O	1633-1635
hypotension	B	1636-1647
(	O	1648-1649
2	O	1649-1650
.	O	1650-1651
0	O	1651-1652
%	O	1652-1653
)	O	1653-1654
or	O	1655-1657
because	O	1658-1665
of	O	1666-1668
renal	B	1669-1674
dysfunction	I	1675-1686
or	O	1687-1689
hyperkalemia	B	1690-1702
(	O	1703-1704
2	O	1704-1705
.	O	1705-1706
3	O	1706-1707
%	O	1707-1708
)	O	1708-1709
.	O	1705-1706

Doses	O	1711-1716
in	O	1717-1719
more	O	1720-1724
than	O	1725-1729
90	O	1730-1732
%	O	1732-1733
of	O	1734-1736
randomized	O	1737-1747
patients	O	1748-1756
in	O	1757-1759
the	O	1760-1763
high	O	1764-1768
-	O	1768-1769
and	O	1770-1773
low	O	1774-1777
-	O	1777-1778
dose	O	1778-1782
groups	O	1783-1789
were	O	1790-1794
titrated	O	1795-1803
to	O	1804-1806
their	O	1807-1812
assigned	O	1813-1821
target	O	1822-1828
,	O	1828-1829
and	O	1830-1833
the	O	1834-1837
mean	O	1838-1842
doses	O	1843-1848
of	O	1849-1851
blinded	O	1852-1859
medication	O	1860-1870
in	O	1871-1873
both	O	1874-1878
groups	O	1879-1885
remained	O	1886-1894
similar	O	1895-1902
throughout	O	1903-1913
the	O	1914-1917
study	O	1918-1923
.	O	1923-1924

Withdrawals	O	1925-1936
occurred	O	1937-1945
in	O	1946-1948
27	O	1949-1951
.	O	1951-1952
1	O	1952-1953
%	O	1953-1954
of	O	1955-1957
the	O	1958-1961
high	O	1962-1966
-	O	1966-1967
and	O	1968-1971
30	O	1972-1974
.	O	1974-1975
7	O	1975-1976
%	O	1976-1977
of	O	1978-1980
the	O	1981-1984
low	O	1985-1988
-	O	1988-1989
dose	O	1989-1993
groups	O	1994-2000
.	O	2000-2001

Subgroups	O	2002-2011
presumed	O	2012-2020
to	O	2021-2023
be	O	2024-2026
at	O	2027-2029
higher	O	2030-2036
risk	O	2037-2041
for	O	2042-2045
ACE	O	2046-2049
inhibitor	O	2050-2059
intolerance	O	2060-2071
(	O	2072-2073
blood	O	2073-2078
pressure	O	2079-2087
,	O	2087-2088
<	O	2089-2090
120	O	2090-2093
mm	O	2094-2096
Hg	O	2097-2099
;	O	2099-2100
creatinine	O	2101-2111
,	O	2111-2112
>	O	2113-2114
or	O	2115-2117
=	O	2118-2119
132	O	2119-2122
.	O	2122-2123
6	O	2123-2124
micromol	O	2125-2133
/	O	2133-2134
L	O	2134-2135
[	O	2136-2137
>	O	2137-2138
or	O	2139-2141
=	O	2142-2143
1	O	2143-2144
.	O	2144-2145
5	O	2145-2146
mg	O	2147-2149
/	O	2149-2150
dL	O	2150-2152
]	O	2152-2153
;	O	2153-2154
age	O	2155-2158
,	O	2158-2159
>	O	2160-2161
or	O	2162-2164
=	O	2165-2166
70	O	2166-2168
years	O	2169-2174
;	O	2174-2175
and	O	2176-2179
patients	O	2180-2188
with	O	2189-2193
diabetes	B	2194-2202
)	O	2202-2203
generally	O	2204-2213
tolerated	O	2214-2223
the	O	2224-2227
high	O	2228-2232
-	O	2232-2233
dose	O	2233-2237
strategy	O	2238-2246
.	O	2246-2247

CONCLUSIONS	O	2248-2259
:	O	2259-2260
These	O	2261-2266
findings	O	2267-2275
demonstrate	O	2276-2287
that	O	2288-2292
ACE	O	2293-2296
inhibitor	O	2297-2306
therapy	O	2307-2314
in	O	2315-2317
most	O	2318-2322
patients	O	2323-2331
with	O	2332-2336
CHF	B	2337-2340
can	O	2341-2344
be	O	2345-2347
successfully	O	2348-2360
titrated	O	2361-2369
to	O	2370-2372
and	O	2373-2376
maintained	O	2377-2387
at	O	2388-2390
high	O	2391-2395
doses	O	2396-2401
,	O	2401-2402
and	O	2403-2406
that	O	2407-2411
more	O	2412-2416
aggressive	O	2417-2427
use	O	2428-2431
of	O	2432-2434
these	O	2435-2440
agents	O	2441-2447
is	O	2448-2450
warranted	O	2451-2460
.	O	2460-2461

Cocaine	O	0-7
,	O	7-8
ethanol	O	9-16
,	O	16-17
and	O	18-21
cocaethylene	O	22-34
cardiotoxity	B	35-47
in	O	48-50
an	O	51-53
animal	O	54-60
model	O	61-66
of	O	67-69
cocaine	B	70-77
and	I	78-81
ethanol	I	82-89
abuse	I	90-95
.	O	95-96

OBJECTIVES	O	97-107
:	O	107-108
Simultaneous	O	109-121
abuse	B	122-127
of	I	128-130
cocaine	I	131-138
and	I	139-142
ethanol	I	143-150
affects	O	151-158
12	O	159-161
million	O	162-169
Americans	O	170-179
annually	O	180-188
.	O	188-189

In	O	190-192
combination	O	193-204
,	O	204-205
these	O	206-211
substances	O	212-222
are	O	223-226
substantially	O	227-240
more	O	241-245
toxic	O	246-251
than	O	252-256
either	O	257-263
drug	O	264-268
alone	O	269-274
.	O	274-275

Their	O	276-281
combined	O	282-290
cardiac	B	291-298
toxicity	I	299-307
may	O	308-311
be	O	312-314
due	O	315-318
to	O	319-321
independent	O	322-333
effects	O	334-341
of	O	342-344
each	O	345-349
drug	O	350-354
;	O	354-355
however	O	356-363
,	O	363-364
they	O	365-369
may	O	370-373
also	O	374-378
be	O	379-381
due	O	382-385
to	O	386-388
cocaethylene	O	389-401
(	O	402-403
CE	O	403-405
)	O	405-406
,	O	406-407
a	O	408-409
cocaine	O	410-417
metabolite	O	418-428
formed	O	429-435
only	O	436-440
in	O	441-443
the	O	444-447
presence	O	448-456
of	O	457-459
ethanol	O	460-467
.	O	467-468

The	O	469-472
purpose	O	473-480
of	O	481-483
this	O	484-488
study	O	489-494
was	O	495-498
to	O	499-501
delineate	O	502-511
the	O	512-515
role	O	516-520
of	O	521-523
CE	O	524-526
in	O	527-529
the	O	530-533
combined	O	534-542
cardiotoxicity	B	543-557
of	O	558-560
cocaine	O	561-568
and	O	569-572
ethanol	O	573-580
in	O	581-583
a	O	584-585
model	O	586-591
simulating	O	592-602
their	O	603-608
abuse	O	609-614
.	O	614-615

METHODS	O	616-623
:	O	623-624
Twenty	O	625-631
-	O	631-632
three	O	632-637
dogs	O	638-642
were	O	643-647
randomized	O	648-658
to	O	659-661
receive	O	662-669
either	O	670-676
1	O	677-678
)	O	678-679
three	O	680-685
intravenous	O	686-697
(	O	698-699
IV	O	699-701
)	O	701-702
boluses	O	703-710
of	O	711-713
cocaine	O	714-721
7	O	722-723
.	O	723-724
5	O	724-725
mg	O	726-728
/	O	728-729
kg	O	729-731
with	O	732-736
ethanol	O	737-744
(	O	745-746
1	O	746-747
g	O	748-749
/	O	749-750
kg	O	750-752
)	O	752-753
as	O	754-756
an	O	757-759
IV	O	760-762
infusion	O	763-771
(	O	772-773
C	O	773-774
+	O	774-775
E	O	775-776
,	O	776-777
n	O	778-779
=	O	780-781
8	O	782-783
)	O	783-784
,	O	784-785
2	O	786-787
)	O	787-788
three	O	789-794
cocaine	O	795-802
boluses	O	803-810
only	O	811-815
(	O	816-817
C	O	817-818
,	O	818-819
n	O	820-821
=	O	822-823
6	O	824-825
)	O	825-826
,	O	826-827
3	O	828-829
)	O	829-830
ethanol	O	831-838
infusion	O	839-847
only	O	848-852
(	O	853-854
E	O	854-855
,	O	855-856
n	O	857-858
=	O	859-860
5	O	861-862
)	O	862-863
,	O	863-864
or	O	865-867
4	O	868-869
)	O	869-870
placebo	O	871-878
boluses	O	879-886
and	O	887-890
infusion	O	891-899
(	O	900-901
n	O	901-902
=	O	903-904
4	O	905-906
)	O	906-907
.	O	907-908

Hemodynamic	O	909-920
measurements	O	921-933
,	O	933-934
electrocardiograms	O	935-953
,	O	953-954
and	O	955-958
serum	O	959-964
drug	O	965-969
concentrations	O	970-984
were	O	985-989
obtained	O	990-998
at	O	999-1001
baseline	O	1002-1010
,	O	1010-1011
and	O	1012-1015
then	O	1016-1020
at	O	1021-1023
fixed	O	1024-1029
time	O	1030-1034
intervals	O	1035-1044
after	O	1045-1050
each	O	1051-1055
drug	O	1056-1060
was	O	1061-1064
administered	O	1065-1077
.	O	1077-1078

RESULTS	O	1079-1086
:	O	1086-1087
Two	O	1088-1091
of	O	1092-1094
eight	O	1095-1100
dogs	O	1101-1105
in	O	1106-1108
the	O	1109-1112
C	O	1113-1114
+	O	1114-1115
E	O	1115-1116
group	O	1117-1122
experienced	O	1123-1134
cardiovascular	B	1135-1149
collapse	I	1150-1158
.	O	1158-1159

The	O	1160-1163
most	O	1164-1168
dramatic	O	1169-1177
hemodynamic	O	1178-1189
changes	O	1190-1197
occurred	O	1198-1206
after	O	1207-1212
each	O	1213-1217
cocaine	O	1218-1225
bolus	O	1226-1231
in	O	1232-1234
the	O	1235-1238
C	O	1239-1240
+	O	1240-1241
E	O	1241-1242
and	O	1243-1246
C	O	1247-1248
only	O	1249-1253
groups	O	1254-1260
;	O	1260-1261
however	O	1262-1269
,	O	1269-1270
persistent	O	1271-1281
hemodynamic	O	1282-1293
changes	O	1294-1301
occurred	O	1302-1310
in	O	1311-1313
the	O	1314-1317
C	O	1318-1319
+	O	1319-1320
E	O	1320-1321
group	O	1322-1327
.	O	1327-1328

Peak	O	1329-1333
CE	O	1334-1336
levels	O	1337-1343
were	O	1344-1348
associated	O	1349-1359
with	O	1360-1364
a	O	1365-1366
45	O	1367-1369
%	O	1369-1370
(	O	1371-1372
SD	O	1372-1374
+	O	1375-1376
/	O	1376-1377
-	O	1377-1378
22	O	1379-1381
%	O	1381-1382
,	O	1382-1383
95	O	1384-1386
%	O	1386-1387
CI	O	1388-1390
=	O	1391-1392
22	O	1393-1395
%	O	1395-1396
to	O	1397-1399
69	O	1400-1402
%	O	1402-1403
)	O	1403-1404
decrease	B	1405-1413
in	I	1414-1416
cardiac	I	1417-1424
output	I	1425-1431
(	O	1432-1433
p	O	1433-1434
<	O	1435-1436
0	O	1437-1438
.	O	1438-1439
05	O	1439-1441
)	O	1441-1442
,	O	1442-1443
a	O	1444-1445
56	O	1446-1448
%	O	1448-1449
(	O	1450-1451
SD	O	1451-1453
+	O	1454-1455
/	O	1455-1456
-	O	1456-1457
23	O	1458-1460
%	O	1460-1461
,	O	1461-1462
95	O	1463-1465
%	O	1465-1466
CI	O	1467-1469
=	O	1470-1471
32	O	1472-1474
%	O	1474-1475
to	O	1476-1478
80	O	1479-1481
%	O	1481-1482
)	O	1482-1483
decrease	O	1484-1492
in	O	1493-1495
dP	O	1496-1498
/	O	1498-1499
dt	O	1499-1501
(	O	1501-1502
max	O	1502-1505
)	O	1505-1506
(	O	1507-1508
p	O	1508-1509
<	O	1510-1511
.	O	1511-1512
006	O	1512-1515
)	O	1515-1516
,	O	1516-1517
and	O	1518-1521
a	O	1522-1523
23	O	1524-1526
%	O	1526-1527
(	O	1528-1529
SD	O	1529-1531
+	O	1532-1533
/	O	1533-1534
-	O	1534-1535
15	O	1536-1538
%	O	1538-1539
,	O	1539-1540
95	O	1541-1543
%	O	1543-1544
CI	O	1545-1547
=	O	1548-1549
7	O	1550-1551
%	O	1551-1552
to	O	1553-1555
49	O	1556-1558
%	O	1558-1559
)	O	1559-1560
decrease	O	1561-1569
in	O	1570-1572
SVO	O	1573-1576
(	O	1576-1577
2	O	1577-1578
)	O	1578-1579
(	O	1580-1581
p	O	1581-1582
<	O	1583-1584
0	O	1585-1586
.	O	1586-1587
025	O	1587-1590
)	O	1590-1591
.	O	1586-1587

Ventricular	B	1593-1604
arrhythmias	I	1605-1616
were	O	1617-1621
primarily	O	1622-1631
observed	O	1632-1640
in	O	1641-1643
the	O	1644-1647
C	O	1648-1649
+	O	1649-1650
E	O	1650-1651
group	O	1652-1657
,	O	1657-1658
in	O	1659-1661
which	O	1662-1667
four	O	1668-1672
of	O	1673-1675
eight	O	1676-1681
dogs	O	1682-1686
experienced	O	1687-1698
ventricular	B	1699-1710
tachycardia	I	1711-1722
.	O	1722-1723

CONCLUSIONS	O	1724-1735
:	O	1735-1736
Cocaine	O	1737-1744
and	O	1745-1748
ethanol	O	1749-1756
in	O	1757-1759
combination	O	1760-1771
were	O	1772-1776
more	O	1777-1781
toxic	O	1782-1787
than	O	1788-1792
either	O	1793-1799
substance	O	1800-1809
alone	O	1810-1815
.	O	1815-1816

Co	O	1817-1819
-	O	1819-1820
administration	O	1820-1834
resulted	O	1835-1843
in	O	1844-1846
prolonged	O	1847-1856
cardiac	B	1857-1864
toxicity	I	1865-1873
and	O	1874-1877
was	O	1878-1881
dysrhythmogenic	O	1882-1897
.	O	1897-1898

Peak	O	1899-1903
serum	O	1904-1909
cocaethylene	O	1910-1922
concentrations	O	1923-1937
were	O	1938-1942
associated	O	1943-1953
with	O	1954-1958
prolonged	O	1959-1968
myocardial	B	1969-1979
depression	I	1980-1990
.	O	1990-1991

Worsening	O	0-9
of	O	10-12
Parkinsonism	B	13-25
after	O	26-31
the	O	32-35
use	O	36-39
of	O	40-42
veralipride	O	43-54
for	O	55-58
treatment	O	59-68
of	O	69-71
menopause	O	72-81
:	O	81-82
case	O	83-87
report	O	88-94
.	O	94-95

We	O	96-98
describe	O	99-107
a	O	108-109
female	O	110-116
patient	O	117-124
with	O	125-129
stable	O	130-136
Parkinson	B	137-146
'	I	146-147
s	I	143-144
disease	I	149-156
who	O	157-160
has	O	161-164
shown	O	165-170
a	O	171-172
marked	O	173-179
worsening	O	180-189
of	O	190-192
her	O	193-196
motor	O	197-202
functions	O	203-212
following	O	213-222
therapy	O	223-230
of	O	231-233
menopause	O	234-243
related	O	244-251
symptoms	O	252-260
with	O	261-265
veralipride	O	266-277
,	O	277-278
as	O	279-281
well	O	282-286
as	O	287-289
the	O	290-293
improvement	O	294-305
of	O	306-308
her	O	309-312
symptoms	O	313-321
back	O	322-326
to	O	327-329
baseline	O	330-338
after	O	339-344
discontinuation	O	345-360
of	O	361-363
the	O	364-367
drug	O	368-372
.	O	372-373

We	O	374-376
emphasize	O	377-386
the	O	387-390
anti	O	391-395
-	O	395-396
dopaminergic	O	396-408
effect	O	409-415
of	O	416-418
veralipride	O	419-430
.	O	430-431

Viracept	O	0-8
and	O	9-12
irregular	B	13-22
heartbeat	I	23-32
warning	O	33-40
.	O	40-41

A	O	42-43
group	O	44-49
of	O	50-52
doctors	O	53-60
in	O	61-63
Boston	O	64-70
warn	O	71-75
that	O	76-80
the	O	81-84
protease	O	85-93
inhibitor	O	94-103
Viracept	O	104-112
may	O	113-116
cause	O	117-122
an	O	123-125
irregular	B	126-135
heart	I	136-141
beat	I	142-146
,	O	146-147
known	O	148-153
as	O	154-156
bradycardia	B	157-168
,	O	168-169
in	O	170-172
people	O	173-179
with	O	180-184
HIV	O	185-188
.	O	188-189

Bradycardia	B	190-201
occurred	O	202-210
in	O	211-213
a	O	214-215
45	O	216-218
-	O	218-219
year	O	219-223
-	O	218-219
old	O	224-227
male	O	228-232
patient	O	233-240
who	O	241-244
was	O	245-248
Viracept	O	249-257
in	O	258-260
combination	O	261-272
with	O	273-277
other	O	278-283
anti	O	284-288
-	O	288-289
HIV	O	289-292
drugs	O	293-298
.	O	298-299

The	O	300-303
symptoms	O	304-312
ceased	O	313-319
after	O	320-325
switching	O	326-335
to	O	336-338
another	O	339-346
drug	O	347-351
combination	O	352-363
.	O	363-364

Frequency	O	0-9
of	O	10-12
appearance	O	13-23
of	O	24-26
myeloperoxidase	O	27-42
-	O	42-43
antineutrophil	O	43-57
cytoplasmic	O	58-69
antibody	O	70-78
(	O	79-80
MPO	O	80-83
-	O	83-84
ANCA	O	84-88
)	O	88-89
in	O	90-92
Graves	B	93-99
'	I	99-100
disease	I	101-108
patients	O	109-117
treated	O	118-125
with	O	126-130
propylthiouracil	O	131-147
and	O	148-151
the	O	152-155
relationship	O	156-168
between	O	169-176
MPO	O	177-180
-	O	180-181
ANCA	O	181-185
and	O	186-189
clinical	O	190-198
manifestations	O	199-213
.	O	213-214

OBJECTIVE	O	215-224
:	O	224-225
Myeloperoxidase	O	226-241
antineutrophil	O	242-256
cytoplasmic	O	257-268
antibody	O	269-277
(	O	278-279
MPO	O	279-282
-	O	282-283
ANCA	O	283-287
)	O	287-288
-	O	282-283
positive	O	289-297
vasculitis	B	298-308
has	O	309-312
been	O	313-317
reported	O	318-326
in	O	327-329
patients	O	330-338
with	O	339-343
Graves	B	344-350
'	I	350-351
disease	I	352-359
who	O	360-363
were	O	364-368
treated	O	369-376
with	O	377-381
propylthiouracil	O	382-398
(	O	399-400
PTU	O	400-403
)	O	403-404
.	O	404-405

The	O	406-409
appearance	O	410-420
of	O	421-423
MPO	O	424-427
-	O	427-428
ANCA	O	428-432
in	O	433-435
these	O	436-441
cases	O	442-447
was	O	448-451
suspected	O	452-461
of	O	462-464
being	O	465-470
related	O	471-478
to	O	479-481
PTU	O	482-485
because	O	486-493
the	O	494-497
titres	O	498-504
of	O	505-507
MPO	O	508-511
-	O	511-512
ANCA	O	512-516
decreased	O	517-526
when	O	527-531
PTU	O	532-535
was	O	536-539
stopped	O	540-547
.	O	547-548

Nevertheless	O	549-561
,	O	561-562
there	O	563-568
have	O	569-573
been	O	574-578
no	O	579-581
studies	O	582-589
on	O	590-592
the	O	593-596
temporal	O	597-605
relationship	O	606-618
between	O	619-626
the	O	627-630
appearance	O	631-641
of	O	642-644
MPO	O	645-648
-	O	648-649
ANCA	O	649-653
and	O	654-657
vasculitis	B	658-668
during	O	669-675
PTU	O	676-679
therapy	O	680-687
,	O	687-688
or	O	689-691
on	O	692-694
the	O	695-698
incidence	O	699-708
of	O	709-711
MPO	O	712-715
-	O	715-716
ANCA	O	716-720
in	O	721-723
untreated	O	724-733
Graves	B	734-740
'	I	740-741
disease	I	742-749
patients	O	750-758
.	O	758-759

Therefore	O	760-769
,	O	769-770
we	O	771-773
sought	O	774-780
to	O	781-783
address	O	784-791
these	O	792-797
parameters	O	798-808
in	O	809-811
patients	O	812-820
with	O	821-825
Graves	B	826-832
'	I	832-833
disease	I	834-841
.	O	841-842

PATIENTS	O	843-851
:	O	851-852
We	O	853-855
investigated	O	856-868
102	O	869-872
untreated	O	873-882
patients	O	883-891
with	O	892-896
hyperthyroidism	B	897-912
due	O	913-916
to	O	917-919
Graves	B	920-926
'	I	926-927
disease	I	928-935
for	O	936-939
the	O	940-943
presence	O	944-952
of	O	953-955
MPO	O	956-959
-	O	959-960
ANCA	O	960-964
,	O	964-965
and	O	966-969
for	O	970-973
the	O	974-977
development	O	978-989
vasculitis	B	990-1000
after	O	1001-1006
starting	O	1007-1015
PTU	O	1016-1019
therapy	O	1020-1027
.	O	1027-1028

Twenty	O	1029-1035
-	O	1035-1036
nine	O	1036-1040
of	O	1041-1043
them	O	1044-1048
were	O	1049-1053
later	O	1054-1059
excluded	O	1060-1068
because	O	1069-1076
of	O	1077-1079
adverse	O	1080-1087
effects	O	1088-1095
of	O	1096-1098
PTU	O	1099-1102
or	O	1103-1105
because	O	1106-1113
the	O	1114-1117
observation	O	1118-1129
period	O	1130-1136
was	O	1137-1140
less	O	1141-1145
than	O	1146-1150
3	O	1151-1152
months	O	1153-1159
.	O	1159-1160

The	O	1161-1164
remaining	O	1165-1174
73	O	1175-1177
patients	O	1178-1186
(	O	1187-1188
55	O	1188-1190
women	O	1191-1196
and	O	1197-1200
18	O	1201-1203
men	O	1204-1207
)	O	1207-1208
,	O	1208-1209
all	O	1210-1213
of	O	1214-1216
whom	O	1217-1221
were	O	1222-1226
examined	O	1227-1235
for	O	1236-1239
more	O	1240-1244
than	O	1245-1249
3	O	1250-1251
months	O	1252-1258
,	O	1258-1259
were	O	1260-1264
adopted	O	1265-1272
as	O	1273-1275
the	O	1276-1279
subjects	O	1280-1288
of	O	1289-1291
the	O	1292-1295
investigation	O	1296-1309
.	O	1309-1310

The	O	1311-1314
median	O	1315-1321
observation	O	1322-1333
period	O	1334-1340
was	O	1341-1344
23	O	1345-1347
.	O	1347-1348
6	O	1348-1349
months	O	1350-1356
(	O	1357-1358
range	O	1358-1363
:	O	1363-1364
3	O	1365-1366
-	O	1366-1367
37	O	1367-1369
months	O	1370-1376
)	O	1376-1377
.	O	1377-1378

MEASUREMENTS	O	1379-1391
:	O	1391-1392
MPO	O	1393-1396
-	O	1396-1397
ANCA	O	1397-1401
was	O	1402-1405
measured	O	1406-1414
at	O	1415-1417
intervals	O	1418-1427
of	O	1428-1430
2	O	1431-1432
-	O	1432-1433
6	O	1433-1434
months	O	1435-1441
.	O	1441-1442

RESULTS	O	1443-1450
:	O	1450-1451
Before	O	1452-1458
treatment	O	1459-1468
,	O	1468-1469
the	O	1470-1473
MPO	O	1474-1477
-	O	1477-1478
ANCA	O	1478-1482
titres	O	1483-1489
of	O	1490-1492
all	O	1493-1496
102	O	1497-1500
untreated	O	1501-1510
Graves	B	1511-1517
'	I	1517-1518
disease	I	1519-1526
patients	O	1527-1535
were	O	1536-1540
within	O	1541-1547
the	O	1548-1551
reference	O	1552-1561
range	O	1562-1567
(	O	1568-1569
below	O	1569-1574
10	O	1575-1577
U	O	1578-1579
/	O	1579-1580
ml	O	1580-1582
)	O	1582-1583
.	O	1583-1584

Three	O	1585-1590
(	O	1591-1592
4	O	1592-1593
.	O	1593-1594
1	O	1594-1595
%	O	1595-1596
)	O	1596-1597
of	O	1598-1600
the	O	1601-1604
73	O	1605-1607
patients	O	1608-1616
were	O	1617-1621
positive	O	1622-1630
for	O	1631-1634
MPO	O	1635-1638
-	O	1638-1639
ANCA	O	1639-1643
at	O	1644-1646
13	O	1647-1649
,	O	1649-1650
16	O	1651-1653
and	O	1654-1657
17	O	1658-1660
months	O	1661-1667
,	O	1667-1668
respectively	O	1669-1681
,	O	1681-1682
after	O	1683-1688
the	O	1689-1692
start	O	1693-1698
of	O	1699-1701
PTU	O	1702-1705
therapy	O	1706-1713
.	O	1713-1714

In	O	1715-1717
two	O	1718-1721
of	O	1722-1724
them	O	1725-1729
,	O	1729-1730
the	O	1731-1734
MPO	O	1735-1738
-	O	1738-1739
ANCA	O	1739-1743
titres	O	1744-1750
transiently	O	1751-1762
increased	O	1763-1772
to	O	1773-1775
12	O	1776-1778
.	O	1778-1779
8	O	1779-1780
and	O	1781-1784
15	O	1785-1787
.	O	1787-1788
0	O	1788-1789
U	O	1790-1791
/	O	1791-1792
ml	O	1792-1794
,	O	1794-1795
respectively	O	1796-1808
,	O	1808-1809
despite	O	1810-1817
continued	O	1818-1827
PTU	O	1828-1831
therapy	O	1832-1839
,	O	1839-1840
but	O	1841-1844
no	O	1845-1847
vasculitic	B	1848-1858
disorders	I	1859-1868
developed	O	1869-1878
.	O	1878-1879

In	O	1880-1882
the	O	1883-1886
third	O	1887-1892
patient	O	1893-1900
,	O	1900-1901
the	O	1902-1905
MPO	O	1906-1909
-	O	1909-1910
ANCA	O	1910-1914
titre	O	1915-1920
increased	O	1921-1930
to	O	1931-1933
204	O	1934-1937
U	O	1938-1939
/	O	1939-1940
ml	O	1940-1942
and	O	1943-1946
she	O	1947-1950
developed	O	1951-1960
a	O	1961-1962
higher	O	1963-1969
fever	B	1970-1975
,	O	1975-1976
oral	B	1977-1981
ulcers	I	1982-1988
and	O	1989-1992
polyarthralgia	B	1993-2007
,	O	2007-2008
but	O	2009-2012
the	O	2013-2016
symptoms	O	2017-2025
resolved	O	2026-2034
2	O	2035-2036
weeks	O	2037-2042
after	O	2043-2048
stopping	O	2049-2057
PTU	O	2058-2061
therapy	O	2062-2069
,	O	2069-2070
and	O	2071-2074
the	O	2075-2078
MPO	O	2079-2082
-	O	2082-2083
ANCA	O	2083-2087
titre	O	2088-2093
decreased	O	2094-2103
to	O	2104-2106
20	O	2107-2109
.	O	2109-2110
7	O	2110-2111
U	O	2112-2113
/	O	2113-2114
ml	O	2114-2116
by	O	2117-2119
4	O	2120-2121
months	O	2122-2128
after	O	2129-2134
discontinuing	O	2135-2148
PTU	O	2149-2152
.	O	2152-2153

CONCLUSIONS	O	2154-2165
:	O	2165-2166
PTU	O	2167-2170
therapy	O	2171-2178
may	O	2179-2182
be	O	2183-2185
related	O	2186-2193
to	O	2194-2196
the	O	2197-2200
appearance	O	2201-2211
of	O	2212-2214
MPO	O	2215-2218
-	O	2218-2219
ANCA	O	2219-2223
,	O	2223-2224
but	O	2225-2228
MPO	O	2229-2232
-	O	2232-2233
ANCA	O	2233-2237
does	O	2238-2242
not	O	2243-2246
appear	O	2247-2253
to	O	2254-2256
be	O	2257-2259
closely	O	2260-2267
related	O	2268-2275
to	O	2276-2278
vasculitis	B	2279-2289
.	O	2289-2290

Prevalence	O	0-10
of	O	11-13
heart	B	14-19
disease	I	20-27
in	O	28-30
asymptomatic	O	31-43
chronic	O	44-51
cocaine	O	52-59
users	O	60-65
.	O	65-66

To	O	67-69
determine	O	70-79
the	O	80-83
prevalence	O	84-94
of	O	95-97
heart	B	98-103
disease	I	104-111
in	O	112-114
outpatient	O	115-125
young	O	126-131
asymptomatic	O	132-144
chronic	O	145-152
cocaine	O	153-160
users	O	161-166
,	O	166-167
35	O	168-170
cocaine	O	171-178
users	O	179-184
and	O	185-188
32	O	189-191
age	O	192-195
-	O	195-196
matched	O	196-203
controls	O	204-212
underwent	O	213-222
resting	O	223-230
and	O	231-234
exercise	O	235-243
electrocardiography	O	244-263
(	O	264-265
ECG	O	265-268
)	O	268-269
and	O	270-273
Doppler	O	274-281
echocardiography	O	282-298
.	O	298-299

Findings	O	300-308
consistent	O	309-319
with	O	320-324
coronary	B	325-333
artery	I	334-340
disease	I	341-348
were	O	349-353
detected	O	354-362
in	O	363-365
12	O	366-368
(	O	369-370
34	O	370-372
%	O	372-373
)	O	373-374
patients	O	375-383
and	O	384-387
3	O	388-389
(	O	390-391
9	O	391-392
%	O	392-393
)	O	393-394
controls	O	395-403
(	O	404-405
p	O	405-406
=	O	407-408
0	O	409-410
.	O	410-411
01	O	411-413
)	O	413-414
.	O	410-411

Decreased	O	416-425
left	O	426-430
ventricular	O	431-442
systolic	O	443-451
function	O	452-460
was	O	461-464
demonstrated	O	465-477
in	O	478-480
5	O	481-482
(	O	483-484
14	O	484-486
%	O	486-487
)	O	487-488
patients	O	489-497
,	O	497-498
but	O	499-502
in	O	503-505
none	O	506-510
of	O	511-513
the	O	514-517
controls	O	518-526
(	O	527-528
p	O	528-529
=	O	530-531
0	O	532-533
.	O	533-534
055	O	534-537
)	O	537-538
.	O	533-534

Finally	O	540-547
,	O	547-548
resting	O	549-556
and	O	557-560
peak	O	561-565
exercise	O	566-574
abnormal	B	575-583
left	I	584-588
ventricular	I	589-600
filling	I	601-608
was	O	609-612
detected	O	613-621
in	O	622-624
38	O	625-627
and	O	628-631
35	O	632-634
%	O	634-635
of	O	636-638
patients	O	639-647
as	O	648-650
compared	O	651-659
to	O	660-662
19	O	663-665
and	O	666-669
9	O	670-671
%	O	671-672
of	O	673-675
controls	O	676-684
,	O	684-685
respectively	O	686-698
(	O	699-700
p	O	700-701
=	O	702-703
0	O	704-705
.	O	705-706
11	O	706-708
and	O	709-712
0	O	713-714
.	O	714-715
02	O	715-717
,	O	717-718
respectively	O	719-731
)	O	731-732
.	O	732-733

We	O	734-736
conclude	O	737-745
that	O	746-750
coronary	B	751-759
artery	I	760-766
or	I	767-769
myocardial	I	770-780
disease	I	781-788
is	O	789-791
common	O	792-798
(	O	799-800
38	O	800-802
%	O	802-803
)	O	803-804
in	O	805-807
young	O	808-813
asymptomatic	O	814-826
chronic	O	827-834
cocaine	O	835-842
users	O	843-848
.	O	848-849

Therefore	O	850-859
,	O	859-860
screening	O	861-870
ECG	O	871-874
and	O	875-878
echocardiography	O	879-895
may	O	896-899
be	O	900-902
warranted	O	903-912
in	O	913-915
these	O	916-921
patients	O	922-930
.	O	930-931

Cardioprotective	O	0-16
effects	O	17-24
of	O	25-27
Picrorrhiza	O	28-39
kurroa	O	40-46
against	O	47-54
isoproterenol	O	55-68
-	O	68-69
induced	O	69-76
myocardial	O	77-87
stress	O	88-94
in	O	95-97
rats	O	98-102
.	O	102-103

The	O	104-107
cardioprotective	O	108-124
effect	O	125-131
of	O	132-134
the	O	135-138
ethanol	O	139-146
extract	O	147-154
of	O	155-157
Picrorrhiza	O	158-169
kurroa	O	170-176
rhizomes	O	177-185
and	O	186-189
roots	O	190-195
(	O	196-197
PK	O	197-199
)	O	199-200
on	O	201-203
isoproterenol	O	204-217
-	O	217-218
induced	O	218-225
myocardial	B	226-236
infarction	I	237-247
in	O	248-250
rats	O	251-255
with	O	256-260
respect	O	261-268
to	O	269-271
lipid	O	272-277
metabolism	O	278-288
in	O	289-291
serum	O	292-297
and	O	298-301
heart	O	302-307
tissue	O	308-314
has	O	315-318
been	O	319-323
investigated	O	324-336
.	O	336-337

Oral	O	338-342
pre	O	343-346
-	O	346-347
treatment	O	347-356
with	O	357-361
PK	O	362-364
(	O	365-366
80	O	366-368
mg	O	369-371
kg	O	372-374
(	O	374-375
-	O	375-376
1	O	376-377
)	O	377-378
day	O	379-382
(	O	382-383
-	O	383-384
1	O	384-385
)	O	385-386
for	O	387-390
15	O	391-393
days	O	394-398
)	O	398-399
significantly	O	400-413
prevented	O	414-423
the	O	424-427
isoproterenol	O	428-441
-	O	441-442
induced	O	442-449
myocardial	B	450-460
infarction	I	461-471
and	O	472-475
maintained	O	476-486
the	O	487-490
rats	O	491-495
at	O	496-498
near	O	499-503
normal	O	504-510
status	O	511-517
.	O	517-518

Phase	O	0-5
2	O	6-7
early	O	8-13
afterdepolarization	O	14-33
as	O	34-36
a	O	37-38
trigger	O	39-46
of	O	47-49
polymorphic	O	50-61
ventricular	B	62-73
tachycardia	I	74-85
in	O	86-88
acquired	O	89-97
long	B	98-102
-	I	102-103
QT	I	103-105
syndrome	I	106-114
:	O	115-116
direct	O	117-123
evidence	O	124-132
from	O	133-137
intracellular	O	138-151
recordings	O	152-162
in	O	163-165
the	O	166-169
intact	O	170-176
left	O	177-181
ventricular	O	182-193
wall	O	194-198
.	O	198-199

BACKGROUND	O	200-210
:	O	210-211
This	O	212-216
study	O	217-222
examined	O	223-231
the	O	232-235
role	O	236-240
of	O	241-243
phase	O	244-249
2	O	250-251
early	O	252-257
afterdepolarization	O	258-277
(	O	278-279
EAD	O	279-282
)	O	282-283
in	O	284-286
producing	O	287-296
a	O	297-298
trigger	O	299-306
to	O	307-309
initiate	O	310-318
torsade	B	319-326
de	I	327-329
pointes	I	330-337
(	O	338-339
TdP	B	339-342
)	O	342-343
with	O	344-348
QT	B	349-351
prolongation	I	352-364
induced	O	365-372
by	O	373-375
dl	O	376-378
-	O	378-379
sotalol	O	379-386
and	O	387-390
azimilide	O	391-400
.	O	400-401

The	O	402-405
contribution	O	406-418
of	O	419-421
transmural	O	422-432
dispersion	O	433-443
of	O	444-446
repolarization	O	447-461
(	O	462-463
TDR	O	463-466
)	O	466-467
to	O	468-470
transmural	O	471-481
propagation	O	482-493
of	O	494-496
EAD	O	497-500
and	O	501-504
the	O	505-508
maintenance	O	509-520
of	O	521-523
TdP	B	524-527
was	O	528-531
also	O	532-536
evaluated	O	537-546
.	O	546-547

METHODS	O	548-555
AND	O	556-559
RESULTS	O	560-567
:	O	567-568
Transmembrane	O	569-582
action	O	583-589
potentials	O	590-600
from	O	601-605
epicardium	O	606-616
,	O	616-617
midmyocardium	O	618-631
,	O	631-632
and	O	633-636
endocardium	O	637-648
were	O	649-653
recorded	O	654-662
simultaneously	O	663-677
,	O	677-678
together	O	679-687
with	O	688-692
a	O	693-694
transmural	O	695-705
ECG	O	706-709
,	O	709-710
in	O	711-713
arterially	O	714-724
perfused	O	725-733
canine	O	734-740
and	O	741-744
rabbit	O	745-751
left	O	752-756
ventricular	O	757-768
preparations	O	769-781
.	O	781-782

dl	O	783-785
-	O	785-786
Sotalol	O	786-793
preferentially	O	794-808
prolonged	O	809-818
action	O	819-825
potential	O	826-835
duration	O	836-844
(	O	845-846
APD	O	846-849
)	O	849-850
in	O	851-853
M	O	854-855
cells	O	856-861
dose	O	862-866
-	O	866-867
dependently	O	867-878
(	O	879-880
1	O	880-881
to	O	882-884
100	O	885-888
micromol	O	889-897
/	O	897-898
L	O	898-899
)	O	899-900
,	O	900-901
leading	O	902-909
to	O	910-912
QT	B	913-915
prolongation	I	916-928
and	O	929-932
an	O	933-935
increase	O	936-944
in	O	945-947
TDR	O	948-951
.	O	951-952

Azimilide	O	953-962
,	O	962-963
however	O	964-971
,	O	971-972
significantly	O	973-986
prolonged	O	987-996
APD	O	997-1000
and	O	1001-1004
QT	O	1005-1007
interval	O	1008-1016
at	O	1017-1019
concentrations	O	1020-1034
from	O	1035-1039
0	O	1040-1041
.	O	1041-1042
1	O	1042-1043
to	O	1044-1046
10	O	1047-1049
micromol	O	1050-1058
/	O	1058-1059
L	O	1059-1060
but	O	1061-1064
shortened	O	1065-1074
them	O	1075-1079
at	O	1080-1082
30	O	1083-1085
micromol	O	1086-1094
/	O	1094-1095
L	O	1095-1096
.	O	1096-1097

Unlike	O	1098-1104
dl	O	1105-1107
-	O	1107-1108
sotalol	O	1108-1115
,	O	1115-1116
azimilide	O	1117-1126
(	O	1127-1128
>	O	1128-1129
3	O	1129-1130
micromol	O	1131-1139
/	O	1139-1140
L	O	1140-1141
)	O	1141-1142
increased	O	1143-1152
epicardial	O	1153-1163
APD	O	1164-1167
markedly	O	1168-1176
,	O	1176-1177
causing	O	1178-1185
a	O	1186-1187
diminished	O	1188-1198
TDR	O	1199-1202
.	O	1202-1203

Although	O	1204-1212
both	O	1213-1217
dl	O	1218-1220
-	O	1220-1221
sotalol	O	1221-1228
and	O	1229-1232
azimilide	O	1233-1242
rarely	O	1243-1249
induced	O	1250-1257
EADs	O	1258-1262
in	O	1263-1265
canine	O	1266-1272
left	O	1273-1277
ventricles	O	1278-1288
,	O	1288-1289
they	O	1290-1294
produced	O	1295-1303
frequent	O	1304-1312
EADs	O	1313-1317
in	O	1318-1320
rabbits	O	1321-1328
,	O	1328-1329
in	O	1330-1332
which	O	1333-1338
more	O	1339-1343
pronounced	O	1344-1354
QT	B	1355-1357
prolongation	I	1358-1370
was	O	1371-1374
seen	O	1375-1379
.	O	1379-1380

An	O	1381-1383
increase	O	1384-1392
in	O	1393-1395
TDR	O	1396-1399
by	O	1400-1402
dl	O	1403-1405
-	O	1405-1406
sotalol	O	1406-1413
facilitated	O	1414-1425
transmural	O	1426-1436
propagation	O	1437-1448
of	O	1449-1451
EADs	O	1452-1456
that	O	1457-1461
initiated	O	1462-1471
multiple	O	1472-1480
episodes	O	1481-1489
of	O	1490-1492
spontaneous	O	1493-1504
TdP	B	1505-1508
in	O	1509-1511
3	O	1512-1513
of	O	1514-1516
6	O	1517-1518
rabbit	O	1519-1525
left	O	1526-1530
ventricles	O	1531-1541
.	O	1541-1542

Of	O	1543-1545
note	O	1546-1550
,	O	1550-1551
although	O	1552-1560
azimilide	O	1561-1570
(	O	1571-1572
3	O	1572-1573
to	O	1574-1576
10	O	1577-1579
micromol	O	1580-1588
/	O	1588-1589
L	O	1589-1590
)	O	1590-1591
increased	O	1592-1601
APD	O	1602-1605
more	O	1606-1610
than	O	1611-1615
dl	O	1616-1618
-	O	1618-1619
sotalol	O	1619-1626
,	O	1626-1627
its	O	1628-1631
EADs	O	1632-1636
often	O	1637-1642
failed	O	1643-1649
to	O	1650-1652
propagate	O	1653-1662
transmurally	O	1663-1675
,	O	1675-1676
probably	O	1677-1685
because	O	1686-1693
of	O	1694-1696
a	O	1697-1698
diminished	O	1699-1709
TDR	O	1710-1713
.	O	1713-1714

CONCLUSIONS	O	1715-1726
:	O	1726-1727
This	O	1728-1732
study	O	1733-1738
provides	O	1739-1747
the	O	1748-1751
first	O	1752-1757
direct	O	1758-1764
evidence	O	1765-1773
from	O	1774-1778
intracellular	O	1779-1792
action	O	1793-1799
potential	O	1800-1809
recordings	O	1810-1820
that	O	1821-1825
phase	O	1826-1831
2	O	1832-1833
EAD	O	1834-1837
can	O	1838-1841
be	O	1842-1844
generated	O	1845-1854
from	O	1855-1859
intact	O	1860-1866
ventricular	O	1867-1878
wall	O	1879-1883
and	O	1884-1887
produce	O	1888-1895
a	O	1896-1897
trigger	O	1898-1905
to	O	1906-1908
initiate	O	1909-1917
the	O	1918-1921
onset	O	1922-1927
of	O	1928-1930
TdP	B	1931-1934
under	O	1935-1940
QT	B	1941-1943
prolongation	I	1944-1956
.	O	1956-1957

Prenatal	O	0-8
cocaine	O	9-16
exposure	O	17-25
and	O	26-29
cranial	O	30-37
sonographic	O	38-49
findings	O	50-58
in	O	59-61
preterm	B	62-69
infants	I	70-77
.	O	77-78

PURPOSE	O	79-86
:	O	86-87
Prenatal	O	88-96
cocaine	O	97-104
exposure	O	105-113
has	O	114-117
been	O	118-122
linked	O	123-129
with	O	130-134
subependymal	O	135-147
hemorrhage	B	148-158
and	O	159-162
the	O	163-166
formation	O	167-176
of	O	177-179
cysts	B	180-185
that	O	186-190
are	O	191-194
detectable	O	195-205
on	O	206-208
cranial	O	209-216
sonography	O	217-227
in	O	228-230
neonates	O	231-239
born	O	240-244
at	O	245-247
term	O	248-252
.	O	252-253

We	O	254-256
sought	O	257-263
to	O	264-266
determine	O	267-276
if	O	277-279
prenatal	O	280-288
cocaine	O	289-296
exposure	O	297-305
increases	O	306-315
the	O	316-319
incidence	O	320-329
of	O	330-332
subependymal	B	333-345
cysts	I	346-351
in	O	352-354
preterm	B	355-362
infants	I	363-370
.	O	370-371

METHODS	O	372-379
:	O	379-380
We	O	381-383
retrospectively	O	384-399
reviewed	O	400-408
the	O	409-412
medical	O	413-420
records	O	421-428
and	O	429-432
cranial	O	433-440
sonograms	O	441-450
obtained	O	451-459
during	O	460-466
a	O	467-468
1	O	469-470
-	O	470-471
year	O	471-475
period	O	476-482
on	O	483-485
122	O	486-489
premature	B	490-499
(	I	500-501
<	I	501-502
36	I	503-505
weeks	I	506-511
of	I	512-514
gestation	I	515-524
)	I	524-525
infants	I	526-533
.	O	533-534

Infants	O	535-542
were	O	543-547
categorized	O	548-559
into	O	560-564
1	O	565-566
of	O	567-569
2	O	570-571
groups	O	572-578
:	O	578-579
those	O	580-585
exposed	O	586-593
to	O	594-596
cocaine	O	597-604
and	O	605-608
those	O	609-614
not	O	615-618
exposed	O	619-626
to	O	627-629
cocaine	O	630-637
.	O	637-638

Infants	O	639-646
were	O	647-651
assigned	O	652-660
to	O	661-663
the	O	664-667
cocaine	O	668-675
-	O	675-676
exposed	O	676-683
group	O	684-689
if	O	690-692
there	O	693-698
was	O	699-702
a	O	703-704
maternal	O	705-713
history	O	714-721
of	O	722-724
cocaine	B	725-732
abuse	I	733-738
during	O	739-745
pregnancy	O	746-755
or	O	756-758
if	O	759-761
maternal	O	762-770
or	O	771-773
neonatal	O	774-782
urine	O	783-788
toxicology	O	789-799
results	O	800-807
were	O	808-812
positive	O	813-821
at	O	822-824
the	O	825-828
time	O	829-833
of	O	834-836
delivery	O	837-845
.	O	845-846

RESULTS	O	847-854
:	O	854-855
Five	O	856-860
of	O	861-863
the	O	864-867
122	O	868-871
infants	O	872-879
were	O	880-884
excluded	O	885-893
from	O	894-898
the	O	899-902
study	O	903-908
because	O	909-916
of	O	917-919
insufficient	O	920-932
medical	O	933-940
and	O	941-944
drug	O	945-949
histories	O	950-959
.	O	959-960

The	O	961-964
incidence	O	965-974
of	O	975-977
subependymal	B	978-990
cysts	I	991-996
in	O	997-999
the	O	1000-1003
117	O	1004-1007
remaining	O	1008-1017
infants	O	1018-1025
was	O	1026-1029
14	O	1030-1032
%	O	1032-1033
(	O	1034-1035
16	O	1035-1037
of	O	1038-1040
117	O	1041-1044
)	O	1044-1045
.	O	1045-1046

The	O	1047-1050
incidence	O	1051-1060
of	O	1061-1063
subependymal	B	1064-1076
cysts	I	1077-1082
in	O	1083-1085
infants	O	1086-1093
exposed	O	1094-1101
to	O	1102-1104
cocaine	O	1105-1112
prenatally	O	1113-1123
was	O	1124-1127
44	O	1128-1130
%	O	1130-1131
(	O	1132-1133
8	O	1133-1134
of	O	1135-1137
18	O	1138-1140
)	O	1140-1141
compared	O	1142-1150
with	O	1151-1155
8	O	1156-1157
%	O	1157-1158
(	O	1159-1160
8	O	1160-1161
of	O	1162-1164
99	O	1165-1167
)	O	1167-1168
in	O	1169-1171
the	O	1172-1175
unexposed	O	1176-1185
group	O	1186-1191
(	O	1192-1193
p	O	1193-1194
<	O	1195-1196
0	O	1197-1198
.	O	1198-1199
01	O	1199-1201
)	O	1201-1202
.	O	1198-1199

CONCLUSIONS	O	1204-1215
:	O	1215-1216
We	O	1217-1219
found	O	1220-1225
an	O	1226-1228
increased	O	1229-1238
incidence	O	1239-1248
of	O	1249-1251
subependymal	B	1252-1264
cyst	I	1265-1269
formation	O	1270-1279
in	O	1280-1282
preterm	B	1283-1290
infants	I	1291-1298
who	O	1299-1302
were	O	1303-1307
exposed	O	1308-1315
to	O	1316-1318
cocaine	O	1319-1326
prenatally	O	1327-1337
.	O	1337-1338

This	O	1339-1343
result	O	1344-1350
is	O	1351-1353
consistent	O	1354-1364
with	O	1365-1369
results	O	1370-1377
of	O	1378-1380
similar	O	1381-1388
studies	O	1389-1396
in	O	1397-1399
term	O	1400-1404
infants	O	1405-1412
.	O	1412-1413

Thalidomide	O	0-11
neuropathy	B	12-22
in	O	23-25
patients	O	26-34
treated	O	35-42
for	O	43-46
metastatic	O	47-57
prostate	B	58-66
cancer	I	67-73
.	O	73-74

We	O	75-77
prospectively	O	78-91
evaluated	O	92-101
thalidomide	O	102-113
-	O	113-114
induced	O	114-121
neuropathy	B	122-132
using	O	133-138
electrodiagnostic	O	139-156
studies	O	157-164
.	O	164-165

Sixty	O	166-171
-	O	171-172
seven	O	172-177
men	O	178-181
with	O	182-186
metastatic	O	187-197
androgen	O	198-206
-	O	206-207
independent	O	207-218
prostate	B	219-227
cancer	I	228-234
in	O	235-237
an	O	238-240
open	O	241-245
-	O	245-246
label	O	246-251
trial	O	252-257
of	O	258-260
oral	O	261-265
thalidomide	O	266-277
underwent	O	278-287
neurologic	O	288-298
examinations	O	299-311
and	O	312-315
nerve	O	316-321
conduction	O	322-332
studies	O	333-340
(	O	341-342
NCS	O	342-345
)	O	345-346
prior	O	347-352
to	O	353-355
and	O	356-359
at	O	360-362
3	O	363-364
-	O	364-365
month	O	365-370
intervals	O	371-380
during	O	381-387
treatment	O	388-397
.	O	397-398

NCS	O	399-402
included	O	403-411
recording	O	412-421
of	O	422-424
sensory	O	425-432
nerve	O	433-438
action	O	439-445
potentials	O	446-456
(	O	457-458
SNAPs	O	458-463
)	O	463-464
from	O	465-469
median	O	470-476
,	O	476-477
radial	O	478-484
,	O	484-485
ulnar	O	486-491
,	O	491-492
and	O	493-496
sural	O	497-502
nerves	O	503-509
.	O	509-510

SNAP	O	511-515
amplitudes	O	516-526
for	O	527-530
each	O	531-535
nerve	O	536-541
were	O	542-546
expressed	O	547-556
as	O	557-559
the	O	560-563
percentage	O	564-574
of	O	575-577
its	O	578-581
baseline	O	582-590
,	O	590-591
and	O	592-595
the	O	596-599
mean	O	600-604
of	O	605-607
the	O	608-611
four	O	612-616
was	O	617-620
termed	O	621-627
the	O	628-631
SNAP	O	632-636
index	O	637-642
.	O	642-643

A	O	644-645
40	O	646-648
%	O	648-649
decline	O	650-657
in	O	658-660
the	O	661-664
SNAP	O	665-669
index	O	670-675
was	O	676-679
considered	O	680-690
clinically	O	691-701
significant	O	702-713
.	O	713-714

Thalidomide	O	715-726
was	O	727-730
discontinued	O	731-743
in	O	744-746
55	O	747-749
patients	O	750-758
for	O	759-762
lack	O	763-767
of	O	768-770
therapeutic	O	771-782
response	O	783-791
.	O	791-792

Of	O	793-795
67	O	796-798
patients	O	799-807
initially	O	808-817
enrolled	O	818-826
,	O	826-827
24	O	828-830
remained	O	831-839
on	O	840-842
thalidomide	O	843-854
for	O	855-858
3	O	859-860
months	O	861-867
,	O	867-868
8	O	869-870
remained	O	871-879
at	O	880-882
6	O	883-884
months	O	885-891
,	O	891-892
and	O	893-896
3	O	897-898
remained	O	899-907
at	O	908-910
9	O	911-912
months	O	913-919
.	O	919-920

Six	O	921-924
patients	O	925-933
developed	O	934-943
neuropathy	B	944-954
.	O	954-955

Clinical	O	956-964
symptoms	O	965-973
and	O	974-977
a	O	978-979
decline	O	980-987
in	O	988-990
the	O	991-994
SNAP	O	995-999
index	O	1000-1005
occurred	O	1006-1014
concurrently	O	1015-1027
.	O	1027-1028

Older	O	1029-1034
age	O	1035-1038
and	O	1039-1042
cumulative	O	1043-1053
dose	O	1054-1058
were	O	1059-1063
possible	O	1064-1072
contributing	O	1073-1085
factors	O	1086-1093
.	O	1093-1094

Neuropathy	B	1095-1105
may	O	1106-1109
thus	O	1110-1114
be	O	1115-1117
a	O	1118-1119
common	O	1120-1126
complication	O	1127-1139
of	O	1140-1142
thalidomide	O	1143-1154
in	O	1155-1157
older	O	1158-1163
patients	O	1164-1172
.	O	1172-1173

The	O	1174-1177
SNAP	O	1178-1182
index	O	1183-1188
can	O	1189-1192
be	O	1193-1195
used	O	1196-1200
to	O	1201-1203
monitor	O	1204-1211
peripheral	B	1212-1222
neuropathy	I	1223-1233
,	O	1233-1234
but	O	1235-1238
not	O	1239-1242
for	O	1243-1246
early	O	1247-1252
detection	O	1253-1262
.	O	1262-1263

Overexpression	O	0-14
of	O	15-17
copper	O	18-24
/	O	24-25
zinc	O	25-29
-	O	29-30
superoxide	O	30-40
dismutase	O	41-50
protects	O	51-59
from	O	60-64
kanamycin	O	65-74
-	O	74-75
induced	O	75-82
hearing	B	83-90
loss	I	91-95
.	O	95-96

The	O	97-100
participation	O	101-114
of	O	115-117
reactive	O	118-126
oxygen	O	127-133
species	O	134-141
in	O	142-144
aminoglycoside	O	145-159
-	O	159-160
induced	O	160-167
ototoxicity	B	168-179
has	O	180-183
been	O	184-188
deduced	O	189-196
from	O	197-201
observations	O	202-214
that	O	215-219
aminoglycoside	O	220-234
-	O	234-235
iron	O	235-239
complexes	O	240-249
catalyze	O	250-258
the	O	259-262
formation	O	263-272
of	O	273-275
superoxide	O	276-286
radicals	O	287-295
in	O	296-298
vitro	O	299-304
and	O	305-308
that	O	309-313
antioxidants	O	314-326
attenuate	O	327-336
ototoxicity	B	337-348
in	O	349-351
vivo	O	352-356
.	O	356-357

We	O	358-360
therefore	O	361-370
hypothesized	O	371-383
that	O	384-388
overexpression	O	389-403
of	O	404-406
Cu	O	407-409
/	O	409-410
Zn	O	410-412
-	O	412-413
superoxide	O	413-423
dismutase	O	424-433
(	O	434-435
h	O	435-436
-	O	436-437
SOD1	O	437-441
)	O	441-442
should	O	443-449
protect	O	450-457
transgenic	O	458-468
mice	O	469-473
from	O	474-478
ototoxicity	B	479-490
.	O	490-491

Immunocytochemistry	O	492-511
confirmed	O	512-521
expression	O	522-532
of	O	533-535
h	O	536-537
-	O	537-538
SOD1	O	538-542
in	O	543-545
inner	O	546-551
ear	O	552-555
tissues	O	556-563
of	O	564-566
transgenic	O	567-577
C57BL	O	578-583
/	O	583-584
6	O	584-585
-	O	585-586
TgN	O	586-589
[	O	589-590
SOD1	O	590-594
]	O	594-595
3Cje	O	595-599
mice	O	600-604
.	O	604-605

Transgenic	O	606-616
and	O	617-620
nontransgenic	O	621-634
littermates	O	635-646
received	O	647-655
kanamycin	O	656-665
(	O	666-667
400	O	667-670
mg	O	671-673
/	O	673-674
kg	O	674-676
body	O	677-681
weight	O	682-688
/	O	688-689
day	O	689-692
)	O	692-693
for	O	694-697
10	O	698-700
days	O	701-705
beginning	O	706-715
on	O	716-718
day	O	719-722
10	O	723-725
after	O	726-731
birth	O	732-737
.	O	737-738

Auditory	O	739-747
thresholds	O	748-758
were	O	759-763
tested	O	764-770
by	O	771-773
evoked	O	774-780
auditory	O	781-789
brain	O	790-795
stem	O	796-800
responses	O	801-810
at	O	811-813
1	O	814-815
month	O	816-821
after	O	822-827
birth	O	828-833
.	O	833-834

In	O	835-837
nontransgenic	O	838-851
animals	O	852-859
,	O	859-860
the	O	861-864
threshold	O	865-874
in	O	875-877
the	O	878-881
kanamycin	O	882-891
-	O	891-892
treated	O	892-899
group	O	900-905
was	O	906-909
45	O	910-912
-	O	912-913
50	O	913-915
dB	O	916-918
higher	O	919-925
than	O	926-930
in	O	931-933
saline	O	934-940
-	O	940-941
injected	O	941-949
controls	O	950-958
.	O	958-959

In	O	960-962
the	O	963-966
transgenic	O	967-977
group	O	978-983
,	O	983-984
kanamycin	O	985-994
increased	O	995-1004
the	O	1005-1008
threshold	O	1009-1018
by	O	1019-1021
only	O	1022-1026
15	O	1027-1029
dB	O	1030-1032
over	O	1033-1037
the	O	1038-1041
respective	O	1042-1052
controls	O	1053-1061
.	O	1061-1062

The	O	1063-1066
effects	O	1067-1074
were	O	1075-1079
similar	O	1080-1087
at	O	1088-1090
12	O	1091-1093
and	O	1094-1097
24	O	1098-1100
kHz	O	1101-1104
.	O	1104-1105

The	O	1106-1109
protection	O	1110-1120
by	O	1121-1123
overexpression	O	1124-1138
of	O	1139-1141
superoxide	O	1142-1152
dismutase	O	1153-1162
supports	O	1163-1171
the	O	1172-1175
hypothesis	O	1176-1186
that	O	1187-1191
oxidant	O	1192-1199
stress	O	1200-1206
plays	O	1207-1212
a	O	1213-1214
significant	O	1215-1226
role	O	1227-1231
in	O	1232-1234
aminoglycoside	O	1235-1249
-	O	1249-1250
induced	O	1250-1257
ototoxicity	B	1258-1269
.	O	1269-1270

The	O	1271-1274
results	O	1275-1282
also	O	1283-1287
suggest	O	1288-1295
transgenic	O	1296-1306
animals	O	1307-1314
as	O	1315-1317
suitable	O	1318-1326
models	O	1327-1333
to	O	1334-1336
investigate	O	1337-1348
the	O	1349-1352
underlying	O	1353-1363
mechanisms	O	1364-1374
and	O	1375-1378
possible	O	1379-1387
strategies	O	1388-1398
for	O	1399-1402
prevention	O	1403-1413
.	O	1413-1414

Prednisone	O	0-10
induces	O	11-18
anxiety	B	19-26
and	O	27-30
glial	O	31-36
cerebral	O	37-45
changes	O	46-53
in	O	54-56
rats	O	57-61
.	O	61-62

OBJECTIVE	O	63-72
:	O	72-73
To	O	74-76
assess	O	77-83
whether	O	84-91
prednisone	O	92-102
(	O	103-104
PDN	O	104-107
)	O	107-108
produces	O	109-117
anxiety	B	118-125
and	O	126-129
/	O	129-130
or	O	130-132
cerebral	O	133-141
glial	O	142-147
changes	O	148-155
in	O	156-158
rats	O	159-163
.	O	163-164

METHODS	O	165-172
:	O	172-173
Male	O	174-178
Wistar	O	179-185
rats	O	186-190
were	O	191-195
studied	O	196-203
and	O	204-207
3	O	208-209
groups	O	210-216
were	O	217-221
formed	O	222-228
(	O	229-230
8	O	230-231
rats	O	232-236
per	O	237-240
group	O	241-246
)	O	246-247
.	O	247-248

The	O	249-252
moderate	O	253-261
-	O	261-262
dose	O	262-266
group	O	267-272
received	O	273-281
5	O	282-283
mg	O	284-286
/	O	286-287
kg	O	287-289
/	O	286-287
day	O	290-293
PDN	O	294-297
released	O	298-306
from	O	307-311
a	O	312-313
subcutaneous	O	314-326
implant	O	327-334
.	O	334-335

In	O	336-338
the	O	339-342
high	O	343-347
-	O	347-348
dose	O	348-352
group	O	353-358
,	O	358-359
implants	O	360-368
containing	O	369-379
PDN	O	380-383
equivalent	O	384-394
to	O	395-397
60	O	398-400
mg	O	401-403
/	O	403-404
kg	O	404-406
/	O	403-404
day	O	407-410
were	O	411-415
applied	O	416-423
.	O	423-424

In	O	425-427
the	O	428-431
control	O	432-439
group	O	440-445
implants	O	446-454
contained	O	455-464
no	O	465-467
PDN	O	468-471
.	O	471-472

Anxiety	B	473-480
was	O	481-484
assessed	O	485-493
using	O	494-499
an	O	500-502
open	O	503-507
field	O	508-513
and	O	514-517
elevated	O	518-526
plus	O	527-531
-	O	531-532
maze	O	532-536
devices	O	537-544
.	O	544-545

The	O	546-549
number	O	550-556
of	O	557-559
cells	O	560-565
and	O	566-569
cytoplasmic	O	570-581
transformation	O	582-596
of	O	597-599
astrocytes	O	600-610
and	O	611-614
microglia	O	615-624
cells	O	625-630
were	O	631-635
assessed	O	636-644
by	O	645-647
immunohistochemical	O	648-667
analyses	O	668-676
.	O	676-677

RESULTS	O	678-685
:	O	685-686
Anxiety	B	687-694
was	O	695-698
documented	O	699-709
in	O	710-712
both	O	713-717
groups	O	718-724
of	O	725-727
PDN	O	728-731
treated	O	732-739
rats	O	740-744
compared	O	745-753
with	O	754-758
controls	O	759-767
.	O	767-768

The	O	769-772
magnitude	O	773-782
of	O	783-785
transformation	O	786-800
of	O	801-803
the	O	804-807
microglia	O	808-817
assessed	O	818-826
by	O	827-829
the	O	830-833
number	O	834-840
of	O	841-843
intersections	O	844-857
was	O	858-861
significantly	O	862-875
higher	O	876-882
in	O	883-885
the	O	886-889
PDN	O	890-893
groups	O	894-900
than	O	901-905
in	O	906-908
controls	O	909-917
in	O	918-920
the	O	921-924
prefrontal	O	925-935
cortex	O	936-942
(	O	943-944
moderate	O	944-952
-	O	952-953
dose	O	953-957
,	O	957-958
24	O	959-961
.	O	961-962
1	O	962-963
;	O	963-964
high	O	965-969
-	O	969-970
dose	O	970-974
,	O	974-975
23	O	976-978
.	O	978-979
6	O	979-980
;	O	980-981
controls	O	982-990
18	O	991-993
.	O	993-994
7	O	994-995
;	O	995-996
p	O	997-998
<	O	999-1000
0	O	1001-1002
.	O	1002-1003
01	O	1003-1005
)	O	1005-1006
and	O	1007-1010
striatum	O	1011-1019
(	O	1020-1021
moderate	O	1021-1029
-	O	1029-1030
dose	O	1030-1034
25	O	1035-1037
.	O	1037-1038
6	O	1038-1039
;	O	1039-1040
high	O	1041-1045
-	O	1045-1046
dose	O	1046-1050
26	O	1051-1053
.	O	1053-1054
3	O	1054-1055
;	O	1055-1056
controls	O	1057-1065
18	O	1066-1068
.	O	1068-1069
9	O	1069-1070
;	O	1070-1071
p	O	1072-1073
<	O	1074-1075
0	O	1076-1077
.	O	1077-1078
01	O	1078-1080
)	O	1080-1081
,	O	1081-1082
but	O	1083-1086
not	O	1087-1090
in	O	1091-1093
hippocampus	O	1094-1105
.	O	1105-1106

The	O	1107-1110
number	O	1111-1117
of	O	1118-1120
stained	O	1121-1128
microglia	O	1129-1138
cells	O	1139-1144
was	O	1145-1148
significantly	O	1149-1162
higher	O	1163-1169
in	O	1170-1172
the	O	1173-1176
PDN	O	1177-1180
treated	O	1181-1188
groups	O	1189-1195
in	O	1196-1198
the	O	1199-1202
prefrontal	O	1203-1213
cortex	O	1214-1220
than	O	1221-1225
in	O	1226-1228
controls	O	1229-1237
(	O	1238-1239
moderate	O	1239-1247
-	O	1247-1248
dose	O	1248-1252
,	O	1252-1253
29	O	1254-1256
.	O	1256-1257
1	O	1257-1258
;	O	1258-1259
high	O	1260-1264
-	O	1264-1265
dose	O	1265-1269
,	O	1269-1270
28	O	1271-1273
.	O	1273-1274
4	O	1274-1275
;	O	1275-1276
control	O	1277-1284
,	O	1284-1285
17	O	1286-1288
.	O	1288-1289
7	O	1287-1288
cells	O	1291-1296
per	O	1297-1300
field	O	1301-1306
;	O	1306-1307
p	O	1308-1309
<	O	1310-1311
0	O	1312-1313
.	O	1313-1314
01	O	1314-1316
)	O	1316-1317
.	O	1313-1314

Stained	O	1319-1326
microglia	O	1327-1336
cells	O	1337-1342
were	O	1343-1347
significantly	O	1348-1361
more	O	1362-1366
numerous	O	1367-1375
striatum	O	1376-1384
and	O	1385-1388
hippocampus	O	1389-1400
in	O	1401-1403
the	O	1404-1407
high	O	1408-1412
-	O	1412-1413
dose	O	1413-1417
group	O	1418-1423
compared	O	1424-1432
to	O	1433-1435
controls	O	1436-1444
.	O	1444-1445

CONCLUSION	O	1446-1456
:	O	1456-1457
Subacute	O	1458-1466
exposure	O	1467-1475
to	O	1476-1478
PDN	O	1479-1482
induced	O	1483-1490
anxiety	B	1491-1498
and	O	1499-1502
reactivity	O	1503-1513
of	O	1514-1516
microglia	O	1517-1526
.	O	1526-1527

The	O	1528-1531
relevance	O	1532-1541
of	O	1542-1544
these	O	1545-1550
features	O	1551-1559
for	O	1560-1563
patients	O	1564-1572
using	O	1573-1578
PDN	O	1579-1582
remains	O	1583-1590
to	O	1591-1593
be	O	1594-1596
elucidated	O	1597-1607
.	O	1607-1608

Phase	O	0-5
II	O	6-8
study	O	9-14
of	O	15-17
carboplatin	O	18-29
and	O	30-33
liposomal	O	34-43
doxorubicin	O	44-55
in	O	56-58
patients	O	59-67
with	O	68-72
recurrent	O	73-82
squamous	B	83-91
cell	I	92-96
carcinoma	I	97-106
of	I	107-109
the	I	110-113
cervix	I	114-120
.	O	120-121

BACKGROUND	O	122-132
:	O	132-133
The	O	134-137
activity	O	138-146
of	O	147-149
the	O	150-153
combination	O	154-165
of	O	166-168
carboplatin	O	169-180
and	O	181-184
liposomal	O	185-194
doxorubicin	O	195-206
was	O	207-210
tested	O	211-217
in	O	218-220
a	O	221-222
Phase	O	223-228
II	O	229-231
study	O	232-237
of	O	238-240
patients	O	241-249
with	O	250-254
recurrent	O	255-264
cervical	B	265-273
carcinoma	I	274-283
.	O	283-284

METHODS	O	285-292
:	O	292-293
The	O	294-297
combination	O	298-309
of	O	310-312
carboplatin	O	313-324
(	O	325-326
area	O	326-330
under	O	331-336
the	O	337-340
concentration	O	341-354
curve	O	355-360
[	O	361-362
AUC	O	362-365
]	O	365-366
,	O	366-367
5	O	368-369
)	O	369-370
and	O	371-374
liposomal	O	375-384
doxorubicin	O	385-396
(	O	397-398
Doxil	O	398-403
;	O	403-404
starting	O	405-413
dose	O	414-418
,	O	418-419
40	O	420-422
mg	O	423-425
/	O	425-426
m	O	423-424
(	O	427-428
2	O	428-429
)	O	429-430
)	O	429-430
was	O	432-435
administered	O	436-448
intravenously	O	449-462
every	O	463-468
28	O	469-471
days	O	472-476
to	O	477-479
37	O	480-482
patients	O	483-491
with	O	492-496
recurrent	O	497-506
squamous	B	507-515
cell	I	516-520
cervical	I	521-529
carcinoma	I	530-539
to	O	540-542
determine	O	543-552
antitumor	O	553-562
activity	O	563-571
and	O	572-575
toxicity	B	576-584
profile	O	585-592
.	O	592-593

RESULTS	O	594-601
:	O	601-602
Twenty	O	603-609
-	O	609-610
nine	O	610-614
patients	O	615-623
were	O	624-628
assessable	O	629-639
for	O	640-643
response	O	644-652
,	O	652-653
and	O	654-657
35	O	658-660
patients	O	661-669
were	O	670-674
assessable	O	675-685
for	O	686-689
toxicity	B	690-698
.	O	698-699

The	O	700-703
overall	O	704-711
response	O	712-720
rate	O	721-725
was	O	726-729
38	O	730-732
%	O	732-733
,	O	733-734
the	O	735-738
median	O	739-745
time	O	746-750
to	O	751-753
response	O	754-762
was	O	763-766
10	O	767-769
weeks	O	770-775
,	O	775-776
the	O	777-780
median	O	781-787
duration	O	788-796
of	O	797-799
response	O	800-808
was	O	809-812
26	O	813-815
weeks	O	816-821
,	O	821-822
and	O	823-826
the	O	827-830
median	O	831-837
survival	O	838-846
was	O	847-850
37	O	851-853
weeks	O	854-859
.	O	859-860

The	O	861-864
main	O	865-869
toxic	O	870-875
effect	O	876-882
was	O	883-886
myelosuppression	B	887-903
,	O	903-904
with	O	905-909
Grade	O	910-915
3	O	916-917
and	O	918-921
4	O	922-923
neutropenia	B	924-935
in	O	936-938
16	O	939-941
patients	O	942-950
,	O	950-951
anemia	B	952-958
in	O	959-961
12	O	962-964
patients	O	965-973
,	O	973-974
thrombocytopenia	B	975-991
in	O	992-994
11	O	995-997
patients	O	998-1006
,	O	1006-1007
and	O	1008-1011
neutropenic	B	1012-1023
fever	I	1024-1029
in	O	1030-1032
3	O	1033-1034
patients	O	1035-1043
.	O	1043-1044

Four	O	1045-1049
patients	O	1050-1058
had	O	1059-1062
five	O	1063-1067
infusion	O	1068-1076
-	O	1076-1077
related	O	1077-1084
reactions	O	1085-1094
during	O	1095-1101
the	O	1102-1105
infusion	O	1106-1114
of	O	1115-1117
liposomal	O	1118-1127
doxorubicin	O	1128-1139
,	O	1139-1140
leading	O	1141-1148
to	O	1149-1151
treatment	O	1152-1161
discontinuation	O	1162-1177
in	O	1178-1180
three	O	1181-1186
patients	O	1187-1195
.	O	1195-1196

Grade	O	1197-1202
>	O	1203-1204
or	O	1205-1207
=	O	1208-1209
2	O	1210-1211
nonhematologic	O	1212-1226
toxicity	B	1227-1235
included	O	1236-1244
nausea	B	1245-1251
in	O	1252-1254
17	O	1255-1257
patients	O	1258-1266
,	O	1266-1267
emesis	B	1268-1274
in	O	1275-1277
14	O	1278-1280
patients	O	1281-1289
,	O	1289-1290
fatigue	B	1291-1298
in	O	1299-1301
9	O	1302-1303
patients	O	1304-1312
,	O	1312-1313
mucositis	B	1314-1323
and	O	1324-1327
/	O	1327-1328
or	O	1328-1330
stomatitis	B	1331-1341
in	O	1342-1344
8	O	1345-1346
patients	O	1347-1355
,	O	1355-1356
constipation	B	1357-1369
in	O	1370-1372
6	O	1373-1374
patients	O	1375-1383
,	O	1383-1384
weight	B	1385-1391
loss	I	1392-1396
in	O	1397-1399
5	O	1400-1401
patients	O	1402-1410
,	O	1410-1411
hand	B	1412-1416
-	I	1416-1417
foot	I	1417-1421
syndrome	I	1422-1430
in	O	1431-1433
2	O	1434-1435
patients	O	1436-1444
,	O	1444-1445
and	O	1446-1449
skin	B	1450-1454
reactions	I	1455-1464
in	O	1465-1467
3	O	1468-1469
patients	O	1470-1478
.	O	1478-1479

CONCLUSIONS	O	1480-1491
:	O	1491-1492
The	O	1493-1496
combination	O	1497-1508
of	O	1509-1511
carboplatin	O	1512-1523
and	O	1524-1527
liposomal	O	1528-1537
doxorubicin	O	1538-1549
has	O	1550-1553
modest	O	1554-1560
activity	O	1561-1569
in	O	1570-1572
patients	O	1573-1581
with	O	1582-1586
recurrent	O	1587-1596
cervical	B	1597-1605
carcinoma	I	1606-1615
.	O	1615-1616

Antimicrobial	O	0-13
-	O	13-14
induced	O	14-21
mania	B	22-27
(	O	28-29
antibiomania	B	29-41
)	O	41-42
:	O	42-43
a	O	44-45
review	O	46-52
of	O	53-55
spontaneous	O	56-67
reports	O	68-75
.	O	75-76

The	O	77-80
authors	O	81-88
reviewed	O	89-97
reported	O	98-106
cases	O	107-112
of	O	113-115
antibiotic	O	116-126
-	O	126-127
induced	O	127-134
manic	B	135-140
episodes	O	141-149
by	O	150-152
means	O	153-158
of	O	159-161
a	O	162-163
MEDLINE	O	164-171
and	O	172-175
PsychLit	O	176-184
search	O	185-191
for	O	192-195
reports	O	196-203
of	O	204-206
antibiotic	O	207-217
-	O	217-218
induced	O	218-225
mania	B	226-231
.	O	231-232

Unpublished	O	233-244
reports	O	245-252
were	O	253-257
requested	O	258-267
from	O	268-272
the	O	273-276
World	O	277-282
Health	O	283-289
Organization	O	290-302
(	O	303-304
WHO	O	304-307
)	O	307-308
and	O	309-312
the	O	313-316
Food	O	317-321
and	O	322-325
Drug	O	326-330
Administration	O	331-345
(	O	346-347
FDA	O	347-350
)	O	350-351
.	O	351-352

Twenty	O	353-359
-	O	359-360
one	O	360-363
reports	O	364-371
of	O	372-374
antimicrobial	O	375-388
-	O	388-389
induced	O	389-396
mania	B	397-402
were	O	403-407
found	O	408-413
in	O	414-416
the	O	417-420
literature	O	421-431
.	O	431-432

There	O	433-438
were	O	439-443
6	O	444-445
cases	O	446-451
implicating	O	452-463
clarithromycin	O	464-478
,	O	478-479
13	O	480-482
implicating	O	483-494
isoniazid	O	495-504
,	O	504-505
and	O	506-509
1	O	510-511
case	O	512-516
each	O	517-521
implicating	O	522-533
erythromycin	O	534-546
and	O	547-550
amoxicillin	O	551-562
.	O	562-563

The	O	564-567
WHO	O	568-571
reported	O	572-580
82	O	581-583
cases	O	584-589
.	O	589-590

Of	O	591-593
these	O	594-599
,	O	599-600
clarithromycin	O	601-615
was	O	616-619
implicated	O	620-630
in	O	631-633
23	O	634-636
(	O	637-638
27	O	638-640
.	O	640-641
6	O	641-642
%	O	642-643
)	O	643-644
cases	O	645-650
,	O	650-651
ciprofloxacin	O	652-665
in	O	666-668
12	O	669-671
(	O	672-673
14	O	673-675
.	O	675-676
4	O	674-675
%	O	677-678
)	O	678-679

cases	O	680-685
,	O	685-686
and	O	687-690
ofloxacin	O	691-700
in	O	701-703
10	O	704-706
(	O	707-708
12	O	708-710
%	O	710-711
)	O	711-712
cases	O	713-718
.	O	718-719

Cotrimoxazole	O	720-733
,	O	733-734
metronidazole	O	735-748
,	O	748-749
and	O	750-753
erythromycin	O	754-766
were	O	767-771
involved	O	772-780
in	O	781-783
15	O	784-786
reported	O	787-795
manic	B	796-801
episodes	O	802-810
.	O	810-811

Cases	O	812-817
reported	O	818-826
by	O	827-829
the	O	830-833
FDA	O	834-837
showed	O	838-844
clarithromycin	O	845-859
and	O	860-863
ciprofloxacin	O	864-877
to	O	878-880
be	O	881-883
the	O	884-887
most	O	888-892
frequently	O	893-903
associated	O	904-914
with	O	915-919
the	O	920-923
development	O	924-935
of	O	936-938
mania	B	939-944
.	O	944-945

Statistical	O	946-957
analysis	O	958-966
of	O	967-969
the	O	970-973
data	O	974-978
would	O	979-984
not	O	985-988
have	O	989-993
demonstrated	O	994-1006
a	O	1007-1008
significant	O	1009-1020
statistical	O	1021-1032
correlative	O	1033-1044
risk	O	1045-1049
and	O	1050-1053
was	O	1054-1057
therefore	O	1058-1067
not	O	1068-1071
undertaken	O	1072-1082
.	O	1082-1083

Patients	O	1084-1092
have	O	1093-1097
an	O	1098-1100
increased	O	1101-1110
risk	O	1111-1115
of	O	1116-1118
developing	O	1119-1129
mania	B	1130-1135
while	O	1136-1141
being	O	1142-1147
treated	O	1148-1155
with	O	1156-1160
antimicrobials	O	1161-1175
.	O	1175-1176

Although	O	1177-1185
this	O	1186-1190
is	O	1191-1193
not	O	1194-1197
a	O	1198-1199
statistically	O	1200-1213
significant	O	1214-1225
risk	O	1226-1230
,	O	1230-1231
physicians	O	1232-1242
must	O	1243-1247
be	O	1248-1250
aware	O	1251-1256
of	O	1257-1259
the	O	1260-1263
effect	O	1264-1270
and	O	1271-1274
reversibility	O	1275-1288
.	O	1288-1289

Further	O	1290-1297
research	O	1298-1306
clearly	O	1307-1314
is	O	1315-1317
required	O	1318-1326
to	O	1327-1329
determine	O	1330-1339
the	O	1340-1343
incidence	O	1344-1353
of	O	1354-1356
antimicrobial	O	1357-1370
-	O	1370-1371
induced	O	1371-1378
mania	B	1379-1384
,	O	1384-1385
the	O	1386-1389
relative	O	1390-1398
risk	O	1399-1403
factors	O	1404-1411
of	O	1412-1414
developing	O	1415-1425
an	O	1426-1428
antimicrobial	O	1429-1442
-	O	1442-1443
induced	O	1443-1450
manic	B	1451-1456
episode	O	1457-1464
among	O	1465-1470
various	O	1471-1478
demographic	O	1479-1490
populations	O	1491-1502
,	O	1502-1503
and	O	1504-1507
the	O	1508-1511
incidence	O	1512-1521
of	O	1522-1524
patients	O	1525-1533
who	O	1534-1537
continue	O	1538-1546
to	O	1547-1549
have	O	1550-1554
persistent	O	1555-1565
affective	O	1566-1575
disorders	O	1576-1585
once	O	1586-1590
the	O	1591-1594
initial	O	1595-1602
episode	O	1603-1610
,	O	1610-1611
which	O	1612-1617
occurs	O	1618-1624
while	O	1625-1630
the	O	1631-1634
patient	O	1635-1642
is	O	1643-1645
taking	O	1646-1652
antibiotics	O	1653-1664
,	O	1664-1665
subsides	O	1666-1674
.	O	1674-1675

The	O	1676-1679
authors	O	1680-1687
elected	O	1688-1695
to	O	1696-1698
name	O	1699-1703
this	O	1704-1708
syndrome	O	1709-1717
"	O	1718-1719
antibiomania	B	1719-1731
.	O	1731-1732
"	O	1718-1719

Levodopa	O	0-8
-	O	8-9
induced	O	9-16
ocular	B	17-23
dyskinesias	I	24-35
in	O	36-38
Parkinson	B	39-48
'	I	48-49
s	I	45-46
disease	I	51-58
.	O	58-59

Levodopa	O	60-68
-	O	68-69
induced	O	69-76
ocular	B	77-83
dyskinesias	I	84-95
are	O	96-99
very	O	100-104
uncommon	O	105-113
.	O	113-114

Usually	O	115-122
they	O	123-127
occur	O	128-133
simultaneously	O	134-148
with	O	149-153
limb	O	154-158
peak	O	159-163
-	O	163-164
dose	O	164-168
choreatic	B	169-178
dyskinesias	I	179-190
.	O	190-191

We	O	192-194
report	O	195-201
on	O	202-204
a	O	205-206
patient	O	207-214
with	O	215-219
leftward	O	220-228
and	O	229-232
upward	O	233-239
deviations	O	240-250
of	O	251-253
gaze	O	254-258
during	O	259-265
the	O	266-269
peak	O	270-274
effect	O	275-281
of	O	282-284
levodopa	O	285-293
,	O	293-294
and	O	295-298
hypothesize	O	299-310
that	O	311-315
a	O	316-317
severe	O	318-324
dopaminergic	O	325-337
denervation	O	338-349
in	O	350-352
the	O	353-356
caudate	O	357-364
nucleus	O	365-372
is	O	373-375
needed	O	376-382
for	O	383-386
the	O	387-390
appearance	O	391-401
of	O	402-404
these	O	405-410
levodopa	O	411-419
-	O	419-420
induce	O	420-426
ocular	B	427-433
dyskinesias	I	434-445
.	O	445-446

A	O	0-1
comparison	O	2-12
of	O	13-15
glyceryl	O	16-24
trinitrate	O	25-35
with	O	36-40
diclofenac	O	41-51
for	O	52-55
the	O	56-59
treatment	O	60-69
of	O	70-72
primary	O	73-80
dysmenorrhea	B	81-93
:	O	93-94
an	O	95-97
open	O	98-102
,	O	102-103
randomized	O	104-114
,	O	114-115
cross	O	116-121
-	O	121-122
over	O	122-126
trial	O	127-132
.	O	132-133

Primary	O	134-141
dysmenorrhea	B	142-154
is	O	155-157
a	O	158-159
syndrome	O	160-168
characterized	O	169-182
by	O	183-185
painful	O	186-193
uterine	O	194-201
contractility	O	202-215
caused	O	216-222
by	O	223-225
a	O	226-227
hypersecretion	O	228-242
of	O	243-245
endometrial	O	246-257
prostaglandins	O	258-272
;	O	272-273
non	O	274-277
-	O	277-278
steroidal	O	278-287
anti	O	288-292
-	O	292-293
inflammatory	O	293-305
drugs	O	306-311
are	O	312-315
the	O	316-319
first	O	320-325
choice	O	326-332
for	O	333-336
its	O	337-340
treatment	O	341-350
.	O	350-351

However	O	352-359
,	O	359-360
in	O	361-363
vivo	O	364-368
and	O	369-372
in	O	373-375
vitro	O	376-381
studies	O	382-389
have	O	390-394
demonstrated	O	395-407
that	O	408-412
myometrial	O	413-423
cells	O	424-429
are	O	430-433
also	O	434-438
targets	O	439-446
of	O	447-449
the	O	450-453
relaxant	O	454-462
effects	O	463-470
of	O	471-473
nitric	O	474-480
oxide	O	481-486
(	O	487-488
NO	O	488-490
)	O	490-491
.	O	491-492

The	O	493-496
aim	O	497-500
of	O	501-503
the	O	504-507
present	O	508-515
study	O	516-521
was	O	522-525
to	O	526-528
determine	O	529-538
the	O	539-542
efficacy	O	543-551
of	O	552-554
glyceryl	O	555-563
trinitrate	O	564-574
(	O	575-576
GTN	O	576-579
)	O	579-580
,	O	580-581
an	O	582-584
NO	O	585-587
donor	O	588-593
,	O	593-594
in	O	595-597
the	O	598-601
resolution	O	602-612
of	O	613-615
primary	O	616-623
dysmenorrhea	B	624-636
in	O	637-639
comparison	O	640-650
with	O	651-655
diclofenac	O	656-666
(	O	667-668
DCF	O	668-671
)	O	671-672
.	O	672-673

A	O	674-675
total	O	676-681
of	O	682-684
24	O	685-687
patients	O	688-696
with	O	697-701
the	O	702-705
diagnosis	O	706-715
of	O	716-718
severe	O	719-725
primary	O	726-733
dysmenorrhea	B	734-746
were	O	747-751
studied	O	752-759
during	O	760-766
two	O	767-770
consecutive	O	771-782
menstrual	O	783-792
cycles	O	793-799
.	O	799-800

In	O	801-803
an	O	804-806
open	O	807-811
,	O	811-812
cross	O	813-818
-	O	818-819
over	O	819-823
,	O	823-824
controlled	O	825-835
design	O	836-842
,	O	842-843
patients	O	844-852
were	O	853-857
randomized	O	858-868
to	O	869-871
receive	O	872-879
either	O	880-886
DCF	O	887-890
per	O	891-894
os	O	895-897
or	O	898-900
GTN	O	901-904
patches	O	905-912
the	O	913-916
first	O	917-922
days	O	923-927
of	O	928-930
menses	O	931-937
,	O	937-938
when	O	939-943
menstrual	O	944-953
cramps	O	954-960
became	O	961-967
unendurable	O	968-979
.	O	979-980

In	O	981-983
the	O	984-987
subsequent	O	988-998
cycle	O	999-1004
the	O	1005-1008
other	O	1009-1014
treatment	O	1015-1024
was	O	1025-1028
used	O	1029-1033
.	O	1033-1034

Patients	O	1035-1043
received	O	1044-1052
up	O	1053-1055
to	O	1056-1058
3	O	1059-1060
doses	O	1061-1066
/	O	1066-1067
day	O	1067-1070
of	O	1071-1073
50	O	1074-1076
mg	O	1077-1079
DCF	O	1080-1083
or	O	1084-1086
2	O	1087-1088
.	O	1088-1089
5	O	1089-1090
mg	O	1091-1093
/	O	1093-1094
24	O	1094-1096
h	O	1097-1098
transdermal	O	1099-1110
GTN	O	1111-1114
for	O	1115-1118
the	O	1119-1122
first	O	1123-1128
3	O	1129-1130
days	O	1131-1135
of	O	1136-1138
the	O	1139-1142
cycle	O	1143-1148
,	O	1148-1149
according	O	1150-1159
to	O	1160-1162
their	O	1163-1168
needs	O	1169-1174
.	O	1174-1175

The	O	1176-1179
participants	O	1180-1192
recorded	O	1193-1201
menstrual	O	1202-1211
symptoms	O	1212-1220
and	O	1221-1224
possible	O	1225-1233
side	O	1234-1238
-	O	1238-1239
effects	O	1239-1246
at	O	1247-1249
different	O	1250-1259
times	O	1260-1265
(	O	1266-1267
0	O	1267-1268
,	O	1268-1269
30	O	1270-1272
,	O	1272-1273
60	O	1274-1276
,	O	1276-1277
120	O	1278-1281
minutes	O	1282-1289
)	O	1289-1290
after	O	1291-1296
the	O	1297-1300
first	O	1301-1306
dose	O	1307-1311
of	O	1312-1314
medication	O	1315-1325
on	O	1326-1328
the	O	1329-1332
first	O	1333-1338
day	O	1339-1342
of	O	1343-1345
the	O	1346-1349
cycle	O	1350-1355
,	O	1355-1356
with	O	1357-1361
both	O	1362-1366
drugs	O	1367-1372
.	O	1372-1373

The	O	1374-1377
difference	O	1378-1388
in	O	1389-1391
pain	B	1392-1396
intensity	O	1397-1406
score	O	1407-1412
(	O	1413-1414
DPI	O	1414-1417
)	O	1417-1418
was	O	1419-1422
the	O	1423-1426
main	O	1427-1431
outcome	O	1432-1439
variable	O	1440-1448
.	O	1448-1449

Both	O	1450-1454
treatments	O	1455-1465
significantly	O	1466-1479
reduced	O	1480-1487
DPI	O	1488-1491
by	O	1492-1494
the	O	1495-1498
30th	O	1499-1503
minute	O	1504-1510
(	O	1511-1512
GTN	O	1512-1515
,	O	1515-1516
-	O	1517-1518
12	O	1518-1520
.	O	1520-1521
8	O	1521-1522
+	O	1523-1524
/	O	1524-1525
-	O	1525-1526
17	O	1527-1529
.	O	1529-1530
9	O	1530-1531
;	O	1531-1532
DCF	O	1533-1536
,	O	1536-1537
-	O	1538-1539
18	O	1539-1541
.	O	1541-1542
9	O	1542-1543
+	O	1544-1545
/	O	1545-1546
-	O	1546-1547
16	O	1548-1550
.	O	1550-1551
6	O	1549-1550
)	O	1552-1553
.	O	1550-1551

However	O	1555-1562
,	O	1562-1563
DCF	O	1564-1567
continued	O	1568-1577
to	O	1578-1580
be	O	1581-1583
effective	O	1584-1593
in	O	1594-1596
reducing	O	1597-1605
pelvic	B	1606-1612
pain	I	1613-1617
for	O	1618-1621
two	O	1622-1625
hours	O	1626-1631
,	O	1631-1632
whereas	O	1633-1640
GTN	O	1641-1644
scores	O	1645-1651
remained	O	1652-1660
more	O	1661-1665
or	O	1666-1668
less	O	1669-1673
stable	O	1674-1680
after	O	1681-1686
30	O	1687-1689
min	O	1690-1693
and	O	1694-1697
significantly	O	1698-1711
higher	O	1712-1718
than	O	1719-1723
those	O	1724-1729
for	O	1730-1733
DFC	O	1734-1737
(	O	1738-1739
after	O	1739-1744
one	O	1745-1748
hour	O	1749-1753
:	O	1753-1754
GTN	O	1755-1758
,	O	1758-1759
-	O	1760-1761
12	O	1761-1763
.	O	1763-1764
8	O	1764-1765
+	O	1766-1767
/	O	1767-1768
-	O	1768-1769
17	O	1770-1772
.	O	1772-1773
9	O	1773-1774
;	O	1774-1775
DFC	O	1776-1779
,	O	1779-1780
-	O	1781-1782
18	O	1782-1784
.	O	1784-1785
9	O	1785-1786
+	O	1787-1788
/	O	1788-1789
-	O	1789-1790
16	O	1791-1793
.	O	1793-1794
6	O	1792-1793
and	O	1796-1799
after	O	1800-1805
two	O	1806-1809
hours	O	1810-1815
:	O	1815-1816
GTN	O	1817-1820
,	O	1820-1821
-	O	1822-1823
23	O	1823-1825
.	O	1825-1826
7	O	1826-1827
+	O	1828-1829
/	O	1829-1830
-	O	1830-1831
20	O	1832-1834
.	O	1834-1835
5	O	1835-1836
;	O	1836-1837
DFC	O	1838-1841
,	O	1841-1842
-	O	1843-1844
59	O	1844-1846
.	O	1846-1847
7	O	1847-1848
+	O	1849-1850
/	O	1850-1851
-	O	1851-1852
17	O	1853-1855
.	O	1855-1856
9	O	1856-1857
,	O	1857-1858
p	O	1859-1860
=	O	1861-1862
0	O	1863-1864
.	O	1864-1865
0001	O	1865-1869
)	O	1869-1870
.	O	1864-1865

Low	B	1872-1875
back	I	1876-1880
pain	I	1881-1885
was	O	1886-1889
also	O	1890-1894
relieved	O	1895-1903
by	O	1904-1906
both	O	1907-1911
drugs	O	1912-1917
.	O	1917-1918

Headache	B	1919-1927
was	O	1928-1931
significantly	O	1932-1945
increased	O	1946-1955
by	O	1956-1958
GTN	O	1959-1962
but	O	1963-1966
not	O	1967-1970
by	O	1971-1973
DCF	O	1974-1977
.	O	1977-1978

Eight	O	1979-1984
patients	O	1985-1993
stopped	O	1994-2001
using	O	2002-2007
GTN	O	2008-2011
because	O	2012-2019
headache	B	2020-2028
-	O	2028-2029
-	O	2028-2029
attributed	O	2030-2040
to	O	2041-2043
its	O	2044-2047
use	O	2048-2051
-	O	2051-2052
-	O	2051-2052
became	O	2053-2059
intolerable	O	2060-2071
.	O	2071-2072

These	O	2073-2078
findings	O	2079-2087
indicate	O	2088-2096
that	O	2097-2101
GTN	O	2102-2105
has	O	2106-2109
a	O	2110-2111
reduced	O	2112-2119
efficacy	O	2120-2128
and	O	2129-2132
tolerability	O	2133-2145
by	O	2146-2148
comparison	O	2149-2159
with	O	2160-2164
DCF	O	2165-2168
in	O	2169-2171
the	O	2172-2175
treatment	O	2176-2185
of	O	2186-2188
primary	O	2189-2196
dysmenorrhea	B	2197-2209
.	O	2209-2210

Temocapril	O	0-10
,	O	10-11
a	O	12-13
long	O	14-18
-	O	18-19
acting	O	19-25
non	O	26-29
-	O	29-30
SH	O	30-32
group	O	33-38
angiotensin	O	39-50
converting	O	51-61
enzyme	O	62-68
inhibitor	O	69-78
,	O	78-79
modulates	O	80-89
glomerular	B	90-100
injury	I	101-107
in	O	108-110
chronic	O	111-118
puromycin	O	119-128
aminonucleoside	O	129-144
nephrosis	B	145-154
.	O	154-155

The	O	156-159
purpose	O	160-167
of	O	168-170
the	O	171-174
present	O	175-182
study	O	183-188
was	O	189-192
to	O	193-195
determine	O	196-205
whether	O	206-213
chronic	O	214-221
administration	O	222-236
of	O	237-239
temocapril	O	240-250
,	O	250-251
a	O	252-253
long	O	254-258
-	O	258-259
acting	O	259-265
non	O	266-269
-	O	269-270
SH	O	270-272
group	O	273-278
angiotensin	O	279-290
converting	O	291-301
enzyme	O	302-308
(	O	309-310
ACE	O	310-313
)	O	313-314
inhibitor	O	315-324
,	O	324-325
reduced	O	326-333
proteinuria	B	334-345
,	O	345-346
inhibited	O	347-356
glomerular	O	357-367
hypertrophy	B	368-379
and	O	380-383
prevented	O	384-393
glomerulosclerosis	B	394-412
in	O	413-415
chronic	O	416-423
puromycin	O	424-433
aminonucleoside	O	434-449
(	O	450-451
PAN	O	451-454
)	O	454-455
-	O	456-457
induced	O	458-465
nephrotic	B	466-475
rats	O	476-480
.	O	480-481

Nephrosis	B	482-491
was	O	492-495
induced	O	496-503
by	O	504-506
injection	O	507-516
of	O	517-519
PAN	O	520-523
(	O	524-525
15mg	O	525-529
/	O	529-530
100g	O	530-534
body	O	535-539
weight	O	540-546
)	O	546-547
in	O	548-550
male	O	551-555
Sprague	O	556-563
-	O	563-564
Dawley	O	564-570
(	O	571-572
SD	O	572-574
)	O	574-575
rats	O	576-580
.	O	580-581

Four	O	582-586
groups	O	587-593
were	O	594-598
used	O	599-603
,	O	603-604
i	O	605-606
)	O	606-607
the	O	608-611
PAN	O	612-615
group	O	616-621
(	O	622-623
14	O	623-625
)	O	625-626
,	O	626-627
ii	O	628-630
)	O	630-631
PAN	O	632-635
/	O	635-636
temocapril	O	636-646
(	O	647-648
13	O	648-650
)	O	650-651
,	O	651-652
iii	O	653-656
)	O	656-657
temocapril	O	658-668
(	O	669-670
14	O	670-672
)	O	672-673
and	O	674-677
iv	O	678-680
)	O	680-681
untreated	O	682-691
controls	O	692-700
(	O	701-702
15	O	702-704
)	O	704-705
.	O	705-706

Temocapril	O	707-717
(	O	718-719
8	O	719-720
mg	O	721-723
/	O	723-724
kg	O	724-726
/	O	723-724
day	O	727-730
)	O	730-731
was	O	732-735
administered	O	736-748
to	O	749-751
the	O	752-755
rats	O	756-760
which	O	761-766
were	O	767-771
killed	O	772-778
at	O	779-781
weeks	O	782-787
4	O	788-789
,	O	789-790
14	O	791-793
or	O	794-796
20	O	797-799
.	O	799-800

At	O	801-803
each	O	804-808
time	O	809-813
point	O	814-819
,	O	819-820
systolic	O	821-829
blood	O	830-835
pressure	O	836-844
(	O	845-846
BP	O	846-848
)	O	848-849
,	O	849-850
urinary	O	851-858
protein	O	859-866
excretion	O	867-876
and	O	877-880
renal	O	881-886
histopathological	O	887-904
findings	O	905-913
were	O	914-918
evaluated	O	919-928
,	O	928-929
and	O	930-933
morphometric	O	934-946
image	O	947-952
analysis	O	953-961
was	O	962-965
done	O	966-970
.	O	970-971

Systolic	O	972-980
BP	O	981-983
in	O	984-986
the	O	987-990
PAN	O	991-994
group	O	995-1000
was	O	1001-1004
significantly	O	1005-1018
high	O	1019-1023
at	O	1024-1026
4	O	1027-1028
,	O	1028-1029
14	O	1030-1032
and	O	1033-1036
20	O	1037-1039
weeks	O	1040-1045
,	O	1045-1046
but	O	1047-1050
was	O	1051-1054
normal	O	1055-1061
in	O	1062-1064
the	O	1065-1068
PAN	O	1069-1072
/	O	1072-1073
temocapril	O	1073-1083
group	O	1084-1089
.	O	1089-1090

Urinary	O	1091-1098
protein	O	1099-1106
excretion	O	1107-1116
in	O	1117-1119
the	O	1120-1123
PAN	O	1124-1127
group	O	1128-1133
increased	O	1134-1143
significantly	O	1144-1157
,	O	1157-1158
peaking	O	1159-1166
at	O	1167-1169
8	O	1170-1171
days	O	1172-1176
,	O	1176-1177
then	O	1178-1182
decreased	O	1183-1192
at	O	1193-1195
4	O	1196-1197
weeks	O	1198-1203
,	O	1203-1204
but	O	1205-1208
rose	O	1209-1213
again	O	1214-1219
significantly	O	1220-1233
at	O	1234-1236
14	O	1237-1239
and	O	1240-1243
20	O	1244-1246
weeks	O	1247-1252
.	O	1252-1253

Temocapril	O	1254-1264
did	O	1265-1268
not	O	1269-1272
attenuate	O	1273-1282
proteinuria	B	1283-1294
at	O	1295-1297
8	O	1298-1299
days	O	1300-1304
,	O	1304-1305
but	O	1306-1309
it	O	1310-1312
did	O	1313-1316
markedly	O	1317-1325
lower	O	1326-1331
it	O	1332-1334
from	O	1335-1339
weeks	O	1340-1345
4	O	1346-1347
to	O	1348-1350
20	O	1351-1353
.	O	1353-1354

The	O	1355-1358
glomerulosclerosis	B	1359-1377
index	O	1378-1383
(	O	1384-1385
GSI	O	1385-1388
)	O	1388-1389
was	O	1390-1393
6	O	1394-1395
.	O	1395-1396
21	O	1396-1398
%	O	1399-1400
at	O	1401-1403
4	O	1404-1405
weeks	O	1406-1411
and	O	1412-1415
respectively	O	1416-1428
25	O	1429-1431
.	O	1431-1432
35	O	1432-1434
%	O	1435-1436
and	O	1437-1440
30	O	1441-1443
.	O	1443-1444
49	O	1444-1446

%	O	1447-1448
at	O	1449-1451
14	O	1452-1454
and	O	1455-1458
20	O	1459-1461
weeks	O	1462-1467
in	O	1468-1470
the	O	1471-1474
PAN	O	1475-1478
group	O	1479-1484
.	O	1484-1485

There	O	1486-1491
was	O	1492-1495
a	O	1496-1497
significant	O	1498-1509
correlation	O	1510-1521
between	O	1522-1529
urinary	O	1530-1537
protein	O	1538-1545
excretion	O	1546-1555
and	O	1556-1559
GSI	O	1560-1563
(	O	1564-1565
r	O	1565-1566
=	O	1567-1568
0	O	1569-1570
.	O	1570-1571
808	O	1571-1574
,	O	1574-1575
p	O	1576-1577
<	O	1578-1579
0	O	1580-1581
.	O	1581-1582
0001	O	1582-1586
)	O	1586-1587
.	O	1581-1582

The	O	1589-1592
ratio	O	1593-1598
of	O	1599-1601
glomerular	O	1602-1612
tuft	O	1613-1617
area	O	1618-1622
to	O	1623-1625
the	O	1626-1629
area	O	1630-1634
of	O	1635-1637
Bowman	O	1638-1644
'	O	1644-1645
s	O	1645-1646
capsules	O	1647-1655
(	O	1656-1657
GT	O	1657-1659
/	O	1659-1660
BC	O	1660-1662
)	O	1662-1663
in	O	1664-1666
the	O	1667-1670
PAN	O	1671-1674
group	O	1675-1680
was	O	1681-1684
significantly	O	1685-1698
increased	O	1699-1708
,	O	1708-1709
but	O	1710-1713
it	O	1714-1716
was	O	1717-1720
significantly	O	1721-1734
lower	O	1735-1740
in	O	1741-1743
the	O	1744-1747
PAN	O	1748-1751
/	O	1751-1752
temocapril	O	1752-1762
group	O	1763-1768
.	O	1768-1769

It	O	1770-1772
appears	O	1773-1780
that	O	1781-1785
temocapril	O	1786-1796
was	O	1797-1800
effective	O	1801-1810
in	O	1811-1813
retarding	O	1814-1823
renal	O	1824-1829
progression	O	1830-1841
and	O	1842-1845
protected	O	1846-1855
renal	O	1856-1861
function	O	1862-1870
in	O	1871-1873
PAN	O	1874-1877
neprotic	B	1878-1886
rats	O	1887-1891
.	O	1891-1892

Pulmonary	B	0-9
hypertension	I	10-22
after	O	23-28
ibuprofen	O	29-38
prophylaxis	O	39-50
in	O	51-53
very	O	54-58
preterm	O	59-66
infants	O	67-74
.	O	74-75

We	O	76-78
report	O	79-85
three	O	86-91
cases	O	92-97
of	O	98-100
severe	O	101-107
hypoxaemia	B	108-118
after	O	119-124
ibuprofen	O	125-134
administration	O	135-149
during	O	150-156
a	O	157-158
randomised	O	159-169
controlled	O	170-180
trial	O	181-186
of	O	187-189
prophylactic	O	190-202
treatment	O	203-212
of	O	213-215
patent	B	216-222
ductus	I	223-229
arteriosus	I	230-240
with	O	241-245
ibuprofen	O	246-255
in	O	256-258
premature	O	259-268
infants	O	269-276
born	O	277-281
at	O	282-284
less	O	285-289
than	O	290-294
28	O	295-297
weeks	O	298-303
of	O	304-306
gestation	O	307-316
.	O	316-317

Echocardiography	O	318-334
showed	O	335-341
severely	O	342-350
decreased	O	351-360
pulmonary	O	361-370
blood	O	371-376
flow	O	377-381
.	O	381-382

Hypoxaemia	B	383-393
resolved	O	394-402
quickly	O	403-410
on	O	411-413
inhaled	O	414-421
nitric	O	422-428
oxide	O	429-434
therapy	O	435-442
.	O	442-443

We	O	444-446
suggest	O	447-454
that	O	455-459
investigators	O	460-473
involved	O	474-482
in	O	483-485
similar	O	486-493
trials	O	494-500
pay	O	501-504
close	O	505-510
attention	O	511-520
to	O	521-523
pulmonary	O	524-533
pressure	O	534-542
if	O	543-545
hypoxaemia	B	546-556
occurs	O	557-563
after	O	564-569
prophylactic	O	570-582
administration	O	583-597
of	O	598-600
ibuprofen	O	601-610
.	O	610-611

Hyponatremia	B	0-12
and	O	13-16
syndrome	B	17-25
of	I	26-28
inappropriate	I	29-42
anti	I	43-47
-	I	47-48
diuretic	I	48-56
hormone	I	57-64
reported	O	65-73
with	O	74-78
the	O	79-82
use	O	83-86
of	O	87-89
Vincristine	O	90-101
:	O	101-102
an	O	103-105
over	O	106-110
-	O	110-111
representation	O	111-125
of	O	126-128
Asians	O	129-135
?	O	135-136

PURPOSE	O	137-144
:	O	144-145
This	O	146-150
retrospective	O	151-164
study	O	165-170
used	O	171-175
a	O	176-177
pharmaceutical	O	178-192
company	O	193-200
'	O	200-201
s	O	201-202
global	O	203-209
safety	O	210-216
database	O	217-225
to	O	226-228
determine	O	229-238
the	O	239-242
reporting	O	243-252
rate	O	253-257
of	O	258-260
hyponatremia	B	261-273
and	O	274-277
/	O	277-278
or	O	278-280
syndrome	B	281-289
of	I	290-292
inappropriate	I	293-306
secretion	I	307-316
of	I	317-319
anti	I	320-324
-	I	324-325
diuretic	I	325-333
hormone	I	334-341
(	O	342-343
SIADH	B	343-348
)	O	348-349
among	O	350-355
vincristine	O	356-367
-	O	367-368
treated	O	368-375
patients	O	376-384
and	O	385-388
to	O	389-391
explore	O	392-399
the	O	400-403
possibility	O	404-415
of	O	416-418
at	O	419-421
-	O	421-422
risk	O	422-426
population	O	427-437
subgroups	O	438-447
.	O	447-448

METHOD	O	449-455
:	O	455-456
We	O	457-459
searched	O	460-468
the	O	469-472
Eli	O	473-476
Lilly	O	477-482
and	O	483-486
Company	O	487-494
'	O	494-495
s	O	495-496
computerized	O	497-509
adverse	O	510-517
event	O	518-523
database	O	524-532
for	O	533-536
all	O	537-540
reported	O	541-549
cases	O	550-555
of	O	556-558
hyponatremia	B	559-571
and	O	572-575
/	O	575-576
or	O	576-578
SIADH	B	579-584
as	O	585-587
of	O	588-590
1	O	591-592
November	O	593-601
1999	O	602-606
that	O	607-611
had	O	612-615
been	O	616-620
reported	O	621-629
during	O	630-636
the	O	637-640
use	O	641-644
of	O	645-647
vincristine	O	648-659
.	O	659-660

RESULTS	O	661-668
:	O	668-669
A	O	670-671
total	O	672-677
of	O	678-680
76	O	681-683
cases	O	684-689
of	O	690-692
hyponatremia	B	693-705
and	O	706-709
/	O	709-710
or	O	710-712
SIADH	B	713-718
associated	O	719-729
with	O	730-734
vincristine	O	735-746
use	O	747-750
were	O	751-755
identified	O	756-766
.	O	766-767

The	O	768-771
overall	O	772-779
reporting	O	780-789
rate	O	790-794
was	O	795-798
estimated	O	799-808
to	O	809-811
be	O	812-814
1	O	815-816
.	O	816-817
3	O	817-818
/	O	818-819
100	O	819-822
,	O	822-823
000	O	823-826
treated	O	827-834
patients	O	835-843
.	O	843-844

The	O	845-848
average	O	849-856
age	O	857-860
of	O	861-863
patients	O	864-872
was	O	873-876
35	O	877-879
.	O	879-880
6	O	880-881
+	O	882-883
/	O	883-884
-	O	884-885
28	O	886-888
.	O	888-889
3	O	889-890
years	O	891-896
,	O	896-897
and	O	898-901
62	O	902-904
%	O	904-905
were	O	906-910
males	O	911-916
.	O	916-917

Approximately	O	918-931
75	O	932-934
%	O	934-935
of	O	936-938
the	O	939-942
patients	O	943-951
were	O	952-956
receiving	O	957-966
treatment	O	967-976
for	O	977-980
leukemia	B	981-989
or	O	990-992
lymphoma	B	993-1001
.	O	1001-1002

Among	O	1003-1008
the	O	1009-1012
39	O	1013-1015
reports	O	1016-1023
that	O	1024-1028
included	O	1029-1037
information	O	1038-1049
on	O	1050-1052
race	O	1053-1057
,	O	1057-1058
the	O	1059-1062
racial	O	1063-1069
distribution	O	1070-1082
was	O	1083-1086
:	O	1086-1087
1	O	1088-1089
Black	O	1090-1095
,	O	1095-1096
3	O	1097-1098
Caucasian	O	1099-1108
,	O	1108-1109
and	O	1110-1113
35	O	1114-1116
Asian	O	1117-1122
.	O	1122-1123

CONCLUSION	O	1124-1134
:	O	1134-1135
Our	O	1136-1139
data	O	1140-1144
suggest	O	1145-1152
that	O	1153-1157
Asian	O	1158-1163
patients	O	1164-1172
may	O	1173-1176
be	O	1177-1179
at	O	1180-1182
increased	O	1183-1192
risk	O	1193-1197
of	O	1198-1200
hyponatremia	B	1201-1213
and	O	1214-1217
/	O	1217-1218
or	O	1218-1220
SIADH	B	1221-1226
associated	O	1227-1237
with	O	1238-1242
vincristine	O	1243-1254
use	O	1255-1258
.	O	1258-1259

Although	O	1260-1268
the	O	1269-1272
overall	O	1273-1280
reported	O	1281-1289
rate	O	1290-1294
of	O	1295-1297
SIADH	B	1298-1303
associated	O	1304-1314
with	O	1315-1319
vincristine	O	1320-1331
is	O	1332-1334
very	O	1335-1339
low	O	1340-1343
,	O	1343-1344
physicians	O	1345-1355
caring	O	1356-1362
for	O	1363-1366
Asian	O	1367-1372
oncology	O	1373-1381
patients	O	1382-1390
should	O	1391-1397
be	O	1398-1400
aware	O	1401-1406
of	O	1407-1409
this	O	1410-1414
potential	O	1415-1424
serious	O	1425-1432
but	O	1433-1436
reversible	O	1437-1447
adverse	O	1448-1455
event	O	1456-1461
.	O	1461-1462

Delayed	O	0-7
toxicity	B	8-16
of	O	17-19
cyclophosphamide	O	20-36
on	O	37-39
the	O	40-43
bladder	O	44-51
of	O	52-54
DBA	O	55-58
/	O	58-59
2	O	59-60
and	O	61-64
C57BL	O	65-70
/	O	70-71
6	O	71-72
female	O	73-79
mouse	O	80-85
.	O	85-86

The	O	87-90
present	O	91-98
study	O	99-104
describes	O	105-114
the	O	115-118
delayed	O	119-126
development	O	127-138
of	O	139-141
a	O	142-143
severe	O	144-150
bladder	O	151-158
pathology	O	159-168
in	O	169-171
a	O	172-173
susceptible	O	174-185
strain	O	186-192
of	O	193-195
mice	O	196-200
(	O	201-202
DBA	O	202-205
/	O	205-206
2	O	206-207
)	O	207-208
but	O	209-212
not	O	213-216
in	O	217-219
a	O	220-221
resistant	O	222-231
strain	O	232-238
(	O	239-240
C57BL	O	240-245
/	O	245-246
6	O	246-247
)	O	247-248
when	O	249-253
both	O	254-258
were	O	259-263
treated	O	264-271
with	O	272-276
a	O	277-278
single	O	279-285
300	O	286-289
mg	O	290-292
/	O	292-293
kg	O	293-295
dose	O	296-300
of	O	301-303
cyclophosphamide	O	304-320
(	O	321-322
CY	O	322-324
)	O	324-325
.	O	325-326

Inbred	O	327-333
DBA	O	334-337
/	O	337-338
2	O	338-339
and	O	340-343
C57BL	O	344-349
/	O	349-350
6	O	350-351
female	O	352-358
mice	O	359-363
were	O	364-368
injected	O	369-377
with	O	378-382
CY	O	383-385
,	O	385-386
and	O	387-390
the	O	391-394
effect	O	395-401
of	O	402-404
the	O	405-408
drug	O	409-413
on	O	414-416
the	O	417-420
bladder	O	421-428
was	O	429-432
assessed	O	433-441
during	O	442-448
100	O	449-452
days	O	453-457
by	O	458-460
light	O	461-466
microscopy	O	467-477
using	O	478-483
different	O	484-493
staining	O	494-502
procedures	O	503-513
,	O	513-514
and	O	515-518
after	O	519-524
30	O	525-527
days	O	528-532
by	O	533-535
conventional	O	536-548
electron	O	549-557
microscopy	O	558-568
.	O	568-569

Early	O	570-575
CY	O	576-578
toxicity	B	579-587
caused	O	588-594
a	O	595-596
typical	O	597-604
haemorrhagic	B	605-617
cystitis	B	618-626
in	O	627-629
both	O	630-634
strains	O	635-642
that	O	643-647
was	O	648-651
completely	O	652-662
repaired	O	663-671
in	O	672-674
about	O	675-680
7	O	681-682
-	O	682-683
10	O	683-685
days	O	686-690
.	O	690-691

After	O	692-697
30	O	698-700
days	O	701-705
of	O	706-708
CY	O	709-711
injection	O	712-721
ulcerous	O	722-730
and	O	731-734
non	O	735-738
-	O	738-739
ulcerous	O	739-747
forms	O	748-753
of	O	754-756
chronic	O	757-764
cystitis	B	765-773
appeared	O	774-782
in	O	783-785
86	O	786-788
%	O	788-789
of	O	790-792
DBA	O	793-796
/	O	796-797
2	O	797-798
mice	O	799-803
but	O	804-807
only	O	808-812
in	O	813-815
4	O	816-817
%	O	817-818
of	O	819-821
C57BL	O	822-827
/	O	827-828
6	O	828-829
mice	O	830-834
.	O	834-835

Delayed	O	836-843
cystitis	B	844-852
was	O	853-856
characterized	O	857-870
by	O	871-873
infiltration	O	874-886
and	O	887-890
transepithelial	O	891-906
passage	O	907-914
into	O	915-919
the	O	920-923
lumen	O	924-929
of	O	930-932
inflammatory	O	933-945
cells	O	946-951
and	O	952-955
by	O	956-958
frequent	O	959-967
exfoliation	O	968-979
of	O	980-982
the	O	983-986
urothelium	O	987-997
.	O	997-998

Mast	O	999-1003
cells	O	1004-1009
appeared	O	1010-1018
in	O	1019-1021
the	O	1022-1025
connective	O	1026-1036
and	O	1037-1040
muscular	O	1041-1049
layers	O	1050-1056
of	O	1057-1059
the	O	1060-1063
bladder	O	1064-1071
at	O	1072-1074
a	O	1075-1076
much	O	1077-1081
higher	O	1082-1088
number	O	1089-1095
in	O	1096-1098
DBA	O	1099-1102
/	O	1102-1103
2	O	1103-1104
mice	O	1105-1109
than	O	1110-1114
in	O	1115-1117
C57BL	O	1118-1123
/	O	1123-1124
6	O	1124-1125
mice	O	1126-1130
or	O	1131-1133
untreated	O	1134-1143
controls	O	1144-1152
.	O	1152-1153

Electron	O	1154-1162
microscopy	O	1163-1173
disclosed	O	1174-1183
the	O	1184-1187
absence	O	1188-1195
of	O	1196-1198
the	O	1199-1202
typical	O	1203-1210
discoidal	O	1211-1220
vesicles	O	1221-1229
normally	O	1230-1238
present	O	1239-1246
in	O	1247-1249
the	O	1250-1253
cytoplasm	O	1254-1263
of	O	1264-1266
surface	O	1267-1274
cells	O	1275-1280
.	O	1280-1281

Instead	O	1282-1289
,	O	1289-1290
numerous	O	1291-1299
abnormal	O	1300-1308
vesicles	O	1309-1317
containing	O	1318-1328
one	O	1329-1332
or	O	1333-1335
several	O	1336-1343
dark	O	1344-1348
granules	O	1349-1357
were	O	1358-1362
observed	O	1363-1371
in	O	1372-1374
the	O	1375-1378
cytoplasm	O	1379-1388
of	O	1389-1391
cells	O	1392-1397
from	O	1398-1402
all	O	1403-1406
the	O	1407-1410
epithelial	O	1411-1421
layers	O	1422-1428
.	O	1428-1429

Delayed	O	1430-1437
cystitis	B	1438-1446
still	O	1447-1452
persisted	O	1453-1462
in	O	1463-1465
DBA	O	1466-1469
/	O	1469-1470
2	O	1470-1471
mice	O	1472-1476
100	O	1477-1480
days	O	1481-1485
after	O	1486-1491
treatment	O	1492-1501
.	O	1501-1502

These	O	1503-1508
results	O	1509-1516
indicate	O	1517-1525
that	O	1526-1530
delayed	O	1531-1538
toxicity	B	1539-1547
of	O	1548-1550
CY	O	1551-1553
in	O	1554-1556
female	O	1557-1563
DBA	O	1564-1567
/	O	1567-1568
2	O	1568-1569
mice	O	1570-1574
causes	O	1575-1581
a	O	1582-1583
bladder	O	1584-1591
pathology	O	1592-1601
that	O	1602-1606
is	O	1607-1609
not	O	1610-1613
observed	O	1614-1622
in	O	1623-1625
C57BL	O	1626-1631
/	O	1631-1632
6	O	1632-1633
mice	O	1634-1638
.	O	1638-1639

This	O	1640-1644
pathology	O	1645-1654
resembles	O	1655-1664
interstitial	B	1665-1677
cystitis	I	1678-1686
in	O	1687-1689
humans	O	1690-1696
and	O	1697-1700
could	O	1701-1706
perhaps	O	1707-1714
be	O	1715-1717
used	O	1718-1722
as	O	1723-1725
an	O	1726-1728
animal	O	1729-1735
model	O	1736-1741
for	O	1742-1745
studies	O	1746-1753
on	O	1754-1756
the	O	1757-1760
disease	O	1761-1768
.	O	1768-1769

High	O	0-4
-	O	4-5
dose	O	5-9
5	O	10-11
-	O	11-12
fluorouracil	O	12-24
/	O	25-26
folinic	O	27-34
acid	O	35-39
in	O	40-42
combination	O	43-54
with	O	55-59
three	O	60-65
-	O	65-66
weekly	O	66-72
mitomycin	O	73-82
C	O	83-84
in	O	85-87
the	O	88-91
treatment	O	92-101
of	O	102-104
advanced	O	105-113
gastric	B	114-121
cancer	I	122-128
.	O	128-129

A	O	130-131
phase	O	132-137
II	O	138-140
study	O	141-146
.	O	146-147

BACKGROUND	O	148-158
:	O	158-159
The	O	160-163
24	O	164-166
-	O	166-167
hour	O	167-171
continuous	O	172-182
infusion	O	183-191
of	O	192-194
5	O	195-196
-	O	196-197
fluorouracil	O	197-209
(	O	210-211
5	O	211-212
-	O	212-213
FU	O	213-215
)	O	215-216
and	O	217-220
folinic	O	221-228
acid	O	229-233
(	O	234-235
FA	O	235-237
)	O	237-238
as	O	239-241
part	O	242-246
of	O	247-249
several	O	250-257
new	O	258-261
multidrug	O	262-271
chemotherapy	O	272-284
regimens	O	285-293
in	O	294-296
advanced	O	297-305
gastric	B	306-313
cancer	I	314-320
(	O	321-322
AGC	B	322-325
)	O	325-326
has	O	327-330
shown	O	331-336
to	O	337-339
be	O	340-342
effective	O	343-352
,	O	352-353
with	O	354-358
low	O	359-362
toxicity	B	363-371
.	O	371-372

In	O	373-375
a	O	376-377
previous	O	378-386
phase	O	387-392
II	O	393-395
study	O	396-401
with	O	402-406
3	O	407-408
-	O	408-409
weekly	O	409-415
bolus	O	416-421
5	O	422-423
-	O	423-424
FU	O	424-426
,	O	426-427
FA	O	428-430
and	O	431-434
mitomycin	O	435-444
C	O	445-446
(	O	447-448
MMC	O	448-451
)	O	451-452
we	O	453-455
found	O	456-461
a	O	462-463
low	O	464-467
toxicity	B	468-476
rate	O	477-481
and	O	482-485
response	O	486-494
rates	O	495-500
comparable	O	501-511
to	O	512-514
those	O	515-520
of	O	521-523
regimens	O	524-532
such	O	533-537
as	O	538-540
ELF	O	541-544
,	O	544-545
FAM	O	546-549
or	O	550-552
FAMTX	O	553-558
,	O	558-559
and	O	560-563
a	O	564-565
promising	O	566-575
median	O	576-582
overall	O	583-590
survival	O	591-599
.	O	599-600

In	O	601-603
order	O	604-609
to	O	610-612
improve	O	613-620
this	O	621-625
MMC	O	626-629
-	O	629-630
dependent	O	630-639
schedule	O	640-648
we	O	649-651
initiated	O	652-661
a	O	662-663
phase	O	664-669
II	O	670-672
study	O	673-678
with	O	679-683
high	O	684-688
-	O	688-689
dose	O	689-693
5	O	694-695
-	O	695-696
FU	O	696-698
/	O	698-699
FA	O	699-701
and	O	702-705
3	O	706-707
-	O	707-708
weekly	O	708-714
bolus	O	715-720
MMC	O	721-724
.	O	724-725

PATIENTS	O	726-734
AND	O	735-738
METHODS	O	739-746
:	O	746-747
From	O	748-752
February	O	753-761
,	O	761-762
1998	O	763-767
to	O	768-770
September	O	771-780
,	O	780-781
2000	O	782-786
we	O	787-789
recruited	O	790-799
33	O	800-802
patients	O	803-811
with	O	812-816
AGC	B	817-820
to	O	821-823
receive	O	824-831
weekly	O	832-838
24	O	839-841
-	O	841-842
hour	O	842-846
5	O	847-848
-	O	848-849
FU	O	849-851
2	O	852-853
,	O	853-854
600	O	854-857
mg	O	858-860
/	O	860-861
m	O	858-859
(	O	862-863
2	O	863-864
)	O	864-865
preceded	O	866-874
by	O	875-877
2	O	878-879
-	O	879-880
hour	O	880-884
FA	O	885-887
500	O	888-891
mg	O	892-894
/	O	894-895
m	O	892-893
(	O	896-897
2	O	897-898
)	O	898-899
for	O	900-903
6	O	904-905
weeks	O	906-911
,	O	911-912
followed	O	913-921
by	O	922-924
a	O	925-926
2	O	927-928
-	O	928-929
week	O	929-933
rest	O	934-938
period	O	939-945
.	O	945-946

Bolus	O	947-952
MMC	O	953-956
10	O	957-959
mg	O	960-962
/	O	962-963
m	O	960-961
(	O	964-965
2	O	965-966
)	O	966-967
was	O	968-971
added	O	972-977
in	O	978-980
3	O	981-982
-	O	982-983
weekly	O	983-989
intervals	O	990-999
.	O	999-1000

Treatment	O	1001-1010
given	O	1011-1016
on	O	1017-1019
an	O	1020-1022
outpatient	O	1023-1033
basis	O	1034-1039
,	O	1039-1040
using	O	1041-1046
portable	O	1047-1055
pump	O	1056-1060
systems	O	1061-1068
,	O	1068-1069
was	O	1070-1073
repeated	O	1074-1082
on	O	1083-1085
day	O	1086-1089
57	O	1090-1092
.	O	1092-1093

Patients	O	1094-1102
'	O	1102-1103
characteristics	O	1104-1119
were	O	1120-1124
:	O	1124-1125
male	O	1126-1130
/	O	1130-1131
female	O	1131-1137
ratio	O	1138-1143
20	O	1144-1146
/	O	1146-1147
13	O	1147-1149
;	O	1149-1150
median	O	1151-1157
age	O	1158-1161
57	O	1162-1164
(	O	1165-1166
27	O	1166-1168
-	O	1168-1169
75	O	1169-1171
)	O	1171-1172
years	O	1173-1178
;	O	1178-1179
median	O	1180-1186
WHO	O	1187-1190
status	O	1191-1197
1	O	1198-1199
(	O	1200-1201
0	O	1201-1202
-	O	1202-1203
2	O	1203-1204
)	O	1204-1205
.	O	1205-1206

18	O	1207-1209
patients	O	1210-1218
had	O	1219-1222
a	O	1223-1224
primary	O	1225-1232
AGC	B	1233-1236
,	O	1236-1237
and	O	1238-1241
15	O	1242-1244
showed	O	1245-1251
a	O	1252-1253
relapsed	O	1254-1262
AGC	B	1263-1266
.	O	1266-1267

Median	O	1268-1274
follow	O	1275-1281
-	O	1281-1282
up	O	1282-1284
was	O	1285-1288
11	O	1289-1291
.	O	1291-1292
8	O	1292-1293
months	O	1294-1300
(	O	1301-1302
range	O	1302-1307
of	O	1308-1310
those	O	1311-1316
surviving	O	1317-1326
:	O	1326-1327
2	O	1328-1329
.	O	1329-1330
7	O	1330-1331
-	O	1331-1332
11	O	1332-1334
.	O	1329-1330
8	O	1335-1336

months	O	1337-1343
)	O	1343-1344
.	O	1344-1345

RESULTS	O	1346-1353
:	O	1353-1354
32	O	1355-1357
patients	O	1358-1366
were	O	1367-1371
evaluable	O	1372-1381
for	O	1382-1385
response	O	1386-1394
-	O	1395-1396
complete	O	1397-1405
remission	O	1406-1415
9	O	1416-1417
.	O	1417-1418
1	O	1418-1419
%	O	1419-1420
(	O	1421-1422
n	O	1422-1423
=	O	1424-1425
3	O	1426-1427
)	O	1427-1428
,	O	1428-1429
partial	O	1430-1437
remission	O	1438-1447
45	O	1448-1450
.	O	1450-1451
5	O	1449-1450
%	O	1452-1453
(	O	1454-1455
n	O	1455-1456
=	O	1457-1458
15	O	1459-1461
)	O	1461-1462
,	O	1462-1463
no	O	1464-1466
change	O	1467-1473
27	O	1474-1476
.	O	1476-1477
3	O	1477-1478
%	O	1478-1479
(	O	1480-1481
n	O	1481-1482
=	O	1483-1484
9	O	1485-1486
)	O	1486-1487
,	O	1487-1488
progressive	O	1489-1500
disease	O	1501-1508
15	O	1509-1511
.	O	1511-1512
1	O	1509-1510
%	O	1513-1514
(	O	1515-1516
n	O	1516-1517
=	O	1518-1519
5	O	1520-1521
)	O	1521-1522
.	O	1522-1523

Median	O	1524-1530
overall	O	1531-1538
survival	O	1539-1547
time	O	1548-1552
was	O	1553-1556
10	O	1557-1559
.	O	1559-1560
2	O	1560-1561
months	O	1562-1568
[	O	1569-1570
95	O	1570-1572
%	O	1572-1573
confidence	O	1574-1584
interval	O	1585-1593
(	O	1594-1595
CI	O	1595-1597
)	O	1597-1598
:	O	1598-1599
8	O	1600-1601
.	O	1601-1602
7	O	1602-1603
-	O	1603-1604
11	O	1604-1606
.	O	1601-1602
6	O	1607-1608
]	O	1608-1609
,	O	1609-1610

and	O	1611-1614
median	O	1615-1621
progression	O	1622-1633
-	O	1633-1634
free	O	1634-1638
survival	O	1639-1647
time	O	1648-1652
was	O	1653-1656
7	O	1657-1658
.	O	1658-1659
6	O	1659-1660
months	O	1661-1667
(	O	1668-1669
95	O	1669-1671
%	O	1671-1672
CI	O	1673-1675
:	O	1675-1676
4	O	1677-1678
.	O	1678-1679
4	O	1677-1678
-	O	1680-1681
10	O	1681-1683
.	O	1678-1679
9	O	1684-1685
)	O	1685-1686
.	O	1678-1679

The	O	1688-1691
worst	O	1692-1697
toxicities	B	1698-1708
(	O	1709-1710
%	O	1710-1711
)	O	1711-1712
observed	O	1713-1721
were	O	1722-1726
(	O	1727-1728
CTC	O	1728-1731
-	O	1731-1732
NCI	O	1732-1735
1	O	1736-1737
/	O	1737-1738
2	O	1738-1739
/	O	1737-1738
3	O	1740-1741
)	O	1741-1742
:	O	1742-1743
leukopenia	B	1744-1754
45	O	1755-1757
.	O	1757-1758
5	O	1756-1757
/	O	1759-1760
18	O	1760-1762
.	O	1757-1758
2	O	1763-1764
/	O	1759-1760
6	O	1765-1766
.	O	1757-1758
1	O	1760-1761
,	O	1768-1769
thrombocytopenia	B	1770-1786
33	O	1787-1789
.	O	1789-1790
3	O	1787-1788
/	O	1791-1792
9	O	1792-1793
.	O	1789-1790
1	O	1794-1795
/	O	1791-1792
6	O	1796-1797
.	O	1789-1790
1	O	1794-1795
,	O	1799-1800
vomitus	B	1801-1808
24	O	1809-1811
.	O	1811-1812
2	O	1809-1810
/	O	1813-1814
9	O	1814-1815
.	O	1811-1812
1	O	1816-1817
/	O	1813-1814
0	O	1818-1819
,	O	1819-1820

diarrhea	B	1821-1829
36	O	1830-1832
.	O	1832-1833
4	O	1833-1834
/	O	1834-1835
6	O	1831-1832
.	O	1832-1833
1	O	1837-1838
/	O	1834-1835
3	O	1830-1831
.	O	1832-1833
0	O	1841-1842
,	O	1842-1843

stomatitis	B	1844-1854
18	O	1855-1857
.	O	1857-1858
2	O	1858-1859
/	O	1859-1860
9	O	1860-1861
.	O	1857-1858
1	O	1855-1856
/	O	1859-1860
0	O	1864-1865
,	O	1865-1866

hand	B	1867-1871
-	I	1871-1872
foot	I	1872-1876
syndrome	I	1877-1885
12	O	1886-1888
.	O	1888-1889
1	O	1886-1887
/	O	1890-1891
0	O	1891-1892
/	O	1890-1891
0	O	1891-1892
.	O	1888-1889

Two	O	1896-1899
patients	O	1900-1908
developed	O	1909-1918
hemolytic	B	1919-1928
-	I	1928-1929
uremic	I	1929-1935
syndrome	I	1936-1944
(	O	1945-1946
HUS	B	1946-1949
)	O	1949-1950
.	O	1950-1951

CONCLUSIONS	O	1952-1963
:	O	1963-1964
High	O	1965-1969
-	O	1969-1970
dose	O	1970-1974
5	O	1975-1976
-	O	1976-1977
FU	O	1977-1979
/	O	1979-1980
FA	O	1980-1982
/	O	1979-1980
MMC	O	1983-1986
is	O	1987-1989
an	O	1990-1992
effective	O	1993-2002
and	O	2003-2006
well	O	2007-2011
-	O	2011-2012
tolerated	O	2012-2021
outpatient	O	2022-2032
regimen	O	2033-2040
for	O	2041-2044
AGC	B	2045-2048
(	O	2049-2050
objective	O	2050-2059
response	O	2060-2068
rate	O	2069-2073
54	O	2074-2076
.	O	2076-2077
6	O	2077-2078
%	O	2078-2079
)	O	2079-2080
.	O	2076-2077

It	O	2082-2084
may	O	2085-2088
serve	O	2089-2094
as	O	2095-2097
an	O	2098-2100
alternative	O	2101-2112
to	O	2113-2115
cisplatin	O	2116-2125
-	O	2125-2126
containing	O	2126-2136
regimens	O	2137-2145
;	O	2145-2146
however	O	2147-2154
,	O	2154-2155
it	O	2156-2158
has	O	2159-2162
to	O	2163-2165
be	O	2166-2168
considered	O	2169-2179
that	O	2180-2184
possibly	O	2185-2193
HUS	B	2194-2197
may	O	2198-2201
occur	O	2202-2207
.	O	2207-2208

Persistent	O	0-10
sterile	O	11-18
leukocyturia	B	19-31
is	O	32-34
associated	O	35-45
with	O	46-50
impaired	B	51-59
renal	I	60-65
function	I	66-74
in	O	75-77
human	B	78-83
immunodeficiency	I	84-100
virus	I	101-106
type	I	107-111
1	I	112-113
-	I	113-114
infected	I	114-122
children	O	123-131
treated	O	132-139
with	O	140-144
indinavir	O	145-154
.	O	154-155

BACKGROUND	O	156-166
:	O	166-167
Prolonged	O	168-177
administration	O	178-192
of	O	193-195
indinavir	O	196-205
is	O	206-208
associated	O	209-219
with	O	220-224
the	O	225-228
occurrence	O	229-239
of	O	240-242
a	O	243-244
variety	O	245-252
of	O	253-255
renal	O	256-261
complications	O	262-275
in	O	276-278
adults	O	279-285
.	O	285-286

These	O	287-292
well	O	293-297
-	O	297-298
documented	O	298-308
side	O	309-313
effects	O	314-321
have	O	322-326
restricted	O	327-337
the	O	338-341
use	O	342-345
of	O	346-348
this	O	349-353
potent	O	354-360
protease	O	361-369
inhibitor	O	370-379
in	O	380-382
children	O	383-391
.	O	391-392

DESIGN	O	393-399
:	O	399-400
A	O	401-402
prospective	O	403-414
study	O	415-420
to	O	421-423
monitor	O	424-431
indinavir	O	432-441
-	O	441-442
related	O	442-449
nephrotoxicity	B	450-464
in	O	465-467
a	O	468-469
cohort	O	470-476
of	O	477-479
30	O	480-482
human	B	483-488
immunodeficiency	I	489-505
virus	I	506-511
type	I	512-516
1	I	517-518
-	I	518-519
infected	I	519-527
children	O	528-536
treated	O	537-544
with	O	545-549
indinavir	O	550-559
.	O	559-560

METHODS	O	561-568
:	O	568-569
Urinary	O	570-577
pH	O	578-580
,	O	580-581
albumin	O	582-589
,	O	589-590
creatinine	O	591-601
,	O	601-602
the	O	603-606
presence	O	607-615
of	O	616-618
erythrocytes	O	619-631
,	O	631-632
leukocytes	O	633-643
,	O	643-644
bacteria	O	645-653
and	O	654-657
crystals	O	658-666
,	O	666-667
and	O	668-671
culture	O	672-679
were	O	680-684
analyzed	O	685-693
every	O	694-699
3	O	700-701
months	O	702-708
for	O	709-712
96	O	713-715
weeks	O	716-721
.	O	721-722

Serum	O	723-728
creatinine	O	729-739
levels	O	740-746
were	O	747-751
routinely	O	752-761
determined	O	762-772
at	O	773-775
the	O	776-779
same	O	780-784
time	O	785-789
points	O	790-796
.	O	796-797

Steady	O	798-804
-	O	804-805
state	O	805-810
pharmacokinetics	O	811-827
of	O	828-830
indinavir	O	831-840
were	O	841-845
done	O	846-850
at	O	851-853
week	O	854-858
4	O	859-860
after	O	861-866
the	O	867-870
initiation	O	871-881
of	O	882-884
indinavir	O	885-894
.	O	894-895

RESULTS	O	896-903
:	O	903-904
The	O	905-908
cumulative	O	909-919
incidence	O	920-929
of	O	930-932
persistent	O	933-943
sterile	O	944-951
leukocyturia	B	952-964
(	O	965-966
>	O	966-967
or	O	968-970
=	O	971-972
75	O	972-974
cells	O	975-980
/	O	980-981
micro	O	982-987
L	O	988-989
in	O	990-992
at	O	993-995
least	O	996-1001
2	O	1002-1003
consecutive	O	1004-1015
visits	O	1016-1022
)	O	1022-1023
after	O	1024-1029
96	O	1030-1032
weeks	O	1033-1038
was	O	1039-1042
53	O	1043-1045
%	O	1045-1046
.	O	1046-1047

Persistent	O	1048-1058
sterile	O	1059-1066
leukocyturia	B	1067-1079
was	O	1080-1083
frequently	O	1084-1094
associated	O	1095-1105
with	O	1106-1110
a	O	1111-1112
mild	O	1113-1117
increase	O	1118-1126
in	O	1127-1129
the	O	1130-1133
urine	O	1134-1139
albumin	O	1140-1147
/	O	1147-1148
creatinine	O	1148-1158
ratio	O	1159-1164
and	O	1165-1168
by	O	1169-1171
microscopic	O	1172-1183
hematuria	B	1184-1193
.	O	1193-1194

The	O	1195-1198
cumulative	O	1199-1209
incidence	O	1210-1219
of	O	1220-1222
serum	O	1223-1228
creatinine	O	1229-1239
levels	O	1240-1246
>	O	1247-1248
50	O	1248-1250
%	O	1250-1251
above	O	1252-1257
normal	O	1258-1264
was	O	1265-1268
33	O	1269-1271
%	O	1271-1272
after	O	1273-1278
96	O	1279-1281
weeks	O	1282-1287
.	O	1287-1288

Children	O	1289-1297
with	O	1298-1302
persistent	O	1303-1313
sterile	O	1314-1321
leukocyturia	B	1322-1334
more	O	1335-1339
frequently	O	1340-1350
had	O	1351-1354
serum	O	1355-1360
creatinine	O	1361-1371
levels	O	1372-1378
of	O	1379-1381
50	O	1382-1384
%	O	1384-1385
above	O	1386-1391
normal	O	1392-1398
than	O	1399-1403
those	O	1404-1409
children	O	1410-1418
without	O	1419-1426
persistent	O	1427-1437
sterile	O	1438-1445
leukocyturia	B	1446-1458
.	O	1458-1459

In	O	1460-1462
children	O	1463-1471
younger	O	1472-1479
than	O	1480-1484
5	O	1485-1486
.	O	1486-1487
6	O	1487-1488
years	O	1489-1494
,	O	1494-1495
persistent	O	1496-1506
sterile	O	1507-1514
leukocyturia	B	1515-1527
was	O	1528-1531
significantly	O	1532-1545
more	O	1546-1550
frequent	O	1551-1559
than	O	1560-1564
in	O	1565-1567
older	O	1568-1573
children	O	1574-1582
.	O	1582-1583

A	O	1584-1585
higher	O	1586-1592
cumulative	O	1593-1603
incidence	O	1604-1613
of	O	1614-1616
persistent	O	1617-1627
leukocyturia	B	1628-1640
was	O	1641-1644
found	O	1645-1650
in	O	1651-1653
children	O	1654-1662
with	O	1663-1667
an	O	1668-1670
area	O	1671-1675
under	O	1676-1681
the	O	1682-1685
curve	O	1686-1691
>	O	1692-1693
19	O	1693-1695
mg	O	1696-1698
/	O	1698-1699
L	O	1699-1700
x	O	1701-1702
h	O	1703-1704
or	O	1705-1707
a	O	1708-1709
peak	O	1710-1714
serum	O	1715-1720
level	O	1721-1726
of	O	1727-1729
indinavir	O	1730-1739
>	O	1740-1741
12	O	1741-1743
mg	O	1744-1746
/	O	1746-1747
L	O	1747-1748
.	O	1748-1749

In	O	1750-1752
4	O	1753-1754
children	O	1755-1763
,	O	1763-1764
indinavir	O	1765-1774
was	O	1775-1778
discontinued	O	1779-1791
because	O	1792-1799
of	O	1800-1802
nephrotoxicity	B	1803-1817
.	O	1817-1818

Subsequently	O	1819-1831
,	O	1831-1832
the	O	1833-1836
serum	O	1837-1842
creatinine	O	1843-1853
levels	O	1854-1860
decreased	O	1861-1870
,	O	1870-1871
the	O	1872-1875
urine	O	1876-1881
albumin	O	1882-1889
/	O	1889-1890
creatinine	O	1890-1900
ratios	O	1901-1907
returned	O	1908-1916
to	O	1917-1919
zero	O	1920-1924
,	O	1924-1925
and	O	1926-1929
the	O	1930-1933
leukocyturia	B	1934-1946
disappeared	O	1947-1958
within	O	1959-1965
3	O	1966-1967
months	O	1968-1974
.	O	1974-1975

CONCLUSIONS	O	1976-1987
:	O	1987-1988
Children	O	1989-1997
treated	O	1998-2005
with	O	2006-2010
indinavir	O	2011-2020
have	O	2021-2025
a	O	2026-2027
high	O	2028-2032
cumulative	O	2033-2043
incidence	O	2044-2053
of	O	2054-2056
persistent	O	2057-2067
sterile	O	2068-2075
leukocyturia	B	2076-2088
.	O	2088-2089

Children	O	2090-2098
with	O	2099-2103
persistent	O	2104-2114
sterile	O	2115-2122
leukocyturia	B	2123-2135
more	O	2136-2140
frequently	O	2141-2151
had	O	2152-2155
an	O	2156-2158
increase	O	2159-2167
in	O	2168-2170
serum	O	2171-2176
creatinine	O	2177-2187
levels	O	2188-2194
of	O	2195-2197
>	O	2198-2199
50	O	2199-2201
%	O	2201-2202
above	O	2203-2208
normal	O	2209-2215
.	O	2215-2216

Younger	O	2217-2224
children	O	2225-2233
have	O	2234-2238
an	O	2239-2241
additional	O	2242-2252
risk	O	2253-2257
for	O	2258-2261
renal	O	2262-2267
complications	O	2268-2281
.	O	2281-2282

The	O	2283-2286
impairment	B	2287-2297
of	I	2298-2300
the	I	2301-2304
renal	I	2305-2310
function	I	2311-2319
in	O	2320-2322
these	O	2323-2328
children	O	2329-2337
occurred	O	2338-2346
in	O	2347-2349
the	O	2350-2353
absence	O	2354-2361
of	O	2362-2364
clinical	O	2365-2373
symptoms	O	2374-2382
of	O	2383-2385
nephrolithiasis	B	2386-2401
.	O	2401-2402

Indinavir	O	2403-2412
-	O	2412-2413
associated	O	2413-2423
nephrotoxicity	B	2424-2438
must	O	2439-2443
be	O	2444-2446
monitored	O	2447-2456
closely	O	2457-2464
,	O	2464-2465
especially	O	2466-2476
in	O	2477-2479
children	O	2480-2488
with	O	2489-2493
risk	O	2494-2498
factors	O	2499-2506
such	O	2507-2511
as	O	2512-2514
persistent	O	2515-2525
sterile	O	2526-2533
leukocyturia	B	2534-2546
,	O	2546-2547
age	O	2548-2551
<	O	2552-2553
5	O	2553-2554
.	O	2554-2555
6	O	2555-2556
years	O	2557-2562
,	O	2562-2563
an	O	2564-2566
area	O	2567-2571
under	O	2572-2577
the	O	2578-2581
curve	O	2582-2587
of	O	2588-2590
indinavir	O	2591-2600
>	O	2601-2602
19	O	2602-2604
mg	O	2605-2607
/	O	2607-2608
L	O	2608-2609
x	O	2610-2611
h	O	2612-2613
,	O	2613-2614
and	O	2615-2618
a	O	2619-2620
C	O	2621-2622
(	O	2622-2623
max	O	2623-2626
)	O	2626-2627
>	O	2628-2629
12	O	2629-2631
mg	O	2632-2634
/	O	2634-2635
L	O	2635-2636
.	O	2636-2637

Utility	O	0-7
of	O	8-10
troponin	O	11-19
I	O	20-21
in	O	22-24
patients	O	25-33
with	O	34-38
cocaine	O	39-46
-	O	46-47
associated	O	47-57
chest	B	58-63
pain	I	64-68
.	O	68-69

Baseline	O	70-78
electrocardiogram	O	79-96
abnormalities	O	97-110
and	O	111-114
market	O	115-121
elevations	O	122-132
not	O	133-136
associated	O	137-147
with	O	148-152
myocardial	B	153-163
necrosis	I	164-172
make	O	173-177
accurate	O	178-186
diagnosis	O	187-196
of	O	197-199
myocardial	B	200-210
infarction	I	211-221
(	O	222-223
MI	B	223-225
)	O	225-226
difficult	O	227-236
in	O	237-239
patients	O	240-248
with	O	249-253
cocaine	O	254-261
-	O	261-262
associated	O	262-272
chest	B	273-278
pain	I	279-283
.	O	283-284

Troponin	O	285-293
sampling	O	294-302
may	O	303-306
offer	O	307-312
greater	O	313-320
diagnostic	O	321-331
utility	O	332-339
in	O	340-342
these	O	343-348
patients	O	349-357
.	O	357-358

OBJECTIVE	O	359-368
:	O	368-369
To	O	370-372
assess	O	373-379
outcomes	O	380-388
based	O	389-394
on	O	395-397
troponin	O	398-406
positivity	O	407-417
in	O	418-420
patients	O	421-429
with	O	430-434
cocaine	O	435-442
chest	B	443-448
pain	I	449-453
admitted	O	454-462
for	O	463-466
exclusion	O	467-476
of	O	477-479
MI	B	480-482
.	O	482-483

METHODS	O	484-491
:	O	491-492
Outcomes	O	493-501
were	O	502-506
examined	O	507-515
in	O	516-518
patients	O	519-527
admitted	O	528-536
for	O	537-540
possible	O	541-549
MI	B	550-552
after	O	553-558
cocaine	O	559-566
use	O	567-570
.	O	570-571

All	O	572-575
patients	O	576-584
underwent	O	585-594
a	O	595-596
rapid	O	597-602
rule	O	603-607
-	O	607-608
in	O	608-610
protocol	O	611-619
that	O	620-624
included	O	625-633
serial	O	634-640
sampling	O	641-649
of	O	650-652
creatine	O	653-661
kinase	O	662-668
(	O	669-670
CK	O	670-672
)	O	672-673
,	O	673-674
CK	O	675-677
-	O	677-678
MB	O	678-680
,	O	680-681
and	O	682-685
cardiac	O	686-693
troponin	O	694-702
I	O	703-704
(	O	705-706
cTnI	O	706-710
)	O	710-711
over	O	712-716
eight	O	717-722
hours	O	723-728
.	O	728-729

Outcomes	O	730-738
included	O	739-747
CK	O	748-750
-	O	750-751
MB	O	751-753
MI	B	754-756
(	O	757-758
CK	O	758-760
-	O	760-761
MB	O	761-763
>	O	764-765
or	O	765-767
=	O	767-768
8	O	769-770
ng	O	771-773
/	O	773-774
mL	O	774-776
with	O	777-781
a	O	782-783
relative	O	784-792
index	O	793-798
[	O	799-800
(	O	800-801
CK	O	801-803
-	O	803-804
MB	O	804-806
x	O	807-808
100	O	809-812
)	O	812-813
/	O	813-814
total	O	814-819
CK	O	820-822
]	O	822-823
>	O	824-825
or	O	825-827
=	O	827-828
4	O	829-830
,	O	830-831
cardiac	B	832-839
death	I	840-845
,	O	845-846
and	O	847-850
significant	O	851-862
coronary	B	863-871
disease	I	872-879
(	O	880-881
>	O	881-882
or	O	882-884
=	O	884-885
50	O	885-887
%	O	887-888
)	O	888-889
.	O	889-890

RESULTS	O	891-898
:	O	898-899
Of	O	900-902
the	O	903-906
246	O	907-910
admitted	O	911-919
patients	O	920-928
,	O	928-929
34	O	930-932
(	O	933-934
14	O	934-936
%	O	936-937
)	O	937-938
met	O	939-942
CK	O	943-945
-	O	945-946
MB	O	946-948
criteria	O	949-957
for	O	958-961
MI	B	962-964
and	O	965-968
38	O	969-971
(	O	972-973
16	O	973-975
%	O	975-976
)	O	976-977
had	O	978-981
cTnI	O	982-986
elevations	O	987-997
.	O	997-998

Angiography	O	999-1010
was	O	1011-1014
performed	O	1015-1024
in	O	1025-1027
29	O	1028-1030
of	O	1031-1033
38	O	1034-1036
patients	O	1037-1045
who	O	1046-1049
were	O	1050-1054
cTnI	O	1055-1059
-	O	1059-1060
positive	O	1060-1068
,	O	1068-1069
with	O	1070-1074
significant	O	1075-1086
disease	O	1087-1094
present	O	1095-1102
in	O	1103-1105
25	O	1106-1108
(	O	1109-1110
86	O	1110-1112
%	O	1112-1113
)	O	1113-1114
.	O	1114-1115

Three	O	1116-1121
of	O	1122-1124
the	O	1125-1128
four	O	1129-1133
patients	O	1134-1142
without	O	1143-1150
significant	O	1151-1162
disease	O	1163-1170
who	O	1171-1174
had	O	1175-1178
cTnI	O	1179-1183
elevations	O	1184-1194
met	O	1195-1198
CK	O	1199-1201
-	O	1201-1202
MB	O	1202-1204
criteria	O	1205-1213
for	O	1214-1217
MI	B	1218-1220
,	O	1220-1221
and	O	1222-1225
the	O	1226-1229
other	O	1230-1235
had	O	1236-1239
a	O	1240-1241
peak	O	1242-1246
CK	O	1247-1249
-	O	1249-1250
MB	O	1250-1252
level	O	1253-1258
of	O	1259-1261
13	O	1262-1264
ng	O	1265-1267
/	O	1267-1268
mL	O	1268-1270
.	O	1270-1271

Sensitivities	O	1272-1285
,	O	1285-1286
specificities	O	1287-1300
,	O	1300-1301
and	O	1302-1305
positive	O	1306-1314
and	O	1315-1318
negative	O	1319-1327
likelihood	O	1328-1338
ratios	O	1339-1345
for	O	1346-1349
predicting	O	1350-1360
cardiac	B	1361-1368
death	I	1369-1374
or	O	1375-1377
significant	O	1378-1389
disease	O	1390-1397
were	O	1398-1402
high	O	1403-1407
for	O	1408-1411
both	O	1412-1416
CK	O	1417-1419
-	O	1419-1420
MB	O	1420-1422
MI	B	1423-1425
and	O	1426-1429
cTnI	O	1430-1434
and	O	1435-1438
were	O	1439-1443
not	O	1444-1447
significantly	O	1448-1461
different	O	1462-1471
.	O	1471-1472

CONCLUSIONS	O	1473-1484
:	O	1484-1485
Most	O	1486-1490
patients	O	1491-1499
with	O	1500-1504
cTnI	O	1505-1509
elevations	O	1510-1520
meet	O	1521-1525
CK	O	1526-1528
-	O	1528-1529
MB	O	1529-1531
criteria	O	1532-1540
for	O	1541-1544
MI	B	1545-1547
,	O	1547-1548
as	O	1549-1551
well	O	1552-1556
as	O	1557-1559
have	O	1560-1564
a	O	1565-1566
high	O	1567-1571
incidence	O	1572-1581
of	O	1582-1584
underlying	O	1585-1595
significant	O	1596-1607
disease	O	1608-1615
.	O	1615-1616

Troponin	O	1617-1625
appears	O	1626-1633
to	O	1634-1636
have	O	1637-1641
an	O	1642-1644
equivalent	O	1645-1655
diagnostic	O	1656-1666
accuracy	O	1667-1675
compared	O	1676-1684
with	O	1685-1689
CK	O	1690-1692
-	O	1692-1693
MB	O	1693-1695
for	O	1696-1699
diagnosing	O	1700-1710
necrosis	B	1711-1719
in	O	1720-1722
patients	O	1723-1731
with	O	1732-1736
cocaine	O	1737-1744
-	O	1744-1745
associated	O	1745-1755
chest	B	1756-1761
pain	I	1762-1766
and	O	1767-1770
suspected	O	1771-1780
MI	B	1781-1783
.	O	1783-1784

Acute	O	0-5
interstitial	B	6-18
nephritis	I	19-28
due	O	29-32
to	O	33-35
nicergoline	O	36-47
(	O	48-49
Sermion	O	49-56
)	O	56-57
.	O	57-58

We	O	59-61
report	O	62-68
a	O	69-70
case	O	71-75
of	O	76-78
acute	O	79-84
interstitial	B	85-97
nephritis	I	98-107
(	O	108-109
AIN	B	109-112
)	O	112-113
due	O	114-117
to	O	118-120
nicergoline	O	121-132
(	O	133-134
Sermion	O	134-141
)	O	141-142
.	O	142-143

A	O	144-145
50	O	146-148
-	O	148-149
year	O	149-153
-	O	148-149
old	O	154-157
patient	O	158-165
admitted	O	166-174
to	O	175-177
our	O	178-181
hospital	O	182-190
for	O	191-194
fever	B	195-200
and	O	201-204
acute	B	205-210
renal	I	211-216
failure	I	217-224
.	O	224-225

Before	O	226-232
admission	O	233-242
,	O	242-243
he	O	244-246
had	O	247-250
been	O	251-255
taking	O	256-262
nicergoline	O	263-274
and	O	275-278
bendazac	O	279-287
lysine	O	288-294
due	O	295-298
to	O	299-301
retinal	B	302-309
vein	I	310-314
occlusion	I	315-324
at	O	325-327
ophthalmologic	O	328-342
department	O	343-353
.	O	353-354

Thereafter	O	355-365
,	O	365-366
he	O	367-369
experienced	O	370-381
intermittent	O	382-394
fever	B	395-400
and	O	401-404
skin	B	405-409
rash	I	410-414
.	O	414-415

On	O	416-418
admission	O	419-428
,	O	428-429
clinical	O	430-438
symptoms	O	439-447
(	O	448-449
i	O	449-450
.	O	450-451
e	O	451-452
.	O	450-451

arthralgia	B	454-464
and	O	465-468
fever	B	469-474
)	O	474-475
and	O	476-479
laboratory	O	480-490
findings	O	491-499
(	O	500-501
i	O	501-502
.	O	502-503
e	O	503-504
.	O	502-503

eosinophilia	B	506-518
and	O	519-522
renal	B	523-528
failure	I	529-536
)	O	536-537
suggested	O	538-547
AIN	B	548-551
,	O	551-552
and	O	553-556
which	O	557-562
was	O	563-566
confirmed	O	567-576
by	O	577-579
pathologic	O	580-590
findings	O	591-599
on	O	600-602
renal	O	603-608
biopsy	O	609-615
.	O	615-616

A	O	617-618
lymphocyte	O	619-629
transformation	O	630-644
test	O	645-649
demonstrated	O	650-662
a	O	663-664
positive	O	665-673
result	O	674-680
against	O	681-688
nicergoline	O	689-700
.	O	700-701

Treatment	O	702-711
was	O	712-715
consisted	O	716-725
of	O	726-728
withdrawal	O	729-739
of	O	740-742
nicergoline	O	743-754
and	O	755-758
intravenous	O	759-770
methylprednisolone	O	771-789
,	O	789-790
and	O	791-794
his	O	795-798
renal	O	799-804
function	O	805-813
was	O	814-817
completely	O	818-828
recovered	O	829-838
.	O	838-839

To	O	840-842
our	O	843-846
knowledge	O	847-856
,	O	856-857
this	O	858-862
is	O	863-865
the	O	866-869
first	O	870-875
report	O	876-882
of	O	883-885
nicergoline	O	886-897
-	O	897-898
associated	O	898-908
AIN	B	909-912
.	O	912-913

Neuroleptic	B	0-11
malignant	I	12-21
syndrome	I	22-30
complicated	O	31-42
by	O	43-45
massive	O	46-53
intestinal	O	54-64
bleeding	B	65-73
in	O	74-76
a	O	77-78
patient	O	79-86
with	O	87-91
chronic	B	92-99
renal	I	100-105
failure	I	106-113
.	O	113-114

A	O	115-116
patient	O	117-124
with	O	125-129
chronic	B	130-137
renal	I	138-143
failure	I	144-151
(	O	152-153
CRF	B	153-156
)	O	156-157
developed	O	158-167
neuroleptic	B	168-179
malignant	I	180-189
syndrome	I	190-198
(	O	199-200
NMS	B	200-203
)	O	203-204
after	O	205-210
administration	O	211-225
of	O	226-228
risperidone	O	229-240
and	O	241-244
levomepromazine	O	245-260
.	O	260-261

In	O	262-264
addition	O	265-273
to	O	274-276
the	O	277-280
typical	O	281-288
symptoms	O	289-297
of	O	298-300
NMS	B	301-304
,	O	304-305
massive	O	306-313
intestinal	O	314-324
bleeding	B	325-333
was	O	334-337
observed	O	338-346
during	O	347-353
the	O	354-357
episode	O	358-365
.	O	365-366

This	O	367-371
report	O	372-378
suggests	O	379-387
that	O	388-392
NMS	B	393-396
in	O	397-399
a	O	400-401
patient	O	402-409
with	O	410-414
CRF	B	415-418
may	O	419-422
be	O	423-425
complicated	O	426-437
by	O	438-440
intestinal	O	441-451
bleeding	B	452-460
and	O	461-464
needs	O	465-470
special	O	471-478
caution	O	479-486
for	O	487-490
this	O	491-495
complication	O	496-508
.	O	508-509

Blood	O	0-5
brain	O	6-11
barrier	O	12-19
in	O	20-22
right	O	23-28
-	O	28-29
and	O	30-33
left	O	34-38
-	O	38-39
pawed	O	39-44
female	O	45-51
rats	O	52-56
assessed	O	57-65
by	O	66-68
a	O	69-70
new	O	71-74
staining	O	75-83
method	O	84-90
.	O	90-91

The	O	92-95
asymmetrical	O	96-108
breakdown	O	109-118
of	O	119-121
the	O	122-125
blood	O	126-131
-	O	131-132
brain	O	132-137
barrier	O	138-145
(	O	146-147
BBB	O	147-150
)	O	150-151
was	O	152-155
studied	O	156-163
in	O	164-166
female	O	167-173
rats	O	174-178
.	O	178-179

Paw	O	180-183
preference	O	184-194
was	O	195-198
assessed	O	199-207
by	O	208-210
a	O	211-212
food	O	213-217
reaching	O	218-226
test	O	227-231
.	O	231-232

Adrenaline	O	233-243
-	O	243-244
induced	O	244-251
hypertension	B	252-264
was	O	265-268
used	O	269-273
to	O	274-276
destroy	O	277-284
the	O	285-288
BBB	O	289-292
,	O	292-293
which	O	294-299
was	O	300-303
evaluated	O	304-313
using	O	314-319
triphenyltetrazolium	O	320-340
(	O	341-342
TTC	O	342-345
)	O	345-346
staining	O	347-355
of	O	356-358
the	O	359-362
brain	O	363-368
slices	O	369-375
just	O	376-380
after	O	381-386
giving	O	387-393
adrenaline	O	394-404
for	O	405-408
30	O	409-411
s	O	412-413
.	O	413-414

In	O	415-417
normal	O	418-424
rats	O	425-429
,	O	429-430
the	O	431-434
whole	O	435-440
brain	O	441-446
sections	O	447-455
exhibited	O	456-465
complete	O	466-474
staining	O	475-483
with	O	484-488
TTC	O	489-492
.	O	492-493

After	O	494-499
adrenaline	O	500-510
infusion	O	511-519
for	O	520-523
30	O	524-526
s	O	527-528
,	O	528-529
there	O	530-535
were	O	536-540
large	O	541-546
unstained	O	547-556
areas	O	557-562
in	O	563-565
the	O	566-569
left	O	570-574
brain	O	575-580
in	O	581-583
right	O	584-589
-	O	589-590
pawed	O	590-595
animals	O	596-603
,	O	603-604
and	O	605-608
vice	O	609-613
versa	O	614-619
in	O	620-622
left	O	623-627
-	O	627-628
pawed	O	628-633
animals	O	634-641
.	O	641-642

Similar	O	643-650
results	O	651-658
were	O	659-663
obtained	O	664-672
in	O	673-675
seizure	B	676-683
-	O	683-684
induced	O	684-691
breakdown	O	692-701
of	O	702-704
BBB	O	705-708
.	O	708-709

These	O	710-715
results	O	716-723
were	O	724-728
explained	O	729-738
by	O	739-741
an	O	742-744
asymmetric	O	745-755
cerebral	O	756-764
blood	O	765-770
flow	O	771-775
depending	O	776-785
upon	O	786-790
the	O	791-794
paw	O	795-798
preference	O	799-809
in	O	810-812
rats	O	813-817
.	O	817-818

It	O	819-821
was	O	822-825
suggested	O	826-835
that	O	836-840
this	O	841-845
new	O	846-849
method	O	850-856
and	O	857-860
the	O	861-864
results	O	865-872
are	O	873-876
consistent	O	877-887
with	O	888-892
contralateral	O	893-906
motor	O	907-912
control	O	913-920
that	O	921-925
may	O	926-929
be	O	930-932
important	O	933-942
in	O	943-945
determining	O	946-957
the	O	958-961
dominant	O	962-970
cerebral	O	971-979
hemisphere	O	980-990
in	O	991-993
animals	O	994-1001
.	O	1001-1002

Carvedilol	O	0-10
protects	O	11-19
against	O	20-27
doxorubicin	O	28-39
-	O	39-40
induced	O	40-47
mitochondrial	O	48-61
cardiomyopathy	B	62-76
.	O	76-77

Several	O	78-85
cytopathic	O	86-96
mechanisms	O	97-107
have	O	108-112
been	O	113-117
suggested	O	118-127
to	O	128-130
mediate	O	131-138
the	O	139-142
dose	O	143-147
-	O	147-148
limiting	O	148-156
cumulative	O	157-167
and	O	168-171
irreversible	O	172-184
cardiomyopathy	B	185-199
caused	O	200-206
by	O	207-209
doxorubicin	O	210-221
.	O	221-222

Recent	O	223-229
evidence	O	230-238
indicates	O	239-248
that	O	249-253
oxidative	O	254-263
stress	O	264-270
and	O	271-274
mitochondrial	B	275-288
dysfunction	I	289-300
are	O	301-304
key	O	305-308
factors	O	309-316
in	O	317-319
the	O	320-323
pathogenic	O	324-334
process	O	335-342
.	O	342-343

The	O	344-347
objective	O	348-357
of	O	358-360
this	O	361-365
investigation	O	366-379
was	O	380-383
to	O	384-386
test	O	387-391
the	O	392-395
hypothesis	O	396-406
that	O	407-411
carvedilol	O	412-422
,	O	422-423
a	O	424-425
nonselective	O	426-438
beta	O	439-443
-	O	443-444
adrenergic	O	444-454
receptor	O	455-463
antagonist	O	464-474
with	O	475-479
potent	O	480-486
antioxidant	O	487-498
properties	O	499-509
,	O	509-510
protects	O	511-519
against	O	520-527
the	O	528-531
cardiac	O	532-539
and	O	540-543
hepatic	O	544-551
mitochondrial	O	552-565
bioenergetic	O	566-578
dysfunction	O	579-590
associated	O	591-601
with	O	602-606
subchronic	O	607-617
doxorubicin	O	618-629
toxicity	B	630-638
.	O	638-639

Heart	O	640-645
and	O	646-649
liver	O	650-655
mitochondria	O	656-668
were	O	669-673
isolated	O	674-682
from	O	683-687
rats	O	688-692
treated	O	693-700
for	O	701-704
7	O	705-706
weeks	O	707-712
with	O	713-717
doxorubicin	O	718-729
(	O	730-731
2	O	731-732
mg	O	733-735
/	O	735-736
kg	O	736-738
sc	O	739-741
/	O	741-742
week	O	742-746
)	O	746-747
,	O	747-748
carvedilol	O	749-759
(	O	760-761
1	O	761-762
mg	O	763-765
/	O	765-766
kg	O	766-768
ip	O	769-771
/	O	771-772
week	O	772-776
)	O	776-777
,	O	777-778
or	O	779-781
the	O	782-785
combination	O	786-797
of	O	798-800
the	O	801-804
two	O	805-808
drugs	O	809-814
.	O	814-815

Heart	O	816-821
mitochondria	O	822-834
isolated	O	835-843
from	O	844-848
doxorubicin	O	849-860
-	O	860-861
treated	O	861-868
rats	O	869-873
exhibited	O	874-883
depressed	O	884-893
rates	O	894-899
for	O	900-903
state	O	904-909
3	O	910-911
respiration	O	912-923
(	O	924-925
336	O	925-928
+	O	929-930
/	O	930-931
-	O	931-932
26	O	933-935
versus	O	936-942
425	O	943-946
+	O	947-948
/	O	948-949
-	O	949-950
53	O	951-953
natom	O	954-959
O	O	960-961
/	O	961-962
min	O	962-965
/	O	961-962
mg	O	966-968
protein	O	969-976
)	O	976-977
and	O	978-981
a	O	982-983
lower	O	984-989
respiratory	O	990-1001
control	O	1002-1009
ratio	O	1010-1015
(	O	1016-1017
RCR	O	1017-1020
)	O	1020-1021
(	O	1022-1023
4	O	1023-1024
.	O	1024-1025
3	O	1025-1026
+	O	1027-1028
/	O	1028-1029
-	O	1029-1030
0	O	1031-1032
.	O	1032-1033
6	O	1033-1034
versus	O	1035-1041
5	O	1042-1043
.	O	1043-1044
8	O	1044-1045
+	O	1046-1047
/	O	1047-1048
-	O	1048-1049
0	O	1050-1051
.	O	1051-1052
4	O	1052-1053
)	O	1053-1054
compared	O	1055-1063
with	O	1064-1068
cardiac	O	1069-1076
mitochondria	O	1077-1089
isolated	O	1090-1098
from	O	1099-1103
saline	O	1104-1110
-	O	1110-1111
treated	O	1111-1118
rats	O	1119-1123
.	O	1123-1124

Mitochondrial	O	1125-1138
calcium	O	1139-1146
-	O	1146-1147
loading	O	1147-1154
capacity	O	1155-1163
and	O	1164-1167
the	O	1168-1171
activity	O	1172-1180
of	O	1181-1183
NADH	O	1184-1188
-	O	1188-1189
dehydrogenase	O	1189-1202
were	O	1203-1207
also	O	1208-1212
suppressed	O	1213-1223
in	O	1224-1226
cardiac	O	1227-1234
mitochondria	O	1235-1247
from	O	1248-1252
doxorubicin	O	1253-1264
-	O	1264-1265
treated	O	1265-1272
rats	O	1273-1277
.	O	1277-1278

Doxorubicin	O	1279-1290
treatment	O	1291-1300
also	O	1301-1305
caused	O	1306-1312
a	O	1313-1314
decrease	O	1315-1323
in	O	1324-1326
RCR	O	1327-1330
for	O	1331-1334
liver	O	1335-1340
mitochondria	O	1341-1353
(	O	1354-1355
3	O	1355-1356
.	O	1356-1357
9	O	1357-1358
+	O	1359-1360
/	O	1360-1361
-	O	1361-1362
0	O	1363-1364
.	O	1364-1365
9	O	1365-1366
versus	O	1367-1373
5	O	1374-1375
.	O	1375-1376
6	O	1376-1377
+	O	1378-1379
/	O	1379-1380
-	O	1380-1381
0	O	1382-1383
.	O	1383-1384
7	O	1384-1385
for	O	1386-1389
control	O	1390-1397
rats	O	1398-1402
)	O	1402-1403
and	O	1404-1407
inhibition	O	1408-1418
of	O	1419-1421
hepatic	O	1422-1429
cytochrome	O	1430-1440
oxidase	O	1441-1448
activity	O	1449-1457
.	O	1457-1458

Coadministration	O	1459-1475
of	O	1476-1478
carvedilol	O	1479-1489
decreased	O	1490-1499
the	O	1500-1503
extent	O	1504-1510
of	O	1511-1513
cellular	O	1514-1522
vacuolization	O	1523-1536
in	O	1537-1539
cardiac	O	1540-1547
myocytes	O	1548-1556
and	O	1557-1560
prevented	O	1561-1570
the	O	1571-1574
inhibitory	O	1575-1585
effect	O	1586-1592
of	O	1593-1595
doxorubicin	O	1596-1607
on	O	1608-1610
mitochondrial	O	1611-1624
respiration	O	1625-1636
in	O	1637-1639
both	O	1640-1644
heart	O	1645-1650
and	O	1651-1654
liver	O	1655-1660
.	O	1660-1661

Carvedilol	O	1662-1672
also	O	1673-1677
prevented	O	1678-1687
the	O	1688-1691
decrease	O	1692-1700
in	O	1701-1703
mitochondrial	O	1704-1717
Ca	O	1718-1720
(	O	1720-1721
2	O	1721-1722
+	O	1722-1723
)	O	1723-1724
loading	O	1725-1732
capacity	O	1733-1741
and	O	1742-1745
the	O	1746-1749
inhibition	O	1750-1760
of	O	1761-1763
the	O	1764-1767
respiratory	O	1768-1779
complexes	O	1780-1789
of	O	1790-1792
heart	O	1793-1798
mitochondria	O	1799-1811
caused	O	1812-1818
by	O	1819-1821
doxorubicin	O	1822-1833
.	O	1833-1834

Carvedilol	O	1835-1845
by	O	1846-1848
itself	O	1849-1855
did	O	1856-1859
not	O	1860-1863
affect	O	1864-1870
any	O	1871-1874
of	O	1875-1877
the	O	1878-1881
parameters	O	1882-1892
measured	O	1893-1901
for	O	1902-1905
heart	O	1906-1911
or	O	1912-1914
liver	O	1915-1920
mitochondria	O	1921-1933
.	O	1933-1934

It	O	1935-1937
is	O	1938-1940
concluded	O	1941-1950
that	O	1951-1955
this	O	1956-1960
protection	O	1961-1971
by	O	1972-1974
carvedilol	O	1975-1985
against	O	1986-1993
both	O	1994-1998
the	O	1999-2002
structural	O	2003-2013
and	O	2014-2017
functional	O	2018-2028
cardiac	O	2029-2036
tissue	O	2037-2043
damage	O	2044-2050
may	O	2051-2054
afford	O	2055-2061
significant	O	2062-2073
clinical	O	2074-2082
advantage	O	2083-2092
in	O	2093-2095
minimizing	O	2096-2106
the	O	2107-2110
dose	O	2111-2115
-	O	2115-2116
limiting	O	2116-2124
mitochondrial	B	2125-2138
dysfunction	I	2139-2150
and	O	2151-2154
cardiomyopathy	B	2155-2169
that	O	2170-2174
accompanies	O	2175-2186
long	O	2187-2191
-	O	2191-2192
term	O	2192-2196
doxorubicin	O	2197-2208
therapy	O	2209-2216
in	O	2217-2219
cancer	B	2220-2226
patients	O	2227-2235
.	O	2235-2236

Cocaine	O	0-7
-	O	7-8
induced	O	8-15
hyperactivity	B	16-29
is	O	30-32
more	O	33-37
influenced	O	38-48
by	O	49-51
adenosine	O	52-61
receptor	O	62-70
agonists	O	71-79
than	O	80-84
amphetamine	O	85-96
-	O	96-97
induced	O	97-104
hyperactivity	B	105-118
.	O	118-119

The	O	120-123
influence	O	124-133
of	O	134-136
adenosine	O	137-146
receptor	O	147-155
agonists	O	156-164
and	O	165-168
antagonists	O	169-180
on	O	181-183
cocaine	O	184-191
-	O	191-192
and	O	192-195
amphetamine	O	196-207
-	O	207-208
induced	O	208-215
hyperactivity	B	216-229
was	O	230-233
examined	O	234-242
in	O	243-245
mice	O	246-250
.	O	250-251

All	O	252-255
adenosine	O	256-265
receptor	O	266-274
agonists	O	275-283
significantly	O	284-297
decreased	B	298-307
the	I	308-311
locomotor	I	312-321
activity	I	322-330
in	O	331-333
mice	O	334-338
,	O	338-339
and	O	340-343
the	O	344-347
effects	O	348-355
were	O	356-360
dose	O	361-365
-	O	365-366
dependent	O	366-375
.	O	375-376

It	O	377-379
seems	O	380-385
that	O	386-390
adenosine	O	391-400
A1	O	401-403
and	O	404-407
A2	O	408-410
receptors	O	411-420
might	O	421-426
be	O	427-429
involved	O	430-438
in	O	439-441
this	O	442-446
reaction	O	447-455
.	O	455-456

Moreover	O	457-465
,	O	465-466
all	O	467-470
adenosine	O	471-480
receptor	O	481-489
agonists	O	490-498
:	O	498-499
2	O	500-501
-	O	501-502
p	O	502-503
-	O	501-502
(	O	504-505
2	O	500-501
-	O	501-502
carboxyethyl	O	507-519
)	O	519-520
phenethylamino	O	520-534
-	O	501-502
5	O	535-536
'	O	536-537
-	O	501-502
N	O	538-539
-	O	501-502
ethylcarboxamidoadenosine	O	540-565
(	O	566-567
CGS	O	567-570
21680	O	571-576
)	O	576-577
,	O	577-578
A2A	O	579-582
receptor	O	583-591
agonist	O	592-599
,	O	599-600
N6	O	601-603
-	O	603-604
cyclopentyladenosine	O	604-624
(	O	625-626
CPA	O	626-629
)	O	629-630
,	O	630-631
A1	O	632-634
receptor	O	635-643
agonist	O	644-651
,	O	651-652
and	O	653-656
5	O	657-658
'	O	658-659
-	O	659-660
N	O	660-661
-	O	659-660
ethylcarboxamidoadenosine	O	662-687
(	O	688-689
NECA	O	689-693
)	O	693-694
,	O	694-695
A2	O	696-698
/	O	698-699
A1	O	699-701
receptor	O	702-710
agonist	O	711-718
significantly	O	719-732
and	O	733-736
dose	O	737-741
-	O	741-742
dependently	O	742-753
decreased	O	754-763
cocaine	O	764-771
-	O	771-772
induced	O	772-779
locomotor	O	780-789
activity	O	790-798
.	O	798-799

CPA	O	800-803
reduced	O	804-811
cocaine	O	812-819
action	O	820-826
at	O	827-829
the	O	830-833
doses	O	834-839
which	O	840-845
,	O	845-846
given	O	847-852
alone	O	853-858
,	O	858-859
did	O	860-863
not	O	864-867
influence	O	868-877
motility	O	878-886
,	O	886-887
while	O	888-893
CGS	O	894-897
21680	O	898-903
and	O	904-907
NECA	O	908-912
decreased	O	913-922
the	O	923-926
action	O	927-933
of	O	934-936
cocaine	O	937-944
at	O	945-947
the	O	948-951
doses	O	952-957
which	O	958-963
,	O	963-964
given	O	965-970
alone	O	971-976
,	O	976-977
decreased	O	978-987
locomotor	O	988-997
activity	O	998-1006
in	O	1007-1009
animals	O	1010-1017
.	O	1017-1018

These	O	1019-1024
results	O	1025-1032
suggest	O	1033-1040
the	O	1041-1044
involvement	O	1045-1056
of	O	1057-1059
both	O	1060-1064
adenosine	O	1065-1074
receptors	O	1075-1084
in	O	1085-1087
the	O	1088-1091
action	O	1092-1098
of	O	1099-1101
cocaine	O	1102-1109
although	O	1110-1118
agonists	O	1119-1127
of	O	1128-1130
A1	O	1131-1133
receptors	O	1134-1143
seem	O	1144-1148
to	O	1149-1151
have	O	1152-1156
stronger	O	1157-1165
influence	O	1166-1175
on	O	1176-1178
it	O	1179-1181
.	O	1181-1182

The	O	1183-1186
selective	O	1187-1196
blockade	O	1197-1205
of	O	1206-1208
A2	O	1209-1211
adenosine	O	1212-1221
receptor	O	1222-1230
by	O	1231-1233
DMPX	O	1234-1238
(	O	1239-1240
3	O	1240-1241
,	O	1241-1242
7	O	1242-1243
-	O	1243-1244
dimethyl	O	1244-1252
-	O	1243-1244
1	O	1253-1254
-	O	1243-1244
propargylxanthine	O	1255-1272
)	O	1272-1273
significantly	O	1274-1287
enhanced	O	1288-1296
cocaine	O	1297-1304
-	O	1304-1305
induced	O	1305-1312
locomotor	O	1313-1322
activity	O	1323-1331
of	O	1332-1334
animals	O	1335-1342
.	O	1342-1343

Caffeine	O	1344-1352
had	O	1353-1356
similar	O	1357-1364
action	O	1365-1371
but	O	1372-1375
the	O	1376-1379
effect	O	1380-1386
was	O	1387-1390
not	O	1391-1394
significant	O	1395-1406
.	O	1406-1407

CPT	O	1408-1411
(	O	1412-1413
8	O	1413-1414
-	O	1414-1415
cyclopentyltheophylline	O	1415-1438
)	O	1438-1439
-	O	1414-1415
-	O	1414-1415
A1	O	1441-1443
receptor	O	1444-1452
antagonist	O	1453-1463
,	O	1463-1464
did	O	1465-1468
not	O	1469-1472
show	O	1473-1477
any	O	1478-1481
influence	O	1482-1491
in	O	1492-1494
this	O	1495-1499
test	O	1500-1504
.	O	1504-1505

Similarly	O	1506-1515
,	O	1515-1516
all	O	1517-1520
adenosine	O	1521-1530
receptor	O	1531-1539
agonists	O	1540-1548
decreased	O	1549-1558
amphetamine	O	1559-1570
-	O	1570-1571
induced	O	1571-1578
hyperactivity	B	1579-1592
,	O	1592-1593
but	O	1594-1597
at	O	1598-1600
the	O	1601-1604
higher	O	1605-1611
doses	O	1612-1617
than	O	1618-1622
those	O	1623-1628
which	O	1629-1634
were	O	1635-1639
active	O	1640-1646
in	O	1647-1649
cocaine	O	1650-1657
-	O	1657-1658
induced	O	1658-1665
hyperactivity	B	1666-1679
.	O	1679-1680

The	O	1681-1684
selective	O	1685-1694
blockade	O	1695-1703
of	O	1704-1706
A2	O	1707-1709
adenosine	O	1710-1719
receptors	O	1720-1729
(	O	1730-1731
DMPX	O	1731-1735
)	O	1735-1736
and	O	1737-1740
non	O	1741-1744
-	O	1744-1745
selective	O	1745-1754
blockade	O	1755-1763
of	O	1764-1766
adenosine	O	1767-1776
receptors	O	1777-1786
(	O	1787-1788
caffeine	O	1788-1796
)	O	1796-1797
significantly	O	1798-1811
increased	O	1812-1821
the	O	1822-1825
action	O	1826-1832
of	O	1833-1835
amphetamine	O	1836-1847
in	O	1848-1850
the	O	1851-1854
locomotor	O	1855-1864
activity	O	1865-1873
test	O	1874-1878
.	O	1878-1879

Our	O	1880-1883
results	O	1884-1891
have	O	1892-1896
shown	O	1897-1902
that	O	1903-1907
all	O	1908-1911
adenosine	O	1912-1921
receptor	O	1922-1930
agonists	O	1931-1939
(	O	1940-1941
A1	O	1941-1943
and	O	1944-1947
A2	O	1948-1950
)	O	1950-1951
reduce	O	1952-1958
cocaine	O	1959-1966
-	O	1966-1967
and	O	1968-1971
amphetamine	O	1972-1983
-	O	1983-1984
induced	O	1984-1991
locomotor	O	1992-2001
activity	O	2002-2010
and	O	2011-2014
indicate	O	2015-2023
that	O	2024-2028
cocaine	O	2029-2036
-	O	2036-2037
induced	O	2037-2044
hyperactivity	B	2045-2058
is	O	2059-2061
more	O	2062-2066
influenced	O	2067-2077
by	O	2078-2080
adenosine	O	2081-2090
receptor	O	2091-2099
agonists	O	2100-2108
(	O	2109-2110
particularly	O	2110-2122
A1	O	2123-2125
receptors	O	2126-2135
)	O	2135-2136
than	O	2137-2141
amphetamine	O	2142-2153
-	O	2153-2154
induced	O	2154-2161
hyperactivity	B	2162-2175
.	O	2175-2176

Amiodarone	O	0-10
and	O	11-14
the	O	15-18
risk	O	19-23
of	O	24-26
bradyarrhythmia	B	27-42
requiring	O	43-52
permanent	O	53-62
pacemaker	O	63-72
in	O	73-75
elderly	O	76-83
patients	O	84-92
with	O	93-97
atrial	B	98-104
fibrillation	I	105-117
and	O	118-121
prior	O	122-127
myocardial	B	128-138
infarction	I	139-149
.	O	149-150

OBJECTIVES	O	151-161
:	O	161-162
The	O	163-166
aim	O	167-170
of	O	171-173
this	O	174-178
study	O	179-184
was	O	185-188
to	O	189-191
determine	O	192-201
whether	O	202-209
the	O	210-213
use	O	214-217
of	O	218-220
amiodarone	O	221-231
in	O	232-234
patients	O	235-243
with	O	244-248
atrial	B	249-255
fibrillation	I	256-268
(	O	269-270
AF	B	270-272
)	O	272-273
increases	O	274-283
the	O	284-287
risk	O	288-292
of	O	293-295
bradyarrhythmia	B	296-311
requiring	O	312-321
a	O	322-323
permanent	O	324-333
pacemaker	O	334-343
.	O	343-344

BACKGROUND	O	345-355
:	O	355-356
Reports	O	357-364
of	O	365-367
severe	O	368-374
bradyarrhythmia	B	375-390
during	O	391-397
amiodarone	O	398-408
therapy	O	409-416
are	O	417-420
infrequent	O	421-431
and	O	432-435
limited	O	436-443
to	O	444-446
studies	O	447-454
assessing	O	455-464
the	O	465-468
therapy	O	469-476
'	O	476-477
s	O	477-478
use	O	479-482
in	O	483-485
the	O	486-489
management	O	490-500
of	O	501-503
patients	O	504-512
with	O	513-517
ventricular	B	518-529
arrhythmias	I	530-541
.	O	541-542

METHODS	O	543-550
:	O	550-551
A	O	552-553
study	O	554-559
cohort	O	560-566
of	O	567-569
8	O	570-571
,	O	571-572
770	O	572-575
patients	O	576-584
age	O	585-588
>	O	589-590
or	O	591-593
=	O	594-595
65	O	595-597
years	O	598-603
with	O	604-608
a	O	609-610
new	O	611-614
diagnosis	O	615-624
of	O	625-627
AF	B	628-630
was	O	631-634
identified	O	635-645
from	O	646-650
a	O	651-652
provincewide	O	653-665
database	O	666-674
of	O	675-677
Quebec	O	678-684
residents	O	685-694
with	O	695-699
a	O	700-701
myocardial	B	702-712
infarction	I	713-723
(	O	724-725
MI	B	725-727
)	O	727-728
between	O	729-736
1991	O	737-741
and	O	742-745
1999	O	746-750
.	O	750-751

Using	O	752-757
a	O	758-759
nested	O	760-766
case	O	767-771
-	O	771-772
control	O	772-779
design	O	780-786
,	O	786-787
477	O	788-791
cases	O	792-797
of	O	798-800
bradyarrhythmia	B	801-816
requiring	O	817-826
a	O	827-828
permanent	O	829-838
pacemaker	O	839-848
were	O	849-853
matched	O	854-861
(	O	862-863
1	O	863-864
:	O	864-865
4	O	865-866
)	O	866-867
to	O	868-870
1	O	871-872
,	O	872-873
908	O	873-876
controls	O	877-885
.	O	885-886

Multivariable	O	887-900
logistic	O	901-909
regression	O	910-920
was	O	921-924
used	O	925-929
to	O	930-932
estimate	O	933-941
the	O	942-945
odds	O	946-950
ratio	O	951-956
(	O	957-958
OR	O	958-960
)	O	960-961
of	O	962-964
pacemaker	O	965-974
insertion	O	975-984
associated	O	985-995
with	O	996-1000
amiodarone	O	1001-1011
use	O	1012-1015
,	O	1015-1016
controlling	O	1017-1028
for	O	1029-1032
baseline	O	1033-1041
risk	O	1042-1046
factors	O	1047-1054
and	O	1055-1058
exposure	O	1059-1067
to	O	1068-1070
sotalol	O	1071-1078
,	O	1078-1079
Class	O	1080-1085
I	O	1086-1087
antiarrhythmic	O	1088-1102
agents	O	1103-1109
,	O	1109-1110
beta	O	1111-1115
-	O	1115-1116
blockers	O	1116-1124
,	O	1124-1125
calcium	O	1126-1133
channel	O	1134-1141
blockers	O	1142-1150
,	O	1150-1151
and	O	1152-1155
digoxin	O	1156-1163
.	O	1163-1164

RESULTS	O	1165-1172
:	O	1172-1173
amiodarone	O	1174-1184
use	O	1185-1188
was	O	1189-1192
associated	O	1193-1203
with	O	1204-1208
an	O	1209-1211
increased	O	1212-1221
risk	O	1222-1226
of	O	1227-1229
pacemaker	O	1230-1239
insertion	O	1240-1249
(	O	1250-1251
OR	O	1251-1253
:	O	1253-1254
2	O	1255-1256
.	O	1256-1257
14	O	1257-1259
,	O	1259-1260
95	O	1261-1263
%	O	1263-1264
confidence	O	1265-1275
interval	O	1276-1284
[	O	1285-1286
CI	O	1286-1288
]	O	1288-1289
:	O	1289-1290
1	O	1291-1292
.	O	1292-1293
30	O	1293-1295
to	O	1296-1298
3	O	1299-1300
.	O	1300-1301
54	O	1301-1303
)	O	1303-1304
.	O	1300-1301

This	O	1306-1310
effect	O	1311-1317
was	O	1318-1321
modified	O	1322-1330
by	O	1331-1333
gender	O	1334-1340
,	O	1340-1341
with	O	1342-1346
a	O	1347-1348
greater	O	1349-1356
risk	O	1357-1361
in	O	1362-1364
women	O	1365-1370
versus	O	1371-1377
men	O	1378-1381
(	O	1382-1383
OR	O	1383-1385
:	O	1385-1386
3	O	1387-1388
.	O	1388-1389
86	O	1389-1391
,	O	1391-1392
95	O	1393-1395
%	O	1395-1396
CI	O	1397-1399
:	O	1399-1400
1	O	1401-1402
.	O	1402-1403
70	O	1403-1405
to	O	1406-1408
8	O	1409-1410
.	O	1410-1411
75	O	1411-1413
vs	O	1414-1416
.	O	1416-1417
OR	O	1418-1420
:	O	1420-1421
1	O	1422-1423
.	O	1423-1424
52	O	1424-1426
,	O	1426-1427
95	O	1428-1430
%	O	1430-1431
CI	O	1432-1434
:	O	1434-1435
0	O	1436-1437
.	O	1437-1438
80	O	1438-1440
to	O	1441-1443
2	O	1444-1445
.	O	1445-1446
89	O	1446-1448
)	O	1448-1449
.	O	1445-1446

Digoxin	O	1451-1458
was	O	1459-1462
the	O	1463-1466
only	O	1467-1471
other	O	1472-1477
medication	O	1478-1488
associated	O	1489-1499
with	O	1500-1504
an	O	1505-1507
increased	O	1508-1517
risk	O	1518-1522
of	O	1523-1525
pacemaker	O	1526-1535
insertion	O	1536-1545
(	O	1546-1547
OR	O	1547-1549
:	O	1549-1550
1	O	1551-1552
.	O	1552-1553
78	O	1553-1555
,	O	1555-1556
95	O	1557-1559
%	O	1559-1560
CI	O	1561-1563
:	O	1563-1564
1	O	1565-1566
.	O	1566-1567
37	O	1567-1569
to	O	1570-1572
2	O	1573-1574
.	O	1574-1575
31	O	1575-1577
)	O	1577-1578
.	O	1574-1575

CONCLUSIONS	O	1580-1591
:	O	1591-1592
This	O	1593-1597
study	O	1598-1603
suggests	O	1604-1612
that	O	1613-1617
the	O	1618-1621
use	O	1622-1625
of	O	1626-1628
amiodarone	O	1629-1639
in	O	1640-1642
elderly	O	1643-1650
patients	O	1651-1659
with	O	1660-1664
AF	B	1665-1667
and	O	1668-1671
a	O	1672-1673
previous	O	1674-1682
MI	B	1683-1685
increases	O	1686-1695
the	O	1696-1699
risk	O	1700-1704
of	O	1705-1707
bradyarrhythmia	B	1708-1723
requiring	O	1724-1733
a	O	1734-1735
permanent	O	1736-1745
pacemaker	O	1746-1755
.	O	1755-1756

The	O	1757-1760
finding	O	1761-1768
of	O	1769-1771
an	O	1772-1774
augmented	O	1775-1784
risk	O	1785-1789
of	O	1790-1792
pacemaker	O	1793-1802
insertion	O	1803-1812
in	O	1813-1815
elderly	O	1816-1823
women	O	1824-1829
receiving	O	1830-1839
amiodarone	O	1840-1850
requires	O	1851-1859
further	O	1860-1867
investigation	O	1868-1881
.	O	1881-1882

Indomethacin	O	0-12
-	O	12-13
induced	O	13-20
morphologic	O	21-32
changes	O	33-40
in	O	41-43
the	O	44-47
rat	O	48-51
urinary	O	52-59
bladder	O	60-67
epithelium	O	68-78
.	O	78-79

OBJECTIVES	O	80-90
:	O	90-91
To	O	92-94
evaluate	O	95-103
the	O	104-107
morphologic	O	108-119
changes	O	120-127
in	O	128-130
rat	O	131-134
urothelium	O	135-145
induced	O	146-153
by	O	154-156
indomethacin	O	157-169
.	O	169-170

Nonsteroidal	O	171-183
anti	O	184-188
-	O	188-189
inflammatory	O	189-201
drug	O	202-206
-	O	206-207
induced	O	207-214
cystitis	B	215-223
is	O	224-226
a	O	227-228
poorly	O	229-235
recognized	O	236-246
and	O	247-250
under	O	251-256
-	O	256-257
reported	O	257-265
condition	O	266-275
.	O	275-276

In	O	277-279
addition	O	280-288
to	O	289-291
tiaprofenic	O	292-303
acid	O	304-308
,	O	308-309
indomethacin	O	310-322
has	O	323-326
been	O	327-331
reported	O	332-340
to	O	341-343
be	O	344-346
associated	O	347-357
with	O	358-362
this	O	363-367
condition	O	368-377
.	O	377-378

METHODS	O	379-386
:	O	386-387
Three	O	388-393
groups	O	394-400
were	O	401-405
established	O	406-417
:	O	417-418
a	O	419-420
control	O	421-428
group	O	429-434
(	O	435-436
n	O	436-437
=	O	438-439
10	O	440-442
)	O	442-443
,	O	443-444
a	O	445-446
high	O	447-451
-	O	451-452
dose	O	452-456
group	O	457-462
(	O	463-464
n	O	464-465
=	O	466-467
10	O	468-470
)	O	470-471
,	O	471-472
treated	O	473-480
with	O	481-485
one	O	486-489
intraperitoneal	O	490-505
injection	O	506-515
of	O	516-518
indomethacin	O	519-531
20	O	532-534
mg	O	535-537
/	O	537-538
kg	O	538-540
,	O	540-541
and	O	542-545
a	O	546-547
therapeutic	O	548-559
dose	O	560-564
group	O	565-570
(	O	571-572
n	O	572-573
=	O	574-575
10	O	576-578
)	O	578-579
in	O	580-582
which	O	583-588
oral	O	589-593
indomethacin	O	594-606
was	O	607-610
administered	O	611-623
3	O	624-625
.	O	625-626
25	O	626-628
mg	O	629-631
/	O	631-632
kg	O	632-634
body	O	635-639
weight	O	640-646
daily	O	647-652
for	O	653-656
3	O	657-658
weeks	O	659-664
.	O	664-665

The	O	666-669
animals	O	670-677
were	O	678-682
then	O	683-687
killed	O	688-694
and	O	695-698
the	O	699-702
bladders	O	703-711
removed	O	712-719
for	O	720-723
light	O	724-729
and	O	730-733
electron	O	734-742
microscopic	O	743-754
studies	O	755-762
.	O	762-763

RESULTS	O	764-771
:	O	771-772
The	O	773-776
light	O	777-782
microscopic	O	783-794
findings	O	795-803
showed	O	804-810
some	O	811-815
focal	O	816-821
epithelial	O	822-832
degeneration	O	833-845
that	O	846-850
was	O	851-854
more	O	855-859
prominent	O	860-869
in	O	870-872
the	O	873-876
high	O	877-881
-	O	881-882
dose	O	882-886
group	O	887-892
.	O	892-893

When	O	894-898
compared	O	899-907
with	O	908-912
the	O	913-916
control	O	917-924
group	O	925-930
,	O	930-931
both	O	932-936
indomethacin	O	937-949
groups	O	950-956
revealed	O	957-965
statistically	O	966-979
increased	O	980-989
numbers	O	990-997
of	O	998-1000
mast	O	1001-1005
cells	O	1006-1011
in	O	1012-1014
the	O	1015-1018
mucosa	O	1019-1025
(	O	1026-1027
P	O	1027-1028
<	O	1029-1030
0	O	1030-1031
.	O	1031-1032
0001	O	1032-1036
)	O	1036-1037
and	O	1038-1041
penetration	O	1042-1053
of	O	1054-1056
lanthanum	O	1057-1066
nitrate	O	1067-1074
through	O	1075-1082
intercellular	O	1083-1096
areas	O	1097-1102
of	O	1103-1105
the	O	1106-1109
epithelium	O	1110-1120
.	O	1120-1121

Furthermore	O	1122-1133
,	O	1133-1134
the	O	1135-1138
difference	O	1139-1149
in	O	1150-1152
mast	O	1153-1157
cell	O	1158-1162
counts	O	1163-1169
between	O	1170-1177
the	O	1178-1181
high	O	1182-1186
and	O	1187-1190
therapeutic	O	1191-1202
dose	O	1203-1207
groups	O	1208-1214
was	O	1215-1218
also	O	1219-1223
statistically	O	1224-1237
significant	O	1238-1249
(	O	1250-1251
P	O	1251-1252
<	O	1253-1254
0	O	1254-1255
.	O	1255-1256
0001	O	1256-1260
)	O	1260-1261
.	O	1255-1256

CONCLUSIONS	O	1263-1274
:	O	1274-1275
Indomethacin	O	1276-1288
resulted	O	1289-1297
in	O	1298-1300
histopathologic	O	1301-1316
findings	O	1317-1325
typical	O	1326-1333
of	O	1334-1336
interstitial	B	1337-1349
cystitis	I	1350-1358
,	O	1358-1359
such	O	1360-1364
as	O	1365-1367
leaky	O	1368-1373
bladder	O	1374-1381
epithelium	O	1382-1392
and	O	1393-1396
mucosal	O	1397-1404
mastocytosis	B	1405-1417
.	O	1417-1418

The	O	1419-1422
true	O	1423-1427
incidence	O	1428-1437
of	O	1438-1440
nonsteroidal	O	1441-1453
anti	O	1454-1458
-	O	1458-1459
inflammatory	O	1459-1471
drug	O	1472-1476
-	O	1476-1477
induced	O	1477-1484
cystitis	B	1485-1493
in	O	1494-1496
humans	O	1497-1503
must	O	1504-1508
be	O	1509-1511
clarified	O	1512-1521
by	O	1522-1524
prospective	O	1525-1536
clinical	O	1537-1545
trials	O	1546-1552
.	O	1552-1553

An	O	0-2
open	O	3-7
-	O	7-8
label	O	8-13
phase	O	14-19
II	O	20-22
study	O	23-28
of	O	29-31
low	O	32-35
-	O	35-36
dose	O	36-40
thalidomide	O	41-52
in	O	53-55
androgen	O	56-64
-	O	64-65
independent	O	65-76
prostate	B	77-85
cancer	I	86-92
.	O	92-93

The	O	94-97
antiangiogenic	O	98-112
effects	O	113-120
of	O	121-123
thalidomide	O	124-135
have	O	136-140
been	O	141-145
assessed	O	146-154
in	O	155-157
clinical	O	158-166
trials	O	167-173
in	O	174-176
patients	O	177-185
with	O	186-190
various	O	191-198
solid	O	199-204
and	O	205-208
haematological	B	209-223
malignancies	I	224-236
.	O	236-237

Thalidomide	O	238-249
blocks	O	250-256
the	O	257-260
activity	O	261-269
of	O	270-272
angiogenic	O	273-283
agents	O	284-290
including	O	291-300
bFGF	O	301-305
,	O	305-306
VEGF	O	307-311
and	O	312-315
IL	O	316-318
-	O	318-319
6	O	319-320
.	O	320-321

We	O	322-324
undertook	O	325-334
an	O	335-337
open	O	338-342
-	O	342-343
label	O	343-348
study	O	349-354
using	O	355-360
thalidomide	O	361-372
100	O	373-376
mg	O	377-379
once	O	380-384
daily	O	385-390
for	O	391-394
up	O	395-397
to	O	398-400
6	O	401-402
months	O	403-409
in	O	410-412
20	O	413-415
men	O	416-419
with	O	420-424
androgen	O	425-433
-	O	433-434
independent	O	434-445
prostate	B	446-454
cancer	I	455-461
.	O	461-462

The	O	463-466
mean	O	467-471
time	O	472-476
of	O	477-479
study	O	480-485
was	O	486-489
109	O	490-493
days	O	494-498
(	O	499-500
median	O	500-506
107	O	507-510
,	O	510-511
range	O	512-517
4	O	518-519
-	O	519-520
184	O	520-523
days	O	524-528
)	O	528-529
.	O	529-530

Patients	O	531-539
underwent	O	540-549
regular	O	550-557
measurement	O	558-569
of	O	570-572
prostate	O	573-581
-	O	581-582
specific	O	582-590
antigen	O	591-598
(	O	599-600
PSA	O	600-603
)	O	603-604
,	O	604-605
urea	O	606-610
and	O	611-614
electrolytes	O	615-627
,	O	627-628
serum	O	629-634
bFGF	O	635-639
and	O	640-643
VEGF	O	644-648
.	O	648-649

Three	O	650-655
men	O	656-659
(	O	660-661
15	O	661-663
%	O	663-664
)	O	664-665
showed	O	666-672
a	O	673-674
decline	O	675-682
in	O	683-685
serum	O	686-691
PSA	O	692-695
of	O	696-698
at	O	699-701
least	O	702-707
50	O	708-710
%	O	710-711
,	O	711-712
sustained	O	713-722
throughout	O	723-733
treatment	O	734-743
.	O	743-744

Of	O	745-747
16	O	748-750
men	O	751-754
treated	O	755-762
for	O	763-766
at	O	767-769
least	O	770-775
2	O	776-777
months	O	778-784
,	O	784-785
six	O	786-789
(	O	790-791
37	O	791-793
.	O	793-794
5	O	794-795
%	O	795-796
)	O	796-797
showed	O	798-804
a	O	805-806
fall	O	807-811
in	O	812-814
absolute	O	815-823
PSA	O	824-827
by	O	828-830
a	O	831-832
median	O	833-839
of	O	840-842
48	O	843-845
%	O	845-846
.	O	846-847

Increasing	O	848-858
levels	O	859-865
of	O	866-868
serum	O	869-874
bFGF	O	875-879
and	O	880-883
VEGF	O	884-888
were	O	889-893
associated	O	894-904
with	O	905-909
progressive	O	910-921
disease	O	922-929
;	O	929-930
five	O	931-935
of	O	936-938
six	O	939-942
men	O	943-946
who	O	947-950
demonstrated	O	951-963
a	O	964-965
fall	O	966-970
in	O	971-973
PSA	O	974-977
also	O	978-982
showed	O	983-989
a	O	990-991
decline	O	992-999
in	O	1000-1002
bFGF	O	1003-1007
and	O	1008-1011
VEGF	O	1012-1016
levels	O	1017-1023
,	O	1023-1024
and	O	1025-1028
three	O	1029-1034
of	O	1035-1037
four	O	1038-1042
men	O	1043-1046
with	O	1047-1051
a	O	1052-1053
rising	O	1054-1060
PSA	O	1061-1064
showed	O	1065-1071
an	O	1072-1074
increase	O	1075-1083
in	O	1084-1086
both	O	1087-1091
growth	O	1092-1098
factors	O	1099-1106
.	O	1106-1107

Adverse	O	1108-1115
effects	O	1116-1123
included	O	1124-1132
constipation	B	1133-1145
,	O	1145-1146
morning	O	1147-1154
drowsiness	B	1155-1165
,	O	1165-1166
dizziness	B	1167-1176
and	O	1177-1180
rash	B	1181-1185
,	O	1185-1186
and	O	1187-1190
resulted	O	1191-1199
in	O	1200-1202
withdrawal	O	1203-1213
from	O	1214-1218
the	O	1219-1222
study	O	1223-1228
by	O	1229-1231
three	O	1232-1237
men	O	1238-1241
.	O	1241-1242

Evidence	O	1243-1251
of	O	1252-1254
peripheral	B	1255-1265
sensory	I	1266-1273
neuropathy	I	1274-1284
was	O	1285-1288
found	O	1289-1294
in	O	1295-1297
nine	O	1298-1302
of	O	1303-1305
13	O	1306-1308
men	O	1309-1312
before	O	1313-1319
treatment	O	1320-1329
.	O	1329-1330

In	O	1331-1333
the	O	1334-1337
seven	O	1338-1343
men	O	1344-1347
who	O	1348-1351
completed	O	1352-1361
six	O	1362-1365
months	O	1366-1372
on	O	1373-1375
thalidomide	O	1376-1387
,	O	1387-1388
subclinical	O	1389-1400
evidence	O	1401-1409
of	O	1410-1412
peripheral	B	1413-1423
neuropathy	I	1424-1434
was	O	1435-1438
found	O	1439-1444
in	O	1445-1447
four	O	1448-1452
before	O	1453-1459
treatment	O	1460-1469
,	O	1469-1470
but	O	1471-1474
in	O	1475-1477
all	O	1478-1481
seven	O	1482-1487
at	O	1488-1490
repeat	O	1491-1497
testing	O	1498-1505
.	O	1505-1506

The	O	1507-1510
findings	O	1511-1519
indicate	O	1520-1528
that	O	1529-1533
thalidomide	O	1534-1545
may	O	1546-1549
be	O	1550-1552
an	O	1553-1555
option	O	1556-1562
for	O	1563-1566
patients	O	1567-1575
who	O	1576-1579
have	O	1580-1584
failed	O	1585-1591
other	O	1592-1597
forms	O	1598-1603
of	O	1604-1606
therapy	O	1607-1614
,	O	1614-1615
provided	O	1616-1624
close	O	1625-1630
follow	O	1631-1637
-	O	1637-1638
up	O	1638-1640
is	O	1641-1643
maintained	O	1644-1654
for	O	1655-1658
development	O	1659-1670
of	O	1671-1673
peripheral	B	1674-1684
neuropathy	I	1685-1695
.	O	1695-1696

Central	B	0-7
nervous	I	8-15
system	I	16-22
toxicity	I	23-31
following	O	32-41
the	O	42-45
administration	O	46-60
of	O	61-63
levobupivacaine	O	64-79
for	O	80-83
lumbar	O	84-90
plexus	O	91-97
block	O	98-103
:	O	103-104
A	O	105-106
report	O	107-113
of	O	114-116
two	O	117-120
cases	O	121-126
.	O	126-127

BACKGROUND	O	128-138
AND	O	139-142
OBJECTIVES	O	143-153
:	O	153-154
Central	B	155-162
nervous	I	163-170
system	I	171-177
and	I	178-181
cardiac	I	182-189
toxicity	I	190-198
following	O	199-208
the	O	209-212
administration	O	213-227
of	O	228-230
local	O	231-236
anesthetics	O	237-248
is	O	249-251
a	O	252-253
recognized	O	254-264
complication	O	265-277
of	O	278-280
regional	O	281-289
anesthesia	O	290-300
.	O	300-301

Levobupivacaine	O	302-317
,	O	317-318
the	O	319-322
pure	O	323-327
S	O	328-329
(	O	329-330
-	O	330-331
)	O	331-332
enantiomer	O	333-343
of	O	344-346
bupivacaine	O	347-358
,	O	358-359
was	O	360-363
developed	O	364-373
to	O	374-376
improve	O	377-384
the	O	385-388
cardiac	O	389-396
safety	O	397-403
profile	O	404-411
of	O	412-414
bupivacaine	O	415-426
.	O	426-427

We	O	428-430
describe	O	431-439
2	O	440-441
cases	O	442-447
of	O	448-450
grand	B	451-456
mal	I	457-460
seizures	I	461-469
following	O	470-479
accidental	O	480-490
intravascular	O	491-504
injection	O	505-514
of	O	515-517
levobupivacaine	O	518-533
.	O	533-534

CASE	O	535-539
REPORT	O	540-546
:	O	546-547
Two	O	548-551
patients	O	552-560
presenting	O	561-571
for	O	572-575
elective	O	576-584
orthopedic	O	585-595
surgery	O	596-603
of	O	604-606
the	O	607-610
lower	O	611-616
limb	O	617-621
underwent	O	622-631
blockade	O	632-640
of	O	641-643
the	O	644-647
lumbar	O	648-654
plexus	O	655-661
via	O	662-665
the	O	666-669
posterior	O	670-679
approach	O	680-688
.	O	688-689

Immediately	O	690-701
after	O	702-707
the	O	708-711
administration	O	712-726
of	O	727-729
levobupivacaine	O	730-745
0	O	746-747
.	O	747-748
5	O	748-749
%	O	749-750
with	O	751-755
epinephrine	O	756-767
2	O	768-769
.	O	769-770
5	O	770-771
microgram	O	772-781
/	O	781-782
mL	O	782-784
,	O	784-785
the	O	786-789
patients	O	790-798
developed	O	799-808
grand	B	809-814
mal	I	815-818
seizures	I	819-827
,	O	827-828
despite	O	829-836
negative	O	837-845
aspiration	O	846-856
for	O	857-860
blood	O	861-866
and	O	867-870
no	O	871-873
clinical	O	874-882
signs	O	883-888
of	O	889-891
intravenous	O	892-903
epinephrine	O	904-915
administration	O	916-930
.	O	930-931

The	O	932-935
seizures	B	936-944
were	O	945-949
successfully	O	950-962
treated	O	963-970
with	O	971-975
sodium	O	976-982
thiopental	O	983-993
in	O	994-996
addition	O	997-1005
to	O	1006-1008
succinylcholine	O	1009-1024
in	O	1025-1027
1	O	1028-1029
patient	O	1030-1037
.	O	1037-1038

Neither	O	1039-1046
patient	O	1047-1054
developed	O	1055-1064
signs	O	1065-1070
of	O	1071-1073
cardiovascular	B	1074-1088
toxicity	I	1089-1097
.	O	1097-1098

Both	O	1099-1103
patients	O	1104-1112
were	O	1113-1117
treated	O	1118-1125
preoperatively	O	1126-1140
with	O	1141-1145
beta	O	1146-1150
-	O	1150-1151
adrenergic	O	1151-1161
antagonist	O	1162-1172
medications	O	1173-1184
,	O	1184-1185
which	O	1186-1191
may	O	1192-1195
have	O	1196-1200
masked	O	1201-1207
the	O	1208-1211
cardiovascular	O	1212-1226
signs	O	1227-1232
of	O	1233-1235
the	O	1236-1239
unintentional	O	1240-1253
intravascular	O	1254-1267
administration	O	1268-1282
of	O	1283-1285
levobupivacaine	O	1286-1301
with	O	1302-1306
epinephrine	O	1307-1318
.	O	1318-1319

CONCLUSIONS	O	1320-1331
:	O	1331-1332
Although	O	1333-1341
levobupivacaine	O	1342-1357
may	O	1358-1361
have	O	1362-1366
a	O	1367-1368
safer	O	1369-1374
cardiac	B	1375-1382
toxicity	I	1383-1391
profile	O	1392-1399
than	O	1400-1404
racemic	O	1405-1412
bupivacaine	O	1413-1424
,	O	1424-1425
if	O	1426-1428
adequate	O	1429-1437
amounts	O	1438-1445
of	O	1446-1448
levobupivacaine	O	1449-1464
reach	O	1465-1470
the	O	1471-1474
circulation	O	1475-1486
,	O	1486-1487
it	O	1488-1490
will	O	1491-1495
result	O	1496-1502
in	O	1503-1505
convulsions	B	1506-1517
.	O	1517-1518

Plasma	O	1519-1525
concentrations	O	1526-1540
sufficient	O	1541-1551
to	O	1552-1554
result	O	1555-1561
in	O	1562-1564
central	B	1565-1572
nervous	I	1573-1580
system	I	1581-1587
toxicity	I	1588-1596
did	O	1597-1600
not	O	1601-1604
produce	O	1605-1612
manifestations	O	1613-1627
of	O	1628-1630
cardiac	B	1631-1638
toxicity	I	1639-1647
in	O	1648-1650
these	O	1651-1656
2	O	1657-1658
patients	O	1659-1667
.	O	1667-1668

Anaesthetic	O	0-11
complications	O	12-25
associated	O	26-36
with	O	37-41
myotonia	B	42-50
congenita	I	51-60
:	O	60-61
case	O	62-66
study	O	67-72
and	O	73-76
comparison	O	77-87
with	O	88-92
other	O	93-98
myotonic	B	99-107
disorders	I	108-117
.	O	117-118

Myotonia	B	119-127
congenita	I	128-137
(	O	138-139
MC	B	139-141
)	O	141-142
is	O	143-145
caused	O	146-152
by	O	153-155
a	O	156-157
defect	O	158-164
in	O	165-167
the	O	168-171
skeletal	O	172-180
muscle	O	181-187
chloride	O	188-196
channel	O	197-204
function	O	205-213
,	O	213-214
which	O	215-220
may	O	221-224
cause	O	225-230
sustained	B	231-240
membrane	I	241-249
depolarisation	I	250-264
.	O	264-265

We	O	266-268
describe	O	269-277
a	O	278-279
previously	O	280-290
healthy	O	291-298
32	O	299-301
-	O	301-302
year	O	302-306
-	O	301-302
old	O	307-310
woman	O	311-316
who	O	317-320
developed	O	321-330
a	O	331-332
life	O	333-337
-	O	337-338
threatening	O	338-349
muscle	B	350-356
spasm	I	357-362
and	O	363-366
secondary	O	367-376
ventilation	O	377-388
difficulties	O	389-401
following	O	402-411
a	O	412-413
preoperative	O	414-426
injection	O	427-436
of	O	437-439
suxamethonium	O	440-453
.	O	453-454

The	O	455-458
muscle	B	459-465
spasms	I	466-472
disappeared	O	473-484
spontaneously	O	485-498
and	O	499-502
the	O	503-506
surgery	O	507-514
proceeded	O	515-524
without	O	525-532
further	O	533-540
problems	O	541-549
.	O	549-550

When	O	551-555
subsequently	O	556-568
questioned	O	569-579
,	O	579-580
she	O	581-584
reported	O	585-593
minor	O	594-599
symptoms	O	600-608
suggesting	O	609-619
a	O	620-621
myotonic	B	622-630
condition	I	631-640
.	O	640-641

Myotonia	B	642-650
was	O	651-654
found	O	655-660
on	O	661-663
clinical	O	664-672
examination	O	673-684
and	O	685-688
EMG	O	689-692
.	O	692-693

The	O	694-697
diagnosis	O	698-707
MC	B	708-710
was	O	711-714
confirmed	O	715-724
genetically	O	725-736
.	O	736-737

Neither	O	738-745
the	O	746-749
patient	O	750-757
nor	O	758-761
the	O	762-765
anaesthetist	O	766-778
were	O	779-783
aware	O	784-789
of	O	790-792
the	O	793-796
diagnosis	O	797-806
before	O	807-813
this	O	814-818
potentially	O	819-830
lethal	O	831-837
complication	O	838-850
occurred	O	851-859
.	O	859-860

We	O	861-863
give	O	864-868
a	O	869-870
brief	O	871-876
overview	O	877-885
of	O	886-888
ion	B	889-892
channel	I	893-900
disorders	I	901-910
including	O	911-920
malignant	B	921-930
hyperthermia	I	931-943
and	O	944-947
their	O	948-953
anaesthetic	O	954-965
considerations	O	966-980
.	O	980-981

Respiratory	O	0-11
pattern	O	12-19
in	O	20-22
a	O	23-24
rat	O	25-28
model	O	29-34
of	O	35-37
epilepsy	B	38-46
.	O	46-47

PURPOSE	O	48-55
:	O	55-56
Apnea	B	57-62
is	O	63-65
known	O	66-71
to	O	72-74
occur	O	75-80
during	O	81-87
seizures	B	88-96
,	O	96-97
but	O	98-101
systematic	O	102-112
studies	O	113-120
of	O	121-123
ictal	O	124-129
respiratory	O	130-141
changes	O	142-149
in	O	150-152
adults	O	153-159
are	O	160-163
few	O	164-167
.	O	167-168

Data	O	169-173
regarding	O	174-183
respiratory	O	184-195
pattern	O	196-203
defects	O	204-211
during	O	212-218
interictal	O	219-229
periods	O	230-237
also	O	238-242
are	O	243-246
scarce	O	247-253
.	O	253-254

Here	O	255-259
we	O	260-262
sought	O	263-269
to	O	270-272
generate	O	273-281
information	O	282-293
with	O	294-298
regard	O	299-305
to	O	306-308
the	O	309-312
interictal	O	313-323
period	O	324-330
in	O	331-333
animals	O	334-341
with	O	342-346
pilocarpine	O	347-358
-	O	358-359
induced	O	359-366
epilepsy	B	367-375
.	O	375-376

METHODS	O	377-384
:	O	384-385
Twelve	O	386-392
rats	O	393-397
(	O	398-399
six	O	399-402
chronically	O	403-414
epileptic	B	415-424
animals	O	425-432
and	O	433-436
six	O	437-440
controls	O	441-449
)	O	449-450
were	O	451-455
anesthetized	O	456-468
,	O	468-469
given	O	470-475
tracheotomies	O	476-489
,	O	489-490
and	O	491-494
subjected	O	495-504
to	O	505-507
hyperventilation	B	508-524
or	O	525-527
hypoventilation	O	528-543
conditions	O	544-554
.	O	554-555

Breathing	O	556-565
movements	O	566-575
caused	O	576-582
changes	O	583-590
in	O	591-593
thoracic	O	594-602
volume	O	603-609
and	O	610-613
forced	O	614-620
air	O	621-624
to	O	625-627
flow	O	628-632
tidally	O	633-640
through	O	641-648
a	O	649-650
pneumotachograph	O	651-667
.	O	667-668

This	O	669-673
flow	O	674-678
was	O	679-682
measured	O	683-691
by	O	692-694
using	O	695-700
a	O	701-702
differential	O	703-715
pressure	O	716-724
transducer	O	725-735
,	O	735-736
passed	O	737-743
through	O	744-751
a	O	752-753
polygraph	O	754-763
,	O	763-764
and	O	765-768
from	O	769-773
this	O	774-778
to	O	779-781
a	O	782-783
computer	O	784-792
with	O	793-797
custom	O	798-804
software	O	805-813
that	O	814-818
derived	O	819-826
ventilation	O	827-838
(	O	839-840
VE	O	840-842
)	O	842-843
,	O	843-844
tidal	O	845-850
volume	O	851-857
(	O	858-859
VT	O	859-861
)	O	861-862
,	O	862-863
inspiratory	O	864-875
time	O	876-880
(	O	881-882
TI	O	882-884
)	O	884-885
,	O	885-886
expiratory	O	887-897
time	O	898-902
(	O	903-904
TE	O	904-906
)	O	906-907
,	O	907-908
breathing	O	909-918
frequency	O	919-928
(	O	929-930
f	O	930-931
)	O	931-932
,	O	932-933
and	O	934-937
mean	O	938-942
inspiratory	O	943-954
flow	O	955-959
(	O	960-961
VT	O	961-963
/	O	963-964
TI	O	964-966
)	O	966-967
on	O	968-970
a	O	971-972
breath	O	973-979
-	O	979-980
by	O	980-982
-	O	979-980
breath	O	973-979
basis	O	990-995
.	O	995-996

RESULTS	O	997-1004
:	O	1004-1005
The	O	1006-1009
hyperventilation	B	1010-1026
maneuver	O	1027-1035
caused	O	1036-1042
a	O	1043-1044
decrease	O	1045-1053
in	O	1054-1056
spontaneous	O	1057-1068
ventilation	O	1069-1080
in	O	1081-1083
pilocarpine	O	1084-1095
-	O	1095-1096
treated	O	1096-1103
and	O	1104-1107
control	O	1108-1115
rats	O	1116-1120
.	O	1120-1121

Although	O	1122-1130
VE	O	1131-1133
had	O	1134-1137
a	O	1138-1139
similar	O	1140-1147
decrease	O	1148-1156
in	O	1157-1159
both	O	1160-1164
groups	O	1165-1171
,	O	1171-1172
in	O	1173-1175
the	O	1176-1179
epileptic	B	1180-1189
group	O	1190-1195
,	O	1195-1196
the	O	1197-1200
decrease	O	1201-1209
in	O	1210-1212
VE	O	1213-1215
was	O	1216-1219
due	O	1220-1223
to	O	1224-1226
a	O	1227-1228
significant	O	1229-1240
(	O	1241-1242
p	O	1242-1243
<	O	1244-1245
0	O	1246-1247
.	O	1247-1248
05	O	1248-1250
)	O	1250-1251
increase	O	1252-1260
in	O	1261-1263
TE	O	1264-1266
peak	O	1267-1271
in	O	1272-1274
relation	O	1275-1283
to	O	1284-1286
that	O	1287-1291
of	O	1292-1294
the	O	1295-1298
control	O	1299-1306
animals	O	1307-1314
.	O	1314-1315

The	O	1316-1319
hypoventilation	O	1320-1335
maneuver	O	1336-1344
led	O	1345-1348
to	O	1349-1351
an	O	1352-1354
increase	O	1355-1363
in	O	1364-1366
the	O	1367-1370
arterial	O	1371-1379
Paco2	O	1380-1385
,	O	1385-1386
followed	O	1387-1395
by	O	1396-1398
an	O	1399-1401
increase	O	1402-1410
in	O	1411-1413
VE	O	1414-1416
.	O	1416-1417

In	O	1418-1420
the	O	1421-1424
epileptic	B	1425-1434
group	O	1435-1440
,	O	1440-1441
the	O	1442-1445
increase	O	1446-1454
in	O	1455-1457
VE	O	1458-1460
was	O	1461-1464
mediated	O	1465-1473
by	O	1474-1476
a	O	1477-1478
significant	O	1479-1490
(	O	1491-1492
p	O	1492-1493
<	O	1494-1495
0	O	1496-1497
.	O	1497-1498
05	O	1498-1500
)	O	1500-1501
decrease	O	1502-1510
in	O	1511-1513
TE	O	1514-1516
peak	O	1517-1521
compared	O	1522-1530
with	O	1531-1535
the	O	1536-1539
control	O	1540-1547
group	O	1548-1553
.	O	1553-1554

Systemic	O	1555-1563
application	O	1564-1575
of	O	1576-1578
KCN	O	1579-1582
,	O	1582-1583
to	O	1584-1586
evaluate	O	1587-1595
the	O	1596-1599
effects	O	1600-1607
of	O	1608-1610
peripheral	O	1611-1621
chemoreception	O	1622-1636
activation	O	1637-1647
on	O	1648-1650
ventilation	O	1651-1662
,	O	1662-1663
led	O	1664-1667
to	O	1668-1670
a	O	1671-1672
similar	O	1673-1680
increase	O	1681-1689
in	O	1690-1692
VE	O	1693-1695
for	O	1696-1699
both	O	1700-1704
groups	O	1705-1711
.	O	1711-1712

CONCLUSIONS	O	1713-1724
:	O	1724-1725
The	O	1726-1729
data	O	1730-1734
indicate	O	1735-1743
that	O	1744-1748
pilocarpine	O	1749-1760
-	O	1760-1761
treated	O	1761-1768
animals	O	1769-1776
have	O	1777-1781
an	O	1782-1784
altered	O	1785-1792
ability	O	1793-1800
to	O	1801-1803
react	O	1804-1809
to	O	1810-1812
(	O	1813-1814
or	O	1814-1816
compensate	O	1817-1827
for	O	1828-1831
)	O	1831-1832
blood	O	1833-1838
gas	O	1839-1842
changes	O	1843-1850
with	O	1851-1855
changes	O	1856-1863
in	O	1864-1866
ventilation	O	1867-1878
and	O	1879-1882
suggest	O	1883-1890
that	O	1891-1895
it	O	1896-1898
is	O	1899-1901
centrally	O	1902-1911
determined	O	1912-1922
.	O	1922-1923

We	O	1924-1926
speculate	O	1927-1936
on	O	1937-1939
the	O	1940-1943
possible	O	1944-1952
relation	O	1953-1961
of	O	1962-1964
the	O	1965-1968
current	O	1969-1976
findings	O	1977-1985
on	O	1986-1988
treating	O	1989-1997
different	O	1998-2007
epilepsy	B	2008-2016
-	O	2016-2017
associated	O	2017-2027
conditions	O	2028-2038
.	O	2038-2039

Increased	O	0-9
serum	O	10-15
soluble	O	16-23
Fas	O	24-27
in	O	28-30
patients	O	31-39
with	O	40-44
acute	B	45-50
liver	I	51-56
failure	I	57-64
due	O	65-68
to	O	69-71
paracetamol	O	72-83
overdose	B	84-92
.	O	92-93

BACKGROUND	O	94-104
/	O	104-105
AIMS	O	105-109
:	O	109-110
Experimental	O	111-123
studies	O	124-131
have	O	132-136
suggested	O	137-146
that	O	147-151
apoptosis	O	152-161
via	O	162-165
the	O	166-169
Fas	O	170-173
/	O	173-174
Fas	O	170-173
Ligand	O	178-184
signaling	O	185-194
system	O	195-201
may	O	202-205
play	O	206-210
an	O	211-213
important	O	214-223
role	O	224-228
in	O	229-231
the	O	232-235
development	O	236-247
of	O	248-250
acute	B	251-256
liver	I	257-262
failure	I	263-270
.	O	270-271

The	O	272-275
aim	O	276-279
of	O	280-282
the	O	283-286
study	O	287-292
was	O	293-296
to	O	297-299
investigate	O	300-311
the	O	312-315
soluble	O	316-323
form	O	324-328
of	O	329-331
Fas	O	332-335
in	O	336-338
patients	O	339-347
with	O	348-352
acute	B	353-358
liver	I	359-364
failure	I	365-372
.	O	372-373

METHODOLOGY	O	374-385
:	O	385-386
Serum	O	387-392
levels	O	393-399
of	O	400-402
sFas	O	403-407
(	O	408-409
soluble	O	409-416
Fas	O	417-420
)	O	420-421
were	O	422-426
measured	O	427-435
by	O	436-438
ELISA	O	439-444
in	O	445-447
24	O	448-450
patients	O	451-459
with	O	460-464
acute	B	465-470
liver	I	471-476
failure	I	477-484
and	O	485-488
10	O	489-491
normal	O	492-498
control	O	499-506
subjects	O	507-515
.	O	515-516

Serum	O	517-522
levels	O	523-529
of	O	530-532
tumor	B	533-538
necrosis	B	539-547
factor	O	548-554
-	O	554-555
alpha	O	555-560
and	O	561-564
interferon	O	565-575
-	O	575-576
gamma	O	576-581
were	O	582-586
also	O	587-591
determined	O	592-602
by	O	603-605
ELISA	O	606-611
.	O	611-612

RESULTS	O	613-620
:	O	620-621
Serum	O	622-627
sFas	O	628-632
was	O	633-636
significantly	O	637-650
increased	O	651-660
in	O	661-663
patients	O	664-672
with	O	673-677
acute	B	678-683
liver	I	684-689
failure	I	690-697
(	O	698-699
median	O	699-705
,	O	705-706
26	O	707-709
.	O	709-710
8	O	710-711
U	O	712-713
/	O	713-714
mL	O	714-716
;	O	716-717
range	O	718-723
,	O	723-724
6	O	725-726
.	O	726-727
9	O	727-728
-	O	728-729
52	O	729-731
.	O	726-727
7	O	732-733
U	O	734-735
/	O	735-736
mL	O	736-738
)	O	738-739
compared	O	740-748
to	O	749-751
the	O	752-755
normal	O	756-762
controls	O	763-771
(	O	772-773
median	O	773-779
,	O	779-780
8	O	781-782
.	O	782-783
6	O	783-784
U	O	785-786
/	O	786-787
mL	O	787-789
;	O	789-790
range	O	791-796
,	O	796-797
6	O	798-799
.	O	799-800
5	O	800-801
-	O	801-802
12	O	802-804
.	O	799-800
0	O	805-806

U	O	807-808
/	O	808-809
mL	O	809-811
,	O	811-812
P	O	813-814
<	O	815-816
0	O	817-818
.	O	818-819
0001	O	819-823
)	O	823-824
.	O	818-819

Levels	O	826-832
were	O	833-837
significantly	O	838-851
greater	O	852-859
in	O	860-862
patients	O	863-871
with	O	872-876
acute	B	877-882
liver	I	883-888
failure	I	889-896
due	O	897-900
to	O	901-903
paracetamol	O	904-915
overdose	B	916-924
(	O	925-926
median	O	926-932
,	O	932-933
28	O	934-936
.	O	936-937
7	O	937-938
U	O	939-940
/	O	940-941
mL	O	941-943
;	O	943-944
range	O	945-950
,	O	950-951
12	O	952-954
.	O	954-955
8	O	955-956
-	O	956-957
52	O	957-959
.	O	954-955
7	O	960-961

U	O	962-963
/	O	963-964
mL	O	964-966
,	O	966-967
n	O	968-969
=	O	970-971
17	O	972-974
)	O	974-975
than	O	976-980
those	O	981-986
due	O	987-990
to	O	991-993
non	O	994-997
-	O	997-998
A	O	998-999
to	O	1000-1002
E	O	1003-1004
hepatitis	B	1005-1014
(	O	1015-1016
median	O	1016-1022
,	O	1022-1023
12	O	1024-1026
.	O	1026-1027
5	O	1027-1028
U	O	1029-1030
/	O	1030-1031
mL	O	1031-1033
;	O	1033-1034
range	O	1035-1040
,	O	1040-1041
6	O	1042-1043
.	O	1043-1044
9	O	1044-1045
-	O	1045-1046
46	O	1046-1048
.	O	1043-1044
0	O	1049-1050

U	O	1051-1052
/	O	1052-1053
mL	O	1053-1055
,	O	1055-1056
n	O	1057-1058
=	O	1059-1060
7	O	1061-1062
,	O	1062-1063
P	O	1064-1065
<	O	1066-1067
0	O	1068-1069
.	O	1069-1070
01	O	1070-1072
)	O	1072-1073
.	O	1069-1070

There	O	1075-1080
was	O	1081-1084
no	O	1085-1087
relationship	O	1088-1100
of	O	1101-1103
sFas	O	1104-1108
to	O	1109-1111
eventual	O	1112-1120
outcome	O	1121-1128
in	O	1129-1131
the	O	1132-1135
patients	O	1136-1144
.	O	1144-1145

A	O	1146-1147
significant	O	1148-1159
correlation	O	1160-1171
was	O	1172-1175
observed	O	1176-1184
between	O	1185-1192
serum	O	1193-1198
sFas	O	1199-1203
levels	O	1204-1210
and	O	1211-1214
aspartate	O	1215-1224
aminotransferase	O	1225-1241
(	O	1242-1243
r	O	1243-1244
=	O	1245-1246
0	O	1247-1248
.	O	1248-1249
613	O	1249-1252
,	O	1252-1253
P	O	1254-1255
<	O	1256-1257
0	O	1258-1259
.	O	1259-1260
01	O	1260-1262
)	O	1262-1263
.	O	1259-1260

CONCLUSIONS	O	1265-1276
:	O	1276-1277
The	O	1278-1281
increased	O	1282-1291
concentration	O	1292-1305
of	O	1306-1308
sFas	O	1309-1313
in	O	1314-1316
serum	O	1317-1322
of	O	1323-1325
patients	O	1326-1334
with	O	1335-1339
acute	B	1340-1345
liver	I	1346-1351
failure	I	1352-1359
may	O	1360-1363
reflect	O	1364-1371
activation	O	1372-1382
of	O	1383-1385
Fas	O	1386-1389
-	O	1389-1390
mediated	O	1390-1398
apoptosis	O	1399-1408
in	O	1409-1411
the	O	1412-1415
liver	O	1416-1421
and	O	1422-1425
this	O	1426-1430
together	O	1431-1439
with	O	1440-1444
increased	O	1445-1454
tumor	B	1455-1460
necrosis	B	1461-1469
factor	O	1470-1476
-	O	1476-1477
alpha	O	1477-1482
may	O	1483-1486
be	O	1487-1489
an	O	1490-1492
important	O	1493-1502
factor	O	1503-1509
in	O	1510-1512
liver	O	1513-1518
cell	O	1519-1523
loss	O	1524-1528
.	O	1528-1529

Bilateral	O	0-9
subthalamic	O	10-21
nucleus	O	22-29
stimulation	O	30-41
for	O	42-45
Parkinson	B	46-55
'	I	55-56
s	I	52-53
disease	I	58-65
.	O	65-66

High	O	67-71
frequency	O	72-81
stimulation	O	82-93
of	O	94-96
the	O	97-100
subthalamic	O	101-112
nucleus	O	113-120
(	O	121-122
STN	O	122-125
)	O	125-126
is	O	127-129
known	O	130-135
to	O	136-138
ameliorate	O	139-149
the	O	150-153
signs	O	154-159
and	O	160-163
symptoms	O	164-172
of	O	173-175
advanced	O	176-184
Parkinson	B	185-194
'	I	194-195
s	I	191-192
disease	I	197-204
.	O	204-205

AIM	O	206-209
:	O	209-210
We	O	211-213
studied	O	214-221
the	O	222-225
effect	O	226-232
of	O	233-235
high	O	236-240
frequency	O	241-250
STN	O	251-254
stimulation	O	255-266
in	O	267-269
23	O	270-272
patients	O	273-281
.	O	281-282

METHOD	O	283-289
:	O	289-290
Twenty	O	291-297
-	O	297-298
three	O	298-303
patients	O	304-312
suffering	O	313-322
from	O	323-327
severe	O	328-334
Parkinson	B	335-344
'	I	344-345
s	I	341-342
disease	I	347-354
(	O	355-356
Stages	O	356-362
III	O	363-366
-	O	366-367
V	O	367-368
on	O	369-371
Hoehn	O	372-377
and	O	378-381
Yahr	O	382-386
scale	O	387-392
)	O	392-393
and	O	394-397
,	O	397-398
particularly	O	399-411
bradykinesia	B	412-424
,	O	424-425
rigidity	B	426-434
,	O	434-435
and	O	436-439
levodopa	O	440-448
-	O	448-449
induced	O	449-456
dyskinesias	B	457-468
underwent	O	469-478
bilateral	O	479-488
implantation	O	489-501
of	O	502-504
electrodes	O	505-515
in	O	516-518
the	O	519-522
STN	O	523-526
.	O	526-527

Preoperative	O	528-540
and	O	541-544
postoperative	O	545-558
assessments	O	559-570
of	O	571-573
these	O	574-579
patients	O	580-588
at	O	589-591
1	O	592-593
,	O	593-594
3	O	595-596
,	O	596-597
6	O	598-599
and	O	600-603
12	O	604-606
months	O	607-613
follow	O	614-620
-	O	620-621
up	O	621-623
,	O	623-624
in	O	625-627
"	O	628-629
on	O	629-631
"	O	628-629
and	O	633-636
"	O	637-638
off	O	638-641
"	O	637-638
drug	O	643-647
conditions	O	648-658
,	O	658-659
was	O	660-663
carried	O	664-671
out	O	672-675
using	O	676-681
Unified	O	682-689
Parkinson	B	690-699
'	I	699-700
s	I	696-697
Disease	I	702-709
Rating	O	710-716
Scale	O	717-722
,	O	722-723
Hoehn	O	724-729
and	O	730-733
Yahr	O	734-738
staging	O	739-746
,	O	746-747
England	O	748-755
activities	O	756-766
of	O	767-769
daily	O	770-775
living	O	776-782
score	O	783-788
and	O	789-792
video	O	793-798
recordings	O	799-809
.	O	809-810

RESULTS	O	811-818
:	O	818-819
After	O	820-825
one	O	826-829
year	O	830-834
of	O	835-837
electrical	O	838-848
stimulation	O	849-860
of	O	861-863
the	O	864-867
STN	O	868-871
,	O	871-872
the	O	873-876
patients	O	877-885
'	O	885-886
scores	O	887-893
for	O	894-897
activities	O	898-908
of	O	909-911
daily	O	912-917
living	O	918-924
and	O	925-928
motor	O	929-934
examination	O	935-946
scores	O	947-953
(	O	954-955
Unified	O	955-962
Parkinson	B	963-972
'	I	972-973
s	I	969-970
Disease	I	975-982
Rating	O	983-989
Scale	O	990-995
parts	O	996-1001
II	O	1002-1004
and	O	1005-1008
III	O	1009-1012
)	O	1012-1013
off	O	1014-1017
medication	O	1018-1028
improved	O	1029-1037
by	O	1038-1040
62	O	1041-1043
%	O	1043-1044
and	O	1045-1048
61	O	1049-1051
%	O	1051-1052
respectively	O	1053-1065
(	O	1066-1067
p	O	1067-1068
<	O	1068-1069
0	O	1069-1070
.	O	1070-1071
0005	O	1071-1075
)	O	1075-1076
.	O	1070-1071

The	O	1078-1081
subscores	O	1082-1091
for	O	1092-1095
the	O	1096-1099
akinesia	B	1100-1108
,	O	1108-1109
rigidity	B	1110-1118
,	O	1118-1119
tremor	B	1120-1126
and	O	1127-1130
gait	O	1131-1135
also	O	1136-1140
improved	O	1141-1149
.	O	1149-1150

(	O	1151-1152
p	O	1152-1153
<	O	1153-1154
0	O	1154-1155
.	O	1155-1156
0005	O	1156-1160
)	O	1160-1161
.	O	1155-1156

The	O	1163-1166
average	O	1167-1174
levodopa	O	1175-1183
dose	O	1184-1188
decreased	O	1189-1198
from	O	1199-1203
813	O	1204-1207
mg	O	1208-1210
to	O	1211-1213
359	O	1214-1217
mg	O	1218-1220
.	O	1220-1221

The	O	1222-1225
cognitive	O	1226-1235
functions	O	1236-1245
remained	O	1246-1254
unchanged	O	1255-1264
.	O	1264-1265

Two	O	1266-1269
patients	O	1270-1278
developed	O	1279-1288
device	O	1289-1295
-	O	1295-1296
related	O	1296-1303
complications	O	1304-1317
and	O	1318-1321
two	O	1322-1325
patients	O	1326-1334
experienced	O	1335-1346
abnormal	O	1347-1355
weight	O	1356-1362
gain	O	1363-1367
.	O	1367-1368

CONCLUSION	O	1369-1379
:	O	1379-1380
Bilateral	O	1381-1390
subthalamic	O	1391-1402
nucleus	O	1403-1410
stimulation	O	1411-1422
is	O	1423-1425
an	O	1426-1428
effective	O	1429-1438
treatment	O	1439-1448
for	O	1449-1452
advanced	O	1453-1461
Parkinson	B	1462-1471
'	I	1471-1472
s	I	1468-1469
disease	I	1474-1481
.	O	1481-1482

It	O	1483-1485
reduces	O	1486-1493
the	O	1494-1497
severity	O	1498-1506
of	O	1507-1509
"	O	1510-1511
off	O	1511-1514
"	O	1510-1511
phase	O	1516-1521
symptoms	O	1522-1530
,	O	1530-1531
improves	O	1532-1540
the	O	1541-1544
axial	O	1545-1550
symptoms	O	1551-1559
and	O	1560-1563
reduces	O	1564-1571
levodopa	O	1572-1580
requirements	O	1581-1593
.	O	1593-1594

The	O	1595-1598
reduction	O	1599-1608
in	O	1609-1611
the	O	1612-1615
levodopa	O	1616-1624
dose	O	1625-1629
is	O	1630-1632
useful	O	1633-1639
in	O	1640-1642
controlling	O	1643-1654
drug	B	1655-1659
-	I	1659-1660
induced	I	1660-1667
dyskinesias	I	1668-1679
.	O	1679-1680

Ocular	O	0-6
motility	O	7-15
changes	O	16-23
after	O	24-29
subtenon	O	30-38
carboplatin	O	39-50
chemotherapy	O	51-63
for	O	64-67
retinoblastoma	B	68-82
.	O	82-83

BACKGROUND	O	84-94
:	O	94-95
Focal	O	96-101
subtenon	O	102-110
carboplatin	O	111-122
injections	O	123-133
have	O	134-138
recently	O	139-147
been	O	148-152
used	O	153-157
as	O	158-160
a	O	161-162
presumably	O	163-173
toxicity	B	174-182
-	O	182-183
free	O	183-187
adjunct	O	188-195
to	O	196-198
systemic	O	199-207
chemotherapy	O	208-220
for	O	221-224
intraocular	O	225-236
retinoblastoma	B	237-251
.	O	251-252

OBJECTIVE	O	253-262
:	O	262-263
To	O	264-266
report	O	267-273
our	O	274-277
clinical	O	278-286
experience	O	287-297
with	O	298-302
abnormal	B	303-311
ocular	I	312-318
motility	I	319-327
in	O	328-330
patients	O	331-339
treated	O	340-347
with	O	348-352
subtenon	O	353-361
carboplatin	O	362-373
chemotherapy	O	374-386
.	O	386-387

METHODS	O	388-395
:	O	395-396
We	O	397-399
noted	O	400-405
abnormal	B	406-414
ocular	I	415-421
motility	I	422-430
in	O	431-433
10	O	434-436
consecutive	O	437-448
patients	O	449-457
with	O	458-462
retinoblastoma	B	463-477
who	O	478-481
had	O	482-485
received	O	486-494
subtenon	O	495-503
carboplatin	O	504-515
.	O	515-516

During	O	517-523
ocular	O	524-530
manipulation	O	531-543
under	O	544-549
general	O	550-557
anesthesia	O	558-568
,	O	568-569
we	O	570-572
assessed	O	573-581
their	O	582-587
eyes	O	588-592
by	O	593-595
forced	O	596-602
duction	O	603-610
testing	O	611-618
,	O	618-619
comparing	O	620-629
ocular	O	630-636
motility	O	637-645
after	O	646-651
tumor	B	652-657
control	O	658-665
with	O	666-670
ocular	O	671-677
motility	O	678-686
at	O	687-689
diagnosis	O	690-699
.	O	699-700

Eyes	O	701-705
subsequently	O	706-718
enucleated	O	719-729
because	O	730-737
of	O	738-740
treatment	O	741-750
failure	O	751-758
(	O	759-760
n	O	760-761
=	O	762-763
4	O	764-765
)	O	765-766
were	O	767-771
examined	O	772-780
histologically	O	781-795
.	O	795-796

RESULTS	O	797-804
:	O	804-805
Limitation	O	806-816
of	O	817-819
ocular	O	820-826
motility	O	827-835
was	O	836-839
detected	O	840-848
in	O	849-851
all	O	852-855
12	O	856-858
eyes	O	859-863
of	O	864-866
10	O	867-869
patients	O	870-878
treated	O	879-886
for	O	887-890
intraocular	O	891-902
retinoblastoma	B	903-917
with	O	918-922
1	O	923-924
to	O	925-927
6	O	928-929
injections	O	930-940
of	O	941-943
subtenon	O	944-952
carboplatin	O	953-964
as	O	965-967
part	O	968-972
of	O	973-975
multimodality	O	976-989
therapy	O	990-997
.	O	997-998

Histopathological	O	999-1016
examination	O	1017-1028
revealed	O	1029-1037
many	O	1038-1042
lipophages	O	1043-1053
in	O	1054-1056
the	O	1057-1060
periorbital	O	1061-1072
fat	O	1073-1076
surrounding	O	1077-1088
the	O	1089-1092
optic	O	1093-1098
nerve	O	1099-1104
in	O	1105-1107
1	O	1108-1109
eye	O	1110-1113
,	O	1113-1114
indicative	O	1115-1125
of	O	1126-1128
phagocytosis	O	1129-1141
of	O	1142-1144
previously	O	1145-1155
existing	O	1156-1164
fat	O	1165-1168
cells	O	1169-1174
and	O	1175-1178
suggesting	O	1179-1189
prior	O	1190-1195
fat	O	1196-1199
necrosis	B	1200-1208
.	O	1208-1209

The	O	1210-1213
enucleations	O	1214-1226
were	O	1227-1231
technically	O	1232-1243
difficult	O	1244-1253
and	O	1254-1257
hazardous	O	1258-1267
for	O	1268-1271
globe	O	1272-1277
rupture	B	1278-1285
because	O	1286-1293
of	O	1294-1296
extensive	O	1297-1306
orbital	O	1307-1314
soft	O	1315-1319
tissue	O	1320-1326
adhesions	O	1327-1336
.	O	1336-1337

CONCLUSIONS	O	1338-1349
:	O	1349-1350
Subtenon	O	1351-1359
carboplatin	O	1360-1371
chemotherapy	O	1372-1384
is	O	1385-1387
associated	O	1388-1398
with	O	1399-1403
significant	O	1404-1415
fibrosis	B	1416-1424
of	O	1425-1427
orbital	O	1428-1435
soft	O	1436-1440
tissues	O	1441-1448
,	O	1448-1449
leading	O	1450-1457
to	O	1458-1460
mechanical	O	1461-1471
restriction	O	1472-1483
of	O	1484-1486
eye	O	1487-1490
movements	O	1491-1500
and	O	1501-1504
making	O	1505-1511
subsequent	O	1512-1522
enucleation	O	1523-1534
difficult	O	1535-1544
.	O	1544-1545

Subtenon	O	1546-1554
carboplatin	O	1555-1566
is	O	1567-1569
not	O	1570-1573
free	O	1574-1578
of	O	1579-1581
toxicity	B	1582-1590
,	O	1590-1591
and	O	1592-1595
its	O	1596-1599
use	O	1600-1603
is	O	1604-1606
best	O	1607-1611
restricted	O	1612-1622
to	O	1623-1625
specific	O	1626-1634
indications	O	1635-1646
.	O	1646-1647

Ethambutol	O	0-10
and	O	11-14
optic	B	15-20
neuropathy	I	21-31
.	O	31-32

PURPOSE	O	33-40
:	O	40-41
To	O	42-44
demonstrate	O	45-56
the	O	57-60
association	O	61-72
between	O	73-80
ethambutol	O	81-91
and	O	92-95
optic	B	96-101
neuropathy	I	102-112
.	O	112-113

METHOD	O	114-120
:	O	120-121
Thirteen	O	122-130
patients	O	131-139
who	O	140-143
developed	O	144-153
optic	B	154-159
neuropathy	I	160-170
after	O	171-176
being	O	177-182
treated	O	183-190
with	O	191-195
ethambutol	O	196-206
for	O	207-210
tuberculosis	B	211-223
of	I	224-226
the	I	227-230
lung	I	231-235
or	I	236-238
lymph	I	239-244
node	I	245-249
at	O	250-252
Siriraj	O	253-260
Hospital	O	261-269
between	O	270-277
1997	O	278-282
and	O	283-286
2001	O	287-291
were	O	292-296
retrospectively	O	297-312
reviewed	O	313-321
.	O	321-322

The	O	323-326
clinical	O	327-335
characteristics	O	336-351
and	O	352-355
initial	O	356-363
and	O	364-367
final	O	368-373
visual	O	374-380
acuity	O	381-387
were	O	388-392
analyzed	O	393-401
to	O	402-404
determine	O	405-414
visual	O	415-421
outcome	O	422-429
.	O	429-430

RESULTS	O	431-438
:	O	438-439
All	O	440-443
patients	O	444-452
had	O	453-456
optic	B	457-462
neuropathy	I	463-473
between	O	474-481
1	O	482-483
to	O	484-486
6	O	487-488
months	O	489-495
(	O	496-497
mean	O	497-501
=	O	502-503
2	O	504-505
.	O	505-506
9	O	506-507
months	O	508-514
)	O	514-515
after	O	516-521
starting	O	522-530
ethambutol	O	531-541
therapy	O	542-549
at	O	550-552
a	O	553-554
dosage	O	555-561
ranging	O	562-569
from	O	570-574
13	O	575-577
to	O	578-580
20	O	581-583
mg	O	584-586
/	O	586-587
kg	O	587-589
/	O	586-587
day	O	590-593
(	O	594-595
mean	O	595-599
=	O	600-601
17	O	602-604
mg	O	605-607
/	O	607-608
kg	O	608-610
/	O	607-608
day	O	611-614
)	O	614-615
.	O	615-616

Seven	O	617-622
(	O	623-624
54	O	624-626
%	O	626-627
)	O	627-628
of	O	629-631
the	O	632-635
13	O	636-638
patients	O	639-647
experienced	O	648-659
visual	O	660-666
recovery	O	667-675
after	O	676-681
stopping	O	682-690
the	O	691-694
drug	O	695-699
.	O	699-700

Of	O	701-703
6	O	704-705
patients	O	706-714
with	O	715-719
irreversible	O	720-732
visual	B	733-739
impairment	I	740-750
,	O	750-751
4	O	752-753
patients	O	754-762
had	O	763-766
diabetes	B	767-775
mellitus	I	776-784
,	O	784-785
glaucoma	B	786-794
and	O	795-798
a	O	799-800
history	O	801-808
of	O	809-811
heavy	O	812-817
smoking	O	818-825
.	O	825-826

CONCLUSION	O	827-837
:	O	837-838
Early	O	839-844
recognition	O	845-856
of	O	857-859
optic	B	860-865
neuropathy	I	866-876
should	O	877-883
be	O	884-886
considered	O	887-897
in	O	898-900
patients	O	901-909
with	O	910-914
ethambutol	O	915-925
therapy	O	926-933
.	O	933-934

A	O	935-936
low	O	937-940
dose	O	941-945
and	O	946-949
prompt	O	950-956
discontinuation	O	957-972
of	O	973-975
the	O	976-979
drug	O	980-984
is	O	985-987
recommended	O	988-999
particularly	O	1000-1012
in	O	1013-1015
individuals	O	1016-1027
with	O	1028-1032
diabetes	B	1033-1041
mellitus	I	1042-1050
,	O	1050-1051
glaucoma	B	1052-1060
or	O	1061-1063
who	O	1064-1067
are	O	1068-1071
heavy	O	1072-1077
smokers	O	1078-1085
.	O	1085-1086

Treatment	O	0-9
of	O	10-12
compensatory	O	13-25
gustatory	B	26-35
hyperhidrosis	I	36-49
with	O	50-54
topical	O	55-62
glycopyrrolate	O	63-77
.	O	77-78

Gustatory	B	79-88
hyperhidrosis	I	89-102
is	O	103-105
facial	O	106-112
sweating	B	113-121
usually	O	122-129
associated	O	130-140
with	O	141-145
the	O	146-149
eating	O	150-156
of	O	157-159
hot	O	160-163
spicy	O	164-169
food	O	170-174
or	O	175-177
even	O	178-182
smelling	O	183-191
this	O	192-196
food	O	197-201
.	O	201-202

Current	O	203-210
options	O	211-218
of	O	219-221
treatment	O	222-231
include	O	232-239
oral	O	240-244
anticholinergic	O	245-260
drugs	O	261-266
,	O	266-267
the	O	268-271
topical	O	272-279
application	O	280-291
of	O	292-294
anticholinergics	O	295-311
or	O	312-314
aluminum	O	315-323
chloride	O	324-332
,	O	332-333
and	O	334-337
the	O	338-341
injection	O	342-351
of	O	352-354
botulinum	O	355-364
toxin	O	365-370
.	O	370-371

Thirteen	O	372-380
patients	O	381-389
have	O	390-394
been	O	395-399
treated	O	400-407
to	O	408-410
date	O	411-415
with	O	416-420
1	O	421-422
.	O	422-423
5	O	423-424
%	O	424-425
or	O	426-428
2	O	429-430
%	O	430-431
topical	O	432-439
glycopyrrolate	O	440-454
.	O	454-455

All	O	456-459
patients	O	460-468
had	O	469-472
gustatory	B	473-482
hyperhidrosis	I	483-496
,	O	496-497
which	O	498-503
interfered	O	504-514
with	O	515-519
their	O	520-525
social	O	526-532
activities	O	533-543
,	O	543-544
after	O	545-550
transthroacic	O	551-564
endoscopic	O	565-575
sympathectomy	O	576-589
,	O	589-590
and	O	591-594
which	O	595-600
was	O	601-604
associated	O	605-615
with	O	616-620
compensatory	O	621-633
focal	O	634-639
hyperhidrosis	B	640-653
.	O	653-654

After	O	655-660
applying	O	661-669
topical	O	670-677
glycopyrrolate	O	678-692
,	O	692-693
the	O	694-697
subjective	O	698-708
effect	O	709-715
was	O	716-719
excellent	O	720-729
(	O	730-731
no	O	731-733
sweating	B	734-742
after	O	743-748
eating	O	749-755
hot	O	756-759
spicy	O	760-765
food	O	766-770
)	O	770-771
in	O	772-774
10	O	775-777
patients	O	778-786
(	O	787-788
77	O	788-790
%	O	790-791
)	O	791-792
,	O	792-793
and	O	794-797
fair	O	798-802
(	O	803-804
clearly	O	804-811
reduced	O	812-819
sweating	B	820-828
)	O	828-829
in	O	830-832
3	O	833-834
patients	O	835-843
(	O	844-845
23	O	845-847
%	O	847-848
)	O	848-849
.	O	849-850

All	O	851-854
had	O	855-858
reported	O	859-867
incidents	O	868-877
of	O	878-880
being	O	881-886
very	O	887-891
embarrassed	O	892-903
whilst	O	904-910
eating	O	911-917
hot	O	918-921
spicy	O	922-927
foods	O	928-933
.	O	933-934

Adverse	O	935-942
effects	O	943-950
included	O	951-959
a	O	960-961
mildly	O	962-968
dry	B	969-972
mouth	I	973-978
and	O	979-982
a	O	983-984
sore	B	985-989
throat	I	990-996
in	O	997-999
2	O	1000-1001
patients	O	1002-1010
(	O	1011-1012
2	O	1012-1013
%	O	1013-1014
glycopyrrolate	O	1015-1029
)	O	1029-1030
,	O	1030-1031
a	O	1032-1033
light	O	1034-1039
headache	B	1040-1048
in	O	1049-1051
1	O	1052-1053
patient	O	1054-1061
(	O	1062-1063
1	O	1063-1064
.	O	1064-1065
5	O	1065-1066
%	O	1066-1067
glycopyrrolate	O	1068-1082
)	O	1082-1083
.	O	1083-1084

The	O	1085-1088
topical	O	1089-1096
application	O	1097-1108
of	O	1109-1111
a	O	1112-1113
glycopyrrolate	O	1114-1128
pad	O	1129-1132
appeared	O	1133-1141
to	O	1142-1144
be	O	1145-1147
safe	O	1148-1152
,	O	1152-1153
efficacious	O	1154-1165
,	O	1165-1166
well	O	1167-1171
tolerated	O	1172-1181
,	O	1181-1182
and	O	1183-1186
a	O	1187-1188
convenient	O	1189-1199
method	O	1200-1206
of	O	1207-1209
treatment	O	1210-1219
for	O	1220-1223
moderate	O	1224-1232
to	O	1233-1235
severe	O	1236-1242
symptoms	O	1243-1251
of	O	1252-1254
gustatory	B	1255-1264
hyperhidrosis	I	1265-1278
in	O	1279-1281
post	O	1282-1286
transthoracic	O	1287-1300
endoscopic	O	1301-1311
sympathectomy	O	1312-1325
or	O	1326-1328
sympathicotomy	O	1329-1343
patients	O	1344-1352
,	O	1352-1353
with	O	1354-1358
few	O	1359-1362
side	O	1363-1367
effects	O	1368-1375
.	O	1375-1376

Pharmacological	O	0-15
characteristics	O	16-31
and	O	32-35
side	O	36-40
effects	O	41-48
of	O	49-51
a	O	52-53
new	O	54-57
galenic	O	58-65
formulation	O	66-77
of	O	78-80
propofol	O	81-89
without	O	90-97
soyabean	O	98-106
oil	O	107-110
.	O	110-111

We	O	112-114
compared	O	115-123
the	O	124-127
pharmacokinetics	O	128-144
,	O	144-145
pharmacodynamics	O	146-162
and	O	163-166
safety	O	167-173
profile	O	174-181
of	O	182-184
a	O	185-186
new	O	187-190
galenic	O	191-198
formulation	O	199-210
of	O	211-213
propofol	O	214-222
(	O	223-224
AM149	O	224-229
1	O	230-231
%	O	231-232
)	O	232-233
,	O	233-234
which	O	235-240
does	O	241-245
not	O	246-249
contain	O	250-257
soyabean	O	258-266
oil	O	267-270
,	O	270-271
with	O	272-276
a	O	277-278
standard	O	279-287
formulation	O	288-299
of	O	300-302
propofol	O	303-311
(	O	312-313
Disoprivan	O	313-323
1	O	324-325
%	O	325-326
)	O	326-327
.	O	327-328

In	O	329-331
a	O	332-333
randomised	O	334-344
,	O	344-345
double	O	346-352
-	O	352-353
blind	O	353-358
,	O	358-359
cross	O	360-365
-	O	365-366
over	O	366-370
study	O	371-376
,	O	376-377
30	O	378-380
healthy	O	381-388
volunteers	O	389-399
received	O	400-408
a	O	409-410
single	O	411-417
intravenous	O	418-429
bolus	O	430-435
injection	O	436-445
of	O	446-448
2	O	449-450
.	O	450-451
5	O	451-452
mg	O	453-455
.	O	455-456
kg	O	456-458
-	O	458-459
1	O	459-460
propofol	O	461-469
.	O	469-470

Plasma	O	471-477
propofol	O	478-486
levels	O	487-493
were	O	494-498
measured	O	499-507
for	O	508-511
48	O	512-514
h	O	515-516
following	O	517-526
drug	O	527-531
administration	O	532-546
and	O	547-550
evaluated	O	551-560
according	O	561-570
to	O	571-573
a	O	574-575
three	O	576-581
-	O	581-582
compartment	O	582-593
model	O	594-599
.	O	599-600

The	O	601-604
pharmacodynamic	O	605-620
parameters	O	621-631
assessed	O	632-640
included	O	641-649
induction	O	650-659
and	O	660-663
emergence	O	664-673
times	O	674-679
,	O	679-680
respiratory	O	681-692
and	O	693-696
cardiovascular	O	697-711
effects	O	712-719
,	O	719-720
and	O	721-724
pain	B	725-729
on	O	730-732
injection	O	733-742
.	O	742-743

Patients	O	744-752
were	O	753-757
monitored	O	758-767
for	O	768-771
side	O	772-776
effects	O	777-784
over	O	785-789
48	O	790-792
h	O	793-794
.	O	794-795

Owing	O	796-801
to	O	802-804
a	O	805-806
high	O	807-811
incidence	O	812-821
of	O	822-824
thrombophlebitis	B	825-841
,	O	841-842
the	O	843-846
study	O	847-852
was	O	853-856
terminated	O	857-867
prematurely	O	868-879
and	O	880-883
only	O	884-888
the	O	889-892
data	O	893-897
of	O	898-900
the	O	901-904
two	O	905-908
parallel	O	909-917
treatment	O	918-927
groups	O	928-934
(	O	935-936
15	O	936-938
patients	O	939-947
in	O	948-950
each	O	951-955
group	O	956-961
)	O	961-962
were	O	963-967
analysed	O	968-976
.	O	976-977

Plasma	O	978-984
concentrations	O	985-999
did	O	1000-1003
not	O	1004-1007
differ	O	1008-1014
significantly	O	1015-1028
between	O	1029-1036
the	O	1037-1040
two	O	1041-1044
formulations	O	1045-1057
.	O	1057-1058

Anaesthesia	O	1059-1070
induction	O	1071-1080
and	O	1081-1084
emergence	O	1085-1094
times	O	1095-1100
,	O	1100-1101
respiratory	O	1102-1113
and	O	1114-1117
cardiovascular	O	1118-1132
variables	O	1133-1142
showed	O	1143-1149
no	O	1150-1152
significant	O	1153-1164
differences	O	1165-1176
between	O	1177-1184
the	O	1185-1188
two	O	1189-1192
treatment	O	1193-1202
groups	O	1203-1209
.	O	1209-1210

Pain	B	1211-1215
on	O	1216-1218
injection	O	1219-1228
(	O	1229-1230
80	O	1230-1232
vs	O	1233-1235
.	O	1235-1236
20	O	1237-1239
%	O	1239-1240
,	O	1240-1241
p	O	1242-1243
<	O	1244-1245
0	O	1246-1247
.	O	1247-1248
01	O	1248-1250
)	O	1250-1251
and	O	1252-1255
thrombophlebitis	B	1256-1272
(	O	1273-1274
93	O	1274-1276
.	O	1276-1277
3	O	1275-1276
vs	O	1279-1281
.	O	1281-1282
6	O	1283-1284
.	O	1284-1285
6	O	1283-1284
%	O	1286-1287
,	O	1287-1288
p	O	1289-1290
<	O	1291-1292
0	O	1293-1294
.	O	1294-1295
001	O	1295-1298
)	O	1298-1299
occurred	O	1300-1308
more	O	1309-1313
frequently	O	1314-1324
with	O	1325-1329
AM149	O	1330-1335
than	O	1336-1340
with	O	1341-1345
Disoprivan	O	1346-1356
.	O	1356-1357

Although	O	1358-1366
both	O	1367-1371
formulations	O	1372-1384
had	O	1385-1388
similar	O	1389-1396
pharmacokinetic	O	1397-1412
and	O	1413-1416
pharmacodynamic	O	1417-1432
profiles	O	1433-1441
the	O	1442-1445
new	O	1446-1449
formulation	O	1450-1461
is	O	1462-1464
not	O	1465-1468
suitable	O	1469-1477
for	O	1478-1481
clinical	O	1482-1490
use	O	1491-1494
due	O	1495-1498
to	O	1499-1501
the	O	1502-1505
high	O	1506-1510
incidence	O	1511-1520
of	O	1521-1523
thrombophlebitis	B	1524-1540
produced	O	1541-1549
.	O	1549-1550

Vinorelbine	O	0-11
-	O	11-12
related	O	12-19
cardiac	O	20-27
events	O	28-34
:	O	34-35
a	O	36-37
meta	O	38-42
-	O	42-43
analysis	O	43-51
of	O	52-54
randomized	O	55-65
clinical	O	66-74
trials	O	75-81
.	O	81-82

Several	O	83-90
cases	O	91-96
of	O	97-99
cardiac	O	100-107
adverse	O	108-115
reactions	O	116-125
related	O	126-133
to	O	134-136
vinorelbine	O	137-148
(	O	149-150
VNR	O	150-153
)	O	153-154
have	O	155-159
been	O	160-164
reported	O	165-173
in	O	174-176
the	O	177-180
literature	O	181-191
.	O	191-192

In	O	193-195
order	O	196-201
to	O	202-204
quantify	O	205-213
the	O	214-217
incidence	O	218-227
of	O	228-230
these	O	231-236
cardiac	O	237-244
events	O	245-251
,	O	251-252
we	O	253-255
performed	O	256-265
a	O	266-267
meta	O	268-272
-	O	272-273
analysis	O	273-281
of	O	282-284
clinical	O	285-293
trials	O	294-300
comparing	O	301-310
VNR	O	311-314
with	O	315-319
other	O	320-325
chemotherapeutic	O	326-342
agents	O	343-349
in	O	350-352
the	O	353-356
treatment	O	357-366
of	O	367-369
various	O	370-377
malignancies	B	378-390
.	O	390-391

Randomized	O	392-402
clinical	O	403-411
trials	O	412-418
comparing	O	419-428
VNR	O	429-432
with	O	433-437
other	O	438-443
drugs	O	444-449
in	O	450-452
the	O	453-456
treatment	O	457-466
of	O	467-469
cancer	B	470-476
were	O	477-481
searched	O	482-490
in	O	491-493
Medline	O	494-501
,	O	501-502
Embase	O	503-509
,	O	509-510
Evidence	O	511-519
-	O	519-520
based	O	520-525
Medicine	O	526-534
Reviews	O	535-542
databases	O	543-552
and	O	553-556
the	O	557-560
Cochrane	O	561-569
library	O	570-577
from	O	578-582
1987	O	583-587
to	O	588-590
2002	O	591-595
.	O	595-596

Outcomes	O	597-605
of	O	606-608
interest	O	609-617
were	O	618-622
severe	O	623-629
cardiac	O	630-637
events	O	638-644
,	O	644-645
toxic	O	646-651
deaths	O	652-658
and	O	659-662
cardiac	O	663-670
event	O	671-676
-	O	676-677
related	O	677-684
deaths	O	685-691
reported	O	692-700
in	O	701-703
each	O	704-708
publication	O	709-720
.	O	720-721

We	O	722-724
found	O	725-730
19	O	731-733
trials	O	734-740
,	O	740-741
involving	O	742-751
2441	O	752-756
patients	O	757-765
treated	O	766-773
by	O	774-776
VNR	O	777-780
and	O	781-784
2050	O	785-789
control	O	790-797
patients	O	798-806
.	O	806-807

The	O	808-811
incidence	O	812-821
of	O	822-824
cardiac	O	825-832
events	O	833-839
with	O	840-844
VNR	O	845-848
was	O	849-852
1	O	853-854
.	O	854-855
19	O	855-857
%	O	857-858
[	O	859-860
95	O	860-862
%	O	862-863
confidence	O	864-874
interval	O	875-883
(	O	884-885
CI	O	885-887
)	O	887-888
(	O	889-890
0	O	890-891
.	O	891-892
75	O	892-894
;	O	894-895
1	O	896-897
.	O	897-898
67	O	898-900
)	O	900-901
]	O	901-902
.	O	897-898

There	O	904-909
was	O	910-913
no	O	914-916
difference	O	917-927
in	O	928-930
the	O	931-934
risk	O	935-939
of	O	940-942
cardiac	O	943-950
events	O	951-957
between	O	958-965
VNR	O	966-969
and	O	970-973
other	O	974-979
drugs	O	980-985
[	O	986-987
odds	O	987-991
ratio	O	992-997
:	O	997-998
0	O	999-1000
.	O	1000-1001
92	O	1001-1003
,	O	1003-1004
95	O	1005-1007
%	O	1007-1008
CI	O	1009-1011
(	O	1012-1013
0	O	1013-1014
.	O	1014-1015
54	O	1015-1017
;	O	1017-1018
1	O	1019-1020
.	O	1020-1021
55	O	1021-1023
)	O	1023-1024
]	O	1024-1025
.	O	1020-1021

The	O	1027-1030
risk	O	1031-1035
of	O	1036-1038
VNR	O	1039-1042
cardiac	O	1043-1050
events	O	1051-1057
was	O	1058-1061
similar	O	1062-1069
to	O	1070-1072
vindesine	O	1073-1082
(	O	1083-1084
VDS	O	1084-1087
)	O	1087-1088
and	O	1089-1092
other	O	1093-1098
cardiotoxic	B	1099-1110
drugs	O	1111-1116
[	O	1117-1118
fluorouracil	O	1118-1130
,	O	1130-1131
anthracyclines	O	1132-1146
,	O	1146-1147
gemcitabine	O	1148-1159
(	O	1160-1161
GEM	O	1161-1164
)	O	1164-1165
em	O	1166-1168
leader	O	1169-1175
]	O	1176-1177
.	O	1177-1178

Even	O	1179-1183
if	O	1184-1186
it	O	1187-1189
did	O	1190-1193
not	O	1194-1197
reach	O	1198-1203
statistical	O	1204-1215
significance	O	1216-1228
because	O	1229-1236
of	O	1237-1239
a	O	1240-1241
few	O	1242-1245
number	O	1246-1252
of	O	1253-1255
cases	O	1256-1261
,	O	1261-1262
the	O	1263-1266
risk	O	1267-1271
was	O	1272-1275
lower	O	1276-1281
in	O	1282-1284
trials	O	1285-1291
excluding	O	1292-1301
patients	O	1302-1310
with	O	1311-1315
cardiac	O	1316-1323
history	O	1324-1331
,	O	1331-1332
and	O	1333-1336
seemed	O	1337-1343
to	O	1344-1346
be	O	1347-1349
higher	O	1350-1356
in	O	1357-1359
trials	O	1360-1366
including	O	1367-1376
patients	O	1377-1385
with	O	1386-1390
pre	O	1391-1394
-	O	1394-1395
existing	O	1395-1403
cardiac	B	1404-1411
diseases	I	1412-1420
.	O	1420-1421

Vinorelbine	O	1422-1433
-	O	1433-1434
related	O	1434-1441
cardiac	O	1442-1449
events	O	1450-1456
concern	O	1457-1464
about	O	1465-1470
1	O	1471-1472
%	O	1472-1473
of	O	1474-1476
treated	O	1477-1484
patients	O	1485-1493
in	O	1494-1496
clinical	O	1497-1505
trials	O	1506-1512
.	O	1512-1513

However	O	1514-1521
,	O	1521-1522
the	O	1523-1526
risk	O	1527-1531
associated	O	1532-1542
with	O	1543-1547
VNR	O	1548-1551
seems	O	1552-1557
to	O	1558-1560
be	O	1561-1563
similar	O	1564-1571
to	O	1572-1574
that	O	1575-1579
of	O	1580-1582
other	O	1583-1588
chemotherapeutic	O	1589-1605
agents	O	1606-1612
in	O	1613-1615
the	O	1616-1619
same	O	1620-1624
indications	O	1625-1636
.	O	1636-1637

MRI	O	0-3
findings	O	4-12
of	O	13-15
hypoxic	O	16-23
cortical	O	24-32
laminar	O	33-40
necrosis	B	41-49
in	O	50-52
a	O	53-54
child	O	55-60
with	O	61-65
hemolytic	B	66-75
anemia	I	76-82
crisis	O	83-89
.	O	89-90

We	O	91-93
present	O	94-101
magnetic	O	102-110
resonance	O	111-120
imaging	O	121-128
findings	O	129-137
of	O	138-140
a	O	141-142
5	O	143-144
-	O	144-145
year	O	145-149
-	O	144-145
old	O	150-153
girl	O	154-158
who	O	159-162
had	O	163-166
a	O	167-168
rapidly	O	169-176
installing	O	177-187
hemolytic	B	188-197
anemia	I	198-204
crisis	O	205-211
induced	O	212-219
by	O	220-222
trimethoprim	O	223-235
-	O	235-236
sulfomethoxazole	O	236-252
,	O	252-253
resulting	O	254-263
in	O	264-266
cerebral	B	267-275
anoxia	I	276-282
leading	O	283-290
to	O	291-293
permanent	O	294-303
damage	O	304-310
.	O	310-311

Magnetic	O	312-320
Resonance	O	321-330
imaging	O	331-338
revealed	O	339-347
cortical	O	348-356
laminar	O	357-364
necrosis	B	365-373
in	O	374-376
arterial	O	377-385
border	O	386-392
zones	O	393-398
in	O	399-401
both	O	402-406
cerebral	O	407-415
hemispheres	O	416-427
,	O	427-428
ischemic	O	429-437
changes	O	438-445
in	O	446-448
subcortical	O	449-460
white	O	461-466
matter	O	467-473
of	O	474-476
left	O	477-481
cerebral	O	482-490
hemisphere	O	491-501
,	O	501-502
and	O	503-506
in	O	507-509
the	O	510-513
left	O	514-518
putamen	O	519-526
.	O	526-527

Although	O	528-536
cortical	O	537-545
laminar	O	546-553
necrosis	B	554-562
is	O	563-565
a	O	566-567
classic	O	568-575
entity	O	576-582
in	O	583-585
adulthood	O	586-595
related	O	596-603
to	O	604-606
conditions	O	607-617
of	O	618-620
energy	O	621-627
depletions	O	628-638
,	O	638-639
there	O	640-645
are	O	646-649
few	O	650-653
reports	O	654-661
available	O	662-671
in	O	672-674
children	O	675-683
.	O	683-684

A	O	685-686
wide	O	687-691
review	O	692-698
of	O	699-701
the	O	702-705
literature	O	706-716
is	O	717-719
also	O	720-724
presented	O	725-734
.	O	734-735

The	O	0-3
natural	O	4-11
history	O	12-19
of	O	20-22
Vigabatrin	O	23-33
associated	O	34-44
visual	B	45-51
field	I	52-57
defects	I	58-65
in	O	66-68
patients	O	69-77
electing	O	78-86
to	O	87-89
continue	O	90-98
their	O	99-104
medication	O	105-115
.	O	115-116

PURPOSE	O	117-124
:	O	124-125
To	O	126-128
determine	O	129-138
the	O	139-142
natural	O	143-150
history	O	151-158
of	O	159-161
visual	B	162-168
field	I	169-174
defects	I	175-182
in	O	183-185
a	O	186-187
group	O	188-193
of	O	194-196
patients	O	197-205
known	O	206-211
to	O	212-214
have	O	215-219
Vigabatrin	O	220-230
-	O	230-231
associated	O	231-241
changes	O	242-249
who	O	250-253
elected	O	254-261
to	O	262-264
continue	O	265-273
the	O	274-277
medication	O	278-288
because	O	289-296
of	O	297-299
good	O	300-304
seizure	B	305-312
control	O	313-320
.	O	320-321

METHODS	O	322-329
:	O	329-330
All	O	331-334
patients	O	335-343
taking	O	344-350
Vigabatrin	O	351-361
alone	O	362-367
or	O	368-370
in	O	371-373
combination	O	374-385
with	O	386-390
other	O	391-396
antiepileptic	O	397-410
drugs	O	411-416
for	O	417-420
at	O	421-423
least	O	424-429
5	O	430-431
years	O	432-437
(	O	438-439
range	O	439-444
5	O	445-446
-	O	446-447
12	O	447-449
years	O	450-455
)	O	455-456
were	O	457-461
entered	O	462-469
into	O	470-474
a	O	475-476
visual	O	477-483
surveillance	O	484-496
programme	O	497-506
.	O	506-507

Patients	O	508-516
were	O	517-521
followed	O	522-530
up	O	531-533
at	O	534-536
6	O	537-538
-	O	538-539
monthly	O	539-546
intervals	O	547-556
for	O	557-560
not	O	561-564
less	O	565-569
than	O	570-574
18	O	575-577
months	O	578-584
(	O	585-586
range	O	586-591
18	O	592-594
-	O	594-595
43	O	595-597
months	O	598-604
)	O	604-605
.	O	605-606

In	O	607-609
all	O	610-613
,	O	613-614
16	O	615-617
patients	O	618-626
with	O	627-631
unequivocal	O	632-643
defects	O	644-651
continued	O	652-661
the	O	662-665
medication	O	666-676
.	O	676-677

Following	O	678-687
already	O	688-695
published	O	696-705
methodology	O	706-717
(	O	718-719
Eye	O	719-722
2002	O	723-727
;	O	727-728
16	O	729-731
;	O	731-732
567	O	732-735
-	O	735-736
571	O	736-739
)	O	739-740
monocular	O	741-750
mean	O	751-755
radial	O	756-762
degrees	O	763-770
(	O	771-772
MRDs	O	772-776
)	O	776-777
to	O	778-780
the	O	781-784
I	O	785-786
/	O	786-787
4e	O	787-789
isopter	O	790-797
on	O	798-800
Goldmann	O	801-809
perimetry	O	810-819
was	O	820-823
calculated	O	824-834
for	O	835-838
the	O	839-842
right	O	843-848
eye	O	849-852
at	O	853-855
the	O	856-859
time	O	860-864
of	O	865-867
discovery	O	868-877
of	O	878-880
a	O	881-882
visual	B	883-889
field	I	890-895
defect	I	896-902
and	O	903-906
again	O	907-912
after	O	913-918
not	O	919-922
less	O	923-927
than	O	928-932
18	O	933-935
months	O	936-942
follow	O	943-949
-	O	949-950
up	O	950-952
.	O	952-953

RESULTS	O	954-961
:	O	961-962
Mean	O	963-967
right	O	968-973
eye	O	974-977
MRD	O	978-981
at	O	982-984
presentation	O	985-997
was	O	998-1001
36	O	1002-1004
.	O	1004-1005
98	O	1005-1007
degrees	O	1008-1015
(	O	1016-1017
range	O	1017-1022
22	O	1023-1025
.	O	1025-1026
25	O	1026-1028
-	O	1028-1029
51	O	1029-1031
.	O	1025-1026
0	O	1032-1033
)	O	1033-1034
,	O	1034-1035

compared	O	1036-1044
to	O	1045-1047
38	O	1048-1050
.	O	1050-1051
40	O	1051-1053
degrees	O	1054-1061
(	O	1062-1063
range	O	1063-1068
22	O	1069-1071
.	O	1071-1072
5	O	1072-1073
-	O	1073-1074
49	O	1074-1076
.	O	1071-1072
75	O	1077-1079
)	O	1079-1080

after	O	1081-1086
follow	O	1087-1093
-	O	1093-1094
up	O	1094-1096
;	O	1096-1097
P	O	1098-1099
=	O	1099-1100
0	O	1100-1101
.	O	1101-1102
338	O	1102-1105
unpaired	O	1106-1114
t	O	1115-1116
-	O	1116-1117
test	O	1117-1121
.	O	1121-1122

Only	O	1123-1127
one	O	1128-1131
patient	O	1132-1139
demonstrated	O	1140-1152
a	O	1153-1154
deterioration	B	1155-1168
in	I	1169-1171
visual	I	1172-1178
field	I	1179-1184
during	O	1185-1191
the	O	1192-1195
study	O	1196-1201
period	O	1202-1208
and	O	1209-1212
discontinued	O	1213-1225
treatment	O	1226-1235
.	O	1235-1236

CONCLUSION	O	1237-1247
:	O	1247-1248
Established	O	1249-1260
visual	B	1261-1267
field	I	1268-1273
defects	I	1274-1281
presumed	O	1282-1290
to	O	1291-1293
be	O	1294-1296
due	O	1297-1300
to	O	1301-1303
Vigabatrin	O	1304-1314
therapy	O	1315-1322
did	O	1323-1326
not	O	1327-1330
usually	O	1331-1338
progress	O	1339-1347
in	O	1348-1350
spite	O	1351-1356
of	O	1357-1359
continuing	O	1360-1370
use	O	1371-1374
of	O	1375-1377
the	O	1378-1381
medication	O	1382-1392
.	O	1392-1393

These	O	1394-1399
data	O	1400-1404
give	O	1405-1409
support	O	1410-1417
to	O	1418-1420
the	O	1421-1424
hypothesis	O	1425-1435
that	O	1436-1440
the	O	1441-1444
pathogenesis	O	1445-1457
of	O	1458-1460
Vigabatrin	O	1461-1471
-	O	1471-1472
associated	O	1472-1482
visual	B	1483-1489
field	I	1490-1495
defects	I	1496-1503
may	O	1504-1507
be	O	1508-1510
an	O	1511-1513
idiosyncratic	O	1514-1527
adverse	O	1528-1535
drug	O	1536-1540
reaction	O	1541-1549
rather	O	1550-1556
than	O	1557-1561
dose	O	1562-1566
-	O	1566-1567
dependent	O	1567-1576
toxicity	B	1577-1585
.	O	1585-1586

Induction	O	0-9
of	O	10-12
rosaceiform	O	13-24
dermatitis	B	25-35
during	O	36-42
treatment	O	43-52
of	O	53-55
facial	B	56-62
inflammatory	I	63-75
dermatoses	I	76-86
with	O	87-91
tacrolimus	O	92-102
ointment	O	103-111
.	O	111-112

BACKGROUND	O	113-123
:	O	123-124
Tacrolimus	O	125-135
ointment	O	136-144
is	O	145-147
increasingly	O	148-160
used	O	161-165
for	O	166-169
anti	O	170-174
-	O	174-175
inflammatory	O	175-187
treatment	O	188-197
of	O	198-200
sensitive	O	201-210
areas	O	211-216
such	O	217-221
as	O	222-224
the	O	225-228
face	O	229-233
,	O	233-234
and	O	235-238
recent	O	239-245
observations	O	246-258
indicate	O	259-267
that	O	268-272
the	O	273-276
treatment	O	277-286
is	O	287-289
effective	O	290-299
in	O	300-302
steroid	O	303-310
-	O	310-311
aggravated	O	311-321
rosacea	B	322-329
and	O	330-333
perioral	B	334-342
dermatitis	I	343-353
.	O	353-354

We	O	355-357
report	O	358-364
on	O	365-367
rosaceiform	O	368-379
dermatitis	B	380-390
as	O	391-393
a	O	394-395
complication	O	396-408
of	O	409-411
treatment	O	412-421
with	O	422-426
tacrolimus	O	427-437
ointment	O	438-446
.	O	446-447

OBSERVATIONS	O	448-460
:	O	460-461
Six	O	462-465
adult	O	466-471
patients	O	472-480
with	O	481-485
inflammatory	B	486-498
facial	I	499-505
dermatoses	I	506-516
were	O	517-521
treated	O	522-529
with	O	530-534
tacrolimus	O	535-545
ointment	O	546-554
because	O	555-562
of	O	563-565
the	O	566-569
ineffectiveness	O	570-585
of	O	586-588
standard	O	589-597
treatments	O	598-608
.	O	608-609

Within	O	610-616
2	O	617-618
to	O	619-621
3	O	622-623
weeks	O	624-629
of	O	630-632
initially	O	633-642
effective	O	643-652
and	O	653-656
well	O	657-661
-	O	661-662
tolerated	O	662-671
treatment	O	672-681
,	O	681-682
3	O	683-684
patients	O	685-693
with	O	694-698
a	O	699-700
history	O	701-708
of	O	709-711
rosacea	B	712-719
and	O	720-723
1	O	724-725
with	O	726-730
a	O	731-732
history	O	733-740
of	O	741-743
acne	B	744-748
experienced	O	749-760
sudden	O	761-767
worsening	O	768-777
with	O	778-782
pustular	O	783-791
rosaceiform	O	792-803
lesions	O	804-811
.	O	811-812

Biopsy	O	813-819
revealed	O	820-828
an	O	829-831
abundance	O	832-841
of	O	842-844
Demodex	O	845-852
mites	O	853-858
in	O	859-861
2	O	862-863
of	O	864-866
these	O	867-872
patients	O	873-881
.	O	881-882

In	O	883-885
1	O	886-887
patient	O	888-895
with	O	896-900
eyelid	O	901-907
eczema	B	908-914
,	O	914-915
rosaceiform	O	916-927
periocular	B	928-938
dermatitis	I	939-949
gradually	O	950-959
appeared	O	960-968
after	O	969-974
3	O	975-976
weeks	O	977-982
of	O	983-985
treatment	O	986-995
.	O	995-996

In	O	997-999
1	O	1000-1001
patient	O	1002-1009
with	O	1010-1014
atopic	B	1015-1021
dermatitis	I	1022-1032
,	O	1032-1033
telangiectatic	O	1034-1048
and	O	1049-1052
papular	B	1053-1060
rosacea	I	1061-1068
insidiously	O	1069-1080
appeared	O	1081-1089
after	O	1090-1095
5	O	1096-1097
months	O	1098-1104
of	O	1105-1107
treatment	O	1108-1117
.	O	1117-1118

CONCLUSIONS	O	1119-1130
:	O	1130-1131
Our	O	1132-1135
observations	O	1136-1148
suggest	O	1149-1156
that	O	1157-1161
the	O	1162-1165
spectrum	O	1166-1174
of	O	1175-1177
rosaceiform	O	1178-1189
dermatitis	B	1190-1200
as	O	1201-1203
a	O	1204-1205
complication	O	1206-1218
of	O	1219-1221
treatment	O	1222-1231
with	O	1232-1236
tacrolimus	O	1237-1247
ointment	O	1248-1256
is	O	1257-1259
heterogeneous	O	1260-1273
.	O	1273-1274

A	O	1275-1276
variety	O	1277-1284
of	O	1285-1287
factors	O	1288-1295
,	O	1295-1296
such	O	1297-1301
as	O	1302-1304
vasoactive	O	1305-1315
properties	O	1316-1326
of	O	1327-1329
tacrolimus	O	1330-1340
,	O	1340-1341
proliferation	O	1342-1355
of	O	1356-1358
Demodex	O	1359-1366
due	O	1367-1370
to	O	1371-1373
local	O	1374-1379
immunosuppression	O	1380-1397
,	O	1397-1398
and	O	1399-1402
the	O	1403-1406
occlusive	O	1407-1416
properties	O	1417-1427
of	O	1428-1430
the	O	1431-1434
ointment	O	1435-1443
,	O	1443-1444
may	O	1445-1448
be	O	1449-1451
involved	O	1452-1460
in	O	1461-1463
the	O	1464-1467
observed	O	1468-1476
phenomena	O	1477-1486
.	O	1486-1487

Future	O	1488-1494
studies	O	1495-1502
are	O	1503-1506
needed	O	1507-1513
to	O	1514-1516
identify	O	1517-1525
individual	O	1526-1536
risk	O	1537-1541
factors	O	1542-1549
.	O	1549-1550

Structural	O	0-10
abnormalities	O	11-24
in	O	25-27
the	O	28-31
brains	O	32-38
of	O	39-41
human	O	42-47
subjects	O	48-56
who	O	57-60
use	O	61-64
methamphetamine	O	65-80
.	O	80-81

We	O	82-84
visualize	O	85-94
,	O	94-95
for	O	96-99
the	O	100-103
first	O	104-109
time	O	110-114
,	O	114-115
the	O	116-119
profile	O	120-127
of	O	128-130
structural	B	131-141
deficits	I	142-150
in	I	151-153
the	I	154-157
human	I	158-163
brain	I	164-169
associated	O	170-180
with	O	181-185
chronic	O	186-193
methamphetamine	O	194-209
(	O	210-211
MA	O	211-213
)	O	213-214
abuse	O	215-220
.	O	220-221

Studies	O	222-229
of	O	230-232
human	O	233-238
subjects	O	239-247
who	O	248-251
have	O	252-256
used	O	257-261
MA	O	262-264
chronically	O	265-276
have	O	277-281
revealed	O	282-290
deficits	O	291-299
in	O	300-302
dopaminergic	O	303-315
and	O	316-319
serotonergic	O	320-332
systems	O	333-340
and	O	341-344
cerebral	O	345-353
metabolic	B	354-363
abnormalities	I	364-377
.	O	377-378

Using	O	379-384
magnetic	O	385-393
resonance	O	394-403
imaging	O	404-411
(	O	412-413
MRI	O	413-416
)	O	416-417
and	O	418-421
new	O	422-425
computational	O	426-439
brain	O	440-445
-	O	445-446
mapping	O	446-453
techniques	O	454-464
,	O	464-465
we	O	466-468
determined	O	469-479
the	O	480-483
pattern	O	484-491
of	O	492-494
structural	O	495-505
brain	O	506-511
alterations	O	512-523
associated	O	524-534
with	O	535-539
chronic	O	540-547
MA	O	548-550
abuse	O	551-556
in	O	557-559
human	O	560-565
subjects	O	566-574
and	O	575-578
related	O	579-586
these	O	587-592
deficits	O	593-601
to	O	602-604
cognitive	B	605-614
impairment	I	615-625
.	O	625-626

We	O	627-629
used	O	630-634
high	O	635-639
-	O	639-640
resolution	O	640-650
MRI	O	651-654
and	O	655-658
surface	O	659-666
-	O	666-667
based	O	667-672
computational	O	673-686
image	O	687-692
analyses	O	693-701
to	O	702-704
map	O	705-708
regional	O	709-717
abnormalities	B	718-731
in	I	732-734
the	I	735-738
cortex	I	739-745
,	I	745-746
hippocampus	I	747-758
,	I	758-759
white	I	760-765
matter	I	766-772
,	I	772-773
and	I	774-777
ventricles	I	778-788
in	O	789-791
22	O	792-794
human	O	795-800
subjects	O	801-809
who	O	810-813
used	O	814-818
MA	O	819-821
and	O	822-825
21	O	826-828
age	O	829-832
-	O	832-833
matched	O	833-840
,	O	840-841
healthy	O	842-849
controls	O	850-858
.	O	858-859

Cortical	O	860-868
maps	O	869-873
revealed	O	874-882
severe	O	883-889
gray	O	890-894
-	O	894-895
matter	O	895-901
deficits	O	902-910
in	O	911-913
the	O	914-917
cingulate	O	918-927
,	O	927-928
limbic	O	929-935
,	O	935-936
and	O	937-940
paralimbic	O	941-951
cortices	O	952-960
of	O	961-963
MA	O	964-966
abusers	O	967-974
(	O	975-976
averaging	O	976-985
11	O	986-988
.	O	988-989
3	O	989-990
%	O	990-991
below	O	992-997
control	O	998-1005
;	O	1005-1006
p	O	1007-1008
<	O	1009-1010
0	O	1011-1012
.	O	1012-1013
05	O	1013-1015
)	O	1015-1016
.	O	1012-1013

On	O	1018-1020
average	O	1021-1028
,	O	1028-1029
MA	O	1030-1032
abusers	O	1033-1040
had	O	1041-1044
7	O	1045-1046
.	O	1046-1047
8	O	1047-1048
%	O	1048-1049
smaller	O	1050-1057
hippocampal	O	1058-1069
volumes	O	1070-1077
than	O	1078-1082
control	O	1083-1090
subjects	O	1091-1099
(	O	1100-1101
p	O	1101-1102
<	O	1103-1104
0	O	1105-1106
.	O	1106-1107
01	O	1107-1109
;	O	1109-1110
left	O	1111-1115
,	O	1115-1116
p	O	1117-1118
=	O	1119-1120
0	O	1121-1122
.	O	1122-1123
01	O	1123-1125
;	O	1125-1126
right	O	1127-1132
,	O	1132-1133
p	O	1134-1135
<	O	1136-1137
0	O	1138-1139
.	O	1139-1140
05	O	1140-1142
)	O	1142-1143
and	O	1144-1147
significant	O	1148-1159
white	O	1160-1165
-	O	1165-1166
matter	O	1166-1172
hypertrophy	B	1173-1184
(	O	1185-1186
7	O	1186-1187
.	O	1187-1188
0	O	1188-1189
%	O	1189-1190
;	O	1190-1191
p	O	1192-1193
<	O	1194-1195
0	O	1196-1197
.	O	1197-1198
01	O	1198-1200
)	O	1200-1201
.	O	1197-1198

Hippocampal	O	1203-1214
deficits	O	1215-1223
were	O	1224-1228
mapped	O	1229-1235
and	O	1236-1239
correlated	O	1240-1250
with	O	1251-1255
memory	O	1256-1262
performance	O	1263-1274
on	O	1275-1277
a	O	1278-1279
word	O	1280-1284
-	O	1284-1285
recall	O	1285-1291
test	O	1292-1296
(	O	1297-1298
p	O	1298-1299
<	O	1300-1301
0	O	1302-1303
.	O	1303-1304
05	O	1304-1306
)	O	1306-1307
.	O	1303-1304

MRI	O	1309-1312
-	O	1312-1313
based	O	1313-1318
maps	O	1319-1323
suggest	O	1324-1331
that	O	1332-1336
chronic	O	1337-1344
methamphetamine	O	1345-1360
abuse	O	1361-1366
causes	O	1367-1373
a	O	1374-1375
selective	O	1376-1385
pattern	O	1386-1393
of	O	1394-1396
cerebral	O	1397-1405
deterioration	O	1406-1419
that	O	1420-1424
contributes	O	1425-1436
to	O	1437-1439
impaired	B	1440-1448
memory	I	1449-1455
performance	I	1456-1467
.	O	1467-1468

MA	O	1469-1471
may	O	1472-1475
selectively	O	1476-1487
damage	O	1488-1494
the	O	1495-1498
medial	O	1499-1505
temporal	O	1506-1514
lobe	O	1515-1519
and	O	1520-1523
,	O	1523-1524
consistent	O	1525-1535
with	O	1536-1540
metabolic	O	1541-1550
studies	O	1551-1558
,	O	1558-1559
the	O	1560-1563
cingulate	O	1564-1573
-	O	1573-1574
limbic	O	1574-1580
cortex	O	1581-1587
,	O	1587-1588
inducing	O	1589-1597
neuroadaptation	O	1598-1613
,	O	1613-1614
neuropil	O	1615-1623
reduction	O	1624-1633
,	O	1633-1634
or	O	1635-1637
cell	O	1638-1642
death	O	1643-1648
.	O	1648-1649

Prominent	O	1650-1659
white	O	1660-1665
-	O	1665-1666
matter	O	1666-1672
hypertrophy	B	1673-1684
may	O	1685-1688
result	O	1689-1695
from	O	1696-1700
altered	O	1701-1708
myelination	O	1709-1720
and	O	1721-1724
adaptive	O	1725-1733
glial	O	1734-1739
changes	O	1740-1747
,	O	1747-1748
including	O	1749-1758
gliosis	B	1759-1766
secondary	O	1767-1776
to	O	1777-1779
neuronal	B	1780-1788
damage	I	1789-1795
.	O	1795-1796

These	O	1797-1802
brain	O	1803-1808
substrates	O	1809-1819
may	O	1820-1823
help	O	1824-1828
account	O	1829-1836
for	O	1837-1840
the	O	1841-1844
symptoms	O	1845-1853
of	O	1854-1856
MA	O	1857-1859
abuse	O	1860-1865
,	O	1865-1866
providing	O	1867-1876
therapeutic	O	1877-1888
targets	O	1889-1896
for	O	1897-1900
drug	O	1901-1905
-	O	1905-1906
induced	O	1906-1913
brain	B	1914-1919
injury	I	1920-1926
.	O	1926-1927

Disruption	O	0-10
of	O	11-13
hepatic	O	14-21
lipid	O	22-27
homeostasis	O	28-39
in	O	40-42
mice	O	43-47
after	O	48-53
amiodarone	O	54-64
treatment	O	65-74
is	O	75-77
associated	O	78-88
with	O	89-93
peroxisome	O	94-104
proliferator	O	105-117
-	O	117-118
activated	O	118-127
receptor	O	128-136
-	O	136-137
alpha	O	137-142
target	O	143-149
gene	O	150-154
activation	O	155-165
.	O	165-166

Amiodarone	O	167-177
,	O	177-178
an	O	179-181
efficacious	O	182-193
and	O	194-197
widely	O	198-204
used	O	205-209
antiarrhythmic	O	210-224
agent	O	225-230
,	O	230-231
has	O	232-235
been	O	236-240
reported	O	241-249
to	O	250-252
cause	O	253-258
hepatotoxicity	B	259-273
in	O	274-276
some	O	277-281
patients	O	282-290
.	O	290-291

To	O	292-294
gain	O	295-299
insight	O	300-307
into	O	308-312
the	O	313-316
mechanism	O	317-326
of	O	327-329
this	O	330-334
unwanted	O	335-343
effect	O	344-350
,	O	350-351
mice	O	352-356
were	O	357-361
administered	O	362-374
various	O	375-382
doses	O	383-388
of	O	389-391
amiodarone	O	392-402
and	O	403-406
examined	O	407-415
for	O	416-419
changes	O	420-427
in	O	428-430
hepatic	O	431-438
histology	O	439-448
and	O	449-452
gene	O	453-457
regulation	O	458-468
.	O	468-469

Amiodarone	O	470-480
induced	O	481-488
hepatomegaly	B	489-501
,	O	501-502
hepatocyte	O	503-513
microvesicular	O	514-528
lipid	O	529-534
accumulation	O	535-547
,	O	547-548
and	O	549-552
a	O	553-554
significant	O	555-566
decrease	O	567-575
in	O	576-578
serum	O	579-584
triglycerides	O	585-598
and	O	599-602
glucose	O	603-610
.	O	610-611

Northern	O	612-620
blot	O	621-625
analysis	O	626-634
of	O	635-637
hepatic	O	638-645
RNA	O	646-649
revealed	O	650-658
a	O	659-660
dose	O	661-665
-	O	665-666
dependent	O	666-675
increase	O	676-684
in	O	685-687
the	O	688-691
expression	O	692-702
of	O	703-705
a	O	706-707
number	O	708-714
of	O	715-717
genes	O	718-723
critical	O	724-732
for	O	733-736
fatty	O	737-742
acid	O	743-747
oxidation	O	748-757
,	O	757-758
lipoprotein	O	759-770
assembly	O	771-779
,	O	779-780
and	O	781-784
lipid	O	785-790
transport	O	791-800
.	O	800-801

Many	O	802-806
of	O	807-809
these	O	810-815
genes	O	816-821
are	O	822-825
regulated	O	826-835
by	O	836-838
the	O	839-842
peroxisome	O	843-853
proliferator	O	854-866
-	O	866-867
activated	O	867-876
receptor	O	877-885
-	O	885-886
alpha	O	886-891
(	O	892-893
PPARalpha	O	893-902
)	O	902-903
,	O	903-904
a	O	905-906
ligand	O	907-913
-	O	913-914
activated	O	914-923
nuclear	O	924-931
hormone	O	932-939
receptor	O	940-948
transcription	O	949-962
factor	O	963-969
.	O	969-970

The	O	971-974
absence	O	975-982
of	O	983-985
induction	O	986-995
of	O	996-998
these	O	999-1004
genes	O	1005-1010
as	O	1011-1013
well	O	1014-1018
as	O	1019-1021
hepatomegaly	B	1022-1034
in	O	1035-1037
PPARalpha	O	1038-1047
knockout	O	1048-1056
[	O	1057-1058
PPARalpha	O	1058-1067
-	O	1067-1068
/	O	1068-1069
-	O	1067-1068
]	O	1070-1071
mice	O	1072-1076
indicated	O	1077-1086
that	O	1087-1091
the	O	1092-1095
effects	O	1096-1103
of	O	1104-1106
amiodarone	O	1107-1117
were	O	1118-1122
dependent	O	1123-1132
upon	O	1133-1137
the	O	1138-1141
presence	O	1142-1150
of	O	1151-1153
a	O	1154-1155
functional	O	1156-1166
PPARalpha	O	1167-1176
gene	O	1177-1181
.	O	1181-1182

Compared	O	1183-1191
to	O	1192-1194
wild	O	1195-1199
-	O	1199-1200
type	O	1200-1204
mice	O	1205-1209
,	O	1209-1210
treatment	O	1211-1220
of	O	1221-1223
PPARalpha	O	1224-1233
-	O	1233-1234
/	O	1234-1235
-	O	1233-1234
mice	O	1237-1241
with	O	1242-1246
amiodarone	O	1247-1257
resulted	O	1258-1266
in	O	1267-1269
an	O	1270-1272
increased	O	1273-1282
rate	O	1283-1287
and	O	1288-1291
extent	O	1292-1298
of	O	1299-1301
total	O	1302-1307
body	O	1308-1312
weight	B	1313-1319
loss	I	1320-1324
.	O	1324-1325

The	O	1326-1329
inability	O	1330-1339
of	O	1340-1342
amiodarone	O	1343-1353
to	O	1354-1356
directly	O	1357-1365
activate	O	1366-1374
either	O	1375-1381
human	O	1382-1387
or	O	1388-1390
mouse	O	1391-1396
PPARalpha	O	1397-1406
transiently	O	1407-1418
expressed	O	1419-1428
in	O	1429-1431
human	O	1432-1437
HepG2	O	1438-1443
hepatoma	B	1444-1452
cells	O	1453-1458
indicates	O	1459-1468
that	O	1469-1473
the	O	1474-1477
effects	O	1478-1485
of	O	1486-1488
amiodarone	O	1489-1499
on	O	1500-1502
the	O	1503-1506
function	O	1507-1515
of	O	1516-1518
this	O	1519-1523
receptor	O	1524-1532
were	O	1533-1537
indirect	O	1538-1546
.	O	1546-1547

Based	O	1548-1553
upon	O	1554-1558
these	O	1559-1564
results	O	1565-1572
,	O	1572-1573
we	O	1574-1576
conclude	O	1577-1585
that	O	1586-1590
amiodarone	O	1591-1601
disrupts	O	1602-1610
hepatic	O	1611-1618
lipid	O	1619-1624
homeostasis	O	1625-1636
and	O	1637-1640
that	O	1641-1645
the	O	1646-1649
increased	O	1650-1659
expression	O	1660-1670
of	O	1671-1673
PPARalpha	O	1674-1683
target	O	1684-1690
genes	O	1691-1696
is	O	1697-1699
secondary	O	1700-1709
to	O	1710-1712
this	O	1713-1717
toxic	O	1718-1723
effect	O	1724-1730
.	O	1730-1731

These	O	1732-1737
results	O	1738-1745
provide	O	1746-1753
important	O	1754-1763
new	O	1764-1767
mechanistic	O	1768-1779
information	O	1780-1791
regarding	O	1792-1801
the	O	1802-1805
hepatotoxic	B	1806-1817
effects	O	1818-1825
of	O	1826-1828
amiodarone	O	1829-1839
and	O	1840-1843
indicate	O	1844-1852
that	O	1853-1857
PPARalpha	O	1858-1867
protects	O	1868-1876
against	O	1877-1884
amiodarone	O	1885-1895
-	O	1895-1896
induced	O	1896-1903
hepatotoxicity	B	1904-1918
.	O	1918-1919

Safety	O	0-6
and	O	7-10
compliance	O	11-21
with	O	22-26
once	O	27-31
-	O	31-32
daily	O	32-37
niacin	O	38-44
extended	O	45-53
-	O	53-54
release	O	54-61
/	O	61-62
lovastatin	O	62-72
as	O	73-75
initial	O	76-83
therapy	O	84-91
in	O	92-94
the	O	95-98
Impact	O	99-105
of	O	106-108
Medical	O	109-116
Subspecialty	O	117-129
on	O	130-132
Patient	O	133-140
Compliance	O	141-151
to	O	152-154
Treatment	O	155-164
(	O	165-166
IMPACT	O	166-172
)	O	172-173
study	O	174-179
.	O	179-180

Niacin	O	181-187
extended	O	188-196
-	O	196-197
release	O	197-204
/	O	204-205
lovastatin	O	205-215
is	O	216-218
a	O	219-220
new	O	221-224
combination	O	225-236
product	O	237-244
approved	O	245-253
for	O	254-257
treatment	O	258-267
of	O	268-270
primary	O	271-278
hypercholesterolemia	B	279-299
and	O	300-303
mixed	O	304-309
dyslipidemia	B	310-322
.	O	322-323

This	O	324-328
open	O	329-333
-	O	333-334
labeled	O	334-341
,	O	341-342
multicenter	O	343-354
study	O	355-360
evaluated	O	361-370
the	O	371-374
safety	O	375-381
of	O	382-384
bedtime	O	385-392
niacin	O	393-399
extended	O	400-408
-	O	408-409
release	O	409-416
/	O	416-417
lovastatin	O	417-427
when	O	428-432
dosed	O	433-438
as	O	439-441
initial	O	442-449
therapy	O	450-457
and	O	458-461
patient	O	462-469
compliance	O	470-480
to	O	481-483
treatment	O	484-493
in	O	494-496
various	O	497-504
clinical	O	505-513
practice	O	514-522
settings	O	523-531
.	O	531-532

A	O	533-534
total	O	535-540
of	O	541-543
4	O	544-545
,	O	545-546
499	O	546-549
patients	O	550-558
with	O	559-563
dyslipidemia	B	564-576
requiring	O	577-586
drug	O	587-591
intervention	O	592-604
was	O	605-608
enrolled	O	609-617
at	O	618-620
1	O	621-622
,	O	622-623
081	O	623-626
sites	O	627-632
.	O	632-633

Patients	O	634-642
were	O	643-647
treated	O	648-655
with	O	656-660
1	O	661-662
tablet	O	663-669
(	O	670-671
500	O	671-674
mg	O	675-677
of	O	678-680
niacin	O	681-687
extended	O	688-696
-	O	696-697
release	O	697-704
/	O	704-705
20	O	705-707
mg	O	708-710
of	O	711-713
lovastatin	O	714-724
)	O	724-725
once	O	726-730
nightly	O	731-738
for	O	739-742
4	O	743-744
weeks	O	745-750
and	O	751-754
then	O	755-759
2	O	760-761
tablets	O	762-769
for	O	770-773
8	O	774-775
weeks	O	776-781
.	O	781-782

Patients	O	783-791
also	O	792-796
received	O	797-805
dietary	O	806-813
counseling	O	814-824
,	O	824-825
educational	O	826-837
materials	O	838-847
,	O	847-848
and	O	849-852
reminders	O	853-862
to	O	863-865
call	O	866-870
a	O	871-872
toll	O	873-877
-	O	877-878
free	O	878-882
number	O	883-889
that	O	890-894
provided	O	895-903
further	O	904-911
education	O	912-921
about	O	922-927
dyslipidemia	B	928-940
and	O	941-944
niacin	O	945-951
extended	O	952-960
-	O	960-961
release	O	961-968
/	O	968-969
lovastatin	O	969-979
.	O	979-980

Primary	O	981-988
end	O	989-992
points	O	993-999
were	O	1000-1004
study	O	1005-1010
compliance	O	1011-1021
,	O	1021-1022
increases	O	1023-1032
in	O	1033-1035
liver	O	1036-1041
transaminases	O	1042-1055
to	O	1056-1058
>	O	1059-1060
3	O	1060-1061
times	O	1062-1067
the	O	1068-1071
upper	O	1072-1077
limit	O	1078-1083
of	O	1084-1086
normal	O	1087-1093
,	O	1093-1094
and	O	1095-1098
clinical	O	1099-1107
myopathy	B	1108-1116
.	O	1116-1117

Final	O	1118-1123
study	O	1124-1129
status	O	1130-1136
was	O	1137-1140
available	O	1141-1150
for	O	1151-1154
4	O	1155-1156
,	O	1156-1157
217	O	1157-1160
patients	O	1161-1169
(	O	1170-1171
94	O	1171-1173
%	O	1173-1174
)	O	1174-1175
.	O	1175-1176

Compliance	O	1177-1187
to	O	1188-1190
niacin	O	1191-1197
extended	O	1198-1206
-	O	1206-1207
release	O	1207-1214
/	O	1214-1215
lovastatin	O	1215-1225
was	O	1226-1229
77	O	1230-1232
%	O	1232-1233
,	O	1233-1234
with	O	1235-1239
3	O	1240-1241
,	O	1241-1242
245	O	1242-1245
patients	O	1246-1254
completing	O	1255-1265
the	O	1266-1269
study	O	1270-1275
.	O	1275-1276

Patients	O	1277-1285
in	O	1286-1288
the	O	1289-1292
southeast	O	1293-1302
and	O	1303-1306
those	O	1307-1312
enrolled	O	1313-1321
by	O	1322-1324
endocrinologists	O	1325-1341
had	O	1342-1345
the	O	1346-1349
lowest	O	1350-1356
compliance	O	1357-1367
and	O	1368-1371
highest	O	1372-1379
adverse	O	1380-1387
event	O	1388-1393
rates	O	1394-1399
.	O	1399-1400

Flushing	B	1401-1409
was	O	1410-1413
the	O	1414-1417
most	O	1418-1422
common	O	1423-1429
adverse	O	1430-1437
event	O	1438-1443
,	O	1443-1444
reported	O	1445-1453
by	O	1454-1456
18	O	1457-1459
%	O	1459-1460
of	O	1461-1463
patients	O	1464-1472
and	O	1473-1476
leading	O	1477-1484
to	O	1485-1487
discontinuation	O	1488-1503
by	O	1504-1506
6	O	1507-1508
%	O	1508-1509
.	O	1509-1510

Incidence	O	1511-1520
of	O	1521-1523
increased	O	1524-1533
aspartate	O	1534-1543
aminotransferase	O	1544-1560
and	O	1561-1564
/	O	1564-1565
or	O	1565-1567
alanine	O	1568-1575
aminotransferase	O	1576-1592
>	O	1593-1594
3	O	1594-1595
times	O	1596-1601
the	O	1602-1605
upper	O	1606-1611
limit	O	1612-1617
of	O	1618-1620
normal	O	1621-1627
was	O	1628-1631
<	O	1632-1633
0	O	1633-1634
.	O	1634-1635
3	O	1635-1636
%	O	1636-1637
.	O	1634-1635

An	O	1639-1641
increase	O	1642-1650
of	O	1651-1653
creatine	O	1654-1662
phosphokinase	O	1663-1676
to	O	1677-1679
>	O	1680-1681
5	O	1681-1682
times	O	1683-1688
the	O	1689-1692
upper	O	1693-1698
limit	O	1699-1704
of	O	1705-1707
normal	O	1708-1714
occurred	O	1715-1723
in	O	1724-1726
0	O	1727-1728
.	O	1728-1729
24	O	1729-1731
%	O	1731-1732
of	O	1733-1735
patients	O	1736-1744
,	O	1744-1745
and	O	1746-1749
no	O	1750-1752
cases	O	1753-1758
of	O	1759-1761
drug	O	1762-1766
-	O	1766-1767
induced	O	1767-1774
myopathy	B	1775-1783
were	O	1784-1788
observed	O	1789-1797
.	O	1797-1798

Niacin	O	1799-1805
extended	O	1806-1814
-	O	1814-1815
release	O	1815-1822
/	O	1822-1823
lovastatin	O	1823-1833
1	O	1834-1835
,	O	1835-1836
000	O	1836-1839
/	O	1839-1840
40	O	1840-1842
mg	O	1843-1845
,	O	1845-1846
dosed	O	1847-1852
as	O	1853-1855
initial	O	1856-1863
therapy	O	1864-1871
,	O	1871-1872
was	O	1873-1876
associated	O	1877-1887
with	O	1888-1892
good	O	1893-1897
compliance	O	1898-1908
and	O	1909-1912
safety	O	1913-1919
and	O	1920-1923
had	O	1924-1927
very	O	1928-1932
low	O	1933-1936
incidences	O	1937-1947
of	O	1948-1950
increased	O	1951-1960
liver	O	1961-1966
and	O	1967-1970
muscle	O	1971-1977
enzymes	O	1978-1985
.	O	1985-1986

Protective	O	0-10
effect	O	11-17
of	O	18-20
Terminalia	O	21-31
chebula	O	32-39
against	O	40-47
experimental	O	48-60
myocardial	B	61-71
injury	I	72-78
induced	O	79-86
by	O	87-89
isoproterenol	O	90-103
.	O	103-104

Cardioprotective	O	105-121
effect	O	122-128
of	O	129-131
ethanolic	O	132-141
extract	O	142-149
of	O	150-152
Terminalia	O	153-163
chebula	O	164-171
fruits	O	172-178
(	O	179-180
500	O	180-183
mg	O	184-186
/	O	186-187
kg	O	187-189
body	O	190-194
wt	O	195-197
)	O	197-198
was	O	199-202
examined	O	203-211
in	O	212-214
isoproterenol	O	215-228
(	O	229-230
200	O	230-233
mg	O	234-236
/	O	236-237
kg	O	237-239
body	O	240-244
wt	O	245-247
)	O	247-248
induced	O	249-256
myocardial	B	257-267
damage	I	268-274
in	O	275-277
rats	O	278-282
.	O	282-283

In	O	284-286
isoproterenol	O	287-300
administered	O	301-313
rats	O	314-318
,	O	318-319
the	O	320-323
level	O	324-329
of	O	330-332
lipid	O	333-338
peroxides	O	339-348
increased	O	349-358
significantly	O	359-372
in	O	373-375
the	O	376-379
serum	O	380-385
and	O	386-389
heart	O	390-395
.	O	395-396

A	O	397-398
significant	O	399-410
decrease	O	411-419
was	O	420-423
observed	O	424-432
in	O	433-435
the	O	436-439
activity	O	440-448
of	O	449-451
the	O	452-455
myocardial	O	456-466
marker	O	467-473
enzymes	O	474-481
with	O	482-486
a	O	487-488
concomitant	O	489-500
increase	O	501-509
in	O	510-512
their	O	513-518
activity	O	519-527
in	O	528-530
serum	O	531-536
.	O	536-537

Histopathological	O	538-555
examination	O	556-567
was	O	568-571
carried	O	572-579
out	O	580-583
to	O	584-586
confirm	O	587-594
the	O	595-598
myocardial	O	599-609
necrosis	B	610-618
.	O	618-619

T	O	620-621
.	O	621-622
chebula	O	623-630
extract	O	631-638
pretreatment	O	639-651
was	O	652-655
found	O	656-661
to	O	662-664
ameliorate	O	665-675
the	O	676-679
effect	O	680-686
of	O	687-689
isoproterenol	O	690-703
on	O	704-706
lipid	O	707-712
peroxide	O	713-721
formation	O	722-731
and	O	732-735
retained	O	736-744
the	O	745-748
activities	O	749-759
of	O	760-762
the	O	763-766
diagnostic	O	767-777
marker	O	778-784
enzymes	O	785-792
.	O	792-793

A	O	0-1
case	O	2-6
of	O	7-9
postoperative	O	10-23
anxiety	B	24-31
due	O	32-35
to	O	36-38
low	O	39-42
dose	O	43-47
droperidol	O	48-58
used	O	59-63
with	O	64-68
patient	O	69-76
-	O	76-77
controlled	O	77-87
analgesia	O	88-97
.	O	97-98

A	O	99-100
multiparous	O	101-112
woman	O	113-118
in	O	119-121
good	O	122-126
psychological	O	127-140
health	O	141-147
underwent	O	148-157
urgent	O	158-164
caesarean	O	165-174
section	O	175-182
in	O	183-185
labour	O	186-192
.	O	192-193

Postoperatively	O	194-209
,	O	209-210
she	O	211-214
was	O	215-218
given	O	219-224
a	O	225-226
patient	O	227-234
-	O	234-235
controlled	O	235-245
analgesia	O	246-255
device	O	256-262
delivering	O	263-273
boluses	O	274-281
of	O	282-284
diamorphine	O	285-296
0	O	297-298
.	O	298-299
5	O	299-300
mg	O	301-303
and	O	304-307
droperidol	O	308-318
0	O	319-320
.	O	320-321
025	O	321-324
mg	O	325-327
.	O	327-328

Whilst	O	329-335
using	O	336-341
the	O	342-345
device	O	346-352
she	O	353-356
gradually	O	357-366
became	O	367-373
anxious	O	374-381
,	O	381-382
the	O	383-386
feeling	O	387-394
worsening	O	395-404
after	O	405-410
each	O	411-415
bolus	O	416-421
.	O	421-422

The	O	423-426
diagnosis	O	427-436
of	O	437-439
droperidol	O	440-450
-	O	450-451
induced	O	451-458
psychological	B	459-472
disturbance	I	473-484
was	O	485-488
not	O	489-492
made	O	493-497
straight	O	498-506
away	O	507-511
although	O	512-520
on	O	521-523
subsequent	O	524-534
close	O	535-540
questioning	O	541-552
the	O	553-556
patient	O	557-564
gave	O	565-569
a	O	570-571
very	O	572-576
clear	O	577-582
history	O	583-590
.	O	590-591

After	O	592-597
she	O	598-601
had	O	602-605
received	O	606-614
a	O	615-616
total	O	617-622
of	O	623-625
only	O	626-630
0	O	631-632
.	O	632-633
9	O	633-634
mg	O	635-637
droperidol	O	638-648
,	O	648-649
a	O	650-651
syringe	O	652-659
containing	O	660-670
diamorphine	O	671-682
only	O	683-687
was	O	688-691
substituted	O	692-703
and	O	704-707
her	O	708-711
unease	O	712-718
resolved	O	719-727
completely	O	728-738
.	O	738-739

We	O	740-742
feel	O	743-747
that	O	748-752
,	O	752-753
although	O	754-762
the	O	763-766
dramatic	O	767-775
extrapyramidal	O	776-790
side	O	791-795
effects	O	796-803
of	O	804-806
dopaminergic	O	807-819
antiemetics	O	820-831
are	O	832-835
well	O	836-840
known	O	841-846
,	O	846-847
more	O	848-852
subtle	O	853-859
manifestations	O	860-874
may	O	875-878
easily	O	879-885
be	O	886-888
overlooked	O	889-899
.	O	899-900

Accurate	O	0-8
patient	O	9-16
history	O	17-24
contributes	O	25-36
to	O	37-39
differentiating	O	40-55
diabetes	B	56-64
insipidus	I	65-74
:	O	74-75
a	O	76-77
case	O	78-82
study	O	83-88
.	O	88-89

This	O	90-94
case	O	95-99
study	O	100-105
highlights	O	106-116
the	O	117-120
important	O	121-130
contribution	O	131-143
of	O	144-146
nursing	O	147-154
in	O	155-157
obtaining	O	158-167
an	O	168-170
accurate	O	171-179
health	O	180-186
history	O	187-194
.	O	194-195

The	O	196-199
case	O	200-204
discussed	O	205-214
herein	O	215-221
initially	O	222-231
appeared	O	232-240
to	O	241-243
be	O	244-246
neurogenic	B	247-257
diabetes	I	258-266
insipidus	I	267-276
(	O	277-278
DI	B	278-280
)	O	280-281
secondary	O	282-291
to	O	292-294
a	O	295-296
traumatic	B	297-306
brain	I	307-312
injury	I	313-319
.	O	319-320

The	O	321-324
nursing	O	325-332
staff	O	333-338
,	O	338-339
by	O	340-342
reviewing	O	343-352
the	O	353-356
patient	O	357-364
'	O	364-365
s	O	365-366
health	O	367-373
history	O	374-381
with	O	382-386
his	O	387-390
family	O	391-397
,	O	397-398
discovered	O	399-409
a	O	410-411
history	O	412-419
of	O	420-422
polydipsia	B	423-433
and	O	434-437
long	O	438-442
-	O	442-443
standing	O	443-451
lithium	O	452-459
use	O	460-463
.	O	463-464

Lithium	O	465-472
is	O	473-475
implicated	O	476-486
in	O	487-489
drug	O	490-494
-	O	494-495
induced	O	495-502
nephrogenic	B	503-514
DI	I	515-517
,	O	517-518
and	O	519-522
because	O	523-530
the	O	531-534
patient	O	535-542
had	O	543-546
not	O	547-550
received	O	551-559
lithium	O	560-567
since	O	568-573
being	O	574-579
admitted	O	580-588
to	O	589-591
the	O	592-595
hospital	O	596-604
,	O	604-605
his	O	606-609
treatment	O	610-619
changed	O	620-627
to	O	628-630
focus	O	631-636
on	O	637-639
nephrogenic	B	640-651
DI	I	652-654
.	O	654-655

By	O	656-658
combining	O	659-668
information	O	669-680
from	O	681-685
the	O	686-689
patient	O	690-697
history	O	698-705
,	O	705-706
the	O	707-710
physical	O	711-719
examination	O	720-731
,	O	731-732
and	O	733-736
radiologic	O	737-747
and	O	748-751
laboratory	O	752-762
studies	O	763-770
,	O	770-771
the	O	772-775
critical	O	776-784
care	O	785-789
team	O	790-794
demonstrated	O	795-807
that	O	808-812
the	O	813-816
patient	O	817-824
had	O	825-828
been	O	829-833
self	O	834-838
-	O	838-839
treating	O	839-847
his	O	848-851
lithium	O	852-859
-	O	859-860
induced	O	860-867
nephrogenic	B	868-879
DI	I	880-882
and	O	883-886
developed	O	887-896
neurogenic	B	897-907
DI	I	908-910
secondary	O	911-920
to	O	921-923
brain	B	924-929
trauma	I	930-936
.	O	936-937

Thus	O	938-942
successful	O	943-953
treatment	O	954-963
required	O	964-972
that	O	973-977
nephrogenic	O	978-989
and	O	990-993
neurogenic	B	994-1004
DI	I	1005-1007
be	O	1008-1010
treated	O	1011-1018
concomitantly	O	1019-1032
.	O	1032-1033

Factors	O	0-7
contributing	O	8-20
to	O	21-23
ribavirin	O	24-33
-	O	33-34
induced	O	34-41
anemia	B	42-48
.	O	48-49

BACKGROUND	O	50-60
AND	O	61-64
AIM	O	65-68
:	O	68-69
Interferon	O	70-80
and	O	81-84
ribavirin	O	85-94
combination	O	95-106
therapy	O	107-114
for	O	115-118
chronic	B	119-126
hepatitis	I	127-136
C	I	137-138
produces	O	139-147
hemolytic	B	148-157
anemia	I	158-164
.	O	164-165

This	O	166-170
study	O	171-176
was	O	177-180
conducted	O	181-190
to	O	191-193
identify	O	194-202
the	O	203-206
factors	O	207-214
contributing	O	215-227
to	O	228-230
ribavirin	O	231-240
-	O	240-241
induced	O	241-248
anemia	B	249-255
.	O	255-256

METHODS	O	257-264
:	O	264-265
Eighty	O	266-272
-	O	272-273
eight	O	273-278
patients	O	279-287
with	O	288-292
chronic	B	293-300
hepatitis	I	301-310
C	I	311-312
who	O	313-316
received	O	317-325
interferon	O	326-336
-	O	336-337
alpha	O	337-342
-	O	336-337
2b	O	343-345
at	O	346-348
a	O	349-350
dose	O	351-355
of	O	356-358
6	O	359-360
MU	O	361-363
administered	O	364-376
intramuscularly	O	377-392
for	O	393-396
24	O	397-399
weeks	O	400-405
in	O	406-408
combination	O	409-420
with	O	421-425
ribavirin	O	426-435
administered	O	436-448
orally	O	449-455
at	O	456-458
a	O	459-460
dose	O	461-465
of	O	466-468
600	O	469-472
mg	O	473-475
or	O	476-478
800	O	479-482
mg	O	483-485
participated	O	486-498
in	O	499-501
the	O	502-505
study	O	506-511
.	O	511-512

A	O	513-514
hemoglobin	O	515-525
concentration	O	526-539
of	O	540-542
<	O	543-544
10	O	544-546
g	O	547-548
/	O	548-549
dL	O	549-551
was	O	552-555
defined	O	556-563
as	O	564-566
ribavirin	O	567-576
-	O	576-577
induced	O	577-584
anemia	B	585-591
.	O	591-592

RESULTS	O	593-600
:	O	600-601
Ribavirin	O	602-611
-	O	611-612
induced	O	612-619
anemia	B	620-626
occurred	O	627-635
in	O	636-638
18	O	639-641
(	O	642-643
20	O	643-645
.	O	645-646
5	O	646-647
%	O	647-648
)	O	648-649

patients	O	650-658
during	O	659-665
treatment	O	666-675
.	O	675-676

A	O	677-678
2	O	679-680
g	O	681-682
/	O	682-683
dL	O	683-685
decrease	O	686-694
in	O	695-697
hemoglobin	O	698-708
concentrations	O	709-723
in	O	724-726
patients	O	727-735
with	O	736-740
anemia	B	741-747
was	O	748-751
observed	O	752-760
at	O	761-763
week	O	764-768
2	O	769-770
after	O	771-776
the	O	777-780
start	O	781-786
of	O	787-789
treatment	O	790-799
.	O	799-800

The	O	801-804
hemoglobin	O	805-815
concentration	O	816-829
in	O	830-832
patients	O	833-841
with	O	842-846
>	O	847-848
or	O	849-851
=	O	852-853
2	O	853-854
g	O	855-856
/	O	856-857
dL	O	857-859
decrease	O	860-868
at	O	869-871
week	O	872-876
2	O	877-878
was	O	879-882
observed	O	883-891
to	O	892-894
be	O	895-897
significantly	O	898-911
lower	O	912-917
even	O	918-922
after	O	923-928
week	O	929-933
2	O	934-935
than	O	936-940
in	O	941-943
patients	O	944-952
with	O	953-957
<	O	958-959
2	O	959-960
g	O	961-962
/	O	962-963
dL	O	963-965
decrease	O	966-974
(	O	975-976
P	O	976-977
<	O	978-979
0	O	980-981
.	O	981-982
01	O	982-984
)	O	984-985
.	O	981-982

A	O	987-988
significant	O	989-1000
relationship	O	1001-1013
was	O	1014-1017
observed	O	1018-1026
between	O	1027-1034
the	O	1035-1038
rate	O	1039-1043
of	O	1044-1046
reduction	O	1047-1056
of	O	1057-1059
hemoglobin	O	1060-1070
concentrations	O	1071-1085
at	O	1086-1088
week	O	1089-1093
2	O	1094-1095
and	O	1096-1099
the	O	1100-1103
severity	O	1104-1112
of	O	1113-1115
anemia	B	1116-1122
(	O	1123-1124
P	O	1124-1125
<	O	1126-1127
0	O	1128-1129
.	O	1129-1130
01	O	1130-1132
)	O	1132-1133
.	O	1129-1130

Such	O	1135-1139
factors	O	1140-1147
as	O	1148-1150
sex	O	1151-1154
(	O	1155-1156
female	O	1156-1162
)	O	1162-1163
,	O	1163-1164
age	O	1165-1168
(	O	1169-1170
>	O	1170-1171
or	O	1172-1174
=	O	1175-1176
60	O	1176-1178
years	O	1179-1184
old	O	1185-1188
)	O	1188-1189
,	O	1189-1190
and	O	1191-1194
the	O	1195-1198
ribavirin	O	1199-1208
dose	O	1209-1213
by	O	1214-1216
body	O	1217-1221
weight	O	1222-1228
(	O	1229-1230
12	O	1230-1232
mg	O	1233-1235
/	O	1235-1236
kg	O	1236-1238
or	O	1239-1241
more	O	1242-1246
)	O	1246-1247
were	O	1248-1252
significant	O	1253-1264
by	O	1265-1267
univariate	O	1268-1278
analysis	O	1279-1287
.	O	1287-1288

CONCLUSIONS	O	1289-1300
:	O	1300-1301
Careful	O	1302-1309
administration	O	1310-1324
is	O	1325-1327
necessary	O	1328-1337
in	O	1338-1340
patients	O	1341-1349
>	O	1350-1351
or	O	1352-1354
=	O	1355-1356
60	O	1356-1358
years	O	1359-1364
old	O	1365-1368
,	O	1368-1369
in	O	1370-1372
female	O	1373-1379
patients	O	1380-1388
,	O	1388-1389
and	O	1390-1393
in	O	1394-1396
patients	O	1397-1405
receiving	O	1406-1415
a	O	1416-1417
ribavirin	O	1418-1427
dose	O	1428-1432
of	O	1433-1435
12	O	1436-1438
mg	O	1439-1441
/	O	1441-1442
kg	O	1442-1444
or	O	1445-1447
more	O	1448-1452
.	O	1452-1453

Patients	O	1454-1462
who	O	1463-1466
experience	O	1467-1477
a	O	1478-1479
fall	O	1480-1484
in	O	1485-1487
hemoglobin	O	1488-1498
concentrations	O	1499-1513
of	O	1514-1516
2	O	1517-1518
g	O	1519-1520
/	O	1520-1521
dL	O	1521-1523
or	O	1524-1526
more	O	1527-1531
at	O	1532-1534
week	O	1535-1539
2	O	1540-1541
after	O	1542-1547
the	O	1548-1551
start	O	1552-1557
of	O	1558-1560
treatment	O	1561-1570
should	O	1571-1577
be	O	1578-1580
monitored	O	1581-1590
with	O	1591-1595
particular	O	1596-1606
care	O	1607-1611
.	O	1611-1612

Oxidative	O	0-9
damage	O	10-16
precedes	O	17-25
nitrative	O	26-35
damage	O	36-42
in	O	43-45
adriamycin	O	46-56
-	O	56-57
induced	O	57-64
cardiac	O	65-72
mitochondrial	B	73-86
injury	I	87-93
.	O	93-94

The	O	95-98
purpose	O	99-106
of	O	107-109
the	O	110-113
present	O	114-121
study	O	122-127
was	O	128-131
to	O	132-134
determine	O	135-144
if	O	145-147
elevated	O	148-156
reactive	O	157-165
oxygen	O	166-172
(	O	173-174
ROS	O	174-177
)	O	177-178
/	O	178-179
nitrogen	O	179-187
species	O	188-195
(	O	196-197
RNS	O	197-200
)	O	200-201
reported	O	202-210
to	O	211-213
be	O	214-216
present	O	217-224
in	O	225-227
adriamycin	O	228-238
(	O	239-240
ADR	O	240-243
)	O	243-244
-	O	244-245
induced	O	245-252
cardiotoxicity	B	253-267
actually	O	268-276
resulted	O	277-285
in	O	286-288
cardiomyocyte	O	289-302
oxidative	O	303-312
/	O	312-313
nitrative	O	313-322
damage	O	323-329
,	O	329-330
and	O	331-334
to	O	335-337
quantitatively	O	338-352
determine	O	353-362
the	O	363-366
time	O	367-371
course	O	372-378
and	O	379-382
subcellular	O	383-394
localization	O	395-407
of	O	408-410
these	O	411-416
postulated	O	417-427
damage	O	428-434
products	O	435-443
using	O	444-449
an	O	450-452
in	O	453-455
vivo	O	456-460
approach	O	461-469
.	O	469-470

B6C3	O	471-475
mice	O	476-480
were	O	481-485
treated	O	486-493
with	O	494-498
a	O	499-500
single	O	501-507
dose	O	508-512
of	O	513-515
20	O	516-518
mg	O	519-521
/	O	521-522
kg	O	522-524
ADR	O	525-528
.	O	528-529

Ultrastructural	O	530-545
damage	O	546-552
and	O	553-556
levels	O	557-563
of	O	564-566
4	O	567-568
-	O	568-569
hydroxy	O	569-576
-	O	568-569
2	O	577-578
-	O	568-569
nonenal	O	579-586
(	O	587-588
4HNE	O	588-592
)	O	592-593
-	O	593-594
protein	O	594-601
adducts	O	602-609
and	O	610-613
3	O	614-615
-	O	615-616
nitrotyrosine	O	616-629
(	O	630-631
3NT	O	631-634
)	O	634-635
were	O	636-640
analyzed	O	641-649
.	O	649-650

Quantitative	O	651-663
ultrastructural	O	664-679
damage	O	680-686
using	O	687-692
computerized	O	693-705
image	O	706-711
techniques	O	712-722
showed	O	723-729
cardiomyocyte	O	730-743
injury	O	744-750
as	O	751-753
early	O	754-759
as	O	760-762
3	O	763-764
hours	O	765-770
,	O	770-771
with	O	772-776
mitochondria	O	777-789
being	O	790-795
the	O	796-799
most	O	800-804
extensively	O	805-816
and	O	817-820
progressively	O	821-834
injured	O	835-842
subcellular	O	843-854
organelle	O	855-864
.	O	864-865

Analysis	O	866-874
of	O	875-877
4HNE	O	878-882
protein	O	883-890
adducts	O	891-898
by	O	899-901
immunogold	O	902-912
electron	O	913-921
microscopy	O	922-932
showed	O	933-939
appearance	O	940-950
of	O	951-953
4HNE	O	954-958
protein	O	959-966
adducts	O	967-974
in	O	975-977
mitochondria	O	978-990
as	O	991-993
early	O	994-999
as	O	1000-1002
3	O	1003-1004
hours	O	1005-1010
,	O	1010-1011
with	O	1012-1016
a	O	1017-1018
peak	O	1019-1023
at	O	1024-1026
6	O	1027-1028
hours	O	1029-1034
and	O	1035-1038
subsequent	O	1039-1049
decline	O	1050-1057
at	O	1058-1060
24	O	1061-1063
hours	O	1064-1069
.	O	1069-1070

3NT	O	1071-1074
levels	O	1075-1081
were	O	1082-1086
significantly	O	1087-1100
increased	O	1101-1110
in	O	1111-1113
all	O	1114-1117
subcellular	O	1118-1129
compartments	O	1130-1142
at	O	1143-1145
6	O	1146-1147
hours	O	1148-1153
and	O	1154-1157
subsequently	O	1158-1170
declined	O	1171-1179
at	O	1180-1182
24	O	1183-1185
hours	O	1186-1191
.	O	1191-1192

Our	O	1193-1196
data	O	1197-1201
showed	O	1202-1208
ADR	O	1209-1212
induced	O	1213-1220
4HNE	O	1221-1225
-	O	1225-1226
protein	O	1226-1233
adducts	O	1234-1241
in	O	1242-1244
mitochondria	O	1245-1257
at	O	1258-1260
the	O	1261-1264
same	O	1265-1269
time	O	1270-1274
point	O	1275-1280
as	O	1281-1283
when	O	1284-1288
mitochondrial	B	1289-1302
injury	I	1303-1309
initially	O	1310-1319
appeared	O	1320-1328
.	O	1328-1329

These	O	1330-1335
results	O	1336-1343
document	O	1344-1352
for	O	1353-1356
the	O	1357-1360
first	O	1361-1366
time	O	1367-1371
in	O	1372-1374
vivo	O	1375-1379
that	O	1380-1384
mitochondrial	B	1385-1398
oxidative	I	1399-1408
damage	I	1409-1415
precedes	O	1416-1424
nitrative	O	1425-1434
damage	O	1435-1441
.	O	1441-1442

The	O	1443-1446
progressive	O	1447-1458
nature	O	1459-1465
of	O	1466-1468
mitochondrial	B	1469-1482
injury	I	1483-1489
suggests	O	1490-1498
that	O	1499-1503
mitochondria	O	1504-1516
,	O	1516-1517
not	O	1518-1521
other	O	1522-1527
subcellular	O	1528-1539
organelles	O	1540-1550
,	O	1550-1551
are	O	1552-1555
the	O	1556-1559
major	O	1560-1565
site	O	1566-1570
of	O	1571-1573
intracellular	O	1574-1587
injury	O	1588-1594
.	O	1594-1595

Sotalol	O	0-7
-	O	7-8
induced	O	8-15
coronary	B	16-24
spasm	I	25-30
in	O	31-33
a	O	34-35
patient	O	36-43
with	O	44-48
dilated	B	49-56
cardiomyopathy	I	57-71
associated	O	72-82
with	O	83-87
sustained	O	88-97
ventricular	B	98-109
tachycardia	I	110-121
.	O	121-122

A	O	123-124
54	O	125-127
-	O	127-128
year	O	128-132
-	O	127-128
old	O	133-136
man	O	137-140
with	O	141-145
severe	O	146-152
left	O	153-157
ventricular	B	158-169
dysfunction	I	170-181
due	O	182-185
to	O	186-188
dilated	B	189-196
cardiomyopathy	I	197-211
was	O	212-215
referred	O	216-224
to	O	225-227
our	O	228-231
hospital	O	232-240
for	O	241-244
symptomatic	O	245-256
incessant	O	257-266
sustained	O	267-276
ventricular	B	277-288
tachycardia	I	289-300
(	O	301-302
VT	B	302-304
)	O	304-305
.	O	305-306

After	O	307-312
the	O	313-316
administration	O	317-331
of	O	332-334
nifekalant	O	335-345
hydrochloride	O	346-359
,	O	359-360
sustained	O	361-370
VT	B	371-373
was	O	374-377
terminated	O	378-388
.	O	388-389

An	O	390-392
alternate	O	393-402
class	O	403-408
III	O	409-412
agent	O	413-418
,	O	418-419
sotalol	O	420-427
,	O	427-428
was	O	429-432
also	O	433-437
effective	O	438-447
for	O	448-451
the	O	452-455
prevention	O	456-466
of	O	467-469
VT	B	470-472
.	O	472-473

However	O	474-481
,	O	481-482
one	O	483-486
month	O	487-492
after	O	493-498
switching	O	499-508
over	O	509-513
nifekalant	O	514-524
to	O	525-527
sotalol	O	528-535
,	O	535-536
a	O	537-538
short	O	539-544
duration	O	545-553
of	O	554-556
ST	O	557-559
elevation	O	560-569
was	O	570-573
documented	O	574-584
in	O	585-587
ECG	O	588-591
monitoring	O	592-602
at	O	603-605
almost	O	606-612
the	O	613-616
same	O	617-621
time	O	622-626
for	O	627-630
three	O	631-636
consecutive	O	637-648
days	O	649-653
.	O	653-654

ST	O	655-657
elevation	O	658-667
with	O	668-672
chest	O	673-678
discomfort	O	679-689
disappeared	O	690-701
since	O	702-707
he	O	708-710
began	O	711-716
taking	O	717-723
long	O	724-728
-	O	728-729
acting	O	729-735
diltiazem	O	736-745
.	O	745-746

Coronary	B	747-755
vasospasm	I	756-765
may	O	766-769
be	O	770-772
induced	O	773-780
by	O	781-783
the	O	784-787
non	O	788-791
-	O	791-792
selective	O	792-801
beta	O	802-806
-	O	806-807
blocking	O	807-815
properties	O	816-826
of	O	827-829
sotalol	O	830-837
.	O	837-838

Effects	O	0-7
of	O	8-10
the	O	11-14
antidepressant	O	15-29
trazodone	O	30-39
,	O	39-40
a	O	41-42
5	O	43-44
-	O	44-45
HT	O	45-47
2A	O	48-50
/	O	50-51
2C	O	51-53
receptor	O	54-62
antagonist	O	63-73
,	O	73-74
on	O	75-77
dopamine	O	78-86
-	O	86-87
dependent	O	87-96
behaviors	O	97-106
in	O	107-109
rats	O	110-114
.	O	114-115

RATIONALE	O	116-125
:	O	125-126
5	O	127-128
-	O	128-129
Hydroxytryptamine	O	129-146
,	O	146-147
via	O	148-151
stimulation	O	152-163
of	O	164-166
5	O	167-168
-	O	168-169
HT	O	169-171
2C	O	172-174
receptors	O	175-184
,	O	184-185
exerts	O	186-192
a	O	193-194
tonic	O	195-200
inhibitory	O	201-211
influence	O	212-221
on	O	222-224
dopaminergic	O	225-237
neurotransmission	O	238-255
,	O	255-256
whereas	O	257-264
activation	O	265-275
of	O	276-278
5	O	279-280
-	O	280-281
HT	O	281-283
2A	O	284-286
receptors	O	287-296
enhances	O	297-305
stimulated	O	306-316
DAergic	O	317-324
neurotransmission	O	325-342
.	O	342-343

The	O	344-347
antidepressant	O	348-362
trazodone	O	363-372
is	O	373-375
a	O	376-377
5	O	378-379
-	O	379-380
HT	O	380-382
2A	O	383-385
/	O	385-386
2C	O	386-388
receptor	O	389-397
antagonist	O	398-408
.	O	408-409

OBJECTIVES	O	410-420
:	O	420-421
To	O	422-424
evaluate	O	425-433
the	O	434-437
effect	O	438-444
of	O	445-447
trazodone	O	448-457
treatment	O	458-467
on	O	468-470
behaviors	O	471-480
dependent	O	481-490
on	O	491-493
the	O	494-497
functional	O	498-508
status	O	509-515
of	O	516-518
the	O	519-522
nigrostriatal	O	523-536
DAergic	O	537-544
system	O	545-551
.	O	551-552

METHODS	O	553-560
:	O	560-561
The	O	562-565
effect	O	566-572
of	O	573-575
pretreatment	O	576-588
with	O	589-593
trazodone	O	594-603
on	O	604-606
dexamphetamine	O	607-621
-	O	621-622
and	O	623-626
apomorphine	O	627-638
-	O	638-639
induced	O	639-646
oral	B	647-651
stereotypies	I	652-664
,	O	664-665
on	O	666-668
catalepsy	B	669-678
induced	O	679-686
by	O	687-689
haloperidol	O	690-701
and	O	702-705
apomorphine	O	706-717
(	O	718-719
0	O	719-720
.	O	720-721
05	O	721-723
mg	O	724-726
/	O	726-727
kg	O	727-729
,	O	729-730
i	O	731-732
.	O	732-733
p	O	733-734
.	O	732-733
)	O	735-736
,	O	736-737
on	O	738-740
ergometrine	O	741-752
-	O	752-753
induced	O	753-760
wet	O	761-764
dog	O	765-768
shake	O	769-774
(	O	775-776
WDS	O	776-779
)	O	779-780
behavior	O	781-789
and	O	790-793
fluoxetine	O	794-804
-	O	804-805
induced	O	805-812
penile	O	813-819
erections	O	820-829
was	O	830-833
studied	O	834-841
in	O	842-844
rats	O	845-849
.	O	849-850

We	O	851-853
also	O	854-858
investigated	O	859-871
whether	O	872-879
trazodone	O	880-889
induces	O	890-897
catalepsy	B	898-907
in	O	908-910
rats	O	911-915
.	O	915-916

RESULTS	O	917-924
:	O	924-925
Trazodone	O	926-935
at	O	936-938
2	O	939-940
.	O	940-941
5	O	941-942
-	O	942-943
20	O	943-945
mg	O	946-948
/	O	948-949
kg	O	949-951
i	O	952-953
.	O	953-954
p	O	954-955
.	O	953-954
did	O	957-960
not	O	961-964
induce	O	965-971
catalepsy	B	972-981
,	O	981-982
and	O	983-986
did	O	987-990
not	O	991-994
antagonize	O	995-1005
apomorphine	O	1006-1017
(	O	1018-1019
1	O	1019-1020
.	O	1020-1021
5	O	1021-1022
and	O	1023-1026
3	O	1027-1028
mg	O	1029-1031
/	O	1031-1032
kg	O	1032-1034
)	O	1034-1035
stereotypy	O	1036-1046
and	O	1047-1050
apomorphine	O	1051-1062
(	O	1063-1064
0	O	1064-1065
.	O	1065-1066
05	O	1066-1068
mg	O	1069-1071
/	O	1071-1072
kg	O	1072-1074
)	O	1074-1075
-	O	1075-1076
induced	O	1076-1083
catalepsy	B	1084-1093
.	O	1093-1094

However	O	1095-1102
,	O	1102-1103
pretreatment	O	1104-1116
with	O	1117-1121
5	O	1122-1123
,	O	1123-1124
10	O	1125-1127
and	O	1128-1131
20	O	1132-1134
mg	O	1135-1137
/	O	1137-1138
kg	O	1138-1140
i	O	1141-1142
.	O	1142-1143
p	O	1143-1144
.	O	1142-1143
trazodone	O	1146-1155
enhanced	O	1156-1164
dexamphetamine	O	1165-1179
stereotypy	O	1180-1190
,	O	1190-1191
and	O	1192-1195
antagonized	O	1196-1207
haloperidol	O	1208-1219
catalepsy	B	1220-1229
,	O	1229-1230
ergometrine	O	1231-1242
-	O	1242-1243
induced	O	1243-1250
WDS	O	1251-1254
behavior	O	1255-1263
and	O	1264-1267
fluoxetine	O	1268-1278
-	O	1278-1279
induced	O	1279-1286
penile	O	1287-1293
erections	O	1294-1303
.	O	1303-1304

Trazodone	O	1305-1314
at	O	1315-1317
30	O	1318-1320
,	O	1320-1321
40	O	1322-1324
and	O	1325-1328
50	O	1329-1331
mg	O	1332-1334
/	O	1334-1335
kg	O	1335-1337
i	O	1338-1339
.	O	1339-1340
p	O	1340-1341
.	O	1339-1340
induced	O	1343-1350
catalepsy	B	1351-1360
and	O	1361-1364
antagonized	O	1365-1376
apomorphine	O	1377-1388
and	O	1389-1392
dexamphetamine	O	1393-1407
stereotypies	O	1408-1420
.	O	1420-1421

CONCLUSIONS	O	1422-1433
:	O	1433-1434
Our	O	1435-1438
results	O	1439-1446
indicate	O	1447-1455
that	O	1456-1460
trazodone	O	1461-1470
at	O	1471-1473
2	O	1474-1475
.	O	1475-1476
5	O	1476-1477
-	O	1477-1478
20	O	1478-1480
mg	O	1481-1483
/	O	1483-1484
kg	O	1484-1486
does	O	1487-1491
not	O	1492-1495
block	O	1496-1501
pre	O	1502-1505
-	O	1505-1506
and	O	1507-1510
postsynaptic	O	1511-1523
striatal	O	1524-1532
D2	O	1533-1535
DA	O	1536-1538
receptors	O	1539-1548
,	O	1548-1549
while	O	1550-1555
at	O	1556-1558
30	O	1559-1561
,	O	1561-1562
40	O	1563-1565
and	O	1566-1569
50	O	1570-1572
mg	O	1573-1575
/	O	1575-1576
kg	O	1576-1578
it	O	1579-1581
blocks	O	1582-1588
postsynaptic	O	1589-1601
striatal	O	1602-1610
D2	O	1611-1613
DA	O	1614-1616
receptors	O	1617-1626
.	O	1626-1627

Furthermore	O	1628-1639
,	O	1639-1640
at	O	1641-1643
5	O	1644-1645
,	O	1645-1646
10	O	1647-1649
and	O	1650-1653
20	O	1654-1656
mg	O	1657-1659
/	O	1659-1660
kg	O	1660-1662
,	O	1662-1663
trazodone	O	1664-1673
blocks	O	1674-1680
5	O	1681-1682
-	O	1682-1683
HT	O	1683-1685
2A	O	1686-1688
and	O	1689-1692
5	O	1693-1694
-	O	1694-1695
HT	O	1695-1697
2C	O	1698-1700
receptors	O	1701-1710
.	O	1710-1711

We	O	1712-1714
suggest	O	1715-1722
that	O	1723-1727
trazodone	O	1728-1737
(	O	1738-1739
5	O	1739-1740
,	O	1740-1741
10	O	1742-1744
and	O	1745-1748
20	O	1749-1751
mg	O	1752-1754
/	O	1754-1755
kg	O	1755-1757
)	O	1757-1758
,	O	1758-1759
by	O	1760-1762
blocking	O	1763-1771
the	O	1772-1775
5	O	1776-1777
-	O	1777-1778
HT	O	1778-1780
2C	O	1781-1783
receptors	O	1784-1793
,	O	1793-1794
releases	O	1795-1803
the	O	1804-1807
nigrostriatal	O	1808-1821
DAergic	O	1822-1829
neurons	O	1830-1837
from	O	1838-1842
tonic	O	1843-1848
inhibition	O	1849-1859
caused	O	1860-1866
by	O	1867-1869
5	O	1870-1871
-	O	1871-1872
HT	O	1872-1874
,	O	1874-1875
and	O	1876-1879
thereby	O	1880-1887
potentiates	O	1888-1899
dexamphetamine	O	1900-1914
stereotypy	O	1915-1925
and	O	1926-1929
antagonizes	O	1930-1941
haloperidol	O	1942-1953
catalepsy	B	1954-1963
.	O	1963-1964

Swallowing	B	0-10
abnormalities	I	11-24
and	O	25-28
dyskinesia	B	29-39
in	O	40-42
Parkinson	B	43-52
'	I	52-53
s	I	49-50
disease	I	55-62
.	O	62-63

Gastrointestinal	B	64-80
abnormalities	I	81-94
in	O	95-97
Parkinson	B	98-107
'	I	107-108
s	I	104-105
disease	I	110-117
(	O	118-119
PD	B	119-121
)	O	121-122
have	O	123-127
been	O	128-132
known	O	133-138
for	O	139-142
almost	O	143-149
two	O	150-153
centuries	O	154-163
,	O	163-164
but	O	165-168
many	O	169-173
aspects	O	174-181
concerning	O	182-192
their	O	193-198
pathophysiology	O	199-214
have	O	215-219
not	O	220-223
been	O	224-228
completely	O	229-239
clarified	O	240-249
.	O	249-250

The	O	251-254
aim	O	255-258
of	O	259-261
this	O	262-266
study	O	267-272
was	O	273-276
to	O	277-279
characterize	O	280-292
the	O	293-296
oropharyngeal	O	297-310
dynamics	O	311-319
in	O	320-322
PD	B	323-325
patients	O	326-334
with	O	335-339
and	O	340-343
without	O	344-351
levodopa	O	352-360
-	O	360-361
induced	O	361-368
dyskinesia	B	369-379
.	O	379-380

Fifteen	O	381-388
dyskinetic	B	389-399
,	O	399-400
12	O	401-403
nondyskinetic	O	404-417
patients	O	418-426
,	O	426-427
and	O	428-431
a	O	432-433
control	O	434-441
group	O	442-447
were	O	448-452
included	O	453-461
.	O	461-462

Patients	O	463-471
were	O	472-476
asked	O	477-482
about	O	483-488
dysphagia	B	489-498
and	O	499-502
evaluated	O	503-512
with	O	513-517
the	O	518-521
Unified	O	522-529
Parkinson	B	530-539
'	I	539-540
s	I	536-537
Disease	I	542-549
Rating	O	550-556
Scale	O	557-562
Parts	O	563-568
II	O	569-571
and	O	572-575
III	O	576-579
and	O	580-583
the	O	584-587
Hoehn	O	588-593
and	O	594-597
Yahr	O	598-602
scale	O	603-608
.	O	608-609

Deglutition	O	610-621
was	O	622-625
assessed	O	626-634
using	O	635-640
modified	O	641-649
barium	O	650-656
swallow	O	657-664
with	O	665-669
videofluoroscopy	O	670-686
.	O	686-687

Nondyskinetic	O	688-701
patients	O	702-710
,	O	710-711
but	O	712-715
not	O	716-719
the	O	720-723
dyskinetic	B	724-734
ones	O	735-739
,	O	739-740
showed	O	741-747
less	O	748-752
oropharyngeal	O	753-766
swallowing	O	767-777
efficiency	O	778-788
(	O	789-790
OPSE	O	790-794
)	O	794-795
for	O	796-799
liquid	O	800-806
food	O	807-811
than	O	812-816
controls	O	817-825
(	O	826-827
Dunnett	O	827-834
,	O	834-835
P	O	836-837
=	O	838-839
0	O	840-841
.	O	841-842
02	O	842-844
)	O	844-845
.	O	841-842

Dyskinetic	B	847-857
patients	O	858-866
tended	O	867-873
to	O	874-876
have	O	877-881
a	O	882-883
greater	O	884-891
OPSE	O	892-896
than	O	897-901
nondyskinetic	O	902-915
(	O	916-917
Dunnett	O	917-924
,	O	924-925
P	O	926-927
=	O	928-929
0	O	930-931
.	O	931-932
06	O	932-934
)	O	934-935
.	O	931-932

Patients	O	937-945
who	O	946-949
were	O	950-954
using	O	955-960
a	O	961-962
higher	O	963-969
dose	O	970-974
of	O	975-977
levodopa	O	978-986
had	O	987-990
a	O	991-992
greater	O	993-1000
OPSE	O	1001-1005
and	O	1006-1009
a	O	1010-1011
trend	O	1012-1017
toward	O	1018-1024
a	O	1025-1026
smaller	O	1027-1034
oral	O	1035-1039
transit	O	1040-1047
time	O	1048-1052
(	O	1053-1054
Pearson	O	1054-1061
'	O	1061-1062
s	O	1058-1059
correlation	O	1064-1075
,	O	1075-1076
P	O	1077-1078
=	O	1079-1080
0	O	1081-1082
.	O	1082-1083
01	O	1083-1085
and	O	1086-1089
0	O	1090-1091
.	O	1091-1092
08	O	1092-1094
,	O	1094-1095
respectively	O	1096-1108
)	O	1108-1109
.	O	1109-1110

Neither	O	1111-1118
the	O	1119-1122
report	O	1123-1129
of	O	1130-1132
dysphagia	B	1133-1142
nor	O	1143-1146
any	O	1147-1150
of	O	1151-1153
the	O	1154-1157
PD	B	1158-1160
severity	O	1161-1169
parameters	O	1170-1180
correlated	O	1181-1191
to	O	1192-1194
the	O	1195-1198
videofluoroscopic	O	1199-1216
variables	O	1217-1226
.	O	1226-1227

In	O	1228-1230
the	O	1231-1234
current	O	1235-1242
study	O	1243-1248
,	O	1248-1249
dyskinetic	B	1250-1260
patients	O	1261-1269
performed	O	1270-1279
better	O	1280-1286
in	O	1287-1289
swallowing	O	1290-1300
function	O	1301-1309
,	O	1309-1310
which	O	1311-1316
could	O	1317-1322
be	O	1323-1325
explained	O	1326-1335
on	O	1336-1338
the	O	1339-1342
basis	O	1343-1348
of	O	1349-1351
a	O	1352-1353
greater	O	1354-1361
levodopa	O	1362-1370
dose	O	1371-1375
.	O	1375-1376

Our	O	1377-1380
results	O	1381-1388
suggest	O	1389-1396
a	O	1397-1398
role	O	1399-1403
for	O	1404-1407
levodopa	O	1408-1416
in	O	1417-1419
the	O	1420-1423
oral	O	1424-1428
phase	O	1429-1434
of	O	1435-1437
deglutition	O	1438-1449
and	O	1450-1453
confirm	O	1454-1461
that	O	1462-1466
dysphagia	B	1467-1476
is	O	1477-1479
not	O	1480-1483
a	O	1484-1485
good	O	1486-1490
predictor	O	1491-1500
of	O	1501-1503
deglutition	O	1504-1515
alterations	O	1516-1527
in	O	1528-1530
PD	B	1531-1533
.	O	1533-1534

Inhibition	O	0-10
of	O	11-13
nuclear	O	14-21
factor	O	22-28
-	O	28-29
kappaB	O	29-35
activation	O	36-46
attenuates	O	47-57
tubulointerstitial	B	58-76
nephritis	I	77-86
induced	O	87-94
by	O	95-97
gentamicin	O	98-108
.	O	108-109

BACKGROUND	O	110-120
:	O	120-121
Animals	O	122-129
treated	O	130-137
with	O	138-142
gentamicin	O	143-153
can	O	154-157
show	O	158-162
residual	O	163-171
areas	O	172-177
of	O	178-180
interstitial	O	181-193
fibrosis	B	194-202
in	O	203-205
the	O	206-209
renal	O	210-215
cortex	O	216-222
.	O	222-223

This	O	224-228
study	O	229-234
investigated	O	235-247
the	O	248-251
expression	O	252-262
of	O	263-265
nuclear	O	266-273
factor	O	274-280
-	O	280-281
kappaB	O	281-287
(	O	288-289
NF	O	289-291
-	O	291-292
kappaB	O	292-298
)	O	298-299
,	O	299-300
mitogen	O	301-308
-	O	308-309
activated	O	309-318
protein	O	319-326
(	O	327-328
MAP	O	328-331
)	O	331-332
kinases	O	333-340
and	O	341-344
macrophages	O	345-356
in	O	357-359
the	O	360-363
renal	O	364-369
cortex	O	370-376
and	O	377-380
structural	O	381-391
and	O	392-395
functional	O	396-406
renal	O	407-412
changes	O	413-420
of	O	421-423
rats	O	424-428
treated	O	429-436
with	O	437-441
gentamicin	O	442-452
or	O	453-455
gentamicin	O	456-466
+	O	467-468
pyrrolidine	O	469-480
dithiocarbamate	O	481-496
(	O	497-498
PDTC	O	498-502
)	O	502-503
,	O	503-504
an	O	505-507
NF	O	508-510
-	O	510-511
kappaB	O	511-517
inhibitor	O	518-527
.	O	527-528

METHODS	O	529-536
:	O	536-537
38	O	538-540
female	O	541-547
Wistar	O	548-554
rats	O	555-559
were	O	560-564
injected	O	565-573
with	O	574-578
gentamicin	O	579-589
,	O	589-590
40	O	591-593
mg	O	594-596
/	O	596-597
kg	O	597-599
,	O	599-600
twice	O	601-606
a	O	607-608
day	O	609-612
for	O	613-616
9	O	617-618
days	O	619-623
,	O	623-624
38	O	625-627
with	O	628-632
gentamicin	O	633-643
+	O	644-645
PDTC	O	646-650
,	O	650-651
and	O	652-655
28	O	656-658
with	O	659-663
0	O	664-665
.	O	665-666
15	O	666-668
M	O	669-670
NaCl	O	671-675
solution	O	676-684
.	O	684-685

The	O	686-689
animals	O	690-697
were	O	698-702
killed	O	703-709
5	O	710-711
and	O	712-715
30	O	716-718
days	O	719-723
after	O	724-729
these	O	730-735
injections	O	736-746
and	O	747-750
the	O	751-754
kidneys	O	755-762
were	O	763-767
removed	O	768-775
for	O	776-779
histological	O	780-792
and	O	793-796
immunohistochemical	O	797-816
studies	O	817-824
.	O	824-825

The	O	826-829
results	O	830-837
of	O	838-840
the	O	841-844
immunohistochemical	O	845-864
studies	O	865-872
were	O	873-877
scored	O	878-884
according	O	885-894
to	O	895-897
the	O	898-901
extent	O	902-908
of	O	909-911
staining	O	912-920
.	O	920-921

The	O	922-925
fractional	O	926-936
interstitial	O	937-949
area	O	950-954
was	O	955-958
determined	O	959-969
by	O	970-972
morphometry	O	973-984
.	O	984-985

RESULTS	O	986-993
:	O	993-994
Gentamicin	O	995-1005
-	O	1005-1006
treated	O	1006-1013
rats	O	1014-1018
presented	O	1019-1028
a	O	1029-1030
transitory	O	1031-1041
increase	O	1042-1050
in	O	1051-1053
plasma	O	1054-1060
creatinine	O	1061-1071
levels	O	1072-1078
.	O	1078-1079

Increased	O	1080-1089
ED	O	1090-1092
-	O	1092-1093
1	O	1093-1094
,	O	1094-1095
MAP	O	1096-1099
kinases	O	1100-1107
and	O	1108-1111
NF	O	1112-1114
-	O	1114-1115
kappaB	O	1115-1121
staining	O	1122-1130
were	O	1131-1135
also	O	1136-1140
observed	O	1141-1149
in	O	1150-1152
the	O	1153-1156
renal	O	1157-1162
cortex	O	1163-1169
from	O	1170-1174
all	O	1175-1178
gentamicin	O	1179-1189
-	O	1189-1190
treated	O	1190-1197
rats	O	1198-1202
compared	O	1203-1211
to	O	1212-1214
control	O	1215-1222
(	O	1223-1224
p	O	1224-1225
<	O	1226-1227
0	O	1228-1229
.	O	1229-1230
05	O	1230-1232
)	O	1232-1233
.	O	1229-1230

The	O	1235-1238
animals	O	1239-1246
killed	O	1247-1253
on	O	1254-1256
day	O	1257-1260
30	O	1261-1263
also	O	1264-1268
presented	O	1269-1278
fibrosis	B	1279-1287
in	O	1288-1290
the	O	1291-1294
renal	O	1295-1300
cortex	O	1301-1307
despite	O	1308-1315
the	O	1316-1319
recovery	O	1320-1328
of	O	1329-1331
renal	O	1332-1337
function	O	1338-1346
.	O	1346-1347

Treatment	O	1348-1357
with	O	1358-1362
PDTC	O	1363-1367
reduced	O	1368-1375
the	O	1376-1379
functional	O	1380-1390
and	O	1391-1394
structural	O	1395-1405
changes	O	1406-1413
induced	O	1414-1421
by	O	1422-1424
gentamicin	O	1425-1435
.	O	1435-1436

CONCLUSIONS	O	1437-1448
:	O	1448-1449
These	O	1450-1455
data	O	1456-1460
show	O	1461-1465
that	O	1466-1470
inhibition	O	1471-1481
of	O	1482-1484
NF	O	1485-1487
-	O	1487-1488
kappaB	O	1488-1494
activation	O	1495-1505
attenuates	O	1506-1516
tubulointerstitial	B	1517-1535
nephritis	I	1536-1545
induced	O	1546-1553
by	O	1554-1556
gentamicin	O	1557-1567
.	O	1567-1568

Glucose	O	0-7
metabolism	O	8-18
in	O	19-21
patients	O	22-30
with	O	31-35
schizophrenia	B	36-49
treated	O	50-57
with	O	58-62
atypical	O	63-71
antipsychotic	O	72-85
agents	O	86-92
:	O	92-93
a	O	94-95
frequently	O	96-106
sampled	O	107-114
intravenous	O	115-126
glucose	O	127-134
tolerance	O	135-144
test	O	145-149
and	O	150-153
minimal	O	154-161
model	O	162-167
analysis	O	168-176
.	O	176-177

BACKGROUND	O	178-188
:	O	188-189
While	O	190-195
the	O	196-199
incidence	O	200-209
of	O	210-212
new	O	213-216
-	O	216-217
onset	O	217-222
diabetes	B	223-231
mellitus	I	232-240
may	O	241-244
be	O	245-247
increasing	O	248-258
in	O	259-261
patients	O	262-270
with	O	271-275
schizophrenia	B	276-289
treated	O	290-297
with	O	298-302
certain	O	303-310
atypical	O	311-319
antipsychotic	O	320-333
agents	O	334-340
,	O	340-341
it	O	342-344
remains	O	345-352
unclear	O	353-360
whether	O	361-368
atypical	O	369-377
agents	O	378-384
are	O	385-388
directly	O	389-397
affecting	O	398-407
glucose	O	408-415
metabolism	O	416-426
or	O	427-429
simply	O	430-436
increasing	O	437-447
known	O	448-453
risk	O	454-458
factors	O	459-466
for	O	467-470
diabetes	B	471-479
.	O	479-480

OBJECTIVE	O	481-490
:	O	490-491
To	O	492-494
study	O	495-500
the	O	501-504
2	O	505-506
drugs	O	507-512
most	O	513-517
clearly	O	518-525
implicated	O	526-536
(	O	537-538
clozapine	O	538-547
and	O	548-551
olanzapine	O	552-562
)	O	562-563
and	O	564-567
risperidone	O	568-579
using	O	580-585
a	O	586-587
frequently	O	588-598
sampled	O	599-606
intravenous	O	607-618
glucose	O	619-626
tolerance	O	627-636
test	O	637-641
.	O	641-642

DESIGN	O	643-649
:	O	649-650
A	O	651-652
cross	O	653-658
-	O	658-659
sectional	O	659-668
design	O	669-675
in	O	676-678
stable	O	679-685
,	O	685-686
treated	O	687-694
patients	O	695-703
with	O	704-708
schizophrenia	B	709-722
evaluated	O	723-732
using	O	733-738
a	O	739-740
frequently	O	741-751
sampled	O	752-759
intravenous	O	760-771
glucose	O	772-779
tolerance	O	780-789
test	O	790-794
and	O	795-798
the	O	799-802
Bergman	O	803-810
minimal	O	811-818
model	O	819-824
analysis	O	825-833
.	O	833-834

SETTING	O	835-842
:	O	842-843
Subjects	O	844-852
were	O	853-857
recruited	O	858-867
from	O	868-872
an	O	873-875
urban	O	876-881
community	O	882-891
mental	O	892-898
health	O	899-905
clinic	O	906-912
and	O	913-916
were	O	917-921
studied	O	922-929
at	O	930-932
a	O	933-934
general	O	935-942
clinical	O	943-951
research	O	952-960
center	O	961-967
.	O	967-968

Patients	O	969-977
Fifty	O	978-983
subjects	O	984-992
signed	O	993-999
informed	O	1000-1008
consent	O	1009-1016
and	O	1017-1020
41	O	1021-1023
underwent	O	1024-1033
the	O	1034-1037
frequently	O	1038-1048
sampled	O	1049-1056
intravenous	O	1057-1068
glucose	O	1069-1076
tolerance	O	1077-1086
test	O	1087-1091
.	O	1091-1092

Thirty	O	1093-1099
-	O	1099-1100
six	O	1100-1103
nonobese	O	1104-1112
subjects	O	1113-1121
with	O	1122-1126
schizophrenia	B	1127-1140
or	O	1141-1143
schizoaffective	B	1144-1159
disorder	I	1160-1168
,	O	1168-1169
matched	O	1170-1177
by	O	1178-1180
body	O	1181-1185
mass	O	1186-1190
index	O	1191-1196
and	O	1197-1200
treated	O	1201-1208
with	O	1209-1213
either	O	1214-1220
clozapine	O	1221-1230
,	O	1230-1231
olanzapine	O	1232-1242
,	O	1242-1243
or	O	1244-1246
risperidone	O	1247-1258
,	O	1258-1259
were	O	1260-1264
included	O	1265-1273
in	O	1274-1276
the	O	1277-1280
analysis	O	1281-1289
.	O	1289-1290

MAIN	O	1291-1295
OUTCOME	O	1296-1303
MEASURES	O	1304-1312
:	O	1312-1313
Fasting	O	1314-1321
plasma	O	1322-1328
glucose	O	1329-1336
and	O	1337-1340
fasting	O	1341-1348
serum	O	1349-1354
insulin	O	1355-1362
levels	O	1363-1369
,	O	1369-1370
insulin	B	1371-1378
sensitivity	I	1379-1390
index	O	1391-1396
,	O	1396-1397
homeostasis	O	1398-1409
model	O	1410-1415
assessment	O	1416-1426
of	O	1427-1429
insulin	B	1430-1437
resistance	I	1438-1448
,	O	1448-1449
and	O	1450-1453
glucose	O	1454-1461
effectiveness	O	1462-1475
.	O	1475-1476

RESULTS	O	1477-1484
:	O	1484-1485
The	O	1486-1489
mean	O	1490-1494
+	O	1495-1496
/	O	1496-1497
-	O	1497-1498
SD	O	1499-1501
duration	O	1502-1510
of	O	1511-1513
treatment	O	1514-1523
with	O	1524-1528
the	O	1529-1532
identified	O	1533-1543
atypical	O	1544-1552
antipsychotic	O	1553-1566
agent	O	1567-1572
was	O	1573-1576
68	O	1577-1579
.	O	1579-1580
3	O	1580-1581
+	O	1582-1583
/	O	1583-1584
-	O	1584-1585
28	O	1586-1588
.	O	1588-1589
9	O	1589-1590
months	O	1591-1597
(	O	1598-1599
clozapine	O	1599-1608
)	O	1608-1609
,	O	1609-1610
29	O	1611-1613
.	O	1613-1614
5	O	1614-1615
+	O	1616-1617
/	O	1617-1618
-	O	1618-1619
17	O	1620-1622
.	O	1622-1623
5	O	1623-1624
months	O	1625-1631
(	O	1632-1633
olanzapine	O	1633-1643
)	O	1643-1644
,	O	1644-1645
and	O	1646-1649
40	O	1650-1652
.	O	1652-1653
9	O	1653-1654
+	O	1655-1656
/	O	1656-1657
-	O	1657-1658
33	O	1659-1661
.	O	1661-1662
7	O	1662-1663
(	O	1664-1665
risperidone	O	1665-1676
)	O	1676-1677
.	O	1677-1678

Fasting	O	1679-1686
serum	O	1687-1692
insulin	O	1693-1700
concentrations	O	1701-1715
differed	O	1716-1724
among	O	1725-1730
groups	O	1731-1737
(	O	1738-1739
F	O	1739-1740
(	O	1738-1739
33	O	1741-1743
)	O	1743-1744
=	O	1745-1746
3	O	1747-1748
.	O	1748-1749
35	O	1749-1751
;	O	1751-1752
P	O	1753-1754
=	O	1755-1756
.	O	1757-1758
047	O	1758-1761
)	O	1761-1762

(	O	1763-1764
clozapine	O	1764-1773
>	O	1773-1774
olanzapine	O	1774-1784
>	O	1773-1774
risperidone	O	1785-1796
)	O	1796-1797
with	O	1798-1802
significant	O	1803-1814
differences	O	1815-1826
between	O	1827-1834
clozapine	O	1835-1844
and	O	1845-1848
risperidone	O	1849-1860
(	O	1861-1862
t	O	1862-1863
(	O	1861-1862
33	O	1864-1866
)	O	1866-1867
=	O	1868-1869
2	O	1870-1871
.	O	1871-1872
32	O	1872-1874
;	O	1874-1875
P	O	1876-1877
=	O	1878-1879
.	O	1880-1881
03	O	1881-1883
)	O	1883-1884

and	O	1885-1888
olanzapine	O	1889-1899
and	O	1900-1903
risperidone	O	1904-1915
(	O	1916-1917
t	O	1917-1918
(	O	1916-1917
33	O	1919-1921
)	O	1921-1922
=	O	1923-1924
2	O	1925-1926
.	O	1926-1927
15	O	1927-1929
;	O	1929-1930
P	O	1931-1932
=	O	1933-1934
.	O	1935-1936
04	O	1936-1938
)	O	1938-1939
.	O	1935-1936

There	O	1941-1946
was	O	1947-1950
a	O	1951-1952
significant	O	1953-1964
difference	O	1965-1975
in	O	1976-1978
insulin	B	1979-1986
sensitivity	I	1987-1998
index	O	1999-2004
among	O	2005-2010
groups	O	2011-2017
(	O	2018-2019
F	O	2019-2020
(	O	2018-2019
33	O	2021-2023
)	O	2023-2024
=	O	2025-2026
10	O	2027-2029
.	O	2029-2030
66	O	2030-2032
;	O	2032-2033

P	O	2034-2035
<	O	2035-2036
.	O	2036-2037
001	O	2037-2040
)	O	2040-2041
(	O	2042-2043
clozapine	O	2043-2052
<	O	2052-2053
olanzapine	O	2053-2063
<	O	2052-2053
risperidone	O	2064-2075
)	O	2075-2076
,	O	2076-2077
with	O	2078-2082
subjects	O	2083-2091
who	O	2092-2095
received	O	2096-2104
clozapine	O	2105-2114
and	O	2115-2118
olanzapine	O	2119-2129
exhibiting	O	2130-2140
significant	O	2141-2152
insulin	B	2153-2160
resistance	I	2161-2171
compared	O	2172-2180
with	O	2181-2185
subjects	O	2186-2194
who	O	2195-2198
were	O	2199-2203
treated	O	2204-2211
with	O	2212-2216
risperidone	O	2217-2228
(	O	2229-2230
clozapine	O	2230-2239
vs	O	2240-2242
risperidone	O	2243-2254
,	O	2254-2255
t	O	2256-2257
(	O	2257-2258
33	O	2258-2260
)	O	2260-2261
=	O	2262-2263
-	O	2264-2265
4	O	2265-2266
.	O	2266-2267
29	O	2267-2269
;	O	2269-2270

P	O	2271-2272
<	O	2272-2273
.	O	2273-2274
001	O	2274-2277
;	O	2277-2278
olanzapine	O	2279-2289
vs	O	2290-2292
risperidone	O	2293-2304
,	O	2304-2305
t	O	2306-2307
(	O	2307-2308
33	O	2308-2310
)	O	2310-2311
=	O	2312-2313
-	O	2314-2315
3	O	2315-2316
.	O	2316-2317
62	O	2317-2319
;	O	2319-2320

P	O	2321-2322
=	O	2323-2324
.	O	2325-2326
001	O	2326-2329

[	O	2330-2331
P	O	2331-2332
<	O	2332-2333
.	O	2333-2334
001	O	2334-2337
]	O	2337-2338
)	O	2338-2339
.	O	2333-2334

The	O	2341-2344
homeostasis	O	2345-2356
model	O	2357-2362
assessment	O	2363-2373
of	O	2374-2376
insulin	B	2377-2384
resistance	I	2385-2395
also	O	2396-2400
differed	O	2401-2409
significantly	O	2410-2423
among	O	2424-2429
groups	O	2430-2436
(	O	2437-2438
F	O	2438-2439
(	O	2437-2438
33	O	2440-2442
)	O	2442-2443
=	O	2444-2445
4	O	2446-2447
.	O	2447-2448
92	O	2448-2450
;	O	2450-2451
P	O	2452-2453
=	O	2454-2455
.	O	2456-2457
01	O	2457-2459
)	O	2459-2460

(	O	2461-2462
clozapine	O	2462-2471
>	O	2471-2472
olanzapine	O	2472-2482
>	O	2471-2472
risperidone	O	2483-2494
)	O	2494-2495
(	O	2496-2497
clozapine	O	2497-2506
vs	O	2507-2509
risperidone	O	2510-2521
,	O	2521-2522
t	O	2523-2524
(	O	2524-2525
33	O	2525-2527
)	O	2527-2528
=	O	2529-2530
2	O	2531-2532
.	O	2532-2533
94	O	2533-2535
;	O	2535-2536
P	O	2537-2538
=	O	2539-2540
.	O	2541-2542
006	O	2542-2545
;	O	2545-2546

olanzapine	O	2547-2557
vs	O	2558-2560
risperidone	O	2561-2572
,	O	2572-2573
t	O	2574-2575
(	O	2575-2576
33	O	2576-2578
)	O	2578-2579
=	O	2580-2581
2	O	2582-2583
.	O	2583-2584
42	O	2584-2586
;	O	2586-2587
P	O	2588-2589
=	O	2590-2591
.	O	2592-2593
02	O	2593-2595
)	O	2595-2596
.	O	2592-2593

There	O	2598-2603
was	O	2604-2607
a	O	2608-2609
significant	O	2610-2621
difference	O	2622-2632
among	O	2633-2638
groups	O	2639-2645
in	O	2646-2648
glucose	O	2649-2656
effectiveness	O	2657-2670
(	O	2671-2672
F	O	2672-2673
(	O	2671-2672
30	O	2674-2676
)	O	2676-2677
=	O	2678-2679
4	O	2680-2681
.	O	2681-2682
18	O	2682-2684
;	O	2684-2685
P	O	2686-2687
=	O	2688-2689
.	O	2690-2691
02	O	2691-2693
)	O	2693-2694

(	O	2695-2696
clozapine	O	2696-2705
<	O	2705-2706
olanzapine	O	2706-2716
<	O	2705-2706
risperidone	O	2717-2728
)	O	2728-2729
with	O	2730-2734
significant	O	2735-2746
differences	O	2747-2758
between	O	2759-2766
clozapine	O	2767-2776
and	O	2777-2780
risperidone	O	2781-2792
(	O	2793-2794
t	O	2794-2795
(	O	2793-2794
30	O	2796-2798
)	O	2798-2799
=	O	2800-2801
-	O	2802-2803
2	O	2803-2804
.	O	2804-2805
59	O	2805-2807
;	O	2807-2808

P	O	2809-2810
=	O	2811-2812
.	O	2813-2814
02	O	2814-2816
)	O	2816-2817

and	O	2818-2821
olanzapine	O	2822-2832
and	O	2833-2836
risperidone	O	2837-2848
(	O	2849-2850
t	O	2850-2851
(	O	2849-2850
30	O	2852-2854
)	O	2854-2855
=	O	2856-2857
-	O	2858-2859
2	O	2859-2860
.	O	2860-2861
34	O	2861-2863
,	O	2863-2864

P	O	2865-2866
=	O	2867-2868
.	O	2869-2870
03	O	2870-2872
)	O	2872-2873
.	O	2869-2870

CONCLUSIONS	O	2875-2886
:	O	2886-2887
Both	O	2888-2892
nonobese	O	2893-2901
clozapine	O	2902-2911
-	O	2911-2912
and	O	2913-2916
olanzapine	O	2917-2927
-	O	2927-2928
treated	O	2928-2935
groups	O	2936-2942
displayed	O	2943-2952
significant	O	2953-2964
insulin	B	2965-2972
resistance	I	2973-2983
and	O	2984-2987
impairment	O	2988-2998
of	O	2999-3001
glucose	O	3002-3009
effectiveness	O	3010-3023
compared	O	3024-3032
with	O	3033-3037
risperidone	O	3038-3049
-	O	3049-3050
treated	O	3050-3057
subjects	O	3058-3066
.	O	3066-3067

Patients	O	3068-3076
taking	O	3077-3083
clozapine	O	3084-3093
and	O	3094-3097
olanzapine	O	3098-3108
must	O	3109-3113
be	O	3114-3116
examined	O	3117-3125
for	O	3126-3129
insulin	B	3130-3137
resistance	I	3138-3148
and	O	3149-3152
its	O	3153-3156
consequences	O	3157-3169
.	O	3169-3170

Focal	O	0-5
cerebral	B	6-14
ischemia	I	15-23
in	O	24-26
rats	O	27-31
:	O	31-32
effect	O	33-39
of	O	40-42
phenylephrine	O	43-56
-	O	56-57
induced	O	57-64
hypertension	B	65-77
during	O	78-84
reperfusion	O	85-96
.	O	96-97

After	O	98-103
180	O	104-107
min	O	108-111
of	O	112-114
temporary	O	115-124
middle	B	125-131
cerebral	I	132-140
artery	I	141-147
occlusion	I	148-157
in	O	158-160
spontaneously	O	161-174
hypertensive	B	175-187
rats	O	188-192
,	O	192-193
the	O	194-197
effect	O	198-204
of	O	205-207
phenylephrine	O	208-221
-	O	221-222
induced	O	222-229
hypertension	B	230-242
on	O	243-245
ischemic	B	246-254
brain	I	255-260
injury	I	261-267
and	O	268-271
blood	O	272-277
-	O	277-278
brain	O	278-283
barrier	O	284-291
permeability	O	292-304
was	O	305-308
determined	O	309-319
.	O	319-320

Blood	O	321-326
pressure	O	327-335
was	O	336-339
manipulated	O	340-351
by	O	352-354
one	O	355-358
of	O	359-361
the	O	362-365
following	O	366-375
schedules	O	376-385
during	O	386-392
120	O	393-396
min	O	397-400
of	O	401-403
reperfusion	O	404-415
:	O	415-416
Control	O	417-424
,	O	424-425
normotensive	O	426-438
reperfusion	O	439-450
;	O	450-451
90	O	452-454
/	O	454-455
hypertension	B	455-467
(	O	468-469
90	O	469-471
/	O	471-472
HTN	B	472-475
)	O	475-476
,	O	476-477
blood	O	478-483
pressure	O	484-492
was	O	493-496
increased	O	497-506
by	O	507-509
35	O	510-512
mm	O	513-515
Hg	O	516-518
during	O	519-525
the	O	526-529
initial	O	530-537
90	O	538-540
min	O	541-544
of	O	545-547
reperfusion	O	548-559
only	O	560-564
;	O	564-565
15	O	566-568
/	O	568-569
hypertension	B	569-581
(	O	582-583
15	O	583-585
/	O	585-586
HTN	B	586-589
)	O	589-590
,	O	590-591
normotensive	O	592-604
reperfusion	O	605-616
for	O	617-620
30	O	621-623
min	O	624-627
followed	O	628-636
by	O	637-639
15	O	640-642
min	O	643-646
of	O	647-649
hypertension	B	650-662
and	O	663-666
75	O	667-669
min	O	670-673
of	O	674-676
normotension	O	677-689
.	O	689-690

Part	O	691-695
A	O	696-697
,	O	697-698
for	O	699-702
eight	O	703-708
rats	O	709-713
in	O	714-716
each	O	717-721
group	O	722-727
brain	B	728-733
injury	I	734-740
was	O	741-744
evaluated	O	745-754
by	O	755-757
staining	O	758-766
tissue	O	767-773
using	O	774-779
2	O	780-781
,	O	781-782
3	O	782-783
,	O	781-782
5	O	784-785
-	O	785-786
triphenyltetrazolium	O	786-806
chloride	O	807-815
and	O	816-819
edema	B	820-825
was	O	826-829
evaluated	O	830-839
by	O	840-842
microgravimetry	O	843-858
.	O	858-859

Part	O	860-864
B	O	865-866
,	O	866-867
for	O	868-871
eight	O	872-877
different	O	878-887
rats	O	888-892
in	O	893-895
each	O	896-900
group	O	901-906
blood	O	907-912
-	O	912-913
brain	O	913-918
barrier	O	919-926
permeability	O	927-939
was	O	940-943
evaluated	O	944-953
by	O	954-956
measuring	O	957-966
the	O	967-970
amount	O	971-977
and	O	978-981
extent	O	982-988
of	O	989-991
extravasation	O	992-1005
of	O	1006-1008
Evans	O	1009-1014
Blue	O	1015-1019
dye	O	1020-1023
.	O	1023-1024

Brain	B	1025-1030
injury	I	1031-1037
(	O	1038-1039
percentage	O	1039-1049
of	O	1050-1052
the	O	1053-1056
ischemic	B	1057-1065
hemisphere	I	1066-1076
)	O	1076-1077
was	O	1078-1081
less	O	1082-1086
in	O	1087-1089
the	O	1090-1093
15	O	1094-1096
/	O	1096-1097
HTN	B	1097-1100
group	O	1101-1106
(	O	1107-1108
16	O	1108-1110
+	O	1111-1112
/	O	1112-1113
-	O	1113-1114
6	O	1115-1116
,	O	1116-1117
mean	O	1118-1122
+	O	1123-1124
/	O	1124-1125
-	O	1125-1126
SD	O	1127-1129
)	O	1129-1130
versus	O	1131-1137
the	O	1138-1141
90	O	1142-1144
/	O	1144-1145
HTN	B	1145-1148
group	O	1149-1154
(	O	1155-1156
30	O	1156-1158
+	O	1159-1160
/	O	1160-1161
-	O	1161-1162
6	O	1163-1164
)	O	1164-1165
,	O	1165-1166
which	O	1167-1172
was	O	1173-1176
in	O	1177-1179
turn	O	1180-1184
less	O	1185-1189
than	O	1190-1194
the	O	1195-1198
control	O	1199-1206
group	O	1207-1212
(	O	1213-1214
42	O	1214-1216
+	O	1217-1218
/	O	1218-1219
-	O	1219-1220
5	O	1221-1222
)	O	1222-1223
.	O	1223-1224

Specific	O	1225-1233
gravity	O	1234-1241
was	O	1242-1245
greater	O	1246-1253
in	O	1254-1256
the	O	1257-1260
15	O	1261-1263
/	O	1263-1264
HTN	B	1264-1267
group	O	1268-1273
(	O	1274-1275
1	O	1275-1276
.	O	1276-1277
043	O	1277-1280
+	O	1281-1282
/	O	1282-1283
-	O	1283-1284
0	O	1285-1286
.	O	1286-1287
002	O	1287-1290
)	O	1290-1291
versus	O	1292-1298
the	O	1299-1302
90	O	1303-1305
/	O	1305-1306
HTN	B	1306-1309
(	O	1310-1311
1	O	1311-1312
.	O	1312-1313
036	O	1313-1316
+	O	1317-1318
/	O	1318-1319
-	O	1319-1320
0	O	1321-1322
.	O	1322-1323
003	O	1323-1326
)	O	1326-1327
and	O	1328-1331
control	O	1332-1339
(	O	1340-1341
1	O	1341-1342
.	O	1342-1343
037	O	1343-1346
+	O	1347-1348
/	O	1348-1349
-	O	1349-1350
0	O	1351-1352
.	O	1352-1353
003	O	1353-1356
)	O	1356-1357
groups	O	1358-1364
.	O	1364-1365

Evans	O	1366-1371
Blue	O	1372-1376
(	O	1377-1378
mug	O	1378-1381
g	O	1382-1383
-	O	1383-1384
1	O	1384-1385
of	O	1386-1388
brain	O	1389-1394
tissue	O	1395-1401
)	O	1401-1402
was	O	1403-1406
greater	O	1407-1414
in	O	1415-1417
the	O	1418-1421
90	O	1422-1424
/	O	1424-1425
HTN	B	1425-1428
group	O	1429-1434
(	O	1435-1436
24	O	1436-1438
.	O	1438-1439
4	O	1437-1438
+	O	1441-1442
/	O	1442-1443
-	O	1443-1444
6	O	1445-1446
.	O	1446-1447
0	O	1447-1448
)	O	1448-1449
versus	O	1450-1456
the	O	1457-1460
control	O	1461-1468
group	O	1469-1474
(	O	1475-1476
12	O	1476-1478
.	O	1478-1479
3	O	1479-1480
+	O	1481-1482
/	O	1482-1483
-	O	1483-1484
4	O	1485-1486
.	O	1486-1487
1	O	1487-1488
)	O	1488-1489
,	O	1489-1490
which	O	1491-1496
was	O	1497-1500
in	O	1501-1503
turn	O	1504-1508
greater	O	1509-1516
than	O	1517-1521
the	O	1522-1525
15	O	1526-1528
/	O	1528-1529
HTN	B	1529-1532
group	O	1533-1538
(	O	1539-1540
7	O	1540-1541
.	O	1541-1542
3	O	1542-1543
+	O	1544-1545
/	O	1545-1546
-	O	1546-1547
3	O	1548-1549
.	O	1549-1550
2	O	1550-1551
)	O	1551-1552
.	O	1549-1550

This	O	1554-1558
study	O	1559-1564
supports	O	1565-1573
a	O	1574-1575
hypothesis	O	1576-1586
that	O	1587-1591
during	O	1592-1598
reperfusion	O	1599-1610
,	O	1610-1611
a	O	1612-1613
short	O	1614-1619
interval	O	1620-1628
of	O	1629-1631
hypertension	B	1632-1644
decreases	O	1645-1654
brain	B	1655-1660
injury	I	1661-1667
and	O	1668-1671
edema	B	1672-1677
;	O	1677-1678
and	O	1679-1682
that	O	1683-1687
sustained	O	1688-1697
hypertension	B	1698-1710
increases	O	1711-1720
the	O	1721-1724
risk	O	1725-1729
of	O	1730-1732
vasogenic	B	1733-1742
edema	I	1743-1748
.	O	1748-1749

People	O	0-6
aged	O	7-11
over	O	12-16
75	O	17-19
in	O	20-22
atrial	B	23-29
fibrillation	I	30-42
on	O	43-45
warfarin	O	46-54
:	O	54-55
the	O	56-59
rate	O	60-64
of	O	65-67
major	O	68-73
hemorrhage	B	74-84
and	O	85-88
stroke	B	89-95
in	O	96-98
more	O	99-103
than	O	104-108
500	O	109-112
patient	O	113-120
-	O	120-121
years	O	121-126
of	O	127-129
follow	O	130-136
-	O	136-137
up	O	137-139
.	O	139-140

OBJECTIVES	O	141-151
:	O	151-152
To	O	153-155
determine	O	156-165
the	O	166-169
incidence	O	170-179
of	O	180-182
major	O	183-188
hemorrhage	B	189-199
and	O	200-203
stroke	B	204-210
in	O	211-213
people	O	214-220
aged	O	221-225
76	O	226-228
and	O	229-232
older	O	233-238
with	O	239-243
atrial	B	244-250
fibrillation	I	251-263
on	O	264-266
adjusted	O	267-275
-	O	275-276
dose	O	276-280
warfarin	O	281-289
who	O	290-293
had	O	294-297
been	O	298-302
recently	O	303-311
been	O	312-316
admitted	O	317-325
to	O	326-328
hospital	O	329-337
.	O	337-338

DESIGN	O	339-345
:	O	345-346
A	O	347-348
retrospective	O	349-362
observational	O	363-376
cohort	O	377-383
study	O	384-389
.	O	389-390

SETTING	O	391-398
:	O	398-399
A	O	400-401
major	O	402-407
healthcare	O	408-418
network	O	419-426
involving	O	427-436
four	O	437-441
tertiary	O	442-450
hospitals	O	451-460
.	O	460-461

PARTICIPANTS	O	462-474
:	O	474-475
Two	O	476-479
hundred	O	480-487
thirty	O	488-494
-	O	494-495
five	O	495-499
patients	O	500-508
aged	O	509-513
76	O	514-516
and	O	517-520
older	O	521-526
admitted	O	527-535
to	O	536-538
a	O	539-540
major	O	541-546
healthcare	O	547-557
network	O	558-565
between	O	566-573
July	O	574-578
1	O	579-580
,	O	580-581
2001	O	582-586
,	O	586-587
and	O	588-591
June	O	592-596
30	O	597-599
,	O	599-600
2002	O	601-605
,	O	605-606
with	O	607-611
atrial	B	612-618
fibrillation	I	619-631
on	O	632-634
warfarin	O	635-643
were	O	644-648
enrolled	O	649-657
.	O	657-658

MEASUREMENTS	O	659-671
:	O	671-672
Information	O	673-684
regarding	O	685-694
major	O	695-700
bleeding	B	701-709
episodes	O	710-718
,	O	718-719
strokes	B	720-727
,	O	727-728
and	O	729-732
warfarin	O	733-741
use	O	742-745
was	O	746-749
obtained	O	750-758
from	O	759-763
patients	O	764-772
,	O	772-773
relatives	O	774-783
,	O	783-784
primary	O	785-792
physicians	O	793-803
,	O	803-804
and	O	805-808
medical	O	809-816
records	O	817-824
.	O	824-825

RESULTS	O	826-833
:	O	833-834
Two	O	835-838
hundred	O	839-846
twenty	O	847-853
-	O	853-854
eight	O	854-859
patients	O	860-868
(	O	869-870
42	O	870-872
%	O	872-873
men	O	874-877
)	O	877-878
with	O	879-883
a	O	884-885
mean	O	886-890
age	O	891-894
of	O	895-897
81	O	898-900
.	O	900-901
1	O	899-900
(	O	903-904
range	O	904-909
76	O	910-912
-	O	912-913
94	O	913-915
)	O	915-916
were	O	917-921
included	O	922-930
in	O	931-933
the	O	934-937
analysis	O	938-946
.	O	946-947

Total	O	948-953
follow	O	954-960
-	O	960-961
up	O	961-963
on	O	964-966
warfarin	O	967-975
was	O	976-979
530	O	980-983
years	O	984-989
(	O	990-991
mean	O	991-995
28	O	996-998
months	O	999-1005
)	O	1005-1006
.	O	1006-1007

There	O	1008-1013
were	O	1014-1018
53	O	1019-1021
major	O	1022-1027
hemorrhages	B	1028-1039
,	O	1039-1040
for	O	1041-1044
an	O	1045-1047
annual	O	1048-1054
rate	O	1055-1059
of	O	1060-1062
10	O	1063-1065
.	O	1065-1066
0	O	1064-1065
%	O	1067-1068
,	O	1068-1069
including	O	1070-1079
24	O	1080-1082
(	O	1083-1084
45	O	1084-1086
.	O	1086-1087
3	O	1087-1088
%	O	1088-1089
)	O	1089-1090

life	O	1091-1095
-	O	1095-1096
threatening	O	1096-1107
and	O	1108-1111
five	O	1112-1116
(	O	1117-1118
9	O	1118-1119
.	O	1119-1120
4	O	1120-1121
%	O	1121-1122
)	O	1122-1123
fatal	O	1124-1129
bleeds	O	1130-1136
.	O	1136-1137

The	O	1138-1141
annual	O	1142-1148
stroke	B	1149-1155
rate	O	1156-1160
after	O	1161-1166
initiation	O	1167-1177
of	O	1178-1180
warfarin	O	1181-1189
was	O	1190-1193
2	O	1194-1195
.	O	1195-1196
6	O	1196-1197
%	O	1197-1198
.	O	1195-1196

CONCLUSION	O	1200-1210
:	O	1210-1211
The	O	1212-1215
rate	O	1216-1220
of	O	1221-1223
major	O	1224-1229
hemorrhage	B	1230-1240
was	O	1241-1244
high	O	1245-1249
in	O	1250-1252
this	O	1253-1257
old	O	1258-1261
,	O	1261-1262
frail	O	1263-1268
group	O	1269-1274
,	O	1274-1275
but	O	1276-1279
excluding	O	1280-1289
fatalities	O	1290-1300
,	O	1300-1301
resulted	O	1302-1310
in	O	1311-1313
no	O	1314-1316
long	O	1317-1321
-	O	1321-1322
term	O	1322-1326
sequelae	O	1327-1335
,	O	1335-1336
and	O	1337-1340
the	O	1341-1344
stroke	B	1345-1351
rate	O	1352-1356
on	O	1357-1359
warfarin	O	1360-1368
was	O	1369-1372
low	O	1373-1376
,	O	1376-1377
demonstrating	O	1378-1391
how	O	1392-1395
effective	O	1396-1405
warfarin	O	1406-1414
treatment	O	1415-1424
is	O	1425-1427
.	O	1427-1428

Safety	O	0-6
of	O	7-9
celecoxib	O	10-19
in	O	20-22
patients	O	23-31
with	O	32-36
adverse	O	37-44
skin	B	45-49
reactions	I	50-59
to	O	60-62
acetaminophen	O	63-76
(	O	77-78
paracetamol	O	78-89
)	O	89-90
and	O	91-94
nimesulide	O	95-105
associated	O	106-116
or	O	117-119
not	O	120-123
with	O	124-128
common	O	129-135
non	O	136-139
-	O	139-140
steroidal	O	140-149
anti	O	150-154
-	O	154-155
inflammatory	O	155-167
drugs	O	168-173
.	O	173-174

BACKGROUND	O	175-185
:	O	185-186
Acetaminophen	O	187-200
(	O	201-202
paracetamol	O	202-213
-	O	213-214
-	O	213-214
P	O	215-216
)	O	216-217
and	O	218-221
Nimesulide	O	222-232
(	O	233-234
N	O	234-235
)	O	235-236
are	O	237-240
widely	O	241-247
used	O	248-252
analgesic	O	253-262
-	O	262-263
antipyretic	O	263-274
/	O	274-275
anti	O	263-267
-	O	262-263
inflammatory	O	280-292
drugs	O	293-298
.	O	298-299

The	O	300-303
rate	O	304-308
of	O	309-311
adverse	O	312-319
hypersensitivity	B	320-336
reactions	O	337-346
to	O	347-349
these	O	350-355
agents	O	356-362
is	O	363-365
generally	O	366-375
low	O	376-379
.	O	379-380

On	O	381-383
the	O	384-387
contrary	O	388-396
non	O	397-400
-	O	400-401
steroidal	O	401-410
anti	O	411-415
-	O	415-416
inflammatory	O	416-428
drugs	O	429-434
(	O	435-436
NSAIDs	O	436-442
)	O	442-443
are	O	444-447
commonly	O	448-456
involved	O	457-465
in	O	466-468
such	O	469-473
reactions	O	474-483
.	O	483-484

Celecoxib	O	485-494
(	O	495-496
CE	O	496-498
)	O	498-499
is	O	500-502
a	O	503-504
novel	O	505-510
drug	O	511-515
,	O	515-516
with	O	517-521
high	O	522-526
selectivity	O	527-538
and	O	539-542
affinity	O	543-551
for	O	552-555
COX	O	556-559
-	O	559-560
2	O	560-561
enzyme	O	562-568
.	O	568-569

OBJECTIVE	O	570-579
:	O	579-580
We	O	581-583
evaluated	O	584-593
the	O	594-597
tolerability	O	598-610
of	O	611-613
CE	O	614-616
in	O	617-619
a	O	620-621
group	O	622-627
of	O	628-630
patients	O	631-639
with	O	640-644
documented	O	645-655
history	O	656-663
of	O	664-666
adverse	O	667-674
cutaneous	B	675-684
reactions	I	685-694
to	O	695-697
P	O	698-699
and	O	700-703
N	O	704-705
associated	O	706-716
or	O	717-719
not	O	720-723
to	O	724-726
classic	O	727-734
NSAIDs	O	735-741
.	O	741-742

METHODS	O	743-750
:	O	750-751
We	O	752-754
studied	O	755-762
9	O	763-764
patients	O	765-773
with	O	774-778
hypersensitivity	B	779-795
to	O	796-798
P	O	799-800
and	O	801-804
N	O	805-806
with	O	807-811
or	O	812-814
without	O	815-822
associated	O	823-833
reactions	O	834-843
to	O	844-846
classic	O	847-854
NSAIDs	O	855-861
.	O	861-862

The	O	863-866
diagnosis	O	867-876
of	O	877-879
P	O	880-881
and	O	882-885
N	O	886-887
-	O	887-888
induced	O	888-895
skin	B	896-900
reactions	I	901-910
was	O	911-914
based	O	915-920
in	O	921-923
vivo	O	924-928
challenge	O	929-938
.	O	938-939

The	O	940-943
placebo	O	944-951
was	O	952-955
blindly	O	956-963
administered	O	964-976
at	O	977-979
the	O	980-983
beginning	O	984-993
of	O	994-996
each	O	997-1001
challenge	O	1002-1011
.	O	1011-1012

After	O	1013-1018
three	O	1019-1024
days	O	1025-1029
,	O	1029-1030
a	O	1031-1032
cumulative	O	1033-1043
dosage	O	1044-1050
of	O	1051-1053
200	O	1054-1057
mg	O	1058-1060
of	O	1061-1063
CE	O	1064-1066
in	O	1067-1069
refracted	O	1070-1079
doses	O	1080-1085
were	O	1086-1090
given	O	1091-1096
.	O	1096-1097

After	O	1098-1103
2	O	1104-1105
-	O	1105-1106
3	O	1106-1107
days	O	1108-1112
,	O	1112-1113
a	O	1114-1115
single	O	1116-1122
dose	O	1123-1127
of	O	1128-1130
200	O	1131-1134
mg	O	1135-1137
was	O	1138-1141
administered	O	1142-1154
.	O	1154-1155

All	O	1156-1159
patients	O	1160-1168
were	O	1169-1173
observed	O	1174-1182
for	O	1183-1186
6	O	1187-1188
hours	O	1189-1194
after	O	1195-1200
each	O	1201-1205
challenge	O	1206-1215
,	O	1215-1216
and	O	1217-1220
controlled	O	1221-1231
again	O	1232-1237
after	O	1238-1243
24	O	1244-1246
hours	O	1247-1252
to	O	1253-1255
exclude	O	1256-1263
delayed	O	1264-1271
reactions	O	1272-1281
.	O	1281-1282

The	O	1283-1286
challenge	O	1287-1296
was	O	1297-1300
considered	O	1301-1311
positive	O	1312-1320
if	O	1321-1323
one	O	1324-1327
or	O	1328-1330
more	O	1331-1335
of	O	1336-1338
the	O	1339-1342
following	O	1343-1352
appeared	O	1353-1361
:	O	1361-1362
erythema	B	1363-1371
,	O	1371-1372
rush	O	1373-1377
or	O	1378-1380
urticaria	B	1381-1390
-	O	1390-1391
angioedema	B	1391-1401
.	O	1401-1402
RESULTS	O	1403-1410
:	O	1410-1411
No	O	1412-1414
reaction	O	1415-1423
was	O	1424-1427
observed	O	1428-1436
with	O	1437-1441
placebo	O	1442-1449
and	O	1450-1453
eight	O	1454-1459
patients	O	1460-1468
(	O	1469-1470
88	O	1470-1472
.	O	1472-1473
8	O	1470-1471
%	O	1474-1475
)	O	1475-1476
tolerated	O	1477-1486
CE	O	1487-1489
.	O	1489-1490

Only	O	1491-1495
one	O	1496-1499
patient	O	1500-1507
developed	O	1508-1517
a	O	1518-1519
moderate	O	1520-1528
angioedema	B	1529-1539
of	O	1540-1542
the	O	1543-1546
lips	O	1547-1551
.	O	1551-1552

CONCLUSION	O	1553-1563
:	O	1563-1564
Only	O	1565-1569
one	O	1570-1573
hypersensitivity	B	1574-1590
reaction	O	1591-1599
to	O	1600-1602
CE	O	1603-1605
was	O	1606-1609
documented	O	1610-1620
among	O	1621-1626
9	O	1627-1628
P	O	1629-1630
and	O	1631-1634
N	O	1635-1636
-	O	1636-1637
highly	O	1637-1643
NSAIDs	O	1644-1650
intolerant	O	1651-1661
patients	O	1662-1670
.	O	1670-1671

Thus	O	1672-1676
,	O	1676-1677
we	O	1678-1680
conclude	O	1681-1689
that	O	1690-1694
CE	O	1695-1697
is	O	1698-1700
a	O	1701-1702
reasonably	O	1703-1713
safe	O	1714-1718
alternative	O	1719-1730
to	O	1731-1733
be	O	1734-1736
used	O	1737-1741
in	O	1742-1744
subjects	O	1745-1753
who	O	1754-1757
do	O	1758-1760
not	O	1761-1764
tolerate	O	1765-1773
P	O	1774-1775
and	O	1776-1779
N	O	1780-1781
.	O	1781-1782

Case	O	0-4
-	O	4-5
control	O	5-12
study	O	13-18
of	O	19-21
regular	O	22-29
analgesic	O	30-39
and	O	40-43
nonsteroidal	O	44-56
anti	O	57-61
-	O	61-62
inflammatory	O	62-74
use	O	75-78
and	O	79-82
end	B	83-86
-	I	86-87
stage	I	87-92
renal	I	93-98
disease	I	99-106
.	O	106-107

BACKGROUND	O	108-118
:	O	118-119
Studies	O	120-127
on	O	128-130
the	O	131-134
association	O	135-146
between	O	147-154
the	O	155-158
long	O	159-163
-	O	163-164
term	O	164-168
use	O	169-172
of	O	173-175
aspirin	O	176-183
and	O	184-187
other	O	188-193
analgesic	O	194-203
and	O	204-207
nonsteroidal	O	208-220
anti	O	221-225
-	O	225-226
inflammatory	O	226-238
drugs	O	239-244
(	O	245-246
NSAIDs	O	246-252
)	O	252-253
and	O	254-257
end	B	258-261
-	I	261-262
stage	I	262-267
renal	I	268-273
disease	I	274-281
(	O	282-283
ESRD	B	283-287
)	O	287-288
have	O	289-293
given	O	294-299
conflicting	O	300-311
results	O	312-319
.	O	319-320

In	O	321-323
order	O	324-329
to	O	330-332
examine	O	333-340
this	O	341-345
association	O	346-357
,	O	357-358
a	O	359-360
case	O	361-365
-	O	365-366
control	O	366-373
study	O	374-379
with	O	380-384
incident	O	385-393
cases	O	394-399
of	O	400-402
ESRD	B	403-407
was	O	408-411
carried	O	412-419
out	O	420-423
.	O	423-424

METHODS	O	425-432
:	O	432-433
The	O	434-437
cases	O	438-443
were	O	444-448
all	O	449-452
patients	O	453-461
entering	O	462-470
the	O	471-474
local	O	475-480
dialysis	O	481-489
program	O	490-497
because	O	498-505
of	O	506-508
ESRD	B	509-513
in	O	514-516
the	O	517-520
study	O	521-526
area	O	527-531
between	O	532-539
June	O	540-544
1	O	545-546
,	O	546-547
1995	O	548-552
and	O	553-556
November	O	557-565
30	O	566-568
,	O	568-569
1997	O	570-574
.	O	574-575

They	O	576-580
were	O	581-585
classified	O	586-596
according	O	597-606
to	O	607-609
the	O	610-613
underlying	O	614-624
disease	O	625-632
,	O	632-633
which	O	634-639
had	O	640-643
presumably	O	644-654
led	O	655-658
them	O	659-663
to	O	664-666
ESRD	B	667-671
.	O	671-672

Controls	O	673-681
were	O	682-686
patients	O	687-695
admitted	O	696-704
to	O	705-707
the	O	708-711
same	O	712-716
hospitals	O	717-726
from	O	727-731
where	O	732-737
the	O	738-741
cases	O	742-747
arose	O	748-753
,	O	753-754
also	O	755-759
matched	O	760-767
by	O	768-770
age	O	771-774
and	O	775-778
sex	O	779-782
.	O	782-783

Odds	O	784-788
ratios	O	789-795
were	O	796-800
calculated	O	801-811
using	O	812-817
a	O	818-819
conditional	O	820-831
logistic	O	832-840
model	O	841-846
,	O	846-847
including	O	848-857
potential	O	858-867
confounding	O	868-879
factors	O	880-887
,	O	887-888
both	O	889-893
for	O	894-897
the	O	898-901
whole	O	902-907
study	O	908-913
population	O	914-924
and	O	925-928
for	O	929-932
the	O	933-936
various	O	937-944
underlying	O	945-955
diseases	O	956-964
.	O	964-965

RESULTS	O	966-973
:	O	973-974
Five	O	975-979
hundred	O	980-987
and	O	988-991
eighty	O	992-998
-	O	998-999
three	O	999-1004
cases	O	1005-1010
and	O	1011-1014
1190	O	1015-1019
controls	O	1020-1028
were	O	1029-1033
included	O	1034-1042
in	O	1043-1045
the	O	1046-1049
analysis	O	1050-1058
.	O	1058-1059

Long	O	1060-1064
-	O	1064-1065
term	O	1065-1069
use	O	1070-1073
of	O	1074-1076
any	O	1077-1080
analgesic	O	1081-1090
was	O	1091-1094
associated	O	1095-1105
with	O	1106-1110
an	O	1111-1113
overall	O	1114-1121
odds	O	1122-1126
ratio	O	1127-1132
of	O	1133-1135
1	O	1136-1137
.	O	1137-1138
22	O	1138-1140
(	O	1141-1142
95	O	1142-1144
%	O	1144-1145
CI	O	1146-1148
,	O	1148-1149
0	O	1150-1151
.	O	1151-1152
89	O	1152-1154
-	O	1154-1155
1	O	1155-1156
.	O	1151-1152
66	O	1157-1159
)	O	1159-1160
.	O	1151-1152

For	O	1162-1165
specific	O	1166-1174
groups	O	1175-1181
of	O	1182-1184
drugs	O	1185-1190
,	O	1190-1191
the	O	1192-1195
risks	O	1196-1201
were	O	1202-1206
1	O	1207-1208
.	O	1208-1209
56	O	1209-1211
(	O	1212-1213
1	O	1213-1214
.	O	1214-1215
05	O	1215-1217
-	O	1217-1218
2	O	1218-1219
.	O	1214-1215
30	O	1220-1222
)	O	1222-1223

for	O	1224-1227
aspirin	O	1228-1235
,	O	1235-1236
1	O	1237-1238
.	O	1238-1239
03	O	1239-1241
(	O	1242-1243
0	O	1243-1244
.	O	1244-1245
60	O	1245-1247
-	O	1247-1248
1	O	1248-1249
.	O	1244-1245
76	O	1250-1252
)	O	1252-1253
for	O	1254-1257
pyrazolones	O	1258-1269
,	O	1269-1270
0	O	1271-1272
.	O	1272-1273
80	O	1273-1275
(	O	1276-1277
0	O	1277-1278
.	O	1278-1279
39	O	1279-1281
-	O	1281-1282
1	O	1282-1283
.	O	1278-1279
63	O	1284-1286
)	O	1286-1287
for	O	1288-1291
paracetamol	O	1292-1303
,	O	1303-1304
and	O	1305-1308
0	O	1309-1310
.	O	1310-1311
94	O	1311-1313
(	O	1314-1315
0	O	1315-1316
.	O	1316-1317
57	O	1317-1319
-	O	1319-1320
1	O	1320-1321
.	O	1316-1317
56	O	1322-1324
)	O	1324-1325
for	O	1326-1329
nonaspirin	O	1330-1340
NSAIDs	O	1341-1347
.	O	1347-1348

The	O	1349-1352
risk	O	1353-1357
of	O	1358-1360
ESRD	B	1361-1365
associated	O	1366-1376
with	O	1377-1381
aspirin	O	1382-1389
was	O	1390-1393
related	O	1394-1401
to	O	1402-1404
the	O	1405-1408
cumulated	O	1409-1418
dose	O	1419-1423
and	O	1424-1427
duration	O	1428-1436
of	O	1437-1439
use	O	1440-1443
,	O	1443-1444
and	O	1445-1448
it	O	1449-1451
was	O	1452-1455
particularly	O	1456-1468
high	O	1469-1473
among	O	1474-1479
the	O	1480-1483
subset	O	1484-1490
of	O	1491-1493
patients	O	1494-1502
with	O	1503-1507
vascular	O	1508-1516
nephropathy	B	1517-1528
as	O	1529-1531
underlying	O	1532-1542
disease	O	1543-1550
[	O	1551-1552
2	O	1552-1553
.	O	1553-1554
35	O	1554-1556
(	O	1557-1558
1	O	1558-1559
.	O	1559-1560
17	O	1560-1562
-	O	1562-1563
4	O	1563-1564
.	O	1559-1560
72	O	1565-1567
)	O	1567-1568
]	O	1568-1569
.	O	1559-1560

CONCLUSION	O	1571-1581
:	O	1581-1582
Our	O	1583-1586
data	O	1587-1591
indicate	O	1592-1600
that	O	1601-1605
long	O	1606-1610
-	O	1610-1611
term	O	1611-1615
use	O	1616-1619
of	O	1620-1622
nonaspirin	O	1623-1633
analgesic	O	1634-1643
drugs	O	1644-1649
and	O	1650-1653
NSAIDs	O	1654-1660
is	O	1661-1663
not	O	1664-1667
associated	O	1668-1678
with	O	1679-1683
an	O	1684-1686
increased	O	1687-1696
risk	O	1697-1701
of	O	1702-1704
ESRD	B	1705-1709
.	O	1709-1710

However	O	1711-1718
,	O	1718-1719
the	O	1720-1723
chronic	O	1724-1731
use	O	1732-1735
of	O	1736-1738
aspirin	O	1739-1746
may	O	1747-1750
increase	O	1751-1759
the	O	1760-1763
risk	O	1764-1768
of	O	1769-1771
ESRD	B	1772-1776
.	O	1776-1777

Two	O	0-3
cases	O	4-9
of	O	10-12
amisulpride	O	13-24
overdose	B	25-33
:	O	33-34
a	O	35-36
cause	O	37-42
for	O	43-46
prolonged	B	47-56
QT	I	57-59
syndrome	I	60-68
.	O	68-69

Two	O	70-73
cases	O	74-79
of	O	80-82
deliberate	O	83-93
self	O	94-98
-	O	98-99
poisoning	B	99-108
with	O	109-113
5	O	114-115
g	O	116-117
and	O	118-121
3	O	122-123
.	O	123-124
6	O	124-125
g	O	126-127
of	O	128-130
amisulpride	O	131-142
,	O	142-143
respectively	O	144-156
,	O	156-157
are	O	158-161
reported	O	162-170
.	O	170-171

In	O	172-174
both	O	175-179
cases	O	180-185
,	O	185-186
QT	B	187-189
prolongation	I	190-202
and	O	203-206
hypocalcaemia	B	207-220
were	O	221-225
noted	O	226-231
.	O	231-232

The	O	233-236
QT	B	237-239
prolongation	I	240-252
appeared	O	253-261
to	O	262-264
respond	O	265-272
to	O	273-275
administration	O	276-290
of	O	291-293
i	O	294-295
.	O	295-296
v	O	296-297
.	O	295-296

calcium	O	299-306
gluconate	O	307-316
.	O	316-317

Growth	O	0-6
-	O	6-7
associated	O	7-17
protein	O	18-25
43	O	26-28
expression	O	29-39
in	O	40-42
hippocampal	O	43-54
molecular	O	55-64
layer	O	65-70
of	O	71-73
chronic	O	74-81
epileptic	B	82-91
rats	O	92-96
treated	O	97-104
with	O	105-109
cycloheximide	O	110-123
.	O	123-124

PURPOSE	O	125-132
:	O	132-133
GAP43	O	134-139
has	O	140-143
been	O	144-148
thought	O	149-156
to	O	157-159
be	O	160-162
linked	O	163-169
with	O	170-174
mossy	O	175-180
fiber	O	181-186
sprouting	O	187-196
(	O	197-198
MFS	O	198-201
)	O	201-202
in	O	203-205
various	O	206-213
experimental	O	214-226
models	O	227-233
of	O	234-236
epilepsy	B	237-245
.	O	245-246

To	O	247-249
investigate	O	250-261
how	O	262-265
GAP43	O	266-271
expression	O	272-282
(	O	283-284
GAP43	O	284-289
-	O	289-290
ir	O	290-292
)	O	292-293
correlates	O	294-304
with	O	305-309
MFS	O	310-313
,	O	313-314
we	O	315-317
assessed	O	318-326
the	O	327-330
intensity	O	331-340
(	O	341-342
densitometry	O	342-354
)	O	354-355
and	O	356-359
extension	O	360-369
(	O	370-371
width	O	371-376
)	O	376-377
of	O	378-380
GAP43	O	381-386
-	O	386-387
ir	O	387-389
in	O	390-392
the	O	393-396
inner	O	397-402
molecular	O	403-412
layer	O	413-418
of	O	419-421
the	O	422-425
dentate	O	426-433
gyrus	O	434-439
(	O	440-441
IML	O	441-444
)	O	444-445
of	O	446-448
rats	O	449-453
subject	O	454-461
to	O	462-464
status	B	465-471
epilepticus	I	472-483
induced	O	484-491
by	O	492-494
pilocarpine	O	495-506
(	O	507-508
Pilo	O	508-512
)	O	512-513
,	O	513-514
previously	O	515-525
injected	O	526-534
or	O	535-537
not	O	538-541
with	O	542-546
cycloheximide	O	547-560
(	O	561-562
CHX	O	562-565
)	O	565-566
,	O	566-567
which	O	568-573
has	O	574-577
been	O	578-582
shown	O	583-588
to	O	589-591
inhibit	O	592-599
MFS	O	600-603
.	O	603-604

METHODS	O	605-612
:	O	612-613
CHX	O	614-617
was	O	618-621
injected	O	622-630
before	O	631-637
the	O	638-641
Pilo	O	642-646
injection	O	647-656
in	O	657-659
adult	O	660-665
Wistar	O	666-672
rats	O	673-677
.	O	677-678

The	O	679-682
Pilo	O	683-687
group	O	688-693
was	O	694-697
injected	O	698-706
with	O	707-711
the	O	712-715
same	O	716-720
drugs	O	721-726
,	O	726-727
except	O	728-734
for	O	735-738
CHX	O	739-742
.	O	742-743

Animals	O	744-751
were	O	752-756
killed	O	757-763
between	O	764-771
30	O	772-774
and	O	775-778
60	O	779-781
days	O	782-786
later	O	787-792
,	O	792-793
and	O	794-797
brain	O	798-803
sections	O	804-812
were	O	813-817
processed	O	818-827
for	O	828-831
GAP43	O	832-837
immunohistochemistry	O	838-858
.	O	858-859
RESULTS	O	860-867
:	O	867-868
Densitometry	O	869-881
showed	O	882-888
no	O	889-891
significant	O	892-903
difference	O	904-914
regarding	O	915-924
GAP43	O	925-930
-	O	930-931
ir	O	931-933
in	O	934-936
the	O	937-940
IML	O	941-944
between	O	945-952
Pilo	O	953-957
,	O	957-958
CHX	O	959-962
+	O	962-963
Pilo	O	963-967
,	O	967-968
and	O	969-972
control	O	973-980
groups	O	981-987
.	O	987-988

However	O	989-996
,	O	996-997
the	O	998-1001
results	O	1002-1009
of	O	1010-1012
the	O	1013-1016
width	O	1017-1022
of	O	1023-1025
the	O	1026-1029
GAP43	O	1030-1035
-	O	1035-1036
ir	O	1036-1038
band	O	1039-1043
in	O	1044-1046
the	O	1047-1050
IML	O	1051-1054
showed	O	1055-1061
that	O	1062-1066
CHX	O	1067-1070
+	O	1070-1071
Pilo	O	1071-1075
and	O	1076-1079
control	O	1080-1087
animals	O	1088-1095
had	O	1096-1099
a	O	1100-1101
significantly	O	1102-1115
larger	O	1116-1122
band	O	1123-1127
(	O	1128-1129
p	O	1129-1130
=	O	1131-1132
0	O	1133-1134
.	O	1134-1135
03	O	1135-1137
)	O	1137-1138
as	O	1139-1141
compared	O	1142-1150
with	O	1151-1155
that	O	1156-1160
in	O	1161-1163
the	O	1164-1167
Pilo	O	1168-1172
group	O	1173-1178
.	O	1178-1179

CONCLUSIONS	O	1180-1191
:	O	1191-1192
Our	O	1193-1196
current	O	1197-1204
finding	O	1205-1212
that	O	1213-1217
animals	O	1218-1225
in	O	1226-1228
the	O	1229-1232
CHX	O	1233-1236
+	O	1236-1237
Pilo	O	1237-1241
group	O	1242-1247
have	O	1248-1252
a	O	1253-1254
GAP43	O	1255-1260
-	O	1260-1261
ir	O	1261-1263
band	O	1264-1268
in	O	1269-1271
the	O	1272-1275
IML	O	1276-1279
,	O	1279-1280
similar	O	1281-1288
to	O	1289-1291
that	O	1292-1296
of	O	1297-1299
controls	O	1300-1308
,	O	1308-1309
reinforces	O	1310-1320
prior	O	1321-1326
data	O	1327-1331
on	O	1332-1334
the	O	1335-1338
blockade	O	1339-1347
of	O	1348-1350
MFS	O	1351-1354
in	O	1355-1357
these	O	1358-1363
animals	O	1364-1371
.	O	1371-1372

The	O	1373-1376
change	O	1377-1383
in	O	1384-1386
GAP43	O	1387-1392
-	O	1392-1393
ir	O	1393-1395
present	O	1396-1403
in	O	1404-1406
Pilo	O	1407-1411
-	O	1411-1412
treated	O	1412-1419
animals	O	1420-1427
was	O	1428-1431
a	O	1432-1433
thinning	O	1434-1442
of	O	1443-1445
the	O	1446-1449
band	O	1450-1454
to	O	1455-1457
a	O	1458-1459
very	O	1460-1464
narrow	O	1465-1471
layer	O	1472-1477
just	O	1478-1482
above	O	1483-1488
the	O	1489-1492
granule	O	1493-1500
cell	O	1501-1505
layer	O	1506-1511
that	O	1512-1516
is	O	1517-1519
likely	O	1520-1526
to	O	1527-1529
be	O	1530-1532
associated	O	1533-1543
with	O	1544-1548
the	O	1549-1552
loss	O	1553-1557
of	O	1558-1560
hilar	O	1561-1566
cell	O	1567-1571
projections	O	1572-1583
that	O	1584-1588
express	O	1589-1596
GAP	O	1597-1600
-	O	1600-1601
43	O	1601-1603
.	O	1603-1604

Nicotine	O	0-8
antagonizes	O	9-20
caffeine	O	21-29
-	O	29-30
but	O	31-34
not	O	35-38
pentylenetetrazole	O	39-57
-	O	57-58
induced	O	58-65
anxiogenic	O	66-76
effect	O	77-83
in	O	84-86
mice	O	87-91
.	O	91-92

RATIONALE	O	93-102
:	O	102-103
Nicotine	O	104-112
and	O	113-116
caffeine	O	117-125
are	O	126-129
widely	O	130-136
consumed	O	137-145
licit	O	146-151
psychoactive	O	152-164
drugs	O	165-170
worldwide	O	171-180
.	O	180-181

Epidemiological	O	182-197
studies	O	198-205
showed	O	206-212
that	O	213-217
they	O	218-222
were	O	223-227
generally	O	228-237
used	O	238-242
concurrently	O	243-255
.	O	255-256

Although	O	257-265
some	O	266-270
studies	O	271-278
in	O	279-281
experimental	O	282-294
animals	O	295-302
indicate	O	303-311
clear	O	312-317
pharmacological	O	318-333
interactions	O	334-346
between	O	347-354
them	O	355-359
,	O	359-360
no	O	361-363
studies	O	364-371
have	O	372-376
shown	O	377-382
a	O	383-384
specific	O	385-393
interaction	O	394-405
on	O	406-408
anxiety	B	409-416
responses	O	417-426
.	O	426-427

OBJECTIVES	O	428-438
:	O	438-439
The	O	440-443
present	O	444-451
study	O	452-457
investigates	O	458-470
the	O	471-474
effects	O	475-482
of	O	483-485
nicotine	O	486-494
on	O	495-497
anxiety	B	498-505
induced	O	506-513
by	O	514-516
caffeine	O	517-525
and	O	526-529
another	O	530-537
anxiogenic	O	538-548
drug	O	549-553
,	O	553-554
pentylenetetrazole	O	555-573
,	O	573-574
in	O	575-577
mice	O	578-582
.	O	582-583

The	O	584-587
elevated	O	588-596
plus	O	597-601
-	O	601-602
maze	O	602-606
(	O	607-608
EPM	O	608-611
)	O	611-612
test	O	613-617
was	O	618-621
used	O	622-626
to	O	627-629
evaluate	O	630-638
the	O	639-642
effects	O	643-650
of	O	651-653
drugs	O	654-659
on	O	660-662
anxiety	B	663-670
.	O	670-671

METHODS	O	672-679
:	O	679-680
Adult	O	681-686
male	O	687-691
Swiss	O	692-697
Webster	O	698-705
mice	O	706-710
(	O	711-712
25	O	712-714
-	O	714-715
32	O	715-717
g	O	718-719
)	O	719-720
were	O	721-725
given	O	726-731
nicotine	O	732-740
(	O	741-742
0	O	742-743
.	O	743-744
05	O	744-746
-	O	746-747
0	O	742-743
.	O	743-744
25	O	749-751
mg	O	752-754
/	O	754-755
kg	O	755-757
s	O	758-759
.	O	759-760
c	O	760-761
.	O	759-760
)	O	762-763
or	O	764-766
saline	O	767-773
10	O	774-776
min	O	777-780
before	O	781-787
caffeine	O	788-796
(	O	797-798
70	O	798-800
mg	O	801-803
/	O	803-804
kg	O	804-806
i	O	807-808
.	O	808-809
p	O	809-810
.	O	808-809
)	O	811-812
or	O	813-815
pentylenetetrazole	O	816-834
(	O	835-836
15	O	836-838
and	O	839-842
30	O	843-845
mg	O	846-848
/	O	848-849
kg	O	849-851
i	O	852-853
.	O	853-854
p	O	854-855
.	O	853-854
)	O	856-857
injections	O	858-868
.	O	868-869

After	O	870-875
15	O	876-878
min	O	879-882
,	O	882-883
mice	O	884-888
were	O	889-893
evaluated	O	894-903
for	O	904-907
their	O	908-913
open	O	914-918
-	O	918-919
and	O	920-923
closed	O	924-930
-	O	930-931
arm	O	931-934
time	O	935-939
and	O	940-943
entries	O	944-951
on	O	952-954
the	O	955-958
EPM	O	959-962
for	O	963-966
a	O	967-968
10	O	969-971
-	O	971-972
min	O	972-975
session	O	976-983
.	O	983-984

Locomotor	O	985-994
activity	O	995-1003
was	O	1004-1007
recorded	O	1008-1016
for	O	1017-1020
individual	O	1021-1031
groups	O	1032-1038
by	O	1039-1041
using	O	1042-1047
the	O	1048-1051
same	O	1052-1056
treatment	O	1057-1066
protocol	O	1067-1075
with	O	1076-1080
the	O	1081-1084
EPM	O	1085-1088
test	O	1089-1093
.	O	1093-1094

RESULTS	O	1095-1102
:	O	1102-1103
Nicotine	O	1104-1112
(	O	1113-1114
0	O	1114-1115
.	O	1115-1116
05	O	1116-1118
-	O	1118-1119
0	O	1114-1115
.	O	1115-1116
25	O	1121-1123
mg	O	1124-1126
/	O	1126-1127
kg	O	1127-1129
)	O	1129-1130
itself	O	1131-1137
did	O	1138-1141
not	O	1142-1145
produce	O	1146-1153
any	O	1154-1157
significant	O	1158-1169
effect	O	1170-1176
in	O	1177-1179
the	O	1180-1183
EPM	O	1184-1187
test	O	1188-1192
,	O	1192-1193
whereas	O	1194-1201
caffeine	O	1202-1210
(	O	1211-1212
70	O	1212-1214
mg	O	1215-1217
/	O	1217-1218
kg	O	1218-1220
)	O	1220-1221
and	O	1222-1225
pentylenetetrazole	O	1226-1244
(	O	1245-1246
30	O	1246-1248
mg	O	1249-1251
/	O	1251-1252
kg	O	1252-1254
)	O	1254-1255
produced	O	1256-1264
an	O	1265-1267
anxiogenic	O	1268-1278
effect	O	1279-1285
,	O	1285-1286
apparent	O	1287-1295
with	O	1296-1300
decreases	O	1301-1310
in	O	1311-1313
open	O	1314-1318
-	O	1318-1319
arm	O	1319-1322
time	O	1323-1327
and	O	1328-1331
entry	O	1332-1337
.	O	1337-1338

Nicotine	O	1339-1347
(	O	1348-1349
0	O	1349-1350
.	O	1350-1351
25	O	1351-1353
mg	O	1354-1356
/	O	1356-1357
kg	O	1357-1359
)	O	1359-1360
pretreatment	O	1361-1373
blocked	O	1374-1381
the	O	1382-1385
caffeine	O	1386-1394
-	O	1394-1395
but	O	1396-1399
not	O	1400-1403
pentylenetetrazole	O	1404-1422
-	O	1422-1423
induced	O	1423-1430
anxiety	B	1431-1438
.	O	1438-1439

Administration	O	1440-1454
of	O	1455-1457
each	O	1458-1462
drug	O	1463-1467
and	O	1468-1471
their	O	1472-1477
combinations	O	1478-1490
did	O	1491-1494
not	O	1495-1498
produce	O	1499-1506
any	O	1507-1510
effect	O	1511-1517
on	O	1518-1520
locomotor	O	1521-1530
activity	O	1531-1539
.	O	1539-1540

CONCLUSIONS	O	1541-1552
:	O	1552-1553
Our	O	1554-1557
results	O	1558-1565
suggest	O	1566-1573
that	O	1574-1578
the	O	1579-1582
antagonistic	O	1583-1595
effect	O	1596-1602
of	O	1603-1605
nicotine	O	1606-1614
on	O	1615-1617
caffeine	O	1618-1626
-	O	1626-1627
induced	O	1627-1634
anxiety	B	1635-1642
is	O	1643-1645
specific	O	1646-1654
to	O	1655-1657
caffeine	O	1658-1666
,	O	1666-1667
instead	O	1668-1675
of	O	1676-1678
a	O	1679-1680
non	O	1681-1684
-	O	1684-1685
specific	O	1685-1693
anxiolytic	O	1694-1704
effect	O	1705-1711
.	O	1711-1712

Thus	O	1713-1717
,	O	1717-1718
it	O	1719-1721
may	O	1722-1725
extend	O	1726-1732
the	O	1733-1736
current	O	1737-1744
findings	O	1745-1753
on	O	1754-1756
the	O	1757-1760
interaction	O	1761-1772
between	O	1773-1780
nicotine	O	1781-1789
and	O	1790-1793
caffeine	O	1794-1802
.	O	1802-1803

Long	O	0-4
term	O	5-9
hormone	O	10-17
therapy	O	18-25
for	O	26-29
perimenopausal	O	30-44
and	O	45-48
postmenopausal	O	49-63
women	O	64-69
.	O	69-70

BACKGROUND	O	71-81
:	O	81-82
Hormone	O	83-90
therapy	O	91-98
(	O	99-100
HT	O	100-102
)	O	102-103
is	O	104-106
widely	O	107-113
used	O	114-118
for	O	119-122
controlling	O	123-134
menopausal	B	135-145
symptoms	I	146-154
.	O	154-155

It	O	156-158
has	O	159-162
also	O	163-167
been	O	168-172
used	O	173-177
for	O	178-181
the	O	182-185
management	O	186-196
and	O	197-200
prevention	O	201-211
of	O	212-214
cardiovascular	B	215-229
disease	I	230-237
,	O	237-238
osteoporosis	B	239-251
and	O	252-255
dementia	B	256-264
in	O	265-267
older	O	268-273
women	O	274-279
but	O	280-283
the	O	284-287
evidence	O	288-296
supporting	O	297-307
its	O	308-311
use	O	312-315
for	O	316-319
these	O	320-325
indications	O	326-337
is	O	338-340
largely	O	341-348
observational	O	349-362
.	O	362-363

OBJECTIVES	O	364-374
:	O	374-375
To	O	376-378
assess	O	379-385
the	O	386-389
effect	O	390-396
of	O	397-399
long	O	400-404
-	O	404-405
term	O	405-409
HT	O	410-412
on	O	413-415
mortality	O	416-425
,	O	425-426
heart	B	427-432
disease	I	433-440
,	O	440-441
venous	B	442-448
thromboembolism	I	449-464
,	O	464-465
stroke	B	466-472
,	O	472-473
transient	B	474-483
ischaemic	I	484-493
attacks	I	494-501
,	O	501-502
breast	B	503-509
cancer	I	510-516
,	O	516-517
colorectal	B	518-528
cancer	I	529-535
,	O	535-536
ovarian	B	537-544
cancer	I	545-551
,	O	551-552
endometrial	B	553-564
cancer	I	565-571
,	O	571-572
gallbladder	B	573-584
disease	I	585-592
,	O	592-593
cognitive	O	594-603
function	O	604-612
,	O	612-613
dementia	B	614-622
,	O	622-623
fractures	B	624-633
and	O	634-637
quality	O	638-645
of	O	646-648
life	O	649-653
.	O	653-654

SEARCH	O	655-661
STRATEGY	O	662-670
:	O	670-671
We	O	672-674
searched	O	675-683
the	O	684-687
following	O	688-697
databases	O	698-707
up	O	708-710
to	O	711-713
November	O	714-722
2004	O	723-727
:	O	727-728
the	O	729-732
Cochrane	O	733-741
Menstrual	O	742-751
Disorders	O	752-761
and	O	762-765
Subfertility	O	766-778
Group	O	779-784
Trials	O	785-791
Register	O	792-800
,	O	800-801
Cochrane	O	802-810
Central	O	811-818
Register	O	819-827
of	O	828-830
Controlled	O	831-841
Trials	O	842-848
(	O	849-850
CENTRAL	O	850-857
)	O	857-858
,	O	858-859
MEDLINE	O	860-867
,	O	867-868
EMBASE	O	869-875
,	O	875-876
Biological	O	877-887
Abstracts	O	888-897
.	O	897-898

Relevant	O	899-907
non	O	908-911
-	O	911-912
indexed	O	912-919
journals	O	920-928
and	O	929-932
conference	O	933-943
abstracts	O	944-953
were	O	954-958
also	O	959-963
searched	O	964-972
.	O	972-973

SELECTION	O	974-983
CRITERIA	O	984-992
:	O	992-993
Randomised	O	994-1004
double	O	1005-1011
-	O	1011-1012
blind	O	1012-1017
trials	O	1018-1024
of	O	1025-1027
HT	O	1028-1030
(	O	1031-1032
oestrogens	O	1032-1042
with	O	1043-1047
or	O	1048-1050
without	O	1051-1058
progestogens	O	1059-1071
)	O	1071-1072
versus	O	1073-1079
placebo	O	1080-1087
,	O	1087-1088
taken	O	1089-1094
for	O	1095-1098
at	O	1099-1101
least	O	1102-1107
one	O	1108-1111
year	O	1112-1116
by	O	1117-1119
perimenopausal	O	1120-1134
or	O	1135-1137
postmenopausal	O	1138-1152
women	O	1153-1158
.	O	1158-1159

DATA	O	1160-1164
COLLECTION	O	1165-1175
AND	O	1176-1179
ANALYSIS	O	1180-1188
:	O	1188-1189
Fifteen	O	1190-1197
RCTs	O	1198-1202
were	O	1203-1207
included	O	1208-1216
.	O	1216-1217

Trials	O	1218-1224
were	O	1225-1229
assessed	O	1230-1238
for	O	1239-1242
quality	O	1243-1250
and	O	1251-1254
two	O	1255-1258
review	O	1259-1265
authors	O	1266-1273
extracted	O	1274-1283
data	O	1284-1288
independently	O	1289-1302
.	O	1302-1303

They	O	1304-1308
calculated	O	1309-1319
risk	O	1320-1324
ratios	O	1325-1331
for	O	1332-1335
dichotomous	O	1336-1347
outcomes	O	1348-1356
and	O	1357-1360
weighted	O	1361-1369
mean	O	1370-1374
differences	O	1375-1386
for	O	1387-1390
continuous	O	1391-1401
outcomes	O	1402-1410
.	O	1410-1411

Clinical	O	1412-1420
heterogeneity	O	1421-1434
precluded	O	1435-1444
meta	O	1445-1449
-	O	1449-1450
analysis	O	1450-1458
for	O	1459-1462
most	O	1463-1467
outcomes	O	1468-1476
.	O	1476-1477

MAIN	O	1478-1482
RESULTS	O	1483-1490
:	O	1490-1491
All	O	1492-1495
the	O	1496-1499
statistically	O	1500-1513
significant	O	1514-1525
results	O	1526-1533
were	O	1534-1538
derived	O	1539-1546
from	O	1547-1551
the	O	1552-1555
two	O	1556-1559
biggest	O	1560-1567
trials	O	1568-1574
.	O	1574-1575

In	O	1576-1578
relatively	O	1579-1589
healthy	O	1590-1597
women	O	1598-1603
,	O	1603-1604
combined	O	1605-1613
continuous	O	1614-1624
HT	O	1625-1627
significantly	O	1628-1641
increased	O	1642-1651
the	O	1652-1655
risk	O	1656-1660
of	O	1661-1663
venous	B	1664-1670
thromboembolism	I	1671-1686
or	O	1687-1689
coronary	O	1690-1698
event	O	1699-1704
(	O	1705-1706
after	O	1706-1711
one	O	1712-1715
year	O	1716-1720
'	O	1720-1721
s	O	1721-1722
use	O	1723-1726
)	O	1726-1727
,	O	1727-1728
stroke	B	1729-1735
(	O	1736-1737
after	O	1737-1742
3	O	1743-1744
years	O	1745-1750
)	O	1750-1751
,	O	1751-1752
breast	B	1753-1759
cancer	I	1760-1766
(	O	1767-1768
after	O	1768-1773
5	O	1774-1775
years	O	1776-1781
)	O	1781-1782
and	O	1783-1786
gallbladder	B	1787-1798
disease	I	1799-1806
.	O	1806-1807

Long	O	1808-1812
-	O	1812-1813
term	O	1813-1817
oestrogen	O	1818-1827
-	O	1827-1828
only	O	1828-1832
HT	O	1833-1835
also	O	1836-1840
significantly	O	1841-1854
increased	O	1855-1864
the	O	1865-1868
risk	O	1869-1873
of	O	1874-1876
stroke	B	1877-1883
and	O	1884-1887
gallbladder	B	1888-1899
disease	I	1900-1907
.	O	1907-1908

Overall	O	1909-1916
,	O	1916-1917
the	O	1918-1921
only	O	1922-1926
statistically	O	1927-1940
significant	O	1941-1952
benefits	O	1953-1961
of	O	1962-1964
HT	O	1965-1967
were	O	1968-1972
a	O	1973-1974
decreased	O	1975-1984
incidence	O	1985-1994
of	O	1995-1997
fractures	B	1998-2007
and	O	2008-2011
colon	B	2012-2017
cancer	I	2018-2024
with	O	2025-2029
long	O	2030-2034
-	O	2034-2035
term	O	2035-2039
use	O	2040-2043
.	O	2043-2044

Among	O	2045-2050
relatively	O	2051-2061
healthy	O	2062-2069
women	O	2070-2075
over	O	2076-2080
65	O	2081-2083
years	O	2084-2089
taking	O	2090-2096
continuous	O	2097-2107
combined	O	2108-2116
HT	O	2117-2119
,	O	2119-2120
there	O	2121-2126
was	O	2127-2130
a	O	2131-2132
statistically	O	2133-2146
significant	O	2147-2158
increase	O	2159-2167
in	O	2168-2170
the	O	2171-2174
incidence	O	2175-2184
of	O	2185-2187
dementia	B	2188-2196
.	O	2196-2197

Among	O	2198-2203
women	O	2204-2209
with	O	2210-2214
cardiovascular	B	2215-2229
disease	I	2230-2237
,	O	2237-2238
long	O	2239-2243
-	O	2243-2244
term	O	2244-2248
use	O	2249-2252
of	O	2253-2255
combined	O	2256-2264
continuous	O	2265-2275
HT	O	2276-2278
significantly	O	2279-2292
increased	O	2293-2302
the	O	2303-2306
risk	O	2307-2311
of	O	2312-2314
venous	B	2315-2321
thromboembolism	I	2322-2337
.	O	2337-2338

No	O	2339-2341
trials	O	2342-2348
focussed	O	2349-2357
specifically	O	2358-2370
on	O	2371-2373
younger	O	2374-2381
women	O	2382-2387
.	O	2387-2388

However	O	2389-2396
,	O	2396-2397
one	O	2398-2401
trial	O	2402-2407
analysed	O	2408-2416
subgroups	O	2417-2426
of	O	2427-2429
2839	O	2430-2434
relatively	O	2435-2445
healthy	O	2446-2453
50	O	2454-2456
to	O	2457-2459
59	O	2460-2462
year	O	2463-2467
-	O	2467-2468
old	O	2468-2471
women	O	2472-2477
taking	O	2478-2484
combined	O	2485-2493
continuous	O	2494-2504
HT	O	2505-2507
and	O	2508-2511
1637	O	2512-2516
taking	O	2517-2523
oestrogen	O	2524-2533
-	O	2533-2534
only	O	2534-2538
HT	O	2539-2541
,	O	2541-2542
versus	O	2543-2549
similar	O	2550-2557
-	O	2557-2558
sized	O	2558-2563
placebo	O	2564-2571
groups	O	2572-2578
.	O	2578-2579

The	O	2580-2583
only	O	2584-2588
significantly	O	2589-2602
increased	O	2603-2612
risk	O	2613-2617
reported	O	2618-2626
was	O	2627-2630
for	O	2631-2634
venous	B	2635-2641
thromboembolism	I	2642-2657
in	O	2658-2660
women	O	2661-2666
taking	O	2667-2673
combined	O	2674-2682
continuous	O	2683-2693
HT	O	2694-2696
;	O	2696-2697
their	O	2698-2703
absolute	O	2704-2712
risk	O	2713-2717
remained	O	2718-2726
very	O	2727-2731
low	O	2732-2735
.	O	2735-2736

AUTHORS	O	2737-2744
'	O	2744-2745
CONCLUSIONS	O	2746-2757
:	O	2757-2758
HT	O	2759-2761
is	O	2762-2764
not	O	2765-2768
indicated	O	2769-2778
for	O	2779-2782
the	O	2783-2786
routine	O	2787-2794
management	O	2795-2805
of	O	2806-2808
chronic	B	2809-2816
disease	I	2817-2824
.	O	2824-2825

We	O	2826-2828
need	O	2829-2833
more	O	2834-2838
evidence	O	2839-2847
on	O	2848-2850
the	O	2851-2854
safety	O	2855-2861
of	O	2862-2864
HT	O	2865-2867
for	O	2868-2871
menopausal	O	2872-2882
symptom	O	2883-2890
control	O	2891-2898
,	O	2898-2899
though	O	2900-2906
short	O	2907-2912
-	O	2912-2913
term	O	2913-2917
use	O	2918-2921
appears	O	2922-2929
to	O	2930-2932
be	O	2933-2935
relatively	O	2936-2946
safe	O	2947-2951
for	O	2952-2955
healthy	O	2956-2963
younger	O	2964-2971
women	O	2972-2977
.	O	2977-2978

Drug	B	0-4
-	I	4-5
induced	I	5-12
liver	I	13-18
injury	I	19-25
:	O	25-26
an	O	27-29
analysis	O	30-38
of	O	39-41
461	O	42-45
incidences	O	46-56
submitted	O	57-66
to	O	67-69
the	O	70-73
Spanish	O	74-81
registry	O	82-90
over	O	91-95
a	O	96-97
10	O	98-100
-	O	100-101
year	O	101-105
period	O	106-112
.	O	112-113

BACKGROUND	O	114-124
&	O	125-126
AIMS	O	127-131
:	O	131-132
Progress	O	133-141
in	O	142-144
the	O	145-148
understanding	O	149-162
of	O	163-165
susceptibility	O	166-180
factors	O	181-188
to	O	189-191
drug	B	192-196
-	I	196-197
induced	I	197-204
liver	I	205-210
injury	I	211-217
(	O	218-219
DILI	B	219-223
)	O	223-224
and	O	225-228
outcome	O	229-236
predictability	O	237-251
are	O	252-255
hampered	O	256-264
by	O	265-267
the	O	268-271
lack	O	272-276
of	O	277-279
systematic	O	280-290
programs	O	291-299
to	O	300-302
detect	O	303-309
bona	O	310-314
fide	O	315-319
cases	O	320-325
.	O	325-326

METHODS	O	327-334
:	O	334-335
A	O	336-337
cooperative	O	338-349
network	O	350-357
was	O	358-361
created	O	362-369
in	O	370-372
1994	O	373-377
in	O	378-380
Spain	O	381-386
to	O	387-389
identify	O	390-398
all	O	399-402
suspicions	O	403-413
of	O	414-416
DILI	B	417-421
following	O	422-431
a	O	432-433
prospective	O	434-445
structured	O	446-456
report	O	457-463
form	O	464-468
.	O	468-469

The	O	470-473
liver	B	474-479
damage	I	480-486
was	O	487-490
characterized	O	491-504
according	O	505-514
to	O	515-517
hepatocellular	O	518-532
,	O	532-533
cholestatic	B	534-545
,	O	545-546
and	O	547-550
mixed	O	551-556
laboratory	O	557-567
criteria	O	568-576
and	O	577-580
to	O	581-583
histologic	O	584-594
criteria	O	595-603
when	O	604-608
available	O	609-618
.	O	618-619

Further	O	620-627
evaluation	O	628-638
of	O	639-641
causality	O	642-651
assessment	O	652-662
was	O	663-666
centrally	O	667-676
performed	O	677-686
.	O	686-687

RESULTS	O	688-695
:	O	695-696
Since	O	697-702
April	O	703-708
1994	O	709-713
to	O	714-716
August	O	717-723
2004	O	724-728
,	O	728-729
461	O	730-733
out	O	734-737
of	O	738-740
570	O	741-744
submitted	O	745-754
cases	O	755-760
,	O	760-761
involving	O	762-771
505	O	772-775
drugs	O	776-781
,	O	781-782
were	O	783-787
deemed	O	788-794
to	O	795-797
be	O	798-800
related	O	801-808
to	O	809-811
DILI	B	812-816
.	O	816-817

The	O	818-821
antiinfective	O	822-835
group	O	836-841
of	O	842-844
drugs	O	845-850
was	O	851-854
the	O	855-858
more	O	859-863
frequently	O	864-874
incriminated	O	875-887
,	O	887-888
amoxicillin	O	889-900
-	O	900-901
clavulanate	O	901-912
accounting	O	913-923
for	O	924-927
the	O	928-931
12	O	932-934
.	O	934-935
8	O	935-936
%	O	936-937
of	O	938-940
the	O	941-944
whole	O	945-950
series	O	951-957
.	O	957-958

The	O	959-962
hepatocellular	O	963-977
pattern	O	978-985
of	O	986-988
damage	O	989-995
was	O	996-999
the	O	1000-1003
most	O	1004-1008
common	O	1009-1015
(	O	1016-1017
58	O	1017-1019
%	O	1019-1020
)	O	1020-1021
,	O	1021-1022
was	O	1023-1026
inversely	O	1027-1036
correlated	O	1037-1047
with	O	1048-1052
age	O	1053-1056
(	O	1057-1058
P	O	1058-1059
<	O	1060-1061
.	O	1062-1063
0001	O	1063-1067
)	O	1067-1068
,	O	1068-1069

and	O	1070-1073
had	O	1074-1077
the	O	1078-1081
worst	O	1082-1087
outcome	O	1088-1095
(	O	1096-1097
Cox	O	1097-1100
regression	O	1101-1111
,	O	1111-1112
P	O	1113-1114
<	O	1115-1116
.	O	1117-1118
034	O	1118-1121
)	O	1121-1122
.	O	1117-1118

Indeed	O	1124-1130
,	O	1130-1131
the	O	1132-1135
incidence	O	1136-1145
of	O	1146-1148
liver	O	1149-1154
transplantation	O	1155-1170
and	O	1171-1174
death	O	1175-1180
in	O	1181-1183
this	O	1184-1188
group	O	1189-1194
was	O	1195-1198
11	O	1199-1201
.	O	1201-1202
7	O	1202-1203
%	O	1203-1204
if	O	1205-1207
patients	O	1208-1216
had	O	1217-1220
jaundice	B	1221-1229
at	O	1230-1232
presentation	O	1233-1245
,	O	1245-1246
whereas	O	1247-1254
the	O	1255-1258
corresponding	O	1259-1272
figure	O	1273-1279
was	O	1280-1283
3	O	1284-1285
.	O	1285-1286
8	O	1286-1287
%	O	1287-1288
in	O	1289-1291
nonjaundiced	O	1292-1304
patients	O	1305-1313
(	O	1314-1315
P	O	1315-1316
<	O	1317-1318
.	O	1319-1320
04	O	1320-1322
)	O	1322-1323
.	O	1319-1320

Factors	O	1325-1332
associated	O	1333-1343
with	O	1344-1348
the	O	1349-1352
development	O	1353-1364
of	O	1365-1367
fulminant	B	1368-1377
hepatic	I	1378-1385
failure	I	1386-1393
were	O	1394-1398
female	O	1399-1405
sex	O	1406-1409
(	O	1410-1411
OR	O	1411-1413
=	O	1414-1415
25	O	1416-1418
;	O	1418-1419
95	O	1420-1422
%	O	1422-1423
CI	O	1424-1426
:	O	1426-1427
4	O	1428-1429
.	O	1429-1430
1	O	1430-1431
-	O	1431-1432
151	O	1432-1435
;	O	1435-1436
P	O	1437-1438
<	O	1439-1440
.	O	1441-1442
0001	O	1442-1446
)	O	1446-1447
,	O	1447-1448

hepatocellular	O	1449-1463
damage	O	1464-1470
(	O	1471-1472
OR	O	1472-1474
=	O	1475-1476
7	O	1477-1478
.	O	1478-1479
9	O	1479-1480
;	O	1480-1481
95	O	1482-1484
%	O	1484-1485
CI	O	1486-1488
:	O	1488-1489
1	O	1490-1491
.	O	1491-1492
6	O	1492-1493
-	O	1493-1494
37	O	1494-1496
;	O	1496-1497
P	O	1498-1499
<	O	1500-1501
.	O	1502-1503
009	O	1503-1506
)	O	1506-1507
,	O	1507-1508

and	O	1509-1512
higher	O	1513-1519
baseline	O	1520-1528
plasma	O	1529-1535
bilirubin	O	1536-1545
value	O	1546-1551
(	O	1552-1553
OR	O	1553-1555
=	O	1556-1557
1	O	1558-1559
.	O	1559-1560
15	O	1560-1562
;	O	1562-1563
95	O	1564-1566
%	O	1566-1567
CI	O	1568-1570
:	O	1570-1571
1	O	1572-1573
.	O	1573-1574
09	O	1574-1576
-	O	1576-1577
1	O	1572-1573
.	O	1573-1574
22	O	1579-1581
;	O	1581-1582

P	O	1583-1584
<	O	1585-1586
.	O	1587-1588
0001	O	1588-1592
)	O	1592-1593
.	O	1587-1588

CONCLUSIONS	O	1595-1606
:	O	1606-1607
Patients	O	1608-1616
with	O	1617-1621
drug	O	1622-1626
-	O	1626-1627
induced	O	1627-1634
hepatocellular	O	1635-1649
jaundice	B	1650-1658
have	O	1659-1663
11	O	1664-1666
.	O	1666-1667
7	O	1667-1668
%	O	1668-1669
chance	O	1670-1676
of	O	1677-1679
progressing	O	1680-1691
to	O	1692-1694
death	O	1695-1700
or	O	1701-1703
transplantation	O	1704-1719
.	O	1719-1720

Amoxicillin	O	1721-1732
-	O	1732-1733
clavulanate	O	1733-1744
stands	O	1745-1751
out	O	1752-1755
as	O	1756-1758
the	O	1759-1762
most	O	1763-1767
common	O	1768-1774
drug	O	1775-1779
related	O	1780-1787
to	O	1788-1790
DILI	B	1791-1795
.	O	1795-1796

Morphological	O	0-13
evaluation	O	14-24
of	O	25-27
the	O	28-31
effect	O	32-38
of	O	39-41
d	O	42-43
-	O	43-44
ribose	O	44-50
on	O	51-53
adriamycin	O	54-64
-	O	64-65
evoked	O	65-71
cardiotoxicity	B	72-86
in	O	87-89
rats	O	90-94
.	O	94-95

The	O	96-99
influence	O	100-109
of	O	110-112
d	O	113-114
-	O	114-115
ribose	O	115-121
on	O	122-124
adriamycin	O	125-135
-	O	135-136
induced	O	136-143
myocardiopathy	B	144-158
in	O	159-161
rats	O	162-166
was	O	167-170
studied	O	171-178
.	O	178-179

Adriamycin	O	180-190
in	O	191-193
the	O	194-197
cumulative	O	198-208
dose	O	209-213
of	O	214-216
25	O	217-219
mg	O	220-222
/	O	222-223
kg	O	223-225
evoked	O	226-232
fully	O	233-238
developed	O	239-248
cardiac	B	249-256
toxicity	I	257-265
.	O	265-266

D	O	267-268
-	O	268-269
ribose	O	269-275
in	O	276-278
the	O	279-282
multiple	O	283-291
doses	O	292-297
of	O	298-300
200	O	301-304
mg	O	305-307
/	O	307-308
kg	O	308-310
did	O	311-314
not	O	315-318
influence	O	319-328
ADR	O	329-332
cardiotoxicity	B	333-347
.	O	347-348

In	O	0-2
vivo	O	3-7
evidences	O	8-17
suggesting	O	18-28
the	O	29-32
role	O	33-37
of	O	38-40
oxidative	O	41-50
stress	O	51-57
in	O	58-60
pathogenesis	O	61-73
of	O	74-76
vancomycin	O	77-87
-	O	87-88
induced	O	88-95
nephrotoxicity	B	96-110
:	O	110-111
protection	O	112-122
by	O	123-125
erdosteine	O	126-136
.	O	136-137

The	O	138-141
aims	O	142-146
of	O	147-149
this	O	150-154
study	O	155-160
were	O	161-165
to	O	166-168
examine	O	169-176
vancomycin	O	177-187
(	O	188-189
VCM	O	189-192
)	O	192-193
-	O	193-194
induced	O	194-201
oxidative	O	202-211
stress	O	212-218
that	O	219-223
promotes	O	224-232
production	O	233-243
of	O	244-246
reactive	O	247-255
oxygen	O	256-262
species	O	263-270
(	O	271-272
ROS	O	272-275
)	O	275-276
and	O	277-280
to	O	281-283
investigate	O	284-295
the	O	296-299
role	O	300-304
of	O	305-307
erdosteine	O	308-318
,	O	318-319
an	O	320-322
expectorant	O	323-334
agent	O	335-340
,	O	340-341
which	O	342-347
has	O	348-351
also	O	352-356
antioxidant	O	357-368
properties	O	369-379
,	O	379-380
on	O	381-383
kidney	O	384-390
tissue	O	391-397
against	O	398-405
the	O	406-409
possible	O	410-418
VCM	O	419-422
-	O	422-423
induced	O	423-430
renal	B	431-436
impairment	I	437-447
in	O	448-450
rats	O	451-455
.	O	455-456

Rats	O	457-461
were	O	462-466
divided	O	467-474
into	O	475-479
three	O	480-485
groups	O	486-492
:	O	492-493
sham	O	494-498
,	O	498-499
VCM	O	500-503
and	O	504-507
VCM	O	508-511
plus	O	512-516
erdosteine	O	517-527
.	O	527-528

VCM	O	529-532
was	O	533-536
administrated	O	537-550
intraperitoneally	O	551-568
(	O	569-570
i	O	570-571
.	O	571-572
p	O	572-573
.	O	571-572
)	O	574-575
with	O	576-580
200mgkg	O	581-588
(	O	588-589
-	O	589-590
1	O	590-591
)	O	591-592
twice	O	593-598
daily	O	599-604
for	O	605-608
7	O	609-610
days	O	611-615
.	O	615-616

Erdosteine	O	617-627
was	O	628-631
administered	O	632-644
orally	O	645-651
.	O	651-652

VCM	O	653-656
administration	O	657-671
to	O	672-674
control	O	675-682
rats	O	683-687
significantly	O	688-701
increased	O	702-711
renal	O	712-717
malondialdehyde	O	718-733
(	O	734-735
MDA	O	735-738
)	O	738-739
and	O	740-743
urinary	O	744-751
N	O	752-753
-	O	753-754
acetyl	O	754-760
-	O	753-754
beta	O	761-765
-	O	753-754
d	O	766-767
-	O	753-754
glucosaminidase	O	768-783
(	O	784-785
NAG	O	785-788
,	O	788-789
a	O	790-791
marker	O	792-798
of	O	799-801
renal	B	802-807
tubular	I	808-815
injury	I	816-822
)	O	822-823
excretion	O	824-833
but	O	834-837
decreased	O	838-847
superoxide	O	848-858
dismutase	O	859-868
(	O	869-870
SOD	O	870-873
)	O	873-874
and	O	875-878
catalase	O	879-887
(	O	888-889
CAT	O	889-892
)	O	892-893
activities	O	894-904
.	O	904-905

Erdosteine	O	906-916
administration	O	917-931
with	O	932-936
VCM	O	937-940
injections	O	941-951
caused	O	952-958
significantly	O	959-972
decreased	O	973-982
renal	O	983-988
MDA	O	989-992
and	O	993-996
urinary	O	997-1004
NAG	O	1005-1008
excretion	O	1009-1018
,	O	1018-1019
and	O	1020-1023
increased	O	1024-1033
SOD	O	1034-1037
activity	O	1038-1046
,	O	1046-1047
but	O	1048-1051
not	O	1052-1055
CAT	O	1056-1059
activity	O	1060-1068
in	O	1069-1071
renal	O	1072-1077
tissue	O	1078-1084
when	O	1085-1089
compared	O	1090-1098
with	O	1099-1103
VCM	O	1104-1107
alone	O	1108-1113
.	O	1113-1114

Erdosteine	O	1115-1125
showed	O	1126-1132
histopathological	O	1133-1150
protection	O	1151-1161
against	O	1162-1169
VCM	O	1170-1173
-	O	1173-1174
induced	O	1174-1181
nephrotoxicity	B	1182-1196
.	O	1196-1197

There	O	1198-1203
were	O	1204-1208
a	O	1209-1210
significant	O	1211-1222
dilatation	O	1223-1233
of	O	1234-1236
tubular	O	1237-1244
lumens	O	1245-1251
,	O	1251-1252
extensive	O	1253-1262
epithelial	O	1263-1273
cell	O	1274-1278
vacuolization	O	1279-1292
,	O	1292-1293
atrophy	B	1294-1301
,	O	1301-1302
desquamation	B	1303-1315
,	O	1315-1316
and	O	1317-1320
necrosis	B	1321-1329
in	O	1330-1332
VCM	O	1333-1336
-	O	1336-1337
treated	O	1337-1344
rats	O	1345-1349
more	O	1350-1354
than	O	1355-1359
those	O	1360-1365
of	O	1366-1368
the	O	1369-1372
control	O	1373-1380
and	O	1381-1384
the	O	1385-1388
erdosteine	O	1389-1399
groups	O	1400-1406
.	O	1406-1407

Erdosteine	O	1408-1418
caused	O	1419-1425
a	O	1426-1427
marked	O	1428-1434
reduction	O	1435-1444
in	O	1445-1447
the	O	1448-1451
extent	O	1452-1458
of	O	1459-1461
tubular	O	1462-1469
damage	O	1470-1476
.	O	1476-1477

It	O	1478-1480
is	O	1481-1483
concluded	O	1484-1493
that	O	1494-1498
oxidative	O	1499-1508
tubular	O	1509-1516
damage	O	1517-1523
plays	O	1524-1529
an	O	1530-1532
important	O	1533-1542
role	O	1543-1547
in	O	1548-1550
the	O	1551-1554
VCM	O	1555-1558
-	O	1558-1559
induced	O	1559-1566
nephrotoxicity	B	1567-1581
and	O	1582-1585
the	O	1586-1589
modulation	O	1590-1600
of	O	1601-1603
oxidative	O	1604-1613
stress	O	1614-1620
with	O	1621-1625
erdosteine	O	1626-1636
reduces	O	1637-1644
the	O	1645-1648
VCM	O	1649-1652
-	O	1652-1653
induced	O	1653-1660
kidney	B	1661-1667
damage	I	1668-1674
both	O	1675-1679
at	O	1680-1682
the	O	1683-1686
biochemical	O	1687-1698
and	O	1699-1702
histological	O	1703-1715
levels	O	1716-1722
.	O	1722-1723

Does	O	0-4
domperidone	O	5-16
potentiate	O	17-27
mirtazapine	O	28-39
-	O	39-40
associated	O	40-50
restless	B	51-59
legs	I	60-64
syndrome	I	65-73
?	O	73-74

There	O	75-80
is	O	81-83
now	O	84-87
evidence	O	88-96
to	O	97-99
suggest	O	100-107
a	O	108-109
central	O	110-117
role	O	118-122
for	O	123-126
the	O	127-130
dopaminergic	O	131-143
system	O	144-150
in	O	151-153
restless	B	154-162
legs	I	163-167
syndrome	I	168-176
(	O	177-178
RLS	B	178-181
)	O	181-182
.	O	182-183

For	O	184-187
example	O	188-195
,	O	195-196
the	O	197-200
symptoms	O	201-209
of	O	210-212
RLS	B	213-216
can	O	217-220
be	O	221-223
dramatically	O	224-236
improved	O	237-245
by	O	246-248
levodopa	O	249-257
and	O	258-261
dopamine	O	262-270
agonists	O	271-279
,	O	279-280
whereas	O	281-288
central	O	289-296
dopamine	O	297-305
D2	O	306-308
receptor	O	309-317
antagonists	O	318-329
can	O	330-333
induce	O	334-340
or	O	341-343
aggravate	O	344-353
RLS	B	354-357
symptoms	O	358-366
.	O	366-367

To	O	368-370
our	O	371-374
knowledge	O	375-384
,	O	384-385
there	O	386-391
is	O	392-394
no	O	395-397
previous	O	398-406
report	O	407-413
regarding	O	414-423
whether	O	424-431
domperidone	O	432-443
,	O	443-444
a	O	445-446
peripheral	O	447-457
dopamine	O	458-466
D2	O	467-469
receptor	O	470-478
antagonist	O	479-489
,	O	489-490
can	O	491-494
also	O	495-499
induce	O	500-506
or	O	507-509
aggravate	O	510-519
symptoms	O	520-528
of	O	529-531
RLS	B	532-535
.	O	535-536

Mirtazapine	O	537-548
,	O	548-549
the	O	550-553
first	O	554-559
noradrenergic	O	560-573
and	O	574-577
specific	O	578-586
serotonergic	O	587-599
antidepressant	O	600-614
(	O	615-616
NaSSA	O	616-621
)	O	621-622
,	O	622-623
has	O	624-627
been	O	628-632
associated	O	633-643
with	O	644-648
RLS	B	649-652
in	O	653-655
several	O	656-663
recent	O	664-670
publications	O	671-683
.	O	683-684

The	O	685-688
authors	O	689-696
report	O	697-703
here	O	704-708
a	O	709-710
depressed	O	711-720
patient	O	721-728
comorbid	O	729-737
with	O	738-742
postprandial	B	743-755
dyspepsia	I	756-765
who	O	766-769
developed	O	770-779
RLS	B	780-783
after	O	784-789
mirtazapine	O	790-801
had	O	802-805
been	O	806-810
added	O	811-816
to	O	817-819
his	O	820-823
domperidone	O	824-835
therapy	O	836-843
.	O	843-844

Our	O	845-848
patient	O	849-856
started	O	857-864
to	O	865-867
have	O	868-872
symptoms	O	873-881
of	O	882-884
RLS	B	885-888
only	O	889-893
after	O	894-899
he	O	900-902
had	O	903-906
been	O	907-911
treated	O	912-919
with	O	920-924
mirtazapine	O	925-936
,	O	936-937
and	O	938-941
his	O	942-945
RLS	B	946-949
symptoms	O	950-958
resolved	O	959-967
completely	O	968-978
upon	O	979-983
discontinuation	O	984-999
of	O	1000-1002
his	O	1003-1006
mirtazapine	O	1007-1018
.	O	1018-1019

Such	O	1020-1024
a	O	1025-1026
temporal	O	1027-1035
relationship	O	1036-1048
between	O	1049-1056
the	O	1057-1060
use	O	1061-1064
of	O	1065-1067
mirtazapine	O	1068-1079
and	O	1080-1083
the	O	1084-1087
symptoms	O	1088-1096
of	O	1097-1099
RLS	B	1100-1103
in	O	1104-1106
our	O	1107-1110
patient	O	1111-1118
did	O	1119-1122
not	O	1123-1126
support	O	1127-1134
a	O	1135-1136
potentiating	O	1137-1149
effect	O	1150-1156
of	O	1157-1159
domperione	O	1160-1170
on	O	1171-1173
mirtazapine	O	1174-1185
-	O	1185-1186
associated	O	1186-1196
RLS	B	1197-1200
.	O	1200-1201

However	O	1202-1209
,	O	1209-1210
physicians	O	1211-1221
should	O	1222-1228
be	O	1229-1231
aware	O	1232-1237
of	O	1238-1240
the	O	1241-1244
possibility	O	1245-1256
that	O	1257-1261
mirtazapine	O	1262-1273
can	O	1274-1277
be	O	1278-1280
associated	O	1281-1291
with	O	1292-1296
RLS	B	1297-1300
in	O	1301-1303
some	O	1304-1308
individuals	O	1309-1320
,	O	1320-1321
especially	O	1322-1332
those	O	1333-1338
receiving	O	1339-1348
concomitant	O	1349-1360
dopamine	O	1361-1369
D2	O	1370-1372
receptor	O	1373-1381
antagonists	O	1382-1393
.	O	1393-1394

Antiandrogenic	O	0-14
therapy	O	15-22
can	O	23-26
cause	O	27-32
coronary	B	33-41
arterial	I	42-50
disease	I	51-58
.	O	58-59

AIM	O	60-63
:	O	63-64
To	O	65-67
study	O	68-73
the	O	74-77
change	O	78-84
of	O	85-87
lipid	O	88-93
metabolism	O	94-104
by	O	105-107
antiandrogen	O	108-120
therapy	O	121-128
in	O	129-131
patients	O	132-140
with	O	141-145
prostate	B	146-154
cancer	I	155-161
.	O	161-162

MATERIALS	O	163-172
AND	O	173-176
METHODS	O	177-184
:	O	184-185
We	O	186-188
studied	O	189-196
with	O	197-201
a	O	202-203
2	O	204-205
.	O	205-206
5	O	206-207
years	O	208-213
follow	O	214-220
-	O	220-221
up	O	221-223
the	O	224-227
changes	O	228-235
in	O	236-238
plasma	O	239-245
cholesterols	O	246-258
(	O	259-260
C	O	260-261
)	O	261-262
,	O	262-263
triglycerides	O	264-277
(	O	278-279
TG	O	279-281
)	O	281-282
,	O	282-283
lipoproteins	O	284-296
(	O	297-298
LP	O	298-300
)	O	300-301
,	O	301-302
and	O	303-306
apolipoproteins	O	307-322
(	O	323-324
Apo	O	324-327
)	O	327-328
B	O	329-330
-	O	330-331
100	O	331-334
,	O	334-335
A	O	336-337
-	O	337-338
I	O	338-339
,	O	339-340
and	O	341-344
A	O	345-346
-	O	346-347
II	O	347-349
pro	O	350-353
fi	O	354-356
les	O	357-360
in	O	361-363
24	O	364-366
patients	O	367-375
of	O	376-378
mean	O	379-383
age	O	384-387
60	O	388-390
years	O	391-396
with	O	397-401
low	O	402-405
risk	O	406-410
prostate	B	411-419
cancer	I	420-426
(	O	427-428
stage	O	428-433
:	O	433-434
T1cN0M0	O	435-442
,	O	442-443
Gleason	O	444-451
score	O	452-457
:	O	457-458
2	O	459-460
-	O	460-461
5	O	461-462
)	O	462-463
during	O	464-470
treatment	O	471-480
with	O	481-485
cyproterone	O	486-497
acetate	O	498-505
(	O	506-507
CPA	O	507-510
)	O	510-511
without	O	512-519
surgical	O	520-528
management	O	529-539
or	O	540-542
radiation	O	543-552
therapy	O	553-560
.	O	560-561

RESULTS	O	562-569
:	O	569-570
Significant	O	571-582
decreases	O	583-592
of	O	593-595
HDL	O	596-599
-	O	599-600
C	O	600-601
,	O	601-602
Apo	O	603-606
A	O	607-608
-	O	608-609
I	O	609-610
and	O	611-614
Apo	O	615-618
A	O	619-620
-	O	620-621
II	O	621-623
and	O	624-627
an	O	628-630
increase	O	631-639
of	O	640-642
triglyceride	O	643-655
levels	O	656-662
in	O	663-665
VLDL	O	666-670
were	O	671-675
induced	O	676-683
by	O	684-686
CPA	O	687-690
.	O	690-691

After	O	692-697
a	O	698-699
period	O	700-706
of	O	707-709
2	O	710-711
.	O	711-712
5	O	712-713
years	O	714-719
on	O	720-722
CPA	O	723-726
treatment	O	727-736
,	O	736-737
four	O	738-742
patients	O	743-751
out	O	752-755
of	O	756-758
twenty	O	759-765
-	O	765-766
four	O	766-770
were	O	771-775
found	O	776-781
to	O	782-784
be	O	785-787
affected	O	788-796
by	O	797-799
coronary	B	800-808
heart	I	809-814
disease	I	815-822
.	O	822-823

CONCLUSIONS	O	824-835
:	O	835-836
Ischaemic	O	837-846
coronary	B	847-855
arteriosclerosis	I	856-872
with	O	873-877
an	O	878-880
incidence	O	881-890
rate	O	891-895
of	O	896-898
16	O	899-901
.	O	901-902
6	O	900-901
%	O	903-904
as	O	905-907
caused	O	908-914
by	O	915-917
prolonged	O	918-927
CPA	O	928-931
therapy	O	932-939
is	O	940-942
mediated	O	943-951
through	O	952-959
changes	O	960-967
in	O	968-970
HDL	O	971-974
cholesterol	O	975-986
,	O	986-987
Apo	O	988-991
A	O	992-993
-	O	993-994
I	O	994-995
and	O	996-999
Apo	O	1000-1003
A	O	1004-1005
-	O	1005-1006
II	O	1006-1008
pro	O	1009-1012
fi	O	1013-1015
les	O	1016-1019
,	O	1019-1020
other	O	1021-1026
than	O	1027-1031
the	O	1032-1035
well	O	1036-1040
-	O	1040-1041
known	O	1041-1046
hyperglyceridemic	B	1047-1064
effect	I	1065-1071
caused	O	1072-1078
by	O	1079-1081
estrogen	O	1082-1090
.	O	1090-1091

5	O	0-1
-	O	1-2
Fluorouracil	O	2-14
cardiotoxicity	B	15-29
induced	O	30-37
by	O	38-40
alpha	O	41-46
-	O	46-47
fluoro	O	47-53
-	O	46-47
beta	O	54-58
-	O	46-47
alanine	O	59-66
.	O	66-67
Cardiotoxicity	B	68-82
is	O	83-85
a	O	86-87
rare	O	88-92
complication	O	93-105
occurring	O	106-115
during	O	116-122
5	O	123-124
-	O	124-125
fluorouracil	O	125-137
(	O	138-139
5	O	139-140
-	O	140-141
FU	O	141-143
)	O	143-144
treatment	O	145-154
for	O	155-158
malignancies	B	159-171
.	O	171-172

We	O	173-175
herein	O	176-182
report	O	183-189
the	O	190-193
case	O	194-198
of	O	199-201
a	O	202-203
70	O	204-206
-	O	206-207
year	O	207-211
-	O	206-207
old	O	212-215
man	O	216-219
with	O	220-224
5	O	225-226
-	O	226-227
FU	O	227-229
-	O	226-227
induced	O	230-237
cardiotoxicity	B	238-252
,	O	252-253
in	O	254-256
whom	O	257-261
a	O	262-263
high	O	264-268
serum	O	269-274
level	O	275-280
of	O	281-283
alpha	O	284-289
-	O	289-290
fluoro	O	290-296
-	O	289-290
beta	O	297-301
-	O	289-290
alanine	O	302-309
(	O	310-311
FBAL	O	311-315
)	O	315-316
was	O	317-320
observed	O	321-329
.	O	329-330

The	O	331-334
patient	O	335-342
,	O	342-343
who	O	344-347
had	O	348-351
unresectable	O	352-364
colon	B	365-370
cancer	I	371-377
metastases	O	378-388
to	O	389-391
the	O	392-395
liver	O	396-401
and	O	402-405
lung	O	406-410
,	O	410-411
was	O	412-415
referred	O	416-424
to	O	425-427
us	O	428-430
for	O	431-434
chemotherapy	O	435-447
from	O	448-452
an	O	453-455
affiliated	O	456-466
hospital	O	467-475
;	O	475-476
he	O	477-479
had	O	480-483
no	O	484-486
cardiac	O	487-494
history	O	495-502
.	O	502-503

After	O	504-509
admission	O	510-519
,	O	519-520
the	O	521-524
patient	O	525-532
received	O	533-541
a	O	542-543
continuous	O	544-554
intravenous	O	555-566
infusion	O	567-575
of	O	576-578
5	O	579-580
-	O	580-581
FU	O	581-583
(	O	584-585
1000	O	585-589
mg	O	590-592
/	O	592-593
day	O	593-596
)	O	596-597
,	O	597-598
during	O	599-605
which	O	606-611
precordial	B	612-622
pain	I	623-627
with	O	628-632
right	B	633-638
bundle	I	639-645
branch	I	646-652
block	I	653-658
occurred	O	659-667
concomitantly	O	668-681
with	O	682-686
a	O	687-688
high	O	689-693
serum	O	694-699
FBAL	O	700-704
concentration	O	705-718
of	O	719-721
1955	O	722-726
ng	O	727-729
/	O	729-730
ml	O	730-732
.	O	732-733

Both	O	734-738
the	O	739-742
precordial	B	743-753
pain	I	754-758
and	O	759-762
the	O	763-766
electrocardiographic	O	767-787
changes	O	788-795
disappeared	O	796-807
spontaneously	O	808-821
after	O	822-827
the	O	828-831
discontinuation	O	832-847
of	O	848-850
5	O	851-852
-	O	852-853
FU	O	853-855
.	O	855-856

As	O	857-859
the	O	860-863
precordial	B	864-874
pain	I	875-879
in	O	880-882
this	O	883-887
patient	O	888-895
was	O	896-899
considered	O	900-910
to	O	911-913
have	O	914-918
been	O	919-923
due	O	924-927
to	O	928-930
5	O	931-932
-	O	932-933
FU	O	933-935
-	O	932-933
induced	O	936-943
cardiotoxicity	B	944-958
,	O	958-959
the	O	960-963
administration	O	964-978
of	O	979-981
5	O	982-983
-	O	983-984
FU	O	984-986
was	O	987-990
abandoned	O	991-1000
.	O	1000-1001

Instead	O	1002-1009
,	O	1009-1010
oral	O	1011-1015
administration	O	1016-1030
of	O	1031-1033
S	O	1034-1035
-	O	1035-1036
1	O	1036-1037
(	O	1038-1039
a	O	1039-1040
derivative	O	1041-1051
of	O	1052-1054
5	O	1055-1056
-	O	1056-1057
FU	O	1057-1059
)	O	1059-1060
,	O	1060-1061
at	O	1062-1064
200	O	1065-1068
mg	O	1069-1071
/	O	1071-1072
day	O	1072-1075
twice	O	1076-1081
a	O	1082-1083
week	O	1084-1088
,	O	1088-1089
was	O	1090-1093
instituted	O	1094-1104
,	O	1104-1105
because	O	1106-1113
S	O	1114-1115
-	O	1115-1116
1	O	1116-1117
has	O	1118-1121
a	O	1122-1123
strong	O	1124-1130
inhibitory	O	1131-1141
effect	O	1142-1148
on	O	1149-1151
dihydropyrimidine	O	1152-1169
dehydrogenase	O	1170-1183
,	O	1183-1184
which	O	1185-1190
catalyzes	O	1191-1200
the	O	1201-1204
degradative	O	1205-1216
of	O	1217-1219
5	O	1220-1221
-	O	1221-1222
FU	O	1222-1224
into	O	1225-1229
FBAL	O	1230-1234
.	O	1234-1235

The	O	1236-1239
serum	O	1240-1245
FBAL	O	1246-1250
concentration	O	1251-1264
subsequently	O	1265-1277
decreased	O	1278-1287
to	O	1288-1290
352	O	1291-1294
ng	O	1295-1297
/	O	1297-1298
ml	O	1298-1300
,	O	1300-1301
the	O	1302-1305
same	O	1306-1310
as	O	1311-1313
the	O	1314-1317
value	O	1318-1323
measured	O	1324-1332
on	O	1333-1335
the	O	1336-1339
first	O	1340-1345
day	O	1346-1349
of	O	1350-1352
S	O	1353-1354
-	O	1354-1355
1	O	1355-1356
administration	O	1357-1371
.	O	1371-1372

Thereafter	O	1373-1383
,	O	1383-1384
no	O	1385-1387
cardiac	B	1388-1395
symptoms	I	1396-1404
were	O	1405-1409
observed	O	1410-1418
.	O	1418-1419

The	O	1420-1423
patient	O	1424-1431
achieved	O	1432-1440
a	O	1441-1442
partial	O	1443-1450
response	O	1451-1459
6	O	1460-1461
months	O	1462-1468
after	O	1469-1474
the	O	1475-1478
initiation	O	1479-1489
of	O	1490-1492
the	O	1493-1496
S	O	1497-1498
-	O	1498-1499
1	O	1499-1500
treatment	O	1501-1510
.	O	1510-1511

The	O	1512-1515
experience	O	1516-1526
of	O	1527-1529
this	O	1530-1534
case	O	1535-1539
,	O	1539-1540
together	O	1541-1549
with	O	1550-1554
a	O	1555-1556
review	O	1557-1563
of	O	1564-1566
the	O	1567-1570
literature	O	1571-1581
,	O	1581-1582
suggests	O	1583-1591
that	O	1592-1596
FBAL	O	1597-1601
is	O	1602-1604
related	O	1605-1612
to	O	1613-1615
5	O	1616-1617
-	O	1617-1618
FU	O	1618-1620
-	O	1617-1618
induced	O	1621-1628
cardiotoxicity	B	1629-1643
.	O	1643-1644

S	O	1645-1646
-	O	1646-1647
1	O	1647-1648
may	O	1649-1652
be	O	1653-1655
administered	O	1656-1668
safely	O	1669-1675
to	O	1676-1678
patients	O	1679-1687
with	O	1688-1692
5	O	1693-1694
-	O	1694-1695
FU	O	1695-1697
-	O	1694-1695
induced	O	1698-1705
cardiotoxicity	B	1706-1720
.	O	1720-1721

The	O	0-3
influence	O	4-13
of	O	14-16
the	O	17-20
time	O	21-25
interval	O	26-34
between	O	35-42
monoHER	O	43-50
and	O	51-54
doxorubicin	O	55-66
administration	O	67-81
on	O	82-84
the	O	85-88
protection	O	89-99
against	O	100-107
doxorubicin	O	108-119
-	O	119-120
induced	O	120-127
cardiotoxicity	B	128-142
in	O	143-145
mice	O	146-150
.	O	150-151

PURPOSE	O	152-159
:	O	159-160
Despite	O	161-168
its	O	169-172
well	O	173-177
-	O	177-178
known	O	178-183
cardiotoxicity	B	184-198
,	O	198-199
the	O	200-203
anthracyclin	O	204-216
doxorubicin	O	217-228
(	O	229-230
DOX	O	230-233
)	O	233-234
continues	O	235-244
to	O	245-247
be	O	248-250
an	O	251-253
effective	O	254-263
and	O	264-267
widely	O	268-274
used	O	275-279
chemotherapeutic	O	280-296
agent	O	297-302
.	O	302-303

DOX	O	304-307
-	O	307-308
induced	O	308-315
cardiac	B	316-323
damage	I	324-330
presumably	O	331-341
results	O	342-349
from	O	350-354
the	O	355-358
formation	O	359-368
of	O	369-371
free	O	372-376
radicals	O	377-385
by	O	386-388
DOX	O	389-392
.	O	392-393

Reactive	O	394-402
oxygen	O	403-409
species	O	410-417
particularly	O	418-430
affect	O	431-437
the	O	438-441
cardiac	O	442-449
myocytes	O	450-458
because	O	459-466
these	O	467-472
cells	O	473-478
seem	O	479-483
to	O	484-486
have	O	487-491
a	O	492-493
relatively	O	494-504
poor	O	505-509
antioxidant	O	510-521
defense	O	522-529
system	O	530-536
.	O	536-537

The	O	538-541
semisynthetic	O	542-555
flavonoid	O	556-565
monohydroxyethylrutoside	O	566-590
(	O	591-592
monoHER	O	592-599
)	O	599-600
showed	O	601-607
cardioprotection	O	608-624
against	O	625-632
DOX	O	633-636
-	O	636-637
induced	O	637-644
cardiotoxicity	B	645-659
through	O	660-667
its	O	668-671
radical	O	672-679
scavenging	O	680-690
and	O	691-694
iron	O	695-699
chelating	O	700-709
properties	O	710-720
.	O	720-721

Because	O	722-729
of	O	730-732
the	O	733-736
relatively	O	737-747
short	O	748-753
final	O	754-759
half	O	760-764
-	O	764-765
life	O	765-769
of	O	770-772
monoHER	O	773-780
(	O	781-782
about	O	782-787
30	O	788-790
min	O	791-794
)	O	794-795
,	O	795-796
it	O	797-799
is	O	800-802
expected	O	803-811
that	O	812-816
the	O	817-820
time	O	821-825
interval	O	826-834
between	O	835-842
monoHER	O	843-850
and	O	851-854
DOX	O	855-858
might	O	859-864
be	O	865-867
of	O	868-870
influence	O	871-880
on	O	881-883
the	O	884-887
cardioprotective	O	888-904
effect	O	905-911
of	O	912-914
monoHER	O	915-922
.	O	922-923

Therefore	O	924-933
,	O	933-934
the	O	935-938
aim	O	939-942
of	O	943-945
the	O	946-949
present	O	950-957
study	O	958-963
was	O	964-967
to	O	968-970
investigate	O	971-982
this	O	983-987
possible	O	988-996
effect	O	997-1003
.	O	1003-1004

METHODS	O	1005-1012
:	O	1012-1013
Six	O	1014-1017
groups	O	1018-1024
of	O	1025-1027
6	O	1028-1029
BALB	O	1030-1034
/	O	1034-1035
c	O	1035-1036
mice	O	1037-1041
were	O	1042-1046
treated	O	1047-1054
with	O	1055-1059
saline	O	1060-1066
,	O	1066-1067
DOX	O	1068-1071
alone	O	1072-1077
or	O	1078-1080
DOX	O	1081-1084
(	O	1085-1086
4	O	1086-1087
mg	O	1088-1090
/	O	1090-1091
kg	O	1091-1093
i	O	1094-1095
.	O	1095-1096
v	O	1096-1097
.	O	1095-1096
)	O	1098-1099
preceded	O	1100-1108
by	O	1109-1111
monoHER	O	1112-1119
(	O	1120-1121
500	O	1121-1124
mg	O	1125-1127
/	O	1127-1128
kg	O	1128-1130
i	O	1131-1132
.	O	1132-1133
p	O	1133-1134
.	O	1132-1133
)	O	1135-1136
with	O	1137-1141
an	O	1142-1144
interval	O	1145-1153
of	O	1154-1156
10	O	1157-1159
,	O	1159-1160
30	O	1161-1163
,	O	1163-1164
60	O	1165-1167
or	O	1168-1170
120	O	1171-1174
min	O	1175-1178
.	O	1178-1179

After	O	1180-1185
a	O	1186-1187
6	O	1188-1189
-	O	1189-1190
week	O	1190-1194
treatment	O	1195-1204
period	O	1205-1211
and	O	1212-1215
additional	O	1216-1226
observation	O	1227-1238
for	O	1239-1242
2	O	1243-1244
weeks	O	1245-1250
,	O	1250-1251
the	O	1252-1255
mice	O	1256-1260
were	O	1261-1265
sacrificed	O	1266-1276
.	O	1276-1277

Their	O	1278-1283
cardiac	O	1284-1291
tissues	O	1292-1299
were	O	1300-1304
processed	O	1305-1314
for	O	1315-1318
light	O	1319-1324
microscopy	O	1325-1335
,	O	1335-1336
after	O	1337-1342
which	O	1343-1348
cardiomyocyte	B	1349-1362
damage	I	1363-1369
was	O	1370-1373
evaluated	O	1374-1383
according	O	1384-1393
to	O	1394-1396
Billingham	O	1397-1407
(	O	1408-1409
in	O	1409-1411
Cancer	B	1412-1418
Treat	O	1419-1424
Rep	O	1425-1428
62	O	1429-1431
(	O	1431-1432
6	O	1429-1430
)	O	1433-1434
:	O	1434-1435
865	O	1435-1438
-	O	1438-1439
872	O	1439-1442
,	O	1442-1443
1978	O	1444-1448
)	O	1448-1449
.	O	1449-1450

Microscopic	O	1451-1462
evaluation	O	1463-1473
revealed	O	1474-1482
that	O	1483-1487
treatment	O	1488-1497
with	O	1498-1502
DOX	O	1503-1506
alone	O	1507-1512
induced	O	1513-1520
significant	O	1521-1532
cardiac	B	1533-1540
damage	I	1541-1547
in	O	1548-1550
comparison	O	1551-1561
to	O	1562-1564
the	O	1565-1568
saline	O	1569-1575
control	O	1576-1583
group	O	1584-1589
(	O	1590-1591
P	O	1591-1592
<	O	1592-1593
0	O	1593-1594
.	O	1594-1595
001	O	1595-1598
)	O	1598-1599
.	O	1594-1595

RESULTS	O	1601-1608
:	O	1608-1609
The	O	1610-1613
number	O	1614-1620
of	O	1621-1623
damaged	O	1624-1631
cardiomyocytes	O	1632-1646
was	O	1647-1650
9	O	1651-1652
.	O	1652-1653
6	O	1653-1654
-	O	1654-1655
fold	O	1655-1659
(	O	1660-1661
95	O	1661-1663
%	O	1663-1664
CI	O	1665-1667
4	O	1668-1669
.	O	1669-1670
4	O	1668-1669
-	O	1671-1672
21	O	1672-1674
.	O	1669-1670
0	O	1675-1676
)	O	1676-1677

higher	O	1678-1684
in	O	1685-1687
mice	O	1688-1692
treated	O	1693-1700
with	O	1701-1705
DOX	O	1706-1709
alone	O	1710-1715
than	O	1716-1720
that	O	1721-1725
in	O	1726-1728
animals	O	1729-1736
of	O	1737-1739
the	O	1740-1743
control	O	1744-1751
group	O	1752-1757
.	O	1757-1758

The	O	1759-1762
ratio	O	1763-1768
of	O	1769-1771
aberrant	O	1772-1780
cardiomyocytes	O	1781-1795
in	O	1796-1798
mice	O	1799-1803
treated	O	1804-1811
with	O	1812-1816
DOX	O	1817-1820
preceded	O	1821-1829
by	O	1830-1832
monoHER	O	1833-1840
and	O	1841-1844
those	O	1845-1850
in	O	1851-1853
mice	O	1854-1858
treated	O	1859-1866
with	O	1867-1871
saline	O	1872-1878
ranged	O	1879-1885
from	O	1886-1890
1	O	1891-1892
.	O	1892-1893
6	O	1893-1894
to	O	1895-1897
2	O	1898-1899
.	O	1899-1900
8	O	1900-1901
(	O	1902-1903
mean	O	1903-1907
2	O	1908-1909
.	O	1909-1910
2	O	1908-1909
,	O	1911-1912
95	O	1913-1915
%	O	1915-1916
CI	O	1917-1919
1	O	1920-1921
.	O	1921-1922
2	O	1922-1923
-	O	1923-1924
4	O	1924-1925
.	O	1921-1922
1	O	1920-1921
,	O	1927-1928

P	O	1929-1930
=	O	1930-1931
0	O	1931-1932
.	O	1932-1933
019	O	1933-1936
)	O	1936-1937
.	O	1932-1933

The	O	1939-1942
mean	O	1943-1947
protective	O	1948-1958
effect	O	1959-1965
by	O	1966-1968
adding	O	1969-1975
monoHER	O	1976-1983
before	O	1984-1990
DOX	O	1991-1994
led	O	1995-1998
to	O	1999-2001
a	O	2002-2003
significant	O	2004-2015
4	O	2016-2017
.	O	2017-2018
4	O	2016-2017
-	O	2019-2020
fold	O	2020-2024
reduction	O	2025-2034
(	O	2035-2036
P	O	2036-2037
<	O	2037-2038
0	O	2038-2039
.	O	2039-2040
001	O	2040-2043
,	O	2043-2044

95	O	2045-2047
%	O	2047-2048
CI	O	2049-2051
2	O	2052-2053
.	O	2053-2054
3	O	2054-2055
-	O	2055-2056
8	O	2056-2057
.	O	2053-2054
2	O	2052-2053
)	O	2059-2060
of	O	2061-2063
abnormal	O	2064-2072
cardiomyocytes	O	2073-2087
.	O	2087-2088

This	O	2089-2093
protective	O	2094-2104
effect	O	2105-2111
did	O	2112-2115
not	O	2116-2119
depend	O	2120-2126
on	O	2127-2129
the	O	2130-2133
time	O	2134-2138
interval	O	2139-2147
between	O	2148-2155
monoHER	O	2156-2163
and	O	2164-2167
DOX	O	2168-2171
administration	O	2172-2186
(	O	2187-2188
P	O	2188-2189
=	O	2189-2190
0	O	2190-2191
.	O	2191-2192
345	O	2192-2195
)	O	2195-2196
.	O	2191-2192

CONCLUSION	O	2198-2208
:	O	2208-2209
The	O	2210-2213
results	O	2214-2221
indicate	O	2222-2230
that	O	2231-2235
in	O	2236-2238
an	O	2239-2241
outpatient	O	2242-2252
clinical	O	2253-2261
setting	O	2262-2269
monoHER	O	2270-2277
may	O	2278-2281
be	O	2282-2284
administered	O	2285-2297
shortly	O	2298-2305
before	O	2306-2312
DOX	O	2313-2316
.	O	2316-2317

Clinical	O	0-8
evaluation	O	9-19
of	O	20-22
adverse	O	23-30
effects	O	31-38
during	O	39-45
bepridil	O	46-54
administration	O	55-69
for	O	70-73
atrial	B	74-80
fibrillation	I	81-93
and	I	94-97
flutter	I	98-105
.	O	105-106

BACKGROUND	O	107-117
:	O	117-118
Bepridil	O	119-127
hydrochloride	O	128-141
(	O	142-143
Bpd	O	143-146
)	O	146-147
has	O	148-151
attracted	O	152-161
attention	O	162-171
as	O	172-174
an	O	175-177
effective	O	178-187
drug	O	188-192
for	O	193-196
atrial	B	197-203
fibrillation	I	204-216
(	O	217-218
AF	B	218-220
)	O	220-221
and	O	222-225
atrial	B	226-232
flutter	I	233-240
(	O	241-242
AFL	B	242-245
)	O	245-246
.	O	246-247

However	O	248-255
,	O	255-256
serious	O	257-264
adverse	O	265-272
effects	O	273-280
,	O	280-281
including	O	282-291
torsade	B	292-299
de	I	300-302
pointes	I	303-310
(	O	311-312
Tdp	B	312-315
)	O	315-316
,	O	316-317
have	O	318-322
been	O	323-327
reported	O	328-336
.	O	336-337

METHODS	O	338-345
AND	O	346-349
RESULTS	O	350-357
:	O	357-358
Adverse	O	359-366
effects	O	367-374
of	O	375-377
Bpd	O	378-381
requiring	O	382-391
discontinuation	O	392-407
of	O	408-410
treatment	O	411-420
were	O	421-425
evaluated	O	426-435
.	O	435-436

Bpd	O	437-440
was	O	441-444
administered	O	445-457
to	O	458-460
459	O	461-464
patients	O	465-473
(	O	474-475
361	O	475-478
males	O	479-484
,	O	484-485
63	O	486-488
+	O	488-489
/	O	489-490
-	O	490-491
12	O	491-493
years	O	494-499
old	O	500-503
)	O	503-504
comprising	O	505-515
378	O	516-519
AF	B	520-522
and	O	523-526
81	O	527-529
AFL	B	530-533
cases	O	534-539
.	O	539-540

Mean	O	541-545
left	O	546-550
ventricular	O	551-562
ejection	O	563-571
fraction	O	572-580
and	O	581-584
atrial	O	585-591
dimension	O	592-601
(	O	602-603
LAD	O	603-606
)	O	606-607
were	O	608-612
66	O	613-615
+	O	615-616
/	O	616-617
-	O	617-618
11	O	618-620
%	O	620-621
and	O	622-625
40	O	626-628
+	O	628-629
/	O	629-630
-	O	630-631
6	O	631-632
mm	O	633-635
,	O	635-636
respectively	O	637-649
.	O	649-650

Adverse	O	651-658
effects	O	659-666
were	O	667-671
observed	O	672-680
in	O	681-683
19	O	684-686
patients	O	687-695
(	O	696-697
4	O	697-698
%	O	698-699
)	O	699-700
during	O	701-707
an	O	708-710
average	O	711-718
follow	O	719-725
-	O	725-726
up	O	726-728
of	O	729-731
20	O	732-734
months	O	735-741
.	O	741-742

There	O	743-748
was	O	749-752
marked	O	753-759
QT	B	760-762
prolongation	I	763-775
greater	O	776-783
than	O	784-788
0	O	789-790
.	O	790-791
55	O	791-793
s	O	794-795
in	O	796-798
13	O	799-801
patients	O	802-810
,	O	810-811
bradycardia	B	812-823
less	O	824-828
than	O	829-833
40	O	834-836
beats	O	837-842
/	O	842-843
min	O	843-846
in	O	847-849
6	O	850-851
patients	O	852-860
,	O	860-861
dizziness	B	862-871
and	O	872-875
general	O	876-883
fatigue	B	884-891
in	O	892-894
1	O	895-896
patient	O	897-904
each	O	905-909
.	O	909-910

In	O	911-913
4	O	914-915
of	O	916-918
13	O	919-921
patients	O	922-930
with	O	931-935
QT	B	936-938
prolongation	I	939-951
,	O	951-952
Tdp	B	953-956
occurred	O	957-965
.	O	965-966

The	O	967-970
major	O	971-976
triggering	O	977-987
factors	O	988-995
of	O	996-998
Tdp	B	999-1002
were	O	1003-1007
hypokalemia	B	1008-1019
and	O	1020-1023
sudden	O	1024-1030
decrease	O	1031-1039
in	O	1040-1042
heart	O	1043-1048
rate	O	1049-1053
.	O	1053-1054

There	O	1055-1060
were	O	1061-1065
no	O	1066-1068
differences	O	1069-1080
in	O	1081-1083
the	O	1084-1087
clinical	O	1088-1096
backgrounds	O	1097-1108
of	O	1109-1111
the	O	1112-1115
patients	O	1116-1124
with	O	1125-1129
and	O	1130-1133
without	O	1134-1141
Tdp	B	1142-1145
other	O	1146-1151
than	O	1152-1156
LAD	O	1157-1160
and	O	1161-1164
age	O	1165-1168
,	O	1168-1169
which	O	1170-1175
were	O	1176-1180
larger	O	1181-1187
and	O	1188-1191
older	O	1192-1197
in	O	1198-1200
the	O	1201-1204
patients	O	1205-1213
with	O	1214-1218
Tdp	B	1219-1222
.	O	1222-1223

CONCLUSION	O	1224-1234
:	O	1234-1235
Careful	O	1236-1243
observation	O	1244-1255
of	O	1256-1258
serum	O	1259-1264
potassium	O	1265-1274
concentration	O	1275-1288
and	O	1289-1292
the	O	1293-1296
ECG	O	1297-1300
should	O	1301-1307
always	O	1308-1314
be	O	1315-1317
done	O	1318-1322
during	O	1323-1329
Bpd	O	1330-1333
administration	O	1334-1348
,	O	1348-1349
particularly	O	1350-1362
in	O	1363-1365
elderly	O	1366-1373
patients	O	1374-1382
.	O	1382-1383

Enhanced	O	0-8
isoproterenol	O	9-22
-	O	22-23
induced	O	23-30
cardiac	B	31-38
hypertrophy	I	39-50
in	O	51-53
transgenic	O	54-64
rats	O	65-69
with	O	70-74
low	O	75-78
brain	O	79-84
angiotensinogen	O	85-100
.	O	100-101

We	O	102-104
have	O	105-109
previously	O	110-120
shown	O	121-126
that	O	127-131
a	O	132-133
permanent	O	134-143
deficiency	O	144-154
in	O	155-157
the	O	158-161
brain	O	162-167
renin	O	168-173
-	O	173-174
angiotensin	O	174-185
system	O	186-192
(	O	193-194
RAS	O	194-197
)	O	197-198
may	O	199-202
increase	O	203-211
the	O	212-215
sensitivity	O	216-227
of	O	228-230
the	O	231-234
baroreflex	O	235-245
control	O	246-253
of	O	254-256
heart	O	257-262
rate	O	263-267
.	O	267-268

In	O	269-271
this	O	272-276
study	O	277-282
we	O	283-285
aimed	O	286-291
at	O	292-294
studying	O	295-303
the	O	304-307
involvement	O	308-319
of	O	320-322
the	O	323-326
brain	O	327-332
RAS	O	333-336
in	O	337-339
the	O	340-343
cardiac	O	344-351
reactivity	O	352-362
to	O	363-365
the	O	366-369
beta	O	370-374
-	O	374-375
adrenoceptor	O	375-387
(	O	388-389
beta	O	389-393
-	O	393-394
AR	O	394-396
)	O	396-397
agonist	O	398-405
isoproterenol	O	406-419
(	O	420-421
Iso	O	421-424
)	O	424-425
.	O	425-426

Transgenic	O	427-437
rats	O	438-442
with	O	443-447
low	O	448-451
brain	O	452-457
angiotensinogen	O	458-473
(	O	474-475
TGR	O	475-478
)	O	478-479
were	O	480-484
used	O	485-489
.	O	489-490

In	O	491-493
isolated	O	494-502
hearts	O	503-509
,	O	509-510
Iso	O	511-514
induced	O	515-522
a	O	523-524
significantly	O	525-538
greater	O	539-546
increase	O	547-555
in	O	556-558
left	O	559-563
ventricular	O	564-575
(	O	576-577
LV	O	577-579
)	O	579-580
pressure	O	581-589
and	O	590-593
maximal	O	594-601
contraction	O	602-613
(	O	614-615
+	O	615-616
dP	O	616-618
/	O	618-619
dt	O	619-621
(	O	614-615
max	O	622-625
)	O	625-626
)	O	625-626
in	O	628-630
the	O	631-634
TGR	O	635-638
than	O	639-643
in	O	644-646
the	O	647-650
Sprague	O	651-658
-	O	658-659
Dawley	O	659-665
(	O	666-667
SD	O	667-669
)	O	669-670
rats	O	671-675
.	O	675-676

LV	B	677-679
hypertrophy	I	680-691
induced	O	692-699
by	O	700-702
Iso	O	703-706
treatment	O	707-716
was	O	717-720
significantly	O	721-734
higher	O	735-741
in	O	742-744
TGR	O	745-748
than	O	749-753
in	O	754-756
SD	O	757-759
rats	O	760-764
(	O	765-766
in	O	766-768
g	O	769-770
LV	O	771-773
wt	O	774-776
/	O	776-777
100	O	777-780
g	O	781-782
body	O	783-787
wt	O	788-790
,	O	790-791
0	O	792-793
.	O	793-794
28	O	794-796
+	O	797-798
/	O	798-799
-	O	799-800
0	O	801-802
.	O	802-803
004	O	803-806
vs	O	807-809
.	O	809-810
0	O	811-812
.	O	812-813
24	O	813-815
+	O	816-817
/	O	817-818
-	O	818-819
0	O	820-821
.	O	821-822
004	O	822-825
,	O	825-826
respectively	O	827-839
)	O	839-840
.	O	840-841

The	O	842-845
greater	O	846-853
LV	B	854-856
hypertrophy	I	857-868
in	O	869-871
TGR	O	872-875
rats	O	876-880
was	O	881-884
associated	O	885-895
with	O	896-900
more	O	901-905
pronounced	O	906-916
downregulation	O	917-931
of	O	932-934
beta	O	935-939
-	O	939-940
AR	O	940-942
and	O	943-946
upregulation	O	947-959
of	O	960-962
LV	O	963-965
beta	O	966-970
-	O	970-971
AR	O	971-973
kinase	O	974-980
-	O	980-981
1	O	981-982
mRNA	O	983-987
levels	O	988-994
compared	O	995-1003
with	O	1004-1008
those	O	1009-1014
in	O	1015-1017
SD	O	1018-1020
rats	O	1021-1025
.	O	1025-1026

The	O	1027-1030
decrease	O	1031-1039
in	O	1040-1042
the	O	1043-1046
heart	O	1047-1052
rate	O	1053-1057
(	O	1058-1059
HR	O	1059-1061
)	O	1061-1062
induced	O	1063-1070
by	O	1071-1073
the	O	1074-1077
beta	O	1078-1082
-	O	1082-1083
AR	O	1083-1085
antagonist	O	1086-1096
metoprolol	O	1097-1107
in	O	1108-1110
conscious	O	1111-1120
rats	O	1121-1125
was	O	1126-1129
significantly	O	1130-1143
attenuated	O	1144-1154
in	O	1155-1157
TGR	O	1158-1161
compared	O	1162-1170
with	O	1171-1175
SD	O	1176-1178
rats	O	1179-1183
(	O	1184-1185
-	O	1185-1186
9	O	1186-1187
.	O	1187-1188
9	O	1186-1187
+	O	1190-1191
/	O	1191-1192
-	O	1192-1193
1	O	1194-1195
.	O	1195-1196
7	O	1196-1197
%	O	1197-1198
vs	O	1199-1201
.	O	1201-1202
-	O	1203-1204
18	O	1204-1206
.	O	1206-1207
1	O	1204-1205
+	O	1209-1210
/	O	1210-1211
-	O	1211-1212
1	O	1213-1214
.	O	1214-1215
5	O	1215-1216
%	O	1216-1217
)	O	1217-1218
,	O	1218-1219
whereas	O	1220-1227
the	O	1228-1231
effect	O	1232-1238
of	O	1239-1241
parasympathetic	O	1242-1257
blockade	O	1258-1266
by	O	1267-1269
atropine	O	1270-1278
on	O	1279-1281
HR	O	1282-1284
was	O	1285-1288
similar	O	1289-1296
in	O	1297-1299
both	O	1300-1304
strains	O	1305-1312
.	O	1312-1313

These	O	1314-1319
results	O	1320-1327
indicate	O	1328-1336
that	O	1337-1341
TGR	O	1342-1345
are	O	1346-1349
more	O	1350-1354
sensitive	O	1355-1364
to	O	1365-1367
beta	O	1368-1372
-	O	1372-1373
AR	O	1373-1375
agonist	O	1376-1383
-	O	1383-1384
induced	O	1384-1391
cardiac	B	1392-1399
inotropic	I	1400-1409
response	O	1410-1418
and	O	1419-1422
hypertrophy	B	1423-1434
,	O	1434-1435
possibly	O	1436-1444
due	O	1445-1448
to	O	1449-1451
chronically	O	1452-1463
low	O	1464-1467
sympathetic	O	1468-1479
outflow	O	1480-1487
directed	O	1488-1496
to	O	1497-1499
the	O	1500-1503
heart	O	1504-1509
.	O	1509-1510

Drug	O	0-4
-	O	4-5
induced	O	5-12
long	B	13-17
QT	I	18-20
syndrome	I	21-29
in	O	30-32
injection	O	33-42
drug	O	43-47
users	O	48-53
receiving	O	54-63
methadone	O	64-73
:	O	73-74
high	O	75-79
frequency	O	80-89
in	O	90-92
hospitalized	O	93-105
patients	O	106-114
and	O	115-118
risk	O	119-123
factors	O	124-131
.	O	131-132

BACKGROUND	O	133-143
:	O	143-144
Drug	O	145-149
-	O	149-150
induced	O	150-157
long	B	158-162
QT	I	163-165
syndrome	I	166-174
is	O	175-177
a	O	178-179
serious	O	180-187
adverse	O	188-195
drug	O	196-200
reaction	O	201-209
.	O	209-210

Methadone	O	211-220
prolongs	O	221-229
the	O	230-233
QT	O	234-236
interval	O	237-245
in	O	246-248
vitro	O	249-254
in	O	255-257
a	O	258-259
dose	O	260-264
-	O	264-265
dependent	O	265-274
manner	O	275-281
.	O	281-282

In	O	283-285
the	O	286-289
inpatient	O	290-299
setting	O	300-307
,	O	307-308
the	O	309-312
frequency	O	313-322
of	O	323-325
QT	B	326-328
interval	I	329-337
prolongation	I	338-350
with	O	351-355
methadone	O	356-365
treatment	O	366-375
,	O	375-376
its	O	377-380
dose	O	381-385
dependence	O	386-396
,	O	396-397
and	O	398-401
the	O	402-405
importance	O	406-416
of	O	417-419
cofactors	O	420-429
such	O	430-434
as	O	435-437
drug	O	438-442
-	O	442-443
drug	O	438-442
interactions	O	448-460
remain	O	461-467
unknown	O	468-475
.	O	475-476

METHODS	O	477-484
:	O	484-485
We	O	486-488
performed	O	489-498
a	O	499-500
systematic	O	501-511
,	O	511-512
retrospective	O	513-526
study	O	527-532
comparing	O	533-542
active	O	543-549
or	O	550-552
former	O	553-559
intravenous	O	560-571
drug	O	572-576
users	O	577-582
receiving	O	583-592
methadone	O	593-602
and	O	603-606
those	O	607-612
not	O	613-616
receiving	O	617-626
methadone	O	627-636
among	O	637-642
all	O	643-646
patients	O	647-655
hospitalized	O	656-668
over	O	669-673
a	O	674-675
5	O	676-677
-	O	677-678
year	O	678-682
period	O	683-689
in	O	690-692
a	O	693-694
tertiary	O	695-703
care	O	704-708
hospital	O	709-717
.	O	717-718

A	O	719-720
total	O	721-726
of	O	727-729
167	O	730-733
patients	O	734-742
receiving	O	743-752
methadone	O	753-762
fulfilled	O	763-772
the	O	773-776
inclusion	O	777-786
criteria	O	787-795
and	O	796-799
were	O	800-804
compared	O	805-813
with	O	814-818
a	O	819-820
control	O	821-828
group	O	829-834
of	O	835-837
80	O	838-840
injection	O	841-850
drug	O	851-855
users	O	856-861
not	O	862-865
receiving	O	866-875
methadone	O	876-885
.	O	885-886

In	O	887-889
addition	O	890-898
to	O	899-901
methadone	O	902-911
dose	O	912-916
,	O	916-917
15	O	918-920
demographic	O	921-932
,	O	932-933
biological	O	934-944
,	O	944-945
and	O	946-949
pharmacological	O	950-965
variables	O	966-975
were	O	976-980
considered	O	981-991
as	O	992-994
potential	O	995-1004
risk	O	1005-1009
factors	O	1010-1017
for	O	1018-1021
QT	B	1022-1024
prolongation	I	1025-1037
.	O	1037-1038

RESULTS	O	1039-1046
:	O	1046-1047
Among	O	1048-1053
167	O	1054-1057
methadone	O	1058-1067
maintenance	O	1068-1079
patients	O	1080-1088
,	O	1088-1089
the	O	1090-1093
prevalence	O	1094-1104
of	O	1105-1107
QTc	O	1108-1111
prolongation	O	1112-1124
to	O	1125-1127
0	O	1128-1129
.	O	1129-1130
50	O	1130-1132
second	O	1133-1139
(	O	1139-1140
(	O	1139-1140
1	O	1141-1142
/	O	1142-1143
2	O	1143-1144
)	O	1144-1145
)	O	1144-1145
or	O	1147-1149
longer	O	1150-1156
was	O	1157-1160
16	O	1161-1163
.	O	1163-1164
2	O	1164-1165
%	O	1165-1166
compared	O	1167-1175
with	O	1176-1180
0	O	1181-1182
%	O	1182-1183
in	O	1184-1186
80	O	1187-1189
control	O	1190-1197
subjects	O	1198-1206
.	O	1206-1207

Six	O	1208-1211
patients	O	1212-1220
(	O	1221-1222
3	O	1222-1223
.	O	1223-1224
6	O	1224-1225
%	O	1225-1226
)	O	1226-1227
in	O	1228-1230
the	O	1231-1234
methadone	O	1235-1244
group	O	1245-1250
presented	O	1251-1260
torsades	B	1261-1269
de	I	1270-1272
pointes	I	1273-1280
.	O	1280-1281

QTc	O	1282-1285
length	O	1286-1292
was	O	1293-1296
weakly	O	1297-1303
but	O	1304-1307
significantly	O	1308-1321
associated	O	1322-1332
with	O	1333-1337
methadone	O	1338-1347
daily	O	1348-1353
dose	O	1354-1358
(	O	1359-1360
Spearman	O	1360-1368
rank	O	1369-1373
correlation	O	1374-1385
coefficient	O	1386-1397
,	O	1397-1398
0	O	1399-1400
.	O	1400-1401
20	O	1401-1403
;	O	1403-1404
P	O	1405-1406
<	O	1406-1407
.	O	1407-1408
01	O	1408-1410
)	O	1410-1411
.	O	1407-1408

Multivariate	O	1413-1425
regression	O	1426-1436
analysis	O	1437-1445
allowed	O	1446-1453
attribution	O	1454-1465
of	O	1466-1468
31	O	1469-1471
.	O	1471-1472
8	O	1472-1473
%	O	1473-1474
of	O	1475-1477
QTc	O	1478-1481
variability	O	1482-1493
to	O	1494-1496
methadone	O	1497-1506
dose	O	1507-1511
,	O	1511-1512
cytochrome	O	1513-1523
P	O	1524-1525
-	O	1525-1526
450	O	1526-1529
3A4	O	1530-1533
drug	O	1534-1538
-	O	1538-1539
drug	O	1534-1538
interactions	O	1544-1556
,	O	1556-1557
hypokalemia	B	1558-1569
,	O	1569-1570
and	O	1571-1574
altered	O	1575-1582
liver	O	1583-1588
function	O	1589-1597
.	O	1597-1598

CONCLUSIONS	O	1599-1610
:	O	1610-1611
QT	B	1612-1614
interval	I	1615-1623
prolongation	I	1624-1636
in	O	1637-1639
methadone	O	1640-1649
maintenance	O	1650-1661
patients	O	1662-1670
hospitalized	O	1671-1683
in	O	1684-1686
a	O	1687-1688
tertiary	O	1689-1697
care	O	1698-1702
center	O	1703-1709
is	O	1710-1712
a	O	1713-1714
frequent	O	1715-1723
finding	O	1724-1731
.	O	1731-1732

Methadone	O	1733-1742
dose	O	1743-1747
,	O	1747-1748
presence	O	1749-1757
of	O	1758-1760
cytochrome	O	1761-1771
P	O	1772-1773
-	O	1773-1774
450	O	1774-1777
3A4	O	1778-1781
inhibitors	O	1782-1792
,	O	1792-1793
potassium	O	1794-1803
level	O	1804-1809
,	O	1809-1810
and	O	1811-1814
liver	O	1815-1820
function	O	1821-1829
contribute	O	1830-1840
to	O	1841-1843
QT	B	1844-1846
prolongation	I	1847-1859
.	O	1859-1860

Long	B	1861-1865
QT	I	1866-1868
syndrome	I	1869-1877
can	O	1878-1881
occur	O	1882-1887
with	O	1888-1892
low	O	1893-1896
doses	O	1897-1902
of	O	1903-1905
methadone	O	1906-1915
.	O	1915-1916

Mechanisms	O	0-10
of	O	11-13
hypertension	B	14-26
induced	O	27-34
by	O	35-37
nitric	O	38-44
oxide	O	45-50
(	O	51-52
NO	O	52-54
)	O	54-55
deficiency	O	56-66
:	O	66-67
focus	O	68-73
on	O	74-76
venous	O	77-83
function	O	84-92
.	O	92-93

Loss	O	94-98
of	O	99-101
endothelial	O	102-113
cell	O	114-118
-	O	118-119
derived	O	119-126
nitric	O	127-133
oxide	O	134-139
(	O	140-141
NO	O	141-143
)	O	143-144
in	O	145-147
hypertension	B	148-160
is	O	161-163
a	O	164-165
hallmark	O	166-174
of	O	175-177
arterial	B	178-186
dysfunction	I	187-198
.	O	198-199

Experimental	O	200-212
hypertension	B	213-225
created	O	226-233
by	O	234-236
the	O	237-240
removal	O	241-248
of	O	249-251
NO	O	252-254
,	O	254-255
however	O	256-263
,	O	263-264
involves	O	265-273
mechanisms	O	274-284
in	O	285-287
addition	O	288-296
to	O	297-299
decreased	O	300-309
arterial	O	310-318
vasodilator	O	319-330
activity	O	331-339
.	O	339-340

These	O	341-346
include	O	347-354
augmented	O	355-364
endothelin	O	365-375
-	O	375-376
1	O	376-377
(	O	378-379
ET	O	379-381
-	O	381-382
1	O	382-383
)	O	383-384
release	O	385-392
,	O	392-393
increased	O	394-403
sympathetic	O	404-415
nervous	O	416-423
system	O	424-430
activity	O	431-439
,	O	439-440
and	O	441-444
elevated	O	445-453
tissue	O	454-460
oxidative	O	461-470
stress	O	471-477
.	O	477-478

We	O	479-481
hypothesized	O	482-494
that	O	495-499
increased	O	500-509
venous	O	510-516
smooth	O	517-523
muscle	O	524-530
(	O	531-532
venomotor	O	532-541
)	O	541-542
tone	O	543-547
plays	O	548-553
a	O	554-555
role	O	556-560
in	O	561-563
Nomega	O	564-570
-	O	570-571
nitro	O	571-576
-	O	570-571
L	O	577-578
-	O	570-571
arginine	O	579-587
(	O	588-589
LNNA	O	589-593
)	O	593-594
hypertension	B	595-607
through	O	608-615
these	O	616-621
mechanisms	O	622-632
.	O	632-633

Rats	O	634-638
were	O	639-643
treated	O	644-651
with	O	652-656
the	O	657-660
NO	O	661-663
synthase	O	664-672
inhibitor	O	673-682
LNNA	O	683-687
(	O	688-689
0	O	689-690
.	O	690-691
5	O	691-692
g	O	693-694
/	O	694-695
L	O	695-696
in	O	697-699
drinking	O	700-708
water	O	709-714
)	O	714-715
for	O	716-719
2	O	720-721
weeks	O	722-727
.	O	727-728

Mean	O	729-733
arterial	O	734-742
pressure	O	743-751
of	O	752-754
conscious	O	755-764
rats	O	765-769
was	O	770-773
119	O	774-777
+	O	778-779
/	O	779-780
-	O	780-781
2	O	782-783
mm	O	784-786
Hg	O	787-789
in	O	790-792
control	O	793-800
and	O	801-804
194	O	805-808
+	O	809-810
/	O	810-811
-	O	811-812
5	O	813-814
mm	O	815-817
Hg	O	818-820
in	O	821-823
LNNA	O	824-828
rats	O	829-833
(	O	834-835
P	O	835-836
<	O	836-837
0	O	837-838
.	O	838-839
05	O	839-841
)	O	841-842
.	O	838-839

Carotid	O	844-851
arteries	O	852-860
and	O	861-864
vena	O	865-869
cava	O	870-874
were	O	875-879
removed	O	880-887
for	O	888-891
measurement	O	892-903
of	O	904-906
isometric	O	907-916
contraction	O	917-928
.	O	928-929

Maximal	O	930-937
contraction	O	938-949
to	O	950-952
norepinephrine	O	953-967
was	O	968-971
modestly	O	972-980
reduced	O	981-988
in	O	989-991
arteries	O	992-1000
from	O	1001-1005
LNNA	O	1006-1010
compared	O	1011-1019
with	O	1020-1024
control	O	1025-1032
rats	O	1033-1037
whereas	O	1038-1045
the	O	1046-1049
maximum	O	1050-1057
contraction	O	1058-1069
to	O	1070-1072
ET	O	1073-1075
-	O	1075-1076
1	O	1076-1077
was	O	1078-1081
significantly	O	1082-1095
reduced	O	1096-1103
(	O	1104-1105
54	O	1105-1107
%	O	1107-1108
control	O	1109-1116
)	O	1116-1117
.	O	1117-1118

Maximum	O	1119-1126
contraction	O	1127-1138
of	O	1139-1141
vena	O	1142-1146
cava	O	1147-1151
to	O	1152-1154
norepinephrine	O	1155-1169
(	O	1170-1171
37	O	1171-1173
%	O	1173-1174
control	O	1175-1182
)	O	1182-1183
also	O	1184-1188
was	O	1189-1192
reduced	O	1193-1200
but	O	1201-1204
no	O	1205-1207
change	O	1208-1214
in	O	1215-1217
response	O	1218-1226
to	O	1227-1229
ET	O	1230-1232
-	O	1232-1233
1	O	1233-1234
was	O	1235-1238
observed	O	1239-1247
.	O	1247-1248

Mean	O	1249-1253
circulatory	O	1254-1265
filling	O	1266-1273
pressure	O	1274-1282
,	O	1282-1283
an	O	1284-1286
in	O	1287-1289
vivo	O	1290-1294
measure	O	1295-1302
of	O	1303-1305
venomotor	O	1306-1315
tone	O	1316-1320
,	O	1320-1321
was	O	1322-1325
not	O	1326-1329
elevated	O	1330-1338
in	O	1339-1341
LNNA	O	1342-1346
hypertension	B	1347-1359
at	O	1360-1362
1	O	1363-1364
or	O	1365-1367
2	O	1368-1369
weeks	O	1370-1375
after	O	1376-1381
LNNA	O	1382-1386
.	O	1386-1387

The	O	1388-1391
superoxide	O	1392-1402
scavenger	O	1403-1412
tempol	O	1413-1419
(	O	1420-1421
30	O	1421-1423
,	O	1423-1424
100	O	1425-1428
,	O	1428-1429
and	O	1430-1433
300	O	1434-1437
micromol	O	1438-1446
kg	O	1447-1449
(	O	1449-1450
-	O	1450-1451
1	O	1451-1452
)	O	1452-1453
,	O	1453-1454
IV	O	1455-1457
)	O	1457-1458
did	O	1459-1462
not	O	1463-1466
change	O	1467-1473
arterial	O	1474-1482
pressure	O	1483-1491
in	O	1492-1494
control	O	1495-1502
rats	O	1503-1507
but	O	1508-1511
caused	O	1512-1518
a	O	1519-1520
dose	O	1521-1525
-	O	1525-1526
dependent	O	1526-1535
decrease	O	1536-1544
in	O	1545-1547
LNNA	O	1548-1552
rats	O	1553-1557
(	O	1558-1559
-	O	1559-1560
18	O	1560-1562
+	O	1563-1564
/	O	1564-1565
-	O	1565-1566
8	O	1567-1568
,	O	1568-1569
-	O	1570-1571
26	O	1571-1573
+	O	1574-1575
/	O	1575-1576
-	O	1576-1577
15	O	1578-1580
,	O	1580-1581
and	O	1582-1585
-	O	1586-1587
54	O	1587-1589
+	O	1590-1591
/	O	1591-1592
-	O	1592-1593
11	O	1594-1596
mm	O	1597-1599
Hg	O	1600-1602
)	O	1602-1603
.	O	1603-1604

Similarly	O	1605-1614
,	O	1614-1615
ganglionic	O	1616-1626
blockade	O	1627-1635
with	O	1636-1640
hexamethonium	O	1641-1654
caused	O	1655-1661
a	O	1662-1663
significantly	O	1664-1677
greater	O	1678-1685
fall	O	1686-1690
in	O	1691-1693
LNNA	O	1694-1698
hypertensive	B	1699-1711
rats	O	1712-1716
(	O	1717-1718
76	O	1718-1720
+	O	1721-1722
/	O	1722-1723
-	O	1723-1724
9	O	1725-1726
mm	O	1727-1729
Hg	O	1730-1732
)	O	1732-1733
compared	O	1734-1742
with	O	1743-1747
control	O	1748-1755
rats	O	1756-1760
(	O	1761-1762
35	O	1762-1764
+	O	1765-1766
/	O	1766-1767
-	O	1767-1768
10	O	1769-1771
mm	O	1772-1774
Hg	O	1775-1777
)	O	1777-1778
.	O	1778-1779

Carotid	O	1780-1787
arteries	O	1788-1796
,	O	1796-1797
vena	O	1798-1802
cava	O	1803-1807
,	O	1807-1808
and	O	1809-1812
sympathetic	O	1813-1824
ganglia	O	1825-1832
from	O	1833-1837
LNNA	O	1838-1842
rats	O	1843-1847
had	O	1848-1851
higher	O	1852-1858
basal	O	1859-1864
levels	O	1865-1871
of	O	1872-1874
superoxide	O	1875-1885
compared	O	1886-1894
with	O	1895-1899
those	O	1900-1905
from	O	1906-1910
control	O	1911-1918
rats	O	1919-1923
.	O	1923-1924

These	O	1925-1930
data	O	1931-1935
suggest	O	1936-1943
that	O	1944-1948
while	O	1949-1954
NO	O	1955-1957
deficiency	O	1958-1968
increases	O	1969-1978
oxidative	O	1979-1988
stress	O	1989-1995
and	O	1996-1999
sympathetic	O	2000-2011
activity	O	2012-2020
in	O	2021-2023
both	O	2024-2028
arterial	O	2029-2037
and	O	2038-2041
venous	O	2042-2048
vessels	O	2049-2056
,	O	2056-2057
the	O	2058-2061
impact	O	2062-2068
on	O	2069-2071
veins	O	2072-2077
does	O	2078-2082
not	O	2083-2086
make	O	2087-2091
a	O	2092-2093
major	O	2094-2099
contribution	O	2100-2112
to	O	2113-2115
this	O	2116-2120
form	O	2121-2125
of	O	2126-2128
hypertension	B	2129-2141
.	O	2141-2142

Association	O	0-11
of	O	12-14
DRD2	O	15-19
polymorphisms	O	20-33
and	O	34-37
chlorpromazine	O	38-52
-	O	52-53
induced	O	53-60
extrapyramidal	B	61-75
syndrome	I	76-84
in	O	85-87
Chinese	O	88-95
schizophrenic	B	96-109
patients	O	110-118
.	O	118-119

AIM	O	120-123
:	O	123-124
Extrapyramidal	B	125-139
syndrome	I	140-148
(	O	149-150
EPS	B	150-153
)	O	153-154
is	O	155-157
most	O	158-162
commonly	O	163-171
affected	O	172-180
by	O	181-183
typical	O	184-191
antipsychotic	O	192-205
drugs	O	206-211
that	O	212-216
have	O	217-221
a	O	222-223
high	O	224-228
affinity	O	229-237
with	O	238-242
the	O	243-246
D2	O	247-249
receptor	O	250-258
.	O	258-259

Recently	O	260-268
,	O	268-269
many	O	270-274
research	O	275-283
groups	O	284-290
have	O	291-295
reported	O	296-304
on	O	305-307
the	O	308-311
positive	O	312-320
relationship	O	321-333
between	O	334-341
the	O	342-345
genetic	O	346-353
variations	O	354-364
in	O	365-367
the	O	368-371
DRD2	O	372-376
gene	O	377-381
and	O	382-385
the	O	386-389
therapeutic	O	390-401
response	O	402-410
in	O	411-413
schizophrenia	B	414-427
patients	O	428-436
as	O	437-439
a	O	440-441
result	O	442-448
of	O	449-451
the	O	452-455
role	O	456-460
of	O	461-463
variations	O	464-474
in	O	475-477
the	O	478-481
receptor	O	482-490
in	O	491-493
modulating	O	494-504
receptor	O	505-513
expression	O	514-524
.	O	524-525

In	O	526-528
this	O	529-533
study	O	534-539
,	O	539-540
we	O	541-543
evaluate	O	544-552
the	O	553-556
role	O	557-561
DRD2	O	562-566
plays	O	567-572
in	O	573-575
chlorpromazine	O	576-590
-	O	590-591
induced	O	591-598
EPS	B	599-602
in	O	603-605
schizophrenic	B	606-619
patients	O	620-628
.	O	628-629

METHODS	O	630-637
:	O	637-638
We	O	639-641
identified	O	642-652
seven	O	653-658
SNP	O	659-662
(	O	662-663
single	O	663-669
nucleotide	O	670-680
polymorphism	O	681-693
)	O	693-694
(	O	695-696
-	O	696-697
141Cins	O	697-704
>	O	704-705
del	O	705-708
,	O	708-709
TaqIB	O	710-715
,	O	715-716
TaqID	O	717-722
,	O	722-723
Ser311Cys	O	724-733
,	O	733-734
rs6275	O	735-741
,	O	741-742
rs6277	O	743-749
and	O	750-753
TaqIA	O	754-759
)	O	759-760
in	O	761-763
the	O	764-767
DRD2	O	768-772
gene	O	773-777
in	O	778-780
146	O	781-784
schizophrenic	B	785-798
inpatients	O	799-809
(	O	810-811
59	O	811-813
with	O	814-818
EPS	B	819-822
and	O	823-826
87	O	827-829
without	O	830-837
EPS	B	838-841
according	O	842-851
to	O	852-854
the	O	855-858
Simpson	O	859-866
-	O	866-867
Angus	O	867-872
Scale	O	873-878
)	O	878-879
treated	O	880-887
with	O	888-892
chlorpromazine	O	893-907
after	O	908-913
8	O	914-915
weeks	O	916-921
.	O	921-922

The	O	923-926
alleles	O	927-934
of	O	935-937
all	O	938-941
loci	O	942-946
were	O	947-951
determined	O	952-962
by	O	963-965
PCR	O	966-969
(	O	970-971
polymerase	O	971-981
chain	O	982-987
reaction	O	988-996
)	O	996-997
.	O	997-998

RESULTS	O	999-1006
:	O	1006-1007
Polymorphisms	O	1008-1021
TaqID	O	1022-1027
,	O	1027-1028
Ser311Cys	O	1029-1038
and	O	1039-1042
rs6277	O	1043-1049
were	O	1050-1054
not	O	1055-1058
polymorphic	O	1059-1070
in	O	1071-1073
the	O	1074-1077
population	O	1078-1088
recruited	O	1089-1098
in	O	1099-1101
the	O	1102-1105
present	O	1106-1113
study	O	1114-1119
.	O	1119-1120

No	O	1121-1123
statistical	O	1124-1135
significance	O	1136-1148
was	O	1149-1152
found	O	1153-1158
in	O	1159-1161
the	O	1162-1165
allele	O	1166-1172
distribution	O	1173-1185
of	O	1186-1188
-	O	1189-1190
141Cins	O	1190-1197
>	O	1197-1198
del	O	1198-1201
,	O	1201-1202
TaqIB	O	1203-1208
,	O	1208-1209
rs6275	O	1210-1216
and	O	1217-1220
TaqIA	O	1221-1226
or	O	1227-1229
in	O	1230-1232
the	O	1233-1236
estimated	O	1237-1246
haplotypes	O	1247-1257
(	O	1258-1259
constituted	O	1259-1270
by	O	1271-1273
TaqIB	O	1274-1279
,	O	1279-1280
rs6275	O	1281-1287
and	O	1288-1291
TaqIA	O	1292-1297
)	O	1297-1298
in	O	1299-1301
linkage	O	1302-1309
disequilibrium	O	1310-1324
between	O	1325-1332
the	O	1333-1336
two	O	1337-1340
groups	O	1341-1347
.	O	1347-1348

CONCLUSION	O	1349-1359
:	O	1359-1360
Our	O	1361-1364
results	O	1365-1372
did	O	1373-1376
not	O	1377-1380
lend	O	1381-1385
strong	O	1386-1392
support	O	1393-1400
to	O	1401-1403
the	O	1404-1407
view	O	1408-1412
that	O	1413-1417
the	O	1418-1421
genetic	O	1422-1429
variation	O	1430-1439
of	O	1440-1442
the	O	1443-1446
DRD2	O	1447-1451
gene	O	1452-1456
plays	O	1457-1462
a	O	1463-1464
major	O	1465-1470
role	O	1471-1475
in	O	1476-1478
the	O	1479-1482
individually	O	1483-1495
variable	O	1496-1504
adverse	O	1505-1512
effect	O	1513-1519
induced	O	1520-1527
by	O	1528-1530
chlorpromazine	O	1531-1545
,	O	1545-1546
at	O	1547-1549
least	O	1550-1555
in	O	1556-1558
Chinese	O	1559-1566
patients	O	1567-1575
with	O	1576-1580
schizophrenia	B	1581-1594
.	O	1594-1595

Our	O	1596-1599
results	O	1600-1607
confirmed	O	1608-1617
a	O	1618-1619
previous	O	1620-1628
study	O	1629-1634
on	O	1635-1637
the	O	1638-1641
relationship	O	1642-1654
between	O	1655-1662
DRD2	O	1663-1667
and	O	1668-1671
EPS	B	1672-1675
in	O	1676-1678
Caucasians	O	1679-1689
.	O	1689-1690

Physical	O	0-8
training	O	9-17
decreases	O	18-27
susceptibility	O	28-42
to	O	43-45
subsequent	O	46-56
pilocarpine	O	57-68
-	O	68-69
induced	O	69-76
seizures	B	77-85
in	O	86-88
the	O	89-92
rat	O	93-96
.	O	96-97

Regular	O	98-105
motor	O	106-111
activity	O	112-120
has	O	121-124
many	O	125-129
benefits	O	130-138
for	O	139-142
mental	O	143-149
and	O	150-153
physical	O	154-162
condition	O	163-172
but	O	173-176
its	O	177-180
implications	O	181-193
for	O	194-197
epilepsy	B	198-206
are	O	207-210
still	O	211-216
controversial	O	217-230
.	O	230-231

In	O	232-234
order	O	235-240
to	O	241-243
elucidate	O	244-253
this	O	254-258
problem	O	259-266
,	O	266-267
we	O	268-270
have	O	271-275
studied	O	276-283
the	O	284-287
effect	O	288-294
of	O	295-297
long	O	298-302
-	O	302-303
term	O	303-307
physical	O	308-316
activity	O	317-325
on	O	326-328
susceptibility	O	329-343
to	O	344-346
subsequent	O	347-357
seizures	B	358-366
.	O	366-367

Male	O	368-372
Wistar	O	373-379
rats	O	380-384
were	O	385-389
subjected	O	390-399
to	O	400-402
repeated	O	403-411
training	O	412-420
sessions	O	421-429
in	O	430-432
a	O	433-434
treadmill	O	435-444
and	O	445-448
swimming	O	449-457
pool	O	458-462
.	O	462-463

Thereafter	O	464-474
,	O	474-475
seizures	B	476-484
were	O	485-489
induced	O	490-497
by	O	498-500
pilocarpine	O	501-512
injections	O	513-523
in	O	524-526
trained	O	527-534
and	O	535-538
non	O	539-542
-	O	542-543
trained	O	543-550
control	O	551-558
groups	O	559-565
.	O	565-566

During	O	567-573
the	O	574-577
acute	O	578-583
period	O	584-590
of	O	591-593
status	B	594-600
epilepticus	I	601-612
,	O	612-613
we	O	614-616
measured	O	617-625
:	O	625-626
(	O	627-628
1	O	628-629
)	O	629-630
the	O	631-634
latency	O	635-642
of	O	643-645
the	O	646-649
first	O	650-655
motor	O	656-661
sign	O	662-666
,	O	666-667
(	O	668-669
2	O	669-670
)	O	670-671
the	O	672-675
intensity	O	676-685
of	O	686-688
seizures	B	689-697
,	O	697-698
(	O	699-700
3	O	700-701
)	O	701-702
the	O	703-706
time	O	707-711
when	O	712-716
it	O	717-719
occurred	O	720-728
within	O	729-735
the	O	736-739
6	O	740-741
-	O	741-742
h	O	742-743
observation	O	744-755
period	O	756-762
,	O	762-763
and	O	764-767
(	O	768-769
4	O	769-770
)	O	770-771
the	O	772-775
time	O	776-780
when	O	781-785
the	O	786-789
acute	O	790-795
period	O	796-802
ended	O	803-808
.	O	808-809

All	O	810-813
these	O	814-819
behavioral	O	820-830
parameters	O	831-841
showed	O	842-848
statistically	O	849-862
significant	O	863-874
changes	O	875-882
suggesting	O	883-893
that	O	894-898
regular	O	899-906
physical	O	907-915
exercises	O	916-925
decrease	O	926-934
susceptibility	O	935-949
to	O	950-952
subsequently	O	953-965
induced	O	966-973
seizures	B	974-982
and	O	983-986
ameliorate	O	987-997
the	O	998-1001
course	O	1002-1008
of	O	1009-1011
experimentally	O	1012-1026
induced	O	1027-1034
status	B	1035-1041
epilepticus	I	1042-1053
.	O	1053-1054

Tonic	O	0-5
dopaminergic	O	6-18
stimulation	O	19-30
impairs	B	31-38
associative	I	39-50
learning	I	51-59
in	O	60-62
healthy	O	63-70
subjects	O	71-79
.	O	79-80

Endogenous	O	81-91
dopamine	O	92-100
plays	O	101-106
a	O	107-108
central	O	109-116
role	O	117-121
in	O	122-124
salience	O	125-133
coding	O	134-140
during	O	141-147
associative	O	148-159
learning	O	160-168
.	O	168-169

Administration	O	170-184
of	O	185-187
the	O	188-191
dopamine	O	192-200
precursor	O	201-210
levodopa	O	211-219
enhances	O	220-228
learning	O	229-237
in	O	238-240
healthy	O	241-248
subjects	O	249-257
and	O	258-261
stroke	B	262-268
patients	O	269-277
.	O	277-278

Because	O	279-286
levodopa	O	287-295
increases	O	296-305
both	O	306-310
phasic	O	311-317
and	O	318-321
tonic	O	322-327
dopaminergic	O	328-340
neurotransmission	O	341-358
,	O	358-359
the	O	360-363
critical	O	364-372
mechanism	O	373-382
mediating	O	383-392
the	O	393-396
enhancement	O	397-408
of	O	409-411
learning	O	412-420
is	O	421-423
unresolved	O	424-434
.	O	434-435

We	O	436-438
here	O	439-443
probed	O	444-450
how	O	451-454
selective	O	455-464
tonic	O	465-470
dopaminergic	O	471-483
stimulation	O	484-495
affects	O	496-503
associative	O	504-515
learning	O	516-524
.	O	524-525

Forty	O	526-531
healthy	O	532-539
subjects	O	540-548
were	O	549-553
trained	O	554-561
in	O	562-564
a	O	565-566
novel	O	567-572
vocabulary	O	573-583
of	O	584-586
45	O	587-589
concrete	O	590-598
nouns	O	599-604
over	O	605-609
the	O	610-613
course	O	614-620
of	O	621-623
5	O	624-625
consecutive	O	626-637
training	O	638-646
days	O	647-651
in	O	652-654
a	O	655-656
prospective	O	657-668
,	O	668-669
randomized	O	670-680
,	O	680-681
double	O	682-688
-	O	688-689
blind	O	689-694
,	O	694-695
placebo	O	696-703
-	O	703-704
controlled	O	704-714
design	O	715-721
.	O	721-722

Subjects	O	723-731
received	O	732-740
the	O	741-744
tonically	O	745-754
stimulating	O	755-766
dopamine	O	767-775
-	O	775-776
receptor	O	776-784
agonist	O	785-792
pergolide	O	793-802
(	O	803-804
0	O	804-805
.	O	805-806
1	O	806-807
mg	O	808-810
)	O	810-811
vs	O	812-814
placebo	O	815-822
120	O	823-826
min	O	827-830
before	O	831-837
training	O	838-846
on	O	847-849
each	O	850-854
training	O	855-863
day	O	864-867
.	O	867-868

The	O	869-872
dopamine	O	873-881
agonist	O	882-889
significantly	O	890-903
impaired	B	904-912
novel	I	913-918
word	I	919-923
learning	I	924-932
compared	O	933-941
to	O	942-944
placebo	O	945-952
.	O	952-953

This	O	954-958
learning	O	959-967
decrement	O	968-977
persisted	O	978-987
up	O	988-990
to	O	991-993
the	O	994-997
last	O	998-1002
follow	O	1003-1009
-	O	1009-1010
up	O	1010-1012
4	O	1013-1014
weeks	O	1015-1020
post	O	1021-1025
-	O	1025-1026
training	O	1026-1034
.	O	1034-1035

Subjects	O	1036-1044
treated	O	1045-1052
with	O	1053-1057
pergolide	O	1058-1067
also	O	1068-1072
showed	O	1073-1079
restricted	O	1080-1090
emotional	O	1091-1100
responses	O	1101-1110
compared	O	1111-1119
to	O	1120-1122
the	O	1123-1126
PLACEBO	O	1127-1134
group	O	1135-1140
.	O	1140-1141

The	O	1142-1145
extent	O	1146-1152
of	O	1153-1155
'	O	1156-1157
flattened	O	1157-1166
'	O	1156-1157
affect	O	1168-1174
with	O	1175-1179
pergolide	O	1180-1189
was	O	1190-1193
related	O	1194-1201
to	O	1202-1204
the	O	1205-1208
degree	O	1209-1215
of	O	1216-1218
learning	O	1219-1227
inhibition	O	1228-1238
.	O	1238-1239

These	O	1240-1245
findings	O	1246-1254
suggest	O	1255-1262
that	O	1263-1267
tonic	O	1268-1273
occupation	O	1274-1284
of	O	1285-1287
dopamine	O	1288-1296
receptors	O	1297-1306
impairs	O	1307-1314
learning	O	1315-1323
by	O	1324-1326
competition	O	1327-1338
with	O	1339-1343
phasic	O	1344-1350
dopamine	O	1351-1359
signals	O	1360-1367
.	O	1367-1368

Thus	O	1369-1373
,	O	1373-1374
phasic	O	1375-1381
signaling	O	1382-1391
seems	O	1392-1397
to	O	1398-1400
be	O	1401-1403
the	O	1404-1407
critical	O	1408-1416
mechanism	O	1417-1426
by	O	1427-1429
which	O	1430-1435
dopamine	O	1436-1444
enhances	O	1445-1453
associative	O	1454-1465
learning	O	1466-1474
in	O	1475-1477
healthy	O	1478-1485
subjects	O	1486-1494
and	O	1495-1498
stroke	B	1499-1505
patients	O	1506-1514
.	O	1514-1515

Minocycline	O	0-11
-	O	11-12
induced	O	12-19
vasculitis	B	20-30
fulfilling	O	31-41
the	O	42-45
criteria	O	46-54
of	O	55-57
polyarteritis	B	58-71
nodosa	I	72-78
.	O	78-79

A	O	80-81
47	O	82-84
-	O	84-85
year	O	85-89
-	O	84-85
old	O	90-93
man	O	94-97
who	O	98-101
had	O	102-105
been	O	106-110
taking	O	111-117
minocycline	O	118-129
for	O	130-133
palmoplantar	B	134-146
pustulosis	I	147-157
developed	O	158-167
fever	B	168-173
,	O	173-174
myalgias	B	175-183
,	O	183-184
polyneuropathy	B	185-199
,	O	199-200
and	O	201-204
testicular	B	205-215
pain	I	216-220
,	O	220-221
with	O	222-226
elevated	O	227-235
C	O	236-237
-	O	237-238
reactive	O	238-246
protein	O	247-254
(	O	255-256
CRP	O	256-259
)	O	259-260
.	O	260-261

Neither	O	262-269
myeloperoxidase	O	270-285
-	O	285-286
nor	O	287-290
proteinase	O	291-301
-	O	301-302
3	O	302-303
-	O	301-302
antineutrophil	O	304-318
cytoplasmic	O	319-330
antibody	O	331-339
was	O	340-343
positive	O	344-352
.	O	352-353

These	O	354-359
manifestations	O	360-374
met	O	375-378
the	O	379-382
American	O	383-391
College	O	392-399
of	O	400-402
Rheumatology	O	403-415
1990	O	416-420
criteria	O	421-429
for	O	430-433
the	O	434-437
classification	O	438-452
of	O	453-455
polyarteritis	B	456-469
nodosa	I	470-476
.	O	476-477

Stopping	O	478-486
minocycline	O	487-498
led	O	499-502
to	O	503-505
amelioration	O	506-518
of	O	519-521
symptoms	O	522-530
and	O	531-534
normalization	O	535-548
of	O	549-551
CRP	O	552-555
level	O	556-561
.	O	561-562

To	O	563-565
our	O	566-569
knowledge	O	570-579
,	O	579-580
this	O	581-585
is	O	586-588
the	O	589-592
second	O	593-599
case	O	600-604
of	O	605-607
minocycline	O	608-619
-	O	619-620
induced	O	620-627
vasculitis	B	628-638
satisfying	O	639-649
the	O	650-653
criteria	O	654-662
.	O	662-663

Differential	O	664-676
diagnosis	O	677-686
for	O	687-690
drug	O	691-695
-	O	695-696
induced	O	696-703
disease	O	704-711
is	O	712-714
invaluable	O	715-725
even	O	726-730
for	O	731-734
patients	O	735-743
with	O	744-748
classical	O	749-758
polyarteritis	B	759-772
nodosa	I	773-779
.	O	779-780

Intramuscular	O	0-13
hepatitis	B	14-23
B	I	24-25
immune	O	26-32
globulin	O	33-41
combined	O	42-50
with	O	51-55
lamivudine	O	56-66
in	O	67-69
prevention	O	70-80
of	O	81-83
hepatitis	B	84-93
B	I	94-95
recurrence	O	96-106
after	O	107-112
liver	O	113-118
transplantation	O	119-134
.	O	134-135

BACKGROUND	O	136-146
:	O	146-147
Combined	O	148-156
hepatitis	B	157-166
B	I	167-168
immune	O	169-175
globulin	O	176-184
(	O	185-186
HBIg	O	186-190
)	O	190-191
and	O	192-195
lamivudine	O	196-206
in	O	207-209
prophylaxis	O	210-221
of	O	222-224
the	O	225-228
recurrence	O	229-239
of	O	240-242
hepatitis	B	243-252
B	I	253-254
after	O	255-260
liver	O	261-266
transplantation	O	267-282
has	O	283-286
significantly	O	287-300
improved	O	301-309
the	O	310-313
survival	O	314-322
of	O	323-325
HBsAg	O	326-331
positive	O	332-340
patients	O	341-349
.	O	349-350

This	O	351-355
study	O	356-361
was	O	362-365
undertaken	O	366-376
to	O	377-379
evaluate	O	380-388
the	O	389-392
outcomes	O	393-401
of	O	402-404
liver	O	405-410
transplantation	O	411-426
for	O	427-430
patients	O	431-439
with	O	440-444
hepatitis	B	445-454
B	I	455-456
virus	O	457-462
(	O	463-464
HBV	O	464-467
)	O	467-468
.	O	468-469

METHODS	O	470-477
:	O	477-478
A	O	479-480
retrospective	O	481-494
chart	O	495-500
analysis	O	501-509
and	O	510-513
a	O	514-515
review	O	516-522
of	O	523-525
the	O	526-529
organ	O	530-535
transplant	O	536-546
database	O	547-555
identified	O	556-566
51	O	567-569
patients	O	570-578
(	O	579-580
43	O	580-582
men	O	583-586
and	O	587-590
8	O	591-592
women	O	593-598
)	O	598-599
transplanted	O	600-612
for	O	613-616
benign	O	617-623
HBV	O	624-627
-	O	627-628
related	O	628-635
cirrhotic	B	636-645
diseases	I	646-654
between	O	655-662
June	O	663-667
2002	O	668-672
and	O	673-676
December	O	677-685
2004	O	686-690
who	O	691-694
had	O	695-698
survived	O	699-707
more	O	708-712
than	O	713-717
3	O	718-719
months	O	720-726
.	O	726-727

HBIg	O	728-732
was	O	733-736
administered	O	737-749
intravenously	O	750-763
during	O	764-770
the	O	771-774
first	O	775-780
week	O	781-785
and	O	786-789
intramuscularly	O	790-805
thereafter	O	806-816
.	O	816-817

RESULTS	O	818-825
:	O	825-826
At	O	827-829
a	O	830-831
median	O	832-838
follow	O	839-845
-	O	845-846
up	O	846-848
of	O	849-851
14	O	852-854
.	O	854-855
1	O	852-853
months	O	857-863
,	O	863-864
the	O	865-868
overall	O	869-876
recurrence	O	877-887
rate	O	888-892
in	O	893-895
the	O	896-899
51	O	900-902
patients	O	903-911
was	O	912-915
3	O	916-917
.	O	917-918
9	O	918-919
%	O	919-920
(	O	921-922
2	O	922-923
/	O	923-924
51	O	924-926
)	O	926-927
.	O	927-928

The	O	929-932
overall	O	933-940
patient	O	941-948
survival	O	949-957
was	O	958-961
88	O	962-964
.	O	964-965
3	O	965-966
%	O	966-967
,	O	967-968
and	O	969-972
82	O	973-975
.	O	975-976
4	O	976-977
%	O	977-978
after	O	979-984
1	O	985-986
and	O	987-990
2	O	991-992
years	O	993-998
,	O	998-999
respectively	O	1000-1012
.	O	1012-1013

A	O	1014-1015
daily	O	1016-1021
oral	O	1022-1026
dose	O	1027-1031
of	O	1032-1034
100	O	1035-1038
mg	O	1039-1041
lamivudine	O	1042-1052
for	O	1053-1056
2	O	1057-1058
weeks	O	1059-1064
before	O	1065-1071
transplantation	O	1072-1087
for	O	1088-1091
10	O	1092-1094
patients	O	1095-1103
enabled	O	1104-1111
57	O	1112-1114
.	O	1114-1115
1	O	1115-1116
%	O	1116-1117
(	O	1118-1119
4	O	1119-1120
/	O	1120-1121
7	O	1121-1122
)	O	1122-1123
and	O	1124-1127
62	O	1128-1130
.	O	1130-1131
5	O	1131-1132
%	O	1132-1133
(	O	1134-1135
5	O	1135-1136
/	O	1136-1137
8	O	1137-1138
)	O	1138-1139
of	O	1140-1142
HBV	O	1143-1146
-	O	1146-1147
DNA	O	1147-1150
and	O	1151-1154
HBeAg	O	1155-1160
positive	O	1161-1169
patients	O	1170-1178
respectively	O	1179-1191
to	O	1192-1194
convert	O	1195-1202
to	O	1203-1205
be	O	1206-1208
negative	O	1209-1217
.	O	1217-1218

Intramuscular	O	1219-1232
HBIg	O	1233-1237
was	O	1238-1241
well	O	1242-1246
tolerated	O	1247-1256
in	O	1257-1259
all	O	1260-1263
patients	O	1264-1272
.	O	1272-1273

CONCLUSION	O	1274-1284
:	O	1284-1285
Lamivudine	O	1286-1296
combined	O	1297-1305
with	O	1306-1310
intramuscular	O	1311-1324
HBIg	O	1325-1329
can	O	1330-1333
effectively	O	1334-1345
prevent	O	1346-1353
allograft	O	1354-1363
from	O	1364-1368
the	O	1369-1372
recurrence	O	1373-1383
of	O	1384-1386
HBV	O	1387-1390
after	O	1391-1396
liver	O	1397-1402
transplantation	O	1403-1418
.	O	1418-1419

Anticonvulsant	O	0-14
effect	O	15-21
of	O	22-24
eslicarbazepine	O	25-40
acetate	O	41-48
(	O	49-50
BIA	O	50-53
2	O	54-55
-	O	55-56
093	O	56-59
)	O	59-60
on	O	61-63
seizures	B	64-72
induced	O	73-80
by	O	81-83
microperfusion	O	84-98
of	O	99-101
picrotoxin	O	102-112
in	O	113-115
the	O	116-119
hippocampus	O	120-131
of	O	132-134
freely	O	135-141
moving	O	142-148
rats	O	149-153
.	O	153-154

Eslicarbazepine	O	155-170
acetate	O	171-178
(	O	179-180
BIA	O	180-183
2	O	184-185
-	O	185-186
093	O	186-189
,	O	189-190
S	O	191-192
-	O	192-193
(	O	193-194
-	O	192-193
)	O	195-196
-	O	192-193
10	O	197-199
-	O	192-193
acetoxy	O	200-207
-	O	192-193
10	O	197-199
,	O	210-211
11	O	211-213
-	O	192-193
dihydro	O	214-221
-	O	192-193
5H	O	222-224
-	O	192-193
dibenzo	O	225-232
/	O	232-233
b	O	227-228
,	O	210-211
f	O	235-236
/	O	232-233
azepine	O	237-244
-	O	192-193
5	O	222-223
-	O	192-193
carboxamide	O	247-258
)	O	195-196
is	O	260-262
a	O	263-264
novel	O	265-270
antiepileptic	O	271-284
drug	O	285-289
,	O	289-290
now	O	291-294
in	O	295-297
Phase	O	298-303
III	O	304-307
clinical	O	308-316
trials	O	317-323
,	O	323-324
designed	O	325-333
with	O	334-338
the	O	339-342
aim	O	343-346
of	O	347-349
improving	O	350-359
efficacy	O	360-368
and	O	369-372
safety	O	373-379
in	O	380-382
comparison	O	383-393
with	O	394-398
the	O	399-402
structurally	O	403-415
related	O	416-423
drugs	O	424-429
carbamazepine	O	430-443
(	O	444-445
CBZ	O	445-448
)	O	448-449
and	O	450-453
oxcarbazepine	O	454-467
(	O	468-469
OXC	O	469-472
)	O	472-473
.	O	473-474

We	O	475-477
have	O	478-482
studied	O	483-490
the	O	491-494
effects	O	495-502
of	O	503-505
oral	O	506-510
treatment	O	511-520
with	O	521-525
eslicarbazepine	O	526-541
acetate	O	542-549
on	O	550-552
a	O	553-554
whole	O	555-560
-	O	560-561
animal	O	561-567
model	O	568-573
in	O	574-576
which	O	577-582
partial	O	583-590
seizures	B	591-599
can	O	600-603
be	O	604-606
elicited	O	607-615
repeatedly	O	616-626
on	O	627-629
different	O	630-639
days	O	640-644
without	O	645-652
changes	O	653-660
in	O	661-663
threshold	O	664-673
or	O	674-676
seizure	B	677-684
patterns	O	685-693
.	O	693-694

In	O	695-697
the	O	698-701
animals	O	702-709
treated	O	710-717
with	O	718-722
threshold	O	723-732
doses	O	733-738
of	O	739-741
picrotoxin	O	742-752
,	O	752-753
the	O	754-757
average	O	758-765
number	O	766-772
of	O	773-775
seizures	B	776-784
was	O	785-788
2	O	789-790
.	O	790-791
3	O	791-792
+	O	792-793
/	O	793-794
-	O	794-795
1	O	795-796
.	O	790-791
2	O	789-790
,	O	798-799

and	O	800-803
average	O	804-811
seizure	B	812-819
duration	O	820-828
was	O	829-832
39	O	833-835
.	O	835-836
5	O	836-837
+	O	837-838
/	O	838-839
-	O	839-840
8	O	840-841
.	O	835-836
4s	O	842-844
.	O	835-836

Pre	O	846-849
-	O	849-850
treatment	O	850-859
with	O	860-864
a	O	865-866
dose	O	867-871
of	O	872-874
30	O	875-877
mg	O	878-880
/	O	880-881
kg	O	881-883
2h	O	884-886
before	O	887-893
picrotoxin	O	894-904
microperfusion	O	905-919
prevented	O	920-929
seizures	B	930-938
in	O	939-941
the	O	942-945
75	O	946-948
%	O	948-949
of	O	950-952
the	O	953-956
rats	O	957-961
.	O	961-962

Lower	O	963-968
doses	O	969-974
(	O	975-976
3	O	976-977
and	O	978-981
10mg	O	982-986
/	O	986-987
kg	O	987-989
)	O	989-990
did	O	991-994
not	O	995-998
suppress	O	999-1007
seizures	B	1008-1016
,	O	1016-1017
however	O	1018-1025
,	O	1025-1026
after	O	1027-1032
administration	O	1033-1047
of	O	1048-1050
10mg	O	1051-1055
/	O	1055-1056
kg	O	1056-1058
,	O	1058-1059
significant	O	1060-1071
reductions	O	1072-1082
in	O	1083-1085
seizures	B	1086-1094
duration	O	1095-1103
(	O	1104-1105
24	O	1105-1107
.	O	1107-1108
3	O	1108-1109
+	O	1109-1110
/	O	1110-1111
-	O	1111-1112
6	O	1112-1113
.	O	1107-1108
8s	O	1114-1116
)	O	1116-1117

and	O	1118-1121
seizure	B	1122-1129
number	O	1130-1136
(	O	1137-1138
1	O	1138-1139
.	O	1139-1140
6	O	1140-1141
+	O	1141-1142
/	O	1142-1143
-	O	1143-1144
0	O	1144-1145
.	O	1139-1140
34	O	1146-1148
)	O	1148-1149

were	O	1150-1154
found	O	1155-1160
.	O	1160-1161

No	O	1162-1164
adverse	O	1165-1172
effects	O	1173-1180
of	O	1181-1183
eslicarbazepine	O	1184-1199
acetate	O	1200-1207
were	O	1208-1212
observed	O	1213-1221
in	O	1222-1224
the	O	1225-1228
behavioral	O	1229-1239
/	O	1239-1240
EEG	O	1240-1243
patterns	O	1244-1252
studied	O	1253-1260
,	O	1260-1261
including	O	1262-1271
sleep	O	1272-1277
/	O	1277-1278
wakefulness	O	1278-1289
cycle	O	1290-1295
,	O	1295-1296
at	O	1297-1299
the	O	1300-1303
doses	O	1304-1309
studied	O	1310-1317
.	O	1317-1318

Acute	B	0-5
renal	I	6-11
failure	I	12-19
associated	O	20-30
with	O	31-35
prolonged	O	36-45
intake	O	46-52
of	O	53-55
slimming	O	56-64
pills	O	65-70
containing	O	71-81
anthraquinones	O	82-96
.	O	96-97

Chinese	O	98-105
herbal	O	106-112
medicine	O	113-121
preparations	O	122-134
are	O	135-138
widely	O	139-145
available	O	146-155
and	O	156-159
often	O	160-165
regarded	O	166-174
by	O	175-177
the	O	178-181
public	O	182-188
as	O	189-191
natural	O	192-199
and	O	200-203
safe	O	204-208
remedies	O	209-217
for	O	218-221
a	O	222-223
variety	O	224-231
of	O	232-234
medical	O	235-242
conditions	O	243-253
.	O	253-254

Nephropathy	B	255-266
caused	O	267-273
by	O	274-276
Chinese	O	277-284
herbs	O	285-290
has	O	291-294
previously	O	295-305
been	O	306-310
reported	O	311-319
,	O	319-320
usually	O	321-328
involving	O	329-338
the	O	339-342
use	O	343-346
of	O	347-349
aristolochic	O	350-362
acids	O	363-368
.	O	368-369

We	O	370-372
report	O	373-379
a	O	380-381
23	O	382-384
-	O	384-385
year	O	385-389
-	O	384-385
old	O	390-393
woman	O	394-399
who	O	400-403
developed	O	404-413
acute	B	414-419
renal	I	420-425
failure	I	426-433
following	O	434-443
prolonged	O	444-453
use	O	454-457
of	O	458-460
a	O	461-462
proprietary	O	463-474
Chinese	O	475-482
herbal	O	483-489
slimming	O	490-498
pill	O	499-503
that	O	504-508
contained	O	509-518
anthraquinone	O	519-532
derivatives	O	533-544
,	O	544-545
extracted	O	546-555
from	O	556-560
Rhizoma	O	561-568
Rhei	O	569-573
(	O	574-575
rhubarb	O	575-582
)	O	582-583
.	O	583-584

The	O	585-588
renal	B	589-594
injury	I	595-601
was	O	602-605
probably	O	606-614
aggravated	O	615-625
by	O	626-628
the	O	629-632
concomitant	O	633-644
intake	O	645-651
of	O	652-654
a	O	655-656
non	O	657-660
-	O	660-661
steroidal	O	661-670
anti	O	671-675
-	O	675-676
inflammatory	O	676-688
drug	O	689-693
,	O	693-694
diclofenac	O	695-705
.	O	705-706

Renal	O	707-712
pathology	O	713-722
was	O	723-726
that	O	727-731
of	O	732-734
hypocellular	O	735-747
interstitial	O	748-760
fibrosis	B	761-769
.	O	769-770

Spontaneous	O	771-782
renal	O	783-788
recovery	O	789-797
occurred	O	798-806
upon	O	807-811
cessation	O	812-821
of	O	822-824
the	O	825-828
slimming	O	829-837
pills	O	838-843
,	O	843-844
but	O	845-848
mild	O	849-853
interstitial	O	854-866
fibrosis	B	867-875
and	O	876-879
tubular	O	880-887
atrophy	B	888-895
was	O	896-899
still	O	900-905
evident	O	906-913
histologically	O	914-928
4	O	929-930
months	O	931-937
later	O	938-943
.	O	943-944

Although	O	945-953
a	O	954-955
causal	O	956-962
relationship	O	963-975
between	O	976-983
the	O	984-987
use	O	988-991
of	O	992-994
an	O	995-997
anthraquinone	O	998-1011
-	O	1011-1012
containing	O	1012-1022
herbal	O	1023-1029
agent	O	1030-1035
and	O	1036-1039
renal	B	1040-1045
injury	I	1046-1052
remains	O	1053-1060
to	O	1061-1063
be	O	1064-1066
proven	O	1067-1073
,	O	1073-1074
phytotherapy	O	1075-1087
-	O	1087-1088
associated	O	1088-1098
interstitial	O	1099-1111
nephropathy	B	1112-1123
should	O	1124-1130
be	O	1131-1133
considered	O	1134-1144
in	O	1145-1147
patients	O	1148-1156
who	O	1157-1160
present	O	1161-1168
with	O	1169-1173
unexplained	O	1174-1185
renal	B	1186-1191
failure	I	1192-1199
.	O	1199-1200

Chloroacetaldehyde	O	0-18
as	O	19-21
a	O	22-23
sulfhydryl	O	24-34
reagent	O	35-42
:	O	42-43
the	O	44-47
role	O	48-52
of	O	53-55
critical	O	56-64
thiol	O	65-70
groups	O	71-77
in	O	78-80
ifosfamide	O	81-91
nephropathy	B	92-103
.	O	103-104

Chloroacetaldehyde	O	105-123
(	O	124-125
CAA	O	125-128
)	O	128-129
is	O	130-132
a	O	133-134
metabolite	O	135-145
of	O	146-148
the	O	149-152
alkylating	O	153-163
agent	O	164-169
ifosfamide	O	170-180
(	O	181-182
IFO	O	182-185
)	O	185-186
and	O	187-190
putatively	O	191-201
responsible	O	202-213
for	O	214-217
renal	B	218-223
damage	I	224-230
following	O	231-240
anti	O	241-245
-	O	245-246
tumor	B	246-251
therapy	O	252-259
with	O	260-264
IFO	O	265-268
.	O	268-269

Depletion	O	270-279
of	O	280-282
sulfhydryl	O	283-293
(	O	294-295
SH	O	295-297
)	O	297-298
groups	O	299-305
has	O	306-309
been	O	310-314
reported	O	315-323
from	O	324-328
cell	O	329-333
culture	O	334-341
,	O	341-342
animal	O	343-349
and	O	350-353
clinical	O	354-362
studies	O	363-370
.	O	370-371

In	O	372-374
this	O	375-379
work	O	380-384
the	O	385-388
effect	O	389-395
of	O	396-398
CAA	O	399-402
on	O	403-405
human	O	406-411
proximal	O	412-420
tubule	O	421-427
cells	O	428-433
in	O	434-436
primary	O	437-444
culture	O	445-452
(	O	453-454
hRPTEC	O	454-460
)	O	460-461
was	O	462-465
investigated	O	466-478
.	O	478-479

Toxicity	B	480-488
of	O	489-491
CAA	O	492-495
was	O	496-499
determined	O	500-510
by	O	511-513
protein	O	514-521
content	O	522-529
,	O	529-530
cell	O	531-535
number	O	536-542
,	O	542-543
LDH	O	544-547
release	O	548-555
,	O	555-556
trypan	O	557-563
blue	O	564-568
exclusion	O	569-578
assay	O	579-584
and	O	585-588
caspase	O	589-596
-	O	596-597
3	O	597-598
activity	O	599-607
.	O	607-608

Free	O	609-613
thiols	O	614-620
were	O	621-625
measured	O	626-634
by	O	635-637
the	O	638-641
method	O	642-648
of	O	649-651
Ellman	O	652-658
.	O	658-659

CAA	O	660-663
reduced	O	664-671
hRPTEC	O	672-678
cell	O	679-683
number	O	684-690
and	O	691-694
protein	O	695-702
,	O	702-703
induced	O	704-711
a	O	712-713
loss	O	714-718
in	O	719-721
free	O	722-726
intracellular	O	727-740
thiols	O	741-747
and	O	748-751
an	O	752-754
increase	O	755-763
in	O	764-766
necrosis	B	767-775
markers	O	776-783
.	O	783-784

CAA	O	785-788
but	O	789-792
not	O	793-796
acrolein	O	797-805
inhibited	O	806-815
the	O	816-819
cysteine	O	820-828
proteases	O	829-838
caspase	O	839-846
-	O	846-847
3	O	847-848
,	O	848-849
caspase	O	850-857
-	O	857-858
8	O	858-859
and	O	860-863
cathepsin	O	864-873
B	O	874-875
.	O	875-876
Caspase	O	877-884
activation	O	885-895
by	O	896-898
cisplatin	O	899-908
was	O	909-912
inhibited	O	913-922
by	O	923-925
CAA	O	926-929
.	O	929-930

In	O	931-933
cells	O	934-939
stained	O	940-947
with	O	948-952
fluorescent	O	953-964
dyes	O	965-969
targeting	O	970-979
lysosomes	O	980-989
,	O	989-990
CAA	O	991-994
induced	O	995-1002
an	O	1003-1005
increase	O	1006-1014
in	O	1015-1017
lysosomal	O	1018-1027
size	O	1028-1032
and	O	1033-1036
lysosomal	O	1037-1046
leakage	O	1047-1054
.	O	1054-1055

The	O	1056-1059
effects	O	1060-1067
of	O	1068-1070
CAA	O	1071-1074
on	O	1075-1077
cysteine	O	1078-1086
protease	O	1087-1095
activities	O	1096-1106
and	O	1107-1110
thiols	O	1111-1117
could	O	1118-1123
be	O	1124-1126
reproduced	O	1127-1137
in	O	1138-1140
cell	O	1141-1145
lysate	O	1146-1152
.	O	1152-1153

Acidification	O	1154-1167
,	O	1167-1168
which	O	1169-1174
slowed	O	1175-1181
the	O	1182-1185
reaction	O	1186-1194
of	O	1195-1197
CAA	O	1198-1201
with	O	1202-1206
thiol	O	1207-1212
donors	O	1213-1219
,	O	1219-1220
could	O	1221-1226
also	O	1227-1231
attenuate	O	1232-1241
effects	O	1242-1249
of	O	1250-1252
CAA	O	1253-1256
on	O	1257-1259
necrosis	B	1260-1268
markers	O	1269-1276
,	O	1276-1277
thiol	O	1278-1283
depletion	O	1284-1293
and	O	1294-1297
cysteine	O	1298-1306
protease	O	1307-1315
inhibition	O	1316-1326
in	O	1327-1329
living	O	1330-1336
cells	O	1337-1342
.	O	1342-1343

Thus	O	1344-1348
,	O	1348-1349
CAA	O	1350-1353
directly	O	1354-1362
reacts	O	1363-1369
with	O	1370-1374
cellular	O	1375-1383
protein	O	1384-1391
and	O	1392-1395
non	O	1396-1399
-	O	1399-1400
protein	O	1400-1407
thiols	O	1408-1414
,	O	1414-1415
mediating	O	1416-1425
its	O	1426-1429
toxicity	B	1430-1438
on	O	1439-1441
hRPTEC	O	1442-1448
.	O	1448-1449

This	O	1450-1454
effect	O	1455-1461
can	O	1462-1465
be	O	1466-1468
reduced	O	1469-1476
by	O	1477-1479
acidification	O	1480-1493
.	O	1493-1494

Therefore	O	1495-1504
,	O	1504-1505
urinary	O	1506-1513
acidification	O	1514-1527
could	O	1528-1533
be	O	1534-1536
an	O	1537-1539
option	O	1540-1546
to	O	1547-1549
prevent	O	1550-1557
IFO	O	1558-1561
nephropathy	B	1562-1573
in	O	1574-1576
patients	O	1577-1585
.	O	1585-1586

Stereological	O	0-13
methods	O	14-21
reveal	O	22-28
the	O	29-32
robust	O	33-39
size	O	40-44
and	O	45-48
stability	O	49-58
of	O	59-61
ectopic	O	62-69
hilar	O	70-75
granule	O	76-83
cells	O	84-89
after	O	90-95
pilocarpine	O	96-107
-	O	107-108
induced	O	108-115
status	B	116-122
epilepticus	I	123-134
in	O	135-137
the	O	138-141
adult	O	142-147
rat	O	148-151
.	O	151-152

Following	O	153-162
status	B	163-169
epilepticus	I	170-181
in	O	182-184
the	O	185-188
rat	O	189-192
,	O	192-193
dentate	O	194-201
granule	O	202-209
cell	O	210-214
neurogenesis	O	215-227
increases	O	228-237
greatly	O	238-245
,	O	245-246
and	O	247-250
many	O	251-255
of	O	256-258
the	O	259-262
new	O	263-266
neurons	O	267-274
appear	O	275-281
to	O	282-284
develop	O	285-292
ectopically	O	293-304
,	O	304-305
in	O	306-308
the	O	309-312
hilar	O	313-318
region	O	319-325
of	O	326-328
the	O	329-332
hippocampal	O	333-344
formation	O	345-354
.	O	354-355

It	O	356-358
has	O	359-362
been	O	363-367
suggested	O	368-377
that	O	378-382
the	O	383-386
ectopic	O	387-394
hilar	O	395-400
granule	O	401-408
cells	O	409-414
could	O	415-420
contribute	O	421-431
to	O	432-434
the	O	435-438
spontaneous	O	439-450
seizures	B	451-459
that	O	460-464
ultimately	O	465-475
develop	O	476-483
after	O	484-489
status	B	490-496
epilepticus	I	497-508
.	O	508-509

However	O	510-517
,	O	517-518
the	O	519-522
population	O	523-533
has	O	534-537
never	O	538-543
been	O	544-548
quantified	O	549-559
,	O	559-560
so	O	561-563
it	O	564-566
is	O	567-569
unclear	O	570-577
whether	O	578-585
it	O	586-588
is	O	589-591
substantial	O	592-603
enough	O	604-610
to	O	611-613
have	O	614-618
a	O	619-620
strong	O	621-627
influence	O	628-637
on	O	638-640
epileptogenesis	O	641-656
.	O	656-657

To	O	658-660
quantify	O	661-669
this	O	670-674
population	O	675-685
,	O	685-686
the	O	687-690
total	O	691-696
number	O	697-703
of	O	704-706
ectopic	O	707-714
hilar	O	715-720
granule	O	721-728
cells	O	729-734
was	O	735-738
estimated	O	739-748
using	O	749-754
unbiased	O	755-763
stereology	O	764-774
at	O	775-777
different	O	778-787
times	O	788-793
after	O	794-799
pilocarpine	O	800-811
-	O	811-812
induced	O	812-819
status	B	820-826
epilepticus	I	827-838
.	O	838-839

The	O	840-843
number	O	844-850
of	O	851-853
hilar	O	854-859
neurons	O	860-867
immunoreactive	O	868-882
for	O	883-886
Prox	O	887-891
-	O	891-892
1	O	892-893
,	O	893-894
a	O	895-896
granule	O	897-904
-	O	904-905
cell	O	905-909
-	O	904-905
specific	O	910-918
marker	O	919-925
,	O	925-926
was	O	927-930
estimated	O	931-940
using	O	941-946
the	O	947-950
optical	O	951-958
fractionator	O	959-971
method	O	972-978
.	O	978-979

The	O	980-983
results	O	984-991
indicate	O	992-1000
that	O	1001-1005
the	O	1006-1009
size	O	1010-1014
of	O	1015-1017
the	O	1018-1021
hilar	O	1022-1027
ectopic	O	1028-1035
granule	O	1036-1043
cell	O	1044-1048
population	O	1049-1059
after	O	1060-1065
status	B	1066-1072
epilepticus	I	1073-1084
is	O	1085-1087
substantial	O	1088-1099
,	O	1099-1100
and	O	1101-1104
stable	O	1105-1111
over	O	1112-1116
time	O	1117-1121
.	O	1121-1122

Interestingly	O	1123-1136
,	O	1136-1137
the	O	1138-1141
size	O	1142-1146
of	O	1147-1149
the	O	1150-1153
population	O	1154-1164
appears	O	1165-1172
to	O	1173-1175
be	O	1176-1178
correlated	O	1179-1189
with	O	1190-1194
the	O	1195-1198
frequency	O	1199-1208
of	O	1209-1211
behavioral	O	1212-1222
seizures	B	1223-1231
,	O	1231-1232
because	O	1233-1240
animals	O	1241-1248
with	O	1249-1253
more	O	1254-1258
ectopic	O	1259-1266
granule	O	1267-1274
cells	O	1275-1280
in	O	1281-1283
the	O	1284-1287
hilus	O	1288-1293
have	O	1294-1298
more	O	1299-1303
frequent	O	1304-1312
behavioral	O	1313-1323
seizures	B	1324-1332
.	O	1332-1333

The	O	1334-1337
hilar	O	1338-1343
ectopic	O	1344-1351
granule	O	1352-1359
cell	O	1360-1364
population	O	1365-1375
does	O	1376-1380
not	O	1381-1384
appear	O	1385-1391
to	O	1392-1394
vary	O	1395-1399
systematically	O	1400-1414
across	O	1415-1421
the	O	1422-1425
septotemporal	O	1426-1439
axis	O	1440-1444
,	O	1444-1445
although	O	1446-1454
it	O	1455-1457
is	O	1458-1460
associated	O	1461-1471
with	O	1472-1476
an	O	1477-1479
increase	O	1480-1488
in	O	1489-1491
volume	O	1492-1498
of	O	1499-1501
the	O	1502-1505
hilus	O	1506-1511
.	O	1511-1512

The	O	1513-1516
results	O	1517-1524
provide	O	1525-1532
new	O	1533-1536
insight	O	1537-1544
into	O	1545-1549
the	O	1550-1553
potential	O	1554-1563
role	O	1564-1568
of	O	1569-1571
ectopic	O	1572-1579
hilar	O	1580-1585
granule	O	1586-1593
cells	O	1594-1599
in	O	1600-1602
the	O	1603-1606
pilocarpine	O	1607-1618
model	O	1619-1624
of	O	1625-1627
temporal	B	1628-1636
lobe	I	1637-1641
epilepsy	I	1642-1650
.	O	1650-1651

A	O	0-1
prospective	O	2-13
,	O	13-14
open	O	15-19
-	O	19-20
label	O	20-25
trial	O	26-31
of	O	32-34
galantamine	O	35-46
in	O	47-49
autistic	B	50-58
disorder	I	59-67
.	O	67-68

OBJECTIVE	O	69-78
:	O	78-79
Post	O	80-84
-	O	84-85
mortem	O	85-91
studies	O	92-99
have	O	100-104
reported	O	105-113
abnormalities	O	114-127
of	O	128-130
the	O	131-134
cholinergic	O	135-146
system	O	147-153
in	O	154-156
autism	B	157-163
.	O	163-164

The	O	165-168
purpose	O	169-176
of	O	177-179
this	O	180-184
study	O	185-190
was	O	191-194
to	O	195-197
assess	O	198-204
the	O	205-208
use	O	209-212
of	O	213-215
galantamine	O	216-227
,	O	227-228
an	O	229-231
acetylcholinesterase	O	232-252
inhibitor	O	253-262
and	O	263-266
nicotinic	O	267-276
receptor	O	277-285
modulator	O	286-295
,	O	295-296
in	O	297-299
the	O	300-303
treatment	O	304-313
of	O	314-316
interfering	O	317-328
behaviors	O	329-338
in	O	339-341
children	O	342-350
with	O	351-355
autism	B	356-362
.	O	362-363

METHODS	O	364-371
:	O	371-372
Thirteen	O	373-381
medication	O	382-392
-	O	392-393
free	O	393-397
children	O	398-406
with	O	407-411
autism	B	412-418
(	O	419-420
mean	O	420-424
age	O	425-428
,	O	428-429
8	O	430-431
.	O	431-432
8	O	430-431
+	O	434-435
/	O	435-436
-	O	436-437
3	O	438-439
.	O	439-440
5	O	440-441
years	O	442-447
)	O	447-448
participated	O	449-461
in	O	462-464
a	O	465-466
12	O	467-469
-	O	469-470
week	O	470-474
,	O	474-475
open	O	476-480
-	O	480-481
label	O	481-486
trial	O	487-492
of	O	493-495
galantamine	O	496-507
.	O	507-508

Patients	O	509-517
were	O	518-522
rated	O	523-528
monthly	O	529-536
by	O	537-539
parents	O	540-547
on	O	548-550
the	O	551-554
Aberrant	O	555-563
Behavior	O	564-572
Checklist	O	573-582
(	O	583-584
ABC	O	584-587
)	O	587-588
and	O	589-592
the	O	593-596
Conners	O	597-604
'	O	604-605
Parent	O	606-612
Rating	O	613-619
Scale	O	620-625
-	O	625-626
Revised	O	626-633
,	O	633-634
and	O	635-638
by	O	639-641
a	O	642-643
physician	O	644-653
using	O	654-659
the	O	660-663
Children	O	664-672
'	O	672-673
s	O	673-674
Psychiatric	O	675-686
Rating	O	687-693
Scale	O	694-699
and	O	700-703
the	O	704-707
Clinical	O	708-716
Global	O	717-723
Impressions	O	724-735
scale	O	736-741
.	O	741-742

RESULTS	O	743-750
:	O	750-751
Patients	O	752-760
showed	O	761-767
a	O	768-769
significant	O	770-781
reduction	O	782-791
in	O	792-794
parent	O	795-801
-	O	801-802
rated	O	802-807
irritability	B	808-820
and	O	821-824
social	O	825-831
withdrawal	O	832-842
on	O	843-845
the	O	846-849
ABC	O	850-853
as	O	854-856
well	O	857-861
as	O	862-864
significant	O	865-876
improvements	O	877-889
in	O	890-892
emotional	O	893-902
lability	O	903-911
and	O	912-915
inattention	O	916-927
on	O	928-930
the	O	931-934
Conners	O	935-942
'	O	942-943
Parent	O	944-950
Rating	O	951-957
Scale	O	958-963
-	O	963-964
-	O	963-964
Revised	O	965-972
.	O	972-973

Similarly	O	974-983
,	O	983-984
clinician	O	985-994
ratings	O	995-1002
showed	O	1003-1009
reductions	O	1010-1020
in	O	1021-1023
the	O	1024-1027
anger	O	1028-1033
subscale	O	1034-1042
of	O	1043-1045
the	O	1046-1049
Children	O	1050-1058
'	O	1058-1059
s	O	1059-1060
Psychiatric	O	1061-1072
Rating	O	1073-1079
Scale	O	1080-1085
.	O	1085-1086

Eight	O	1087-1092
of	O	1093-1095
13	O	1096-1098
participants	O	1099-1111
were	O	1112-1116
rated	O	1117-1122
as	O	1123-1125
responders	O	1126-1136
on	O	1137-1139
the	O	1140-1143
basis	O	1144-1149
of	O	1150-1152
their	O	1153-1158
improvement	O	1159-1170
scores	O	1171-1177
on	O	1178-1180
the	O	1181-1184
Clinical	O	1185-1193
Global	O	1194-1200
Impressions	O	1201-1212
scale	O	1213-1218
.	O	1218-1219

Overall	O	1220-1227
,	O	1227-1228
galantamine	O	1229-1240
was	O	1241-1244
well	O	1245-1249
-	O	1249-1250
tolerated	O	1250-1259
,	O	1259-1260
with	O	1261-1265
no	O	1266-1268
significant	O	1269-1280
adverse	O	1281-1288
effects	O	1289-1296
apart	O	1297-1302
from	O	1303-1307
headaches	B	1308-1317
in	O	1318-1320
one	O	1321-1324
patient	O	1325-1332
.	O	1332-1333

CONCLUSION	O	1334-1344
:	O	1344-1345
In	O	1346-1348
this	O	1349-1353
open	O	1354-1358
trial	O	1359-1364
,	O	1364-1365
galantamine	O	1366-1377
was	O	1378-1381
well	O	1382-1386
-	O	1386-1387
tolerated	O	1387-1396
and	O	1397-1400
appeared	O	1401-1409
to	O	1410-1412
be	O	1413-1415
beneficial	O	1416-1426
for	O	1427-1430
the	O	1431-1434
treatment	O	1435-1444
of	O	1445-1447
interfering	O	1448-1459
behaviors	O	1460-1469
in	O	1470-1472
children	O	1473-1481
with	O	1482-1486
autism	B	1487-1493
,	O	1493-1494
particularly	O	1495-1507
aggression	B	1508-1518
,	O	1518-1519
behavioral	B	1520-1530
dyscontrol	I	1531-1541
,	O	1541-1542
and	O	1543-1546
inattention	B	1547-1558
.	O	1558-1559

Further	O	1560-1567
controlled	O	1568-1578
trials	O	1579-1585
are	O	1586-1589
warranted	O	1590-1599
.	O	1599-1600

Randomized	O	0-10
comparison	O	11-21
of	O	22-24
olanzapine	O	25-35
versus	O	36-42
risperidone	O	43-54
for	O	55-58
the	O	59-62
treatment	O	63-72
of	O	73-75
first	O	76-81
-	O	81-82
episode	O	82-89
schizophrenia	B	90-103
:	O	103-104
4	O	105-106
-	O	106-107
month	O	107-112
outcomes	O	113-121
.	O	121-122

OBJECTIVE	O	123-132
:	O	132-133
The	O	134-137
authors	O	138-145
compared	O	146-154
4	O	155-156
-	O	156-157
month	O	157-162
treatment	O	163-172
outcomes	O	173-181
for	O	182-185
olanzapine	O	186-196
versus	O	197-203
risperidone	O	204-215
in	O	216-218
patients	O	219-227
with	O	228-232
first	O	233-238
-	O	238-239
episode	O	239-246
schizophrenia	B	247-260
spectrum	O	261-269
disorders	O	270-279
.	O	279-280

METHOD	O	281-287
:	O	287-288
One	O	289-292
hundred	O	293-300
twelve	O	301-307
subjects	O	308-316
(	O	317-318
70	O	318-320
%	O	320-321
male	O	322-326
;	O	326-327
mean	O	328-332
age	O	333-336
=	O	336-337
23	O	337-339
.	O	339-340
3	O	338-339

years	O	342-347
[	O	348-349
SD	O	349-351
=	O	352-353
5	O	354-355
.	O	355-356
1	O	356-357
]	O	357-358
)	O	358-359
with	O	360-364
first	O	365-370
-	O	370-371
episode	O	371-378
schizophrenia	B	379-392
(	O	393-394
75	O	394-396
%	O	396-397
)	O	397-398
,	O	398-399
schizophreniform	B	400-416
disorder	I	417-425
(	O	426-427
17	O	427-429
%	O	429-430
)	O	430-431
,	O	431-432
or	O	433-435
schizoaffective	B	436-451
disorder	I	452-460
(	O	461-462
8	O	462-463
%	O	463-464
)	O	464-465
were	O	466-470
randomly	O	471-479
assigned	O	480-488
to	O	489-491
treatment	O	492-501
with	O	502-506
olanzapine	O	507-517
(	O	518-519
2	O	519-520
.	O	520-521
5	O	521-522
-	O	522-523
20	O	523-525
mg	O	526-528
/	O	528-529
day	O	529-532
)	O	532-533
or	O	534-536
risperidone	O	537-548
(	O	549-550
1	O	550-551
-	O	551-552
6	O	552-553
mg	O	554-556
/	O	556-557
day	O	557-560
)	O	560-561
.	O	561-562

RESULTS	O	563-570
:	O	570-571
Response	O	572-580
rates	O	581-586
did	O	587-590
not	O	591-594
significantly	O	595-608
differ	O	609-615
between	O	616-623
olanzapine	O	624-634
(	O	635-636
43	O	636-638
.	O	638-639
7	O	639-640
%	O	640-641
,	O	641-642
95	O	643-645
%	O	645-646
CI	O	647-649
=	O	649-650
28	O	650-652
.	O	652-653
8	O	651-652
%	O	654-655
-	O	655-656
58	O	656-658
.	O	652-653
6	O	659-660
%	O	654-655
)	O	661-662

and	O	663-666
risperidone	O	667-678
(	O	679-680
54	O	680-682
.	O	682-683
3	O	683-684
%	O	684-685
,	O	685-686
95	O	687-689
%	O	689-690
CI	O	691-693
=	O	693-694
39	O	694-696
.	O	696-697
9	O	695-696
%	O	698-699
-	O	699-700
68	O	700-702
.	O	696-697
7	O	703-704
%	O	698-699
)	O	705-706
.	O	696-697

Among	O	708-713
those	O	714-719
responding	O	720-730
to	O	731-733
treatment	O	734-743
,	O	743-744
more	O	745-749
subjects	O	750-758
in	O	759-761
the	O	762-765
olanzapine	O	766-776
group	O	777-782
(	O	783-784
40	O	784-786
.	O	786-787
9	O	787-788
%	O	788-789
,	O	789-790
95	O	791-793
%	O	793-794
CI	O	795-797
=	O	797-798
16	O	798-800
.	O	800-801
8	O	801-802
%	O	802-803
-	O	803-804
65	O	804-806
.	O	800-801
0	O	807-808
%	O	802-803
)	O	809-810

than	O	811-815
in	O	816-818
the	O	819-822
risperidone	O	823-834
group	O	835-840
(	O	841-842
18	O	842-844
.	O	844-845
9	O	845-846
%	O	846-847
,	O	847-848
95	O	849-851
%	O	851-852
CI	O	853-855
=	O	855-856
0	O	856-857
%	O	857-858
-	O	858-859
39	O	859-861
.	O	861-862
2	O	862-863
%	O	857-858
)	O	864-865

had	O	866-869
subsequent	O	870-880
ratings	O	881-888
not	O	889-892
meeting	O	893-900
response	O	901-909
criteria	O	910-918
.	O	918-919

Negative	O	920-928
symptom	O	929-936
outcomes	O	937-945
and	O	946-949
measures	O	950-958
of	O	959-961
parkinsonism	B	962-974
and	O	975-978
akathisia	B	979-988
did	O	989-992
not	O	993-996
differ	O	997-1003
between	O	1004-1011
medications	O	1012-1023
.	O	1023-1024

Extrapyramidal	B	1025-1039
symptom	I	1040-1047
severity	O	1048-1056
scores	O	1057-1063
were	O	1064-1068
1	O	1069-1070
.	O	1070-1071
4	O	1071-1072
(	O	1073-1074
95	O	1074-1076
%	O	1076-1077
CI	O	1078-1080
=	O	1080-1081
1	O	1081-1082
.	O	1082-1083
2	O	1083-1084
-	O	1084-1085
1	O	1081-1082
.	O	1082-1083
6	O	1087-1088
)	O	1088-1089
with	O	1090-1094
risperidone	O	1095-1106
and	O	1107-1110
1	O	1111-1112
.	O	1112-1113
2	O	1113-1114
(	O	1115-1116
95	O	1116-1118
%	O	1118-1119
CI	O	1120-1122
=	O	1122-1123
1	O	1123-1124
.	O	1124-1125
0	O	1125-1126
-	O	1126-1127
1	O	1123-1124
.	O	1124-1125
4	O	1129-1130
)	O	1130-1131
with	O	1132-1136
olanzapine	O	1137-1147
.	O	1147-1148

Significantly	O	1149-1162
more	O	1163-1167
weight	B	1168-1174
gain	I	1175-1179
occurred	O	1180-1188
with	O	1189-1193
olanzapine	O	1194-1204
than	O	1205-1209
with	O	1210-1214
risperidone	O	1215-1226
:	O	1226-1227
the	O	1228-1231
increase	O	1232-1240
in	O	1241-1243
weight	O	1244-1250
at	O	1251-1253
4	O	1254-1255
months	O	1256-1262
relative	O	1263-1271
to	O	1272-1274
baseline	O	1275-1283
weight	O	1284-1290
was	O	1291-1294
17	O	1295-1297
.	O	1297-1298
3	O	1298-1299
%	O	1299-1300
(	O	1301-1302
95	O	1302-1304
%	O	1304-1305
CI	O	1306-1308
=	O	1308-1309
14	O	1309-1311
.	O	1311-1312
2	O	1312-1313
%	O	1313-1314
-	O	1314-1315
20	O	1315-1317
.	O	1311-1312
5	O	1318-1319
%	O	1313-1314
)	O	1320-1321

with	O	1322-1326
olanzapine	O	1327-1337
and	O	1338-1341
11	O	1342-1344
.	O	1344-1345
3	O	1345-1346
%	O	1346-1347
(	O	1348-1349
95	O	1349-1351
%	O	1351-1352
CI	O	1353-1355
=	O	1355-1356
8	O	1356-1357
.	O	1357-1358
4	O	1358-1359
%	O	1359-1360
-	O	1360-1361
14	O	1361-1363
.	O	1357-1358
3	O	1364-1365
%	O	1359-1360
)	O	1366-1367

with	O	1368-1372
risperidone	O	1373-1384
.	O	1384-1385

Body	O	1386-1390
mass	O	1391-1395
index	O	1396-1401
at	O	1402-1404
baseline	O	1405-1413
and	O	1414-1417
at	O	1418-1420
4	O	1421-1422
months	O	1423-1429
was	O	1430-1433
24	O	1434-1436
.	O	1436-1437
3	O	1437-1438
(	O	1439-1440
95	O	1440-1442
%	O	1442-1443
CI	O	1444-1446
=	O	1446-1447
22	O	1447-1449
.	O	1449-1450
8	O	1450-1451
-	O	1451-1452
25	O	1452-1454
.	O	1449-1450
7	O	1455-1456
)	O	1456-1457

versus	O	1458-1464
28	O	1465-1467
.	O	1467-1468
2	O	1465-1466
(	O	1470-1471
95	O	1471-1473
%	O	1473-1474
CI	O	1475-1477
=	O	1477-1478
26	O	1478-1480
.	O	1480-1481
7	O	1481-1482
-	O	1482-1483
29	O	1483-1485
.	O	1480-1481
7	O	1481-1482
)	O	1487-1488

with	O	1489-1493
olanzapine	O	1494-1504
and	O	1505-1508
23	O	1509-1511
.	O	1511-1512
9	O	1512-1513
(	O	1514-1515
95	O	1515-1517
%	O	1517-1518
CI	O	1519-1521
=	O	1521-1522
22	O	1522-1524
.	O	1524-1525
5	O	1525-1526
-	O	1526-1527
25	O	1527-1529
.	O	1524-1525
3	O	1530-1531
)	O	1531-1532

versus	O	1533-1539
26	O	1540-1542
.	O	1542-1543
7	O	1543-1544
(	O	1545-1546
95	O	1546-1548
%	O	1548-1549
CI	O	1550-1552
=	O	1552-1553
25	O	1553-1555
.	O	1555-1556
2	O	1553-1554
-	O	1557-1558
28	O	1558-1560
.	O	1555-1556
2	O	1553-1554
)	O	1562-1563
with	O	1564-1568
risperidone	O	1569-1580
.	O	1580-1581

CONCLUSIONS	O	1582-1593
:	O	1593-1594
Clinical	O	1595-1603
outcomes	O	1604-1612
with	O	1613-1617
risperidone	O	1618-1629
were	O	1630-1634
equal	O	1635-1640
to	O	1641-1643
those	O	1644-1649
with	O	1650-1654
olanzapine	O	1655-1665
,	O	1665-1666
and	O	1667-1670
response	O	1671-1679
may	O	1680-1683
be	O	1684-1686
more	O	1687-1691
stable	O	1692-1698
.	O	1698-1699

Olanzapine	O	1700-1710
may	O	1711-1714
have	O	1715-1719
an	O	1720-1722
advantage	O	1723-1732
for	O	1733-1736
motor	O	1737-1742
side	O	1743-1747
effects	O	1748-1755
.	O	1755-1756

Both	O	1757-1761
medications	O	1762-1773
caused	O	1774-1780
substantial	O	1781-1792
rapid	O	1793-1798
weight	B	1799-1805
gain	I	1806-1810
,	O	1810-1811
but	O	1812-1815
weight	B	1816-1822
gain	I	1823-1827
was	O	1828-1831
greater	O	1832-1839
with	O	1840-1844
olanzapine	O	1845-1855
.	O	1855-1856

Early	O	0-5
paracentral	O	6-17
visual	B	18-24
field	I	25-30
loss	I	31-35
in	O	36-38
patients	O	39-47
taking	O	48-54
hydroxychloroquine	O	55-73
.	O	73-74

OBJECTIVE	O	75-84
:	O	84-85
To	O	86-88
review	O	89-95
the	O	96-99
natural	O	100-107
history	O	108-115
and	O	116-119
ocular	O	120-126
and	O	127-130
systemic	O	131-139
adverse	O	140-147
effects	O	148-155
of	O	156-158
patients	O	159-167
taking	O	168-174
hydroxychloroquine	O	175-193
sulfate	O	194-201
who	O	202-205
attended	O	206-214
an	O	215-217
ophthalmic	O	218-228
screening	O	229-238
program	O	239-246
.	O	246-247

DESIGN	O	248-254
:	O	254-255
Retrospective	O	256-269
study	O	270-275
.	O	275-276

RESULTS	O	277-284
:	O	284-285
Records	O	286-293
of	O	294-296
262	O	297-300
patients	O	301-309
who	O	310-313
were	O	314-318
taking	O	319-325
hydroxychloroquine	O	326-344
and	O	345-348
screened	O	349-357
in	O	358-360
the	O	361-364
Department	O	365-375
of	O	376-378
Ophthalmology	O	379-392
were	O	393-397
reviewed	O	398-406
.	O	406-407

Of	O	408-410
the	O	411-414
262	O	415-418
patients	O	419-427
,	O	427-428
14	O	429-431
(	O	432-433
18	O	433-435
%	O	435-436
)	O	436-437
of	O	438-440
76	O	441-443
who	O	444-447
had	O	448-451
stopped	O	452-459
treatment	O	460-469
at	O	470-472
the	O	473-476
time	O	477-481
of	O	482-484
the	O	485-488
study	O	489-494
experienced	O	495-506
documented	O	507-517
adverse	O	518-525
effects	O	526-533
.	O	533-534

Systemic	O	535-543
adverse	O	544-551
effects	O	552-559
occurred	O	560-568
in	O	569-571
8	O	572-573
patients	O	574-582
(	O	583-584
10	O	584-586
.	O	586-587
5	O	587-588
%	O	588-589
)	O	589-590
and	O	591-594
ocular	O	595-601
adverse	O	602-609
effects	O	610-617
,	O	617-618
in	O	619-621
5	O	622-623
(	O	624-625
6	O	625-626
.	O	626-627
5	O	627-628
%	O	628-629
)	O	629-630
.	O	626-627

Thirty	O	632-638
-	O	638-639
five	O	639-643
patients	O	644-652
(	O	653-654
13	O	654-656
.	O	656-657
4	O	657-658
%	O	658-659
)	O	659-660
had	O	661-664
visual	B	665-671
field	I	672-677
abnormalities	I	678-691
,	O	691-692
which	O	693-698
were	O	699-703
attributed	O	704-714
to	O	715-717
hydroxychloroquine	O	718-736
treatment	O	737-746
in	O	747-749
4	O	750-751
patients	O	752-760
(	O	761-762
1	O	762-763
.	O	763-764
5	O	764-765
%	O	765-766
)	O	766-767
.	O	763-764

Three	O	769-774
of	O	775-777
the	O	778-781
4	O	782-783
patients	O	784-792
were	O	793-797
taking	O	798-804
less	O	805-809
than	O	810-814
6	O	815-816
.	O	816-817
5	O	817-818
mg	O	819-821
/	O	821-822
kg	O	822-824
per	O	825-828
day	O	829-832
and	O	833-836
all	O	837-840
patients	O	841-849
had	O	850-853
normal	O	854-860
renal	O	861-866
and	O	867-870
liver	O	871-876
function	O	877-885
test	O	886-890
results	O	891-898
.	O	898-899

CONCLUSIONS	O	900-911
:	O	911-912
The	O	913-916
current	O	917-924
study	O	925-930
used	O	931-935
a	O	936-937
protocol	O	938-946
of	O	947-949
visual	O	950-956
acuity	O	957-963
and	O	964-967
color	O	968-973
vision	O	974-980
assessment	O	981-991
,	O	991-992
funduscopy	O	993-1003
,	O	1003-1004
and	O	1005-1008
Humphrey	O	1009-1017
10	O	1018-1020
-	O	1020-1021
2	O	1021-1022
visual	O	1023-1029
field	O	1030-1035
testing	O	1036-1043
and	O	1044-1047
shows	O	1048-1053
that	O	1054-1058
visual	B	1059-1065
field	I	1066-1071
defects	I	1072-1079
appeared	O	1080-1088
before	O	1089-1095
any	O	1096-1099
corresponding	O	1100-1113
changes	O	1114-1121
in	O	1122-1124
any	O	1125-1128
other	O	1129-1134
tested	O	1135-1141
clinical	O	1142-1150
parameters	O	1151-1161
;	O	1161-1162
the	O	1163-1166
defects	O	1167-1174
were	O	1175-1179
reproducible	O	1180-1192
and	O	1193-1196
the	O	1197-1200
test	O	1201-1205
parameters	O	1206-1216
were	O	1217-1221
reliable	O	1222-1230
.	O	1230-1231

Patients	O	1232-1240
taking	O	1241-1247
hydroxychloroquine	O	1248-1266
can	O	1267-1270
demonstrate	O	1271-1282
a	O	1283-1284
toxic	O	1285-1290
reaction	O	1291-1299
in	O	1300-1302
the	O	1303-1306
retina	O	1307-1313
despite	O	1314-1321
the	O	1322-1325
absence	O	1326-1333
of	O	1334-1336
known	O	1337-1342
risk	O	1343-1347
factors	O	1348-1355
.	O	1355-1356

Screening	O	1357-1366
,	O	1366-1367
including	O	1368-1377
Humphrey	O	1378-1386
10	O	1387-1389
-	O	1389-1390
2	O	1390-1391
visual	O	1392-1398
field	O	1399-1404
assessment	O	1405-1415
,	O	1415-1416
is	O	1417-1419
recommended	O	1420-1431
2	O	1432-1433
years	O	1434-1439
after	O	1440-1445
the	O	1446-1449
initial	O	1450-1457
baseline	O	1458-1466
and	O	1467-1470
yearly	O	1471-1477
thereafter	O	1478-1488
.	O	1488-1489

Peri	O	0-4
-	O	4-5
operative	O	5-14
atrioventricular	B	15-31
block	I	32-37
as	O	38-40
a	O	41-42
result	O	43-49
of	O	50-52
chemotherapy	O	53-65
with	O	66-70
epirubicin	O	71-81
and	O	82-85
paclitaxel	O	86-96
.	O	96-97

A	O	98-99
47	O	100-102
-	O	102-103
year	O	103-107
-	O	102-103
old	O	108-111
woman	O	112-117
presented	O	118-127
for	O	128-131
mastectomy	O	132-142
and	O	143-146
immediate	O	147-156
latissimus	O	157-167
dorsi	O	168-173
flap	O	174-178
reconstruction	O	179-193
having	O	194-200
been	O	201-205
diagnosed	O	206-215
with	O	216-220
carcinoma	B	221-230
of	I	231-233
the	I	234-237
breast	I	238-244
6	O	245-246
months	O	247-253
previously	O	254-264
.	O	264-265

In	O	266-268
the	O	269-272
preceding	O	273-282
months	O	283-289
she	O	290-293
had	O	294-297
received	O	298-306
neo	O	307-310
-	O	310-311
adjuvant	O	311-319
chemotherapy	O	320-332
with	O	333-337
epirubicin	O	338-348
,	O	348-349
paclitaxel	O	350-360
(	O	361-362
Taxol	O	362-367
)	O	367-368
and	O	369-372
cyclophosphamide	O	373-389
.	O	389-390

This	O	391-395
had	O	396-399
been	O	400-404
apparently	O	405-415
uncomplicated	O	416-429
and	O	430-433
she	O	434-437
had	O	438-441
maintained	O	442-452
a	O	453-454
remarkably	O	455-465
high	O	466-470
level	O	471-476
of	O	477-479
physical	O	480-488
activity	O	489-497
.	O	497-498

She	O	499-502
was	O	503-506
found	O	507-512
to	O	513-515
be	O	516-518
bradycardic	B	519-530
at	O	531-533
pre	O	534-537
-	O	537-538
operative	O	538-547
assessment	O	548-558
but	O	559-562
had	O	563-566
no	O	567-569
cardiac	O	570-577
symptoms	O	578-586
.	O	586-587

Second	O	588-594
degree	O	595-601
Mobitz	O	602-608
type	O	609-613
II	O	614-616
atrioventricular	B	617-633
block	I	634-639
was	O	640-643
diagnosed	O	644-653
on	O	654-656
electrocardiogram	O	657-674
,	O	674-675
and	O	676-679
temporary	O	680-689
transvenous	O	690-701
ventricular	O	702-713
pacing	O	714-720
instituted	O	721-731
in	O	732-734
the	O	735-738
peri	O	739-743
-	O	743-744
operative	O	744-753
period	O	754-760
.	O	760-761

We	O	762-764
discuss	O	765-772
how	O	773-776
evidence	O	777-785
-	O	785-786
based	O	786-791
guidelines	O	792-802
would	O	803-808
not	O	809-812
have	O	813-817
been	O	818-822
helpful	O	823-830
in	O	831-833
this	O	834-838
case	O	839-843
,	O	843-844
and	O	845-848
how	O	849-852
chemotherapy	O	853-865
can	O	866-869
exhibit	O	870-877
substantial	O	878-889
cardiotoxicity	B	890-904
that	O	905-909
may	O	910-913
develop	O	914-921
over	O	922-926
many	O	927-931
years	O	932-937
.	O	937-938

We	O	939-941
suggest	O	942-949
that	O	950-954
patients	O	955-963
who	O	964-967
have	O	968-972
received	O	973-981
chemotherapy	O	982-994
at	O	995-997
any	O	998-1001
time	O	1002-1006
should	O	1007-1013
have	O	1014-1018
a	O	1019-1020
pre	O	1021-1024
-	O	1024-1025
operative	O	1025-1034
electrocardiogram	O	1035-1052
even	O	1053-1057
if	O	1058-1060
they	O	1061-1065
are	O	1066-1069
asymptomatic	O	1070-1082
.	O	1082-1083

Risks	O	0-5
and	O	6-9
benefits	O	10-18
of	O	19-21
COX	O	22-25
-	O	25-26
2	O	26-27
inhibitors	O	28-38
vs	O	39-41
non	O	42-45
-	O	45-46
selective	O	46-55
NSAIDs	O	56-62
:	O	62-63
does	O	64-68
their	O	69-74
cardiovascular	O	75-89
risk	O	90-94
exceed	O	95-101
their	O	102-107
gastrointestinal	O	108-124
benefit	O	125-132
?	O	132-133

A	O	134-135
retrospective	O	136-149
cohort	O	150-156
study	O	157-162
.	O	162-163

OBJECTIVES	O	164-174
:	O	174-175
The	O	176-179
risk	O	180-184
of	O	185-187
acute	B	188-193
myocardial	I	194-204
infarction	I	205-215
(	O	216-217
AMI	B	217-220
)	O	220-221
with	O	222-226
COX	O	227-230
-	O	230-231
2	O	231-232
inhibitors	O	233-243
may	O	244-247
offset	O	248-254
their	O	255-260
gastrointestinal	O	261-277
(	O	278-279
GI	O	279-281
)	O	281-282
benefit	O	283-290
compared	O	291-299
with	O	300-304
non	O	305-308
-	O	308-309
selective	O	309-318
(	O	319-320
NS	O	320-322
)	O	322-323
non	O	324-327
-	O	327-328
steroidal	O	328-337
anti	O	338-342
-	O	342-343
inflammatory	O	343-355
drugs	O	356-361
(	O	362-363
NSAIDs	O	363-369
)	O	369-370
.	O	370-371

We	O	372-374
aimed	O	375-380
to	O	381-383
compare	O	384-391
the	O	392-395
risks	O	396-401
of	O	402-404
hospitalization	O	405-420
for	O	421-424
AMI	B	425-428
and	O	429-432
GI	B	433-435
bleeding	I	436-444
among	O	445-450
elderly	O	451-458
patients	O	459-467
using	O	468-473
COX	O	474-477
-	O	477-478
2	O	478-479
inhibitors	O	480-490
,	O	490-491
NS	O	492-494
-	O	494-495
NSAIDs	O	495-501
and	O	502-505
acetaminophen	O	506-519
.	O	519-520

METHODS	O	521-528
:	O	528-529
We	O	530-532
conducted	O	533-542
a	O	543-544
retrospective	O	545-558
cohort	O	559-565
study	O	566-571
using	O	572-577
administrative	O	578-592
data	O	593-597
of	O	598-600
patients	O	601-609
>	O	610-611
or	O	612-614
=	O	615-616
65	O	616-618
years	O	619-624
of	O	625-627
age	O	628-631
who	O	632-635
filled	O	636-642
a	O	643-644
prescription	O	645-657
for	O	658-661
NSAID	O	662-667
or	O	668-670
acetaminophen	O	671-684
during	O	685-691
1999	O	692-696
-	O	696-697
2002	O	697-701
.	O	701-702

Outcomes	O	703-711
were	O	712-716
compared	O	717-725
using	O	726-731
Cox	O	732-735
regression	O	736-746
models	O	747-753
with	O	754-758
time	O	759-763
-	O	763-764
dependent	O	764-773
exposures	O	774-783
.	O	783-784

RESULTS	O	785-792
:	O	792-793
Person	O	794-800
-	O	800-801
years	O	801-806
of	O	807-809
exposure	O	810-818
among	O	819-824
non	O	825-828
-	O	828-829
users	O	829-834
of	O	835-837
aspirin	O	838-845
were	O	846-850
:	O	850-851
75	O	852-854
,	O	854-855
761	O	855-858
to	O	859-861
acetaminophen	O	862-875
,	O	875-876
42	O	877-879
,	O	879-880
671	O	880-883
to	O	884-886
rofecoxib	O	887-896
65	O	897-899
,	O	899-900
860	O	900-903
to	O	904-906
celecoxib	O	907-916
,	O	916-917
and	O	918-921
37	O	922-924
,	O	924-925
495	O	925-928
to	O	929-931
NS	O	932-934
-	O	934-935
NSAIDs	O	935-941
.	O	941-942

Among	O	943-948
users	O	949-954
of	O	955-957
aspirin	O	958-965
,	O	965-966
they	O	967-971
were	O	972-976
:	O	976-977
14	O	978-980
,	O	980-981
671	O	981-984
to	O	985-987
rofecoxib	O	988-997
,	O	997-998
22	O	999-1001
,	O	1001-1002
875	O	1002-1005
to	O	1006-1008
celecoxib	O	1009-1018
,	O	1018-1019
9	O	1020-1021
,	O	1021-1022
832	O	1022-1025
to	O	1026-1028
NS	O	1029-1031
-	O	1031-1032
NSAIDs	O	1032-1038
and	O	1039-1042
38	O	1043-1045
,	O	1045-1046
048	O	1046-1049
to	O	1050-1052
acetaminophen	O	1053-1066
.	O	1066-1067

Among	O	1068-1073
non	O	1074-1077
-	O	1077-1078
users	O	1078-1083
of	O	1084-1086
aspirin	O	1087-1094
,	O	1094-1095
the	O	1096-1099
adjusted	O	1100-1108
hazard	O	1109-1115
ratios	O	1116-1122
(	O	1123-1124
95	O	1124-1126
%	O	1126-1127
confidence	O	1128-1138
interval	O	1139-1147
)	O	1147-1148
of	O	1149-1151
hospitalization	O	1152-1167
for	O	1168-1171
AMI	B	1172-1175
/	O	1175-1176
GI	O	1176-1178
vs	O	1179-1181
the	O	1182-1185
acetaminophen	O	1186-1199
(	O	1200-1201
with	O	1201-1205
no	O	1206-1208
aspirin	O	1209-1216
)	O	1216-1217
group	O	1218-1223
were	O	1224-1228
:	O	1228-1229
rofecoxib	O	1230-1239
1	O	1240-1241
.	O	1241-1242
27	O	1242-1244
(	O	1245-1246
1	O	1246-1247
.	O	1247-1248
13	O	1248-1250
,	O	1250-1251
1	O	1252-1253
.	O	1253-1254
42	O	1254-1256
)	O	1256-1257
,	O	1257-1258
celecoxib	O	1259-1268
0	O	1269-1270
.	O	1270-1271
93	O	1271-1273
(	O	1274-1275
0	O	1275-1276
.	O	1276-1277
83	O	1277-1279
,	O	1279-1280
1	O	1281-1282
.	O	1282-1283
03	O	1283-1285
)	O	1285-1286
,	O	1286-1287
naproxen	O	1288-1296
1	O	1297-1298
.	O	1298-1299
59	O	1299-1301
(	O	1302-1303
1	O	1303-1304
.	O	1304-1305
31	O	1305-1307
,	O	1307-1308
1	O	1309-1310
.	O	1310-1311
93	O	1311-1313
)	O	1313-1314
,	O	1314-1315
diclofenac	O	1316-1326
1	O	1327-1328
.	O	1328-1329
17	O	1329-1331
(	O	1332-1333
0	O	1333-1334
.	O	1334-1335
99	O	1335-1337
,	O	1337-1338
1	O	1339-1340
.	O	1340-1341
38	O	1341-1343
)	O	1343-1344
and	O	1345-1348
ibuprofen	O	1349-1358
1	O	1359-1360
.	O	1360-1361
05	O	1361-1363
(	O	1364-1365
0	O	1365-1366
.	O	1366-1367
74	O	1367-1369
,	O	1369-1370
1	O	1371-1372
.	O	1372-1373
51	O	1373-1375
)	O	1375-1376
.	O	1372-1373

Among	O	1378-1383
users	O	1384-1389
of	O	1390-1392
aspirin	O	1393-1400
,	O	1400-1401
they	O	1402-1406
were	O	1407-1411
:	O	1411-1412
rofecoxib	O	1413-1422
1	O	1423-1424
.	O	1424-1425
73	O	1425-1427
(	O	1428-1429
1	O	1429-1430
.	O	1430-1431
52	O	1431-1433
,	O	1433-1434
1	O	1435-1436
.	O	1436-1437
98	O	1437-1439
)	O	1439-1440
,	O	1440-1441
celecoxib	O	1442-1451
1	O	1452-1453
.	O	1453-1454
34	O	1454-1456
(	O	1457-1458
1	O	1458-1459
.	O	1459-1460
19	O	1460-1462
,	O	1462-1463
1	O	1464-1465
.	O	1465-1466
52	O	1466-1468
)	O	1468-1469
,	O	1469-1470
ibuprofen	O	1471-1480
1	O	1481-1482
.	O	1482-1483
51	O	1483-1485
(	O	1486-1487
0	O	1487-1488
.	O	1488-1489
95	O	1489-1491
,	O	1491-1492
2	O	1493-1494
.	O	1494-1495
41	O	1495-1497
)	O	1497-1498
,	O	1498-1499
diclofenac	O	1500-1510
1	O	1511-1512
.	O	1512-1513
69	O	1513-1515
(	O	1516-1517
1	O	1517-1518
.	O	1518-1519
35	O	1519-1521
,	O	1521-1522
2	O	1523-1524
.	O	1524-1525
10	O	1525-1527
)	O	1527-1528
,	O	1528-1529
naproxen	O	1530-1538
1	O	1539-1540
.	O	1540-1541
35	O	1541-1543
(	O	1544-1545
0	O	1545-1546
.	O	1546-1547
97	O	1547-1549
,	O	1549-1550
1	O	1551-1552
.	O	1552-1553
88	O	1553-1555
)	O	1555-1556
and	O	1557-1560
acetaminophen	O	1561-1574
1	O	1575-1576
.	O	1576-1577
29	O	1577-1579
(	O	1580-1581
1	O	1581-1582
.	O	1582-1583
17	O	1583-1585
,	O	1585-1586
1	O	1587-1588
.	O	1588-1589
42	O	1589-1591
)	O	1591-1592
.	O	1588-1589

CONCLUSION	O	1594-1604
:	O	1604-1605
Among	O	1606-1611
non	O	1612-1615
-	O	1615-1616
users	O	1616-1621
of	O	1622-1624
aspirin	O	1625-1632
,	O	1632-1633
naproxen	O	1634-1642
seemed	O	1643-1649
to	O	1650-1652
carry	O	1653-1658
the	O	1659-1662
highest	O	1663-1670
risk	O	1671-1675
for	O	1676-1679
AMI	B	1680-1683
/	O	1683-1684
GI	B	1684-1686
bleeding	I	1687-1695
.	O	1695-1696

The	O	1697-1700
AMI	B	1701-1704
/	O	1704-1705
GI	O	1705-1707
toxicity	B	1708-1716
of	O	1717-1719
celecoxib	O	1720-1729
was	O	1730-1733
similar	O	1734-1741
to	O	1742-1744
that	O	1745-1749
of	O	1750-1752
acetaminophen	O	1753-1766
and	O	1767-1770
seemed	O	1771-1777
to	O	1778-1780
be	O	1781-1783
better	O	1784-1790
than	O	1791-1795
those	O	1796-1801
of	O	1802-1804
rofecoxib	O	1805-1814
and	O	1815-1818
NS	O	1819-1821
-	O	1821-1822
NSAIDs	O	1822-1828
.	O	1828-1829

Among	O	1830-1835
users	O	1836-1841
of	O	1842-1844
aspirin	O	1845-1852
,	O	1852-1853
both	O	1854-1858
celecoxib	O	1859-1868
and	O	1869-1872
naproxen	O	1873-1881
seemed	O	1882-1888
to	O	1889-1891
be	O	1892-1894
the	O	1895-1898
least	O	1899-1904
toxic	O	1905-1910
.	O	1910-1911

Quinine	O	0-7
-	O	7-8
induced	O	8-15
arrhythmia	B	16-26
in	O	27-29
a	O	30-31
patient	O	32-39
with	O	40-44
severe	B	45-51
malaria	I	52-59
.	O	59-60

It	O	61-63
was	O	64-67
reported	O	68-76
that	O	77-81
there	O	82-87
was	O	88-91
a	O	92-93
case	O	94-98
of	O	99-101
severe	B	102-108
malaria	I	109-116
patient	O	117-124
with	O	125-129
jaundice	B	130-138
who	O	139-142
presented	O	143-152
with	O	153-157
arrhythmia	B	158-168
(	O	169-170
premature	B	170-179
ventricular	I	180-191
contraction	I	192-203
)	O	203-204
while	O	205-210
getting	O	211-218
quinine	O	219-226
infusion	O	227-235
was	O	236-239
reported	O	240-248
.	O	248-249

A	O	250-251
man	O	252-255
,	O	255-256
25	O	257-259
years	O	260-265
old	O	266-269
,	O	269-270
was	O	271-274
admitted	O	275-283
to	O	284-286
hospital	O	287-295
with	O	296-300
high	O	301-305
fever	B	306-311
,	O	311-312
chill	B	313-318
,	O	318-319
vomiting	B	320-328
,	O	328-329
jaundice	B	330-338
.	O	338-339

The	O	340-343
patient	O	344-351
was	O	352-355
fully	O	356-361
conscious	O	362-371
,	O	371-372
blood	O	373-378
pressure	O	379-387
120	O	388-391
/	O	391-392
80	O	392-394
mmHg	O	395-399
,	O	399-400
pulse	O	401-406
rate	O	407-411
100	O	412-415
x	O	416-417
/	O	417-418
minute	O	418-424
,	O	424-425
regular	O	426-433
.	O	433-434

On	O	435-437
admission	O	438-447
,	O	447-448
laboratory	O	449-459
examination	O	460-471
showed	O	472-478
Plasmodium	O	479-489
falciparum	O	490-500
(	O	501-502
+	O	502-503
+	O	502-503
+	O	502-503
+	O	502-503
)	O	506-507
,	O	507-508
total	O	509-514
bilirubin	O	515-524
8	O	525-526
.	O	526-527
25	O	527-529
mg	O	530-532
/	O	532-533
dL	O	533-535
,	O	535-536
conjugated	O	537-547
bilirubin	O	548-557
4	O	558-559
.	O	559-560
36	O	560-562
mg	O	563-565
/	O	565-566
dL	O	566-568
,	O	568-569
unconjugated	O	570-582
bilirubin	O	583-592
3	O	593-594
.	O	594-595
89	O	595-597
mg	O	598-600
/	O	600-601
dL	O	601-603
,	O	603-604
potassium	O	605-614
3	O	615-616
.	O	616-617
52	O	617-619
meq	O	620-623
/	O	623-624
L	O	624-625
Patient	O	626-633
was	O	634-637
diagnosed	O	638-647
as	O	648-650
severe	B	651-657
malaria	I	658-665
with	O	666-670
jaundice	B	671-679
and	O	680-683
got	O	684-687
quinine	O	688-695
infusion	O	696-704
in	O	705-707
dextrose	O	708-716
5	O	717-718
%	O	718-719
500	O	720-723
mg	O	724-726
/	O	726-727
8	O	727-728
hour	O	729-733
.	O	733-734

On	O	735-737
the	O	738-741
second	O	742-748
day	O	749-752
the	O	753-756
patient	O	757-764
had	O	765-768
vomitus	B	769-776
,	O	776-777
diarrhea	B	778-786
,	O	786-787
tinnitus	B	788-796
,	O	796-797
loss	B	798-802
of	I	803-805
hearing	I	806-813
.	O	813-814

After	O	815-820
30	O	821-823
hours	O	824-829
of	O	830-832
quinine	O	833-840
infusion	O	841-849
the	O	850-853
patient	O	854-861
felt	O	862-866
palpitation	B	867-878
and	O	879-882
electrocardiography	O	883-902
(	O	903-904
ECG	O	904-907
)	O	907-908
recording	O	909-918
showed	O	919-925
premature	B	926-935
ventricular	I	936-947
contraction	I	948-959
(	O	960-961
PVC	B	961-964
)	O	964-965
>	O	966-967
5	O	968-969
x	O	970-971
/	O	971-972
minute	O	972-978
,	O	978-979
trigemini	O	980-989
,	O	989-990
constant	O	991-999
type	O	1000-1004
-	O	1004-1005
-	O	1004-1005
sinoatrial	B	1006-1016
block	I	1017-1022
,	O	1022-1023
positive	O	1024-1032
U	O	1033-1034
wave	O	1035-1039
.	O	1039-1040

He	O	1041-1043
was	O	1044-1047
treated	O	1048-1055
with	O	1056-1060
lidocaine	O	1061-1070
50	O	1071-1073
mg	O	1074-1076
intravenously	O	1077-1090
followed	O	1091-1099
by	O	1100-1102
infusion	O	1103-1111
1500	O	1112-1116
mg	O	1117-1119
in	O	1120-1122
dextrose	O	1123-1131
5	O	1132-1133
%	O	1133-1134
/	O	1134-1135
24	O	1135-1137
hour	O	1138-1142
and	O	1143-1146
potassium	O	1147-1156
aspartate	O	1157-1166
tablet	O	1167-1173
.	O	1173-1174

Quinine	O	1175-1182
infusion	O	1183-1191
was	O	1192-1195
discontinued	O	1196-1208
and	O	1209-1212
changed	O	1213-1220
with	O	1221-1225
sulfate	O	1226-1233
quinine	O	1234-1241
tablets	O	1242-1249
.	O	1249-1250

Three	O	1251-1256
hours	O	1257-1262
later	O	1263-1268
the	O	1269-1272
patient	O	1273-1280
felt	O	1281-1285
better	O	1286-1292
,	O	1292-1293
the	O	1294-1297
frequency	O	1298-1307
of	O	1308-1310
PVC	B	1311-1314
reduced	O	1315-1322
to	O	1323-1325
4	O	1326-1327
-	O	1328-1329
5	O	1330-1331
x	O	1332-1333
/	O	1333-1334
minute	O	1334-1340
and	O	1341-1344
on	O	1345-1347
the	O	1348-1351
third	O	1352-1357
day	O	1358-1361
ECG	O	1362-1365
was	O	1366-1369
normal	O	1370-1376
,	O	1376-1377
potassium	O	1378-1387
level	O	1388-1393
was	O	1394-1397
3	O	1398-1399
.	O	1399-1400
34	O	1400-1402
meq	O	1403-1406
/	O	1406-1407
L	O	1407-1408
.	O	1408-1409

He	O	1410-1412
was	O	1413-1416
discharged	O	1417-1427
on	O	1428-1430
7th	O	1431-1434
day	O	1435-1438
in	O	1439-1441
good	O	1442-1446
condition	O	1447-1456
.	O	1456-1457

Quinine	O	1458-1465
,	O	1465-1466
like	O	1467-1471
quinidine	O	1472-1481
,	O	1481-1482
is	O	1483-1485
a	O	1486-1487
chincona	O	1488-1496
alkaloid	O	1497-1505
that	O	1506-1510
has	O	1511-1514
anti	O	1515-1519
-	O	1519-1520
arrhythmic	B	1520-1530
property	O	1531-1539
,	O	1539-1540
although	O	1541-1549
it	O	1550-1552
also	O	1553-1557
pro	O	1558-1561
-	O	1561-1562
arrhythmic	B	1562-1572
that	O	1573-1577
can	O	1578-1581
cause	O	1582-1587
various	O	1588-1595
arrhythmias	B	1596-1607
,	O	1607-1608
including	O	1609-1618
severe	O	1619-1625
arrhythmia	B	1626-1636
such	O	1637-1641
as	O	1642-1644
multiple	O	1645-1653
PVC	B	1654-1657
.	O	1657-1658

Administration	O	1659-1673
of	O	1674-1676
parenteral	O	1677-1687
quinine	O	1688-1695
must	O	1696-1700
be	O	1701-1703
done	O	1704-1708
carefully	O	1709-1718
and	O	1719-1722
with	O	1723-1727
good	O	1728-1732
observation	O	1733-1744
because	O	1745-1752
of	O	1753-1755
its	O	1756-1759
pro	O	1760-1763
-	O	1763-1764
arrhythmic	B	1764-1774
effect	O	1775-1781
,	O	1781-1782
especially	O	1783-1793
in	O	1794-1796
older	O	1797-1802
patients	O	1803-1811
who	O	1812-1815
have	O	1816-1820
heart	B	1821-1826
diseases	I	1827-1835
or	O	1836-1838
patients	O	1839-1847
with	O	1848-1852
electrolyte	B	1853-1864
disorder	I	1865-1873
(	O	1874-1875
hypokalemia	B	1875-1886
)	O	1886-1887
which	O	1888-1893
frequently	O	1894-1904
occurs	O	1905-1911
due	O	1912-1915
to	O	1916-1918
vomiting	B	1919-1927
and	O	1928-1931
or	O	1932-1934
diarrhea	B	1935-1943
in	O	1944-1946
malaria	B	1947-1954
cases	O	1955-1960
.	O	1960-1961

Penicillamine	O	0-13
-	O	13-14
related	O	14-21
lichenoid	B	22-31
dermatitis	I	32-42
and	O	43-46
utility	O	47-54
of	O	55-57
zinc	O	58-62
acetate	O	63-70
in	O	71-73
a	O	74-75
Wilson	B	76-82
disease	I	83-90
patient	O	91-98
with	O	99-103
hepatic	O	104-111
presentation	O	112-124
,	O	124-125
anxiety	B	126-133
and	O	134-137
SPECT	O	138-143
abnormalities	O	144-157
.	O	157-158

Wilson	B	159-165
'	I	165-166
s	I	162-163
disease	I	168-175
is	O	176-178
an	O	179-181
autosomal	O	182-191
recessive	O	192-201
disorder	O	202-210
of	O	211-213
hepatic	O	214-221
copper	O	222-228
metabolism	O	229-239
with	O	240-244
consequent	O	245-255
copper	O	256-262
accumulation	O	263-275
and	O	276-279
toxicity	B	280-288
in	O	289-291
many	O	292-296
tissues	O	297-304
and	O	305-308
consequent	O	309-319
hepatic	B	320-327
,	I	327-328
neurologic	I	329-339
and	I	340-343
psychiatric	I	344-355
disorders	I	356-365
.	O	365-366

We	O	367-369
report	O	370-376
a	O	377-378
case	O	379-383
of	O	384-386
Wilson	B	387-393
'	I	393-394
s	I	390-391
disease	I	396-403
with	O	404-408
chronic	B	409-416
liver	I	417-422
disease	I	423-430
;	O	430-431
moreover	O	432-440
,	O	440-441
in	O	442-444
our	O	445-448
patient	O	449-456
,	O	456-457
presenting	O	458-468
also	O	469-473
with	O	474-478
high	O	479-483
levels	O	484-490
of	O	491-493
state	O	494-499
anxiety	B	500-507
without	O	508-515
depression	B	516-526
,	O	526-527
99mTc	O	528-533
-	O	533-534
ECD	O	534-537
-	O	533-534
SPECT	O	538-543
showed	O	544-550
cortical	O	551-559
hypoperfusion	O	560-573
in	O	574-576
frontal	O	577-584
lobes	O	585-590
,	O	590-591
more	O	592-596
marked	O	597-603
on	O	604-606
the	O	607-610
left	O	611-615
frontal	O	616-623
lobe	O	624-628
.	O	628-629

During	O	630-636
the	O	637-640
follow	O	641-647
-	O	647-648
up	O	648-650
of	O	651-653
our	O	654-657
patient	O	658-665
,	O	665-666
penicillamine	O	667-680
was	O	681-684
interrupted	O	685-696
after	O	697-702
the	O	703-706
appearance	O	707-717
of	O	718-720
a	O	721-722
lichenoid	B	723-732
dermatitis	I	733-743
,	O	743-744
and	O	745-748
zinc	O	749-753
acetate	O	754-761
permitted	O	762-771
to	O	772-774
continue	O	775-783
the	O	784-787
successful	O	788-798
treatment	O	799-808
of	O	809-811
the	O	812-815
patient	O	816-823
without	O	824-831
side	O	832-836
-	O	836-837
effects	O	837-844
.	O	844-845

In	O	846-848
our	O	849-852
case	O	853-857
the	O	858-861
therapy	O	862-869
with	O	870-874
zinc	O	875-879
acetate	O	880-887
represented	O	888-899
an	O	900-902
effective	O	903-912
treatment	O	913-922
for	O	923-926
a	O	927-928
Wilson	B	929-935
'	I	935-936
s	I	932-933
disease	I	938-945
patient	O	946-953
in	O	954-956
which	O	957-962
penicillamine	O	963-976
-	O	976-977
related	O	977-984
side	O	985-989
effects	O	990-997
appeared	O	998-1006
.	O	1006-1007

The	O	1008-1011
safety	O	1012-1018
of	O	1019-1021
the	O	1022-1025
zinc	O	1026-1030
acetate	O	1031-1038
allowed	O	1039-1046
us	O	1047-1049
to	O	1050-1052
avoid	O	1053-1058
other	O	1059-1064
potentially	O	1065-1076
toxic	O	1077-1082
chelating	O	1083-1092
drugs	O	1093-1098
;	O	1098-1099
this	O	1100-1104
observation	O	1105-1116
is	O	1117-1119
in	O	1120-1122
line	O	1123-1127
with	O	1128-1132
the	O	1133-1136
growing	O	1137-1144
evidence	O	1145-1153
on	O	1154-1156
the	O	1157-1160
efficacy	O	1161-1169
of	O	1170-1172
the	O	1173-1176
drug	O	1177-1181
in	O	1182-1184
the	O	1185-1188
treatment	O	1189-1198
of	O	1199-1201
Wilson	B	1202-1208
'	I	1208-1209
s	I	1205-1206
disease	I	1211-1218
.	O	1218-1219

Since	O	1220-1225
most	O	1226-1230
of	O	1231-1233
Wilson	B	1234-1240
'	I	1240-1241
s	I	1237-1238
disease	I	1243-1250
penicillamine	O	1251-1264
-	O	1264-1265
treated	O	1265-1272
patients	O	1273-1281
do	O	1282-1284
not	O	1285-1288
seem	O	1289-1293
to	O	1294-1296
develop	O	1297-1304
this	O	1305-1309
skin	B	1310-1314
lesion	I	1315-1321
,	O	1321-1322
it	O	1323-1325
could	O	1326-1331
be	O	1332-1334
conceivable	O	1335-1346
that	O	1347-1351
a	O	1352-1353
specific	O	1354-1362
genetic	O	1363-1370
factor	O	1371-1377
is	O	1378-1380
involved	O	1381-1389
in	O	1390-1392
drug	O	1393-1397
response	O	1398-1406
.	O	1406-1407

Further	O	1408-1415
studies	O	1416-1423
are	O	1424-1427
needed	O	1428-1434
for	O	1435-1438
a	O	1439-1440
better	O	1441-1447
clarification	O	1448-1461
of	O	1462-1464
Wilson	B	1465-1471
'	I	1471-1472
s	I	1468-1469
disease	I	1474-1481
therapy	O	1482-1489
,	O	1489-1490
and	O	1491-1494
in	O	1495-1497
particular	O	1498-1508
to	O	1509-1511
differentiate	O	1512-1525
specific	O	1526-1534
therapies	O	1535-1544
for	O	1545-1548
different	O	1549-1558
Wilson	B	1559-1565
'	I	1565-1566
s	I	1562-1563
disease	I	1568-1575
phenotypes	O	1576-1586
.	O	1586-1587

A	O	0-1
dramatic	O	2-10
drop	B	11-15
in	I	16-18
blood	I	19-24
pressure	I	25-33
following	O	34-43
prehospital	O	44-55
GTN	O	56-59
administration	O	60-74
.	O	74-75

A	O	76-77
male	O	78-82
in	O	83-85
his	O	86-89
sixties	O	90-97
with	O	98-102
no	O	103-105
history	O	106-113
of	O	114-116
cardiac	O	117-124
chest	B	125-130
pain	I	131-135
awoke	O	136-141
with	O	142-146
chest	B	147-152
pain	I	153-157
following	O	158-167
an	O	168-170
afternoon	O	171-180
sleep	O	181-186
.	O	186-187

The	O	188-191
patient	O	192-199
did	O	200-203
not	O	204-207
self	O	208-212
medicate	O	213-221
.	O	221-222

The	O	223-226
patient	O	227-234
'	O	234-235
s	O	235-236
observations	O	237-249
were	O	250-254
within	O	255-261
normal	O	262-268
limits	O	269-275
,	O	275-276
he	O	277-279
was	O	280-283
administered	O	284-296
oxygen	O	297-303
via	O	304-307
a	O	308-309
face	O	310-314
mask	O	315-319
and	O	320-323
glyceryl	O	324-332
trinitrate	O	333-343
(	O	344-345
GTN	O	345-348
)	O	348-349
.	O	349-350

Several	O	351-358
minutes	O	359-366
after	O	367-372
the	O	373-376
GTN	O	377-380
the	O	381-384
patient	O	385-392
experienced	O	393-404
a	O	405-406
sudden	O	407-413
drop	B	414-418
in	I	419-421
blood	I	422-427
pressure	I	428-436
and	O	437-440
heart	O	441-446
rate	O	447-451
,	O	451-452
this	O	453-457
was	O	458-461
rectified	O	462-471
by	O	472-474
atropine	O	475-483
sulphate	O	484-492
and	O	493-496
a	O	497-498
fluid	O	499-504
challenge	O	505-514
.	O	514-515

There	O	516-521
was	O	522-525
no	O	526-528
further	O	529-536
deterioration	O	537-550
in	O	551-553
the	O	554-557
patient	O	558-565
'	O	565-566
s	O	566-567
condition	O	568-577
during	O	578-584
transport	O	585-594
to	O	595-597
hospital	O	598-606
.	O	606-607

There	O	608-613
are	O	614-617
very	O	618-622
few	O	623-626
documented	O	627-637
case	O	638-642
like	O	643-647
this	O	648-652
in	O	653-655
the	O	656-659
prehospital	O	660-671
scientific	O	672-682
literature	O	683-693
.	O	693-694

The	O	695-698
cause	O	699-704
appears	O	705-712
to	O	713-715
be	O	716-718
the	O	719-722
Bezold	O	723-729
-	O	729-730
Jarish	O	730-736
reflex	O	737-743
,	O	743-744
stimulation	O	745-756
of	O	757-759
the	O	760-763
ventricular	O	764-775
walls	O	776-781
which	O	782-787
in	O	788-790
turn	O	791-795
decreases	O	796-805
sympathetic	O	806-817
outflow	O	818-825
from	O	826-830
the	O	831-834
vasomotor	O	835-844
centre	O	845-851
.	O	851-852

Prehospital	O	853-864
care	O	865-869
providers	O	870-879
who	O	880-883
are	O	884-887
managing	O	888-896
any	O	897-900
patient	O	901-908
with	O	909-913
a	O	914-915
syncopal	B	916-924
episode	I	925-932
that	O	933-937
fails	O	938-943
to	O	944-946
recover	O	947-954
within	O	955-961
a	O	962-963
reasonable	O	964-974
time	O	975-979
frame	O	980-985
should	O	986-992
consider	O	993-1001
the	O	1002-1005
Bezold	O	1006-1012
-	O	1012-1013
Jarisch	O	1013-1020
reflex	O	1021-1027
as	O	1028-1030
the	O	1031-1034
cause	O	1035-1040
and	O	1041-1044
manage	O	1045-1051
the	O	1052-1055
patient	O	1056-1063
accordingly	O	1064-1075
.	O	1075-1076

Acute	B	0-5
encephalopathy	I	6-20
and	O	21-24
cerebral	B	25-33
vasospasm	I	34-43
after	O	44-49
multiagent	O	50-60
chemotherapy	O	61-73
including	O	74-83
PEG	O	84-87
-	O	87-88
asparaginase	O	88-100
and	O	101-104
intrathecal	O	105-116
cytarabine	O	117-127
for	O	128-131
the	O	132-135
treatment	O	136-145
of	O	146-148
acute	B	149-154
lymphoblastic	I	155-168
leukemia	I	169-177
.	O	177-178

A	O	179-180
7	O	181-182
-	O	182-183
year	O	183-187
-	O	182-183
old	O	188-191
girl	O	192-196
with	O	197-201
an	O	202-204
unusual	O	205-212
reaction	O	213-221
to	O	222-224
induction	O	225-234
chemotherapy	O	235-247
for	O	248-251
precursor	O	252-261
B	O	262-263
-	O	263-264
cell	O	264-268
acute	B	269-274
lymphoblastic	I	275-288
leukemia	I	289-297
(	O	298-299
ALL	B	299-302
)	O	302-303
is	O	304-306
described	O	307-316
.	O	316-317

The	O	318-321
patient	O	322-329
developed	O	330-339
acute	B	340-345
encephalopathy	I	346-360
evidenced	O	361-370
by	O	371-373
behavioral	O	374-384
changes	O	385-392
,	O	392-393
aphasia	B	394-401
,	O	401-402
incontinence	B	403-415
,	O	415-416
visual	B	417-423
hallucinations	I	424-438
,	O	438-439
and	O	440-443
right	O	444-449
-	O	449-450
sided	O	450-455
weakness	B	456-464
with	O	465-469
diffuse	O	470-477
cerebral	B	478-486
vasospasm	I	487-496
on	O	497-499
magnetic	O	500-508
resonance	O	509-518
angiography	O	519-530
after	O	531-536
the	O	537-540
administration	O	541-555
of	O	556-558
intrathecal	O	559-570
cytarabine	O	571-581
.	O	581-582

Vincristine	O	583-594
,	O	594-595
dexamethasone	O	596-609
,	O	609-610
and	O	611-614
polyethylene	O	615-627
glycol	O	628-634
-	O	634-635
asparaginase	O	635-647
were	O	648-652
also	O	653-657
administered	O	658-670
before	O	671-677
the	O	678-681
episode	O	682-689
as	O	690-692
part	O	693-697
of	O	698-700
induction	O	701-710
therapy	O	711-718
.	O	718-719

Neurologic	O	720-730
status	O	731-737
returned	O	738-746
to	O	747-749
baseline	O	750-758
within	O	759-765
10	O	766-768
days	O	769-773
of	O	774-776
the	O	777-780
acute	O	781-786
event	O	787-792
,	O	792-793
and	O	794-797
magnetic	O	798-806
resonance	O	807-816
angiography	O	817-828
findings	O	829-837
returned	O	838-846
to	O	847-849
normal	O	850-856
4	O	857-858
months	O	859-865
later	O	866-871
.	O	871-872

Comparison	O	0-10
of	O	11-13
valsartan	O	14-23
/	O	23-24
hydrochlorothiazide	O	24-43
combination	O	44-55
therapy	O	56-63
at	O	64-66
doses	O	67-72
up	O	73-75
to	O	76-78
320	O	79-82
/	O	82-83
25	O	83-85
mg	O	86-88
versus	O	89-95
monotherapy	O	96-107
:	O	107-108
a	O	109-110
double	O	111-117
-	O	117-118
blind	O	118-123
,	O	123-124
placebo	O	125-132
-	O	132-133
controlled	O	133-143
study	O	144-149
followed	O	150-158
by	O	159-161
long	O	162-166
-	O	166-167
term	O	167-171
combination	O	172-183
therapy	O	184-191
in	O	192-194
hypertensive	B	195-207
adults	O	208-214
.	O	214-215

BACKGROUND	O	216-226
:	O	226-227
One	O	228-231
third	O	232-237
of	O	238-240
patients	O	241-249
treated	O	250-257
for	O	258-261
hypertension	B	262-274
attain	O	275-281
adequate	O	282-290
blood	O	291-296
pressure	O	297-305
(	O	306-307
BP	O	307-309
)	O	309-310
control	O	311-318
,	O	318-319
and	O	320-323
multidrug	O	324-333
regimens	O	334-342
are	O	343-346
often	O	347-352
required	O	353-361
.	O	361-362

Given	O	363-368
the	O	369-372
lifelong	O	373-381
nature	O	382-388
of	O	389-391
hypertension	B	392-404
,	O	404-405
there	O	406-411
is	O	412-414
a	O	415-416
need	O	417-421
to	O	422-424
evaluate	O	425-433
the	O	434-437
long	O	438-442
-	O	442-443
term	O	443-447
efficacy	O	448-456
and	O	457-460
tolerability	O	461-473
of	O	474-476
higher	O	477-483
doses	O	484-489
of	O	490-492
combination	O	493-504
anti	O	505-509
-	O	509-510
hypertensive	B	510-522
therapies	O	523-532
.	O	532-533

OBJECTIVE	O	534-543
:	O	543-544
This	O	545-549
study	O	550-555
investigated	O	556-568
the	O	569-572
efficacy	O	573-581
and	O	582-585
tolerability	O	586-598
of	O	599-601
valsartan	O	602-611
(	O	612-613
VAL	O	613-616
)	O	616-617
or	O	618-620
hydrochlorothiazide	O	621-640
(	O	641-642
HCTZ	O	642-646
)	O	646-647
-	O	647-648
monotherapy	O	648-659
and	O	660-663
higher	O	664-670
-	O	670-671
dose	O	671-675
combinations	O	676-688
in	O	689-691
patients	O	692-700
with	O	701-705
essential	B	706-715
hypertension	I	716-728
.	O	728-729

METHODS	O	730-737
:	O	737-738
The	O	739-742
first	O	743-748
part	O	749-753
of	O	754-756
this	O	757-761
study	O	762-767
was	O	768-771
an	O	772-774
8	O	775-776
-	O	776-777
week	O	777-781
,	O	781-782
multicenter	O	783-794
,	O	794-795
randomized	O	796-806
,	O	806-807
double	O	808-814
-	O	814-815
blind	O	815-820
,	O	820-821
placebo	O	822-829
controlled	O	830-840
,	O	840-841
parallel	O	842-850
-	O	850-851
group	O	851-856
trial	O	857-862
.	O	862-863

Patients	O	864-872
with	O	873-877
essential	B	878-887
hypertension	I	888-900
(	O	901-902
mean	O	902-906
sitting	O	907-914
diastolic	O	915-924
BP	O	925-927
[	O	928-929
MSDBP	O	929-934
]	O	934-935
,	O	935-936
>	O	937-938
or	O	939-941
=	O	942-943
95	O	943-945
mm	O	946-948
Hg	O	949-951
and	O	952-955
<	O	956-957
110	O	957-960
mm	O	961-963
Hg	O	964-966
)	O	966-967
were	O	968-972
randomized	O	973-983
to	O	984-986
1	O	987-988
of	O	989-991
8	O	992-993
treatment	O	994-1003
groups	O	1004-1010
:	O	1010-1011
VAL	O	1012-1015
160	O	1016-1019
or	O	1020-1022
320	O	1023-1026
mg	O	1027-1029
;	O	1029-1030
HCTZ	O	1031-1035
12	O	1036-1038
.	O	1038-1039
5	O	1039-1040
or	O	1041-1043
25	O	1044-1046
mg	O	1047-1049
;	O	1049-1050
VAL	O	1051-1054
/	O	1054-1055
HCTZ	O	1055-1059
160	O	1060-1063
/	O	1063-1064
12	O	1064-1066
.	O	1066-1067
5	O	1067-1068
,	O	1068-1069
320	O	1070-1073
/	O	1073-1074
12	O	1074-1076
.	O	1076-1077
5	O	1077-1078
,	O	1078-1079
or	O	1080-1082
320	O	1083-1086
/	O	1086-1087
25	O	1087-1089
mg	O	1090-1092
;	O	1092-1093
or	O	1094-1096
placebo	O	1097-1104
.	O	1104-1105

Mean	O	1106-1110
changes	O	1111-1118
in	O	1119-1121
MSDBP	O	1122-1127
and	O	1128-1131
mean	O	1132-1136
sitting	O	1137-1144
systolic	O	1145-1153
BP	O	1154-1156
(	O	1157-1158
MSSBP	O	1158-1163
)	O	1163-1164
were	O	1165-1169
analyzed	O	1170-1178
at	O	1179-1181
the	O	1182-1185
8	O	1186-1187
-	O	1187-1188
week	O	1188-1192
core	O	1193-1197
study	O	1198-1203
end	O	1204-1207
point	O	1208-1213
.	O	1213-1214

VAL	O	1215-1218
/	O	1218-1219
HCTZ	O	1219-1223
320	O	1224-1227
/	O	1227-1228
12	O	1228-1230
.	O	1230-1231
5	O	1231-1232
and	O	1233-1236
320	O	1237-1240
/	O	1240-1241
25	O	1241-1243
mg	O	1244-1246
were	O	1247-1251
further	O	1252-1259
investigated	O	1260-1272
in	O	1273-1275
a	O	1276-1277
54	O	1278-1280
-	O	1280-1281
week	O	1281-1285
,	O	1285-1286
open	O	1287-1291
-	O	1291-1292
label	O	1292-1297
extension	O	1298-1307
.	O	1307-1308

Response	O	1309-1317
was	O	1318-1321
defined	O	1322-1329
as	O	1330-1332
MSDBP	O	1333-1338
<	O	1339-1340
90	O	1340-1342
mm	O	1343-1345
Hg	O	1346-1348
or	O	1349-1351
a	O	1352-1353
>	O	1354-1355
or	O	1356-1358
=	O	1359-1360
10	O	1360-1362
mm	O	1363-1365
Hg	O	1366-1368
decrease	O	1369-1377
compared	O	1378-1386
to	O	1387-1389
baseline	O	1390-1398
.	O	1398-1399

Control	O	1400-1407
was	O	1408-1411
defined	O	1412-1419
as	O	1420-1422
MSDBP	O	1423-1428
<	O	1429-1430
90	O	1430-1432
mm	O	1433-1435
Hg	O	1436-1438
compared	O	1439-1447
with	O	1448-1452
baseline	O	1453-1461
.	O	1461-1462

Tolerability	O	1463-1475
was	O	1476-1479
assessed	O	1480-1488
by	O	1489-1491
monitoring	O	1492-1502
adverse	O	1503-1510
events	O	1511-1517
at	O	1518-1520
randomization	O	1521-1534
and	O	1535-1538
all	O	1539-1542
subsequent	O	1543-1553
study	O	1554-1559
visits	O	1560-1566
and	O	1567-1570
regular	O	1571-1578
evaluation	O	1579-1589
of	O	1590-1592
hematology	O	1593-1603
and	O	1604-1607
blood	O	1608-1613
chemistry	O	1614-1623
.	O	1623-1624

RESULTS	O	1625-1632
:	O	1632-1633
A	O	1634-1635
total	O	1636-1641
of	O	1642-1644
1346	O	1645-1649
patients	O	1650-1658
were	O	1659-1663
randomized	O	1664-1674
into	O	1675-1679
the	O	1680-1683
8	O	1684-1685
-	O	1685-1686
week	O	1686-1690
core	O	1691-1695
study	O	1696-1701
(	O	1702-1703
734	O	1703-1706
men	O	1707-1710
,	O	1710-1711
612	O	1712-1715
women	O	1716-1721
;	O	1721-1722
924	O	1723-1726
white	O	1727-1732
,	O	1732-1733
291	O	1734-1737
black	O	1738-1743
,	O	1743-1744
23	O	1745-1747
Asian	O	1748-1753
,	O	1753-1754
108	O	1755-1758
other	O	1759-1764
;	O	1764-1765
mean	O	1766-1770
age	O	1771-1774
,	O	1774-1775
52	O	1776-1778
.	O	1778-1779
7	O	1779-1780
years	O	1781-1786
;	O	1786-1787
mean	O	1788-1792
weight	O	1793-1799
,	O	1799-1800
92	O	1801-1803
.	O	1803-1804
6	O	1804-1805
kg	O	1806-1808
)	O	1808-1809
.	O	1809-1810

All	O	1811-1814
active	O	1815-1821
treatments	O	1822-1832
were	O	1833-1837
associated	O	1838-1848
with	O	1849-1853
significantly	O	1854-1867
reduced	O	1868-1875
MSSBP	O	1876-1881
and	O	1882-1885
MSDBP	O	1886-1891
during	O	1892-1898
the	O	1899-1902
core	O	1903-1907
8	O	1908-1909
-	O	1909-1910
week	O	1910-1914
study	O	1915-1920
,	O	1920-1921
with	O	1922-1926
each	O	1927-1931
monotherapy	O	1932-1943
significantly	O	1944-1957
contributing	O	1958-1970
to	O	1971-1973
the	O	1974-1977
overall	O	1978-1985
effect	O	1986-1992
of	O	1993-1995
combination	O	1996-2007
therapy	O	2008-2015
(	O	2016-2017
VAL	O	2017-2020
and	O	2021-2024
HCTZ	O	2025-2029
,	O	2029-2030
P	O	2031-2032
<	O	2033-2034
0	O	2035-2036
.	O	2036-2037
001	O	2037-2040
)	O	2040-2041
.	O	2036-2037

Each	O	2043-2047
combination	O	2048-2059
was	O	2060-2063
associated	O	2064-2074
with	O	2075-2079
significantly	O	2080-2093
greater	O	2094-2101
reductions	O	2102-2112
in	O	2113-2115
MSSBP	O	2116-2121
and	O	2122-2125
MSDBP	O	2126-2131
compared	O	2132-2140
with	O	2141-2145
the	O	2146-2149
monotherapies	O	2150-2163
and	O	2164-2167
placebo	O	2168-2175
(	O	2176-2177
all	O	2177-2180
,	O	2180-2181
P	O	2182-2183
<	O	2184-2185
0	O	2186-2187
.	O	2187-2188
001	O	2188-2191
)	O	2191-2192
.	O	2187-2188

The	O	2194-2197
mean	O	2198-2202
reduction	O	2203-2212
in	O	2213-2215
MSSBP	O	2216-2221
/	O	2221-2222
MSDBP	O	2222-2227
with	O	2228-2232
VAL	O	2233-2236
/	O	2236-2237
HCTZ	O	2237-2241
320	O	2242-2245
/	O	2245-2246
25	O	2246-2248
mg	O	2249-2251
was	O	2252-2255
24	O	2256-2258
.	O	2258-2259
7	O	2259-2260
/	O	2260-2261
16	O	2261-2263
.	O	2258-2259
6	O	2262-2263

mm	O	2266-2268
Hg	O	2269-2271
,	O	2271-2272
compared	O	2273-2281
with	O	2282-2286
5	O	2287-2288
.	O	2288-2289
9	O	2289-2290
/	O	2290-2291
7	O	2291-2292
.	O	2288-2289
0	O	2293-2294
mm	O	2295-2297
Hg	O	2298-2300
with	O	2301-2305
placebo	O	2306-2313
.	O	2313-2314

The	O	2315-2318
reduction	O	2319-2328
in	O	2329-2331
MSSBP	O	2332-2337
was	O	2338-2341
significantly	O	2342-2355
greater	O	2356-2363
with	O	2364-2368
VAL	O	2369-2372
/	O	2372-2373
HCTZ	O	2373-2377
320	O	2378-2381
/	O	2381-2382
25	O	2382-2384
mg	O	2385-2387
compared	O	2388-2396
with	O	2397-2401
VAL	O	2402-2405
/	O	2405-2406
HCTZ	O	2406-2410
160	O	2411-2414
/	O	2414-2415
12	O	2415-2417
.	O	2417-2418
5	O	2418-2419
mg	O	2420-2422
(	O	2423-2424
P	O	2424-2425
<	O	2426-2427
0	O	2428-2429
.	O	2429-2430
002	O	2430-2433
)	O	2433-2434
.	O	2429-2430

Rates	O	2436-2441
of	O	2442-2444
response	O	2445-2453
and	O	2454-2457
BP	O	2458-2460
control	O	2461-2468
were	O	2469-2473
significantly	O	2474-2487
higher	O	2488-2494
in	O	2495-2497
the	O	2498-2501
groups	O	2502-2508
that	O	2509-2513
received	O	2514-2522
combination	O	2523-2534
treatment	O	2535-2544
compared	O	2545-2553
with	O	2554-2558
those	O	2559-2564
that	O	2565-2569
received	O	2570-2578
monotherapy	O	2579-2590
.	O	2590-2591

The	O	2592-2595
incidence	O	2596-2605
of	O	2606-2608
hypokalemia	B	2609-2620
was	O	2621-2624
lower	O	2625-2630
with	O	2631-2635
VAL	O	2636-2639
/	O	2639-2640
HCTZ	O	2640-2644
combinations	O	2645-2657
(	O	2658-2659
1	O	2659-2660
.	O	2660-2661
8	O	2661-2662
%	O	2662-2663
-	O	2663-2664
6	O	2664-2665
.	O	2660-2661
1	O	2659-2660
%	O	2662-2663
)	O	2668-2669

than	O	2670-2674
with	O	2675-2679
HCTZ	O	2680-2684
monotherapies	O	2685-2698
(	O	2699-2700
7	O	2700-2701
.	O	2701-2702
1	O	2702-2703
%	O	2703-2704
-	O	2704-2705
13	O	2705-2707
.	O	2701-2702
3	O	2706-2707
%	O	2703-2704
)	O	2710-2711
.	O	2701-2702

The	O	2713-2716
majority	O	2717-2725
of	O	2726-2728
adverse	O	2729-2736
events	O	2737-2743
in	O	2744-2746
the	O	2747-2750
core	O	2751-2755
study	O	2756-2761
were	O	2762-2766
of	O	2767-2769
mild	O	2770-2774
to	O	2775-2777
moderate	O	2778-2786
severity	O	2787-2795
.	O	2795-2796

The	O	2797-2800
efficacy	O	2801-2809
and	O	2810-2813
tolerability	O	2814-2826
of	O	2827-2829
VAL	O	2830-2833
/	O	2833-2834
HCTZ	O	2834-2838
combinations	O	2839-2851
were	O	2852-2856
maintained	O	2857-2867
during	O	2868-2874
the	O	2875-2878
extension	O	2879-2888
(	O	2889-2890
797	O	2890-2893
patients	O	2894-2902
)	O	2902-2903
.	O	2903-2904

CONCLUSIONS	O	2905-2916
:	O	2916-2917
In	O	2918-2920
this	O	2921-2925
study	O	2926-2931
population	O	2932-2942
,	O	2942-2943
combination	O	2944-2955
therapies	O	2956-2965
with	O	2966-2970
VAL	O	2971-2974
/	O	2974-2975
HCTZ	O	2975-2979
were	O	2980-2984
associated	O	2985-2995
with	O	2996-3000
significantly	O	3001-3014
greater	O	3015-3022
BP	O	3023-3025
reductions	O	3026-3036
compared	O	3037-3045
with	O	3046-3050
either	O	3051-3057
monotherapy	O	3058-3069
,	O	3069-3070
were	O	3071-3075
well	O	3076-3080
tolerated	O	3081-3090
,	O	3090-3091
and	O	3092-3095
were	O	3096-3100
associated	O	3101-3111
with	O	3112-3116
less	O	3117-3121
hypokalemia	B	3122-3133
than	O	3134-3138
HCTZ	O	3139-3143
alone	O	3144-3149
.	O	3149-3150

Succimer	O	0-8
chelation	O	9-18
improves	O	19-27
learning	O	28-36
,	O	36-37
attention	O	38-47
,	O	47-48
and	O	49-52
arousal	O	53-60
regulation	O	61-71
in	O	72-74
lead	O	75-79
-	O	79-80
exposed	O	80-87
rats	O	88-92
but	O	93-96
produces	O	97-105
lasting	O	106-113
cognitive	B	114-123
impairment	I	124-134
in	O	135-137
the	O	138-141
absence	O	142-149
of	O	150-152
lead	O	153-157
exposure	O	158-166
.	O	166-167

BACKGROUND	O	168-178
:	O	178-179
There	O	180-185
is	O	186-188
growing	O	189-196
pressure	O	197-205
for	O	206-209
clinicians	O	210-220
to	O	221-223
prescribe	O	224-233
chelation	O	234-243
therapy	O	244-251
at	O	252-254
only	O	255-259
slightly	O	260-268
elevated	O	269-277
blood	O	278-283
lead	O	284-288
levels	O	289-295
.	O	295-296

However	O	297-304
,	O	304-305
very	O	306-310
few	O	311-314
studies	O	315-322
have	O	323-327
evaluated	O	328-337
whether	O	338-345
chelation	O	346-355
improves	O	356-364
cognitive	O	365-374
outcomes	O	375-383
in	O	384-386
Pb	O	387-389
-	O	389-390
exposed	O	390-397
children	O	398-406
,	O	406-407
or	O	408-410
whether	O	411-418
these	O	419-424
agents	O	425-431
have	O	432-436
adverse	O	437-444
effects	O	445-452
that	O	453-457
may	O	458-461
affect	O	462-468
brain	O	469-474
development	O	475-486
in	O	487-489
the	O	490-493
absence	O	494-501
of	O	502-504
Pb	O	505-507
exposure	O	508-516
.	O	516-517

OBJECTIVES	O	518-528
:	O	528-529
The	O	530-533
present	O	534-541
study	O	542-547
was	O	548-551
designed	O	552-560
to	O	561-563
answer	O	564-570
these	O	571-576
questions	O	577-586
,	O	586-587
using	O	588-593
a	O	594-595
rodent	O	596-602
model	O	603-608
of	O	609-611
early	O	612-617
childhood	O	618-627
Pb	O	628-630
exposure	O	631-639
and	O	640-643
treatment	O	644-653
with	O	654-658
succimer	O	659-667
,	O	667-668
a	O	669-670
widely	O	671-677
used	O	678-682
chelating	O	683-692
agent	O	693-698
for	O	699-702
the	O	703-706
treatment	O	707-716
of	O	717-719
Pb	B	720-722
poisoning	I	723-732
.	O	732-733

RESULTS	O	734-741
:	O	741-742
Pb	O	743-745
exposure	O	746-754
produced	O	755-763
lasting	O	764-771
impairments	B	772-783
in	I	784-786
learning	I	787-795
,	I	795-796
attention	I	797-806
,	I	806-807
inhibitory	I	808-818
control	I	819-826
,	I	826-827
and	I	828-831
arousal	I	832-839
regulation	I	840-850
,	O	850-851
paralleling	O	852-863
the	O	864-867
areas	O	868-873
of	O	874-876
dysfunction	O	877-888
seen	O	889-893
in	O	894-896
Pb	O	897-899
-	O	899-900
exposed	O	900-907
children	O	908-916
.	O	916-917

Succimer	O	918-926
treatment	O	927-936
of	O	937-939
the	O	940-943
Pb	O	944-946
-	O	946-947
exposed	O	947-954
rats	O	955-959
significantly	O	960-973
improved	O	974-982
learning	O	983-991
,	O	991-992
attention	O	993-1002
,	O	1002-1003
and	O	1004-1007
arousal	O	1008-1015
regulation	O	1016-1026
,	O	1026-1027
although	O	1028-1036
the	O	1037-1040
efficacy	O	1041-1049
of	O	1050-1052
the	O	1053-1056
treatment	O	1057-1066
varied	O	1067-1073
as	O	1074-1076
a	O	1077-1078
function	O	1079-1087
of	O	1088-1090
the	O	1091-1094
Pb	O	1095-1097
exposure	O	1098-1106
level	O	1107-1112
and	O	1113-1116
the	O	1117-1120
specific	O	1121-1129
functional	O	1130-1140
deficit	O	1141-1148
.	O	1148-1149

In	O	1150-1152
contrast	O	1153-1161
,	O	1161-1162
succimer	O	1163-1171
treatment	O	1172-1181
of	O	1182-1184
rats	O	1185-1189
not	O	1190-1193
previously	O	1194-1204
exposed	O	1205-1212
to	O	1213-1215
Pb	O	1216-1218
produced	O	1219-1227
lasting	O	1228-1235
and	O	1236-1239
pervasive	O	1240-1249
cognitive	B	1250-1259
and	I	1260-1263
affective	I	1264-1273
dysfunction	I	1274-1285
comparable	O	1286-1296
in	O	1297-1299
magnitude	O	1300-1309
to	O	1310-1312
that	O	1313-1317
produced	O	1318-1326
by	O	1327-1329
the	O	1330-1333
higher	O	1334-1340
Pb	O	1341-1343
exposure	O	1344-1352
regimen	O	1353-1360
.	O	1360-1361

CONCLUSIONS	O	1362-1373
:	O	1373-1374
These	O	1375-1380
are	O	1381-1384
the	O	1385-1388
first	O	1389-1394
data	O	1395-1399
,	O	1399-1400
to	O	1401-1403
our	O	1404-1407
knowledge	O	1408-1417
,	O	1417-1418
to	O	1419-1421
show	O	1422-1426
that	O	1427-1431
treatment	O	1432-1441
with	O	1442-1446
any	O	1447-1450
chelating	O	1451-1460
agent	O	1461-1466
can	O	1467-1470
alleviate	O	1471-1480
cognitive	B	1481-1490
deficits	I	1491-1499
due	O	1500-1503
to	O	1504-1506
Pb	O	1507-1509
exposure	O	1510-1518
.	O	1518-1519

These	O	1520-1525
findings	O	1526-1534
suggest	O	1535-1542
that	O	1543-1547
it	O	1548-1550
may	O	1551-1554
be	O	1555-1557
possible	O	1558-1566
to	O	1567-1569
identify	O	1570-1578
a	O	1579-1580
succimer	O	1581-1589
treatment	O	1590-1599
protocol	O	1600-1608
that	O	1609-1613
improves	O	1614-1622
cognitive	O	1623-1632
outcomes	O	1633-1641
in	O	1642-1644
Pb	O	1645-1647
-	O	1647-1648
exposed	O	1648-1655
children	O	1656-1664
.	O	1664-1665

However	O	1666-1673
,	O	1673-1674
they	O	1675-1679
also	O	1680-1684
suggest	O	1685-1692
that	O	1693-1697
succimer	O	1698-1706
treatment	O	1707-1716
should	O	1717-1723
be	O	1724-1726
strongly	O	1727-1735
discouraged	O	1736-1747
for	O	1748-1751
children	O	1752-1760
who	O	1761-1764
do	O	1765-1767
not	O	1768-1771
have	O	1772-1776
elevated	O	1777-1785
tissue	O	1786-1792
levels	O	1793-1799
of	O	1800-1802
Pb	O	1803-1805
or	O	1806-1808
other	O	1809-1814
heavy	O	1815-1820
metals	O	1821-1827
.	O	1827-1828

Caffeine	O	0-8
challenge	O	9-18
test	O	19-23
in	O	24-26
panic	B	27-32
disorder	I	33-41
and	O	42-45
depression	B	46-56
with	O	57-61
panic	B	62-67
attacks	I	68-75
.	O	75-76

Our	O	77-80
aim	O	81-84
was	O	85-88
to	O	89-91
observe	O	92-99
if	O	100-102
patients	O	103-111
with	O	112-116
panic	B	117-122
disorder	I	123-131
(	O	132-133
PD	B	133-135
)	O	135-136
and	O	137-140
patients	O	141-149
with	O	150-154
major	B	155-160
depression	I	161-171
with	O	172-176
panic	B	177-182
attacks	I	183-190
(	O	191-192
MDP	B	192-195
)	O	195-196
(	O	197-198
Diagnostic	O	198-208
and	O	209-212
Statistical	O	213-224
Manual	O	225-231
of	O	232-234
Mental	B	235-241
Disorders	I	242-251
,	O	251-252
Fourth	O	253-259
Edition	O	260-267
criteria	O	268-276
)	O	276-277
respond	O	278-285
in	O	286-288
a	O	289-290
similar	O	291-298
way	O	299-302
to	O	303-305
the	O	306-309
induction	O	310-319
of	O	320-322
panic	B	323-328
attacks	I	329-336
by	O	337-339
an	O	340-342
oral	O	343-347
caffeine	O	348-356
challenge	O	357-366
test	O	367-371
.	O	371-372

We	O	373-375
randomly	O	376-384
selected	O	385-393
29	O	394-396
patients	O	397-405
with	O	406-410
PD	B	411-413
,	O	413-414
27	O	415-417
with	O	418-422
MDP	B	423-426
,	O	426-427
25	O	428-430
with	O	431-435
major	B	436-441
depression	I	442-452
without	O	453-460
panic	B	461-466
attacks	I	467-474
(	O	475-476
MD	B	476-478
)	O	478-479
,	O	479-480
and	O	481-484
28	O	485-487
healthy	O	488-495
volunteers	O	496-506
.	O	506-507

The	O	508-511
patients	O	512-520
had	O	521-524
no	O	525-527
psychotropic	O	528-540
drug	O	541-545
for	O	546-549
at	O	550-552
least	O	553-558
a	O	559-560
4	O	561-562
-	O	562-563
week	O	563-567
period	O	568-574
.	O	574-575

In	O	576-578
a	O	579-580
randomized	O	581-591
double	O	592-598
-	O	598-599
blind	O	599-604
experiment	O	605-615
performed	O	616-625
in	O	626-628
2	O	629-630
occasions	O	631-640
7	O	641-642
days	O	643-647
apart	O	648-653
,	O	653-654
480	O	655-658
mg	O	659-661
caffeine	O	662-670
and	O	671-674
a	O	675-676
caffeine	O	677-685
-	O	685-686
free	O	686-690
(	O	691-692
placebo	O	692-699
)	O	699-700
solution	O	701-709
were	O	710-714
administered	O	715-727
in	O	728-730
a	O	731-732
coffee	O	733-739
form	O	740-744
and	O	745-748
anxiety	B	749-756
scales	O	757-763
were	O	764-768
applied	O	769-776
before	O	777-783
and	O	784-787
after	O	788-793
each	O	794-798
test	O	799-803
.	O	803-804

A	O	805-806
total	O	807-812
of	O	813-815
58	O	816-818
.	O	818-819
6	O	819-820
%	O	820-821
(	O	822-823
n	O	823-824
=	O	825-826
17	O	827-829
)	O	829-830
of	O	831-833
patients	O	834-842
with	O	843-847
PD	B	848-850
,	O	850-851
44	O	852-854
.	O	854-855
4	O	852-853
%	O	856-857
(	O	858-859
n	O	859-860
=	O	861-862
12	O	863-865
)	O	865-866
of	O	867-869
patients	O	870-878
with	O	879-883
MDP	B	884-887
,	O	887-888
12	O	889-891
.	O	891-892
0	O	892-893
%	O	893-894
(	O	895-896
n	O	896-897
=	O	898-899
3	O	900-901
)	O	901-902
of	O	903-905
patients	O	906-914
with	O	915-919
MD	B	920-922
,	O	922-923
and	O	924-927
7	O	928-929
.	O	929-930
1	O	930-931
%	O	931-932
(	O	933-934
n	O	934-935
=	O	935-936
2	O	937-938
)	O	938-939
of	O	940-942
control	O	943-950
subjects	O	951-959
had	O	960-963
a	O	964-965
panic	B	966-971
attack	I	972-978
after	O	979-984
the	O	985-988
480	O	989-992
-	O	992-993
mg	O	993-995
caffeine	O	996-1004
challenge	O	1005-1014
test	O	1015-1019
(	O	1020-1021
chi	O	1021-1024
(	O	1020-1021
2	O	1025-1026
)	O	1026-1027
(	O	1020-1021
3	O	1028-1029
)	O	1026-1027
=	O	1031-1032
16	O	1033-1035
.	O	1035-1036
22	O	1036-1038
,	O	1038-1039

P	O	1040-1041
=	O	1042-1043
.	O	1044-1045
001	O	1045-1048
)	O	1048-1049
.	O	1044-1045

The	O	1051-1054
patients	O	1055-1063
with	O	1064-1068
PD	B	1069-1071
and	O	1072-1075
MDP	B	1076-1079
were	O	1080-1084
more	O	1085-1089
sensitive	O	1090-1099
to	O	1100-1102
caffeine	O	1103-1111
than	O	1112-1116
were	O	1117-1121
patients	O	1122-1130
with	O	1131-1135
MD	B	1136-1138
and	O	1139-1142
healthy	O	1143-1150
volunteers	O	1151-1161
.	O	1161-1162

No	O	1163-1165
panic	B	1166-1171
attack	I	1172-1178
was	O	1179-1182
observed	O	1183-1191
after	O	1192-1197
the	O	1198-1201
caffeine	O	1202-1210
-	O	1210-1211
free	O	1211-1215
solution	O	1216-1224
intake	O	1225-1231
.	O	1231-1232

The	O	1233-1236
patients	O	1237-1245
with	O	1246-1250
MD	B	1251-1253
had	O	1254-1257
a	O	1258-1259
lower	O	1260-1265
heart	O	1266-1271
rate	O	1272-1276
response	O	1277-1285
to	O	1286-1288
the	O	1289-1292
test	O	1293-1297
than	O	1298-1302
all	O	1303-1306
the	O	1307-1310
other	O	1311-1316
groups	O	1317-1323
(	O	1324-1325
2	O	1325-1326
-	O	1326-1327
way	O	1327-1330
analysis	O	1331-1339
of	O	1340-1342
variance	O	1343-1351
,	O	1351-1352
group	O	1353-1358
by	O	1359-1361
time	O	1362-1366
interaction	O	1367-1378
with	O	1379-1383
Greenhouse	O	1384-1394
-	O	1394-1395
Geisser	O	1395-1402
correction	O	1403-1413
:	O	1413-1414
F	O	1415-1416
(	O	1416-1417
3	O	1417-1418
,	O	1418-1419
762	O	1419-1422
)	O	1422-1423
=	O	1424-1425
2	O	1426-1427
.	O	1427-1428
85	O	1428-1430
,	O	1430-1431
P	O	1432-1433
=	O	1434-1435
.	O	1436-1437
026	O	1437-1440
)	O	1440-1441
.	O	1436-1437

Our	O	1443-1446
data	O	1447-1451
suggest	O	1452-1459
that	O	1460-1464
there	O	1465-1470
is	O	1471-1473
an	O	1474-1476
association	O	1477-1488
between	O	1489-1496
panic	B	1497-1502
attacks	I	1503-1510
,	O	1510-1511
no	O	1512-1514
matter	O	1515-1521
if	O	1522-1524
associated	O	1525-1535
with	O	1536-1540
PD	B	1541-1543
or	O	1544-1546
MDP	B	1547-1550
,	O	1550-1551
and	O	1552-1555
hyperreactivity	O	1556-1571
to	O	1572-1574
an	O	1575-1577
oral	O	1578-1582
caffeine	O	1583-1591
challenge	O	1592-1601
test	O	1602-1606
.	O	1606-1607

Mitral	O	0-6
annuloplasty	O	7-19
as	O	20-22
a	O	23-24
ventricular	O	25-36
restoration	O	37-48
method	O	49-55
for	O	56-59
the	O	60-63
failing	B	64-71
left	I	72-76
ventricle	I	77-86
:	O	86-87
a	O	88-89
pilot	O	90-95
study	O	96-101
.	O	101-102

BACKGROUND	O	103-113
AND	O	114-117
AIM	O	118-121
OF	O	122-124
THE	O	125-128
STUDY	O	129-134
:	O	134-135
Undersized	O	136-146
mitral	O	147-153
annuloplasty	O	154-166
(	O	167-168
MAP	O	168-171
)	O	171-172
is	O	173-175
effective	O	176-185
in	O	186-188
patients	O	189-197
with	O	198-202
dilated	B	203-210
cardiomyopathy	I	211-225
and	O	226-229
functional	O	230-240
mitral	B	241-247
regurgitation	I	248-261
(	O	262-263
MR	B	263-265
)	O	265-266
since	O	267-272
,	O	272-273
as	O	274-276
well	O	277-281
as	O	282-284
addressing	O	285-295
the	O	296-299
MR	B	300-302
,	O	302-303
the	O	304-307
MAP	O	308-311
may	O	312-315
also	O	316-320
reshape	O	321-328
the	O	329-332
dilated	O	333-340
left	O	341-345
ventricular	O	346-357
(	O	358-359
LV	O	359-361
)	O	361-362
base	O	363-367
.	O	367-368

However	O	369-376
,	O	376-377
the	O	378-381
direct	O	382-388
benefits	O	389-397
of	O	398-400
this	O	401-405
possible	O	406-414
reshaping	O	415-424
on	O	425-427
LV	O	428-430
function	O	431-439
in	O	440-442
the	O	443-446
absence	O	447-454
of	O	455-457
underlying	O	458-468
MR	B	469-471
remain	O	472-478
incompletely	O	479-491
understood	O	492-502
.	O	502-503

The	O	504-507
study	O	508-513
aim	O	514-517
was	O	518-521
to	O	522-524
identify	O	525-533
these	O	534-539
benefits	O	540-548
in	O	549-551
a	O	552-553
canine	O	554-560
model	O	561-566
of	O	567-569
acute	O	570-575
heart	B	576-581
failure	I	582-589
.	O	589-590

METHODS	O	591-598
:	O	598-599
Six	O	600-603
dogs	O	604-608
underwent	O	609-618
MAP	O	619-622
with	O	623-627
a	O	628-629
prosthetic	O	630-640
band	O	641-645
on	O	646-648
the	O	649-652
posterior	O	653-662
mitral	O	663-669
annulus	O	670-677
,	O	677-678
using	O	679-684
four	O	685-689
mattress	O	690-698
sutures	O	699-706
.	O	706-707

The	O	708-711
sutures	O	712-719
were	O	720-724
passed	O	725-731
individually	O	732-744
through	O	745-752
four	O	753-757
tourniquets	O	758-769
and	O	770-773
exteriorized	O	774-786
untied	O	787-793
via	O	794-797
the	O	798-801
left	O	802-806
atriotomy	O	807-816
.	O	816-817

Sonomicrometry	O	818-832
crystals	O	833-841
were	O	842-846
implanted	O	847-856
around	O	857-863
the	O	864-867
mitral	O	868-874
annulus	O	875-882
and	O	883-886
left	O	887-891
ventricle	O	892-901
to	O	902-904
measure	O	905-912
geometry	O	913-921
and	O	922-925
regional	O	926-934
function	O	935-943
.	O	943-944

Acute	O	945-950
heart	B	951-956
failure	I	957-964
was	O	965-968
induced	O	969-976
by	O	977-979
propranolol	O	980-991
and	O	992-995
volume	O	996-1002
loading	O	1003-1010
after	O	1011-1016
weaning	O	1017-1024
from	O	1025-1029
cardiopulmonary	O	1030-1045
bypass	O	1046-1052
;	O	1052-1053
an	O	1054-1056
absence	O	1057-1064
of	O	1065-1067
MR	B	1068-1070
was	O	1071-1074
confirmed	O	1075-1084
by	O	1085-1087
echocardiography	O	1088-1104
.	O	1104-1105

MAP	O	1106-1109
was	O	1110-1113
accomplished	O	1114-1126
by	O	1127-1129
cinching	O	1130-1138
the	O	1139-1142
tourniquets	O	1143-1154
.	O	1154-1155

Data	O	1156-1160
were	O	1161-1165
acquired	O	1166-1174
at	O	1175-1177
baseline	O	1178-1186
,	O	1186-1187
after	O	1188-1193
induction	O	1194-1203
of	O	1204-1206
acute	O	1207-1212
heart	B	1213-1218
failure	I	1219-1226
,	O	1226-1227
and	O	1228-1231
after	O	1232-1237
MAP	O	1238-1241
.	O	1241-1242

RESULTS	O	1243-1250
:	O	1250-1251
MAP	O	1252-1255
decreased	O	1256-1265
mitral	O	1266-1272
annular	O	1273-1280
dimensions	O	1281-1291
in	O	1292-1294
both	O	1295-1299
commissure	O	1300-1310
-	O	1310-1311
commissure	O	1300-1310
and	O	1322-1325
septal	O	1326-1332
-	O	1332-1333
lateral	O	1333-1340
directions	O	1341-1351
.	O	1351-1352

Concomitantly	O	1353-1366
,	O	1366-1367
the	O	1368-1371
diastolic	O	1372-1381
diameter	O	1382-1390
of	O	1391-1393
the	O	1394-1397
LV	O	1398-1400
base	O	1401-1405
and	O	1406-1409
LV	O	1410-1412
sphericity	O	1413-1423
decreased	O	1424-1433
(	O	1434-1435
i	O	1435-1436
.	O	1436-1437
e	O	1437-1438
.	O	1436-1437
,	O	1439-1440
improved	O	1441-1449
)	O	1449-1450
from	O	1451-1455
37	O	1456-1458
.	O	1458-1459
4	O	1459-1460
+	O	1461-1462
/	O	1462-1463
-	O	1463-1464
9	O	1465-1466
.	O	1466-1467
3	O	1467-1468
to	O	1469-1471
35	O	1472-1474
.	O	1474-1475
9	O	1475-1476
+	O	1477-1478
/	O	1478-1479
-	O	1479-1480
10	O	1481-1483
mm	O	1484-1486
(	O	1487-1488
p	O	1488-1489
=	O	1490-1491
0	O	1492-1493
.	O	1493-1494
063	O	1494-1497
)	O	1497-1498
,	O	1498-1499
and	O	1500-1503
from	O	1504-1508
67	O	1509-1511
.	O	1511-1512
9	O	1512-1513
+	O	1514-1515
/	O	1515-1516
-	O	1516-1517
18	O	1518-1520
.	O	1520-1521
6	O	1521-1522
%	O	1522-1523
to	O	1524-1526
65	O	1527-1529
.	O	1529-1530
3	O	1530-1531
+	O	1532-1533
/	O	1533-1534
-	O	1534-1535
18	O	1536-1538
.	O	1538-1539
9	O	1539-1540
%	O	1540-1541
(	O	1542-1543
p	O	1543-1544
=	O	1545-1546
0	O	1547-1548
.	O	1548-1549
016	O	1549-1552
)	O	1552-1553
,	O	1553-1554
respectively	O	1555-1567
.	O	1567-1568

Decreases	O	1569-1578
were	O	1579-1583
evident	O	1584-1591
in	O	1592-1594
both	O	1595-1599
LV	O	1600-1602
end	O	1603-1606
-	O	1606-1607
diastolic	O	1607-1616
pressure	O	1617-1625
(	O	1626-1627
from	O	1627-1631
17	O	1632-1634
+	O	1635-1636
/	O	1636-1637
-	O	1637-1638
7	O	1639-1640
to	O	1641-1643
15	O	1644-1646
+	O	1647-1648
/	O	1648-1649
-	O	1649-1650
6	O	1651-1652
mmHg	O	1653-1657
,	O	1657-1658
p	O	1659-1660
=	O	1661-1662
0	O	1663-1664
.	O	1664-1665
0480	O	1665-1669
and	O	1670-1673
Tau	O	1674-1677
(	O	1678-1679
from	O	1679-1683
48	O	1684-1686
+	O	1687-1688
/	O	1688-1689
-	O	1689-1690
8	O	1691-1692
to	O	1693-1695
45	O	1696-1698
+	O	1699-1700
/	O	1700-1701
-	O	1701-1702
8	O	1703-1704
ms	O	1705-1707
,	O	1707-1708
p	O	1709-1710
<	O	1711-1712
0	O	1712-1713
.	O	1713-1714
01	O	1714-1716
)	O	1716-1717
,	O	1717-1718
while	O	1719-1724
fractional	O	1725-1735
shortening	O	1736-1746
at	O	1747-1749
the	O	1750-1753
LV	O	1754-1756
base	O	1757-1761
increased	O	1762-1771
from	O	1772-1776
7	O	1777-1778
.	O	1778-1779
7	O	1777-1778
+	O	1781-1782
/	O	1782-1783
-	O	1783-1784
4	O	1785-1786
.	O	1786-1787
5	O	1787-1788
%	O	1788-1789
to	O	1790-1792
9	O	1793-1794
.	O	1794-1795
4	O	1795-1796
+	O	1797-1798
/	O	1798-1799
-	O	1799-1800
4	O	1801-1802
.	O	1802-1803
5	O	1803-1804
%	O	1804-1805
(	O	1806-1807
p	O	1807-1808
=	O	1809-1810
0	O	1811-1812
.	O	1812-1813
045	O	1813-1816
)	O	1816-1817
.	O	1812-1813

After	O	1819-1824
MAP	O	1825-1828
,	O	1828-1829
increases	O	1830-1839
were	O	1840-1844
identified	O	1845-1855
in	O	1856-1858
both	O	1859-1863
cardiac	O	1864-1871
output	O	1872-1878
(	O	1879-1880
from	O	1880-1884
1	O	1885-1886
.	O	1886-1887
54	O	1887-1889
+	O	1890-1891
/	O	1891-1892
-	O	1892-1893
0	O	1894-1895
.	O	1895-1896
57	O	1896-1898
to	O	1899-1901
1	O	1902-1903
.	O	1903-1904
65	O	1904-1906
+	O	1907-1908
/	O	1908-1909
-	O	1909-1910
0	O	1911-1912
.	O	1912-1913
57	O	1913-1915
1	O	1916-1917
/	O	1917-1918
min	O	1918-1921
)	O	1921-1922
and	O	1923-1926
Emax	O	1927-1931
(	O	1932-1933
from	O	1933-1937
1	O	1938-1939
.	O	1939-1940
86	O	1940-1942
+	O	1943-1944
/	O	1944-1945
-	O	1945-1946
0	O	1947-1948
.	O	1948-1949
9	O	1949-1950
to	O	1951-1953
2	O	1954-1955
.	O	1955-1956
41	O	1956-1958
+	O	1959-1960
/	O	1960-1961
-	O	1961-1962
1	O	1963-1964
.	O	1964-1965
31	O	1965-1967
mmHg	O	1968-1972
/	O	1972-1973
ml	O	1973-1975
)	O	1975-1976
.	O	1976-1977

CONCLUSION	O	1978-1988
:	O	1988-1989
The	O	1990-1993
data	O	1994-1998
acquired	O	1999-2007
suggest	O	2008-2015
that	O	2016-2020
isolated	O	2021-2029
MAP	O	2030-2033
may	O	2034-2037
have	O	2038-2042
certain	O	2043-2050
benefits	O	2051-2059
on	O	2060-2062
LV	O	2063-2065
dimension	O	2066-2075
/	O	2075-2076
function	O	2076-2084
in	O	2085-2087
acute	O	2088-2093
heart	B	2094-2099
failure	I	2100-2107
,	O	2107-2108
even	O	2109-2113
in	O	2114-2116
the	O	2117-2120
absence	O	2121-2128
of	O	2129-2131
MR	B	2132-2134
.	O	2134-2135

However	O	2136-2143
,	O	2143-2144
further	O	2145-2152
investigations	O	2153-2167
are	O	2168-2171
warranted	O	2172-2181
in	O	2182-2184
a	O	2185-2186
model	O	2187-2192
of	O	2193-2195
chronic	O	2196-2203
heart	B	2204-2209
failure	I	2210-2217
.	O	2217-2218

Piperacillin	O	0-12
/	O	12-13
tazobactam	O	13-23
-	O	23-24
induced	O	24-31
seizure	B	32-39
rapidly	O	40-47
reversed	O	48-56
by	O	57-59
high	O	60-64
flux	O	65-69
hemodialysis	O	70-82
in	O	83-85
a	O	86-87
patient	O	88-95
on	O	96-98
peritoneal	O	99-109
dialysis	O	110-118
.	O	118-119

Despite	O	120-127
popular	O	128-135
use	O	136-139
of	O	140-142
piperacillin	O	143-155
,	O	155-156
the	O	157-160
dire	O	161-165
neurotoxicity	B	166-179
associated	O	180-190
with	O	191-195
piperacillin	O	196-208
still	O	209-214
goes	O	215-219
unrecognized	O	220-232
,	O	232-233
leading	O	234-241
to	O	242-244
a	O	245-246
delay	O	247-252
in	O	253-255
appropriate	O	256-267
management	O	268-278
.	O	278-279

We	O	280-282
report	O	283-289
a	O	290-291
57	O	292-294
-	O	294-295
year	O	295-299
-	O	294-295
old	O	300-303
woman	O	304-309
with	O	310-314
end	B	315-318
-	I	318-319
stage	I	319-324
renal	I	325-330
disease	I	331-338
receiving	O	339-348
continuous	O	349-359
ambulatory	O	360-370
peritoneal	O	371-381
dialysis	O	382-390
(	O	391-392
CAPD	O	392-396
)	O	396-397
,	O	397-398
who	O	399-402
developed	O	403-412
slurred	O	413-420
speech	O	421-427
,	O	427-428
tremor	B	429-435
,	O	435-436
bizarre	O	437-444
behavior	O	445-453
,	O	453-454
progressive	O	455-466
mental	O	467-473
confusion	B	474-483
,	O	483-484
and	O	485-488
2	O	489-490
episodes	O	491-499
of	O	500-502
generalized	O	503-514
tonic	B	515-520
-	I	520-521
clonic	I	521-527
seizure	I	528-535
(	O	536-537
GTCS	B	537-541
)	O	541-542
after	O	543-548
5	O	549-550
doses	O	551-556
of	O	557-559
piperacillin	O	560-572
/	O	572-573
tazobactam	O	573-583
(	O	584-585
2	O	585-586
g	O	587-588
/	O	588-589
250	O	589-592
mg	O	593-595
)	O	595-596
were	O	597-601
given	O	602-607
for	O	608-611
bronchiectasis	B	612-626
with	O	627-631
secondary	B	632-641
infection	I	642-651
.	O	651-652

The	O	653-656
laboratory	O	657-667
data	O	668-672
revealed	O	673-681
normal	O	682-688
plasma	O	689-695
electrolyte	O	696-707
and	O	708-711
ammonia	O	712-719
levels	O	720-726
but	O	727-730
leukocytosis	B	731-743
.	O	743-744

Neurologic	O	745-755
examinations	O	756-768
showed	O	769-775
dysarthria	B	776-786
and	O	787-790
bilateral	O	791-800
Babinski	O	801-809
sign	O	810-814
.	O	814-815

Computed	O	816-824
tomography	O	825-835
of	O	836-838
brain	O	839-844
and	O	845-848
electroencephalogram	O	849-869
were	O	870-874
unremarkable	O	875-887
.	O	887-888

Despite	O	889-896
the	O	897-900
use	O	901-904
of	O	905-907
antiepileptic	O	908-921
agents	O	922-928
,	O	928-929
another	O	930-937
GTCS	B	938-942
episode	O	943-950
recurred	O	951-959
after	O	960-965
the	O	966-969
sixth	O	970-975
dose	O	976-980
of	O	981-983
piperacillin	O	984-996
/	O	996-997
tazobactam	O	997-1007
.	O	1007-1008
Brain	O	1009-1014
magnetic	O	1015-1023
resonance	O	1024-1033
imaging	O	1034-1041
did	O	1042-1045
not	O	1046-1049
demonstrate	O	1050-1061
acute	O	1062-1067
infarction	B	1068-1078
and	O	1079-1082
organic	B	1083-1090
brain	I	1091-1096
lesions	I	1097-1104
.	O	1104-1105

Initiation	O	1106-1116
of	O	1117-1119
high	O	1120-1124
-	O	1124-1125
flux	O	1125-1129
hemodialysis	O	1130-1142
rapidly	O	1143-1150
reversed	O	1151-1159
the	O	1160-1163
neurologic	O	1164-1174
symptoms	O	1175-1183
within	O	1184-1190
4	O	1191-1192
hours	O	1193-1198
.	O	1198-1199

Piperacillin	O	1200-1212
-	O	1212-1213
induced	O	1213-1220
encephalopathy	B	1221-1235
should	O	1236-1242
be	O	1243-1245
considered	O	1246-1256
in	O	1257-1259
any	O	1260-1263
uremic	B	1264-1270
patients	O	1271-1279
with	O	1280-1284
unexplained	O	1285-1296
neurological	O	1297-1309
manifestations	O	1310-1324
.	O	1324-1325

CAPD	O	1326-1330
is	O	1331-1333
inefficient	O	1334-1345
in	O	1346-1348
removing	O	1349-1357
piperacillin	O	1358-1370
,	O	1370-1371
whereas	O	1372-1379
hemodialysis	O	1380-1392
can	O	1393-1396
rapidly	O	1397-1404
terminate	O	1405-1414
the	O	1415-1418
piperacillin	O	1419-1431
-	O	1431-1432
induced	O	1432-1439
encephalopathy	B	1440-1454
.	O	1454-1455

Frequency	O	0-9
of	O	10-12
transient	O	13-22
ipsilateral	O	23-34
vocal	B	35-40
cord	I	41-45
paralysis	I	46-55
in	O	56-58
patients	O	59-67
undergoing	O	68-78
carotid	O	79-86
endarterectomy	O	87-101
under	O	102-107
local	O	108-113
anesthesia	O	114-124
.	O	124-125

BACKGROUND	O	126-136
:	O	136-137
Especially	O	138-148
because	O	149-156
of	O	157-159
improvements	O	160-172
in	O	173-175
clinical	O	176-184
neurologic	O	185-195
monitoring	O	196-206
,	O	206-207
carotid	O	208-215
endarterectomy	O	216-230
done	O	231-235
under	O	236-241
local	O	242-247
anesthesia	O	248-258
has	O	259-262
become	O	263-269
the	O	270-273
technique	O	274-283
of	O	284-286
choice	O	287-293
in	O	294-296
several	O	297-304
centers	O	305-312
.	O	312-313

Temporary	O	314-323
ipsilateral	O	324-335
vocal	B	336-341
nerve	I	342-347
palsies	I	348-355
due	O	356-359
to	O	360-362
local	O	363-368
anesthetics	O	369-380
have	O	381-385
been	O	386-390
described	O	391-400
,	O	400-401
however	O	402-409
.	O	409-410

Such	O	411-415
complications	O	416-429
are	O	430-433
most	O	434-438
important	O	439-448
in	O	449-451
situations	O	452-462
where	O	463-468
there	O	469-474
is	O	475-477
a	O	478-479
pre	O	480-483
-	O	483-484
existing	O	484-492
contralateral	O	493-506
paralysis	B	507-516
.	O	516-517

We	O	518-520
therefore	O	521-530
examined	O	531-539
the	O	540-543
effect	O	544-550
of	O	551-553
local	O	554-559
anesthesia	O	560-570
on	O	571-573
vocal	O	574-579
cord	O	580-584
function	O	585-593
to	O	594-596
better	O	597-603
understand	O	604-614
its	O	615-618
possible	O	619-627
consequences	O	628-640
.	O	640-641

METHODS	O	642-649
:	O	649-650
This	O	651-655
prospective	O	656-667
study	O	668-673
included	O	674-682
28	O	683-685
patients	O	686-694
undergoing	O	695-705
carotid	O	706-713
endarterectomy	O	714-728
under	O	729-734
local	O	735-740
anesthesia	O	741-751
.	O	751-752

Vocal	O	753-758
cord	O	759-763
function	O	764-772
was	O	773-776
evaluated	O	777-786
before	O	787-793
,	O	793-794
during	O	795-801
,	O	801-802
and	O	803-806
after	O	807-812
surgery	O	813-820
(	O	821-822
postoperative	O	822-835
day	O	836-839
1	O	840-841
)	O	841-842
using	O	843-848
flexible	O	849-857
laryngoscopy	O	858-870
.	O	870-871

Anesthesia	O	872-882
was	O	883-886
performed	O	887-896
by	O	897-899
injecting	O	900-909
20	O	910-912
to	O	913-915
40	O	916-918
mL	O	919-921
of	O	922-924
a	O	925-926
mixture	O	927-934
of	O	935-937
long	O	938-942
-	O	942-943
acting	O	943-949
(	O	950-951
ropivacaine	O	951-962
)	O	962-963
and	O	964-967
short	O	968-973
-	O	973-974
acting	O	974-980
(	O	981-982
prilocaine	O	982-992
)	O	992-993
anesthetic	O	994-1004
.	O	1004-1005

RESULTS	O	1006-1013
:	O	1013-1014
All	O	1015-1018
patients	O	1019-1027
had	O	1028-1031
normal	O	1032-1038
vocal	O	1039-1044
cord	O	1045-1049
function	O	1050-1058
preoperatively	O	1059-1073
.	O	1073-1074

Twelve	O	1075-1081
patients	O	1082-1090
(	O	1091-1092
43	O	1092-1094
%	O	1094-1095
)	O	1095-1096
were	O	1097-1101
found	O	1102-1107
to	O	1108-1110
have	O	1111-1115
intraoperative	O	1116-1130
ipsilateral	O	1131-1142
vocal	B	1143-1148
cord	I	1149-1153
paralysis	I	1154-1163
.	O	1163-1164

It	O	1165-1167
resolved	O	1168-1176
in	O	1177-1179
all	O	1180-1183
cases	O	1184-1189
<	O	1190-1191
or	O	1192-1194
=	O	1195-1196
24	O	1196-1198
hours	O	1199-1204
.	O	1204-1205

There	O	1206-1211
were	O	1212-1216
no	O	1217-1219
significant	O	1220-1231
differences	O	1232-1243
in	O	1244-1246
operating	O	1247-1256
time	O	1257-1261
or	O	1262-1264
volume	O	1265-1271
or	O	1272-1274
frequency	O	1275-1284
of	O	1285-1287
anesthetic	O	1288-1298
administration	O	1299-1313
in	O	1314-1316
patients	O	1317-1325
with	O	1326-1330
temporary	O	1331-1340
vocal	B	1341-1346
cord	I	1347-1351
paralysis	I	1352-1361
compared	O	1362-1370
with	O	1371-1375
those	O	1376-1381
without	O	1382-1389
.	O	1389-1390

CONCLUSION	O	1391-1401
:	O	1401-1402
Local	O	1403-1408
anesthesia	O	1409-1419
led	O	1420-1423
to	O	1424-1426
temporary	O	1427-1436
ipsilateral	O	1437-1448
vocal	B	1449-1454
cord	I	1455-1459
paralysis	I	1460-1469
in	O	1470-1472
almost	O	1473-1479
half	O	1480-1484
of	O	1485-1487
these	O	1488-1493
patients	O	1494-1502
.	O	1502-1503

Because	O	1504-1511
pre	O	1512-1515
-	O	1515-1516
existing	O	1516-1524
paralysis	B	1525-1534
is	O	1535-1537
of	O	1538-1540
a	O	1541-1542
relevant	O	1543-1551
frequency	O	1552-1561
(	O	1562-1563
up	O	1563-1565
to	O	1566-1568
3	O	1569-1570
%	O	1570-1571
)	O	1571-1572
,	O	1572-1573
a	O	1574-1575
preoperative	O	1576-1588
evaluation	O	1589-1599
of	O	1600-1602
vocal	O	1603-1608
cord	O	1609-1613
function	O	1614-1622
before	O	1623-1629
carotid	O	1630-1637
endarterectomy	O	1638-1652
under	O	1653-1658
local	O	1659-1664
anesthesia	O	1665-1675
is	O	1676-1678
recommended	O	1679-1690
to	O	1691-1693
avoid	O	1694-1699
intraoperative	O	1700-1714
bilateral	O	1715-1724
paralysis	B	1725-1734
.	O	1734-1735

In	O	1736-1738
patients	O	1739-1747
with	O	1748-1752
preoperative	O	1753-1765
contralateral	O	1766-1779
vocal	B	1780-1785
cord	I	1786-1790
paralysis	I	1791-1800
,	O	1800-1801
surgery	O	1802-1809
under	O	1810-1815
general	O	1816-1823
anesthesia	O	1824-1834
should	O	1835-1841
be	O	1842-1844
considered	O	1845-1855
.	O	1855-1856

Neuroprotective	O	0-15
effects	O	16-23
of	O	24-26
melatonin	O	27-36
upon	O	37-41
the	O	42-45
offspring	O	46-55
cerebellar	O	56-66
cortex	O	67-73
in	O	74-76
the	O	77-80
rat	O	81-84
model	O	85-90
of	O	91-93
BCNU	O	94-98
-	O	98-99
induced	O	99-106
cortical	B	107-115
dysplasia	I	116-125
.	O	125-126

Cortical	B	127-135
dysplasia	I	136-145
is	O	146-148
a	O	149-150
malformation	O	151-163
characterized	O	164-177
by	O	178-180
defects	O	181-188
in	O	189-191
proliferation	O	192-205
,	O	205-206
migration	O	207-216
and	O	217-220
maturation	O	221-231
.	O	231-232

This	O	233-237
study	O	238-243
was	O	244-247
designed	O	248-256
to	O	257-259
evaluate	O	260-268
the	O	269-272
alterations	O	273-284
in	O	285-287
offspring	O	288-297
rat	O	298-301
cerebellum	O	302-312
induced	O	313-320
by	O	321-323
maternal	O	324-332
exposure	O	333-341
to	O	342-344
carmustine	O	345-355
-	O	355-356
[	O	356-357
1	O	357-358
,	O	358-359
3	O	359-360
-	O	355-356
bis	O	361-364
(	O	365-366
2	O	366-367
-	O	367-368
chloroethyl	O	368-379
)	O	379-380
-	O	367-368
1	O	381-382
-	O	367-368
nitrosoure	O	383-393
]	O	393-394
(	O	395-396
BCNU	O	396-400
)	O	400-401
and	O	402-405
to	O	406-408
investigate	O	409-420
the	O	421-424
effects	O	425-432
of	O	433-435
exogenous	O	436-445
melatonin	O	446-455
upon	O	456-460
cerebellar	O	461-471
BCNU	O	472-476
-	O	476-477
induced	O	477-484
cortical	B	485-493
dysplasia	I	494-503
,	O	503-504
using	O	505-510
histological	O	511-523
and	O	524-527
biochemical	O	528-539
analyses	O	540-548
.	O	548-549

Pregnant	O	550-558
Wistar	O	559-565
rats	O	566-570
were	O	571-575
assigned	O	576-584
to	O	585-587
five	O	588-592
groups	O	593-599
:	O	599-600
intact	O	601-607
-	O	607-608
control	O	608-615
,	O	615-616
saline	O	617-623
-	O	623-624
control	O	624-631
,	O	631-632
melatonin	O	633-642
-	O	642-643
treated	O	643-650
,	O	650-651
BCNU	O	652-656
-	O	656-657
exposed	O	657-664
and	O	665-668
BCNU	O	669-673
-	O	673-674
exposed	O	674-681
plus	O	682-686
melatonin	O	687-696
.	O	696-697

Rats	O	698-702
were	O	703-707
exposed	O	708-715
to	O	716-718
BCNU	O	719-723
on	O	724-726
embryonic	O	727-736
day	O	737-740
15	O	741-743
and	O	744-747
melatonin	O	748-757
was	O	758-761
given	O	762-767
until	O	768-773
delivery	O	774-782
.	O	782-783

Immuno	O	784-790
/	O	790-791
histochemistry	O	791-805
and	O	806-809
electron	O	810-818
microscopy	O	819-829
were	O	830-834
carried	O	835-842
out	O	843-846
on	O	847-849
the	O	850-853
offspring	O	854-863
cerebellum	O	864-874
,	O	874-875
and	O	876-879
levels	O	880-886
of	O	887-889
malondialdehyde	O	890-905
and	O	906-909
superoxide	O	910-920
dismutase	O	921-930
were	O	931-935
determined	O	936-946
.	O	946-947

Histopathologically	O	948-967
,	O	967-968
typical	O	969-976
findings	O	977-985
were	O	986-990
observed	O	991-999
in	O	1000-1002
the	O	1003-1006
cerebella	O	1007-1016
from	O	1017-1021
the	O	1022-1025
control	O	1026-1033
groups	O	1034-1040
,	O	1040-1041
but	O	1042-1045
the	O	1046-1049
findings	O	1050-1058
consistent	O	1059-1069
with	O	1070-1074
early	O	1075-1080
embryonic	O	1081-1090
development	O	1091-1102
were	O	1103-1107
noted	O	1108-1113
in	O	1114-1116
BCNU	O	1117-1121
-	O	1121-1122
exposed	O	1122-1129
cortical	B	1130-1138
dysplasia	I	1139-1148
group	O	1149-1154
.	O	1154-1155

There	O	1156-1161
was	O	1162-1165
a	O	1166-1167
marked	O	1168-1174
increase	O	1175-1183
in	O	1184-1186
the	O	1187-1190
number	O	1191-1197
of	O	1198-1200
TUNEL	O	1201-1206
positive	O	1207-1215
cells	O	1216-1221
and	O	1222-1225
nestin	O	1226-1232
positive	O	1233-1241
cells	O	1242-1247
in	O	1248-1250
BCNU	O	1251-1255
-	O	1255-1256
exposed	O	1256-1263
group	O	1264-1269
,	O	1269-1270
but	O	1271-1274
a	O	1275-1276
decreased	O	1277-1286
immunoreactivity	O	1287-1303
to	O	1304-1306
glial	O	1307-1312
fibrillary	O	1313-1323
acidic	O	1324-1330
protein	O	1331-1338
,	O	1338-1339
synaptophysin	O	1340-1353
and	O	1354-1357
transforming	O	1358-1370
growth	O	1371-1377
factor	O	1378-1384
beta1	O	1385-1390
was	O	1391-1394
observed	O	1395-1403
,	O	1403-1404
indicating	O	1405-1415
a	O	1416-1417
delayed	O	1418-1425
maturation	O	1426-1436
,	O	1436-1437
and	O	1438-1441
melatonin	O	1442-1451
significantly	O	1452-1465
reversed	O	1466-1474
these	O	1475-1480
changes	O	1481-1488
.	O	1488-1489

Malondialdehyde	O	1490-1505
level	O	1506-1511
in	O	1512-1514
BCNU	O	1515-1519
-	O	1519-1520
exposed	O	1520-1527
group	O	1528-1533
was	O	1534-1537
higher	O	1538-1544
than	O	1545-1549
those	O	1550-1555
in	O	1556-1558
control	O	1559-1566
groups	O	1567-1573
and	O	1574-1577
melatonin	O	1578-1587
decreased	O	1588-1597
malondialdehyde	O	1598-1613
levels	O	1614-1620
in	O	1621-1623
BCNU	O	1624-1628
group	O	1629-1634
(	O	1635-1636
P	O	1636-1637
<	O	1637-1638
0	O	1638-1639
.	O	1639-1640
01	O	1640-1642
)	O	1642-1643
,	O	1643-1644

while	O	1645-1650
there	O	1651-1656
were	O	1657-1661
no	O	1662-1664
significant	O	1665-1676
differences	O	1677-1688
in	O	1689-1691
the	O	1692-1695
superoxide	O	1696-1706
dismutase	O	1707-1716
levels	O	1717-1723
between	O	1724-1731
these	O	1732-1737
groups	O	1738-1744
.	O	1744-1745

These	O	1746-1751
data	O	1752-1756
suggest	O	1757-1764
that	O	1765-1769
exposure	O	1770-1778
of	O	1779-1781
animals	O	1782-1789
to	O	1790-1792
BCNU	O	1793-1797
during	O	1798-1804
pregnancy	O	1805-1814
leads	O	1815-1820
to	O	1821-1823
delayed	O	1824-1831
maturation	O	1832-1842
of	O	1843-1845
offspring	O	1846-1855
cerebellum	O	1856-1866
and	O	1867-1870
melatonin	O	1871-1880
protects	O	1881-1889
the	O	1890-1893
cerebellum	O	1894-1904
against	O	1905-1912
the	O	1913-1916
effects	O	1917-1924
of	O	1925-1927
BCNU	O	1928-1932
.	O	1932-1933

Myo	O	0-3
-	O	3-4
inositol	O	4-12
-	O	3-4
1	O	13-14
-	O	3-4
phosphate	O	15-24
(	O	25-26
MIP	O	26-29
)	O	29-30
synthase	O	31-39
inhibition	O	40-50
:	O	50-51
in	O	52-54
-	O	54-55
vivo	O	55-59
study	O	60-65
in	O	66-68
rats	O	69-73
.	O	73-74

Lithium	O	75-82
and	O	83-86
valproate	O	87-96
are	O	97-100
the	O	101-104
prototypic	O	105-115
mood	O	116-120
stabilizers	O	121-132
and	O	133-136
have	O	137-141
diverse	O	142-149
structures	O	150-160
and	O	161-164
targets	O	165-172
.	O	172-173

Both	O	174-178
drugs	O	179-184
influence	O	185-194
inositol	O	195-203
metabolism	O	204-214
.	O	214-215

Lithium	O	216-223
inhibits	O	224-232
IMPase	O	233-239
and	O	240-243
valproate	O	244-253
inhibits	O	254-262
MIP	O	263-266
synthase	O	267-275
.	O	275-276

This	O	277-281
study	O	282-287
shows	O	288-293
that	O	294-298
MIP	O	299-302
synthase	O	303-311
inhibition	O	312-322
does	O	323-327
not	O	328-331
replicate	O	332-341
or	O	342-344
augment	O	345-352
the	O	353-356
effects	O	357-364
of	O	365-367
lithium	O	368-375
in	O	376-378
the	O	379-382
inositol	O	383-391
sensitive	O	392-401
pilocarpine	O	402-413
-	O	413-414
induced	O	414-421
seizures	B	422-430
model	O	431-436
.	O	436-437

This	O	438-442
lack	O	443-447
of	O	448-450
effects	O	451-458
may	O	459-462
stem	O	463-467
from	O	468-472
the	O	473-476
low	O	477-480
contribution	O	481-493
of	O	494-496
de	O	497-499
-	O	499-500
novo	O	500-504
synthesis	O	505-514
to	O	515-517
cellular	O	518-526
inositol	O	527-535
supply	O	536-542
or	O	543-545
to	O	546-548
the	O	549-552
inhibition	O	553-563
of	O	564-566
the	O	567-570
de	O	571-573
-	O	573-574
novo	O	574-578
synthesis	O	579-588
by	O	589-591
lithium	O	592-599
itself	O	600-606
.	O	606-607

Non	O	0-3
-	O	3-4
steroidal	O	4-13
anti	O	14-18
-	O	18-19
inflammatory	O	19-31
drugs	O	32-37
-	O	37-38
associated	O	38-48
acute	O	49-54
interstitial	B	55-67
nephritis	I	68-77
with	O	78-82
granular	O	83-91
tubular	O	92-99
basement	O	100-108
membrane	O	109-117
deposits	O	118-126
.	O	126-127

Acute	B	128-133
tubulo	I	134-140
-	I	140-141
interstitial	I	141-153
nephritis	I	154-163
(	O	164-165
ATIN	B	165-169
)	O	169-170
is	O	171-173
an	O	174-176
important	O	177-186
cause	O	187-192
of	O	193-195
acute	B	196-201
renal	I	202-207
failure	I	208-215
resulting	O	216-225
from	O	226-230
a	O	231-232
variety	O	233-240
of	O	241-243
insults	O	244-251
,	O	251-252
including	O	253-262
immune	O	263-269
complex	O	270-277
-	O	277-278
mediated	O	278-286
tubulo	B	287-293
-	I	293-294
interstitial	I	294-306
injury	I	307-313
,	O	313-314
but	O	315-318
drugs	O	319-324
such	O	325-329
as	O	330-332
non	O	333-336
-	O	336-337
steroidal	O	337-346
anti	O	347-351
-	O	351-352
inflammatory	O	352-364
drugs	O	365-370
(	O	371-372
NSAIDs	O	372-378
)	O	378-379
are	O	380-383
a	O	384-385
far	O	386-389
more	O	390-394
frequent	O	395-403
cause	O	404-409
.	O	409-410

Overall	O	411-418
,	O	418-419
as	O	420-422
an	O	423-425
entity	O	426-432
,	O	432-433
ATIN	B	434-438
remains	O	439-446
under	O	447-452
-	O	452-453
diagnosed	O	453-462
,	O	462-463
as	O	464-466
symptoms	O	467-475
resolve	O	476-483
spontaneously	O	484-497
if	O	498-500
the	O	501-504
medication	O	505-515
is	O	516-518
stopped	O	519-526
.	O	526-527

We	O	528-530
report	O	531-537
on	O	538-540
a	O	541-542
14	O	543-545
-	O	545-546
year	O	546-550
-	O	545-546
old	O	551-554
boy	O	555-558
who	O	559-562
developed	O	563-572
acute	B	573-578
renal	I	579-584
failure	I	585-592
2	O	593-594
weeks	O	595-600
after	O	601-606
aortic	O	607-613
valve	O	614-619
surgery	O	620-627
.	O	627-628

He	O	629-631
was	O	632-635
put	O	636-639
on	O	640-642
aspirin	O	643-650
following	O	651-660
surgery	O	661-668
and	O	669-672
took	O	673-677
ibuprofen	O	678-687
for	O	688-691
fever	B	692-697
for	O	698-701
nearly	O	702-708
a	O	709-710
week	O	711-715
prior	O	716-721
to	O	722-724
presentation	O	725-737
.	O	737-738

He	O	739-741
then	O	742-746
presented	O	747-756
to	O	757-759
the	O	760-763
emergency	O	764-773
department	O	774-784
feeling	O	785-792
quite	O	793-798
ill	O	799-802
and	O	803-806
was	O	807-810
found	O	811-816
to	O	817-819
have	O	820-824
a	O	825-826
blood	O	827-832
urea	O	833-837
nitrogen	O	838-846
(	O	847-848
BUN	O	848-851
)	O	851-852
concentration	O	853-866
of	O	867-869
of	O	870-872
147	O	873-876
mg	O	877-879
/	O	879-880
dl	O	880-882
,	O	882-883
creatinine	O	884-894
of	O	895-897
15	O	898-900
.	O	900-901
3	O	901-902
mg	O	903-905
/	O	905-906
dl	O	906-908
and	O	909-912
serum	O	913-918
potassium	O	919-928
of	O	929-931
8	O	932-933
.	O	933-934
7	O	934-935
mEq	O	936-939
/	O	939-940
l	O	940-941
.	O	941-942

Dialysis	O	943-951
was	O	952-955
immediately	O	956-967
initiated	O	968-977
.	O	977-978

A	O	979-980
kidney	O	981-987
biopsy	O	988-994
showed	O	995-1001
inflammatory	O	1002-1014
infiltrate	O	1015-1025
consistent	O	1026-1036
with	O	1037-1041
ATIN	B	1042-1046
.	O	1046-1047

However	O	1048-1055
,	O	1055-1056
in	O	1057-1059
the	O	1060-1063
tubular	O	1064-1071
basement	O	1072-1080
membrane	O	1081-1089
(	O	1090-1091
TBM	O	1091-1094
)	O	1094-1095
,	O	1095-1096
very	O	1097-1101
intense	O	1102-1109
granular	O	1110-1118
deposits	O	1119-1127
of	O	1128-1130
polyclonal	O	1131-1141
IgG	O	1142-1145
and	O	1146-1149
C3	O	1150-1152
were	O	1153-1157
noted	O	1158-1163
.	O	1163-1164

He	O	1165-1167
needed	O	1168-1174
dialysis	O	1175-1183
for	O	1184-1187
2	O	1188-1189
weeks	O	1190-1195
and	O	1196-1199
was	O	1200-1203
treated	O	1204-1211
successfully	O	1212-1224
with	O	1225-1229
steroids	O	1230-1238
for	O	1239-1242
6	O	1243-1244
months	O	1245-1251
.	O	1251-1252

His	O	1253-1256
renal	O	1257-1262
recovery	O	1263-1271
and	O	1272-1275
disappearance	O	1276-1289
of	O	1290-1292
proteinuria	B	1293-1304
took	O	1305-1309
a	O	1310-1311
year	O	1312-1316
.	O	1316-1317

In	O	1318-1320
conclusion	O	1321-1331
,	O	1331-1332
this	O	1333-1337
is	O	1338-1340
a	O	1341-1342
first	O	1343-1348
report	O	1349-1355
of	O	1356-1358
NSAIDs	O	1359-1365
-	O	1365-1366
associated	O	1366-1376
ATIN	B	1377-1381
,	O	1381-1382
showing	O	1383-1390
deposits	O	1391-1399
of	O	1400-1402
granular	O	1403-1411
immune	O	1412-1418
complex	O	1419-1426
present	O	1427-1434
only	O	1435-1439
in	O	1440-1442
the	O	1443-1446
TBM	O	1447-1450
and	O	1451-1454
not	O	1455-1458
in	O	1459-1461
the	O	1462-1465
glomeruli	O	1466-1475
.	O	1475-1476

Rifampicin	O	0-10
-	O	10-11
associated	O	11-21
segmental	O	22-31
necrotizing	O	32-43
glomerulonephritis	B	44-62
in	O	63-65
staphylococcal	B	66-80
endocarditis	I	81-93
.	O	93-94

Segmental	O	95-104
necrotising	O	105-116
glomerulonephritis	B	117-135
has	O	136-139
been	O	140-144
reported	O	145-153
as	O	154-156
complication	O	157-169
of	O	170-172
rifampicin	O	173-183
therapy	O	184-191
in	O	192-194
patients	O	195-203
receiving	O	204-213
treatment	O	214-223
for	O	224-227
tuberculosis	B	228-240
.	O	240-241

Changing	O	242-250
epidemiology	O	251-263
of	O	264-266
infections	B	267-277
such	O	278-282
as	O	283-285
infective	B	286-295
endocarditis	I	296-308
(	O	309-310
IE	B	310-312
)	O	312-313
has	O	314-317
led	O	318-321
to	O	322-324
an	O	325-327
increase	O	328-336
in	O	337-339
the	O	340-343
use	O	344-347
of	O	348-350
rifampicin	O	351-361
for	O	362-365
Staphylococcal	B	366-380
infections	I	381-391
.	O	391-392

We	O	393-395
describe	O	396-404
a	O	405-406
case	O	407-411
of	O	412-414
a	O	415-416
patient	O	417-424
with	O	425-429
Staphylococcal	B	430-444
IE	I	445-447
who	O	448-451
developed	O	452-461
acute	B	462-467
renal	I	468-473
failure	I	474-481
secondary	O	482-491
to	O	492-494
a	O	495-496
segmental	O	497-506
necrotising	O	507-518
glomerulonephritis	B	519-537
while	O	538-543
being	O	544-549
treated	O	550-557
with	O	558-562
rifampicin	O	563-573
,	O	573-574
and	O	575-578
review	O	579-585
the	O	586-589
literature	O	590-600
regarding	O	601-610
this	O	611-615
complication	O	616-628
of	O	629-631
rifampicin	O	632-642
therapy	O	643-650
.	O	650-651

Rate	O	0-4
of	O	5-7
YMDD	O	8-12
motif	O	13-18
mutants	O	19-26
in	O	27-29
lamivudine	O	30-40
-	O	40-41
untreated	O	41-50
Iranian	O	51-58
patients	O	59-67
with	O	68-72
chronic	B	73-80
hepatitis	I	81-90
B	I	91-92
virus	I	93-98
infection	I	99-108
.	O	108-109

BACKGROUND	O	110-120
:	O	120-121
Lamivudine	O	122-132
is	O	133-135
used	O	136-140
for	O	141-144
the	O	145-148
treatment	O	149-158
of	O	159-161
chronic	B	162-169
hepatitis	I	170-179
B	I	180-181
patients	O	182-190
.	O	190-191

Recent	O	192-198
studies	O	199-206
show	O	207-211
that	O	212-216
the	O	217-220
YMDD	O	221-225
motif	O	226-231
mutants	O	232-239
(	O	240-241
resistant	O	241-250
hepatitis	B	251-260
B	I	261-262
virus	O	263-268
)	O	268-269
occur	O	270-275
as	O	276-278
natural	O	279-286
genome	O	287-293
variability	O	294-305
in	O	306-308
lamivudine	O	309-319
-	O	319-320
untreated	O	320-329
chronic	B	330-337
hepatitis	I	338-347
B	I	348-349
patients	O	350-358
.	O	358-359

In	O	360-362
this	O	363-367
study	O	368-373
we	O	374-376
aimed	O	377-382
to	O	383-385
determine	O	386-395
the	O	396-399
rate	O	400-404
of	O	405-407
YMDD	O	408-412
motif	O	413-418
mutants	O	419-426
in	O	427-429
lamivudine	O	430-440
-	O	440-441
untreated	O	441-450
chronic	B	451-458
hepatitis	I	459-468
B	I	469-470
patients	O	471-479
in	O	480-482
Iran	O	483-487
.	O	487-488

PATIENTS	O	489-497
AND	O	498-501
METHODS	O	502-509
:	O	509-510
A	O	511-512
total	O	513-518
of	O	519-521
77	O	522-524
chronic	B	525-532
hepatitis	I	533-542
B	I	543-544
patients	O	545-553
who	O	554-557
had	O	558-561
not	O	562-565
been	O	566-570
treated	O	571-578
with	O	579-583
lamivudine	O	584-594
were	O	595-599
included	O	600-608
in	O	609-611
the	O	612-615
study	O	616-621
.	O	621-622

Serum	O	623-628
samples	O	629-636
from	O	637-641
patients	O	642-650
were	O	651-655
tested	O	656-662
by	O	663-665
polymerase	O	666-676
chain	O	677-682
reaction	O	683-691
-	O	691-692
restriction	O	692-703
fragment	O	704-712
length	O	713-719
polymorphism	O	720-732
(	O	733-734
PCR	O	734-737
-	O	737-738
RFLP	O	738-742
)	O	742-743
for	O	744-747
detection	O	748-757
of	O	758-760
YMDD	O	761-765
motif	O	766-771
mutants	O	772-779
.	O	779-780

All	O	781-784
patients	O	785-793
were	O	794-798
also	O	799-803
tested	O	804-810
for	O	811-814
liver	O	815-820
enzymes	O	821-828
,	O	828-829
anti	O	830-834
-	O	834-835
HCV	O	835-838
,	O	838-839
HBeAg	O	840-845
,	O	845-846
and	O	847-850
anti	O	851-855
-	O	855-856
HBe	O	856-859
.	O	859-860

RESULTS	O	861-868
:	O	868-869
Of	O	870-872
the	O	873-876
77	O	877-879
patients	O	880-888
enrolled	O	889-897
in	O	898-900
the	O	901-904
study	O	905-910
,	O	910-911
73	O	912-914
%	O	914-915
were	O	916-920
male	O	921-925
and	O	926-929
27	O	930-932
%	O	932-933
were	O	934-938
female	O	939-945
.	O	945-946

Mean	O	947-951
ALT	O	952-955
and	O	956-959
AST	O	960-963
levels	O	964-970
were	O	971-975
124	O	976-979
.	O	979-980
4	O	978-979
+	O	981-982
/	O	982-983
-	O	983-984
73	O	984-986
.	O	979-980
4	O	978-979
and	O	989-992
103	O	993-996
.	O	996-997
1	O	993-994
+	O	998-999
/	O	999-1000
-	O	1000-1001
81	O	1001-1003

IU	O	1004-1006
/	O	1006-1007
l	O	1007-1008
,	O	1008-1009
respectively	O	1010-1022
.	O	1022-1023

HBeAg	O	1024-1029
was	O	1030-1033
positive	O	1034-1042
in	O	1043-1045
40	O	1046-1048
%	O	1048-1049
and	O	1050-1053
anti	O	1054-1058
-	O	1058-1059
HBe	O	1059-1062
in	O	1063-1065
60	O	1066-1068
%	O	1068-1069
of	O	1070-1072
the	O	1073-1076
patients	O	1077-1085
.	O	1085-1086

Anti	O	1087-1091
-	O	1091-1092
HCV	O	1092-1095
was	O	1096-1099
negative	O	1100-1108
in	O	1109-1111
all	O	1112-1115
of	O	1116-1118
them	O	1119-1123
.	O	1123-1124

YMDD	O	1125-1129
motif	O	1130-1135
mutants	O	1136-1143
were	O	1144-1148
not	O	1149-1152
detected	O	1153-1161
in	O	1162-1164
any	O	1165-1168
of	O	1169-1171
the	O	1172-1175
patients	O	1176-1184
despite	O	1185-1192
the	O	1193-1196
liver	O	1197-1202
enzyme	O	1203-1209
levels	O	1210-1216
and	O	1217-1220
the	O	1221-1224
presence	O	1225-1233
of	O	1234-1236
HBeAg	O	1237-1242
or	O	1243-1245
anti	O	1246-1250
-	O	1250-1251
HBe	O	1251-1254
.	O	1254-1255

CONCLUSION	O	1256-1266
:	O	1266-1267
Although	O	1268-1276
the	O	1277-1280
natural	O	1281-1288
occurrence	O	1289-1299
of	O	1300-1302
YMDD	O	1303-1307
motif	O	1308-1313
mutants	O	1314-1321
in	O	1322-1324
lamivudine	O	1325-1335
-	O	1335-1336
untreated	O	1336-1345
patients	O	1346-1354
with	O	1355-1359
chronic	B	1360-1367
hepatitis	I	1368-1377
B	I	1378-1379
has	O	1380-1383
been	O	1384-1388
reported	O	1389-1397
,	O	1397-1398
these	O	1399-1404
mutants	O	1405-1412
were	O	1413-1417
not	O	1418-1421
detected	O	1422-1430
in	O	1431-1433
Iranian	O	1434-1441
lamivudine	O	1442-1452
-	O	1452-1453
untreated	O	1453-1462
chronic	B	1463-1470
hepatitis	I	1471-1480
B	I	1481-1482
patients	O	1483-1491
.	O	1491-1492

Branch	O	0-6
retinal	B	7-14
vein	I	15-19
occlusion	I	20-29
and	O	30-33
fluoxetine	O	34-44
.	O	44-45

A	O	46-47
case	O	48-52
of	O	53-55
branch	O	56-62
retinal	B	63-70
vein	I	71-75
occlusion	I	76-85
associated	O	86-96
with	O	97-101
fluoxetine	O	102-112
-	O	112-113
induced	O	113-120
secondary	O	121-130
hypertension	B	131-143
is	O	144-146
described	O	147-156
.	O	156-157

Although	O	158-166
an	O	167-169
infrequent	O	170-180
complication	O	181-193
of	O	194-196
selective	O	197-206
serotonin	O	207-216
reuptake	O	217-225
inhibitor	O	226-235
therapy	O	236-243
,	O	243-244
it	O	245-247
is	O	248-250
important	O	251-260
that	O	261-265
ophthalmologists	O	266-282
are	O	283-286
aware	O	287-292
that	O	293-297
these	O	298-303
agents	O	304-310
can	O	311-314
cause	O	315-320
hypertension	B	321-333
because	O	334-341
this	O	342-346
class	O	347-352
of	O	353-355
drugs	O	356-361
is	O	362-364
widely	O	365-371
prescribed	O	372-382
.	O	382-383

The	O	0-3
differential	O	4-16
effects	O	17-24
of	O	25-27
bupivacaine	O	28-39
and	O	40-43
lidocaine	O	44-53
on	O	54-56
prostaglandin	O	57-70
E2	O	71-73
release	O	74-81
,	O	81-82
cyclooxygenase	O	83-97
gene	O	98-102
expression	O	103-113
and	O	114-117
pain	B	118-122
in	O	123-125
a	O	126-127
clinical	O	128-136
pain	B	137-141
model	O	142-147
.	O	147-148

BACKGROUND	O	149-159
:	O	159-160
In	O	161-163
addition	O	164-172
to	O	173-175
blocking	O	176-184
nociceptive	O	185-196
input	O	197-202
from	O	203-207
surgical	O	208-216
sites	O	217-222
,	O	222-223
long	O	224-228
-	O	228-229
acting	O	229-235
local	O	236-241
anesthetics	O	242-253
might	O	254-259
directly	O	260-268
modulate	O	269-277
inflammation	B	278-290
.	O	290-291

In	O	292-294
the	O	295-298
present	O	299-306
study	O	307-312
,	O	312-313
we	O	314-316
describe	O	317-325
the	O	326-329
proinflammatory	O	330-345
effects	O	346-353
of	O	354-356
bupivacaine	O	357-368
on	O	369-371
local	O	372-377
prostaglandin	O	378-391
E2	O	392-394
(	O	395-396
PGE2	O	396-400
)	O	400-401
production	O	402-412
and	O	413-416
cyclooxygenase	O	417-431
(	O	432-433
COX	O	433-436
)	O	436-437
gene	O	438-442
expression	O	443-453
that	O	454-458
increases	O	459-468
postoperative	B	469-482
pain	I	483-487
in	O	488-490
human	O	491-496
subjects	O	497-505
.	O	505-506

METHODS	O	507-514
:	O	514-515
Subjects	O	516-524
(	O	525-526
n	O	526-527
=	O	528-529
114	O	530-533
)	O	533-534
undergoing	O	535-545
extraction	O	546-556
of	O	557-559
impacted	O	560-568
third	O	569-574
molars	O	575-581
received	O	582-590
either	O	591-597
2	O	598-599
%	O	599-600
lidocaine	O	601-610
or	O	611-613
0	O	614-615
.	O	615-616
5	O	616-617
%	O	617-618
bupivacaine	O	619-630
before	O	631-637
surgery	O	638-645
and	O	646-649
either	O	650-656
rofecoxib	O	657-666
50	O	667-669
mg	O	670-672
or	O	673-675
placebo	O	676-683
orally	O	684-690
90	O	691-693
min	O	694-697
before	O	698-704
surgery	O	705-712
and	O	713-716
for	O	717-720
the	O	721-724
following	O	725-734
48	O	735-737
h	O	738-739
.	O	739-740

Oral	O	741-745
mucosal	O	746-753
biopsies	O	754-762
were	O	763-767
taken	O	768-773
before	O	774-780
surgery	O	781-788
and	O	789-792
48	O	793-795
h	O	796-797
after	O	798-803
surgery	O	804-811
.	O	811-812

After	O	813-818
extraction	O	819-829
,	O	829-830
a	O	831-832
microdialysis	O	833-846
probe	O	847-852
was	O	853-856
placed	O	857-863
at	O	864-866
the	O	867-870
surgical	O	871-879
site	O	880-884
for	O	885-888
PGE2	O	889-893
and	O	894-897
thromboxane	O	898-909
B2	O	910-912
(	O	913-914
TXB2	O	914-918
)	O	918-919
measurements	O	920-932
.	O	932-933

RESULTS	O	934-941
:	O	941-942
The	O	943-946
bupivacaine	O	947-958
/	O	958-959
rofecoxib	O	959-968
group	O	969-974
reported	O	975-983
significantly	O	984-997
less	O	998-1002
pain	B	1003-1007
,	O	1007-1008
as	O	1009-1011
assessed	O	1012-1020
by	O	1021-1023
a	O	1024-1025
visual	O	1026-1032
analog	O	1033-1039
scale	O	1040-1045
,	O	1045-1046
compared	O	1047-1055
with	O	1056-1060
the	O	1061-1064
other	O	1065-1070
three	O	1071-1076
treatment	O	1077-1086
groups	O	1087-1093
over	O	1094-1098
the	O	1099-1102
first	O	1103-1108
4	O	1109-1110
h	O	1111-1112
.	O	1112-1113

However	O	1114-1121
,	O	1121-1122
the	O	1123-1126
bupivacaine	O	1127-1138
/	O	1138-1139
placebo	O	1139-1146
group	O	1147-1152
reported	O	1153-1161
significantly	O	1162-1175
more	O	1176-1180
pain	B	1181-1185
at	O	1186-1188
24	O	1189-1191
h	O	1192-1193
and	O	1194-1197
PGE2	O	1198-1202
levels	O	1203-1209
during	O	1210-1216
the	O	1217-1220
first	O	1221-1226
4	O	1227-1228
h	O	1229-1230
were	O	1231-1235
significantly	O	1236-1249
higher	O	1250-1256
than	O	1257-1261
the	O	1262-1265
other	O	1266-1271
three	O	1272-1277
treatment	O	1278-1287
groups	O	1288-1294
.	O	1294-1295

Moreover	O	1296-1304
,	O	1304-1305
bupivacaine	O	1306-1317
significantly	O	1318-1331
increased	O	1332-1341
COX	O	1342-1345
-	O	1345-1346
2	O	1346-1347
gene	O	1348-1352
expression	O	1353-1363
at	O	1364-1366
48	O	1367-1369
h	O	1370-1371
as	O	1372-1374
compared	O	1375-1383
with	O	1384-1388
the	O	1389-1392
lidocaine	O	1393-1402
/	O	1402-1403
placebo	O	1403-1410
group	O	1411-1416
.	O	1416-1417

Thromboxane	O	1418-1429
levels	O	1430-1436
were	O	1437-1441
not	O	1442-1445
significantly	O	1446-1459
affected	O	1460-1468
by	O	1469-1471
any	O	1472-1475
of	O	1476-1478
the	O	1479-1482
treatments	O	1483-1493
,	O	1493-1494
indicating	O	1495-1505
that	O	1506-1510
the	O	1511-1514
effects	O	1515-1522
seen	O	1523-1527
were	O	1528-1532
attributable	O	1533-1545
to	O	1546-1548
inhibition	O	1549-1559
of	O	1560-1562
COX	O	1563-1566
-	O	1566-1567
2	O	1567-1568
,	O	1568-1569
but	O	1570-1573
not	O	1574-1577
COX	O	1578-1581
-	O	1581-1582
1	O	1582-1583
.	O	1583-1584

CONCLUSIONS	O	1585-1596
:	O	1596-1597
These	O	1598-1603
results	O	1604-1611
suggest	O	1612-1619
that	O	1620-1624
bupivacaine	O	1625-1636
stimulates	O	1637-1647
COX	O	1648-1651
-	O	1651-1652
2	O	1652-1653
gene	O	1654-1658
expression	O	1659-1669
after	O	1670-1675
tissue	B	1676-1682
injury	I	1683-1689
,	O	1689-1690
which	O	1691-1696
is	O	1697-1699
associated	O	1700-1710
with	O	1711-1715
higher	O	1716-1722
PGE2	O	1723-1727
production	O	1728-1738
and	O	1739-1742
pain	B	1743-1747
after	O	1748-1753
the	O	1754-1757
local	O	1758-1763
anesthetic	O	1764-1774
effect	O	1775-1781
dissipates	O	1782-1792
.	O	1792-1793

p75NTR	O	0-6
expression	O	7-17
in	O	18-20
rat	O	21-24
urinary	O	25-32
bladder	O	33-40
sensory	O	41-48
neurons	O	49-56
and	O	57-60
spinal	O	61-67
cord	O	68-72
with	O	73-77
cyclophosphamide	O	78-94
-	O	94-95
induced	O	95-102
cystitis	B	103-111
.	O	111-112

A	O	113-114
role	O	115-119
for	O	120-123
nerve	O	124-129
growth	O	130-136
factor	O	137-143
(	O	144-145
NGF	O	145-148
)	O	148-149
in	O	150-152
contributing	O	153-165
to	O	166-168
increased	O	169-178
voiding	O	179-186
frequency	O	187-196
and	O	197-200
altered	O	201-208
sensation	O	209-218
from	O	219-223
the	O	224-227
urinary	O	228-235
bladder	O	236-243
has	O	244-247
been	O	248-252
suggested	O	253-262
.	O	262-263

Previous	O	264-272
studies	O	273-280
have	O	281-285
examined	O	286-294
the	O	295-298
expression	O	299-309
and	O	310-313
regulation	O	314-324
of	O	325-327
tyrosine	O	328-336
kinase	O	337-343
receptors	O	344-353
(	O	354-355
Trks	O	355-359
)	O	359-360
in	O	361-363
micturition	O	364-375
reflexes	O	376-384
with	O	385-389
urinary	B	390-397
bladder	I	398-405
inflammation	I	406-418
.	O	418-419

The	O	420-423
present	O	424-431
studies	O	432-439
examine	O	440-447
the	O	448-451
expression	O	452-462
and	O	463-466
regulation	O	467-477
of	O	478-480
another	O	481-488
receptor	O	489-497
known	O	498-503
to	O	504-506
bind	O	507-511
NGF	O	512-515
,	O	515-516
p75	O	517-520
(	O	520-521
NTR	O	521-524
)	O	524-525
,	O	525-526
after	O	527-532
various	O	533-540
durations	O	541-550
of	O	551-553
bladder	B	554-561
inflammation	I	562-574
induced	O	575-582
by	O	583-585
cyclophosphamide	O	586-602
(	O	603-604
CYP	O	604-607
)	O	607-608
.	O	608-609

CYP	O	610-613
-	O	613-614
induced	O	614-621
cystitis	B	622-630
increased	O	631-640
(	O	641-642
P	O	642-643
<	O	644-645
or	O	646-648
=	O	649-650
0	O	651-652
.	O	652-653
001	O	653-656
)	O	656-657
p75	O	658-661
(	O	661-662
NTR	O	662-665
)	O	665-666
expression	O	667-677
in	O	678-680
the	O	681-684
superficial	O	685-696
lateral	O	697-704
and	O	705-708
medial	O	709-715
dorsal	O	716-722
horn	O	723-727
in	O	728-730
L1	O	731-733
-	O	733-734
L2	O	734-736
and	O	737-740
L6	O	741-743
-	O	743-744
S1	O	744-746
spinal	O	747-753
segments	O	754-762
.	O	762-763

The	O	764-767
number	O	768-774
of	O	775-777
p75	O	778-781
(	O	781-782
NTR	O	782-785
)	O	785-786
-	O	786-787
immunoreactive	O	787-801
(	O	802-803
-	O	803-804
IR	O	804-806
)	O	806-807
cells	O	808-813
in	O	814-816
the	O	817-820
lumbosacral	O	821-832
dorsal	O	833-839
root	O	840-844
ganglia	O	845-852
(	O	853-854
DRG	O	854-857
)	O	857-858
also	O	859-863
increased	O	864-873
(	O	874-875
P	O	875-876
<	O	877-878
or	O	879-881
=	O	882-883
0	O	884-885
.	O	885-886
05	O	886-888
)	O	888-889
with	O	890-894
CYP	O	895-898
-	O	898-899
induced	O	899-906
cystitis	B	907-915
(	O	916-917
acute	O	917-922
,	O	922-923
intermediate	O	924-936
,	O	936-937
and	O	938-941
chronic	O	942-949
)	O	949-950
.	O	950-951

Quantitative	O	952-964
,	O	964-965
real	O	966-970
-	O	970-971
time	O	971-975
polymerase	O	976-986
chain	O	987-992
reaction	O	993-1001
also	O	1002-1006
demonstrated	O	1007-1019
significant	O	1020-1031
increases	O	1032-1041
(	O	1042-1043
P	O	1043-1044
<	O	1045-1046
or	O	1047-1049
=	O	1050-1051
0	O	1052-1053
.	O	1053-1054
01	O	1054-1056
)	O	1056-1057
in	O	1058-1060
p75	O	1061-1064
(	O	1064-1065
NTR	O	1065-1068
)	O	1068-1069
mRNA	O	1070-1074
in	O	1075-1077
DRG	O	1078-1081
with	O	1082-1086
intermediate	O	1087-1099
and	O	1100-1103
chronic	O	1104-1111
CYP	O	1112-1115
-	O	1115-1116
induced	O	1116-1123
cystitis	B	1124-1132
.	O	1132-1133

Retrograde	O	1134-1144
dye	O	1145-1148
-	O	1148-1149
tracing	O	1149-1156
techniques	O	1157-1167
with	O	1168-1172
Fastblue	O	1173-1181
were	O	1182-1186
used	O	1187-1191
to	O	1192-1194
identify	O	1195-1203
presumptive	O	1204-1215
bladder	O	1216-1223
afferent	O	1224-1232
cells	O	1233-1238
in	O	1239-1241
the	O	1242-1245
lumbosacral	O	1246-1257
DRG	O	1258-1261
.	O	1261-1262

In	O	1263-1265
bladder	O	1266-1273
afferent	O	1274-1282
cells	O	1283-1288
in	O	1289-1291
DRG	O	1292-1295
,	O	1295-1296
p75	O	1297-1300
(	O	1300-1301
NTR	O	1301-1304
)	O	1304-1305
-	O	1305-1306
IR	O	1306-1308
was	O	1309-1312
also	O	1313-1317
increased	O	1318-1327
(	O	1328-1329
P	O	1329-1330
<	O	1331-1332
or	O	1333-1335
=	O	1336-1337
0	O	1338-1339
.	O	1339-1340
01	O	1340-1342
)	O	1342-1343
with	O	1344-1348
cystitis	B	1349-1357
.	O	1357-1358

In	O	1359-1361
addition	O	1362-1370
to	O	1371-1373
increases	O	1374-1383
in	O	1384-1386
p75	O	1387-1390
(	O	1390-1391
NTR	O	1391-1394
)	O	1394-1395
-	O	1395-1396
IR	O	1396-1398
in	O	1399-1401
DRG	O	1402-1405
cell	O	1406-1410
bodies	O	1411-1417
,	O	1417-1418
increases	O	1419-1428
(	O	1429-1430
P	O	1430-1431
<	O	1432-1433
or	O	1434-1436
=	O	1437-1438
0	O	1439-1440
.	O	1440-1441
001	O	1441-1444
)	O	1444-1445
in	O	1446-1448
pericellular	O	1449-1461
(	O	1462-1463
encircling	O	1463-1473
DRG	O	1474-1477
cells	O	1478-1483
)	O	1483-1484
p75	O	1485-1488
(	O	1488-1489
NTR	O	1489-1492
)	O	1492-1493
-	O	1493-1494
IR	O	1494-1496
in	O	1497-1499
DRG	O	1500-1503
also	O	1504-1508
increased	O	1509-1518
.	O	1518-1519

Confocal	O	1520-1528
analyses	O	1529-1537
demonstrated	O	1538-1550
that	O	1551-1555
pericellular	O	1556-1568
p75	O	1569-1572
(	O	1572-1573
NTR	O	1573-1576
)	O	1576-1577
-	O	1577-1578
IR	O	1578-1580
was	O	1581-1584
not	O	1585-1588
colocalized	O	1589-1600
with	O	1601-1605
the	O	1606-1609
glial	O	1610-1615
marker	O	1616-1622
,	O	1622-1623
glial	O	1624-1629
fibrillary	O	1630-1640
acidic	O	1641-1647
protein	O	1648-1655
(	O	1656-1657
GFAP	O	1657-1661
)	O	1661-1662
.	O	1662-1663

These	O	1664-1669
studies	O	1670-1677
demonstrate	O	1678-1689
that	O	1690-1694
p75	O	1695-1698
(	O	1698-1699
NTR	O	1699-1702
)	O	1702-1703
expression	O	1704-1714
in	O	1715-1717
micturition	O	1718-1729
reflexes	O	1730-1738
is	O	1739-1741
present	O	1742-1749
constitutively	O	1750-1764
and	O	1765-1768
modified	O	1769-1777
by	O	1778-1780
bladder	B	1781-1788
inflammation	I	1789-1801
.	O	1801-1802

The	O	1803-1806
functional	O	1807-1817
significance	O	1818-1830
of	O	1831-1833
p75	O	1834-1837
(	O	1837-1838
NTR	O	1838-1841
)	O	1841-1842
expression	O	1843-1853
in	O	1854-1856
micturition	O	1857-1868
reflexes	O	1869-1877
remains	O	1878-1885
to	O	1886-1888
be	O	1889-1891
determined	O	1892-1902
.	O	1902-1903

Azathioprine	O	0-12
-	O	12-13
induced	O	13-20
suicidal	O	21-29
erythrocyte	O	30-41
death	O	42-47
.	O	47-48

BACKGROUND	O	49-59
:	O	59-60
Azathioprine	O	61-73
is	O	74-76
widely	O	77-83
used	O	84-88
as	O	89-91
an	O	92-94
immunosuppressive	O	95-112
drug	O	113-117
.	O	117-118

The	O	119-122
side	O	123-127
effects	O	128-135
of	O	136-138
azathioprine	O	139-151
include	O	152-159
anemia	B	160-166
,	O	166-167
which	O	168-173
has	O	174-177
been	O	178-182
attributed	O	183-193
to	O	194-196
bone	O	197-201
marrow	O	202-208
suppression	O	209-220
.	O	220-221

Alternatively	O	222-235
,	O	235-236
anemia	B	237-243
could	O	244-249
result	O	250-256
from	O	257-261
accelerated	O	262-273
suicidal	O	274-282
erythrocyte	O	283-294
death	O	295-300
or	O	301-303
eryptosis	O	304-313
,	O	313-314
which	O	315-320
is	O	321-323
characterized	O	324-337
by	O	338-340
exposure	O	341-349
of	O	350-352
phosphatidylserine	O	353-371
(	O	372-373
PS	O	373-375
)	O	375-376
at	O	377-379
the	O	380-383
erythrocyte	O	384-395
surface	O	396-403
and	O	404-407
by	O	408-410
cell	O	411-415
shrinkage	O	416-425
.	O	425-426

METHODS	O	427-434
:	O	434-435
The	O	436-439
present	O	440-447
experiments	O	448-459
explored	O	460-468
whether	O	469-476
azathioprine	O	477-489
influences	O	490-500
eryptosis	O	501-510
.	O	510-511

According	O	512-521
to	O	522-524
annexin	O	525-532
V	O	533-534
binding	O	535-542
,	O	542-543
erythrocytes	O	544-556
from	O	557-561
patients	O	562-570
indeed	O	571-577
showed	O	578-584
a	O	585-586
significant	O	587-598
increase	O	599-607
of	O	608-610
PS	O	611-613
exposure	O	614-622
within	O	623-629
1	O	630-631
week	O	632-636
of	O	637-639
treatment	O	640-649
with	O	650-654
azathioprine	O	655-667
.	O	667-668

In	O	669-671
a	O	672-673
second	O	674-680
series	O	681-687
,	O	687-688
cytosolic	O	689-698
Ca2	O	699-702
+	O	702-703
activity	O	704-712
(	O	713-714
Fluo3	O	714-719
fluorescence	O	720-732
)	O	732-733
,	O	733-734
cell	O	735-739
volume	O	740-746
(	O	747-748
forward	O	748-755
scatter	O	756-763
)	O	763-764
,	O	764-765
and	O	766-769
PS	O	770-772
-	O	772-773
exposure	O	773-781
(	O	782-783
annexin	O	783-790
V	O	791-792
binding	O	793-800
)	O	800-801
were	O	802-806
determined	O	807-817
by	O	818-820
FACS	O	821-825
analysis	O	826-834
in	O	835-837
erythrocytes	O	838-850
from	O	851-855
healthy	O	856-863
volunteers	O	864-874
.	O	874-875

RESULTS	O	876-883
:	O	883-884
Exposure	O	885-893
to	O	894-896
azathioprine	O	897-909
(	O	910-911
>	O	911-912
or	O	913-915
=	O	916-917
2	O	917-918
microg	O	919-925
/	O	925-926
mL	O	926-928
)	O	928-929
for	O	930-933
48	O	934-936
hours	O	937-942
increased	O	943-952
cytosolic	O	953-962
Ca2	O	963-966
+	O	966-967
activity	O	968-976
and	O	977-980
annexin	O	981-988
V	O	989-990
binding	O	991-998
and	O	999-1002
decreased	O	1003-1012
forward	O	1013-1020
scatter	O	1021-1028
.	O	1028-1029

The	O	1030-1033
effect	O	1034-1040
of	O	1041-1043
azathioprine	O	1044-1056
on	O	1057-1059
both	O	1060-1064
annexin	O	1065-1072
V	O	1073-1074
binding	O	1075-1082
and	O	1083-1086
forward	O	1087-1094
scatter	O	1095-1102
was	O	1103-1106
significantly	O	1107-1120
blunted	O	1121-1128
in	O	1129-1131
the	O	1132-1135
nominal	O	1136-1143
absence	O	1144-1151
of	O	1152-1154
extracellular	O	1155-1168
Ca2	O	1169-1172
+	O	1172-1173
.	O	1173-1174

CONCLUSIONS	O	1175-1186
:	O	1186-1187
Azathioprine	O	1188-1200
triggers	O	1201-1209
suicidal	O	1210-1218
erythrocyte	O	1219-1230
death	O	1231-1236
,	O	1236-1237
an	O	1238-1240
effect	O	1241-1247
presumably	O	1248-1258
contributing	O	1259-1271
to	O	1272-1274
azathioprine	O	1275-1287
-	O	1287-1288
induced	O	1288-1295
anemia	B	1296-1302
.	O	1302-1303

Clinical	O	0-8
comparison	O	9-19
of	O	20-22
cardiorespiratory	O	23-40
effects	O	41-48
during	O	49-55
unilateral	O	56-66
and	O	67-70
conventional	O	71-83
spinal	O	84-90
anaesthesia	O	91-102
.	O	102-103

BACKGROUND	O	104-114
:	O	114-115
Spinal	O	116-122
anaesthesia	O	123-134
is	O	135-137
widely	O	138-144
employed	O	145-153
in	O	154-156
clinical	O	157-165
practice	O	166-174
but	O	175-178
has	O	179-182
the	O	183-186
main	O	187-191
drawback	O	192-200
of	O	201-203
post	O	204-208
-	O	208-209
spinal	O	209-215
block	O	216-221
hypotension	B	222-233
.	O	233-234

Efforts	O	235-242
must	O	243-247
therefore	O	248-257
continue	O	258-266
to	O	267-269
be	O	270-272
made	O	273-277
to	O	278-280
obviate	O	281-288
this	O	289-293
setback	O	294-301
OBJECTIVE	O	302-311
:	O	311-312
To	O	313-315
evaluate	O	316-324
the	O	325-328
cardiovascular	O	329-343
and	O	344-347
respiratory	O	348-359
changes	O	360-367
during	O	368-374
unilateral	O	375-385
and	O	386-389
conventional	O	390-402
spinal	O	403-409
anaesthesia	O	410-421
.	O	421-422

METHODS	O	423-430
:	O	430-431
With	O	432-436
ethical	O	437-444
approval	O	445-453
,	O	453-454
we	O	455-457
studied	O	458-465
74	O	466-468
American	O	469-477
Society	O	478-485
of	O	486-488
Anesthesiologists	O	489-506
(	O	507-508
ASA	O	508-511
)	O	511-512
,	O	512-513
physical	O	514-522
status	O	523-529
class	O	530-535
1	O	536-537
and	O	538-541
2	O	542-543
patients	O	544-552
scheduled	O	553-562
for	O	563-566
elective	O	567-575
unilateral	O	576-586
lower	O	587-592
limb	O	593-597
surgery	O	598-605
.	O	605-606

Patients	O	607-615
were	O	616-620
randomly	O	621-629
allocated	O	630-639
into	O	640-644
one	O	645-648
of	O	649-651
two	O	652-655
groups	O	656-662
:	O	662-663
lateral	O	664-671
and	O	672-675
conventional	O	676-688
spinal	O	689-695
anaesthesia	O	696-707
groups	O	708-714
.	O	714-715

In	O	716-718
the	O	719-722
lateral	O	723-730
position	O	731-739
with	O	740-744
operative	O	745-754
side	O	755-759
down	O	760-764
,	O	764-765
patients	O	766-774
recived	O	775-782
10	O	783-785
mg	O	786-788
(	O	789-790
2mls	O	790-794
)	O	794-795
of	O	796-798
0	O	799-800
.	O	800-801
5	O	801-802
%	O	802-803
hyperbaric	O	804-814
bupivacaine	O	815-826
through	O	827-834
a	O	835-836
25	O	837-839
-	O	839-840
gauge	O	840-845
spinal	O	846-852
needle	O	853-859
.	O	859-860

Patients	O	861-869
in	O	870-872
the	O	873-876
unilateral	O	877-887
group	O	888-893
were	O	894-898
maintained	O	899-909
in	O	910-912
the	O	913-916
lateral	O	917-924
position	O	925-933
for	O	934-937
15	O	938-940
minutes	O	941-948
following	O	949-958
spinal	O	959-965
injection	O	966-975
while	O	976-981
those	O	982-987
in	O	988-990
the	O	991-994
conventional	O	995-1007
group	O	1008-1013
were	O	1014-1018
turned	O	1019-1025
supine	O	1026-1032
immediately	O	1033-1044
after	O	1045-1050
injection	O	1051-1060
.	O	1060-1061

Blood	O	1062-1067
pressure	O	1068-1076
,	O	1076-1077
heart	O	1078-1083
rate	O	1084-1088
,	O	1088-1089
respiratory	O	1090-1101
rate	O	1102-1106
and	O	1107-1110
oxygen	O	1111-1117
saturation	O	1118-1128
were	O	1129-1133
monitored	O	1134-1143
over	O	1144-1148
1	O	1149-1150
hour	O	1151-1155
.	O	1155-1156

RESULTS	O	1157-1164
:	O	1164-1165
Three	O	1166-1171
patients	O	1172-1180
(	O	1181-1182
8	O	1182-1183
.	O	1183-1184
1	O	1184-1185
%	O	1185-1186
)	O	1186-1187
in	O	1188-1190
the	O	1191-1194
unilateral	O	1195-1205
group	O	1206-1211
and	O	1212-1215
5	O	1216-1217
(	O	1218-1219
13	O	1219-1221
.	O	1221-1222
5	O	1222-1223
%	O	1223-1224
)	O	1224-1225
in	O	1226-1228
the	O	1229-1232
conventional	O	1233-1245
group	O	1246-1251
developed	O	1252-1261
hypotension	B	1262-1273
,	O	1273-1274
P	O	1275-1276
=	O	1276-1277
0	O	1278-1279
.	O	1279-1280
71	O	1280-1282
.	O	1279-1280

Four	O	1284-1288
(	O	1289-1290
10	O	1290-1292
.	O	1292-1293
8	O	1293-1294
%	O	1294-1295
)	O	1295-1296
patients	O	1297-1305
in	O	1306-1308
the	O	1309-1312
conventional	O	1313-1325
group	O	1326-1331
and	O	1332-1335
1	O	1336-1337
(	O	1338-1339
2	O	1339-1340
.	O	1340-1341
7	O	1341-1342
%	O	1342-1343
)	O	1343-1344
in	O	1345-1347
the	O	1348-1351
unilateral	O	1352-1362
group	O	1363-1368
,	O	1368-1369
P	O	1370-1371
=	O	1371-1372
0	O	1373-1374
.	O	1374-1375
17	O	1375-1377
required	O	1378-1386
epinephrine	O	1387-1398
infusion	O	1399-1407
to	O	1408-1410
treat	O	1411-1416
hypotension	B	1417-1428
.	O	1428-1429

Patients	O	1430-1438
in	O	1439-1441
the	O	1442-1445
conventional	O	1446-1458
group	O	1459-1464
had	O	1465-1468
statistically	O	1469-1482
significant	O	1483-1494
greater	O	1495-1502
fall	O	1503-1507
in	O	1508-1510
the	O	1511-1514
systolic	O	1515-1523
blood	O	1524-1529
pressures	O	1530-1539
at	O	1540-1542
15	O	1543-1545
,	O	1545-1546
30	O	1547-1549
and	O	1550-1553
45	O	1554-1556
minutes	O	1557-1564
when	O	1565-1569
compared	O	1570-1578
to	O	1579-1581
the	O	1582-1585
baseline	O	1586-1594
(	O	1595-1596
P	O	1596-1597
=	O	1597-1598
0	O	1599-1600
.	O	1600-1601
003	O	1601-1604
,	O	1604-1605
0	O	1606-1607
.	O	1607-1608
001	O	1608-1611
and	O	1612-1615
0	O	1616-1617
.	O	1617-1618
004	O	1618-1621
)	O	1621-1622
.	O	1617-1618

The	O	1624-1627
mean	O	1628-1632
respiratory	O	1633-1644
rate	O	1645-1649
and	O	1650-1653
oxygen	O	1654-1660
saturations	O	1661-1672
in	O	1673-1675
the	O	1676-1679
two	O	1680-1683
groups	O	1684-1690
were	O	1691-1695
similar	O	1696-1703
.	O	1703-1704

CONCLUSION	O	1705-1715
:	O	1715-1716
Compared	O	1717-1725
to	O	1726-1728
conventional	O	1729-1741
spinal	O	1742-1748
anaesthesia	O	1749-1760
,	O	1760-1761
unilateral	O	1762-1772
spinal	O	1773-1779
anaesthesia	O	1780-1791
was	O	1792-1795
associated	O	1796-1806
with	O	1807-1811
fewer	O	1812-1817
cardiovascular	O	1818-1832
perturbations	O	1833-1846
.	O	1846-1847

Also	O	1848-1852
,	O	1852-1853
the	O	1854-1857
type	O	1858-1862
of	O	1863-1865
spinal	O	1866-1872
block	O	1873-1878
instituted	O	1879-1889
affected	O	1890-1898
neither	O	1899-1906
the	O	1907-1910
respiratory	O	1911-1922
rate	O	1923-1927
nor	O	1928-1931
the	O	1932-1935
arterial	O	1936-1944
oxygen	O	1945-1951
saturation	O	1952-1962
.	O	1962-1963

Spectrum	O	0-8
of	O	9-11
adverse	O	12-19
events	O	20-26
after	O	27-32
generic	O	33-40
HAART	O	41-46
in	O	47-49
southern	O	50-58
Indian	O	59-65
HIV	B	66-69
-	I	69-70
infected	I	70-78
patients	O	79-87
.	O	87-88

To	O	89-91
determine	O	92-101
the	O	102-105
incidence	O	106-115
of	O	116-118
clinically	O	119-129
significant	O	130-141
adverse	O	142-149
events	O	150-156
after	O	157-162
long	O	163-167
-	O	167-168
term	O	168-172
,	O	172-173
fixed	O	174-179
-	O	179-180
dose	O	180-184
,	O	184-185
generic	O	186-193
highly	O	194-200
active	O	201-207
antiretroviral	O	208-222
therapy	O	223-230
(	O	231-232
HAART	O	232-237
)	O	237-238
use	O	239-242
among	O	243-248
HIV	B	249-252
-	I	252-253
infected	I	253-261
individuals	O	262-273
in	O	274-276
South	O	277-282
India	O	283-288
,	O	288-289
we	O	290-292
examined	O	293-301
the	O	302-305
experiences	O	306-317
of	O	318-320
3154	O	321-325
HIV	B	326-329
-	I	329-330
infected	I	330-338
individuals	O	339-350
who	O	351-354
received	O	355-363
a	O	364-365
minimum	O	366-373
of	O	374-376
3	O	377-378
months	O	379-385
of	O	386-388
generic	O	389-396
HAART	O	397-402
between	O	403-410
February	O	411-419
1996	O	420-424
and	O	425-428
December	O	429-437
2006	O	438-442
at	O	443-445
a	O	446-447
tertiary	O	448-456
HIV	O	457-460
care	O	461-465
referral	O	466-474
center	O	475-481
in	O	482-484
South	O	485-490
India	O	491-496
.	O	496-497

The	O	498-501
most	O	502-506
common	O	507-513
regimens	O	514-522
were	O	523-527
3TC	O	528-531
+	O	532-533
d4T	O	534-537
+	O	538-539
nevirapine	O	540-550
(	O	551-552
NVP	O	552-555
)	O	555-556
(	O	557-558
54	O	558-560
.	O	560-561
8	O	561-562
%	O	562-563
)	O	563-564
,	O	564-565
zidovudine	O	566-576
(	O	577-578
AZT	O	578-581
)	O	581-582
+	O	583-584
3TC	O	585-588
+	O	589-590
NVP	O	591-594
(	O	595-596
14	O	596-598
.	O	598-599
5	O	599-600
%	O	600-601
)	O	601-602
,	O	602-603
3TC	O	604-607
+	O	608-609
d4T	O	610-613
+	O	614-615
efavirenz	O	616-625
(	O	626-627
EFV	O	627-630
)	O	630-631
(	O	632-633
20	O	633-635
.	O	635-636
1	O	636-637
%	O	637-638
)	O	638-639
,	O	639-640
and	O	641-644
AZT	O	645-648
+	O	649-650
3TC	O	651-654
+	O	655-656
EFV	O	657-660
(	O	661-662
5	O	662-663
.	O	663-664
4	O	664-665
%	O	665-666
)	O	666-667
.	O	663-664

The	O	669-672
most	O	673-677
common	O	678-684
adverse	O	685-692
events	O	693-699
and	O	700-703
median	O	704-710
CD4	O	711-714
at	O	715-717
time	O	718-722
of	O	723-725
event	O	726-731
were	O	732-736
rash	B	737-741
(	O	742-743
15	O	743-745
.	O	745-746
2	O	746-747
%	O	747-748
;	O	748-749

CD4	O	750-753
,	O	753-754
285	O	755-758
cells	O	759-764
/	O	764-765
microL	O	765-771
)	O	771-772
and	O	773-776
peripheral	B	777-787
neuropathy	I	788-798
(	O	799-800
9	O	800-801
.	O	801-802
0	O	802-803
%	O	803-804
and	O	805-808
348	O	809-812
cells	O	813-818
/	O	818-819
microL	O	819-825
)	O	825-826
.	O	826-827

Clinically	O	828-838
significant	O	839-850
anemia	B	851-857
(	O	858-859
hemoglobin	O	859-869
<	O	870-871
7	O	871-872
g	O	873-874
/	O	874-875
dL	O	875-877
)	O	877-878
was	O	879-882
observed	O	883-891
in	O	892-894
5	O	895-896
.	O	896-897
4	O	897-898
%	O	898-899
of	O	900-902
patients	O	903-911
(	O	912-913
CD4	O	913-916
,	O	916-917
165	O	918-921
cells	O	922-927
/	O	927-928
microL	O	928-934
)	O	934-935
and	O	936-939
hepatitis	B	940-949
(	O	950-951
clinical	O	951-959
jaundice	B	960-968
with	O	969-973
alanine	O	974-981
aminotransferase	O	982-998
>	O	999-1000
5	O	1001-1002
times	O	1003-1008
upper	O	1009-1014
limits	O	1015-1021
of	O	1022-1024
normal	O	1025-1031
)	O	1031-1032
in	O	1033-1035
3	O	1036-1037
.	O	1037-1038
5	O	1038-1039
%	O	1039-1040
of	O	1041-1043
patients	O	1044-1052
(	O	1053-1054
CD4	O	1054-1057
,	O	1057-1058
260	O	1059-1062
cells	O	1063-1068
/	O	1068-1069
microL	O	1069-1075
)	O	1075-1076
.	O	1076-1077

Women	O	1078-1083
were	O	1084-1088
significantly	O	1089-1102
more	O	1103-1107
likely	O	1108-1114
to	O	1115-1117
experience	O	1118-1128
lactic	B	1129-1135
acidosis	I	1136-1144
,	O	1144-1145
while	O	1146-1151
men	O	1152-1155
were	O	1156-1160
significantly	O	1161-1174
more	O	1175-1179
likely	O	1180-1186
to	O	1187-1189
experience	O	1190-1200
immune	B	1201-1207
reconstitution	I	1208-1222
syndrome	I	1223-1231
(	O	1232-1233
p	O	1233-1234
<	O	1235-1236
0	O	1237-1238
.	O	1238-1239
05	O	1239-1241
)	O	1241-1242
.	O	1238-1239

Among	O	1244-1249
the	O	1250-1253
patients	O	1254-1262
with	O	1263-1267
1	O	1268-1269
year	O	1270-1274
of	O	1275-1277
follow	O	1278-1284
-	O	1284-1285
up	O	1285-1287
,	O	1287-1288
NVP	O	1289-1292
therapy	O	1293-1300
was	O	1301-1304
significantly	O	1305-1318
associated	O	1319-1329
with	O	1330-1334
developing	O	1335-1345
rash	B	1346-1350
and	O	1351-1354
d4T	O	1355-1358
therapy	O	1359-1366
with	O	1367-1371
developing	O	1372-1382
peripheral	B	1383-1393
neuropathy	I	1394-1404
(	O	1405-1406
p	O	1406-1407
<	O	1408-1409
0	O	1410-1411
.	O	1411-1412
05	O	1412-1414
)	O	1414-1415
.	O	1411-1412

Anemia	B	1417-1423
and	O	1424-1427
hepatitis	B	1428-1437
often	O	1438-1443
occur	O	1444-1449
within	O	1450-1456
12	O	1457-1459
weeks	O	1460-1465
of	O	1466-1468
initiating	O	1469-1479
generic	O	1480-1487
HAART	O	1488-1493
.	O	1493-1494

Frequent	O	1495-1503
and	O	1504-1507
early	O	1508-1513
monitoring	O	1514-1524
for	O	1525-1528
these	O	1529-1534
toxicities	B	1535-1545
is	O	1546-1548
warranted	O	1549-1558
in	O	1559-1561
developing	O	1562-1572
countries	O	1573-1582
where	O	1583-1588
generic	O	1589-1596
HAART	O	1597-1602
is	O	1603-1605
increasingly	O	1606-1618
available	O	1619-1628
.	O	1628-1629

Thalidomide	O	0-11
and	O	12-15
sensory	B	16-23
neurotoxicity	I	24-37
:	O	37-38
a	O	39-40
neurophysiological	O	41-59
study	O	60-65
.	O	65-66

BACKGROUND	O	67-77
:	O	77-78
Recent	O	79-85
studies	O	86-93
confirmed	O	94-103
a	O	104-105
high	O	106-110
incidence	O	111-120
of	O	121-123
sensory	B	124-131
axonal	I	132-138
neuropathy	I	139-149
in	O	150-152
patients	O	153-161
treated	O	162-169
with	O	170-174
different	O	175-184
doses	O	185-190
of	O	191-193
thalidomide	O	194-205
.	O	205-206

The	O	207-210
study	O	211-216
'	O	216-217
s	O	211-212
aims	O	219-223
were	O	224-228
to	O	229-231
measure	O	232-239
variations	O	240-250
in	O	251-253
sural	O	254-259
nerve	O	260-265
sensory	O	266-273
action	O	274-280
potential	O	281-290
(	O	291-292
SAP	O	292-295
)	O	295-296
amplitude	O	297-306
in	O	307-309
patients	O	310-318
with	O	319-323
refractory	O	324-334
cutaneous	B	335-344
lupus	I	345-350
erythematosus	I	351-364
(	O	365-366
CLE	B	366-369
)	O	369-370
treated	O	371-378
with	O	379-383
thalidomide	O	384-395
and	O	396-399
use	O	400-403
these	O	404-409
findings	O	410-418
to	O	419-421
identify	O	422-430
the	O	431-434
neurotoxic	B	435-445
potential	O	446-455
of	O	456-458
thalidomide	O	459-470
and	O	471-474
the	O	475-478
recovery	O	479-487
capacity	O	488-496
of	O	497-499
sensory	O	500-507
fibres	O	508-514
after	O	515-520
discontinuation	O	521-536
of	O	537-539
treatment	O	540-549
.	O	549-550

PATIENTS	O	551-559
AND	O	560-563
METHODS	O	564-571
:	O	571-572
Clinical	O	573-581
and	O	582-585
electrophysiological	O	586-606
data	O	607-611
in	O	612-614
12	O	615-617
female	O	618-624
patients	O	625-633
with	O	634-638
CLE	B	639-642
during	O	643-649
treatment	O	650-659
with	O	660-664
thalidomide	O	665-676
and	O	677-680
up	O	681-683
to	O	684-686
47	O	687-689
months	O	690-696
after	O	697-702
discontinuation	O	703-718
of	O	719-721
treatment	O	722-731
were	O	732-736
analysed	O	737-745
.	O	745-746

Sural	O	747-752
nerve	O	753-758
SAP	O	759-762
amplitude	O	763-772
reduction	O	773-782
>	O	783-784
or	O	785-787
=	O	788-789
40	O	789-791
%	O	791-792
was	O	793-796
the	O	797-800
criteria	O	801-809
for	O	810-813
discontinuing	O	814-827
therapy	O	828-835
.	O	835-836

RESULTS	O	837-844
:	O	844-845
During	O	846-852
treatment	O	853-862
,	O	862-863
11	O	864-866
patients	O	867-875
showed	O	876-882
a	O	883-884
reduction	O	885-894
in	O	895-897
sural	O	898-903
nerve	O	904-909
SAP	O	910-913
amplitude	O	914-923
compared	O	924-932
to	O	933-935
baseline	O	936-944
values	O	945-951
(	O	952-953
9	O	953-954
with	O	955-959
a	O	960-961
reduction	O	962-971
>	O	972-973
or	O	974-976
=	O	977-978
50	O	978-980
%	O	980-981
and	O	982-985
2	O	986-987
<	O	988-989
50	O	989-991
%	O	991-992
)	O	992-993
.	O	993-994

One	O	995-998
patient	O	999-1006
showed	O	1007-1013
no	O	1014-1016
changes	O	1017-1024
in	O	1025-1027
SAP	O	1028-1031
amplitude	O	1032-1041
.	O	1041-1042

Five	O	1043-1047
patients	O	1048-1056
complained	O	1057-1067
of	O	1068-1070
paresthesias	B	1071-1083
and	O	1084-1087
leg	O	1088-1091
cramps	B	1092-1098
.	O	1098-1099

After	O	1100-1105
thalidomide	O	1106-1117
treatment	O	1118-1127
,	O	1127-1128
sural	O	1129-1134
SAP	O	1135-1138
amplitude	O	1139-1148
recovered	O	1149-1158
in	O	1159-1161
3	O	1162-1163
patients	O	1164-1172
.	O	1172-1173

At	O	1174-1176
detection	O	1177-1186
of	O	1187-1189
reduction	O	1190-1199
in	O	1200-1202
sural	O	1203-1208
nerve	O	1209-1214
SAP	O	1215-1218
amplitude	O	1219-1228
,	O	1228-1229
the	O	1230-1233
median	O	1234-1240
thalidomide	O	1241-1252
cumulative	O	1253-1263
dose	O	1264-1268
was	O	1269-1272
21	O	1273-1275
.	O	1275-1276
4	O	1276-1277
g	O	1278-1279
.	O	1279-1280

The	O	1281-1284
threshold	O	1285-1294
neurotoxic	B	1295-1305
dosage	O	1306-1312
is	O	1313-1315
lower	O	1316-1321
than	O	1322-1326
previously	O	1327-1337
reported	O	1338-1346
.	O	1346-1347

CONCLUSIONS	O	1348-1359
:	O	1359-1360
Sural	O	1361-1366
nerve	O	1367-1372
SAP	O	1373-1376
amplitude	O	1377-1386
reduction	O	1387-1396
is	O	1397-1399
a	O	1400-1401
reliable	O	1402-1410
and	O	1411-1414
sensitive	O	1415-1424
marker	O	1425-1431
of	O	1432-1434
degeneration	O	1435-1447
and	O	1448-1451
recovery	O	1452-1460
of	O	1461-1463
sensory	O	1464-1471
fibres	O	1472-1478
.	O	1478-1479

This	O	1480-1484
electrophysiological	O	1485-1505
parameter	O	1506-1515
provides	O	1516-1524
information	O	1525-1536
about	O	1537-1542
subclinical	O	1543-1554
neurotoxic	B	1555-1565
potential	O	1566-1575
of	O	1576-1578
thalidomide	O	1579-1590
but	O	1591-1594
is	O	1595-1597
not	O	1598-1601
helpful	O	1602-1609
in	O	1610-1612
predicting	O	1613-1623
the	O	1624-1627
appearance	O	1628-1638
of	O	1639-1641
sensory	O	1642-1649
symptoms	O	1650-1658
.	O	1658-1659

Amiodarone	O	0-10
-	O	10-11
related	O	11-18
pulmonary	B	19-28
mass	I	29-33
and	O	34-37
unique	O	38-44
membranous	B	45-55
glomerulonephritis	I	56-74
in	O	75-77
a	O	78-79
patient	O	80-87
with	O	88-92
valvular	B	93-101
heart	I	102-107
disease	I	108-115
:	O	115-116
Diagnostic	O	117-127
pitfall	O	128-135
and	O	136-139
new	O	140-143
findings	O	144-152
.	O	152-153

Amiodarone	O	154-164
is	O	165-167
an	O	168-170
anti	O	171-175
-	O	175-176
arrhythmic	B	176-186
drug	O	187-191
for	O	192-195
life	O	196-200
-	O	200-201
threatening	O	201-212
tachycardia	B	213-224
,	O	224-225
but	O	226-229
various	O	230-237
adverse	O	238-245
effects	O	246-253
have	O	254-258
been	O	259-263
reported	O	264-272
.	O	272-273

Reported	O	274-282
herein	O	283-289
is	O	290-292
an	O	293-295
autopsy	O	296-303
case	O	304-308
of	O	309-311
valvular	B	312-320
heart	I	321-326
disease	I	327-334
,	O	334-335
in	O	336-338
a	O	339-340
patient	O	341-348
who	O	349-352
developed	O	353-362
a	O	363-364
lung	B	365-369
mass	I	370-374
(	O	375-376
1	O	376-377
.	O	377-378
5	O	378-379
cm	O	380-382
in	O	383-385
diameter	O	386-394
)	O	394-395
and	O	396-399
proteinuria	B	400-411
(	O	412-413
2	O	413-414
.	O	414-415
76	O	415-417
g	O	418-419
/	O	419-420
day	O	420-423
)	O	423-424
after	O	425-430
treatment	O	431-440
with	O	441-445
amiodarone	O	446-456
for	O	457-460
a	O	461-462
long	O	463-467
time	O	468-472
.	O	472-473

The	O	474-477
lung	B	478-482
mass	I	483-487
was	O	488-491
highly	O	492-498
suspected	O	499-508
to	O	509-511
be	O	512-514
lung	B	515-519
cancer	I	520-526
on	O	527-529
CT	O	530-532
and	O	533-536
positron	O	537-545
emission	O	546-554
tomography	O	555-565
,	O	565-566
but	O	567-570
histologically	O	571-585
the	O	586-589
lesion	O	590-596
was	O	597-600
composed	O	601-609
of	O	610-612
lymphoplasmacytic	O	613-630
infiltrates	O	631-642
in	O	643-645
alveolar	O	646-654
walls	O	655-660
and	O	661-664
intra	O	665-670
-	O	670-671
alveolar	O	671-679
accumulation	O	680-692
of	O	693-695
foamy	O	696-701
macrophages	O	702-713
containing	O	714-724
characteristic	O	725-739
myelinoid	O	740-749
bodies	O	750-756
,	O	756-757
indicating	O	758-768
that	O	769-773
it	O	774-776
was	O	777-780
an	O	781-783
amiodarone	O	784-794
-	O	794-795
related	O	795-802
lesion	O	803-809
.	O	809-810

In	O	811-813
addition	O	814-822
,	O	822-823
the	O	824-827
lung	O	828-832
tissue	O	833-839
had	O	840-843
unevenly	O	844-852
distributed	O	853-864
hemosiderin	B	865-876
deposition	O	877-887
,	O	887-888
and	O	889-892
abnormally	O	893-903
tortuous	O	904-912
capillaries	O	913-924
were	O	925-929
seen	O	930-934
in	O	935-937
the	O	938-941
mass	O	942-946
and	O	947-950
in	O	951-953
heavily	O	954-961
hemosiderotic	B	962-975
lung	O	976-980
portions	O	981-989
outside	O	990-997
the	O	998-1001
mass	O	1002-1006
.	O	1006-1007

In	O	1008-1010
the	O	1011-1014
kidneys	O	1015-1022
,	O	1022-1023
glomeruli	O	1024-1033
had	O	1034-1037
membrane	O	1038-1046
spikes	O	1047-1053
,	O	1053-1054
prominent	O	1055-1064
swelling	O	1065-1073
of	O	1074-1076
podocytes	O	1077-1086
and	O	1087-1090
subepithelial	O	1091-1104
deposits	O	1105-1113
,	O	1113-1114
which	O	1115-1120
were	O	1121-1125
sometimes	O	1126-1135
large	O	1136-1141
and	O	1142-1145
hump	O	1146-1150
-	O	1150-1151
like	O	1151-1155
.	O	1155-1156

Autoimmune	B	1157-1167
diseases	I	1168-1176
,	O	1176-1177
viral	B	1178-1183
hepatitis	I	1184-1193
,	O	1193-1194
malignant	O	1195-1204
neoplasms	B	1205-1214
or	O	1215-1217
other	O	1218-1223
diseases	O	1224-1232
with	O	1233-1237
a	O	1238-1239
known	O	1240-1245
relationship	O	1246-1258
to	O	1259-1261
membranous	B	1262-1272
glomerulonephritis	I	1273-1291
were	O	1292-1296
not	O	1297-1300
found	O	1301-1306
.	O	1306-1307

The	O	1308-1311
present	O	1312-1319
case	O	1320-1324
highlights	O	1325-1335
the	O	1336-1339
possibility	O	1340-1351
that	O	1352-1356
differential	O	1357-1369
diagnosis	O	1370-1379
between	O	1380-1387
an	O	1388-1390
amiodarone	O	1391-1401
-	O	1401-1402
related	O	1402-1409
pulmonary	B	1410-1419
lesion	I	1420-1426
and	O	1427-1430
a	O	1431-1432
neoplasm	B	1433-1441
can	O	1442-1445
be	O	1446-1448
very	O	1449-1453
difficult	O	1454-1463
radiologically	O	1464-1478
,	O	1478-1479
and	O	1480-1483
suggests	O	1484-1492
that	O	1493-1497
membranous	B	1498-1508
glomerulonephritis	I	1509-1527
might	O	1528-1533
be	O	1534-1536
another	O	1537-1544
possible	O	1545-1553
complication	O	1554-1566
of	O	1567-1569
amiodarone	O	1570-1580
treatment	O	1581-1590
.	O	1590-1591

Risk	O	0-4
of	O	5-7
coronary	B	8-16
artery	I	17-23
disease	I	24-31
associated	O	32-42
with	O	43-47
initial	O	48-55
sulphonylurea	O	56-69
treatment	O	70-79
of	O	80-82
patients	O	83-91
with	O	92-96
type	B	97-101
2	I	102-103
diabetes	I	104-112
:	O	112-113
a	O	114-115
matched	O	116-123
case	O	124-128
-	O	128-129
control	O	129-136
study	O	137-142
.	O	142-143

AIMS	O	144-148
:	O	148-149
This	O	150-154
study	O	155-160
sought	O	161-167
to	O	168-170
assess	O	171-177
the	O	178-181
risk	O	182-186
of	O	187-189
developing	O	190-200
coronary	B	201-209
artery	I	210-216
disease	I	217-224
(	O	225-226
CAD	B	226-229
)	O	229-230
associated	O	231-241
with	O	242-246
initial	O	247-254
treatment	O	255-264
of	O	265-267
type	B	268-272
2	I	273-274
diabetes	I	275-283
with	O	284-288
different	O	289-298
sulphonylureas	O	299-313
.	O	313-314

METHODS	O	315-322
:	O	322-323
In	O	324-326
type	B	327-331
2	I	332-333
diabetic	I	334-342
patients	O	343-351
,	O	351-352
cases	O	353-358
who	O	359-362
developed	O	363-372
CAD	B	373-376
were	O	377-381
compared	O	382-390
retrospectively	O	391-406
with	O	407-411
controls	O	412-420
that	O	421-425
did	O	426-429
not	O	430-433
.	O	433-434

The	O	435-438
20	O	439-441
-	O	441-442
year	O	442-446
risk	O	447-451
of	O	452-454
CAD	B	455-458
at	O	459-461
diagnosis	O	462-471
of	O	472-474
diabetes	B	475-483
,	O	483-484
using	O	485-490
the	O	491-494
UKPDS	O	495-500
risk	O	501-505
engine	O	506-512
,	O	512-513
was	O	514-517
used	O	518-522
to	O	523-525
match	O	526-531
cases	O	532-537
with	O	538-542
controls	O	543-551
.	O	551-552

RESULTS	O	553-560
:	O	560-561
The	O	562-565
76	O	566-568
cases	O	569-574
of	O	575-577
CAD	B	578-581
were	O	582-586
compared	O	587-595
with	O	596-600
152	O	601-604
controls	O	605-613
.	O	613-614

The	O	615-618
hazard	O	619-625
of	O	626-628
developing	O	629-639
CAD	B	640-643
(	O	644-645
95	O	645-647
%	O	647-648
CI	O	649-651
)	O	651-652
associated	O	653-663
with	O	664-668
initial	O	669-676
treatment	O	677-686
increased	O	687-696
by	O	697-699
2	O	700-701
.	O	701-702
4	O	702-703
-	O	703-704
fold	O	704-708
(	O	709-710
1	O	710-711
.	O	711-712
3	O	712-713
-	O	713-714
4	O	714-715
.	O	711-712
3	O	712-713
,	O	717-718

P	O	719-720
=	O	720-721
0	O	721-722
.	O	722-723
004	O	723-726
)	O	726-727
with	O	728-732
glibenclamide	O	733-746
;	O	746-747
2	O	748-749
-	O	749-750
fold	O	750-754
(	O	755-756
0	O	756-757
.	O	757-758
9	O	758-759
-	O	759-760
4	O	760-761
.	O	757-758
6	O	762-763
,	O	763-764
P	O	765-766
=	O	766-767
0	O	767-768
.	O	768-769
099	O	769-772
)	O	772-773
with	O	774-778
glipizide	O	779-788
;	O	788-789
2	O	790-791
.	O	791-792
9	O	792-793
-	O	793-794
fold	O	794-798
(	O	799-800
1	O	800-801
.	O	801-802
6	O	802-803
-	O	803-804
5	O	804-805
.	O	801-802
1	O	800-801
,	O	807-808

P	O	809-810
=	O	810-811
0	O	811-812
.	O	812-813
000	O	813-816
)	O	816-817
with	O	818-822
either	O	823-829
,	O	829-830
and	O	831-834
was	O	835-838
unchanged	O	839-848
with	O	849-853
metformin	O	854-863
.	O	863-864

The	O	865-868
hazard	O	869-875
decreased	O	876-885
0	O	886-887
.	O	887-888
3	O	888-889
-	O	889-890
fold	O	890-894
(	O	895-896
0	O	896-897
.	O	897-898
7	O	898-899
-	O	899-900
1	O	900-901
.	O	897-898
7	O	898-899
,	O	903-904
P	O	905-906
=	O	906-907
0	O	907-908
.	O	908-909
385	O	909-912
)	O	912-913
with	O	914-918
glimepiride	O	919-930
,	O	930-931
0	O	932-933
.	O	933-934
4	O	934-935
-	O	935-936
fold	O	936-940
(	O	941-942
0	O	942-943
.	O	943-944
7	O	944-945
-	O	945-946
1	O	946-947
.	O	943-944
3	O	948-949
,	O	949-950
P	O	951-952
=	O	952-953
0	O	953-954
.	O	954-955
192	O	955-958
)	O	958-959
with	O	960-964
gliclazide	O	965-975
,	O	975-976
and	O	977-980
0	O	981-982
.	O	982-983
4	O	983-984
-	O	984-985
fold	O	985-989
(	O	990-991
0	O	991-992
.	O	992-993
7	O	993-994
-	O	994-995
1	O	995-996
.	O	992-993
1	O	995-996
,	O	998-999
P	O	1000-1001
=	O	1001-1002
0	O	1002-1003
.	O	1003-1004
09	O	1004-1006
)	O	1006-1007
with	O	1008-1012
either	O	1013-1019
.	O	1019-1020

CONCLUSIONS	O	1021-1032
:	O	1032-1033
Initiating	O	1034-1044
treatment	O	1045-1054
of	O	1055-1057
type	B	1058-1062
2	I	1063-1064
diabetes	I	1065-1073
with	O	1074-1078
glibenclamide	O	1079-1092
or	O	1093-1095
glipizide	O	1096-1105
is	O	1106-1108
associated	O	1109-1119
with	O	1120-1124
increased	O	1125-1134
risk	O	1135-1139
of	O	1140-1142
CAD	B	1143-1146
in	O	1147-1149
comparison	O	1150-1160
to	O	1161-1163
gliclazide	O	1164-1174
or	O	1175-1177
glimepiride	O	1178-1189
.	O	1189-1190

If	O	1191-1193
confirmed	O	1194-1203
,	O	1203-1204
this	O	1205-1209
may	O	1210-1213
be	O	1214-1216
important	O	1217-1226
because	O	1227-1234
most	O	1235-1239
Indian	O	1240-1246
patients	O	1247-1255
receive	O	1256-1263
the	O	1264-1267
cheaper	O	1268-1275
older	O	1276-1281
sulphonylureas	O	1282-1296
,	O	1296-1297
and	O	1298-1301
present	O	1302-1309
guidelines	O	1310-1320
do	O	1321-1323
not	O	1324-1327
distinguish	O	1328-1339
between	O	1340-1347
individual	O	1348-1358
agents	O	1359-1365
.	O	1365-1366

Reduced	O	0-7
progression	O	8-19
of	O	20-22
adriamycin	O	23-33
nephropathy	B	34-45
in	O	46-48
spontaneously	O	49-62
hypertensive	B	63-75
rats	O	76-80
treated	O	81-88
by	O	89-91
losartan	O	92-100
.	O	100-101

BACKGROUND	O	102-112
:	O	112-113
The	O	114-117
aim	O	118-121
of	O	122-124
the	O	125-128
study	O	129-134
was	O	135-138
to	O	139-141
investigate	O	142-153
the	O	154-157
antihypertensive	O	158-174
effects	O	175-182
of	O	183-185
angiotensin	O	186-197
II	O	198-200
type	O	201-205
-	O	205-206
1	O	206-207
receptor	O	208-216
blocker	O	217-224
,	O	224-225
losartan	O	226-234
,	O	234-235
and	O	236-239
its	O	240-243
potential	O	244-253
in	O	254-256
slowing	O	257-264
down	O	265-269
renal	B	270-275
disease	I	276-283
progression	O	284-295
in	O	296-298
spontaneously	O	299-312
hypertensive	B	313-325
rats	O	326-330
(	O	331-332
SHR	O	332-335
)	O	335-336
with	O	337-341
adriamycin	O	342-352
(	O	353-354
ADR	O	354-357
)	O	357-358
nephropathy	B	359-370
.	O	370-371

METHODS	O	372-379
:	O	379-380
Six	O	381-384
-	O	384-385
month	O	385-390
-	O	384-385
old	O	391-394
female	O	395-401
SHR	O	402-405
were	O	406-410
randomly	O	411-419
selected	O	420-428
in	O	429-431
six	O	432-435
groups	O	436-442
.	O	442-443

Two	O	444-447
control	O	448-455
groups	O	456-462
(	O	463-464
SH	O	464-466
(	O	463-464
6	O	467-468
)	O	468-469
,	O	469-470
SH	O	471-473
(	O	473-474
12	O	474-476
)	O	476-477
)	O	476-477
received	O	479-487
vehicle	O	488-495
.	O	495-496

Groups	O	497-503
ADR	O	504-507
(	O	507-508
6	O	508-509
)	O	509-510
,	O	510-511
ADR	O	512-515
+	O	515-516
LOS	O	516-519
(	O	519-520
6	O	520-521
)	O	521-522
and	O	523-526
ADR	O	527-530
(	O	530-531
12	O	531-533
)	O	533-534
,	O	534-535
and	O	536-539
ADR	O	540-543
+	O	543-544
LOS	O	544-547
(	O	547-548
12	O	548-550
)	O	550-551
received	O	552-560
ADR	O	561-564
(	O	565-566
2	O	566-567
mg	O	568-570
/	O	570-571
kg	O	571-573
/	O	570-571
b	O	574-575
.	O	575-576
w	O	576-577
.	O	575-576

i	O	579-580
.	O	580-581
v	O	581-582
.	O	580-581
)	O	583-584
twice	O	585-590
in	O	591-593
a	O	594-595
3	O	596-597
-	O	597-598
week	O	598-602
interval	O	603-611
.	O	611-612

Group	O	613-618
ADR	O	619-622
+	O	622-623
LOS	O	623-626
(	O	626-627
6	O	627-628
)	O	628-629
received	O	630-638
losartan	O	639-647
(	O	648-649
10	O	649-651
mg	O	652-654
/	O	654-655
kg	O	655-657
/	O	654-655
b	O	658-659
.	O	659-660
w	O	660-661
.	O	659-660
/	O	654-655
day	O	663-666
by	O	667-669
gavages	O	670-677
)	O	677-678
for	O	679-682
6	O	683-684
weeks	O	685-690
and	O	691-694
group	O	695-700
ADR	O	701-704
+	O	704-705
LOS	O	705-708
(	O	708-709
12	O	709-711
)	O	711-712
for	O	713-716
12	O	717-719
weeks	O	720-725
after	O	726-731
second	O	732-738
injection	O	739-748
of	O	749-751
ADR	O	752-755
.	O	755-756

Animals	O	757-764
were	O	765-769
killed	O	770-776
after	O	777-782
6	O	783-784
or	O	785-787
12	O	788-790
weeks	O	791-796
,	O	796-797
respectively	O	798-810
.	O	810-811

Haemodynamic	O	812-824
measurements	O	825-837
were	O	838-842
performed	O	843-852
on	O	853-855
anaesthetized	O	856-869
animals	O	870-877
,	O	877-878
blood	O	879-884
and	O	885-888
urine	O	889-894
samples	O	895-902
were	O	903-907
taken	O	908-913
for	O	914-917
biochemical	O	918-929
analysis	O	930-938
and	O	939-942
the	O	943-946
left	O	947-951
kidney	O	952-958
was	O	959-962
processed	O	963-972
for	O	973-976
morphological	O	977-990
studies	O	991-998
.	O	998-999

RESULTS	O	1000-1007
:	O	1007-1008
Short	O	1009-1014
-	O	1014-1015
term	O	1015-1019
losartan	O	1020-1028
treatment	O	1029-1038
,	O	1038-1039
besides	O	1040-1047
antihypertensive	O	1048-1064
effect	O	1065-1071
,	O	1071-1072
improved	O	1073-1081
glomerular	O	1082-1092
filtration	O	1093-1103
rate	O	1104-1108
and	O	1109-1112
ameliorated	O	1113-1124
glomerulosclerosis	B	1125-1143
resulting	O	1144-1153
in	O	1154-1156
decreased	O	1157-1166
proteinuria	B	1167-1178
.	O	1178-1179

Prolonged	O	1180-1189
treatment	O	1190-1199
with	O	1200-1204
losartan	O	1205-1213
showed	O	1214-1220
further	O	1221-1228
reduction	O	1229-1238
of	O	1239-1241
glomerulosclerosis	B	1242-1260
associated	O	1261-1271
with	O	1272-1276
reduced	O	1277-1284
progression	O	1285-1296
of	O	1297-1299
tubular	O	1300-1307
atrophy	B	1308-1315
and	O	1316-1319
interstitial	B	1320-1332
fibrosis	I	1333-1341
,	O	1341-1342
thus	O	1343-1347
preventing	O	1348-1358
heavy	O	1359-1364
proteinuria	B	1365-1376
and	O	1377-1380
chronic	B	1381-1388
renal	I	1389-1394
failure	I	1395-1402
.	O	1402-1403

Losartan	O	1404-1412
reduced	O	1413-1420
uraemia	B	1421-1428
and	O	1429-1432
increased	O	1433-1442
urea	O	1443-1447
clearance	O	1448-1457
in	O	1458-1460
advanced	O	1461-1469
ADR	O	1470-1473
nephropathy	B	1474-1485
in	O	1486-1488
SHR	O	1489-1492
.	O	1492-1493

Histological	O	1494-1506
examination	O	1507-1518
showed	O	1519-1525
that	O	1526-1530
losartan	O	1531-1539
could	O	1540-1545
prevent	O	1546-1553
tubular	O	1554-1561
atrophy	B	1562-1569
,	O	1569-1570
interstitial	O	1571-1583
infiltration	O	1584-1596
and	O	1597-1600
fibrosis	B	1601-1609
in	O	1610-1612
ADR	O	1613-1616
nephropathy	B	1617-1628
.	O	1628-1629

CONCLUSION	O	1630-1640
:	O	1640-1641
Losartan	O	1642-1650
reduces	O	1651-1658
the	O	1659-1662
rate	O	1663-1667
of	O	1668-1670
progression	O	1671-1682
of	O	1683-1685
ADR	O	1686-1689
-	O	1689-1690
induced	O	1690-1697
focal	B	1698-1703
segmental	I	1704-1713
glomerulosclerosis	I	1714-1732
to	O	1733-1735
end	B	1736-1739
-	I	1739-1740
stage	I	1740-1745
renal	I	1746-1751
disease	I	1752-1759
in	O	1760-1762
SHR	O	1763-1766
.	O	1766-1767

The	O	0-3
risks	O	4-9
of	O	10-12
aprotinin	O	13-22
and	O	23-26
tranexamic	O	27-37
acid	O	38-42
in	O	43-45
cardiac	O	46-53
surgery	O	54-61
:	O	61-62
a	O	63-64
one	O	65-68
-	O	68-69
year	O	69-73
follow	O	74-80
-	O	80-81
up	O	81-83
of	O	84-86
1188	O	87-91
consecutive	O	92-103
patients	O	104-112
.	O	112-113

BACKGROUND	O	114-124
:	O	124-125
Our	O	126-129
aim	O	130-133
was	O	134-137
to	O	138-140
investigate	O	141-152
postoperative	O	153-166
complications	O	167-180
and	O	181-184
mortality	O	185-194
after	O	195-200
administration	O	201-215
of	O	216-218
aprotinin	O	219-228
compared	O	229-237
to	O	238-240
tranexamic	O	241-251
acid	O	252-256
in	O	257-259
an	O	260-262
unselected	O	263-273
,	O	273-274
consecutive	O	275-286
cohort	O	287-293
.	O	293-294

METHODS	O	295-302
:	O	302-303
Perioperative	O	304-317
data	O	318-322
from	O	323-327
consecutive	O	328-339
cardiac	O	340-347
surgery	O	348-355
patients	O	356-364
were	O	365-369
prospectively	O	370-383
collected	O	384-393
between	O	394-401
September	O	402-411
2005	O	412-416
and	O	417-420
June	O	421-425
2006	O	426-430
in	O	431-433
a	O	434-435
university	O	436-446
-	O	446-447
affiliated	O	447-457
clinic	O	458-464
(	O	465-466
n	O	466-467
=	O	468-469
1188	O	470-474
)	O	474-475
.	O	475-476

During	O	477-483
the	O	484-487
first	O	488-493
5	O	494-495
mo	O	496-498
,	O	498-499
596	O	500-503
patients	O	504-512
received	O	513-521
aprotinin	O	522-531
(	O	532-533
Group	O	533-538
A	O	539-540
)	O	540-541
;	O	541-542
in	O	543-545
the	O	546-549
next	O	550-554
5	O	555-556
mo	O	557-559
,	O	559-560
592	O	561-564
patients	O	565-573
were	O	574-578
treated	O	579-586
with	O	587-591
tranexamic	O	592-602
acid	O	603-607
(	O	608-609
Group	O	609-614
T	O	615-616
)	O	616-617
.	O	617-618

Except	O	619-625
for	O	626-629
antifibrinolytic	O	630-646
therapy	O	647-654
,	O	654-655
the	O	656-659
anesthetic	O	660-670
and	O	671-674
surgical	O	675-683
protocols	O	684-693
remained	O	694-702
unchanged	O	703-712
.	O	712-713

RESULTS	O	714-721
:	O	721-722
The	O	723-726
pre	O	727-730
-	O	730-731
and	O	732-735
intraoperative	O	736-750
variables	O	751-760
were	O	761-765
comparable	O	766-776
between	O	777-784
the	O	785-788
treatment	O	789-798
groups	O	799-805
.	O	805-806

Postoperatively	O	807-822
,	O	822-823
a	O	824-825
significantly	O	826-839
higher	O	840-846
incidence	O	847-856
of	O	857-859
seizures	B	860-868
was	O	869-872
found	O	873-878
in	O	879-881
Group	O	882-887
T	O	888-889
(	O	890-891
4	O	891-892
.	O	892-893
6	O	893-894
%	O	894-895
vs	O	896-898
1	O	899-900
.	O	900-901
2	O	901-902
%	O	902-903
,	O	903-904
P	O	905-906
<	O	907-908
0	O	909-910
.	O	910-911
001	O	911-914
)	O	914-915
.	O	910-911

This	O	917-921
difference	O	922-932
was	O	933-936
also	O	937-941
significant	O	942-953
in	O	954-956
the	O	957-960
primary	O	961-968
valve	O	969-974
surgery	O	975-982
and	O	983-986
the	O	987-990
high	O	991-995
risk	O	996-1000
surgery	O	1001-1008
subgroups	O	1009-1018
(	O	1019-1020
7	O	1020-1021
.	O	1021-1022
9	O	1022-1023
%	O	1023-1024
vs	O	1025-1027
1	O	1028-1029
.	O	1029-1030
2	O	1030-1031
%	O	1031-1032
,	O	1032-1033
P	O	1034-1035
=	O	1036-1037
0	O	1038-1039
.	O	1039-1040
003	O	1040-1043
;	O	1043-1044
7	O	1045-1046
.	O	1046-1047
3	O	1047-1048
%	O	1048-1049
vs	O	1050-1052
2	O	1053-1054
.	O	1054-1055
4	O	1055-1056
%	O	1056-1057
,	O	1057-1058
P	O	1059-1060
=	O	1061-1062
0	O	1063-1064
.	O	1064-1065
035	O	1065-1068
,	O	1068-1069
respectively	O	1070-1082
)	O	1082-1083
.	O	1083-1084

Persistent	O	1085-1095
atrial	O	1096-1102
fibrillation	O	1103-1115
(	O	1116-1117
7	O	1117-1118
.	O	1118-1119
9	O	1119-1120
%	O	1120-1121
vs	O	1122-1124
2	O	1125-1126
.	O	1126-1127
3	O	1127-1128
%	O	1128-1129
,	O	1129-1130
P	O	1131-1132
=	O	1133-1134
0	O	1135-1136
.	O	1136-1137
020	O	1137-1140
)	O	1140-1141
and	O	1142-1145
renal	B	1146-1151
failure	I	1152-1159
(	O	1160-1161
9	O	1161-1162
.	O	1162-1163
7	O	1163-1164
%	O	1164-1165
vs	O	1166-1168
1	O	1169-1170
.	O	1170-1171
7	O	1171-1172
%	O	1172-1173
,	O	1173-1174
P	O	1175-1176
=	O	1177-1178
0	O	1179-1180
.	O	1180-1181
002	O	1181-1184
)	O	1184-1185
were	O	1186-1190
also	O	1191-1195
more	O	1196-1200
common	O	1201-1207
in	O	1208-1210
Group	O	1211-1216
T	O	1217-1218
,	O	1218-1219
in	O	1220-1222
the	O	1223-1226
primary	O	1227-1234
valve	O	1235-1240
surgery	O	1241-1248
subgroup	O	1249-1257
.	O	1257-1258

On	O	1259-1261
the	O	1262-1265
contrary	O	1266-1274
,	O	1274-1275
among	O	1276-1281
primary	O	1282-1289
coronary	O	1290-1298
artery	O	1299-1305
bypass	O	1306-1312
surgery	O	1313-1320
patients	O	1321-1329
,	O	1329-1330
there	O	1331-1336
were	O	1337-1341
more	O	1342-1346
acute	O	1347-1352
myocardial	B	1353-1363
infarctions	I	1364-1375
and	O	1376-1379
renal	B	1380-1385
dysfunction	I	1386-1397
in	O	1398-1400
Group	O	1401-1406
A	O	1407-1408
(	O	1409-1410
5	O	1410-1411
.	O	1411-1412
8	O	1412-1413
%	O	1413-1414
vs	O	1415-1417
2	O	1418-1419
.	O	1419-1420
0	O	1420-1421
%	O	1421-1422
,	O	1422-1423
P	O	1424-1425
=	O	1426-1427
0	O	1428-1429
.	O	1429-1430
027	O	1430-1433
;	O	1433-1434
22	O	1435-1437
.	O	1437-1438
5	O	1438-1439
%	O	1439-1440
vs	O	1441-1443
15	O	1444-1446
.	O	1446-1447
2	O	1447-1448
%	O	1448-1449
,	O	1449-1450
P	O	1451-1452
=	O	1453-1454
0	O	1455-1456
.	O	1456-1457
036	O	1457-1460
,	O	1460-1461
respectively	O	1462-1474
)	O	1474-1475
.	O	1475-1476

The	O	1477-1480
1	O	1481-1482
-	O	1482-1483
yr	O	1483-1485
mortality	O	1486-1495
was	O	1496-1499
significantly	O	1500-1513
higher	O	1514-1520
after	O	1521-1526
aprotinin	O	1527-1536
treatment	O	1537-1546
in	O	1547-1549
the	O	1550-1553
high	O	1554-1558
risk	O	1559-1563
surgery	O	1564-1571
group	O	1572-1577
(	O	1578-1579
17	O	1579-1581
.	O	1581-1582
7	O	1580-1581
%	O	1583-1584
vs	O	1585-1587
9	O	1588-1589
.	O	1589-1590
8	O	1590-1591
%	O	1591-1592
,	O	1592-1593
P	O	1594-1595
=	O	1596-1597
0	O	1598-1599
.	O	1599-1600
034	O	1600-1603
)	O	1603-1604
.	O	1599-1600

CONCLUSION	O	1606-1616
:	O	1616-1617
Both	O	1618-1622
antifibrinolytic	O	1623-1639
drugs	O	1640-1645
bear	O	1646-1650
the	O	1651-1654
risk	O	1655-1659
of	O	1660-1662
adverse	O	1663-1670
outcome	O	1671-1678
depending	O	1679-1688
on	O	1689-1691
the	O	1692-1695
type	O	1696-1700
of	O	1701-1703
cardiac	O	1704-1711
surgery	O	1712-1719
.	O	1719-1720

Administration	O	1721-1735
of	O	1736-1738
aprotinin	O	1739-1748
should	O	1749-1755
be	O	1756-1758
avoided	O	1759-1766
in	O	1767-1769
coronary	O	1770-1778
artery	O	1779-1785
bypass	O	1786-1792
graft	O	1793-1798
and	O	1799-1802
high	O	1803-1807
risk	O	1808-1812
patients	O	1813-1821
,	O	1821-1822
whereas	O	1823-1830
administration	O	1831-1845
of	O	1846-1848
tranexamic	O	1849-1859
acid	O	1860-1864
is	O	1865-1867
not	O	1868-1871
recommended	O	1872-1883
in	O	1884-1886
valve	O	1887-1892
surgery	O	1893-1900
.	O	1900-1901

The	O	0-3
biological	O	4-14
properties	O	15-25
of	O	26-28
the	O	29-32
optical	O	33-40
isomers	O	41-48
of	O	49-51
propranolol	O	52-63
and	O	64-67
their	O	68-73
effects	O	74-81
on	O	82-84
cardiac	B	85-92
arrhythmias	I	93-104
.	O	104-105

1	O	106-107
.	O	107-108

The	O	109-112
optical	O	113-120
isomers	O	121-128
of	O	129-131
propranolol	O	132-143
have	O	144-148
been	O	149-153
compared	O	154-162
for	O	163-166
their	O	167-172
beta	O	173-177
-	O	177-178
blocking	O	178-186
and	O	187-190
antiarrhythmic	O	191-205
activities	O	206-216
.	O	216-217
2	O	217-218
.	O	216-217

In	O	220-222
blocking	O	223-231
the	O	232-235
positive	O	236-244
inotropic	O	245-254
and	O	255-258
chronotropic	O	259-271
responses	O	272-281
to	O	282-284
isoprenaline	O	285-297
,	O	297-298
(	O	299-300
+	O	300-301
)	O	301-302
-	O	302-303
propranolol	O	303-314
had	O	315-318
less	O	319-323
than	O	324-328
one	O	329-332
hundredth	O	333-342
the	O	343-346
potency	O	347-354
of	O	355-357
(	O	358-359
-	O	359-360
)	O	360-361
-	O	359-360
propranolol	O	362-373
.	O	373-374

At	O	375-377
dose	O	378-382
levels	O	383-389
of	O	390-392
(	O	393-394
+	O	394-395
)	O	395-396
-	O	396-397
propranolol	O	397-408
which	O	409-414
attenuated	O	415-425
the	O	426-429
responses	O	430-439
to	O	440-442
isoprenaline	O	443-455
,	O	455-456
there	O	457-462
was	O	463-466
a	O	467-468
significant	O	469-480
prolongation	O	481-493
of	O	494-496
the	O	497-500
PR	O	501-503
interval	O	504-512
of	O	513-515
the	O	516-519
electrocardiogram	O	520-537
.	O	537-538
3	O	538-539
.	O	537-538

The	O	541-544
metabolic	O	545-554
responses	O	555-564
to	O	565-567
isoprenaline	O	568-580
in	O	581-583
dogs	O	584-588
(	O	589-590
an	O	590-592
increase	O	593-601
in	O	602-604
circulating	O	605-616
glucose	O	617-624
,	O	624-625
lactate	O	626-633
and	O	634-637
free	O	638-642
fatty	O	643-648
acids	O	649-654
)	O	654-655
were	O	656-660
all	O	661-664
blocked	O	665-672
by	O	673-675
(	O	676-677
-	O	677-678
)	O	678-679
-	O	677-678
propranolol	O	680-691
.	O	691-692

(	O	693-694
+	O	694-695
)	O	695-696
-	O	696-697
Propranolol	O	697-708
had	O	709-712
no	O	713-715
effect	O	716-722
on	O	723-725
fatty	O	726-731
acid	O	732-736
mobilization	O	737-749
but	O	750-753
significantly	O	754-767
reduced	O	768-775
the	O	776-779
increments	O	780-790
in	O	791-793
both	O	794-798
lactate	O	799-806
and	O	807-810
glucose	O	811-818
.	O	818-819
4	O	819-820
.	O	818-819

Both	O	822-826
isomers	O	827-834
of	O	835-837
propranolol	O	838-849
possessed	O	850-859
similar	O	860-867
depressant	O	868-878
potency	O	879-886
on	O	887-889
isolated	O	890-898
atrial	O	899-905
muscle	O	906-912
taken	O	913-918
from	O	919-923
guinea	O	924-930
-	O	930-931
pigs	O	931-935
.	O	935-936
5	O	936-937
.	O	935-936

The	O	939-942
isomers	O	943-950
of	O	951-953
propranolol	O	954-965
exhibited	O	966-975
similar	O	976-983
local	O	984-989
anaesthetic	O	990-1001
potencies	O	1002-1011
on	O	1012-1014
an	O	1015-1017
isolated	O	1018-1026
frog	O	1027-1031
nerve	O	1032-1037
preparation	O	1038-1049
at	O	1050-1052
a	O	1053-1054
level	O	1055-1060
approximately	O	1061-1074
three	O	1075-1080
times	O	1081-1086
that	O	1087-1091
of	O	1092-1094
procaine	O	1095-1103
.	O	1103-1104

The	O	1105-1108
racemic	O	1109-1116
compound	O	1117-1125
was	O	1126-1129
significantly	O	1130-1143
less	O	1144-1148
potent	O	1149-1155
than	O	1156-1160
either	O	1161-1167
isomer	O	1168-1174
.	O	1174-1175
6	O	1175-1176
.	O	1174-1175

Both	O	1178-1182
isomers	O	1183-1190
of	O	1191-1193
propranolol	O	1194-1205
were	O	1206-1210
capable	O	1211-1218
of	O	1219-1221
preventing	O	1222-1232
adrenaline	O	1233-1243
-	O	1243-1244
induced	O	1244-1251
cardiac	B	1252-1259
arrhythmias	I	1260-1271
in	O	1272-1274
cats	O	1275-1279
anaesthetized	O	1280-1293
with	O	1294-1298
halothane	O	1299-1308
,	O	1308-1309
but	O	1310-1313
the	O	1314-1317
mean	O	1318-1322
dose	O	1323-1327
of	O	1328-1330
(	O	1331-1332
-	O	1332-1333
)	O	1333-1334
-	O	1332-1333
propranolol	O	1335-1346
was	O	1347-1350
0	O	1351-1352
.	O	1352-1353
09	O	1353-1355
+	O	1355-1356
/	O	1356-1357
-	O	1357-1358
0	O	1351-1352
.	O	1352-1353
02	O	1360-1362

mg	O	1363-1365
/	O	1365-1366
kg	O	1366-1368
whereas	O	1369-1376
that	O	1377-1381
of	O	1382-1384
(	O	1385-1386
+	O	1386-1387
)	O	1387-1388
-	O	1388-1389
propranolol	O	1389-1400
was	O	1401-1404
4	O	1405-1406
.	O	1406-1407
2	O	1407-1408
+	O	1408-1409
/	O	1409-1410
-	O	1410-1411
1	O	1411-1412
.	O	1406-1407
2	O	1407-1408

mg	O	1415-1417
/	O	1417-1418
kg	O	1418-1420
.	O	1420-1421

At	O	1422-1424
the	O	1425-1428
effective	O	1429-1438
dose	O	1439-1443
level	O	1444-1449
of	O	1450-1452
(	O	1453-1454
+	O	1454-1455
)	O	1455-1456
-	O	1456-1457
propranolol	O	1457-1468
there	O	1469-1474
was	O	1475-1478
a	O	1479-1480
significant	O	1481-1492
prolongation	O	1493-1505
of	O	1506-1508
the	O	1509-1512
PR	O	1513-1515
interval	O	1516-1524
of	O	1525-1527
the	O	1528-1531
electrocardiogram	O	1532-1549
.	O	1549-1550

Blockade	O	1551-1559
of	O	1560-1562
arrhythmias	B	1563-1574
with	O	1575-1579
both	O	1580-1584
isomers	O	1585-1592
was	O	1593-1596
surmountable	O	1597-1609
by	O	1610-1612
increasing	O	1613-1623
the	O	1624-1627
dose	O	1628-1632
of	O	1633-1635
adrenaline	O	1636-1646
.	O	1646-1647
7	O	1647-1648
.	O	1646-1647

Both	O	1650-1654
isomers	O	1655-1662
of	O	1663-1665
propranolol	O	1666-1677
were	O	1678-1682
also	O	1683-1687
capable	O	1688-1695
of	O	1696-1698
reversing	O	1699-1708
ventricular	B	1709-1720
tachycardia	I	1721-1732
caused	O	1733-1739
by	O	1740-1742
ouabain	O	1743-1750
in	O	1751-1753
anaesthetized	O	1754-1767
cats	O	1768-1772
and	O	1773-1776
dogs	O	1777-1781
.	O	1781-1782

The	O	1783-1786
dose	O	1787-1791
of	O	1792-1794
(	O	1795-1796
-	O	1796-1797
)	O	1797-1798
-	O	1796-1797
propranolol	O	1799-1810
was	O	1811-1814
significantly	O	1815-1828
smaller	O	1829-1836
than	O	1837-1841
that	O	1842-1846
of	O	1847-1849
(	O	1850-1851
+	O	1851-1852
)	O	1852-1853
-	O	1853-1854
propranolol	O	1854-1865
in	O	1866-1868
both	O	1869-1873
species	O	1874-1881
but	O	1882-1885
much	O	1886-1890
higher	O	1891-1897
than	O	1898-1902
that	O	1903-1907
required	O	1908-1916
to	O	1917-1919
produce	O	1920-1927
evidence	O	1928-1936
of	O	1937-1939
beta	O	1940-1944
-	O	1944-1945
blockade	O	1945-1953
.	O	1953-1954
8	O	1954-1955
.	O	1953-1954

The	O	1957-1960
implications	O	1961-1973
of	O	1974-1976
these	O	1977-1982
results	O	1983-1990
are	O	1991-1994
discussed	O	1995-2004
.	O	2004-2005

Topotecan	O	0-9
in	O	10-12
combination	O	13-24
with	O	25-29
radiotherapy	O	30-42
in	O	43-45
unresectable	O	46-58
glioblastoma	B	59-71
:	O	71-72
a	O	73-74
phase	O	75-80
2	O	81-82
study	O	83-88
.	O	88-89

Improving	O	90-99
glioblastoma	B	100-112
multiforme	I	113-123
(	O	124-125
GBM	B	125-128
)	O	128-129
treatment	O	130-139
with	O	140-144
radio	O	145-150
-	O	150-151
chemotherapy	O	151-163
remains	O	164-171
a	O	172-173
challenge	O	174-183
.	O	183-184

Topotecan	O	185-194
is	O	195-197
an	O	198-200
attractive	O	201-211
option	O	212-218
as	O	219-221
it	O	222-224
exhibits	O	225-233
growth	O	234-240
inhibition	O	241-251
of	O	252-254
human	O	255-260
glioma	B	261-267
as	O	268-270
well	O	271-275
as	O	276-278
brain	O	279-284
penetration	O	285-296
.	O	296-297

The	O	298-301
present	O	302-309
study	O	310-315
assessed	O	316-324
the	O	325-328
combination	O	329-340
of	O	341-343
radiotherapy	O	344-356
(	O	357-358
60	O	358-360
Gy	O	361-363
/	O	363-364
30	O	364-366
fractions	O	367-376
/	O	376-377
40	O	377-379
days	O	380-384
)	O	384-385
and	O	386-389
topotecan	O	390-399
(	O	400-401
0	O	401-402
.	O	402-403
9	O	403-404
mg	O	405-407
/	O	407-408
m	O	405-406
(	O	409-410
2	O	410-411
)	O	411-412
/	O	407-408
day	O	413-416
on	O	417-419
days	O	420-424
1	O	425-426
-	O	426-427
5	O	427-428
on	O	429-431
weeks	O	432-437
1	O	438-439
,	O	439-440
3	O	441-442
and	O	443-446
5	O	447-448
)	O	448-449
in	O	450-452
50	O	453-455
adults	O	456-462
with	O	463-467
histologically	O	468-482
proven	O	483-489
and	O	490-493
untreated	O	494-503
GBM	B	504-507
.	O	507-508

The	O	509-512
incidence	O	513-522
of	O	523-525
non	O	526-529
-	O	529-530
hematological	O	530-543
toxicities	B	544-554
was	O	555-558
low	O	559-562
and	O	563-566
grade	O	567-572
3	O	573-574
-	O	574-575
4	O	575-576
hematological	O	577-590
toxicities	B	591-601
were	O	602-606
reported	O	607-615
in	O	616-618
20	O	619-621
patients	O	622-630
(	O	631-632
mainly	O	632-638
lymphopenia	B	639-650
and	O	651-654
neutropenia	B	655-666
)	O	666-667
.	O	667-668

Partial	O	669-676
response	O	677-685
and	O	686-689
stabilization	O	690-703
rates	O	704-709
were	O	710-714
2	O	715-716
%	O	716-717
and	O	718-721
32	O	722-724
%	O	724-725
,	O	725-726
respectively	O	727-739
,	O	739-740
with	O	741-745
an	O	746-748
overall	O	749-756
time	O	757-761
to	O	762-764
progression	O	765-776
of	O	777-779
12	O	780-782
weeks	O	783-788
.	O	788-789

One	O	790-793
-	O	793-794
year	O	794-798
overall	O	799-806
survival	O	807-815
(	O	816-817
OS	O	817-819
)	O	819-820
rate	O	821-825
was	O	826-829
42	O	830-832
%	O	832-833
,	O	833-834
with	O	835-839
a	O	840-841
median	O	842-848
OS	O	849-851
of	O	852-854
40	O	855-857
weeks	O	858-863
.	O	863-864

Topotecan	O	865-874
in	O	875-877
combination	O	878-889
with	O	890-894
radiotherapy	O	895-907
was	O	908-911
well	O	912-916
tolerated	O	917-926
.	O	926-927

However	O	928-935
,	O	935-936
while	O	937-942
response	O	943-951
and	O	952-955
stabilization	O	956-969
concerned	O	970-979
one	O	980-983
-	O	983-984
third	O	984-989
of	O	990-992
the	O	993-996
patients	O	997-1005
,	O	1005-1006
the	O	1007-1010
study	O	1011-1016
did	O	1017-1020
not	O	1021-1024
show	O	1025-1029
increased	O	1030-1039
benefits	O	1040-1048
in	O	1049-1051
terms	O	1052-1057
of	O	1058-1060
survival	O	1061-1069
in	O	1070-1072
patients	O	1073-1081
with	O	1082-1086
unresectable	O	1087-1099
GBM	B	1100-1103
.	O	1103-1104

Long	O	0-4
-	O	4-5
term	O	5-9
lithium	O	10-17
therapy	O	18-25
leading	O	26-33
to	O	34-36
hyperparathyroidism	B	37-56
:	O	56-57
a	O	58-59
case	O	60-64
report	O	65-71
.	O	71-72

PURPOSE	O	73-80
:	O	80-81
This	O	82-86
paper	O	87-92
reviews	O	93-100
the	O	101-104
effect	O	105-111
of	O	112-114
chronic	O	115-122
lithium	O	123-130
therapy	O	131-138
on	O	139-141
serum	O	142-147
calcium	O	148-155
level	O	156-161
and	O	162-165
parathyroid	O	166-177
glands	O	178-184
,	O	184-185
its	O	186-189
pathogenesis	O	190-202
,	O	202-203
and	O	204-207
treatment	O	208-217
options	O	218-225
.	O	225-226

We	O	227-229
examined	O	230-238
the	O	239-242
case	O	243-247
of	O	248-250
a	O	251-252
lithium	O	253-260
-	O	260-261
treated	O	261-268
patient	O	269-276
who	O	277-280
had	O	281-284
recurrent	O	285-294
hypercalcemia	B	295-308
to	O	309-311
better	O	312-318
understand	O	319-329
the	O	330-333
disease	O	334-341
process	O	342-349
.	O	349-350

CONCLUSION	O	351-361
:	O	361-362
Primary	B	363-370
hyperparathyroidism	I	371-390
is	O	391-393
a	O	394-395
rare	O	396-400
but	O	401-404
potentially	O	405-416
life	O	417-421
-	O	421-422
threatening	O	422-433
side	O	434-438
effect	O	439-445
of	O	446-448
long	O	449-453
-	O	453-454
term	O	454-458
lithium	O	459-466
therapy	O	467-474
.	O	474-475

Careful	O	476-483
patient	O	484-491
selection	O	492-501
and	O	502-505
long	O	506-510
-	O	510-511
term	O	511-515
follow	O	516-522
-	O	522-523
up	O	523-525
can	O	526-529
reduce	O	530-536
morbidity	O	537-546
.	O	546-547

PRACTICAL	O	548-557
IMPLICATIONS	O	558-570
:	O	570-571
As	O	572-574
much	O	575-579
as	O	580-582
15	O	583-585
%	O	585-586
of	O	587-589
lithium	O	590-597
-	O	597-598
treated	O	598-605
patients	O	606-614
become	O	615-621
hypercalcemic	B	622-635
.	O	635-636

By	O	637-639
routinely	O	640-649
monitoring	O	650-660
serum	O	661-666
calcium	O	667-674
levels	O	675-681
,	O	681-682
healthcare	O	683-693
providers	O	694-703
can	O	704-707
improve	O	708-715
the	O	716-719
quality	O	720-727
of	O	728-730
life	O	731-735
of	O	736-738
this	O	739-743
patient	O	744-751
group	O	752-757
.	O	757-758

Comparison	O	0-10
of	O	11-13
laryngeal	O	14-23
mask	O	24-28
with	O	29-33
endotracheal	O	34-46
tube	O	47-51
for	O	52-55
anesthesia	O	56-66
in	O	67-69
endoscopic	O	70-80
sinus	O	81-86
surgery	O	87-94
.	O	94-95

BACKGROUND	O	96-106
:	O	106-107
The	O	108-111
purpose	O	112-119
of	O	120-122
this	O	123-127
study	O	128-133
was	O	134-137
to	O	138-140
compare	O	141-148
surgical	O	149-157
conditions	O	158-168
,	O	168-169
including	O	170-179
the	O	180-183
amount	O	184-190
of	O	191-193
intraoperative	O	194-208
bleeding	B	209-217
as	O	218-220
well	O	221-225
as	O	226-228
intraoperative	O	229-243
blood	O	244-249
pressure	O	250-258
,	O	258-259
during	O	260-266
functional	O	267-277
endoscopic	O	278-288
sinus	O	289-294
surgery	O	295-302
(	O	303-304
FESS	O	304-308
)	O	308-309
using	O	310-315
flexible	O	316-324
reinforced	O	325-335
laryngeal	O	336-345
mask	O	346-350
airway	O	351-357
(	O	358-359
FRLMA	O	359-364
)	O	364-365
versus	O	366-372
endotracheal	O	373-385
tube	O	386-390
(	O	391-392
ETT	O	392-395
)	O	395-396
in	O	397-399
maintaining	O	400-411
controlled	O	412-422
hypotension	B	423-434
anesthesia	O	435-445
induced	O	446-453
by	O	454-456
propofol	O	457-465
-	O	465-466
remifentanil	O	466-478
total	O	479-484
i	O	485-486
.	O	486-487
v	O	487-488
.	O	486-487

anesthesia	O	490-500
(	O	501-502
TIVA	O	502-506
)	O	506-507
.	O	507-508

METHODS	O	509-516
:	O	516-517
Sixty	O	518-523
normotensive	O	524-536
American	O	537-545
Society	O	546-553
of	O	554-556
Anesthesiologists	O	557-574
I	O	575-576
-	O	576-577
II	O	577-579
adult	O	580-585
patients	O	586-594
undergoing	O	595-605
FESS	O	606-610
under	O	611-616
controlled	O	617-627
hypotension	B	628-639
anesthesia	O	640-650
caused	O	651-657
by	O	658-660
propofol	O	661-669
-	O	669-670
remifentanil	O	670-682
-	O	669-670
TIVA	O	683-687
were	O	688-692
randomly	O	693-701
assigned	O	702-710
into	O	711-715
two	O	716-719
groups	O	720-726
:	O	726-727
group	O	728-733
I	O	734-735
,	O	735-736
FRLMA	O	737-742
;	O	742-743
group	O	744-749
II	O	750-752
,	O	752-753
ETT	O	754-757
.	O	757-758

Hemorrhage	B	759-769
was	O	770-773
measured	O	774-782
and	O	783-786
the	O	787-790
visibility	O	791-801
of	O	802-804
the	O	805-808
operative	O	809-818
field	O	819-824
was	O	825-828
evaluated	O	829-838
according	O	839-848
to	O	849-851
a	O	852-853
six	O	854-857
-	O	857-858
point	O	858-863
scale	O	864-869
.	O	869-870

RESULTS	O	871-878
:	O	878-879
Controlled	O	880-890
hypotension	B	891-902
was	O	903-906
achieved	O	907-915
within	O	916-922
a	O	923-924
shorter	O	925-932
period	O	933-939
using	O	940-945
laryngeal	O	946-955
mask	O	956-960
using	O	961-966
lower	O	967-972
rates	O	973-978
of	O	979-981
remifentanil	O	982-994
infusion	O	995-1003
and	O	1004-1007
lower	O	1008-1013
total	O	1014-1019
dose	O	1020-1024
of	O	1025-1027
remifentanil	O	1028-1040
.	O	1040-1041

CONCLUSION	O	1042-1052
:	O	1052-1053
In	O	1054-1056
summary	O	1057-1064
,	O	1064-1065
our	O	1066-1069
results	O	1070-1077
indicate	O	1078-1086
that	O	1087-1091
airway	O	1092-1098
management	O	1099-1109
using	O	1110-1115
FRLMA	O	1116-1121
during	O	1122-1128
controlled	O	1129-1139
hypotension	B	1140-1151
anesthesia	O	1152-1162
provided	O	1163-1171
better	O	1172-1178
surgical	O	1179-1187
conditions	O	1188-1198
in	O	1199-1201
terms	O	1202-1207
of	O	1208-1210
quality	O	1211-1218
of	O	1219-1221
operative	O	1222-1231
field	O	1232-1237
and	O	1238-1241
blood	O	1242-1247
loss	O	1248-1252
and	O	1253-1256
allowed	O	1257-1264
for	O	1265-1268
convenient	O	1269-1279
induced	O	1280-1287
hypotension	B	1288-1299
with	O	1300-1304
low	O	1305-1308
doses	O	1309-1314
of	O	1315-1317
remifentanil	O	1318-1330
during	O	1331-1337
TIVA	O	1338-1342
in	O	1343-1345
patients	O	1346-1354
undergoing	O	1355-1365
FESS	O	1366-1370
.	O	1370-1371

Nonalcoholic	B	0-12
fatty	I	13-18
liver	I	19-24
disease	I	25-32
during	O	33-39
valproate	O	40-49
therapy	O	50-57
.	O	57-58

Valproic	O	59-67
acid	O	68-72
(	O	73-74
VPA	O	74-77
)	O	77-78
is	O	79-81
effective	O	82-91
for	O	92-95
the	O	96-99
treatment	O	100-109
of	O	110-112
many	O	113-117
types	O	118-123
of	O	124-126
epilepsy	B	127-135
,	O	135-136
but	O	137-140
its	O	141-144
use	O	145-148
can	O	149-152
be	O	153-155
associated	O	156-166
with	O	167-171
an	O	172-174
increase	O	175-183
in	O	184-186
body	O	187-191
weight	O	192-198
.	O	198-199

We	O	200-202
report	O	203-209
a	O	210-211
case	O	212-216
of	O	217-219
nonalcoholic	B	220-232
fatty	I	233-238
liver	I	239-244
disease	I	245-252
(	O	253-254
NAFLD	B	254-259
)	O	259-260
arising	O	261-268
in	O	269-271
a	O	272-273
child	O	274-279
who	O	280-283
developed	O	284-293
obesity	B	294-301
during	O	302-308
VPA	O	309-312
treatment	O	313-322
.	O	322-323

Laboratory	O	324-334
data	O	335-339
revealed	O	340-348
hyperinsulinemia	B	349-365
with	O	366-370
insulin	B	371-378
resistance	I	379-389
.	O	389-390

After	O	391-396
the	O	397-400
withdrawal	O	401-411
of	O	412-414
VPA	O	415-418
therapy	O	419-426
,	O	426-427
our	O	428-431
patient	O	432-439
showed	O	440-446
a	O	447-448
significant	O	449-460
weight	B	461-467
loss	I	468-472
,	O	472-473
a	O	474-475
decrease	O	476-484
of	O	485-487
body	O	488-492
mass	O	493-497
index	O	498-503
,	O	503-504
and	O	505-508
normalization	O	509-522
of	O	523-525
metabolic	O	526-535
and	O	536-539
endocrine	O	540-549
parameters	O	550-560
;	O	560-561
moreover	O	562-570
,	O	570-571
ultrasound	O	572-582
measurements	O	583-595
showed	O	596-602
a	O	603-604
complete	O	605-613
normalization	O	614-627
.	O	627-628

The	O	629-632
present	O	633-640
case	O	641-645
suggests	O	646-654
that	O	655-659
obesity	B	660-667
,	O	667-668
hyperinsulinemia	B	669-685
,	O	685-686
insulin	B	687-694
resistance	I	695-705
,	O	705-706
and	O	707-710
long	O	711-715
-	O	715-716
term	O	716-720
treatment	O	721-730
with	O	731-735
VPA	O	736-739
may	O	740-743
be	O	744-746
all	O	747-750
associated	O	751-761
with	O	762-766
the	O	767-770
development	O	771-782
of	O	783-785
NAFLD	B	786-791
;	O	791-792
this	O	793-797
side	O	798-802
effect	O	803-809
is	O	810-812
reversible	O	813-823
after	O	824-829
VPA	O	830-833
withdrawal	O	834-844
.	O	844-845

Carbimazole	O	0-11
induced	O	12-19
ANCA	B	20-24
positive	I	25-33
vasculitis	I	34-44
.	O	44-45

Anti	O	46-50
-	O	50-51
thyroid	O	51-58
drugs	O	59-64
,	O	64-65
like	O	66-70
carbimazole	O	71-82
and	O	83-86
propylthiouracil	O	87-103
(	O	104-105
PTU	O	105-108
)	O	108-109
are	O	110-113
commonly	O	114-122
prescribed	O	123-133
for	O	134-137
the	O	138-141
treatment	O	142-151
of	O	152-154
hyperthyroidism	B	155-170
.	O	170-171

One	O	172-175
should	O	176-182
be	O	183-185
aware	O	186-191
of	O	192-194
the	O	195-198
side	O	199-203
effects	O	204-211
of	O	212-214
antithyroid	O	215-226
medications	O	227-238
.	O	238-239

Antineutrophil	B	240-254
cytoplasmic	I	255-266
antibody	I	267-275
(	I	276-277
ANCA	I	277-281
)	I	281-282
-	I	282-283
-	I	282-283
associated	I	284-294
vasculitis	I	295-305
is	O	306-308
a	O	309-310
potentially	O	311-322
life	O	323-327
-	O	327-328
threatening	O	328-339
adverse	O	340-347
effect	O	348-354
of	O	355-357
antithyroidmedications	O	358-380
.	O	380-381

We	O	382-384
report	O	385-391
a	O	392-393
patient	O	394-401
with	O	402-406
Graves	B	407-413
'	I	413-414
disease	I	415-422
who	O	423-426
developed	O	427-436
ANCA	O	437-441
positive	O	442-450
carbimazole	O	451-462
induced	O	463-470
vasculitis	B	471-481
.	O	481-482

The	O	483-486
episode	O	487-494
was	O	495-498
characterized	O	499-512
by	O	513-515
a	O	516-517
vasculitic	B	518-528
skin	B	529-533
rash	I	534-538
associated	O	539-549
with	O	550-554
large	O	555-560
joint	O	561-566
arthritis	B	567-576
,	O	576-577
pyrexia	B	578-585
and	O	586-589
parotiditis	B	590-601
but	O	602-605
no	O	606-608
renal	O	609-614
or	O	615-617
pulmonary	O	618-627
involvement	O	628-639
.	O	639-640

He	O	641-643
was	O	644-647
referred	O	648-656
to	O	657-659
us	O	660-662
for	O	663-666
neurological	O	667-679
evaluation	O	680-690
because	O	691-698
he	O	699-701
had	O	702-705
difficulty	O	706-716
in	O	717-719
getting	O	720-727
up	O	728-730
from	O	731-735
squatting	O	736-745
position	O	746-754
and	O	755-758
was	O	759-762
suspected	O	763-772
to	O	773-775
have	O	776-780
myositis	B	781-789
.	O	789-790

Carbimazole	O	791-802
and	O	803-806
methimazole	O	807-818
have	O	819-823
a	O	824-825
lower	O	826-831
incidence	O	832-841
of	O	842-844
reported	O	845-853
ANCA	O	854-858
positive	O	859-867
side	O	868-872
effects	O	873-880
than	O	881-885
PUT	O	886-889
.	O	889-890

To	O	891-893
the	O	894-897
best	O	898-902
of	O	903-905
our	O	906-909
knowledge	O	910-919
this	O	920-924
is	O	925-927
the	O	928-931
first	O	932-937
ANCA	O	938-942
positive	O	943-951
carbimazole	O	952-963
induced	O	964-971
vasculitis	B	972-982
case	O	983-987
reported	O	988-996
from	O	997-1001
India	O	1002-1007
.	O	1007-1008

Aspirin	O	0-7
for	O	8-11
the	O	12-15
primary	O	16-23
prevention	O	24-34
of	O	35-37
cardiovascular	O	38-52
events	O	53-59
:	O	59-60
an	O	61-63
update	O	64-70
of	O	71-73
the	O	74-77
evidence	O	78-86
for	O	87-90
the	O	91-94
U	O	95-96
.	O	96-97
S	O	97-98
.	O	96-97
Preventive	O	100-110
Services	O	111-119
Task	O	120-124
Force	O	125-130
.	O	130-131

BACKGROUND	O	132-142
:	O	142-143
Coronary	B	144-152
heart	I	153-158
disease	I	159-166
and	O	167-170
cerebrovascular	B	171-186
disease	I	187-194
are	O	195-198
leading	O	199-206
causes	O	207-213
of	O	214-216
death	O	217-222
in	O	223-225
the	O	226-229
United	O	230-236
States	O	237-243
.	O	243-244

In	O	245-247
2002	O	248-252
,	O	252-253
the	O	254-257
U	O	258-259
.	O	259-260
S	O	260-261
.	O	259-260
Preventive	O	263-273
Services	O	274-282
Task	O	283-287
Force	O	288-293
(	O	294-295
USPSTF	O	295-301
)	O	301-302
strongly	O	303-311
recommended	O	312-323
that	O	324-328
clinicians	O	329-339
discuss	O	340-347
aspirin	O	348-355
with	O	356-360
adults	O	361-367
who	O	368-371
are	O	372-375
at	O	376-378
increased	O	379-388
risk	O	389-393
for	O	394-397
coronary	B	398-406
heart	I	407-412
disease	I	413-420
.	O	420-421

PURPOSE	O	422-429
:	O	429-430
To	O	431-433
determine	O	434-443
the	O	444-447
benefits	O	448-456
and	O	457-460
harms	O	461-466
of	O	467-469
taking	O	470-476
aspirin	O	477-484
for	O	485-488
the	O	489-492
primary	O	493-500
prevention	O	501-511
of	O	512-514
myocardial	B	515-525
infarctions	I	526-537
,	O	537-538
strokes	B	539-546
,	O	546-547
and	O	548-551
death	O	552-557
.	O	557-558

DATA	O	559-563
SOURCES	O	564-571
:	O	571-572
MEDLINE	O	573-580
and	O	581-584
Cochrane	O	585-593
Library	O	594-601
(	O	602-603
search	O	603-609
dates	O	610-615
,	O	615-616
1	O	617-618
January	O	619-626
2001	O	627-631
to	O	632-634
28	O	635-637
August	O	638-644
2008	O	645-649
)	O	649-650
,	O	650-651
recent	O	652-658
systematic	O	659-669
reviews	O	670-677
,	O	677-678
reference	O	679-688
lists	O	689-694
of	O	695-697
retrieved	O	698-707
articles	O	708-716
,	O	716-717
and	O	718-721
suggestions	O	722-733
from	O	734-738
experts	O	739-746
.	O	746-747

STUDY	O	748-753
SELECTION	O	754-763
:	O	763-764
English	O	765-772
-	O	772-773
language	O	773-781
randomized	O	782-792
,	O	792-793
controlled	O	794-804
trials	O	805-811
(	O	812-813
RCTs	O	813-817
)	O	817-818
;	O	818-819
case	O	820-824
-	O	824-825
control	O	825-832
studies	O	833-840
;	O	840-841
meta	O	842-846
-	O	846-847
analyses	O	847-855
;	O	855-856
and	O	857-860
systematic	O	861-871
reviews	O	872-879
of	O	880-882
aspirin	O	883-890
versus	O	891-897
control	O	898-905
for	O	906-909
the	O	910-913
primary	O	914-921
prevention	O	922-932
of	O	933-935
cardiovascular	B	936-950
disease	I	951-958
(	O	959-960
CVD	B	960-963
)	O	963-964
were	O	965-969
selected	O	970-978
to	O	979-981
answer	O	982-988
the	O	989-992
following	O	993-1002
questions	O	1003-1012
:	O	1012-1013
Does	O	1014-1018
aspirin	O	1019-1026
decrease	O	1027-1035
coronary	O	1036-1044
heart	O	1045-1050
events	O	1051-1057
,	O	1057-1058
strokes	B	1059-1066
,	O	1066-1067
death	O	1068-1073
from	O	1074-1078
coronary	O	1079-1087
heart	O	1088-1093
events	O	1094-1100
or	O	1101-1103
stroke	B	1104-1110
,	O	1110-1111
or	O	1112-1114
all	O	1115-1118
-	O	1118-1119
cause	O	1119-1124
mortality	O	1125-1134
in	O	1135-1137
adults	O	1138-1144
without	O	1145-1152
known	O	1153-1158
CVD	B	1159-1162
?	O	1162-1163
Does	O	1164-1168
aspirin	O	1169-1176
increase	O	1177-1185
gastrointestinal	B	1186-1202
bleeding	I	1203-1211
or	O	1212-1214
hemorrhagic	B	1215-1226
strokes	I	1227-1234
?	O	1234-1235

DATA	O	1236-1240
EXTRACTION	O	1241-1251
:	O	1251-1252
All	O	1253-1256
studies	O	1257-1264
were	O	1265-1269
reviewed	O	1270-1278
,	O	1278-1279
abstracted	O	1280-1290
,	O	1290-1291
and	O	1292-1295
rated	O	1296-1301
for	O	1302-1305
quality	O	1306-1313
by	O	1314-1316
using	O	1317-1322
predefined	O	1323-1333
USPSTF	O	1334-1340
criteria	O	1341-1349
.	O	1349-1350

DATA	O	1351-1355
SYNTHESIS	O	1356-1365
:	O	1365-1366
New	O	1367-1370
evidence	O	1371-1379
from	O	1380-1384
1	O	1385-1386
good	O	1387-1391
-	O	1391-1392
quality	O	1392-1399
RCT	O	1400-1403
,	O	1403-1404
1	O	1405-1406
good	O	1407-1411
-	O	1411-1412
quality	O	1412-1419
meta	O	1420-1424
-	O	1424-1425
analysis	O	1425-1433
,	O	1433-1434
and	O	1435-1438
2	O	1439-1440
fair	O	1441-1445
-	O	1445-1446
quality	O	1446-1453
subanalyses	O	1454-1465
of	O	1466-1468
RCTs	O	1469-1473
demonstrates	O	1474-1486
that	O	1487-1491
aspirin	O	1492-1499
use	O	1500-1503
reduces	O	1504-1511
the	O	1512-1515
number	O	1516-1522
of	O	1523-1525
CVD	B	1526-1529
events	O	1530-1536
in	O	1537-1539
patients	O	1540-1548
without	O	1549-1556
known	O	1557-1562
CVD	B	1563-1566
.	O	1566-1567

Men	O	1568-1571
in	O	1572-1574
these	O	1575-1580
studies	O	1581-1588
experienced	O	1589-1600
fewer	O	1601-1606
myocardial	B	1607-1617
infarctions	I	1618-1629
and	O	1630-1633
women	O	1634-1639
experienced	O	1640-1651
fewer	O	1652-1657
ischemic	O	1658-1666
strokes	B	1667-1674
.	O	1674-1675

Aspirin	O	1676-1683
does	O	1684-1688
not	O	1689-1692
seem	O	1693-1697
to	O	1698-1700
affect	O	1701-1707
CVD	B	1708-1711
mortality	O	1712-1721
or	O	1722-1724
all	O	1725-1728
-	O	1728-1729
cause	O	1729-1734
mortality	O	1735-1744
in	O	1745-1747
either	O	1748-1754
men	O	1755-1758
or	O	1759-1761
women	O	1762-1767
.	O	1767-1768

The	O	1769-1772
use	O	1773-1776
of	O	1777-1779
aspirin	O	1780-1787
for	O	1788-1791
primary	O	1792-1799
prevention	O	1800-1810
increases	O	1811-1820
the	O	1821-1824
risk	O	1825-1829
for	O	1830-1833
major	O	1834-1839
bleeding	B	1840-1848
events	O	1849-1855
,	O	1855-1856
primarily	O	1857-1866
gastrointestinal	B	1867-1883
bleeding	I	1884-1892
events	O	1893-1899
,	O	1899-1900
in	O	1901-1903
both	O	1904-1908
men	O	1909-1912
and	O	1913-1916
women	O	1917-1922
.	O	1922-1923

Men	O	1924-1927
have	O	1928-1932
an	O	1933-1935
increased	O	1936-1945
risk	O	1946-1950
for	O	1951-1954
hemorrhagic	B	1955-1966
strokes	I	1967-1974
with	O	1975-1979
aspirin	O	1980-1987
use	O	1988-1991
.	O	1991-1992

A	O	1993-1994
new	O	1995-1998
RCT	O	1999-2002
and	O	2003-2006
meta	O	2007-2011
-	O	2011-2012
analysis	O	2012-2020
suggest	O	2021-2028
that	O	2029-2033
the	O	2034-2037
risk	O	2038-2042
for	O	2043-2046
hemorrhagic	B	2047-2058
strokes	I	2059-2066
in	O	2067-2069
women	O	2070-2075
is	O	2076-2078
not	O	2079-2082
statistically	O	2083-2096
significantly	O	2097-2110
increased	O	2111-2120
.	O	2120-2121

LIMITATIONS	O	2122-2133
:	O	2133-2134
New	O	2135-2138
evidence	O	2139-2147
on	O	2148-2150
aspirin	O	2151-2158
for	O	2159-2162
the	O	2163-2166
primary	O	2167-2174
prevention	O	2175-2185
of	O	2186-2188
CVD	B	2189-2192
is	O	2193-2195
limited	O	2196-2203
.	O	2203-2204

The	O	2205-2208
dose	O	2209-2213
of	O	2214-2216
aspirin	O	2217-2224
used	O	2225-2229
in	O	2230-2232
the	O	2233-2236
RCTs	O	2237-2241
varied	O	2242-2248
,	O	2248-2249
which	O	2250-2255
prevented	O	2256-2265
the	O	2266-2269
estimation	O	2270-2280
of	O	2281-2283
the	O	2284-2287
most	O	2288-2292
appropriate	O	2293-2304
dose	O	2305-2309
for	O	2310-2313
primary	O	2314-2321
prevention	O	2322-2332
.	O	2332-2333

Several	O	2334-2341
of	O	2342-2344
the	O	2345-2348
RCTs	O	2349-2353
were	O	2354-2358
conducted	O	2359-2368
within	O	2369-2375
populations	O	2376-2387
of	O	2388-2390
health	O	2391-2397
professionals	O	2398-2411
,	O	2411-2412
which	O	2413-2418
potentially	O	2419-2430
limits	O	2431-2437
generalizability	O	2438-2454
.	O	2454-2455

CONCLUSION	O	2456-2466
:	O	2466-2467
Aspirin	O	2468-2475
reduces	O	2476-2483
the	O	2484-2487
risk	O	2488-2492
for	O	2493-2496
myocardial	B	2497-2507
infarction	I	2508-2518
in	O	2519-2521
men	O	2522-2525
and	O	2526-2529
strokes	B	2530-2537
in	O	2538-2540
women	O	2541-2546
.	O	2546-2547

Aspirin	O	2548-2555
use	O	2556-2559
increases	O	2560-2569
the	O	2570-2573
risk	O	2574-2578
for	O	2579-2582
serious	O	2583-2590
bleeding	B	2591-2599
events	O	2600-2606
.	O	2606-2607

Reducing	O	0-8
harm	O	9-13
associated	O	14-24
with	O	25-29
anticoagulation	O	30-45
:	O	45-46
practical	O	47-56
considerations	O	57-71
of	O	72-74
argatroban	O	75-85
therapy	O	86-93
in	O	94-96
heparin	O	97-104
-	O	104-105
induced	O	105-112
thrombocytopenia	B	113-129
.	O	129-130

Argatroban	O	131-141
is	O	142-144
a	O	145-146
hepatically	O	147-158
metabolized	O	159-170
,	O	170-171
direct	O	172-178
thrombin	O	179-187
inhibitor	O	188-197
used	O	198-202
for	O	203-206
prophylaxis	O	207-218
or	O	219-221
treatment	O	222-231
of	O	232-234
thrombosis	B	235-245
in	O	246-248
heparin	O	249-256
-	O	256-257
induced	O	257-264
thrombocytopenia	B	265-281
(	O	282-283
HIT	B	283-286
)	O	286-287
and	O	288-291
for	O	292-295
patients	O	296-304
with	O	305-309
or	O	310-312
at	O	313-315
risk	O	316-320
of	O	321-323
HIT	B	324-327
undergoing	O	328-338
percutaneous	O	339-351
coronary	O	352-360
intervention	O	361-373
(	O	374-375
PCI	O	375-378
)	O	378-379
.	O	379-380

The	O	381-384
objective	O	385-394
of	O	395-397
this	O	398-402
review	O	403-409
is	O	410-412
to	O	413-415
summarize	O	416-425
practical	O	426-435
considerations	O	436-450
of	O	451-453
argatroban	O	454-464
therapy	O	465-472
in	O	473-475
HIT	B	476-479
.	O	479-480

The	O	481-484
US	O	485-487
FDA	O	488-491
-	O	491-492
recommended	O	492-503
argatroban	O	504-514
dose	O	515-519
in	O	520-522
HIT	B	523-526
is	O	527-529
2	O	530-531
microg	O	532-538
/	O	538-539
kg	O	539-541
/	O	538-539
min	O	542-545
(	O	546-547
reduced	O	547-554
in	O	555-557
patients	O	558-566
with	O	567-571
hepatic	B	572-579
impairment	I	580-590
and	O	591-594
in	O	595-597
paediatric	O	598-608
patients	O	609-617
)	O	617-618
,	O	618-619
adjusted	O	620-628
to	O	629-631
achieve	O	632-639
activated	O	640-649
partial	O	650-657
thromboplastin	O	658-672
times	O	673-678
(	O	679-680
aPTTs	O	680-685
)	O	685-686
1	O	687-688
.	O	688-689
5	O	689-690
-	O	690-691
3	O	691-692
times	O	693-698
baseline	O	699-707
(	O	708-709
not	O	709-712
>	O	713-714
100	O	714-717
seconds	O	718-725
)	O	725-726
.	O	726-727

Contemporary	O	728-740
experiences	O	741-752
indicate	O	753-761
that	O	762-766
reduced	O	767-774
doses	O	775-780
are	O	781-784
also	O	785-789
needed	O	790-796
in	O	797-799
patients	O	800-808
with	O	809-813
conditions	O	814-824
associated	O	825-835
with	O	836-840
hepatic	O	841-848
hypoperfusion	O	849-862
,	O	862-863
e	O	864-865
.	O	865-866
g	O	866-867
.	O	865-866

heart	B	869-874
failure	I	875-882
,	O	882-883
yet	O	884-887
are	O	888-891
unnecessary	O	892-903
for	O	904-907
renal	B	908-913
dysfunction	I	914-925
,	O	925-926
adult	O	927-932
age	O	933-936
,	O	936-937
sex	O	938-941
,	O	941-942
race	O	943-947
/	O	947-948
ethnicity	O	948-957
or	O	958-960
obesity	B	961-968
.	O	968-969

Argatroban	O	970-980
0	O	981-982
.	O	982-983
5	O	983-984
-	O	984-985
1	O	985-986
.	O	982-983
2	O	987-988

microg	O	989-995
/	O	995-996
kg	O	996-998
/	O	995-996
min	O	999-1002
typically	O	1003-1012
supports	O	1013-1021
therapeutic	O	1022-1033
aPTTs	O	1034-1039
.	O	1039-1040

The	O	1041-1044
FDA	O	1045-1048
-	O	1048-1049
recommended	O	1049-1060
dose	O	1061-1065
during	O	1066-1072
PCI	O	1073-1076
is	O	1077-1079
25	O	1080-1082
microg	O	1083-1089
/	O	1089-1090
kg	O	1090-1092
/	O	1089-1090
min	O	1093-1096
(	O	1097-1098
350	O	1098-1101
microg	O	1102-1108
/	O	1108-1109
kg	O	1109-1111
initial	O	1112-1119
bolus	O	1120-1125
)	O	1125-1126
,	O	1126-1127
adjusted	O	1128-1136
to	O	1137-1139
achieve	O	1140-1147
activated	O	1148-1157
clotting	O	1158-1166
times	O	1167-1172
(	O	1173-1174
ACTs	O	1174-1178
)	O	1178-1179
of	O	1180-1182
300	O	1183-1186
-	O	1186-1187
450	O	1187-1190
sec	O	1191-1194
.	O	1194-1195

For	O	1196-1199
PCI	O	1200-1203
,	O	1203-1204
argatroban	O	1205-1215
has	O	1216-1219
not	O	1220-1223
been	O	1224-1228
investigated	O	1229-1241
in	O	1242-1244
hepatically	O	1245-1256
impaired	O	1257-1265
patients	O	1266-1274
;	O	1274-1275
dose	O	1276-1280
adjustment	O	1281-1291
is	O	1292-1294
unnecessary	O	1295-1306
for	O	1307-1310
adult	O	1311-1316
age	O	1317-1320
,	O	1320-1321
sex	O	1322-1325
,	O	1325-1326
race	O	1327-1331
/	O	1331-1332
ethnicity	O	1332-1341
or	O	1342-1344
obesity	B	1345-1352
,	O	1352-1353
and	O	1354-1357
lesser	O	1358-1364
doses	O	1365-1370
may	O	1371-1374
be	O	1375-1377
adequate	O	1378-1386
with	O	1387-1391
concurrent	O	1392-1402
glycoprotein	O	1403-1415
IIb	O	1416-1419
/	O	1419-1420
IIIa	O	1420-1424
inhibition	O	1425-1435
.	O	1435-1436

Argatroban	O	1437-1447
prolongs	O	1448-1456
the	O	1457-1460
International	O	1461-1474
Normalized	O	1475-1485
Ratio	O	1486-1491
,	O	1491-1492
and	O	1493-1496
published	O	1497-1506
approaches	O	1507-1517
for	O	1518-1521
monitoring	O	1522-1532
the	O	1533-1536
argatroban	O	1537-1547
-	O	1547-1548
to	O	1548-1550
-	O	1547-1548
warfarin	O	1551-1559
transition	O	1560-1570
should	O	1571-1577
be	O	1578-1580
followed	O	1581-1589
.	O	1589-1590

Major	O	1591-1596
bleeding	B	1597-1605
with	O	1606-1610
argatroban	O	1611-1621
is	O	1622-1624
0	O	1625-1626
-	O	1626-1627
10	O	1627-1629
%	O	1629-1630
in	O	1631-1633
the	O	1634-1637
non	O	1638-1641
-	O	1641-1642
interventional	O	1642-1656
setting	O	1657-1664
and	O	1665-1668
0	O	1669-1670
-	O	1670-1671
5	O	1671-1672
.	O	1672-1673
8	O	1673-1674
%	O	1674-1675
periprocedurally	O	1676-1692
.	O	1692-1693

Argatroban	O	1694-1704
has	O	1705-1708
no	O	1709-1711
specific	O	1712-1720
antidote	O	1721-1729
,	O	1729-1730
and	O	1731-1734
if	O	1735-1737
excessive	O	1738-1747
anticoagulation	O	1748-1763
occurs	O	1764-1770
,	O	1770-1771
argatroban	O	1772-1782
infusion	O	1783-1791
should	O	1792-1798
be	O	1799-1801
stopped	O	1802-1809
or	O	1810-1812
reduced	O	1813-1820
.	O	1820-1821

Improved	O	1822-1830
familiarity	O	1831-1842
of	O	1843-1845
healthcare	O	1846-1856
professionals	O	1857-1870
with	O	1871-1875
argatroban	O	1876-1886
therapy	O	1887-1894
in	O	1895-1897
HIT	B	1898-1901
,	O	1901-1902
including	O	1903-1912
in	O	1913-1915
special	O	1916-1923
populations	O	1924-1935
and	O	1936-1939
during	O	1940-1946
PCI	O	1947-1950
,	O	1950-1951
may	O	1952-1955
facilitate	O	1956-1966
reduction	O	1967-1976
of	O	1977-1979
harm	O	1980-1984
associated	O	1985-1995
with	O	1996-2000
HIT	B	2001-2004
(	O	2005-2006
e	O	2006-2007
.	O	2007-2008
g	O	2008-2009
.	O	2007-2008

fewer	O	2011-2016
thromboses	O	2017-2027
)	O	2027-2028
or	O	2029-2031
its	O	2032-2035
treatment	O	2036-2045
(	O	2046-2047
e	O	2047-2048
.	O	2048-2049
g	O	2049-2050
.	O	2048-2049

fewer	O	2052-2057
argatroban	O	2058-2068
medication	O	2069-2079
errors	O	2080-2086
)	O	2086-2087
.	O	2087-2088

Rhabdomyolysis	B	0-14
and	O	15-18
brain	O	19-24
ischemic	B	25-33
stroke	I	34-40
in	O	41-43
a	O	44-45
heroin	O	46-52
-	O	52-53
dependent	O	53-62
male	O	63-67
under	O	68-73
methadone	O	74-83
maintenance	O	84-95
therapy	O	96-103
.	O	103-104

OBJECTIVE	O	105-114
:	O	114-115
There	O	116-121
are	O	122-125
several	O	126-133
complications	O	134-147
associated	O	148-158
with	O	159-163
heroin	B	164-170
abuse	I	171-176
,	O	176-177
some	O	178-182
of	O	183-185
which	O	186-191
are	O	192-195
life	O	196-200
-	O	200-201
threatening	O	201-212
.	O	212-213

Methadone	O	214-223
may	O	224-227
aggravate	O	228-237
this	O	238-242
problem	O	243-250
.	O	250-251

METHOD	O	252-258
:	O	258-259
A	O	260-261
clinical	O	262-270
case	O	271-275
description	O	276-287
.	O	287-288

RESULTS	O	289-296
:	O	296-297
A	O	298-299
33	O	300-302
-	O	302-303
year	O	303-307
-	O	302-303
old	O	308-311
man	O	312-315
presented	O	316-325
with	O	326-330
rhabdomyolysis	B	331-345
and	O	346-349
cerebral	O	350-358
ischemic	B	359-367
stroke	I	368-374
after	O	375-380
intravenous	O	381-392
heroin	O	393-399
.	O	399-400

He	O	401-403
had	O	404-407
used	O	408-412
heroin	O	413-419
since	O	420-425
age	O	426-429
20	O	430-432
,	O	432-433
and	O	434-437
had	O	438-441
used	O	442-446
150	O	447-450
mg	O	451-453
methadone	O	454-463
daily	O	464-469
for	O	470-473
6	O	474-475
months	O	476-482
.	O	482-483

He	O	484-486
was	O	487-490
found	O	491-496
unconsciousness	B	497-512
at	O	513-515
home	O	516-520
and	O	521-524
was	O	525-528
sent	O	529-533
to	O	534-536
our	O	537-540
hospital	O	541-549
.	O	549-550

In	O	551-553
the	O	554-557
ER	O	558-560
,	O	560-561
his	O	562-565
opiate	O	566-572
level	O	573-578
was	O	579-582
4497	O	583-587
ng	O	588-590
/	O	590-591
ml	O	591-593
.	O	593-594

In	O	595-597
the	O	598-601
ICU	O	602-605
,	O	605-606
we	O	607-609
found	O	610-615
rhabdomyolysis	B	616-630
,	O	630-631
acute	B	632-637
renal	I	638-643
failure	I	644-651
and	O	652-655
acute	O	656-661
respiratory	B	662-673
failure	I	674-681
.	O	681-682

After	O	683-688
transfer	O	689-697
to	O	698-700
an	O	701-703
internal	O	704-712
ward	O	713-717
,	O	717-718
we	O	719-721
noted	O	722-727
aphasia	B	728-735
and	O	736-739
weakness	B	740-748
of	O	749-751
his	O	752-755
left	O	756-760
limbs	O	761-766
.	O	766-767

After	O	768-773
MRI	O	774-777
,	O	777-778
we	O	779-781
found	O	782-787
cerebral	B	788-796
ischemic	I	797-805
infarction	I	806-816
.	O	816-817

CONCLUSION	O	818-828
:	O	828-829
Those	O	830-835
using	O	836-841
methadone	O	842-851
and	O	852-855
heroin	O	856-862
simultaneously	O	863-877
may	O	878-881
increase	O	882-890
risk	O	891-895
of	O	896-898
rhabdomyolysis	B	899-913
and	O	914-917
ischemic	B	918-926
stroke	I	927-933
.	O	933-934

Patients	O	935-943
under	O	944-949
methadone	O	950-959
maintenance	O	960-971
therapy	O	972-979
should	O	980-986
be	O	987-989
warned	O	990-996
regarding	O	997-1006
these	O	1007-1012
serious	O	1013-1020
adverse	O	1021-1028
events	O	1029-1035
.	O	1035-1036

Hypotheses	O	1037-1047
of	O	1048-1050
heroin	O	1051-1057
-	O	1057-1058
related	O	1058-1065
rhabdomyolysis	B	1066-1080
and	O	1081-1084
stroke	B	1085-1091
in	O	1092-1094
heroin	O	1095-1101
abusers	O	1102-1109
are	O	1110-1113
discussed	O	1114-1123
.	O	1123-1124

Increased	O	0-9
vulnerability	O	10-23
to	O	24-26
6	O	27-28
-	O	28-29
hydroxydopamine	O	29-44
lesion	O	45-51
and	O	52-55
reduced	O	56-63
development	O	64-75
of	O	76-78
dyskinesias	B	79-90
in	O	91-93
mice	O	94-98
lacking	O	99-106
CB1	O	107-110
cannabinoid	O	111-122
receptors	O	123-132
.	O	132-133

Motor	O	134-139
impairment	O	140-150
,	O	150-151
dopamine	O	152-160
(	O	161-162
DA	O	162-164
)	O	164-165
neuronal	O	166-174
activity	O	175-183
and	O	184-187
proenkephalin	O	188-201
(	O	202-203
PENK	O	203-207
)	O	207-208
gene	O	209-213
expression	O	214-224
in	O	225-227
the	O	228-231
caudate	O	232-239
-	O	239-240
putamen	O	240-247
(	O	248-249
CPu	O	249-252
)	O	252-253
were	O	254-258
measured	O	259-267
in	O	268-270
6	O	271-272
-	O	272-273
OHDA	O	273-277
-	O	272-273
lesioned	O	278-286
and	O	287-290
treated	O	291-298
(	O	299-300
L	O	300-301
-	O	301-302
DOPA	O	302-306
+	O	306-307
benserazide	O	307-318
)	O	318-319
CB1	O	320-323
KO	O	324-326
and	O	327-330
WT	O	331-333
mice	O	334-338
.	O	338-339

A	O	340-341
lesion	O	342-348
induced	O	349-356
by	O	357-359
6	O	360-361
-	O	361-362
OHDA	O	362-366
produced	O	367-375
more	O	376-380
severe	O	381-387
motor	O	388-393
deterioration	O	394-407
in	O	408-410
CB1	O	411-414
KO	O	415-417
mice	O	418-422
accompanied	O	423-434
by	O	435-437
more	O	438-442
loss	O	443-447
of	O	448-450
DA	O	451-453
neurons	O	454-461
and	O	462-465
increased	O	466-475
PENK	O	476-480
gene	O	481-485
expression	O	486-496
in	O	497-499
the	O	500-503
CPu	O	504-507
.	O	507-508

Oxidative	O	509-518
/	O	518-519
nitrosative	O	519-530
and	O	531-534
neuroinflammatory	O	535-552
parameters	O	553-563
were	O	564-568
estimated	O	569-578
in	O	579-581
the	O	582-585
CPu	O	586-589
and	O	590-593
cingulate	O	594-603
cortex	O	604-610
(	O	611-612
Cg	O	612-614
)	O	614-615
.	O	615-616

CB1	O	617-620
KO	O	621-623
mice	O	624-628
exhibited	O	629-638
higher	O	639-645
MDA	O	646-649
levels	O	650-656
and	O	657-660
iNOS	O	661-665
protein	O	666-673
expression	O	674-684
in	O	685-687
the	O	688-691
CPu	O	692-695
and	O	696-699
Cg	O	700-702
compared	O	703-711
to	O	712-714
WT	O	715-717
mice	O	718-722
.	O	722-723

Treatment	O	724-733
with	O	734-738
L	O	739-740
-	O	740-741
DOPA	O	741-745
+	O	745-746
benserazide	O	746-757
(	O	758-759
12	O	759-761
weeks	O	762-767
)	O	767-768
resulted	O	769-777
in	O	778-780
less	O	781-785
severe	O	786-792
dyskinesias	B	793-804
in	O	805-807
CB1	O	808-811
KO	O	812-814
than	O	815-819
in	O	820-822
WT	O	823-825
mice	O	826-830
.	O	830-831

The	O	832-835
results	O	836-843
revealed	O	844-852
that	O	853-857
the	O	858-861
lack	O	862-866
of	O	867-869
cannabinoid	O	870-881
CB1	O	882-885
receptors	O	886-895
increased	O	896-905
the	O	906-909
severity	O	910-918
of	O	919-921
motor	O	922-927
impairment	O	928-938
and	O	939-942
DA	O	943-945
lesion	O	946-952
,	O	952-953
and	O	954-957
reduced	O	958-965
L	O	966-967
-	O	967-968
DOPA	O	968-972
-	O	967-968
induced	O	973-980
dyskinesias	B	981-992
.	O	992-993

These	O	994-999
results	O	1000-1007
suggest	O	1008-1015
that	O	1016-1020
activation	O	1021-1031
of	O	1032-1034
CB1	O	1035-1038
receptors	O	1039-1048
offers	O	1049-1055
neuroprotection	O	1056-1071
against	O	1072-1079
dopaminergic	O	1080-1092
lesion	O	1093-1099
and	O	1100-1103
the	O	1104-1107
development	O	1108-1119
of	O	1120-1122
L	O	1123-1124
-	O	1124-1125
DOPA	O	1125-1129
-	O	1124-1125
induced	O	1130-1137
dyskinesias	B	1138-1149
.	O	1149-1150

Animal	O	0-6
model	O	7-12
of	O	13-15
mania	B	16-21
induced	O	22-29
by	O	30-32
ouabain	O	33-40
:	O	40-41
Evidence	O	42-50
of	O	51-53
oxidative	O	54-63
stress	O	64-70
in	O	71-73
submitochondrial	O	74-90
particles	O	91-100
of	O	101-103
the	O	104-107
rat	O	108-111
brain	O	112-117
.	O	117-118

The	O	119-122
intracerebroventricular	O	123-146
(	O	147-148
ICV	O	148-151
)	O	151-152
administration	O	153-167
of	O	168-170
ouabain	O	171-178
(	O	179-180
a	O	180-181
Na	O	182-184
(	O	184-185
+	O	185-186
)	O	186-187
/	O	187-188
K	O	188-189
(	O	184-185
+	O	185-186
)	O	186-187
-	O	192-193
ATPase	O	193-199
inhibitor	O	200-209
)	O	209-210
in	O	211-213
rats	O	214-218
has	O	219-222
been	O	223-227
suggested	O	228-237
to	O	238-240
mimic	O	241-246
some	O	247-251
symptoms	O	252-260
of	O	261-263
human	O	264-269
bipolar	B	270-277
mania	I	278-283
.	O	283-284

Clinical	O	285-293
studies	O	294-301
have	O	302-306
shown	O	307-312
that	O	313-317
bipolar	B	318-325
disorder	I	326-334
may	O	335-338
be	O	339-341
related	O	342-349
to	O	350-352
mitochondrial	B	353-366
dysfunction	I	367-378
.	O	378-379

Herein	O	380-386
,	O	386-387
we	O	388-390
investigated	O	391-403
the	O	404-407
behavioral	O	408-418
and	O	419-422
biochemical	O	423-434
effects	O	435-442
induced	O	443-450
by	O	451-453
the	O	454-457
ICV	O	458-461
administration	O	462-476
of	O	477-479
ouabain	O	480-487
in	O	488-490
rats	O	491-495
.	O	495-496

To	O	497-499
achieve	O	500-507
this	O	508-512
aim	O	513-516
,	O	516-517
the	O	518-521
effects	O	522-529
of	O	530-532
ouabain	O	533-540
injection	O	541-550
immediately	O	551-562
after	O	563-568
and	O	569-572
7	O	573-574
days	O	575-579
following	O	580-589
a	O	590-591
single	O	592-598
ICV	O	599-602
administration	O	603-617
(	O	618-619
at	O	619-621
concentrations	O	622-636
of	O	637-639
10	O	640-642
(	O	642-643
-	O	643-644
2	O	644-645
)	O	645-646
and	O	647-650
10	O	651-653
(	O	653-654
-	O	654-655
3	O	655-656
)	O	656-657
M	O	657-658
)	O	656-657
on	O	660-662
locomotion	O	663-673
was	O	674-677
measured	O	678-686
using	O	687-692
the	O	693-696
open	O	697-701
-	O	701-702
field	O	702-707
test	O	708-712
.	O	712-713

Additionally	O	714-726
,	O	726-727
thiobarbituric	O	728-742
acid	O	743-747
reactive	O	748-756
substances	O	757-767
(	O	768-769
TBARSs	O	769-775
)	O	775-776
and	O	777-780
superoxide	O	781-791
production	O	792-802
were	O	803-807
measured	O	808-816
in	O	817-819
submitochondrial	O	820-836
particles	O	837-846
of	O	847-849
the	O	850-853
prefrontal	O	854-864
cortex	O	865-871
,	O	871-872
hippocampus	O	873-884
,	O	884-885
striatum	O	886-894
and	O	895-898
amygdala	O	899-907
.	O	907-908

Our	O	909-912
findings	O	913-921
demonstrated	O	922-934
that	O	935-939
ouabain	O	940-947
at	O	948-950
10	O	951-953
(	O	953-954
-	O	954-955
2	O	955-956
)	O	956-957
and	O	958-961
10	O	962-964
(	O	964-965
-	O	965-966
3	O	966-967
)	O	967-968
M	O	968-969
induced	O	970-977
hyperlocomotion	B	978-993
in	O	994-996
rats	O	997-1001
,	O	1001-1002
and	O	1003-1006
this	O	1007-1011
response	O	1012-1020
remained	O	1021-1029
up	O	1030-1032
to	O	1033-1035
7	O	1036-1037
days	O	1038-1042
following	O	1043-1052
a	O	1053-1054
single	O	1055-1061
ICV	O	1062-1065
injection	O	1066-1075
.	O	1075-1076

In	O	1077-1079
addition	O	1080-1088
,	O	1088-1089
we	O	1090-1092
observed	O	1093-1101
that	O	1102-1106
the	O	1107-1110
persistent	O	1111-1121
increase	O	1122-1130
in	O	1131-1133
the	O	1134-1137
rat	O	1138-1141
spontaneous	O	1142-1153
locomotion	O	1154-1164
is	O	1165-1167
associated	O	1168-1178
with	O	1179-1183
increased	O	1184-1193
TBARS	O	1194-1199
levels	O	1200-1206
and	O	1207-1210
superoxide	O	1211-1221
generation	O	1222-1232
in	O	1233-1235
submitochondrial	O	1236-1252
particles	O	1253-1262
in	O	1263-1265
the	O	1266-1269
prefrontal	O	1270-1280
cortex	O	1281-1287
,	O	1287-1288
striatum	O	1289-1297
and	O	1298-1301
amygdala	O	1302-1310
.	O	1310-1311

In	O	1312-1314
conclusion	O	1315-1325
,	O	1325-1326
ouabain	O	1327-1334
-	O	1334-1335
induced	O	1335-1342
mania	B	1343-1348
-	O	1348-1349
like	O	1349-1353
behavior	O	1354-1362
may	O	1363-1366
provide	O	1367-1374
a	O	1375-1376
useful	O	1377-1383
animal	O	1384-1390
model	O	1391-1396
to	O	1397-1399
test	O	1400-1404
the	O	1405-1408
hypothesis	O	1409-1419
of	O	1420-1422
the	O	1423-1426
involvement	O	1427-1438
of	O	1439-1441
oxidative	O	1442-1451
stress	O	1452-1458
in	O	1459-1461
bipolar	B	1462-1469
disorder	I	1470-1478
.	O	1478-1479

Intraoperative	O	0-14
dialysis	O	15-23
during	O	24-30
liver	O	31-36
transplantation	O	37-52
with	O	53-57
citrate	O	58-65
dialysate	O	66-75
.	O	75-76

Liver	O	77-82
transplantation	O	83-98
for	O	99-102
acutely	O	103-110
ill	O	111-114
patients	O	115-123
with	O	124-128
fulminant	B	129-138
liver	I	139-144
failure	I	145-152
carries	O	153-160
high	O	161-165
intraoperative	O	166-180
and	O	181-184
immediate	O	185-194
postoperative	O	195-208
risks	O	209-214
.	O	214-215

These	O	216-221
are	O	222-225
increased	O	226-235
with	O	236-240
the	O	241-244
presence	O	245-253
of	O	254-256
concomitant	O	257-268
acute	B	269-274
kidney	I	275-281
injury	I	282-288
(	O	289-290
AKI	B	290-293
)	O	293-294
and	O	295-298
intraoperative	O	299-313
dialysis	O	314-322
is	O	323-325
sometimes	O	326-335
required	O	336-344
to	O	345-347
allow	O	348-353
the	O	354-357
transplant	O	358-368
to	O	369-371
proceed	O	372-379
.	O	379-380

The	O	381-384
derangements	O	385-397
in	O	398-400
the	O	401-404
procoagulant	O	405-417
and	O	418-421
anticoagulant	O	422-435
pathways	O	436-444
during	O	445-451
fulminant	B	452-461
liver	I	462-467
failure	I	468-475
can	O	476-479
lead	O	480-484
to	O	485-487
difficulties	O	488-500
with	O	501-505
anticoagulation	O	506-521
during	O	522-528
dialysis	O	529-537
,	O	537-538
especially	O	539-549
when	O	550-554
continued	O	555-564
in	O	565-567
the	O	568-571
operating	O	572-581
room	O	582-586
.	O	586-587

Systemic	O	588-596
anticoagulation	O	597-612
is	O	613-615
unsafe	O	616-622
and	O	623-626
regional	O	627-635
citrate	O	636-643
anticoagulation	O	644-659
in	O	660-662
the	O	663-666
absence	O	667-674
of	O	675-677
a	O	678-679
functional	O	680-690
liver	O	691-696
carries	O	697-704
the	O	705-708
risk	O	709-713
of	O	714-716
citrate	O	717-724
toxicity	B	725-733
.	O	733-734

Citrate	O	735-742
dialysate	O	743-752
,	O	752-753
a	O	754-755
new	O	756-759
dialysate	O	760-769
with	O	770-774
citric	O	775-781
acid	O	782-786
can	O	787-790
be	O	791-793
used	O	794-798
for	O	799-802
anticoagulation	O	803-818
in	O	819-821
patients	O	822-830
who	O	831-834
cannot	O	835-841
tolerate	O	842-850
heparin	O	851-858
or	O	859-861
regional	O	862-870
citrate	O	871-878
.	O	878-879

We	O	880-882
report	O	883-889
a	O	890-891
case	O	892-896
of	O	897-899
a	O	900-901
40	O	902-904
-	O	904-905
year	O	905-909
-	O	904-905
old	O	910-913
female	O	914-920
with	O	921-925
acetaminophen	O	926-939
-	O	939-940
induced	O	940-947
fulminant	B	948-957
liver	I	958-963
failure	I	964-971
with	O	972-976
associated	O	977-987
AKI	B	988-991
who	O	992-995
underwent	O	996-1005
intraoperative	O	1006-1020
dialytic	O	1021-1029
support	O	1030-1037
during	O	1038-1044
liver	O	1045-1050
transplantation	O	1051-1066
anticoagulated	O	1067-1081
with	O	1082-1086
citrate	O	1087-1094
dialysate	O	1095-1104
during	O	1105-1111
the	O	1112-1115
entire	O	1116-1122
procedure	O	1123-1132
.	O	1132-1133

The	O	1134-1137
patient	O	1138-1145
tolerated	O	1146-1155
the	O	1156-1159
procedure	O	1160-1169
well	O	1170-1174
without	O	1175-1182
any	O	1183-1186
signs	O	1187-1192
of	O	1193-1195
citrate	O	1196-1203
toxicity	B	1204-1212
and	O	1213-1216
maintained	O	1217-1227
adequate	O	1228-1236
anticoagulation	O	1237-1252
for	O	1253-1256
patency	O	1257-1264
of	O	1265-1267
the	O	1268-1271
dialysis	O	1272-1280
circuit	O	1281-1288
.	O	1288-1289

Citrate	O	1290-1297
dialysate	O	1298-1307
is	O	1308-1310
a	O	1311-1312
safe	O	1313-1317
alternative	O	1318-1329
for	O	1330-1333
intradialytic	O	1334-1347
support	O	1348-1355
of	O	1356-1358
liver	O	1359-1364
transplantation	O	1365-1380
in	O	1381-1383
fulminant	B	1384-1393
liver	I	1394-1399
failure	I	1400-1407
.	O	1407-1408

Delirium	B	0-8
in	O	9-11
a	O	12-13
patient	O	14-21
with	O	22-26
toxic	O	27-32
flecainide	O	33-43
plasma	O	44-50
concentrations	O	51-65
:	O	65-66
the	O	67-70
role	O	71-75
of	O	76-78
a	O	79-80
pharmacokinetic	O	81-96
drug	O	97-101
interaction	O	102-113
with	O	114-118
paroxetine	O	119-129
.	O	129-130

OBJECTIVE	O	131-140
:	O	140-141
To	O	142-144
describe	O	145-153
a	O	154-155
case	O	156-160
of	O	161-163
flecainide	O	164-174
-	O	174-175
induced	O	175-182
delirium	B	183-191
associated	O	192-202
with	O	203-207
a	O	208-209
pharmacokinetic	O	210-225
drug	O	226-230
interaction	O	231-242
with	O	243-247
paroxetine	O	248-258
.	O	258-259

CASE	O	260-264
SUMMARY	O	265-272
:	O	272-273
A	O	274-275
69	O	276-278
-	O	278-279
year	O	279-283
-	O	278-279
old	O	284-287
white	O	288-293
female	O	294-300
presented	O	301-310
to	O	311-313
the	O	314-317
emergency	O	318-327
department	O	328-338
with	O	339-343
a	O	344-345
history	O	346-353
of	O	354-356
confusion	B	357-366
and	O	367-370
paranoia	B	371-379
over	O	380-384
the	O	385-388
past	O	389-393
several	O	394-401
days	O	402-406
.	O	406-407

On	O	408-410
admission	O	411-420
the	O	421-424
patient	O	425-432
was	O	433-436
taking	O	437-443
carvedilol	O	444-454
12	O	455-457
mg	O	458-460
twice	O	461-466
daily	O	467-472
,	O	472-473
warfarin	O	474-482
2	O	483-484
mg	O	485-487
/	O	487-488
day	O	488-491
,	O	491-492
folic	O	493-498
acid	O	499-503
1	O	504-505
mg	O	506-508
/	O	508-509
day	O	509-512
,	O	512-513
levothyroxine	O	514-527
100	O	528-531
microg	O	532-538
/	O	538-539
day	O	539-542
,	O	542-543
pantoprazole	O	544-556
40	O	557-559
mg	O	560-562
/	O	562-563
day	O	563-566
,	O	566-567
paroxetine	O	568-578
40	O	579-581
mg	O	582-584
/	O	584-585
day	O	585-588
,	O	588-589
and	O	590-593
flecainide	O	594-604
100	O	605-608
mg	O	609-611
twice	O	612-617
daily	O	618-623
.	O	623-624

Flecainide	O	625-635
had	O	636-639
been	O	640-644
started	O	645-652
2	O	653-654
weeks	O	655-660
prior	O	661-666
for	O	667-670
atrial	B	671-677
fibrillation	I	678-690
.	O	690-691

Laboratory	O	692-702
test	O	703-707
findings	O	708-716
on	O	717-719
admission	O	720-729
were	O	730-734
notable	O	735-742
only	O	743-747
for	O	748-751
a	O	752-753
flecainide	O	754-764
plasma	O	765-771
concentration	O	772-785
of	O	786-788
1360	O	789-793
microg	O	794-800
/	O	800-801
L	O	801-802
(	O	803-804
reference	O	804-813
range	O	814-819
200	O	820-823
-	O	823-824
1000	O	824-828
)	O	828-829
.	O	829-830

A	O	831-832
metabolic	O	833-842
drug	O	843-847
interaction	O	848-859
between	O	860-867
flecainide	O	868-878
and	O	879-882
paroxetine	O	883-893
,	O	893-894
which	O	895-900
the	O	901-904
patient	O	905-912
had	O	913-916
been	O	917-921
taking	O	922-928
for	O	929-932
more	O	933-937
than	O	938-942
5	O	943-944
years	O	945-950
,	O	950-951
was	O	952-955
considered	O	956-966
.	O	966-967

Paroxetine	O	968-978
was	O	979-982
discontinued	O	983-995
and	O	996-999
the	O	1000-1003
dose	O	1004-1008
of	O	1009-1011
flecainide	O	1012-1022
was	O	1023-1026
reduced	O	1027-1034
to	O	1035-1037
50	O	1038-1040
mg	O	1041-1043
twice	O	1044-1049
daily	O	1050-1055
.	O	1055-1056

Her	O	1057-1060
delirium	B	1061-1069
resolved	O	1070-1078
3	O	1079-1080
days	O	1081-1085
later	O	1086-1091
.	O	1091-1092

DISCUSSION	O	1093-1103
:	O	1103-1104
Flecainide	O	1105-1115
and	O	1116-1119
pharmacologically	O	1120-1137
similar	O	1138-1145
agents	O	1146-1152
that	O	1153-1157
interact	O	1158-1166
with	O	1167-1171
sodium	O	1172-1178
channels	O	1179-1187
may	O	1188-1191
cause	O	1192-1197
delirium	B	1198-1206
in	O	1207-1209
susceptible	O	1210-1221
patients	O	1222-1230
.	O	1230-1231

A	O	1232-1233
MEDLINE	O	1234-1241
search	O	1242-1248
(	O	1249-1250
1966	O	1250-1254
-	O	1254-1255
January	O	1255-1262
2009	O	1263-1267
)	O	1267-1268
revealed	O	1269-1277
one	O	1278-1281
in	O	1282-1284
vivo	O	1285-1289
pharmacokinetic	O	1290-1305
study	O	1306-1311
on	O	1312-1314
the	O	1315-1318
interaction	O	1319-1330
between	O	1331-1338
flecainide	O	1339-1349
,	O	1349-1350
a	O	1351-1352
CYP2D6	O	1353-1359
substrate	O	1360-1369
,	O	1369-1370
and	O	1371-1374
paroxetine	O	1375-1385
,	O	1385-1386
a	O	1387-1388
CYP2D6	O	1389-1395
inhibitor	O	1396-1405
,	O	1405-1406
as	O	1407-1409
well	O	1410-1414
as	O	1415-1417
3	O	1418-1419
case	O	1420-1424
reports	O	1425-1432
of	O	1433-1435
flecainide	O	1436-1446
-	O	1446-1447
induced	O	1447-1454
delirium	B	1455-1463
.	O	1463-1464

According	O	1465-1474
to	O	1475-1477
the	O	1478-1481
Naranjo	O	1482-1489
probability	O	1490-1501
scale	O	1502-1507
,	O	1507-1508
flecainide	O	1509-1519
was	O	1520-1523
the	O	1524-1527
probable	O	1528-1536
cause	O	1537-1542
of	O	1543-1545
the	O	1546-1549
patient	O	1550-1557
'	O	1557-1558
s	O	1558-1559
delirium	B	1560-1568
;	O	1568-1569
the	O	1570-1573
Horn	O	1574-1578
Drug	O	1579-1583
Interaction	O	1584-1595
Probability	O	1596-1607
Scale	O	1608-1613
indicates	O	1614-1623
a	O	1624-1625
possible	O	1626-1634
pharmacokinetic	O	1635-1650
drug	O	1651-1655
interaction	O	1656-1667
between	O	1668-1675
flecainide	O	1676-1686
and	O	1687-1690
paroxetine	O	1691-1701
.	O	1701-1702

CONCLUSIONS	O	1703-1714
:	O	1714-1715
Supratherapeutic	O	1716-1732
flecainide	O	1733-1743
plasma	O	1744-1750
concentrations	O	1751-1765
may	O	1766-1769
cause	O	1770-1775
delirium	B	1776-1784
.	O	1784-1785

Because	O	1786-1793
toxicity	B	1794-1802
may	O	1803-1806
occur	O	1807-1812
when	O	1813-1817
flecainide	O	1818-1828
is	O	1829-1831
prescribed	O	1832-1842
with	O	1843-1847
paroxetine	O	1848-1858
and	O	1859-1862
other	O	1863-1868
potent	O	1869-1875
CYP2D6	O	1876-1882
inhibitors	O	1883-1893
,	O	1893-1894
flecainide	O	1895-1905
plasma	O	1906-1912
concentrations	O	1913-1927
should	O	1928-1934
be	O	1935-1937
monitored	O	1938-1947
closely	O	1948-1955
with	O	1956-1960
commencement	O	1961-1973
of	O	1974-1976
CYP2D6	O	1977-1983
inhibitors	O	1984-1994
.	O	1994-1995

Efficacy	O	0-8
of	O	9-11
everolimus	O	12-22
(	O	23-24
RAD001	O	24-30
)	O	30-31
in	O	32-34
patients	O	35-43
with	O	44-48
advanced	O	49-57
NSCLC	B	58-63
previously	O	64-74
treated	O	75-82
with	O	83-87
chemotherapy	O	88-100
alone	O	101-106
or	O	107-109
with	O	110-114
chemotherapy	O	115-127
and	O	128-131
EGFR	O	132-136
inhibitors	O	137-147
.	O	147-148

BACKGROUND	O	149-159
:	O	159-160
Treatment	O	161-170
options	O	171-178
are	O	179-182
scarce	O	183-189
in	O	190-192
pretreated	O	193-203
advanced	O	204-212
non	B	213-216
-	I	216-217
small	I	217-222
-	I	216-217
cell	I	223-227
lung	I	228-232
cancer	I	233-239
(	O	240-241
NSCLC	B	241-246
)	O	246-247
patients	O	248-256
.	O	256-257

RAD001	O	258-264
,	O	264-265
an	O	266-268
oral	O	269-273
inhibitor	O	274-283
of	O	284-286
the	O	287-290
mammalian	O	291-300
target	O	301-307
of	O	308-310
rapamycin	O	311-320
(	O	321-322
mTOR	O	322-326
)	O	326-327
,	O	327-328
has	O	329-332
shown	O	333-338
phase	O	339-344
I	O	345-346
efficacy	O	347-355
in	O	356-358
NSCLC	B	359-364
.	O	364-365

METHODS	O	366-373
:	O	373-374
Stage	O	375-380
IIIb	O	381-385
or	O	386-388
IV	O	389-391
NSCLC	B	392-397
patients	O	398-406
,	O	406-407
with	O	408-412
two	O	413-416
or	O	417-419
fewer	O	420-425
prior	O	426-431
chemotherapy	O	432-444
regimens	O	445-453
,	O	453-454
one	O	455-458
platinum	O	459-467
based	O	468-473
(	O	474-475
stratum	O	475-482
1	O	483-484
)	O	484-485
or	O	486-488
both	O	489-493
chemotherapy	O	494-506
and	O	507-510
epidermal	O	511-520
growth	O	521-527
factor	O	528-534
receptor	O	535-543
tyrosine	O	544-552
kinase	O	553-559
inhibitors	O	560-570
(	O	571-572
stratum	O	572-579
2	O	580-581
)	O	581-582
,	O	582-583
received	O	584-592
RAD001	O	593-599
10	O	600-602
mg	O	603-605
/	O	605-606
day	O	606-609
until	O	610-615
progression	O	616-627
or	O	628-630
unacceptable	O	631-643
toxicity	B	644-652
.	O	652-653

Primary	O	654-661
objective	O	662-671
was	O	672-675
overall	O	676-683
response	O	684-692
rate	O	693-697
(	O	698-699
ORR	O	699-702
)	O	702-703
.	O	703-704

Analyses	O	705-713
of	O	714-716
markers	O	717-724
associated	O	725-735
with	O	736-740
the	O	741-744
mTOR	O	745-749
pathway	O	750-757
were	O	758-762
carried	O	763-770
out	O	771-774
on	O	775-777
archival	O	778-786
tumor	B	787-792
from	O	793-797
a	O	798-799
subgroup	O	800-808
using	O	809-814
immunohistochemistry	O	815-835
(	O	836-837
IHC	O	837-840
)	O	840-841
and	O	842-845
direct	O	846-852
mutation	O	853-861
sequencing	O	862-872
.	O	872-873

RESULTS	O	874-881
:	O	881-882
Eighty	O	883-889
-	O	889-890
five	O	890-894
patients	O	895-903
were	O	904-908
enrolled	O	909-917
,	O	917-918
42	O	919-921
in	O	922-924
stratum	O	925-932
1	O	933-934
and	O	935-938
43	O	939-941
in	O	942-944
stratum	O	945-952
.	O	952-953

ORR	O	954-957
was	O	958-961
4	O	962-963
.	O	963-964
7	O	964-965
%	O	965-966
(	O	967-968
7	O	968-969
.	O	969-970
1	O	970-971
%	O	971-972
stratum	O	973-980
1	O	981-982
;	O	982-983
2	O	984-985
.	O	985-986
3	O	986-987
%	O	987-988
stratum	O	989-996
2	O	997-998
)	O	998-999
.	O	999-1000

Overall	O	1001-1008
disease	O	1009-1016
control	O	1017-1024
rate	O	1025-1029
was	O	1030-1033
47	O	1034-1036
.	O	1036-1037
1	O	1037-1038
%	O	1038-1039
.	O	1036-1037

Median	O	1041-1047
progression	O	1048-1059
-	O	1059-1060
free	O	1060-1064
survivals	O	1065-1074
(	O	1075-1076
PFSs	O	1076-1080
)	O	1080-1081
were	O	1082-1086
2	O	1087-1088
.	O	1088-1089
6	O	1089-1090
(	O	1091-1092
stratum	O	1092-1099
1	O	1100-1101
)	O	1101-1102
and	O	1103-1106
2	O	1107-1108
.	O	1108-1109
7	O	1109-1110
months	O	1111-1117
(	O	1118-1119
stratum	O	1119-1126
2	O	1127-1128
)	O	1128-1129
.	O	1129-1130

Common	O	1131-1137
>	O	1138-1139
or	O	1140-1142
=	O	1143-1144
grade	O	1144-1149
3	O	1150-1151
events	O	1152-1158
were	O	1159-1163
fatigue	B	1164-1171
,	O	1171-1172
dyspnea	B	1173-1180
,	O	1180-1181
stomatitis	B	1182-1192
,	O	1192-1193
anemia	B	1194-1200
,	O	1200-1201
and	O	1202-1205
thrombocytopenia	B	1206-1222
.	O	1222-1223

Pneumonitis	B	1224-1235
,	O	1235-1236
probably	O	1237-1245
or	O	1246-1248
possibly	O	1249-1257
related	O	1258-1265
,	O	1265-1266
mainly	O	1267-1273
grade	O	1274-1279
1	O	1280-1281
/	O	1281-1282
2	O	1282-1283
,	O	1283-1284
occurred	O	1285-1293
in	O	1294-1296
25	O	1297-1299
%	O	1299-1300
.	O	1300-1301

Cox	O	1302-1305
regression	O	1306-1316
analysis	O	1317-1325
of	O	1326-1328
IHC	O	1329-1332
scores	O	1333-1339
found	O	1340-1345
that	O	1346-1350
only	O	1351-1355
phospho	O	1356-1363
AKT	O	1364-1367
(	O	1368-1369
pAKT	O	1369-1373
)	O	1373-1374
was	O	1375-1378
a	O	1379-1380
significant	O	1381-1392
independent	O	1393-1404
predictor	O	1405-1414
of	O	1415-1417
worse	O	1418-1423
PFS	O	1424-1427
.	O	1427-1428

CONCLUSIONS	O	1429-1440
:	O	1440-1441
RAD001	O	1442-1448
10	O	1449-1451
mg	O	1452-1454
/	O	1454-1455
day	O	1455-1458
was	O	1459-1462
well	O	1463-1467
tolerated	O	1468-1477
,	O	1477-1478
showing	O	1479-1486
modest	O	1487-1493
clinical	O	1494-1502
activity	O	1503-1511
in	O	1512-1514
pretreated	O	1515-1525
NSCLC	B	1526-1531
.	O	1531-1532

Evaluation	O	1533-1543
of	O	1544-1546
RAD001	O	1547-1553
plus	O	1554-1558
standard	O	1559-1567
therapy	O	1568-1575
for	O	1576-1579
metastatic	O	1580-1590
NSCLC	B	1591-1596
continues	O	1597-1606
.	O	1606-1607

Posttransplant	O	0-14
anemia	B	15-21
:	O	21-22
the	O	23-26
role	O	27-31
of	O	32-34
sirolimus	O	35-44
.	O	44-45

Posttransplant	O	46-60
anemia	B	61-67
is	O	68-70
a	O	71-72
common	O	73-79
problem	O	80-87
that	O	88-92
may	O	93-96
hinder	O	97-103
patients	O	104-112
'	O	112-113
quality	O	114-121
of	O	122-124
life	O	125-129
.	O	129-130

It	O	131-133
occurs	O	134-140
in	O	141-143
12	O	144-146
to	O	147-149
76	O	150-152
%	O	152-153
of	O	154-156
patients	O	157-165
,	O	165-166
and	O	167-170
is	O	171-173
most	O	174-178
common	O	179-185
in	O	186-188
the	O	189-192
immediate	O	193-202
posttransplant	O	203-217
period	O	218-224
.	O	224-225

A	O	226-227
variety	O	228-235
of	O	236-238
factors	O	239-246
have	O	247-251
been	O	252-256
identified	O	257-267
that	O	268-272
increase	O	273-281
the	O	282-285
risk	O	286-290
of	O	291-293
posttransplant	O	294-308
anemia	B	309-315
,	O	315-316
of	O	317-319
which	O	320-325
the	O	326-329
level	O	330-335
of	O	336-338
renal	O	339-344
function	O	345-353
is	O	354-356
most	O	357-361
important	O	362-371
.	O	371-372

Sirolimus	O	373-382
,	O	382-383
a	O	384-385
mammalian	O	386-395
target	O	396-402
of	O	403-405
rapamycin	O	406-415
inhibitor	O	416-425
,	O	425-426
has	O	427-430
been	O	431-435
implicated	O	436-446
as	O	447-449
playing	O	450-457
a	O	458-459
special	O	460-467
role	O	468-472
in	O	473-475
posttransplant	O	476-490
anemia	B	491-497
.	O	497-498

This	O	499-503
review	O	504-510
considers	O	511-520
anemia	B	521-527
associated	O	528-538
with	O	539-543
sirolimus	O	544-553
,	O	553-554
including	O	555-564
its	O	565-568
presentation	O	569-581
,	O	581-582
mechanisms	O	583-593
,	O	593-594
and	O	595-598
management	O	599-609
.	O	609-610

Coronary	O	0-8
computerized	O	9-21
tomography	O	22-32
angiography	O	33-44
for	O	45-48
rapid	O	49-54
discharge	O	55-64
of	O	65-67
low	O	68-71
-	O	71-72
risk	O	72-76
patients	O	77-85
with	O	86-90
cocaine	O	91-98
-	O	98-99
associated	O	99-109
chest	B	110-115
pain	I	116-120
.	O	120-121

BACKGROUND	O	122-132
:	O	132-133
Most	O	134-138
patients	O	139-147
presenting	O	148-158
to	O	159-161
emergency	O	162-171
departments	O	172-183
(	O	184-185
EDs	O	185-188
)	O	188-189
with	O	190-194
cocaine	O	195-202
-	O	202-203
associated	O	203-213
chest	B	214-219
pain	I	220-224
are	O	225-228
admitted	O	229-237
for	O	238-241
at	O	242-244
least	O	245-250
12	O	251-253
hours	O	254-259
and	O	260-263
receive	O	264-271
a	O	272-273
"	O	274-275
rule	O	275-279
out	O	280-283
acute	B	284-289
coronary	I	290-298
syndrome	I	299-307
"	O	307-308
protocol	O	309-317
,	O	317-318
often	O	319-324
with	O	325-329
noninvasive	O	330-341
testing	O	342-349
prior	O	350-355
to	O	356-358
discharge	O	359-368
.	O	368-369

In	O	370-372
patients	O	373-381
without	O	382-389
cocaine	O	390-397
use	O	398-401
,	O	401-402
coronary	O	403-411
computerized	O	412-424
tomography	O	425-435
angiography	O	436-447
(	O	448-449
CTA	O	449-452
)	O	452-453
has	O	454-457
been	O	458-462
shown	O	463-468
to	O	469-471
be	O	472-474
useful	O	475-481
for	O	482-485
identifying	O	486-497
a	O	498-499
group	O	500-505
of	O	506-508
patients	O	509-517
at	O	518-520
low	O	521-524
risk	O	525-529
for	O	530-533
cardiac	O	534-541
events	O	542-548
who	O	549-552
can	O	553-556
be	O	557-559
safely	O	560-566
discharged	O	567-577
.	O	577-578

It	O	579-581
is	O	582-584
unclear	O	585-592
whether	O	593-600
a	O	601-602
coronary	O	603-611
CTA	O	612-615
strategy	O	616-624
would	O	625-630
be	O	631-633
efficacious	O	634-645
in	O	646-648
cocaine	O	649-656
-	O	656-657
associated	O	657-667
chest	B	668-673
pain	I	674-678
,	O	678-679
as	O	680-682
coronary	B	683-691
vasospasm	I	692-701
may	O	702-705
account	O	706-713
for	O	714-717
some	O	718-722
of	O	723-725
the	O	726-729
ischemia	B	730-738
.	O	738-739

We	O	740-742
studied	O	743-750
whether	O	751-758
a	O	759-760
negative	O	761-769
coronary	O	770-778
CTA	O	779-782
in	O	783-785
patients	O	786-794
with	O	795-799
cocaine	O	800-807
-	O	807-808
associated	O	808-818
chest	B	819-824
pain	I	825-829
could	O	830-835
identify	O	836-844
a	O	845-846
subset	O	847-853
safe	O	854-858
for	O	859-862
discharge	O	863-872
.	O	872-873

METHODS	O	874-881
:	O	881-882
We	O	883-885
prospectively	O	886-899
evaluated	O	900-909
the	O	910-913
safety	O	914-920
of	O	921-923
coronary	O	924-932
CTA	O	933-936
for	O	937-940
low	O	941-944
-	O	944-945
risk	O	945-949
patients	O	950-958
who	O	959-962
presented	O	963-972
to	O	973-975
the	O	976-979
ED	O	980-982
with	O	983-987
cocaineassociated	O	988-1005
chest	B	1006-1011
pain	I	1012-1016
(	O	1017-1018
self	O	1018-1022
-	O	1022-1023
reported	O	1023-1031
or	O	1032-1034
positive	O	1035-1043
urine	O	1044-1049
test	O	1050-1054
)	O	1054-1055
.	O	1055-1056

Consecutive	O	1057-1068
patients	O	1069-1077
received	O	1078-1086
either	O	1087-1093
immediate	O	1094-1103
coronary	O	1104-1112
CTA	O	1113-1116
in	O	1117-1119
the	O	1120-1123
ED	O	1124-1126
(	O	1127-1128
without	O	1128-1135
serial	O	1136-1142
markers	O	1143-1150
)	O	1150-1151
or	O	1152-1154
underwent	O	1155-1164
coronary	O	1165-1173
CTA	O	1174-1177
after	O	1178-1183
a	O	1184-1185
brief	O	1186-1191
observation	O	1192-1203
period	O	1204-1210
with	O	1211-1215
serial	O	1216-1222
cardiac	O	1223-1230
marker	O	1231-1237
measurements	O	1238-1250
.	O	1250-1251

Patients	O	1252-1260
with	O	1261-1265
negative	O	1266-1274
coronary	O	1275-1283
CTA	O	1284-1287
(	O	1288-1289
maximal	O	1289-1296
stenosis	B	1297-1305
less	O	1306-1310
than	O	1311-1315
50	O	1316-1318
%	O	1318-1319
)	O	1319-1320
were	O	1321-1325
discharged	O	1326-1336
.	O	1336-1337

The	O	1338-1341
main	O	1342-1346
outcome	O	1347-1354
was	O	1355-1358
30	O	1359-1361
-	O	1361-1362
day	O	1362-1365
cardiovascular	O	1366-1380
death	O	1381-1386
or	O	1387-1389
myocardial	B	1390-1400
infarction	I	1401-1411
.	O	1411-1412

RESULTS	O	1413-1420
:	O	1420-1421
A	O	1422-1423
total	O	1424-1429
of	O	1430-1432
59	O	1433-1435
patients	O	1436-1444
with	O	1445-1449
cocaine	O	1450-1457
-	O	1457-1458
associated	O	1458-1468
chest	B	1469-1474
pain	I	1475-1479
were	O	1480-1484
evaluated	O	1485-1494
.	O	1494-1495

Patients	O	1496-1504
had	O	1505-1508
a	O	1509-1510
mean	O	1511-1515
age	O	1516-1519
of	O	1520-1522
45	O	1523-1525
.	O	1525-1526
6	O	1526-1527
+	O	1528-1529
/	O	1529-1530
-	O	1530-1531
6	O	1532-1533
.	O	1533-1534
6	O	1532-1533
yrs	O	1536-1539
and	O	1540-1543
were	O	1544-1548
86	O	1549-1551
%	O	1551-1552
black	O	1553-1558
,	O	1558-1559
66	O	1560-1562
%	O	1562-1563
male	O	1564-1568
.	O	1568-1569

Seventy	O	1570-1577
-	O	1577-1578
nine	O	1578-1582
percent	O	1583-1590
had	O	1591-1594
a	O	1595-1596
normal	O	1597-1603
or	O	1604-1606
nonspecific	O	1607-1618
ECG	O	1619-1622
and	O	1623-1626
85	O	1627-1629
%	O	1629-1630
had	O	1631-1634
a	O	1635-1636
TIMI	O	1637-1641
score	O	1642-1647
<	O	1648-1649
2	O	1649-1650
.	O	1650-1651

Twenty	O	1652-1658
patients	O	1659-1667
received	O	1668-1676
coronary	O	1677-1685
CTA	O	1686-1689
immediately	O	1690-1701
in	O	1702-1704
the	O	1705-1708
ED	O	1709-1711
,	O	1711-1712
18	O	1713-1715
of	O	1716-1718
whom	O	1719-1723
were	O	1724-1728
discharged	O	1729-1739
following	O	1740-1749
CTA	O	1750-1753
(	O	1754-1755
90	O	1755-1757
%	O	1757-1758
)	O	1758-1759
.	O	1759-1760

Thirty	O	1761-1767
-	O	1767-1768
nine	O	1768-1772
received	O	1773-1781
coronary	O	1782-1790
CTA	O	1791-1794
after	O	1795-1800
a	O	1801-1802
brief	O	1803-1808
observation	O	1809-1820
period	O	1821-1827
,	O	1827-1828
with	O	1829-1833
37	O	1834-1836
discharged	O	1837-1847
home	O	1848-1852
following	O	1853-1862
CTA	O	1863-1866
(	O	1867-1868
95	O	1868-1870
%	O	1870-1871
)	O	1871-1872
.	O	1872-1873

Six	O	1874-1877
patients	O	1878-1886
had	O	1887-1890
coronary	B	1891-1899
stenosis	I	1900-1908
>	O	1909-1910
or	O	1910-1912
=	O	1912-1913
50	O	1913-1915
%	O	1915-1916
.	O	1916-1917

During	O	1918-1924
the	O	1925-1928
30	O	1929-1931
-	O	1931-1932
day	O	1932-1935
follow	O	1936-1942
-	O	1942-1943
up	O	1943-1945
period	O	1946-1952
,	O	1952-1953
no	O	1954-1956
patients	O	1957-1965
died	O	1966-1970
of	O	1971-1973
a	O	1974-1975
cardiovascular	O	1976-1990
event	O	1991-1996
(	O	1997-1998
0	O	1998-1999
%	O	1999-2000
;	O	2000-2001
95	O	2002-2004
%	O	2004-2005
CI	O	2006-2008
,	O	2008-2009
0	O	2010-2011
-	O	2011-2012
6	O	2012-2013
.	O	2013-2014
1	O	2014-2015
%	O	2015-2016
)	O	2016-2017
and	O	2018-2021
no	O	2022-2024
patient	O	2025-2032
sustained	O	2033-2042
a	O	2043-2044
nonfatal	O	2045-2053
myocardial	B	2054-2064
infarction	I	2065-2075
(	O	2076-2077
0	O	2077-2078
%	O	2078-2079
;	O	2079-2080
95	O	2081-2083
%	O	2083-2084
CI	O	2085-2087
,	O	2087-2088
0	O	2089-2090
-	O	2090-2091
6	O	2091-2092
.	O	2092-2093
1	O	2093-2094
%	O	2094-2095
)	O	2095-2096
.	O	2092-2093

CONCLUSIONS	O	2098-2109
:	O	2109-2110
Although	O	2111-2119
cocaine	O	2120-2127
-	O	2127-2128
associated	O	2128-2138
myocardial	B	2139-2149
ischemia	I	2150-2158
can	O	2159-2162
result	O	2163-2169
from	O	2170-2174
coronary	O	2175-2183
vasoconstriction	O	2184-2200
,	O	2200-2201
patients	O	2202-2210
with	O	2211-2215
cocaine	O	2216-2223
associated	O	2224-2234
chest	B	2235-2240
pain	I	2241-2245
,	O	2245-2246
a	O	2247-2248
non	O	2249-2252
-	O	2252-2253
ischemic	B	2253-2261
ECG	O	2262-2265
,	O	2265-2266
and	O	2267-2270
a	O	2271-2272
TIMI	O	2273-2277
risk	O	2278-2282
score	O	2283-2288
<	O	2289-2290
2	O	2290-2291
may	O	2292-2295
be	O	2296-2298
safely	O	2299-2305
discharged	O	2306-2316
from	O	2317-2321
the	O	2322-2325
ED	O	2326-2328
after	O	2329-2334
a	O	2335-2336
negative	O	2337-2345
coronary	O	2346-2354
CTA	O	2355-2358
with	O	2359-2363
a	O	2364-2365
low	O	2366-2369
risk	O	2370-2374
of	O	2375-2377
30	O	2378-2380
-	O	2380-2381
day	O	2381-2384
adverse	O	2385-2392
events	O	2393-2399
.	O	2399-2400

Late	O	0-4
fulminant	O	5-14
posterior	B	15-24
reversible	I	25-35
encephalopathy	I	36-50
syndrome	I	51-59
after	O	60-65
liver	O	66-71
transplant	O	72-82
.	O	82-83

OBJECTIVES	O	84-94
:	O	94-95
Posterior	B	96-105
leukoencephalopathy	I	106-125
due	O	126-129
to	O	130-132
calcineurin	O	133-144
-	O	144-145
inhibitor	O	145-154
-	O	144-145
related	O	155-162
neurotoxicity	B	163-176
is	O	177-179
a	O	180-181
rare	O	182-186
but	O	187-190
severe	O	191-197
complication	O	198-210
that	O	211-215
results	O	216-223
from	O	224-228
treatment	O	229-238
with	O	239-243
immunosuppressive	O	244-261
agents	O	262-268
(	O	269-270
primarily	O	270-279
those	O	280-285
administered	O	286-298
after	O	299-304
a	O	305-306
liver	O	307-312
or	O	313-315
kidney	O	316-322
transplant	O	323-333
)	O	333-334
.	O	334-335

The	O	336-339
pathophysiologic	O	340-356
mechanisms	O	357-367
of	O	368-370
that	O	371-375
disorder	O	376-384
remain	O	385-391
unknown	O	392-399
.	O	399-400

CASE	O	401-405
:	O	405-406
We	O	407-409
report	O	410-416
the	O	417-420
case	O	421-425
of	O	426-428
a	O	429-430
46	O	431-433
-	O	433-434
year	O	434-438
-	O	433-434
old	O	439-442
woman	O	443-448
who	O	449-452
received	O	453-461
a	O	462-463
liver	O	464-469
transplant	O	470-480
in	O	481-483
our	O	484-487
center	O	488-494
as	O	495-497
treatment	O	498-507
for	O	508-511
alcoholic	B	512-521
cirrhosis	I	522-531
and	O	532-535
in	O	536-538
whom	O	539-543
either	O	544-550
a	O	551-552
fulminant	O	553-562
course	O	563-569
of	O	570-572
posterior	B	573-582
leukoencephalopathy	I	583-602
or	O	603-605
posterior	B	606-615
reversible	I	616-626
encephalopathy	I	627-641
syndrome	I	642-650
developed	O	651-660
110	O	661-664
days	O	665-669
after	O	670-675
transplant	O	676-686
.	O	686-687

After	O	688-693
an	O	694-696
initially	O	697-706
uneventful	O	707-717
course	O	718-724
after	O	725-730
the	O	731-734
transplant	O	735-745
,	O	745-746
the	O	747-750
patient	O	751-758
rapidly	O	759-766
fell	O	767-771
into	O	772-776
deep	O	777-781
coma	O	782-786
.	O	786-787

RESULTS	O	788-795
:	O	795-796
Cerebral	O	797-805
MRI	O	806-809
scan	O	810-814
showed	O	815-821
typical	O	822-829
signs	O	830-835
of	O	836-838
enhancement	O	839-850
in	O	851-853
the	O	854-857
pontine	O	858-865
and	O	866-869
posterior	O	870-879
regions	O	880-887
.	O	887-888

Switching	O	889-898
the	O	899-902
immunosuppressive	O	903-920
regimen	O	921-928
from	O	929-933
tacrolimus	O	934-944
to	O	945-947
cyclosporine	O	948-960
did	O	961-964
not	O	965-968
improve	O	969-976
the	O	977-980
clinical	O	981-989
situation	O	990-999
.	O	999-1000

The	O	1001-1004
termination	O	1005-1016
of	O	1017-1019
treatment	O	1020-1029
with	O	1030-1034
any	O	1035-1038
calcineurin	O	1039-1050
inhibitor	O	1051-1060
resulted	O	1061-1069
in	O	1070-1072
a	O	1073-1074
complete	O	1075-1083
resolution	O	1084-1094
of	O	1095-1097
that	O	1098-1102
complication	O	1103-1115
.	O	1115-1116

CONCLUSIONS	O	1117-1128
:	O	1128-1129
Posterior	B	1130-1139
reversible	I	1140-1150
encephalopathy	I	1151-1165
syndrome	I	1166-1174
after	O	1175-1180
liver	O	1181-1186
transplant	O	1187-1197
is	O	1198-1200
rare	O	1201-1205
.	O	1205-1206

We	O	1207-1209
recommend	O	1210-1219
a	O	1220-1221
complete	O	1222-1230
cessation	O	1231-1240
of	O	1241-1243
any	O	1244-1247
calcineurin	O	1248-1259
inhibitor	O	1260-1269
rather	O	1270-1276
than	O	1277-1281
a	O	1282-1283
dose	O	1284-1288
reduction	O	1289-1298
.	O	1298-1299

Prolonged	O	0-9
hypothermia	B	10-21
as	O	22-24
a	O	25-26
bridge	O	27-33
to	O	34-36
recovery	O	37-45
for	O	46-49
cerebral	B	50-58
edema	I	59-64
and	O	65-68
intracranial	B	69-81
hypertension	I	82-94
associated	O	95-105
with	O	106-110
fulminant	B	111-120
hepatic	I	121-128
failure	I	129-136
.	O	136-137

BACKGROUND	O	138-148
:	O	148-149
To	O	150-152
review	O	153-159
evidence	O	160-168
-	O	168-169
based	O	169-174
treatment	O	175-184
options	O	185-192
in	O	193-195
patients	O	196-204
with	O	205-209
cerebral	B	210-218
edema	I	219-224
complicating	O	225-237
fulminant	B	238-247
hepatic	I	248-255
failure	I	256-263
(	O	264-265
FHF	B	265-268
)	O	268-269
and	O	270-273
discuss	O	274-281
the	O	282-285
potential	O	286-295
applications	O	296-308
of	O	309-311
hypothermia	B	312-323
.	O	323-324

METHOD	O	325-331
:	O	331-332
Case	O	333-337
-	O	337-338
based	O	338-343
observations	O	344-356
from	O	357-361
a	O	362-363
medical	O	364-371
intensive	O	372-381
care	O	382-386
unit	O	387-391
(	O	392-393
MICU	O	393-397
)	O	397-398
in	O	399-401
a	O	402-403
tertiary	O	404-412
care	O	413-417
facility	O	418-426
in	O	427-429
a	O	430-431
27	O	432-434
-	O	434-435
year	O	435-439
-	O	434-435
old	O	440-443
female	O	444-450
with	O	451-455
FHF	B	456-459
from	O	460-464
acetaminophen	O	465-478
and	O	479-482
resultant	O	483-492
cerebral	B	493-501
edema	I	502-507
.	O	507-508

RESULTS	O	509-516
:	O	516-517
Our	O	518-521
patient	O	522-529
was	O	530-533
admitted	O	534-542
to	O	543-545
the	O	546-549
MICU	O	550-554
after	O	555-560
being	O	561-566
found	O	567-572
unresponsive	O	573-585
with	O	586-590
presumed	O	591-599
toxicity	B	600-608
from	O	609-613
acetaminophen	O	614-627
which	O	628-633
was	O	634-637
ingested	O	638-646
over	O	647-651
a	O	652-653
2	O	654-655
-	O	655-656
day	O	656-659
period	O	660-666
.	O	666-667

The	O	668-671
patient	O	672-679
had	O	680-683
depressed	O	684-693
of	O	694-696
mental	O	697-703
status	O	704-710
lasting	O	711-718
at	O	719-721
least	O	722-727
24	O	728-730
h	O	731-732
prior	O	733-738
to	O	739-741
admission	O	742-751
.	O	751-752

Initial	O	753-760
evaluation	O	761-771
confirmed	O	772-781
FHF	B	782-785
from	O	786-790
acetaminophen	O	791-804
and	O	805-808
cerebral	B	809-817
edema	I	818-823
.	O	823-824

The	O	825-828
patient	O	829-836
was	O	837-840
treated	O	841-848
with	O	849-853
hyperosmolar	O	854-866
therapy	O	867-874
,	O	874-875
hyperventilation	B	876-892
,	O	892-893
sedation	O	894-902
,	O	902-903
and	O	904-907
chemical	O	908-916
paralysis	B	917-926
.	O	926-927

Her	O	928-931
intracranial	O	932-944
pressure	O	945-953
remained	O	954-962
elevated	O	963-971
despite	O	972-979
maximal	O	980-987
medical	O	988-995
therapy	O	996-1003
.	O	1003-1004

We	O	1005-1007
then	O	1008-1012
initiated	O	1013-1022
therapeutic	O	1023-1034
hypothermia	B	1035-1046
which	O	1047-1052
was	O	1053-1056
continued	O	1057-1066
for	O	1067-1070
5	O	1071-1072
days	O	1073-1077
.	O	1077-1078

At	O	1079-1081
re	O	1082-1084
-	O	1084-1085
warming	O	1085-1092
,	O	1092-1093
patient	O	1094-1101
had	O	1102-1105
resolution	O	1106-1116
of	O	1117-1119
her	O	1120-1123
cerebral	B	1124-1132
edema	I	1133-1138
and	O	1139-1142
intracranial	B	1143-1155
hypertension	I	1156-1168
.	O	1168-1169

At	O	1170-1172
discharge	O	1173-1182
,	O	1182-1183
she	O	1184-1187
had	O	1188-1191
complete	O	1192-1200
recovery	O	1201-1209
of	O	1210-1212
neurological	O	1213-1225
and	O	1226-1229
hepatic	O	1230-1237
functions	O	1238-1247
.	O	1247-1248

CONCLUSION	O	1249-1259
:	O	1259-1260
In	O	1261-1263
patients	O	1264-1272
with	O	1273-1277
FHF	B	1278-1281
and	O	1282-1285
cerebral	B	1286-1294
edema	I	1295-1300
from	O	1301-1305
acetaminophen	O	1306-1319
overdose	B	1320-1328
,	O	1328-1329
prolonged	O	1330-1339
therapeutic	O	1340-1351
hypothermia	B	1352-1363
could	O	1364-1369
potentially	O	1370-1381
be	O	1382-1384
used	O	1385-1389
as	O	1390-1392
a	O	1393-1394
life	O	1395-1399
saving	O	1400-1406
therapy	O	1407-1414
and	O	1415-1418
a	O	1419-1420
bridge	O	1421-1427
to	O	1428-1430
hepatic	O	1431-1438
and	O	1439-1442
neurological	O	1443-1455
recovery	O	1456-1464
.	O	1464-1465

A	O	1466-1467
clinical	O	1468-1476
trial	O	1477-1482
of	O	1483-1485
hypothermia	B	1486-1497
in	O	1498-1500
patients	O	1501-1509
with	O	1510-1514
this	O	1515-1519
condition	O	1520-1529
is	O	1530-1532
warranted	O	1533-1542
.	O	1542-1543

Binasal	B	0-7
visual	I	8-14
field	I	15-20
defects	I	21-28
are	O	29-32
not	O	33-36
specific	O	37-45
to	O	46-48
vigabatrin	O	49-59
.	O	59-60

This	O	61-65
study	O	66-71
investigated	O	72-84
the	O	85-88
visual	B	89-95
defects	I	96-103
associated	O	104-114
with	O	115-119
the	O	120-123
antiepileptic	O	124-137
drug	O	138-142
vigabatrin	O	143-153
(	O	154-155
VGB	O	155-158
)	O	158-159
.	O	159-160

Two	O	161-164
hundred	O	165-172
four	O	173-177
people	O	178-184
with	O	185-189
epilepsy	B	190-198
were	O	199-203
grouped	O	204-211
on	O	212-214
the	O	215-218
basis	O	219-224
of	O	225-227
antiepileptic	O	228-241
drug	O	242-246
therapy	O	247-254
(	O	255-256
current	O	256-263
,	O	263-264
previous	O	265-273
,	O	273-274
or	O	275-277
no	O	278-280
exposure	O	281-289
to	O	290-292
VGB	O	293-296
)	O	296-297
.	O	297-298

Groups	O	299-305
were	O	306-310
matched	O	311-318
with	O	319-323
respect	O	324-331
to	O	332-334
age	O	335-338
,	O	338-339
gender	O	340-346
,	O	346-347
and	O	348-351
seizure	B	352-359
frequency	O	360-369
.	O	369-370

All	O	371-374
patients	O	375-383
underwent	O	384-393
objective	O	394-403
assessment	O	404-414
of	O	415-417
electrophysiological	O	418-438
function	O	439-447
(	O	448-449
wide	O	449-453
-	O	453-454
field	O	454-459
multifocal	O	460-470
electroretinography	O	471-490
)	O	490-491
and	O	492-495
conventional	O	496-508
visual	O	509-515
field	O	516-521
testing	O	522-529
(	O	530-531
static	O	531-537
perimetry	O	538-547
)	O	547-548
.	O	548-549

Bilateral	O	550-559
visual	O	560-566
field	O	567-572
constriction	O	573-585
was	O	586-589
observed	O	590-598
in	O	599-601
59	O	602-604
%	O	604-605
of	O	606-608
patients	O	609-617
currently	O	618-627
taking	O	628-634
VGB	O	635-638
,	O	638-639
43	O	640-642
%	O	642-643
of	O	644-646
patients	O	647-655
who	O	656-659
previously	O	660-670
took	O	671-675
VGB	O	676-679
,	O	679-680
and	O	681-684
24	O	685-687
%	O	687-688
of	O	689-691
patients	O	692-700
with	O	701-705
no	O	706-708
exposure	O	709-717
to	O	718-720
VGB	O	721-724
.	O	724-725

Assessment	O	726-736
of	O	737-739
retinal	O	740-747
function	O	748-756
revealed	O	757-765
abnormal	O	766-774
responses	O	775-784
in	O	785-787
48	O	788-790
%	O	790-791
of	O	792-794
current	O	795-802
VGB	O	803-806
users	O	807-812
and	O	813-816
22	O	817-819
%	O	819-820
of	O	821-823
prior	O	824-829
VGB	O	830-833
users	O	834-839
,	O	839-840
but	O	841-844
in	O	845-847
none	O	848-852
of	O	853-855
the	O	856-859
patients	O	860-868
without	O	869-876
previous	O	877-885
exposure	O	886-894
to	O	895-897
VGB	O	898-901
.	O	901-902

Bilateral	B	903-912
visual	I	913-919
field	I	920-925
abnormalities	I	926-939
are	O	940-943
common	O	944-950
in	O	951-953
the	O	954-957
treated	O	958-965
epilepsy	B	966-974
population	O	975-985
,	O	985-986
irrespective	O	987-999
of	O	1000-1002
drug	O	1003-1007
history	O	1008-1015
.	O	1015-1016

Assessment	O	1017-1027
by	O	1028-1030
conventional	O	1031-1043
static	O	1044-1050
perimetry	O	1051-1060
may	O	1061-1064
neither	O	1065-1072
be	O	1073-1075
sufficiently	O	1076-1088
sensitive	O	1089-1098
nor	O	1099-1102
specific	O	1103-1111
to	O	1112-1114
reliably	O	1115-1123
identify	O	1124-1132
retinal	B	1133-1140
toxicity	I	1141-1149
associated	O	1150-1160
with	O	1161-1165
VGB	O	1166-1169
.	O	1169-1170

Smoking	O	0-7
of	O	8-10
crack	O	11-16
cocaine	O	17-24
as	O	25-27
a	O	28-29
risk	O	30-34
factor	O	35-41
for	O	42-45
HIV	B	46-49
infection	I	50-59
among	O	60-65
people	O	66-72
who	O	73-76
use	O	77-80
injection	O	81-90
drugs	O	91-96
.	O	96-97

BACKGROUND	O	98-108
:	O	108-109
Little	O	110-116
is	O	117-119
known	O	120-125
about	O	126-131
the	O	132-135
possible	O	136-144
role	O	145-149
that	O	150-154
smoking	O	155-162
crack	O	163-168
cocaine	O	169-176
has	O	177-180
on	O	181-183
the	O	184-187
incidence	O	188-197
of	O	198-200
HIV	B	201-204
infection	I	205-214
.	O	214-215

Given	O	216-221
the	O	222-225
increasing	O	226-236
use	O	237-240
of	O	241-243
crack	O	244-249
cocaine	O	250-257
,	O	257-258
we	O	259-261
sought	O	262-268
to	O	269-271
examine	O	272-279
whether	O	280-287
use	O	288-291
of	O	292-294
this	O	295-299
illicit	O	300-307
drug	O	308-312
has	O	313-316
become	O	317-323
a	O	324-325
risk	O	326-330
factor	O	331-337
for	O	338-341
HIV	B	342-345
infection	I	346-355
.	O	355-356

METHODS	O	357-364
:	O	364-365
We	O	366-368
included	O	369-377
data	O	378-382
from	O	383-387
people	O	388-394
participating	O	395-408
in	O	409-411
the	O	412-415
Vancouver	O	416-425
Injection	O	426-435
Drug	O	436-440
Users	O	441-446
Study	O	447-452
who	O	453-456
reported	O	457-465
injecting	O	466-475
illicit	O	476-483
drugs	O	484-489
at	O	490-492
least	O	493-498
once	O	499-503
in	O	504-506
the	O	507-510
month	O	511-516
before	O	517-523
enrolment	O	524-533
,	O	533-534
lived	O	535-540
in	O	541-543
the	O	544-547
greater	O	548-555
Vancouver	O	556-565
area	O	566-570
,	O	570-571
were	O	572-576
HIV	O	577-580
-	O	580-581
negative	O	581-589
at	O	590-592
enrolment	O	593-602
and	O	603-606
completed	O	607-616
at	O	617-619
least	O	620-625
1	O	626-627
follow	O	628-634
-	O	634-635
up	O	635-637
study	O	638-643
visit	O	644-649
.	O	649-650

To	O	651-653
determine	O	654-663
whether	O	664-671
the	O	672-675
risk	O	676-680
of	O	681-683
HIV	B	684-687
seroconversion	I	688-702
among	O	703-708
daily	O	709-714
smokers	O	715-722
of	O	723-725
crack	O	726-731
cocaine	O	732-739
changed	O	740-747
over	O	748-752
time	O	753-757
,	O	757-758
we	O	759-761
used	O	762-766
Cox	O	767-770
proportional	O	771-783
hazards	O	784-791
regression	O	792-802
and	O	803-806
divided	O	807-814
the	O	815-818
study	O	819-824
into	O	825-829
3	O	830-831
periods	O	832-839
:	O	839-840
May	O	841-844
1	O	845-846
,	O	846-847
1996	O	848-852
-	O	852-853
Nov	O	853-856
.	O	856-857

30	O	858-860
,	O	860-861
1999	O	862-866
(	O	867-868
period	O	868-874
1	O	875-876
)	O	876-877
,	O	877-878
Dec	O	879-882
.	O	882-883
1	O	884-885
,	O	885-886
1999	O	887-891
-	O	891-892
Nov	O	892-895
.	O	895-896

30	O	897-899
,	O	899-900
2002	O	901-905
(	O	906-907
period	O	907-913
2	O	914-915
)	O	915-916
,	O	916-917
and	O	918-921
Dec	O	922-925
.	O	925-926
1	O	927-928
,	O	928-929
2002	O	930-934
-	O	934-935
Dec	O	935-938
.	O	938-939

30	O	940-942
,	O	942-943
2005	O	944-948
(	O	949-950
period	O	950-956
3	O	957-958
)	O	958-959
.	O	959-960

RESULTS	O	961-968
:	O	968-969
Overall	O	970-977
,	O	977-978
1048	O	979-983
eligible	O	984-992
injection	O	993-1002
drug	O	1003-1007
users	O	1008-1013
were	O	1014-1018
included	O	1019-1027
in	O	1028-1030
our	O	1031-1034
study	O	1035-1040
.	O	1040-1041

Of	O	1042-1044
these	O	1045-1050
,	O	1050-1051
137	O	1052-1055
acquired	O	1056-1064
HIV	B	1065-1068
infection	I	1069-1078
during	O	1079-1085
follow	O	1086-1092
-	O	1092-1093
up	O	1093-1095
.	O	1095-1096

The	O	1097-1100
mean	O	1101-1105
proportion	O	1106-1116
of	O	1117-1119
participants	O	1120-1132
who	O	1133-1136
reported	O	1137-1145
daily	O	1146-1151
smoking	O	1152-1159
of	O	1160-1162
crack	O	1163-1168
cocaine	O	1169-1176
increased	O	1177-1186
from	O	1187-1191
11	O	1192-1194
.	O	1194-1195
6	O	1195-1196
%	O	1196-1197
in	O	1198-1200
period	O	1201-1207
1	O	1208-1209
to	O	1210-1212
39	O	1213-1215
.	O	1215-1216
7	O	1216-1217
%	O	1217-1218
in	O	1219-1221
period	O	1222-1228
3	O	1229-1230
.	O	1230-1231

After	O	1232-1237
adjusting	O	1238-1247
for	O	1248-1251
potential	O	1252-1261
confounders	O	1262-1273
,	O	1273-1274
we	O	1275-1277
found	O	1278-1283
that	O	1284-1288
the	O	1289-1292
risk	O	1293-1297
of	O	1298-1300
HIV	B	1301-1304
seroconversion	I	1305-1319
among	O	1320-1325
participants	O	1326-1338
who	O	1339-1342
were	O	1343-1347
daily	O	1348-1353
smokers	O	1354-1361
of	O	1362-1364
crack	O	1365-1370
cocaine	O	1371-1378
increased	O	1379-1388
over	O	1389-1393
time	O	1394-1398
(	O	1399-1400
period	O	1400-1406
1	O	1407-1408
:	O	1408-1409
hazard	O	1410-1416
ratio	O	1417-1422
[	O	1423-1424
HR	O	1424-1426
]	O	1426-1427
1	O	1428-1429
.	O	1429-1430
03	O	1430-1432
,	O	1432-1433
95	O	1434-1436
%	O	1436-1437
confidence	O	1438-1448
interval	O	1449-1457
[	O	1458-1459
CI	O	1459-1461
]	O	1461-1462
0	O	1463-1464
.	O	1464-1465
57	O	1465-1467
-	O	1467-1468
1	O	1468-1469
.	O	1464-1465
85	O	1470-1472
;	O	1472-1473

period	O	1474-1480
2	O	1481-1482
:	O	1482-1483
HR	O	1484-1486
1	O	1487-1488
.	O	1488-1489
68	O	1489-1491
,	O	1491-1492
95	O	1493-1495
%	O	1495-1496
CI	O	1497-1499
1	O	1500-1501
.	O	1501-1502
01	O	1502-1504
-	O	1504-1505
2	O	1505-1506
.	O	1501-1502
80	O	1507-1509
;	O	1509-1510

and	O	1511-1514
period	O	1515-1521
3	O	1522-1523
:	O	1523-1524
HR	O	1525-1527
2	O	1528-1529
.	O	1529-1530
74	O	1530-1532
,	O	1532-1533
95	O	1534-1536
%	O	1536-1537
CI	O	1538-1540
1	O	1541-1542
.	O	1542-1543
06	O	1543-1545
-	O	1545-1546
7	O	1546-1547
.	O	1542-1543
11	O	1548-1550
)	O	1550-1551
.	O	1542-1543

INTERPRETATION	O	1553-1567
:	O	1567-1568
Smoking	O	1569-1576
of	O	1577-1579
crack	O	1580-1585
cocaine	O	1586-1593
was	O	1594-1597
found	O	1598-1603
to	O	1604-1606
be	O	1607-1609
an	O	1610-1612
independent	O	1613-1624
risk	O	1625-1629
factor	O	1630-1636
for	O	1637-1640
HIV	B	1641-1644
seroconversion	I	1645-1659
among	O	1660-1665
people	O	1666-1672
who	O	1673-1676
were	O	1677-1681
injection	O	1682-1691
drug	O	1692-1696
users	O	1697-1702
.	O	1702-1703

This	O	1704-1708
finding	O	1709-1716
points	O	1717-1723
to	O	1724-1726
the	O	1727-1730
urgent	O	1731-1737
need	O	1738-1742
for	O	1743-1746
evidence	O	1747-1755
-	O	1755-1756
based	O	1756-1761
public	O	1762-1768
health	O	1769-1775
initiatives	O	1776-1787
targeted	O	1788-1796
at	O	1797-1799
people	O	1800-1806
who	O	1807-1810
smoke	O	1811-1816
crack	O	1817-1822
cocaine	O	1823-1830
.	O	1830-1831

Fluoxetine	O	0-10
improves	O	11-19
the	O	20-23
memory	B	24-30
deficits	I	31-39
caused	O	40-46
by	O	47-49
the	O	50-53
chemotherapy	O	54-66
agent	O	67-72
5	O	73-74
-	O	74-75
fluorouracil	O	75-87
.	O	87-88

Cancer	B	89-95
patients	O	96-104
who	O	105-108
have	O	109-113
been	O	114-118
treated	O	119-126
with	O	127-131
systemic	O	132-140
adjuvant	O	141-149
chemotherapy	O	150-162
have	O	163-167
described	O	168-177
experiencing	O	178-190
deteriorations	O	191-205
in	O	206-208
cognition	O	209-218
.	O	218-219

A	O	220-221
widely	O	222-228
used	O	229-233
chemotherapeutic	O	234-250
agent	O	251-256
,	O	256-257
5	O	258-259
-	O	259-260
fluorouracil	O	260-272
(	O	273-274
5	O	274-275
-	O	275-276
FU	O	276-278
)	O	278-279
,	O	279-280
readily	O	281-288
crosses	O	289-296
the	O	297-300
blood	O	301-306
-	O	306-307
brain	O	307-312
barrier	O	313-320
and	O	321-324
so	O	325-327
could	O	328-333
have	O	334-338
a	O	339-340
direct	O	341-347
effect	O	348-354
on	O	355-357
brain	O	358-363
function	O	364-372
.	O	372-373

In	O	374-376
particular	O	377-387
this	O	388-392
anti	O	393-397
mitotic	O	398-405
drug	O	406-410
could	O	411-416
reduce	O	417-423
cell	O	424-428
proliferation	O	429-442
in	O	443-445
the	O	446-449
neurogenic	O	450-460
regions	O	461-468
of	O	469-471
the	O	472-475
adult	O	476-481
brain	O	482-487
.	O	487-488

In	O	489-491
contrast	O	492-500
reports	O	501-508
indicate	O	509-517
that	O	518-522
hippocampal	O	523-534
dependent	O	535-544
neurogenesis	O	545-557
and	O	558-561
cognition	O	562-571
are	O	572-575
enhanced	O	576-584
by	O	585-587
the	O	588-591
SSRI	O	592-596
antidepressant	O	597-611
Fluoxetine	O	612-622
.	O	622-623

In	O	624-626
this	O	627-631
investigation	O	632-645
the	O	646-649
behavioural	O	650-661
effects	O	662-669
of	O	670-672
chronic	O	673-680
(	O	681-682
two	O	682-685
week	O	686-690
)	O	690-691
treatment	O	692-701
with	O	702-706
5	O	707-708
-	O	708-709
FU	O	709-711
and	O	712-715
(	O	716-717
three	O	717-722
weeks	O	723-728
)	O	728-729
with	O	730-734
Fluoxetine	O	735-745
either	O	746-752
separately	O	753-763
or	O	764-766
in	O	767-769
combination	O	770-781
with	O	782-786
5	O	787-788
-	O	788-789
FU	O	789-791
were	O	792-796
tested	O	797-803
on	O	804-806
adult	O	807-812
Lister	O	813-819
hooded	O	820-826
rats	O	827-831
.	O	831-832

Behavioural	O	833-844
effects	O	845-852
were	O	853-857
tested	O	858-864
using	O	865-870
a	O	871-872
context	O	873-880
dependent	O	881-890
conditioned	O	891-902
emotional	O	903-912
response	O	913-921
test	O	922-926
(	O	927-928
CER	O	928-931
)	O	931-932
which	O	933-938
showed	O	939-945
that	O	946-950
animals	O	951-958
treated	O	959-966
with	O	967-971
5	O	972-973
-	O	973-974
FU	O	974-976
had	O	977-980
a	O	981-982
significant	O	983-994
reduction	O	995-1004
in	O	1005-1007
freezing	O	1008-1016
time	O	1017-1021
compared	O	1022-1030
to	O	1031-1033
controls	O	1034-1042
.	O	1042-1043

A	O	1044-1045
separate	O	1046-1054
group	O	1055-1060
of	O	1061-1063
animals	O	1064-1071
was	O	1072-1075
tested	O	1076-1082
using	O	1083-1088
a	O	1089-1090
hippocampal	O	1091-1102
dependent	O	1103-1112
spatial	O	1113-1120
working	O	1121-1128
memory	O	1129-1135
test	O	1136-1140
,	O	1140-1141
the	O	1142-1145
object	O	1146-1152
location	O	1153-1161
recognition	O	1162-1173
test	O	1174-1178
(	O	1179-1180
OLR	O	1180-1183
)	O	1183-1184
.	O	1184-1185

Animals	O	1186-1193
treated	O	1194-1201
only	O	1202-1206
with	O	1207-1211
5	O	1212-1213
-	O	1213-1214
FU	O	1214-1216
showed	O	1217-1223
significant	O	1224-1235
deficits	O	1236-1244
in	O	1245-1247
their	O	1248-1253
ability	O	1254-1261
to	O	1262-1264
carry	O	1265-1270
out	O	1271-1274
the	O	1275-1278
OLR	O	1279-1282
task	O	1283-1287
but	O	1288-1291
co	O	1292-1294
administration	O	1295-1309
of	O	1310-1312
Fluoxetine	O	1313-1323
improved	O	1324-1332
their	O	1333-1338
performance	O	1339-1350
.	O	1350-1351

5	O	1352-1353
-	O	1353-1354
FU	O	1354-1356
chemotherapy	O	1357-1369
caused	O	1370-1376
a	O	1377-1378
significant	O	1379-1390
reduction	O	1391-1400
in	O	1401-1403
the	O	1404-1407
number	O	1408-1414
of	O	1415-1417
proliferating	O	1418-1431
cells	O	1432-1437
in	O	1438-1440
the	O	1441-1444
sub	O	1445-1448
granular	O	1449-1457
zone	O	1458-1462
of	O	1463-1465
the	O	1466-1469
dentate	O	1470-1477
gyrus	O	1478-1483
compared	O	1484-1492
to	O	1493-1495
controls	O	1496-1504
.	O	1504-1505

This	O	1506-1510
reduction	O	1511-1520
was	O	1521-1524
eliminated	O	1525-1535
when	O	1536-1540
Fluoxetine	O	1541-1551
was	O	1552-1555
co	O	1556-1558
administered	O	1559-1571
with	O	1572-1576
5	O	1577-1578
-	O	1578-1579
FU	O	1579-1581
.	O	1581-1582

Fluoxetine	O	1583-1593
on	O	1594-1596
its	O	1597-1600
own	O	1601-1604
had	O	1605-1608
no	O	1609-1611
effect	O	1612-1618
on	O	1619-1621
proliferating	O	1622-1635
cell	O	1636-1640
number	O	1641-1647
or	O	1648-1650
behaviour	O	1651-1660
.	O	1660-1661

These	O	1662-1667
findings	O	1668-1676
suggest	O	1677-1684
that	O	1685-1689
5	O	1690-1691
-	O	1691-1692
FU	O	1692-1694
can	O	1695-1698
negatively	O	1699-1709
affect	O	1710-1716
both	O	1717-1721
cell	O	1722-1726
proliferation	O	1727-1740
and	O	1741-1744
hippocampal	O	1745-1756
dependent	O	1757-1766
working	O	1767-1774
memory	O	1775-1781
and	O	1782-1785
that	O	1786-1790
these	O	1791-1796
deficits	O	1797-1805
can	O	1806-1809
be	O	1810-1812
reversed	O	1813-1821
by	O	1822-1824
the	O	1825-1828
simultaneous	O	1829-1841
administration	O	1842-1856
of	O	1857-1859
the	O	1860-1863
antidepressant	O	1864-1878
Fluoxetine	O	1879-1889
.	O	1889-1890

Liver	O	0-5
-	O	5-6
specific	O	6-14
ablation	O	15-23
of	O	24-26
integrin	O	27-35
-	O	35-36
linked	O	36-42
kinase	O	43-49
in	O	50-52
mice	O	53-57
results	O	58-65
in	O	66-68
enhanced	O	69-77
and	O	78-81
prolonged	O	82-91
cell	O	92-96
proliferation	O	97-110
and	O	111-114
hepatomegaly	B	115-127
after	O	128-133
phenobarbital	O	134-147
administration	O	148-162
.	O	162-163

We	O	164-166
have	O	167-171
recently	O	172-180
demonstrated	O	181-193
that	O	194-198
disruption	O	199-209
of	O	210-212
extracellular	O	213-226
matrix	O	227-233
(	O	234-235
ECM	O	235-238
)	O	238-239
/	O	239-240
integrin	O	240-248
signaling	O	249-258
via	O	259-262
elimination	O	263-274
of	O	275-277
integrin	O	278-286
-	O	286-287
linked	O	287-293
kinase	O	294-300
(	O	301-302
ILK	O	302-305
)	O	305-306
in	O	307-309
hepatocytes	O	310-321
interferes	O	322-332
with	O	333-337
signals	O	338-345
leading	O	346-353
to	O	354-356
termination	O	357-368
of	O	369-371
liver	O	372-377
regeneration	O	378-390
.	O	390-391

This	O	392-396
study	O	397-402
investigates	O	403-415
the	O	416-419
role	O	420-424
of	O	425-427
ILK	O	428-431
in	O	432-434
liver	O	435-440
enlargement	O	441-452
induced	O	453-460
by	O	461-463
phenobarbital	O	464-477
(	O	478-479
PB	O	479-481
)	O	481-482
.	O	482-483

Wild	O	484-488
-	O	488-489
type	O	489-493
(	O	494-495
WT	O	495-497
)	O	497-498
and	O	499-502
ILK	O	503-506
:	O	506-507
liver	O	507-512
-	O	512-513
/	O	513-514
-	O	512-513
mice	O	516-520
were	O	521-525
given	O	526-531
PB	O	532-534
(	O	535-536
0	O	536-537
.	O	537-538
1	O	538-539
%	O	539-540
in	O	541-543
drinking	O	544-552
water	O	553-558
)	O	558-559
for	O	560-563
10	O	564-566
days	O	567-571
.	O	571-572

Livers	O	573-579
were	O	580-584
harvested	O	585-594
on	O	595-597
2	O	598-599
,	O	599-600
5	O	601-602
,	O	602-603
and	O	604-607
10	O	608-610
days	O	611-615
during	O	616-622
PB	O	623-625
administration	O	626-640
.	O	640-641

In	O	642-644
the	O	645-648
hepatocyte	O	649-659
-	O	659-660
specific	O	660-668
ILK	O	669-672
/	O	672-673
liver	O	673-678
-	O	678-679
/	O	672-673
-	O	678-679
mice	O	682-686
,	O	686-687
the	O	688-691
liver	O	692-697
:	O	697-698
body	O	698-702
weight	O	703-709
ratio	O	710-715
was	O	716-719
more	O	720-724
than	O	725-729
double	O	730-736
as	O	737-739
compared	O	740-748
to	O	749-751
0	O	752-753
h	O	754-755
at	O	756-758
day	O	759-762
2	O	763-764
(	O	765-766
2	O	766-767
.	O	767-768
5	O	768-769
times	O	770-775
)	O	775-776
,	O	776-777
while	O	778-783
at	O	784-786
days	O	787-791
5	O	792-793
and	O	794-797
10	O	798-800
,	O	800-801
it	O	802-804
was	O	805-808
enlarged	O	809-817
three	O	818-823
times	O	824-829
.	O	829-830

In	O	831-833
the	O	834-837
WT	O	838-840
mice	O	841-845
,	O	845-846
the	O	847-850
increase	O	851-859
was	O	860-863
as	O	864-866
expected	O	867-875
from	O	876-880
previous	O	881-889
literature	O	890-900
(	O	901-902
1	O	902-903
.	O	903-904
8	O	904-905
times	O	906-911
)	O	911-912
and	O	913-916
seems	O	917-922
to	O	923-925
have	O	926-930
leveled	O	931-938
off	O	939-942
after	O	943-948
day	O	949-952
2	O	953-954
.	O	954-955

There	O	956-961
were	O	962-966
slightly	O	967-975
increased	O	976-985
proliferating	O	986-999
cell	O	1000-1004
nuclear	O	1005-1012
antigen	O	1013-1020
-	O	1020-1021
positive	O	1021-1029
cells	O	1030-1035
in	O	1036-1038
the	O	1039-1042
ILK	O	1043-1046
/	O	1046-1047
liver	O	1047-1052
-	O	1052-1053
/	O	1046-1047
-	O	1052-1053
animals	O	1056-1063
at	O	1064-1066
day	O	1067-1070
2	O	1071-1072
as	O	1073-1075
compared	O	1076-1084
to	O	1085-1087
WT	O	1088-1090
after	O	1091-1096
PB	O	1097-1099
administration	O	1100-1114
.	O	1114-1115

In	O	1116-1118
the	O	1119-1122
WT	O	1123-1125
animals	O	1126-1133
,	O	1133-1134
the	O	1135-1138
proliferative	O	1139-1152
response	O	1153-1161
had	O	1162-1165
come	O	1166-1170
back	O	1171-1175
to	O	1176-1178
normal	O	1179-1185
by	O	1186-1188
days	O	1189-1193
5	O	1194-1195
and	O	1196-1199
10	O	1200-1202
.	O	1202-1203

Hepatocytes	O	1204-1215
of	O	1216-1218
the	O	1219-1222
ILK	O	1223-1226
/	O	1226-1227
liver	O	1227-1232
-	O	1232-1233
/	O	1226-1227
-	O	1232-1233
mice	O	1236-1240
continued	O	1241-1250
to	O	1251-1253
proliferate	O	1254-1265
up	O	1266-1268
until	O	1269-1274
day	O	1275-1278
10	O	1279-1281
.	O	1281-1282

ILK	O	1283-1286
/	O	1286-1287
liver	O	1287-1292
-	O	1292-1293
/	O	1286-1287
-	O	1292-1293
mice	O	1296-1300
also	O	1301-1305
showed	O	1306-1312
increased	O	1313-1322
expression	O	1323-1333
of	O	1334-1336
key	O	1337-1340
genes	O	1341-1346
involved	O	1347-1355
in	O	1356-1358
hepatocyte	O	1359-1369
proliferation	O	1370-1383
at	O	1384-1386
different	O	1387-1396
time	O	1397-1401
points	O	1402-1408
during	O	1409-1415
PB	O	1416-1418
administration	O	1419-1433
.	O	1433-1434

In	O	1435-1437
summary	O	1438-1445
,	O	1445-1446
ECM	O	1447-1450
proteins	O	1451-1459
communicate	O	1460-1471
with	O	1472-1476
the	O	1477-1480
signaling	O	1481-1490
machinery	O	1491-1500
of	O	1501-1503
dividing	O	1504-1512
cells	O	1513-1518
via	O	1519-1522
ILK	O	1523-1526
to	O	1527-1529
regulate	O	1530-1538
hepatocyte	O	1539-1549
proliferation	O	1550-1563
and	O	1564-1567
termination	O	1568-1579
of	O	1580-1582
the	O	1583-1586
proliferative	O	1587-1600
response	O	1601-1609
.	O	1609-1610

Lack	O	1611-1615
of	O	1616-1618
ILK	O	1619-1622
in	O	1623-1625
the	O	1626-1629
hepatocytes	O	1630-1641
imparts	O	1642-1649
prolonged	O	1650-1659
proliferative	O	1660-1673
response	O	1674-1682
not	O	1683-1686
only	O	1687-1691
to	O	1692-1694
stimuli	O	1695-1702
related	O	1703-1710
to	O	1711-1713
liver	O	1714-1719
regeneration	O	1720-1732
but	O	1733-1736
also	O	1737-1741
to	O	1742-1744
xenobiotic	O	1745-1755
chemical	O	1756-1764
mitogens	O	1765-1773
,	O	1773-1774
such	O	1775-1779
as	O	1780-1782
PB	O	1783-1785
.	O	1785-1786

Decreased	O	0-9
Expression	O	10-20
of	O	21-23
Na	O	24-26
/	O	26-27
K	O	27-28
-	O	28-29
ATPase	O	29-35
,	O	35-36
NHE3	O	37-41
,	O	41-42
NBC1	O	43-47
,	O	47-48
AQP1	O	49-53
and	O	54-57
OAT	O	58-61
in	O	62-64
Gentamicin	O	65-75
-	O	75-76
induced	O	76-83
Nephropathy	B	84-95
.	O	95-96

The	O	97-100
present	O	101-108
study	O	109-114
was	O	115-118
aimed	O	119-124
to	O	125-127
determine	O	128-137
whether	O	138-145
there	O	146-151
is	O	152-154
an	O	155-157
altered	O	158-165
regulation	O	166-176
of	O	177-179
tubular	O	180-187
transporters	O	188-200
in	O	201-203
gentamicin	O	204-214
-	O	214-215
induced	O	215-222
nephropathy	B	223-234
.	O	234-235

Sprague	O	236-243
-	O	243-244
Dawley	O	244-250
male	O	251-255
rats	O	256-260
(	O	261-262
200	O	262-265
~	O	265-266
250	O	266-269
g	O	270-271
)	O	271-272
were	O	273-277
subcutaneously	O	278-292
injected	O	293-301
with	O	302-306
gentamicin	O	307-317
(	O	318-319
100	O	319-322
mg	O	323-325
/	O	325-326
kg	O	326-328
per	O	329-332
day	O	333-336
)	O	336-337
for	O	338-341
7	O	342-343
days	O	344-348
,	O	348-349
and	O	350-353
the	O	354-357
expression	O	358-368
of	O	369-371
tubular	O	372-379
transporters	O	380-392
was	O	393-396
determined	O	397-407
by	O	408-410
immunoblotting	O	411-425
and	O	426-429
immunohistochemistry	O	430-450
.	O	450-451

The	O	452-455
mRNA	O	456-460
and	O	461-464
protein	O	465-472
expression	O	473-483
of	O	484-486
OAT	O	487-490
was	O	491-494
also	O	495-499
determined	O	500-510
.	O	510-511

Gentamicin	O	512-522
-	O	522-523
treated	O	523-530
rats	O	531-535
exhibited	O	536-545
significantly	O	546-559
decreased	O	560-569
creatinine	O	570-580
clearance	O	581-590
along	O	591-596
with	O	597-601
increased	O	602-611
plasma	O	612-618
creatinine	O	619-629
levels	O	630-636
.	O	636-637

Accordingly	O	638-649
,	O	649-650
the	O	651-654
fractional	O	655-665
excretion	O	666-675
of	O	676-678
sodium	O	679-685
increased	O	686-695
.	O	695-696

Urine	O	697-702
volume	O	703-709
was	O	710-713
increased	O	714-723
,	O	723-724
while	O	725-730
urine	O	731-736
osmolality	O	737-747
and	O	748-751
free	O	752-756
water	O	757-762
reabsorption	O	763-775
were	O	776-780
decreased	O	781-790
.	O	790-791

Immunoblotting	O	792-806
and	O	807-810
immunohistochemistry	O	811-831
revealed	O	832-840
decreased	O	841-850
expression	O	851-861
of	O	862-864
Na	O	865-867
(	O	867-868
+	O	868-869
)	O	869-870
/	O	870-871
K	O	871-872
(	O	867-868
+	O	868-869
)	O	869-870
-	O	875-876
ATPase	O	876-882
,	O	882-883
NHE3	O	884-888
,	O	888-889
NBC1	O	890-894
,	O	894-895
and	O	896-899
AQP1	O	900-904
in	O	905-907
the	O	908-911
kidney	O	912-918
of	O	919-921
gentamicin	O	922-932
-	O	932-933
treated	O	933-940
rats	O	941-945
.	O	945-946

The	O	947-950
expression	O	951-961
of	O	962-964
OAT1	O	965-969
and	O	970-973
OAT3	O	974-978
was	O	979-982
also	O	983-987
decreased	O	988-997
.	O	997-998

Gentamicin	O	999-1009
-	O	1009-1010
induced	O	1010-1017
nephropathy	B	1018-1029
may	O	1030-1033
at	O	1034-1036
least	O	1037-1042
in	O	1043-1045
part	O	1046-1050
be	O	1051-1053
causally	O	1054-1062
related	O	1063-1070
with	O	1071-1075
a	O	1076-1077
decreased	O	1078-1087
expression	O	1088-1098
of	O	1099-1101
Na	O	1102-1104
(	O	1104-1105
+	O	1105-1106
)	O	1106-1107
/	O	1107-1108
K	O	1108-1109
(	O	1104-1105
+	O	1105-1106
)	O	1106-1107
-	O	1112-1113
ATPase	O	1113-1119
,	O	1119-1120
NHE3	O	1121-1125
,	O	1125-1126
NBC1	O	1127-1131
,	O	1131-1132
AQP1	O	1133-1137
and	O	1138-1141
OAT	O	1142-1145
.	O	1145-1146

Longitudinal	O	0-12
association	O	13-24
of	O	25-27
alcohol	O	28-35
use	O	36-39
with	O	40-44
HIV	B	45-48
disease	I	49-56
progression	O	57-68
and	O	69-72
psychological	O	73-86
health	O	87-93
of	O	94-96
women	O	97-102
with	O	103-107
HIV	O	108-111
.	O	111-112

We	O	113-115
evaluated	O	116-125
the	O	126-129
association	O	130-141
of	O	142-144
alcohol	O	145-152
consumption	O	153-164
and	O	165-168
depression	B	169-179
,	O	179-180
and	O	181-184
their	O	185-190
effects	O	191-198
on	O	199-201
HIV	B	202-205
disease	I	206-213
progression	O	214-225
among	O	226-231
women	O	232-237
with	O	238-242
HIV	O	243-246
.	O	246-247

The	O	248-251
study	O	252-257
included	O	258-266
871	O	267-270
women	O	271-276
with	O	277-281
HIV	O	282-285
who	O	286-289
were	O	290-294
recruited	O	295-304
from	O	305-309
1993	O	310-314
-	O	314-315
1995	O	315-319
in	O	320-322
four	O	323-327
US	O	328-330
cities	O	331-337
.	O	337-338

The	O	339-342
participants	O	343-355
had	O	356-359
physical	O	360-368
examination	O	369-380
,	O	380-381
medical	O	382-389
record	O	390-396
extraction	O	397-407
,	O	407-408
and	O	409-412
venipuncture	O	413-425
,	O	425-426
CD4	O	427-430
+	O	430-431
T	O	431-432
-	O	432-433
cell	O	433-437
counts	O	438-444
determination	O	445-458
,	O	458-459
measurement	O	460-471
of	O	472-474
depression	B	475-485
symptoms	O	486-494
(	O	495-496
using	O	496-501
the	O	502-505
self	O	506-510
-	O	510-511
report	O	511-517
Center	O	518-524
for	O	525-528
Epidemiological	O	529-544
Studies	O	545-552
-	O	552-553
Depression	B	553-563
Scale	O	564-569
)	O	569-570
,	O	570-571
and	O	572-575
alcohol	O	576-583
use	O	584-587
assessment	O	588-598
at	O	599-601
enrollment	O	602-612
,	O	612-613
and	O	614-617
semiannually	O	618-630
until	O	631-636
March	O	637-642
2000	O	643-647
.	O	647-648

Multilevel	O	649-659
random	O	660-666
coefficient	O	667-678
ordinal	O	679-686
models	O	687-693
as	O	694-696
well	O	697-701
as	O	702-704
multilevel	O	705-715
models	O	716-722
with	O	723-727
joint	O	728-733
responses	O	734-743
were	O	744-748
used	O	749-753
in	O	754-756
the	O	757-760
analysis	O	761-769
.	O	769-770

There	O	771-776
was	O	777-780
no	O	781-783
significant	O	784-795
association	O	796-807
between	O	808-815
level	O	816-821
of	O	822-824
alcohol	O	825-832
use	O	833-836
and	O	837-840
CD4	O	841-844
+	O	844-845
T	O	846-847
-	O	847-848
cell	O	848-852
counts	O	853-859
.	O	859-860

When	O	861-865
participants	O	866-878
were	O	879-883
stratified	O	884-894
by	O	895-897
antiretroviral	O	898-912
therapy	O	913-920
(	O	921-922
ART	O	922-925
)	O	925-926
use	O	927-930
,	O	930-931
the	O	932-935
association	O	936-947
between	O	948-955
alcohol	O	956-963
and	O	964-967
CD4	O	968-971
+	O	971-972
T	O	973-974
-	O	974-975
cell	O	975-979
did	O	980-983
not	O	984-987
reach	O	988-993
statistical	O	994-1005
significance	O	1006-1018
.	O	1018-1019

The	O	1020-1023
association	O	1024-1035
between	O	1036-1043
alcohol	O	1044-1051
consumption	O	1052-1063
and	O	1064-1067
depression	B	1068-1078
was	O	1079-1082
significant	O	1083-1094
(	O	1095-1096
p	O	1096-1097
<	O	1097-1098
0	O	1098-1099
.	O	1099-1100
001	O	1100-1103
)	O	1103-1104
.	O	1099-1100

Depression	B	1106-1116
had	O	1117-1120
a	O	1121-1122
significant	O	1123-1134
negative	O	1135-1143
effect	O	1144-1150
on	O	1151-1153
CD4	O	1154-1157
+	O	1157-1158
T	O	1159-1160
-	O	1160-1161
cell	O	1161-1165
counts	O	1166-1172
over	O	1173-1177
time	O	1178-1182
regardless	O	1183-1193
of	O	1194-1196
ART	O	1197-1200
use	O	1201-1204
.	O	1204-1205

Our	O	1206-1209
findings	O	1210-1218
suggest	O	1219-1226
that	O	1227-1231
alcohol	O	1232-1239
consumption	O	1240-1251
has	O	1252-1255
a	O	1256-1257
direct	O	1258-1264
association	O	1265-1276
with	O	1277-1281
depression	B	1282-1292
.	O	1292-1293

Moreover	O	1294-1302
,	O	1302-1303
depression	B	1304-1314
is	O	1315-1317
associated	O	1318-1328
with	O	1329-1333
HIV	B	1334-1337
disease	I	1338-1345
progression	O	1346-1357
.	O	1357-1358

Our	O	1359-1362
findings	O	1363-1371
have	O	1372-1376
implications	O	1377-1389
for	O	1390-1393
the	O	1394-1397
provision	O	1398-1407
of	O	1408-1410
alcohol	O	1411-1418
use	O	1419-1422
interventions	O	1423-1436
and	O	1437-1440
psychological	O	1441-1454
resources	O	1455-1464
to	O	1465-1467
improve	O	1468-1475
the	O	1476-1479
health	O	1480-1486
of	O	1487-1489
women	O	1490-1495
with	O	1496-1500
HIV	O	1501-1504
.	O	1504-1505

Chemokine	O	0-9
CCL2	O	10-14
and	O	15-18
its	O	19-22
receptor	O	23-31
CCR2	O	32-36
are	O	37-40
increased	O	41-50
in	O	51-53
the	O	54-57
hippocampus	O	58-69
following	O	70-79
pilocarpine	O	80-91
-	O	91-92
induced	O	92-99
status	B	100-106
epilepticus	I	107-118
.	O	118-119

BACKGROUND	O	120-130
:	O	130-131
Neuroinflammation	B	132-149
occurs	O	150-156
after	O	157-162
seizures	B	163-171
and	O	172-175
is	O	176-178
implicated	O	179-189
in	O	190-192
epileptogenesis	O	193-208
.	O	208-209

CCR2	O	210-214
is	O	215-217
a	O	218-219
chemokine	O	220-229
receptor	O	230-238
for	O	239-242
CCL2	O	243-247
and	O	248-251
their	O	252-257
interaction	O	258-269
mediates	O	270-278
monocyte	O	279-287
infiltration	O	288-300
in	O	301-303
the	O	304-307
neuroinflammatory	B	308-325
cascade	O	326-333
triggered	O	334-343
in	O	344-346
different	O	347-356
brain	O	357-362
pathologies	O	363-374
.	O	374-375

In	O	376-378
this	O	379-383
work	O	384-388
CCR2	O	389-393
and	O	394-397
CCL2	O	398-402
expression	O	403-413
were	O	414-418
examined	O	419-427
following	O	428-437
status	B	438-444
epilepticus	I	445-456
(	O	457-458
SE	B	458-460
)	O	460-461
induced	O	462-469
by	O	470-472
pilocarpine	O	473-484
injection	O	485-494
.	O	494-495

METHODS	O	496-503
:	O	503-504
SE	B	505-507
was	O	508-511
induced	O	512-519
by	O	520-522
pilocarpine	O	523-534
injection	O	535-544
.	O	544-545

Control	O	546-553
rats	O	554-558
were	O	559-563
injected	O	564-572
with	O	573-577
saline	O	578-584
instead	O	585-592
of	O	593-595
pilocarpine	O	596-607
.	O	607-608

Five	O	609-613
days	O	614-618
after	O	619-624
SE	B	625-627
,	O	627-628
CCR2	O	629-633
staining	O	634-642
in	O	643-645
neurons	O	646-653
and	O	654-657
glial	O	658-663
cells	O	664-669
was	O	670-673
examined	O	674-682
using	O	683-688
imunohistochemical	O	689-707
analyses	O	708-716
.	O	716-717

The	O	718-721
number	O	722-728
of	O	729-731
CCR2	O	732-736
positive	O	737-745
cells	O	746-751
was	O	752-755
determined	O	756-766
using	O	767-772
stereology	O	773-783
probes	O	784-790
in	O	791-793
the	O	794-797
hippocampus	O	798-809
.	O	809-810

CCL2	O	811-815
expression	O	816-826
in	O	827-829
the	O	830-833
hippocampus	O	834-845
was	O	846-849
examined	O	850-858
by	O	859-861
molecular	O	862-871
assay	O	872-877
.	O	877-878

RESULTS	O	879-886
:	O	886-887
Increased	O	888-897
CCR2	O	898-902
was	O	903-906
observed	O	907-915
in	O	916-918
the	O	919-922
hippocampus	O	923-934
after	O	935-940
SE	B	941-943
.	O	943-944

Seizures	B	945-953
also	O	954-958
resulted	O	959-967
in	O	968-970
alterations	O	971-982
to	O	983-985
the	O	986-989
cell	O	990-994
types	O	995-1000
expressing	O	1001-1011
CCR2	O	1012-1016
.	O	1016-1017

Increased	O	1018-1027
numbers	O	1028-1035
of	O	1036-1038
neurons	O	1039-1046
that	O	1047-1051
expressed	O	1052-1061
CCR2	O	1062-1066
was	O	1067-1070
observed	O	1071-1079
following	O	1080-1089
SE	B	1090-1092
.	O	1092-1093

Microglial	O	1094-1104
cells	O	1105-1110
were	O	1111-1115
more	O	1116-1120
closely	O	1121-1128
apposed	O	1129-1136
to	O	1137-1139
the	O	1140-1143
CCR2	O	1144-1148
-	O	1148-1149
labeled	O	1149-1156
cells	O	1157-1162
in	O	1163-1165
SE	B	1166-1168
rats	O	1169-1173
.	O	1173-1174

In	O	1175-1177
addition	O	1178-1186
,	O	1186-1187
rats	O	1188-1192
that	O	1193-1197
experienced	O	1198-1209
SE	B	1210-1212
exhibited	O	1213-1222
CCR2	O	1223-1227
-	O	1227-1228
labeling	O	1228-1236
in	O	1237-1239
populations	O	1240-1251
of	O	1252-1254
hypertrophied	B	1255-1268
astrocytes	O	1269-1279
,	O	1279-1280
especially	O	1281-1291
in	O	1292-1294
CA1	O	1295-1298
and	O	1299-1302
dentate	O	1303-1310
gyrus	O	1311-1316
.	O	1316-1317

These	O	1318-1323
CCR2	O	1324-1328
+	O	1328-1329
astroctytes	O	1330-1341
were	O	1342-1346
not	O	1347-1350
observed	O	1351-1359
in	O	1360-1362
control	O	1363-1370
rats	O	1371-1375
.	O	1375-1376

Examination	O	1377-1388
of	O	1389-1391
CCL2	O	1392-1396
expression	O	1397-1407
showed	O	1408-1414
that	O	1415-1419
it	O	1420-1422
was	O	1423-1426
elevated	O	1427-1435
in	O	1436-1438
the	O	1439-1442
hippocampus	O	1443-1454
following	O	1455-1464
SE	B	1465-1467
.	O	1467-1468

CONCLUSION	O	1469-1479
:	O	1479-1480
The	O	1481-1484
data	O	1485-1489
show	O	1490-1494
that	O	1495-1499
CCR2	O	1500-1504
and	O	1505-1508
CCL2	O	1509-1513
are	O	1514-1517
up	O	1518-1520
-	O	1520-1521
regulated	O	1521-1530
in	O	1531-1533
the	O	1534-1537
hippocampus	O	1538-1549
after	O	1550-1555
pilocarpine	O	1556-1567
-	O	1567-1568
induced	O	1568-1575
SE	B	1576-1578
.	O	1578-1579

Seizures	B	1580-1588
also	O	1589-1593
result	O	1594-1600
in	O	1601-1603
changes	O	1604-1611
to	O	1612-1614
CCR2	O	1615-1619
receptor	O	1620-1628
expression	O	1629-1639
in	O	1640-1642
neurons	O	1643-1650
and	O	1651-1654
astrocytes	O	1655-1665
.	O	1665-1666

These	O	1667-1672
changes	O	1673-1680
might	O	1681-1686
be	O	1687-1689
involved	O	1690-1698
in	O	1699-1701
detrimental	O	1702-1713
neuroplasticity	O	1714-1729
and	O	1730-1733
neuroinflammatory	B	1734-1751
changes	O	1752-1759
that	O	1760-1764
occur	O	1765-1770
following	O	1771-1780
seizures	B	1781-1789
.	O	1789-1790

Metallothionein	O	0-15
induction	O	16-25
reduces	O	26-33
caspase	O	34-41
-	O	41-42
3	O	42-43
activity	O	44-52
and	O	53-56
TNFalpha	O	57-65
levels	O	66-72
with	O	73-77
preservation	O	78-90
of	O	91-93
cognitive	O	94-103
function	O	104-112
and	O	113-116
intact	O	117-123
hippocampal	O	124-135
neurons	O	136-143
in	O	144-146
carmustine	O	147-157
-	O	157-158
treated	O	158-165
rats	O	166-170
.	O	170-171

Hippocampal	O	172-183
integrity	O	184-193
is	O	194-196
essential	O	197-206
for	O	207-210
cognitive	O	211-220
functions	O	221-230
.	O	230-231

On	O	232-234
the	O	235-238
other	O	239-244
hand	O	245-249
,	O	249-250
induction	O	251-260
of	O	261-263
metallothionein	O	264-279
(	O	280-281
MT	O	281-283
)	O	283-284
by	O	285-287
ZnSO	O	288-292
(	O	292-293
4	O	293-294
)	O	294-295
and	O	296-299
its	O	300-303
role	O	304-308
in	O	309-311
neuroprotection	O	312-327
has	O	328-331
been	O	332-336
documented	O	337-347
.	O	347-348

The	O	349-352
present	O	353-360
study	O	361-366
aimed	O	367-372
to	O	373-375
explore	O	376-383
the	O	384-387
effect	O	388-394
of	O	395-397
MT	O	398-400
induction	O	401-410
on	O	411-413
carmustine	O	414-424
(	O	425-426
BCNU	O	426-430
)	O	430-431
-	O	431-432
induced	O	432-439
hippocampal	O	440-451
cognitive	B	452-461
dysfunction	I	462-473
in	O	474-476
rats	O	477-481
.	O	481-482

A	O	483-484
total	O	485-490
of	O	491-493
60	O	494-496
male	O	497-501
Wistar	O	502-508
albino	O	509-515
rats	O	516-520
were	O	521-525
randomly	O	526-534
divided	O	535-542
into	O	543-547
four	O	548-552
groups	O	553-559
(	O	560-561
15	O	561-563
/	O	563-564
group	O	564-569
)	O	569-570
:	O	570-571
The	O	572-575
control	O	576-583
group	O	584-589
injected	O	590-598
with	O	599-603
single	O	604-610
doses	O	611-616
of	O	617-619
normal	O	620-626
saline	O	627-633
(	O	634-635
i	O	635-636
.	O	636-637
c	O	637-638
.	O	636-637
v	O	639-640
)	O	640-641
followed	O	642-650
24	O	651-653
h	O	654-655
later	O	656-661
by	O	662-664
BCNU	O	665-669
solvent	O	670-677
(	O	678-679
i	O	679-680
.	O	680-681
v	O	681-682
)	O	682-683
.	O	680-681

The	O	685-688
second	O	689-695
group	O	696-701
administered	O	702-714
ZnSO	O	715-719
(	O	719-720
4	O	720-721
)	O	721-722
(	O	723-724
0	O	724-725
.	O	725-726
1	O	726-727
micromol	O	728-736
/	O	736-737
10	O	737-739
microl	O	740-746
normal	O	747-753
saline	O	754-760
,	O	760-761
i	O	762-763
.	O	763-764
c	O	764-765
.	O	763-764
v	O	766-767
,	O	767-768
once	O	769-773
)	O	773-774
then	O	775-779
BCNU	O	780-784
solvent	O	785-792
(	O	793-794
i	O	794-795
.	O	795-796
v	O	796-797
)	O	797-798
after	O	799-804
24	O	805-807
h	O	808-809
.	O	809-810

Third	O	811-816
group	O	817-822
received	O	823-831
BCNU	O	832-836
(	O	837-838
20	O	838-840
mg	O	841-843
/	O	843-844
kg	O	844-846
,	O	846-847
i	O	848-849
.	O	849-850
v	O	850-851
,	O	851-852
once	O	853-857
)	O	857-858
24	O	859-861
h	O	862-863
after	O	864-869
injection	O	870-879
with	O	880-884
normal	O	885-891
saline	O	892-898
(	O	899-900
i	O	900-901
.	O	901-902
c	O	902-903
.	O	901-902
v	O	904-905
)	O	905-906
.	O	901-902

Fourth	O	908-914
group	O	915-920
received	O	921-929
a	O	930-931
single	O	932-938
dose	O	939-943
of	O	944-946
ZnSO	O	947-951
(	O	951-952
4	O	952-953
)	O	953-954
(	O	955-956
0	O	956-957
.	O	957-958
1	O	958-959
micromol	O	960-968
/	O	968-969
10	O	969-971
microl	O	972-978
normal	O	979-985
saline	O	986-992
,	O	992-993
i	O	994-995
.	O	995-996
c	O	996-997
.	O	995-996
v	O	998-999
)	O	999-1000
then	O	1001-1005
BCNU	O	1006-1010
(	O	1011-1012
20	O	1012-1014
mg	O	1015-1017
/	O	1017-1018
kg	O	1018-1020
,	O	1020-1021
i	O	1022-1023
.	O	1023-1024
v	O	1024-1025
,	O	1025-1026
once	O	1027-1031
)	O	1031-1032
after	O	1033-1038
24	O	1039-1041
h	O	1042-1043
.	O	1043-1044

The	O	1045-1048
obtained	O	1049-1057
data	O	1058-1062
revealed	O	1063-1071
that	O	1072-1076
BCNU	O	1077-1081
administration	O	1082-1096
resulted	O	1097-1105
in	O	1106-1108
deterioration	B	1109-1122
of	I	1123-1125
learning	I	1126-1134
and	I	1135-1138
short	I	1139-1144
-	I	1144-1145
term	I	1145-1149
memory	I	1150-1156
(	O	1157-1158
STM	O	1158-1161
)	O	1161-1162
,	O	1162-1163
as	O	1164-1166
measured	O	1167-1175
by	O	1176-1178
using	O	1179-1184
radial	O	1185-1191
arm	O	1192-1195
water	O	1196-1201
maze	O	1202-1206
,	O	1206-1207
accompanied	O	1208-1219
with	O	1220-1224
decreased	O	1225-1234
hippocampal	O	1235-1246
glutathione	O	1247-1258
reductase	O	1259-1268
(	O	1269-1270
GR	O	1270-1272
)	O	1272-1273
activity	O	1274-1282
and	O	1283-1286
reduced	O	1287-1294
glutathione	O	1295-1306
(	O	1307-1308
GSH	O	1308-1311
)	O	1311-1312
content	O	1313-1320
.	O	1320-1321

Also	O	1322-1326
,	O	1326-1327
BCNU	O	1328-1332
administration	O	1333-1347
increased	O	1348-1357
serum	O	1358-1363
tumor	B	1364-1369
necrosis	B	1370-1378
factor	O	1379-1385
-	O	1385-1386
alpha	O	1386-1391
(	O	1392-1393
TNFalpha	O	1393-1401
)	O	1401-1402
,	O	1402-1403
hippocampal	O	1404-1415
MT	O	1416-1418
and	O	1419-1422
malondialdehyde	O	1423-1438
(	O	1439-1440
MDA	O	1440-1443
)	O	1443-1444
contents	O	1445-1453
as	O	1454-1456
well	O	1457-1461
as	O	1462-1464
caspase	O	1465-1472
-	O	1472-1473
3	O	1473-1474
activity	O	1475-1483
in	O	1484-1486
addition	O	1487-1495
to	O	1496-1498
histological	O	1499-1511
alterations	O	1512-1523
.	O	1523-1524

ZnSO	O	1525-1529
(	O	1529-1530
4	O	1530-1531
)	O	1531-1532
pretreatment	O	1533-1545
counteracted	O	1546-1558
BCNU	O	1559-1563
-	O	1563-1564
induced	O	1564-1571
inhibition	O	1572-1582
of	O	1583-1585
GR	O	1586-1588
and	O	1589-1592
depletion	O	1593-1602
of	O	1603-1605
GSH	O	1606-1609
and	O	1610-1613
resulted	O	1614-1622
in	O	1623-1625
significant	O	1626-1637
reduction	O	1638-1647
in	O	1648-1650
the	O	1651-1654
levels	O	1655-1661
of	O	1662-1664
MDA	O	1665-1668
and	O	1669-1672
TNFalpha	O	1673-1681
as	O	1682-1684
well	O	1685-1689
as	O	1690-1692
the	O	1693-1696
activity	O	1697-1705
of	O	1706-1708
caspase	O	1709-1716
-	O	1716-1717
3	O	1717-1718
.	O	1718-1719

The	O	1720-1723
histological	O	1724-1736
features	O	1737-1745
were	O	1746-1750
improved	O	1751-1759
in	O	1760-1762
hippocampus	O	1763-1774
of	O	1775-1777
rats	O	1778-1782
treated	O	1783-1790
with	O	1791-1795
ZnSO	O	1796-1800
(	O	1800-1801
4	O	1801-1802
)	O	1802-1803
+	O	1804-1805
BCNU	O	1806-1810
compared	O	1811-1819
to	O	1820-1822
only	O	1823-1827
BCNU	O	1828-1832
-	O	1832-1833
treated	O	1833-1840
animals	O	1841-1848
.	O	1848-1849

In	O	1850-1852
conclusion	O	1853-1863
,	O	1863-1864
MT	O	1865-1867
induction	O	1868-1877
halts	O	1878-1883
BCNU	O	1884-1888
-	O	1888-1889
induced	O	1889-1896
hippocampal	O	1897-1908
toxicity	B	1909-1917
as	O	1918-1920
it	O	1921-1923
prevented	O	1924-1933
GR	O	1934-1936
inhibition	O	1937-1947
and	O	1948-1951
GSH	O	1952-1955
depletion	O	1956-1965
and	O	1966-1969
counteracted	O	1970-1982
the	O	1983-1986
increased	O	1987-1996
levels	O	1997-2003
of	O	2004-2006
TNFalpha	O	2007-2015
,	O	2015-2016
MDA	O	2017-2020
and	O	2021-2024
caspase	O	2025-2032
-	O	2032-2033
3	O	2033-2034
activity	O	2035-2043
with	O	2044-2048
subsequent	O	2049-2059
preservation	O	2060-2072
of	O	2073-2075
cognition	O	2076-2085
.	O	2085-2086

Fatal	O	0-5
carbamazepine	O	6-19
induced	O	20-27
fulminant	B	28-37
eosinophilic	I	38-50
(	O	51-52
hypersensitivity	B	52-68
)	O	68-69
myocarditis	B	70-81
:	O	81-82
emphasis	O	83-91
on	O	92-94
anatomical	O	95-105
and	O	106-109
histological	O	110-122
characteristics	O	123-138
,	O	138-139
mechanisms	O	140-150
and	O	151-154
genetics	O	155-163
of	O	164-166
drug	B	167-171
hypersensitivity	I	172-188
and	O	189-192
differential	O	193-205
diagnosis	O	206-215
.	O	215-216

The	O	217-220
most	O	221-225
severe	O	226-232
adverse	O	233-240
reactions	O	241-250
to	O	251-253
carbamazepine	O	254-267
have	O	268-272
been	O	273-277
observed	O	278-286
in	O	287-289
the	O	290-293
haemopoietic	O	294-306
system	O	307-313
,	O	313-314
the	O	315-318
liver	O	319-324
and	O	325-328
the	O	329-332
cardiovascular	O	333-347
system	O	348-354
.	O	354-355

A	O	356-357
frequently	O	358-368
fatal	O	369-374
,	O	374-375
although	O	376-384
exceptionally	O	385-398
rare	O	399-403
side	O	404-408
effect	O	409-415
of	O	416-418
carbamazepine	O	419-432
is	O	433-435
necrotizing	O	436-447
eosinophilic	O	448-460
(	O	461-462
hypersensitivity	B	462-478
)	O	478-479
myocarditis	B	480-491
.	O	491-492

We	O	493-495
report	O	496-502
a	O	503-504
case	O	505-509
of	O	510-512
hypersensitivity	B	513-529
myocarditis	B	530-541
secondary	O	542-551
to	O	552-554
administration	O	555-569
of	O	570-572
carbamazepine	O	573-586
.	O	586-587

Acute	O	588-593
hypersensitivity	B	594-610
myocarditis	B	611-622
was	O	623-626
not	O	627-630
suspected	O	631-640
clinically	O	641-651
,	O	651-652
and	O	653-656
the	O	657-660
diagnosis	O	661-670
was	O	671-674
made	O	675-679
post	O	680-684
-	O	684-685
mortem	O	685-691
.	O	691-692

Histology	O	693-702
revealed	O	703-711
diffuse	O	712-719
infiltration	O	720-732
of	O	733-735
the	O	736-739
myocardium	O	740-750
by	O	751-753
eosinophils	O	754-765
and	O	766-769
lymphocytes	O	770-781
with	O	782-786
myocyte	O	787-794
damage	O	795-801
.	O	801-802

Clinically	O	803-813
,	O	813-814
death	O	815-820
was	O	821-824
due	O	825-828
to	O	829-831
cardiogenic	B	832-843
shock	I	844-849
.	O	849-850

To	O	851-853
best	O	854-858
of	O	859-861
our	O	862-865
knowledge	O	866-875
this	O	876-880
is	O	881-883
the	O	884-887
second	O	888-894
case	O	895-899
of	O	900-902
fatal	O	903-908
carbamazepine	O	909-922
induced	O	923-930
myocarditis	B	931-942
reported	O	943-951
in	O	952-954
English	O	955-962
literature	O	963-973
.	O	973-974

Neuropsychiatric	O	0-16
behaviors	O	17-26
in	O	27-29
the	O	30-33
MPTP	O	34-38
marmoset	O	39-47
model	O	48-53
of	O	54-56
Parkinson	B	57-66
'	I	66-67
s	I	63-64
disease	I	69-76
.	O	76-77

OBJECTIVES	O	78-88
:	O	88-89
Neuropsychiatric	O	90-106
symptoms	O	107-115
are	O	116-119
increasingly	O	120-132
recognised	O	133-143
as	O	144-146
a	O	147-148
significant	O	149-160
problem	O	161-168
in	O	169-171
patients	O	172-180
with	O	181-185
Parkinson	B	186-195
'	I	195-196
s	I	192-193
disease	I	198-205
(	O	206-207
PD	B	207-209
)	O	209-210
.	O	210-211

These	O	212-217
symptoms	O	218-226
may	O	227-230
be	O	231-233
due	O	234-237
to	O	238-240
'	O	241-242
sensitisation	O	242-255
'	O	241-242
following	O	257-266
repeated	O	267-275
levodopa	O	276-284
treatment	O	285-294
or	O	295-297
a	O	298-299
direct	O	300-306
effect	O	307-313
of	O	314-316
dopamine	O	317-325
on	O	326-328
the	O	329-332
disease	O	333-340
state	O	341-346
.	O	346-347

The	O	348-351
levodopa	O	352-360
-	O	360-361
treated	O	361-368
MPTP	O	369-373
-	O	373-374
lesioned	O	374-382
marmoset	O	383-391
was	O	392-395
used	O	396-400
as	O	401-403
a	O	404-405
model	O	406-411
of	O	412-414
neuropsychiatric	B	415-431
symptoms	I	432-440
in	O	441-443
PD	B	444-446
patients	O	447-455
.	O	455-456

Here	O	457-461
we	O	462-464
compare	O	465-472
the	O	473-476
time	O	477-481
course	O	482-488
of	O	489-491
levodopa	O	492-500
-	O	500-501
induced	O	501-508
motor	O	509-514
fluctuations	O	515-527
and	O	528-531
neuropsychiatric	B	532-548
-	I	548-549
like	I	549-553
behaviors	I	554-563
to	O	564-566
determine	O	567-576
the	O	577-580
relationship	O	581-593
between	O	594-601
duration	O	602-610
of	O	611-613
treatment	O	614-623
and	O	624-627
onset	O	628-633
of	O	634-636
symptoms	O	637-645
.	O	645-646

METHODS	O	647-654
:	O	654-655
Marmosets	O	656-665
were	O	666-670
administered	O	671-683
1	O	684-685
-	O	685-686
methyl	O	686-692
-	O	685-686
4	O	693-694
-	O	685-686
phenyl	O	695-701
-	O	685-686
1	O	684-685
,	O	703-704
2	O	704-705
,	O	703-704
3	O	706-707
,	O	703-704
6	O	708-709
-	O	685-686
tetrahydropyridine	O	710-728
(	O	729-730
2	O	730-731
.	O	731-732
0	O	732-733
mg	O	734-736
/	O	736-737
kg	O	737-739
s	O	740-741
.	O	741-742
c	O	742-743
.	O	741-742
)	O	744-745
for	O	746-749
five	O	750-754
days	O	755-759
,	O	759-760
resulting	O	761-770
in	O	771-773
stable	O	774-780
parkinsonism	B	781-793
.	O	793-794

Levodopa	O	795-803
(	O	804-805
15	O	805-807
mg	O	808-810
/	O	810-811
kg	O	811-813
and	O	814-817
benserazide	O	818-829
,	O	829-830
3	O	831-832
.	O	832-833
75	O	833-835
mg	O	836-838
/	O	838-839
kg	O	839-841
)	O	841-842
p	O	843-844
.	O	844-845
o	O	845-846
.	O	844-845
b	O	848-849
.	O	849-850
i	O	850-851
.	O	849-850
d	O	852-853
,	O	853-854
was	O	855-858
administered	O	859-871
for	O	872-875
30	O	876-878
days	O	879-883
.	O	883-884

Animals	O	885-892
were	O	893-897
evaluated	O	898-907
for	O	908-911
parkinsonian	B	912-924
disability	I	925-935
,	O	935-936
dyskinesia	B	937-947
and	O	948-951
on	O	952-954
-	O	954-955
time	O	955-959
(	O	960-961
motor	O	961-966
fluctuations	O	967-979
)	O	979-980
and	O	981-984
neuropsychiatric	B	985-1001
-	I	1001-1002
like	I	1002-1006
behaviors	I	1007-1016
on	O	1017-1019
Day	O	1020-1023
0	O	1024-1025
(	O	1026-1027
prior	O	1027-1032
to	O	1033-1035
levodopa	O	1036-1044
)	O	1044-1045
and	O	1046-1049
on	O	1050-1052
Days	O	1053-1057
1	O	1058-1059
,	O	1059-1060
7	O	1061-1062
,	O	1062-1063
13	O	1064-1066
,	O	1066-1067
27	O	1068-1070
and	O	1071-1074
30	O	1075-1077
of	O	1078-1080
treatment	O	1081-1090
using	O	1091-1096
post	O	1097-1101
hoc	O	1102-1105
DVD	O	1106-1109
analysis	O	1110-1118
by	O	1119-1121
a	O	1122-1123
trained	O	1124-1131
rater	O	1132-1137
,	O	1137-1138
blind	O	1139-1144
to	O	1145-1147
the	O	1148-1151
treatment	O	1152-1161
day	O	1162-1165
.	O	1165-1166

RESULTS	O	1167-1174
:	O	1174-1175
The	O	1176-1179
neuropsychiatric	B	1180-1196
-	I	1196-1197
like	I	1197-1201
behavior	I	1202-1210
rating	O	1211-1217
scale	O	1218-1223
demonstrated	O	1224-1236
high	O	1237-1241
interrater	O	1242-1252
reliability	O	1253-1264
between	O	1265-1272
three	O	1273-1278
trained	O	1279-1286
raters	O	1287-1293
of	O	1294-1296
differing	O	1297-1306
professional	O	1307-1319
backgrounds	O	1320-1331
.	O	1331-1332

As	O	1333-1335
anticipated	O	1336-1347
,	O	1347-1348
animals	O	1349-1356
exhibited	O	1357-1366
a	O	1367-1368
progressive	O	1369-1380
increase	O	1381-1389
in	O	1390-1392
levodopa	O	1393-1401
-	O	1401-1402
induced	O	1402-1409
motor	O	1410-1415
fluctuations	O	1416-1428
,	O	1428-1429
dyskinesia	B	1430-1440
and	O	1441-1444
wearing	O	1445-1452
-	O	1452-1453
off	O	1453-1456
,	O	1456-1457
that	O	1458-1462
correlated	O	1463-1473
with	O	1474-1478
the	O	1479-1482
duration	O	1483-1491
of	O	1492-1494
levodopa	O	1495-1503
therapy	O	1504-1511
.	O	1511-1512

In	O	1513-1515
contrast	O	1516-1524
,	O	1524-1525
levodopa	O	1526-1534
-	O	1534-1535
induced	O	1535-1542
neuropsychiatric	B	1543-1559
-	I	1559-1560
like	I	1560-1564
behaviors	I	1565-1574
were	O	1575-1579
present	O	1580-1587
on	O	1588-1590
Day	O	1591-1594
1	O	1595-1596
of	O	1597-1599
levodopa	O	1600-1608
treatment	O	1609-1618
and	O	1619-1622
their	O	1623-1628
severity	O	1629-1637
did	O	1638-1641
not	O	1642-1645
correlate	O	1646-1655
with	O	1656-1660
duration	O	1661-1669
of	O	1670-1672
treatment	O	1673-1682
.	O	1682-1683

CONCLUSIONS	O	1684-1695
:	O	1695-1696
The	O	1697-1700
data	O	1701-1705
suggest	O	1706-1713
that	O	1714-1718
neuropsychiatric	B	1719-1735
disorders	I	1736-1745
in	O	1746-1748
PD	B	1749-1751
are	O	1752-1755
more	O	1756-1760
likely	O	1761-1767
an	O	1768-1770
interaction	O	1771-1782
between	O	1783-1790
levodopa	O	1791-1799
and	O	1800-1803
the	O	1804-1807
disease	O	1808-1815
state	O	1816-1821
than	O	1822-1826
a	O	1827-1828
consequence	O	1829-1840
of	O	1841-1843
sensitisation	O	1844-1857
to	O	1858-1860
repeated	O	1861-1869
dopaminergic	O	1870-1882
therapy	O	1883-1890
.	O	1890-1891

Contrast	O	0-8
medium	O	9-15
nephrotoxicity	B	16-30
after	O	31-36
renal	O	37-42
artery	O	43-49
and	O	50-53
coronary	O	54-62
angioplasty	O	63-74
.	O	74-75

BACKGROUND	O	76-86
:	O	86-87
Renal	B	88-93
dysfunction	I	94-105
induced	O	106-113
by	O	114-116
iodinated	O	117-126
contrast	O	127-135
medium	O	136-142
(	O	143-144
CM	O	144-146
)	O	146-147
administration	O	148-162
can	O	163-166
minimize	O	167-175
the	O	176-179
benefit	O	180-187
of	O	188-190
the	O	191-194
interventional	O	195-209
procedure	O	210-219
in	O	220-222
patients	O	223-231
undergoing	O	232-242
renal	O	243-248
angioplasty	O	249-260
(	O	261-262
PTRA	O	262-266
)	O	266-267
.	O	267-268

PURPOSE	O	269-276
:	O	276-277
To	O	278-280
compare	O	281-288
the	O	289-292
susceptibility	O	293-307
to	O	308-310
nephrotoxic	B	311-322
effect	O	323-329
of	O	330-332
CM	O	333-335
in	O	336-338
patients	O	339-347
undergoing	O	348-358
PTRA	O	359-363
with	O	364-368
that	O	369-373
of	O	374-376
patients	O	377-385
submitted	O	386-395
to	O	396-398
percutaneous	O	399-411
coronary	O	412-420
intervention	O	421-433
(	O	434-435
PCI	O	435-438
)	O	438-439
.	O	439-440

MATERIAL	O	441-449
AND	O	450-453
METHODS	O	454-461
:	O	461-462
A	O	463-464
total	O	465-470
of	O	471-473
33	O	474-476
patients	O	477-485
successfully	O	486-498
treated	O	499-506
with	O	507-511
PTRA	O	512-516
(	O	517-518
PTRA	O	518-522
group	O	523-528
,	O	528-529
mean	O	530-534
age	O	535-538
70	O	539-541
+	O	541-542
/	O	542-543
-	O	543-544
12	O	544-546
years	O	547-552
,	O	552-553
23	O	554-556
female	O	557-563
,	O	563-564
basal	O	565-570
creatinine	O	571-581
1	O	582-583
.	O	583-584
46	O	584-586
+	O	586-587
/	O	587-588
-	O	588-589
0	O	589-590
.	O	583-584
79	O	591-593
,	O	593-594

range	O	595-600
0	O	601-602
.	O	602-603
7	O	603-604
-	O	604-605
4	O	605-606
.	O	602-603
9	O	607-608

mg	O	609-611
/	O	611-612
dl	O	612-614
)	O	614-615
were	O	616-620
compared	O	621-629
with	O	630-634
33	O	635-637
patients	O	638-646
undergoing	O	647-657
successful	O	658-668
PCI	O	669-672
(	O	673-674
PCI	O	674-677
group	O	678-683
)	O	683-684
,	O	684-685
matched	O	686-693
for	O	694-697
basal	O	698-703
creatinine	O	704-714
(	O	715-716
1	O	716-717
.	O	717-718
44	O	718-720
+	O	720-721
/	O	721-722
-	O	722-723
0	O	723-724
.	O	717-718
6	O	725-726
,	O	726-727

range	O	728-733
0	O	734-735
.	O	735-736
7	O	736-737
-	O	737-738
3	O	738-739
.	O	735-736
4	O	740-741

mg	O	742-744
/	O	744-745
dl	O	745-747
)	O	747-748
,	O	748-749
gender	O	750-756
,	O	756-757
and	O	758-761
age	O	762-765
.	O	765-766

In	O	767-769
both	O	770-774
groups	O	775-781
postprocedural	O	782-796
(	O	797-798
48	O	798-800
h	O	801-802
)	O	802-803
serum	O	804-809
creatinine	O	810-820
was	O	821-824
measured	O	825-833
.	O	833-834

RESULTS	O	835-842
:	O	842-843
Postprocedural	O	844-858
creatinine	O	859-869
level	O	870-875
decreased	O	876-885
nonsignificantly	O	886-902
in	O	903-905
the	O	906-909
PTRA	O	910-914
group	O	915-920
(	O	921-922
1	O	922-923
.	O	923-924
46	O	924-926
+	O	926-927
/	O	927-928
-	O	928-929
0	O	929-930
.	O	923-924
8	O	931-932
vs	O	933-935
.	O	935-936
1	O	937-938
.	O	938-939
34	O	939-941
+	O	941-942
/	O	942-943
-	O	943-944
0	O	944-945
.	O	938-939
5	O	946-947
mg	O	948-950
/	O	950-951
dl	O	951-953
,	O	953-954
P	O	955-956
=	O	956-957
NS	O	957-959
)	O	959-960
and	O	961-964
increased	O	965-974
significantly	O	975-988
in	O	989-991
the	O	992-995
PCI	O	996-999
group	O	1000-1005
(	O	1006-1007
1	O	1007-1008
.	O	1008-1009
44	O	1009-1011
+	O	1011-1012
/	O	1012-1013
-	O	1013-1014
0	O	1014-1015
.	O	1008-1009
6	O	1016-1017
vs	O	1018-1020
.	O	1020-1021
1	O	1022-1023
.	O	1023-1024
57	O	1024-1026
+	O	1026-1027
/	O	1027-1028
-	O	1028-1029
0	O	1029-1030
.	O	1023-1024
7	O	1025-1026
mg	O	1033-1035
/	O	1035-1036
dl	O	1036-1038
,	O	1038-1039
P	O	1040-1041
<	O	1041-1042
0	O	1042-1043
.	O	1043-1044
02	O	1044-1046
)	O	1046-1047
.	O	1043-1044

Changes	O	1049-1056
in	O	1057-1059
serum	O	1060-1065
creatinine	O	1066-1076
after	O	1077-1082
intervention	O	1083-1095
(	O	1096-1097
after	O	1097-1102
-	O	1102-1103
before	O	1103-1109
)	O	1109-1110
were	O	1111-1115
significantly	O	1116-1129
different	O	1130-1139
between	O	1140-1147
the	O	1148-1151
PTRA	O	1152-1156
and	O	1157-1160
PCI	O	1161-1164
groups	O	1165-1171
(	O	1172-1173
-	O	1173-1174
0	O	1174-1175
.	O	1175-1176
12	O	1176-1178
+	O	1178-1179
/	O	1179-1180
-	O	1173-1174
0	O	1174-1175
.	O	1175-1176
5	O	1183-1184
vs	O	1185-1187
.	O	1187-1188
0	O	1189-1190
.	O	1190-1191
13	O	1191-1193
+	O	1193-1194
/	O	1194-1195
-	O	1195-1196
0	O	1189-1190
.	O	1190-1191
3	O	1192-1193
,	O	1199-1200

P	O	1201-1202
=	O	1202-1203
0	O	1203-1204
.	O	1204-1205
014	O	1205-1208
)	O	1208-1209
.	O	1204-1205

This	O	1211-1215
difference	O	1216-1226
was	O	1227-1230
not	O	1231-1234
related	O	1235-1242
to	O	1243-1245
either	O	1246-1252
a	O	1253-1254
different	O	1255-1264
clinical	O	1265-1273
risk	O	1274-1278
profile	O	1279-1286
or	O	1287-1289
to	O	1290-1292
the	O	1293-1296
volume	O	1297-1303
of	O	1304-1306
CM	O	1307-1309
administered	O	1310-1322
.	O	1322-1323

CONCLUSION	O	1324-1334
:	O	1334-1335
In	O	1336-1338
this	O	1339-1343
preliminary	O	1344-1355
study	O	1356-1361
patients	O	1362-1370
submitted	O	1371-1380
to	O	1381-1383
PTRA	O	1384-1388
showed	O	1389-1395
a	O	1396-1397
lower	O	1398-1403
susceptibility	O	1404-1418
to	O	1419-1421
renal	B	1422-1427
damage	I	1428-1434
induced	O	1435-1442
by	O	1443-1445
CM	O	1446-1448
administration	O	1449-1463
than	O	1464-1468
PCI	O	1469-1472
patients	O	1473-1481
.	O	1481-1482

The	O	1483-1486
effectiveness	O	1487-1500
of	O	1501-1503
PTRA	O	1504-1508
on	O	1509-1511
renal	O	1512-1517
function	O	1518-1526
seems	O	1527-1532
to	O	1533-1535
be	O	1536-1538
barely	O	1539-1545
influenced	O	1546-1556
by	O	1557-1559
CM	O	1560-1562
toxicity	B	1563-1571
.	O	1571-1572

Medical	O	0-7
and	O	8-11
psychiatric	O	12-23
outcomes	O	24-32
for	O	33-36
patients	O	37-45
transplanted	O	46-58
for	O	59-62
acetaminophen	O	63-76
-	O	76-77
induced	O	77-84
acute	B	85-90
liver	I	91-96
failure	I	97-104
:	O	104-105
a	O	106-107
case	O	108-112
-	O	112-113
control	O	113-120
study	O	121-126
.	O	126-127

BACKGROUND	O	128-138
:	O	138-139
Acetaminophen	O	140-153
-	O	153-154
induced	O	154-161
hepatotoxicity	B	162-176
is	O	177-179
the	O	180-183
most	O	184-188
common	O	189-195
cause	O	196-201
of	O	202-204
acute	B	205-210
liver	I	211-216
failure	I	217-224
(	O	225-226
ALF	B	226-229
)	O	229-230
in	O	231-233
the	O	234-237
UK	O	238-240
.	O	240-241

Patients	O	242-250
often	O	251-256
consume	O	257-264
the	O	265-268
drug	O	269-273
with	O	274-278
suicidal	O	279-287
intent	O	288-294
or	O	295-297
with	O	298-302
a	O	303-304
background	O	305-315
of	O	316-318
substance	O	319-328
dependence	O	329-339
.	O	339-340

AIMS	O	341-345
AND	O	346-349
METHODS	O	350-357
:	O	357-358
We	O	359-361
compared	O	362-370
the	O	371-374
severity	O	375-383
of	O	384-386
pretransplant	O	387-400
illness	O	401-408
,	O	408-409
psychiatric	O	410-421
co	O	422-424
-	O	424-425
morbidity	O	425-434
,	O	434-435
medical	O	436-443
and	O	444-447
psychosocial	O	448-460
outcomes	O	461-469
of	O	470-472
all	O	473-476
patients	O	477-485
who	O	486-489
had	O	490-493
undergone	O	494-503
liver	O	504-509
transplantation	O	510-525
(	O	526-527
LT	O	527-529
)	O	529-530
emergently	O	531-541
between	O	542-549
1999	O	550-554
-	O	554-555
2004	O	555-559
for	O	560-563
acetaminophen	O	564-577
-	O	577-578
induced	O	578-585
ALF	B	586-589
(	O	590-591
n	O	591-592
=	O	592-593
36	O	593-595
)	O	595-596
with	O	597-601
age	O	602-605
-	O	605-606
and	O	607-610
sex	O	611-614
-	O	614-615
matched	O	615-622
patients	O	623-631
undergoing	O	632-642
emergent	O	643-651
LT	O	652-654
for	O	655-658
non	O	659-662
-	O	662-663
acetaminophen	O	663-676
-	O	662-663
induced	O	677-684
ALF	B	685-688
(	O	689-690
n	O	690-691
=	O	691-692
35	O	692-694
)	O	694-695
and	O	696-699
elective	O	700-708
LT	O	709-711
for	O	712-715
chronic	B	716-723
liver	I	724-729
disease	I	730-737
(	O	738-739
CLD	B	739-742
,	O	742-743
n	O	744-745
=	O	745-746
34	O	746-748
)	O	748-749
.	O	749-750

RESULTS	O	751-758
:	O	758-759
Acetaminophen	O	760-773
-	O	773-774
induced	O	774-781
ALF	B	782-785
patients	O	786-794
undergoing	O	795-805
LT	O	806-808
had	O	809-812
a	O	813-814
greater	O	815-822
severity	O	823-831
of	O	832-834
pre	O	835-838
-	O	838-839
LT	O	839-841
illness	O	842-849
reflected	O	850-859
by	O	860-862
higher	O	863-869
Acute	O	870-875
Physiology	O	876-886
and	O	887-890
Chronic	O	891-898
Health	O	899-905
Evaluation	O	906-916
II	O	917-919
scores	O	920-926
and	O	927-930
requirement	O	931-942
for	O	943-946
organ	O	947-952
support	O	953-960
compared	O	961-969
with	O	970-974
the	O	975-978
other	O	979-984
two	O	985-988
groups	O	989-995
.	O	995-996

Twenty	O	997-1003
(	O	1004-1005
56	O	1005-1007
%	O	1007-1008
)	O	1008-1009
acetaminophen	O	1010-1023
-	O	1023-1024
induced	O	1024-1031
ALF	B	1032-1035
patients	O	1036-1044
had	O	1045-1048
a	O	1049-1050
formal	O	1051-1057
psychiatric	O	1058-1069
diagnosis	O	1070-1079
before	O	1080-1086
LT	O	1087-1089
(	O	1090-1091
non	O	1091-1094
-	O	1094-1095
acetaminophen	O	1095-1108
-	O	1094-1095
induced	O	1109-1116
ALF	B	1117-1120
=	O	1120-1121
0	O	1121-1122
/	O	1122-1123
35	O	1123-1125
,	O	1125-1126
CLD	B	1127-1130
=	O	1130-1131
2	O	1131-1132
/	O	1132-1133
34	O	1133-1135
;	O	1135-1136
P	O	1137-1138
<	O	1138-1139
0	O	1139-1140
.	O	1140-1141
01	O	1141-1143
for	O	1144-1147
all	O	1148-1151
)	O	1151-1152
and	O	1153-1156
nine	O	1157-1161
(	O	1162-1163
25	O	1163-1165
%	O	1165-1166
)	O	1166-1167
had	O	1168-1171
a	O	1172-1173
previous	O	1174-1182
suicide	O	1183-1190
attempt	O	1191-1198
.	O	1198-1199

During	O	1200-1206
follow	O	1207-1213
-	O	1213-1214
up	O	1214-1216
(	O	1217-1218
median	O	1218-1224
5	O	1225-1226
years	O	1227-1232
)	O	1232-1233
,	O	1233-1234
there	O	1235-1240
were	O	1241-1245
no	O	1246-1248
significant	O	1249-1260
differences	O	1261-1272
in	O	1273-1275
rejection	O	1276-1285
(	O	1286-1287
acute	O	1287-1292
and	O	1293-1296
chronic	O	1297-1304
)	O	1304-1305
,	O	1305-1306
graft	O	1307-1312
failure	O	1313-1320
or	O	1321-1323
survival	O	1324-1332
between	O	1333-1340
the	O	1341-1344
groups	O	1345-1351
(	O	1352-1353
acetaminophen	O	1353-1366
-	O	1366-1367
induced	O	1367-1374
ALF	B	1375-1378
1	O	1379-1380
year	O	1381-1385
87	O	1386-1388
%	O	1388-1389
,	O	1389-1390
5	O	1391-1392
years	O	1393-1398
75	O	1399-1401
%	O	1401-1402
;	O	1402-1403
non	O	1404-1407
-	O	1407-1408
acetaminophen	O	1408-1421
-	O	1407-1408
induced	O	1422-1429
ALF	B	1430-1433
88	O	1434-1436
%	O	1436-1437
,	O	1437-1438
78	O	1439-1441
%	O	1441-1442
;	O	1442-1443
CLD	B	1444-1447
93	O	1448-1450
%	O	1450-1451
,	O	1451-1452
82	O	1453-1455
%	O	1455-1456
:	O	1456-1457
P	O	1458-1459
>	O	1459-1460
0	O	1460-1461
.	O	1461-1462
6	O	1462-1463
log	O	1464-1467
rank	O	1468-1472
)	O	1472-1473
.	O	1473-1474

Two	O	1475-1478
acetaminophen	O	1479-1492
-	O	1492-1493
induced	O	1493-1500
ALF	B	1501-1504
patients	O	1505-1513
reattempted	O	1514-1525
suicide	O	1526-1533
post	O	1534-1538
-	O	1538-1539
LT	O	1539-1541
(	O	1542-1543
one	O	1543-1546
died	O	1547-1551
8	O	1552-1553
years	O	1554-1559
post	O	1560-1564
-	O	1564-1565
LT	O	1565-1567
)	O	1567-1568
.	O	1568-1569

CONCLUSIONS	O	1570-1581
:	O	1581-1582
Despite	O	1583-1590
a	O	1591-1592
high	O	1593-1597
prevalence	O	1598-1608
of	O	1609-1611
psychiatric	O	1612-1623
disturbance	O	1624-1635
,	O	1635-1636
outcomes	O	1637-1645
for	O	1646-1649
patients	O	1650-1658
transplanted	O	1659-1671
emergently	O	1672-1682
for	O	1683-1686
acetaminophen	O	1687-1700
-	O	1700-1701
induced	O	1701-1708
ALF	B	1709-1712
were	O	1713-1717
comparable	O	1718-1728
to	O	1729-1731
those	O	1732-1737
transplanted	O	1738-1750
for	O	1751-1754
non	O	1755-1758
-	O	1758-1759
acetaminophen	O	1759-1772
-	O	1758-1759
induced	O	1773-1780
ALF	B	1781-1784
and	O	1785-1788
electively	O	1789-1799
for	O	1800-1803
CLD	B	1804-1807
.	O	1807-1808

Multidisciplinary	O	1809-1826
approaches	O	1827-1837
with	O	1838-1842
long	O	1843-1847
-	O	1847-1848
term	O	1848-1852
psychiatric	O	1853-1864
follow	O	1865-1871
-	O	1871-1872
up	O	1872-1874
may	O	1875-1878
contribute	O	1879-1889
to	O	1890-1892
low	O	1893-1896
post	O	1897-1901
-	O	1901-1902
transplant	O	1902-1912
suicide	O	1913-1920
rates	O	1921-1926
seen	O	1927-1931
and	O	1932-1935
low	O	1936-1939
rates	O	1940-1945
of	O	1946-1948
graft	O	1949-1954
loss	O	1955-1959
because	O	1960-1967
of	O	1968-1970
non	O	1971-1974
-	O	1974-1975
compliance	O	1975-1985
.	O	1985-1986

Studies	O	0-7
of	O	8-10
synergy	O	11-18
between	O	19-26
morphine	O	27-35
and	O	36-39
a	O	40-41
novel	O	42-47
sodium	O	48-54
channel	O	55-62
blocker	O	63-70
,	O	70-71
CNSB002	O	72-79
,	O	79-80
in	O	81-83
rat	O	84-87
models	O	88-94
of	O	95-97
inflammatory	O	98-110
and	O	111-114
neuropathic	B	115-126
pain	I	127-131
.	O	131-132

OBJECTIVE	O	133-142
:	O	142-143
This	O	144-148
study	O	149-154
determined	O	155-165
the	O	166-169
antihyperalgesic	O	170-186
effect	O	187-193
of	O	194-196
CNSB002	O	197-204
,	O	204-205
a	O	206-207
sodium	O	208-214
channel	O	215-222
blocker	O	223-230
with	O	231-235
antioxidant	O	236-247
properties	O	248-258
given	O	259-264
alone	O	265-270
and	O	271-274
in	O	275-277
combinations	O	278-290
with	O	291-295
morphine	O	296-304
in	O	305-307
rat	O	308-311
models	O	312-318
of	O	319-321
inflammatory	O	322-334
and	O	335-338
neuropathic	B	339-350
pain	I	351-355
.	O	355-356

DESIGN	O	357-363
:	O	363-364
Dose	O	365-369
response	O	370-378
curves	O	379-385
for	O	386-389
nonsedating	O	390-401
doses	O	402-407
of	O	408-410
morphine	O	411-419
and	O	420-423
CNSB002	O	424-431
given	O	432-437
intraperitoneally	O	438-455
alone	O	456-461
and	O	462-465
together	O	466-474
in	O	475-477
combinations	O	478-490
were	O	491-495
constructed	O	496-507
for	O	508-511
antihyperalgesic	O	512-528
effect	O	529-535
using	O	536-541
paw	O	542-545
withdrawal	O	546-556
from	O	557-561
noxious	O	562-569
heat	O	570-574
in	O	575-577
two	O	578-581
rat	O	582-585
pain	B	586-590
models	O	591-597
:	O	597-598
carrageenan	O	599-610
-	O	610-611
induced	O	611-618
paw	O	619-622
inflammation	B	623-635
and	O	636-639
streptozotocin	O	640-654
(	O	655-656
STZ	O	656-659
)	O	659-660
-	O	660-661
induced	O	661-668
diabetic	B	669-677
neuropathy	I	678-688
.	O	688-689

RESULTS	O	690-697
:	O	697-698
The	O	699-702
maximum	O	703-710
nonsedating	O	711-722
doses	O	723-728
were	O	729-733
:	O	733-734
morphine	O	735-743
,	O	743-744
3	O	745-746
.	O	746-747
2	O	747-748
mg	O	749-751
/	O	751-752
kg	O	752-754
;	O	754-755
CNSB002	O	756-763
10	O	764-766
.	O	766-767
0	O	765-766
mg	O	769-771
/	O	771-772
kg	O	772-774
;	O	774-775
5	O	776-777
.	O	777-778
0	O	778-779
mg	O	780-782
/	O	782-783
kg	O	783-785
CNSB002	O	786-793
with	O	794-798
morphine	O	799-807
3	O	808-809
.	O	809-810
2	O	810-811
mg	O	812-814
/	O	814-815
kg	O	815-817
in	O	818-820
combination	O	821-832
.	O	832-833

The	O	834-837
doses	O	838-843
calculated	O	844-854
to	O	855-857
cause	O	858-863
50	O	864-866
%	O	866-867
reversal	O	868-876
of	O	877-879
hyperalgesia	B	880-892
(	O	893-894
ED50	O	894-898
)	O	898-899
were	O	900-904
7	O	905-906
.	O	906-907
54	O	907-909
(	O	910-911
1	O	911-912
.	O	912-913
81	O	913-915
)	O	915-916
and	O	917-920
4	O	921-922
.	O	922-923
83	O	923-925
(	O	926-927
1	O	927-928
.	O	928-929
54	O	929-931
)	O	931-932
in	O	933-935
the	O	936-939
carrageenan	O	940-951
model	O	952-957
and	O	958-961
44	O	962-964
.	O	964-965
18	O	965-967
(	O	968-969
1	O	969-970
.	O	970-971
37	O	971-973
)	O	973-974
and	O	975-978
9	O	979-980
.	O	980-981
14	O	981-983
(	O	984-985
1	O	985-986
.	O	986-987
24	O	987-989
)	O	989-990
in	O	991-993
the	O	994-997
STZ	O	998-1001
-	O	1001-1002
induced	O	1002-1009
neuropathy	B	1010-1020
model	O	1021-1026
for	O	1027-1030
CNSB002	O	1031-1038
and	O	1039-1042
morphine	O	1043-1051
,	O	1051-1052
respectively	O	1053-1065
(	O	1066-1067
mg	O	1067-1069
/	O	1069-1070
kg	O	1070-1072
;	O	1072-1073
mean	O	1074-1078
,	O	1078-1079
SEM	O	1080-1083
)	O	1083-1084
.	O	1084-1085

These	O	1086-1091
values	O	1092-1098
were	O	1099-1103
greater	O	1104-1111
than	O	1112-1116
the	O	1117-1120
maximum	O	1121-1128
nonsedating	O	1129-1140
doses	O	1141-1146
.	O	1146-1147

The	O	1148-1151
ED50	O	1152-1156
values	O	1157-1163
for	O	1164-1167
morphine	O	1168-1176
when	O	1177-1181
given	O	1182-1187
in	O	1188-1190
combination	O	1191-1202
with	O	1203-1207
CNSB002	O	1208-1215
(	O	1216-1217
5	O	1217-1218
mg	O	1219-1221
/	O	1221-1222
kg	O	1222-1224
)	O	1224-1225
were	O	1226-1230
less	O	1231-1235
than	O	1236-1240
the	O	1241-1244
maximum	O	1245-1252
nonsedating	O	1253-1264
dose	O	1265-1269
:	O	1269-1270
0	O	1271-1272
.	O	1272-1273
56	O	1273-1275
(	O	1276-1277
1	O	1277-1278
.	O	1278-1279
55	O	1279-1281
)	O	1281-1282
in	O	1283-1285
the	O	1286-1289
carrageenan	O	1290-1301
model	O	1302-1307
and	O	1308-1311
1	O	1312-1313
.	O	1313-1314
37	O	1314-1316
(	O	1317-1318
1	O	1318-1319
.	O	1319-1320
23	O	1320-1322
)	O	1322-1323
in	O	1324-1326
the	O	1327-1330
neuropathy	B	1331-1341
model	O	1342-1347
(	O	1348-1349
mg	O	1349-1351
/	O	1351-1352
kg	O	1352-1354
;	O	1354-1355
mean	O	1356-1360
,	O	1360-1361
SEM	O	1362-1365
)	O	1365-1366
.	O	1366-1367

The	O	1368-1371
antinociception	O	1372-1387
after	O	1388-1393
morphine	O	1394-1402
(	O	1403-1404
3	O	1404-1405
.	O	1405-1406
2	O	1406-1407
mg	O	1408-1410
/	O	1410-1411
kg	O	1411-1413
)	O	1413-1414
was	O	1415-1418
increased	O	1419-1428
by	O	1429-1431
co	O	1432-1434
-	O	1434-1435
administration	O	1435-1449
with	O	1450-1454
CNSB002	O	1455-1462
from	O	1463-1467
28	O	1468-1470
.	O	1470-1471
0	O	1471-1472
and	O	1473-1476
31	O	1477-1479
.	O	1479-1480
7	O	1480-1481
%	O	1481-1482
to	O	1483-1485
114	O	1486-1489
.	O	1489-1490
6	O	1490-1491
and	O	1492-1495
56	O	1496-1498
.	O	1498-1499
9	O	1499-1500
%	O	1500-1501
reversal	O	1502-1510
of	O	1511-1513
hyperalgesia	B	1514-1526
in	O	1527-1529
the	O	1530-1533
inflammatory	O	1534-1546
and	O	1547-1550
neuropathic	B	1551-1562
models	O	1563-1569
,	O	1569-1570
respectively	O	1571-1583
(	O	1584-1585
P	O	1585-1586
<	O	1587-1588
0	O	1589-1590
.	O	1590-1591
01	O	1591-1593
;	O	1593-1594
one	O	1595-1598
-	O	1598-1599
way	O	1599-1602
analysis	O	1603-1611
of	O	1612-1614
variance	O	1615-1623
-	O	1623-1624
significantly	O	1624-1637
greater	O	1638-1645
than	O	1646-1650
either	O	1651-1657
drug	O	1658-1662
given	O	1663-1668
alone	O	1669-1674
)	O	1674-1675
.	O	1675-1676

CONCLUSIONS	O	1677-1688
:	O	1688-1689
The	O	1690-1693
maximum	O	1694-1701
antihyperalgesic	O	1702-1718
effect	O	1719-1725
achievable	O	1726-1736
with	O	1737-1741
nonsedating	O	1742-1753
doses	O	1754-1759
of	O	1760-1762
morphine	O	1763-1771
may	O	1772-1775
be	O	1776-1778
increased	O	1779-1788
significantly	O	1789-1802
when	O	1803-1807
the	O	1808-1811
drug	O	1812-1816
is	O	1817-1819
used	O	1820-1824
in	O	1825-1827
combination	O	1828-1839
with	O	1840-1844
CNSB002	O	1845-1852
.	O	1852-1853

Heparin	O	0-7
-	O	7-8
induced	O	8-15
thrombocytopenia	B	16-32
:	O	32-33
a	O	34-35
practical	O	36-45
review	O	46-52
.	O	52-53

Heparin	O	54-61
-	O	61-62
induced	O	62-69
thrombocytopenia	B	70-86
(	O	87-88
HIT	B	88-91
)	O	91-92
remains	O	93-100
under	O	101-106
-	O	106-107
recognized	O	107-117
despite	O	118-125
its	O	126-129
potentially	O	130-141
devastating	O	142-153
outcomes	O	154-162
.	O	162-163

It	O	164-166
begins	O	167-173
when	O	174-178
heparin	O	179-186
exposure	O	187-195
stimulates	O	196-206
the	O	207-210
formation	O	211-220
of	O	221-223
heparin	O	224-231
-	O	231-232
platelet	O	232-240
factor	O	241-247
4	O	248-249
antibodies	O	250-260
,	O	260-261
which	O	262-267
in	O	268-270
turn	O	271-275
triggers	O	276-284
the	O	285-288
release	O	289-296
of	O	297-299
procoagulant	O	300-312
platelet	O	313-321
particles	O	322-331
.	O	331-332

Thrombosis	B	333-343
and	O	344-347
thrombocytopenia	B	348-364
that	O	365-369
follow	O	370-376
comprise	O	377-385
the	O	386-389
2	O	390-391
hallmark	O	392-400
traits	O	401-407
of	O	408-410
HIT	B	411-414
,	O	414-415
with	O	416-420
the	O	421-424
former	O	425-431
largely	O	432-439
responsible	O	440-451
for	O	452-455
significant	O	456-467
vascular	O	468-476
complications	O	477-490
.	O	490-491

The	O	492-495
prevalence	O	496-506
of	O	507-509
HIT	B	510-513
varies	O	514-520
among	O	521-526
several	O	527-534
subgroups	O	535-544
,	O	544-545
with	O	546-550
greater	O	551-558
incidence	O	559-568
in	O	569-571
surgical	O	572-580
as	O	581-583
compared	O	584-592
with	O	593-597
medical	O	598-605
populations	O	606-617
.	O	617-618

HIT	B	619-622
must	O	623-627
be	O	628-630
acknowledged	O	631-643
for	O	644-647
its	O	648-651
intense	O	652-659
predilection	O	660-672
for	O	673-676
thrombosis	B	677-687
and	O	688-691
suspected	O	692-701
whenever	O	702-710
thrombosis	B	711-721
occurs	O	722-728
after	O	729-734
heparin	O	735-742
exposure	O	743-751
.	O	751-752

Early	O	753-758
recognition	O	759-770
that	O	771-775
incorporates	O	776-788
the	O	789-792
clinical	O	793-801
and	O	802-805
serologic	O	806-815
clues	O	816-821
is	O	822-824
paramount	O	825-834
to	O	835-837
timely	O	838-844
institution	O	845-856
of	O	857-859
treatment	O	860-869
,	O	869-870
as	O	871-873
its	O	874-877
delay	O	878-883
may	O	884-887
result	O	888-894
in	O	895-897
catastrophic	O	898-910
outcomes	O	911-919
.	O	919-920

The	O	921-924
treatment	O	925-934
of	O	935-937
HIT	B	938-941
mandates	O	942-950
an	O	951-953
immediate	O	954-963
cessation	O	964-973
of	O	974-976
all	O	977-980
heparin	O	981-988
exposure	O	989-997
and	O	998-1001
the	O	1002-1005
institution	O	1006-1017
of	O	1018-1020
an	O	1021-1023
antithrombotic	O	1024-1038
therapy	O	1039-1046
,	O	1046-1047
most	O	1048-1052
commonly	O	1053-1061
using	O	1062-1067
a	O	1068-1069
direct	O	1070-1076
thrombin	O	1077-1085
inhibitor	O	1086-1095
.	O	1095-1096

Current	O	1097-1104
"	O	1105-1106
diagnostic	O	1106-1116
"	O	1105-1106
tests	O	1118-1123
,	O	1123-1124
which	O	1125-1130
primarily	O	1131-1140
include	O	1141-1148
functional	O	1149-1159
and	O	1160-1163
antigenic	O	1164-1173
assays	O	1174-1180
,	O	1180-1181
have	O	1182-1186
more	O	1187-1191
of	O	1192-1194
a	O	1195-1196
confirmatory	O	1197-1209
than	O	1210-1214
diagnostic	O	1215-1225
role	O	1226-1230
in	O	1231-1233
the	O	1234-1237
management	O	1238-1248
of	O	1249-1251
HIT	B	1252-1255
.	O	1255-1256

Special	O	1257-1264
attention	O	1265-1274
must	O	1275-1279
be	O	1280-1282
paid	O	1283-1287
to	O	1288-1290
cardiac	O	1291-1298
patients	O	1299-1307
who	O	1308-1311
are	O	1312-1315
often	O	1316-1321
exposed	O	1322-1329
to	O	1330-1332
heparin	O	1333-1340
multiple	O	1341-1349
times	O	1350-1355
during	O	1356-1362
their	O	1363-1368
course	O	1369-1375
of	O	1376-1378
treatment	O	1379-1388
.	O	1388-1389

Direct	O	1390-1396
thrombin	O	1397-1405
inhibitors	O	1406-1416
are	O	1417-1420
appropriate	O	1421-1432
,	O	1432-1433
evidence	O	1434-1442
-	O	1442-1443
based	O	1443-1448
alternatives	O	1449-1461
to	O	1462-1464
heparin	O	1465-1472
in	O	1473-1475
patients	O	1476-1484
with	O	1485-1489
a	O	1490-1491
history	O	1492-1499
of	O	1500-1502
HIT	B	1503-1506
,	O	1506-1507
who	O	1508-1511
need	O	1512-1516
to	O	1517-1519
undergo	O	1520-1527
percutaneous	O	1528-1540
coronary	O	1541-1549
intervention	O	1550-1562
.	O	1562-1563

As	O	1564-1566
heparin	O	1567-1574
remains	O	1575-1582
one	O	1583-1586
of	O	1587-1589
the	O	1590-1593
most	O	1594-1598
frequently	O	1599-1609
used	O	1610-1614
medications	O	1615-1626
today	O	1627-1632
with	O	1633-1637
potential	O	1638-1647
for	O	1648-1651
HIT	B	1652-1655
with	O	1656-1660
every	O	1661-1666
heparin	O	1667-1674
exposure	O	1675-1683
,	O	1683-1684
a	O	1685-1686
close	O	1687-1692
vigilance	O	1693-1702
of	O	1703-1705
platelet	O	1706-1714
counts	O	1715-1721
must	O	1722-1726
be	O	1727-1729
practiced	O	1730-1739
whenever	O	1740-1748
heparin	O	1749-1756
is	O	1757-1759
initiated	O	1760-1769
.	O	1769-1770

Abductor	O	0-8
paralysis	B	9-18
after	O	19-24
botox	O	25-30
injection	O	31-40
for	O	41-44
adductor	B	45-53
spasmodic	I	54-63
dysphonia	I	64-73
.	O	73-74

OBJECTIVES	O	75-85
/	O	85-86
HYPOTHESIS	O	86-96
:	O	96-97
Botulinum	O	98-107
toxin	O	108-113
(	O	114-115
Botox	O	115-120
)	O	120-121
injections	O	122-132
into	O	133-137
the	O	138-141
thyroarytenoid	O	142-156
muscles	O	157-164
are	O	165-168
the	O	169-172
current	O	173-180
standard	O	181-189
of	O	190-192
care	O	193-197
for	O	198-201
adductor	B	202-210
spasmodic	I	211-220
dysphonia	I	221-230
(	O	231-232
ADSD	B	232-236
)	O	236-237
.	O	237-238

Reported	O	239-247
adverse	O	248-255
effects	O	256-263
include	O	264-271
a	O	272-273
period	O	274-280
of	O	281-283
breathiness	O	284-295
,	O	295-296
throat	B	297-303
pain	I	304-308
,	O	308-309
and	O	310-313
difficulty	O	314-324
with	O	325-329
swallowing	O	330-340
liquids	O	341-348
.	O	348-349

Here	O	350-354
we	O	355-357
report	O	358-364
multiple	O	365-373
cases	O	374-379
of	O	380-382
bilateral	O	383-392
abductor	O	393-401
paralysis	B	402-411
following	O	412-421
Botox	O	422-427
injections	O	428-438
for	O	439-442
ADSD	B	443-447
,	O	447-448
a	O	449-450
complication	O	451-463
previously	O	464-474
unreported	O	475-485
.	O	485-486

STUDY	O	487-492
DESIGN	O	493-499
:	O	499-500
Retrospective	O	501-514
case	O	515-519
series	O	520-526
.	O	526-527

METHODS	O	528-535
:	O	535-536
Patients	O	537-545
that	O	546-550
received	O	551-559
Botox	O	560-565
injections	O	566-576
for	O	577-580
spasmodic	B	581-590
dysphonia	I	591-600
between	O	601-608
January	O	609-616
2000	O	617-621
and	O	622-625
October	O	626-633
2009	O	634-638
were	O	639-643
evaluated	O	644-653
.	O	653-654

Patients	O	655-663
with	O	664-668
ADSD	B	669-673
were	O	674-678
identified	O	679-689
.	O	689-690

The	O	691-694
number	O	695-701
of	O	702-704
treatments	O	705-715
received	O	716-724
and	O	725-728
adverse	O	729-736
effects	O	737-744
were	O	745-749
noted	O	750-755
.	O	755-756

For	O	757-760
patients	O	761-769
with	O	770-774
bilateral	O	775-784
abductor	O	785-793
paralysis	B	794-803
,	O	803-804
age	O	805-808
,	O	808-809
sex	O	810-813
,	O	813-814
paralytic	O	815-824
Botox	O	825-830
dose	O	831-835
,	O	835-836
prior	O	837-842
Botox	O	843-848
dose	O	849-853
,	O	853-854
and	O	855-858
course	O	859-865
following	O	866-875
paralysis	B	876-885
were	O	886-890
noted	O	891-896
.	O	896-897

RESULTS	O	898-905
:	O	905-906
From	O	907-911
a	O	912-913
database	O	914-922
of	O	923-925
452	O	926-929
patients	O	930-938
receiving	O	939-948
Botox	O	949-954
,	O	954-955
352	O	956-959
patients	O	960-968
had	O	969-972
been	O	973-977
diagnosed	O	978-987
with	O	988-992
ADSD	B	993-997
.	O	997-998

Of	O	999-1001
these	O	1002-1007
352	O	1008-1011
patients	O	1012-1020
,	O	1020-1021
eight	O	1022-1027
patients	O	1028-1036
suffered	O	1037-1045
bilateral	O	1046-1055
abductor	O	1056-1064
paralysis	B	1065-1074
,	O	1074-1075
and	O	1076-1079
two	O	1080-1083
suffered	O	1084-1092
this	O	1093-1097
complication	O	1098-1110
twice	O	1111-1116
.	O	1116-1117

All	O	1118-1121
affected	O	1122-1130
patients	O	1131-1139
were	O	1140-1144
females	O	1145-1152
over	O	1153-1157
the	O	1158-1161
age	O	1162-1165
of	O	1166-1168
50	O	1169-1171
years	O	1172-1177
.	O	1177-1178

Most	O	1179-1183
patients	O	1184-1192
had	O	1193-1196
received	O	1197-1205
treatments	O	1206-1216
prior	O	1217-1222
to	O	1223-1225
abductor	O	1226-1234
paralysis	B	1235-1244
and	O	1245-1248
continued	O	1249-1258
receiving	O	1259-1268
after	O	1269-1274
paralysis	B	1275-1284
.	O	1284-1285

Seven	O	1286-1291
patients	O	1292-1300
recovered	O	1301-1310
after	O	1311-1316
a	O	1317-1318
brief	O	1319-1324
period	O	1325-1331
of	O	1332-1334
activity	O	1335-1343
restrictions	O	1344-1356
,	O	1356-1357
and	O	1358-1361
one	O	1362-1365
underwent	O	1366-1375
a	O	1376-1377
tracheotomy	O	1378-1389
.	O	1389-1390

The	O	1391-1394
incidence	O	1395-1404
of	O	1405-1407
abductor	O	1408-1416
paralysis	B	1417-1426
after	O	1427-1432
Botox	O	1433-1438
injection	O	1439-1448
for	O	1449-1452
ADSD	B	1453-1457
was	O	1458-1461
0	O	1462-1463
.	O	1463-1464
34	O	1464-1466
%	O	1466-1467
.	O	1463-1464

CONCLUSIONS	O	1469-1480
:	O	1480-1481
Bilateral	O	1482-1491
abductor	O	1492-1500
paralysis	B	1501-1510
is	O	1511-1513
a	O	1514-1515
rare	O	1516-1520
complication	O	1521-1533
of	O	1534-1536
Botox	O	1537-1542
injections	O	1543-1553
for	O	1554-1557
ADSD	B	1558-1562
,	O	1562-1563
causing	O	1564-1571
difficulty	O	1572-1582
with	O	1583-1587
breathing	O	1588-1597
upon	O	1598-1602
exertion	O	1603-1611
.	O	1611-1612

The	O	1613-1616
likely	O	1617-1623
mechanism	O	1624-1633
of	O	1634-1636
paralysis	B	1637-1646
is	O	1647-1649
diffusion	O	1650-1659
of	O	1660-1662
Botox	O	1663-1668
around	O	1669-1675
the	O	1676-1679
muscular	O	1680-1688
process	O	1689-1696
of	O	1697-1699
the	O	1700-1703
arytenoid	O	1704-1713
to	O	1714-1716
the	O	1717-1720
posterior	O	1721-1730
cricoarytenoid	O	1731-1745
muscles	O	1746-1753
.	O	1753-1754

The	O	1755-1758
paralysis	B	1759-1768
is	O	1769-1771
temporary	O	1772-1781
,	O	1781-1782
and	O	1783-1786
watchful	O	1787-1795
waiting	O	1796-1803
with	O	1804-1808
restriction	O	1809-1820
of	O	1821-1823
activity	O	1824-1832
is	O	1833-1835
the	O	1836-1839
recommended	O	1840-1851
management	O	1852-1862
.	O	1862-1863

Mitochondrial	B	0-13
impairment	I	14-24
contributes	O	25-36
to	O	37-39
cocaine	O	40-47
-	O	47-48
induced	O	48-55
cardiac	B	56-63
dysfunction	I	64-75
:	O	75-76
Prevention	O	77-87
by	O	88-90
the	O	91-94
targeted	O	95-103
antioxidant	O	104-115
MitoQ	O	116-121
.	O	121-122

The	O	123-126
goal	O	127-131
of	O	132-134
this	O	135-139
study	O	140-145
was	O	146-149
to	O	150-152
assess	O	153-159
mitochondrial	O	160-173
function	O	174-182
and	O	183-186
ROS	O	187-190
production	O	191-201
in	O	202-204
an	O	205-207
experimental	O	208-220
model	O	221-226
of	O	227-229
cocaine	O	230-237
-	O	237-238
induced	O	238-245
cardiac	B	246-253
dysfunction	I	254-265
.	O	265-266

We	O	267-269
hypothesized	O	270-282
that	O	283-287
cocaine	B	288-295
abuse	I	296-301
may	O	302-305
lead	O	306-310
to	O	311-313
altered	O	314-321
mitochondrial	O	322-335
function	O	336-344
that	O	345-349
in	O	350-352
turn	O	353-357
may	O	358-361
cause	O	362-367
left	B	368-372
ventricular	I	373-384
dysfunction	I	385-396
.	O	396-397

Seven	O	398-403
days	O	404-408
of	O	409-411
cocaine	O	412-419
administration	O	420-434
to	O	435-437
rats	O	438-442
led	O	443-446
to	O	447-449
an	O	450-452
increased	O	453-462
oxygen	O	463-469
consumption	O	470-481
detected	O	482-490
in	O	491-493
cardiac	O	494-501
fibers	O	502-508
,	O	508-509
specifically	O	510-522
through	O	523-530
complex	O	531-538
I	O	539-540
and	O	541-544
complex	O	545-552
III	O	553-556
.	O	556-557

ROS	O	558-561
levels	O	562-568
were	O	569-573
increased	O	574-583
,	O	583-584
specifically	O	585-597
in	O	598-600
interfibrillar	O	601-615
mitochondria	O	616-628
.	O	628-629

In	O	630-632
parallel	O	633-641
there	O	642-647
was	O	648-651
a	O	652-653
decrease	O	654-662
in	O	663-665
ATP	O	666-669
synthesis	O	670-679
,	O	679-680
whereas	O	681-688
no	O	689-691
difference	O	692-702
was	O	703-706
observed	O	707-715
in	O	716-718
subsarcolemmal	O	719-733
mitochondria	O	734-746
.	O	746-747

This	O	748-752
uncoupling	O	753-763
effect	O	764-770
on	O	771-773
oxidative	O	774-783
phosphorylation	O	784-799
was	O	800-803
not	O	804-807
detectable	O	808-818
after	O	819-824
short	O	825-830
-	O	830-831
term	O	831-835
exposure	O	836-844
to	O	845-847
cocaine	O	848-855
,	O	855-856
suggesting	O	857-867
that	O	868-872
these	O	873-878
mitochondrial	B	879-892
abnormalities	I	893-906
were	O	907-911
a	O	912-913
late	O	914-918
rather	O	919-925
than	O	926-930
a	O	931-932
primary	O	933-940
event	O	941-946
in	O	947-949
the	O	950-953
pathological	O	954-966
response	O	967-975
to	O	976-978
cocaine	O	979-986
.	O	986-987

MitoQ	O	988-993
,	O	993-994
a	O	995-996
mitochondrial	O	997-1010
-	O	1010-1011
targeted	O	1011-1019
antioxidant	O	1020-1031
,	O	1031-1032
was	O	1033-1036
shown	O	1037-1042
to	O	1043-1045
completely	O	1046-1056
prevent	O	1057-1064
these	O	1065-1070
mitochondrial	B	1071-1084
abnormalities	I	1085-1098
as	O	1099-1101
well	O	1102-1106
as	O	1107-1109
cardiac	B	1110-1117
dysfunction	I	1118-1129
characterized	O	1130-1143
here	O	1144-1148
by	O	1149-1151
a	O	1152-1153
diastolic	B	1154-1163
dysfunction	I	1164-1175
studied	O	1176-1183
with	O	1184-1188
a	O	1189-1190
conductance	O	1191-1202
catheter	O	1203-1211
to	O	1212-1214
obtain	O	1215-1221
pressure	O	1222-1230
-	O	1230-1231
volume	O	1231-1237
data	O	1238-1242
.	O	1242-1243

Taken	O	1244-1249
together	O	1250-1258
,	O	1258-1259
these	O	1260-1265
results	O	1266-1273
extend	O	1274-1280
previous	O	1281-1289
studies	O	1290-1297
and	O	1298-1301
demonstrate	O	1302-1313
that	O	1314-1318
cocaine	O	1319-1326
-	O	1326-1327
induced	O	1327-1334
cardiac	B	1335-1342
dysfunction	I	1343-1354
may	O	1355-1358
be	O	1359-1361
due	O	1362-1365
to	O	1366-1368
a	O	1369-1370
mitochondrial	B	1371-1384
defect	I	1385-1391
.	O	1391-1392

Trimethoprim	O	0-12
-	O	12-13
induced	O	13-20
immune	O	21-27
hemolytic	B	28-37
anemia	I	38-44
in	O	45-47
a	O	48-49
pediatric	O	50-59
oncology	O	60-68
patient	O	69-76
presenting	O	77-87
as	O	88-90
an	O	91-93
acute	O	94-99
hemolytic	O	100-109
transfusion	O	110-121
reaction	O	122-130
.	O	130-131

A	O	132-133
10	O	134-136
-	O	136-137
year	O	137-141
-	O	136-137
old	O	142-145
male	O	146-150
with	O	151-155
acute	B	156-161
leukemia	I	162-170
presented	O	171-180
with	O	181-185
post	O	186-190
-	O	190-191
chemotherapy	O	191-203
anemia	B	204-210
.	O	210-211

During	O	212-218
red	O	219-222
cell	O	223-227
transfusion	O	228-239
,	O	239-240
he	O	241-243
developed	O	244-253
hemoglobinuria	B	254-268
.	O	268-269

Transfusion	O	270-281
reaction	O	282-290
workup	O	291-297
was	O	298-301
negative	O	302-310
.	O	310-311

Drug	O	312-316
-	O	316-317
induced	O	317-324
immune	O	325-331
hemolytic	B	332-341
anemia	I	342-348
was	O	349-352
suspected	O	353-362
because	O	363-370
of	O	371-373
positive	O	374-382
direct	O	383-389
antiglobulin	O	390-402
test	O	403-407
,	O	407-408
negative	O	409-417
eluate	O	418-424
,	O	424-425
and	O	426-429
microspherocytes	O	430-446
on	O	447-449
smear	O	450-455
pre	O	456-459
-	O	459-460
and	O	461-464
post	O	465-469
-	O	469-470
transfusion	O	470-481
.	O	481-482

Drug	O	483-487
studies	O	488-495
using	O	496-501
the	O	502-505
indirect	O	506-514
antiglobulin	O	515-527
test	O	528-532
were	O	533-537
strongly	O	538-546
positive	O	547-555
with	O	556-560
trimethoprim	O	561-573
and	O	574-577
trimethoprim	O	578-590
-	O	590-591
sulfamethoxazole	O	591-607
but	O	608-611
negative	O	612-620
with	O	621-625
sulfamethoxazole	O	626-642
.	O	642-643

The	O	644-647
patient	O	648-655
recovered	O	656-665
after	O	666-671
discontinuing	O	672-685
the	O	686-689
drug	O	690-694
,	O	694-695
with	O	696-700
no	O	701-703
recurrence	O	704-714
in	O	715-717
2	O	718-719
years	O	720-725
.	O	725-726

Other	O	727-732
causes	O	733-739
of	O	740-742
anemia	B	743-749
should	O	750-756
be	O	757-759
considered	O	760-770
in	O	771-773
patients	O	774-782
with	O	783-787
worse	O	788-793
-	O	793-794
than	O	794-798
-	O	793-794
expected	O	799-807
anemia	B	808-814
after	O	815-820
chemotherapy	O	821-833
.	O	833-834

Furthermore	O	835-846
,	O	846-847
hemolysis	B	848-857
during	O	858-864
transfusion	O	865-876
is	O	877-879
not	O	880-883
always	O	884-890
a	O	891-892
transfusion	O	893-904
reaction	O	905-913
.	O	913-914

Blockade	O	0-8
of	O	9-11
endothelial	O	12-23
-	O	23-24
mesenchymal	O	24-35
transition	O	36-46
by	O	47-49
a	O	50-51
Smad3	O	52-57
inhibitor	O	58-67
delays	O	68-74
the	O	75-78
early	O	79-84
development	O	85-96
of	O	97-99
streptozotocin	O	100-114
-	O	114-115
induced	O	115-122
diabetic	B	123-131
nephropathy	I	132-143
.	O	143-144

OBJECTIVE	O	145-154
:	O	154-155
A	O	156-157
multicenter	O	158-169
,	O	169-170
controlled	O	171-181
trial	O	182-187
showed	O	188-194
that	O	195-199
early	O	200-205
blockade	O	206-214
of	O	215-217
the	O	218-221
renin	O	222-227
-	O	227-228
angiotensin	O	228-239
system	O	240-246
in	O	247-249
patients	O	250-258
with	O	259-263
type	B	264-268
1	I	269-270
diabetes	I	271-279
and	O	280-283
normoalbuminuria	O	284-300
did	O	301-304
not	O	305-308
retard	O	309-315
the	O	316-319
progression	O	320-331
of	O	332-334
nephropathy	B	335-346
,	O	346-347
suggesting	O	348-358
that	O	359-363
other	O	364-369
mechanism	O	370-379
(	O	379-380
s	O	377-378
)	O	381-382
are	O	383-386
involved	O	387-395
in	O	396-398
the	O	399-402
pathogenesis	O	403-415
of	O	416-418
early	O	419-424
diabetic	B	425-433
nephropathy	I	434-445
(	O	446-447
diabetic	B	447-455
nephropathy	I	456-467
)	O	467-468
.	O	468-469

We	O	470-472
have	O	473-477
previously	O	478-488
demonstrated	O	489-501
that	O	502-506
endothelial	O	507-518
-	O	518-519
mesenchymal	O	519-530
-	O	518-519
transition	O	531-541
(	O	542-543
EndoMT	O	543-549
)	O	549-550
contributes	O	551-562
to	O	563-565
the	O	566-569
early	O	570-575
development	O	576-587
of	O	588-590
renal	O	591-596
interstitial	O	597-609
fibrosis	B	610-618
independently	O	619-632
of	O	633-635
microalbuminuria	O	636-652
in	O	653-655
mice	O	656-660
with	O	661-665
streptozotocin	O	666-680
(	O	681-682
STZ	O	682-685
)	O	685-686
-	O	686-687
induced	O	687-694
diabetes	B	695-703
.	O	703-704

In	O	705-707
the	O	708-711
present	O	712-719
study	O	720-725
,	O	725-726
we	O	727-729
hypothesized	O	730-742
that	O	743-747
blocking	O	748-756
EndoMT	O	757-763
reduces	O	764-771
the	O	772-775
early	O	776-781
development	O	782-793
of	O	794-796
diabetic	B	797-805
nephropathy	I	806-817
.	O	817-818

RESEARCH	O	819-827
DESIGN	O	828-834
AND	O	835-838
METHODS	O	839-846
:	O	846-847
EndoMT	O	848-854
was	O	855-858
induced	O	859-866
in	O	867-869
a	O	870-871
mouse	O	872-877
pancreatic	O	878-888
microvascular	O	889-902
endothelial	O	903-914
cell	O	915-919
line	O	920-924
(	O	925-926
MMEC	O	926-930
)	O	930-931
in	O	932-934
the	O	935-938
presence	O	939-947
of	O	948-950
advanced	O	951-959
glycation	O	960-969
end	O	970-973
products	O	974-982
(	O	983-984
AGEs	O	984-988
)	O	988-989
and	O	990-993
in	O	994-996
the	O	997-1000
endothelial	O	1001-1012
lineage	O	1013-1020
-	O	1020-1021
traceble	O	1021-1029
mouse	O	1030-1035
line	O	1036-1040
Tie2	O	1041-1045
-	O	1045-1046
Cre	O	1046-1049
;	O	1049-1050
Loxp	O	1050-1054
-	O	1045-1046
EGFP	O	1055-1059
by	O	1060-1062
administration	O	1063-1077
of	O	1078-1080
AGEs	O	1081-1085
,	O	1085-1086
with	O	1087-1091
nonglycated	O	1092-1103
mouse	O	1104-1109
albumin	O	1110-1117
serving	O	1118-1125
as	O	1126-1128
a	O	1129-1130
control	O	1131-1138
.	O	1138-1139

Phosphorylated	O	1140-1154
Smad3	O	1155-1160
was	O	1161-1164
detected	O	1165-1173
by	O	1174-1176
immunoprecipitation	O	1177-1196
/	O	1196-1197
Western	O	1197-1204
blotting	O	1205-1213
and	O	1214-1217
confocal	O	1218-1226
microscopy	O	1227-1237
.	O	1237-1238

Blocking	O	1239-1247
studies	O	1248-1255
using	O	1256-1261
receptor	O	1262-1270
for	O	1271-1274
AGE	O	1275-1278
siRNA	O	1279-1284
and	O	1285-1288
a	O	1289-1290
specific	O	1291-1299
inhibitor	O	1300-1309
of	O	1310-1312
Smad3	O	1313-1318
(	O	1319-1320
SIS3	O	1320-1324
)	O	1324-1325
were	O	1326-1330
performed	O	1331-1340
in	O	1341-1343
MMECs	O	1344-1349
and	O	1350-1353
in	O	1354-1356
STZ	O	1357-1360
-	O	1360-1361
induced	O	1361-1368
diabetic	B	1369-1377
nephropathy	I	1378-1389
in	O	1390-1392
Tie2	O	1393-1397
-	O	1397-1398
Cre	O	1398-1401
;	O	1401-1402
Loxp	O	1402-1406
-	O	1397-1398
EGFP	O	1407-1411
mice	O	1412-1416
.	O	1416-1417

RESULTS	O	1418-1425
:	O	1425-1426
Confocal	O	1427-1435
microscopy	O	1436-1446
and	O	1447-1450
real	O	1451-1455
-	O	1455-1456
time	O	1456-1460
PCR	O	1461-1464
demonstrated	O	1465-1477
that	O	1478-1482
AGEs	O	1483-1487
induced	O	1488-1495
EndoMT	O	1496-1502
in	O	1503-1505
MMECs	O	1506-1511
and	O	1512-1515
in	O	1516-1518
Tie2	O	1519-1523
-	O	1523-1524
Cre	O	1524-1527
;	O	1527-1528
Loxp	O	1528-1532
-	O	1523-1524
EGFP	O	1533-1537
mice	O	1538-1542
.	O	1542-1543

Immunoprecipitation	O	1544-1563
/	O	1563-1564
Western	O	1564-1571
blotting	O	1572-1580
showed	O	1581-1587
that	O	1588-1592
Smad3	O	1593-1598
was	O	1599-1602
activated	O	1603-1612
by	O	1613-1615
AGEs	O	1616-1620
but	O	1621-1624
was	O	1625-1628
inhibited	O	1629-1638
by	O	1639-1641
SIS3	O	1642-1646
in	O	1647-1649
MMECs	O	1650-1655
and	O	1656-1659
in	O	1660-1662
STZ	O	1663-1666
-	O	1666-1667
induced	O	1667-1674
diabetic	B	1675-1683
nephropathy	I	1684-1695
.	O	1695-1696

Confocal	O	1697-1705
microscopy	O	1706-1716
and	O	1717-1720
real	O	1721-1725
-	O	1725-1726
time	O	1726-1730
PCR	O	1731-1734
further	O	1735-1742
demonstrated	O	1743-1755
that	O	1756-1760
SIS3	O	1761-1765
abrogated	O	1766-1775
EndoMT	O	1776-1782
,	O	1782-1783
reduced	O	1784-1791
renal	O	1792-1797
fibrosis	B	1798-1806
,	O	1806-1807
and	O	1808-1811
retarded	O	1812-1820
progression	O	1821-1832
of	O	1833-1835
nephropathy	B	1836-1847
.	O	1847-1848

CONCLUSIONS	O	1849-1860
:	O	1860-1861
EndoMT	O	1862-1868
is	O	1869-1871
a	O	1872-1873
novel	O	1874-1879
pathway	O	1880-1887
leading	O	1888-1895
to	O	1896-1898
early	O	1899-1904
development	O	1905-1916
of	O	1917-1919
diabetic	B	1920-1928
nephropathy	I	1929-1940
.	O	1940-1941

Blockade	O	1942-1950
of	O	1951-1953
EndoMT	O	1954-1960
by	O	1961-1963
SIS3	O	1964-1968
may	O	1969-1972
provide	O	1973-1980
a	O	1981-1982
new	O	1983-1986
strategy	O	1987-1995
to	O	1996-1998
retard	O	1999-2005
the	O	2006-2009
progression	O	2010-2021
of	O	2022-2024
diabetic	B	2025-2033
nephropathy	I	2034-2045
and	O	2046-2049
other	O	2050-2055
diabetes	B	2056-2064
complications	I	2065-2078
.	O	2078-2079

Cytostatic	O	0-10
and	O	11-14
anti	O	15-19
-	O	19-20
angiogenic	O	20-30
effects	O	31-38
of	O	39-41
temsirolimus	O	42-54
in	O	55-57
refractory	O	58-68
mantle	B	69-75
cell	I	76-80
lymphoma	I	81-89
.	O	89-90

Mantle	B	91-97
cell	I	98-102
lymphoma	I	103-111
(	O	112-113
MCL	B	113-116
)	O	116-117
is	O	118-120
a	O	121-122
rare	O	123-127
and	O	128-131
aggressive	O	132-142
type	O	143-147
of	O	148-150
B	B	151-152
-	I	152-153
cell	I	153-157
non	I	158-161
-	I	161-162
Hodgkin	I	162-169
'	I	169-170
s	I	170-171
lymphoma	I	172-180
.	O	180-181

Patients	O	182-190
become	O	191-197
progressively	O	198-211
refractory	O	212-222
to	O	223-225
conventional	O	226-238
chemotherapy	O	239-251
,	O	251-252
and	O	253-256
their	O	257-262
prognosis	O	263-272
is	O	273-275
poor	O	276-280
.	O	280-281

However	O	282-289
,	O	289-290
a	O	291-292
38	O	293-295
%	O	295-296
remission	O	297-306
rate	O	307-311
has	O	312-315
been	O	316-320
recently	O	321-329
reported	O	330-338
in	O	339-341
refractory	O	342-352
MCL	B	353-356
treated	O	357-364
with	O	365-369
temsirolimus	O	370-382
,	O	382-383
a	O	384-385
mTOR	O	386-390
inhibitor	O	391-400
.	O	400-401
Here	O	401-405
we	O	406-408
had	O	409-412
the	O	413-416
opportunity	O	417-428
to	O	429-431
study	O	432-437
a	O	438-439
case	O	440-444
of	O	445-447
refractory	O	448-458
MCL	B	459-462
who	O	463-466
had	O	467-470
tumor	B	471-476
regression	O	477-487
two	O	488-491
months	O	492-498
after	O	499-504
temsirolimus	O	505-517
treatment	O	518-527
,	O	527-528
and	O	529-532
a	O	533-534
progression	O	535-546
-	O	546-547
free	O	547-551
survival	O	552-560
of	O	561-563
10	O	564-566
months	O	567-573
.	O	573-574

In	O	575-577
this	O	578-582
case	O	583-587
,	O	587-588
lymph	O	589-594
node	O	595-599
biopsies	O	600-608
were	O	609-613
performed	O	614-623
before	O	624-630
and	O	631-634
six	O	635-638
months	O	639-645
after	O	646-651
temsirolimus	O	652-664
therapy	O	665-672
.	O	672-673

Comparison	O	674-684
of	O	685-687
the	O	688-691
two	O	692-695
biopsies	O	696-704
showed	O	705-711
that	O	712-716
temsirolimus	O	717-729
inhibited	O	730-739
tumor	B	740-745
cell	O	746-750
proliferation	O	751-764
through	O	765-772
cell	O	773-777
cycle	O	778-783
arrest	O	784-790
,	O	790-791
but	O	792-795
did	O	796-799
not	O	800-803
induce	O	804-810
any	O	811-814
change	O	815-821
in	O	822-824
the	O	825-828
number	O	829-835
of	O	836-838
apoptotic	O	839-848
tumor	B	849-854
cells	O	855-860
.	O	860-861

Apart	O	862-867
from	O	868-872
this	O	873-877
cytostatic	O	878-888
effect	O	889-895
,	O	895-896
temsirolimus	O	897-909
had	O	910-913
an	O	914-916
antiangiogenic	O	917-931
effect	O	932-938
with	O	939-943
decrease	O	944-952
of	O	953-955
tumor	B	956-961
microvessel	O	962-973
density	O	974-981
and	O	982-985
of	O	986-988
VEGF	O	989-993
expression	O	994-1004
.	O	1004-1005

Moreover	O	1006-1014
,	O	1014-1015
numerous	O	1016-1024
patchy	O	1025-1031
,	O	1031-1032
well	O	1033-1037
-	O	1037-1038
limited	O	1038-1045
fibrotic	O	1046-1054
areas	O	1055-1060
,	O	1060-1061
compatible	O	1062-1072
with	O	1073-1077
post	O	1078-1082
-	O	1082-1083
necrotic	B	1083-1091
tissue	O	1092-1098
repair	O	1099-1105
,	O	1105-1106
were	O	1107-1111
found	O	1112-1117
after	O	1118-1123
6	O	1124-1125
-	O	1125-1126
month	O	1126-1131
temsirolimus	O	1132-1144
therapy	O	1145-1152
.	O	1152-1153

Thus	O	1154-1158
,	O	1158-1159
temsirolimus	O	1160-1172
reduced	O	1173-1180
tumor	B	1181-1186
burden	O	1187-1193
through	O	1194-1201
associated	O	1202-1212
cytostatic	O	1213-1223
and	O	1224-1227
anti	O	1228-1232
-	O	1232-1233
angiogenic	O	1233-1243
effects	O	1244-1251
.	O	1251-1252
This	O	1252-1256
dual	O	1257-1261
effect	O	1262-1268
of	O	1269-1271
temsirolimus	O	1272-1284
on	O	1285-1287
tumor	B	1288-1293
tissue	O	1294-1300
could	O	1301-1306
contribute	O	1307-1317
to	O	1318-1320
its	O	1321-1324
recently	O	1325-1333
reported	O	1334-1342
efficiency	O	1343-1353
in	O	1354-1356
refractory	O	1357-1367
MCL	B	1368-1371
resistant	O	1372-1381
to	O	1382-1384
conventional	O	1385-1397
chemotherapy	O	1398-1410
.	O	1410-1411

Syncope	B	0-7
caused	O	8-14
by	O	15-17
hyperkalemia	B	18-30
during	O	31-37
use	O	38-41
of	O	42-44
a	O	45-46
combined	O	47-55
therapy	O	56-63
with	O	64-68
the	O	69-72
angiotensin	O	73-84
-	O	84-85
converting	O	85-95
enzyme	O	96-102
inhibitor	O	103-112
and	O	113-116
spironolactone	O	117-131
.	O	131-132

A	O	133-134
76	O	135-137
year	O	138-142
-	O	142-143
old	O	143-146
woman	O	147-152
with	O	153-157
a	O	158-159
history	O	160-167
of	O	168-170
coronary	O	171-179
artery	O	180-186
bypass	O	187-193
grafting	O	194-202
and	O	203-206
prior	O	207-212
myocardial	B	213-223
infarction	I	224-234
was	O	235-238
transferred	O	239-250
to	O	251-253
the	O	254-257
emergency	O	258-267
room	O	268-272
with	O	273-277
loss	B	278-282
of	I	283-285
consciousness	I	286-299
due	O	300-303
to	O	304-306
marked	O	307-313
bradycardia	B	314-325
caused	O	326-332
by	O	333-335
hyperkalemia	B	336-348
.	O	348-349

The	O	350-353
concentration	O	354-367
of	O	368-370
serum	O	371-376
potassium	O	377-386
was	O	387-390
high	O	391-395
,	O	395-396
and	O	397-400
normal	O	401-407
sinus	O	408-413
rhythm	O	414-420
was	O	421-424
restored	O	425-433
after	O	434-439
correction	O	440-450
of	O	451-453
the	O	454-457
serum	O	458-463
potassium	O	464-473
level	O	474-479
.	O	479-480

The	O	481-484
cause	O	485-490
of	O	491-493
hyperkalemia	B	494-506
was	O	507-510
considered	O	511-521
to	O	522-524
be	O	525-527
several	O	528-535
doses	O	536-541
of	O	542-544
spiranolactone	O	545-559
,	O	559-560
an	O	561-563
aldosterone	O	564-575
antagonist	O	576-586
,	O	586-587
in	O	588-590
addition	O	591-599
to	O	600-602
the	O	603-606
long	O	607-611
-	O	611-612
term	O	612-616
intake	O	617-623
of	O	624-626
ramipril	O	627-635
,	O	635-636
an	O	637-639
ACE	O	640-643
inhibitor	O	644-653
.	O	653-654

This	O	655-659
case	O	660-664
is	O	665-667
a	O	668-669
good	O	670-674
example	O	675-682
of	O	683-685
electrolyte	O	686-697
imbalance	O	698-707
causing	O	708-715
acute	O	716-721
life	O	722-726
-	O	726-727
threatening	O	727-738
cardiac	O	739-746
events	O	747-753
.	O	753-754

Clinicians	O	755-765
should	O	766-772
be	O	773-775
alert	O	776-781
to	O	782-784
the	O	785-788
possibility	O	789-800
of	O	801-803
hyperkalemia	B	804-816
,	O	816-817
especially	O	818-828
in	O	829-831
elderly	O	832-839
patients	O	840-848
using	O	849-854
ACE	O	855-858
/	O	858-859
ARB	O	859-862
in	O	863-865
combination	O	866-877
with	O	878-882
potassium	O	883-892
sparing	O	893-900
agents	O	901-907
and	O	908-911
who	O	912-915
have	O	916-920
mild	O	921-925
renal	B	926-931
disturbance	I	932-943
.	O	943-944

Diffuse	O	0-7
skeletal	O	8-16
pain	B	17-21
after	O	22-27
administration	O	28-42
of	O	43-45
alendronate	O	46-57
.	O	57-58

BACKGROUND	O	59-69
:	O	69-70
Osteoporosis	B	71-83
is	O	84-86
caused	O	87-93
by	O	94-96
bone	O	97-101
resorption	O	102-112
in	O	113-115
excess	O	116-122
of	O	123-125
bone	O	126-130
formation	O	131-140
,	O	140-141
and	O	142-145
bisphosphonates	O	146-161
,	O	161-162
are	O	163-166
used	O	167-171
to	O	172-174
inhibit	O	175-182
bone	O	183-187
resorption	O	188-198
.	O	198-199

Alendronate	O	200-211
,	O	211-212
a	O	213-214
biphosphonate	O	215-228
,	O	228-229
is	O	230-232
effective	O	233-242
for	O	243-246
both	O	247-251
the	O	252-255
treatment	O	256-265
and	O	266-269
prevention	O	270-280
of	O	281-283
osteoporosis	B	284-296
in	O	297-299
postmenopausal	O	300-314
women	O	315-320
.	O	320-321

Side	O	322-326
effects	O	327-334
are	O	335-338
relatively	O	339-349
few	O	350-353
and	O	354-357
prominently	O	358-369
gastrointestinal	O	370-386
.	O	386-387

Musculoskeletal	B	388-403
pain	I	404-408
may	O	409-412
be	O	413-415
an	O	416-418
important	O	419-428
side	O	429-433
effect	O	434-440
in	O	441-443
these	O	444-449
patients	O	450-458
.	O	458-459

We	O	460-462
presented	O	463-472
a	O	473-474
patient	O	475-482
admitted	O	483-491
to	O	492-494
our	O	495-498
out	O	499-502
-	O	502-503
patient	O	503-510
clinic	O	511-517
with	O	518-522
diffuse	O	523-530
skeletal	O	531-539
pain	B	540-544
after	O	545-550
three	O	551-556
consecutive	O	557-568
administration	O	569-583
of	O	584-586
alendronate	O	587-598
.	O	598-599

CONCLUSION	O	600-610
:	O	610-611
We	O	612-614
conclude	O	615-623
that	O	624-628
patients	O	629-637
with	O	638-642
osteoporosis	B	643-655
can	O	656-659
report	O	660-666
pain	B	667-671
,	O	671-672
and	O	673-676
bisphosphonate	O	677-691
-	O	691-692
related	O	692-699
pain	B	700-704
should	O	705-711
also	O	712-716
be	O	717-719
considered	O	720-730
before	O	731-737
ascribing	O	738-747
this	O	748-752
complaint	O	753-762
to	O	763-765
osteoporosis	B	766-778
.	O	778-779

Cerebrospinal	O	0-13
fluid	O	14-19
penetration	O	20-31
of	O	32-34
high	O	35-39
-	O	39-40
dose	O	40-44
daptomycin	O	45-55
in	O	56-58
suspected	O	59-68
Staphylococcus	O	69-83
aureus	O	84-90
meningitis	B	91-101
.	O	101-102

OBJECTIVE	O	103-112
:	O	112-113
To	O	114-116
report	O	117-123
a	O	124-125
case	O	126-130
of	O	131-133
methicillin	O	134-145
-	O	145-146
sensitive	O	146-155
Staphylococcus	O	156-170
aureus	O	171-177
(	O	178-179
MSSA	O	179-183
)	O	183-184
bacteremia	B	185-195
with	O	196-200
suspected	O	201-210
MSSA	O	211-215
meningitis	B	216-226
treated	O	227-234
with	O	235-239
high	O	240-244
-	O	244-245
dose	O	245-249
daptomycin	O	250-260
assessed	O	261-269
with	O	270-274
concurrent	O	275-285
serum	O	286-291
and	O	292-295
cerebrospinal	O	296-309
fluid	O	310-315
(	O	316-317
CSF	O	317-320
)	O	320-321
concentrations	O	322-336
.	O	336-337

CASE	O	338-342
SUMMARY	O	343-350
:	O	350-351
A	O	352-353
54	O	354-356
-	O	356-357
year	O	357-361
-	O	356-357
old	O	362-365
male	O	366-370
presented	O	371-380
to	O	381-383
the	O	384-387
emergency	O	388-397
department	O	398-408
with	O	409-413
generalized	O	414-425
weakness	B	426-434
and	O	435-438
presumed	O	439-447
health	O	448-454
-	O	454-455
care	O	455-459
-	O	454-455
associated	O	460-470
pneumonia	B	471-480
shown	O	481-486
on	O	487-489
chest	O	490-495
radiograph	O	496-506
.	O	506-507

Treatment	O	508-517
was	O	518-521
empirically	O	522-533
initiated	O	534-543
with	O	544-548
vancomycin	O	549-559
,	O	559-560
levofloxacin	O	561-573
,	O	573-574
and	O	575-578
piperacillin	O	579-591
/	O	591-592
tazobactam	O	592-602
.	O	602-603
Blood	O	604-609
cultures	O	610-618
revealed	O	619-627
S	O	628-629
.	O	629-630
aureus	O	631-637
susceptible	O	638-649
to	O	650-652
oxacillin	O	653-662
.	O	662-663

Empiric	O	664-671
antibiotic	O	672-682
treatment	O	683-692
was	O	693-696
narrowed	O	697-705
to	O	706-708
nafcillin	O	709-718
on	O	719-721
day	O	722-725
4	O	726-727
.	O	727-728
On	O	729-731
day	O	732-735
8	O	736-737
,	O	737-738
the	O	739-742
patient	O	743-750
developed	O	751-760
acute	B	761-766
renal	I	767-772
failure	I	773-780
(	O	781-782
serum	O	782-787
creatinine	O	788-798
1	O	799-800
.	O	800-801
9	O	801-802
mg	O	803-805
/	O	805-806
dL	O	806-808
,	O	808-809
increased	O	810-819
from	O	820-824
1	O	825-826
.	O	826-827
2	O	827-828
mg	O	829-831
/	O	831-832
dL	O	832-834
the	O	835-838
previous	O	839-847
day	O	848-851
and	O	852-855
0	O	856-857
.	O	857-858
8	O	858-859
mg	O	860-862
/	O	862-863
dL	O	863-865
on	O	866-868
admission	O	869-878
)	O	878-879
.	O	879-880

The	O	881-884
patient	O	885-892
'	O	892-893
s	O	893-894
Glasgow	O	895-902
Coma	O	903-907
Score	O	908-913
was	O	914-917
3	O	918-919
,	O	919-920
with	O	921-925
normal	O	926-932
findings	O	933-941
shown	O	942-947
on	O	948-950
computed	O	951-959
tomography	O	960-970
scan	O	971-975
of	O	976-978
the	O	979-982
head	O	983-987
72	O	988-990
hours	O	991-996
following	O	997-1006
an	O	1007-1009
episode	O	1010-1017
of	O	1018-1020
cardiac	B	1021-1028
arrest	I	1029-1035
on	O	1036-1038
day	O	1039-1042
10	O	1043-1045
.	O	1045-1046

The	O	1047-1050
patient	O	1051-1058
experienced	O	1059-1070
relapsing	O	1071-1080
MSSA	O	1081-1085
bacteremia	B	1086-1096
on	O	1097-1099
day	O	1100-1103
9	O	1104-1105
,	O	1105-1106
increasing	O	1107-1117
the	O	1118-1121
suspicion	O	1122-1131
for	O	1132-1135
a	O	1136-1137
central	O	1138-1145
nervous	O	1146-1153
system	O	1154-1160
(	O	1161-1162
CNS	O	1162-1165
)	O	1165-1166
infection	B	1167-1176
.	O	1176-1177

Nafcillin	O	1178-1187
was	O	1188-1191
discontinued	O	1192-1204
and	O	1205-1208
daptomycin	O	1209-1219
9	O	1220-1221
mg	O	1222-1224
/	O	1224-1225
kg	O	1225-1227
daily	O	1228-1233
was	O	1234-1237
initiated	O	1238-1247
for	O	1248-1251
suspected	O	1252-1261
meningitis	B	1262-1272
and	O	1273-1276
was	O	1277-1280
continued	O	1281-1290
until	O	1291-1296
the	O	1297-1300
patient	O	1301-1308
'	O	1308-1309
s	O	1309-1310
death	O	1311-1316
on	O	1317-1319
day	O	1320-1323
16	O	1324-1326
.	O	1326-1327

Daptomycin	O	1328-1338
serum	O	1339-1344
and	O	1345-1348
CSF	O	1349-1352
trough	O	1353-1359
concentrations	O	1360-1374
were	O	1375-1379
11	O	1380-1382
.	O	1382-1383
21	O	1383-1385
ug	O	1386-1388
/	O	1388-1389
mL	O	1389-1391
and	O	1392-1395
0	O	1396-1397
.	O	1397-1398
52	O	1398-1400
ug	O	1401-1403
/	O	1403-1404
mL	O	1404-1406
,	O	1406-1407
respectively	O	1408-1420
,	O	1420-1421
prior	O	1422-1427
to	O	1428-1430
the	O	1431-1434
third	O	1435-1440
dose	O	1441-1445
.	O	1445-1446

Lumbar	O	1447-1453
puncture	O	1454-1462
results	O	1463-1470
were	O	1471-1475
inconclusive	O	1476-1488
and	O	1489-1492
no	O	1493-1495
further	O	1496-1503
blood	O	1504-1509
cultures	O	1510-1518
were	O	1519-1523
positive	O	1524-1532
for	O	1533-1536
MSSA	O	1537-1541
.	O	1541-1542

Creatine	O	1543-1551
kinase	O	1552-1558
levels	O	1559-1565
were	O	1566-1570
normal	O	1571-1577
prior	O	1578-1583
to	O	1584-1586
daptomycin	O	1587-1597
therapy	O	1598-1605
and	O	1606-1609
were	O	1610-1614
not	O	1615-1618
reassessed	O	1619-1629
.	O	1629-1630

DISCUSSION	O	1631-1641
:	O	1641-1642
Daptomycin	O	1643-1653
was	O	1654-1657
initiated	O	1658-1667
in	O	1668-1670
our	O	1671-1674
patient	O	1675-1682
secondary	O	1683-1692
to	O	1693-1695
possible	O	1696-1704
nafcillin	O	1705-1714
-	O	1714-1715
induced	O	1715-1722
acute	O	1723-1728
interstitial	B	1729-1741
nephritis	I	1742-1751
and	O	1752-1755
relapsing	O	1756-1765
bacteremia	B	1766-1776
.	O	1776-1777

At	O	1778-1780
a	O	1781-1782
dose	O	1783-1787
of	O	1788-1790
9	O	1791-1792
mg	O	1793-1795
/	O	1795-1796
kg	O	1796-1798
,	O	1798-1799
resultant	O	1800-1809
penetration	O	1810-1821
of	O	1822-1824
5	O	1825-1826
%	O	1826-1827
was	O	1828-1831
higher	O	1832-1838
than	O	1839-1843
in	O	1844-1846
previous	O	1847-1855
reports	O	1856-1863
,	O	1863-1864
more	O	1865-1869
consistent	O	1870-1880
with	O	1881-1885
inflamed	O	1886-1894
meninges	O	1895-1903
.	O	1903-1904

CONCLUSIONS	O	1905-1916
:	O	1916-1917
High	O	1918-1922
-	O	1922-1923
dose	O	1923-1927
daptomycin	O	1928-1938
may	O	1939-1942
be	O	1943-1945
an	O	1946-1948
alternative	O	1949-1960
option	O	1961-1967
for	O	1968-1971
MSSA	O	1972-1976
bacteremia	B	1977-1987
with	O	1988-1992
or	O	1993-1995
without	O	1996-2003
a	O	2004-2005
CNS	O	2006-2009
source	O	2010-2016
in	O	2017-2019
patients	O	2020-2028
who	O	2029-2032
have	O	2033-2037
failed	O	2038-2044
or	O	2045-2047
cannot	O	2048-2054
tolerate	O	2055-2063
standard	O	2064-2072
therapy	O	2073-2080
.	O	2080-2081

Further	O	2082-2089
clinical	O	2090-2098
evaluation	O	2099-2109
in	O	2110-2112
patients	O	2113-2121
with	O	2122-2126
confirmed	O	2127-2136
meningitis	B	2137-2147
is	O	2148-2150
warranted	O	2151-2160
.	O	2160-2161

The	O	0-3
role	O	4-8
of	O	9-11
nitric	O	12-18
oxide	O	19-24
in	O	25-27
convulsions	B	28-39
induced	O	40-47
by	O	48-50
lindane	O	51-58
in	O	59-61
rats	O	62-66
.	O	66-67

Lindane	O	68-75
is	O	76-78
an	O	79-81
organochloride	O	82-96
pesticide	O	97-106
and	O	107-110
scabicide	O	111-120
.	O	120-121

It	O	122-124
evokes	O	125-131
convulsions	B	132-143
mainly	O	144-150
trough	O	151-157
the	O	158-161
blockage	O	162-170
of	O	171-173
GABA	O	174-178
(	O	178-179
A	O	175-176
)	O	180-181
receptors	O	182-191
.	O	191-192

Nitric	O	193-199
oxide	O	200-205
(	O	206-207
NO	O	207-209
)	O	209-210
,	O	210-211
gaseous	O	212-219
neurotransmitter	O	220-236
,	O	236-237
has	O	238-241
contradictor	O	242-254
role	O	255-259
in	O	260-262
epileptogenesis	O	263-278
due	O	279-282
to	O	283-285
opposite	O	286-294
effects	O	295-302
of	O	303-305
L	O	306-307
-	O	307-308
arginine	O	308-316
,	O	316-317
precursor	O	318-327
of	O	328-330
NO	O	331-333
syntheses	O	334-343
(	O	344-345
NOS	O	345-348
)	O	348-349
,	O	349-350
and	O	351-354
L	O	355-356
-	O	356-357
NAME	O	357-361
(	O	362-363
NOS	O	363-366
inhibitor	O	367-376
)	O	376-377
observed	O	378-386
in	O	387-389
different	O	390-399
epilepsy	B	400-408
models	O	409-415
.	O	415-416

The	O	417-420
aim	O	421-424
of	O	425-427
the	O	428-431
current	O	432-439
study	O	440-445
was	O	446-449
to	O	450-452
determine	O	453-462
the	O	463-466
effects	O	467-474
of	O	475-477
NO	O	478-480
on	O	481-483
the	O	484-487
behavioral	O	488-498
and	O	499-502
EEG	O	503-506
characteristics	O	507-522
of	O	523-525
lindane	O	526-533
-	O	533-534
induced	O	534-541
epilepsy	B	542-550
in	O	551-553
male	O	554-558
Wistar	O	559-565
albino	O	566-572
rats	O	573-577
.	O	577-578

The	O	579-582
administration	O	583-597
of	O	598-600
L	O	601-602
-	O	602-603
arginine	O	603-611
(	O	612-613
600	O	613-616
,	O	616-617
800	O	618-621
and	O	622-625
1000	O	626-630
mg	O	631-633
/	O	633-634
kg	O	634-636
,	O	636-637
i	O	638-639
.	O	639-640
p	O	640-641
.	O	639-640
)	O	642-643
in	O	644-646
dose	O	647-651
-	O	651-652
dependent	O	652-661
manner	O	662-668
significantly	O	669-682
increased	O	683-692
convulsion	B	693-703
incidence	O	704-713
and	O	714-717
severity	O	718-726
and	O	727-730
shortened	O	731-740
latency	O	741-748
time	O	749-753
to	O	754-756
first	O	757-762
convulsion	B	763-773
elicited	O	774-782
by	O	783-785
lower	O	786-791
lindane	O	792-799
dose	O	800-804
(	O	805-806
4	O	806-807
mg	O	808-810
/	O	810-811
kg	O	811-813
,	O	813-814
i	O	815-816
.	O	816-817
p	O	817-818
.	O	816-817
)	O	819-820
.	O	816-817

On	O	822-824
the	O	825-828
contrary	O	829-837
,	O	837-838
pretreatment	O	839-851
with	O	852-856
L	O	857-858
-	O	858-859
NAME	O	859-863
(	O	864-865
500	O	865-868
,	O	868-869
700	O	870-873
and	O	874-877
900	O	878-881
mg	O	882-884
/	O	884-885
kg	O	885-887
,	O	887-888
i	O	889-890
.	O	890-891
p	O	891-892
.	O	890-891
)	O	893-894
decreased	O	895-904
convulsion	B	905-915
incidence	O	916-925
and	O	926-929
severity	O	930-938
and	O	939-942
prolonged	O	943-952
latency	O	953-960
time	O	961-965
to	O	966-968
convulsion	B	969-979
following	O	980-989
injection	O	990-999
with	O	1000-1004
a	O	1005-1006
convulsive	B	1007-1017
dose	O	1018-1022
of	O	1023-1025
lindane	O	1026-1033
(	O	1034-1035
8	O	1035-1036
mg	O	1037-1039
/	O	1039-1040
kg	O	1040-1042
,	O	1042-1043
i	O	1044-1045
.	O	1045-1046
p	O	1046-1047
.	O	1045-1046
)	O	1048-1049
.	O	1045-1046

EEG	O	1051-1054
analyses	O	1055-1063
showed	O	1064-1070
increase	O	1071-1079
of	O	1080-1082
number	O	1083-1089
and	O	1090-1093
duration	O	1094-1102
of	O	1103-1105
ictal	O	1106-1111
periods	O	1112-1119
in	O	1120-1122
EEG	O	1123-1126
of	O	1127-1129
rats	O	1130-1134
receiving	O	1135-1144
l	O	1145-1146
-	O	1146-1147
arginine	O	1147-1155
prior	O	1156-1161
to	O	1162-1164
lindane	O	1165-1172
and	O	1173-1176
decrease	O	1177-1185
of	O	1186-1188
this	O	1189-1193
number	O	1194-1200
in	O	1201-1203
rats	O	1204-1208
pretreated	O	1209-1219
with	O	1220-1224
L	O	1225-1226
-	O	1226-1227
NAME	O	1227-1231
.	O	1231-1232

These	O	1233-1238
results	O	1239-1246
support	O	1247-1254
the	O	1255-1258
conclusion	O	1259-1269
that	O	1270-1274
NO	O	1275-1277
plays	O	1278-1283
a	O	1284-1285
role	O	1286-1290
of	O	1291-1293
endogenous	O	1294-1304
convulsant	O	1305-1315
in	O	1316-1318
rat	O	1319-1322
model	O	1323-1328
of	O	1329-1331
lindane	O	1332-1339
seizures	B	1340-1348
.	O	1348-1349

Long	O	0-4
-	O	4-5
term	O	5-9
oral	O	10-14
galactose	O	15-24
treatment	O	25-34
prevents	O	35-43
cognitive	B	44-53
deficits	I	54-62
in	O	63-65
male	O	66-70
Wistar	O	71-77
rats	O	78-82
treated	O	83-90
intracerebroventricularly	O	91-116
with	O	117-121
streptozotocin	O	122-136
.	O	136-137

Basic	O	138-143
and	O	144-147
clinical	O	148-156
research	O	157-165
has	O	166-169
demonstrated	O	170-182
that	O	183-187
dementia	B	188-196
of	O	197-199
sporadic	O	200-208
Alzheimer	B	209-218
'	I	218-219
s	I	219-220
disease	I	221-228
(	O	229-230
sAD	O	230-233
)	O	233-234
type	O	235-239
is	O	240-242
associated	O	243-253
with	O	254-258
dysfunction	O	259-270
of	O	271-273
the	O	274-277
insulin	O	278-285
-	O	285-286
receptor	O	286-294
(	O	295-296
IR	O	296-298
)	O	298-299
system	O	300-306
followed	O	307-315
by	O	316-318
decreased	O	319-328
glucose	O	329-336
transport	O	337-346
via	O	347-350
glucose	O	351-358
transporter	O	359-370
GLUT4	O	371-376
and	O	377-380
decreased	O	381-390
glucose	O	391-398
metabolism	O	399-409
in	O	410-412
brain	O	413-418
cells	O	419-424
.	O	424-425

An	O	426-428
alternative	O	429-440
source	O	441-447
of	O	448-450
energy	O	451-457
is	O	458-460
d	O	461-462
-	O	462-463
galactose	O	463-472
(	O	473-474
the	O	474-477
C	O	478-479
-	O	479-480
4	O	480-481
-	O	479-480
epimer	O	482-488
of	O	489-491
d	O	492-493
-	O	493-494
glucose	O	494-501
)	O	501-502
which	O	503-508
is	O	509-511
transported	O	512-523
into	O	524-528
the	O	529-532
brain	O	533-538
by	O	539-541
insulin	O	542-549
-	O	549-550
independent	O	550-561
GLUT3	O	562-567
transporter	O	568-579
where	O	580-585
it	O	586-588
might	O	589-594
be	O	595-597
metabolized	O	598-609
to	O	610-612
glucose	O	613-620
via	O	621-624
the	O	625-628
Leloir	O	629-635
pathway	O	636-643
.	O	643-644

Exclusively	O	645-656
parenteral	O	657-667
daily	O	668-673
injections	O	674-684
of	O	685-687
galactose	O	688-697
induce	O	698-704
memory	B	705-711
deterioration	I	712-725
in	O	726-728
rodents	O	729-736
and	O	737-740
are	O	741-744
used	O	745-749
to	O	750-752
generate	O	753-761
animal	O	762-768
aging	O	769-774
model	O	775-780
,	O	780-781
but	O	782-785
the	O	786-789
effects	O	790-797
of	O	798-800
oral	O	801-805
galactose	O	806-815
treatment	O	816-825
on	O	826-828
cognitive	O	829-838
functions	O	839-848
have	O	849-853
never	O	854-859
been	O	860-864
tested	O	865-871
.	O	871-872

We	O	873-875
have	O	876-880
investigated	O	881-893
the	O	894-897
effects	O	898-905
of	O	906-908
continuous	O	909-919
daily	O	920-925
oral	O	926-930
galactose	O	931-940
(	O	941-942
200	O	942-945
mg	O	946-948
/	O	948-949
kg	O	949-951
/	O	948-949
day	O	952-955
)	O	955-956
treatment	O	957-966
on	O	967-969
cognitive	B	970-979
deficits	I	980-988
in	O	989-991
streptozotocin	O	992-1006
-	O	1006-1007
induced	O	1007-1014
(	O	1015-1016
STZ	O	1016-1019
-	O	1019-1020
icv	O	1020-1023
)	O	1023-1024
rat	O	1025-1028
model	O	1029-1034
of	O	1035-1037
sAD	O	1038-1041
,	O	1041-1042
tested	O	1043-1049
by	O	1050-1052
Morris	O	1053-1059
Water	O	1060-1065
Maze	O	1066-1070
and	O	1071-1074
Passive	O	1075-1082
Avoidance	O	1083-1092
test	O	1093-1097
,	O	1097-1098
respectively	O	1099-1111
.	O	1111-1112

One	O	1113-1116
month	O	1117-1122
of	O	1123-1125
oral	O	1126-1130
galactose	O	1131-1140
treatment	O	1141-1150
initiated	O	1151-1160
immediately	O	1161-1172
after	O	1173-1178
the	O	1179-1182
STZ	O	1183-1186
-	O	1186-1187
icv	O	1187-1190
administration	O	1191-1205
,	O	1205-1206
successfully	O	1207-1219
prevented	O	1220-1229
development	O	1230-1241
of	O	1242-1244
the	O	1245-1248
STZ	O	1249-1252
-	O	1252-1253
icv	O	1253-1256
-	O	1252-1253
induced	O	1257-1264
cognitive	B	1265-1274
deficits	I	1275-1283
.	O	1283-1284

Beneficial	O	1285-1295
effect	O	1296-1302
of	O	1303-1305
oral	O	1306-1310
galactose	O	1311-1320
was	O	1321-1324
independent	O	1325-1336
of	O	1337-1339
the	O	1340-1343
rat	O	1344-1347
age	O	1348-1351
and	O	1352-1355
of	O	1356-1358
the	O	1359-1362
galactose	O	1363-1372
dose	O	1373-1377
ranging	O	1378-1385
from	O	1386-1390
100	O	1391-1394
to	O	1395-1397
300	O	1398-1401
mg	O	1402-1404
/	O	1404-1405
kg	O	1405-1407
/	O	1404-1405
day	O	1408-1411
.	O	1411-1412

Additionally	O	1413-1425
,	O	1425-1426
oral	O	1427-1431
galactose	O	1432-1441
administration	O	1442-1456
led	O	1457-1460
to	O	1461-1463
the	O	1464-1467
appearance	O	1468-1478
of	O	1479-1481
galactose	O	1482-1491
in	O	1492-1494
the	O	1495-1498
blood	O	1499-1504
.	O	1504-1505

The	O	1506-1509
increase	O	1510-1518
of	O	1519-1521
galactose	O	1522-1531
concentration	O	1532-1545
in	O	1546-1548
the	O	1549-1552
cerebrospinal	O	1553-1566
fluid	O	1567-1572
was	O	1573-1576
several	O	1577-1584
times	O	1585-1590
lower	O	1591-1596
after	O	1597-1602
oral	O	1603-1607
than	O	1608-1612
after	O	1613-1618
parenteral	O	1619-1629
administration	O	1630-1644
of	O	1645-1647
the	O	1648-1651
same	O	1652-1656
galactose	O	1657-1666
dose	O	1667-1671
.	O	1671-1672

Oral	O	1673-1677
galactose	O	1678-1687
exposure	O	1688-1696
might	O	1697-1702
have	O	1703-1707
beneficial	O	1708-1718
effects	O	1719-1726
on	O	1727-1729
learning	O	1730-1738
and	O	1739-1742
memory	O	1743-1749
ability	O	1750-1757
and	O	1758-1761
could	O	1762-1767
be	O	1768-1770
worth	O	1771-1776
investigating	O	1777-1790
for	O	1791-1794
improvement	O	1795-1806
of	O	1807-1809
cognitive	B	1810-1819
deficits	I	1820-1828
associated	O	1829-1839
with	O	1840-1844
glucose	B	1845-1852
hypometabolism	I	1853-1867
in	O	1868-1870
AD	B	1871-1873
.	O	1873-1874

